data_2k1q_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2k1q _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.104 0.478 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -103.77 129.91 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.564 -0.71 . . . . 0.0 109.868 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -116.3 158.54 23.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.561 -0.712 . . . . 0.0 110.489 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.04 121.29 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.663 -0.648 . . . . 0.0 109.597 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -118.48 142.67 32.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.699 -0.626 . . . . 0.0 109.899 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.3 t -142.05 159.67 41.76 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.516 -0.74 . . . . 0.0 111.246 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.7 p -124.56 -170.12 2.09 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -84.02 5.89 24.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.528 -0.732 . . . . 0.0 110.91 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -128.65 -38.94 1.67 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.073 -1.017 . . . . 0.0 111.191 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -149.91 170.1 19.61 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.311 -0.868 . . . . 0.0 111.159 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 47.8 m -119.75 147.35 44.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.68 -0.638 . . . . 0.0 109.792 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 10.3 p90 -156.43 -178.63 7.48 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.391 -0.818 . . . . 0.0 110.275 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 74.0 mt -113.89 153.35 29.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.0 110.804 -178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.43 161.34 31.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.711 -0.618 . . . . 0.0 109.972 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -126.23 140.12 52.79 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.573 -0.705 . . . . 0.0 110.4 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 38.5 t -98.33 105.48 17.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.59 -0.693 . . . . 0.0 110.489 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.0 t -109.98 129.99 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.423 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 56.8 t30 57.98 38.36 26.82 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.439 -0.788 . . . . 0.0 110.479 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.52 19.93 76.7 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.0 t -131.99 129.97 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.137 -1.214 . . . . 0.0 110.167 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 87.5 m -75.66 148.89 38.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.516 -0.74 . . . . 0.0 109.464 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -138.2 149.95 46.29 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.448 -0.783 . . . . 0.0 111.212 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.461 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.9 t -168.65 -179.09 3.67 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.457 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 10.6 p -89.17 158.33 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.448 -0.783 . . . . 0.0 110.027 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.427 ' CE1' HG22 ' A' ' 78' ' ' VAL . 57.1 t80 -76.39 -39.97 52.25 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.493 -0.754 . . . . 0.0 112.066 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.457 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.3 p-80 -64.95 -24.28 67.47 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.116 -0.99 . . . . 0.0 110.567 -178.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.425 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -84.28 -56.98 2.44 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 179.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -96.89 -61.28 1.43 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.68 -0.894 . . . . 0.0 109.987 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 79.96 -179.39 53.26 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 78.9 p -79.33 64.59 4.26 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.596 -0.943 . . . . 0.0 109.768 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.23 167.54 21.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.62 -0.675 . . . . 0.0 110.414 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.2 t -65.39 139.32 58.54 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 109.826 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.415 ' HG ' ' CZ2' ' A' ' 85' ' ' TRP . 0.1 OUTLIER -112.83 131.13 55.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.589 -0.694 . . . . 0.0 110.291 -179.576 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.53 109.29 21.9 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.564 -0.71 . . . . 0.0 109.815 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -105.53 -165.96 23.59 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.09 -32.36 34.53 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 124.025 1.539 . . . . 0.0 110.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.62 -31.09 59.76 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.83 -140.83 10.1 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -75.02 161.36 38.83 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.819 1.431 . . . . 0.0 110.292 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.5 mt -131.53 139.37 50.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.448 -0.782 . . . . 0.0 110.439 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.0 p -81.87 150.74 27.64 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.549 -0.719 . . . . 0.0 109.946 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 78.2 mm-40 -87.42 132.3 34.03 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.484 -0.76 . . . . 0.0 110.095 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -110.01 -44.86 3.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.552 -0.718 . . . . 0.0 110.116 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' A' ' 179' ' ' MET . 83.9 m-85 -130.01 150.04 51.46 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.584 -0.697 . . . . 0.0 110.507 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.6 p -148.17 136.32 21.2 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.007 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -149.98 89.32 1.59 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.427 HG22 ' CE1' ' A' ' 56' ' ' TYR . 63.0 t -61.3 -40.09 84.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.623 -0.673 . . . . 0.0 109.988 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -61.58 -43.91 97.99 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.508 -0.745 . . . . 0.0 110.654 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -87.6 -0.01 56.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.583 -0.698 . . . . 0.0 110.749 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 8.4 t70 53.48 46.5 26.05 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.06 -1.025 . . . . 0.0 110.506 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 40.3 mt -144.25 138.39 27.96 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.543 -0.723 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.403 ' CG1' HG23 ' A' ' 54' ' ' THR . 8.3 p -134.12 157.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.605 -0.684 . . . . 0.0 109.26 179.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -138.43 153.66 22.59 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.196 -1.161 . . . . 0.0 110.196 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.461 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 5.8 m-90 -120.99 151.67 39.46 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.776 -0.838 . . . . 0.0 110.022 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -68.51 115.85 8.39 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.538 -0.726 . . . . 0.0 109.338 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.06 130.08 90.13 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.525 -0.735 . . . . 0.0 110.262 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.04 159.99 51.21 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.831 1.437 . . . . 0.0 110.285 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.67 156.32 58.01 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.897 1.472 . . . . 0.0 110.4 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.33 26.56 59.31 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.66 152.29 30.63 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.467 -1.019 . . . . 0.0 110.143 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -92.79 168.94 10.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.566 -0.709 . . . . 0.0 110.256 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.9 p -137.84 158.71 43.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.74 -0.6 . . . . 0.0 110.228 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 51.4 mt -108.02 131.63 54.38 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.526 -0.734 . . . . 0.0 110.485 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.7 p -76.91 160.06 77.3 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.555 -0.716 . . . . 0.0 109.784 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -75.58 163.68 33.64 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.832 1.438 . . . . 0.0 110.655 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.69 129.53 38.44 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.694 -0.629 . . . . 0.0 110.27 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -134.68 55.6 1.89 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.716 -0.615 . . . . 0.0 109.661 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.8 p -143.88 -7.82 0.73 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 120.027 -0.669 . . . . 0.0 112.26 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.97 39.54 97.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.8 m -99.94 119.99 39.1 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.544 -0.974 . . . . 0.0 110.404 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -66.71 -39.71 88.14 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.731 -0.606 . . . . 0.0 110.442 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 139.61 57.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.531 -0.731 . . . . 0.0 110.491 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.8 mt -139.29 153.1 47.72 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 0.0 110.409 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -115.73 123.72 49.01 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.53 -0.731 . . . . 0.0 109.887 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.3 tp -99.91 133.29 44.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.592 -0.693 . . . . 0.0 110.595 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.9 t -91.57 120.05 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.677 -0.639 . . . . 0.0 109.447 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.4 m -97.99 152.35 19.36 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.462 -0.774 . . . . 0.0 110.419 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 28.0 ptt85 -59.08 -20.03 49.68 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.639 -0.663 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -94.59 26.76 3.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.452 -0.78 . . . . 0.0 110.214 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.49 40.07 31.16 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.348 -0.845 . . . . 0.0 110.663 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.49 135.03 54.62 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.572 -0.705 . . . . 0.0 109.976 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.97 120.03 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.579 -0.701 . . . . 0.0 110.022 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 49.0 mm -106.19 117.36 57.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.622 -0.674 . . . . 0.0 109.79 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -64.42 120.74 8.13 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.801 1.422 . . . . 0.0 110.374 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.98 126.32 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.586 -0.696 . . . . 0.0 109.796 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -86.9 130.53 34.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.553 -0.717 . . . . 0.0 109.805 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 37.5 ttp180 -73.46 126.14 29.52 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.624 -0.672 . . . . 0.0 110.338 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -120.16 23.78 10.79 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.587 -0.696 . . . . 0.0 110.209 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.38 -179.06 42.18 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -63.19 -39.96 96.13 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.571 -0.958 . . . . 0.0 110.406 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 76.9 p -132.83 22.2 4.21 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.555 -0.715 . . . . 0.0 110.786 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -124.86 138.6 54.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.346 -0.847 . . . . 0.0 110.322 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.18 169.81 23.51 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.4 p -121.25 153.51 37.55 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.62 -0.929 . . . . 0.0 110.059 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 tp -99.27 119.87 38.63 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.505 -0.747 . . . . 0.0 110.221 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -68.61 -39.01 81.04 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.544 -0.722 . . . . 0.0 110.039 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.28 116.13 55.47 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.601 -0.687 . . . . 0.0 110.064 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -65.81 116.34 3.91 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.724 1.381 . . . . 0.0 110.43 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 5.7 mtt180 -122.69 160.04 50.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.581 -0.699 . . . . 0.0 110.139 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -67.43 152.04 79.36 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 124.017 1.536 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.32 -32.15 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.568 -0.708 . . . . 0.0 110.395 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.8 t -59.96 -38.66 83.1 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.511 -0.743 . . . . 0.0 110.162 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.539 -0.726 . . . . 0.0 110.34 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -81.46 -18.35 45.59 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 0.0 111.109 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -60.4 140.02 57.4 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.183 -0.948 . . . . 0.0 110.115 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 86.37 13.64 67.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.5 p -116.13 -8.29 11.79 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.127 -1.219 . . . . 0.0 110.908 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.7 t -59.97 139.08 57.66 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.123 -0.986 . . . . 0.0 109.698 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.33 -23.44 35.82 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.99 151.71 47.39 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 179.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -93.87 148.78 2.15 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.841 1.443 . . . . 0.0 111.427 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.406 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.3 mp -104.66 130.3 52.71 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -118.47 131.51 56.25 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.351 -0.843 . . . . 0.0 111.549 -178.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.422 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.5 p -70.01 159.16 85.32 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 178.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.85 -26.64 24.87 Favored 'Trans proline' 0 N--CA 1.502 1.992 0 O-C-N 123.504 1.265 . . . . 0.0 112.359 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.9 m -62.63 -39.99 95.57 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.261 -0.9 . . . . 0.0 109.96 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.67 36.37 0.79 Allowed Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.4 m170 -132.48 149.61 52.3 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.419 -1.048 . . . . 0.0 110.128 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 142.48 52.78 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.576 -0.702 . . . . 0.0 110.45 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 34.4 m -117.17 -22.81 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.626 -0.671 . . . . 0.0 110.613 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 167.63 -169.92 41.45 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.4 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 96.9 mt -127.84 139.94 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.517 -0.99 . . . . 0.0 110.224 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -65.82 136.79 56.65 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.649 -0.657 . . . . 0.0 109.981 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -114.97 -52.39 2.69 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 0.0 110.427 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.72 160.02 42.17 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.463 -0.773 . . . . 0.0 110.393 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -109.96 151.13 27.5 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.66 -0.65 . . . . 0.0 110.203 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -108.27 119.6 58.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.666 -0.647 . . . . 0.0 109.693 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -134.1 158.96 42.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.693 -0.63 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 4.6 p -99.97 -50.68 3.92 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.71 . . . . 0.0 110.391 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -142.89 61.62 1.41 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.928 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.05 -7.47 81.57 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.8 t -116.82 125.92 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 109.905 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.81 127.86 43.2 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.592 -0.693 . . . . 0.0 110.422 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -107.14 -17.16 14.24 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.519 -0.738 . . . . 0.0 110.743 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -146.81 159.78 43.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.325 -0.859 . . . . 0.0 110.036 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -133.84 160.04 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.462 -0.774 . . . . 0.0 110.938 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.51 138.4 53.19 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.658 . . . . 0.0 110.015 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -140.3 155.65 46.75 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.404 -0.81 . . . . 0.0 110.794 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 59.3 t -94.47 126.04 49.5 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.56 -0.712 . . . . 0.0 109.459 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.46 158.58 57.03 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.795 1.419 . . . . 0.0 110.696 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 57.7 t -65.59 -24.66 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.665 -0.647 . . . . 0.0 110.478 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -58.6 -37.96 76.94 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.383 -0.823 . . . . 0.0 110.579 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 81.1 p -60.13 -34.45 73.54 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.524 -0.735 . . . . 0.0 110.417 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.4 ' CE ' ' CD1' ' A' ' 153' ' ' ILE . 68.3 mtt -61.14 -40.02 92.26 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.478 -0.764 . . . . 0.0 110.411 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.55 -42.14 95.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.496 -0.752 . . . . 0.0 110.495 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 75.2 p -70.03 -39.51 75.72 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.395 -0.816 . . . . 0.0 110.417 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 86.5 m -60.04 -50.03 75.32 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' MET . . . . . 0.421 ' HG3' ' CE1' ' A' ' 75' ' ' TYR . 59.9 ttp . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.609 -0.682 . . . . 0.0 110.239 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.1 0.476 . . . . 0.0 110.181 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.416 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.587 -0.696 . . . . 0.0 110.226 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 120.64 0.257 . . . . 0.0 111.171 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.02 128.41 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.113 -0.992 . . . . 0.0 109.946 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -116.31 146.29 42.54 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.588 -0.695 . . . . 0.0 109.992 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.3 t -91.55 122.81 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.405 ' HB ' ' CD1' ' A' ' 64' ' ' LEU . 32.7 m -115.62 140.17 38.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.734 -0.604 . . . . 0.0 109.707 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.1 m -138.4 162.87 33.35 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.562 -0.711 . . . . 0.0 110.753 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.55 -170.5 2.24 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.72 -0.612 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.08 -42.83 95.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.534 -0.728 . . . . 0.0 110.736 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.9 t -128.28 -7.66 5.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.385 -0.822 . . . . 0.0 111.849 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.8 tp60 -115.16 156.87 24.49 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.067 -1.02 . . . . 0.0 110.67 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.7 p -149.96 138.1 20.38 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.718 -0.614 . . . . 0.0 109.759 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.405 ' CE1' ' O ' ' A' ' 58' ' ' GLY . 20.0 p90 -164.39 -178.89 5.69 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.533 -0.73 . . . . 0.0 110.456 -179.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.6 mt -114.3 159.2 20.46 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.476 -0.765 . . . . 0.0 110.862 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -139.1 162.64 34.46 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.697 -0.627 . . . . 0.0 109.989 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.5 t -122.29 140.68 52.35 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.423 -0.798 . . . . 0.0 110.673 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.3 t -98.87 104.06 16.07 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.569 -0.707 . . . . 0.0 110.109 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.61 132.77 56.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.604 -0.685 . . . . 0.0 109.899 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 54.35 39.94 31.34 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.596 -0.69 . . . . 0.0 111.016 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 20.83 76.67 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.9 t -130.0 130.0 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.249 -1.148 . . . . 0.0 109.852 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.1 t -78.93 147.31 33.08 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.483 -0.761 . . . . 0.0 109.403 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.447 ' CG ' ' CE ' ' A' ' 175' ' ' MET . 57.5 m95 -128.66 150.38 50.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.538 -0.726 . . . . 0.0 110.932 -179.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.448 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.3 t -166.11 -179.73 5.29 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.458 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -100.46 154.25 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.73 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -70.05 -40.11 75.3 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.63 -0.669 . . . . 0.0 111.811 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.458 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.1 p-80 -70.62 -22.1 62.57 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.099 -1.001 . . . . 0.0 110.843 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.405 ' O ' ' CE1' ' A' ' 43' ' ' PHE . . . -93.32 -46.41 3.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.907 -1.677 . . . . 0.0 108.907 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.43 -49.31 3.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.658 -0.907 . . . . 0.0 110.334 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.49 -162.3 41.17 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.2 t -93.12 63.37 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.577 -0.955 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.92 161.77 36.78 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.58 -0.7 . . . . 0.0 110.266 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 63.1 p -65.42 139.59 58.55 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.634 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.405 ' CD1' ' HB ' ' A' ' 36' ' ' VAL . 0.1 OUTLIER -112.53 141.28 46.47 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.618 -0.677 . . . . 0.0 110.011 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.27 115.16 24.49 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.511 -0.743 . . . . 0.0 110.252 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.04 176.42 16.17 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.63 -31.97 69.59 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.793 1.417 . . . . 0.0 110.29 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.63 -31.41 66.84 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.657 -0.652 . . . . 0.0 109.829 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.7 -153.71 24.32 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.02 145.0 48.78 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.918 1.483 . . . . 0.0 110.092 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.42 HG22 ' CG ' ' A' ' 85' ' ' TRP . 85.6 mt -119.99 129.49 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.608 -0.682 . . . . 0.0 110.356 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 m -85.49 130.26 34.62 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.963 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.43 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 44.8 mm-40 -55.69 139.93 43.25 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.513 -0.742 . . . . 0.0 110.917 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.0 ttt -113.68 -49.1 2.9 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.73 -0.606 . . . . 0.0 110.179 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 70.3 m-85 -120.0 140.0 51.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.588 -0.695 . . . . 0.0 110.27 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 26.2 m -135.78 129.36 32.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.641 -0.662 . . . . 0.0 110.215 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -142.43 96.75 3.0 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.577 -0.702 . . . . 0.0 110.226 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 76.5 t -65.7 -39.99 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.593 -0.692 . . . . 0.0 110.049 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -60.01 -49.84 76.07 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.551 -0.718 . . . . 0.0 110.816 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -89.31 -0.05 57.17 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 110.934 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.4 t70 52.79 47.41 24.74 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.0 -1.062 . . . . 0.0 110.665 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 62.8 mt -141.63 137.14 31.63 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.443 -0.786 . . . . 0.0 111.141 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.6 m -138.37 161.35 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.555 -0.716 . . . . 0.0 109.301 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.32 164.56 26.55 Favored Glycine 0 N--CA 1.495 2.632 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.586 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.448 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 7.7 m-90 -123.13 159.38 28.67 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.829 -0.806 . . . . 0.0 109.253 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -79.9 109.34 14.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.45 -0.781 . . . . 0.0 109.528 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.68 141.08 87.17 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.59 -0.694 . . . . 0.0 110.298 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.03 160.02 51.12 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.917 1.482 . . . . 0.0 110.323 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.83 160.12 42.42 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.305 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.79 29.85 64.65 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.51 144.09 34.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.533 -0.981 . . . . 0.0 110.095 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 31.8 ttt180 -84.69 128.64 34.71 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.69 -0.631 . . . . 0.0 109.703 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.4 p -111.43 162.58 14.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.593 -0.692 . . . . 0.0 110.539 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -106.37 131.99 52.93 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.614 -0.679 . . . . 0.0 110.73 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.4 p -75.46 160.01 80.56 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.597 -0.689 . . . . 0.0 109.691 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.51 162.63 40.85 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.825 1.434 . . . . 0.0 110.772 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -79.26 130.05 35.07 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.618 -0.676 . . . . 0.0 110.101 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.56 55.6 1.88 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.651 -0.656 . . . . 0.0 109.72 179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.79 -8.02 0.74 Allowed 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 119.916 -0.714 . . . . 0.0 112.296 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.66 34.77 89.74 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 m -87.0 112.34 21.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.515 -0.991 . . . . 0.0 110.405 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -59.99 -39.97 87.56 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.6 -0.688 . . . . 0.0 110.35 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -63.15 132.88 53.27 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.613 -0.68 . . . . 0.0 110.184 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.4 mt -134.63 146.12 49.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.66 -0.65 . . . . 0.0 110.492 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.82 121.54 44.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.504 -0.748 . . . . 0.0 109.984 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 64.0 tp -95.51 137.94 33.88 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.547 -0.72 . . . . 0.0 110.408 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.24 119.96 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.598 -0.689 . . . . 0.0 109.75 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.2 p -97.74 170.07 9.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.487 -0.758 . . . . 0.0 110.573 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -70.06 -20.19 63.25 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.646 -0.659 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -94.32 26.59 3.28 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.323 -0.861 . . . . 0.0 110.679 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 39.03 30.46 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.273 -0.892 . . . . 0.0 110.751 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -120.14 137.08 54.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.688 -0.633 . . . . 0.0 109.723 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -120.04 143.4 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.446 -0.783 . . . . 0.0 110.67 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 46.0 pt -129.94 158.8 72.77 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.757 -0.59 . . . . 0.0 109.914 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -90.89 130.96 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.817 1.43 . . . . 0.0 110.588 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -130.1 130.01 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.699 -0.625 . . . . 0.0 109.548 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -82.81 149.28 27.29 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.507 -0.745 . . . . 0.0 110.175 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.0 ttt180 -95.56 119.94 34.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.581 -0.7 . . . . 0.0 110.123 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -110.04 19.94 18.46 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.615 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.7 179.41 42.69 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -61.47 -40.03 93.06 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.592 -0.946 . . . . 0.0 110.296 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 44.5 p -130.31 23.63 5.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.548 -0.72 . . . . 0.0 110.681 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -124.53 137.85 54.38 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.41 -0.806 . . . . 0.0 110.299 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -137.51 162.94 25.49 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 76.8 p -119.51 148.35 43.39 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.586 -0.949 . . . . 0.0 110.349 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 tp -95.27 126.84 40.86 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.595 -0.69 . . . . 0.0 110.158 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -61.26 -39.95 92.26 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.656 -0.653 . . . . 0.0 110.388 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.4 p -120.39 149.6 50.13 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.536 -0.728 . . . . 0.0 110.339 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -79.88 121.46 4.54 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.969 1.51 . . . . 0.0 110.491 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -122.16 160.56 47.07 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.565 -0.709 . . . . 0.0 110.116 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.53 150.76 80.24 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.955 1.502 . . . . 0.0 110.464 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 64.7 t -62.49 -30.18 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.628 -0.67 . . . . 0.0 109.783 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.2 m -60.03 -38.33 82.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.631 -0.668 . . . . 0.0 110.371 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -59.94 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.469 -0.77 . . . . 0.0 110.029 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.2 mp -86.94 -22.99 25.27 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.486 -0.759 . . . . 0.0 110.572 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 4.2 tptm -60.17 129.96 44.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.388 -0.82 . . . . 0.0 110.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.68 -9.84 73.19 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.1 p -89.94 -0.06 57.36 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.038 -1.272 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.1 m -59.92 139.95 57.03 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.108 -0.995 . . . . 0.0 109.765 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.17 -20.36 51.11 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.11 154.79 43.77 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -98.01 147.49 0.73 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 O-C-N 123.803 1.423 . . . . 0.0 111.134 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.405 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.7 mp -104.41 109.19 20.95 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -98.4 132.15 44.09 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.503 -0.748 . . . . 0.0 111.507 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.424 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.01 159.84 82.74 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.89 -26.58 25.0 Favored 'Trans proline' 0 N--CA 1.502 2.011 0 O-C-N 123.456 1.24 . . . . 0.0 112.266 -178.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.67 -40.1 96.01 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.181 -0.949 . . . . 0.0 109.848 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.68 36.13 0.8 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -131.81 146.37 52.1 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.459 -1.024 . . . . 0.0 110.29 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.59 143.65 57.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.554 -0.716 . . . . 0.0 110.324 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.1 t -118.25 -37.81 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.513 -0.742 . . . . 0.0 110.054 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.5 -170.39 39.04 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 67.9 mt -127.93 133.33 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.523 -0.986 . . . . 0.0 110.24 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -61.78 137.04 58.21 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.607 -0.683 . . . . 0.0 109.908 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.8 ttt180 -116.88 -52.35 2.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.514 -0.742 . . . . 0.0 110.099 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -149.79 159.99 43.91 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.499 -0.751 . . . . 0.0 110.397 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -115.19 151.83 33.73 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.668 -0.645 . . . . 0.0 110.267 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -107.88 119.14 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.589 -0.694 . . . . 0.0 109.714 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.78 155.19 47.09 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.664 -0.647 . . . . 0.0 110.471 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 2.8 m -103.42 -60.31 1.58 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.57 -0.706 . . . . 0.0 110.272 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 71.8 mtt180 -127.92 66.72 1.35 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.704 -0.622 . . . . 0.0 109.933 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 71.84 22.58 78.7 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 14.6 p -139.3 127.75 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.417 -1.049 . . . . 0.0 109.866 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.32 124.2 34.71 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.549 -0.719 . . . . 0.0 110.807 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -107.57 -19.93 13.4 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.694 -0.629 . . . . 0.0 110.073 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -150.04 157.36 43.06 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.454 -0.779 . . . . 0.0 109.849 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.9 m -133.03 164.3 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -0.764 . . . . 0.0 110.792 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -125.13 134.83 52.29 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.558 -0.714 . . . . 0.0 110.218 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -134.18 157.78 45.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.519 -0.738 . . . . 0.0 110.095 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 67.0 t -94.54 124.38 55.37 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.539 -0.726 . . . . 0.0 109.754 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.5 147.9 87.19 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.784 1.413 . . . . 0.0 110.41 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.89 -23.83 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.71 -0.619 . . . . 0.0 110.675 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -59.97 -40.75 90.12 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.372 -0.83 . . . . 0.0 110.633 -179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.8 p -70.0 -36.42 75.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.458 -0.776 . . . . 0.0 110.252 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.2 mtp -59.94 -40.09 87.76 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.604 -0.685 . . . . 0.0 110.378 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 75.3 mt-10 -64.34 -39.95 94.91 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.645 -0.659 . . . . 0.0 110.105 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -61.81 -40.0 93.71 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.67 -0.644 . . . . 0.0 110.049 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.4 m -60.12 -39.97 88.08 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.558 -0.714 . . . . 0.0 110.176 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.479 -0.763 . . . . 0.0 110.238 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.101 0.476 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.412 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp . . . . . 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 110.136 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 . . . . . 0 N--CA 1.495 1.782 0 CA-C-O 121.159 0.504 . . . . 0.0 109.827 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.14 125.72 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.548 -0.72 . . . . 0.0 109.698 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -119.32 159.6 23.83 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.714 -0.617 . . . . 0.0 110.491 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.7 t -88.29 115.43 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.62 -0.675 . . . . 0.0 109.545 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.417 ' CG1' ' CD2' ' A' ' 64' ' ' LEU . 57.6 t -110.37 148.14 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.317 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -143.63 171.25 14.43 Favored 'General case' 0 N--CA 1.494 1.745 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.408 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 15.3 p -140.44 179.34 6.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.902 -0.499 . . . . 0.0 109.997 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -75.13 -8.56 56.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.5 -0.75 . . . . 0.0 111.036 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -109.82 -43.71 3.97 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.218 -0.926 . . . . 0.0 111.64 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -148.88 177.35 9.62 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.251 -0.905 . . . . 0.0 111.296 -179.071 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.3 m -122.58 149.65 43.68 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.588 -0.695 . . . . 0.0 110.279 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 18.9 p90 -164.0 -177.65 5.17 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.245 -0.91 . . . . 0.0 110.461 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.36 141.35 47.15 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.545 -0.722 . . . . 0.0 110.635 -178.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -114.75 154.53 28.34 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.656 -0.652 . . . . 0.0 109.946 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 75.2 p -120.1 131.25 55.0 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.411 -0.806 . . . . 0.0 110.387 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.7 t -93.06 110.02 21.5 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.583 -0.698 . . . . 0.0 110.74 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -114.58 132.27 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.684 -0.635 . . . . 0.0 109.516 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 29.5 m120 55.56 39.0 30.96 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.516 -0.74 . . . . 0.0 110.933 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.96 19.07 75.06 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -130.67 130.01 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.267 -1.137 . . . . 0.0 109.851 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.6 m -76.79 139.53 40.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 109.443 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -133.03 136.45 45.98 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.508 -0.745 . . . . 0.0 110.898 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 29.9 p -150.73 -179.85 7.61 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 9.6 p -88.25 150.19 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.284 -0.885 . . . . 0.0 110.238 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.401 ' CE2' HG21 ' A' ' 78' ' ' VAL . 60.3 t80 -60.06 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.571 -0.706 . . . . 0.0 111.891 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.468 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 5.7 p-80 -59.69 -24.29 63.83 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.09 -1.007 . . . . 0.0 110.739 -178.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.88 -42.49 20.3 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.24 95.45 2.17 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.771 -0.841 . . . . 0.0 109.786 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.63 -165.1 4.54 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 88.0 p -71.15 69.79 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.621 -0.929 . . . . 0.0 109.87 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.99 179.22 6.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.562 -0.711 . . . . 0.0 110.293 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 33.0 p -64.93 139.9 58.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.646 -0.659 . . . . 0.0 109.801 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.417 ' CD2' ' CG1' ' A' ' 36' ' ' VAL . 14.8 tp -113.28 137.94 50.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.653 -0.654 . . . . 0.0 110.159 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.76 109.88 22.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.655 -0.653 . . . . 0.0 109.955 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.51 -175.07 15.84 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -64.78 -32.69 55.88 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 O-C-N 123.895 1.471 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -74.82 -31.5 61.7 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.575 -0.703 . . . . 0.0 110.06 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.41 -147.15 18.55 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.08 140.65 15.94 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.832 1.438 . . . . 0.0 110.377 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.49 140.02 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.606 -0.684 . . . . 0.0 110.351 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.6 t -93.23 133.48 36.39 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.537 -0.727 . . . . 0.0 110.439 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.425 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 34.1 tt0 -71.53 140.55 49.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.42 -0.8 . . . . 0.0 110.699 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.5 mmm -105.87 -29.1 10.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.663 -0.648 . . . . 0.0 110.323 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -118.39 139.61 51.12 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.565 -0.709 . . . . 0.0 110.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.2 m -139.97 135.34 32.65 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.522 -0.736 . . . . 0.0 110.414 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -150.05 98.95 2.77 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.602 -0.687 . . . . 0.0 109.897 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.401 HG21 ' CE2' ' A' ' 56' ' ' TYR . 67.3 t -69.67 -44.82 79.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.543 -0.723 . . . . 0.0 110.329 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.03 -50.02 75.38 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.553 -0.717 . . . . 0.0 110.46 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.8 tp-100 -80.41 -8.49 59.55 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.67 -0.644 . . . . 0.0 110.767 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.1 t70 56.56 45.24 22.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.173 -0.955 . . . . 0.0 110.248 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 75.8 mt -130.01 148.89 51.91 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.565 -0.709 . . . . 0.0 110.721 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.421 HG22 ' CH2' ' A' ' 85' ' ' TRP . 32.6 m -149.97 169.92 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.66 -0.65 . . . . 0.0 109.626 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -165.05 160.31 33.58 Favored Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.845 -1.169 . . . . 0.0 110.416 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.425 ' CD1' ' HA ' ' A' ' 73' ' ' GLN . 16.1 m-90 -129.89 149.92 51.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.657 -0.908 . . . . 0.0 109.429 179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -60.9 120.13 9.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.322 -0.861 . . . . 0.0 109.63 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -75.73 141.64 72.5 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.588 -0.695 . . . . 0.0 110.307 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.01 160.02 51.15 Favored 'Trans proline' 0 N--CA 1.49 1.275 0 O-C-N 123.902 1.475 . . . . 0.0 110.32 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.69 143.79 38.31 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 O-C-N 123.947 1.498 . . . . 0.0 110.274 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.48 -22.08 42.75 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.17 46.95 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.286 -1.126 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -92.81 165.42 12.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.611 -0.681 . . . . 0.0 110.109 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.2 p -130.48 169.95 14.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.473 -0.767 . . . . 0.0 110.307 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.3 mt -103.38 132.0 50.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.573 -0.705 . . . . 0.0 110.379 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.405 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 50.9 p -72.06 159.99 83.92 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.594 -0.691 . . . . 0.0 109.941 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -83.26 150.27 13.51 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.766 1.403 . . . . 0.0 110.698 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 49.1 t -65.07 132.04 48.14 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.583 -0.698 . . . . 0.0 110.196 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.7 p -135.98 53.16 1.95 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.626 -0.671 . . . . 0.0 109.765 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.9 p -143.85 -3.49 0.88 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.332 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.94 32.31 74.84 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -91.44 129.95 37.35 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.58 -0.953 . . . . 0.0 110.331 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.9 m -77.48 -30.14 52.97 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.622 -0.674 . . . . 0.0 110.315 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.56 133.77 56.42 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.54 -0.725 . . . . 0.0 110.346 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 90.4 mt -134.95 151.66 51.05 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.631 -0.668 . . . . 0.0 110.359 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -119.85 123.17 42.97 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.512 -0.743 . . . . 0.0 109.969 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.0 tp -99.64 133.06 44.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.525 -0.734 . . . . 0.0 110.461 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.3 t -95.72 119.97 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.625 -0.672 . . . . 0.0 109.582 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -92.09 168.13 11.59 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.514 -0.741 . . . . 0.0 110.476 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 37.1 mtp-105 -60.14 -27.3 66.96 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.614 -0.679 . . . . 0.0 110.318 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.413 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -93.69 29.07 2.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.494 -0.754 . . . . 0.0 110.744 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.77 40.0 30.97 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.197 -0.939 . . . . 0.0 111.057 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -99.44 168.7 9.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.562 -0.711 . . . . 0.0 109.928 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.03 129.98 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.485 -0.759 . . . . 0.0 110.328 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.26 104.31 40.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.576 -0.702 . . . . 0.0 109.657 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.4 105.84 0.65 Allowed 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 123.79 1.416 . . . . 0.0 110.431 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.2 t -110.04 120.02 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.625 -0.672 . . . . 0.0 109.799 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.3 tpt180 -77.75 142.78 38.49 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.459 -0.776 . . . . 0.0 109.756 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -78.01 129.97 35.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.536 -0.727 . . . . 0.0 110.379 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -128.63 22.5 5.91 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.594 -0.692 . . . . 0.0 110.328 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 172.1 -179.86 43.46 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.376 -1.489 . . . . 0.0 109.376 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -66.79 -40.05 88.01 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.496 -1.002 . . . . 0.0 110.393 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.8 p -129.79 27.34 5.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.54 -0.725 . . . . 0.0 110.532 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.09 162.91 30.47 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.437 -0.789 . . . . 0.0 110.233 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -158.77 175.69 35.76 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 77.5 p -129.21 148.85 51.19 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.607 -0.937 . . . . 0.0 110.262 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 mp -100.76 123.12 44.5 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.607 -0.683 . . . . 0.0 110.438 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.04 -39.96 95.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.507 -0.746 . . . . 0.0 109.781 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -107.91 112.14 61.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.619 -0.675 . . . . 0.0 109.838 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.32 128.99 22.78 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.801 1.421 . . . . 0.0 110.631 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -125.09 160.03 56.51 Favored Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.592 -0.692 . . . . 0.0 109.906 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -65.48 153.95 75.88 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.863 1.454 . . . . 0.0 110.28 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 79.8 t -63.54 -34.75 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.658 -0.651 . . . . 0.0 110.102 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.4 p -59.74 -36.5 76.73 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.55 -0.719 . . . . 0.0 110.466 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.409 ' CD2' HD11 ' A' ' 135' ' ' LEU . 38.2 t80 -59.96 -40.01 87.55 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.11 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.409 HD11 ' CD2' ' A' ' 134' ' ' TYR . 9.5 mp -85.27 -16.18 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.563 -0.711 . . . . 0.0 111.119 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.23 132.83 55.14 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.173 -0.954 . . . . 0.0 110.069 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 89.98 -6.89 82.54 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 p -93.08 -0.04 57.17 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.254 -1.145 . . . . 0.0 111.168 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.1 m -59.97 139.91 57.09 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.058 -1.026 . . . . 0.0 109.706 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.58 -19.65 53.54 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.49 167.87 3.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -106.07 149.04 0.11 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 O-C-N 123.801 1.422 . . . . 0.0 111.206 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 85.2 mt -110.01 102.51 11.24 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.8 mp -98.12 133.69 42.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.517 -0.739 . . . . 0.0 111.713 -178.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.419 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -70.0 159.41 84.38 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.419 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.88 -26.14 23.61 Favored 'Trans proline' 0 N--CA 1.501 1.946 0 O-C-N 123.423 1.223 . . . . 0.0 112.393 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.7 m -62.73 -39.99 95.81 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.262 -0.899 . . . . 0.0 110.029 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.29 36.36 0.75 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . 0.405 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 2.9 m-70 -132.26 143.25 49.78 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.423 -1.045 . . . . 0.0 110.193 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.92 142.69 58.35 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.593 -0.692 . . . . 0.0 110.332 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.6 t -114.91 -43.63 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.575 -0.703 . . . . 0.0 109.891 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.74 -170.0 33.67 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 96.9 mt -123.86 139.36 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.618 -0.931 . . . . 0.0 110.375 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -64.26 136.43 57.17 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.687 -0.633 . . . . 0.0 109.774 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.3 ttt180 -115.94 -52.27 2.62 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.32 159.95 41.47 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.618 -0.676 . . . . 0.0 110.25 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.04 150.36 34.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.602 -0.686 . . . . 0.0 110.348 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.0 t -109.94 120.0 60.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.673 -0.642 . . . . 0.0 109.751 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -129.77 145.29 51.56 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.63 -0.669 . . . . 0.0 110.426 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.4 m -70.0 -48.86 56.44 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.684 -0.635 . . . . 0.0 110.119 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -162.64 54.73 0.21 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.658 -0.651 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 113.21 -17.89 21.49 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.0 t -111.68 120.52 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.226 -1.161 . . . . 0.0 109.781 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.82 123.73 37.36 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.542 -0.724 . . . . 0.0 110.527 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 52.3 mttp -108.57 -24.77 11.23 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.634 -0.666 . . . . 0.0 110.197 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.78 158.77 43.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.46 -0.775 . . . . 0.0 110.102 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 28.7 m -140.24 170.62 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.565 -0.71 . . . . 0.0 110.545 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -128.93 139.91 51.91 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.646 -0.659 . . . . 0.0 109.905 179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -138.92 157.44 46.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.533 -0.729 . . . . 0.0 110.458 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 59.6 t -96.16 121.52 60.38 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.606 -0.684 . . . . 0.0 109.49 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -65.01 150.06 88.56 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.845 1.445 . . . . 0.0 110.408 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 87.8 t -60.84 -25.83 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.606 -0.684 . . . . 0.0 110.529 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 65.2 mm-40 -59.97 -36.98 78.3 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.46 -0.775 . . . . 0.0 110.497 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 80.8 p -60.09 -33.12 71.66 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.427 -0.796 . . . . 0.0 110.548 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.9 mtt -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.507 -0.745 . . . . 0.0 110.541 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -60.11 -40.0 88.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.595 -0.691 . . . . 0.0 110.406 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -60.93 -40.13 92.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 110.279 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -67.11 -50.04 62.87 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.481 -0.762 . . . . 0.0 110.206 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 78.7 mtm . . . . . 0 N--CA 1.496 1.855 0 O-C-N 121.498 -0.751 . . . . 0.0 110.07 179.847 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.1 0.476 . . . . 0.0 110.086 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.414 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.625 -0.672 . . . . 0.0 110.41 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 . . . . . 0 N--CA 1.497 1.91 0 CA-C-O 121.135 0.493 . . . . 0.0 109.841 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -114.78 128.85 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.582 -0.699 . . . . 0.0 109.628 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -124.03 159.95 28.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.579 -0.701 . . . . 0.0 110.316 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -108.29 122.18 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.67 -0.644 . . . . 0.0 109.636 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.8 m -118.44 156.76 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.615 -0.678 . . . . 0.0 110.3 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 62.7 m -135.88 167.34 21.37 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.598 -0.688 . . . . 0.0 110.907 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.3 m -134.44 170.68 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.742 -0.599 . . . . 0.0 109.986 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -65.29 -16.63 63.77 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.501 -0.749 . . . . 0.0 111.109 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 m -117.39 -35.02 4.12 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.189 -0.944 . . . . 0.0 111.628 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -150.81 170.68 18.68 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.225 -0.922 . . . . 0.0 111.096 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 85.9 p -130.43 155.69 46.01 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.36 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -162.46 -178.33 6.2 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.383 -0.823 . . . . 0.0 110.256 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.5 mt -113.66 152.84 29.87 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.519 -0.738 . . . . 0.0 110.9 -178.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -132.41 161.09 34.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.662 -0.649 . . . . 0.0 110.013 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.2 t -122.95 139.0 54.52 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.572 -0.705 . . . . 0.0 110.518 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 46.4 t -93.96 104.65 16.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.36 -0.838 . . . . 0.0 110.422 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -112.44 133.35 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.692 -0.63 . . . . 0.0 109.714 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 56.97 38.25 29.26 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.502 -0.749 . . . . 0.0 110.893 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.2 27.11 74.06 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -141.79 131.85 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -1.07 . . . . 0.0 110.064 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.33 144.97 39.86 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.423 -0.798 . . . . 0.0 109.06 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -129.93 150.99 50.98 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 111.087 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.463 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -168.82 -179.78 3.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.823 -0.548 . . . . 0.0 109.574 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.467 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.5 p -90.04 160.02 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.478 -0.764 . . . . 0.0 110.218 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.415 ' CZ ' HG21 ' A' ' 78' ' ' VAL . 60.2 t80 -73.27 -44.62 58.94 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.538 -0.726 . . . . 0.0 111.779 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.467 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.7 p-80 -60.6 -24.66 65.65 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.134 -0.979 . . . . 0.0 110.704 -178.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -75.7 -47.78 11.44 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -137.09 94.53 2.96 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.751 -0.852 . . . . 0.0 109.271 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.06 62.81 1.33 Allowed Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.8 t 53.38 39.97 30.65 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.255 -1.144 . . . . 0.0 110.809 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -110.02 179.29 4.15 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.571 -0.705 . . . . 0.0 110.021 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 87.0 m -64.9 139.13 58.73 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.866 -0.733 . . . . 0.0 109.225 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.423 HD23 ' CZ2' ' A' ' 85' ' ' TRP . 12.6 tp -125.78 133.12 52.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.549 -0.719 . . . . 0.0 110.177 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.76 113.54 25.1 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.586 -0.697 . . . . 0.0 109.922 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.43 -179.26 17.54 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -62.28 -31.13 82.02 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.871 1.459 . . . . 0.0 110.649 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -75.87 -20.19 58.28 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.563 -0.71 . . . . 0.0 110.626 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.54 -133.27 7.42 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -84.25 146.05 11.06 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.9 1.474 . . . . 0.0 110.136 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -120.02 129.98 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.589 -0.694 . . . . 0.0 110.34 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.5 p -87.45 147.09 25.56 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.48 -0.762 . . . . 0.0 110.442 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 15.3 mp0 -87.66 140.01 29.95 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.7 mmm -119.23 -41.8 2.71 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.573 -0.704 . . . . 0.0 110.422 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -120.06 140.0 51.68 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.519 -0.738 . . . . 0.0 110.684 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 33.4 m -139.97 130.01 24.93 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.605 -0.684 . . . . 0.0 110.09 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -142.19 98.33 3.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.499 -0.751 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.415 HG21 ' CZ ' ' A' ' 56' ' ' TYR . 94.1 t -70.05 -40.15 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.59 -0.693 . . . . 0.0 109.96 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.1 -47.31 86.43 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.72 . . . . 0.0 110.644 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -87.14 -0.03 56.04 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.505 -0.747 . . . . 0.0 110.801 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.8 t70 52.96 45.14 29.42 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.113 -0.992 . . . . 0.0 110.543 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 64.5 mt -139.94 143.31 36.53 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.445 -0.784 . . . . 0.0 111.069 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 35.4 m -147.47 160.01 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.641 -0.662 . . . . 0.0 109.61 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.75 159.97 28.03 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.463 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 15.3 m-90 -118.22 166.91 12.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.666 -0.902 . . . . 0.0 109.53 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -72.49 119.88 17.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.501 -0.749 . . . . 0.0 109.271 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.8 140.35 98.04 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.495 -0.753 . . . . 0.0 110.296 -179.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.96 159.98 51.29 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.926 1.487 . . . . 0.0 110.268 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.82 142.11 31.4 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.905 1.476 . . . . 0.0 110.225 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.48 29.29 49.59 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.79 152.12 26.1 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.561 -0.964 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -88.3 167.57 13.43 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.689 -0.632 . . . . 0.0 110.038 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 47.5 t -144.04 164.37 30.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.623 -0.673 . . . . 0.0 110.16 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.4 mt -110.16 149.2 30.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.601 -0.687 . . . . 0.0 110.653 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.5 p -89.95 177.76 2.26 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.694 -0.629 . . . . 0.0 109.984 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -88.74 159.11 6.25 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 O-C-N 123.801 1.421 . . . . 0.0 110.566 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 48.9 t -68.76 130.39 42.67 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.716 -0.615 . . . . 0.0 110.113 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 38.7 p -134.49 54.04 1.96 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.738 -0.601 . . . . 0.0 109.754 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.71 -5.95 0.8 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.561 -0.712 . . . . 0.0 112.37 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.98 38.2 93.84 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -100.01 122.35 42.77 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.575 -0.956 . . . . 0.0 110.463 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.4 m -69.95 -29.43 66.55 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.643 -0.66 . . . . 0.0 110.176 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -64.31 132.58 50.6 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.542 -0.724 . . . . 0.0 110.21 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.1 mt -136.63 149.95 48.27 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.554 -0.716 . . . . 0.0 110.458 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -112.49 120.5 41.85 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.519 -0.738 . . . . 0.0 110.057 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.2 tp -93.7 131.45 39.02 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.432 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.21 119.98 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.516 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.1 m -97.56 169.78 9.48 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.52 -0.738 . . . . 0.0 110.62 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -62.54 -27.62 69.3 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.682 -0.636 . . . . 0.0 110.129 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -94.6 28.38 2.65 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.24 41.9 31.76 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.195 -0.94 . . . . 0.0 111.036 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -100.04 122.12 42.43 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.516 -0.74 . . . . 0.0 109.961 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.86 70.61 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.665 . . . . 0.0 110.308 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 tp -70.0 129.99 90.31 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.57 -0.706 . . . . 0.0 109.862 179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.71 134.33 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.781 1.411 . . . . 0.0 110.599 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.86 130.06 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.636 -0.665 . . . . 0.0 109.558 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -92.37 133.55 35.76 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.49 -0.756 . . . . 0.0 110.095 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -80.42 125.85 30.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.652 -0.655 . . . . 0.0 110.357 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -122.48 24.23 9.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.587 -0.696 . . . . 0.0 110.288 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -178.49 -177.36 47.1 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.12 -40.0 78.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.539 -0.977 . . . . 0.0 110.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.2 p -133.09 24.46 4.21 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.513 -0.742 . . . . 0.0 110.691 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.44 151.79 50.54 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.3 171.56 25.05 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.4 p -115.24 154.55 28.86 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.912 . . . . 0.0 110.04 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -99.99 119.98 39.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.51 -0.744 . . . . 0.0 110.069 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -66.71 -39.98 88.24 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.583 -0.698 . . . . 0.0 110.101 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.3 m -110.22 114.36 55.74 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.622 -0.674 . . . . 0.0 110.169 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.67 114.26 2.66 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.782 1.412 . . . . 0.0 110.439 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -125.59 160.08 57.6 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.628 -0.67 . . . . 0.0 110.081 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.71 157.08 53.71 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.853 1.449 . . . . 0.0 110.362 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.7 m -67.06 -23.89 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.595 -0.691 . . . . 0.0 110.636 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.1 m -59.98 -39.98 87.53 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.469 -0.769 . . . . 0.0 110.328 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -59.91 -50.13 74.96 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.483 -0.761 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.409 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.93 -26.1 63.98 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.684 -0.635 . . . . 0.0 110.097 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.8 tptm -58.74 129.95 44.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.437 -0.79 . . . . 0.0 110.311 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.95 -10.06 72.39 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.407 -0.902 . . . . 0.0 110.866 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 59.5 p -94.57 -3.22 50.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.0 -1.294 . . . . 0.0 111.251 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.079 -1.013 . . . . 0.0 109.667 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.24 -22.18 38.76 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -178.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.57 155.62 44.02 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -95.77 150.07 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.845 1.445 . . . . 0.0 111.219 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.404 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.7 mp -106.61 108.99 20.78 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -98.8 130.28 45.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 111.579 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.423 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.02 159.54 83.88 Favored Pre-proline 0 N--CA 1.495 1.815 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.9 -26.51 24.82 Favored 'Trans proline' 0 N--CA 1.501 1.929 0 O-C-N 123.494 1.26 . . . . 0.0 112.28 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.1 m -62.68 -39.96 95.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.258 -0.901 . . . . 0.0 109.99 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.23 35.99 0.84 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -131.8 149.47 52.45 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.409 -1.054 . . . . 0.0 110.314 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.21 139.96 56.06 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.66 -0.65 . . . . 0.0 110.272 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 64.7 t -114.46 -36.15 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.584 -0.697 . . . . 0.0 109.99 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 179.52 -166.61 36.03 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.401 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 96.6 mt -130.97 140.07 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.563 -0.963 . . . . 0.0 110.263 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -64.25 138.57 58.51 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.7 -0.625 . . . . 0.0 109.58 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -118.49 -52.25 2.37 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.473 -0.767 . . . . 0.0 110.428 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -152.79 160.06 43.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.593 -0.692 . . . . 0.0 110.184 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -109.81 151.88 26.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.616 -0.677 . . . . 0.0 110.256 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -108.47 116.97 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.662 -0.649 . . . . 0.0 109.751 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.3 p -129.88 142.39 50.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.653 -0.654 . . . . 0.0 110.254 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.1 m -69.69 -49.61 51.78 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.566 -0.709 . . . . 0.0 110.103 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -162.91 54.15 0.19 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.71 -0.619 . . . . 0.0 109.823 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 114.78 -18.51 16.89 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -112.9 120.77 63.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.29 -1.124 . . . . 0.0 109.758 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -86.61 130.1 34.62 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.549 -0.72 . . . . 0.0 110.522 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -112.47 -26.15 8.84 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.583 -0.698 . . . . 0.0 110.33 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.32 157.99 44.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.663 -0.648 . . . . 0.0 109.974 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.25 179.5 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.431 -0.793 . . . . 0.0 110.608 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -135.36 134.58 39.94 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -138.18 153.13 49.2 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.35 -0.844 . . . . 0.0 110.809 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 60.5 t -95.09 119.12 66.26 Favored Pre-proline 0 N--CA 1.493 1.675 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -62.38 155.23 58.75 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.771 1.406 . . . . 0.0 110.589 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 93.7 t -56.78 -23.18 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.611 -0.681 . . . . 0.0 110.669 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -60.04 -33.13 71.61 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.375 -0.828 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 18.4 t -60.07 -37.99 81.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.453 -0.78 . . . . 0.0 110.393 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.401 ' CE ' ' CD1' ' A' ' 153' ' ' ILE . 67.6 mtt -59.97 -39.97 87.46 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.521 -0.737 . . . . 0.0 110.502 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -62.31 -39.9 94.53 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.594 -0.691 . . . . 0.0 110.189 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.6 m -70.09 -39.97 75.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.596 -0.69 . . . . 0.0 109.965 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 84.8 m -59.98 -49.54 77.25 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.588 -0.695 . . . . 0.0 110.317 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.497 1.92 0 O-C-N 121.542 -0.723 . . . . 0.0 110.295 -179.935 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.046 0.45 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.408 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp . . . . . 0 N--CA 1.496 1.865 0 O-C-N 121.647 -0.658 . . . . 0.0 109.985 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 . . . . . 0 N--CA 1.495 1.776 0 CA-C-O 121.085 0.469 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 123.27 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.688 -0.632 . . . . 0.0 109.817 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -123.72 157.89 32.9 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.589 -0.695 . . . . 0.0 110.312 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 67.9 t -87.34 131.71 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.605 -0.685 . . . . 0.0 109.812 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.13 152.89 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.587 -0.696 . . . . 0.0 110.367 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 64.0 m -135.96 -177.89 4.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.705 -0.622 . . . . 0.0 110.34 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -144.75 -169.13 3.1 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.32 -38.67 80.87 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.395 -0.816 . . . . 0.0 110.098 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.1 t -138.58 -7.22 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.443 -0.786 . . . . 0.0 112.514 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -114.55 151.39 33.44 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.868 -1.145 . . . . 0.0 111.163 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -136.09 141.49 44.22 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.584 -0.697 . . . . 0.0 110.238 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -170.32 -177.53 2.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.426 -0.796 . . . . 0.0 110.023 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 54.1 mt -113.13 167.9 10.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.49 -0.756 . . . . 0.0 110.253 -178.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -145.9 160.04 42.38 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.664 -0.647 . . . . 0.0 110.265 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.8 t -120.57 140.2 51.85 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.597 -0.69 . . . . 0.0 110.18 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 37.7 t -99.23 109.96 22.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.417 -0.802 . . . . 0.0 110.407 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.19 130.03 64.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.541 -0.724 . . . . 0.0 109.701 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 56.14 39.93 30.25 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.544 -0.723 . . . . 0.0 110.868 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.94 19.92 75.73 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.0 t -131.06 130.01 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.267 -1.137 . . . . 0.0 109.958 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 78.4 m -77.41 140.43 39.89 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.415 -0.803 . . . . 0.0 109.461 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -130.62 147.09 52.25 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.517 -0.739 . . . . 0.0 110.936 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.439 HG22 ' CZ3' ' A' ' 85' ' ' TRP . 6.4 t -167.66 -179.19 4.21 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.464 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.6 p -88.68 156.63 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 110.356 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -70.04 -44.37 69.36 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.594 -0.691 . . . . 0.0 111.887 -178.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.464 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.9 p-80 -60.78 -24.26 65.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.195 -0.941 . . . . 0.0 110.787 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -77.1 -48.96 7.88 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -128.49 101.09 6.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.784 -0.833 . . . . 0.0 109.534 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.26 -164.93 2.34 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 35.0 p -72.21 65.92 0.62 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.655 -0.909 . . . . 0.0 109.844 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.39 169.87 16.77 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.604 -0.685 . . . . 0.0 110.595 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.7 p -69.89 159.92 32.78 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.579 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.453 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 16.0 tp -115.51 140.8 48.83 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.543 -0.723 . . . . 0.0 110.335 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.91 109.7 22.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.576 -0.702 . . . . 0.0 110.109 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.63 179.98 16.32 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.99 -32.34 65.21 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.854 1.45 . . . . 0.0 110.431 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 87.0 mttt -71.08 -31.49 67.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.663 -0.648 . . . . 0.0 110.037 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.11 -162.2 25.99 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.02 137.82 38.59 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.866 1.456 . . . . 0.0 110.155 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.7 mt -120.06 130.04 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.615 -0.678 . . . . 0.0 110.49 -179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 77.8 p -80.4 149.98 29.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.927 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -100.86 144.42 29.84 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.523 -0.736 . . . . 0.0 111.218 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 30.2 mtm -117.3 -21.76 8.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.631 . . . . 0.0 110.59 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -125.57 147.44 49.28 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.417 -0.802 . . . . 0.0 110.403 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.9 t -169.32 129.72 1.08 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.59 -0.694 . . . . 0.0 109.921 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.607 -0.683 . . . . 0.0 110.258 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 69.3 t -69.8 -49.61 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.582 -0.699 . . . . 0.0 109.811 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -60.28 -48.57 81.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.606 -0.684 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -79.33 -10.11 59.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.634 -0.666 . . . . 0.0 110.612 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.0 t70 54.16 49.94 17.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.15 -0.969 . . . . 0.0 110.701 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 39.0 mt -143.25 130.98 21.38 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.385 -0.822 . . . . 0.0 111.43 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.03 159.98 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.609 -0.682 . . . . 0.0 109.592 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.14 159.06 27.82 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.453 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 9.3 m-90 -122.52 160.03 26.46 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.747 -0.855 . . . . 0.0 109.725 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -77.79 107.77 10.53 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.543 -0.723 . . . . 0.0 109.51 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.45 137.84 86.29 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.594 -0.691 . . . . 0.0 110.291 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.04 158.79 55.45 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 O-C-N 123.93 1.49 . . . . 0.0 110.221 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.64 146.48 61.06 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.976 1.514 . . . . 0.0 110.388 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.94 -26.37 24.72 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -68.06 140.05 56.27 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.46 -1.023 . . . . 0.0 110.119 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -81.82 158.62 24.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.522 -0.736 . . . . 0.0 109.884 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -130.07 169.76 14.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.573 -0.704 . . . . 0.0 110.167 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.0 mt -106.03 131.91 52.75 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.625 -0.672 . . . . 0.0 110.731 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -73.66 160.03 83.11 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.577 -0.702 . . . . 0.0 109.793 179.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -77.35 161.12 32.04 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.787 1.414 . . . . 0.0 110.636 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.8 t -74.07 129.91 38.77 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.722 -0.611 . . . . 0.0 110.134 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -132.85 54.12 1.97 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.679 -0.638 . . . . 0.0 109.689 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.62 -8.12 0.75 Allowed 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.371 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.97 42.57 98.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.97 119.93 39.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.525 -0.985 . . . . 0.0 110.422 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.6 m -63.31 -39.99 96.11 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 110.48 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -60.71 129.98 44.25 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.561 -0.712 . . . . 0.0 110.481 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 93.2 mt -133.08 150.19 52.1 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.673 -0.642 . . . . 0.0 110.404 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -115.72 121.37 42.31 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.483 -0.76 . . . . 0.0 109.948 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 44.6 tp -101.05 143.82 30.71 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.528 -0.732 . . . . 0.0 110.369 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.7 t -108.87 129.12 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.57 -0.706 . . . . 0.0 109.87 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 75.2 p -106.26 178.85 4.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.543 -0.723 . . . . 0.0 110.597 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 68.3 mtm180 -59.98 -28.26 67.53 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.594 -0.691 . . . . 0.0 110.58 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -90.3 19.08 5.39 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.467 -0.77 . . . . 0.0 111.122 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.51 40.02 30.81 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.102 -0.999 . . . . 0.0 110.706 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -100.16 139.34 35.97 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.73 -0.606 . . . . 0.0 109.936 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 64.7 t -93.74 117.39 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.624 -0.672 . . . . 0.0 109.955 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . 0.46 HG22 HD11 ' A' ' 114' ' ' ILE . 86.9 mt -107.53 110.05 62.73 Favored Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.694 -0.629 . . . . 0.0 109.599 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.85 116.4 4.55 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 123.886 1.466 . . . . 0.0 110.462 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.1 t -120.01 125.2 74.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.678 -0.639 . . . . 0.0 109.643 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -86.23 130.03 34.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.572 -0.705 . . . . 0.0 109.97 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.75 127.87 33.71 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.622 -0.674 . . . . 0.0 110.376 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 12.0 mmm180 -129.68 22.21 5.47 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.665 -0.647 . . . . 0.0 110.245 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.51 -179.75 43.07 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -67.51 -40.66 85.15 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.591 -0.946 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.7 p -131.67 22.51 4.66 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.493 -0.754 . . . . 0.0 110.743 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.38 151.93 51.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.384 -0.822 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.46 -173.98 18.17 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -125.49 154.91 41.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.641 -0.917 . . . . 0.0 110.162 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 25.1 tp -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.575 -0.703 . . . . 0.0 110.207 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -68.37 -36.61 79.44 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 0.0 109.964 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -111.04 113.05 55.06 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.685 -0.635 . . . . 0.0 110.039 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.28 116.57 3.82 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.726 1.382 . . . . 0.0 110.545 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -128.03 160.04 63.64 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.602 -0.686 . . . . 0.0 110.082 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.71 157.09 62.77 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.907 1.477 . . . . 0.0 110.398 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.4 m -66.12 -24.78 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.614 -0.679 . . . . 0.0 110.487 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.2 t -59.88 -38.44 82.22 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.456 -0.778 . . . . 0.0 110.332 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.585 -0.697 . . . . 0.0 110.342 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 10.7 mp -83.11 -16.86 45.17 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.477 -0.765 . . . . 0.0 111.038 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.59 140.01 58.83 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.269 -0.894 . . . . 0.0 110.078 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.56 6.05 89.11 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 63.2 m -112.58 19.48 17.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.129 -1.218 . . . . 0.0 110.757 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -72.28 147.91 45.94 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.304 -0.873 . . . . 0.0 109.935 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.58 -15.31 60.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.02 139.98 48.17 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -87.79 148.93 7.2 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 O-C-N 123.77 1.405 . . . . 0.0 111.224 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.8 mp -105.6 120.02 40.59 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -108.77 131.18 55.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.463 -0.773 . . . . 0.0 111.704 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.441 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.97 82.09 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.4 Cg_endo -51.72 -23.12 14.8 Favored 'Trans proline' 0 N--CA 1.502 2.004 0 O-C-N 123.51 1.268 . . . . 0.0 112.272 -178.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -66.32 -39.98 89.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.247 -0.908 . . . . 0.0 109.89 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.25 34.67 0.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -131.77 144.72 51.15 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.422 -1.046 . . . . 0.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -69.91 138.67 52.63 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.515 -0.74 . . . . 0.0 110.125 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.3 p -118.05 -21.87 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.591 -0.693 . . . . 0.0 110.814 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 178.68 -173.75 46.02 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 95.5 mt -131.55 139.99 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.605 -0.938 . . . . 0.0 110.096 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.2 t80 -61.0 139.64 58.0 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.579 -0.7 . . . . 0.0 110.148 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -120.21 -52.02 2.19 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.59 -0.694 . . . . 0.0 110.333 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.87 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.571 -0.706 . . . . 0.0 110.432 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.01 153.88 23.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.552 -0.717 . . . . 0.0 110.408 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.05 119.22 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.637 -0.664 . . . . 0.0 109.888 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -137.07 158.59 44.11 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.683 . . . . 0.0 110.307 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 6.2 p -99.0 -51.95 3.7 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.595 -0.691 . . . . 0.0 110.486 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -142.94 63.06 1.39 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.565 -0.709 . . . . 0.0 110.013 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.99 -8.81 79.14 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.66 126.55 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.193 -1.181 . . . . 0.0 109.967 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.58 131.69 46.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.6 -0.687 . . . . 0.0 110.372 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -113.66 -15.42 12.49 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.565 -0.709 . . . . 0.0 110.746 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 158.71 43.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.345 -0.847 . . . . 0.0 109.846 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.04 160.01 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.523 -0.736 . . . . 0.0 110.546 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -123.04 136.11 54.71 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.732 -0.605 . . . . 0.0 109.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -139.11 160.0 40.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.497 -0.752 . . . . 0.0 110.457 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.6 t -99.89 124.6 43.21 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.59 -0.693 . . . . 0.0 109.553 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -65.34 147.59 87.64 Favored 'Trans proline' 0 N--CA 1.489 1.259 0 O-C-N 123.82 1.432 . . . . 0.0 110.186 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 35.7 m -60.6 -24.68 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.68 -0.638 . . . . 0.0 110.996 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -60.5 -39.97 89.67 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.485 -0.759 . . . . 0.0 110.693 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.2 p -61.67 -43.3 99.11 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.434 -0.791 . . . . 0.0 110.906 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.1 mtm -63.54 -39.98 95.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.825 . . . . 0.0 110.456 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -60.43 -40.01 89.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.424 -0.798 . . . . 0.0 110.029 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.0 m -70.23 -26.11 63.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.632 -0.668 . . . . 0.0 110.528 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.7 m -59.94 -40.83 90.29 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.517 -0.739 . . . . 0.0 110.282 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.2 mtt . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.471 -0.768 . . . . 0.0 110.208 179.883 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 60.2 tt0 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.03 0.443 . . . . 0.0 110.131 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . . . . . . . . . 8.8 mp . . . . . 0 N--CA 1.495 1.788 0 O-C-N 121.608 -0.682 . . . . 0.0 110.222 179.973 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 . . . . . 0 N--CA 1.496 1.848 0 CA-C-O 120.87 0.367 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.0 t -108.94 127.56 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.492 -0.755 . . . . 0.0 109.799 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -121.16 155.5 34.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.666 -0.647 . . . . 0.0 110.345 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 63.7 t -91.52 120.59 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.668 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 33.4 m -116.56 158.32 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.659 -0.651 . . . . 0.0 110.156 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 33.0 m -145.68 172.77 12.79 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.126 -0.629 . . . . 0.0 110.577 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.93 -172.38 2.91 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.19 88.56 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.374 -0.829 . . . . 0.0 110.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 23.2 m -131.47 -7.12 3.72 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.526 -0.734 . . . . 0.0 111.975 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -113.96 159.71 19.62 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.967 -1.083 . . . . 0.0 110.906 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.2 t -146.1 136.96 24.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.403 ' CE1' ' O ' ' A' ' 58' ' ' GLY . 25.0 p90 -166.72 -177.42 3.89 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.315 -0.866 . . . . 0.0 110.528 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.3 mt -113.05 159.07 19.54 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.598 -0.689 . . . . 0.0 110.81 -178.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -133.4 156.69 47.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.643 -0.661 . . . . 0.0 110.044 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 47.3 m -121.82 134.57 54.9 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.444 -0.785 . . . . 0.0 110.44 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 31.7 t -92.76 110.44 21.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.56 -0.713 . . . . 0.0 110.594 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.416 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 63.1 t -119.46 134.84 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.593 -0.692 . . . . 0.0 109.641 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 54.93 38.37 30.33 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.534 -0.729 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 26.04 74.81 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.4 t -139.9 131.73 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.364 -1.08 . . . . 0.0 109.906 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.8 m -75.29 148.57 39.27 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.377 -0.827 . . . . 0.0 109.181 179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.44 ' CG ' ' CE ' ' A' ' 175' ' ' MET . 60.8 m95 -129.99 151.04 50.97 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.726 0.774 . . . . 0.0 111.313 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.459 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -169.37 -179.88 3.64 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.451 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 12.4 p -95.62 155.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.828 . . . . 0.0 110.37 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -70.01 -40.86 75.0 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.509 -0.745 . . . . 0.0 111.599 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.451 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.9 p-80 -70.04 -24.4 63.26 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.148 -0.97 . . . . 0.0 110.621 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.403 ' O ' ' CE1' ' A' ' 43' ' ' PHE . . . -83.38 -56.28 2.71 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -101.97 -53.51 2.92 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.756 -0.849 . . . . 0.0 109.964 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.08 -168.99 46.87 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 97.9 p -86.48 64.45 8.54 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.644 -0.915 . . . . 0.0 109.911 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -140.27 170.02 16.6 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.533 -0.729 . . . . 0.0 110.38 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.9 m -65.3 139.59 58.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.549 -0.719 . . . . 0.0 110.043 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.454 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -113.56 136.22 53.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.64 -0.663 . . . . 0.0 110.014 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.28 119.08 33.17 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -123.05 176.42 16.6 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.69 -32.36 68.49 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.852 1.449 . . . . 0.0 110.414 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -71.89 -31.32 66.29 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.629 -0.67 . . . . 0.0 110.169 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.86 -156.57 26.72 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -70.04 154.33 66.76 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.872 1.459 . . . . 0.0 110.359 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.5 mt -130.35 142.65 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.579 -0.7 . . . . 0.0 110.311 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.4 p -99.47 139.98 34.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.496 -0.752 . . . . 0.0 110.591 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.5 mm100 -71.04 144.55 50.35 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.613 -0.679 . . . . 0.0 111.216 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 95.1 mmm -119.21 -45.41 2.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.65 -0.656 . . . . 0.0 110.211 179.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -120.02 139.94 51.74 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.592 -0.693 . . . . 0.0 110.449 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 30.3 p -130.48 139.92 50.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.58 -0.7 . . . . 0.0 110.329 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -148.33 82.59 1.48 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.616 -0.678 . . . . 0.0 110.083 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 94.2 t -62.34 -44.68 99.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.634 -0.666 . . . . 0.0 110.011 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.96 -44.54 94.36 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.508 -0.745 . . . . 0.0 110.216 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.8 tp60 -89.97 -0.0 57.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.514 -0.741 . . . . 0.0 111.002 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.2 t70 52.79 49.63 19.85 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.016 -1.052 . . . . 0.0 110.498 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 54.9 mt -140.02 144.51 36.97 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.601 -0.687 . . . . 0.0 111.101 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 34.9 m -149.93 159.67 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.565 -0.709 . . . . 0.0 109.611 179.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.58 28.24 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.459 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 8.5 m-90 -120.9 159.98 24.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.824 -0.81 . . . . 0.0 109.742 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -68.45 122.47 18.5 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.425 -0.797 . . . . 0.0 109.373 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -75.42 130.54 79.52 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.538 -0.726 . . . . 0.0 110.187 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.06 159.97 51.29 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.887 1.467 . . . . 0.0 110.293 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.21 160.13 50.2 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 O-C-N 123.883 1.465 . . . . 0.0 110.275 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.58 29.43 69.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.06 156.64 21.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.615 -0.932 . . . . 0.0 110.113 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -99.12 139.72 34.35 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.0 p -118.84 157.74 27.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.616 -0.677 . . . . 0.0 110.181 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 76.7 mt -112.32 131.53 55.47 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.566 -0.709 . . . . 0.0 110.563 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.6 p -82.2 159.99 63.79 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.565 -0.709 . . . . 0.0 109.969 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.61 165.81 30.72 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.823 1.433 . . . . 0.0 110.4 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 13.5 t -87.2 149.98 24.24 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.891 0.853 . . . . 0.0 110.367 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.6 m -133.91 62.21 1.66 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 m -141.57 -9.02 0.95 Allowed 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.831 -177.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.51 26.45 56.95 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 79.5 p -80.02 160.0 26.02 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.461 -1.023 . . . . 0.0 110.493 -179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.7 m -107.42 -27.07 10.67 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.707 -0.62 . . . . 0.0 110.329 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -73.83 129.37 37.77 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.75 . . . . 0.0 110.015 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 85.0 mt -135.3 150.05 49.92 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.576 -0.703 . . . . 0.0 110.662 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -108.69 119.94 41.0 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.492 -0.755 . . . . 0.0 109.562 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.0 tp -100.97 141.51 33.75 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.48 -0.762 . . . . 0.0 110.78 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.88 130.03 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.631 -0.668 . . . . 0.0 109.703 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 73.9 p -111.89 169.97 8.47 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.442 -0.786 . . . . 0.0 110.705 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 23.1 ptt-85 -64.68 -16.17 62.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.611 -0.68 . . . . 0.0 111.005 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -89.97 17.4 6.86 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.222 -0.923 . . . . 0.0 110.828 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.44 40.01 31.46 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.081 -1.012 . . . . 0.0 110.51 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -113.38 156.56 23.22 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.658 -0.651 . . . . 0.0 109.853 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.6 p -130.0 130.36 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.551 -0.718 . . . . 0.0 110.233 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 16.1 tt -131.86 130.06 22.11 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.69 -0.631 . . . . 0.0 109.893 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.71 126.79 12.37 Favored 'Trans proline' 0 N--CA 1.49 1.265 0 O-C-N 123.856 1.45 . . . . 0.0 110.355 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -120.04 125.58 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.692 -0.63 . . . . 0.0 109.72 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -86.23 149.99 24.7 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.484 -0.76 . . . . 0.0 110.059 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 70.0 ttp85 -93.71 120.65 34.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -110.01 20.0 18.41 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.649 -0.657 . . . . 0.0 110.349 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.55 -177.26 42.61 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.94 -40.03 91.72 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.526 -0.985 . . . . 0.0 110.281 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.6 p -132.33 26.43 4.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.521 -0.737 . . . . 0.0 110.394 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 16.6 tpt180 -124.35 139.97 53.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.451 -0.781 . . . . 0.0 110.495 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.54 167.22 25.35 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 78.3 p -118.95 152.33 36.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.937 . . . . 0.0 110.104 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -94.17 119.09 32.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.556 -0.715 . . . . 0.0 110.118 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.2 mp -65.79 -40.0 91.5 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.57 -0.706 . . . . 0.0 109.951 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 58.6 m -111.43 118.59 47.04 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.674 -0.641 . . . . 0.0 110.109 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.54 117.42 4.59 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 O-C-N 123.73 1.384 . . . . 0.0 110.352 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 21.3 mtt180 -129.87 159.95 67.4 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.54 -0.725 . . . . 0.0 110.267 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.27 160.22 43.34 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 O-C-N 123.931 1.49 . . . . 0.0 110.414 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 33.6 m -67.39 -25.02 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.665 -0.647 . . . . 0.0 110.816 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.4 p -59.96 -40.06 87.76 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.453 -0.779 . . . . 0.0 110.224 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -59.87 -49.82 76.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.534 -0.728 . . . . 0.0 110.023 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.404 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -70.03 -30.45 67.74 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.611 -0.681 . . . . 0.0 109.82 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 tptm -59.92 131.02 49.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.596 -0.69 . . . . 0.0 110.156 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.2 62.66 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.5 m -116.27 12.84 15.5 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.127 -1.219 . . . . 0.0 110.888 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.1 t -62.03 145.15 53.95 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.292 -0.88 . . . . 0.0 109.915 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.06 -12.08 68.8 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.94 140.39 47.9 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -92.05 150.31 3.2 Favored 'Trans proline' 0 C--N 1.316 -1.168 0 O-C-N 123.85 1.448 . . . . 0.0 111.393 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 9.7 mp -100.39 103.05 14.42 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.9 mp -85.74 149.54 25.21 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-O 122.083 0.944 . . . . 0.0 112.289 -177.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 1.6 t -87.78 145.2 36.32 Favored Pre-proline 0 N--CA 1.492 1.655 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -53.71 -24.8 31.45 Favored 'Trans proline' 0 N--CA 1.502 1.98 0 O-C-N 123.291 1.153 . . . . 0.0 110.375 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.3 m -71.87 -36.51 70.13 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.33 39.77 0.57 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 38.5 m170 -130.02 138.69 50.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.438 -1.037 . . . . 0.0 110.594 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.95 141.55 58.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.444 -0.785 . . . . 0.0 109.899 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.9 t -115.3 -44.0 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.508 -0.745 . . . . 0.0 110.582 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -170.64 -171.07 35.63 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.2 mt -132.92 140.03 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.937 . . . . 0.0 110.441 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -67.87 138.09 55.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.623 -0.673 . . . . 0.0 109.811 179.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.8 ttp180 -124.24 -52.58 1.74 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.538 -0.726 . . . . 0.0 110.499 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -139.78 159.5 42.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.514 -0.741 . . . . 0.0 110.286 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.41 136.45 54.96 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.604 -0.685 . . . . 0.0 110.612 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.1 t -93.7 119.82 42.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.37 159.91 40.58 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.235 -179.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 76.1 p -138.88 142.28 38.58 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 53.76 28.01 7.69 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.289 -0.882 . . . . 0.0 110.671 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 80.69 22.89 61.04 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.5 t -129.98 129.99 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.265 -1.138 . . . . 0.0 110.039 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -91.54 124.03 35.4 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.26 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 40.9 mttm -112.72 -26.38 8.63 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.587 -0.696 . . . . 0.0 110.352 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.2 161.57 38.54 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.532 -0.73 . . . . 0.0 109.838 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.03 178.49 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.517 -0.739 . . . . 0.0 111.476 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -134.03 135.52 43.42 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -139.99 145.59 38.03 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.326 -0.859 . . . . 0.0 110.719 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 72.9 t -86.7 124.72 68.88 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.627 -0.671 . . . . 0.0 109.353 179.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -66.54 162.52 36.46 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.845 1.444 . . . . 0.0 110.343 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 96.8 t -70.03 -24.67 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.681 -0.637 . . . . 0.0 110.487 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -57.93 -39.93 79.21 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.375 -0.828 . . . . 0.0 110.575 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.6 p -69.31 -38.43 78.24 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.44 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 93.0 mtp -60.19 -40.52 90.34 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.654 -0.654 . . . . 0.0 110.35 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -69.26 -39.97 78.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.623 -0.673 . . . . 0.0 110.336 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.12 -39.92 91.84 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.606 -0.684 . . . . 0.0 110.074 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.7 m -60.11 -47.52 85.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.545 -0.722 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.631 -0.668 . . . . 0.0 110.41 -179.765 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.166 0.508 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.416 HD22 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.531 -0.731 . . . . 0.0 110.234 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 121.136 0.493 . . . . 0.0 110.214 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -102.64 126.52 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.701 . . . . 0.0 110.037 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -117.21 151.61 36.55 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.564 -0.71 . . . . 0.0 110.146 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.7 p -89.67 136.15 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.512 -0.743 . . . . 0.0 110.069 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -129.7 136.97 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.695 -0.628 . . . . 0.0 110.006 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.6 m -136.13 170.93 15.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -133.11 -170.67 2.51 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.636 -0.665 . . . . 0.0 109.449 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.3 -24.2 67.57 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.642 -0.661 . . . . 0.0 111.427 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.3 t -137.24 -15.45 1.47 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.133 -0.979 . . . . 0.0 113.175 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -125.29 149.66 47.85 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.872 -1.143 . . . . 0.0 111.249 -178.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 29.2 p -132.77 142.36 48.97 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.824 -0.548 . . . . 0.0 110.094 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -163.91 -177.33 5.03 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.469 -0.769 . . . . 0.0 109.88 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 29.1 mt -112.46 179.18 4.06 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.391 -0.818 . . . . 0.0 110.775 -177.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -155.36 160.34 40.63 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.784 -0.573 . . . . 0.0 109.725 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.1 t -125.65 138.41 53.91 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.481 -0.762 . . . . 0.0 110.231 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.9 t -96.66 107.01 19.38 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.474 -0.766 . . . . 0.0 110.653 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.427 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.2 t -110.35 130.0 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.717 -0.614 . . . . 0.0 109.348 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 56.84 36.37 27.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.502 -0.749 . . . . 0.0 110.725 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.28 17.7 79.71 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.2 t -131.21 130.03 63.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.942 0 O-C-N 121.118 -1.225 . . . . 0.0 110.102 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.3 t -73.06 150.05 42.66 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.511 -0.743 . . . . 0.0 109.592 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.427 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 87.4 m95 -135.72 150.0 49.4 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.528 -0.733 . . . . 0.0 110.93 -179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.435 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.0 t -168.51 -179.69 3.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.856 -0.528 . . . . 0.0 109.584 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.466 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.4 p -91.46 157.2 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.018 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.417 ' CZ ' HG23 ' A' ' 78' ' ' VAL . 57.7 t80 -72.93 -43.65 62.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.543 -0.723 . . . . 0.0 112.14 -178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.466 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.8 p-80 -60.84 -24.63 66.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.12 -0.988 . . . . 0.0 110.714 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.419 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -90.85 -35.51 7.18 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.362 -1.895 . . . . 0.0 108.362 178.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -135.59 97.0 3.56 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.792 -0.828 . . . . 0.0 109.879 179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -80.03 -166.24 33.24 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 79.1 p -72.26 65.84 0.62 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.626 -0.926 . . . . 0.0 109.631 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.22 169.82 16.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.0 110.382 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.0 m -74.94 139.25 42.88 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.661 -0.649 . . . . 0.0 110.141 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -108.51 133.47 52.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.626 -0.671 . . . . 0.0 109.705 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.71 112.72 20.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.636 -0.665 . . . . 0.0 110.209 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -112.2 -176.74 19.95 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.79 -32.65 67.17 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.854 1.45 . . . . 0.0 110.499 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -74.93 -31.12 61.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.667 -0.646 . . . . 0.0 109.934 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.65 -144.17 13.27 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.61 155.13 49.94 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.817 1.43 . . . . 0.0 110.238 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 49.1 mm -129.49 139.93 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.558 -0.714 . . . . 0.0 110.455 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 80.5 m -101.04 120.92 40.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.567 -0.708 . . . . 0.0 110.076 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.4 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 32.2 tt0 -77.0 139.53 40.1 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.546 -0.721 . . . . 0.0 110.681 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 42.2 mtp -109.95 -30.01 8.0 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.663 -0.648 . . . . 0.0 110.441 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -112.85 138.42 49.72 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.523 -0.736 . . . . 0.0 110.612 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.0 p -139.41 126.91 21.62 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.706 -0.621 . . . . 0.0 110.023 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 -142.02 90.97 2.3 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.489 -0.757 . . . . 0.0 110.26 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.417 HG23 ' CZ ' ' A' ' 56' ' ' TYR . 91.1 t -66.26 -40.35 86.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.6 -0.687 . . . . 0.0 109.882 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.58 -45.01 95.53 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.647 -0.658 . . . . 0.0 110.601 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.6 tp60 -87.79 -0.01 56.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.504 -0.747 . . . . 0.0 110.816 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.6 t70 53.54 42.71 31.88 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.055 -1.028 . . . . 0.0 110.538 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 67.0 mt -140.92 147.69 39.25 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.45 -0.781 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 34.6 m -148.32 177.1 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.695 -0.628 . . . . 0.0 109.404 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -156.29 158.25 28.51 Favored Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.838 -1.172 . . . . 0.0 110.518 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.435 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.0 m-90 -120.38 160.77 22.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.816 -0.814 . . . . 0.0 109.848 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.2 tt0 -75.2 109.96 9.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.57 -0.706 . . . . 0.0 109.297 179.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.89 153.96 87.21 Favored Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.545 -0.722 . . . . 0.0 110.01 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.09 159.69 52.28 Favored 'Trans proline' 0 N--CA 1.488 1.196 0 O-C-N 123.83 1.437 . . . . 0.0 110.281 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.06 141.71 71.26 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.95 1.5 . . . . 0.0 110.357 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.18 27.47 72.84 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.19 149.87 26.57 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.467 -1.019 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 13.3 tpt180 -87.74 139.23 30.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.616 -0.678 . . . . 0.0 109.308 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.2 p -128.99 168.38 16.11 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.426 -0.796 . . . . 0.0 110.554 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 34.7 mt -111.65 131.97 54.91 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.735 -0.603 . . . . 0.0 110.714 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.404 ' OG1' ' CD2' ' A' ' 149' ' ' HIS . 73.8 p -74.76 159.95 81.98 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 109.799 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.29 161.01 46.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 O-C-N 123.865 1.456 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.8 t -70.25 134.73 48.31 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.721 -0.612 . . . . 0.0 110.063 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 22.4 p -136.15 52.35 1.98 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.667 -0.646 . . . . 0.0 109.827 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.1 p -143.81 -8.09 0.73 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.516 -0.74 . . . . 0.0 112.387 -179.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.01 42.26 98.3 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 54.0 m -100.0 120.04 39.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -1.04 . . . . 0.0 110.305 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.3 m -62.83 -40.05 96.22 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.579 -0.701 . . . . 0.0 110.429 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 137.54 58.06 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.538 -0.726 . . . . 0.0 110.497 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 89.3 mt -138.47 142.84 39.43 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.637 -0.664 . . . . 0.0 110.643 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -106.85 120.37 41.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.587 -0.696 . . . . 0.0 109.581 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.1 tp -102.57 146.16 28.56 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.406 -0.809 . . . . 0.0 110.829 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.4 t -105.34 130.01 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.676 -0.64 . . . . 0.0 109.647 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 76.3 p -98.25 173.57 6.93 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.573 -0.704 . . . . 0.0 111.004 -179.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 61.9 ttt-85 -70.0 -24.26 63.27 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.745 -0.597 . . . . 0.0 110.514 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -94.03 29.25 2.18 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.44 -0.787 . . . . 0.0 110.737 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.42 40.03 31.26 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.308 -0.87 . . . . 0.0 110.724 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -116.1 145.94 42.63 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.528 -0.733 . . . . 0.0 109.542 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.9 p -130.0 133.59 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.538 -0.726 . . . . 0.0 110.575 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 81.3 mt -124.91 150.06 64.95 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.651 -0.655 . . . . 0.0 109.485 179.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -81.46 123.05 4.22 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.945 1.498 . . . . 0.0 110.593 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 61.2 t -119.91 124.32 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 109.648 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -81.96 130.61 35.13 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.527 -0.733 . . . . 0.0 110.049 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -77.45 128.23 33.87 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.68 -0.638 . . . . 0.0 110.344 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -119.46 23.02 11.45 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.662 -0.649 . . . . 0.0 110.429 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.75 176.9 38.2 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -60.12 -40.82 91.07 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.54 -0.976 . . . . 0.0 110.127 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 20.8 p -130.0 27.4 5.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.622 -0.674 . . . . 0.0 110.331 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 3.1 tpt85 -128.93 137.06 51.19 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.461 -0.774 . . . . 0.0 110.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.2 166.57 26.0 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -124.87 146.22 49.41 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.558 -0.966 . . . . 0.0 110.058 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mp -97.73 125.25 42.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -66.73 -40.04 88.22 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.544 -0.723 . . . . 0.0 109.81 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.6 m -107.55 114.32 60.73 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.661 -0.649 . . . . 0.0 109.94 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.28 124.49 13.02 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.839 1.441 . . . . 0.0 110.487 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.9 mmt180 -120.48 160.09 45.38 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.641 -0.662 . . . . 0.0 109.972 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.33 156.67 62.01 Favored 'Trans proline' 0 N--CA 1.489 1.257 0 O-C-N 123.942 1.496 . . . . 0.0 110.385 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.7 t -66.83 -29.93 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.596 -0.69 . . . . 0.0 110.003 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.9 m -59.95 -40.05 87.67 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.482 -0.762 . . . . 0.0 110.352 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -61.76 -40.0 93.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.75 . . . . 0.0 109.994 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 4.5 mm? -69.22 -30.43 68.58 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.595 -0.691 . . . . 0.0 110.479 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 mmmm -60.01 140.4 56.81 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.388 -0.82 . . . . 0.0 110.246 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.01 14.67 80.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.0 m -114.78 10.06 16.46 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.283 -1.127 . . . . 0.0 110.936 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.7 m -62.06 140.2 58.39 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.223 -0.923 . . . . 0.0 110.048 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.75 -18.15 57.29 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.43 113.76 5.21 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.56 150.21 24.54 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.833 1.438 . . . . 0.0 110.82 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.407 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 6.5 mp -101.49 109.1 20.85 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -100.0 129.96 46.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.555 -0.716 . . . . 0.0 111.064 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 27.3 p -69.9 158.64 86.74 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.725 -0.61 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -53.77 -20.87 18.35 Favored 'Trans proline' 0 N--CA 1.501 1.925 0 O-C-N 123.634 1.333 . . . . 0.0 112.56 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.8 p -67.22 -36.47 81.75 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.077 -1.015 . . . . 0.0 109.917 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 119.4 34.65 0.99 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . 0.404 ' CD2' ' OG1' ' A' ' 95' ' ' THR . 33.1 m170 -131.83 146.79 52.33 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.431 -1.04 . . . . 0.0 110.175 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.53 146.46 50.18 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.581 -0.699 . . . . 0.0 110.293 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 57.4 t -117.69 -40.1 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.579 -0.701 . . . . 0.0 109.991 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.22 -168.85 34.22 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 93.8 mt -133.19 140.01 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.487 -1.008 . . . . 0.0 110.464 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -59.98 139.03 57.69 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.547 -0.72 . . . . 0.0 110.036 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 29.9 ttp85 -123.19 -52.01 1.86 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.573 -0.704 . . . . 0.0 110.186 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -146.9 160.41 42.36 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.677 . . . . 0.0 110.295 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.21 144.49 44.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.559 -0.713 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.7 t -110.03 120.05 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 120.18 -0.608 . . . . 0.0 109.807 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.4 145.87 51.88 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.689 -0.632 . . . . 0.0 110.345 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.5 m -70.05 -49.2 53.58 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.61 -0.681 . . . . 0.0 110.265 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -163.92 53.83 0.15 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.574 -0.703 . . . . 0.0 109.889 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 116.11 -17.58 14.76 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.11 126.3 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.217 -1.167 . . . . 0.0 109.777 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.54 126.95 40.15 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.567 -0.708 . . . . 0.0 110.398 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -112.29 -18.1 12.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.604 -0.685 . . . . 0.0 110.717 179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -149.1 159.14 44.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.218 -0.926 . . . . 0.0 110.157 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.8 m -140.01 166.86 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.531 -0.731 . . . . 0.0 110.853 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -119.97 136.78 54.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.655 -0.653 . . . . 0.0 109.773 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -138.04 155.68 48.56 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.493 -0.754 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 60.4 t -92.91 123.89 60.02 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.621 -0.674 . . . . 0.0 109.578 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.22 154.0 75.57 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.842 1.443 . . . . 0.0 110.581 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.1 t -59.91 -23.47 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.594 -0.691 . . . . 0.0 110.575 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -58.16 -38.36 76.47 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.444 -0.785 . . . . 0.0 110.555 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.6 p -60.03 -37.11 78.79 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.311 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.4 mtt -60.13 -40.02 88.29 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.466 -0.771 . . . . 0.0 110.441 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -60.16 -41.27 92.44 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.565 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 73.5 p -72.92 -40.04 65.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.44 -0.787 . . . . 0.0 110.311 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.9 m -70.06 -44.4 69.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.622 -0.674 . . . . 0.0 110.121 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.337 -179.721 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.061 0.457 . . . . 0.0 110.088 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.42 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.634 -0.666 . . . . 0.0 110.231 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . 0.402 ' CG ' ' CG ' ' A' ' 92' ' ' ARG . 47.7 mt-10 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 121.115 0.483 . . . . 0.0 110.041 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -107.13 125.42 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 0.0 109.952 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -115.75 143.26 45.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.515 -0.741 . . . . 0.0 110.413 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.42 132.65 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.588 -0.695 . . . . 0.0 109.987 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 26.7 m -128.77 159.86 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.634 -0.666 . . . . 0.0 109.972 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 m -139.43 160.52 39.65 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.62 -0.675 . . . . 0.0 110.478 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.37 -176.93 3.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.758 -0.589 . . . . 0.0 109.841 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.68 -12.53 59.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.622 -0.674 . . . . 0.0 110.803 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 41.7 p -120.04 -30.02 4.78 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.242 -0.911 . . . . 0.0 111.191 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -156.39 169.58 24.26 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.281 -0.887 . . . . 0.0 110.633 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.0 p -126.84 158.28 37.08 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.591 -0.693 . . . . 0.0 110.438 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.405 ' CE2' ' O ' ' A' ' 58' ' ' GLY . 24.8 p90 -168.98 -176.38 2.62 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.507 -0.746 . . . . 0.0 109.89 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.8 mt -111.83 176.36 5.05 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.491 -0.755 . . . . 0.0 110.454 -178.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -147.91 159.98 43.29 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.786 -0.571 . . . . 0.0 110.069 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 39.8 p -120.17 130.88 54.79 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.577 -0.702 . . . . 0.0 110.525 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 33.8 t -92.52 109.66 21.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.429 -0.794 . . . . 0.0 110.386 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.428 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.6 t -119.2 131.74 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.603 -0.685 . . . . 0.0 109.641 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.57 39.35 27.77 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.539 -0.726 . . . . 0.0 110.845 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.03 20.04 75.98 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.69 130.01 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.143 -1.21 . . . . 0.0 110.022 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 94.1 m -72.63 149.93 43.48 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.44 -0.788 . . . . 0.0 109.457 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.446 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 83.4 m95 -131.79 151.07 51.93 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.524 -0.735 . . . . 0.0 111.175 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.457 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.1 t -167.65 -179.94 4.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 7.5 p -97.05 147.75 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.155 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.414 ' CZ ' HG21 ' A' ' 78' ' ' VAL . 58.3 t80 -60.05 -46.94 87.88 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.611 -0.68 . . . . 0.0 112.095 -178.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.468 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.5 p-80 -64.7 -24.08 67.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.159 -0.963 . . . . 0.0 110.91 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.405 ' O ' ' CE2' ' A' ' 43' ' ' PHE . . . -83.61 -52.96 3.53 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -109.42 -57.41 2.17 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.688 -0.89 . . . . 0.0 110.101 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.5 -163.8 52.98 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.1 p -88.98 66.2 7.78 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.662 -0.905 . . . . 0.0 110.037 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -139.63 168.39 19.93 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.508 -0.745 . . . . 0.0 110.282 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 60.2 m -65.0 139.63 58.78 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.056 -0.657 . . . . 0.0 109.961 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.417 HD22 ' CE2' ' A' ' 85' ' ' TRP . 13.8 tp -117.42 138.96 51.48 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.689 -0.632 . . . . 0.0 109.903 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.83 110.04 22.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.549 -0.719 . . . . 0.0 110.193 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.76 -179.65 19.06 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.04 -31.89 76.06 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.821 1.432 . . . . 0.0 110.469 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 6.7 mtpm? -73.06 -31.17 64.23 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.701 -0.624 . . . . 0.0 109.964 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.46 -150.41 21.6 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.71 147.11 44.45 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.886 1.466 . . . . 0.0 110.148 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -129.99 140.03 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.549 -0.719 . . . . 0.0 110.57 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.7 t -99.94 144.22 29.25 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.548 -0.72 . . . . 0.0 109.774 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -90.13 150.0 22.22 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.407 -0.808 . . . . 0.0 111.232 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 50.2 mtp -116.04 -25.98 7.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.762 -0.586 . . . . 0.0 110.427 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -122.86 139.96 53.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 60.9 m -141.38 133.72 28.13 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.621 -0.674 . . . . 0.0 110.312 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -145.54 95.66 2.69 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.509 -0.744 . . . . 0.0 110.019 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.414 HG21 ' CZ ' ' A' ' 56' ' ' TYR . 80.2 t -66.27 -43.09 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.513 -0.742 . . . . 0.0 110.066 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -49.88 75.9 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.55 -0.719 . . . . 0.0 110.474 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 37.0 tp60 -81.72 -8.65 59.72 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.588 -0.695 . . . . 0.0 110.509 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.0 t70 57.5 45.9 18.81 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.115 -0.991 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 82.6 mt -138.16 139.09 39.21 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.549 -0.719 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 34.7 m -144.39 158.04 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.627 -0.671 . . . . 0.0 109.439 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -140.62 157.94 25.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.457 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 7.3 m-90 -116.67 161.07 19.77 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.782 -0.834 . . . . 0.0 109.639 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -70.99 114.23 8.83 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.515 -0.741 . . . . 0.0 109.312 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.03 136.52 87.2 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 110.212 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 159.97 51.3 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.864 1.455 . . . . 0.0 110.228 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -66.15 153.63 77.32 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 123.882 1.464 . . . . 0.0 110.322 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.16 27.36 66.37 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.87 139.88 40.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.506 -0.996 . . . . 0.0 110.138 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.402 ' CG ' ' CG ' ' A' ' 32' ' ' GLU . 27.4 tpt180 -80.11 159.92 25.92 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.658 -0.651 . . . . 0.0 109.531 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.7 p -129.63 167.92 17.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.554 -0.716 . . . . 0.0 110.173 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 59.9 mt -109.8 131.54 54.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.526 -0.733 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.432 HG21 ' CD2' ' A' ' 149' ' ' HIS . 9.8 t -75.37 159.97 80.86 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.582 -0.699 . . . . 0.0 109.986 179.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -84.76 164.17 12.07 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.753 1.396 . . . . 0.0 110.815 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . 0.438 ' SG ' ' SG ' ' A' ' 99' ' ' CYS . 43.8 t -82.59 138.94 34.07 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.658 -0.651 . . . . 0.0 110.194 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -136.09 51.64 2.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.812 -0.555 . . . . 0.0 109.681 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . 0.438 ' SG ' ' SG ' ' A' ' 97' ' ' CYS . 29.2 p -143.43 -8.61 0.76 Allowed 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.843 -0.743 . . . . 0.0 112.411 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 33.44 74.75 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 86.0 p -76.73 149.92 36.31 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.431 -1.041 . . . . 0.0 110.415 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -92.66 -29.22 16.21 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.625 -0.672 . . . . 0.0 110.286 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -77.43 135.27 38.27 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.554 -0.716 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.4 mt -135.04 155.12 51.3 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.508 -0.745 . . . . 0.0 110.599 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -119.99 114.6 22.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.556 -0.715 . . . . 0.0 109.788 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.3 tp -100.41 140.01 35.27 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.617 -0.677 . . . . 0.0 110.445 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.96 129.94 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.626 -0.671 . . . . 0.0 110.052 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 59.5 p -102.2 -179.58 4.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.592 -0.692 . . . . 0.0 110.42 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.9 mtp-105 -59.88 -22.52 62.47 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.535 -0.728 . . . . 0.0 110.808 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -90.11 19.57 4.9 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.276 -0.89 . . . . 0.0 111.15 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.0 40.07 31.21 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.123 -0.986 . . . . 0.0 110.686 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -106.76 134.84 49.3 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.611 -0.68 . . . . 0.0 109.957 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.08 123.48 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 109.982 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.5 pt -119.97 150.0 50.01 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.564 -0.71 . . . . 0.0 110.06 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -87.99 128.03 2.27 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.933 1.491 . . . . 0.0 110.44 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.9 t -124.75 129.41 73.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.662 -0.649 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 51.6 mmm-85 -80.35 156.0 26.93 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.572 -0.705 . . . . 0.0 110.309 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -101.14 118.63 37.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.634 -0.666 . . . . 0.0 110.064 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.8 mmm180 -113.13 20.02 16.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.59 -0.694 . . . . 0.0 110.437 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.02 -171.43 42.39 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.02 -39.93 90.66 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.566 -0.961 . . . . 0.0 110.442 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.0 p -132.69 24.14 4.34 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.524 -0.735 . . . . 0.0 110.816 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -126.26 139.88 52.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.325 -0.859 . . . . 0.0 110.506 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.84 169.35 27.97 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 52.1 p -112.06 156.82 21.58 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.41 -1.053 . . . . 0.0 110.537 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 24.2 tp -98.59 120.4 38.94 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.559 -0.713 . . . . 0.0 110.074 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.93 -40.21 92.39 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.569 -0.707 . . . . 0.0 110.352 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.2 p -117.8 127.25 26.76 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.504 -0.747 . . . . 0.0 110.075 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.31 117.93 5.36 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.87 1.458 . . . . 0.0 110.381 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 48.6 mtp85 -120.08 160.01 44.86 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.708 . . . . 0.0 110.227 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.77 148.84 83.35 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.875 1.461 . . . . 0.0 110.31 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.3 m -62.07 -26.59 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.613 -0.68 . . . . 0.0 110.426 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.4 t -59.95 -39.92 87.22 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -60.06 -49.16 78.73 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.607 -0.683 . . . . 0.0 110.227 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.4 mp -69.97 -28.93 65.95 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.466 -0.771 . . . . 0.0 110.537 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmtp -60.01 140.02 57.06 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.476 -0.765 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.99 9.99 86.09 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 28.9 m -112.05 16.79 20.09 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.141 -1.211 . . . . 0.0 110.785 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -60.17 140.03 57.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.287 -0.883 . . . . 0.0 110.023 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.34 -18.07 57.59 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -51.4 124.94 24.17 Favored Glycine 0 N--CA 1.5 2.906 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -80.77 146.32 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.868 1.457 . . . . 0.0 111.304 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 6.4 mp -106.71 106.77 17.46 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.406 ' N ' ' CD1' ' A' ' 144' ' ' LEU . 9.8 mp -95.74 131.21 42.26 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.527 -0.733 . . . . 0.0 111.242 -178.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.431 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.75 159.39 84.14 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -51.92 -21.83 12.88 Favored 'Trans proline' 0 N--CA 1.501 1.954 0 O-C-N 123.506 1.266 . . . . 0.0 112.671 -178.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -69.77 -38.39 76.73 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.18 -0.95 . . . . 0.0 109.872 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.58 37.23 0.74 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . 0.432 ' CD2' HG21 ' A' ' 95' ' ' THR . 29.5 m170 -133.37 149.6 51.85 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.495 -1.003 . . . . 0.0 110.221 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.72 139.99 58.82 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.52 -0.737 . . . . 0.0 110.216 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 49.6 t -115.96 -35.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.582 -0.698 . . . . 0.0 110.009 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.7 -169.98 38.69 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 90.0 mt -130.04 139.89 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.564 -0.962 . . . . 0.0 110.229 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -59.99 139.14 57.63 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.507 -0.746 . . . . 0.0 110.12 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -119.95 -52.34 2.21 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.615 -0.678 . . . . 0.0 110.29 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -152.58 166.88 30.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.522 -0.736 . . . . 0.0 110.5 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.25 148.55 43.01 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.627 -0.671 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.94 120.03 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.624 -0.672 . . . . 0.0 109.796 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.63 149.87 51.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.719 -0.613 . . . . 0.0 110.376 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.8 p -80.09 -47.48 14.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.568 -0.707 . . . . 0.0 110.41 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -161.65 57.41 0.27 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.671 -0.643 . . . . 0.0 110.033 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.03 -11.65 40.83 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.9 t -118.24 126.52 75.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.137 -1.213 . . . . 0.0 109.686 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.7 123.53 40.42 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.512 -0.743 . . . . 0.0 110.627 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -105.8 -18.46 14.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.723 -0.611 . . . . 0.0 110.392 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.6 158.77 44.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 109.821 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -130.07 -173.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.481 -0.762 . . . . 0.0 110.518 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -146.44 127.17 14.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.705 -0.622 . . . . 0.0 109.444 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -127.42 156.22 42.42 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.453 -0.779 . . . . 0.0 110.946 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.2 t -92.82 121.41 66.01 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -64.17 154.92 68.06 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.79 1.416 . . . . 0.0 110.496 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 97.1 t -58.97 -24.06 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.612 -0.68 . . . . 0.0 110.531 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -59.85 -40.08 87.33 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.365 -0.835 . . . . 0.0 110.346 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 22.4 t -63.42 -38.42 91.06 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.476 -0.765 . . . . 0.0 110.144 179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.446 ' CE ' ' CD1' ' A' ' 53' ' ' TRP . 93.3 mtp -60.0 -41.58 92.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.631 -0.668 . . . . 0.0 110.317 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.13 -40.08 78.5 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.567 -0.708 . . . . 0.0 110.162 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.1 m -61.06 -39.98 91.92 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.627 -0.671 . . . . 0.0 110.156 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.6 m -60.14 -40.36 89.55 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.542 -0.724 . . . . 0.0 110.114 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.495 1.795 0 O-C-N 121.594 -0.691 . . . . 0.0 110.169 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.001 0.429 . . . . 0.0 110.058 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.417 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.683 . . . . 0.0 110.245 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 121.09 0.472 . . . . 0.0 110.313 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.6 t -120.34 129.61 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.546 -0.721 . . . . 0.0 109.77 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -129.99 158.35 39.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.517 -0.739 . . . . 0.0 110.451 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.78 125.28 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.696 -0.628 . . . . 0.0 109.413 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.79 158.16 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.577 -0.702 . . . . 0.0 110.159 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.5 m -133.36 173.04 11.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.684 -0.635 . . . . 0.0 110.556 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 35.0 m -139.69 171.54 14.08 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.09 -28.18 56.69 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.438 -0.789 . . . . 0.0 111.204 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.0 m -135.37 -7.26 2.26 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.263 -0.898 . . . . 0.0 112.597 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.7 mm-40 -129.98 159.17 37.48 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.89 -1.131 . . . . 0.0 111.69 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 68.1 m -132.12 133.98 44.92 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -164.67 -177.4 4.76 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.242 -0.911 . . . . 0.0 111.068 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 51.6 mt -112.63 146.61 38.32 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.666 -0.647 . . . . 0.0 110.279 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -111.24 161.01 16.44 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.58 -0.7 . . . . 0.0 110.165 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 63.6 p -125.16 143.38 50.96 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.593 -0.692 . . . . 0.0 110.314 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 93.3 m -102.85 113.18 26.4 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.574 -0.704 . . . . 0.0 110.501 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.3 130.0 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.658 -0.652 . . . . 0.0 109.428 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 55.49 36.68 27.64 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.421 -0.799 . . . . 0.0 110.76 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.69 19.16 74.67 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -132.36 130.05 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.202 -1.175 . . . . 0.0 109.998 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.5 m -78.21 144.97 35.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.483 -0.761 . . . . 0.0 109.514 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -128.36 151.41 49.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.525 -0.734 . . . . 0.0 110.863 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.447 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -167.77 -179.8 4.43 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.444 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 10.9 p -95.29 154.2 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.816 . . . . 0.0 110.562 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.415 ' CZ ' HG23 ' A' ' 78' ' ' VAL . 58.7 t80 -69.95 -40.12 75.63 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.683 -0.636 . . . . 0.0 111.873 -178.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.444 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.4 p-80 -68.26 -24.35 64.88 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.135 -0.978 . . . . 0.0 110.499 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.408 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -82.64 -59.12 2.27 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -102.37 -47.95 4.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.069 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 66.0 -165.68 37.85 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.2 m -83.72 64.42 7.99 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.582 -0.952 . . . . 0.0 109.951 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -140.02 164.84 28.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.514 -0.741 . . . . 0.0 110.324 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.3 t -65.37 140.05 58.62 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.578 -0.701 . . . . 0.0 110.05 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.452 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 14.5 tp -109.9 130.54 55.51 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.658 -0.651 . . . . 0.0 110.178 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.46 118.45 30.57 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.578 -0.701 . . . . 0.0 110.106 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -122.89 177.74 16.48 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.63 -31.98 69.57 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.795 1.419 . . . . 0.0 110.338 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 61.0 tptt -70.55 -31.55 68.64 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.606 -0.684 . . . . 0.0 109.633 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.01 -150.41 22.01 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.79 155.75 53.51 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.891 1.469 . . . . 0.0 110.228 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.415 HG23 ' CD1' ' A' ' 85' ' ' TRP . 85.1 mt -125.91 139.94 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.555 -0.715 . . . . 0.0 110.272 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 73.1 m -94.39 137.9 32.99 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.413 -0.804 . . . . 0.0 110.265 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -70.16 139.96 52.49 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.575 -0.703 . . . . 0.0 110.599 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.82 -51.3 2.66 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.564 -0.71 . . . . 0.0 109.952 179.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -120.03 140.06 51.56 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.514 -0.742 . . . . 0.0 110.213 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.6 p -131.64 137.61 48.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.497 -0.752 . . . . 0.0 110.367 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -150.04 90.72 1.7 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.578 -0.702 . . . . 0.0 110.215 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.415 HG23 ' CZ ' ' A' ' 56' ' ' TYR . 85.9 t -68.04 -42.33 85.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.543 -0.723 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.91 -42.8 94.66 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.717 . . . . 0.0 110.27 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 39.0 tp60 -89.98 0.12 57.27 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.537 -0.727 . . . . 0.0 110.93 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 8.4 t70 53.65 44.63 29.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.059 -1.026 . . . . 0.0 110.687 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 70.9 mt -140.25 144.37 36.45 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.407 -0.808 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 35.8 m -148.2 155.64 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.578 -0.701 . . . . 0.0 109.452 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -139.95 161.25 26.33 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.452 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 9.2 m-90 -117.75 160.06 21.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.751 -0.852 . . . . 0.0 109.565 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -74.54 104.42 5.24 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.463 -0.773 . . . . 0.0 109.677 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -71.37 130.04 88.16 Favored Pre-proline 0 N--CA 1.494 1.775 0 O-C-N 121.541 -0.724 . . . . 0.0 110.239 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.08 159.98 51.24 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.827 1.435 . . . . 0.0 110.271 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.9 157.71 51.04 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.968 1.51 . . . . 0.0 110.319 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.9 -24.86 30.52 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.03 159.99 26.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.445 -1.032 . . . . 0.0 110.159 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 83.6 mtt180 -100.39 159.31 15.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.59 -0.694 . . . . 0.0 110.109 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.3 p -129.91 170.03 14.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.511 -0.743 . . . . 0.0 110.271 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -102.48 138.49 39.32 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.635 -0.666 . . . . 0.0 110.505 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.419 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 4.8 p -76.05 160.03 79.25 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.629 -0.669 . . . . 0.0 109.946 179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.55 153.32 30.41 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.779 1.41 . . . . 0.0 110.6 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 53.4 t -68.73 135.11 50.77 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.543 -0.723 . . . . 0.0 110.131 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.5 t -136.1 52.07 2.0 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.708 -0.62 . . . . 0.0 109.692 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.83 -8.51 0.72 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.542 -0.723 . . . . 0.0 112.405 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.96 33.84 80.66 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 p -88.15 139.64 30.29 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.533 -0.981 . . . . 0.0 110.411 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.5 m -82.1 -30.0 31.46 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.646 -0.659 . . . . 0.0 110.353 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -66.62 129.87 41.3 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.502 -0.749 . . . . 0.0 110.162 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.6 mt -137.14 139.81 41.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.7 . . . . 0.0 110.631 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.5 120.51 42.39 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.56 -0.713 . . . . 0.0 109.862 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.4 tp -103.1 140.06 37.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.5 -0.75 . . . . 0.0 110.488 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -90.44 138.66 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.585 -0.697 . . . . 0.0 109.758 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 13.5 m -110.2 159.48 17.34 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.519 -0.738 . . . . 0.0 110.489 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.7 ttp180 -60.1 -21.37 61.42 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.588 -0.695 . . . . 0.0 110.63 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.07 27.45 3.2 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.267 -0.896 . . . . 0.0 110.528 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.61 39.98 31.56 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.39 -0.819 . . . . 0.0 110.622 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -124.21 139.59 53.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.656 -0.653 . . . . 0.0 109.737 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -126.13 139.09 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.482 -0.761 . . . . 0.0 110.59 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.2 mp -124.52 150.05 63.6 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.733 -0.604 . . . . 0.0 109.559 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -79.15 133.41 10.94 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.888 1.468 . . . . 0.0 110.492 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.02 129.99 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.671 -0.643 . . . . 0.0 109.653 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.4 tpt180 -85.38 150.0 25.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.52 -0.738 . . . . 0.0 110.193 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -91.15 119.96 31.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.65 -0.656 . . . . 0.0 110.336 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -110.21 20.02 18.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.608 -0.683 . . . . 0.0 110.508 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.11 -174.26 43.59 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -65.8 -39.94 91.41 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.999 . . . . 0.0 110.245 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.6 p -130.74 24.52 5.04 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.553 -0.717 . . . . 0.0 110.535 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -124.93 139.96 53.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 110.36 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.37 165.79 25.67 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 91.1 p -115.86 153.78 30.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.463 -1.022 . . . . 0.0 110.152 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.2 tp -99.72 119.96 38.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.584 -0.697 . . . . 0.0 110.193 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.0 mp -68.96 -38.51 79.45 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.527 -0.733 . . . . 0.0 109.863 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.0 m -110.0 113.84 56.68 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.677 -0.639 . . . . 0.0 110.051 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -64.66 118.52 5.49 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.799 1.421 . . . . 0.0 110.523 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -122.44 160.02 50.05 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.626 -0.671 . . . . 0.0 110.211 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -66.15 154.88 72.37 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.913 1.481 . . . . 0.0 110.42 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 90.6 t -61.63 -39.97 85.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.607 -0.683 . . . . 0.0 110.126 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.3 p -56.14 -33.85 65.56 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.476 -0.765 . . . . 0.0 110.663 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -60.02 -39.95 87.64 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.556 -0.715 . . . . 0.0 110.107 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.5 mp -84.82 -20.95 30.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.542 -0.724 . . . . 0.0 110.931 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -59.9 139.85 57.08 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.251 -0.906 . . . . 0.0 110.117 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.66 10.05 86.19 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 18.2 m -116.14 10.3 14.93 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.19 -1.182 . . . . 0.0 110.884 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.2 t -65.0 150.49 47.98 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.164 -0.96 . . . . 0.0 109.597 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.56 -22.23 40.18 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.5 148.57 21.04 Favored Glycine 0 N--CA 1.498 2.83 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -98.8 147.57 0.58 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.889 1.468 . . . . 0.0 111.024 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.38 108.33 19.91 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 mp -99.77 129.94 45.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.456 -0.777 . . . . 0.0 111.296 -178.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.418 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.03 158.31 87.67 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.0 Cg_endo -51.87 -25.36 21.22 Favored 'Trans proline' 0 N--CA 1.501 1.918 0 O-C-N 123.547 1.288 . . . . 0.0 112.343 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.2 m -62.74 -40.0 95.85 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.266 -0.896 . . . . 0.0 109.886 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.06 36.86 0.79 Allowed Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . 0.419 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 4.3 m-70 -132.95 143.69 49.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.445 -1.033 . . . . 0.0 110.188 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.42 142.33 58.23 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.523 -0.736 . . . . 0.0 110.233 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.6 t -115.34 -38.06 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.579 -0.701 . . . . 0.0 110.043 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.09 -168.38 36.23 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.89 140.02 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.469 -1.018 . . . . 0.0 110.379 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -63.75 139.77 58.8 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.677 -0.639 . . . . 0.0 110.11 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.5 ttt180 -119.9 -52.42 2.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.57 -0.706 . . . . 0.0 110.331 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.28 158.77 44.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.514 -0.742 . . . . 0.0 110.335 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.94 152.02 31.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.619 -0.676 . . . . 0.0 110.488 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.86 119.77 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.736 -0.603 . . . . 0.0 109.692 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.26 144.22 51.14 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.721 -0.612 . . . . 0.0 110.373 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.5 m -69.86 -49.77 49.14 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.619 -0.676 . . . . 0.0 110.056 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -163.65 54.17 0.16 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.711 -0.618 . . . . 0.0 109.854 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.32 -16.51 17.33 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.15 125.15 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.228 -1.16 . . . . 0.0 109.661 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -95.3 123.05 38.61 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.591 -0.693 . . . . 0.0 110.578 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -105.2 -21.31 13.28 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.601 -0.687 . . . . 0.0 110.274 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.94 159.12 43.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.365 -0.834 . . . . 0.0 109.913 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 19.7 m -131.53 -175.73 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.551 -0.718 . . . . 0.0 110.519 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -142.93 132.18 23.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.77 -0.581 . . . . 0.0 109.595 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -133.23 155.79 48.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.523 -0.736 . . . . 0.0 110.894 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.9 t -92.7 124.27 59.29 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.564 -0.71 . . . . 0.0 109.332 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.49 150.31 75.29 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.721 1.379 . . . . 0.0 110.675 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 95.0 t -59.48 -24.04 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.666 -0.646 . . . . 0.0 110.408 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -59.12 -39.58 82.76 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.382 -0.824 . . . . 0.0 110.314 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.4 p -60.01 -39.34 85.5 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.555 -0.716 . . . . 0.0 110.212 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 67.7 mtt -59.92 -40.46 88.94 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 110.452 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.28 -40.02 88.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.675 -0.64 . . . . 0.0 110.281 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.4 m -60.76 -40.4 92.35 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.472 -0.767 . . . . 0.0 110.106 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -69.86 -41.03 75.4 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.58 -0.7 . . . . 0.0 110.079 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.835 0 O-C-N 121.594 -0.691 . . . . 0.0 110.348 -179.891 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.109 0.48 . . . . 0.0 110.074 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.416 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp . . . . . 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.0 110.343 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 N--CA 1.497 1.893 0 CA-C-O 120.971 0.415 . . . . 0.0 110.553 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 82.7 t -116.86 128.54 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.401 -0.812 . . . . 0.0 109.663 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -129.27 154.44 46.83 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.533 -0.729 . . . . 0.0 110.6 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -91.74 128.36 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.17 159.69 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.614 -0.679 . . . . 0.0 110.36 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 58.6 m -137.85 162.48 33.87 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.517 0.675 . . . . 0.0 111.032 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.2 m -134.51 169.37 17.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.792 -0.567 . . . . 0.0 109.678 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -67.11 -12.67 60.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 111.323 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 48.6 p -118.39 -30.53 5.2 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.042 -1.036 . . . . 0.0 111.555 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -159.17 170.04 22.83 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.202 -0.936 . . . . 0.0 110.967 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 t -123.88 155.23 38.46 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.489 -0.757 . . . . 0.0 110.574 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -166.26 -177.71 4.22 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.546 -0.721 . . . . 0.0 110.091 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 63.7 mt -113.28 153.78 27.87 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.523 -0.736 . . . . 0.0 110.443 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -127.89 161.09 29.89 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.557 -0.714 . . . . 0.0 110.356 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 86.9 m -120.04 130.23 54.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.635 -0.666 . . . . 0.0 110.108 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.4 t -89.94 104.0 16.61 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.628 -0.67 . . . . 0.0 110.42 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.424 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.3 t -111.06 132.81 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.479 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.77 38.71 29.67 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.559 -0.713 . . . . 0.0 110.678 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.94 20.07 75.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.4 t -132.31 129.89 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.234 -1.156 . . . . 0.0 110.079 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 5.2 t -71.81 146.49 47.97 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.539 -0.726 . . . . 0.0 109.433 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.424 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 59.5 m95 -129.4 151.05 50.46 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.474 -0.766 . . . . 0.0 111.273 -179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.438 HG23 ' CZ3' ' A' ' 85' ' ' TRP . 6.4 t -169.78 -179.81 3.43 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.456 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.1 p -94.53 156.36 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.423 -0.798 . . . . 0.0 110.073 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.412 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 58.2 t80 -70.04 -42.35 73.02 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.548 -0.72 . . . . 0.0 111.79 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.456 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.5 p-80 -64.77 -20.76 66.54 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.144 -0.973 . . . . 0.0 110.643 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -86.84 -47.69 4.69 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -125.41 90.98 3.32 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.679 -0.895 . . . . 0.0 109.942 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.42 -169.99 2.0 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 20.4 p -72.22 66.93 0.66 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.438 -1.036 . . . . 0.0 109.555 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.62 166.8 23.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.62 -0.675 . . . . 0.0 110.729 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.2 m -65.58 139.62 58.46 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.778 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.458 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -108.32 132.72 53.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.636 -0.665 . . . . 0.0 110.11 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.7 118.37 30.6 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.549 -0.719 . . . . 0.0 110.36 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.09 -176.91 18.25 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.132 -1.587 . . . . 0.0 109.132 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.51 -32.51 70.36 Favored 'Trans proline' 0 N--CA 1.491 1.35 0 O-C-N 123.836 1.44 . . . . 0.0 110.579 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 76.0 tttt -75.46 -31.11 60.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.598 -0.689 . . . . 0.0 109.974 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.3 -140.26 9.22 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.06 156.93 47.14 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 O-C-N 123.806 1.424 . . . . 0.0 110.25 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.4 mt -127.41 139.99 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.065 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 p -88.46 150.76 22.97 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.755 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -96.75 140.03 31.94 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.612 -0.68 . . . . 0.0 110.441 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.6 mmm -119.29 -32.77 4.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.577 -0.702 . . . . 0.0 110.856 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -132.75 149.97 52.21 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.405 -0.809 . . . . 0.0 110.869 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.3 p -143.56 137.86 28.71 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.672 -0.643 . . . . 0.0 110.026 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -150.02 93.92 2.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.467 -0.771 . . . . 0.0 110.169 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.412 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 88.0 t -69.96 -43.06 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -59.87 -45.46 92.41 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.514 -0.741 . . . . 0.0 110.608 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -85.71 -0.07 54.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.579 -0.7 . . . . 0.0 110.737 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 8.3 t70 53.73 45.29 28.26 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.036 -1.04 . . . . 0.0 110.704 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 57.6 mt -142.24 146.89 35.65 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.524 -0.735 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 35.4 m -149.24 160.0 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.555 -0.715 . . . . 0.0 109.735 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.34 153.75 24.18 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.458 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 7.5 m-90 -114.58 168.09 10.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.668 -0.901 . . . . 0.0 109.535 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -77.57 110.05 12.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -0.788 . . . . 0.0 109.268 179.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.05 129.98 90.26 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.598 -0.689 . . . . 0.0 110.204 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.96 159.95 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 123.791 1.416 . . . . 0.0 110.28 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.35 160.14 50.54 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.961 1.506 . . . . 0.0 110.285 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 84.49 28.75 31.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.99 150.03 49.61 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.527 -0.984 . . . . 0.0 110.094 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -100.02 119.98 39.11 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.521 -0.737 . . . . 0.0 110.342 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.5 p -81.24 170.03 16.59 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.656 -0.653 . . . . 0.0 110.161 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 79.3 mt -109.57 131.85 54.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.586 -0.696 . . . . 0.0 110.807 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.7 p -72.74 160.06 83.8 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.576 -0.703 . . . . 0.0 109.95 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.36 164.44 24.08 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.87 1.458 . . . . 0.0 110.594 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 54.1 t -80.16 129.99 34.9 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.537 -0.727 . . . . 0.0 110.241 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -133.24 55.79 1.88 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.646 -0.659 . . . . 0.0 109.522 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.95 -8.12 0.72 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.607 -0.683 . . . . 0.0 112.394 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.06 35.27 91.2 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -84.97 113.07 21.14 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.513 -0.992 . . . . 0.0 110.485 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -60.03 -40.01 87.88 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.64 -0.662 . . . . 0.0 110.342 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -64.89 138.66 58.51 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.55 -0.719 . . . . 0.0 110.414 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.5 mt -135.58 150.0 49.57 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.615 -0.678 . . . . 0.0 110.319 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -117.84 114.4 23.2 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.583 -0.698 . . . . 0.0 109.857 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.2 tp -96.5 145.64 25.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.568 -0.707 . . . . 0.0 110.467 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.01 128.69 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.662 -0.649 . . . . 0.0 109.928 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 71.1 p -105.12 -178.59 3.7 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.597 -0.69 . . . . 0.0 110.441 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 55.0 mtp180 -69.76 -20.95 63.48 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.562 -0.711 . . . . 0.0 110.808 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.81 21.24 4.96 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.356 -0.84 . . . . 0.0 110.908 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.12 39.93 31.16 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.154 -0.966 . . . . 0.0 110.622 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -106.4 168.32 9.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.588 -0.695 . . . . 0.0 110.008 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.7 p -129.97 129.97 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.559 -0.713 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 mp -119.62 109.28 38.35 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.633 -0.667 . . . . 0.0 109.87 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -65.16 109.83 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.764 1.402 . . . . 0.0 110.263 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -110.83 124.12 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.608 -0.683 . . . . 0.0 109.937 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 35.1 mmm-85 -79.75 155.22 28.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.586 -0.696 . . . . 0.0 110.175 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -98.18 119.69 37.28 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -122.64 22.63 9.8 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.23 -176.95 47.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -70.07 -40.04 75.29 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.506 -0.997 . . . . 0.0 110.532 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -131.0 29.07 4.74 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.449 -0.782 . . . . 0.0 110.686 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -138.44 162.5 34.31 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.451 -0.78 . . . . 0.0 110.474 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -162.24 -179.39 36.83 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 79.4 p -120.92 149.01 43.28 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.542 -0.975 . . . . 0.0 110.232 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.4 tp -93.44 119.28 32.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.591 -0.693 . . . . 0.0 109.996 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.7 mp -65.02 -39.95 94.16 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.593 -0.692 . . . . 0.0 109.959 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.3 p -110.87 119.97 44.72 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.601 -0.687 . . . . 0.0 110.033 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.23 117.74 5.05 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.736 1.388 . . . . 0.0 110.281 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 13.1 mmt85 -120.59 160.0 45.97 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.56 -0.712 . . . . 0.0 110.197 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.58 159.21 54.41 Favored 'Trans proline' 0 N--CA 1.489 1.255 0 O-C-N 123.875 1.461 . . . . 0.0 110.475 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 92.5 t -64.66 -33.15 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.538 -0.726 . . . . 0.0 109.98 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 56.0 m -60.07 -38.09 81.82 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.588 -0.695 . . . . 0.0 110.223 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -60.05 -40.04 88.02 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.559 -0.713 . . . . 0.0 110.212 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.3 mp -83.6 -23.34 31.96 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.529 -0.732 . . . . 0.0 110.756 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.11 140.06 57.12 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.339 -0.851 . . . . 0.0 110.246 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.05 4.2 89.63 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.8 m -109.53 -0.89 18.59 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.075 -1.25 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 31.0 t -60.01 141.47 55.59 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.108 -0.995 . . . . 0.0 109.754 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 100.05 -19.79 51.64 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.75 147.05 44.0 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -92.38 144.78 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.925 1.487 . . . . 0.0 111.181 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.35 111.11 23.25 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -99.65 131.72 45.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.526 -0.733 . . . . 0.0 111.453 -178.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.436 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.05 160.03 82.06 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -52.0 -22.88 15.47 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 O-C-N 123.532 1.28 . . . . 0.0 112.161 -178.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.66 -40.03 88.45 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.225 -0.922 . . . . 0.0 109.881 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.19 35.66 0.86 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -132.03 148.14 52.49 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.467 -1.019 . . . . 0.0 110.445 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.71 143.51 57.34 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.599 -0.688 . . . . 0.0 110.273 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 54.4 t -118.29 -40.87 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.536 -0.727 . . . . 0.0 110.052 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.57 -175.59 41.41 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.402 HG23 HD12 ' A' ' 153' ' ' ILE . 89.0 mt -122.91 130.34 74.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.535 -0.979 . . . . 0.0 110.391 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -60.34 134.6 57.22 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.55 -0.719 . . . . 0.0 109.818 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.7 ttt180 -113.24 -52.13 2.78 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.458 -0.777 . . . . 0.0 110.443 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -155.09 160.01 40.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.44 -0.787 . . . . 0.0 110.558 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -111.73 153.71 26.08 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.614 -0.679 . . . . 0.0 110.193 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.05 118.99 58.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.625 -0.672 . . . . 0.0 109.751 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -132.99 149.29 52.24 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.654 -0.654 . . . . 0.0 110.307 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.7 p -82.26 -42.9 18.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.645 -0.659 . . . . 0.0 110.61 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -160.34 59.93 0.34 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.131 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 98.75 -10.01 62.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.33 122.25 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.134 -1.215 . . . . 0.0 109.843 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.57 126.12 41.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.68 -0.637 . . . . 0.0 110.78 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 47.5 mmtt -107.14 -25.45 11.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.733 -0.605 . . . . 0.0 110.118 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.73 154.54 46.37 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.728 . . . . 0.0 110.04 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 26.8 m -126.21 -171.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.557 -0.714 . . . . 0.0 110.786 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -146.93 134.57 21.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.69 -0.631 . . . . 0.0 109.444 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -137.48 159.19 42.64 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.446 -0.784 . . . . 0.0 110.8 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 65.5 t -98.42 121.2 57.49 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -62.37 159.94 33.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.711 1.374 . . . . 0.0 110.517 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 89.4 t -69.39 -27.09 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.615 -0.678 . . . . 0.0 110.829 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -58.18 -39.67 79.5 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.366 -0.834 . . . . 0.0 110.7 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 89.3 p -67.08 -38.46 85.77 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.454 -0.779 . . . . 0.0 110.246 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.424 ' HE1' ' CE2' ' A' ' 53' ' ' TRP . 87.9 mtp -60.0 -40.04 87.85 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.489 -0.757 . . . . 0.0 110.319 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -64.27 -40.01 95.11 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.506 -0.746 . . . . 0.0 110.3 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.5 m -67.93 -28.78 67.77 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.713 -0.617 . . . . 0.0 110.372 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.1 m -59.97 -40.07 87.83 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.571 -0.706 . . . . 0.0 110.272 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.5 mtt . . . . . 0 N--CA 1.496 1.873 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 179.995 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.165 0.507 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.411 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 110.45 -179.767 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 . . . . . 0 N--CA 1.496 1.867 0 CA-C-O 121.123 0.487 . . . . 0.0 110.047 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.2 t -105.58 127.21 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.538 -0.726 . . . . 0.0 109.959 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -116.28 150.14 38.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.586 -0.696 . . . . 0.0 110.334 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 12.5 p -79.72 129.02 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.63 -0.669 . . . . 0.0 110.04 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -125.14 154.29 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 110.031 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.5 m -149.84 171.48 16.69 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.016 -0.673 . . . . 0.0 110.511 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.9 p -140.93 -173.35 3.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.766 -0.584 . . . . 0.0 109.434 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.34 -0.81 26.99 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.497 -0.752 . . . . 0.0 111.219 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.4 m -118.59 -46.75 2.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.109 -0.994 . . . . 0.0 111.359 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -147.76 171.18 16.09 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.268 -0.895 . . . . 0.0 111.407 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 32.1 t -119.15 146.65 44.98 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.664 -0.647 . . . . 0.0 109.926 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 15.1 p90 -158.17 -176.44 5.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.486 -0.758 . . . . 0.0 110.215 -179.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 42.0 mt -111.54 167.65 10.16 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.565 -0.709 . . . . 0.0 110.338 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -142.91 155.69 44.77 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.698 -0.626 . . . . 0.0 110.039 -179.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 73.4 p -120.28 129.45 54.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.453 -0.78 . . . . 0.0 110.177 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 35.0 t -91.13 107.42 19.19 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.514 -0.741 . . . . 0.0 110.517 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.6 t -115.29 135.87 53.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.624 -0.673 . . . . 0.0 109.552 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 54.78 37.42 28.41 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.536 -0.727 . . . . 0.0 111.021 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 23.14 77.35 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.6 t -138.25 129.91 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.248 -1.148 . . . . 0.0 110.089 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.0 t -68.45 148.47 50.59 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.418 -0.801 . . . . 0.0 109.454 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 48.8 m95 -140.08 142.95 36.08 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.197 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.454 ' CG2' ' CZ3' ' A' ' 85' ' ' TRP . 7.9 t -170.07 -178.6 2.9 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.451 HG22 ' CE1' ' A' ' 57' ' ' HIS . 12.7 p -83.23 159.01 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 110.401 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.425 ' CD1' ' HA2' ' A' ' 60' ' ' GLY . 55.5 t80 -76.99 -40.03 48.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.67 -0.644 . . . . 0.0 112.069 -178.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.451 ' CE1' HG22 ' A' ' 55' ' ' VAL . 2.9 p-80 -61.0 -24.67 66.32 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.113 -0.992 . . . . 0.0 110.848 -178.626 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.446 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -74.75 -49.01 11.17 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -114.86 -55.56 2.47 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.561 -0.964 . . . . 0.0 110.458 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.425 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 85.09 -172.33 47.44 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 47.8 t -80.14 65.13 5.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.526 -0.985 . . . . 0.0 109.848 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -141.81 170.06 16.43 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.587 -0.696 . . . . 0.0 110.267 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.1 m -65.57 139.77 58.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.527 -0.733 . . . . 0.0 109.851 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.426 HD22 ' CD2' ' A' ' 85' ' ' TRP . 20.4 tp -108.81 141.02 41.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.692 -0.63 . . . . 0.0 110.099 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.15 111.56 23.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.57 -0.706 . . . . 0.0 110.166 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.12 -178.29 18.23 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -62.1 -31.96 83.37 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 O-C-N 123.765 1.403 . . . . 0.0 110.518 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.4 tttt -74.61 -31.27 61.97 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.669 -0.644 . . . . 0.0 109.769 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.33 -154.38 23.45 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.41 146.82 69.86 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 O-C-N 123.816 1.43 . . . . 0.0 109.953 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -130.3 139.98 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.514 -0.741 . . . . 0.0 110.599 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.3 m -89.83 139.9 30.13 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.563 -0.711 . . . . 0.0 110.211 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.416 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 1.6 pp0? -83.2 150.25 26.33 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.519 -0.738 . . . . 0.0 111.383 -179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.2 mtp -110.37 -29.93 7.9 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.821 -0.549 . . . . 0.0 109.944 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -131.76 148.39 52.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.72 -0.613 . . . . 0.0 110.459 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.15 125.98 11.17 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.663 -0.648 . . . . 0.0 109.628 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -141.92 95.57 2.83 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.528 -0.733 . . . . 0.0 110.152 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 91.9 t -61.43 -44.67 98.95 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.673 -0.642 . . . . 0.0 109.921 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.15 -48.75 80.39 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.551 -0.718 . . . . 0.0 110.256 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -80.07 -9.15 59.68 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.66 -0.65 . . . . 0.0 110.478 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.7 t0 56.79 48.18 16.63 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.22 -0.925 . . . . 0.0 110.422 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 81.3 mt -137.96 149.83 46.49 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.48 -0.762 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -150.05 149.97 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.611 -0.68 . . . . 0.0 109.493 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -133.86 149.55 19.75 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.335 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.454 ' CZ3' ' CG2' ' A' ' 54' ' ' THR . 5.3 m-90 -120.16 168.19 11.47 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.68 -0.894 . . . . 0.0 110.204 179.516 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -72.86 120.42 18.46 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -68.98 132.24 90.5 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.448 -0.782 . . . . 0.0 109.958 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.99 157.07 61.15 Favored 'Trans proline' 0 N--CA 1.49 1.294 0 O-C-N 123.84 1.442 . . . . 0.0 110.478 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.56 160.23 48.94 Favored 'Trans proline' 0 N--CA 1.49 1.282 0 O-C-N 123.936 1.493 . . . . 0.0 110.185 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 29.97 70.44 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.04 160.87 22.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.6 -0.941 . . . . 0.0 110.106 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 75.1 mtp85 -105.19 153.75 21.13 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 110.275 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 54.5 m -111.3 160.9 16.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.605 -0.684 . . . . 0.0 110.294 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.5 mt -100.31 131.85 46.01 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.595 -0.691 . . . . 0.0 110.524 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.3 p -77.04 159.95 77.27 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.608 -0.682 . . . . 0.0 110.006 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -85.57 158.24 10.71 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 O-C-N 123.799 1.421 . . . . 0.0 110.54 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.4 t -79.81 129.75 34.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.587 -0.695 . . . . 0.0 110.087 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -132.88 56.45 1.85 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.677 -0.64 . . . . 0.0 109.678 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.87 -8.1 0.73 Allowed 'General case' 0 N--CA 1.497 1.913 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.252 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.92 46.09 94.73 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.98 119.77 38.77 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.518 -0.989 . . . . 0.0 110.45 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -62.95 -40.03 96.43 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.703 -0.623 . . . . 0.0 110.355 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -63.3 132.55 51.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.543 -0.723 . . . . 0.0 110.354 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.0 mt -137.29 145.24 43.22 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.568 -0.708 . . . . 0.0 110.488 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.47 122.15 46.05 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.541 -0.725 . . . . 0.0 109.858 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.6 tp -103.69 146.17 28.98 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.671 . . . . 0.0 110.605 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.67 130.07 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.65 -0.656 . . . . 0.0 109.758 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -93.09 170.04 9.95 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.487 -0.758 . . . . 0.0 110.754 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 5.4 ttt-85 -64.6 -21.07 66.61 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.639 -0.663 . . . . 0.0 110.623 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.6 t60 -94.42 29.41 2.25 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.416 -0.803 . . . . 0.0 110.488 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.7 40.02 30.86 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -107.44 157.32 18.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.648 -0.658 . . . . 0.0 109.926 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.7 p -129.99 130.32 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.589 -0.694 . . . . 0.0 110.193 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 76.5 mt -128.86 150.04 73.96 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.569 -0.707 . . . . 0.0 109.827 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -87.14 132.07 3.17 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.919 1.484 . . . . 0.0 110.409 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -129.84 130.01 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.641 -0.662 . . . . 0.0 109.526 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -92.18 136.21 33.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.455 -0.778 . . . . 0.0 110.192 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -79.17 128.82 33.78 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.571 -0.706 . . . . 0.0 110.318 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -121.68 23.02 10.38 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.616 -0.677 . . . . 0.0 110.169 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.0 179.73 41.23 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -61.37 -40.82 95.71 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.488 -1.007 . . . . 0.0 110.233 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 78.6 p -132.64 26.52 4.38 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.57 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -129.74 140.04 51.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.493 -0.754 . . . . 0.0 110.134 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.14 169.76 25.63 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -114.71 157.37 23.26 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.621 -0.929 . . . . 0.0 110.071 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.9 tp -100.41 119.15 38.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.566 -0.709 . . . . 0.0 110.165 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -69.68 -37.29 76.61 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.477 -0.765 . . . . 0.0 109.741 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.9 t -108.57 109.96 61.42 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.63 -0.669 . . . . 0.0 109.95 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.79 116.26 3.71 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.839 1.441 . . . . 0.0 110.469 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -119.95 160.03 44.47 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.544 -0.723 . . . . 0.0 110.185 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.74 157.74 60.62 Favored 'Trans proline' 0 N--CA 1.491 1.358 0 O-C-N 123.877 1.462 . . . . 0.0 110.442 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 94.3 t -61.53 -36.05 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.608 -0.682 . . . . 0.0 110.01 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -40.09 87.66 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.547 -0.721 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -59.89 -40.08 87.52 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.544 -0.723 . . . . 0.0 110.285 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.8 mp -82.65 -24.52 33.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.521 -0.737 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.39 140.23 57.29 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.295 -0.878 . . . . 0.0 109.972 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.02 10.23 85.8 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 20.6 m -116.17 18.83 15.23 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.173 -1.192 . . . . 0.0 110.606 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 1.8 m -69.95 149.95 47.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.356 -0.84 . . . . 0.0 109.857 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.05 -11.89 69.37 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.86 137.81 48.25 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -87.22 142.32 6.23 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.807 1.425 . . . . 0.0 111.327 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 6.8 mp -103.6 109.56 21.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -102.74 132.33 48.96 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.457 -0.777 . . . . 0.0 111.62 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -68.56 159.62 80.62 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -51.9 -26.07 23.53 Favored 'Trans proline' 0 N--CA 1.5 1.874 0 O-C-N 123.446 1.235 . . . . 0.0 112.391 -178.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -62.69 -40.01 95.76 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.231 -0.918 . . . . 0.0 109.809 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 122.02 34.01 0.87 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.52 145.72 51.37 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.428 -1.042 . . . . 0.0 110.157 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.8 136.86 45.49 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.671 -0.643 . . . . 0.0 110.255 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.8 p -116.14 -21.28 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 110.78 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.29 -176.59 45.5 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.402 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 92.7 mt -130.81 140.07 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.402 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.5 t80 -60.87 139.99 57.82 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.58 -0.7 . . . . 0.0 109.862 179.573 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 64.4 ttt180 -120.68 -52.5 2.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.56 -0.712 . . . . 0.0 110.393 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -149.32 157.62 43.49 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.486 -0.758 . . . . 0.0 110.325 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.23 145.52 37.19 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.548 -0.72 . . . . 0.0 110.265 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.1 t -110.0 119.96 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.631 -0.668 . . . . 0.0 109.794 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -130.59 152.17 50.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.639 -0.663 . . . . 0.0 110.39 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 p -77.8 -45.16 25.28 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.65 -0.656 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 45.6 ptt85 -164.0 54.78 0.16 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.621 -0.674 . . . . 0.0 109.975 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 111.93 -14.63 26.44 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.29 120.74 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.185 -1.185 . . . . 0.0 109.963 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -84.45 129.32 34.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.657 -0.652 . . . . 0.0 110.447 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 21.4 pttm -111.44 -24.31 10.25 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.621 -0.674 . . . . 0.0 110.604 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.13 159.23 42.68 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.619 -0.676 . . . . 0.0 109.909 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 m -134.91 167.32 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.611 -0.681 . . . . 0.0 110.668 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -126.78 139.65 52.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.669 -0.644 . . . . 0.0 109.771 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -138.04 154.7 49.28 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.402 -0.811 . . . . 0.0 110.833 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.6 t -93.29 121.15 65.89 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.68 -0.637 . . . . 0.0 109.472 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.64 154.11 75.57 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.734 1.386 . . . . 0.0 110.544 -179.602 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 63.7 t -62.99 -26.75 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.571 -0.706 . . . . 0.0 110.35 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -59.12 -39.9 83.75 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.478 -0.764 . . . . 0.0 110.351 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 86.2 p -60.0 -38.29 82.18 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.487 -0.758 . . . . 0.0 110.216 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.402 ' CE ' ' CD1' ' A' ' 153' ' ' ILE . 69.0 mtt -61.86 -40.03 93.93 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.507 -0.745 . . . . 0.0 110.257 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -41.81 92.85 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.539 -179.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 72.8 p -70.03 -27.46 64.68 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.3 m -60.06 -45.39 93.03 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.425 -0.797 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.6 mtt . . . . . 0 N--CA 1.497 1.9 0 O-C-N 121.578 -0.701 . . . . 0.0 110.083 179.939 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.045 0.45 . . . . 0.0 110.139 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.414 HD22 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.617 -0.677 . . . . 0.0 110.25 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 . . . . . 0 N--CA 1.498 1.941 0 CA-C-O 120.823 0.344 . . . . 0.0 110.498 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.3 t -108.21 126.74 64.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.503 -0.748 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -123.39 154.41 39.03 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.484 -0.76 . . . . 0.0 110.584 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.9 t -90.3 122.77 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.617 -0.677 . . . . 0.0 109.276 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.37 152.71 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.564 -0.71 . . . . 0.0 110.176 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.2 m -141.75 169.56 17.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.662 -0.648 . . . . 0.0 110.513 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -132.37 -169.77 2.29 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.73 -41.73 87.11 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.42 -0.8 . . . . 0.0 110.575 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.8 m -134.24 -6.86 2.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.479 -0.763 . . . . 0.0 112.025 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.8 tp60 -111.76 160.43 17.32 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.899 -1.126 . . . . 0.0 110.864 -179.214 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -147.56 137.91 23.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.452 -0.78 . . . . 0.0 110.402 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 29.0 p90 -169.11 -177.67 2.99 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.312 -0.868 . . . . 0.0 110.434 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 54.6 mt -112.99 159.94 18.61 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.429 -0.795 . . . . 0.0 110.672 -178.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -136.26 159.84 40.53 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.689 -0.632 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 23.0 m -123.8 139.29 54.12 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.444 -0.785 . . . . 0.0 110.351 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.0 t -94.38 111.03 22.76 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 110.637 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.404 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.1 t -117.2 130.31 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.704 -0.623 . . . . 0.0 109.662 179.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.46 39.44 28.01 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.503 -0.748 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.85 19.89 75.56 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -133.53 129.77 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -1.163 . . . . 0.0 110.025 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 89.3 m -74.49 147.67 41.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.391 -0.818 . . . . 0.0 109.419 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.404 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 67.5 m95 -129.94 151.66 50.26 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.394 -0.816 . . . . 0.0 110.824 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.46 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.3 t -167.41 -179.62 4.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.756 -0.59 . . . . 0.0 109.771 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.477 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 9.4 p -90.03 158.19 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.454 -0.779 . . . . 0.0 110.319 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -74.27 -42.31 59.82 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.599 -0.688 . . . . 0.0 111.477 -179.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.477 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.3 p-80 -70.03 -22.48 63.09 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.148 -0.97 . . . . 0.0 110.799 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -81.31 -59.98 2.31 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 179.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -91.01 -52.34 4.89 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.639 -0.918 . . . . 0.0 110.204 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 -174.33 47.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 36.4 p -81.93 61.7 5.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.561 -0.964 . . . . 0.0 109.806 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -141.53 170.13 16.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.582 -0.699 . . . . 0.0 110.533 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.5 p -66.32 156.71 33.63 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.678 -0.639 . . . . 0.0 109.725 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.423 HD22 ' CE3' ' A' ' 85' ' ' TRP . 27.3 tp -118.3 140.5 49.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.575 -0.703 . . . . 0.0 110.28 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.27 109.72 21.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.663 -0.648 . . . . 0.0 109.998 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.19 -174.31 15.79 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.4 -32.35 71.82 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 O-C-N 123.907 1.477 . . . . 0.0 110.542 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.4 mttt -77.15 -31.03 55.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.667 -0.646 . . . . 0.0 110.01 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.75 -150.57 21.8 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -75.03 138.69 23.28 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.89 1.469 . . . . 0.0 110.358 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.4 HG22 HD12 ' A' ' 71' ' ' ILE . 85.2 mt -119.97 129.96 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.621 -0.674 . . . . 0.0 110.577 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.9 p -82.51 142.53 31.78 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.525 -0.735 . . . . 0.0 109.753 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.77 149.97 21.33 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.432 -0.793 . . . . 0.0 111.254 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.6 mmm -115.43 -26.3 7.61 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.752 -0.592 . . . . 0.0 110.451 179.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -119.95 139.95 51.66 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.396 -0.815 . . . . 0.0 110.724 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 91.7 m -140.35 130.0 24.3 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.654 -0.654 . . . . 0.0 109.944 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -137.37 103.27 5.03 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.389 -0.819 . . . . 0.0 110.441 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 70.9 t -71.15 -45.24 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.51 -0.744 . . . . 0.0 110.224 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -60.11 -49.89 75.85 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.437 -0.79 . . . . 0.0 110.223 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 3.7 tp-100 -80.04 -9.99 59.74 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.538 -0.726 . . . . 0.0 110.582 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 2.7 t70 56.01 44.95 24.66 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.147 -0.97 . . . . 0.0 109.985 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 64.9 mt -141.77 131.5 24.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.655 -0.653 . . . . 0.0 110.902 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.1 m -129.96 159.98 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -137.47 157.34 23.98 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.553 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.46 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 8.6 m-90 -115.39 157.05 24.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.874 -0.78 . . . . 0.0 109.467 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -69.48 108.16 3.66 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.521 -0.737 . . . . 0.0 109.377 179.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.16 143.34 91.09 Favored Pre-proline 0 N--CA 1.496 1.844 0 O-C-N 121.495 -0.753 . . . . 0.0 110.359 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.1 158.42 56.57 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.089 1.573 . . . . 0.0 110.154 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.98 153.33 63.37 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.886 1.466 . . . . 0.0 110.27 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.12 29.68 62.17 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.28 154.33 20.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.514 -0.992 . . . . 0.0 110.09 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -80.18 159.25 26.06 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 110.005 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 97.2 p -139.98 159.73 41.53 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.292 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 7.7 mt -106.09 132.19 52.46 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.591 -0.693 . . . . 0.0 110.482 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 86.7 m -80.0 141.29 54.5 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.693 -0.63 . . . . 0.0 109.916 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -64.04 163.58 25.13 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.812 1.427 . . . . 0.0 110.377 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.5 t -87.74 123.54 32.66 Favored 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.65 0.738 . . . . 0.0 110.937 -179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.0 m -118.21 59.66 0.8 Allowed 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 177.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 3.5 m -141.76 -9.31 0.93 Allowed 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 119.99 -0.684 . . . . 0.0 111.899 -177.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.12 25.47 54.07 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.089 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -70.23 130.81 43.04 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.525 -0.985 . . . . 0.0 110.723 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.4 m -74.37 -39.99 62.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.73 -0.606 . . . . 0.0 110.464 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.4 130.51 42.74 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.518 -0.739 . . . . 0.0 110.546 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.8 mt -131.23 140.2 49.82 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.649 -0.657 . . . . 0.0 110.637 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -106.85 124.37 49.52 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.494 -0.754 . . . . 0.0 109.817 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.7 tp -108.48 145.43 34.71 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.394 -0.816 . . . . 0.0 110.924 -179.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.05 120.99 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.674 -0.641 . . . . 0.0 109.706 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.9 p -95.31 173.03 7.74 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.55 -0.719 . . . . 0.0 110.547 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 3.5 ptp180 -69.33 -11.95 61.25 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.544 -0.723 . . . . 0.0 111.103 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.01 21.69 5.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.209 -0.932 . . . . 0.0 110.399 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.33 40.05 31.42 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.222 -0.924 . . . . 0.0 110.575 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -124.02 147.65 47.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.658 -0.651 . . . . 0.0 109.64 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.0 p -129.98 130.69 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.565 -0.709 . . . . 0.0 110.405 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.8 pt -121.1 150.0 52.61 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.679 -0.638 . . . . 0.0 109.796 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -81.57 123.27 4.24 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.937 1.493 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -119.7 120.95 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.715 -0.616 . . . . 0.0 109.6 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -76.73 149.67 36.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.48 -0.762 . . . . 0.0 110.039 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -90.89 120.06 31.6 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.359 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -109.94 20.09 18.36 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.659 -0.651 . . . . 0.0 110.399 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.85 -179.97 39.78 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.72 -39.92 90.41 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.972 . . . . 0.0 110.301 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.4 p -130.92 25.1 4.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.557 -0.714 . . . . 0.0 110.522 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -124.25 139.53 53.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.439 -0.788 . . . . 0.0 110.254 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.77 165.79 26.41 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 99.8 p -120.21 155.51 33.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.648 -0.913 . . . . 0.0 110.129 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.2 tp -99.97 119.5 38.35 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.516 -0.74 . . . . 0.0 110.158 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.04 -39.91 94.03 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.493 -0.754 . . . . 0.0 109.961 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 85.6 p -110.66 120.2 44.4 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.39 120.87 7.93 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 123.763 1.402 . . . . 0.0 110.4 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.2 mmt180 -129.93 159.98 67.34 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.539 -0.726 . . . . 0.0 110.251 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.39 156.72 61.82 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.982 1.517 . . . . 0.0 110.423 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 33.9 m -67.06 -25.44 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.658 -0.651 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.7 m -59.94 -40.04 87.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.41 -0.806 . . . . 0.0 110.272 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 88.5 t80 -60.06 -40.08 88.23 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.497 -0.752 . . . . 0.0 109.935 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -83.85 -25.39 30.34 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.535 -0.728 . . . . 0.0 110.287 179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -59.96 132.02 52.66 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.408 -0.808 . . . . 0.0 110.105 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 91.96 0.93 70.84 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.306 -0.95 . . . . 0.0 110.732 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -109.96 19.99 18.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.136 -1.214 . . . . 0.0 110.66 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.4 t -68.65 147.68 51.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.327 -0.858 . . . . 0.0 109.724 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.78 -14.5 62.98 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.26 148.85 43.17 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -96.81 148.31 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.875 1.461 . . . . 0.0 111.123 -179.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.5 mp -103.94 108.96 20.53 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 mp -99.93 134.79 42.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.461 -0.774 . . . . 0.0 111.773 -178.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.422 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 28.5 p -70.03 159.93 82.41 Favored Pre-proline 0 N--CA 1.494 1.75 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -52.62 -22.13 16.28 Favored 'Trans proline' 0 N--CA 1.5 1.904 0 O-C-N 123.512 1.269 . . . . 0.0 112.056 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 8.6 t -67.63 -42.92 81.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.228 -0.92 . . . . 0.0 110.055 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 125.51 35.93 0.59 Allowed Glycine 0 N--CA 1.496 2.671 0 C-N-CA 120.069 -1.062 . . . . 0.0 110.904 179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -133.02 144.63 50.2 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.237 -1.155 . . . . 0.0 110.283 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.67 145.21 55.19 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.588 -0.695 . . . . 0.0 110.357 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.2 t -119.15 -38.91 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.523 -0.735 . . . . 0.0 110.118 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.99 -177.73 42.47 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.431 HD13 HG21 ' A' ' 153' ' ' ILE . 85.4 mt -121.61 132.02 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -1.013 . . . . 0.0 110.521 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -60.32 137.16 58.18 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.586 -0.696 . . . . 0.0 109.799 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 68.5 ttt180 -121.17 -52.72 2.06 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.498 -0.752 . . . . 0.0 110.33 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -143.16 159.96 41.32 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.508 -0.745 . . . . 0.0 110.073 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.84 136.05 54.92 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.627 -0.671 . . . . 0.0 110.553 -179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.6 t -90.0 119.74 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.7 p -135.52 153.69 51.64 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.487 -0.758 . . . . 0.0 111.404 -179.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 37.1 m -130.53 137.38 49.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.756 -0.59 . . . . 0.0 109.522 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 21.7 mmt180 54.21 37.14 26.63 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.272 -0.893 . . . . 0.0 110.755 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 74.19 23.28 76.31 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.4 t -129.98 129.87 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.295 -1.12 . . . . 0.0 110.065 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.78 125.57 35.75 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.539 -0.725 . . . . 0.0 110.131 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.51 -29.61 7.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.541 -0.725 . . . . 0.0 110.455 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.89 162.85 34.45 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.57 -0.706 . . . . 0.0 109.941 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -136.02 165.59 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.432 -0.792 . . . . 0.0 110.965 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -126.37 135.86 51.98 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.629 -0.67 . . . . 0.0 109.995 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -139.88 147.41 40.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.496 -0.752 . . . . 0.0 110.64 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 33.0 m -89.96 125.0 62.1 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.497 -0.752 . . . . 0.0 109.556 179.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.88 159.96 39.5 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.746 1.393 . . . . 0.0 110.711 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 89.9 t -60.22 -25.23 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.596 -0.69 . . . . 0.0 110.594 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -58.73 -39.01 79.62 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.456 -0.777 . . . . 0.0 110.354 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 67.5 m -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.468 -0.77 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.3 mtm -69.99 -37.37 75.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.35 -0.844 . . . . 0.0 110.331 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -59.97 -40.15 88.09 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.513 -0.742 . . . . 0.0 110.468 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 70.1 p -65.31 -37.12 86.16 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.471 -0.768 . . . . 0.0 110.253 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.0 m -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.593 -0.692 . . . . 0.0 110.139 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.534 -0.729 . . . . 0.0 110.058 179.888 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.1 0.476 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.414 HD22 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp . . . . . 0 N--CA 1.495 1.801 0 O-C-N 121.535 -0.728 . . . . 0.0 110.041 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 N--CA 1.497 1.875 0 CA-C-O 121.101 0.477 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.8 124.65 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.592 -0.692 . . . . 0.0 109.793 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -119.13 155.11 32.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.667 -0.645 . . . . 0.0 110.512 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.8 t -90.21 131.04 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.621 -0.674 . . . . 0.0 109.539 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.8 m -123.91 158.38 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.68 -0.637 . . . . 0.0 110.194 -179.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.12 179.35 6.56 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.71 -0.619 . . . . 0.0 110.362 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.46 -170.9 3.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.67 -0.643 . . . . 0.0 109.479 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.03 -38.88 84.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.523 -0.736 . . . . 0.0 110.258 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.6 t -136.92 -6.71 1.87 Allowed 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.546 -0.721 . . . . 0.0 112.555 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -118.8 156.71 28.93 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 120.839 -1.163 . . . . 0.0 111.129 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.1 m -136.34 139.75 42.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.566 -0.709 . . . . 0.0 110.341 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -165.61 -177.16 4.24 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.238 -0.914 . . . . 0.0 110.075 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 21.7 mt -112.33 175.16 5.55 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.529 -0.732 . . . . 0.0 110.273 -178.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -149.64 156.85 42.59 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.692 -0.63 . . . . 0.0 110.087 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 27.6 m -119.51 139.92 51.33 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.699 -0.626 . . . . 0.0 110.063 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.3 t -101.35 109.35 21.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.453 -0.78 . . . . 0.0 110.476 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.4 t -120.38 134.28 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.69 -0.631 . . . . 0.0 109.842 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 m120 55.23 38.52 30.52 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.534 -0.729 . . . . 0.0 111.144 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.63 26.67 74.22 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 80.9 t -140.47 130.03 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.338 -1.095 . . . . 0.0 109.956 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 23.7 t -86.71 108.58 18.73 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.468 -0.77 . . . . 0.0 109.37 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -91.42 151.21 20.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.595 -0.691 . . . . 0.0 111.05 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.462 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.5 t -159.88 -179.71 8.06 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.46 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 10.5 p -96.59 152.35 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.448 -0.783 . . . . 0.0 110.443 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.58 -0.7 . . . . 0.0 112.091 -178.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.46 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.9 p-80 -68.85 -19.52 64.26 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.139 -0.976 . . . . 0.0 111.068 -178.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -91.13 -52.28 2.42 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 179.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -103.2 -47.68 4.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.628 -0.925 . . . . 0.0 110.123 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.2 -168.89 40.78 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.4 t -86.41 64.68 8.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.546 -0.973 . . . . 0.0 109.837 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -141.89 170.05 16.45 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.602 -0.686 . . . . 0.0 110.363 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.1 p -66.13 150.14 49.21 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.618 -0.676 . . . . 0.0 109.944 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.413 HD21 ' CZ2' ' A' ' 85' ' ' TRP . 19.2 tp -117.08 142.62 46.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.611 -0.681 . . . . 0.0 110.082 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -97.62 110.26 22.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.621 -0.675 . . . . 0.0 110.093 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.33 177.11 16.31 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.7 -31.78 68.98 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.85 1.448 . . . . 0.0 110.412 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -71.7 -31.47 66.78 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.597 -0.689 . . . . 0.0 109.999 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.88 -160.56 26.21 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.94 137.23 40.73 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.886 1.466 . . . . 0.0 110.036 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.6 mt -119.94 129.98 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.506 -0.746 . . . . 0.0 110.564 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.3 p -84.86 150.23 25.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.574 -0.704 . . . . 0.0 109.707 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 10.5 pm0 -98.53 148.12 24.08 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.481 -0.762 . . . . 0.0 111.008 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.9 mtp -113.95 -25.55 8.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.766 -0.584 . . . . 0.0 110.504 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -120.01 135.88 54.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.428 -0.795 . . . . 0.0 110.572 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.9 m -140.91 126.11 18.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 109.88 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 30.1 t-20 -140.5 104.51 4.77 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.349 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 75.8 t -69.97 -45.3 77.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 0.0 109.871 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -59.87 -49.69 76.7 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.554 -0.716 . . . . 0.0 110.213 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 53.6 tt0 -79.95 -9.99 59.73 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.583 -0.698 . . . . 0.0 110.832 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.0 t70 55.2 46.22 24.25 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.031 -1.043 . . . . 0.0 110.446 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 41.3 mt -143.36 130.43 20.69 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.552 -0.717 . . . . 0.0 111.075 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.1 m -130.94 159.99 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.615 -0.678 . . . . 0.0 109.265 178.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.76 157.92 23.91 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.597 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.462 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 6.0 m-90 -119.93 160.28 23.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.792 -0.828 . . . . 0.0 109.778 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -71.88 124.57 25.15 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.088 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -72.7 130.01 86.08 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.489 -0.757 . . . . 0.0 110.212 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.02 159.64 52.47 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 O-C-N 123.876 1.461 . . . . 0.0 110.356 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.41 139.7 42.11 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.85 1.447 . . . . 0.0 110.306 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.58 -20.33 50.84 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.01 47.1 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.305 -1.115 . . . . 0.0 110.221 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.8 mtp85 -92.16 170.01 10.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.573 -0.705 . . . . 0.0 110.165 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -132.37 160.01 37.58 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 80.5 mt -110.74 132.23 54.37 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 -179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.9 p -76.34 160.05 78.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.693 -0.629 . . . . 0.0 109.95 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -77.21 164.04 29.67 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.833 1.438 . . . . 0.0 110.651 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 47.1 t -73.06 128.57 35.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.647 -0.658 . . . . 0.0 110.212 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.7 p -132.05 54.42 1.94 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.725 -0.609 . . . . 0.0 109.715 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.59 -7.52 0.77 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.519 -0.738 . . . . 0.0 112.376 -179.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.98 94.36 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -100.08 123.6 44.51 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.668 -0.901 . . . . 0.0 110.49 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 79.5 p -70.04 -26.06 63.86 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.617 -0.677 . . . . 0.0 110.352 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -63.73 129.99 42.38 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.58 -0.7 . . . . 0.0 109.969 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.2 mt -137.4 136.08 37.54 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.6 -0.688 . . . . 0.0 110.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.88 119.99 40.83 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.55 -0.719 . . . . 0.0 109.718 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 57.2 tp -98.21 140.05 33.09 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.512 -0.742 . . . . 0.0 110.387 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.82 130.01 53.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.538 -0.726 . . . . 0.0 109.937 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 22.9 p -98.2 179.17 4.84 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.583 -0.698 . . . . 0.0 110.761 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 15.8 ttt-85 -70.01 -18.58 63.32 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.692 -0.63 . . . . 0.0 110.969 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -93.21 25.46 3.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.293 -0.879 . . . . 0.0 110.868 -179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.14 38.97 30.2 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.347 -0.846 . . . . 0.0 110.765 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -120.25 139.58 52.47 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.662 -0.648 . . . . 0.0 109.599 179.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.0 m -116.66 140.07 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.515 -0.741 . . . . 0.0 110.701 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 mp -124.32 149.99 62.7 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.681 -0.637 . . . . 0.0 109.572 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -83.6 126.53 4.1 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.842 1.443 . . . . 0.0 110.651 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -128.82 130.05 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.715 -0.616 . . . . 0.0 109.477 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.0 tpt180 -85.48 146.16 27.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.497 -0.752 . . . . 0.0 110.186 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -82.81 124.35 30.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.596 -0.69 . . . . 0.0 110.319 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -114.42 19.93 15.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.28 178.76 39.24 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -59.99 -41.11 91.35 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.509 -0.995 . . . . 0.0 110.293 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.1 p -130.43 25.52 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.464 -0.773 . . . . 0.0 110.654 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.2 tpp85 -126.84 140.49 52.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.507 -0.746 . . . . 0.0 110.356 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.27 166.81 25.95 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.5 p -124.83 147.43 48.75 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.588 -0.948 . . . . 0.0 110.201 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 mp -95.43 121.7 37.38 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.583 -0.698 . . . . 0.0 110.312 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -61.8 -40.07 93.94 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.53 -0.731 . . . . 0.0 109.86 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.9 p -108.58 117.95 53.11 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.711 -0.618 . . . . 0.0 109.757 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.19 124.46 13.02 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.744 1.391 . . . . 0.0 110.63 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -121.46 160.17 47.18 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.591 -0.693 . . . . 0.0 110.013 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.09 158.88 56.14 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.93 1.489 . . . . 0.0 110.437 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 68.4 t -66.65 -29.99 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.62 -0.675 . . . . 0.0 110.033 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.6 t -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.552 -0.717 . . . . 0.0 110.295 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -60.01 -49.54 77.28 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.461 -0.774 . . . . 0.0 110.02 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.5 mp -69.91 -29.33 66.49 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.632 -0.667 . . . . 0.0 110.626 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 139.98 56.95 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.386 -0.821 . . . . 0.0 110.083 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.54 13.08 83.01 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 16.7 m -115.3 17.25 16.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.281 -1.129 . . . . 0.0 110.766 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.8 m -60.04 144.32 49.72 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.34 -19.34 54.68 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.52 109.8 1.36 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -77.09 151.18 30.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.875 1.46 . . . . 0.0 110.852 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.409 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 6.5 mp -99.72 110.44 22.84 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.086 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -100.01 128.39 46.1 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.662 -0.649 . . . . 0.0 111.17 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.411 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.0 157.89 88.67 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.663 -0.648 . . . . 0.0 109.266 179.066 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.1 Cg_endo -52.16 -24.96 21.71 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 O-C-N 123.516 1.271 . . . . 0.0 112.314 -178.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 51.7 m -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.269 -0.895 . . . . 0.0 110.003 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.03 35.77 0.8 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.4 m170 -132.91 149.2 52.27 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -1.01 . . . . 0.0 110.289 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 145.52 51.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.628 -0.67 . . . . 0.0 110.223 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 57.6 t -118.23 -38.38 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.595 -0.691 . . . . 0.0 109.961 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -171.39 -170.02 34.98 Favored Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 85.4 mt -130.99 140.02 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.466 -1.02 . . . . 0.0 110.286 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -62.41 138.55 58.47 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.536 -0.727 . . . . 0.0 109.873 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.6 ttp180 -122.54 -52.1 1.93 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.627 -0.671 . . . . 0.0 110.319 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -149.64 161.88 41.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.487 -0.758 . . . . 0.0 110.421 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.92 149.81 39.53 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.649 -0.657 . . . . 0.0 110.161 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -109.95 117.99 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.645 -0.659 . . . . 0.0 109.885 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -137.47 160.53 38.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.642 . . . . 0.0 110.229 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 33.1 m -117.99 -56.63 2.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.573 -0.704 . . . . 0.0 110.765 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -109.33 29.96 7.06 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 110.42 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 100.18 0.3 55.94 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -116.39 126.04 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.098 -1.236 . . . . 0.0 109.649 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.78 123.62 37.24 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.653 . . . . 0.0 110.303 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -104.57 -24.04 13.04 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.651 -0.656 . . . . 0.0 110.503 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 159.65 41.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.429 -0.794 . . . . 0.0 110.184 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -141.37 162.4 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.507 -0.746 . . . . 0.0 110.635 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 -114.89 138.39 50.86 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.615 -0.678 . . . . 0.0 110.053 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -140.04 155.31 47.12 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.531 -0.73 . . . . 0.0 110.299 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 58.6 t -96.21 122.78 57.04 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.53 -0.731 . . . . 0.0 109.65 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -65.66 155.83 67.02 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.777 1.409 . . . . 0.0 110.615 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 61.3 t -63.78 -22.92 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.61 -0.681 . . . . 0.0 110.731 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.99 -39.11 84.61 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -0.829 . . . . 0.0 110.424 -179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.0 p -59.81 -34.39 72.99 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.437 -0.789 . . . . 0.0 110.51 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.0 mtt -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.527 -0.733 . . . . 0.0 110.492 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -59.95 -40.06 87.7 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.1 m -60.59 -48.61 81.01 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.504 -0.748 . . . . 0.0 110.05 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 87.3 m -70.01 -46.17 65.68 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.575 -0.703 . . . . 0.0 110.0 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.639 -0.663 . . . . 0.0 110.181 -179.91 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.155 0.502 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.415 HD21 ' CG ' ' A' ' 57' ' ' HIS . 9.7 mp . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.567 -0.708 . . . . 0.0 110.149 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 121.034 0.445 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.55 128.51 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -124.84 159.78 30.27 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.567 -0.708 . . . . 0.0 110.075 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.17 113.81 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.519 -0.738 . . . . 0.0 109.83 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.409 ' HB ' ' CD1' ' A' ' 64' ' ' LEU . 34.5 m -110.17 143.21 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.677 -0.64 . . . . 0.0 109.763 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 37.4 t -137.22 173.82 11.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.51 -0.744 . . . . 0.0 111.18 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 27.7 m -144.3 169.22 18.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.921 -0.487 . . . . 0.0 109.895 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -66.76 -16.72 64.45 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.669 -0.644 . . . . 0.0 110.617 179.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.8 m -111.05 -39.1 4.87 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.345 -0.847 . . . . 0.0 111.748 -179.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -146.86 170.7 16.49 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.157 -0.964 . . . . 0.0 111.573 -179.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.3 p -128.23 151.95 48.66 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.636 -0.665 . . . . 0.0 110.311 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -165.87 -178.02 4.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.374 -0.829 . . . . 0.0 110.334 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 76.2 mt -113.61 150.45 33.09 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.506 -0.746 . . . . 0.0 110.717 -178.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.46 159.13 34.23 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.655 -0.653 . . . . 0.0 110.055 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 62.8 m -120.33 131.6 54.93 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.664 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.4 t -90.16 102.56 15.28 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.547 -0.721 . . . . 0.0 110.136 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.404 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.7 t -109.97 130.12 63.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.582 -0.699 . . . . 0.0 109.593 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.41 39.98 27.74 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.437 -0.789 . . . . 0.0 110.66 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 19.98 75.97 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 110.869 -0.893 . . . . 0.0 110.869 179.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.4 t -131.84 129.98 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.161 -1.2 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.0 m -74.79 147.81 40.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.53 -0.731 . . . . 0.0 109.42 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.421 ' CD2' ' HE1' ' A' ' 175' ' ' MET . 74.5 m95 -129.97 152.31 49.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.426 -0.796 . . . . 0.0 111.072 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.459 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.0 t -169.5 -179.71 3.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.466 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.0 p -90.99 156.7 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.458 -0.776 . . . . 0.0 110.484 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -70.01 -42.69 72.69 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.57 -0.706 . . . . 0.0 111.194 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.466 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.2 p-80 -71.51 -19.06 62.24 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.281 -0.887 . . . . 0.0 111.014 -179.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -73.84 -57.57 4.84 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -87.18 -41.59 13.63 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.583 -0.951 . . . . 0.0 110.139 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 75.72 28.91 60.25 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.28 57.45 4.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.361 -1.082 . . . . 0.0 110.54 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.53 178.99 6.82 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.081 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 77.7 p -65.06 139.49 58.74 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.209 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.418 ' HG ' ' CZ2' ' A' ' 85' ' ' TRP . 0.1 OUTLIER -115.04 130.04 56.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.576 -0.702 . . . . 0.0 110.842 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.23 109.38 20.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.551 -0.718 . . . . 0.0 109.663 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.29 -154.47 13.11 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -72.55 -31.04 11.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.928 1.489 . . . . 0.0 110.445 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -83.67 -22.43 32.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.586 -0.697 . . . . 0.0 110.74 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 135.31 -139.52 10.87 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.91 154.91 34.01 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.904 1.476 . . . . 0.0 110.083 179.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.411 HG22 HD11 ' A' ' 71' ' ' ILE . 85.7 mt -131.45 140.01 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.554 -0.716 . . . . 0.0 110.575 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 91.9 m -95.27 140.0 30.78 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.559 -0.713 . . . . 0.0 109.943 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.415 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 8.9 tt0 -93.05 140.05 29.9 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 0.0 110.58 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.2 mmm -112.18 -29.98 7.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.629 -0.669 . . . . 0.0 110.566 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -118.41 139.77 50.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.585 -0.697 . . . . 0.0 110.569 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.3 m -139.97 132.12 28.07 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.513 -0.742 . . . . 0.0 109.93 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -136.23 96.62 3.42 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.443 -0.786 . . . . 0.0 110.5 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 82.6 t -70.02 -40.03 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.595 -0.691 . . . . 0.0 109.899 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.97 -47.34 86.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.562 -0.711 . . . . 0.0 110.297 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -90.05 0.15 57.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.531 -0.731 . . . . 0.0 110.97 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 t70 53.8 46.42 25.82 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.061 -1.025 . . . . 0.0 110.481 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 67.6 mt -141.45 135.92 30.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.476 -0.765 . . . . 0.0 110.747 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.4 m -134.01 164.44 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.606 -0.684 . . . . 0.0 109.432 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.75 156.79 26.05 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.871 -1.157 . . . . 0.0 110.343 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.459 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 7.2 m-90 -116.48 152.71 33.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.85 -0.794 . . . . 0.0 109.52 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -66.61 106.37 1.78 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.41 -0.806 . . . . 0.0 109.606 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -71.51 143.57 87.81 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.576 -0.703 . . . . 0.0 110.097 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.95 150.4 66.97 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.965 1.508 . . . . 0.0 110.338 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.01 159.76 44.91 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.849 1.447 . . . . 0.0 110.094 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.79 29.6 69.2 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.76 149.81 28.5 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.48 -1.012 . . . . 0.0 109.949 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -85.21 146.03 27.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.626 -0.671 . . . . 0.0 109.283 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.4 p -136.91 174.14 10.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.577 -0.702 . . . . 0.0 110.601 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 44.0 mt -108.39 149.8 28.23 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.675 -0.641 . . . . 0.0 110.598 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.0 p -90.03 176.18 3.24 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.649 -0.657 . . . . 0.0 110.003 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -89.49 160.49 5.42 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 O-C-N 123.807 1.425 . . . . 0.0 110.609 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.3 t -68.7 133.13 47.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.671 -0.643 . . . . 0.0 110.158 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.4 t -135.95 53.41 1.95 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.678 -0.639 . . . . 0.0 109.751 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.88 -8.2 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.554 -0.716 . . . . 0.0 112.378 -179.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 38.17 93.9 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -99.95 124.16 44.99 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.565 -0.962 . . . . 0.0 110.502 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 19.6 p -69.91 -34.27 73.28 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.614 -0.679 . . . . 0.0 110.133 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -61.67 129.98 43.64 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.574 -0.704 . . . . 0.0 109.903 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 90.2 mt -135.64 149.99 49.49 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.55 -0.719 . . . . 0.0 110.771 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.54 140.01 47.65 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.617 -0.677 . . . . 0.0 109.556 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 52.3 tp -115.2 142.16 47.04 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.496 -0.752 . . . . 0.0 110.677 -179.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 130.06 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.634 -0.666 . . . . 0.0 109.761 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 24.9 p -110.22 -179.9 3.91 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.519 -0.738 . . . . 0.0 110.643 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 32.8 mtp-105 -60.04 -26.38 66.08 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.586 -0.697 . . . . 0.0 110.652 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -89.96 17.91 6.32 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.393 -0.817 . . . . 0.0 111.181 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.09 38.38 27.26 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.057 -1.027 . . . . 0.0 110.748 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -100.76 139.8 35.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.699 -0.626 . . . . 0.0 109.893 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 63.4 t -110.02 119.99 60.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.597 -0.689 . . . . 0.0 109.928 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . 0.453 HD11 HG23 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -118.91 122.16 29.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.646 -0.659 . . . . 0.0 109.435 179.868 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.33 132.9 32.98 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.744 1.392 . . . . 0.0 110.368 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.2 t -129.93 130.04 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.678 -0.639 . . . . 0.0 109.731 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -86.36 132.72 33.89 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.497 -0.752 . . . . 0.0 109.972 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -70.76 130.03 40.65 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.581 -0.699 . . . . 0.0 110.438 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 24.5 mmm-85 -102.4 -20.9 14.38 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.653 -0.654 . . . . 0.0 110.377 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.24 -167.98 29.68 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -59.98 -39.98 87.56 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.606 -0.937 . . . . 0.0 110.401 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.4 p -129.89 25.37 5.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.508 -0.745 . . . . 0.0 110.581 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -125.88 140.04 52.98 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.483 -0.76 . . . . 0.0 110.278 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.87 167.18 24.69 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -127.82 150.03 50.01 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.576 -0.956 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.4 mp -103.02 131.39 50.04 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.442 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -61.79 -39.99 93.64 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.585 -0.697 . . . . 0.0 109.745 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.5 p -118.36 149.98 46.97 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.684 -0.635 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -84.42 82.65 1.8 Allowed 'Trans proline' 0 N--CA 1.489 1.237 0 O-C-N 123.843 1.444 . . . . 0.0 110.747 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -71.59 159.98 83.92 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 109.836 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.67 149.31 67.28 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.939 1.494 . . . . 0.0 110.292 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.4 -34.0 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.622 -0.674 . . . . 0.0 110.046 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.6 t -58.41 -36.67 73.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.549 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -60.06 -39.92 87.69 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.487 -0.758 . . . . 0.0 110.11 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.7 mp -81.37 -20.84 39.73 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.562 -0.711 . . . . 0.0 110.826 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -59.97 139.74 57.21 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.23 -0.919 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.6 1.07 86.12 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.5 m -101.51 3.07 39.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.107 -1.231 . . . . 0.0 110.975 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.9 t -59.97 139.93 57.08 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.145 -0.972 . . . . 0.0 109.863 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.96 -17.85 57.89 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.67 140.84 43.14 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 179.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -87.96 144.91 6.34 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.831 1.438 . . . . 0.0 111.471 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 8.3 mp -103.32 129.95 50.47 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -118.46 130.9 56.21 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.366 -0.834 . . . . 0.0 111.598 -178.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.439 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -70.02 159.75 83.09 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.76 -26.91 25.05 Favored 'Trans proline' 0 N--CA 1.501 1.96 0 O-C-N 123.475 1.25 . . . . 0.0 112.368 -178.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.78 -40.02 96.02 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.222 -0.924 . . . . 0.0 109.963 179.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.2 36.46 0.81 Allowed Glycine 0 N--CA 1.496 2.641 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -132.83 151.1 52.08 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.462 -1.023 . . . . 0.0 110.337 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.08 139.96 57.59 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.623 -0.673 . . . . 0.0 110.435 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 33.9 m -117.19 -22.19 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.597 -0.689 . . . . 0.0 110.726 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 171.39 -171.53 44.05 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 86.0 mt -128.82 140.02 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.542 -0.975 . . . . 0.0 110.154 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -71.15 135.47 47.64 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.66 -0.65 . . . . 0.0 109.962 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.4 ttp85 -116.52 -53.01 2.54 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.617 -0.677 . . . . 0.0 110.178 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -148.18 159.96 43.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.757 . . . . 0.0 110.391 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -115.95 151.58 35.12 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.63 . . . . 0.0 110.262 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.51 120.03 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.704 -0.622 . . . . 0.0 109.525 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.09 158.13 41.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.707 -0.621 . . . . 0.0 110.632 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.0 m -101.77 -61.06 1.43 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.67 -0.644 . . . . 0.0 110.309 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -129.03 63.69 1.48 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.681 -0.637 . . . . 0.0 110.066 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.98 9.99 86.08 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 25.3 m -126.75 132.09 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.206 -1.173 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.7 124.28 38.64 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.513 -0.742 . . . . 0.0 110.215 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.86 -29.9 8.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.648 -0.657 . . . . 0.0 110.232 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.26 151.44 45.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.638 -0.663 . . . . 0.0 110.125 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.96 159.96 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.617 -0.677 . . . . 0.0 110.669 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -121.97 130.67 53.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.668 -0.645 . . . . 0.0 109.934 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -134.37 159.92 39.54 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.539 -0.726 . . . . 0.0 110.501 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.3 t -93.42 126.49 50.13 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.615 -0.678 . . . . 0.0 109.368 179.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.94 157.37 53.11 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.771 1.406 . . . . 0.0 110.599 -179.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.85 -25.7 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.614 -0.679 . . . . 0.0 110.387 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -60.02 -39.97 87.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.422 -0.799 . . . . 0.0 110.364 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.7 t -65.42 -37.47 87.04 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.12 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.421 ' HE1' ' CD2' ' A' ' 53' ' ' TRP . 95.4 mtp -60.05 -41.82 93.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.56 -0.712 . . . . 0.0 110.293 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -69.12 -40.05 78.56 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.55 -0.719 . . . . 0.0 110.104 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.75 -40.08 93.87 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.673 -0.642 . . . . 0.0 109.92 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.2 m -59.95 -41.06 91.03 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.558 -0.714 . . . . 0.0 110.189 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.642 -0.661 . . . . 0.0 110.176 -179.812 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.013 0.435 . . . . 0.0 110.136 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.414 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.4 mp . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.622 -0.674 . . . . 0.0 110.165 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 N--CA 1.495 1.818 0 CA-C-O 121.103 0.477 . . . . 0.0 110.201 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.67 126.91 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.537 -0.727 . . . . 0.0 109.947 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -119.12 142.91 47.5 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.555 -0.716 . . . . 0.0 110.359 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -78.39 128.83 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.604 -0.685 . . . . 0.0 110.339 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.27 146.44 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.636 -0.665 . . . . 0.0 109.593 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.2 m -144.49 171.02 14.94 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.519 -0.738 . . . . 0.0 110.897 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.8 p -133.78 -170.92 2.6 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.93 -32.54 72.05 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.676 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 m -133.09 -11.1 2.94 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.356 -0.84 . . . . 0.0 112.639 -178.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -114.94 154.03 29.49 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.837 -1.165 . . . . 0.0 111.182 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.3 m -143.89 128.29 17.91 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.697 -0.627 . . . . 0.0 109.863 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -159.56 -178.72 7.31 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.307 -0.871 . . . . 0.0 110.469 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 69.8 mt -113.96 155.6 25.55 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.519 -0.738 . . . . 0.0 110.533 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.52 160.52 33.88 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.625 -0.672 . . . . 0.0 110.304 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 87.1 m -119.97 130.78 54.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.553 -0.717 . . . . 0.0 110.142 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.2 t -89.34 104.03 16.62 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.541 -0.724 . . . . 0.0 110.67 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.18 130.1 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.621 -0.674 . . . . 0.0 109.492 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.21 39.55 28.67 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.428 -0.795 . . . . 0.0 110.707 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.98 19.97 75.85 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.1 t -133.73 129.98 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.224 -1.162 . . . . 0.0 110.031 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.9 m -71.57 147.52 47.56 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.437 -0.789 . . . . 0.0 109.667 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -139.71 145.47 38.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.47 -0.769 . . . . 0.0 110.867 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.452 ' CG2' ' CZ3' ' A' ' 85' ' ' TRP . 7.6 t -170.02 -178.74 2.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.723 -0.61 . . . . 0.0 109.758 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.46 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -78.22 162.13 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.524 -0.735 . . . . 0.0 110.388 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -86.97 -35.1 19.04 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.6 -0.687 . . . . 0.0 111.773 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.46 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.2 p-80 -63.34 -22.14 66.7 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.02 -1.05 . . . . 0.0 110.583 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.434 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -79.68 -60.05 2.54 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.105 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.99 1.68 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.583 -0.951 . . . . 0.0 109.943 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.11 36.84 20.33 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.3 p 53.72 40.05 31.0 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.48 -1.012 . . . . 0.0 110.71 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -111.57 179.5 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.672 -0.642 . . . . 0.0 109.755 179.551 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.7 m -64.74 139.36 58.75 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.489 -0.757 . . . . 0.0 109.102 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.423 HD23 ' CD2' ' A' ' 85' ' ' TRP . 12.5 tp -119.89 138.52 53.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.488 -0.757 . . . . 0.0 110.524 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -112.53 109.52 19.15 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.635 -0.666 . . . . 0.0 109.947 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.82 -172.59 25.55 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.44 -32.34 49.89 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.88 1.463 . . . . 0.0 110.362 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -75.96 -31.12 58.89 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.561 -0.712 . . . . 0.0 109.973 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.64 -144.92 14.25 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.72 155.61 58.33 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 O-C-N 123.85 1.447 . . . . 0.0 110.303 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 83.9 mt -130.05 140.01 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.553 -0.717 . . . . 0.0 110.102 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 23.2 m -87.31 150.49 23.83 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.486 -0.758 . . . . 0.0 110.789 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 72.8 mt-30 -93.08 139.95 30.01 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.544 -0.722 . . . . 0.0 110.484 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.8 mmm -118.45 -32.48 4.61 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.545 -0.722 . . . . 0.0 110.55 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -138.2 150.71 47.01 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.461 -0.774 . . . . 0.0 110.532 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 90.2 m -149.59 134.07 17.53 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.534 -0.729 . . . . 0.0 109.813 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.4 t-20 -141.71 100.32 3.73 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.495 -0.753 . . . . 0.0 110.424 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 74.6 t -70.0 -38.24 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.002 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -60.0 -45.36 92.99 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.544 -0.723 . . . . 0.0 110.495 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.98 2.79 54.72 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.464 -0.772 . . . . 0.0 111.121 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.7 t0 54.46 47.69 22.24 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.965 -1.084 . . . . 0.0 110.438 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 71.3 mt -140.0 143.07 36.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.547 -0.721 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.5 144.68 28.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.619 -0.676 . . . . 0.0 109.248 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -128.28 153.5 19.53 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.292 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.452 ' CZ3' ' CG2' ' A' ' 54' ' ' THR . 8.4 m-90 -120.21 168.07 11.6 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.693 -0.887 . . . . 0.0 109.887 179.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -76.73 109.11 10.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.498 -0.751 . . . . 0.0 109.349 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.03 140.66 97.93 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.473 -0.767 . . . . 0.0 110.196 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.05 159.95 51.37 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.847 1.446 . . . . 0.0 110.262 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.05 157.52 59.54 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.931 1.49 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.98 30.01 70.36 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.04 140.67 47.65 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.554 -0.968 . . . . 0.0 110.221 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.89 152.8 23.3 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.53 -0.731 . . . . 0.0 109.786 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.7 p -130.0 170.04 14.48 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.536 -0.727 . . . . 0.0 110.433 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 66.6 mt -110.01 143.73 39.58 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.607 -0.683 . . . . 0.0 110.632 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 42.9 p -85.96 172.74 7.96 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.628 -0.67 . . . . 0.0 110.042 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -83.48 161.29 14.8 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.925 1.487 . . . . 0.0 110.534 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 53.2 t -77.79 129.98 36.14 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.655 -0.653 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 35.3 m -135.54 56.81 1.82 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.675 -0.64 . . . . 0.0 109.511 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 p -143.94 -4.44 0.83 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.626 -0.671 . . . . 0.0 112.288 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 39.97 96.45 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.9 m -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.53 -0.982 . . . . 0.0 110.471 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.7 p -69.97 -27.3 64.61 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.676 -0.64 . . . . 0.0 110.376 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -66.39 129.43 39.8 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 110.124 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 95.4 mt -134.96 150.0 50.3 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.699 -0.626 . . . . 0.0 110.706 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -117.35 123.95 47.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.556 -0.715 . . . . 0.0 109.694 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 43.1 tp -99.99 139.99 34.86 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.461 -0.775 . . . . 0.0 110.757 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.11 139.96 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.671 -0.643 . . . . 0.0 109.853 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.8 p -119.59 173.14 7.18 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.524 -0.735 . . . . 0.0 110.624 -179.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -62.89 -25.67 68.41 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.532 -0.73 . . . . 0.0 110.627 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -92.64 24.41 3.56 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.418 -0.801 . . . . 0.0 110.922 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.1 23.09 4.97 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.237 -0.915 . . . . 0.0 110.849 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -94.85 155.44 16.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.811 . . . . 0.0 109.734 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.1 p -130.02 129.94 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.517 -0.74 . . . . 0.0 110.505 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . 0.457 HD11 HG21 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -114.38 123.31 32.63 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.614 -0.679 . . . . 0.0 109.36 179.708 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -65.35 129.55 22.99 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.79 1.416 . . . . 0.0 110.484 -179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.3 t -129.14 130.02 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.696 -0.627 . . . . 0.0 109.663 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -86.01 149.46 25.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.505 -0.747 . . . . 0.0 109.967 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 46.2 ttp180 -90.62 120.01 31.34 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.559 -0.713 . . . . 0.0 110.412 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -112.49 20.04 17.01 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.64 -0.663 . . . . 0.0 110.519 179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.86 -179.94 40.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -62.64 -39.99 95.6 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.58 -0.953 . . . . 0.0 110.279 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 33.8 p -130.66 24.17 5.06 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.525 -0.734 . . . . 0.0 110.601 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -126.55 139.31 53.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.417 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.99 170.84 24.13 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 94.8 p -120.16 153.08 36.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.979 . . . . 0.0 110.085 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.6 tp -98.2 118.64 35.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.53 -0.732 . . . . 0.0 110.234 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.3 mp -65.62 -40.04 92.14 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -110.0 110.11 58.92 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.61 -0.681 . . . . 0.0 110.138 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -64.99 115.64 3.39 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.848 1.446 . . . . 0.0 110.391 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.416 ' HD3' ' CD2' ' A' ' 134' ' ' TYR . 6.8 mtt180 -126.97 160.04 61.42 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.572 -0.705 . . . . 0.0 110.224 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.15 156.83 56.99 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 O-C-N 123.862 1.453 . . . . 0.0 110.255 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 33.8 m -59.96 -30.01 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.516 -0.74 . . . . 0.0 110.305 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -62.15 -32.37 72.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.595 -0.69 . . . . 0.0 109.924 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.422 ' CZ ' HD12 ' A' ' 135' ' ' LEU . 0.0 OUTLIER -59.98 -39.99 87.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.582 -0.699 . . . . 0.0 110.058 -179.812 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.447 ' CD2' ' CZ ' ' A' ' 154' ' ' PHE . 8.2 tp -100.22 -1.92 35.22 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.489 -0.757 . . . . 0.0 111.527 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.04 139.99 52.76 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.113 -0.992 . . . . 0.0 109.851 179.52 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 83.3 -3.2 85.51 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.4 m -107.98 15.06 24.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.099 -1.236 . . . . 0.0 110.626 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -69.92 149.92 47.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 109.345 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.09 -19.95 52.5 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.45 151.0 29.17 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -95.38 149.14 1.51 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.826 1.435 . . . . 0.0 111.187 -179.102 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 84.4 mt -101.59 108.02 19.46 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -99.98 130.02 46.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 111.401 -178.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.428 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.64 83.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -52.32 -22.62 16.24 Favored 'Trans proline' 0 N--CA 1.501 1.957 0 O-C-N 123.569 1.299 . . . . 0.0 112.222 -178.755 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.28 -40.0 89.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.28 -0.888 . . . . 0.0 109.959 179.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.35 35.69 0.85 Allowed Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 35.1 m170 -131.46 146.33 52.2 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.422 -1.046 . . . . 0.0 110.321 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.33 144.31 57.19 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.649 -0.657 . . . . 0.0 110.3 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.7 t -118.91 -39.74 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.619 -0.676 . . . . 0.0 109.931 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -167.33 33.9 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 153' ' ' ILE . 91.0 mt -130.0 137.04 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.51 -0.994 . . . . 0.0 110.332 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . 0.447 ' CZ ' ' CD2' ' A' ' 135' ' ' LEU . 20.1 t80 -64.7 138.3 58.31 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.606 -0.684 . . . . 0.0 109.427 179.344 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -116.23 -52.43 2.59 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.537 -0.727 . . . . 0.0 110.534 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -157.45 161.62 38.92 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.563 -0.711 . . . . 0.0 110.563 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.04 151.74 26.81 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.657 -0.652 . . . . 0.0 110.017 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -108.26 118.03 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.605 -0.685 . . . . 0.0 109.734 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -132.96 166.85 21.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.694 -0.629 . . . . 0.0 110.337 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 29.4 m -126.81 -54.24 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.498 -0.752 . . . . 0.0 110.363 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.7 mmt180 -102.04 26.76 7.24 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.537 -0.727 . . . . 0.0 110.388 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.37 -2.31 57.58 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.99 128.7 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.108 -1.231 . . . . 0.0 109.659 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.82 127.42 35.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.628 -0.67 . . . . 0.0 110.722 -179.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -102.82 -19.66 14.6 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.632 -0.667 . . . . 0.0 110.313 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.93 160.71 39.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.093 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.77 173.95 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.554 -0.716 . . . . 0.0 110.409 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -133.76 132.83 41.0 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.664 -0.648 . . . . 0.0 109.886 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -136.69 156.06 49.04 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.422 -0.799 . . . . 0.0 110.59 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.8 t -98.54 123.46 50.01 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.661 -0.649 . . . . 0.0 109.373 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -63.42 153.04 77.09 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.726 1.382 . . . . 0.0 110.646 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 67.2 t -57.06 -21.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.634 -0.667 . . . . 0.0 110.756 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -57.36 -37.11 72.1 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.319 -0.863 . . . . 0.0 110.615 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.5 t -60.08 -34.85 74.02 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.512 -0.742 . . . . 0.0 110.489 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.5 mtt -59.96 -40.02 87.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.483 -0.761 . . . . 0.0 110.495 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.35 -40.02 89.24 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.726 . . . . 0.0 110.334 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -66.37 -39.98 89.44 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.588 -0.695 . . . . 0.0 110.108 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.2 m -60.59 -46.8 88.88 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.484 -0.76 . . . . 0.0 110.171 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.497 1.909 0 O-C-N 121.521 -0.737 . . . . 0.0 110.205 -179.893 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.412 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.686 -0.634 . . . . 0.0 110.472 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 N--CA 1.497 1.895 0 CA-C-O 121.046 0.451 . . . . 0.0 110.365 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.38 131.57 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.566 -0.709 . . . . 0.0 109.97 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -124.22 158.85 31.48 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.563 -0.711 . . . . 0.0 110.177 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.2 t -93.28 114.74 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.626 -0.671 . . . . 0.0 109.911 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.405 ' CG1' ' CD2' ' A' ' 64' ' ' LEU . 61.3 t -116.32 139.6 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 21.9 m -146.84 173.88 11.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.322 -0.861 . . . . 0.0 111.167 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.6 p -129.83 -179.17 5.04 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.836 -0.54 . . . . 0.0 109.576 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.26 -7.99 52.39 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.677 -0.639 . . . . 0.0 111.05 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -108.71 -37.61 5.85 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.118 -0.988 . . . . 0.0 111.772 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -152.83 169.25 23.25 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.172 -0.955 . . . . 0.0 111.299 -179.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 30.3 t -121.7 147.16 46.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.541 -0.725 . . . . 0.0 110.656 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -159.44 -177.72 6.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 -179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.7 mt -113.18 157.4 21.74 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.383 -0.823 . . . . 0.0 110.225 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -134.89 146.5 49.26 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.492 -0.755 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 35.2 m -100.82 124.87 47.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.639 -0.663 . . . . 0.0 110.029 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.9 t -87.15 103.13 15.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.584 -0.697 . . . . 0.0 110.164 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.31 130.37 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.61 -0.681 . . . . 0.0 109.631 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 37.5 t30 57.15 39.41 28.96 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.423 -0.798 . . . . 0.0 110.606 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.97 20.61 76.36 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.01 130.03 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.257 -1.143 . . . . 0.0 109.976 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -74.5 140.34 44.48 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.455 -0.778 . . . . 0.0 109.275 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 62.6 m95 -132.07 137.38 47.75 Favored 'General case' 0 N--CA 1.494 1.746 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.792 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -160.06 -179.65 7.96 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.452 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 13.4 p -78.94 161.28 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 111.295 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.407 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 48.8 t80 -74.12 -41.92 60.86 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.686 -0.634 . . . . 0.0 111.613 -179.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.452 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.3 p-80 -59.11 -24.62 63.12 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.155 -0.966 . . . . 0.0 110.707 -178.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -72.58 -50.45 15.07 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.996 -2.042 . . . . 0.0 107.996 178.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -148.58 78.23 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.752 -0.852 . . . . 0.0 109.45 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -84.63 102.82 2.59 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 21.4 p 48.97 56.03 8.38 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.68 -0.894 . . . . 0.0 111.468 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -139.82 174.76 10.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -64.91 139.2 58.74 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 120.044 -0.662 . . . . 0.0 109.6 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.418 HD21 ' CG ' ' A' ' 85' ' ' TRP . 12.0 tp -116.29 157.63 24.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.619 -0.676 . . . . 0.0 110.333 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -134.4 109.56 8.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.696 -0.628 . . . . 0.0 109.727 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.25 -164.01 15.69 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.78 -32.65 8.98 Favored 'Trans proline' 0 N--CA 1.49 1.31 0 O-C-N 123.95 1.5 . . . . 0.0 110.378 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 58.6 tptt -75.73 -31.19 59.5 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.681 -0.637 . . . . 0.0 109.823 -179.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.53 -149.21 20.91 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.14 141.09 20.44 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.89 1.468 . . . . 0.0 110.13 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.3 mt -130.02 140.07 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.483 -0.761 . . . . 0.0 110.259 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.7 t -85.1 137.27 33.14 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.533 -0.729 . . . . 0.0 110.514 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.43 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 24.9 tt0 -77.12 141.14 40.32 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.509 -0.744 . . . . 0.0 110.662 -179.659 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.1 mmm -110.71 -29.02 8.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.629 -0.669 . . . . 0.0 110.365 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.0 139.99 51.64 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.492 -0.755 . . . . 0.0 110.662 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 32.0 m -137.83 136.62 37.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.549 -0.719 . . . . 0.0 110.09 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 26.4 m120 -149.75 92.15 1.88 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.528 -0.733 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.407 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 92.1 t -70.0 -43.53 79.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.545 -0.722 . . . . 0.0 110.055 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -60.1 -43.77 95.33 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.482 -0.761 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.5 tp60 -90.11 0.08 57.34 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.553 -0.717 . . . . 0.0 110.881 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 4.1 t0 54.09 46.24 25.84 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.039 -1.038 . . . . 0.0 110.289 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 54.0 mt -134.03 147.58 50.97 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.514 -0.741 . . . . 0.0 110.959 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.413 HG23 ' CH2' ' A' ' 85' ' ' TRP . 16.1 m -150.25 168.89 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.646 -0.659 . . . . 0.0 109.786 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.425 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -163.36 157.84 30.09 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.43 ' CD1' ' HA ' ' A' ' 73' ' ' GLN . 9.9 m-90 -128.11 159.96 33.5 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.97 . . . . 0.0 109.813 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -67.13 113.06 4.78 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.521 -0.737 . . . . 0.0 109.597 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -78.35 135.16 61.65 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.522 -0.736 . . . . 0.0 110.265 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.95 159.97 51.32 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.83 1.437 . . . . 0.0 110.338 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.12 159.62 53.15 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 O-C-N 123.916 1.482 . . . . 0.0 110.286 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.17 -21.15 47.75 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.07 160.06 25.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.403 -1.057 . . . . 0.0 110.232 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 74.8 mtp85 -96.01 161.52 13.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.629 -0.669 . . . . 0.0 110.204 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 71.1 m -125.65 157.78 36.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.671 -0.643 . . . . 0.0 110.191 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 85.0 mt -110.01 132.17 54.4 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 110.559 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.1 p -78.04 159.95 74.73 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.601 -0.687 . . . . 0.0 110.05 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.6 163.91 28.85 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.8 1.421 . . . . 0.0 110.809 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . 0.418 ' SG ' ' SG ' ' A' ' 99' ' ' CYS . 49.1 t -78.64 132.7 37.17 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.641 -0.662 . . . . 0.0 110.163 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.9 p -132.52 53.17 2.03 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.785 -0.572 . . . . 0.0 109.63 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . 0.418 ' SG ' ' SG ' ' A' ' 97' ' ' CYS . 29.1 p -143.47 -8.48 0.76 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 119.907 -0.717 . . . . 0.0 112.412 -179.059 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.03 34.21 82.56 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 80.3 p -83.62 138.13 33.49 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.51 -0.994 . . . . 0.0 110.448 -179.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.6 m -81.72 -30.98 32.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.559 -0.713 . . . . 0.0 110.385 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -69.99 130.06 41.17 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.53 -0.731 . . . . 0.0 110.187 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.1 mt -131.02 149.55 52.56 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.65 -0.656 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -119.97 113.91 21.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.52 -0.738 . . . . 0.0 109.701 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 39.7 tp -96.67 142.87 28.19 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.55 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.99 129.96 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.616 -0.677 . . . . 0.0 109.832 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 26.9 p -100.02 -172.31 2.2 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.488 -0.758 . . . . 0.0 110.567 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 86.9 mtm-85 -59.97 -28.98 68.12 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.586 -0.696 . . . . 0.0 110.57 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.26 20.04 5.45 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.603 -0.685 . . . . 0.0 111.018 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 26.33 6.7 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.115 -0.991 . . . . 0.0 110.745 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -80.07 159.99 25.95 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.605 -0.684 . . . . 0.0 109.911 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.4 t -109.97 119.95 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.569 -0.707 . . . . 0.0 109.97 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 mp -114.32 110.0 48.29 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.68 . . . . 0.0 109.69 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.42 117.29 4.6 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.869 1.458 . . . . 0.0 110.354 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.0 t -120.05 129.13 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.701 -0.625 . . . . 0.0 109.737 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 mmm-85 -82.51 150.08 27.18 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.711 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -94.13 114.14 26.22 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -108.5 19.98 19.13 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.559 -0.713 . . . . 0.0 110.355 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.05 -178.54 40.07 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -61.32 -40.01 92.62 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.231 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.3 p -131.84 26.08 4.65 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.536 -0.728 . . . . 0.0 110.495 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.3 tpt180 -125.71 140.23 52.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.465 -0.772 . . . . 0.0 110.286 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.01 166.51 27.48 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 89.9 p -120.01 151.4 39.03 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.926 . . . . 0.0 110.265 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 tp -94.07 115.2 27.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.651 -0.656 . . . . 0.0 110.003 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.2 mp -62.15 -40.05 94.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.528 -0.732 . . . . 0.0 110.449 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 54.4 m -108.98 119.99 47.23 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -66.01 121.03 8.27 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 O-C-N 123.799 1.421 . . . . 0.0 110.537 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . 0.449 ' CD ' ' CE2' ' A' ' 134' ' ' TYR . 89.4 mtt-85 -128.88 160.44 63.32 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.618 -0.676 . . . . 0.0 110.136 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.06 163.76 32.75 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.94 1.495 . . . . 0.0 110.517 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 67.2 t -67.02 -40.04 84.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.646 -0.659 . . . . 0.0 110.344 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.9 p -53.87 -30.87 47.64 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.409 -0.807 . . . . 0.0 110.991 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . 0.449 ' CE2' ' CD ' ' A' ' 130' ' ' ARG . 36.9 t80 -60.06 -40.01 87.99 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.454 -0.779 . . . . 0.0 110.091 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.418 HD13 ' CD2' ' A' ' 134' ' ' TYR . 9.0 mp -87.92 -23.73 23.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.57 -0.706 . . . . 0.0 110.625 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.2 tptm -59.99 129.32 41.22 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.347 -0.846 . . . . 0.0 110.0 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.04 -10.05 75.3 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.2 m -104.04 16.79 25.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.164 -1.197 . . . . 0.0 110.877 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -69.94 151.82 45.18 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.08 -17.93 57.81 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.56 149.46 28.49 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -98.39 146.71 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.852 1.448 . . . . 0.0 111.263 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.3 mp -102.69 105.52 16.0 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -93.35 130.89 38.95 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.728 . . . . 0.0 111.363 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.435 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -69.98 159.31 84.71 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.99 -23.04 15.77 Favored 'Trans proline' 0 N--CA 1.502 1.993 0 O-C-N 123.418 1.22 . . . . 0.0 112.144 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -65.71 -39.99 91.77 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.335 -0.853 . . . . 0.0 109.823 179.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.71 35.3 0.85 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.0 m170 -132.72 146.02 51.51 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.456 -1.026 . . . . 0.0 110.3 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.79 140.02 58.83 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.623 -0.673 . . . . 0.0 110.201 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.1 -51.06 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.523 -0.736 . . . . 0.0 109.995 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -160.35 -172.21 27.29 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.425 HD11 HG22 ' A' ' 153' ' ' ILE . 89.6 mt -128.23 135.71 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.585 -0.95 . . . . 0.0 110.352 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -64.16 134.81 55.56 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 109.582 179.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.4 ttm105 -120.44 -52.45 2.15 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.489 -0.757 . . . . 0.0 110.733 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -142.25 157.29 45.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.751 . . . . 0.0 110.264 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.87 139.16 52.82 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 110.493 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -92.44 117.14 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.67 160.02 40.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.465 -0.772 . . . . 0.0 111.647 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 35.8 p -139.31 139.26 37.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.815 -0.553 . . . . 0.0 109.509 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.0 mtm180 55.62 30.87 16.18 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.466 -0.771 . . . . 0.0 110.539 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.02 22.89 64.84 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.1 t -129.53 129.73 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.341 -1.094 . . . . 0.0 109.89 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.06 129.98 46.17 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.542 -0.724 . . . . 0.0 110.5 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -118.83 -30.05 5.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.55 -0.719 . . . . 0.0 110.732 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -136.4 157.41 46.85 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.442 -0.786 . . . . 0.0 110.229 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.8 m -135.46 157.51 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.558 -0.714 . . . . 0.0 110.757 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -120.27 135.82 54.87 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.599 -0.688 . . . . 0.0 109.809 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -137.01 154.5 50.38 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.698 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 95.8 t -98.27 125.07 44.75 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.572 -0.705 . . . . 0.0 109.183 179.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -62.35 155.9 54.54 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 O-C-N 123.713 1.375 . . . . 0.0 110.797 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 96.3 t -56.19 -21.64 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.674 -0.641 . . . . 0.0 110.853 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -56.7 -37.25 70.64 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.362 -0.836 . . . . 0.0 110.768 -179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 28.2 t -59.99 -44.54 94.45 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.392 -0.817 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 78.0 mtm -67.34 -39.92 85.85 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -60.3 -40.58 91.01 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -62.84 -40.04 96.2 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.616 -0.677 . . . . 0.0 110.055 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.5 m -60.95 -40.04 91.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.6 -0.687 . . . . 0.0 110.056 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.84 0 O-C-N 121.534 -0.729 . . . . 0.0 110.259 -179.851 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 44.4 tp10 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.048 0.452 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . . . . . . . . . 10.7 mp . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.598 -0.689 . . . . 0.0 110.07 179.976 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 . . . . . 0 N--CA 1.496 1.875 0 CA-C-O 120.928 0.394 . . . . 0.0 110.513 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.3 t -109.99 127.25 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.495 -0.753 . . . . 0.0 109.695 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -131.68 156.84 45.17 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.672 . . . . 0.0 110.376 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 32.6 m -90.08 118.58 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.705 -0.622 . . . . 0.0 110.387 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.85 141.04 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.469 -0.769 . . . . 0.0 109.288 179.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 19.3 m -146.59 -178.92 6.42 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.748 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.3 p -141.49 -168.63 2.69 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.846 -0.534 . . . . 0.0 110.239 -179.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.47 -35.11 67.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.594 -0.691 . . . . 0.0 111.511 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.4 t -137.33 -8.01 1.74 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.266 -0.896 . . . . 0.0 113.033 -178.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 19.1 tp60 -115.38 143.71 44.88 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.881 -1.137 . . . . 0.0 110.88 -179.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.9 m -129.29 138.69 51.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.749 -0.595 . . . . 0.0 109.835 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.9 p90 -166.5 -177.52 4.03 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.46 -0.775 . . . . 0.0 110.466 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 69.2 mt -112.98 146.43 39.06 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.557 -0.714 . . . . 0.0 110.172 -178.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -128.68 161.21 30.21 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.631 -0.668 . . . . 0.0 110.261 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 t -121.3 140.55 51.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.558 -0.714 . . . . 0.0 110.146 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.9 t -97.42 110.08 22.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.579 -0.701 . . . . 0.0 110.352 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.2 130.0 62.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 109.476 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 55.67 40.0 30.89 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.483 -0.761 . . . . 0.0 110.762 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.06 22.15 77.16 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -131.84 130.0 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.235 -1.156 . . . . 0.0 110.123 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -72.09 146.0 47.83 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.452 -0.78 . . . . 0.0 109.296 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -139.97 137.2 34.53 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.357 -0.839 . . . . 0.0 111.645 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.411 HG22 ' CZ3' ' A' ' 85' ' ' TRP . 13.4 t -161.09 173.88 14.52 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.442 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.466 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.9 p -78.64 150.37 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.267 -0.896 . . . . 0.0 110.838 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.411 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.2 t80 -60.05 -49.2 78.59 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.58 -0.7 . . . . 0.0 111.894 -178.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.466 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.4 p-80 -57.94 -24.41 57.78 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.029 -1.044 . . . . 0.0 110.926 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -75.48 -46.31 15.51 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 178.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -136.38 94.53 3.03 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.723 -0.869 . . . . 0.0 109.433 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.73 -166.62 3.39 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.0 p -71.57 69.62 0.63 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.622 -0.928 . . . . 0.0 109.964 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.3 178.76 7.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.559 -0.713 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 31.0 p -65.54 147.38 53.51 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.713 . . . . 0.0 109.619 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.436 HD23 ' CD2' ' A' ' 85' ' ' TRP . 12.9 tp -113.1 133.4 55.03 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.611 -0.681 . . . . 0.0 109.99 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.03 109.63 21.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.617 -0.677 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.72 -171.74 17.76 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.24 -32.55 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.908 1.478 . . . . 0.0 110.456 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -76.14 -31.31 58.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.584 -0.698 . . . . 0.0 109.787 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.01 -146.15 17.24 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.7 144.43 31.4 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.895 1.471 . . . . 0.0 110.182 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.03 140.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.485 -0.759 . . . . 0.0 110.316 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.3 m -86.05 136.3 33.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.529 -0.732 . . . . 0.0 110.288 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.428 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 16.4 pt20 -83.38 149.49 26.68 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.589 -0.694 . . . . 0.0 110.959 -179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 82.1 mtp -119.27 -18.92 8.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.666 -0.646 . . . . 0.0 110.986 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -128.12 147.98 50.56 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.245 -0.909 . . . . 0.0 110.588 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.8 p -144.49 126.0 14.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.743 -0.598 . . . . 0.0 109.975 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -142.48 90.75 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.62 -0.675 . . . . 0.0 110.053 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.411 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 86.7 t -69.82 -46.69 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.579 -0.7 . . . . 0.0 109.911 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -41.82 92.85 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.594 -0.691 . . . . 0.0 110.277 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -90.31 -0.11 57.49 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.571 -0.706 . . . . 0.0 111.149 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 t70 53.25 44.49 30.1 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.99 -1.069 . . . . 0.0 110.85 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 45.5 mt -132.93 146.53 51.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.3 -0.875 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.413 HG23 ' CH2' ' A' ' 85' ' ' TRP . 30.6 m -152.83 169.58 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.65 -0.656 . . . . 0.0 109.667 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.408 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -164.9 157.78 30.35 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.436 ' CD2' HD23 ' A' ' 64' ' ' LEU . 10.2 m-90 -128.67 168.1 16.27 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.66 -0.906 . . . . 0.0 109.835 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 54.8 tp60 -70.85 119.38 14.9 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.444 -0.785 . . . . 0.0 109.375 179.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.52 149.91 95.58 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.532 -0.73 . . . . 0.0 110.099 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.96 154.34 67.04 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.884 1.465 . . . . 0.0 110.369 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.42 152.98 74.97 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.941 1.495 . . . . 0.0 110.178 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 30.0 70.42 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.79 147.74 30.44 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.481 -1.011 . . . . 0.0 110.12 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.4 mtp85 -88.82 150.05 23.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.575 -0.703 . . . . 0.0 109.958 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -126.95 169.91 12.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.605 -0.685 . . . . 0.0 110.111 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.3 mt -109.15 137.4 47.11 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.581 -0.699 . . . . 0.0 110.738 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' THR . . . . . 0.411 ' OG1' ' CE1' ' A' ' 149' ' ' HIS . 3.3 p -79.29 165.68 46.86 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.652 -0.655 . . . . 0.0 109.904 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -80.11 153.29 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.827 1.435 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.3 t -65.04 131.63 47.09 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.663 -0.648 . . . . 0.0 110.117 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.2 t -135.97 54.26 1.91 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.714 -0.616 . . . . 0.0 109.727 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.89 -7.87 0.73 Allowed 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.599 -0.688 . . . . 0.0 112.322 -179.127 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.76 33.82 87.95 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.9 p -95.8 132.46 41.01 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.543 -0.975 . . . . 0.0 110.406 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.3 m -80.0 -26.65 39.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.641 . . . . 0.0 110.409 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -66.4 129.92 41.46 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.435 -0.791 . . . . 0.0 110.296 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 95.3 mt -131.29 157.13 44.12 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.54 -0.725 . . . . 0.0 110.558 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -119.94 115.73 24.36 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.528 -0.732 . . . . 0.0 109.876 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 65.0 tp -93.37 138.28 31.86 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.578 -0.701 . . . . 0.0 110.699 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.2 t -97.89 130.05 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.688 -0.633 . . . . 0.0 109.524 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -106.43 165.67 11.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.453 -0.779 . . . . 0.0 110.509 -179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -59.99 -27.34 66.78 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.627 -0.671 . . . . 0.0 110.489 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.8 t60 -94.49 29.22 2.32 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.528 -0.732 . . . . 0.0 110.62 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.28 39.95 31.3 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.236 -0.915 . . . . 0.0 110.777 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -104.62 127.62 52.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.612 -0.68 . . . . 0.0 109.972 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 120.13 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.498 -0.751 . . . . 0.0 109.993 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 40.2 pt -114.44 146.9 36.84 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.616 -0.678 . . . . 0.0 109.975 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -87.03 113.04 0.96 Allowed 'Trans proline' 0 N--CA 1.49 1.271 0 O-C-N 123.852 1.448 . . . . 0.0 110.531 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.0 119.94 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 109.517 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -79.34 136.95 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.493 -0.754 . . . . 0.0 110.259 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -80.01 129.6 34.62 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.661 -0.649 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -124.64 23.6 8.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.544 -0.722 . . . . 0.0 110.292 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.78 -177.92 47.41 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -68.75 -39.96 80.03 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.57 -0.959 . . . . 0.0 110.429 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.7 p -129.84 26.18 5.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.525 -0.735 . . . . 0.0 110.506 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.89 159.99 35.78 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.534 -0.729 . . . . 0.0 110.253 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -153.1 172.72 32.05 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.7 p -126.36 147.0 49.82 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.529 -0.983 . . . . 0.0 110.227 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.7 mp -99.79 121.14 40.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.547 -0.721 . . . . 0.0 110.256 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.88 -40.02 91.43 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.703 . . . . 0.0 109.955 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.7 m -109.95 112.91 57.65 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.588 -0.695 . . . . 0.0 109.967 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -64.19 127.47 19.32 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 123.845 1.445 . . . . 0.0 110.515 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 31.8 mtt-85 -127.04 160.04 61.61 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.568 -0.708 . . . . 0.0 110.041 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.09 146.43 81.95 Favored 'Trans proline' 0 N--CA 1.49 1.303 0 O-C-N 123.953 1.501 . . . . 0.0 110.303 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.1 m -60.03 -27.06 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.613 -0.679 . . . . 0.0 110.547 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -59.94 -40.06 87.64 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.468 -0.77 . . . . 0.0 110.389 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -65.36 -39.94 92.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.469 -0.77 . . . . 0.0 110.116 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 4.5 mm? -70.36 -27.16 64.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.595 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -58.21 140.04 53.84 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.388 -0.82 . . . . 0.0 110.448 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 87.28 6.98 77.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 56.0 p -111.43 -4.27 14.92 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.026 -1.279 . . . . 0.0 111.245 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.3 m -59.96 140.05 56.99 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.057 -1.027 . . . . 0.0 109.777 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.32 -23.7 35.06 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.65 150.08 42.65 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -91.8 156.74 3.43 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.785 1.413 . . . . 0.0 111.571 -179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 9.8 mp -116.4 102.99 10.01 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.79 133.19 38.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.561 -0.712 . . . . 0.0 111.661 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.418 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.05 159.37 84.56 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.8 Cg_endo -52.61 -26.16 28.39 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 O-C-N 123.505 1.266 . . . . 0.0 112.276 -178.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.2 m -62.51 -40.06 95.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.32 39.52 0.58 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . 0.411 ' CE1' ' OG1' ' A' ' 95' ' ' THR . 3.6 m-70 -137.28 144.96 42.95 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.478 -1.013 . . . . 0.0 110.039 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.62 140.01 57.91 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.552 -0.717 . . . . 0.0 110.244 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 63.0 t -112.63 -36.25 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.581 -0.7 . . . . 0.0 109.814 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.91 -168.51 38.75 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.56 140.1 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.543 -0.975 . . . . 0.0 110.216 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -60.56 136.4 58.04 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.632 -0.667 . . . . 0.0 109.91 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.9 ttt180 -115.72 -52.22 2.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.532 -0.73 . . . . 0.0 110.369 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -156.12 160.04 39.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.529 -0.732 . . . . 0.0 110.294 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.72 151.06 28.18 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.645 -0.659 . . . . 0.0 110.311 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.91 119.51 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.672 -0.643 . . . . 0.0 109.68 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -135.02 154.38 51.74 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.634 -0.666 . . . . 0.0 110.305 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.3 m -103.02 -48.68 3.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.549 -0.72 . . . . 0.0 110.653 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.5 mtm180 -131.04 50.2 2.25 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.53 -0.731 . . . . 0.0 110.373 -179.457 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.97 -4.36 83.16 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 59.6 t -113.29 129.4 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -1.21 . . . . 0.0 109.688 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -99.97 123.95 44.77 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.589 -0.694 . . . . 0.0 110.595 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.25 -18.35 13.62 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.59 -0.694 . . . . 0.0 110.698 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.48 153.7 43.89 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.328 -0.858 . . . . 0.0 110.224 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.75 163.58 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.517 -0.74 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -122.18 134.14 54.72 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.653 -0.654 . . . . 0.0 110.224 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -132.25 157.42 44.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.44 -0.787 . . . . 0.0 110.227 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 58.0 t -93.43 120.67 66.29 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.572 -0.705 . . . . 0.0 109.589 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.33 148.72 84.82 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.762 1.401 . . . . 0.0 110.492 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.5 -23.58 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.734 -0.604 . . . . 0.0 110.738 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -59.51 -34.58 72.78 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.626 -179.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.7 p -69.75 -37.37 76.43 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.493 -0.755 . . . . 0.0 110.435 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 67.1 mtt -59.96 -50.01 75.43 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.458 -0.776 . . . . 0.0 110.873 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -64.49 -29.3 70.34 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.494 -0.754 . . . . 0.0 110.359 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -60.51 -42.56 96.65 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.455 -0.778 . . . . 0.0 110.021 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -70.0 -40.8 75.07 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.497 1.893 0 O-C-N 121.528 -0.732 . . . . 0.0 110.331 -179.872 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.053 0.454 . . . . 0.0 110.15 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.41 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.6 mp . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.531 -0.731 . . . . 0.0 110.245 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 121.039 0.447 . . . . 0.0 110.298 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.34 130.04 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 109.757 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -128.03 158.56 37.59 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.54 -0.725 . . . . 0.0 110.53 -179.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.2 t -95.27 128.43 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 0.0 109.499 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 29.2 m -129.3 158.97 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.591 -0.693 . . . . 0.0 109.83 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -153.46 164.04 38.89 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.8 p -118.71 -169.68 1.76 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.635 -0.665 . . . . 0.0 109.598 179.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.99 -34.31 73.14 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.586 -0.696 . . . . 0.0 110.985 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 54.7 p -131.21 -10.69 3.71 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.184 -0.947 . . . . 0.0 112.64 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.2 tp60 -117.92 153.42 33.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.92 -1.113 . . . . 0.0 111.289 -179.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 35.2 t -138.44 138.31 38.04 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.623 -0.673 . . . . 0.0 109.736 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -167.24 -178.08 3.94 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.305 -0.872 . . . . 0.0 110.527 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 66.4 mt -113.61 157.61 21.89 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.619 -0.676 . . . . 0.0 110.649 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -135.24 162.29 32.97 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.742 -0.599 . . . . 0.0 110.112 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -124.63 139.8 53.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.3 t -97.57 113.94 25.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.411 -0.806 . . . . 0.0 110.619 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . 0.419 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 61.4 t -121.03 133.88 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.609 -0.682 . . . . 0.0 109.945 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.54 39.95 27.39 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.509 -0.745 . . . . 0.0 111.256 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.9 26.89 73.78 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 178.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 65.5 t -140.02 138.59 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.468 -1.019 . . . . 0.0 109.696 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -81.07 147.37 30.16 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 109.298 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . 0.447 ' CG ' ' CE ' ' A' ' 175' ' ' MET . 61.1 m95 -130.13 153.06 48.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.455 -0.778 . . . . 0.0 110.868 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.454 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.5 t -169.62 -179.5 3.39 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 9.1 p -95.25 144.87 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.476 -0.765 . . . . 0.0 110.473 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.413 ' CZ ' HG23 ' A' ' 78' ' ' VAL . 64.9 t80 -60.47 -42.59 96.54 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.716 -0.615 . . . . 0.0 111.694 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.468 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.9 p-80 -70.02 -20.14 63.28 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.043 -1.036 . . . . 0.0 110.895 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -89.19 -43.32 5.34 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.6 85.05 2.19 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.668 -0.901 . . . . 0.0 109.804 179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.2 -168.8 1.55 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.5 p -72.78 67.45 0.81 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.618 -0.93 . . . . 0.0 109.707 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -140.02 169.78 17.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.622 -0.674 . . . . 0.0 110.476 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.9 m -65.53 139.58 58.49 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.676 -0.64 . . . . 0.0 110.088 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.469 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 16.4 tp -115.3 133.47 56.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.625 -0.672 . . . . 0.0 109.801 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.78 119.37 30.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.555 -0.716 . . . . 0.0 110.334 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -125.42 176.37 17.25 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.03 -32.18 75.92 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.788 1.415 . . . . 0.0 110.455 -179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.2 mmtt -70.21 -31.39 68.81 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.555 -0.716 . . . . 0.0 109.782 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.31 -151.12 22.38 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.87 154.65 63.26 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.886 1.466 . . . . 0.0 110.131 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.41 HG22 HD11 ' A' ' 71' ' ' ILE . 86.0 mt -129.98 139.91 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.56 -0.713 . . . . 0.0 110.675 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.5 m -100.57 138.8 37.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.589 -0.694 . . . . 0.0 110.274 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 143.81 51.91 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.562 -0.711 . . . . 0.0 110.817 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' MET . . . . . 0.417 ' HB3' ' CD2' ' A' ' 75' ' ' TYR . 5.5 mtp -119.16 -50.03 2.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.532 -0.73 . . . . 0.0 110.452 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . 0.417 ' CD2' ' HB3' ' A' ' 74' ' ' MET . 98.8 m-85 -120.0 140.01 51.61 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.754 . . . . 0.0 110.462 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.5 m -136.03 133.02 37.0 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.556 -0.715 . . . . 0.0 110.411 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.7 t30 -145.83 100.56 3.43 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.495 -0.753 . . . . 0.0 109.98 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.413 HG23 ' CZ ' ' A' ' 56' ' ' TYR . 59.8 t -69.98 -36.66 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.543 -0.723 . . . . 0.0 110.312 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -59.95 -50.0 75.48 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.469 -0.77 . . . . 0.0 110.981 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.5 mm-40 -90.47 0.15 57.43 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.466 -0.771 . . . . 0.0 111.309 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 2.6 t70 55.33 40.09 31.41 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.921 -1.112 . . . . 0.0 109.747 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.24 132.34 52.98 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.671 -0.643 . . . . 0.0 110.742 -179.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.406 ' CG2' HG23 ' A' ' 54' ' ' THR . 27.1 m -145.08 157.16 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.645 -0.659 . . . . 0.0 109.462 179.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -144.84 175.03 24.72 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.594 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.469 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 8.5 m-90 -130.04 159.97 35.11 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.916 -0.755 . . . . 0.0 109.631 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -66.53 123.33 19.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.365 -0.834 . . . . 0.0 109.152 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -79.37 139.74 55.89 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.504 -0.747 . . . . 0.0 110.193 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.98 159.17 54.2 Favored 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.824 1.434 . . . . 0.0 110.4 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.52 136.1 27.76 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.961 1.506 . . . . 0.0 110.286 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.13 -24.16 33.39 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.1 140.01 57.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.374 -1.074 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -80.91 158.9 25.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.635 -0.666 . . . . 0.0 109.659 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.8 p -130.49 168.93 16.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.521 -0.737 . . . . 0.0 110.325 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.5 mt -112.94 140.01 48.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.561 -0.712 . . . . 0.0 110.702 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 44.6 p -82.1 165.54 42.4 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.647 -0.658 . . . . 0.0 110.142 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -81.63 162.04 19.14 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.797 1.42 . . . . 0.0 110.662 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -73.66 130.16 39.45 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.64 -0.662 . . . . 0.0 110.137 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.97 54.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.741 -0.599 . . . . 0.0 109.816 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.73 -8.49 0.73 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.713 . . . . 0.0 112.383 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 42.85 97.29 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -100.0 119.97 39.1 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.522 -0.987 . . . . 0.0 110.531 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.9 m -62.78 -40.08 96.19 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.649 -0.657 . . . . 0.0 110.296 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -63.41 130.47 44.57 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.583 -0.698 . . . . 0.0 110.261 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 95.8 mt -137.97 155.37 48.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.617 -0.677 . . . . 0.0 110.577 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -106.69 135.58 47.98 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.465 -0.772 . . . . 0.0 109.545 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 39.8 tp -105.09 127.21 52.79 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.449 -0.782 . . . . 0.0 110.747 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 140.03 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.536 -0.727 . . . . 0.0 109.777 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.2 m -130.07 170.06 14.49 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.524 -0.735 . . . . 0.0 110.516 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 44.2 mtm180 -60.04 -23.2 63.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.51 -0.744 . . . . 0.0 110.781 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.11 19.37 5.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.395 -0.816 . . . . 0.0 111.194 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.49 39.9 30.63 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.077 -1.015 . . . . 0.0 110.693 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -113.27 157.65 21.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.533 -0.729 . . . . 0.0 109.955 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.4 m -129.43 133.68 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.52 -0.738 . . . . 0.0 110.371 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . 0.457 HD13 HG22 ' A' ' 114' ' ' ILE . 49.0 mm -122.48 147.82 51.16 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.602 -0.687 . . . . 0.0 109.701 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -82.65 129.75 5.74 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.906 1.477 . . . . 0.0 110.378 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.0 t -130.0 130.02 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.697 -0.627 . . . . 0.0 109.602 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 54.2 mmm-85 -79.53 153.1 29.78 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.517 -0.74 . . . . 0.0 110.276 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 51.4 ttt-85 -99.34 119.07 37.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.64 -0.662 . . . . 0.0 109.921 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.1 mmm-85 -114.6 24.34 11.93 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.671 -0.643 . . . . 0.0 110.219 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 162.07 -175.41 38.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -64.57 -39.97 94.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.53 -0.982 . . . . 0.0 110.378 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 52.8 p -130.87 28.87 4.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.543 -0.723 . . . . 0.0 110.753 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.6 tpp85 -132.44 146.63 52.09 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.422 -0.799 . . . . 0.0 110.656 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -160.69 169.83 36.48 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 53.3 p -109.24 158.38 17.91 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.468 -1.019 . . . . 0.0 110.234 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.7 tp -102.02 119.94 39.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.541 -0.725 . . . . 0.0 110.152 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 7.6 mp -65.44 -40.04 92.79 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.988 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.8 109.94 59.35 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -66.14 118.68 5.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.82 1.432 . . . . 0.0 110.415 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -120.04 160.01 44.75 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.598 -0.689 . . . . 0.0 110.127 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.2 157.93 54.93 Favored 'Trans proline' 0 N--CA 1.491 1.352 0 O-C-N 123.919 1.484 . . . . 0.0 110.242 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 63.4 t -67.13 -30.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.601 -0.687 . . . . 0.0 110.191 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.6 p -60.04 -39.74 86.97 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.515 -0.74 . . . . 0.0 110.414 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -64.35 -40.02 95.03 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.566 -0.709 . . . . 0.0 110.222 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.4 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 4.5 mm? -70.02 -30.75 68.14 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.453 -0.779 . . . . 0.0 110.555 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -60.04 142.75 53.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.469 -0.769 . . . . 0.0 110.218 -179.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.96 8.72 87.41 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 17.5 m -113.37 -7.73 13.47 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.182 -1.187 . . . . 0.0 110.966 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 30.6 t -59.92 140.33 56.76 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.091 -1.005 . . . . 0.0 109.99 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.3 -21.23 42.05 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -61.45 145.05 48.85 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -86.88 142.16 6.52 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.836 1.44 . . . . 0.0 111.262 -179.457 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.25 122.09 43.04 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 mp -112.13 133.77 54.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.474 -0.766 . . . . 0.0 111.537 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.428 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.08 160.03 82.1 Favored Pre-proline 0 N--CA 1.497 1.912 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.072 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -52.13 -23.02 16.32 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 O-C-N 123.464 1.244 . . . . 0.0 112.235 -178.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -65.84 -40.01 91.34 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.325 -0.859 . . . . 0.0 109.854 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.99 34.33 0.91 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -131.68 145.52 51.69 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.464 -1.021 . . . . 0.0 110.326 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.29 137.19 46.55 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.545 -0.722 . . . . 0.0 110.265 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 9.2 p -115.54 -22.49 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.536 -0.728 . . . . 0.0 110.696 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.65 -170.93 43.51 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 63.5 mt -129.93 140.03 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.595 -0.944 . . . . 0.0 110.055 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -61.64 138.24 58.29 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.652 -0.655 . . . . 0.0 109.911 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -118.49 -52.3 2.37 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.545 -0.722 . . . . 0.0 110.563 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.11 160.39 42.9 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.57 -0.706 . . . . 0.0 110.403 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.94 147.58 39.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.599 -0.688 . . . . 0.0 110.384 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.01 120.03 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.677 -0.64 . . . . 0.0 109.642 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -125.93 143.99 50.86 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.645 -0.659 . . . . 0.0 110.631 -179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 58.6 m -82.01 -56.42 3.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.663 . . . . 0.0 110.44 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -134.7 58.0 1.79 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.529 -0.732 . . . . 0.0 110.08 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.4 -10.0 75.76 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.86 121.35 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.128 -1.219 . . . . 0.0 109.688 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -78.83 128.3 33.18 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.631 -0.668 . . . . 0.0 110.552 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -111.5 -25.97 9.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.639 -0.663 . . . . 0.0 110.398 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.36 159.17 42.78 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.585 -0.697 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.8 160.01 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.539 -0.726 . . . . 0.0 111.006 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -121.76 133.88 54.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.682 -0.636 . . . . 0.0 110.055 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -138.18 151.44 47.71 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.421 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.3 t -88.09 123.42 68.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.497 -0.752 . . . . 0.0 109.505 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.34 155.13 71.76 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.764 1.402 . . . . 0.0 110.56 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 88.9 t -58.24 -21.74 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.681 -0.637 . . . . 0.0 110.654 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -57.64 -40.01 78.27 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.268 -0.895 . . . . 0.0 110.656 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 3.4 m -73.65 -35.32 65.24 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.448 -0.783 . . . . 0.0 109.683 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.0 mtp -63.14 -40.48 97.71 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.66 -0.65 . . . . 0.0 110.133 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -69.54 -39.92 77.17 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.611 -0.681 . . . . 0.0 110.381 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.9 m -65.48 -39.97 92.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.662 -0.649 . . . . 0.0 110.075 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 90.5 m -61.72 -48.62 79.91 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.533 -0.729 . . . . 0.0 110.069 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.6 ttt . . . . . 0 N--CA 1.496 1.852 0 O-C-N 121.56 -0.712 . . . . 0.0 110.308 -179.868 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.108 0.48 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.409 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.2 mp . . . . . 0 N--CA 1.496 1.829 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . 0.403 ' HB3' ' CD2' ' A' ' 94' ' ' LEU . 45.3 mt-10 . . . . . 0 N--CA 1.5 2.044 0 CA-C-O 120.816 0.341 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 65.9 t -147.76 131.86 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.386 -0.821 . . . . 0.0 109.647 179.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -124.72 155.17 39.7 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.522 -0.736 . . . . 0.0 110.583 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.9 t -102.92 122.04 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.682 -0.636 . . . . 0.0 109.605 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.403 ' HB ' ' CD1' ' A' ' 64' ' ' LEU . 34.1 m -117.1 145.2 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.658 -0.651 . . . . 0.0 109.772 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -131.85 168.5 17.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.548 -0.72 . . . . 0.0 110.6 -179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.0 m -141.91 173.23 11.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.584 -0.698 . . . . 0.0 110.376 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -68.88 -12.71 61.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.592 -0.692 . . . . 0.0 111.044 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 43.2 p -111.16 -41.5 4.17 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.202 -0.936 . . . . 0.0 111.088 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -157.48 168.14 28.17 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.402 -0.811 . . . . 0.0 110.831 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 80.6 p -119.85 152.64 37.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 3.7 p90 -154.26 -178.22 6.98 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.525 -0.735 . . . . 0.0 110.136 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 35.0 mt -113.49 153.76 28.16 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.487 -0.758 . . . . 0.0 110.817 -178.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -131.12 162.19 30.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.686 -0.634 . . . . 0.0 109.972 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 7.6 t -124.44 143.61 50.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.474 -0.766 . . . . 0.0 110.59 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 97.1 m -96.53 108.93 21.59 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.568 -0.707 . . . . 0.0 110.154 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.5 t -123.35 133.84 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.543 -0.723 . . . . 0.0 109.612 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 54.71 36.53 26.44 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.521 -0.737 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.03 20.02 75.96 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.38 129.97 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.226 -1.161 . . . . 0.0 110.043 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 90.7 m -74.23 149.2 40.94 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.473 -0.767 . . . . 0.0 109.527 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 77.1 m95 -136.11 151.85 50.23 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.512 -0.742 . . . . 0.0 111.069 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.469 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.4 t -168.4 -178.49 3.58 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.847 -0.533 . . . . 0.0 109.778 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.469 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.7 p -82.08 161.27 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.568 -0.707 . . . . 0.0 110.01 179.265 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -85.37 -34.6 21.74 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.399 -0.813 . . . . 0.0 111.796 -178.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.469 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.6 p-80 -70.01 -20.1 63.29 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.996 -1.065 . . . . 0.0 110.941 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -78.22 -51.15 5.85 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 179.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -95.16 -50.43 5.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.509 -0.995 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.3 30.81 36.03 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.0 t 56.87 40.02 29.16 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.302 -1.116 . . . . 0.0 110.283 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.06 178.67 4.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.69 -0.631 . . . . 0.0 109.737 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -65.46 138.79 58.34 Favored 'General case' 0 N--CA 1.494 1.726 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.181 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.403 ' CD1' ' HB ' ' A' ' 36' ' ' VAL . 0.1 OUTLIER -118.24 142.74 47.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.5 -0.75 . . . . 0.0 110.214 -179.406 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.99 115.94 30.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.645 -0.659 . . . . 0.0 109.911 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.58 174.29 15.25 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -62.78 -31.83 78.16 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.762 1.401 . . . . 0.0 110.422 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -71.93 -31.29 66.21 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.767 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.03 -147.58 19.03 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.63 151.32 64.04 Favored 'Trans proline' 0 N--CA 1.49 1.296 0 O-C-N 123.878 1.462 . . . . 0.0 110.241 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.436 ' CG2' ' CG ' ' A' ' 85' ' ' TRP . 85.8 mt -120.02 129.67 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.626 -0.671 . . . . 0.0 110.271 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.8 p -91.56 144.46 25.52 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.464 -0.772 . . . . 0.0 110.149 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . 0.422 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 0.4 OUTLIER -88.0 134.17 33.79 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.558 -0.714 . . . . 0.0 110.872 -179.566 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.1 mmm -116.57 -33.22 4.95 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.625 -0.672 . . . . 0.0 110.239 179.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -131.27 137.67 48.96 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.577 -0.702 . . . . 0.0 110.326 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 84.6 m -139.97 130.62 25.75 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.528 -0.733 . . . . 0.0 109.978 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -136.86 100.67 4.37 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.545 -0.722 . . . . 0.0 110.353 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 67.8 t -70.01 -35.55 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.594 -0.691 . . . . 0.0 110.025 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -60.0 -47.88 84.0 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.606 -0.684 . . . . 0.0 110.512 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.96 3.03 54.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.479 -0.763 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 9.1 t70 54.08 49.4 18.89 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.113 -0.992 . . . . 0.0 110.425 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 68.4 mt -140.94 141.24 34.5 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.589 -0.694 . . . . 0.0 111.047 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -139.15 140.5 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -125.71 158.09 19.92 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.469 ' CZ3' HG21 ' A' ' 54' ' ' THR . 11.2 m-90 -119.89 167.16 12.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.681 -0.893 . . . . 0.0 109.88 179.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -71.19 115.86 10.83 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.605 -0.685 . . . . 0.0 109.429 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.07 146.34 94.83 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.554 -0.716 . . . . 0.0 110.187 -179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.91 159.8 51.97 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.981 1.516 . . . . 0.0 110.314 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.02 151.2 61.64 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 124.019 1.536 . . . . 0.0 110.369 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.06 29.46 70.6 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.13 139.41 38.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.56 -0.965 . . . . 0.0 110.266 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -88.86 143.41 26.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.599 -0.688 . . . . 0.0 109.842 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.4 p -128.99 159.62 35.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 110.571 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . 0.403 ' CD2' ' HB3' ' A' ' 32' ' ' GLU . 3.2 mm? -79.94 160.0 26.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.608 -0.682 . . . . 0.0 110.504 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.6 p -103.08 150.31 37.73 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.681 -0.637 . . . . 0.0 109.884 179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -60.53 141.32 95.03 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 O-C-N 123.783 1.412 . . . . 0.0 110.738 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . 0.414 ' SG ' ' SG ' ' A' ' 145' ' ' CYS . 32.1 t -60.06 133.95 56.58 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.506 -0.746 . . . . 0.0 110.129 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -136.48 57.24 1.78 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.232 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.5 -8.8 0.75 Allowed 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.463 -178.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.08 44.1 96.54 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.2 m -108.36 132.59 53.59 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.537 -0.978 . . . . 0.0 110.671 -179.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -76.78 -27.26 55.21 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.661 -0.649 . . . . 0.0 110.427 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.76 129.97 41.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.463 -0.773 . . . . 0.0 110.214 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.6 mt -135.18 145.65 47.95 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.572 -0.705 . . . . 0.0 110.65 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -106.93 130.79 54.54 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.524 -0.735 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.7 tp -108.5 143.09 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.529 -0.732 . . . . 0.0 110.682 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.02 129.97 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.666 -0.646 . . . . 0.0 109.533 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 77.3 p -102.58 176.76 5.06 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.509 -0.745 . . . . 0.0 110.791 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -68.44 -19.45 64.57 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.719 -0.613 . . . . 0.0 110.742 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -92.37 24.04 3.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.382 -0.824 . . . . 0.0 110.981 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.58 39.35 31.11 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.231 -0.918 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -114.46 159.47 20.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.592 -0.692 . . . . 0.0 109.724 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.92 136.45 58.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.539 -0.725 . . . . 0.0 110.437 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 16.6 tt -129.9 131.18 23.34 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.561 -0.712 . . . . 0.0 109.809 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.61 126.05 12.95 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.77 1.405 . . . . 0.0 110.552 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -124.11 129.91 73.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.785 -0.572 . . . . 0.0 109.691 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -86.77 136.57 32.95 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.446 -0.784 . . . . 0.0 109.945 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -84.38 121.43 27.53 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 110.435 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -110.03 20.06 18.33 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.642 -0.661 . . . . 0.0 110.449 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 164.85 -179.95 39.21 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -69.68 -40.08 76.58 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.482 -1.011 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 88.8 p -120.26 21.88 11.56 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.928 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -133.79 140.22 46.79 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.394 -0.816 . . . . 0.0 110.328 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.73 163.23 26.21 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -126.69 144.99 50.75 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.587 -0.949 . . . . 0.0 110.295 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.7 mp -100.03 129.94 46.14 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.628 -0.67 . . . . 0.0 110.44 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.6 mp -68.73 -40.03 80.1 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.642 -0.661 . . . . 0.0 109.723 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -109.15 112.69 59.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.661 -0.65 . . . . 0.0 109.878 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.95 136.77 50.04 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.756 1.398 . . . . 0.0 110.567 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 20.1 mmt85 -129.84 160.0 67.11 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.712 . . . . 0.0 110.093 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.06 152.23 83.05 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.875 1.46 . . . . 0.0 110.375 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.3 m -64.99 -25.56 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.605 -0.684 . . . . 0.0 110.487 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.7 m -59.99 -40.03 87.77 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.0 110.286 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -66.64 -39.96 88.48 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.593 -0.692 . . . . 0.0 109.987 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.403 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -65.19 -34.46 78.43 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.636 -0.665 . . . . 0.0 110.264 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -60.02 142.98 53.0 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.461 -0.774 . . . . 0.0 110.324 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.97 9.73 86.37 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.146 -1.182 . . . . 0.0 110.146 -179.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 15.9 m -116.9 -6.94 11.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.266 -1.137 . . . . 0.0 110.945 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.2 t -60.06 139.95 57.14 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.208 -0.932 . . . . 0.0 110.074 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.97 -17.66 56.9 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.04 151.48 44.85 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -95.66 144.97 1.25 Allowed 'Trans proline' 0 N--CA 1.489 1.211 0 O-C-N 123.797 1.419 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.4 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 9.4 mp -96.26 103.18 15.06 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.336 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.9 mp -82.64 159.63 22.63 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.902 0.858 . . . . 0.0 111.905 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.414 ' SG ' ' SG ' ' A' ' 97' ' ' CYS . 0.0 OUTLIER -96.15 164.27 18.9 Favored Pre-proline 0 N--CA 1.494 1.727 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.669 179.832 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -65.71 -30.57 50.39 Favored 'Trans proline' 0 N--CA 1.49 1.272 0 O-C-N 123.922 1.485 . . . . 0.0 108.378 177.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -70.0 -36.72 75.36 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.01 41.98 0.53 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -130.01 145.74 51.66 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.468 -1.019 . . . . 0.0 110.651 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -69.99 140.32 52.92 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.421 -0.799 . . . . 0.0 109.867 179.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.3 t -112.91 -44.39 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 110.262 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.43 -179.52 44.15 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 45.9 mt -120.02 130.72 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.611 -0.935 . . . . 0.0 110.157 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -60.09 136.49 58.04 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.648 -0.657 . . . . 0.0 109.961 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -115.49 -52.73 2.64 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.526 -0.734 . . . . 0.0 110.414 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.89 158.64 44.4 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.558 -0.714 . . . . 0.0 110.23 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -109.95 148.39 31.7 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.401 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.0 t -110.03 119.99 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.732 -0.605 . . . . 0.0 109.65 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.34 148.63 52.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.608 -0.683 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 94.0 m -69.99 -47.02 63.87 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.625 -0.672 . . . . 0.0 110.018 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -164.63 53.41 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.716 -0.615 . . . . 0.0 109.84 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.66 -18.06 15.36 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.64 120.04 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.276 -1.132 . . . . 0.0 109.775 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -92.22 124.94 36.67 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.602 -0.686 . . . . 0.0 110.445 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.67 -29.16 7.22 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.693 -0.629 . . . . 0.0 110.199 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -129.89 150.15 51.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.612 -0.68 . . . . 0.0 110.053 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.3 m -130.06 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.539 -0.726 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -122.9 132.86 54.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.698 -0.626 . . . . 0.0 109.838 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -139.94 160.01 40.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.492 -0.755 . . . . 0.0 110.616 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.8 t -94.19 123.58 58.5 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.584 -0.697 . . . . 0.0 109.248 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -62.76 153.15 74.38 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.743 1.391 . . . . 0.0 110.65 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 69.3 t -58.09 -24.36 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.605 -0.684 . . . . 0.0 110.565 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.07 -39.98 87.94 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.397 -0.815 . . . . 0.0 110.388 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 53.3 m -60.15 -40.49 90.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.462 -0.774 . . . . 0.0 110.358 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.4 mtm -70.07 -40.0 75.28 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.61 -0.681 . . . . 0.0 110.214 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.0 -40.3 88.74 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.516 -0.74 . . . . 0.0 110.25 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -63.64 -40.38 96.73 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.572 -0.705 . . . . 0.0 109.85 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -69.95 -40.16 75.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.538 -0.726 . . . . 0.0 110.076 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.7 ttm . . . . . 0 N--CA 1.496 1.839 0 O-C-N 121.746 -0.596 . . . . 0.0 110.32 -179.742 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.127 0.489 . . . . 0.0 110.048 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.412 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 110.251 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 N--CA 1.496 1.836 0 CA-C-O 121.124 0.488 . . . . 0.0 110.005 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.91 127.53 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.607 -0.683 . . . . 0.0 109.838 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -123.95 156.56 36.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.563 -0.711 . . . . 0.0 110.288 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.3 t -89.16 119.02 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.735 -0.603 . . . . 0.0 109.834 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.9 t -109.23 144.43 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.2 m -144.71 164.68 30.27 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.209 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.0 p -141.53 -179.57 6.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.759 -0.588 . . . . 0.0 109.797 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.78 -6.55 49.56 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.51 -0.744 . . . . 0.0 111.119 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.1 m -105.18 -57.31 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.17 -0.956 . . . . 0.0 111.17 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -143.22 169.04 18.36 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.422 -0.799 . . . . 0.0 110.789 -179.282 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 70.5 m -116.92 148.46 41.33 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.512 -0.743 . . . . 0.0 110.591 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 24.9 p90 -163.1 -178.05 5.79 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.445 -0.784 . . . . 0.0 110.071 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 62.6 mt -113.15 148.8 34.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.492 -0.755 . . . . 0.0 110.327 -178.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.3 159.74 32.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.662 -0.648 . . . . 0.0 109.937 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 58.8 m -119.93 138.78 53.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.571 -0.706 . . . . 0.0 110.546 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 45.1 m -93.14 110.97 22.47 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.644 -0.66 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.9 t -120.0 130.01 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.552 -0.718 . . . . 0.0 109.297 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.12 35.64 26.02 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.348 -0.845 . . . . 0.0 110.387 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.97 75.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -130.06 130.0 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.189 -1.183 . . . . 0.0 110.278 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 34.1 t -76.0 129.94 37.65 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.416 -0.802 . . . . 0.0 109.408 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 42.3 m95 -126.4 137.1 53.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.462 -0.774 . . . . 0.0 111.68 -179.119 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.1 t -161.26 -179.6 7.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.45 HG22 ' CE1' ' A' ' 57' ' ' HIS . 14.5 p -81.19 155.29 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.314 -0.866 . . . . 0.0 110.67 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' TYR . . . . . 0.424 ' CD2' ' HA2' ' A' ' 60' ' ' GLY . 59.8 t80 -71.03 -39.93 72.03 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.752 -0.593 . . . . 0.0 111.935 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' HIS . . . . . 0.45 ' CE1' HG22 ' A' ' 55' ' ' VAL . 2.8 p-80 -63.56 -24.65 67.9 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.979 -1.076 . . . . 0.0 110.833 -178.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . 0.437 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -76.18 -51.45 6.82 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -108.14 -59.69 1.82 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.958 . . . . 0.0 110.07 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . 0.424 ' HA2' ' CD2' ' A' ' 56' ' ' TYR . . . 80.6 -176.51 54.64 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.9 t -79.84 68.13 5.83 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.554 -0.968 . . . . 0.0 109.806 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -142.47 177.73 8.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.623 -0.673 . . . . 0.0 110.243 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 58.9 m -65.14 139.93 58.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 109.899 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LEU . . . . . 0.425 HD22 ' CD2' ' A' ' 85' ' ' TRP . 12.7 tp -111.74 136.58 50.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.619 -0.676 . . . . 0.0 110.262 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -102.35 109.94 21.74 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.576 -0.703 . . . . 0.0 110.068 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.51 179.96 20.4 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -64.87 -32.35 55.51 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.878 1.462 . . . . 0.0 110.336 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -75.81 -31.19 59.31 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.638 -0.664 . . . . 0.0 110.046 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.88 -150.37 22.53 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.24 144.02 45.28 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 O-C-N 123.844 1.444 . . . . 0.0 110.269 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 51.1 mm -126.57 130.02 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.633 -0.667 . . . . 0.0 110.389 -179.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.9 p -77.62 149.76 34.73 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.523 -0.736 . . . . 0.0 109.915 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -100.42 140.5 34.59 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.523 -0.735 . . . . 0.0 110.834 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.4 mmm -113.38 -25.0 9.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.702 -0.623 . . . . 0.0 110.356 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -119.96 140.01 51.58 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 110.551 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 80.6 m -149.25 130.0 14.15 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.525 -0.735 . . . . 0.0 109.954 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 -149.91 98.07 2.67 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 110.319 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' VAL . . . . . 0.409 HG21 ' CZ ' ' A' ' 56' ' ' TYR . 81.1 t -70.01 -40.45 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.541 -0.724 . . . . 0.0 110.082 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -44.8 94.25 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.57 -0.707 . . . . 0.0 110.319 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -89.99 0.05 57.32 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.563 -0.71 . . . . 0.0 111.118 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 4.8 t0 53.58 45.14 28.75 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.059 -1.026 . . . . 0.0 110.781 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 50.8 mt -134.46 143.53 47.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.481 -0.762 . . . . 0.0 110.682 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.41 HG13 ' CH2' ' A' ' 85' ' ' TRP . 7.1 p -150.06 157.58 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . 0.423 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -152.76 160.07 28.81 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.594 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' TRP . . . . . 0.425 ' CD2' HD22 ' A' ' 64' ' ' LEU . 11.3 m-90 -127.74 154.61 45.16 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.628 -0.925 . . . . 0.0 109.735 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -63.45 116.75 5.86 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.51 -0.744 . . . . 0.0 109.574 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -77.52 135.59 64.8 Favored Pre-proline 0 N--CA 1.495 1.786 0 O-C-N 121.553 -0.717 . . . . 0.0 110.225 -179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 160.0 51.23 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 123.868 1.457 . . . . 0.0 110.217 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.41 156.53 50.22 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 O-C-N 123.87 1.458 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.77 -22.04 42.94 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.97 159.99 26.09 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -1.124 . . . . 0.0 110.216 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -96.47 165.4 12.19 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.521 -0.737 . . . . 0.0 110.282 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -132.42 169.11 17.0 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.6 -0.687 . . . . 0.0 110.227 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.2 mt -119.25 138.28 53.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.547 -0.721 . . . . 0.0 110.617 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -82.91 166.61 34.71 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.582 -0.698 . . . . 0.0 110.144 179.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -79.18 166.12 23.05 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.868 1.457 . . . . 0.0 110.533 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 31.1 t -69.43 136.65 51.87 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.3 p -136.59 55.55 1.84 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.729 -0.607 . . . . 0.0 109.585 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 31.7 p -143.46 -8.46 0.76 Allowed 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.792 -0.763 . . . . 0.0 112.51 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.46 97.31 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.0 m -108.71 160.3 16.07 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.543 -0.975 . . . . 0.0 110.496 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -108.9 21.69 16.89 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.715 . . . . 0.0 110.798 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -99.94 120.05 39.2 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.371 -0.831 . . . . 0.0 110.051 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.5 mt -130.57 133.13 45.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.557 -0.714 . . . . 0.0 110.537 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.0 120.0 40.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.507 -0.745 . . . . 0.0 109.693 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.8 tp -81.79 128.35 33.92 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.481 -0.762 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -97.85 118.6 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.626 -0.672 . . . . 0.0 109.37 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.4 p -104.32 177.93 4.7 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.553 -0.717 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -60.0 -22.77 63.0 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.602 -0.686 . . . . 0.0 110.461 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.46 19.07 5.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.344 -0.848 . . . . 0.0 111.126 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.84 40.0 31.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.1 -1.0 . . . . 0.0 110.924 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -100.31 122.81 43.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.572 -0.705 . . . . 0.0 109.961 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.1 m -59.97 -39.36 79.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.577 -0.702 . . . . 0.0 110.501 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 50.8 mm 51.29 92.44 0.06 OUTLIER Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.38 -0.825 . . . . 0.0 110.648 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.93 121.41 8.44 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.94 1.495 . . . . 0.0 110.656 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.5 t -127.2 129.99 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.665 -0.647 . . . . 0.0 109.52 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.5 tpt180 -86.88 132.07 33.92 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.507 -0.746 . . . . 0.0 110.125 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.09 130.64 41.39 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.512 -0.743 . . . . 0.0 110.004 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -128.49 20.43 6.17 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.542 -0.724 . . . . 0.0 110.605 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -179.43 172.41 44.31 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -59.97 -40.64 89.78 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.47 -1.018 . . . . 0.0 110.278 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -133.43 28.98 3.98 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.561 -0.712 . . . . 0.0 110.616 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 22.0 ttp180 -139.89 138.37 35.61 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.422 -0.798 . . . . 0.0 110.592 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -126.4 -176.49 14.51 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 86.8 p -133.24 150.87 51.93 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.557 -0.967 . . . . 0.0 110.211 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.3 mp -97.26 130.04 44.51 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.517 -0.739 . . . . 0.0 110.316 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -67.64 -40.03 84.6 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.582 -0.699 . . . . 0.0 110.02 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -115.36 127.83 26.47 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -67.67 120.74 7.76 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.755 1.398 . . . . 0.0 110.468 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -120.46 160.06 45.44 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.588 -0.695 . . . . 0.0 110.009 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.68 154.19 73.66 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.956 1.503 . . . . 0.0 110.415 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.7 m -67.18 -23.28 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.661 -0.649 . . . . 0.0 110.619 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 66.5 m -59.95 -40.06 87.71 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.403 -0.81 . . . . 0.0 110.211 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -60.0 -46.72 88.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.437 -0.789 . . . . 0.0 109.644 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.405 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.99 -29.42 66.51 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.672 -0.642 . . . . 0.0 109.545 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.3 tptm -60.03 129.46 41.9 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.6 -0.688 . . . . 0.0 110.006 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.82 -8.29 80.01 Favored Glycine 0 N--CA 1.495 2.592 0 C-N-CA 120.269 -0.967 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.0 p -96.86 6.01 49.47 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.071 -1.252 . . . . 0.0 111.135 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.03 142.94 53.11 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.038 -1.039 . . . . 0.0 109.929 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.92 -14.93 63.02 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.25 145.77 44.02 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -92.03 141.54 2.46 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.859 1.452 . . . . 0.0 111.673 -179.066 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.7 mp -93.51 104.38 16.52 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.0 mp -81.99 157.24 24.3 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 122.082 0.944 . . . . 0.0 111.867 -177.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.57 162.2 24.13 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.496 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -63.98 -29.82 66.71 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.789 1.415 . . . . 0.0 108.577 177.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 79.6 p -70.91 -36.12 72.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 178.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.05 41.27 0.56 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -129.97 154.32 47.49 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.984 . . . . 0.0 110.592 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.32 119.55 25.81 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.504 -0.747 . . . . 0.0 109.857 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 63.1 t -90.71 -42.01 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.566 -0.709 . . . . 0.0 110.483 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -166.51 -168.87 29.35 Favored Glycine 0 N--CA 1.497 2.741 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.301 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ILE . . . . . 0.401 HD12 HG21 ' A' ' 153' ' ' ILE . 94.2 mt -130.37 140.01 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.591 -0.947 . . . . 0.0 110.352 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -63.44 139.69 58.8 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.679 -0.638 . . . . 0.0 109.725 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.9 ttp85 -123.14 -52.76 1.85 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.48 -0.763 . . . . 0.0 110.529 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -147.99 165.18 31.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.491 -0.755 . . . . 0.0 110.436 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.95 143.87 49.21 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.621 -0.674 . . . . 0.0 110.371 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.06 119.9 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.76 -0.587 . . . . 0.0 109.456 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.7 p -125.97 146.03 50.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.545 -0.722 . . . . 0.0 110.693 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 39.9 m -82.89 -64.2 1.22 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.447 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -129.21 62.96 1.5 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.499 -0.751 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.91 -8.76 79.22 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.621 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.2 m -115.8 131.14 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.154 -1.203 . . . . 0.0 110.299 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.34 124.93 34.4 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.638 -0.664 . . . . 0.0 110.3 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -108.79 -29.61 8.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.687 -0.633 . . . . 0.0 110.005 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -138.27 150.8 47.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.45 175.46 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.644 -0.66 . . . . 0.0 110.597 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -131.15 131.35 44.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.682 -0.637 . . . . 0.0 109.574 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -129.48 153.07 48.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.347 -0.845 . . . . 0.0 110.528 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 90.5 t -93.55 119.53 67.14 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.607 -0.683 . . . . 0.0 109.429 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.63 153.51 74.67 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.808 1.425 . . . . 0.0 110.578 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.3 t -62.74 -27.42 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.629 -0.67 . . . . 0.0 110.428 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -59.94 -39.31 85.1 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.591 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 85.9 p -59.96 -45.14 93.62 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.504 -0.748 . . . . 0.0 110.669 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 76.7 mtm -69.97 -40.04 75.61 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.396 -0.815 . . . . 0.0 110.38 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.01 -40.04 87.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.479 -0.763 . . . . 0.0 110.259 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.5 m -63.98 -39.99 95.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.574 -0.703 . . . . 0.0 109.881 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 88.6 m -70.05 -40.15 75.27 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.596 -0.69 . . . . 0.0 110.063 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.6 ttm . . . . . 0 N--CA 1.495 1.789 0 O-C-N 121.648 -0.658 . . . . 0.0 110.396 -179.718 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.088 0.47 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 189' ' ' LEU . . . . . 0.41 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.496 1.836 0 O-C-N 121.622 -0.673 . . . . 0.0 110.188 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.066 0.46 . . . . 0.0 110.333 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.9 100.23 0.75 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.7 ttp180 -131.94 133.64 44.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.916 . . . . 0.0 110.141 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -40.01 87.97 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.603 -0.686 . . . . 0.0 110.301 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt 38.59 42.06 0.54 Allowed 'General case' 0 N--CA 1.509 2.519 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 m120 -75.09 130.93 40.11 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.528 -0.732 . . . . 0.0 110.12 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -149.77 159.69 44.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.54 -0.725 . . . . 0.0 110.177 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.2 t -88.33 138.96 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.594 -0.692 . . . . 0.0 109.816 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.95 130.79 48.49 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.502 -0.748 . . . . 0.0 110.252 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -169.9 100.23 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.58 -33.93 76.69 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.552 -0.97 . . . . 0.0 110.25 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -103.77 129.91 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.564 -0.71 . . . . 0.0 109.868 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -116.3 158.54 23.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.561 -0.712 . . . . 0.0 110.489 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.04 121.29 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.663 -0.648 . . . . 0.0 109.597 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 29.7 m -118.48 142.67 32.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.699 -0.626 . . . . 0.0 109.899 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.3 t -142.05 159.67 41.76 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.516 -0.74 . . . . 0.0 111.246 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.7 p -124.56 -170.12 2.09 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -84.02 5.89 24.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.528 -0.732 . . . . 0.0 110.91 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -128.65 -38.94 1.67 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.073 -1.017 . . . . 0.0 111.191 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -149.91 170.1 19.61 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.311 -0.868 . . . . 0.0 111.159 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 47.8 m -119.75 147.35 44.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.68 -0.638 . . . . 0.0 109.792 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 10.3 p90 -156.43 -178.63 7.48 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.391 -0.818 . . . . 0.0 110.275 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 74.0 mt -113.89 153.35 29.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.0 110.804 -178.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.43 161.34 31.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.711 -0.618 . . . . 0.0 109.972 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -126.23 140.12 52.79 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.573 -0.705 . . . . 0.0 110.4 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 38.5 t -98.33 105.48 17.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.59 -0.693 . . . . 0.0 110.489 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.0 t -109.98 129.99 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.423 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 56.8 t30 57.98 38.36 26.82 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.439 -0.788 . . . . 0.0 110.479 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.52 19.93 76.7 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.0 t -131.99 129.97 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.137 -1.214 . . . . 0.0 110.167 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 87.5 m -75.66 148.89 38.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.516 -0.74 . . . . 0.0 109.464 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -138.2 149.95 46.29 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.448 -0.783 . . . . 0.0 111.212 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.461 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.9 t -168.65 -179.09 3.67 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.457 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 10.6 p -89.17 158.33 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.448 -0.783 . . . . 0.0 110.027 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.427 ' CE1' HG22 ' A' ' 78' ' ' VAL . 57.1 t80 -76.39 -39.97 52.25 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.493 -0.754 . . . . 0.0 112.066 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.457 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.3 p-80 -64.95 -24.28 67.47 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.116 -0.99 . . . . 0.0 110.567 -178.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.425 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -84.28 -56.98 2.44 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 179.093 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -96.89 -61.28 1.43 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.68 -0.894 . . . . 0.0 109.987 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 79.96 -179.39 53.26 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 78.9 p -79.33 64.59 4.26 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.596 -0.943 . . . . 0.0 109.768 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.23 167.54 21.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.62 -0.675 . . . . 0.0 110.414 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.2 t -65.39 139.32 58.54 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 109.826 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.415 ' HG ' ' CZ2' ' A' ' 85' ' ' TRP . 0.1 OUTLIER -112.83 131.13 55.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.589 -0.694 . . . . 0.0 110.291 -179.576 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.53 109.29 21.9 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.564 -0.71 . . . . 0.0 109.815 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -105.53 -165.96 23.59 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.09 -32.36 34.53 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 124.025 1.539 . . . . 0.0 110.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.62 -31.09 59.76 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.83 -140.83 10.1 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -75.02 161.36 38.83 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.819 1.431 . . . . 0.0 110.292 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.5 mt -131.53 139.37 50.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.448 -0.782 . . . . 0.0 110.439 -179.639 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.0 p -81.87 150.74 27.64 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.549 -0.719 . . . . 0.0 109.946 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 78.2 mm-40 -87.42 132.3 34.03 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.484 -0.76 . . . . 0.0 110.095 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -110.01 -44.86 3.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.552 -0.718 . . . . 0.0 110.116 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . 0.421 ' CE1' ' HG3' ' A' ' 179' ' ' MET . 83.9 m-85 -130.01 150.04 51.46 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.584 -0.697 . . . . 0.0 110.507 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.6 p -148.17 136.32 21.2 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.007 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -149.98 89.32 1.59 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.427 HG22 ' CE1' ' A' ' 56' ' ' TYR . 63.0 t -61.3 -40.09 84.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.623 -0.673 . . . . 0.0 109.988 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -61.58 -43.91 97.99 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.508 -0.745 . . . . 0.0 110.654 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -87.6 -0.01 56.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.583 -0.698 . . . . 0.0 110.749 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 8.4 t70 53.48 46.5 26.05 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.06 -1.025 . . . . 0.0 110.506 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 40.3 mt -144.25 138.39 27.96 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.543 -0.723 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.403 ' CG1' HG23 ' A' ' 54' ' ' THR . 8.3 p -134.12 157.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.605 -0.684 . . . . 0.0 109.26 179.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -138.43 153.66 22.59 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.196 -1.161 . . . . 0.0 110.196 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.461 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 5.8 m-90 -120.99 151.67 39.46 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.776 -0.838 . . . . 0.0 110.022 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -68.51 115.85 8.39 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.538 -0.726 . . . . 0.0 109.338 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.06 130.08 90.13 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.525 -0.735 . . . . 0.0 110.262 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.04 159.99 51.21 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.831 1.437 . . . . 0.0 110.285 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.67 156.32 58.01 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.897 1.472 . . . . 0.0 110.4 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.33 26.56 59.31 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.66 152.29 30.63 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.467 -1.019 . . . . 0.0 110.143 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -92.79 168.94 10.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.566 -0.709 . . . . 0.0 110.256 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.9 p -137.84 158.71 43.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.74 -0.6 . . . . 0.0 110.228 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 51.4 mt -108.02 131.63 54.38 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.526 -0.734 . . . . 0.0 110.485 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.7 p -76.91 160.06 77.3 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.555 -0.716 . . . . 0.0 109.784 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -75.58 163.68 33.64 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.832 1.438 . . . . 0.0 110.655 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 49.1 t -72.69 129.53 38.44 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.694 -0.629 . . . . 0.0 110.27 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -134.68 55.6 1.89 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.716 -0.615 . . . . 0.0 109.661 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.8 p -143.88 -7.82 0.73 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 120.027 -0.669 . . . . 0.0 112.26 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.97 39.54 97.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.8 m -99.94 119.99 39.1 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.544 -0.974 . . . . 0.0 110.404 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -66.71 -39.71 88.14 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.731 -0.606 . . . . 0.0 110.442 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 139.61 57.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.531 -0.731 . . . . 0.0 110.491 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.8 mt -139.29 153.1 47.72 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 0.0 110.409 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -115.73 123.72 49.01 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.53 -0.731 . . . . 0.0 109.887 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.3 tp -99.91 133.29 44.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.592 -0.693 . . . . 0.0 110.595 -179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.9 t -91.57 120.05 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.677 -0.639 . . . . 0.0 109.447 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.4 m -97.99 152.35 19.36 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.462 -0.774 . . . . 0.0 110.419 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 28.0 ptt85 -59.08 -20.03 49.68 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.639 -0.663 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -94.59 26.76 3.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.452 -0.78 . . . . 0.0 110.214 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.49 40.07 31.16 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.348 -0.845 . . . . 0.0 110.663 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.49 135.03 54.62 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.572 -0.705 . . . . 0.0 109.976 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.97 120.03 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.579 -0.701 . . . . 0.0 110.022 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 49.0 mm -106.19 117.36 57.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.622 -0.674 . . . . 0.0 109.79 179.777 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -64.42 120.74 8.13 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.801 1.422 . . . . 0.0 110.374 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.98 126.32 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.586 -0.696 . . . . 0.0 109.796 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -86.9 130.53 34.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.553 -0.717 . . . . 0.0 109.805 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 37.5 ttp180 -73.46 126.14 29.52 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.624 -0.672 . . . . 0.0 110.338 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -120.16 23.78 10.79 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.587 -0.696 . . . . 0.0 110.209 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.38 -179.06 42.18 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -63.19 -39.96 96.13 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.571 -0.958 . . . . 0.0 110.406 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 76.9 p -132.83 22.2 4.21 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.555 -0.715 . . . . 0.0 110.786 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -124.86 138.6 54.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.346 -0.847 . . . . 0.0 110.322 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.18 169.81 23.51 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.4 p -121.25 153.51 37.55 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.62 -0.929 . . . . 0.0 110.059 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 16.8 tp -99.27 119.87 38.63 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.505 -0.747 . . . . 0.0 110.221 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -68.61 -39.01 81.04 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.544 -0.722 . . . . 0.0 110.039 179.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.28 116.13 55.47 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.601 -0.687 . . . . 0.0 110.064 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -65.81 116.34 3.91 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.724 1.381 . . . . 0.0 110.43 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 5.7 mtt180 -122.69 160.04 50.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.581 -0.699 . . . . 0.0 110.139 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -67.43 152.04 79.36 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 124.017 1.536 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.32 -32.15 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.568 -0.708 . . . . 0.0 110.395 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.8 t -59.96 -38.66 83.1 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.511 -0.743 . . . . 0.0 110.162 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.539 -0.726 . . . . 0.0 110.34 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -81.46 -18.35 45.59 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 0.0 111.109 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -60.4 140.02 57.4 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.183 -0.948 . . . . 0.0 110.115 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 86.37 13.64 67.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.5 p -116.13 -8.29 11.79 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.127 -1.219 . . . . 0.0 110.908 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.7 t -59.97 139.08 57.66 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.123 -0.986 . . . . 0.0 109.698 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.33 -23.44 35.82 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.99 151.71 47.39 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 179.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -93.87 148.78 2.15 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.841 1.443 . . . . 0.0 111.427 -179.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.406 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.3 mp -104.66 130.3 52.71 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -118.47 131.51 56.25 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.351 -0.843 . . . . 0.0 111.549 -178.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.422 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.5 p -70.01 159.16 85.32 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 178.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.85 -26.64 24.87 Favored 'Trans proline' 0 N--CA 1.502 1.992 0 O-C-N 123.504 1.265 . . . . 0.0 112.359 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.9 m -62.63 -39.99 95.57 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.261 -0.9 . . . . 0.0 109.96 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.67 36.37 0.79 Allowed Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.4 m170 -132.48 149.61 52.3 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.419 -1.048 . . . . 0.0 110.128 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 142.48 52.78 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.576 -0.702 . . . . 0.0 110.45 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 34.4 m -117.17 -22.81 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.626 -0.671 . . . . 0.0 110.613 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 167.63 -169.92 41.45 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.4 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 96.9 mt -127.84 139.94 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.517 -0.99 . . . . 0.0 110.224 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 24.7 t80 -65.82 136.79 56.65 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.649 -0.657 . . . . 0.0 109.981 179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -114.97 -52.39 2.69 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 0.0 110.427 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.72 160.02 42.17 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.463 -0.773 . . . . 0.0 110.393 -179.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -109.96 151.13 27.5 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.66 -0.65 . . . . 0.0 110.203 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -108.27 119.6 58.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.666 -0.647 . . . . 0.0 109.693 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -134.1 158.96 42.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.693 -0.63 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 4.6 p -99.97 -50.68 3.92 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.71 . . . . 0.0 110.391 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -142.89 61.62 1.41 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.928 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.05 -7.47 81.57 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.8 t -116.82 125.92 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 109.905 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.81 127.86 43.2 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.592 -0.693 . . . . 0.0 110.422 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -107.14 -17.16 14.24 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.519 -0.738 . . . . 0.0 110.743 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -146.81 159.78 43.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.325 -0.859 . . . . 0.0 110.036 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -133.84 160.04 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.462 -0.774 . . . . 0.0 110.938 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.51 138.4 53.19 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.658 . . . . 0.0 110.015 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -140.3 155.65 46.75 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.404 -0.81 . . . . 0.0 110.794 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 59.3 t -94.47 126.04 49.5 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.56 -0.712 . . . . 0.0 109.459 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.46 158.58 57.03 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.795 1.419 . . . . 0.0 110.696 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 57.7 t -65.59 -24.66 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.665 -0.647 . . . . 0.0 110.478 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -58.6 -37.96 76.94 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.383 -0.823 . . . . 0.0 110.579 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 81.1 p -60.13 -34.45 73.54 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.524 -0.735 . . . . 0.0 110.417 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.4 ' CE ' ' CD1' ' A' ' 153' ' ' ILE . 68.3 mtt -61.14 -40.02 92.26 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.478 -0.764 . . . . 0.0 110.411 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.55 -42.14 95.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.496 -0.752 . . . . 0.0 110.495 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 75.2 p -70.03 -39.51 75.72 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.395 -0.816 . . . . 0.0 110.417 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 86.5 m -60.04 -50.03 75.32 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' MET . . . . . 0.421 ' HG3' ' CE1' ' A' ' 75' ' ' TYR . 59.9 ttp -68.63 -39.99 80.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.609 -0.682 . . . . 0.0 110.239 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -63.7 -39.98 95.64 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.608 -0.682 . . . . 0.0 110.274 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.05 -43.78 95.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.575 -0.703 . . . . 0.0 110.483 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 79.7 p -159.8 153.59 22.91 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.551 -0.718 . . . . 0.0 110.465 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 61.4 mttp -109.99 20.26 18.14 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.671 -0.643 . . . . 0.0 110.677 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 49.4 tttm 54.11 39.98 31.19 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.222 -0.924 . . . . 0.0 110.654 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 58.4 tttp -99.98 125.76 46.05 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.709 . . . . 0.0 110.094 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.6 pttt . . . . . 0 N--CA 1.497 1.915 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.492 -179.883 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 59.9 tt0 -127.95 129.99 47.7 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.181 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.416 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -77.84 143.35 37.91 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.587 -0.696 . . . . 0.0 110.226 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.457 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.4 t . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.072 0.463 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.91 170.66 54.07 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.4 ttp180 -59.91 -40.78 90.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.582 -0.952 . . . . 0.0 110.197 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -160.16 39.74 0.18 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.545 -0.722 . . . . 0.0 110.117 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.1 mttm -69.62 -40.02 76.84 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.639 -0.663 . . . . 0.0 110.259 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -134.87 150.44 50.46 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.569 -0.707 . . . . 0.0 110.293 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -129.48 152.96 48.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.638 -0.663 . . . . 0.0 110.018 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.3 t -109.98 120.01 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.531 -0.731 . . . . 0.0 110.016 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.73 33.23 3.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.605 -0.684 . . . . 0.0 110.238 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.26 173.25 45.74 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -102.71 9.77 38.98 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.656 -0.908 . . . . 0.0 111.171 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.02 128.41 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.113 -0.992 . . . . 0.0 109.946 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -116.31 146.29 42.54 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.588 -0.695 . . . . 0.0 109.992 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.3 t -91.55 122.81 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.405 ' HB ' ' CD1' ' A' ' 64' ' ' LEU . 32.7 m -115.62 140.17 38.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.734 -0.604 . . . . 0.0 109.707 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.1 m -138.4 162.87 33.35 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.562 -0.711 . . . . 0.0 110.753 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.55 -170.5 2.24 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.72 -0.612 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.08 -42.83 95.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.534 -0.728 . . . . 0.0 110.736 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.9 t -128.28 -7.66 5.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.385 -0.822 . . . . 0.0 111.849 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.8 tp60 -115.16 156.87 24.49 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.067 -1.02 . . . . 0.0 110.67 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.7 p -149.96 138.1 20.38 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.718 -0.614 . . . . 0.0 109.759 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.405 ' CE1' ' O ' ' A' ' 58' ' ' GLY . 20.0 p90 -164.39 -178.89 5.69 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.533 -0.73 . . . . 0.0 110.456 -179.591 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.6 mt -114.3 159.2 20.46 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.476 -0.765 . . . . 0.0 110.862 -178.48 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -139.1 162.64 34.46 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.697 -0.627 . . . . 0.0 109.989 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.5 t -122.29 140.68 52.35 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.423 -0.798 . . . . 0.0 110.673 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.3 t -98.87 104.06 16.07 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.569 -0.707 . . . . 0.0 110.109 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.61 132.77 56.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.604 -0.685 . . . . 0.0 109.899 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 54.35 39.94 31.34 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.596 -0.69 . . . . 0.0 111.016 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 20.83 76.67 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.9 t -130.0 130.0 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.249 -1.148 . . . . 0.0 109.852 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.1 t -78.93 147.31 33.08 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.483 -0.761 . . . . 0.0 109.403 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.447 ' CG ' ' CE ' ' A' ' 175' ' ' MET . 57.5 m95 -128.66 150.38 50.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.538 -0.726 . . . . 0.0 110.932 -179.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.448 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.3 t -166.11 -179.73 5.29 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.458 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -100.46 154.25 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.73 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -70.05 -40.11 75.3 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.63 -0.669 . . . . 0.0 111.811 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.458 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.1 p-80 -70.62 -22.1 62.57 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.099 -1.001 . . . . 0.0 110.843 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.405 ' O ' ' CE1' ' A' ' 43' ' ' PHE . . . -93.32 -46.41 3.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.907 -1.677 . . . . 0.0 108.907 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.43 -49.31 3.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.658 -0.907 . . . . 0.0 110.334 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.49 -162.3 41.17 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.2 t -93.12 63.37 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.577 -0.955 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.92 161.77 36.78 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.58 -0.7 . . . . 0.0 110.266 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 63.1 p -65.42 139.59 58.55 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.634 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.405 ' CD1' ' HB ' ' A' ' 36' ' ' VAL . 0.1 OUTLIER -112.53 141.28 46.47 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.618 -0.677 . . . . 0.0 110.011 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.27 115.16 24.49 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.511 -0.743 . . . . 0.0 110.252 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.04 176.42 16.17 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.63 -31.97 69.59 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.793 1.417 . . . . 0.0 110.29 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.63 -31.41 66.84 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.657 -0.652 . . . . 0.0 109.829 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.7 -153.71 24.32 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.02 145.0 48.78 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.918 1.483 . . . . 0.0 110.092 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.42 HG22 ' CG ' ' A' ' 85' ' ' TRP . 85.6 mt -119.99 129.49 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.608 -0.682 . . . . 0.0 110.356 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 m -85.49 130.26 34.62 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.963 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.43 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 44.8 mm-40 -55.69 139.93 43.25 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.513 -0.742 . . . . 0.0 110.917 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.0 ttt -113.68 -49.1 2.9 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.73 -0.606 . . . . 0.0 110.179 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 70.3 m-85 -120.0 140.0 51.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.588 -0.695 . . . . 0.0 110.27 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 26.2 m -135.78 129.36 32.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.641 -0.662 . . . . 0.0 110.215 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -142.43 96.75 3.0 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.577 -0.702 . . . . 0.0 110.226 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 76.5 t -65.7 -39.99 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.593 -0.692 . . . . 0.0 110.049 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -60.01 -49.84 76.07 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.551 -0.718 . . . . 0.0 110.816 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -89.31 -0.05 57.17 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 110.934 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.4 t70 52.79 47.41 24.74 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.0 -1.062 . . . . 0.0 110.665 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 62.8 mt -141.63 137.14 31.63 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.443 -0.786 . . . . 0.0 111.141 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.6 m -138.37 161.35 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.555 -0.716 . . . . 0.0 109.301 178.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.32 164.56 26.55 Favored Glycine 0 N--CA 1.495 2.632 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.586 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.448 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 7.7 m-90 -123.13 159.38 28.67 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.829 -0.806 . . . . 0.0 109.253 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -79.9 109.34 14.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.45 -0.781 . . . . 0.0 109.528 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.68 141.08 87.17 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.59 -0.694 . . . . 0.0 110.298 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.03 160.02 51.12 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.917 1.482 . . . . 0.0 110.323 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.83 160.12 42.42 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.305 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.79 29.85 64.65 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.51 144.09 34.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.533 -0.981 . . . . 0.0 110.095 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 31.8 ttt180 -84.69 128.64 34.71 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.69 -0.631 . . . . 0.0 109.703 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.4 p -111.43 162.58 14.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.593 -0.692 . . . . 0.0 110.539 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 16.1 mt -106.37 131.99 52.93 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.614 -0.679 . . . . 0.0 110.73 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.4 p -75.46 160.01 80.56 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.597 -0.689 . . . . 0.0 109.691 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.51 162.63 40.85 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.825 1.434 . . . . 0.0 110.772 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -79.26 130.05 35.07 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.618 -0.676 . . . . 0.0 110.101 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.56 55.6 1.88 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.651 -0.656 . . . . 0.0 109.72 179.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.79 -8.02 0.74 Allowed 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 119.916 -0.714 . . . . 0.0 112.296 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.66 34.77 89.74 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 m -87.0 112.34 21.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.515 -0.991 . . . . 0.0 110.405 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -59.99 -39.97 87.56 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.6 -0.688 . . . . 0.0 110.35 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -63.15 132.88 53.27 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.613 -0.68 . . . . 0.0 110.184 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.4 mt -134.63 146.12 49.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.66 -0.65 . . . . 0.0 110.492 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.82 121.54 44.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.504 -0.748 . . . . 0.0 109.984 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 64.0 tp -95.51 137.94 33.88 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.547 -0.72 . . . . 0.0 110.408 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.24 119.96 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.598 -0.689 . . . . 0.0 109.75 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.2 p -97.74 170.07 9.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.487 -0.758 . . . . 0.0 110.573 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 29.9 mtp-105 -70.06 -20.19 63.25 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.646 -0.659 . . . . 0.0 110.813 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -94.32 26.59 3.28 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.323 -0.861 . . . . 0.0 110.679 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 39.03 30.46 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.273 -0.892 . . . . 0.0 110.751 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -120.14 137.08 54.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.688 -0.633 . . . . 0.0 109.723 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -120.04 143.4 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.446 -0.783 . . . . 0.0 110.67 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 46.0 pt -129.94 158.8 72.77 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.757 -0.59 . . . . 0.0 109.914 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -90.89 130.96 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.817 1.43 . . . . 0.0 110.588 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -130.1 130.01 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.699 -0.625 . . . . 0.0 109.548 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -82.81 149.28 27.29 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.507 -0.745 . . . . 0.0 110.175 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.0 ttt180 -95.56 119.94 34.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.581 -0.7 . . . . 0.0 110.123 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -110.04 19.94 18.46 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.615 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.7 179.41 42.69 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -61.47 -40.03 93.06 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.592 -0.946 . . . . 0.0 110.296 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 44.5 p -130.31 23.63 5.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.548 -0.72 . . . . 0.0 110.681 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -124.53 137.85 54.38 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.41 -0.806 . . . . 0.0 110.299 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -137.51 162.94 25.49 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 76.8 p -119.51 148.35 43.39 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.586 -0.949 . . . . 0.0 110.349 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 tp -95.27 126.84 40.86 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.595 -0.69 . . . . 0.0 110.158 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -61.26 -39.95 92.26 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.656 -0.653 . . . . 0.0 110.388 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.4 p -120.39 149.6 50.13 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.536 -0.728 . . . . 0.0 110.339 -179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -79.88 121.46 4.54 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.969 1.51 . . . . 0.0 110.491 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -122.16 160.56 47.07 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.565 -0.709 . . . . 0.0 110.116 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.53 150.76 80.24 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.955 1.502 . . . . 0.0 110.464 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 64.7 t -62.49 -30.18 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.628 -0.67 . . . . 0.0 109.783 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.2 m -60.03 -38.33 82.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.631 -0.668 . . . . 0.0 110.371 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -59.94 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.469 -0.77 . . . . 0.0 110.029 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.2 mp -86.94 -22.99 25.27 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.486 -0.759 . . . . 0.0 110.572 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 4.2 tptm -60.17 129.96 44.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.388 -0.82 . . . . 0.0 110.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.68 -9.84 73.19 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.1 p -89.94 -0.06 57.36 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.038 -1.272 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.1 m -59.92 139.95 57.03 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.108 -0.995 . . . . 0.0 109.765 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.17 -20.36 51.11 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.11 154.79 43.77 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -98.01 147.49 0.73 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 O-C-N 123.803 1.423 . . . . 0.0 111.134 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.405 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.7 mp -104.41 109.19 20.95 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -98.4 132.15 44.09 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.503 -0.748 . . . . 0.0 111.507 -178.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.424 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.01 159.84 82.74 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.89 -26.58 25.0 Favored 'Trans proline' 0 N--CA 1.502 2.011 0 O-C-N 123.456 1.24 . . . . 0.0 112.266 -178.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.67 -40.1 96.01 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.181 -0.949 . . . . 0.0 109.848 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.68 36.13 0.8 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -131.81 146.37 52.1 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.459 -1.024 . . . . 0.0 110.29 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.59 143.65 57.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.554 -0.716 . . . . 0.0 110.324 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.1 t -118.25 -37.81 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.513 -0.742 . . . . 0.0 110.054 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.5 -170.39 39.04 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 67.9 mt -127.93 133.33 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.523 -0.986 . . . . 0.0 110.24 -179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -61.78 137.04 58.21 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.607 -0.683 . . . . 0.0 109.908 179.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.8 ttt180 -116.88 -52.35 2.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.514 -0.742 . . . . 0.0 110.099 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -149.79 159.99 43.91 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.499 -0.751 . . . . 0.0 110.397 -179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -115.19 151.83 33.73 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.668 -0.645 . . . . 0.0 110.267 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -107.88 119.14 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.589 -0.694 . . . . 0.0 109.714 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.78 155.19 47.09 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.664 -0.647 . . . . 0.0 110.471 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 2.8 m -103.42 -60.31 1.58 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.57 -0.706 . . . . 0.0 110.272 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 71.8 mtt180 -127.92 66.72 1.35 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.704 -0.622 . . . . 0.0 109.933 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 71.84 22.58 78.7 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 14.6 p -139.3 127.75 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.417 -1.049 . . . . 0.0 109.866 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.32 124.2 34.71 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.549 -0.719 . . . . 0.0 110.807 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -107.57 -19.93 13.4 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.694 -0.629 . . . . 0.0 110.073 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -150.04 157.36 43.06 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.454 -0.779 . . . . 0.0 109.849 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.9 m -133.03 164.3 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -0.764 . . . . 0.0 110.792 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -125.13 134.83 52.29 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.558 -0.714 . . . . 0.0 110.218 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -134.18 157.78 45.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.519 -0.738 . . . . 0.0 110.095 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 67.0 t -94.54 124.38 55.37 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.539 -0.726 . . . . 0.0 109.754 179.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.5 147.9 87.19 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.784 1.413 . . . . 0.0 110.41 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 96.5 t -59.89 -23.83 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.71 -0.619 . . . . 0.0 110.675 -179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -59.97 -40.75 90.12 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.372 -0.83 . . . . 0.0 110.633 -179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.8 p -70.0 -36.42 75.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.458 -0.776 . . . . 0.0 110.252 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.2 mtp -59.94 -40.09 87.76 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.604 -0.685 . . . . 0.0 110.378 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 75.3 mt-10 -64.34 -39.95 94.91 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.645 -0.659 . . . . 0.0 110.105 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -61.81 -40.0 93.71 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.67 -0.644 . . . . 0.0 110.049 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.4 m -60.12 -39.97 88.08 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.558 -0.714 . . . . 0.0 110.176 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -60.54 -39.98 89.86 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.479 -0.763 . . . . 0.0 110.238 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -66.71 -40.02 88.29 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.595 -0.691 . . . . 0.0 110.071 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.77 -40.05 88.07 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.54 -0.725 . . . . 0.0 110.153 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.5 t -69.97 150.01 47.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.621 -0.674 . . . . 0.0 110.153 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.4 135.97 40.03 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.552 -0.718 . . . . 0.0 110.215 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -60.22 -39.96 88.5 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.58 -0.7 . . . . 0.0 110.309 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 21.1 tptm -60.1 -39.95 87.95 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.524 -0.735 . . . . 0.0 110.171 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.9 tptt . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 118.084 -0.96 . . . . 0.0 110.153 -179.932 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -123.72 131.03 53.51 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.762 -1.175 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.412 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp -70.0 146.01 51.37 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 110.136 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.47 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.63 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.2 p . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.115 0.483 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -174.33 176.1 46.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.6 mmt-85 -119.98 140.67 50.59 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.606 -0.938 . . . . 0.0 110.186 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -108.82 129.43 55.39 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 110.164 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -62.89 140.06 58.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.566 -0.709 . . . . 0.0 110.17 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -75.34 73.21 2.41 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.582 -0.699 . . . . 0.0 110.459 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 95.6 mt-30 -99.79 112.26 24.53 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.14 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 96.9 t -69.97 -40.19 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.66 -0.65 . . . . 0.0 109.743 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -150.97 159.98 44.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.633 -0.667 . . . . 0.0 109.917 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 160.81 42.95 0.02 OUTLIER Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -61.84 -38.28 87.63 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.532 -0.981 . . . . 0.0 109.827 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.14 125.72 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.548 -0.72 . . . . 0.0 109.698 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -119.32 159.6 23.83 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.714 -0.617 . . . . 0.0 110.491 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.7 t -88.29 115.43 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.62 -0.675 . . . . 0.0 109.545 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.417 ' CG1' ' CD2' ' A' ' 64' ' ' LEU . 57.6 t -110.37 148.14 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.317 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -143.63 171.25 14.43 Favored 'General case' 0 N--CA 1.494 1.745 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.408 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 15.3 p -140.44 179.34 6.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.902 -0.499 . . . . 0.0 109.997 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -75.13 -8.56 56.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.5 -0.75 . . . . 0.0 111.036 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -109.82 -43.71 3.97 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.218 -0.926 . . . . 0.0 111.64 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.41 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 5.2 pt20 -148.88 177.35 9.62 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.251 -0.905 . . . . 0.0 111.296 -179.071 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.3 m -122.58 149.65 43.68 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.588 -0.695 . . . . 0.0 110.279 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 18.9 p90 -164.0 -177.65 5.17 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.245 -0.91 . . . . 0.0 110.461 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.2 mt -113.36 141.35 47.15 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.545 -0.722 . . . . 0.0 110.635 -178.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -114.75 154.53 28.34 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.656 -0.652 . . . . 0.0 109.946 179.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 75.2 p -120.1 131.25 55.0 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.411 -0.806 . . . . 0.0 110.387 -179.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.7 t -93.06 110.02 21.5 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.583 -0.698 . . . . 0.0 110.74 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -114.58 132.27 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.684 -0.635 . . . . 0.0 109.516 179.639 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 29.5 m120 55.56 39.0 30.96 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.516 -0.74 . . . . 0.0 110.933 -179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.96 19.07 75.06 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -130.67 130.01 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.267 -1.137 . . . . 0.0 109.851 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.6 m -76.79 139.53 40.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 109.443 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -133.03 136.45 45.98 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.508 -0.745 . . . . 0.0 110.898 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 29.9 p -150.73 -179.85 7.61 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 9.6 p -88.25 150.19 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.284 -0.885 . . . . 0.0 110.238 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.401 ' CE2' HG21 ' A' ' 78' ' ' VAL . 60.3 t80 -60.06 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.571 -0.706 . . . . 0.0 111.891 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.468 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 5.7 p-80 -59.69 -24.29 63.83 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.09 -1.007 . . . . 0.0 110.739 -178.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -76.88 -42.49 20.3 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -151.24 95.45 2.17 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.771 -0.841 . . . . 0.0 109.786 179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.63 -165.1 4.54 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 88.0 p -71.15 69.79 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.621 -0.929 . . . . 0.0 109.87 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.99 179.22 6.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.562 -0.711 . . . . 0.0 110.293 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 33.0 p -64.93 139.9 58.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.646 -0.659 . . . . 0.0 109.801 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.417 ' CD2' ' CG1' ' A' ' 36' ' ' VAL . 14.8 tp -113.28 137.94 50.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.653 -0.654 . . . . 0.0 110.159 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.76 109.88 22.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.655 -0.653 . . . . 0.0 109.955 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.51 -175.07 15.84 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -64.78 -32.69 55.88 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 O-C-N 123.895 1.471 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -74.82 -31.5 61.7 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.575 -0.703 . . . . 0.0 110.06 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.41 -147.15 18.55 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.08 140.65 15.94 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.832 1.438 . . . . 0.0 110.377 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.49 140.02 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.606 -0.684 . . . . 0.0 110.351 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.6 t -93.23 133.48 36.39 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.537 -0.727 . . . . 0.0 110.439 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.425 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 34.1 tt0 -71.53 140.55 49.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.42 -0.8 . . . . 0.0 110.699 -179.474 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.5 mmm -105.87 -29.1 10.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.663 -0.648 . . . . 0.0 110.323 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -118.39 139.61 51.12 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.565 -0.709 . . . . 0.0 110.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.2 m -139.97 135.34 32.65 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.522 -0.736 . . . . 0.0 110.414 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -150.05 98.95 2.77 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.602 -0.687 . . . . 0.0 109.897 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.401 HG21 ' CE2' ' A' ' 56' ' ' TYR . 67.3 t -69.67 -44.82 79.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.543 -0.723 . . . . 0.0 110.329 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.03 -50.02 75.38 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.553 -0.717 . . . . 0.0 110.46 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 1.8 tp-100 -80.41 -8.49 59.55 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.67 -0.644 . . . . 0.0 110.767 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.1 t70 56.56 45.24 22.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.173 -0.955 . . . . 0.0 110.248 -179.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 75.8 mt -130.01 148.89 51.91 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.565 -0.709 . . . . 0.0 110.721 -179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.421 HG22 ' CH2' ' A' ' 85' ' ' TRP . 32.6 m -149.97 169.92 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.66 -0.65 . . . . 0.0 109.626 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -165.05 160.31 33.58 Favored Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.845 -1.169 . . . . 0.0 110.416 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.425 ' CD1' ' HA ' ' A' ' 73' ' ' GLN . 16.1 m-90 -129.89 149.92 51.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.657 -0.908 . . . . 0.0 109.429 179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -60.9 120.13 9.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.322 -0.861 . . . . 0.0 109.63 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -75.73 141.64 72.5 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.588 -0.695 . . . . 0.0 110.307 -179.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.01 160.02 51.15 Favored 'Trans proline' 0 N--CA 1.49 1.275 0 O-C-N 123.902 1.475 . . . . 0.0 110.32 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.69 143.79 38.31 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 O-C-N 123.947 1.498 . . . . 0.0 110.274 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.48 -22.08 42.75 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.17 46.95 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.286 -1.126 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -92.81 165.42 12.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.611 -0.681 . . . . 0.0 110.109 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.2 p -130.48 169.95 14.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.473 -0.767 . . . . 0.0 110.307 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.3 mt -103.38 132.0 50.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.573 -0.705 . . . . 0.0 110.379 -179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.405 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 50.9 p -72.06 159.99 83.92 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.594 -0.691 . . . . 0.0 109.941 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -83.26 150.27 13.51 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.766 1.403 . . . . 0.0 110.698 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 49.1 t -65.07 132.04 48.14 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.583 -0.698 . . . . 0.0 110.196 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.7 p -135.98 53.16 1.95 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.626 -0.671 . . . . 0.0 109.765 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.9 p -143.85 -3.49 0.88 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.332 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.94 32.31 74.84 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -91.44 129.95 37.35 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.58 -0.953 . . . . 0.0 110.331 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.9 m -77.48 -30.14 52.97 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.622 -0.674 . . . . 0.0 110.315 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.56 133.77 56.42 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.54 -0.725 . . . . 0.0 110.346 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 90.4 mt -134.95 151.66 51.05 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.631 -0.668 . . . . 0.0 110.359 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -119.85 123.17 42.97 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.512 -0.743 . . . . 0.0 109.969 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.0 tp -99.64 133.06 44.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.525 -0.734 . . . . 0.0 110.461 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.3 t -95.72 119.97 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.625 -0.672 . . . . 0.0 109.582 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -92.09 168.13 11.59 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.514 -0.741 . . . . 0.0 110.476 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 37.1 mtp-105 -60.14 -27.3 66.96 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.614 -0.679 . . . . 0.0 110.318 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.413 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -93.69 29.07 2.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.494 -0.754 . . . . 0.0 110.744 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.77 40.0 30.97 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.197 -0.939 . . . . 0.0 111.057 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -99.44 168.7 9.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.562 -0.711 . . . . 0.0 109.928 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -130.03 129.98 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.485 -0.759 . . . . 0.0 110.328 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 82.8 mt -121.26 104.31 40.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.576 -0.702 . . . . 0.0 109.657 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.4 105.84 0.65 Allowed 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 123.79 1.416 . . . . 0.0 110.431 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.2 t -110.04 120.02 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.625 -0.672 . . . . 0.0 109.799 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.3 tpt180 -77.75 142.78 38.49 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.459 -0.776 . . . . 0.0 109.756 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -78.01 129.97 35.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.536 -0.727 . . . . 0.0 110.379 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -128.63 22.5 5.91 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.594 -0.692 . . . . 0.0 110.328 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 172.1 -179.86 43.46 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.376 -1.489 . . . . 0.0 109.376 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -66.79 -40.05 88.01 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.496 -1.002 . . . . 0.0 110.393 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.8 p -129.79 27.34 5.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.54 -0.725 . . . . 0.0 110.532 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.09 162.91 30.47 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.437 -0.789 . . . . 0.0 110.233 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -158.77 175.69 35.76 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 77.5 p -129.21 148.85 51.19 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.607 -0.937 . . . . 0.0 110.262 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 mp -100.76 123.12 44.5 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.607 -0.683 . . . . 0.0 110.438 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.0 mp -64.04 -39.96 95.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.507 -0.746 . . . . 0.0 109.781 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -107.91 112.14 61.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.619 -0.675 . . . . 0.0 109.838 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.32 128.99 22.78 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.801 1.421 . . . . 0.0 110.631 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -125.09 160.03 56.51 Favored Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.592 -0.692 . . . . 0.0 109.906 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -65.48 153.95 75.88 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.863 1.454 . . . . 0.0 110.28 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 79.8 t -63.54 -34.75 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.658 -0.651 . . . . 0.0 110.102 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.4 p -59.74 -36.5 76.73 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.55 -0.719 . . . . 0.0 110.466 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.409 ' CD2' HD11 ' A' ' 135' ' ' LEU . 38.2 t80 -59.96 -40.01 87.55 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.11 179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.409 HD11 ' CD2' ' A' ' 134' ' ' TYR . 9.5 mp -85.27 -16.18 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.563 -0.711 . . . . 0.0 111.119 -179.775 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.23 132.83 55.14 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.173 -0.954 . . . . 0.0 110.069 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 89.98 -6.89 82.54 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 p -93.08 -0.04 57.17 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.254 -1.145 . . . . 0.0 111.168 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.1 m -59.97 139.91 57.09 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.058 -1.026 . . . . 0.0 109.706 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.58 -19.65 53.54 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.49 167.87 3.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -106.07 149.04 0.11 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 O-C-N 123.801 1.422 . . . . 0.0 111.206 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 85.2 mt -110.01 102.51 11.24 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.8 mp -98.12 133.69 42.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.517 -0.739 . . . . 0.0 111.713 -178.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.419 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -70.0 159.41 84.38 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.419 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.88 -26.14 23.61 Favored 'Trans proline' 0 N--CA 1.501 1.946 0 O-C-N 123.423 1.223 . . . . 0.0 112.393 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.7 m -62.73 -39.99 95.81 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.262 -0.899 . . . . 0.0 110.029 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.29 36.36 0.75 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . 0.405 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 2.9 m-70 -132.26 143.25 49.78 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.423 -1.045 . . . . 0.0 110.193 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.92 142.69 58.35 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.593 -0.692 . . . . 0.0 110.332 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.6 t -114.91 -43.63 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.575 -0.703 . . . . 0.0 109.891 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.74 -170.0 33.67 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 96.9 mt -123.86 139.36 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.618 -0.931 . . . . 0.0 110.375 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.2 t80 -64.26 136.43 57.17 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.687 -0.633 . . . . 0.0 109.774 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.3 ttt180 -115.94 -52.27 2.62 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.32 159.95 41.47 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.618 -0.676 . . . . 0.0 110.25 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.04 150.36 34.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.602 -0.686 . . . . 0.0 110.348 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.0 t -109.94 120.0 60.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.673 -0.642 . . . . 0.0 109.751 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -129.77 145.29 51.56 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.63 -0.669 . . . . 0.0 110.426 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.4 m -70.0 -48.86 56.44 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.684 -0.635 . . . . 0.0 110.119 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -162.64 54.73 0.21 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.658 -0.651 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 113.21 -17.89 21.49 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.0 t -111.68 120.52 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.226 -1.161 . . . . 0.0 109.781 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.82 123.73 37.36 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.542 -0.724 . . . . 0.0 110.527 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 52.3 mttp -108.57 -24.77 11.23 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.634 -0.666 . . . . 0.0 110.197 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.78 158.77 43.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.46 -0.775 . . . . 0.0 110.102 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 28.7 m -140.24 170.62 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.565 -0.71 . . . . 0.0 110.545 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -128.93 139.91 51.91 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.646 -0.659 . . . . 0.0 109.905 179.774 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -138.92 157.44 46.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.533 -0.729 . . . . 0.0 110.458 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 59.6 t -96.16 121.52 60.38 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.606 -0.684 . . . . 0.0 109.49 179.604 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -65.01 150.06 88.56 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.845 1.445 . . . . 0.0 110.408 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 87.8 t -60.84 -25.83 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.606 -0.684 . . . . 0.0 110.529 -179.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 65.2 mm-40 -59.97 -36.98 78.3 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.46 -0.775 . . . . 0.0 110.497 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 80.8 p -60.09 -33.12 71.66 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.427 -0.796 . . . . 0.0 110.548 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.9 mtt -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.507 -0.745 . . . . 0.0 110.541 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -60.11 -40.0 88.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.595 -0.691 . . . . 0.0 110.406 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -60.93 -40.13 92.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 110.279 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -67.11 -50.04 62.87 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.481 -0.762 . . . . 0.0 110.206 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 78.7 mtm -68.81 -39.67 79.96 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.498 -0.751 . . . . 0.0 110.07 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -60.02 -39.99 87.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.609 -0.682 . . . . 0.0 110.172 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.96 -42.64 94.55 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.629 -0.669 . . . . 0.0 110.256 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.5 t -150.07 99.96 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.537 -0.727 . . . . 0.0 110.202 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -60.73 -40.03 90.84 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.58 -0.7 . . . . 0.0 110.169 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -80.14 156.27 27.07 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.527 -0.733 . . . . 0.0 110.331 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -79.97 159.74 26.18 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.57 -0.706 . . . . 0.0 110.402 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.112 179.997 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -120.04 134.04 55.36 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.71 -1.196 . . . . 0.0 110.086 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.414 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -68.06 140.41 56.28 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.625 -0.672 . . . . 0.0 110.41 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.4 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.485 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.063 0.458 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.19 -40.01 96.7 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.6 mtm-85 -129.94 149.74 51.53 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.563 -0.963 . . . . 0.0 110.294 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -130.0 139.68 51.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.563 -0.711 . . . . 0.0 110.134 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.83 120.0 39.48 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.649 -0.657 . . . . 0.0 110.264 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -94.29 -39.66 10.39 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.53 -0.731 . . . . 0.0 110.221 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -139.82 150.89 45.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.568 -0.707 . . . . 0.0 110.206 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.0 t -60.65 -42.92 93.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.532 -0.73 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -122.54 139.8 53.49 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.632 -0.668 . . . . 0.0 110.193 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.32 27.71 0.88 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -65.94 -39.97 90.94 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.601 -0.941 . . . . 0.0 109.841 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -114.78 128.85 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.582 -0.699 . . . . 0.0 109.628 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -124.03 159.95 28.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.579 -0.701 . . . . 0.0 110.316 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -108.29 122.18 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.67 -0.644 . . . . 0.0 109.636 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.8 m -118.44 156.76 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.615 -0.678 . . . . 0.0 110.3 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 62.7 m -135.88 167.34 21.37 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.598 -0.688 . . . . 0.0 110.907 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.3 m -134.44 170.68 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.742 -0.599 . . . . 0.0 109.986 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -65.29 -16.63 63.77 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.501 -0.749 . . . . 0.0 111.109 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 m -117.39 -35.02 4.12 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.189 -0.944 . . . . 0.0 111.628 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -150.81 170.68 18.68 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.225 -0.922 . . . . 0.0 111.096 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 85.9 p -130.43 155.69 46.01 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.36 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 18.1 p90 -162.46 -178.33 6.2 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.383 -0.823 . . . . 0.0 110.256 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.5 mt -113.66 152.84 29.87 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.519 -0.738 . . . . 0.0 110.9 -178.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -132.41 161.09 34.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.662 -0.649 . . . . 0.0 110.013 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.2 t -122.95 139.0 54.52 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.572 -0.705 . . . . 0.0 110.518 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 46.4 t -93.96 104.65 16.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.36 -0.838 . . . . 0.0 110.422 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -112.44 133.35 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.692 -0.63 . . . . 0.0 109.714 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 56.97 38.25 29.26 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.502 -0.749 . . . . 0.0 110.893 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.2 27.11 74.06 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -141.79 131.85 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -1.07 . . . . 0.0 110.064 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.33 144.97 39.86 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.423 -0.798 . . . . 0.0 109.06 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -129.93 150.99 50.98 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 111.087 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.463 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -168.82 -179.78 3.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.823 -0.548 . . . . 0.0 109.574 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.467 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.5 p -90.04 160.02 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.478 -0.764 . . . . 0.0 110.218 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.415 ' CZ ' HG21 ' A' ' 78' ' ' VAL . 60.2 t80 -73.27 -44.62 58.94 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.538 -0.726 . . . . 0.0 111.779 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.467 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.7 p-80 -60.6 -24.66 65.65 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.134 -0.979 . . . . 0.0 110.704 -178.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -75.7 -47.78 11.44 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 178.512 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -137.09 94.53 2.96 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.751 -0.852 . . . . 0.0 109.271 179.243 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.06 62.81 1.33 Allowed Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.8 t 53.38 39.97 30.65 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.255 -1.144 . . . . 0.0 110.809 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -110.02 179.29 4.15 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.571 -0.705 . . . . 0.0 110.021 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 87.0 m -64.9 139.13 58.73 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.866 -0.733 . . . . 0.0 109.225 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.423 HD23 ' CZ2' ' A' ' 85' ' ' TRP . 12.6 tp -125.78 133.12 52.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.549 -0.719 . . . . 0.0 110.177 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.76 113.54 25.1 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.586 -0.697 . . . . 0.0 109.922 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.43 -179.26 17.54 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -62.28 -31.13 82.02 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.871 1.459 . . . . 0.0 110.649 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -75.87 -20.19 58.28 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.563 -0.71 . . . . 0.0 110.626 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.54 -133.27 7.42 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -84.25 146.05 11.06 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.9 1.474 . . . . 0.0 110.136 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -120.02 129.98 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.589 -0.694 . . . . 0.0 110.34 -179.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.5 p -87.45 147.09 25.56 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.48 -0.762 . . . . 0.0 110.442 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 15.3 mp0 -87.66 140.01 29.95 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.7 mmm -119.23 -41.8 2.71 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.573 -0.704 . . . . 0.0 110.422 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -120.06 140.0 51.68 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.519 -0.738 . . . . 0.0 110.684 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 33.4 m -139.97 130.01 24.93 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.605 -0.684 . . . . 0.0 110.09 179.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -142.19 98.33 3.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.499 -0.751 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.415 HG21 ' CZ ' ' A' ' 56' ' ' TYR . 94.1 t -70.05 -40.15 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.59 -0.693 . . . . 0.0 109.96 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.1 -47.31 86.43 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.72 . . . . 0.0 110.644 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -87.14 -0.03 56.04 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.505 -0.747 . . . . 0.0 110.801 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.8 t70 52.96 45.14 29.42 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.113 -0.992 . . . . 0.0 110.543 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 64.5 mt -139.94 143.31 36.53 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.445 -0.784 . . . . 0.0 111.069 -179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 35.4 m -147.47 160.01 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.641 -0.662 . . . . 0.0 109.61 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.75 159.97 28.03 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.463 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 15.3 m-90 -118.22 166.91 12.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.666 -0.902 . . . . 0.0 109.53 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -72.49 119.88 17.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.501 -0.749 . . . . 0.0 109.271 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.8 140.35 98.04 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.495 -0.753 . . . . 0.0 110.296 -179.462 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.96 159.98 51.29 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.926 1.487 . . . . 0.0 110.268 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.82 142.11 31.4 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.905 1.476 . . . . 0.0 110.225 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.48 29.29 49.59 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.79 152.12 26.1 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.561 -0.964 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -88.3 167.57 13.43 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.689 -0.632 . . . . 0.0 110.038 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 47.5 t -144.04 164.37 30.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.623 -0.673 . . . . 0.0 110.16 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.4 mt -110.16 149.2 30.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.601 -0.687 . . . . 0.0 110.653 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 24.5 p -89.95 177.76 2.26 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.694 -0.629 . . . . 0.0 109.984 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -88.74 159.11 6.25 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 O-C-N 123.801 1.421 . . . . 0.0 110.566 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 48.9 t -68.76 130.39 42.67 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.716 -0.615 . . . . 0.0 110.113 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 38.7 p -134.49 54.04 1.96 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.738 -0.601 . . . . 0.0 109.754 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.71 -5.95 0.8 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.561 -0.712 . . . . 0.0 112.37 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.98 38.2 93.84 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -100.01 122.35 42.77 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.575 -0.956 . . . . 0.0 110.463 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.4 m -69.95 -29.43 66.55 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.643 -0.66 . . . . 0.0 110.176 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -64.31 132.58 50.6 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.542 -0.724 . . . . 0.0 110.21 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.1 mt -136.63 149.95 48.27 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.554 -0.716 . . . . 0.0 110.458 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 62.9 m-85 -112.49 120.5 41.85 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.519 -0.738 . . . . 0.0 110.057 179.694 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.2 tp -93.7 131.45 39.02 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.432 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.21 119.98 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.516 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.1 m -97.56 169.78 9.48 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.52 -0.738 . . . . 0.0 110.62 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 29.8 mtp-105 -62.54 -27.62 69.3 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.682 -0.636 . . . . 0.0 110.129 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -94.6 28.38 2.65 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.24 41.9 31.76 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.195 -0.94 . . . . 0.0 111.036 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -100.04 122.12 42.43 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.516 -0.74 . . . . 0.0 109.961 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.6 p -97.86 70.61 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.665 . . . . 0.0 110.308 -179.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 tp -70.0 129.99 90.31 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.57 -0.706 . . . . 0.0 109.862 179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -75.71 134.33 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.781 1.411 . . . . 0.0 110.599 -179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.86 130.06 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.636 -0.665 . . . . 0.0 109.558 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -92.37 133.55 35.76 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.49 -0.756 . . . . 0.0 110.095 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -80.42 125.85 30.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.652 -0.655 . . . . 0.0 110.357 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -122.48 24.23 9.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.587 -0.696 . . . . 0.0 110.288 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -178.49 -177.36 47.1 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.12 -40.0 78.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.539 -0.977 . . . . 0.0 110.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.2 p -133.09 24.46 4.21 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.513 -0.742 . . . . 0.0 110.691 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.44 151.79 50.54 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.3 171.56 25.05 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.4 p -115.24 154.55 28.86 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.912 . . . . 0.0 110.04 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -99.99 119.98 39.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.51 -0.744 . . . . 0.0 110.069 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -66.71 -39.98 88.24 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.583 -0.698 . . . . 0.0 110.101 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.3 m -110.22 114.36 55.74 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.622 -0.674 . . . . 0.0 110.169 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.67 114.26 2.66 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.782 1.412 . . . . 0.0 110.439 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -125.59 160.08 57.6 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.628 -0.67 . . . . 0.0 110.081 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.71 157.08 53.71 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.853 1.449 . . . . 0.0 110.362 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.7 m -67.06 -23.89 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.595 -0.691 . . . . 0.0 110.636 -179.801 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.1 m -59.98 -39.98 87.53 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.469 -0.769 . . . . 0.0 110.328 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -59.91 -50.13 74.96 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.483 -0.761 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.409 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.93 -26.1 63.98 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.684 -0.635 . . . . 0.0 110.097 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.8 tptm -58.74 129.95 44.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.437 -0.79 . . . . 0.0 110.311 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.95 -10.06 72.39 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.407 -0.902 . . . . 0.0 110.866 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 59.5 p -94.57 -3.22 50.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.0 -1.294 . . . . 0.0 111.251 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.079 -1.013 . . . . 0.0 109.667 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.24 -22.18 38.76 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -178.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.57 155.62 44.02 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -95.77 150.07 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.845 1.445 . . . . 0.0 111.219 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.404 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.7 mp -106.61 108.99 20.78 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -98.8 130.28 45.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 111.579 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.423 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.02 159.54 83.88 Favored Pre-proline 0 N--CA 1.495 1.815 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.423 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.9 -26.51 24.82 Favored 'Trans proline' 0 N--CA 1.501 1.929 0 O-C-N 123.494 1.26 . . . . 0.0 112.28 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.1 m -62.68 -39.96 95.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.258 -0.901 . . . . 0.0 109.99 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.23 35.99 0.84 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -131.8 149.47 52.45 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.409 -1.054 . . . . 0.0 110.314 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -68.21 139.96 56.06 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.66 -0.65 . . . . 0.0 110.272 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 64.7 t -114.46 -36.15 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.584 -0.697 . . . . 0.0 109.99 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 179.52 -166.61 36.03 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.401 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 96.6 mt -130.97 140.07 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.563 -0.963 . . . . 0.0 110.263 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -64.25 138.57 58.51 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.7 -0.625 . . . . 0.0 109.58 179.507 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -118.49 -52.25 2.37 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.473 -0.767 . . . . 0.0 110.428 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -152.79 160.06 43.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.593 -0.692 . . . . 0.0 110.184 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -109.81 151.88 26.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.616 -0.677 . . . . 0.0 110.256 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -108.47 116.97 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.662 -0.649 . . . . 0.0 109.751 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.3 p -129.88 142.39 50.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.653 -0.654 . . . . 0.0 110.254 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.1 m -69.69 -49.61 51.78 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.566 -0.709 . . . . 0.0 110.103 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -162.91 54.15 0.19 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.71 -0.619 . . . . 0.0 109.823 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 114.78 -18.51 16.89 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.509 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -112.9 120.77 63.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.29 -1.124 . . . . 0.0 109.758 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -86.61 130.1 34.62 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.549 -0.72 . . . . 0.0 110.522 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -112.47 -26.15 8.84 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.583 -0.698 . . . . 0.0 110.33 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.32 157.99 44.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.663 -0.648 . . . . 0.0 109.974 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.25 179.5 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.431 -0.793 . . . . 0.0 110.608 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -135.36 134.58 39.94 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -138.18 153.13 49.2 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.35 -0.844 . . . . 0.0 110.809 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 60.5 t -95.09 119.12 66.26 Favored Pre-proline 0 N--CA 1.493 1.675 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 179.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -62.38 155.23 58.75 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.771 1.406 . . . . 0.0 110.589 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 93.7 t -56.78 -23.18 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.611 -0.681 . . . . 0.0 110.669 -179.726 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -60.04 -33.13 71.61 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.375 -0.828 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 18.4 t -60.07 -37.99 81.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.453 -0.78 . . . . 0.0 110.393 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.401 ' CE ' ' CD1' ' A' ' 153' ' ' ILE . 67.6 mtt -59.97 -39.97 87.46 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.521 -0.737 . . . . 0.0 110.502 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -62.31 -39.9 94.53 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.594 -0.691 . . . . 0.0 110.189 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.6 m -70.09 -39.97 75.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.596 -0.69 . . . . 0.0 109.965 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 84.8 m -59.98 -49.54 77.25 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.588 -0.695 . . . . 0.0 110.317 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -68.22 -39.97 82.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.542 -0.723 . . . . 0.0 110.295 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 38.4 ttt180 -69.75 -39.97 76.42 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.608 -0.683 . . . . 0.0 110.206 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.96 -29.04 66.06 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.556 -0.715 . . . . 0.0 110.316 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 25.4 m -92.65 42.83 1.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.588 -0.695 . . . . 0.0 110.541 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -59.96 -49.98 75.56 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.401 -0.812 . . . . 0.0 110.262 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -151.0 120.02 6.69 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 81.8 mttt -143.27 159.99 41.31 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.551 -0.718 . . . . 0.0 110.192 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 29.9 tptp . . . . . 0 N--CA 1.501 2.114 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.686 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -145.01 130.02 18.39 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.208 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.408 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp -73.51 145.54 45.53 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.647 -0.658 . . . . 0.0 109.985 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.457 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.653 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.017 0.437 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 178.77 -172.07 44.31 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -119.97 140.0 51.6 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.531 -0.982 . . . . 0.0 110.005 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -108.3 21.02 17.92 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.51 -0.744 . . . . 0.0 110.723 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.97 120.42 39.77 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.4 -0.812 . . . . 0.0 110.204 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -158.05 159.97 36.9 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.527 -0.733 . . . . 0.0 110.225 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -99.99 123.41 44.21 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.604 -0.685 . . . . 0.0 110.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -69.8 -26.3 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.587 -0.695 . . . . 0.0 110.556 -179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -123.57 149.1 45.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.449 -0.782 . . . . 0.0 110.25 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 140.41 59.02 0.04 OUTLIER Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -67.3 -37.44 83.38 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.48 -1.012 . . . . 0.0 109.903 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 123.27 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.688 -0.632 . . . . 0.0 109.817 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -123.72 157.89 32.9 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.589 -0.695 . . . . 0.0 110.312 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 67.9 t -87.34 131.71 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.605 -0.685 . . . . 0.0 109.812 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.1 m -127.13 152.89 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.587 -0.696 . . . . 0.0 110.367 179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 64.0 m -135.96 -177.89 4.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.705 -0.622 . . . . 0.0 110.34 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -144.75 -169.13 3.1 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.32 -38.67 80.87 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.395 -0.816 . . . . 0.0 110.098 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.1 t -138.58 -7.22 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.443 -0.786 . . . . 0.0 112.514 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -114.55 151.39 33.44 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.868 -1.145 . . . . 0.0 111.163 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -136.09 141.49 44.22 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.584 -0.697 . . . . 0.0 110.238 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 32.8 p90 -170.32 -177.53 2.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.426 -0.796 . . . . 0.0 110.023 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 54.1 mt -113.13 167.9 10.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.49 -0.756 . . . . 0.0 110.253 -178.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -145.9 160.04 42.38 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.664 -0.647 . . . . 0.0 110.265 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.8 t -120.57 140.2 51.85 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.597 -0.69 . . . . 0.0 110.18 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 37.7 t -99.23 109.96 22.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.417 -0.802 . . . . 0.0 110.407 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.19 130.03 64.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.541 -0.724 . . . . 0.0 109.701 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 56.14 39.93 30.25 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.544 -0.723 . . . . 0.0 110.868 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.94 19.92 75.73 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.0 t -131.06 130.01 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.267 -1.137 . . . . 0.0 109.958 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 78.4 m -77.41 140.43 39.89 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.415 -0.803 . . . . 0.0 109.461 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -130.62 147.09 52.25 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.517 -0.739 . . . . 0.0 110.936 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.439 HG22 ' CZ3' ' A' ' 85' ' ' TRP . 6.4 t -167.66 -179.19 4.21 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.464 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.6 p -88.68 156.63 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 110.356 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -70.04 -44.37 69.36 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.594 -0.691 . . . . 0.0 111.887 -178.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.464 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.9 p-80 -60.78 -24.26 65.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.195 -0.941 . . . . 0.0 110.787 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -77.1 -48.96 7.88 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 178.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -128.49 101.09 6.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.784 -0.833 . . . . 0.0 109.534 179.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.26 -164.93 2.34 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 35.0 p -72.21 65.92 0.62 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.655 -0.909 . . . . 0.0 109.844 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.39 169.87 16.77 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.604 -0.685 . . . . 0.0 110.595 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.7 p -69.89 159.92 32.78 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.579 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.453 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 16.0 tp -115.51 140.8 48.83 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.543 -0.723 . . . . 0.0 110.335 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.91 109.7 22.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.576 -0.702 . . . . 0.0 110.109 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.63 179.98 16.32 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.99 -32.34 65.21 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.854 1.45 . . . . 0.0 110.431 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 87.0 mttt -71.08 -31.49 67.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.663 -0.648 . . . . 0.0 110.037 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.11 -162.2 25.99 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.02 137.82 38.59 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.866 1.456 . . . . 0.0 110.155 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.7 mt -120.06 130.04 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.615 -0.678 . . . . 0.0 110.49 -179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 77.8 p -80.4 149.98 29.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.927 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -100.86 144.42 29.84 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.523 -0.736 . . . . 0.0 111.218 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 30.2 mtm -117.3 -21.76 8.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.631 . . . . 0.0 110.59 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -125.57 147.44 49.28 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.417 -0.802 . . . . 0.0 110.403 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.9 t -169.32 129.72 1.08 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.59 -0.694 . . . . 0.0 109.921 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.607 -0.683 . . . . 0.0 110.258 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 69.3 t -69.8 -49.61 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.582 -0.699 . . . . 0.0 109.811 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -60.28 -48.57 81.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.606 -0.684 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 50.7 tt0 -79.33 -10.11 59.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.634 -0.666 . . . . 0.0 110.612 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.0 t70 54.16 49.94 17.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.15 -0.969 . . . . 0.0 110.701 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 39.0 mt -143.25 130.98 21.38 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.385 -0.822 . . . . 0.0 111.43 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.03 159.98 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.609 -0.682 . . . . 0.0 109.592 178.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.14 159.06 27.82 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.453 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 9.3 m-90 -122.52 160.03 26.46 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.747 -0.855 . . . . 0.0 109.725 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.5 tt0 -77.79 107.77 10.53 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.543 -0.723 . . . . 0.0 109.51 179.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.45 137.84 86.29 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.594 -0.691 . . . . 0.0 110.291 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.04 158.79 55.45 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 O-C-N 123.93 1.49 . . . . 0.0 110.221 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.64 146.48 61.06 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.976 1.514 . . . . 0.0 110.388 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.94 -26.37 24.72 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -68.06 140.05 56.27 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.46 -1.023 . . . . 0.0 110.119 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -81.82 158.62 24.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.522 -0.736 . . . . 0.0 109.884 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -130.07 169.76 14.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.573 -0.704 . . . . 0.0 110.167 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 45.0 mt -106.03 131.91 52.75 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.625 -0.672 . . . . 0.0 110.731 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -73.66 160.03 83.11 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.577 -0.702 . . . . 0.0 109.793 179.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -77.35 161.12 32.04 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.787 1.414 . . . . 0.0 110.636 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.8 t -74.07 129.91 38.77 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.722 -0.611 . . . . 0.0 110.134 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -132.85 54.12 1.97 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.679 -0.638 . . . . 0.0 109.689 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.62 -8.12 0.75 Allowed 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.371 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.97 42.57 98.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.97 119.93 39.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.525 -0.985 . . . . 0.0 110.422 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.6 m -63.31 -39.99 96.11 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 110.48 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -60.71 129.98 44.25 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.561 -0.712 . . . . 0.0 110.481 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 93.2 mt -133.08 150.19 52.1 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.673 -0.642 . . . . 0.0 110.404 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -115.72 121.37 42.31 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.483 -0.76 . . . . 0.0 109.948 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 44.6 tp -101.05 143.82 30.71 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.528 -0.732 . . . . 0.0 110.369 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.7 t -108.87 129.12 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.57 -0.706 . . . . 0.0 109.87 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 75.2 p -106.26 178.85 4.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.543 -0.723 . . . . 0.0 110.597 -179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 68.3 mtm180 -59.98 -28.26 67.53 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.594 -0.691 . . . . 0.0 110.58 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -90.3 19.08 5.39 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.467 -0.77 . . . . 0.0 111.122 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.51 40.02 30.81 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.102 -0.999 . . . . 0.0 110.706 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -100.16 139.34 35.97 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.73 -0.606 . . . . 0.0 109.936 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 64.7 t -93.74 117.39 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.624 -0.672 . . . . 0.0 109.955 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . 0.46 HG22 HD11 ' A' ' 114' ' ' ILE . 86.9 mt -107.53 110.05 62.73 Favored Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.694 -0.629 . . . . 0.0 109.599 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.85 116.4 4.55 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 123.886 1.466 . . . . 0.0 110.462 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.1 t -120.01 125.2 74.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.678 -0.639 . . . . 0.0 109.643 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -86.23 130.03 34.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.572 -0.705 . . . . 0.0 109.97 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.75 127.87 33.71 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.622 -0.674 . . . . 0.0 110.376 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 12.0 mmm180 -129.68 22.21 5.47 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.665 -0.647 . . . . 0.0 110.245 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.51 -179.75 43.07 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -67.51 -40.66 85.15 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.591 -0.946 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.7 p -131.67 22.51 4.66 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.493 -0.754 . . . . 0.0 110.743 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.38 151.93 51.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.384 -0.822 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.46 -173.98 18.17 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -125.49 154.91 41.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.641 -0.917 . . . . 0.0 110.162 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 25.1 tp -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.575 -0.703 . . . . 0.0 110.207 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -68.37 -36.61 79.44 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 0.0 109.964 179.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -111.04 113.05 55.06 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.685 -0.635 . . . . 0.0 110.039 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.28 116.57 3.82 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.726 1.382 . . . . 0.0 110.545 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -128.03 160.04 63.64 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.602 -0.686 . . . . 0.0 110.082 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.71 157.09 62.77 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.907 1.477 . . . . 0.0 110.398 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.4 m -66.12 -24.78 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.614 -0.679 . . . . 0.0 110.487 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.2 t -59.88 -38.44 82.22 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.456 -0.778 . . . . 0.0 110.332 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.585 -0.697 . . . . 0.0 110.342 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 10.7 mp -83.11 -16.86 45.17 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.477 -0.765 . . . . 0.0 111.038 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.59 140.01 58.83 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.269 -0.894 . . . . 0.0 110.078 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.56 6.05 89.11 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 63.2 m -112.58 19.48 17.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.129 -1.218 . . . . 0.0 110.757 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -72.28 147.91 45.94 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.304 -0.873 . . . . 0.0 109.935 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.58 -15.31 60.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.02 139.98 48.17 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -87.79 148.93 7.2 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 O-C-N 123.77 1.405 . . . . 0.0 111.224 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.8 mp -105.6 120.02 40.59 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -108.77 131.18 55.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.463 -0.773 . . . . 0.0 111.704 -178.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.441 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.97 82.09 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.4 Cg_endo -51.72 -23.12 14.8 Favored 'Trans proline' 0 N--CA 1.502 2.004 0 O-C-N 123.51 1.268 . . . . 0.0 112.272 -178.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -66.32 -39.98 89.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.247 -0.908 . . . . 0.0 109.89 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.25 34.67 0.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -131.77 144.72 51.15 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.422 -1.046 . . . . 0.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -69.91 138.67 52.63 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.515 -0.74 . . . . 0.0 110.125 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.3 p -118.05 -21.87 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.591 -0.693 . . . . 0.0 110.814 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 178.68 -173.75 46.02 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 95.5 mt -131.55 139.99 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.605 -0.938 . . . . 0.0 110.096 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.2 t80 -61.0 139.64 58.0 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.579 -0.7 . . . . 0.0 110.148 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -120.21 -52.02 2.19 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.59 -0.694 . . . . 0.0 110.333 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.24 160.55 41.87 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.571 -0.706 . . . . 0.0 110.432 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.01 153.88 23.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.552 -0.717 . . . . 0.0 110.408 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.05 119.22 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.637 -0.664 . . . . 0.0 109.888 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -137.07 158.59 44.11 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.683 . . . . 0.0 110.307 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 6.2 p -99.0 -51.95 3.7 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.595 -0.691 . . . . 0.0 110.486 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -142.94 63.06 1.39 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.565 -0.709 . . . . 0.0 110.013 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.99 -8.81 79.14 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.66 126.55 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.193 -1.181 . . . . 0.0 109.967 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.58 131.69 46.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.6 -0.687 . . . . 0.0 110.372 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -113.66 -15.42 12.49 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.565 -0.709 . . . . 0.0 110.746 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 158.71 43.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.345 -0.847 . . . . 0.0 109.846 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.04 160.01 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.523 -0.736 . . . . 0.0 110.546 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -123.04 136.11 54.71 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.732 -0.605 . . . . 0.0 109.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -139.11 160.0 40.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.497 -0.752 . . . . 0.0 110.457 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 88.6 t -99.89 124.6 43.21 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.59 -0.693 . . . . 0.0 109.553 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -65.34 147.59 87.64 Favored 'Trans proline' 0 N--CA 1.489 1.259 0 O-C-N 123.82 1.432 . . . . 0.0 110.186 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 35.7 m -60.6 -24.68 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.68 -0.638 . . . . 0.0 110.996 -179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -60.5 -39.97 89.67 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.485 -0.759 . . . . 0.0 110.693 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.2 p -61.67 -43.3 99.11 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.434 -0.791 . . . . 0.0 110.906 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.1 mtm -63.54 -39.98 95.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.825 . . . . 0.0 110.456 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -60.43 -40.01 89.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.424 -0.798 . . . . 0.0 110.029 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.0 m -70.23 -26.11 63.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.632 -0.668 . . . . 0.0 110.528 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.7 m -59.94 -40.83 90.29 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.517 -0.739 . . . . 0.0 110.282 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.2 mtt -69.15 -39.91 78.52 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.471 -0.768 . . . . 0.0 110.208 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 37.7 ttt180 -70.02 -39.99 75.46 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.555 -0.715 . . . . 0.0 110.231 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.11 -49.93 75.71 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.58 -0.7 . . . . 0.0 110.496 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.6 t -155.9 160.01 39.79 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.591 -0.693 . . . . 0.0 110.251 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 27.8 tttt -102.26 -158.02 0.64 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.566 -0.709 . . . . 0.0 109.955 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 55.9 tttp -60.04 -40.02 87.92 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.392 -0.817 . . . . 0.0 110.284 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -127.93 28.11 5.61 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.599 -0.688 . . . . 0.0 110.349 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 85.3 tttt . . . . . 0 N--CA 1.502 2.151 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.684 -179.963 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 60.2 tt0 -127.56 137.37 52.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.131 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . . . . . . . . . 8.8 mp -88.8 137.43 32.33 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.608 -0.682 . . . . 0.0 110.222 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.411 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.501 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.048 0.451 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.17 166.62 50.1 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -129.98 150.11 51.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.604 -0.939 . . . . 0.0 110.174 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -59.92 -40.04 87.52 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.547 -0.721 . . . . 0.0 110.41 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -125.8 111.37 14.79 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.48 -0.763 . . . . 0.0 110.255 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 t30 -149.95 93.41 2.02 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.568 -0.708 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -121.41 129.93 53.3 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.57 -0.706 . . . . 0.0 110.181 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.05 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.497 -0.752 . . . . 0.0 110.342 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -138.5 135.57 35.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.636 -0.665 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 140.21 93.82 0.24 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -67.0 -22.55 65.9 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.599 -0.942 . . . . 0.0 110.693 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.0 t -108.94 127.56 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.492 -0.755 . . . . 0.0 109.799 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -121.16 155.5 34.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.666 -0.647 . . . . 0.0 110.345 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 63.7 t -91.52 120.59 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.668 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 33.4 m -116.56 158.32 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.659 -0.651 . . . . 0.0 110.156 -179.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 33.0 m -145.68 172.77 12.79 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.126 -0.629 . . . . 0.0 110.577 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.93 -172.38 2.91 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.19 88.56 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.374 -0.829 . . . . 0.0 110.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 23.2 m -131.47 -7.12 3.72 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.526 -0.734 . . . . 0.0 111.975 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -113.96 159.71 19.62 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.967 -1.083 . . . . 0.0 110.906 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.2 t -146.1 136.96 24.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.403 ' CE1' ' O ' ' A' ' 58' ' ' GLY . 25.0 p90 -166.72 -177.42 3.89 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.315 -0.866 . . . . 0.0 110.528 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 73.3 mt -113.05 159.07 19.54 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.598 -0.689 . . . . 0.0 110.81 -178.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -133.4 156.69 47.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.643 -0.661 . . . . 0.0 110.044 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 47.3 m -121.82 134.57 54.9 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.444 -0.785 . . . . 0.0 110.44 -179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 31.7 t -92.76 110.44 21.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.56 -0.713 . . . . 0.0 110.594 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.416 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 63.1 t -119.46 134.84 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.593 -0.692 . . . . 0.0 109.641 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 54.93 38.37 30.33 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.534 -0.729 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 26.04 74.81 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 178.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.4 t -139.9 131.73 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.364 -1.08 . . . . 0.0 109.906 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.8 m -75.29 148.57 39.27 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.377 -0.827 . . . . 0.0 109.181 179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.44 ' CG ' ' CE ' ' A' ' 175' ' ' MET . 60.8 m95 -129.99 151.04 50.97 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.726 0.774 . . . . 0.0 111.313 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.459 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -169.37 -179.88 3.64 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.451 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 12.4 p -95.62 155.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.828 . . . . 0.0 110.37 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 62.1 t80 -70.01 -40.86 75.0 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.509 -0.745 . . . . 0.0 111.599 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.451 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.9 p-80 -70.04 -24.4 63.26 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.148 -0.97 . . . . 0.0 110.621 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.403 ' O ' ' CE1' ' A' ' 43' ' ' PHE . . . -83.38 -56.28 2.71 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -101.97 -53.51 2.92 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.756 -0.849 . . . . 0.0 109.964 179.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.08 -168.99 46.87 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 97.9 p -86.48 64.45 8.54 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.644 -0.915 . . . . 0.0 109.911 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -140.27 170.02 16.6 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.533 -0.729 . . . . 0.0 110.38 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.9 m -65.3 139.59 58.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.549 -0.719 . . . . 0.0 110.043 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.454 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -113.56 136.22 53.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.64 -0.663 . . . . 0.0 110.014 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.28 119.08 33.17 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -123.05 176.42 16.6 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.69 -32.36 68.49 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.852 1.449 . . . . 0.0 110.414 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -71.89 -31.32 66.29 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.629 -0.67 . . . . 0.0 110.169 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.86 -156.57 26.72 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -70.04 154.33 66.76 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.872 1.459 . . . . 0.0 110.359 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.5 mt -130.35 142.65 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.579 -0.7 . . . . 0.0 110.311 -179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.4 p -99.47 139.98 34.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.496 -0.752 . . . . 0.0 110.591 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.5 mm100 -71.04 144.55 50.35 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.613 -0.679 . . . . 0.0 111.216 -179.739 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 95.1 mmm -119.21 -45.41 2.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.65 -0.656 . . . . 0.0 110.211 179.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -120.02 139.94 51.74 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.592 -0.693 . . . . 0.0 110.449 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 30.3 p -130.48 139.92 50.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.58 -0.7 . . . . 0.0 110.329 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -148.33 82.59 1.48 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.616 -0.678 . . . . 0.0 110.083 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 94.2 t -62.34 -44.68 99.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.634 -0.666 . . . . 0.0 110.011 -179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.96 -44.54 94.36 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.508 -0.745 . . . . 0.0 110.216 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.8 tp60 -89.97 -0.0 57.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.514 -0.741 . . . . 0.0 111.002 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.2 t70 52.79 49.63 19.85 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.016 -1.052 . . . . 0.0 110.498 -179.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 54.9 mt -140.02 144.51 36.97 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.601 -0.687 . . . . 0.0 111.101 -179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 34.9 m -149.93 159.67 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.565 -0.709 . . . . 0.0 109.611 179.214 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.58 28.24 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.459 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 8.5 m-90 -120.9 159.98 24.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.824 -0.81 . . . . 0.0 109.742 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -68.45 122.47 18.5 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.425 -0.797 . . . . 0.0 109.373 179.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -75.42 130.54 79.52 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.538 -0.726 . . . . 0.0 110.187 -179.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.06 159.97 51.29 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.887 1.467 . . . . 0.0 110.293 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.21 160.13 50.2 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 O-C-N 123.883 1.465 . . . . 0.0 110.275 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.58 29.43 69.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.06 156.64 21.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.615 -0.932 . . . . 0.0 110.113 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -99.12 139.72 34.35 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.0 p -118.84 157.74 27.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.616 -0.677 . . . . 0.0 110.181 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 76.7 mt -112.32 131.53 55.47 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.566 -0.709 . . . . 0.0 110.563 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.6 p -82.2 159.99 63.79 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.565 -0.709 . . . . 0.0 109.969 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.61 165.81 30.72 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.823 1.433 . . . . 0.0 110.4 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 13.5 t -87.2 149.98 24.24 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.891 0.853 . . . . 0.0 110.367 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.6 m -133.91 62.21 1.66 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 m -141.57 -9.02 0.95 Allowed 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.831 -177.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.51 26.45 56.95 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 79.5 p -80.02 160.0 26.02 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.461 -1.023 . . . . 0.0 110.493 -179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.7 m -107.42 -27.07 10.67 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.707 -0.62 . . . . 0.0 110.329 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -73.83 129.37 37.77 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.75 . . . . 0.0 110.015 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 85.0 mt -135.3 150.05 49.92 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.576 -0.703 . . . . 0.0 110.662 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -108.69 119.94 41.0 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.492 -0.755 . . . . 0.0 109.562 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.0 tp -100.97 141.51 33.75 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.48 -0.762 . . . . 0.0 110.78 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.88 130.03 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.631 -0.668 . . . . 0.0 109.703 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 73.9 p -111.89 169.97 8.47 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.442 -0.786 . . . . 0.0 110.705 -179.501 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 23.1 ptt-85 -64.68 -16.17 62.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.611 -0.68 . . . . 0.0 111.005 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -89.97 17.4 6.86 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.222 -0.923 . . . . 0.0 110.828 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.44 40.01 31.46 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.081 -1.012 . . . . 0.0 110.51 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -113.38 156.56 23.22 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.658 -0.651 . . . . 0.0 109.853 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.6 p -130.0 130.36 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.551 -0.718 . . . . 0.0 110.233 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 16.1 tt -131.86 130.06 22.11 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.69 -0.631 . . . . 0.0 109.893 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.71 126.79 12.37 Favored 'Trans proline' 0 N--CA 1.49 1.265 0 O-C-N 123.856 1.45 . . . . 0.0 110.355 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -120.04 125.58 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.692 -0.63 . . . . 0.0 109.72 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -86.23 149.99 24.7 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.484 -0.76 . . . . 0.0 110.059 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 70.0 ttp85 -93.71 120.65 34.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -110.01 20.0 18.41 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.649 -0.657 . . . . 0.0 110.349 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.55 -177.26 42.61 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.94 -40.03 91.72 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.526 -0.985 . . . . 0.0 110.281 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.6 p -132.33 26.43 4.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.521 -0.737 . . . . 0.0 110.394 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 16.6 tpt180 -124.35 139.97 53.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.451 -0.781 . . . . 0.0 110.495 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.54 167.22 25.35 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 78.3 p -118.95 152.33 36.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.937 . . . . 0.0 110.104 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -94.17 119.09 32.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.556 -0.715 . . . . 0.0 110.118 -179.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.2 mp -65.79 -40.0 91.5 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.57 -0.706 . . . . 0.0 109.951 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 58.6 m -111.43 118.59 47.04 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.674 -0.641 . . . . 0.0 110.109 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.54 117.42 4.59 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 O-C-N 123.73 1.384 . . . . 0.0 110.352 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 21.3 mtt180 -129.87 159.95 67.4 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.54 -0.725 . . . . 0.0 110.267 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.27 160.22 43.34 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 O-C-N 123.931 1.49 . . . . 0.0 110.414 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 33.6 m -67.39 -25.02 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.665 -0.647 . . . . 0.0 110.816 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.4 p -59.96 -40.06 87.76 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.453 -0.779 . . . . 0.0 110.224 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -59.87 -49.82 76.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.534 -0.728 . . . . 0.0 110.023 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.404 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -70.03 -30.45 67.74 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.611 -0.681 . . . . 0.0 109.82 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 tptm -59.92 131.02 49.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.596 -0.69 . . . . 0.0 110.156 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.2 62.66 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.5 m -116.27 12.84 15.5 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.127 -1.219 . . . . 0.0 110.888 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.1 t -62.03 145.15 53.95 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.292 -0.88 . . . . 0.0 109.915 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.06 -12.08 68.8 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.94 140.39 47.9 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -92.05 150.31 3.2 Favored 'Trans proline' 0 C--N 1.316 -1.168 0 O-C-N 123.85 1.448 . . . . 0.0 111.393 -179.084 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 9.7 mp -100.39 103.05 14.42 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.9 mp -85.74 149.54 25.21 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-O 122.083 0.944 . . . . 0.0 112.289 -177.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 1.6 t -87.78 145.2 36.32 Favored Pre-proline 0 N--CA 1.492 1.655 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -53.71 -24.8 31.45 Favored 'Trans proline' 0 N--CA 1.502 1.98 0 O-C-N 123.291 1.153 . . . . 0.0 110.375 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.3 m -71.87 -36.51 70.13 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.33 39.77 0.57 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 38.5 m170 -130.02 138.69 50.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.438 -1.037 . . . . 0.0 110.594 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -64.95 141.55 58.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.444 -0.785 . . . . 0.0 109.899 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.9 t -115.3 -44.0 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.508 -0.745 . . . . 0.0 110.582 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -170.64 -171.07 35.63 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.2 mt -132.92 140.03 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.937 . . . . 0.0 110.441 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -67.87 138.09 55.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.623 -0.673 . . . . 0.0 109.811 179.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.8 ttp180 -124.24 -52.58 1.74 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.538 -0.726 . . . . 0.0 110.499 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -139.78 159.5 42.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.514 -0.741 . . . . 0.0 110.286 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.41 136.45 54.96 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.604 -0.685 . . . . 0.0 110.612 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.1 t -93.7 119.82 42.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.37 159.91 40.58 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.235 -179.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 76.1 p -138.88 142.28 38.58 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 53.76 28.01 7.69 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.289 -0.882 . . . . 0.0 110.671 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 80.69 22.89 61.04 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.5 t -129.98 129.99 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.265 -1.138 . . . . 0.0 110.039 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -91.54 124.03 35.4 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.26 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 40.9 mttm -112.72 -26.38 8.63 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.587 -0.696 . . . . 0.0 110.352 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.2 161.57 38.54 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.532 -0.73 . . . . 0.0 109.838 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.03 178.49 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.517 -0.739 . . . . 0.0 111.476 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -134.03 135.52 43.42 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -139.99 145.59 38.03 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.326 -0.859 . . . . 0.0 110.719 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 72.9 t -86.7 124.72 68.88 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.627 -0.671 . . . . 0.0 109.353 179.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -66.54 162.52 36.46 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.845 1.444 . . . . 0.0 110.343 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 96.8 t -70.03 -24.67 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.681 -0.637 . . . . 0.0 110.487 -179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -57.93 -39.93 79.21 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.375 -0.828 . . . . 0.0 110.575 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.6 p -69.31 -38.43 78.24 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.44 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 93.0 mtp -60.19 -40.52 90.34 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.654 -0.654 . . . . 0.0 110.35 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -69.26 -39.97 78.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.623 -0.673 . . . . 0.0 110.336 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.12 -39.92 91.84 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.606 -0.684 . . . . 0.0 110.074 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.7 m -60.11 -47.52 85.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.545 -0.722 . . . . 0.0 110.375 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.02 -49.98 75.52 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.631 -0.668 . . . . 0.0 110.41 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -69.68 -40.07 76.6 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.213 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.75 -27.07 64.64 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.602 -0.686 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 5.3 m -79.94 89.72 5.32 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.572 -0.705 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -160.08 29.13 0.17 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.554 -0.716 . . . . 0.0 110.054 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -66.54 -30.03 70.25 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.462 -0.774 . . . . 0.0 110.457 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -60.05 -39.99 87.87 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.538 -0.726 . . . . 0.0 110.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.185 -179.965 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -117.31 129.98 56.24 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.116 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.416 HD22 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -70.1 140.03 52.63 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.531 -0.731 . . . . 0.0 110.234 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.575 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.624 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.5 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.135 0.493 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.2 -179.97 48.38 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -108.16 139.76 42.36 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.604 -0.939 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -150.23 155.33 39.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.606 -0.684 . . . . 0.0 110.329 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -80.04 160.0 25.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.656 -0.653 . . . . 0.0 110.226 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -60.05 -39.93 87.68 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -62.65 139.99 58.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.538 -0.726 . . . . 0.0 109.87 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.41 129.28 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.58 -0.7 . . . . 0.0 110.027 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -62.43 -40.06 95.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.571 -0.706 . . . . 0.0 110.234 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.67 146.83 6.13 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.3 -37.23 84.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.622 -0.928 . . . . 0.0 110.214 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -102.64 126.52 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.701 . . . . 0.0 110.037 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -117.21 151.61 36.55 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.564 -0.71 . . . . 0.0 110.146 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.7 p -89.67 136.15 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.512 -0.743 . . . . 0.0 110.069 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -129.7 136.97 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.695 -0.628 . . . . 0.0 110.006 -179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.6 m -136.13 170.93 15.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -133.11 -170.67 2.51 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.636 -0.665 . . . . 0.0 109.449 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.3 -24.2 67.57 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.642 -0.661 . . . . 0.0 111.427 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.3 t -137.24 -15.45 1.47 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.133 -0.979 . . . . 0.0 113.175 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -125.29 149.66 47.85 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.872 -1.143 . . . . 0.0 111.249 -178.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 29.2 p -132.77 142.36 48.97 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.824 -0.548 . . . . 0.0 110.094 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.1 p90 -163.91 -177.33 5.03 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.469 -0.769 . . . . 0.0 109.88 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 29.1 mt -112.46 179.18 4.06 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.391 -0.818 . . . . 0.0 110.775 -177.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -155.36 160.34 40.63 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.784 -0.573 . . . . 0.0 109.725 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.1 t -125.65 138.41 53.91 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.481 -0.762 . . . . 0.0 110.231 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.9 t -96.66 107.01 19.38 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.474 -0.766 . . . . 0.0 110.653 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.427 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.2 t -110.35 130.0 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.717 -0.614 . . . . 0.0 109.348 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 56.84 36.37 27.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.502 -0.749 . . . . 0.0 110.725 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.28 17.7 79.71 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.2 t -131.21 130.03 63.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.942 0 O-C-N 121.118 -1.225 . . . . 0.0 110.102 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.3 t -73.06 150.05 42.66 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.511 -0.743 . . . . 0.0 109.592 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.427 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 87.4 m95 -135.72 150.0 49.4 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.528 -0.733 . . . . 0.0 110.93 -179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.435 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.0 t -168.51 -179.69 3.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.856 -0.528 . . . . 0.0 109.584 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.466 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.4 p -91.46 157.2 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.018 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.417 ' CZ ' HG23 ' A' ' 78' ' ' VAL . 57.7 t80 -72.93 -43.65 62.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.543 -0.723 . . . . 0.0 112.14 -178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.466 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.8 p-80 -60.84 -24.63 66.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.12 -0.988 . . . . 0.0 110.714 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.419 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -90.85 -35.51 7.18 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.362 -1.895 . . . . 0.0 108.362 178.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -135.59 97.0 3.56 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.792 -0.828 . . . . 0.0 109.879 179.62 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -80.03 -166.24 33.24 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 79.1 p -72.26 65.84 0.62 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.626 -0.926 . . . . 0.0 109.631 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.22 169.82 16.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.0 110.382 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 69.0 m -74.94 139.25 42.88 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.661 -0.649 . . . . 0.0 110.141 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -108.51 133.47 52.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.626 -0.671 . . . . 0.0 109.705 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.71 112.72 20.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.636 -0.665 . . . . 0.0 110.209 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -112.2 -176.74 19.95 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.79 -32.65 67.17 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.854 1.45 . . . . 0.0 110.499 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -74.93 -31.12 61.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.667 -0.646 . . . . 0.0 109.934 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.65 -144.17 13.27 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -73.61 155.13 49.94 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.817 1.43 . . . . 0.0 110.238 179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 49.1 mm -129.49 139.93 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.558 -0.714 . . . . 0.0 110.455 -179.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 80.5 m -101.04 120.92 40.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.567 -0.708 . . . . 0.0 110.076 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.4 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 32.2 tt0 -77.0 139.53 40.1 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.546 -0.721 . . . . 0.0 110.681 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 42.2 mtp -109.95 -30.01 8.0 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.663 -0.648 . . . . 0.0 110.441 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -112.85 138.42 49.72 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.523 -0.736 . . . . 0.0 110.612 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.0 p -139.41 126.91 21.62 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.706 -0.621 . . . . 0.0 110.023 179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 -142.02 90.97 2.3 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.489 -0.757 . . . . 0.0 110.26 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.417 HG23 ' CZ ' ' A' ' 56' ' ' TYR . 91.1 t -66.26 -40.35 86.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.6 -0.687 . . . . 0.0 109.882 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.58 -45.01 95.53 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.647 -0.658 . . . . 0.0 110.601 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.6 tp60 -87.79 -0.01 56.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.504 -0.747 . . . . 0.0 110.816 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.6 t70 53.54 42.71 31.88 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.055 -1.028 . . . . 0.0 110.538 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 67.0 mt -140.92 147.69 39.25 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.45 -0.781 . . . . 0.0 111.036 -179.643 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 34.6 m -148.32 177.1 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.695 -0.628 . . . . 0.0 109.404 179.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -156.29 158.25 28.51 Favored Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.838 -1.172 . . . . 0.0 110.518 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.435 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.0 m-90 -120.38 160.77 22.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.816 -0.814 . . . . 0.0 109.848 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.2 tt0 -75.2 109.96 9.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.57 -0.706 . . . . 0.0 109.297 179.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.89 153.96 87.21 Favored Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.545 -0.722 . . . . 0.0 110.01 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.09 159.69 52.28 Favored 'Trans proline' 0 N--CA 1.488 1.196 0 O-C-N 123.83 1.437 . . . . 0.0 110.281 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.06 141.71 71.26 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.95 1.5 . . . . 0.0 110.357 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.18 27.47 72.84 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.19 149.87 26.57 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.467 -1.019 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 13.3 tpt180 -87.74 139.23 30.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.616 -0.678 . . . . 0.0 109.308 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.2 p -128.99 168.38 16.11 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.426 -0.796 . . . . 0.0 110.554 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 34.7 mt -111.65 131.97 54.91 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.735 -0.603 . . . . 0.0 110.714 -179.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.404 ' OG1' ' CD2' ' A' ' 149' ' ' HIS . 73.8 p -74.76 159.95 81.98 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 109.799 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.29 161.01 46.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 O-C-N 123.865 1.456 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.8 t -70.25 134.73 48.31 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.721 -0.612 . . . . 0.0 110.063 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 22.4 p -136.15 52.35 1.98 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.667 -0.646 . . . . 0.0 109.827 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.1 p -143.81 -8.09 0.73 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.516 -0.74 . . . . 0.0 112.387 -179.143 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.01 42.26 98.3 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 54.0 m -100.0 120.04 39.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -1.04 . . . . 0.0 110.305 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.3 m -62.83 -40.05 96.22 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.579 -0.701 . . . . 0.0 110.429 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 137.54 58.06 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.538 -0.726 . . . . 0.0 110.497 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 89.3 mt -138.47 142.84 39.43 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.637 -0.664 . . . . 0.0 110.643 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -106.85 120.37 41.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.587 -0.696 . . . . 0.0 109.581 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.1 tp -102.57 146.16 28.56 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.406 -0.809 . . . . 0.0 110.829 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.4 t -105.34 130.01 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.676 -0.64 . . . . 0.0 109.647 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 76.3 p -98.25 173.57 6.93 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.573 -0.704 . . . . 0.0 111.004 -179.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 61.9 ttt-85 -70.0 -24.26 63.27 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.745 -0.597 . . . . 0.0 110.514 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -94.03 29.25 2.18 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.44 -0.787 . . . . 0.0 110.737 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.42 40.03 31.26 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.308 -0.87 . . . . 0.0 110.724 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -116.1 145.94 42.63 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.528 -0.733 . . . . 0.0 109.542 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.9 p -130.0 133.59 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.538 -0.726 . . . . 0.0 110.575 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 81.3 mt -124.91 150.06 64.95 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.651 -0.655 . . . . 0.0 109.485 179.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -81.46 123.05 4.22 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.945 1.498 . . . . 0.0 110.593 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 61.2 t -119.91 124.32 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 109.648 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -81.96 130.61 35.13 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.527 -0.733 . . . . 0.0 110.049 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -77.45 128.23 33.87 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.68 -0.638 . . . . 0.0 110.344 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -119.46 23.02 11.45 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.662 -0.649 . . . . 0.0 110.429 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.75 176.9 38.2 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -60.12 -40.82 91.07 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.54 -0.976 . . . . 0.0 110.127 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 20.8 p -130.0 27.4 5.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.622 -0.674 . . . . 0.0 110.331 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 3.1 tpt85 -128.93 137.06 51.19 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.461 -0.774 . . . . 0.0 110.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.2 166.57 26.0 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -124.87 146.22 49.41 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.558 -0.966 . . . . 0.0 110.058 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mp -97.73 125.25 42.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -66.73 -40.04 88.22 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.544 -0.723 . . . . 0.0 109.81 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.6 m -107.55 114.32 60.73 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.661 -0.649 . . . . 0.0 109.94 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.28 124.49 13.02 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.839 1.441 . . . . 0.0 110.487 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.9 mmt180 -120.48 160.09 45.38 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.641 -0.662 . . . . 0.0 109.972 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.33 156.67 62.01 Favored 'Trans proline' 0 N--CA 1.489 1.257 0 O-C-N 123.942 1.496 . . . . 0.0 110.385 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 65.7 t -66.83 -29.93 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.596 -0.69 . . . . 0.0 110.003 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.9 m -59.95 -40.05 87.67 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.482 -0.762 . . . . 0.0 110.352 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -61.76 -40.0 93.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.75 . . . . 0.0 109.994 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.408 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 4.5 mm? -69.22 -30.43 68.58 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.595 -0.691 . . . . 0.0 110.479 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 mmmm -60.01 140.4 56.81 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.388 -0.82 . . . . 0.0 110.246 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.01 14.67 80.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.0 m -114.78 10.06 16.46 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.283 -1.127 . . . . 0.0 110.936 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.7 m -62.06 140.2 58.39 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.223 -0.923 . . . . 0.0 110.048 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.75 -18.15 57.29 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.43 113.76 5.21 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.56 150.21 24.54 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.833 1.438 . . . . 0.0 110.82 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.407 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 6.5 mp -101.49 109.1 20.85 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -100.0 129.96 46.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.555 -0.716 . . . . 0.0 111.064 -179.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 27.3 p -69.9 158.64 86.74 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.725 -0.61 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -53.77 -20.87 18.35 Favored 'Trans proline' 0 N--CA 1.501 1.925 0 O-C-N 123.634 1.333 . . . . 0.0 112.56 -178.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.8 p -67.22 -36.47 81.75 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.077 -1.015 . . . . 0.0 109.917 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 119.4 34.65 0.99 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . 0.404 ' CD2' ' OG1' ' A' ' 95' ' ' THR . 33.1 m170 -131.83 146.79 52.33 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.431 -1.04 . . . . 0.0 110.175 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.53 146.46 50.18 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.581 -0.699 . . . . 0.0 110.293 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 57.4 t -117.69 -40.1 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.579 -0.701 . . . . 0.0 109.991 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.22 -168.85 34.22 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 93.8 mt -133.19 140.01 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.487 -1.008 . . . . 0.0 110.464 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -59.98 139.03 57.69 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.547 -0.72 . . . . 0.0 110.036 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 29.9 ttp85 -123.19 -52.01 1.86 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.573 -0.704 . . . . 0.0 110.186 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -146.9 160.41 42.36 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.677 . . . . 0.0 110.295 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.21 144.49 44.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.559 -0.713 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.7 t -110.03 120.05 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 120.18 -0.608 . . . . 0.0 109.807 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.4 145.87 51.88 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.689 -0.632 . . . . 0.0 110.345 179.862 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.5 m -70.05 -49.2 53.58 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.61 -0.681 . . . . 0.0 110.265 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -163.92 53.83 0.15 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.574 -0.703 . . . . 0.0 109.889 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 116.11 -17.58 14.76 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.11 126.3 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.217 -1.167 . . . . 0.0 109.777 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.54 126.95 40.15 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.567 -0.708 . . . . 0.0 110.398 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -112.29 -18.1 12.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.604 -0.685 . . . . 0.0 110.717 179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -149.1 159.14 44.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.218 -0.926 . . . . 0.0 110.157 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.8 m -140.01 166.86 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.531 -0.731 . . . . 0.0 110.853 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -119.97 136.78 54.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.655 -0.653 . . . . 0.0 109.773 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -138.04 155.68 48.56 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.493 -0.754 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 60.4 t -92.91 123.89 60.02 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.621 -0.674 . . . . 0.0 109.578 179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.22 154.0 75.57 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.842 1.443 . . . . 0.0 110.581 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.1 t -59.91 -23.47 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.594 -0.691 . . . . 0.0 110.575 -179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -58.16 -38.36 76.47 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.444 -0.785 . . . . 0.0 110.555 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.6 p -60.03 -37.11 78.79 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.311 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.4 mtt -60.13 -40.02 88.29 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.466 -0.771 . . . . 0.0 110.441 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -60.16 -41.27 92.44 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.565 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 73.5 p -72.92 -40.04 65.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.44 -0.787 . . . . 0.0 110.311 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.9 m -70.06 -44.4 69.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.622 -0.674 . . . . 0.0 110.121 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.78 -40.17 91.6 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.337 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 62.8 ttt180 -60.18 -40.05 88.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.536 -0.728 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.83 -40.02 79.69 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.574 -0.704 . . . . 0.0 110.212 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 13.5 m 50.99 -160.0 0.08 Allowed 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.397 -0.815 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -149.44 120.31 7.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -107.64 -29.97 8.85 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.579 -0.701 . . . . 0.0 110.197 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -156.76 159.98 38.82 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.539 -0.726 . . . . 0.0 110.326 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 22.9 mmmt . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.16 179.928 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -121.9 137.75 54.67 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 118.74 -1.184 . . . . 0.0 110.088 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.42 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp -84.13 135.55 34.35 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.634 -0.666 . . . . 0.0 110.231 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CG ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.412 ' H2A' ' CD2' ' A' ' 57' ' ' HIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.079 0.466 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.14 -169.11 49.49 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 52.97 40.0 30.34 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.46 -1.023 . . . . 0.0 110.787 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.7 88.42 1.55 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.651 -0.656 . . . . 0.0 110.163 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -132.43 150.03 52.23 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 110.312 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -110.03 24.48 12.96 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.688 -0.633 . . . . 0.0 110.432 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -109.27 151.24 26.81 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.499 -0.751 . . . . 0.0 110.194 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 p -86.97 136.63 22.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.571 -0.705 . . . . 0.0 110.344 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -65.3 140.11 58.66 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.591 -0.693 . . . . 0.0 110.411 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.3 110.68 0.48 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . 0.402 ' CG ' ' CG ' ' A' ' 92' ' ' ARG . 47.7 mt-10 -66.34 -37.85 86.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.539 -0.977 . . . . 0.0 110.041 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -107.13 125.42 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 0.0 109.952 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -115.75 143.26 45.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.515 -0.741 . . . . 0.0 110.413 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.42 132.65 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.588 -0.695 . . . . 0.0 109.987 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 26.7 m -128.77 159.86 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.634 -0.666 . . . . 0.0 109.972 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 m -139.43 160.52 39.65 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.62 -0.675 . . . . 0.0 110.478 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.37 -176.93 3.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.758 -0.589 . . . . 0.0 109.841 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.68 -12.53 59.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.622 -0.674 . . . . 0.0 110.803 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 41.7 p -120.04 -30.02 4.78 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.242 -0.911 . . . . 0.0 111.191 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -156.39 169.58 24.26 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.281 -0.887 . . . . 0.0 110.633 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.0 p -126.84 158.28 37.08 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.591 -0.693 . . . . 0.0 110.438 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.405 ' CE2' ' O ' ' A' ' 58' ' ' GLY . 24.8 p90 -168.98 -176.38 2.62 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.507 -0.746 . . . . 0.0 109.89 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 77.8 mt -111.83 176.36 5.05 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.491 -0.755 . . . . 0.0 110.454 -178.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -147.91 159.98 43.29 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.786 -0.571 . . . . 0.0 110.069 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 39.8 p -120.17 130.88 54.79 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.577 -0.702 . . . . 0.0 110.525 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 33.8 t -92.52 109.66 21.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.429 -0.794 . . . . 0.0 110.386 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.428 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.6 t -119.2 131.74 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.603 -0.685 . . . . 0.0 109.641 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.57 39.35 27.77 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.539 -0.726 . . . . 0.0 110.845 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.03 20.04 75.98 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 178.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.69 130.01 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.143 -1.21 . . . . 0.0 110.022 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 94.1 m -72.63 149.93 43.48 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.44 -0.788 . . . . 0.0 109.457 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.446 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 83.4 m95 -131.79 151.07 51.93 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.524 -0.735 . . . . 0.0 111.175 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.457 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.1 t -167.65 -179.94 4.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 7.5 p -97.05 147.75 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.155 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.414 ' CZ ' HG21 ' A' ' 78' ' ' VAL . 58.3 t80 -60.05 -46.94 87.88 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.611 -0.68 . . . . 0.0 112.095 -178.594 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.468 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.5 p-80 -64.7 -24.08 67.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.159 -0.963 . . . . 0.0 110.91 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.405 ' O ' ' CE2' ' A' ' 43' ' ' PHE . . . -83.61 -52.96 3.53 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -109.42 -57.41 2.17 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.688 -0.89 . . . . 0.0 110.101 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.5 -163.8 52.98 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.1 p -88.98 66.2 7.78 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.662 -0.905 . . . . 0.0 110.037 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -139.63 168.39 19.93 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.508 -0.745 . . . . 0.0 110.282 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 60.2 m -65.0 139.63 58.78 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.056 -0.657 . . . . 0.0 109.961 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.417 HD22 ' CE2' ' A' ' 85' ' ' TRP . 13.8 tp -117.42 138.96 51.48 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.689 -0.632 . . . . 0.0 109.903 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.83 110.04 22.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.549 -0.719 . . . . 0.0 110.193 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.76 -179.65 19.06 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.04 -31.89 76.06 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.821 1.432 . . . . 0.0 110.469 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 6.7 mtpm? -73.06 -31.17 64.23 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.701 -0.624 . . . . 0.0 109.964 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.46 -150.41 21.6 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.71 147.11 44.45 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.886 1.466 . . . . 0.0 110.148 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -129.99 140.03 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.549 -0.719 . . . . 0.0 110.57 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.7 t -99.94 144.22 29.25 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.548 -0.72 . . . . 0.0 109.774 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -90.13 150.0 22.22 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.407 -0.808 . . . . 0.0 111.232 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 50.2 mtp -116.04 -25.98 7.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.762 -0.586 . . . . 0.0 110.427 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -122.86 139.96 53.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 60.9 m -141.38 133.72 28.13 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.621 -0.674 . . . . 0.0 110.312 179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -145.54 95.66 2.69 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.509 -0.744 . . . . 0.0 110.019 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.414 HG21 ' CZ ' ' A' ' 56' ' ' TYR . 80.2 t -66.27 -43.09 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.513 -0.742 . . . . 0.0 110.066 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -49.88 75.9 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.55 -0.719 . . . . 0.0 110.474 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 37.0 tp60 -81.72 -8.65 59.72 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.588 -0.695 . . . . 0.0 110.509 179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.0 t70 57.5 45.9 18.81 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.115 -0.991 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 82.6 mt -138.16 139.09 39.21 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.549 -0.719 . . . . 0.0 110.953 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 34.7 m -144.39 158.04 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.627 -0.671 . . . . 0.0 109.439 179.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -140.62 157.94 25.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.457 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 7.3 m-90 -116.67 161.07 19.77 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.782 -0.834 . . . . 0.0 109.639 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -70.99 114.23 8.83 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.515 -0.741 . . . . 0.0 109.312 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.03 136.52 87.2 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 110.212 -179.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 159.97 51.3 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.864 1.455 . . . . 0.0 110.228 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -66.15 153.63 77.32 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 123.882 1.464 . . . . 0.0 110.322 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.16 27.36 66.37 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.87 139.88 40.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.506 -0.996 . . . . 0.0 110.138 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.402 ' CG ' ' CG ' ' A' ' 32' ' ' GLU . 27.4 tpt180 -80.11 159.92 25.92 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.658 -0.651 . . . . 0.0 109.531 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.7 p -129.63 167.92 17.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.554 -0.716 . . . . 0.0 110.173 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 59.9 mt -109.8 131.54 54.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.526 -0.733 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.432 HG21 ' CD2' ' A' ' 149' ' ' HIS . 9.8 t -75.37 159.97 80.86 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.582 -0.699 . . . . 0.0 109.986 179.505 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -84.76 164.17 12.07 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.753 1.396 . . . . 0.0 110.815 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 43.8 t -82.59 138.94 34.07 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.658 -0.651 . . . . 0.0 110.194 -179.814 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -136.09 51.64 2.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.812 -0.555 . . . . 0.0 109.681 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.2 p -143.43 -8.61 0.76 Allowed 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.843 -0.743 . . . . 0.0 112.411 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 33.44 74.75 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 86.0 p -76.73 149.92 36.31 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.431 -1.041 . . . . 0.0 110.415 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -92.66 -29.22 16.21 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.625 -0.672 . . . . 0.0 110.286 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -77.43 135.27 38.27 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.554 -0.716 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.4 mt -135.04 155.12 51.3 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.508 -0.745 . . . . 0.0 110.599 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -119.99 114.6 22.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.556 -0.715 . . . . 0.0 109.788 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.3 tp -100.41 140.01 35.27 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.617 -0.677 . . . . 0.0 110.445 -179.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.96 129.94 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.626 -0.671 . . . . 0.0 110.052 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 59.5 p -102.2 -179.58 4.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.592 -0.692 . . . . 0.0 110.42 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 31.9 mtp-105 -59.88 -22.52 62.47 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.535 -0.728 . . . . 0.0 110.808 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -90.11 19.57 4.9 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.276 -0.89 . . . . 0.0 111.15 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.0 40.07 31.21 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.123 -0.986 . . . . 0.0 110.686 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -106.76 134.84 49.3 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.611 -0.68 . . . . 0.0 109.957 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.08 123.48 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 109.982 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.5 pt -119.97 150.0 50.01 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.564 -0.71 . . . . 0.0 110.06 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -87.99 128.03 2.27 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.933 1.491 . . . . 0.0 110.44 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.9 t -124.75 129.41 73.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.662 -0.649 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 51.6 mmm-85 -80.35 156.0 26.93 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.572 -0.705 . . . . 0.0 110.309 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -101.14 118.63 37.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.634 -0.666 . . . . 0.0 110.064 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.8 mmm180 -113.13 20.02 16.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.59 -0.694 . . . . 0.0 110.437 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.02 -171.43 42.39 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.02 -39.93 90.66 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.566 -0.961 . . . . 0.0 110.442 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.0 p -132.69 24.14 4.34 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.524 -0.735 . . . . 0.0 110.816 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -126.26 139.88 52.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.325 -0.859 . . . . 0.0 110.506 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.84 169.35 27.97 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 52.1 p -112.06 156.82 21.58 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.41 -1.053 . . . . 0.0 110.537 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 24.2 tp -98.59 120.4 38.94 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.559 -0.713 . . . . 0.0 110.074 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 mp -60.93 -40.21 92.39 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.569 -0.707 . . . . 0.0 110.352 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.2 p -117.8 127.25 26.76 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.504 -0.747 . . . . 0.0 110.075 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.31 117.93 5.36 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.87 1.458 . . . . 0.0 110.381 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 48.6 mtp85 -120.08 160.01 44.86 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.708 . . . . 0.0 110.227 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.77 148.84 83.35 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.875 1.461 . . . . 0.0 110.31 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.3 m -62.07 -26.59 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.613 -0.68 . . . . 0.0 110.426 -179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.4 t -59.95 -39.92 87.22 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 65.0 t80 -60.06 -49.16 78.73 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.607 -0.683 . . . . 0.0 110.227 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.4 mp -69.97 -28.93 65.95 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.466 -0.771 . . . . 0.0 110.537 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmtp -60.01 140.02 57.06 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.476 -0.765 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.99 9.99 86.09 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 28.9 m -112.05 16.79 20.09 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.141 -1.211 . . . . 0.0 110.785 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -60.17 140.03 57.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.287 -0.883 . . . . 0.0 110.023 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.34 -18.07 57.59 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -51.4 124.94 24.17 Favored Glycine 0 N--CA 1.5 2.906 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -80.77 146.32 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.868 1.457 . . . . 0.0 111.304 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.401 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 6.4 mp -106.71 106.77 17.46 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.406 ' N ' ' CD1' ' A' ' 144' ' ' LEU . 9.8 mp -95.74 131.21 42.26 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.527 -0.733 . . . . 0.0 111.242 -178.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.431 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.75 159.39 84.14 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.431 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -51.92 -21.83 12.88 Favored 'Trans proline' 0 N--CA 1.501 1.954 0 O-C-N 123.506 1.266 . . . . 0.0 112.671 -178.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -69.77 -38.39 76.73 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.18 -0.95 . . . . 0.0 109.872 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.58 37.23 0.74 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . 0.432 ' CD2' HG21 ' A' ' 95' ' ' THR . 29.5 m170 -133.37 149.6 51.85 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.495 -1.003 . . . . 0.0 110.221 179.783 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.72 139.99 58.82 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.52 -0.737 . . . . 0.0 110.216 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 49.6 t -115.96 -35.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.582 -0.698 . . . . 0.0 110.009 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.7 -169.98 38.69 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 90.0 mt -130.04 139.89 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.564 -0.962 . . . . 0.0 110.229 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -59.99 139.14 57.63 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.507 -0.746 . . . . 0.0 110.12 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -119.95 -52.34 2.21 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.615 -0.678 . . . . 0.0 110.29 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -152.58 166.88 30.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.522 -0.736 . . . . 0.0 110.5 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.25 148.55 43.01 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.627 -0.671 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.94 120.03 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.624 -0.672 . . . . 0.0 109.796 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -133.63 149.87 51.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.719 -0.613 . . . . 0.0 110.376 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.8 p -80.09 -47.48 14.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.568 -0.707 . . . . 0.0 110.41 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -161.65 57.41 0.27 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.671 -0.643 . . . . 0.0 110.033 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.03 -11.65 40.83 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.9 t -118.24 126.52 75.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.137 -1.213 . . . . 0.0 109.686 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.7 123.53 40.42 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.512 -0.743 . . . . 0.0 110.627 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -105.8 -18.46 14.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.723 -0.611 . . . . 0.0 110.392 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.6 158.77 44.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 109.821 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -130.07 -173.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.481 -0.762 . . . . 0.0 110.518 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -146.44 127.17 14.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.705 -0.622 . . . . 0.0 109.444 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -127.42 156.22 42.42 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.453 -0.779 . . . . 0.0 110.946 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 63.2 t -92.82 121.41 66.01 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -64.17 154.92 68.06 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.79 1.416 . . . . 0.0 110.496 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 97.1 t -58.97 -24.06 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.612 -0.68 . . . . 0.0 110.531 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -59.85 -40.08 87.33 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.365 -0.835 . . . . 0.0 110.346 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 22.4 t -63.42 -38.42 91.06 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.476 -0.765 . . . . 0.0 110.144 179.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.446 ' CE ' ' CD1' ' A' ' 53' ' ' TRP . 93.3 mtp -60.0 -41.58 92.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.631 -0.668 . . . . 0.0 110.317 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.13 -40.08 78.5 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.567 -0.708 . . . . 0.0 110.162 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.1 m -61.06 -39.98 91.92 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.627 -0.671 . . . . 0.0 110.156 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.6 m -60.14 -40.36 89.55 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.542 -0.724 . . . . 0.0 110.114 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -68.25 -39.98 82.08 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.594 -0.691 . . . . 0.0 110.169 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 27.1 mmt180 -65.13 -40.07 93.93 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.569 -0.707 . . . . 0.0 110.137 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.22 -40.82 91.5 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.607 -0.683 . . . . 0.0 110.281 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.99 -164.72 0.06 Allowed 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.429 -0.794 . . . . 0.0 110.947 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -63.44 -27.7 69.47 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.624 -0.672 . . . . 0.0 110.531 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -59.97 -39.97 87.47 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.501 -0.75 . . . . 0.0 110.469 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 58.3 mttm -119.95 140.04 51.52 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.57 -0.706 . . . . 0.0 110.21 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 22.0 pttm . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.283 -179.973 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -119.96 137.94 53.77 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 118.744 -1.183 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.417 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp -89.09 141.53 28.42 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.683 . . . . 0.0 110.245 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.467 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 m . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.107 0.479 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.01 177.44 54.3 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.3 mtt180 -100.19 125.86 46.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.526 -0.984 . . . . 0.0 110.193 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.67 -40.0 90.5 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.539 -0.726 . . . . 0.0 110.24 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 ttmm 56.75 167.94 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.148 0 O-C-N 121.507 -0.745 . . . . 0.0 110.586 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -80.42 166.97 20.74 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.47 -0.769 . . . . 0.0 110.338 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -70.07 140.74 52.83 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.555 -0.715 . . . . 0.0 110.155 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.6 p -139.0 140.39 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.623 -0.673 . . . . 0.0 110.21 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -94.38 139.84 30.59 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.567 -0.708 . . . . 0.0 110.197 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -131.03 31.23 3.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -59.93 -37.29 79.08 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.518 -0.99 . . . . 0.0 110.313 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.6 t -120.34 129.61 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.546 -0.721 . . . . 0.0 109.77 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -129.99 158.35 39.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.517 -0.739 . . . . 0.0 110.451 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.78 125.28 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.696 -0.628 . . . . 0.0 109.413 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.6 m -124.79 158.16 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.577 -0.702 . . . . 0.0 110.159 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.5 m -133.36 173.04 11.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.684 -0.635 . . . . 0.0 110.556 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 35.0 m -139.69 171.54 14.08 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.09 -28.18 56.69 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.438 -0.789 . . . . 0.0 111.204 -179.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.0 m -135.37 -7.26 2.26 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.263 -0.898 . . . . 0.0 112.597 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.7 mm-40 -129.98 159.17 37.48 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.89 -1.131 . . . . 0.0 111.69 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 68.1 m -132.12 133.98 44.92 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -164.67 -177.4 4.76 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.242 -0.911 . . . . 0.0 111.068 -179.054 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 51.6 mt -112.63 146.61 38.32 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.666 -0.647 . . . . 0.0 110.279 -178.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -111.24 161.01 16.44 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.58 -0.7 . . . . 0.0 110.165 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 63.6 p -125.16 143.38 50.96 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.593 -0.692 . . . . 0.0 110.314 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 93.3 m -102.85 113.18 26.4 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.574 -0.704 . . . . 0.0 110.501 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.3 130.0 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.658 -0.652 . . . . 0.0 109.428 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 55.49 36.68 27.64 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.421 -0.799 . . . . 0.0 110.76 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.69 19.16 74.67 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.331 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -132.36 130.05 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.202 -1.175 . . . . 0.0 109.998 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.5 m -78.21 144.97 35.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.483 -0.761 . . . . 0.0 109.514 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -128.36 151.41 49.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.525 -0.734 . . . . 0.0 110.863 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.447 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -167.77 -179.8 4.43 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.444 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 10.9 p -95.29 154.2 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.816 . . . . 0.0 110.562 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.415 ' CZ ' HG23 ' A' ' 78' ' ' VAL . 58.7 t80 -69.95 -40.12 75.63 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.683 -0.636 . . . . 0.0 111.873 -178.87 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.444 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.4 p-80 -68.26 -24.35 64.88 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.135 -0.978 . . . . 0.0 110.499 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.408 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -82.64 -59.12 2.27 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -102.37 -47.95 4.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.069 179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 66.0 -165.68 37.85 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.2 m -83.72 64.42 7.99 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.582 -0.952 . . . . 0.0 109.951 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -140.02 164.84 28.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.514 -0.741 . . . . 0.0 110.324 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.3 t -65.37 140.05 58.62 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.578 -0.701 . . . . 0.0 110.05 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.452 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 14.5 tp -109.9 130.54 55.51 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.658 -0.651 . . . . 0.0 110.178 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.46 118.45 30.57 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.578 -0.701 . . . . 0.0 110.106 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -122.89 177.74 16.48 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.63 -31.98 69.57 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.795 1.419 . . . . 0.0 110.338 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 61.0 tptt -70.55 -31.55 68.64 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.606 -0.684 . . . . 0.0 109.633 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.01 -150.41 22.01 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.79 155.75 53.51 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.891 1.469 . . . . 0.0 110.228 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.415 HG23 ' CD1' ' A' ' 85' ' ' TRP . 85.1 mt -125.91 139.94 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.555 -0.715 . . . . 0.0 110.272 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 73.1 m -94.39 137.9 32.99 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.413 -0.804 . . . . 0.0 110.265 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -70.16 139.96 52.49 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.575 -0.703 . . . . 0.0 110.599 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.82 -51.3 2.66 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.564 -0.71 . . . . 0.0 109.952 179.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -120.03 140.06 51.56 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.514 -0.742 . . . . 0.0 110.213 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.6 p -131.64 137.61 48.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.497 -0.752 . . . . 0.0 110.367 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -150.04 90.72 1.7 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.578 -0.702 . . . . 0.0 110.215 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.415 HG23 ' CZ ' ' A' ' 56' ' ' TYR . 85.9 t -68.04 -42.33 85.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.543 -0.723 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.91 -42.8 94.66 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.717 . . . . 0.0 110.27 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 39.0 tp60 -89.98 0.12 57.27 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.537 -0.727 . . . . 0.0 110.93 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 8.4 t70 53.65 44.63 29.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.059 -1.026 . . . . 0.0 110.687 -179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 70.9 mt -140.25 144.37 36.45 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.407 -0.808 . . . . 0.0 110.923 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 35.8 m -148.2 155.64 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.578 -0.701 . . . . 0.0 109.452 179.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -139.95 161.25 26.33 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.452 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 9.2 m-90 -117.75 160.06 21.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.751 -0.852 . . . . 0.0 109.565 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -74.54 104.42 5.24 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.463 -0.773 . . . . 0.0 109.677 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -71.37 130.04 88.16 Favored Pre-proline 0 N--CA 1.494 1.775 0 O-C-N 121.541 -0.724 . . . . 0.0 110.239 -179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.08 159.98 51.24 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.827 1.435 . . . . 0.0 110.271 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.9 157.71 51.04 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.968 1.51 . . . . 0.0 110.319 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.9 -24.86 30.52 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.03 159.99 26.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.445 -1.032 . . . . 0.0 110.159 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 83.6 mtt180 -100.39 159.31 15.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.59 -0.694 . . . . 0.0 110.109 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.3 p -129.91 170.03 14.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.511 -0.743 . . . . 0.0 110.271 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -102.48 138.49 39.32 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.635 -0.666 . . . . 0.0 110.505 -179.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.419 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 4.8 p -76.05 160.03 79.25 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.629 -0.669 . . . . 0.0 109.946 179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.55 153.32 30.41 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.779 1.41 . . . . 0.0 110.6 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 53.4 t -68.73 135.11 50.77 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.543 -0.723 . . . . 0.0 110.131 179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.5 t -136.1 52.07 2.0 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.708 -0.62 . . . . 0.0 109.692 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.83 -8.51 0.72 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.542 -0.723 . . . . 0.0 112.405 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.96 33.84 80.66 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 p -88.15 139.64 30.29 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.533 -0.981 . . . . 0.0 110.411 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.5 m -82.1 -30.0 31.46 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.646 -0.659 . . . . 0.0 110.353 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -66.62 129.87 41.3 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.502 -0.749 . . . . 0.0 110.162 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.6 mt -137.14 139.81 41.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.7 . . . . 0.0 110.631 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.5 120.51 42.39 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.56 -0.713 . . . . 0.0 109.862 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.4 tp -103.1 140.06 37.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.5 -0.75 . . . . 0.0 110.488 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -90.44 138.66 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.585 -0.697 . . . . 0.0 109.758 179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 13.5 m -110.2 159.48 17.34 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.519 -0.738 . . . . 0.0 110.489 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 2.7 ttp180 -60.1 -21.37 61.42 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.588 -0.695 . . . . 0.0 110.63 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.07 27.45 3.2 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.267 -0.896 . . . . 0.0 110.528 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.61 39.98 31.56 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.39 -0.819 . . . . 0.0 110.622 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -124.21 139.59 53.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.656 -0.653 . . . . 0.0 109.737 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -126.13 139.09 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.482 -0.761 . . . . 0.0 110.59 -179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.2 mp -124.52 150.05 63.6 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.733 -0.604 . . . . 0.0 109.559 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -79.15 133.41 10.94 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.888 1.468 . . . . 0.0 110.492 -179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.02 129.99 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.671 -0.643 . . . . 0.0 109.653 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.4 tpt180 -85.38 150.0 25.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.52 -0.738 . . . . 0.0 110.193 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -91.15 119.96 31.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.65 -0.656 . . . . 0.0 110.336 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -110.21 20.02 18.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.608 -0.683 . . . . 0.0 110.508 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.11 -174.26 43.59 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -65.8 -39.94 91.41 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.999 . . . . 0.0 110.245 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.6 p -130.74 24.52 5.04 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.553 -0.717 . . . . 0.0 110.535 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -124.93 139.96 53.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 110.36 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.37 165.79 25.67 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 91.1 p -115.86 153.78 30.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.463 -1.022 . . . . 0.0 110.152 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.2 tp -99.72 119.96 38.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.584 -0.697 . . . . 0.0 110.193 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.0 mp -68.96 -38.51 79.45 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.527 -0.733 . . . . 0.0 109.863 179.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.0 m -110.0 113.84 56.68 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.677 -0.639 . . . . 0.0 110.051 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -64.66 118.52 5.49 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.799 1.421 . . . . 0.0 110.523 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -122.44 160.02 50.05 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.626 -0.671 . . . . 0.0 110.211 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -66.15 154.88 72.37 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.913 1.481 . . . . 0.0 110.42 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 90.6 t -61.63 -39.97 85.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.607 -0.683 . . . . 0.0 110.126 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.3 p -56.14 -33.85 65.56 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.476 -0.765 . . . . 0.0 110.663 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -60.02 -39.95 87.64 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.556 -0.715 . . . . 0.0 110.107 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.5 mp -84.82 -20.95 30.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.542 -0.724 . . . . 0.0 110.931 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -59.9 139.85 57.08 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.251 -0.906 . . . . 0.0 110.117 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.66 10.05 86.19 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 18.2 m -116.14 10.3 14.93 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.19 -1.182 . . . . 0.0 110.884 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.2 t -65.0 150.49 47.98 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.164 -0.96 . . . . 0.0 109.597 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.56 -22.23 40.18 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.551 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.5 148.57 21.04 Favored Glycine 0 N--CA 1.498 2.83 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -98.8 147.57 0.58 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.889 1.468 . . . . 0.0 111.024 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.38 108.33 19.91 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 mp -99.77 129.94 45.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.456 -0.777 . . . . 0.0 111.296 -178.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.418 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.03 158.31 87.67 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.0 Cg_endo -51.87 -25.36 21.22 Favored 'Trans proline' 0 N--CA 1.501 1.918 0 O-C-N 123.547 1.288 . . . . 0.0 112.343 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.2 m -62.74 -40.0 95.85 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.266 -0.896 . . . . 0.0 109.886 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.06 36.86 0.79 Allowed Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . 0.419 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 4.3 m-70 -132.95 143.69 49.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.445 -1.033 . . . . 0.0 110.188 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.42 142.33 58.23 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.523 -0.736 . . . . 0.0 110.233 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.6 t -115.34 -38.06 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.579 -0.701 . . . . 0.0 110.043 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.09 -168.38 36.23 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.89 140.02 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.469 -1.018 . . . . 0.0 110.379 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.0 t80 -63.75 139.77 58.8 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.677 -0.639 . . . . 0.0 110.11 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.5 ttt180 -119.9 -52.42 2.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.57 -0.706 . . . . 0.0 110.331 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.28 158.77 44.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.514 -0.742 . . . . 0.0 110.335 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -113.94 152.02 31.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.619 -0.676 . . . . 0.0 110.488 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.86 119.77 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.736 -0.603 . . . . 0.0 109.692 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.26 144.22 51.14 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.721 -0.612 . . . . 0.0 110.373 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.5 m -69.86 -49.77 49.14 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.619 -0.676 . . . . 0.0 110.056 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -163.65 54.17 0.16 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.711 -0.618 . . . . 0.0 109.854 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.32 -16.51 17.33 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.15 125.15 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.228 -1.16 . . . . 0.0 109.661 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -95.3 123.05 38.61 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.591 -0.693 . . . . 0.0 110.578 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -105.2 -21.31 13.28 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.601 -0.687 . . . . 0.0 110.274 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.94 159.12 43.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.365 -0.834 . . . . 0.0 109.913 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 19.7 m -131.53 -175.73 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.551 -0.718 . . . . 0.0 110.519 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -142.93 132.18 23.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.77 -0.581 . . . . 0.0 109.595 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -133.23 155.79 48.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.523 -0.736 . . . . 0.0 110.894 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.9 t -92.7 124.27 59.29 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.564 -0.71 . . . . 0.0 109.332 179.246 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.49 150.31 75.29 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.721 1.379 . . . . 0.0 110.675 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 95.0 t -59.48 -24.04 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.666 -0.646 . . . . 0.0 110.408 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -59.12 -39.58 82.76 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.382 -0.824 . . . . 0.0 110.314 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.4 p -60.01 -39.34 85.5 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.555 -0.716 . . . . 0.0 110.212 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 67.7 mtt -59.92 -40.46 88.94 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 110.452 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.28 -40.02 88.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.675 -0.64 . . . . 0.0 110.281 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.4 m -60.76 -40.4 92.35 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.472 -0.767 . . . . 0.0 110.106 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -69.86 -41.03 75.4 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.58 -0.7 . . . . 0.0 110.079 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -68.7 -39.99 80.23 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.594 -0.691 . . . . 0.0 110.348 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -61.39 -39.91 92.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.22 -50.97 71.54 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.599 -0.688 . . . . 0.0 110.301 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 2.9 m 50.14 40.01 20.81 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.465 -0.772 . . . . 0.0 111.073 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -131.24 147.17 52.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.532 -0.73 . . . . 0.0 110.169 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -100.11 29.19 4.39 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.378 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.536 -0.728 . . . . 0.0 110.249 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.289 -179.973 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -119.68 130.03 54.84 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.074 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.416 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp -71.08 139.98 50.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.0 110.343 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.568 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 59.5 m . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.076 0.465 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.0 -26.29 25.04 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -133.49 136.86 45.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.436 -1.038 . . . . 0.0 110.18 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.5 t0 52.43 45.43 28.54 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.383 -0.823 . . . . 0.0 110.812 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -60.82 -40.56 93.19 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.455 -0.778 . . . . 0.0 110.395 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -139.96 24.68 2.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.496 -0.753 . . . . 0.0 110.751 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -92.67 118.82 31.45 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.458 -0.776 . . . . 0.0 110.229 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 66.7 t -70.13 -50.01 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.612 -0.68 . . . . 0.0 110.13 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -160.03 160.24 33.0 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.497 -0.752 . . . . 0.0 110.471 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -141.52 29.58 2.25 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -60.23 -37.2 79.61 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -1.009 . . . . 0.0 110.553 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 82.7 t -116.86 128.54 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.401 -0.812 . . . . 0.0 109.663 179.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -129.27 154.44 46.83 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.533 -0.729 . . . . 0.0 110.6 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -91.74 128.36 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.0 m -126.17 159.69 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.614 -0.679 . . . . 0.0 110.36 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 58.6 m -137.85 162.48 33.87 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.517 0.675 . . . . 0.0 111.032 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.2 m -134.51 169.37 17.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.792 -0.567 . . . . 0.0 109.678 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -67.11 -12.67 60.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 111.323 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 48.6 p -118.39 -30.53 5.2 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.042 -1.036 . . . . 0.0 111.555 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -159.17 170.04 22.83 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.202 -0.936 . . . . 0.0 110.967 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 t -123.88 155.23 38.46 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.489 -0.757 . . . . 0.0 110.574 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 16.8 p90 -166.26 -177.71 4.22 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.546 -0.721 . . . . 0.0 110.091 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 63.7 mt -113.28 153.78 27.87 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.523 -0.736 . . . . 0.0 110.443 -178.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -127.89 161.09 29.89 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.557 -0.714 . . . . 0.0 110.356 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 86.9 m -120.04 130.23 54.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.635 -0.666 . . . . 0.0 110.108 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.4 t -89.94 104.0 16.61 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.628 -0.67 . . . . 0.0 110.42 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.424 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.3 t -111.06 132.81 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.479 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.77 38.71 29.67 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.559 -0.713 . . . . 0.0 110.678 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.94 20.07 75.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.146 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.4 t -132.31 129.89 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.234 -1.156 . . . . 0.0 110.079 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 5.2 t -71.81 146.49 47.97 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.539 -0.726 . . . . 0.0 109.433 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.424 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 59.5 m95 -129.4 151.05 50.46 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.474 -0.766 . . . . 0.0 111.273 -179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.438 HG23 ' CZ3' ' A' ' 85' ' ' TRP . 6.4 t -169.78 -179.81 3.43 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.456 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.1 p -94.53 156.36 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.423 -0.798 . . . . 0.0 110.073 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.412 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 58.2 t80 -70.04 -42.35 73.02 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.548 -0.72 . . . . 0.0 111.79 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.456 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 3.5 p-80 -64.77 -20.76 66.54 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.144 -0.973 . . . . 0.0 110.643 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -86.84 -47.69 4.69 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.011 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -125.41 90.98 3.32 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.679 -0.895 . . . . 0.0 109.942 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.42 -169.99 2.0 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 20.4 p -72.22 66.93 0.66 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.438 -1.036 . . . . 0.0 109.555 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.62 166.8 23.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.62 -0.675 . . . . 0.0 110.729 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.2 m -65.58 139.62 58.46 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.778 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.458 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -108.32 132.72 53.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.636 -0.665 . . . . 0.0 110.11 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.7 118.37 30.6 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.549 -0.719 . . . . 0.0 110.36 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.09 -176.91 18.25 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.132 -1.587 . . . . 0.0 109.132 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.51 -32.51 70.36 Favored 'Trans proline' 0 N--CA 1.491 1.35 0 O-C-N 123.836 1.44 . . . . 0.0 110.579 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 76.0 tttt -75.46 -31.11 60.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.598 -0.689 . . . . 0.0 109.974 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.3 -140.26 9.22 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.06 156.93 47.14 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 O-C-N 123.806 1.424 . . . . 0.0 110.25 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.4 mt -127.41 139.99 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.065 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 p -88.46 150.76 22.97 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.755 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -96.75 140.03 31.94 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.612 -0.68 . . . . 0.0 110.441 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.6 mmm -119.29 -32.77 4.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.577 -0.702 . . . . 0.0 110.856 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -132.75 149.97 52.21 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.405 -0.809 . . . . 0.0 110.869 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.3 p -143.56 137.86 28.71 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.672 -0.643 . . . . 0.0 110.026 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -150.02 93.92 2.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.467 -0.771 . . . . 0.0 110.169 179.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.412 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 88.0 t -69.96 -43.06 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -59.87 -45.46 92.41 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.514 -0.741 . . . . 0.0 110.608 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 -85.71 -0.07 54.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.579 -0.7 . . . . 0.0 110.737 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 8.3 t70 53.73 45.29 28.26 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.036 -1.04 . . . . 0.0 110.704 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 57.6 mt -142.24 146.89 35.65 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.524 -0.735 . . . . 0.0 110.924 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 35.4 m -149.24 160.0 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.555 -0.715 . . . . 0.0 109.735 179.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.34 153.75 24.18 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.458 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 7.5 m-90 -114.58 168.09 10.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.668 -0.901 . . . . 0.0 109.535 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -77.57 110.05 12.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -0.788 . . . . 0.0 109.268 179.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.05 129.98 90.26 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.598 -0.689 . . . . 0.0 110.204 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.96 159.95 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 123.791 1.416 . . . . 0.0 110.28 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.35 160.14 50.54 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.961 1.506 . . . . 0.0 110.285 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 84.49 28.75 31.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.99 150.03 49.61 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.527 -0.984 . . . . 0.0 110.094 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -100.02 119.98 39.11 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.521 -0.737 . . . . 0.0 110.342 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.5 p -81.24 170.03 16.59 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.656 -0.653 . . . . 0.0 110.161 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 79.3 mt -109.57 131.85 54.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.586 -0.696 . . . . 0.0 110.807 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.7 p -72.74 160.06 83.8 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.576 -0.703 . . . . 0.0 109.95 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.36 164.44 24.08 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.87 1.458 . . . . 0.0 110.594 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 54.1 t -80.16 129.99 34.9 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.537 -0.727 . . . . 0.0 110.241 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -133.24 55.79 1.88 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.646 -0.659 . . . . 0.0 109.522 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.95 -8.12 0.72 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.607 -0.683 . . . . 0.0 112.394 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.06 35.27 91.2 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -84.97 113.07 21.14 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.513 -0.992 . . . . 0.0 110.485 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -60.03 -40.01 87.88 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.64 -0.662 . . . . 0.0 110.342 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -64.89 138.66 58.51 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.55 -0.719 . . . . 0.0 110.414 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.5 mt -135.58 150.0 49.57 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.615 -0.678 . . . . 0.0 110.319 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -117.84 114.4 23.2 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.583 -0.698 . . . . 0.0 109.857 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.2 tp -96.5 145.64 25.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.568 -0.707 . . . . 0.0 110.467 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.01 128.69 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.662 -0.649 . . . . 0.0 109.928 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 71.1 p -105.12 -178.59 3.7 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.597 -0.69 . . . . 0.0 110.441 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 55.0 mtp180 -69.76 -20.95 63.48 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.562 -0.711 . . . . 0.0 110.808 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.81 21.24 4.96 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.356 -0.84 . . . . 0.0 110.908 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.12 39.93 31.16 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.154 -0.966 . . . . 0.0 110.622 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -106.4 168.32 9.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.588 -0.695 . . . . 0.0 110.008 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.7 p -129.97 129.97 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.559 -0.713 . . . . 0.0 110.183 179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 mp -119.62 109.28 38.35 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.633 -0.667 . . . . 0.0 109.87 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -65.16 109.83 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.764 1.402 . . . . 0.0 110.263 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -110.83 124.12 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.608 -0.683 . . . . 0.0 109.937 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 35.1 mmm-85 -79.75 155.22 28.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.586 -0.696 . . . . 0.0 110.175 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -98.18 119.69 37.28 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -122.64 22.63 9.8 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.23 -176.95 47.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -70.07 -40.04 75.29 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.506 -0.997 . . . . 0.0 110.532 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -131.0 29.07 4.74 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.449 -0.782 . . . . 0.0 110.686 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -138.44 162.5 34.31 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.451 -0.78 . . . . 0.0 110.474 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -162.24 -179.39 36.83 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 79.4 p -120.92 149.01 43.28 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.542 -0.975 . . . . 0.0 110.232 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.4 tp -93.44 119.28 32.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.591 -0.693 . . . . 0.0 109.996 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.7 mp -65.02 -39.95 94.16 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.593 -0.692 . . . . 0.0 109.959 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.3 p -110.87 119.97 44.72 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.601 -0.687 . . . . 0.0 110.033 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.23 117.74 5.05 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.736 1.388 . . . . 0.0 110.281 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 13.1 mmt85 -120.59 160.0 45.97 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.56 -0.712 . . . . 0.0 110.197 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.58 159.21 54.41 Favored 'Trans proline' 0 N--CA 1.489 1.255 0 O-C-N 123.875 1.461 . . . . 0.0 110.475 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 92.5 t -64.66 -33.15 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.538 -0.726 . . . . 0.0 109.98 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 56.0 m -60.07 -38.09 81.82 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.588 -0.695 . . . . 0.0 110.223 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -60.05 -40.04 88.02 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.559 -0.713 . . . . 0.0 110.212 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.3 mp -83.6 -23.34 31.96 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.529 -0.732 . . . . 0.0 110.756 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.11 140.06 57.12 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.339 -0.851 . . . . 0.0 110.246 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.05 4.2 89.63 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.8 m -109.53 -0.89 18.59 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.075 -1.25 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 31.0 t -60.01 141.47 55.59 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.108 -0.995 . . . . 0.0 109.754 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 100.05 -19.79 51.64 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.75 147.05 44.0 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -92.38 144.78 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.925 1.487 . . . . 0.0 111.181 -179.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.4 mp -101.35 111.11 23.25 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -99.65 131.72 45.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.526 -0.733 . . . . 0.0 111.453 -178.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.436 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.05 160.03 82.06 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -52.0 -22.88 15.47 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 O-C-N 123.532 1.28 . . . . 0.0 112.161 -178.684 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.66 -40.03 88.45 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.225 -0.922 . . . . 0.0 109.881 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.19 35.66 0.86 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -132.03 148.14 52.49 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.467 -1.019 . . . . 0.0 110.445 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.71 143.51 57.34 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.599 -0.688 . . . . 0.0 110.273 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 54.4 t -118.29 -40.87 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.536 -0.727 . . . . 0.0 110.052 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.57 -175.59 41.41 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.402 HG23 HD12 ' A' ' 153' ' ' ILE . 89.0 mt -122.91 130.34 74.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.535 -0.979 . . . . 0.0 110.391 -179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 23.1 t80 -60.34 134.6 57.22 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.55 -0.719 . . . . 0.0 109.818 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.7 ttt180 -113.24 -52.13 2.78 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.458 -0.777 . . . . 0.0 110.443 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -155.09 160.01 40.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.44 -0.787 . . . . 0.0 110.558 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -111.73 153.71 26.08 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.614 -0.679 . . . . 0.0 110.193 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.05 118.99 58.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.625 -0.672 . . . . 0.0 109.751 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -132.99 149.29 52.24 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.654 -0.654 . . . . 0.0 110.307 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.7 p -82.26 -42.9 18.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.645 -0.659 . . . . 0.0 110.61 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -160.34 59.93 0.34 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.131 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 98.75 -10.01 62.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.33 122.25 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.134 -1.215 . . . . 0.0 109.843 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.57 126.12 41.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.68 -0.637 . . . . 0.0 110.78 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 47.5 mmtt -107.14 -25.45 11.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.733 -0.605 . . . . 0.0 110.118 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.73 154.54 46.37 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.728 . . . . 0.0 110.04 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 26.8 m -126.21 -171.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.557 -0.714 . . . . 0.0 110.786 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -146.93 134.57 21.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.69 -0.631 . . . . 0.0 109.444 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -137.48 159.19 42.64 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.446 -0.784 . . . . 0.0 110.8 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 65.5 t -98.42 121.2 57.49 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -62.37 159.94 33.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.711 1.374 . . . . 0.0 110.517 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 89.4 t -69.39 -27.09 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.615 -0.678 . . . . 0.0 110.829 -179.304 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -58.18 -39.67 79.5 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.366 -0.834 . . . . 0.0 110.7 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 89.3 p -67.08 -38.46 85.77 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.454 -0.779 . . . . 0.0 110.246 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.424 ' HE1' ' CE2' ' A' ' 53' ' ' TRP . 87.9 mtp -60.0 -40.04 87.85 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.489 -0.757 . . . . 0.0 110.319 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -64.27 -40.01 95.11 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.506 -0.746 . . . . 0.0 110.3 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.5 m -67.93 -28.78 67.77 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.713 -0.617 . . . . 0.0 110.372 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.1 m -59.97 -40.07 87.83 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.571 -0.706 . . . . 0.0 110.272 -179.76 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.5 mtt -61.55 -41.87 98.0 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -69.97 -39.95 75.67 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.556 -0.715 . . . . 0.0 110.234 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -81.72 -12.67 58.52 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.571 -0.706 . . . . 0.0 111.093 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.4 t -59.98 -50.03 75.35 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.242 -0.911 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 85.3 tttt 50.64 71.16 0.44 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.338 -0.851 . . . . 0.0 110.93 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -60.02 136.29 57.97 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.469 -0.769 . . . . 0.0 110.372 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -129.34 27.35 5.33 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.617 -0.677 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.6 tptm . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.053 -179.961 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -119.98 140.01 51.61 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 118.731 -1.188 . . . . 0.0 110.071 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.411 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp -83.94 140.79 31.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 110.45 -179.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.46 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.493 1.683 0 CA-C-O 121.078 0.466 . . . . 0.0 110.281 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 160.05 44.58 0.02 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -99.89 120.44 39.78 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.616 -0.932 . . . . 0.0 110.208 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -128.07 26.82 5.74 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.568 -0.707 . . . . 0.0 110.431 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.1 tptt 57.0 -160.0 0.23 Allowed 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.346 -0.846 . . . . 0.0 110.317 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 m120 -69.43 -39.96 77.53 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.562 -0.712 . . . . 0.0 110.446 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -75.91 158.64 31.81 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.55 -0.719 . . . . 0.0 110.255 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -109.97 9.95 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.5 -0.75 . . . . 0.0 111.074 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -151.56 160.0 43.86 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.17 -0.956 . . . . 0.0 110.203 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.92 88.15 0.07 OUTLIER Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -62.14 -34.88 77.21 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.549 -0.971 . . . . 0.0 110.047 179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.2 t -105.58 127.21 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.538 -0.726 . . . . 0.0 109.959 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -116.28 150.14 38.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.586 -0.696 . . . . 0.0 110.334 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 12.5 p -79.72 129.02 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.63 -0.669 . . . . 0.0 110.04 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.4 m -125.14 154.29 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 110.031 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.5 m -149.84 171.48 16.69 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.016 -0.673 . . . . 0.0 110.511 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.9 p -140.93 -173.35 3.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.766 -0.584 . . . . 0.0 109.434 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.34 -0.81 26.99 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.497 -0.752 . . . . 0.0 111.219 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.4 m -118.59 -46.75 2.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.109 -0.994 . . . . 0.0 111.359 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -147.76 171.18 16.09 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.268 -0.895 . . . . 0.0 111.407 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 32.1 t -119.15 146.65 44.98 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.664 -0.647 . . . . 0.0 109.926 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.403 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 15.1 p90 -158.17 -176.44 5.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.486 -0.758 . . . . 0.0 110.215 -179.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 42.0 mt -111.54 167.65 10.16 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.565 -0.709 . . . . 0.0 110.338 -178.309 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -142.91 155.69 44.77 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.698 -0.626 . . . . 0.0 110.039 -179.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 73.4 p -120.28 129.45 54.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.453 -0.78 . . . . 0.0 110.177 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 35.0 t -91.13 107.42 19.19 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.514 -0.741 . . . . 0.0 110.517 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.6 t -115.29 135.87 53.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.624 -0.673 . . . . 0.0 109.552 179.525 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 54.78 37.42 28.41 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.536 -0.727 . . . . 0.0 111.021 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 23.14 77.35 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.6 t -138.25 129.91 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.248 -1.148 . . . . 0.0 110.089 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.0 t -68.45 148.47 50.59 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.418 -0.801 . . . . 0.0 109.454 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 48.8 m95 -140.08 142.95 36.08 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.197 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.454 ' CG2' ' CZ3' ' A' ' 85' ' ' TRP . 7.9 t -170.07 -178.6 2.9 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.451 HG22 ' CE1' ' A' ' 57' ' ' HIS . 12.7 p -83.23 159.01 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 110.401 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.425 ' CD1' ' HA2' ' A' ' 60' ' ' GLY . 55.5 t80 -76.99 -40.03 48.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.67 -0.644 . . . . 0.0 112.069 -178.805 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.451 ' CE1' HG22 ' A' ' 55' ' ' VAL . 2.9 p-80 -61.0 -24.67 66.32 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.113 -0.992 . . . . 0.0 110.848 -178.626 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.446 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -74.75 -49.01 11.17 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -114.86 -55.56 2.47 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.561 -0.964 . . . . 0.0 110.458 -179.874 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.425 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 85.09 -172.33 47.44 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 47.8 t -80.14 65.13 5.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.526 -0.985 . . . . 0.0 109.848 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -141.81 170.06 16.43 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.587 -0.696 . . . . 0.0 110.267 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.1 m -65.57 139.77 58.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.527 -0.733 . . . . 0.0 109.851 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.426 HD22 ' CD2' ' A' ' 85' ' ' TRP . 20.4 tp -108.81 141.02 41.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.692 -0.63 . . . . 0.0 110.099 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.15 111.56 23.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.57 -0.706 . . . . 0.0 110.166 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.12 -178.29 18.23 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -62.1 -31.96 83.37 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 O-C-N 123.765 1.403 . . . . 0.0 110.518 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.4 tttt -74.61 -31.27 61.97 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.669 -0.644 . . . . 0.0 109.769 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.33 -154.38 23.45 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.41 146.82 69.86 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 O-C-N 123.816 1.43 . . . . 0.0 109.953 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -130.3 139.98 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.514 -0.741 . . . . 0.0 110.599 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.3 m -89.83 139.9 30.13 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.563 -0.711 . . . . 0.0 110.211 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.416 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 1.6 pp0? -83.2 150.25 26.33 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.519 -0.738 . . . . 0.0 111.383 -179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.2 mtp -110.37 -29.93 7.9 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.821 -0.549 . . . . 0.0 109.944 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -131.76 148.39 52.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.72 -0.613 . . . . 0.0 110.459 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.15 125.98 11.17 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.663 -0.648 . . . . 0.0 109.628 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -141.92 95.57 2.83 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.528 -0.733 . . . . 0.0 110.152 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 91.9 t -61.43 -44.67 98.95 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.673 -0.642 . . . . 0.0 109.921 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.15 -48.75 80.39 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.551 -0.718 . . . . 0.0 110.256 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -80.07 -9.15 59.68 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.66 -0.65 . . . . 0.0 110.478 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 5.7 t0 56.79 48.18 16.63 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.22 -0.925 . . . . 0.0 110.422 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 81.3 mt -137.96 149.83 46.49 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.48 -0.762 . . . . 0.0 110.892 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -150.05 149.97 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.611 -0.68 . . . . 0.0 109.493 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -133.86 149.55 19.75 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.335 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.454 ' CZ3' ' CG2' ' A' ' 54' ' ' THR . 5.3 m-90 -120.16 168.19 11.47 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.68 -0.894 . . . . 0.0 110.204 179.516 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -72.86 120.42 18.46 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.455 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -68.98 132.24 90.5 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.448 -0.782 . . . . 0.0 109.958 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.99 157.07 61.15 Favored 'Trans proline' 0 N--CA 1.49 1.294 0 O-C-N 123.84 1.442 . . . . 0.0 110.478 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.56 160.23 48.94 Favored 'Trans proline' 0 N--CA 1.49 1.282 0 O-C-N 123.936 1.493 . . . . 0.0 110.185 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 29.97 70.44 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.04 160.87 22.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.6 -0.941 . . . . 0.0 110.106 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 75.1 mtp85 -105.19 153.75 21.13 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 110.275 -179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 54.5 m -111.3 160.9 16.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.605 -0.684 . . . . 0.0 110.294 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.5 mt -100.31 131.85 46.01 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.595 -0.691 . . . . 0.0 110.524 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.3 p -77.04 159.95 77.27 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.608 -0.682 . . . . 0.0 110.006 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -85.57 158.24 10.71 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 O-C-N 123.799 1.421 . . . . 0.0 110.54 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.4 t -79.81 129.75 34.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.587 -0.695 . . . . 0.0 110.087 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -132.88 56.45 1.85 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.677 -0.64 . . . . 0.0 109.678 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.87 -8.1 0.73 Allowed 'General case' 0 N--CA 1.497 1.913 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.252 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.92 46.09 94.73 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.98 119.77 38.77 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.518 -0.989 . . . . 0.0 110.45 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -62.95 -40.03 96.43 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.703 -0.623 . . . . 0.0 110.355 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -63.3 132.55 51.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.543 -0.723 . . . . 0.0 110.354 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.0 mt -137.29 145.24 43.22 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.568 -0.708 . . . . 0.0 110.488 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.47 122.15 46.05 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.541 -0.725 . . . . 0.0 109.858 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.6 tp -103.69 146.17 28.98 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.671 . . . . 0.0 110.605 -179.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.67 130.07 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.65 -0.656 . . . . 0.0 109.758 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -93.09 170.04 9.95 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.487 -0.758 . . . . 0.0 110.754 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 5.4 ttt-85 -64.6 -21.07 66.61 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.639 -0.663 . . . . 0.0 110.623 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.6 t60 -94.42 29.41 2.25 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.416 -0.803 . . . . 0.0 110.488 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.7 40.02 30.86 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -107.44 157.32 18.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.648 -0.658 . . . . 0.0 109.926 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.7 p -129.99 130.32 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.589 -0.694 . . . . 0.0 110.193 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 76.5 mt -128.86 150.04 73.96 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.569 -0.707 . . . . 0.0 109.827 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -87.14 132.07 3.17 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.919 1.484 . . . . 0.0 110.409 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -129.84 130.01 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.641 -0.662 . . . . 0.0 109.526 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -92.18 136.21 33.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.455 -0.778 . . . . 0.0 110.192 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -79.17 128.82 33.78 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.571 -0.706 . . . . 0.0 110.318 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -121.68 23.02 10.38 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.616 -0.677 . . . . 0.0 110.169 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.0 179.73 41.23 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -61.37 -40.82 95.71 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.488 -1.007 . . . . 0.0 110.233 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 78.6 p -132.64 26.52 4.38 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.57 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -129.74 140.04 51.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.493 -0.754 . . . . 0.0 110.134 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.14 169.76 25.63 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -114.71 157.37 23.26 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.621 -0.929 . . . . 0.0 110.071 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.9 tp -100.41 119.15 38.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.566 -0.709 . . . . 0.0 110.165 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -69.68 -37.29 76.61 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.477 -0.765 . . . . 0.0 109.741 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.9 t -108.57 109.96 61.42 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.63 -0.669 . . . . 0.0 109.95 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.79 116.26 3.71 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.839 1.441 . . . . 0.0 110.469 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -119.95 160.03 44.47 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.544 -0.723 . . . . 0.0 110.185 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.74 157.74 60.62 Favored 'Trans proline' 0 N--CA 1.491 1.358 0 O-C-N 123.877 1.462 . . . . 0.0 110.442 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 94.3 t -61.53 -36.05 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.608 -0.682 . . . . 0.0 110.01 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -40.09 87.66 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.547 -0.721 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -59.89 -40.08 87.52 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.544 -0.723 . . . . 0.0 110.285 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.8 mp -82.65 -24.52 33.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.521 -0.737 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.39 140.23 57.29 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.295 -0.878 . . . . 0.0 109.972 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.02 10.23 85.8 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 20.6 m -116.17 18.83 15.23 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.173 -1.192 . . . . 0.0 110.606 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 1.8 m -69.95 149.95 47.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.356 -0.84 . . . . 0.0 109.857 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.05 -11.89 69.37 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.86 137.81 48.25 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -87.22 142.32 6.23 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.807 1.425 . . . . 0.0 111.327 -179.253 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.403 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 6.8 mp -103.6 109.56 21.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -102.74 132.33 48.96 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.457 -0.777 . . . . 0.0 111.62 -178.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -68.56 159.62 80.62 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -51.9 -26.07 23.53 Favored 'Trans proline' 0 N--CA 1.5 1.874 0 O-C-N 123.446 1.235 . . . . 0.0 112.391 -178.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -62.69 -40.01 95.76 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.231 -0.918 . . . . 0.0 109.809 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 122.02 34.01 0.87 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.52 145.72 51.37 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.428 -1.042 . . . . 0.0 110.157 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.8 136.86 45.49 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.671 -0.643 . . . . 0.0 110.255 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 8.8 p -116.14 -21.28 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 110.78 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.29 -176.59 45.5 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.402 ' CD1' ' CE ' ' A' ' 175' ' ' MET . 92.7 mt -130.81 140.07 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.402 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.5 t80 -60.87 139.99 57.82 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.58 -0.7 . . . . 0.0 109.862 179.573 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 64.4 ttt180 -120.68 -52.5 2.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.56 -0.712 . . . . 0.0 110.393 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -149.32 157.62 43.49 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.486 -0.758 . . . . 0.0 110.325 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.23 145.52 37.19 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.548 -0.72 . . . . 0.0 110.265 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.1 t -110.0 119.96 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.631 -0.668 . . . . 0.0 109.794 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -130.59 152.17 50.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.639 -0.663 . . . . 0.0 110.39 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 p -77.8 -45.16 25.28 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.65 -0.656 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 45.6 ptt85 -164.0 54.78 0.16 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.621 -0.674 . . . . 0.0 109.975 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 111.93 -14.63 26.44 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.29 120.74 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.185 -1.185 . . . . 0.0 109.963 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -84.45 129.32 34.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.657 -0.652 . . . . 0.0 110.447 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 21.4 pttm -111.44 -24.31 10.25 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.621 -0.674 . . . . 0.0 110.604 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.13 159.23 42.68 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.619 -0.676 . . . . 0.0 109.909 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 m -134.91 167.32 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.611 -0.681 . . . . 0.0 110.668 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -126.78 139.65 52.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.669 -0.644 . . . . 0.0 109.771 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -138.04 154.7 49.28 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.402 -0.811 . . . . 0.0 110.833 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.6 t -93.29 121.15 65.89 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.68 -0.637 . . . . 0.0 109.472 179.623 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.64 154.11 75.57 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.734 1.386 . . . . 0.0 110.544 -179.602 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 63.7 t -62.99 -26.75 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.571 -0.706 . . . . 0.0 110.35 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -59.12 -39.9 83.75 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.478 -0.764 . . . . 0.0 110.351 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 86.2 p -60.0 -38.29 82.18 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.487 -0.758 . . . . 0.0 110.216 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.402 ' CE ' ' CD1' ' A' ' 153' ' ' ILE . 69.0 mtt -61.86 -40.03 93.93 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.507 -0.745 . . . . 0.0 110.257 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -41.81 92.85 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.539 -179.529 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 72.8 p -70.03 -27.46 64.68 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.3 m -60.06 -45.39 93.03 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.425 -0.797 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.6 mtt -67.26 -39.98 86.18 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.578 -0.701 . . . . 0.0 110.083 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 78.0 mtp180 -69.73 -25.59 63.91 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.479 -0.763 . . . . 0.0 110.396 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.81 94.93 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.526 -0.734 . . . . 0.0 110.803 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -139.97 -67.5 0.43 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.371 -0.831 . . . . 0.0 111.039 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -103.27 113.27 26.63 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.472 -0.768 . . . . 0.0 110.439 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.04 -39.99 75.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.658 -0.651 . . . . 0.0 110.112 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -137.38 159.99 40.35 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.545 -0.722 . . . . 0.0 110.242 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt . . . . . 0 N--CA 1.501 2.098 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.778 179.956 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 61.5 tt0 -158.85 159.95 35.62 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 118.711 -1.195 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.414 HD22 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp -109.88 146.52 34.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.617 -0.677 . . . . 0.0 110.25 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.421 ' H2A' ' CD2' ' A' ' 57' ' ' HIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 28.2 m . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.162 0.506 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.04 -40.1 96.59 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -108.41 130.05 55.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.619 -0.93 . . . . 0.0 110.141 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -120.47 142.41 49.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.574 -0.704 . . . . 0.0 110.171 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -100.05 128.08 46.18 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.587 -0.696 . . . . 0.0 110.304 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -118.73 32.12 6.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.587 -0.696 . . . . 0.0 110.113 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 57.23 -86.79 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.624 -0.673 . . . . 0.0 110.65 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 p -134.75 129.65 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.035 -1.041 . . . . 0.0 110.265 179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -114.02 -29.96 6.84 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.547 -0.721 . . . . 0.0 110.26 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.47 125.06 2.96 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -64.17 -24.8 67.82 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.586 -0.949 . . . . 0.0 110.498 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.3 t -108.21 126.74 64.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.503 -0.748 . . . . 0.0 109.82 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -123.39 154.41 39.03 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.484 -0.76 . . . . 0.0 110.584 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.9 t -90.3 122.77 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.617 -0.677 . . . . 0.0 109.276 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.37 152.71 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.564 -0.71 . . . . 0.0 110.176 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.2 m -141.75 169.56 17.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.662 -0.648 . . . . 0.0 110.513 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -132.37 -169.77 2.29 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -58.73 -41.73 87.11 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.42 -0.8 . . . . 0.0 110.575 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.8 m -134.24 -6.86 2.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.479 -0.763 . . . . 0.0 112.025 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.402 ' HG3' ' CD2' ' B' ' 191' ' ' FE3 . 16.8 tp60 -111.76 160.43 17.32 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.899 -1.126 . . . . 0.0 110.864 -179.214 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -147.56 137.91 23.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.452 -0.78 . . . . 0.0 110.402 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 29.0 p90 -169.11 -177.67 2.99 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.312 -0.868 . . . . 0.0 110.434 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 54.6 mt -112.99 159.94 18.61 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.429 -0.795 . . . . 0.0 110.672 -178.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -136.26 159.84 40.53 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.689 -0.632 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 23.0 m -123.8 139.29 54.12 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.444 -0.785 . . . . 0.0 110.351 -179.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.0 t -94.38 111.03 22.76 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 110.637 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.404 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.1 t -117.2 130.31 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.704 -0.623 . . . . 0.0 109.662 179.553 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.46 39.44 28.01 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.503 -0.748 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.85 19.89 75.56 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.01 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -133.53 129.77 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -1.163 . . . . 0.0 110.025 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 89.3 m -74.49 147.67 41.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.391 -0.818 . . . . 0.0 109.419 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.404 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 67.5 m95 -129.94 151.66 50.26 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.394 -0.816 . . . . 0.0 110.824 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.46 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.3 t -167.41 -179.62 4.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.756 -0.59 . . . . 0.0 109.771 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.477 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 9.4 p -90.03 158.19 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.454 -0.779 . . . . 0.0 110.319 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 71.4 t80 -74.27 -42.31 59.82 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.599 -0.688 . . . . 0.0 111.477 -179.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.477 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.3 p-80 -70.03 -22.48 63.09 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.148 -0.97 . . . . 0.0 110.799 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -81.31 -59.98 2.31 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 179.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -91.01 -52.34 4.89 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.639 -0.918 . . . . 0.0 110.204 179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 -174.33 47.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 36.4 p -81.93 61.7 5.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.561 -0.964 . . . . 0.0 109.806 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -141.53 170.13 16.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.582 -0.699 . . . . 0.0 110.533 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.5 p -66.32 156.71 33.63 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.678 -0.639 . . . . 0.0 109.725 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.423 HD22 ' CE3' ' A' ' 85' ' ' TRP . 27.3 tp -118.3 140.5 49.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.575 -0.703 . . . . 0.0 110.28 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.27 109.72 21.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.663 -0.648 . . . . 0.0 109.998 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.19 -174.31 15.79 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.4 -32.35 71.82 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 O-C-N 123.907 1.477 . . . . 0.0 110.542 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.4 mttt -77.15 -31.03 55.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.667 -0.646 . . . . 0.0 110.01 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.75 -150.57 21.8 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -75.03 138.69 23.28 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.89 1.469 . . . . 0.0 110.358 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.4 HG22 HD12 ' A' ' 71' ' ' ILE . 85.2 mt -119.97 129.96 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.621 -0.674 . . . . 0.0 110.577 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.9 p -82.51 142.53 31.78 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.525 -0.735 . . . . 0.0 109.753 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.77 149.97 21.33 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.432 -0.793 . . . . 0.0 111.254 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.6 mmm -115.43 -26.3 7.61 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.752 -0.592 . . . . 0.0 110.451 179.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -119.95 139.95 51.66 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.396 -0.815 . . . . 0.0 110.724 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 91.7 m -140.35 130.0 24.3 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.654 -0.654 . . . . 0.0 109.944 179.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -137.37 103.27 5.03 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.389 -0.819 . . . . 0.0 110.441 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 70.9 t -71.15 -45.24 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.51 -0.744 . . . . 0.0 110.224 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -60.11 -49.89 75.85 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.437 -0.79 . . . . 0.0 110.223 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 3.7 tp-100 -80.04 -9.99 59.74 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.538 -0.726 . . . . 0.0 110.582 179.694 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 2.7 t70 56.01 44.95 24.66 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.147 -0.97 . . . . 0.0 109.985 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 64.9 mt -141.77 131.5 24.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.655 -0.653 . . . . 0.0 110.902 -179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.1 m -129.96 159.98 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.66 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -137.47 157.34 23.98 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.553 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.46 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 8.6 m-90 -115.39 157.05 24.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.874 -0.78 . . . . 0.0 109.467 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -69.48 108.16 3.66 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.521 -0.737 . . . . 0.0 109.377 179.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.16 143.34 91.09 Favored Pre-proline 0 N--CA 1.496 1.844 0 O-C-N 121.495 -0.753 . . . . 0.0 110.359 -179.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.1 158.42 56.57 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.089 1.573 . . . . 0.0 110.154 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.98 153.33 63.37 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.886 1.466 . . . . 0.0 110.27 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.12 29.68 62.17 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.28 154.33 20.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.514 -0.992 . . . . 0.0 110.09 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -80.18 159.25 26.06 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 110.005 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 97.2 p -139.98 159.73 41.53 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.292 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 7.7 mt -106.09 132.19 52.46 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.591 -0.693 . . . . 0.0 110.482 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 86.7 m -80.0 141.29 54.5 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.693 -0.63 . . . . 0.0 109.916 179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -64.04 163.58 25.13 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.812 1.427 . . . . 0.0 110.377 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.5 t -87.74 123.54 32.66 Favored 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.65 0.738 . . . . 0.0 110.937 -179.377 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.0 m -118.21 59.66 0.8 Allowed 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 177.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 3.5 m -141.76 -9.31 0.93 Allowed 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 119.99 -0.684 . . . . 0.0 111.899 -177.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.12 25.47 54.07 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.089 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -70.23 130.81 43.04 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.525 -0.985 . . . . 0.0 110.723 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.4 m -74.37 -39.99 62.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.73 -0.606 . . . . 0.0 110.464 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.4 130.51 42.74 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.518 -0.739 . . . . 0.0 110.546 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.8 mt -131.23 140.2 49.82 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.649 -0.657 . . . . 0.0 110.637 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -106.85 124.37 49.52 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.494 -0.754 . . . . 0.0 109.817 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 37.7 tp -108.48 145.43 34.71 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.394 -0.816 . . . . 0.0 110.924 -179.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.05 120.99 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.674 -0.641 . . . . 0.0 109.706 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.9 p -95.31 173.03 7.74 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.55 -0.719 . . . . 0.0 110.547 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 3.5 ptp180 -69.33 -11.95 61.25 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.544 -0.723 . . . . 0.0 111.103 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.01 21.69 5.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.209 -0.932 . . . . 0.0 110.399 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.33 40.05 31.42 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.222 -0.924 . . . . 0.0 110.575 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -124.02 147.65 47.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.658 -0.651 . . . . 0.0 109.64 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.0 p -129.98 130.69 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.565 -0.709 . . . . 0.0 110.405 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.8 pt -121.1 150.0 52.61 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.679 -0.638 . . . . 0.0 109.796 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -81.57 123.27 4.24 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.937 1.493 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -119.7 120.95 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.715 -0.616 . . . . 0.0 109.6 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -76.73 149.67 36.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.48 -0.762 . . . . 0.0 110.039 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.6 ttt180 -90.89 120.06 31.6 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.359 -179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -109.94 20.09 18.36 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.659 -0.651 . . . . 0.0 110.399 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.85 -179.97 39.78 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.72 -39.92 90.41 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.972 . . . . 0.0 110.301 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.4 p -130.92 25.1 4.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.557 -0.714 . . . . 0.0 110.522 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -124.25 139.53 53.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.439 -0.788 . . . . 0.0 110.254 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.77 165.79 26.41 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 99.8 p -120.21 155.51 33.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.648 -0.913 . . . . 0.0 110.129 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 14.2 tp -99.97 119.5 38.35 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.516 -0.74 . . . . 0.0 110.158 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.04 -39.91 94.03 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.493 -0.754 . . . . 0.0 109.961 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 85.6 p -110.66 120.2 44.4 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.39 120.87 7.93 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 123.763 1.402 . . . . 0.0 110.4 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.2 mmt180 -129.93 159.98 67.34 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.539 -0.726 . . . . 0.0 110.251 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.39 156.72 61.82 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.982 1.517 . . . . 0.0 110.423 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 33.9 m -67.06 -25.44 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.658 -0.651 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.7 m -59.94 -40.04 87.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.41 -0.806 . . . . 0.0 110.272 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 88.5 t80 -60.06 -40.08 88.23 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.497 -0.752 . . . . 0.0 109.935 -179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -83.85 -25.39 30.34 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.535 -0.728 . . . . 0.0 110.287 179.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -59.96 132.02 52.66 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.408 -0.808 . . . . 0.0 110.105 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 91.96 0.93 70.84 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.306 -0.95 . . . . 0.0 110.732 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -109.96 19.99 18.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.136 -1.214 . . . . 0.0 110.66 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.4 t -68.65 147.68 51.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.327 -0.858 . . . . 0.0 109.724 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.78 -14.5 62.98 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.26 148.85 43.17 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -96.81 148.31 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.875 1.461 . . . . 0.0 111.123 -179.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.5 mp -103.94 108.96 20.53 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 mp -99.93 134.79 42.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.461 -0.774 . . . . 0.0 111.773 -178.482 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.422 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 28.5 p -70.03 159.93 82.41 Favored Pre-proline 0 N--CA 1.494 1.75 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -52.62 -22.13 16.28 Favored 'Trans proline' 0 N--CA 1.5 1.904 0 O-C-N 123.512 1.269 . . . . 0.0 112.056 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 8.6 t -67.63 -42.92 81.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.228 -0.92 . . . . 0.0 110.055 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 125.51 35.93 0.59 Allowed Glycine 0 N--CA 1.496 2.671 0 C-N-CA 120.069 -1.062 . . . . 0.0 110.904 179.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -133.02 144.63 50.2 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.237 -1.155 . . . . 0.0 110.283 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.67 145.21 55.19 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.588 -0.695 . . . . 0.0 110.357 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.2 t -119.15 -38.91 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.523 -0.735 . . . . 0.0 110.118 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.99 -177.73 42.47 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.431 HD13 HG21 ' A' ' 153' ' ' ILE . 85.4 mt -121.61 132.02 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -1.013 . . . . 0.0 110.521 -179.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -60.32 137.16 58.18 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.586 -0.696 . . . . 0.0 109.799 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 68.5 ttt180 -121.17 -52.72 2.06 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.498 -0.752 . . . . 0.0 110.33 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -143.16 159.96 41.32 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.508 -0.745 . . . . 0.0 110.073 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.84 136.05 54.92 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.627 -0.671 . . . . 0.0 110.553 -179.795 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.6 t -90.0 119.74 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.7 p -135.52 153.69 51.64 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.487 -0.758 . . . . 0.0 111.404 -179.14 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 37.1 m -130.53 137.38 49.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.756 -0.59 . . . . 0.0 109.522 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 21.7 mmt180 54.21 37.14 26.63 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.272 -0.893 . . . . 0.0 110.755 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 74.19 23.28 76.31 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.4 t -129.98 129.87 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.295 -1.12 . . . . 0.0 110.065 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.78 125.57 35.75 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.539 -0.725 . . . . 0.0 110.131 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.51 -29.61 7.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.541 -0.725 . . . . 0.0 110.455 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.89 162.85 34.45 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.57 -0.706 . . . . 0.0 109.941 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -136.02 165.59 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.432 -0.792 . . . . 0.0 110.965 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -126.37 135.86 51.98 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.629 -0.67 . . . . 0.0 109.995 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -139.88 147.41 40.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.496 -0.752 . . . . 0.0 110.64 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 33.0 m -89.96 125.0 62.1 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.497 -0.752 . . . . 0.0 109.556 179.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.88 159.96 39.5 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.746 1.393 . . . . 0.0 110.711 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 89.9 t -60.22 -25.23 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.596 -0.69 . . . . 0.0 110.594 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -58.73 -39.01 79.62 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.456 -0.777 . . . . 0.0 110.354 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 67.5 m -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.468 -0.77 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.3 mtm -69.99 -37.37 75.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.35 -0.844 . . . . 0.0 110.331 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -59.97 -40.15 88.09 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.513 -0.742 . . . . 0.0 110.468 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 70.1 p -65.31 -37.12 86.16 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.471 -0.768 . . . . 0.0 110.253 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.0 m -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.593 -0.692 . . . . 0.0 110.139 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -67.61 -36.69 81.32 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.534 -0.729 . . . . 0.0 110.058 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 15.1 tpt180 -59.88 -40.08 87.46 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.558 -0.714 . . . . 0.0 110.11 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.02 -39.99 87.76 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.595 -0.69 . . . . 0.0 110.239 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 80.0 p -73.09 160.04 32.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.525 -0.734 . . . . 0.0 110.105 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 22.2 pttm -90.96 15.29 11.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.586 -0.696 . . . . 0.0 111.075 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 85.4 tttt 57.83 163.27 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.274 -0.891 . . . . 0.0 110.596 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -60.08 -40.01 88.08 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.4 -0.812 . . . . 0.0 110.231 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 60.1 tptt . . . . . 0 N--CA 1.501 2.113 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.632 -179.955 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -120.05 135.31 54.98 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 118.684 -1.206 . . . . 0.0 109.993 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.414 HD22 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp -69.95 139.52 52.87 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.535 -0.728 . . . . 0.0 110.041 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.606 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.678 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 16.9 m . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.094 0.473 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.94 -162.87 47.03 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 -100.09 124.97 46.09 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.552 -0.969 . . . . 0.0 110.12 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -129.94 170.0 14.51 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.601 -0.687 . . . . 0.0 110.321 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 52.94 40.01 30.26 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.399 -0.813 . . . . 0.0 110.89 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -149.27 91.62 1.86 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.532 -0.73 . . . . 0.0 110.317 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -159.81 -43.73 0.05 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.583 -0.698 . . . . 0.0 110.094 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.6 p -136.49 140.26 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.615 -0.678 . . . . 0.0 110.126 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -96.11 130.45 43.13 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.585 -0.697 . . . . 0.0 109.968 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 173.64 73.07 0.05 OUTLIER Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.98 -38.08 89.71 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.642 -0.917 . . . . 0.0 110.116 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.8 124.65 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.592 -0.692 . . . . 0.0 109.793 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -119.13 155.11 32.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.667 -0.645 . . . . 0.0 110.512 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.8 t -90.21 131.04 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.621 -0.674 . . . . 0.0 109.539 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.8 m -123.91 158.38 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.68 -0.637 . . . . 0.0 110.194 -179.712 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.12 179.35 6.56 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.71 -0.619 . . . . 0.0 110.362 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -141.46 -170.9 3.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.67 -0.643 . . . . 0.0 109.479 -179.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.03 -38.88 84.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.523 -0.736 . . . . 0.0 110.258 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.6 t -136.92 -6.71 1.87 Allowed 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.546 -0.721 . . . . 0.0 112.555 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -118.8 156.71 28.93 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 120.839 -1.163 . . . . 0.0 111.129 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.1 m -136.34 139.75 42.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.566 -0.709 . . . . 0.0 110.341 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -165.61 -177.16 4.24 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.238 -0.914 . . . . 0.0 110.075 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 21.7 mt -112.33 175.16 5.55 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.529 -0.732 . . . . 0.0 110.273 -178.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -149.64 156.85 42.59 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.692 -0.63 . . . . 0.0 110.087 -179.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 27.6 m -119.51 139.92 51.33 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.699 -0.626 . . . . 0.0 110.063 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.3 t -101.35 109.35 21.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.453 -0.78 . . . . 0.0 110.476 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.4 t -120.38 134.28 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.69 -0.631 . . . . 0.0 109.842 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 28.7 m120 55.23 38.52 30.52 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.534 -0.729 . . . . 0.0 111.144 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.63 26.67 74.22 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 80.9 t -140.47 130.03 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.338 -1.095 . . . . 0.0 109.956 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 23.7 t -86.71 108.58 18.73 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.468 -0.77 . . . . 0.0 109.37 179.677 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -91.42 151.21 20.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.595 -0.691 . . . . 0.0 111.05 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.462 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.5 t -159.88 -179.71 8.06 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.46 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 10.5 p -96.59 152.35 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.448 -0.783 . . . . 0.0 110.443 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 60.1 t80 -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.58 -0.7 . . . . 0.0 112.091 -178.671 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.46 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.9 p-80 -68.85 -19.52 64.26 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.139 -0.976 . . . . 0.0 111.068 -178.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -91.13 -52.28 2.42 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 179.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -103.2 -47.68 4.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.628 -0.925 . . . . 0.0 110.123 179.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.2 -168.89 40.78 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.4 t -86.41 64.68 8.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.546 -0.973 . . . . 0.0 109.837 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -141.89 170.05 16.45 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.602 -0.686 . . . . 0.0 110.363 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.1 p -66.13 150.14 49.21 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.618 -0.676 . . . . 0.0 109.944 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.413 HD21 ' CZ2' ' A' ' 85' ' ' TRP . 19.2 tp -117.08 142.62 46.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.611 -0.681 . . . . 0.0 110.082 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -97.62 110.26 22.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.621 -0.675 . . . . 0.0 110.093 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.33 177.11 16.31 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.7 -31.78 68.98 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.85 1.448 . . . . 0.0 110.412 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -71.7 -31.47 66.78 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.597 -0.689 . . . . 0.0 109.999 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.88 -160.56 26.21 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.94 137.23 40.73 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.886 1.466 . . . . 0.0 110.036 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.6 mt -119.94 129.98 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.506 -0.746 . . . . 0.0 110.564 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.3 p -84.86 150.23 25.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.574 -0.704 . . . . 0.0 109.707 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 10.5 pm0 -98.53 148.12 24.08 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.481 -0.762 . . . . 0.0 111.008 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.9 mtp -113.95 -25.55 8.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.766 -0.584 . . . . 0.0 110.504 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -120.01 135.88 54.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.428 -0.795 . . . . 0.0 110.572 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 29.9 m -140.91 126.11 18.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 109.88 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 30.1 t-20 -140.5 104.51 4.77 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.349 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 75.8 t -69.97 -45.3 77.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 0.0 109.871 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -59.87 -49.69 76.7 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.554 -0.716 . . . . 0.0 110.213 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 53.6 tt0 -79.95 -9.99 59.73 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.583 -0.698 . . . . 0.0 110.832 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.0 t70 55.2 46.22 24.25 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.031 -1.043 . . . . 0.0 110.446 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 41.3 mt -143.36 130.43 20.69 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.552 -0.717 . . . . 0.0 111.075 -179.757 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.1 m -130.94 159.99 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.615 -0.678 . . . . 0.0 109.265 178.583 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.76 157.92 23.91 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.597 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.462 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 6.0 m-90 -119.93 160.28 23.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.792 -0.828 . . . . 0.0 109.778 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -71.88 124.57 25.15 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.088 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -72.7 130.01 86.08 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.489 -0.757 . . . . 0.0 110.212 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.02 159.64 52.47 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 O-C-N 123.876 1.461 . . . . 0.0 110.356 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.41 139.7 42.11 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.85 1.447 . . . . 0.0 110.306 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.58 -20.33 50.84 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.01 47.1 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.305 -1.115 . . . . 0.0 110.221 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.8 mtp85 -92.16 170.01 10.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.573 -0.705 . . . . 0.0 110.165 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -132.37 160.01 37.58 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 80.5 mt -110.74 132.23 54.37 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 -179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.9 p -76.34 160.05 78.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.693 -0.629 . . . . 0.0 109.95 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -77.21 164.04 29.67 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.833 1.438 . . . . 0.0 110.651 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 47.1 t -73.06 128.57 35.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.647 -0.658 . . . . 0.0 110.212 -179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.7 p -132.05 54.42 1.94 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.725 -0.609 . . . . 0.0 109.715 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.59 -7.52 0.77 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.519 -0.738 . . . . 0.0 112.376 -179.043 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.98 94.36 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -100.08 123.6 44.51 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.668 -0.901 . . . . 0.0 110.49 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 79.5 p -70.04 -26.06 63.86 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.617 -0.677 . . . . 0.0 110.352 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -63.73 129.99 42.38 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.58 -0.7 . . . . 0.0 109.969 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 96.2 mt -137.4 136.08 37.54 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.6 -0.688 . . . . 0.0 110.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.88 119.99 40.83 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.55 -0.719 . . . . 0.0 109.718 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 57.2 tp -98.21 140.05 33.09 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.512 -0.742 . . . . 0.0 110.387 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.82 130.01 53.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.538 -0.726 . . . . 0.0 109.937 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 22.9 p -98.2 179.17 4.84 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.583 -0.698 . . . . 0.0 110.761 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 15.8 ttt-85 -70.01 -18.58 63.32 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.692 -0.63 . . . . 0.0 110.969 -179.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -93.21 25.46 3.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.293 -0.879 . . . . 0.0 110.868 -179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.14 38.97 30.2 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.347 -0.846 . . . . 0.0 110.765 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -120.25 139.58 52.47 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.662 -0.648 . . . . 0.0 109.599 179.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.0 m -116.66 140.07 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.515 -0.741 . . . . 0.0 110.701 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 mp -124.32 149.99 62.7 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.681 -0.637 . . . . 0.0 109.572 179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -83.6 126.53 4.1 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.842 1.443 . . . . 0.0 110.651 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -128.82 130.05 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.715 -0.616 . . . . 0.0 109.477 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.0 tpt180 -85.48 146.16 27.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.497 -0.752 . . . . 0.0 110.186 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -82.81 124.35 30.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.596 -0.69 . . . . 0.0 110.319 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -114.42 19.93 15.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.28 178.76 39.24 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -59.99 -41.11 91.35 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.509 -0.995 . . . . 0.0 110.293 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.1 p -130.43 25.52 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.464 -0.773 . . . . 0.0 110.654 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.2 tpp85 -126.84 140.49 52.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.507 -0.746 . . . . 0.0 110.356 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.27 166.81 25.95 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.5 p -124.83 147.43 48.75 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.588 -0.948 . . . . 0.0 110.201 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 mp -95.43 121.7 37.38 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.583 -0.698 . . . . 0.0 110.312 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -61.8 -40.07 93.94 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.53 -0.731 . . . . 0.0 109.86 179.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.9 p -108.58 117.95 53.11 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.711 -0.618 . . . . 0.0 109.757 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.19 124.46 13.02 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.744 1.391 . . . . 0.0 110.63 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -121.46 160.17 47.18 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.591 -0.693 . . . . 0.0 110.013 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.09 158.88 56.14 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.93 1.489 . . . . 0.0 110.437 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 68.4 t -66.65 -29.99 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.62 -0.675 . . . . 0.0 110.033 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.6 t -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.552 -0.717 . . . . 0.0 110.295 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 64.7 t80 -60.01 -49.54 77.28 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.461 -0.774 . . . . 0.0 110.02 179.868 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 4.5 mp -69.91 -29.33 66.49 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.632 -0.667 . . . . 0.0 110.626 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 139.98 56.95 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.386 -0.821 . . . . 0.0 110.083 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.54 13.08 83.01 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 16.7 m -115.3 17.25 16.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.281 -1.129 . . . . 0.0 110.766 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.8 m -60.04 144.32 49.72 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.34 -19.34 54.68 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.52 109.8 1.36 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -77.09 151.18 30.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.875 1.46 . . . . 0.0 110.852 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.409 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 6.5 mp -99.72 110.44 22.84 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.086 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -100.01 128.39 46.1 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.662 -0.649 . . . . 0.0 111.17 -178.867 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.411 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.0 157.89 88.67 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.663 -0.648 . . . . 0.0 109.266 179.066 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.1 Cg_endo -52.16 -24.96 21.71 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 O-C-N 123.516 1.271 . . . . 0.0 112.314 -178.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 51.7 m -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.269 -0.895 . . . . 0.0 110.003 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.03 35.77 0.8 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.4 m170 -132.91 149.2 52.27 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -1.01 . . . . 0.0 110.289 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 145.52 51.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.628 -0.67 . . . . 0.0 110.223 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 57.6 t -118.23 -38.38 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.595 -0.691 . . . . 0.0 109.961 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -171.39 -170.02 34.98 Favored Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 85.4 mt -130.99 140.02 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.466 -1.02 . . . . 0.0 110.286 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -62.41 138.55 58.47 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.536 -0.727 . . . . 0.0 109.873 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.6 ttp180 -122.54 -52.1 1.93 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.627 -0.671 . . . . 0.0 110.319 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -149.64 161.88 41.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.487 -0.758 . . . . 0.0 110.421 -179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.92 149.81 39.53 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.649 -0.657 . . . . 0.0 110.161 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -109.95 117.99 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.645 -0.659 . . . . 0.0 109.885 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -137.47 160.53 38.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.642 . . . . 0.0 110.229 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 33.1 m -117.99 -56.63 2.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.573 -0.704 . . . . 0.0 110.765 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -109.33 29.96 7.06 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 110.42 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 100.18 0.3 55.94 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -116.39 126.04 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.098 -1.236 . . . . 0.0 109.649 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.78 123.62 37.24 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.653 . . . . 0.0 110.303 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -104.57 -24.04 13.04 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.651 -0.656 . . . . 0.0 110.503 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 159.65 41.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.429 -0.794 . . . . 0.0 110.184 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -141.37 162.4 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.507 -0.746 . . . . 0.0 110.635 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 -114.89 138.39 50.86 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.615 -0.678 . . . . 0.0 110.053 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -140.04 155.31 47.12 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.531 -0.73 . . . . 0.0 110.299 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 58.6 t -96.21 122.78 57.04 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.53 -0.731 . . . . 0.0 109.65 179.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -65.66 155.83 67.02 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.777 1.409 . . . . 0.0 110.615 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 61.3 t -63.78 -22.92 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.61 -0.681 . . . . 0.0 110.731 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.99 -39.11 84.61 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -0.829 . . . . 0.0 110.424 -179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.0 p -59.81 -34.39 72.99 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.437 -0.789 . . . . 0.0 110.51 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.0 mtt -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.527 -0.733 . . . . 0.0 110.492 -179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -59.95 -40.06 87.7 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.1 m -60.59 -48.61 81.01 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.504 -0.748 . . . . 0.0 110.05 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 87.3 m -70.01 -46.17 65.68 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.575 -0.703 . . . . 0.0 110.0 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -61.19 -39.97 92.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.639 -0.663 . . . . 0.0 110.181 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 33.6 ttt85 -59.99 -39.98 87.6 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.563 -0.711 . . . . 0.0 110.326 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . 0.406 ' O ' ' N ' ' A' ' 183' ' ' LYS . . . -60.04 -41.28 91.91 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.482 -0.761 . . . . 0.0 110.207 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 7.2 t 64.51 -69.06 0.09 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.717 -0.615 . . . . 0.0 111.046 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 181' ' ' ALA . 61.7 pttt -149.98 169.99 19.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.196 -0.94 . . . . 0.0 110.229 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -138.91 159.92 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.471 -0.768 . . . . 0.0 110.331 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -62.82 140.04 58.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 110.14 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.135 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -149.8 149.95 31.28 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 118.696 -1.202 . . . . 0.0 110.117 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.415 HD21 ' CG ' ' A' ' 57' ' ' HIS . 9.7 mp -103.73 139.97 38.24 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.567 -0.708 . . . . 0.0 110.149 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.424 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.114 0.483 . . . . 0.0 110.279 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.96 -100.02 2.62 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -64.23 139.94 58.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.666 -0.902 . . . . 0.0 110.122 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -73.12 150.59 42.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.579 -0.7 . . . . 0.0 110.258 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -125.26 25.3 7.19 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.644 -0.66 . . . . 0.0 110.602 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -110.41 119.89 40.66 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.414 -0.804 . . . . 0.0 110.274 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -69.41 -40.31 77.4 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.533 -0.729 . . . . 0.0 110.321 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.93 160.01 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.605 -0.684 . . . . 0.0 110.433 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -126.53 -49.52 1.52 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.517 -0.74 . . . . 0.0 110.37 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.93 148.6 23.6 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.8 mt-10 -68.53 -36.84 79.4 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.579 -0.954 . . . . 0.0 109.993 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.55 128.51 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -124.84 159.78 30.27 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.567 -0.708 . . . . 0.0 110.075 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.17 113.81 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.519 -0.738 . . . . 0.0 109.83 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.409 ' HB ' ' CD1' ' A' ' 64' ' ' LEU . 34.5 m -110.17 143.21 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.677 -0.64 . . . . 0.0 109.763 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 37.4 t -137.22 173.82 11.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.51 -0.744 . . . . 0.0 111.18 -179.125 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 27.7 m -144.3 169.22 18.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.921 -0.487 . . . . 0.0 109.895 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -66.76 -16.72 64.45 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.669 -0.644 . . . . 0.0 110.617 179.522 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.8 m -111.05 -39.1 4.87 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.345 -0.847 . . . . 0.0 111.748 -179.062 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -146.86 170.7 16.49 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.157 -0.964 . . . . 0.0 111.573 -179.106 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.3 p -128.23 151.95 48.66 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.636 -0.665 . . . . 0.0 110.311 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 30.7 p90 -165.87 -178.02 4.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.374 -0.829 . . . . 0.0 110.334 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 76.2 mt -113.61 150.45 33.09 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.506 -0.746 . . . . 0.0 110.717 -178.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.46 159.13 34.23 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.655 -0.653 . . . . 0.0 110.055 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 62.8 m -120.33 131.6 54.93 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.664 -179.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.4 t -90.16 102.56 15.28 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.547 -0.721 . . . . 0.0 110.136 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.404 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.7 t -109.97 130.12 63.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.582 -0.699 . . . . 0.0 109.593 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.41 39.98 27.74 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.437 -0.789 . . . . 0.0 110.66 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 19.98 75.97 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 110.869 -0.893 . . . . 0.0 110.869 179.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.4 t -131.84 129.98 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.161 -1.2 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.0 m -74.79 147.81 40.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.53 -0.731 . . . . 0.0 109.42 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.421 ' CD2' ' HE1' ' A' ' 175' ' ' MET . 74.5 m95 -129.97 152.31 49.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.426 -0.796 . . . . 0.0 111.072 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.459 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 6.0 t -169.5 -179.71 3.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.466 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.0 p -90.99 156.7 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.458 -0.776 . . . . 0.0 110.484 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 86.5 t80 -70.01 -42.69 72.69 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.57 -0.706 . . . . 0.0 111.194 -179.42 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.466 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.2 p-80 -71.51 -19.06 62.24 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.281 -0.887 . . . . 0.0 111.014 -179.194 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -73.84 -57.57 4.84 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.355 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -87.18 -41.59 13.63 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.583 -0.951 . . . . 0.0 110.139 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 75.72 28.91 60.25 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.28 57.45 4.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.361 -1.082 . . . . 0.0 110.54 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.53 178.99 6.82 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.081 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 77.7 p -65.06 139.49 58.74 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.209 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.418 ' HG ' ' CZ2' ' A' ' 85' ' ' TRP . 0.1 OUTLIER -115.04 130.04 56.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.576 -0.702 . . . . 0.0 110.842 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.23 109.38 20.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.551 -0.718 . . . . 0.0 109.663 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.29 -154.47 13.11 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -72.55 -31.04 11.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.928 1.489 . . . . 0.0 110.445 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -83.67 -22.43 32.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.586 -0.697 . . . . 0.0 110.74 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 135.31 -139.52 10.87 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.91 154.91 34.01 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.904 1.476 . . . . 0.0 110.083 179.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.411 HG22 HD11 ' A' ' 71' ' ' ILE . 85.7 mt -131.45 140.01 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.554 -0.716 . . . . 0.0 110.575 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 91.9 m -95.27 140.0 30.78 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.559 -0.713 . . . . 0.0 109.943 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.415 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 8.9 tt0 -93.05 140.05 29.9 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 0.0 110.58 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.2 mmm -112.18 -29.98 7.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.629 -0.669 . . . . 0.0 110.566 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -118.41 139.77 50.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.585 -0.697 . . . . 0.0 110.569 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.3 m -139.97 132.12 28.07 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.513 -0.742 . . . . 0.0 109.93 179.675 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -136.23 96.62 3.42 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.443 -0.786 . . . . 0.0 110.5 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 82.6 t -70.02 -40.03 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.595 -0.691 . . . . 0.0 109.899 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.97 -47.34 86.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.562 -0.711 . . . . 0.0 110.297 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -90.05 0.15 57.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.531 -0.731 . . . . 0.0 110.97 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 3.8 t70 53.8 46.42 25.82 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.061 -1.025 . . . . 0.0 110.481 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 67.6 mt -141.45 135.92 30.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.476 -0.765 . . . . 0.0 110.747 -179.759 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 33.4 m -134.01 164.44 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.606 -0.684 . . . . 0.0 109.432 179.023 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.75 156.79 26.05 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.871 -1.157 . . . . 0.0 110.343 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.459 ' CH2' ' CG2' ' A' ' 54' ' ' THR . 7.2 m-90 -116.48 152.71 33.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.85 -0.794 . . . . 0.0 109.52 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -66.61 106.37 1.78 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.41 -0.806 . . . . 0.0 109.606 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -71.51 143.57 87.81 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.576 -0.703 . . . . 0.0 110.097 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.95 150.4 66.97 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.965 1.508 . . . . 0.0 110.338 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.01 159.76 44.91 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.849 1.447 . . . . 0.0 110.094 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.79 29.6 69.2 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.76 149.81 28.5 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.48 -1.012 . . . . 0.0 109.949 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -85.21 146.03 27.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.626 -0.671 . . . . 0.0 109.283 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.4 p -136.91 174.14 10.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.577 -0.702 . . . . 0.0 110.601 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 44.0 mt -108.39 149.8 28.23 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.675 -0.641 . . . . 0.0 110.598 -179.853 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.0 p -90.03 176.18 3.24 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.649 -0.657 . . . . 0.0 110.003 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -89.49 160.49 5.42 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 O-C-N 123.807 1.425 . . . . 0.0 110.609 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.3 t -68.7 133.13 47.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.671 -0.643 . . . . 0.0 110.158 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.4 t -135.95 53.41 1.95 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.678 -0.639 . . . . 0.0 109.751 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.88 -8.2 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.554 -0.716 . . . . 0.0 112.378 -179.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 38.17 93.9 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -99.95 124.16 44.99 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.565 -0.962 . . . . 0.0 110.502 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 19.6 p -69.91 -34.27 73.28 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.614 -0.679 . . . . 0.0 110.133 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -61.67 129.98 43.64 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.574 -0.704 . . . . 0.0 109.903 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 90.2 mt -135.64 149.99 49.49 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.55 -0.719 . . . . 0.0 110.771 -179.63 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.54 140.01 47.65 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.617 -0.677 . . . . 0.0 109.556 179.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 52.3 tp -115.2 142.16 47.04 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.496 -0.752 . . . . 0.0 110.677 -179.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 130.06 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.634 -0.666 . . . . 0.0 109.761 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 24.9 p -110.22 -179.9 3.91 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.519 -0.738 . . . . 0.0 110.643 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 32.8 mtp-105 -60.04 -26.38 66.08 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.586 -0.697 . . . . 0.0 110.652 -179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -89.96 17.91 6.32 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.393 -0.817 . . . . 0.0 111.181 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.09 38.38 27.26 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.057 -1.027 . . . . 0.0 110.748 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -100.76 139.8 35.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.699 -0.626 . . . . 0.0 109.893 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 63.4 t -110.02 119.99 60.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.597 -0.689 . . . . 0.0 109.928 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . 0.453 HD11 HG23 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -118.91 122.16 29.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.646 -0.659 . . . . 0.0 109.435 179.868 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -65.33 132.9 32.98 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.744 1.392 . . . . 0.0 110.368 -179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.2 t -129.93 130.04 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.678 -0.639 . . . . 0.0 109.731 -179.955 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -86.36 132.72 33.89 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.497 -0.752 . . . . 0.0 109.972 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -70.76 130.03 40.65 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.581 -0.699 . . . . 0.0 110.438 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 24.5 mmm-85 -102.4 -20.9 14.38 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.653 -0.654 . . . . 0.0 110.377 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.24 -167.98 29.68 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -59.98 -39.98 87.56 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.606 -0.937 . . . . 0.0 110.401 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.4 p -129.89 25.37 5.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.508 -0.745 . . . . 0.0 110.581 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -125.88 140.04 52.98 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.483 -0.76 . . . . 0.0 110.278 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.87 167.18 24.69 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -127.82 150.03 50.01 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.576 -0.956 . . . . 0.0 110.211 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.4 mp -103.02 131.39 50.04 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.442 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.9 mp -61.79 -39.99 93.64 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.585 -0.697 . . . . 0.0 109.745 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.5 p -118.36 149.98 46.97 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.684 -0.635 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -84.42 82.65 1.8 Allowed 'Trans proline' 0 N--CA 1.489 1.237 0 O-C-N 123.843 1.444 . . . . 0.0 110.747 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -71.59 159.98 83.92 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 109.836 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.67 149.31 67.28 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.939 1.494 . . . . 0.0 110.292 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.4 -34.0 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.622 -0.674 . . . . 0.0 110.046 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.6 t -58.41 -36.67 73.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.549 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 64.9 t80 -60.06 -39.92 87.69 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.487 -0.758 . . . . 0.0 110.11 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.7 mp -81.37 -20.84 39.73 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.562 -0.711 . . . . 0.0 110.826 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -59.97 139.74 57.21 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.23 -0.919 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.6 1.07 86.12 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.5 m -101.51 3.07 39.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.107 -1.231 . . . . 0.0 110.975 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.9 t -59.97 139.93 57.08 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.145 -0.972 . . . . 0.0 109.863 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.96 -17.85 57.89 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.67 140.84 43.14 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 179.454 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -87.96 144.91 6.34 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.831 1.438 . . . . 0.0 111.471 -178.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 8.3 mp -103.32 129.95 50.47 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.495 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -118.46 130.9 56.21 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.366 -0.834 . . . . 0.0 111.598 -178.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.439 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -70.02 159.75 83.09 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.764 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.76 -26.91 25.05 Favored 'Trans proline' 0 N--CA 1.501 1.96 0 O-C-N 123.475 1.25 . . . . 0.0 112.368 -178.509 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.78 -40.02 96.02 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.222 -0.924 . . . . 0.0 109.963 179.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.2 36.46 0.81 Allowed Glycine 0 N--CA 1.496 2.641 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -132.83 151.1 52.08 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.462 -1.023 . . . . 0.0 110.337 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -67.08 139.96 57.59 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.623 -0.673 . . . . 0.0 110.435 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 33.9 m -117.19 -22.19 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.597 -0.689 . . . . 0.0 110.726 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 171.39 -171.53 44.05 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 86.0 mt -128.82 140.02 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.542 -0.975 . . . . 0.0 110.154 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -71.15 135.47 47.64 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.66 -0.65 . . . . 0.0 109.962 179.664 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.4 ttp85 -116.52 -53.01 2.54 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.617 -0.677 . . . . 0.0 110.178 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -148.18 159.96 43.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.757 . . . . 0.0 110.391 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -115.95 151.58 35.12 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.63 . . . . 0.0 110.262 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.51 120.03 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.704 -0.622 . . . . 0.0 109.525 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.09 158.13 41.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.707 -0.621 . . . . 0.0 110.632 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.0 m -101.77 -61.06 1.43 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.67 -0.644 . . . . 0.0 110.309 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -129.03 63.69 1.48 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.681 -0.637 . . . . 0.0 110.066 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.98 9.99 86.08 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 25.3 m -126.75 132.09 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.206 -1.173 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.7 124.28 38.64 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.513 -0.742 . . . . 0.0 110.215 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.86 -29.9 8.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.648 -0.657 . . . . 0.0 110.232 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.26 151.44 45.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.638 -0.663 . . . . 0.0 110.125 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.6 m -129.96 159.96 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.617 -0.677 . . . . 0.0 110.669 179.989 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -121.97 130.67 53.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.668 -0.645 . . . . 0.0 109.934 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -134.37 159.92 39.54 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.539 -0.726 . . . . 0.0 110.501 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.3 t -93.42 126.49 50.13 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.615 -0.678 . . . . 0.0 109.368 179.392 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.94 157.37 53.11 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.771 1.406 . . . . 0.0 110.599 -179.575 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.85 -25.7 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.614 -0.679 . . . . 0.0 110.387 -179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -60.02 -39.97 87.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.422 -0.799 . . . . 0.0 110.364 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.7 t -65.42 -37.47 87.04 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.12 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.421 ' HE1' ' CD2' ' A' ' 53' ' ' TRP . 95.4 mtp -60.05 -41.82 93.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.56 -0.712 . . . . 0.0 110.293 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -69.12 -40.05 78.56 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.55 -0.719 . . . . 0.0 110.104 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.75 -40.08 93.87 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.673 -0.642 . . . . 0.0 109.92 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.2 m -59.95 -41.06 91.03 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.558 -0.714 . . . . 0.0 110.189 -179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.04 -46.45 89.47 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.642 -0.661 . . . . 0.0 110.176 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 61.3 ttt85 -69.98 -40.02 75.59 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.652 -0.655 . . . . 0.0 110.001 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.52 -24.27 66.36 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.579 -0.701 . . . . 0.0 110.6 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 58.3 m -60.05 -39.98 87.82 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.397 -0.815 . . . . 0.0 110.327 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -106.18 110.01 22.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.577 -0.702 . . . . 0.0 110.031 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 29.9 tptp -155.79 140.98 17.5 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.602 -0.686 . . . . 0.0 110.131 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 10.4 ptmm? -150.03 160.04 43.93 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.679 . . . . 0.0 110.258 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.255 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -100.66 129.95 46.64 Favored 'General case' 0 N--CA 1.491 1.598 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.136 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.414 HD21 ' CG ' ' A' ' 57' ' ' HIS . 10.4 mp -62.59 140.01 58.64 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.622 -0.674 . . . . 0.0 110.165 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.436 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.56 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.091 0.472 . . . . 0.0 110.19 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.03 69.97 0.04 OUTLIER Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 52.68 39.98 29.44 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.44 -1.035 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -105.04 109.99 22.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.642 -0.661 . . . . 0.0 110.168 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -121.57 137.18 54.84 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.553 -0.717 . . . . 0.0 110.138 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t-20 -136.75 127.48 27.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.608 -0.683 . . . . 0.0 110.228 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 52.87 92.03 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.368 -0.832 . . . . 0.0 110.659 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.0 p -60.02 -39.7 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.597 -0.689 . . . . 0.0 110.301 -179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -111.88 126.97 55.67 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.591 -0.693 . . . . 0.0 109.98 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 179.88 43.05 0.08 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -64.7 -34.33 78.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.618 -0.93 . . . . 0.0 110.201 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.67 126.91 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.537 -0.727 . . . . 0.0 109.947 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -119.12 142.91 47.5 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.555 -0.716 . . . . 0.0 110.359 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -78.39 128.83 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.604 -0.685 . . . . 0.0 110.339 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 34.4 m -122.27 146.44 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.636 -0.665 . . . . 0.0 109.593 179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.2 m -144.49 171.02 14.94 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.519 -0.738 . . . . 0.0 110.897 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.8 p -133.78 -170.92 2.6 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.93 -32.54 72.05 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.676 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 m -133.09 -11.1 2.94 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.356 -0.84 . . . . 0.0 112.639 -178.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -114.94 154.03 29.49 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.837 -1.165 . . . . 0.0 111.182 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.3 m -143.89 128.29 17.91 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.697 -0.627 . . . . 0.0 109.863 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -159.56 -178.72 7.31 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.307 -0.871 . . . . 0.0 110.469 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 69.8 mt -113.96 155.6 25.55 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.519 -0.738 . . . . 0.0 110.533 -178.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.52 160.52 33.88 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.625 -0.672 . . . . 0.0 110.304 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 87.1 m -119.97 130.78 54.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.553 -0.717 . . . . 0.0 110.142 -179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.2 t -89.34 104.03 16.62 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.541 -0.724 . . . . 0.0 110.67 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.18 130.1 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.621 -0.674 . . . . 0.0 109.492 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.21 39.55 28.67 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.428 -0.795 . . . . 0.0 110.707 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.98 19.97 75.85 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.1 t -133.73 129.98 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.224 -1.162 . . . . 0.0 110.031 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.9 m -71.57 147.52 47.56 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.437 -0.789 . . . . 0.0 109.667 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -139.71 145.47 38.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.47 -0.769 . . . . 0.0 110.867 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.452 ' CG2' ' CZ3' ' A' ' 85' ' ' TRP . 7.6 t -170.02 -178.74 2.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.723 -0.61 . . . . 0.0 109.758 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.46 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -78.22 162.13 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.524 -0.735 . . . . 0.0 110.388 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -86.97 -35.1 19.04 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.6 -0.687 . . . . 0.0 111.773 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.46 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.2 p-80 -63.34 -22.14 66.7 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.02 -1.05 . . . . 0.0 110.583 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.434 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -79.68 -60.05 2.54 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.105 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -84.12 -61.99 1.68 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.583 -0.951 . . . . 0.0 109.943 179.421 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.11 36.84 20.33 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.3 p 53.72 40.05 31.0 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.48 -1.012 . . . . 0.0 110.71 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -111.57 179.5 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.672 -0.642 . . . . 0.0 109.755 179.551 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.7 m -64.74 139.36 58.75 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.489 -0.757 . . . . 0.0 109.102 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.423 HD23 ' CD2' ' A' ' 85' ' ' TRP . 12.5 tp -119.89 138.52 53.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.488 -0.757 . . . . 0.0 110.524 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -112.53 109.52 19.15 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.635 -0.666 . . . . 0.0 109.947 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.82 -172.59 25.55 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.44 -32.34 49.89 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.88 1.463 . . . . 0.0 110.362 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -75.96 -31.12 58.89 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.561 -0.712 . . . . 0.0 109.973 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.64 -144.92 14.25 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.72 155.61 58.33 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 O-C-N 123.85 1.447 . . . . 0.0 110.303 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 83.9 mt -130.05 140.01 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.553 -0.717 . . . . 0.0 110.102 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 23.2 m -87.31 150.49 23.83 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.486 -0.758 . . . . 0.0 110.789 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 72.8 mt-30 -93.08 139.95 30.01 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.544 -0.722 . . . . 0.0 110.484 179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.8 mmm -118.45 -32.48 4.61 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.545 -0.722 . . . . 0.0 110.55 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -138.2 150.71 47.01 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.461 -0.774 . . . . 0.0 110.532 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 90.2 m -149.59 134.07 17.53 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.534 -0.729 . . . . 0.0 109.813 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.4 t-20 -141.71 100.32 3.73 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.495 -0.753 . . . . 0.0 110.424 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 74.6 t -70.0 -38.24 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.002 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -60.0 -45.36 92.99 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.544 -0.723 . . . . 0.0 110.495 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.98 2.79 54.72 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.464 -0.772 . . . . 0.0 111.121 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.7 t0 54.46 47.69 22.24 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.965 -1.084 . . . . 0.0 110.438 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 71.3 mt -140.0 143.07 36.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.547 -0.721 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.7 p -139.5 144.68 28.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.619 -0.676 . . . . 0.0 109.248 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -128.28 153.5 19.53 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.292 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.452 ' CZ3' ' CG2' ' A' ' 54' ' ' THR . 8.4 m-90 -120.21 168.07 11.6 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.693 -0.887 . . . . 0.0 109.887 179.478 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -76.73 109.11 10.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.498 -0.751 . . . . 0.0 109.349 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.03 140.66 97.93 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.473 -0.767 . . . . 0.0 110.196 -179.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.05 159.95 51.37 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.847 1.446 . . . . 0.0 110.262 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.05 157.52 59.54 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.931 1.49 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.98 30.01 70.36 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.04 140.67 47.65 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.554 -0.968 . . . . 0.0 110.221 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.89 152.8 23.3 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.53 -0.731 . . . . 0.0 109.786 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.7 p -130.0 170.04 14.48 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.536 -0.727 . . . . 0.0 110.433 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 66.6 mt -110.01 143.73 39.58 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.607 -0.683 . . . . 0.0 110.632 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 42.9 p -85.96 172.74 7.96 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.628 -0.67 . . . . 0.0 110.042 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -83.48 161.29 14.8 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.925 1.487 . . . . 0.0 110.534 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 53.2 t -77.79 129.98 36.14 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.655 -0.653 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 35.3 m -135.54 56.81 1.82 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.675 -0.64 . . . . 0.0 109.511 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 p -143.94 -4.44 0.83 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.626 -0.671 . . . . 0.0 112.288 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 39.97 96.45 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.9 m -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.53 -0.982 . . . . 0.0 110.471 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.7 p -69.97 -27.3 64.61 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.676 -0.64 . . . . 0.0 110.376 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -66.39 129.43 39.8 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 110.124 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 95.4 mt -134.96 150.0 50.3 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.699 -0.626 . . . . 0.0 110.706 -179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -117.35 123.95 47.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.556 -0.715 . . . . 0.0 109.694 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 43.1 tp -99.99 139.99 34.86 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.461 -0.775 . . . . 0.0 110.757 -179.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.11 139.96 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.671 -0.643 . . . . 0.0 109.853 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.8 p -119.59 173.14 7.18 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.524 -0.735 . . . . 0.0 110.624 -179.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 72.7 mtp180 -62.89 -25.67 68.41 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.532 -0.73 . . . . 0.0 110.627 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -92.64 24.41 3.56 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.418 -0.801 . . . . 0.0 110.922 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.1 23.09 4.97 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.237 -0.915 . . . . 0.0 110.849 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -94.85 155.44 16.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.811 . . . . 0.0 109.734 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.1 p -130.02 129.94 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.517 -0.74 . . . . 0.0 110.505 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . 0.457 HD11 HG21 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -114.38 123.31 32.63 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.614 -0.679 . . . . 0.0 109.36 179.708 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -65.35 129.55 22.99 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.79 1.416 . . . . 0.0 110.484 -179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.3 t -129.14 130.02 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.696 -0.627 . . . . 0.0 109.663 179.929 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -86.01 149.46 25.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.505 -0.747 . . . . 0.0 109.967 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 46.2 ttp180 -90.62 120.01 31.34 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.559 -0.713 . . . . 0.0 110.412 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -112.49 20.04 17.01 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.64 -0.663 . . . . 0.0 110.519 179.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.86 -179.94 40.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -62.64 -39.99 95.6 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.58 -0.953 . . . . 0.0 110.279 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 33.8 p -130.66 24.17 5.06 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.525 -0.734 . . . . 0.0 110.601 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -126.55 139.31 53.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.417 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.99 170.84 24.13 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 94.8 p -120.16 153.08 36.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.979 . . . . 0.0 110.085 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.6 tp -98.2 118.64 35.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.53 -0.732 . . . . 0.0 110.234 -179.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.3 mp -65.62 -40.04 92.14 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -110.0 110.11 58.92 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.61 -0.681 . . . . 0.0 110.138 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -64.99 115.64 3.39 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.848 1.446 . . . . 0.0 110.391 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.416 ' HD3' ' CD2' ' A' ' 134' ' ' TYR . 6.8 mtt180 -126.97 160.04 61.42 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.572 -0.705 . . . . 0.0 110.224 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.15 156.83 56.99 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 O-C-N 123.862 1.453 . . . . 0.0 110.255 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 33.8 m -59.96 -30.01 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.516 -0.74 . . . . 0.0 110.305 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -62.15 -32.37 72.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.595 -0.69 . . . . 0.0 109.924 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.422 ' CZ ' HD12 ' A' ' 135' ' ' LEU . 0.0 OUTLIER -59.98 -39.99 87.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.582 -0.699 . . . . 0.0 110.058 -179.812 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.447 ' CD2' ' CZ ' ' A' ' 154' ' ' PHE . 8.2 tp -100.22 -1.92 35.22 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.489 -0.757 . . . . 0.0 111.527 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.04 139.99 52.76 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.113 -0.992 . . . . 0.0 109.851 179.52 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 83.3 -3.2 85.51 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.4 m -107.98 15.06 24.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.099 -1.236 . . . . 0.0 110.626 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -69.92 149.92 47.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 109.345 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.09 -19.95 52.5 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.45 151.0 29.17 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -95.38 149.14 1.51 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.826 1.435 . . . . 0.0 111.187 -179.102 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 84.4 mt -101.59 108.02 19.46 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -99.98 130.02 46.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 111.401 -178.665 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.428 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.64 83.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -52.32 -22.62 16.24 Favored 'Trans proline' 0 N--CA 1.501 1.957 0 O-C-N 123.569 1.299 . . . . 0.0 112.222 -178.755 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.28 -40.0 89.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.28 -0.888 . . . . 0.0 109.959 179.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.35 35.69 0.85 Allowed Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 35.1 m170 -131.46 146.33 52.2 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.422 -1.046 . . . . 0.0 110.321 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.33 144.31 57.19 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.649 -0.657 . . . . 0.0 110.3 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 58.7 t -118.91 -39.74 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.619 -0.676 . . . . 0.0 109.931 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -167.33 33.9 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.415 HG21 HD13 ' A' ' 153' ' ' ILE . 91.0 mt -130.0 137.04 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.51 -0.994 . . . . 0.0 110.332 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . 0.447 ' CZ ' ' CD2' ' A' ' 135' ' ' LEU . 20.1 t80 -64.7 138.3 58.31 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.606 -0.684 . . . . 0.0 109.427 179.344 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -116.23 -52.43 2.59 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.537 -0.727 . . . . 0.0 110.534 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -157.45 161.62 38.92 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.563 -0.711 . . . . 0.0 110.563 -179.758 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.04 151.74 26.81 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.657 -0.652 . . . . 0.0 110.017 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -108.26 118.03 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.605 -0.685 . . . . 0.0 109.734 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -132.96 166.85 21.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.694 -0.629 . . . . 0.0 110.337 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 29.4 m -126.81 -54.24 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.498 -0.752 . . . . 0.0 110.363 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.7 mmt180 -102.04 26.76 7.24 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.537 -0.727 . . . . 0.0 110.388 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.37 -2.31 57.58 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.99 128.7 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.108 -1.231 . . . . 0.0 109.659 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.82 127.42 35.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.628 -0.67 . . . . 0.0 110.722 -179.632 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -102.82 -19.66 14.6 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.632 -0.667 . . . . 0.0 110.313 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.93 160.71 39.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.093 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.77 173.95 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.554 -0.716 . . . . 0.0 110.409 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -133.76 132.83 41.0 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.664 -0.648 . . . . 0.0 109.886 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -136.69 156.06 49.04 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.422 -0.799 . . . . 0.0 110.59 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.8 t -98.54 123.46 50.01 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.661 -0.649 . . . . 0.0 109.373 179.31 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -63.42 153.04 77.09 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.726 1.382 . . . . 0.0 110.646 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 67.2 t -57.06 -21.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.634 -0.667 . . . . 0.0 110.756 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -57.36 -37.11 72.1 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.319 -0.863 . . . . 0.0 110.615 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.5 t -60.08 -34.85 74.02 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.512 -0.742 . . . . 0.0 110.489 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 68.5 mtt -59.96 -40.02 87.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.483 -0.761 . . . . 0.0 110.495 -179.769 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.35 -40.02 89.24 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.726 . . . . 0.0 110.334 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -66.37 -39.98 89.44 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.588 -0.695 . . . . 0.0 110.108 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.2 m -60.59 -46.8 88.88 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.484 -0.76 . . . . 0.0 110.171 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -64.8 -40.05 94.6 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.521 -0.737 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 54.5 mtt180 -69.38 -39.93 77.71 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.586 -0.696 . . . . 0.0 110.305 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.1 87.94 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.569 -0.707 . . . . 0.0 110.358 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 31.4 t -118.16 87.32 2.7 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.514 -0.742 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -60.17 -40.03 88.5 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.598 -0.689 . . . . 0.0 110.162 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -121.3 130.04 53.44 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.602 -0.686 . . . . 0.0 110.137 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.2 tptt -122.92 129.98 52.27 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 110.122 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.113 179.999 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -114.09 129.92 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 118.766 -1.174 . . . . 0.0 110.112 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.412 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp -77.48 140.56 39.82 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.686 -0.634 . . . . 0.0 110.472 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.419 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.53 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.2 p . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.061 0.458 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.47 -39.98 97.06 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -118.46 139.99 50.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.568 -0.96 . . . . 0.0 110.171 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -139.74 86.2 2.09 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.542 -0.724 . . . . 0.0 110.085 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -160.0 -43.16 0.05 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.63 -0.669 . . . . 0.0 110.137 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -119.52 140.32 50.69 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.654 -0.653 . . . . 0.0 110.056 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -129.79 160.03 34.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.646 -0.659 . . . . 0.0 110.281 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 57.7 t 51.86 69.94 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.431 -0.793 . . . . 0.0 110.743 -179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -69.77 -40.05 76.32 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.58 -0.7 . . . . 0.0 110.03 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.73 147.36 4.76 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -68.73 -37.99 79.84 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.555 -0.968 . . . . 0.0 110.365 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.38 131.57 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.566 -0.709 . . . . 0.0 109.97 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -124.22 158.85 31.48 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.563 -0.711 . . . . 0.0 110.177 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.2 t -93.28 114.74 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.626 -0.671 . . . . 0.0 109.911 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.405 ' CG1' ' CD2' ' A' ' 64' ' ' LEU . 61.3 t -116.32 139.6 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 21.9 m -146.84 173.88 11.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.322 -0.861 . . . . 0.0 111.167 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.6 p -129.83 -179.17 5.04 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.836 -0.54 . . . . 0.0 109.576 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.26 -7.99 52.39 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.677 -0.639 . . . . 0.0 111.05 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -108.71 -37.61 5.85 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.118 -0.988 . . . . 0.0 111.772 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.418 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 0.4 OUTLIER -152.83 169.25 23.25 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.172 -0.955 . . . . 0.0 111.299 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 30.3 t -121.7 147.16 46.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.541 -0.725 . . . . 0.0 110.656 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 21.0 p90 -159.44 -177.72 6.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 -179.771 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 82.7 mt -113.18 157.4 21.74 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.383 -0.823 . . . . 0.0 110.225 -178.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -134.89 146.5 49.26 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.492 -0.755 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 35.2 m -100.82 124.87 47.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.639 -0.663 . . . . 0.0 110.029 179.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.9 t -87.15 103.13 15.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.584 -0.697 . . . . 0.0 110.164 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.31 130.37 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.61 -0.681 . . . . 0.0 109.631 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 37.5 t30 57.15 39.41 28.96 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.423 -0.798 . . . . 0.0 110.606 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.97 20.61 76.36 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.327 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.01 130.03 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.257 -1.143 . . . . 0.0 109.976 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -74.5 140.34 44.48 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.455 -0.778 . . . . 0.0 109.275 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 62.6 m95 -132.07 137.38 47.75 Favored 'General case' 0 N--CA 1.494 1.746 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.792 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 11.8 t -160.06 -179.65 7.96 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.452 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 13.4 p -78.94 161.28 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 111.295 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.407 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 48.8 t80 -74.12 -41.92 60.86 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.686 -0.634 . . . . 0.0 111.613 -179.171 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.452 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.3 p-80 -59.11 -24.62 63.12 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.155 -0.966 . . . . 0.0 110.707 -178.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -72.58 -50.45 15.07 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.996 -2.042 . . . . 0.0 107.996 178.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -148.58 78.23 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.752 -0.852 . . . . 0.0 109.45 179.015 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -84.63 102.82 2.59 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.294 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 21.4 p 48.97 56.03 8.38 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.68 -0.894 . . . . 0.0 111.468 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -139.82 174.76 10.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -64.91 139.2 58.74 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 120.044 -0.662 . . . . 0.0 109.6 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.418 HD21 ' CG ' ' A' ' 85' ' ' TRP . 12.0 tp -116.29 157.63 24.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.619 -0.676 . . . . 0.0 110.333 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -134.4 109.56 8.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.696 -0.628 . . . . 0.0 109.727 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.25 -164.01 15.69 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.78 -32.65 8.98 Favored 'Trans proline' 0 N--CA 1.49 1.31 0 O-C-N 123.95 1.5 . . . . 0.0 110.378 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 58.6 tptt -75.73 -31.19 59.5 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.681 -0.637 . . . . 0.0 109.823 -179.616 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.53 -149.21 20.91 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.14 141.09 20.44 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.89 1.468 . . . . 0.0 110.13 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.3 mt -130.02 140.07 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.483 -0.761 . . . . 0.0 110.259 -179.709 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.7 t -85.1 137.27 33.14 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.533 -0.729 . . . . 0.0 110.514 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.43 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 24.9 tt0 -77.12 141.14 40.32 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.509 -0.744 . . . . 0.0 110.662 -179.659 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.1 mmm -110.71 -29.02 8.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.629 -0.669 . . . . 0.0 110.365 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.0 139.99 51.64 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.492 -0.755 . . . . 0.0 110.662 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 32.0 m -137.83 136.62 37.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.549 -0.719 . . . . 0.0 110.09 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 26.4 m120 -149.75 92.15 1.88 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.528 -0.733 . . . . 0.0 110.461 -179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.407 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 92.1 t -70.0 -43.53 79.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.545 -0.722 . . . . 0.0 110.055 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -60.1 -43.77 95.33 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.482 -0.761 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 38.5 tp60 -90.11 0.08 57.34 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.553 -0.717 . . . . 0.0 110.881 -179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 4.1 t0 54.09 46.24 25.84 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.039 -1.038 . . . . 0.0 110.289 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 54.0 mt -134.03 147.58 50.97 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.514 -0.741 . . . . 0.0 110.959 -179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.413 HG23 ' CH2' ' A' ' 85' ' ' TRP . 16.1 m -150.25 168.89 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.646 -0.659 . . . . 0.0 109.786 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.425 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -163.36 157.84 30.09 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.43 ' CD1' ' HA ' ' A' ' 73' ' ' GLN . 9.9 m-90 -128.11 159.96 33.5 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.97 . . . . 0.0 109.813 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -67.13 113.06 4.78 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.521 -0.737 . . . . 0.0 109.597 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -78.35 135.16 61.65 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.522 -0.736 . . . . 0.0 110.265 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.95 159.97 51.32 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.83 1.437 . . . . 0.0 110.338 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.12 159.62 53.15 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 O-C-N 123.916 1.482 . . . . 0.0 110.286 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.17 -21.15 47.75 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.07 160.06 25.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.403 -1.057 . . . . 0.0 110.232 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 74.8 mtp85 -96.01 161.52 13.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.629 -0.669 . . . . 0.0 110.204 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 71.1 m -125.65 157.78 36.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.671 -0.643 . . . . 0.0 110.191 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 85.0 mt -110.01 132.17 54.4 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 110.559 -179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.1 p -78.04 159.95 74.73 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.601 -0.687 . . . . 0.0 110.05 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.6 163.91 28.85 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.8 1.421 . . . . 0.0 110.809 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 49.1 t -78.64 132.7 37.17 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.641 -0.662 . . . . 0.0 110.163 -179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.9 p -132.52 53.17 2.03 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.785 -0.572 . . . . 0.0 109.63 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.47 -8.48 0.76 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 119.907 -0.717 . . . . 0.0 112.412 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.03 34.21 82.56 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 80.3 p -83.62 138.13 33.49 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.51 -0.994 . . . . 0.0 110.448 -179.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.6 m -81.72 -30.98 32.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.559 -0.713 . . . . 0.0 110.385 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -69.99 130.06 41.17 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.53 -0.731 . . . . 0.0 110.187 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.1 mt -131.02 149.55 52.56 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.65 -0.656 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -119.97 113.91 21.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.52 -0.738 . . . . 0.0 109.701 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 39.7 tp -96.67 142.87 28.19 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.55 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.99 129.96 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.616 -0.677 . . . . 0.0 109.832 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 26.9 p -100.02 -172.31 2.2 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.488 -0.758 . . . . 0.0 110.567 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 86.9 mtm-85 -59.97 -28.98 68.12 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.586 -0.696 . . . . 0.0 110.57 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.26 20.04 5.45 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.603 -0.685 . . . . 0.0 111.018 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 26.33 6.7 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.115 -0.991 . . . . 0.0 110.745 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -80.07 159.99 25.95 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.605 -0.684 . . . . 0.0 109.911 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.4 t -109.97 119.95 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.569 -0.707 . . . . 0.0 109.97 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 5.3 mp -114.32 110.0 48.29 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.68 . . . . 0.0 109.69 179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.42 117.29 4.6 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.869 1.458 . . . . 0.0 110.354 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.0 t -120.05 129.13 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.701 -0.625 . . . . 0.0 109.737 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 mmm-85 -82.51 150.08 27.18 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.711 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -94.13 114.14 26.22 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -108.5 19.98 19.13 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.559 -0.713 . . . . 0.0 110.355 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.05 -178.54 40.07 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -61.32 -40.01 92.62 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.231 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.3 p -131.84 26.08 4.65 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.536 -0.728 . . . . 0.0 110.495 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.3 tpt180 -125.71 140.23 52.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.465 -0.772 . . . . 0.0 110.286 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.01 166.51 27.48 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 89.9 p -120.01 151.4 39.03 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.926 . . . . 0.0 110.265 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 tp -94.07 115.2 27.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.651 -0.656 . . . . 0.0 110.003 -179.959 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 10.2 mp -62.15 -40.05 94.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.528 -0.732 . . . . 0.0 110.449 -179.854 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 54.4 m -108.98 119.99 47.23 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -66.01 121.03 8.27 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 O-C-N 123.799 1.421 . . . . 0.0 110.537 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . 0.449 ' CD ' ' CE2' ' A' ' 134' ' ' TYR . 89.4 mtt-85 -128.88 160.44 63.32 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.618 -0.676 . . . . 0.0 110.136 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.06 163.76 32.75 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.94 1.495 . . . . 0.0 110.517 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 67.2 t -67.02 -40.04 84.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.646 -0.659 . . . . 0.0 110.344 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.9 p -53.87 -30.87 47.64 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.409 -0.807 . . . . 0.0 110.991 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . 0.449 ' CE2' ' CD ' ' A' ' 130' ' ' ARG . 36.9 t80 -60.06 -40.01 87.99 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.454 -0.779 . . . . 0.0 110.091 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.418 HD13 ' CD2' ' A' ' 134' ' ' TYR . 9.0 mp -87.92 -23.73 23.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.57 -0.706 . . . . 0.0 110.625 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.2 tptm -59.99 129.32 41.22 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.347 -0.846 . . . . 0.0 110.0 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.04 -10.05 75.3 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.2 m -104.04 16.79 25.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.164 -1.197 . . . . 0.0 110.877 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -69.94 151.82 45.18 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.08 -17.93 57.81 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.56 149.46 28.49 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 55.3 Cg_endo -98.39 146.71 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.852 1.448 . . . . 0.0 111.263 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 6.3 mp -102.69 105.52 16.0 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -93.35 130.89 38.95 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.728 . . . . 0.0 111.363 -178.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.435 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -69.98 159.31 84.71 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.99 -23.04 15.77 Favored 'Trans proline' 0 N--CA 1.502 1.993 0 O-C-N 123.418 1.22 . . . . 0.0 112.144 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -65.71 -39.99 91.77 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.335 -0.853 . . . . 0.0 109.823 179.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.71 35.3 0.85 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.0 m170 -132.72 146.02 51.51 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.456 -1.026 . . . . 0.0 110.3 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.79 140.02 58.83 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.623 -0.673 . . . . 0.0 110.201 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 47.0 t -111.1 -51.06 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.523 -0.736 . . . . 0.0 109.995 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -160.35 -172.21 27.29 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.425 HD11 HG22 ' A' ' 153' ' ' ILE . 89.6 mt -128.23 135.71 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.585 -0.95 . . . . 0.0 110.352 -179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -64.16 134.81 55.56 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 109.582 179.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.4 ttm105 -120.44 -52.45 2.15 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.489 -0.757 . . . . 0.0 110.733 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -142.25 157.29 45.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.751 . . . . 0.0 110.264 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.87 139.16 52.82 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 110.493 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -92.44 117.14 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.67 160.02 40.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.465 -0.772 . . . . 0.0 111.647 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 35.8 p -139.31 139.26 37.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.815 -0.553 . . . . 0.0 109.509 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.0 mtm180 55.62 30.87 16.18 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.466 -0.771 . . . . 0.0 110.539 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.02 22.89 64.84 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.1 t -129.53 129.73 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.341 -1.094 . . . . 0.0 109.89 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.06 129.98 46.17 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.542 -0.724 . . . . 0.0 110.5 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -118.83 -30.05 5.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.55 -0.719 . . . . 0.0 110.732 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -136.4 157.41 46.85 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.442 -0.786 . . . . 0.0 110.229 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.8 m -135.46 157.51 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.558 -0.714 . . . . 0.0 110.757 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -120.27 135.82 54.87 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.599 -0.688 . . . . 0.0 109.809 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -137.01 154.5 50.38 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.698 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 95.8 t -98.27 125.07 44.75 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.572 -0.705 . . . . 0.0 109.183 179.082 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -62.35 155.9 54.54 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 O-C-N 123.713 1.375 . . . . 0.0 110.797 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 96.3 t -56.19 -21.64 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.674 -0.641 . . . . 0.0 110.853 -179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -56.7 -37.25 70.64 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.362 -0.836 . . . . 0.0 110.768 -179.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 28.2 t -59.99 -44.54 94.45 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.392 -0.817 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 78.0 mtm -67.34 -39.92 85.85 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -60.3 -40.58 91.01 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -62.84 -40.04 96.2 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.616 -0.677 . . . . 0.0 110.055 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.5 m -60.95 -40.04 91.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.6 -0.687 . . . . 0.0 110.056 -179.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.63 -40.0 93.31 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.534 -0.729 . . . . 0.0 110.259 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 58.1 ttt180 -61.49 -40.14 93.5 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.569 -0.707 . . . . 0.0 110.13 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.91 -53.51 17.63 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 9.3 p 50.6 -166.8 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.528 -0.732 . . . . 0.0 110.97 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 54.84 -87.76 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.705 -0.622 . . . . 0.0 110.874 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 55.7 tttp 51.65 65.67 1.42 Allowed 'General case' 0 N--CA 1.501 2.107 0 O-C-N 120.997 -1.064 . . . . 0.0 110.82 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.485 -0.759 . . . . 0.0 110.265 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 54.9 tttm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.181 -179.908 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 44.4 tp10 -118.69 131.67 56.15 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 118.741 -1.184 . . . . 0.0 110.122 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . . . . . . . . . 10.7 mp -67.31 140.01 57.28 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.598 -0.689 . . . . 0.0 110.07 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.573 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.716 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.8 m . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.106 0.479 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 160.06 44.01 0.02 OUTLIER Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 84.7 mtt180 -60.07 -39.99 87.97 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.578 -0.954 . . . . 0.0 110.217 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -108.29 25.01 12.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.519 -0.738 . . . . 0.0 110.553 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -96.29 25.1 5.18 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.437 -0.79 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 18.7 p-10 -106.86 20.94 18.3 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.327 -0.858 . . . . 0.0 110.628 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -80.04 161.38 25.42 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.467 -0.771 . . . . 0.0 110.13 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.1 t -102.02 127.28 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.597 -0.689 . . . . 0.0 110.023 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.43 141.7 52.07 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.697 -0.627 . . . . 0.0 110.461 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -176.37 120.06 0.73 Allowed Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -68.74 -26.76 65.41 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.594 -0.945 . . . . 0.0 110.513 -179.811 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.3 t -109.99 127.25 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.495 -0.753 . . . . 0.0 109.695 179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -131.68 156.84 45.17 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.672 . . . . 0.0 110.376 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 32.6 m -90.08 118.58 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.705 -0.622 . . . . 0.0 110.387 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 48.2 t -114.85 141.04 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.469 -0.769 . . . . 0.0 109.288 179.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 19.3 m -146.59 -178.92 6.42 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.748 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.3 p -141.49 -168.63 2.69 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.846 -0.534 . . . . 0.0 110.239 -179.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.47 -35.11 67.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.594 -0.691 . . . . 0.0 111.511 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.4 t -137.33 -8.01 1.74 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.266 -0.896 . . . . 0.0 113.033 -178.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 19.1 tp60 -115.38 143.71 44.88 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.881 -1.137 . . . . 0.0 110.88 -179.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.9 m -129.29 138.69 51.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.749 -0.595 . . . . 0.0 109.835 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.9 p90 -166.5 -177.52 4.03 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.46 -0.775 . . . . 0.0 110.466 -179.411 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 69.2 mt -112.98 146.43 39.06 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.557 -0.714 . . . . 0.0 110.172 -178.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -128.68 161.21 30.21 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.631 -0.668 . . . . 0.0 110.261 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 8.1 t -121.3 140.55 51.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.558 -0.714 . . . . 0.0 110.146 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.9 t -97.42 110.08 22.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.579 -0.701 . . . . 0.0 110.352 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.2 130.0 62.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 109.476 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 55.67 40.0 30.89 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.483 -0.761 . . . . 0.0 110.762 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.06 22.15 77.16 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.255 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -131.84 130.0 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.235 -1.156 . . . . 0.0 110.123 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -72.09 146.0 47.83 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.452 -0.78 . . . . 0.0 109.296 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -139.97 137.2 34.53 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.357 -0.839 . . . . 0.0 111.645 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.411 HG22 ' CZ3' ' A' ' 85' ' ' TRP . 13.4 t -161.09 173.88 14.52 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.442 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.466 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 8.9 p -78.64 150.37 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.267 -0.896 . . . . 0.0 110.838 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.411 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.2 t80 -60.05 -49.2 78.59 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.58 -0.7 . . . . 0.0 111.894 -178.711 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.466 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 4.4 p-80 -57.94 -24.41 57.78 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.029 -1.044 . . . . 0.0 110.926 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -75.48 -46.31 15.51 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 178.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -136.38 94.53 3.03 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.723 -0.869 . . . . 0.0 109.433 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.73 -166.62 3.39 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.0 p -71.57 69.62 0.63 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.622 -0.928 . . . . 0.0 109.964 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.3 178.76 7.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.559 -0.713 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 31.0 p -65.54 147.38 53.51 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.713 . . . . 0.0 109.619 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.436 HD23 ' CD2' ' A' ' 85' ' ' TRP . 12.9 tp -113.1 133.4 55.03 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.611 -0.681 . . . . 0.0 109.99 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.03 109.63 21.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.617 -0.677 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.72 -171.74 17.76 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.24 -32.55 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.908 1.478 . . . . 0.0 110.456 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -76.14 -31.31 58.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.584 -0.698 . . . . 0.0 109.787 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.01 -146.15 17.24 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.7 144.43 31.4 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.895 1.471 . . . . 0.0 110.182 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.03 140.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.485 -0.759 . . . . 0.0 110.316 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.3 m -86.05 136.3 33.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.529 -0.732 . . . . 0.0 110.288 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.428 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 16.4 pt20 -83.38 149.49 26.68 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.589 -0.694 . . . . 0.0 110.959 -179.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 82.1 mtp -119.27 -18.92 8.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.666 -0.646 . . . . 0.0 110.986 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -128.12 147.98 50.56 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.245 -0.909 . . . . 0.0 110.588 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.8 p -144.49 126.0 14.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.743 -0.598 . . . . 0.0 109.975 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -142.48 90.75 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.62 -0.675 . . . . 0.0 110.053 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.411 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 86.7 t -69.82 -46.69 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.579 -0.7 . . . . 0.0 109.911 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -41.82 92.85 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.594 -0.691 . . . . 0.0 110.277 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 45.3 tt0 -90.31 -0.11 57.49 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.571 -0.706 . . . . 0.0 111.149 -179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 1.6 t70 53.25 44.49 30.1 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.99 -1.069 . . . . 0.0 110.85 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 45.5 mt -132.93 146.53 51.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.3 -0.875 . . . . 0.0 111.12 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.413 HG23 ' CH2' ' A' ' 85' ' ' TRP . 30.6 m -152.83 169.58 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.65 -0.656 . . . . 0.0 109.667 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.408 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -164.9 157.78 30.35 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.436 ' CD2' HD23 ' A' ' 64' ' ' LEU . 10.2 m-90 -128.67 168.1 16.27 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.66 -0.906 . . . . 0.0 109.835 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 54.8 tp60 -70.85 119.38 14.9 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.444 -0.785 . . . . 0.0 109.375 179.056 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.52 149.91 95.58 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.532 -0.73 . . . . 0.0 110.099 -179.893 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.96 154.34 67.04 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.884 1.465 . . . . 0.0 110.369 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.42 152.98 74.97 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.941 1.495 . . . . 0.0 110.178 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 30.0 70.42 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.79 147.74 30.44 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.481 -1.011 . . . . 0.0 110.12 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.4 mtp85 -88.82 150.05 23.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.575 -0.703 . . . . 0.0 109.958 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -126.95 169.91 12.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.605 -0.685 . . . . 0.0 110.111 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.3 mt -109.15 137.4 47.11 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.581 -0.699 . . . . 0.0 110.738 -179.765 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' THR . . . . . 0.411 ' OG1' ' CE1' ' A' ' 149' ' ' HIS . 3.3 p -79.29 165.68 46.86 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.652 -0.655 . . . . 0.0 109.904 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -80.11 153.29 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.827 1.435 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.3 t -65.04 131.63 47.09 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.663 -0.648 . . . . 0.0 110.117 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.2 t -135.97 54.26 1.91 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.714 -0.616 . . . . 0.0 109.727 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.89 -7.87 0.73 Allowed 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.599 -0.688 . . . . 0.0 112.322 -179.127 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.76 33.82 87.95 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.9 p -95.8 132.46 41.01 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.543 -0.975 . . . . 0.0 110.406 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.3 m -80.0 -26.65 39.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.641 . . . . 0.0 110.409 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -66.4 129.92 41.46 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.435 -0.791 . . . . 0.0 110.296 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 95.3 mt -131.29 157.13 44.12 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.54 -0.725 . . . . 0.0 110.558 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -119.94 115.73 24.36 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.528 -0.732 . . . . 0.0 109.876 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 65.0 tp -93.37 138.28 31.86 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.578 -0.701 . . . . 0.0 110.699 -179.507 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.2 t -97.89 130.05 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.688 -0.633 . . . . 0.0 109.524 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -106.43 165.67 11.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.453 -0.779 . . . . 0.0 110.509 -179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 72.3 mtp180 -59.99 -27.34 66.78 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.627 -0.671 . . . . 0.0 110.489 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.8 t60 -94.49 29.22 2.32 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.528 -0.732 . . . . 0.0 110.62 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.28 39.95 31.3 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.236 -0.915 . . . . 0.0 110.777 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -104.62 127.62 52.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.612 -0.68 . . . . 0.0 109.972 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 120.13 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.498 -0.751 . . . . 0.0 109.993 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 40.2 pt -114.44 146.9 36.84 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.616 -0.678 . . . . 0.0 109.975 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -87.03 113.04 0.96 Allowed 'Trans proline' 0 N--CA 1.49 1.271 0 O-C-N 123.852 1.448 . . . . 0.0 110.531 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.0 119.94 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 109.517 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -79.34 136.95 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.493 -0.754 . . . . 0.0 110.259 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -80.01 129.6 34.62 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.661 -0.649 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -124.64 23.6 8.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.544 -0.722 . . . . 0.0 110.292 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.78 -177.92 47.41 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -68.75 -39.96 80.03 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.57 -0.959 . . . . 0.0 110.429 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.7 p -129.84 26.18 5.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.525 -0.735 . . . . 0.0 110.506 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.89 159.99 35.78 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.534 -0.729 . . . . 0.0 110.253 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -153.1 172.72 32.05 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.7 p -126.36 147.0 49.82 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.529 -0.983 . . . . 0.0 110.227 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.7 mp -99.79 121.14 40.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.547 -0.721 . . . . 0.0 110.256 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.8 mp -60.88 -40.02 91.43 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.703 . . . . 0.0 109.955 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.7 m -109.95 112.91 57.65 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.588 -0.695 . . . . 0.0 109.967 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -64.19 127.47 19.32 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 123.845 1.445 . . . . 0.0 110.515 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 31.8 mtt-85 -127.04 160.04 61.61 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.568 -0.708 . . . . 0.0 110.041 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.09 146.43 81.95 Favored 'Trans proline' 0 N--CA 1.49 1.303 0 O-C-N 123.953 1.501 . . . . 0.0 110.303 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.1 m -60.03 -27.06 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.613 -0.679 . . . . 0.0 110.547 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -59.94 -40.06 87.64 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.468 -0.77 . . . . 0.0 110.389 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -65.36 -39.94 92.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.469 -0.77 . . . . 0.0 110.116 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.404 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 4.5 mm? -70.36 -27.16 64.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.595 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -58.21 140.04 53.84 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.388 -0.82 . . . . 0.0 110.448 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 87.28 6.98 77.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 56.0 p -111.43 -4.27 14.92 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.026 -1.279 . . . . 0.0 111.245 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.3 m -59.96 140.05 56.99 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.057 -1.027 . . . . 0.0 109.777 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.32 -23.7 35.06 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.117 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.65 150.08 42.65 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -91.8 156.74 3.43 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.785 1.413 . . . . 0.0 111.571 -179.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 9.8 mp -116.4 102.99 10.01 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 9.9 mp -94.79 133.19 38.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.561 -0.712 . . . . 0.0 111.661 -178.358 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.418 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.05 159.37 84.56 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.912 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.418 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.8 Cg_endo -52.61 -26.16 28.39 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 O-C-N 123.505 1.266 . . . . 0.0 112.276 -178.643 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.2 m -62.51 -40.06 95.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.32 39.52 0.58 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . 0.411 ' CE1' ' OG1' ' A' ' 95' ' ' THR . 3.6 m-70 -137.28 144.96 42.95 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.478 -1.013 . . . . 0.0 110.039 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -66.62 140.01 57.91 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.552 -0.717 . . . . 0.0 110.244 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 63.0 t -112.63 -36.25 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.581 -0.7 . . . . 0.0 109.814 -179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.91 -168.51 38.75 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 96.7 mt -129.56 140.1 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.543 -0.975 . . . . 0.0 110.216 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -60.56 136.4 58.04 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.632 -0.667 . . . . 0.0 109.91 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.9 ttt180 -115.72 -52.22 2.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.532 -0.73 . . . . 0.0 110.369 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -156.12 160.04 39.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.529 -0.732 . . . . 0.0 110.294 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.72 151.06 28.18 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.645 -0.659 . . . . 0.0 110.311 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.91 119.51 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.672 -0.643 . . . . 0.0 109.68 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -135.02 154.38 51.74 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.634 -0.666 . . . . 0.0 110.305 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.3 m -103.02 -48.68 3.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.549 -0.72 . . . . 0.0 110.653 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.5 mtm180 -131.04 50.2 2.25 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.53 -0.731 . . . . 0.0 110.373 -179.457 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.97 -4.36 83.16 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 59.6 t -113.29 129.4 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -1.21 . . . . 0.0 109.688 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -99.97 123.95 44.77 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.589 -0.694 . . . . 0.0 110.595 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.25 -18.35 13.62 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.59 -0.694 . . . . 0.0 110.698 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.48 153.7 43.89 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.328 -0.858 . . . . 0.0 110.224 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.75 163.58 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.517 -0.74 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -122.18 134.14 54.72 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.653 -0.654 . . . . 0.0 110.224 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -132.25 157.42 44.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.44 -0.787 . . . . 0.0 110.227 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 58.0 t -93.43 120.67 66.29 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.572 -0.705 . . . . 0.0 109.589 179.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.33 148.72 84.82 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.762 1.401 . . . . 0.0 110.492 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.5 -23.58 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.734 -0.604 . . . . 0.0 110.738 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -59.51 -34.58 72.78 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.626 -179.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.7 p -69.75 -37.37 76.43 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.493 -0.755 . . . . 0.0 110.435 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 67.1 mtt -59.96 -50.01 75.43 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.458 -0.776 . . . . 0.0 110.873 -179.572 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -64.49 -29.3 70.34 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.494 -0.754 . . . . 0.0 110.359 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -60.51 -42.56 96.65 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.455 -0.778 . . . . 0.0 110.021 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -70.0 -40.8 75.07 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -63.04 -40.06 96.58 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.528 -0.732 . . . . 0.0 110.331 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -68.58 -40.0 80.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.617 -0.677 . . . . 0.0 110.314 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.96 -40.01 95.44 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.527 -0.733 . . . . 0.0 110.245 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 46.7 t -60.01 -50.02 75.39 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.496 -0.753 . . . . 0.0 110.49 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.0 pttt -69.94 -29.59 66.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.422 -0.799 . . . . 0.0 110.417 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 85.3 tttt 52.8 85.13 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.375 -0.828 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt 54.22 176.85 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.365 -0.834 . . . . 0.0 110.692 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.7 tttp . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.221 -179.947 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -119.95 138.32 53.53 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.15 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.41 HD22 ' CG ' ' A' ' 57' ' ' HIS . 9.6 mp -89.34 138.57 31.32 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.531 -0.731 . . . . 0.0 110.245 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.411 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.443 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.4 m . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.01 0.433 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.01 140.52 11.43 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -60.06 -39.94 87.75 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.473 -1.016 . . . . 0.0 110.283 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 42.8 t0 55.24 85.24 0.07 Allowed 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.367 -0.833 . . . . 0.0 110.619 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -80.01 -11.07 59.81 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.571 -0.706 . . . . 0.0 111.212 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -91.3 117.8 29.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.135 -0.978 . . . . 0.0 110.419 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 56.7 tp60 -59.97 -49.49 77.47 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.552 -0.718 . . . . 0.0 110.308 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.7 m -142.97 106.83 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.66 -0.65 . . . . 0.0 110.395 179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -69.99 -39.99 75.59 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.435 -0.79 . . . . 0.0 110.214 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.71 89.13 0.11 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -63.15 -37.23 86.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.614 -0.933 . . . . 0.0 110.298 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.34 130.04 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 109.757 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -128.03 158.56 37.59 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.54 -0.725 . . . . 0.0 110.53 -179.626 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.2 t -95.27 128.43 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 0.0 109.499 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 29.2 m -129.3 158.97 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.591 -0.693 . . . . 0.0 109.83 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -153.46 164.04 38.89 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.8 p -118.71 -169.68 1.76 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.635 -0.665 . . . . 0.0 109.598 179.376 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.99 -34.31 73.14 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.586 -0.696 . . . . 0.0 110.985 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 54.7 p -131.21 -10.69 3.71 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.184 -0.947 . . . . 0.0 112.64 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.2 tp60 -117.92 153.42 33.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.92 -1.113 . . . . 0.0 111.289 -179.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 35.2 t -138.44 138.31 38.04 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.623 -0.673 . . . . 0.0 109.736 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -167.24 -178.08 3.94 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.305 -0.872 . . . . 0.0 110.527 -179.55 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 66.4 mt -113.61 157.61 21.89 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.619 -0.676 . . . . 0.0 110.649 -178.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -135.24 162.29 32.97 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.742 -0.599 . . . . 0.0 110.112 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -124.63 139.8 53.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.3 t -97.57 113.94 25.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.411 -0.806 . . . . 0.0 110.619 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . 0.419 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 61.4 t -121.03 133.88 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.609 -0.682 . . . . 0.0 109.945 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.54 39.95 27.39 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.509 -0.745 . . . . 0.0 111.256 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.9 26.89 73.78 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 178.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 65.5 t -140.02 138.59 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.468 -1.019 . . . . 0.0 109.696 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -81.07 147.37 30.16 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 109.298 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . 0.447 ' CG ' ' CE ' ' A' ' 175' ' ' MET . 61.1 m95 -130.13 153.06 48.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.455 -0.778 . . . . 0.0 110.868 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.454 ' CG2' ' CH2' ' A' ' 85' ' ' TRP . 5.5 t -169.62 -179.5 3.39 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.468 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 9.1 p -95.25 144.87 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.476 -0.765 . . . . 0.0 110.473 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.413 ' CZ ' HG23 ' A' ' 78' ' ' VAL . 64.9 t80 -60.47 -42.59 96.54 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.716 -0.615 . . . . 0.0 111.694 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.468 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.9 p-80 -70.02 -20.14 63.28 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.043 -1.036 . . . . 0.0 110.895 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -89.19 -43.32 5.34 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 178.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.6 85.05 2.19 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.668 -0.901 . . . . 0.0 109.804 179.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.2 -168.8 1.55 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.5 p -72.78 67.45 0.81 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.618 -0.93 . . . . 0.0 109.707 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -140.02 169.78 17.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.622 -0.674 . . . . 0.0 110.476 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.9 m -65.53 139.58 58.49 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.676 -0.64 . . . . 0.0 110.088 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.469 ' CD2' ' CH2' ' A' ' 85' ' ' TRP . 16.4 tp -115.3 133.47 56.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.625 -0.672 . . . . 0.0 109.801 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.78 119.37 30.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.555 -0.716 . . . . 0.0 110.334 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -125.42 176.37 17.25 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.03 -32.18 75.92 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.788 1.415 . . . . 0.0 110.455 -179.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.2 mmtt -70.21 -31.39 68.81 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.555 -0.716 . . . . 0.0 109.782 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.31 -151.12 22.38 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.87 154.65 63.26 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.886 1.466 . . . . 0.0 110.131 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.41 HG22 HD11 ' A' ' 71' ' ' ILE . 86.0 mt -129.98 139.91 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.56 -0.713 . . . . 0.0 110.675 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.5 m -100.57 138.8 37.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.589 -0.694 . . . . 0.0 110.274 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 143.81 51.91 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.562 -0.711 . . . . 0.0 110.817 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' MET . . . . . 0.417 ' HB3' ' CD2' ' A' ' 75' ' ' TYR . 5.5 mtp -119.16 -50.03 2.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.532 -0.73 . . . . 0.0 110.452 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . 0.417 ' CD2' ' HB3' ' A' ' 74' ' ' MET . 98.8 m-85 -120.0 140.01 51.61 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.754 . . . . 0.0 110.462 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 24.5 m -136.03 133.02 37.0 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.556 -0.715 . . . . 0.0 110.411 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.7 t30 -145.83 100.56 3.43 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.495 -0.753 . . . . 0.0 109.98 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.413 HG23 ' CZ ' ' A' ' 56' ' ' TYR . 59.8 t -69.98 -36.66 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.543 -0.723 . . . . 0.0 110.312 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -59.95 -50.0 75.48 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.469 -0.77 . . . . 0.0 110.981 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.5 mm-40 -90.47 0.15 57.43 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.466 -0.771 . . . . 0.0 111.309 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 2.6 t70 55.33 40.09 31.41 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.921 -1.112 . . . . 0.0 109.747 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -125.24 132.34 52.98 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.671 -0.643 . . . . 0.0 110.742 -179.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.406 ' CG2' HG23 ' A' ' 54' ' ' THR . 27.1 m -145.08 157.16 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.645 -0.659 . . . . 0.0 109.462 179.05 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -144.84 175.03 24.72 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.594 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.469 ' CH2' ' CD2' ' A' ' 64' ' ' LEU . 8.5 m-90 -130.04 159.97 35.11 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.916 -0.755 . . . . 0.0 109.631 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -66.53 123.33 19.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.365 -0.834 . . . . 0.0 109.152 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -79.37 139.74 55.89 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.504 -0.747 . . . . 0.0 110.193 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.98 159.17 54.2 Favored 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.824 1.434 . . . . 0.0 110.4 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.52 136.1 27.76 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.961 1.506 . . . . 0.0 110.286 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.13 -24.16 33.39 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -60.1 140.01 57.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.374 -1.074 . . . . 0.0 110.3 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -80.91 158.9 25.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.635 -0.666 . . . . 0.0 109.659 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.8 p -130.49 168.93 16.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.521 -0.737 . . . . 0.0 110.325 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.5 mt -112.94 140.01 48.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.561 -0.712 . . . . 0.0 110.702 -179.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 44.6 p -82.1 165.54 42.4 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.647 -0.658 . . . . 0.0 110.142 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -81.63 162.04 19.14 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.797 1.42 . . . . 0.0 110.662 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -73.66 130.16 39.45 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.64 -0.662 . . . . 0.0 110.137 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.97 54.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.741 -0.599 . . . . 0.0 109.816 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.73 -8.49 0.73 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.713 . . . . 0.0 112.383 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 42.85 97.29 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -100.0 119.97 39.1 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.522 -0.987 . . . . 0.0 110.531 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.9 m -62.78 -40.08 96.19 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.649 -0.657 . . . . 0.0 110.296 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -63.41 130.47 44.57 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.583 -0.698 . . . . 0.0 110.261 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 95.8 mt -137.97 155.37 48.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.617 -0.677 . . . . 0.0 110.577 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -106.69 135.58 47.98 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.465 -0.772 . . . . 0.0 109.545 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 39.8 tp -105.09 127.21 52.79 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.449 -0.782 . . . . 0.0 110.747 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 140.03 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.536 -0.727 . . . . 0.0 109.777 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.2 m -130.07 170.06 14.49 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.524 -0.735 . . . . 0.0 110.516 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 44.2 mtm180 -60.04 -23.2 63.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.51 -0.744 . . . . 0.0 110.781 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.11 19.37 5.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.395 -0.816 . . . . 0.0 111.194 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.49 39.9 30.63 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.077 -1.015 . . . . 0.0 110.693 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -113.27 157.65 21.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.533 -0.729 . . . . 0.0 109.955 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.4 m -129.43 133.68 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.52 -0.738 . . . . 0.0 110.371 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . 0.457 HD13 HG22 ' A' ' 114' ' ' ILE . 49.0 mm -122.48 147.82 51.16 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.602 -0.687 . . . . 0.0 109.701 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -82.65 129.75 5.74 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.906 1.477 . . . . 0.0 110.378 179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.0 t -130.0 130.02 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.697 -0.627 . . . . 0.0 109.602 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 54.2 mmm-85 -79.53 153.1 29.78 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.517 -0.74 . . . . 0.0 110.276 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 51.4 ttt-85 -99.34 119.07 37.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.64 -0.662 . . . . 0.0 109.921 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.1 mmm-85 -114.6 24.34 11.93 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.671 -0.643 . . . . 0.0 110.219 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 162.07 -175.41 38.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -64.57 -39.97 94.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.53 -0.982 . . . . 0.0 110.378 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 52.8 p -130.87 28.87 4.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.543 -0.723 . . . . 0.0 110.753 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.6 tpp85 -132.44 146.63 52.09 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.422 -0.799 . . . . 0.0 110.656 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -160.69 169.83 36.48 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 53.3 p -109.24 158.38 17.91 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.468 -1.019 . . . . 0.0 110.234 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.7 tp -102.02 119.94 39.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.541 -0.725 . . . . 0.0 110.152 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 7.6 mp -65.44 -40.04 92.79 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.988 179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.8 109.94 59.35 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -66.14 118.68 5.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.82 1.432 . . . . 0.0 110.415 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -120.04 160.01 44.75 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.598 -0.689 . . . . 0.0 110.127 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.2 157.93 54.93 Favored 'Trans proline' 0 N--CA 1.491 1.352 0 O-C-N 123.919 1.484 . . . . 0.0 110.242 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 63.4 t -67.13 -30.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.601 -0.687 . . . . 0.0 110.191 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.6 p -60.04 -39.74 86.97 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.515 -0.74 . . . . 0.0 110.414 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -64.35 -40.02 95.03 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.566 -0.709 . . . . 0.0 110.222 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.4 ' N ' ' CD2' ' A' ' 135' ' ' LEU . 4.5 mm? -70.02 -30.75 68.14 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.453 -0.779 . . . . 0.0 110.555 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -60.04 142.75 53.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.469 -0.769 . . . . 0.0 110.218 -179.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.96 8.72 87.41 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 17.5 m -113.37 -7.73 13.47 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.182 -1.187 . . . . 0.0 110.966 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 30.6 t -59.92 140.33 56.76 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.091 -1.005 . . . . 0.0 109.99 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 102.3 -21.23 42.05 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -61.45 145.05 48.85 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -86.88 142.16 6.52 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.836 1.44 . . . . 0.0 111.262 -179.457 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . . . . . . . . . 9.7 mp -101.25 122.09 43.04 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.0 mp -112.13 133.77 54.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.474 -0.766 . . . . 0.0 111.537 -178.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.428 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.08 160.03 82.1 Favored Pre-proline 0 N--CA 1.497 1.912 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.072 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . 0.428 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -52.13 -23.02 16.32 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 O-C-N 123.464 1.244 . . . . 0.0 112.235 -178.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -65.84 -40.01 91.34 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.325 -0.859 . . . . 0.0 109.854 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.99 34.33 0.91 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -131.68 145.52 51.69 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.464 -1.021 . . . . 0.0 110.326 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.29 137.19 46.55 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.545 -0.722 . . . . 0.0 110.265 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 9.2 p -115.54 -22.49 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.536 -0.728 . . . . 0.0 110.696 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.65 -170.93 43.51 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 63.5 mt -129.93 140.03 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.595 -0.944 . . . . 0.0 110.055 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 20.7 t80 -61.64 138.24 58.29 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.652 -0.655 . . . . 0.0 109.911 179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -118.49 -52.3 2.37 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.545 -0.722 . . . . 0.0 110.563 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.11 160.39 42.9 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.57 -0.706 . . . . 0.0 110.403 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -114.94 147.58 39.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.599 -0.688 . . . . 0.0 110.384 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.01 120.03 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.677 -0.64 . . . . 0.0 109.642 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -125.93 143.99 50.86 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.645 -0.659 . . . . 0.0 110.631 -179.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 58.6 m -82.01 -56.42 3.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.663 . . . . 0.0 110.44 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 mmt180 -134.7 58.0 1.79 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.529 -0.732 . . . . 0.0 110.08 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.4 -10.0 75.76 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.86 121.35 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.128 -1.219 . . . . 0.0 109.688 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -78.83 128.3 33.18 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.631 -0.668 . . . . 0.0 110.552 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -111.5 -25.97 9.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.639 -0.663 . . . . 0.0 110.398 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.36 159.17 42.78 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.585 -0.697 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.8 160.01 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.539 -0.726 . . . . 0.0 111.006 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -121.76 133.88 54.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.682 -0.636 . . . . 0.0 110.055 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -138.18 151.44 47.71 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.421 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 57.3 t -88.09 123.42 68.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.497 -0.752 . . . . 0.0 109.505 179.505 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.34 155.13 71.76 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.764 1.402 . . . . 0.0 110.56 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 88.9 t -58.24 -21.74 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.681 -0.637 . . . . 0.0 110.654 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -57.64 -40.01 78.27 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.268 -0.895 . . . . 0.0 110.656 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 3.4 m -73.65 -35.32 65.24 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.448 -0.783 . . . . 0.0 109.683 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.0 mtp -63.14 -40.48 97.71 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.66 -0.65 . . . . 0.0 110.133 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -69.54 -39.92 77.17 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.611 -0.681 . . . . 0.0 110.381 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.9 m -65.48 -39.97 92.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.662 -0.649 . . . . 0.0 110.075 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 90.5 m -61.72 -48.62 79.91 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.533 -0.729 . . . . 0.0 110.069 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.6 ttt -60.07 -48.47 81.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.56 -0.712 . . . . 0.0 110.308 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 58.6 ttp180 -60.11 -39.9 87.8 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.578 -0.701 . . . . 0.0 110.208 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.83 -39.96 87.84 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.587 -0.695 . . . . 0.0 110.146 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 2.3 m 52.31 40.03 28.41 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.42 -0.8 . . . . 0.0 110.821 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -102.56 140.04 37.36 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.693 . . . . 0.0 110.275 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -102.87 140.03 37.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.526 -0.734 . . . . 0.0 110.196 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt 55.37 -87.24 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.676 -0.64 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.8 tptt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.121 -0.987 . . . . 0.0 110.078 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -119.79 133.15 55.71 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 118.738 -1.185 . . . . 0.0 110.071 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.409 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.2 mp -69.99 140.05 52.87 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.407 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.4 t . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 62.75 -133.78 44.05 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 52.88 40.03 30.12 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.414 -1.051 . . . . 0.0 110.737 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -67.58 -39.69 84.85 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.542 -0.724 . . . . 0.0 110.284 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 53.1 179.31 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.431 -0.793 . . . . 0.0 110.767 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 -108.79 119.96 41.07 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.522 -0.736 . . . . 0.0 110.256 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -60.61 -40.02 90.29 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.6 -0.688 . . . . 0.0 110.476 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.3 t -117.47 120.74 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.621 -0.674 . . . . 0.0 110.092 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -112.12 -27.24 8.45 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.597 -0.689 . . . . 0.0 110.432 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.4 11.58 11.71 Favored Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.804 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . 0.403 ' HB3' ' CD2' ' A' ' 94' ' ' LEU . 45.3 mt-10 56.08 20.64 4.51 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.214 -1.168 . . . . 0.0 111.086 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 65.9 t -147.76 131.86 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.386 -0.821 . . . . 0.0 109.647 179.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -124.72 155.17 39.7 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.522 -0.736 . . . . 0.0 110.583 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.9 t -102.92 122.04 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.682 -0.636 . . . . 0.0 109.605 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.403 ' HB ' ' CD1' ' A' ' 64' ' ' LEU . 34.1 m -117.1 145.2 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.658 -0.651 . . . . 0.0 109.772 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 6.2 t -131.85 168.5 17.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.548 -0.72 . . . . 0.0 110.6 -179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.0 m -141.91 173.23 11.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.584 -0.698 . . . . 0.0 110.376 -179.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -68.88 -12.71 61.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.592 -0.692 . . . . 0.0 111.044 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 43.2 p -111.16 -41.5 4.17 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.202 -0.936 . . . . 0.0 111.088 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -157.48 168.14 28.17 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.402 -0.811 . . . . 0.0 110.831 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 80.6 p -119.85 152.64 37.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 3.7 p90 -154.26 -178.22 6.98 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.525 -0.735 . . . . 0.0 110.136 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 35.0 mt -113.49 153.76 28.16 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.487 -0.758 . . . . 0.0 110.817 -178.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -131.12 162.19 30.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.686 -0.634 . . . . 0.0 109.972 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 7.6 t -124.44 143.61 50.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.474 -0.766 . . . . 0.0 110.59 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 97.1 m -96.53 108.93 21.59 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.568 -0.707 . . . . 0.0 110.154 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.5 t -123.35 133.84 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.543 -0.723 . . . . 0.0 109.612 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 54.71 36.53 26.44 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.521 -0.737 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.03 20.02 75.96 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.38 129.97 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.226 -1.161 . . . . 0.0 110.043 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 90.7 m -74.23 149.2 40.94 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.473 -0.767 . . . . 0.0 109.527 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 77.1 m95 -136.11 151.85 50.23 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.512 -0.742 . . . . 0.0 111.069 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.469 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.4 t -168.4 -178.49 3.58 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.847 -0.533 . . . . 0.0 109.778 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.469 ' CG2' ' CE1' ' A' ' 57' ' ' HIS . 11.7 p -82.08 161.27 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.568 -0.707 . . . . 0.0 110.01 179.265 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 65.9 t80 -85.37 -34.6 21.74 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.399 -0.813 . . . . 0.0 111.796 -178.827 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.469 ' CE1' ' CG2' ' A' ' 55' ' ' VAL . 2.6 p-80 -70.01 -20.1 63.29 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.996 -1.065 . . . . 0.0 110.941 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -78.22 -51.15 5.85 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 179.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -95.16 -50.43 5.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.509 -0.995 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.3 30.81 36.03 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.0 t 56.87 40.02 29.16 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.302 -1.116 . . . . 0.0 110.283 -179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.06 178.67 4.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.69 -0.631 . . . . 0.0 109.737 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -65.46 138.79 58.34 Favored 'General case' 0 N--CA 1.494 1.726 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.181 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.403 ' CD1' ' HB ' ' A' ' 36' ' ' VAL . 0.1 OUTLIER -118.24 142.74 47.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.5 -0.75 . . . . 0.0 110.214 -179.406 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.99 115.94 30.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.645 -0.659 . . . . 0.0 109.911 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.58 174.29 15.25 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -62.78 -31.83 78.16 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.762 1.401 . . . . 0.0 110.422 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -71.93 -31.29 66.21 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.767 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.03 -147.58 19.03 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.63 151.32 64.04 Favored 'Trans proline' 0 N--CA 1.49 1.296 0 O-C-N 123.878 1.462 . . . . 0.0 110.241 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.436 ' CG2' ' CG ' ' A' ' 85' ' ' TRP . 85.8 mt -120.02 129.67 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.626 -0.671 . . . . 0.0 110.271 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.8 p -91.56 144.46 25.52 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.464 -0.772 . . . . 0.0 110.149 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . 0.422 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 0.4 OUTLIER -88.0 134.17 33.79 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.558 -0.714 . . . . 0.0 110.872 -179.566 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.1 mmm -116.57 -33.22 4.95 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.625 -0.672 . . . . 0.0 110.239 179.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -131.27 137.67 48.96 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.577 -0.702 . . . . 0.0 110.326 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 84.6 m -139.97 130.62 25.75 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.528 -0.733 . . . . 0.0 109.978 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -136.86 100.67 4.37 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.545 -0.722 . . . . 0.0 110.353 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 67.8 t -70.01 -35.55 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.594 -0.691 . . . . 0.0 110.025 179.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -60.0 -47.88 84.0 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.606 -0.684 . . . . 0.0 110.512 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.96 3.03 54.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.479 -0.763 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 9.1 t70 54.08 49.4 18.89 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.113 -0.992 . . . . 0.0 110.425 -179.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 68.4 mt -140.94 141.24 34.5 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.589 -0.694 . . . . 0.0 111.047 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -139.15 140.5 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.844 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -125.71 158.09 19.92 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.469 ' CZ3' HG21 ' A' ' 54' ' ' THR . 11.2 m-90 -119.89 167.16 12.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.681 -0.893 . . . . 0.0 109.88 179.569 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -71.19 115.86 10.83 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.605 -0.685 . . . . 0.0 109.429 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.07 146.34 94.83 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.554 -0.716 . . . . 0.0 110.187 -179.66 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.91 159.8 51.97 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.981 1.516 . . . . 0.0 110.314 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.02 151.2 61.64 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 124.019 1.536 . . . . 0.0 110.369 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.06 29.46 70.6 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.13 139.41 38.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.56 -0.965 . . . . 0.0 110.266 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -88.86 143.41 26.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.599 -0.688 . . . . 0.0 109.842 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.4 p -128.99 159.62 35.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 110.571 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . 0.403 ' CD2' ' HB3' ' A' ' 32' ' ' GLU . 3.2 mm? -79.94 160.0 26.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.608 -0.682 . . . . 0.0 110.504 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.6 p -103.08 150.31 37.73 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.681 -0.637 . . . . 0.0 109.884 179.633 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -60.53 141.32 95.03 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 O-C-N 123.783 1.412 . . . . 0.0 110.738 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 32.1 t -60.06 133.95 56.58 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.506 -0.746 . . . . 0.0 110.129 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -136.48 57.24 1.78 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.232 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.5 -8.8 0.75 Allowed 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.463 -178.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.08 44.1 96.54 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.2 m -108.36 132.59 53.59 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.537 -0.978 . . . . 0.0 110.671 -179.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -76.78 -27.26 55.21 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.661 -0.649 . . . . 0.0 110.427 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.76 129.97 41.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.463 -0.773 . . . . 0.0 110.214 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.6 mt -135.18 145.65 47.95 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.572 -0.705 . . . . 0.0 110.65 -179.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -106.93 130.79 54.54 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.524 -0.735 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 50.7 tp -108.5 143.09 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.529 -0.732 . . . . 0.0 110.682 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.02 129.97 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.666 -0.646 . . . . 0.0 109.533 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 77.3 p -102.58 176.76 5.06 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.509 -0.745 . . . . 0.0 110.791 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 11.9 ttp180 -68.44 -19.45 64.57 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.719 -0.613 . . . . 0.0 110.742 -179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -92.37 24.04 3.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.382 -0.824 . . . . 0.0 110.981 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.58 39.35 31.11 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.231 -0.918 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -114.46 159.47 20.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.592 -0.692 . . . . 0.0 109.724 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.92 136.45 58.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.539 -0.725 . . . . 0.0 110.437 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 16.6 tt -129.9 131.18 23.34 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.561 -0.712 . . . . 0.0 109.809 179.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.61 126.05 12.95 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.77 1.405 . . . . 0.0 110.552 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -124.11 129.91 73.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.785 -0.572 . . . . 0.0 109.691 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -86.77 136.57 32.95 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.446 -0.784 . . . . 0.0 109.945 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -84.38 121.43 27.53 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 110.435 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -110.03 20.06 18.33 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.642 -0.661 . . . . 0.0 110.449 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 164.85 -179.95 39.21 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -69.68 -40.08 76.58 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.482 -1.011 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 88.8 p -120.26 21.88 11.56 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.928 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -133.79 140.22 46.79 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.394 -0.816 . . . . 0.0 110.328 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.73 163.23 26.21 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -126.69 144.99 50.75 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.587 -0.949 . . . . 0.0 110.295 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 10.7 mp -100.03 129.94 46.14 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.628 -0.67 . . . . 0.0 110.44 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.6 mp -68.73 -40.03 80.1 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.642 -0.661 . . . . 0.0 109.723 179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -109.15 112.69 59.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.661 -0.65 . . . . 0.0 109.878 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.95 136.77 50.04 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.756 1.398 . . . . 0.0 110.567 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 20.1 mmt85 -129.84 160.0 67.11 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.712 . . . . 0.0 110.093 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.06 152.23 83.05 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.875 1.46 . . . . 0.0 110.375 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.3 m -64.99 -25.56 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.605 -0.684 . . . . 0.0 110.487 -179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.7 m -59.99 -40.03 87.77 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.0 110.286 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -66.64 -39.96 88.48 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.593 -0.692 . . . . 0.0 109.987 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.403 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -65.19 -34.46 78.43 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.636 -0.665 . . . . 0.0 110.264 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -60.02 142.98 53.0 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.461 -0.774 . . . . 0.0 110.324 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.97 9.73 86.37 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.146 -1.182 . . . . 0.0 110.146 -179.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 15.9 m -116.9 -6.94 11.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.266 -1.137 . . . . 0.0 110.945 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.2 t -60.06 139.95 57.14 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.208 -0.932 . . . . 0.0 110.074 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.97 -17.66 56.9 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.378 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.04 151.48 44.85 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -95.66 144.97 1.25 Allowed 'Trans proline' 0 N--CA 1.489 1.211 0 O-C-N 123.797 1.419 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.4 ' CD1' ' N ' ' A' ' 143' ' ' LEU . 9.4 mp -96.26 103.18 15.06 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.336 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 10.9 mp -82.64 159.63 22.63 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.902 0.858 . . . . 0.0 111.905 -178.006 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.15 164.27 18.9 Favored Pre-proline 0 N--CA 1.494 1.727 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.669 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -65.71 -30.57 50.39 Favored 'Trans proline' 0 N--CA 1.49 1.272 0 O-C-N 123.922 1.485 . . . . 0.0 108.378 177.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -70.0 -36.72 75.36 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.01 41.98 0.53 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -130.01 145.74 51.66 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.468 -1.019 . . . . 0.0 110.651 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -69.99 140.32 52.92 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.421 -0.799 . . . . 0.0 109.867 179.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 59.3 t -112.91 -44.39 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 110.262 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.43 -179.52 44.15 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 45.9 mt -120.02 130.72 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.611 -0.935 . . . . 0.0 110.157 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -60.09 136.49 58.04 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.648 -0.657 . . . . 0.0 109.961 179.778 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -115.49 -52.73 2.64 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.526 -0.734 . . . . 0.0 110.414 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.89 158.64 44.4 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.558 -0.714 . . . . 0.0 110.23 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -109.95 148.39 31.7 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.401 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.0 t -110.03 119.99 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.732 -0.605 . . . . 0.0 109.65 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.34 148.63 52.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.608 -0.683 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 94.0 m -69.99 -47.02 63.87 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.625 -0.672 . . . . 0.0 110.018 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -164.63 53.41 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.716 -0.615 . . . . 0.0 109.84 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.66 -18.06 15.36 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.54 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.64 120.04 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.276 -1.132 . . . . 0.0 109.775 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -92.22 124.94 36.67 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.602 -0.686 . . . . 0.0 110.445 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.67 -29.16 7.22 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.693 -0.629 . . . . 0.0 110.199 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -129.89 150.15 51.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.612 -0.68 . . . . 0.0 110.053 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.3 m -130.06 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.539 -0.726 . . . . 0.0 110.653 -179.722 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -122.9 132.86 54.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.698 -0.626 . . . . 0.0 109.838 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -139.94 160.01 40.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.492 -0.755 . . . . 0.0 110.616 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 62.8 t -94.19 123.58 58.5 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.584 -0.697 . . . . 0.0 109.248 179.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -62.76 153.15 74.38 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.743 1.391 . . . . 0.0 110.65 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 69.3 t -58.09 -24.36 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.605 -0.684 . . . . 0.0 110.565 -179.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.07 -39.98 87.94 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.397 -0.815 . . . . 0.0 110.388 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 53.3 m -60.15 -40.49 90.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.462 -0.774 . . . . 0.0 110.358 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.4 mtm -70.07 -40.0 75.28 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.61 -0.681 . . . . 0.0 110.214 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.0 -40.3 88.74 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.516 -0.74 . . . . 0.0 110.25 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -63.64 -40.38 96.73 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.572 -0.705 . . . . 0.0 109.85 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -69.95 -40.16 75.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.538 -0.726 . . . . 0.0 110.076 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.7 ttm -60.45 -40.2 90.28 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.746 -0.596 . . . . 0.0 110.32 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -60.07 -40.06 88.22 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.595 -0.691 . . . . 0.0 110.166 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.25 -40.08 78.08 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.519 -0.738 . . . . 0.0 110.05 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 18.2 p 49.53 39.95 18.12 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.587 -0.696 . . . . 0.0 111.152 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.7 tttp -100.07 120.06 39.27 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.619 -0.675 . . . . 0.0 110.14 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -128.26 29.35 5.36 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.583 -0.698 . . . . 0.0 110.262 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 59.3 tptt -59.97 -39.98 87.52 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.617 -0.677 . . . . 0.0 110.223 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.9 tptt . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.123 -179.945 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -116.8 130.04 56.47 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 118.7 -1.2 . . . . 0.0 110.048 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.412 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -73.58 143.41 46.44 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 110.251 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.3 p . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.023 0.439 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 159.97 -80.02 0.16 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.0 ttt180 55.99 -87.22 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.634 -0.921 . . . . 0.0 110.665 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -111.57 24.96 12.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.01 -1.056 . . . . 0.0 110.464 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -91.85 119.98 32.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 110.325 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -149.58 88.78 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.652 -0.655 . . . . 0.0 109.96 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.61 -40.01 80.58 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.635 -0.666 . . . . 0.0 110.521 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -147.85 148.34 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.54 -0.725 . . . . 0.0 110.429 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -154.6 159.97 41.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.518 -0.738 . . . . 0.0 110.157 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 146.86 129.96 2.04 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -62.55 -37.75 87.36 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.633 -0.922 . . . . 0.0 110.005 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.91 127.53 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.607 -0.683 . . . . 0.0 109.838 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -123.95 156.56 36.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.563 -0.711 . . . . 0.0 110.288 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.3 t -89.16 119.02 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.735 -0.603 . . . . 0.0 109.834 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 58.9 t -109.23 144.43 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.2 m -144.71 164.68 30.27 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.209 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.0 p -141.53 -179.57 6.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.759 -0.588 . . . . 0.0 109.797 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.78 -6.55 49.56 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.51 -0.744 . . . . 0.0 111.119 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.1 m -105.18 -57.31 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.17 -0.956 . . . . 0.0 111.17 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' GLN . . . . . 0.415 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 2.8 pt20 -143.22 169.04 18.36 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.422 -0.799 . . . . 0.0 110.789 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 70.5 m -116.92 148.46 41.33 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.512 -0.743 . . . . 0.0 110.591 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 24.9 p90 -163.1 -178.05 5.79 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.445 -0.784 . . . . 0.0 110.071 -179.725 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' LEU . . . . . . . . . . . . . 62.6 mt -113.15 148.8 34.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.492 -0.755 . . . . 0.0 110.327 -178.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.3 159.74 32.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.662 -0.648 . . . . 0.0 109.937 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 58.8 m -119.93 138.78 53.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.571 -0.706 . . . . 0.0 110.546 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 45.1 m -93.14 110.97 22.47 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.644 -0.66 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.9 t -120.0 130.01 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.552 -0.718 . . . . 0.0 109.297 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.12 35.64 26.02 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.348 -0.845 . . . . 0.0 110.387 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.0 19.97 75.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -130.06 130.0 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.189 -1.183 . . . . 0.0 110.278 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 34.1 t -76.0 129.94 37.65 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.416 -0.802 . . . . 0.0 109.408 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 42.3 m95 -126.4 137.1 53.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.462 -0.774 . . . . 0.0 111.68 -179.119 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 15.1 t -161.26 -179.6 7.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.45 HG22 ' CE1' ' A' ' 57' ' ' HIS . 14.5 p -81.19 155.29 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.314 -0.866 . . . . 0.0 110.67 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' TYR . . . . . 0.424 ' CD2' ' HA2' ' A' ' 60' ' ' GLY . 59.8 t80 -71.03 -39.93 72.03 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.752 -0.593 . . . . 0.0 111.935 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' HIS . . . . . 0.45 ' CE1' HG22 ' A' ' 55' ' ' VAL . 2.8 p-80 -63.56 -24.65 67.9 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.979 -1.076 . . . . 0.0 110.833 -178.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . 0.437 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -76.18 -51.45 6.82 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -108.14 -59.69 1.82 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.958 . . . . 0.0 110.07 179.721 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . 0.424 ' HA2' ' CD2' ' A' ' 56' ' ' TYR . . . 80.6 -176.51 54.64 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.9 t -79.84 68.13 5.83 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.554 -0.968 . . . . 0.0 109.806 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -142.47 177.73 8.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.623 -0.673 . . . . 0.0 110.243 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 58.9 m -65.14 139.93 58.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 109.899 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LEU . . . . . 0.425 HD22 ' CD2' ' A' ' 85' ' ' TRP . 12.7 tp -111.74 136.58 50.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.619 -0.676 . . . . 0.0 110.262 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -102.35 109.94 21.74 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.576 -0.703 . . . . 0.0 110.068 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.51 179.96 20.4 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -64.87 -32.35 55.51 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.878 1.462 . . . . 0.0 110.336 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -75.81 -31.19 59.31 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.638 -0.664 . . . . 0.0 110.046 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.88 -150.37 22.53 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.24 144.02 45.28 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 O-C-N 123.844 1.444 . . . . 0.0 110.269 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 51.1 mm -126.57 130.02 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.633 -0.667 . . . . 0.0 110.389 -179.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.9 p -77.62 149.76 34.73 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.523 -0.736 . . . . 0.0 109.915 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -100.42 140.5 34.59 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.523 -0.735 . . . . 0.0 110.834 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.4 mmm -113.38 -25.0 9.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.702 -0.623 . . . . 0.0 110.356 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -119.96 140.01 51.58 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 110.551 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 80.6 m -149.25 130.0 14.15 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.525 -0.735 . . . . 0.0 109.954 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 -149.91 98.07 2.67 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 110.319 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' VAL . . . . . 0.409 HG21 ' CZ ' ' A' ' 56' ' ' TYR . 81.1 t -70.01 -40.45 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.541 -0.724 . . . . 0.0 110.082 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -44.8 94.25 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.57 -0.707 . . . . 0.0 110.319 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 12.3 tt0 -89.99 0.05 57.32 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.563 -0.71 . . . . 0.0 111.118 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 4.8 t0 53.58 45.14 28.75 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.059 -1.026 . . . . 0.0 110.781 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 50.8 mt -134.46 143.53 47.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.481 -0.762 . . . . 0.0 110.682 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.41 HG13 ' CH2' ' A' ' 85' ' ' TRP . 7.1 p -150.06 157.58 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . 0.423 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -152.76 160.07 28.81 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.594 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' TRP . . . . . 0.425 ' CD2' HD22 ' A' ' 64' ' ' LEU . 11.3 m-90 -127.74 154.61 45.16 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.628 -0.925 . . . . 0.0 109.735 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -63.45 116.75 5.86 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.51 -0.744 . . . . 0.0 109.574 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -77.52 135.59 64.8 Favored Pre-proline 0 N--CA 1.495 1.786 0 O-C-N 121.553 -0.717 . . . . 0.0 110.225 -179.648 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 160.0 51.23 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 123.868 1.457 . . . . 0.0 110.217 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.41 156.53 50.22 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 O-C-N 123.87 1.458 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.77 -22.04 42.94 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.97 159.99 26.09 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -1.124 . . . . 0.0 110.216 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -96.47 165.4 12.19 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.521 -0.737 . . . . 0.0 110.282 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -132.42 169.11 17.0 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.6 -0.687 . . . . 0.0 110.227 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.2 mt -119.25 138.28 53.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.547 -0.721 . . . . 0.0 110.617 -179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -82.91 166.61 34.71 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.582 -0.698 . . . . 0.0 110.144 179.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -79.18 166.12 23.05 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.868 1.457 . . . . 0.0 110.533 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 31.1 t -69.43 136.65 51.87 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.3 p -136.59 55.55 1.84 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.729 -0.607 . . . . 0.0 109.585 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 31.7 p -143.46 -8.46 0.76 Allowed 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.792 -0.763 . . . . 0.0 112.51 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.46 97.31 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.0 m -108.71 160.3 16.07 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.543 -0.975 . . . . 0.0 110.496 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -108.9 21.69 16.89 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.715 . . . . 0.0 110.798 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -99.94 120.05 39.2 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.371 -0.831 . . . . 0.0 110.051 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 56.5 mt -130.57 133.13 45.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.557 -0.714 . . . . 0.0 110.537 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.0 120.0 40.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.507 -0.745 . . . . 0.0 109.693 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.8 tp -81.79 128.35 33.92 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.481 -0.762 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -97.85 118.6 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.626 -0.672 . . . . 0.0 109.37 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.4 p -104.32 177.93 4.7 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.553 -0.717 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -60.0 -22.77 63.0 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.602 -0.686 . . . . 0.0 110.461 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.46 19.07 5.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.344 -0.848 . . . . 0.0 111.126 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.84 40.0 31.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.1 -1.0 . . . . 0.0 110.924 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -100.31 122.81 43.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.572 -0.705 . . . . 0.0 109.961 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.1 m -59.97 -39.36 79.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.577 -0.702 . . . . 0.0 110.501 -179.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 50.8 mm 51.29 92.44 0.06 OUTLIER Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.38 -0.825 . . . . 0.0 110.648 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.93 121.41 8.44 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.94 1.495 . . . . 0.0 110.656 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.5 t -127.2 129.99 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.665 -0.647 . . . . 0.0 109.52 179.726 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.5 tpt180 -86.88 132.07 33.92 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.507 -0.746 . . . . 0.0 110.125 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.09 130.64 41.39 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.512 -0.743 . . . . 0.0 110.004 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -128.49 20.43 6.17 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.542 -0.724 . . . . 0.0 110.605 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -179.43 172.41 44.31 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -59.97 -40.64 89.78 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.47 -1.018 . . . . 0.0 110.278 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -133.43 28.98 3.98 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.561 -0.712 . . . . 0.0 110.616 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 22.0 ttp180 -139.89 138.37 35.61 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.422 -0.798 . . . . 0.0 110.592 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -126.4 -176.49 14.51 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 86.8 p -133.24 150.87 51.93 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.557 -0.967 . . . . 0.0 110.211 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.3 mp -97.26 130.04 44.51 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.517 -0.739 . . . . 0.0 110.316 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.7 mp -67.64 -40.03 84.6 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.582 -0.699 . . . . 0.0 110.02 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -115.36 127.83 26.47 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -67.67 120.74 7.76 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.755 1.398 . . . . 0.0 110.468 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -120.46 160.06 45.44 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.588 -0.695 . . . . 0.0 110.009 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.68 154.19 73.66 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.956 1.503 . . . . 0.0 110.415 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.7 m -67.18 -23.28 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.661 -0.649 . . . . 0.0 110.619 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 66.5 m -59.95 -40.06 87.71 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.403 -0.81 . . . . 0.0 110.211 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -60.0 -46.72 88.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.437 -0.789 . . . . 0.0 109.644 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.405 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.99 -29.42 66.51 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.672 -0.642 . . . . 0.0 109.545 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.3 tptm -60.03 129.46 41.9 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.6 -0.688 . . . . 0.0 110.006 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.82 -8.29 80.01 Favored Glycine 0 N--CA 1.495 2.592 0 C-N-CA 120.269 -0.967 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.0 p -96.86 6.01 49.47 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.071 -1.252 . . . . 0.0 111.135 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.03 142.94 53.11 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.038 -1.039 . . . . 0.0 109.929 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.92 -14.93 63.02 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.25 145.77 44.02 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -92.03 141.54 2.46 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.859 1.452 . . . . 0.0 111.673 -179.066 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' LEU . . . . . 0.4 ' N ' ' CD1' ' A' ' 143' ' ' LEU . 9.7 mp -93.51 104.38 16.52 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 11.0 mp -81.99 157.24 24.3 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 122.082 0.944 . . . . 0.0 111.867 -177.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.57 162.2 24.13 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.496 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -63.98 -29.82 66.71 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.789 1.415 . . . . 0.0 108.577 177.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 79.6 p -70.91 -36.12 72.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 178.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.05 41.27 0.56 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -129.97 154.32 47.49 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.984 . . . . 0.0 110.592 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.32 119.55 25.81 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.504 -0.747 . . . . 0.0 109.857 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' VAL . . . . . . . . . . . . . 63.1 t -90.71 -42.01 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.566 -0.709 . . . . 0.0 110.483 -179.49 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -166.51 -168.87 29.35 Favored Glycine 0 N--CA 1.497 2.741 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.301 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ILE . . . . . 0.401 HD12 HG21 ' A' ' 153' ' ' ILE . 94.2 mt -130.37 140.01 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.591 -0.947 . . . . 0.0 110.352 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -63.44 139.69 58.8 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.679 -0.638 . . . . 0.0 109.725 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.9 ttp85 -123.14 -52.76 1.85 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.48 -0.763 . . . . 0.0 110.529 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -147.99 165.18 31.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.491 -0.755 . . . . 0.0 110.436 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.95 143.87 49.21 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.621 -0.674 . . . . 0.0 110.371 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.06 119.9 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.76 -0.587 . . . . 0.0 109.456 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.7 p -125.97 146.03 50.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.545 -0.722 . . . . 0.0 110.693 -179.706 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 39.9 m -82.89 -64.2 1.22 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.447 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 10.3 mmm180 -129.21 62.96 1.5 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.499 -0.751 . . . . 0.0 110.406 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.91 -8.76 79.22 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.621 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.2 m -115.8 131.14 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.154 -1.203 . . . . 0.0 110.299 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.34 124.93 34.4 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.638 -0.664 . . . . 0.0 110.3 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -108.79 -29.61 8.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.687 -0.633 . . . . 0.0 110.005 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -138.27 150.8 47.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -130.45 175.46 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.644 -0.66 . . . . 0.0 110.597 -179.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -131.15 131.35 44.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.682 -0.637 . . . . 0.0 109.574 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -129.48 153.07 48.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.347 -0.845 . . . . 0.0 110.528 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' VAL . . . . . . . . . . . . . 90.5 t -93.55 119.53 67.14 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.607 -0.683 . . . . 0.0 109.429 179.466 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.63 153.51 74.67 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.808 1.425 . . . . 0.0 110.578 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.3 t -62.74 -27.42 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.629 -0.67 . . . . 0.0 110.428 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -59.94 -39.31 85.1 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.591 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 85.9 p -59.96 -45.14 93.62 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.504 -0.748 . . . . 0.0 110.669 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 76.7 mtm -69.97 -40.04 75.61 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.396 -0.815 . . . . 0.0 110.38 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.01 -40.04 87.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.479 -0.763 . . . . 0.0 110.259 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.5 m -63.98 -39.99 95.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.574 -0.703 . . . . 0.0 109.881 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 88.6 m -70.05 -40.15 75.27 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.596 -0.69 . . . . 0.0 110.063 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.6 ttm -60.51 -40.06 90.05 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.648 -0.658 . . . . 0.0 110.396 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 24.7 mmt85 -67.35 -39.95 85.8 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.544 -0.722 . . . . 0.0 110.252 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -70.0 -56.2 7.6 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.51 -0.744 . . . . 0.0 110.209 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 53.01 179.24 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.437 -0.789 . . . . 0.0 110.802 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -68.07 -40.0 82.81 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.581 -0.699 . . . . 0.0 110.155 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 28.2 ttpp -120.05 140.03 51.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.566 -0.709 . . . . 0.0 110.066 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.91 139.95 34.84 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.186 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 54.8 tttm . . . . . 0 N--CA 1.493 1.723 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.127 -179.87 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -128.52 130.58 47.67 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 189' ' ' LEU . . . . . 0.41 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -70.0 141.2 52.98 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.622 -0.673 . . . . 0.0 110.188 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 190' ' ' OBF . . . . . 0.619 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 191' ' ' FE3 . . . . . 0.685 CLD1 ' N ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.104 0.478 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -103.77 129.91 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.564 -0.71 . . . . 0.0 109.868 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -116.3 158.54 23.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.561 -0.712 . . . . 0.0 110.489 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.04 121.29 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.663 -0.648 . . . . 0.0 109.597 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.407 ' HB ' HD11 ' A' ' 64' ' ' LEU . 29.7 m -118.48 142.67 32.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.699 -0.626 . . . . 0.0 109.899 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.3 t -142.05 159.67 41.76 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.516 -0.74 . . . . 0.0 111.246 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.7 p -124.56 -170.12 2.09 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -84.02 5.89 24.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.528 -0.732 . . . . 0.0 110.91 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -128.65 -38.94 1.67 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.073 -1.017 . . . . 0.0 111.191 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -149.91 170.1 19.61 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.311 -0.868 . . . . 0.0 111.159 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 47.8 m -119.75 147.35 44.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.68 -0.638 . . . . 0.0 109.792 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 10.3 p90 -156.43 -178.63 7.48 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.391 -0.818 . . . . 0.0 110.275 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.553 HD11 ' CA ' ' A' ' 109' ' ' ARG . 74.0 mt -113.89 153.35 29.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.0 110.804 -178.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.43 161.34 31.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.711 -0.618 . . . . 0.0 109.972 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -126.23 140.12 52.79 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.573 -0.705 . . . . 0.0 110.4 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 38.5 t -98.33 105.48 17.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.59 -0.693 . . . . 0.0 110.489 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.0 t -109.98 129.99 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.423 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 56.8 t30 57.98 38.36 26.82 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.439 -0.788 . . . . 0.0 110.479 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.52 19.93 76.7 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.0 t -131.99 129.97 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.137 -1.214 . . . . 0.0 110.167 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 87.5 m -75.66 148.89 38.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.516 -0.74 . . . . 0.0 109.464 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -138.2 149.95 46.29 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.448 -0.783 . . . . 0.0 111.212 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.9 t -168.65 -179.09 3.67 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.85 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.6 p -89.17 158.33 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.448 -0.783 . . . . 0.0 110.027 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.471 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.1 t80 -76.39 -39.97 52.25 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.493 -0.754 . . . . 0.0 112.066 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.85 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.3 p-80 -64.95 -24.28 67.47 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.116 -0.99 . . . . 0.0 110.567 -178.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.565 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -84.28 -56.98 2.44 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 179.093 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.562 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -96.89 -61.28 1.43 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.68 -0.894 . . . . 0.0 109.987 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.427 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 79.96 -179.39 53.26 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 78.9 p -79.33 64.59 4.26 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.596 -0.943 . . . . 0.0 109.768 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.23 167.54 21.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.62 -0.675 . . . . 0.0 110.414 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.2 t -65.39 139.32 58.54 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 109.826 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.74 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -112.83 131.13 55.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.589 -0.694 . . . . 0.0 110.291 -179.576 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.53 109.29 21.9 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.564 -0.71 . . . . 0.0 109.815 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -105.53 -165.96 23.59 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.09 -32.36 34.53 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 124.025 1.539 . . . . 0.0 110.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.62 -31.09 59.76 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.83 -140.83 10.1 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -75.02 161.36 38.83 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.819 1.431 . . . . 0.0 110.292 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.74 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.5 mt -131.53 139.37 50.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.448 -0.782 . . . . 0.0 110.439 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.0 p -81.87 150.74 27.64 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.549 -0.719 . . . . 0.0 109.946 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 78.2 mm-40 -87.42 132.3 34.03 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.484 -0.76 . . . . 0.0 110.095 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -110.01 -44.86 3.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.552 -0.718 . . . . 0.0 110.116 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' TYR . . . . . 0.432 ' CE1' ' HG3' ' A' ' 179' ' ' MET . 83.9 m-85 -130.01 150.04 51.46 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.584 -0.697 . . . . 0.0 110.507 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.6 p -148.17 136.32 21.2 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.007 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -149.98 89.32 1.59 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.471 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 63.0 t -61.3 -40.09 84.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.623 -0.673 . . . . 0.0 109.988 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -61.58 -43.91 97.99 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.508 -0.745 . . . . 0.0 110.654 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.778 ' HG2' HD12 ' A' ' 82' ' ' LEU . 12.1 tt0 -87.6 -0.01 56.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.583 -0.698 . . . . 0.0 110.749 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.48 46.5 26.05 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.06 -1.025 . . . . 0.0 110.506 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' HG2' ' A' ' 80' ' ' GLN . 40.3 mt -144.25 138.39 27.96 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.543 -0.723 . . . . 0.0 110.875 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 54' ' ' THR . 8.3 p -134.12 157.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.605 -0.684 . . . . 0.0 109.26 179.076 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -138.43 153.66 22.59 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.196 -1.161 . . . . 0.0 110.196 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 5.8 m-90 -120.99 151.67 39.46 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.776 -0.838 . . . . 0.0 110.022 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -68.51 115.85 8.39 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.538 -0.726 . . . . 0.0 109.338 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.06 130.08 90.13 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.525 -0.735 . . . . 0.0 110.262 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.04 159.99 51.21 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.831 1.437 . . . . 0.0 110.285 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.67 156.32 58.01 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.897 1.472 . . . . 0.0 110.4 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.33 26.56 59.31 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.66 152.29 30.63 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.467 -1.019 . . . . 0.0 110.143 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -92.79 168.94 10.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.566 -0.709 . . . . 0.0 110.256 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.9 p -137.84 158.71 43.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.74 -0.6 . . . . 0.0 110.228 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.473 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 51.4 mt -108.02 131.63 54.38 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.526 -0.734 . . . . 0.0 110.485 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.7 p -76.91 160.06 77.3 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.555 -0.716 . . . . 0.0 109.784 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -75.58 163.68 33.64 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.832 1.438 . . . . 0.0 110.655 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.793 ' HB2' HG12 ' A' ' 151' ' ' VAL . 49.1 t -72.69 129.53 38.44 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.694 -0.629 . . . . 0.0 110.27 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -134.68 55.6 1.89 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.716 -0.615 . . . . 0.0 109.661 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.8 p -143.88 -7.82 0.73 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 120.027 -0.669 . . . . 0.0 112.26 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.97 39.54 97.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.8 m -99.94 119.99 39.1 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.544 -0.974 . . . . 0.0 110.404 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -66.71 -39.71 88.14 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.731 -0.606 . . . . 0.0 110.442 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 139.61 57.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.531 -0.731 . . . . 0.0 110.491 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.927 HD22 HG21 ' A' ' 151' ' ' VAL . 92.8 mt -139.29 153.1 47.72 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 0.0 110.409 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -115.73 123.72 49.01 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.53 -0.731 . . . . 0.0 109.887 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.639 HD13 HD11 ' A' ' 143' ' ' LEU . 66.3 tp -99.91 133.29 44.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.592 -0.693 . . . . 0.0 110.595 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.9 t -91.57 120.05 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.677 -0.639 . . . . 0.0 109.447 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.4 m -97.99 152.35 19.36 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.462 -0.774 . . . . 0.0 110.419 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.553 ' CA ' HD11 ' A' ' 44' ' ' LEU . 28.0 ptt85 -59.08 -20.03 49.68 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.639 -0.663 . . . . 0.0 110.751 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -94.59 26.76 3.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.452 -0.78 . . . . 0.0 110.214 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.49 40.07 31.16 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.348 -0.845 . . . . 0.0 110.663 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.49 135.03 54.62 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.572 -0.705 . . . . 0.0 109.976 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.97 120.03 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.579 -0.701 . . . . 0.0 110.022 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.523 ' O ' HG23 ' A' ' 116' ' ' VAL . 49.0 mm -106.19 117.36 57.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.622 -0.674 . . . . 0.0 109.79 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -64.42 120.74 8.13 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.801 1.422 . . . . 0.0 110.374 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.6 t -119.98 126.32 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.586 -0.696 . . . . 0.0 109.796 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -86.9 130.53 34.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.553 -0.717 . . . . 0.0 109.805 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 37.5 ttp180 -73.46 126.14 29.52 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.624 -0.672 . . . . 0.0 110.338 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -120.16 23.78 10.79 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.587 -0.696 . . . . 0.0 110.209 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.38 -179.06 42.18 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -63.19 -39.96 96.13 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.571 -0.958 . . . . 0.0 110.406 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 76.9 p -132.83 22.2 4.21 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.555 -0.715 . . . . 0.0 110.786 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -124.86 138.6 54.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.346 -0.847 . . . . 0.0 110.322 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.18 169.81 23.51 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.4 p -121.25 153.51 37.55 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.62 -0.929 . . . . 0.0 110.059 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.51 HD11 HG21 ' A' ' 114' ' ' ILE . 16.8 tp -99.27 119.87 38.63 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.505 -0.747 . . . . 0.0 110.221 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -68.61 -39.01 81.04 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.544 -0.722 . . . . 0.0 110.039 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.28 116.13 55.47 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.601 -0.687 . . . . 0.0 110.064 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -65.81 116.34 3.91 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.724 1.381 . . . . 0.0 110.43 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 5.7 mtt180 -122.69 160.04 50.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.581 -0.699 . . . . 0.0 110.139 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -67.43 152.04 79.36 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 124.017 1.536 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.32 -32.15 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.568 -0.708 . . . . 0.0 110.395 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.8 t -59.96 -38.66 83.1 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.511 -0.743 . . . . 0.0 110.162 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.539 -0.726 . . . . 0.0 110.34 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -81.46 -18.35 45.59 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 0.0 111.109 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -60.4 140.02 57.4 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.183 -0.948 . . . . 0.0 110.115 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 86.37 13.64 67.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.5 p -116.13 -8.29 11.79 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.127 -1.219 . . . . 0.0 110.908 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.7 t -59.97 139.08 57.66 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.123 -0.986 . . . . 0.0 109.698 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 97.33 -23.44 35.82 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.99 151.71 47.39 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 179.505 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.47 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.9 Cg_endo -93.87 148.78 2.15 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.841 1.443 . . . . 0.0 111.427 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.903 ' O ' HG22 ' A' ' 151' ' ' VAL . 9.3 mp -104.66 130.3 52.71 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.411 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.47 131.51 56.25 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.351 -0.843 . . . . 0.0 111.549 -178.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.5 p -70.01 159.16 85.32 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 178.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.85 -26.64 24.87 Favored 'Trans proline' 0 N--CA 1.502 1.992 0 O-C-N 123.504 1.265 . . . . 0.0 112.359 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.9 m -62.63 -39.99 95.57 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.261 -0.9 . . . . 0.0 109.96 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.67 36.37 0.79 Allowed Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -132.48 149.61 52.3 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.419 -1.048 . . . . 0.0 110.128 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -70.0 142.48 52.78 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.576 -0.702 . . . . 0.0 110.45 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.927 HG21 HD22 ' A' ' 104' ' ' LEU . 34.4 m -117.17 -22.81 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.626 -0.671 . . . . 0.0 110.613 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 167.63 -169.92 41.45 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' HE1' ' A' ' 175' ' ' MET . 96.9 mt -127.84 139.94 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.517 -0.99 . . . . 0.0 110.224 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.495 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.7 t80 -65.82 136.79 56.65 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.649 -0.657 . . . . 0.0 109.981 179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -114.97 -52.39 2.69 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 0.0 110.427 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -153.72 160.02 42.17 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.463 -0.773 . . . . 0.0 110.393 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.495 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.96 151.13 27.5 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.66 -0.65 . . . . 0.0 110.203 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -108.27 119.6 58.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.666 -0.647 . . . . 0.0 109.693 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -134.1 158.96 42.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.693 -0.63 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 4.6 p -99.97 -50.68 3.92 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.71 . . . . 0.0 110.391 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -142.89 61.62 1.41 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.928 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.05 -7.47 81.57 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.8 t -116.82 125.92 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 109.905 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.81 127.86 43.2 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.592 -0.693 . . . . 0.0 110.422 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -107.14 -17.16 14.24 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.519 -0.738 . . . . 0.0 110.743 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -146.81 159.78 43.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.325 -0.859 . . . . 0.0 110.036 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -133.84 160.04 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.462 -0.774 . . . . 0.0 110.938 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.51 138.4 53.19 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.658 . . . . 0.0 110.015 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -140.3 155.65 46.75 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.404 -0.81 . . . . 0.0 110.794 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.554 HG11 HD11 ' A' ' 82' ' ' LEU . 59.3 t -94.47 126.04 49.5 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.56 -0.712 . . . . 0.0 109.459 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.46 158.58 57.03 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.795 1.419 . . . . 0.0 110.696 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 57.7 t -65.59 -24.66 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.665 -0.647 . . . . 0.0 110.478 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -58.6 -37.96 76.94 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.383 -0.823 . . . . 0.0 110.579 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 81.1 p -60.13 -34.45 73.54 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.524 -0.735 . . . . 0.0 110.417 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.431 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.3 mtt -61.14 -40.02 92.26 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.478 -0.764 . . . . 0.0 110.411 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.55 -42.14 95.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.496 -0.752 . . . . 0.0 110.495 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 75.2 p -70.03 -39.51 75.72 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.395 -0.816 . . . . 0.0 110.417 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 86.5 m -60.04 -50.03 75.32 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.432 ' HG3' ' CE1' ' A' ' 75' ' ' TYR . 59.9 ttp . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.609 -0.682 . . . . 0.0 110.239 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.427 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.9 tt0 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.1 0.476 . . . . 0.0 110.181 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.807 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.587 -0.696 . . . . 0.0 110.226 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.541 ' OE1' HD21 ' A' ' 94' ' ' LEU . 28.3 mt-10 . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 120.64 0.257 . . . . 0.0 111.171 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.02 128.41 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.113 -0.992 . . . . 0.0 109.946 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -116.31 146.29 42.54 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.588 -0.695 . . . . 0.0 109.992 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.3 t -91.55 122.81 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.615 ' HB ' HD12 ' A' ' 64' ' ' LEU . 32.7 m -115.62 140.17 38.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.734 -0.604 . . . . 0.0 109.707 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.1 m -138.4 162.87 33.35 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.562 -0.711 . . . . 0.0 110.753 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.55 -170.5 2.24 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.72 -0.612 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.08 -42.83 95.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.534 -0.728 . . . . 0.0 110.736 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.9 t -128.28 -7.66 5.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.385 -0.822 . . . . 0.0 111.849 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.8 tp60 -115.16 156.87 24.49 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.067 -1.02 . . . . 0.0 110.67 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.7 p -149.96 138.1 20.38 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.718 -0.614 . . . . 0.0 109.759 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.623 ' HZ ' HD21 ' A' ' 64' ' ' LEU . 20.0 p90 -164.39 -178.89 5.69 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.533 -0.73 . . . . 0.0 110.456 -179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.555 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.6 mt -114.3 159.2 20.46 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.476 -0.765 . . . . 0.0 110.862 -178.48 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.54 ' HB1' ' O ' ' A' ' 53' ' ' TRP . . . -139.1 162.64 34.46 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.697 -0.627 . . . . 0.0 109.989 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.5 t -122.29 140.68 52.35 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.423 -0.798 . . . . 0.0 110.673 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.3 t -98.87 104.06 16.07 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.569 -0.707 . . . . 0.0 110.109 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.61 132.77 56.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.604 -0.685 . . . . 0.0 109.899 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 54.35 39.94 31.34 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.596 -0.69 . . . . 0.0 111.016 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 20.83 76.67 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.9 t -130.0 130.0 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.249 -1.148 . . . . 0.0 109.852 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.1 t -78.93 147.31 33.08 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.483 -0.761 . . . . 0.0 109.403 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.54 ' O ' ' HB1' ' A' ' 45' ' ' ALA . 57.5 m95 -128.66 150.38 50.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.538 -0.726 . . . . 0.0 110.932 -179.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.89 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.3 t -166.11 -179.73 5.29 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.866 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -100.46 154.25 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.73 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -70.05 -40.11 75.3 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.63 -0.669 . . . . 0.0 111.811 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.866 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.1 p-80 -70.62 -22.1 62.57 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.099 -1.001 . . . . 0.0 110.843 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.699 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -93.32 -46.41 3.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.907 -1.677 . . . . 0.0 108.907 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.422 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.43 -49.31 3.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.658 -0.907 . . . . 0.0 110.334 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.49 -162.3 41.17 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.2 t -93.12 63.37 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.577 -0.955 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.92 161.77 36.78 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.58 -0.7 . . . . 0.0 110.266 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 63.1 p -65.42 139.59 58.55 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.634 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.623 HD21 ' HZ ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -112.53 141.28 46.47 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.618 -0.677 . . . . 0.0 110.011 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.27 115.16 24.49 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.511 -0.743 . . . . 0.0 110.252 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.04 176.42 16.17 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.63 -31.97 69.59 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.793 1.417 . . . . 0.0 110.29 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.63 -31.41 66.84 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.657 -0.652 . . . . 0.0 109.829 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.7 -153.71 24.32 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.02 145.0 48.78 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.918 1.483 . . . . 0.0 110.092 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.585 HG22 ' CD1' ' A' ' 85' ' ' TRP . 85.6 mt -119.99 129.49 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.608 -0.682 . . . . 0.0 110.356 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 m -85.49 130.26 34.62 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.963 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.439 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 44.8 mm-40 -55.69 139.93 43.25 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.513 -0.742 . . . . 0.0 110.917 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.0 ttt -113.68 -49.1 2.9 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.73 -0.606 . . . . 0.0 110.179 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 70.3 m-85 -120.0 140.0 51.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.588 -0.695 . . . . 0.0 110.27 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.814 ' HA ' HG12 ' A' ' 83' ' ' VAL . 26.2 m -135.78 129.36 32.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.641 -0.662 . . . . 0.0 110.215 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -142.43 96.75 3.0 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.577 -0.702 . . . . 0.0 110.226 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 76.5 t -65.7 -39.99 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.593 -0.692 . . . . 0.0 110.049 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -60.01 -49.84 76.07 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.551 -0.718 . . . . 0.0 110.816 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -89.31 -0.05 57.17 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 110.934 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.4 t70 52.79 47.41 24.74 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.0 -1.062 . . . . 0.0 110.665 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.497 HD11 HG11 ' A' ' 170' ' ' VAL . 62.8 mt -141.63 137.14 31.63 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.443 -0.786 . . . . 0.0 111.141 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.814 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.6 m -138.37 161.35 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.555 -0.716 . . . . 0.0 109.301 178.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.32 164.56 26.55 Favored Glycine 0 N--CA 1.495 2.632 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.586 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.89 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.7 m-90 -123.13 159.38 28.67 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.829 -0.806 . . . . 0.0 109.253 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -79.9 109.34 14.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.45 -0.781 . . . . 0.0 109.528 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.68 141.08 87.17 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.59 -0.694 . . . . 0.0 110.298 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.03 160.02 51.12 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.917 1.482 . . . . 0.0 110.323 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.83 160.12 42.42 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.305 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.79 29.85 64.65 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.51 144.09 34.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.533 -0.981 . . . . 0.0 110.095 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 31.8 ttt180 -84.69 128.64 34.71 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.69 -0.631 . . . . 0.0 109.703 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.4 p -111.43 162.58 14.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.593 -0.692 . . . . 0.0 110.539 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.541 HD21 ' OE1' ' A' ' 32' ' ' GLU . 16.1 mt -106.37 131.99 52.93 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.614 -0.679 . . . . 0.0 110.73 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.4 p -75.46 160.01 80.56 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.597 -0.689 . . . . 0.0 109.691 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.51 162.63 40.85 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.825 1.434 . . . . 0.0 110.772 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.711 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.6 t -79.26 130.05 35.07 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.618 -0.676 . . . . 0.0 110.101 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.56 55.6 1.88 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.651 -0.656 . . . . 0.0 109.72 179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.79 -8.02 0.74 Allowed 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 119.916 -0.714 . . . . 0.0 112.296 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.66 34.77 89.74 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 m -87.0 112.34 21.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.515 -0.991 . . . . 0.0 110.405 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -59.99 -39.97 87.56 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.6 -0.688 . . . . 0.0 110.35 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -63.15 132.88 53.27 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.613 -0.68 . . . . 0.0 110.184 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.51 ' CD2' HG21 ' A' ' 151' ' ' VAL . 91.4 mt -134.63 146.12 49.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.66 -0.65 . . . . 0.0 110.492 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.82 121.54 44.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.504 -0.748 . . . . 0.0 109.984 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.543 HD13 HD11 ' A' ' 143' ' ' LEU . 64.0 tp -95.51 137.94 33.88 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.547 -0.72 . . . . 0.0 110.408 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.24 119.96 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.598 -0.689 . . . . 0.0 109.75 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.2 p -97.74 170.07 9.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.487 -0.758 . . . . 0.0 110.573 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.555 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.9 mtp-105 -70.06 -20.19 63.25 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.646 -0.659 . . . . 0.0 110.813 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -94.32 26.59 3.28 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.323 -0.861 . . . . 0.0 110.679 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 39.03 30.46 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.273 -0.892 . . . . 0.0 110.751 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -120.14 137.08 54.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.688 -0.633 . . . . 0.0 109.723 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -120.04 143.4 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.446 -0.783 . . . . 0.0 110.67 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 46.0 pt -129.94 158.8 72.77 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.757 -0.59 . . . . 0.0 109.914 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -90.89 130.96 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.817 1.43 . . . . 0.0 110.588 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -130.1 130.01 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.699 -0.625 . . . . 0.0 109.548 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -82.81 149.28 27.29 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.507 -0.745 . . . . 0.0 110.175 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.0 ttt180 -95.56 119.94 34.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.581 -0.7 . . . . 0.0 110.123 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -110.04 19.94 18.46 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.615 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.7 179.41 42.69 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -61.47 -40.03 93.06 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.592 -0.946 . . . . 0.0 110.296 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 44.5 p -130.31 23.63 5.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.548 -0.72 . . . . 0.0 110.681 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -124.53 137.85 54.38 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.41 -0.806 . . . . 0.0 110.299 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -137.51 162.94 25.49 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 76.8 p -119.51 148.35 43.39 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.586 -0.949 . . . . 0.0 110.349 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.636 HD23 ' O ' ' A' ' 128' ' ' SER . 8.6 tp -95.27 126.84 40.86 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.595 -0.69 . . . . 0.0 110.158 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -61.26 -39.95 92.26 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.656 -0.653 . . . . 0.0 110.388 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' SER . . . . . 0.636 ' O ' HD23 ' A' ' 126' ' ' LEU . 79.4 p -120.39 149.6 50.13 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.536 -0.728 . . . . 0.0 110.339 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.411 ' HB2' ' CG2' ' A' ' 163' ' ' VAL . 48.0 Cg_endo -79.88 121.46 4.54 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.969 1.51 . . . . 0.0 110.491 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -122.16 160.56 47.07 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.565 -0.709 . . . . 0.0 110.116 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.53 150.76 80.24 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.955 1.502 . . . . 0.0 110.464 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 64.7 t -62.49 -30.18 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.628 -0.67 . . . . 0.0 109.783 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.2 m -60.03 -38.33 82.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.631 -0.668 . . . . 0.0 110.371 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -59.94 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.469 -0.77 . . . . 0.0 110.029 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.2 mp -86.94 -22.99 25.27 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.486 -0.759 . . . . 0.0 110.572 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 4.2 tptm -60.17 129.96 44.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.388 -0.82 . . . . 0.0 110.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.68 -9.84 73.19 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.1 p -89.94 -0.06 57.36 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.038 -1.272 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.1 m -59.92 139.95 57.03 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.108 -0.995 . . . . 0.0 109.765 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.17 -20.36 51.11 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.11 154.79 43.77 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.472 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.6 Cg_endo -98.01 147.49 0.73 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 O-C-N 123.803 1.423 . . . . 0.0 111.134 -179.597 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -104.41 109.19 20.95 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.738 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.4 132.15 44.09 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.503 -0.748 . . . . 0.0 111.507 -178.659 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.435 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.01 159.84 82.74 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.89 -26.58 25.0 Favored 'Trans proline' 0 N--CA 1.502 2.011 0 O-C-N 123.456 1.24 . . . . 0.0 112.266 -178.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.67 -40.1 96.01 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.181 -0.949 . . . . 0.0 109.848 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.68 36.13 0.8 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -131.81 146.37 52.1 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.459 -1.024 . . . . 0.0 110.29 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.525 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.59 143.65 57.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.554 -0.716 . . . . 0.0 110.324 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.748 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.1 t -118.25 -37.81 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.513 -0.742 . . . . 0.0 110.054 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.5 -170.39 39.04 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' CE ' ' A' ' 175' ' ' MET . 67.9 mt -127.93 133.33 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.523 -0.986 . . . . 0.0 110.24 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.619 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.2 t80 -61.78 137.04 58.21 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.607 -0.683 . . . . 0.0 109.908 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.8 ttt180 -116.88 -52.35 2.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.514 -0.742 . . . . 0.0 110.099 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.79 159.99 43.91 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.499 -0.751 . . . . 0.0 110.397 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.619 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.19 151.83 33.73 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.668 -0.645 . . . . 0.0 110.267 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -107.88 119.14 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.589 -0.694 . . . . 0.0 109.714 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.78 155.19 47.09 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.664 -0.647 . . . . 0.0 110.471 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 2.8 m -103.42 -60.31 1.58 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.57 -0.706 . . . . 0.0 110.272 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 71.8 mtt180 -127.92 66.72 1.35 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.704 -0.622 . . . . 0.0 109.933 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 71.84 22.58 78.7 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 163' ' ' VAL . 14.6 p -139.3 127.75 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.417 -1.049 . . . . 0.0 109.866 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.32 124.2 34.71 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.549 -0.719 . . . . 0.0 110.807 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -107.57 -19.93 13.4 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.694 -0.629 . . . . 0.0 110.073 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -150.04 157.36 43.06 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.454 -0.779 . . . . 0.0 109.849 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.9 m -133.03 164.3 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -0.764 . . . . 0.0 110.792 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -125.13 134.83 52.29 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.558 -0.714 . . . . 0.0 110.218 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -134.18 157.78 45.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.519 -0.738 . . . . 0.0 110.095 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.497 HG11 HD11 ' A' ' 82' ' ' LEU . 67.0 t -94.54 124.38 55.37 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.539 -0.726 . . . . 0.0 109.754 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.5 147.9 87.19 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.784 1.413 . . . . 0.0 110.41 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.5 t -59.89 -23.83 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.71 -0.619 . . . . 0.0 110.675 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -59.97 -40.75 90.12 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.372 -0.83 . . . . 0.0 110.633 -179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.8 p -70.0 -36.42 75.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.458 -0.776 . . . . 0.0 110.252 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.2 mtp -59.94 -40.09 87.76 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.604 -0.685 . . . . 0.0 110.378 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 75.3 mt-10 -64.34 -39.95 94.91 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.645 -0.659 . . . . 0.0 110.105 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -61.81 -40.0 93.71 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.67 -0.644 . . . . 0.0 110.049 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.4 m -60.12 -39.97 88.08 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.558 -0.714 . . . . 0.0 110.176 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.479 -0.763 . . . . 0.0 110.238 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.463 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.101 0.476 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.866 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp . . . . . 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 110.136 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 . . . . . 0 N--CA 1.495 1.782 0 CA-C-O 121.159 0.504 . . . . 0.0 109.827 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.14 125.72 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.548 -0.72 . . . . 0.0 109.698 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -119.32 159.6 23.83 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.714 -0.617 . . . . 0.0 110.491 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.7 t -88.29 115.43 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.62 -0.675 . . . . 0.0 109.545 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.924 HG11 HD21 ' A' ' 64' ' ' LEU . 57.6 t -110.37 148.14 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.317 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -143.63 171.25 14.43 Favored 'General case' 0 N--CA 1.494 1.745 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.408 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 15.3 p -140.44 179.34 6.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.902 -0.499 . . . . 0.0 109.997 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -75.13 -8.56 56.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.5 -0.75 . . . . 0.0 111.036 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -109.82 -43.71 3.97 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.218 -0.926 . . . . 0.0 111.64 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -148.88 177.35 9.62 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.251 -0.905 . . . . 0.0 111.296 -179.071 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.3 m -122.58 149.65 43.68 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.588 -0.695 . . . . 0.0 110.279 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.763 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.9 p90 -164.0 -177.65 5.17 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.245 -0.91 . . . . 0.0 110.461 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.594 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.2 mt -113.36 141.35 47.15 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.545 -0.722 . . . . 0.0 110.635 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.515 ' CB ' HG21 ' A' ' 36' ' ' VAL . . . -114.75 154.53 28.34 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.656 -0.652 . . . . 0.0 109.946 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.477 HG21 ' HB3' ' A' ' 142' ' ' PRO . 75.2 p -120.1 131.25 55.0 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.411 -0.806 . . . . 0.0 110.387 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.7 t -93.06 110.02 21.5 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.583 -0.698 . . . . 0.0 110.74 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.421 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.8 t -114.58 132.27 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.684 -0.635 . . . . 0.0 109.516 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.421 ' OD1' HG12 ' A' ' 48' ' ' VAL . 29.5 m120 55.56 39.0 30.96 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.516 -0.74 . . . . 0.0 110.933 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.593 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.96 19.07 75.06 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -130.67 130.01 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.267 -1.137 . . . . 0.0 109.851 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.6 m -76.79 139.53 40.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 109.443 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -133.03 136.45 45.98 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.508 -0.745 . . . . 0.0 110.898 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 45' ' ' ALA . 29.9 p -150.73 -179.85 7.61 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.746 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.6 p -88.25 150.19 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.284 -0.885 . . . . 0.0 110.238 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.423 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.3 t80 -60.06 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.571 -0.706 . . . . 0.0 111.891 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.822 ' CG ' HD23 ' B' ' 189' ' ' LEU . 5.7 p-80 -59.69 -24.29 63.83 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.09 -1.007 . . . . 0.0 110.739 -178.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.643 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.88 -42.49 20.3 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.763 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -151.24 95.45 2.17 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.771 -0.841 . . . . 0.0 109.786 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.63 -165.1 4.54 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.401 ' HB3' HG21 ' A' ' 76' ' ' THR . 88.0 p -71.15 69.79 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.621 -0.929 . . . . 0.0 109.87 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.99 179.22 6.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.562 -0.711 . . . . 0.0 110.293 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 33.0 p -64.93 139.9 58.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.646 -0.659 . . . . 0.0 109.801 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.924 HD21 HG11 ' A' ' 36' ' ' VAL . 14.8 tp -113.28 137.94 50.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.653 -0.654 . . . . 0.0 110.159 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.76 109.88 22.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.655 -0.653 . . . . 0.0 109.955 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.51 -175.07 15.84 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -64.78 -32.69 55.88 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 O-C-N 123.895 1.471 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -74.82 -31.5 61.7 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.575 -0.703 . . . . 0.0 110.06 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.41 -147.15 18.55 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.08 140.65 15.94 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.832 1.438 . . . . 0.0 110.377 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.49 140.02 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.606 -0.684 . . . . 0.0 110.351 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.6 t -93.23 133.48 36.39 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.537 -0.727 . . . . 0.0 110.439 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 34.1 tt0 -71.53 140.55 49.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.42 -0.8 . . . . 0.0 110.699 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.5 mmm -105.87 -29.1 10.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.663 -0.648 . . . . 0.0 110.323 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -118.39 139.61 51.12 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.565 -0.709 . . . . 0.0 110.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.401 HG21 ' HB3' ' A' ' 61' ' ' SER . 24.2 m -139.97 135.34 32.65 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.522 -0.736 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -150.05 98.95 2.77 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.602 -0.687 . . . . 0.0 109.897 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.42 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.3 t -69.67 -44.82 79.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.543 -0.723 . . . . 0.0 110.329 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.03 -50.02 75.38 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.553 -0.717 . . . . 0.0 110.46 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.648 ' HG2' HD12 ' A' ' 82' ' ' LEU . 1.8 tp-100 -80.41 -8.49 59.55 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.67 -0.644 . . . . 0.0 110.767 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.1 t70 56.56 45.24 22.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.173 -0.955 . . . . 0.0 110.248 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.648 HD12 ' HG2' ' A' ' 80' ' ' GLN . 75.8 mt -130.01 148.89 51.91 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.565 -0.709 . . . . 0.0 110.721 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.457 HG13 ' C ' ' A' ' 82' ' ' LEU . 32.6 m -149.97 169.92 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.66 -0.65 . . . . 0.0 109.626 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -165.05 160.31 33.58 Favored Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.845 -1.169 . . . . 0.0 110.416 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.729 ' CE2' HD22 ' A' ' 64' ' ' LEU . 16.1 m-90 -129.89 149.92 51.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.657 -0.908 . . . . 0.0 109.429 179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.9 120.13 9.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.322 -0.861 . . . . 0.0 109.63 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.593 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.73 141.64 72.5 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.588 -0.695 . . . . 0.0 110.307 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.01 160.02 51.15 Favored 'Trans proline' 0 N--CA 1.49 1.275 0 O-C-N 123.902 1.475 . . . . 0.0 110.32 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.69 143.79 38.31 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 O-C-N 123.947 1.498 . . . . 0.0 110.274 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.48 -22.08 42.75 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.17 46.95 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.286 -1.126 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -92.81 165.42 12.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.611 -0.681 . . . . 0.0 110.109 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.2 p -130.48 169.95 14.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.473 -0.767 . . . . 0.0 110.307 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -103.38 132.0 50.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.573 -0.705 . . . . 0.0 110.379 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.414 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 50.9 p -72.06 159.99 83.92 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.594 -0.691 . . . . 0.0 109.941 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -83.26 150.27 13.51 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.766 1.403 . . . . 0.0 110.698 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -65.07 132.04 48.14 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.583 -0.698 . . . . 0.0 110.196 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.7 p -135.98 53.16 1.95 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.626 -0.671 . . . . 0.0 109.765 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.9 p -143.85 -3.49 0.88 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.332 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.94 32.31 74.84 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -91.44 129.95 37.35 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.58 -0.953 . . . . 0.0 110.331 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.9 m -77.48 -30.14 52.97 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.622 -0.674 . . . . 0.0 110.315 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.56 133.77 56.42 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.54 -0.725 . . . . 0.0 110.346 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.464 ' CD2' HG21 ' A' ' 151' ' ' VAL . 90.4 mt -134.95 151.66 51.05 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.631 -0.668 . . . . 0.0 110.359 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -119.85 123.17 42.97 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.512 -0.743 . . . . 0.0 109.969 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.453 HD13 HD21 ' A' ' 143' ' ' LEU . 67.0 tp -99.64 133.06 44.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.525 -0.734 . . . . 0.0 110.461 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.3 t -95.72 119.97 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.625 -0.672 . . . . 0.0 109.582 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -92.09 168.13 11.59 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.514 -0.741 . . . . 0.0 110.476 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.594 ' HA ' HD11 ' A' ' 44' ' ' LEU . 37.1 mtp-105 -60.14 -27.3 66.96 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.614 -0.679 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.413 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -93.69 29.07 2.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.494 -0.754 . . . . 0.0 110.744 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.77 40.0 30.97 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.197 -0.939 . . . . 0.0 111.057 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -99.44 168.7 9.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.562 -0.711 . . . . 0.0 109.928 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 113' ' ' VAL . 8.8 p -130.03 129.98 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.485 -0.759 . . . . 0.0 110.328 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.574 ' O ' HG23 ' A' ' 116' ' ' VAL . 82.8 mt -121.26 104.31 40.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.576 -0.702 . . . . 0.0 109.657 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.4 105.84 0.65 Allowed 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 123.79 1.416 . . . . 0.0 110.431 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.2 t -110.04 120.02 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.625 -0.672 . . . . 0.0 109.799 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.3 tpt180 -77.75 142.78 38.49 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.459 -0.776 . . . . 0.0 109.756 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -78.01 129.97 35.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.536 -0.727 . . . . 0.0 110.379 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -128.63 22.5 5.91 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.594 -0.692 . . . . 0.0 110.328 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 172.1 -179.86 43.46 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.376 -1.489 . . . . 0.0 109.376 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -66.79 -40.05 88.01 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.496 -1.002 . . . . 0.0 110.393 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.8 p -129.79 27.34 5.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.54 -0.725 . . . . 0.0 110.532 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.09 162.91 30.47 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.437 -0.789 . . . . 0.0 110.233 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -158.77 175.69 35.76 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 77.5 p -129.21 148.85 51.19 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.607 -0.937 . . . . 0.0 110.262 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 mp -100.76 123.12 44.5 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.607 -0.683 . . . . 0.0 110.438 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.525 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -64.04 -39.96 95.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.507 -0.746 . . . . 0.0 109.781 179.594 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -107.91 112.14 61.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.619 -0.675 . . . . 0.0 109.838 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.32 128.99 22.78 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.801 1.421 . . . . 0.0 110.631 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -125.09 160.03 56.51 Favored Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.592 -0.692 . . . . 0.0 109.906 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -65.48 153.95 75.88 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.863 1.454 . . . . 0.0 110.28 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.517 HG11 ' OE1' ' B' ' 188' ' ' GLU . 79.8 t -63.54 -34.75 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.658 -0.651 . . . . 0.0 110.102 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.4 p -59.74 -36.5 76.73 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.55 -0.719 . . . . 0.0 110.466 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -59.96 -40.01 87.55 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.11 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.5 mp -85.27 -16.18 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.563 -0.711 . . . . 0.0 111.119 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.23 132.83 55.14 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.173 -0.954 . . . . 0.0 110.069 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 89.98 -6.89 82.54 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 p -93.08 -0.04 57.17 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.254 -1.145 . . . . 0.0 111.168 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.1 m -59.97 139.91 57.09 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.058 -1.026 . . . . 0.0 109.706 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.473 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.58 -19.65 53.54 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.093 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.49 167.87 3.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.477 ' HB3' HG21 ' A' ' 46' ' ' THR . 56.3 Cg_endo -106.07 149.04 0.11 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 O-C-N 123.801 1.422 . . . . 0.0 111.206 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.453 HD21 HD13 ' A' ' 106' ' ' LEU . 85.2 mt -110.01 102.51 11.24 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.513 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -98.12 133.69 42.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.517 -0.739 . . . . 0.0 111.713 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -70.0 159.41 84.38 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.88 -26.14 23.61 Favored 'Trans proline' 0 N--CA 1.501 1.946 0 O-C-N 123.423 1.223 . . . . 0.0 112.393 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.7 m -62.73 -39.99 95.81 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.262 -0.899 . . . . 0.0 110.029 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.29 36.36 0.75 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' HIS . . . . . 0.414 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 2.9 m-70 -132.26 143.25 49.78 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.423 -1.045 . . . . 0.0 110.193 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.92 142.69 58.35 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.593 -0.692 . . . . 0.0 110.332 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -114.91 -43.63 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.575 -0.703 . . . . 0.0 109.891 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.74 -170.0 33.67 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.448 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.9 mt -123.86 139.36 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.618 -0.931 . . . . 0.0 110.375 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.44 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.2 t80 -64.26 136.43 57.17 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.687 -0.633 . . . . 0.0 109.774 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.3 ttt180 -115.94 -52.27 2.62 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.32 159.95 41.47 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.618 -0.676 . . . . 0.0 110.25 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.04 150.36 34.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.602 -0.686 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.0 t -109.94 120.0 60.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.673 -0.642 . . . . 0.0 109.751 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.438 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -129.77 145.29 51.56 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.63 -0.669 . . . . 0.0 110.426 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.4 m -70.0 -48.86 56.44 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.684 -0.635 . . . . 0.0 110.119 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -162.64 54.73 0.21 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.658 -0.651 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 113.21 -17.89 21.49 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.0 t -111.68 120.52 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.226 -1.161 . . . . 0.0 109.781 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.82 123.73 37.36 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.542 -0.724 . . . . 0.0 110.527 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 52.3 mttp -108.57 -24.77 11.23 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.634 -0.666 . . . . 0.0 110.197 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.78 158.77 43.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.46 -0.775 . . . . 0.0 110.102 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 28.7 m -140.24 170.62 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.565 -0.71 . . . . 0.0 110.545 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -128.93 139.91 51.91 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.646 -0.659 . . . . 0.0 109.905 179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -138.92 157.44 46.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.533 -0.729 . . . . 0.0 110.458 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 82' ' ' LEU . 59.6 t -96.16 121.52 60.38 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.606 -0.684 . . . . 0.0 109.49 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -65.01 150.06 88.56 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.845 1.445 . . . . 0.0 110.408 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 151' ' ' VAL . 87.8 t -60.84 -25.83 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.606 -0.684 . . . . 0.0 110.529 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 65.2 mm-40 -59.97 -36.98 78.3 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.46 -0.775 . . . . 0.0 110.497 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 80.8 p -60.09 -33.12 71.66 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.427 -0.796 . . . . 0.0 110.548 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.448 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.9 mtt -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.507 -0.745 . . . . 0.0 110.541 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -60.11 -40.0 88.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.595 -0.691 . . . . 0.0 110.406 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -60.93 -40.13 92.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 110.279 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -67.11 -50.04 62.87 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.481 -0.762 . . . . 0.0 110.206 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 78.7 mtm . . . . . 0 N--CA 1.496 1.855 0 O-C-N 121.498 -0.751 . . . . 0.0 110.07 179.847 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.517 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.2 tt0 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.1 0.476 . . . . 0.0 110.086 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.822 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.625 -0.672 . . . . 0.0 110.41 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 . . . . . 0 N--CA 1.497 1.91 0 CA-C-O 121.135 0.493 . . . . 0.0 109.841 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -114.78 128.85 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.582 -0.699 . . . . 0.0 109.628 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -124.03 159.95 28.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.579 -0.701 . . . . 0.0 110.316 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -108.29 122.18 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.67 -0.644 . . . . 0.0 109.636 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.539 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.8 m -118.44 156.76 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.615 -0.678 . . . . 0.0 110.3 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 62.7 m -135.88 167.34 21.37 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.598 -0.688 . . . . 0.0 110.907 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.3 m -134.44 170.68 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.742 -0.599 . . . . 0.0 109.986 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -65.29 -16.63 63.77 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.501 -0.749 . . . . 0.0 111.109 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 m -117.39 -35.02 4.12 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.189 -0.944 . . . . 0.0 111.628 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -150.81 170.68 18.68 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.225 -0.922 . . . . 0.0 111.096 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 85.9 p -130.43 155.69 46.01 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.36 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.692 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.1 p90 -162.46 -178.33 6.2 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.383 -0.823 . . . . 0.0 110.256 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.685 HD11 ' HA ' ' A' ' 109' ' ' ARG . 73.5 mt -113.66 152.84 29.87 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.519 -0.738 . . . . 0.0 110.9 -178.399 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -132.41 161.09 34.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.662 -0.649 . . . . 0.0 110.013 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.2 t -122.95 139.0 54.52 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.572 -0.705 . . . . 0.0 110.518 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 46.4 t -93.96 104.65 16.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.36 -0.838 . . . . 0.0 110.422 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -112.44 133.35 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.692 -0.63 . . . . 0.0 109.714 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 56.97 38.25 29.26 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.502 -0.749 . . . . 0.0 110.893 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.2 27.11 74.06 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.079 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -141.79 131.85 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -1.07 . . . . 0.0 110.064 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.33 144.97 39.86 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.423 -0.798 . . . . 0.0 109.06 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -129.93 150.99 50.98 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 111.087 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.932 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -168.82 -179.78 3.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.823 -0.548 . . . . 0.0 109.574 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.811 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.5 p -90.04 160.02 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.478 -0.764 . . . . 0.0 110.218 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 60.2 t80 -73.27 -44.62 58.94 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.538 -0.726 . . . . 0.0 111.779 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.859 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.7 p-80 -60.6 -24.66 65.65 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.134 -0.979 . . . . 0.0 110.704 -178.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.584 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.7 -47.78 11.44 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 178.512 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.692 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -137.09 94.53 2.96 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.751 -0.852 . . . . 0.0 109.271 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.06 62.81 1.33 Allowed Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.8 t 53.38 39.97 30.65 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.255 -1.144 . . . . 0.0 110.809 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -110.02 179.29 4.15 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.571 -0.705 . . . . 0.0 110.021 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 87.0 m -64.9 139.13 58.73 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.866 -0.733 . . . . 0.0 109.225 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.854 HD22 ' CZ2' ' A' ' 85' ' ' TRP . 12.6 tp -125.78 133.12 52.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.549 -0.719 . . . . 0.0 110.177 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.76 113.54 25.1 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.586 -0.697 . . . . 0.0 109.922 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.43 -179.26 17.54 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -62.28 -31.13 82.02 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.871 1.459 . . . . 0.0 110.649 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -75.87 -20.19 58.28 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.563 -0.71 . . . . 0.0 110.626 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.54 -133.27 7.42 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -84.25 146.05 11.06 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.9 1.474 . . . . 0.0 110.136 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.9 mt -120.02 129.98 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.589 -0.694 . . . . 0.0 110.34 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.5 p -87.45 147.09 25.56 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.48 -0.762 . . . . 0.0 110.442 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -87.66 140.01 29.95 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.7 mmm -119.23 -41.8 2.71 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.573 -0.704 . . . . 0.0 110.422 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -120.06 140.0 51.68 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.519 -0.738 . . . . 0.0 110.684 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.489 ' HA ' HG12 ' A' ' 83' ' ' VAL . 33.4 m -139.97 130.01 24.93 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.605 -0.684 . . . . 0.0 110.09 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -142.19 98.33 3.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.499 -0.751 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 94.1 t -70.05 -40.15 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.59 -0.693 . . . . 0.0 109.96 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.1 -47.31 86.43 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.72 . . . . 0.0 110.644 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -87.14 -0.03 56.04 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.505 -0.747 . . . . 0.0 110.801 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.448 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.8 t70 52.96 45.14 29.42 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.113 -0.992 . . . . 0.0 110.543 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.952 HD11 HG11 ' A' ' 170' ' ' VAL . 64.5 mt -139.94 143.31 36.53 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.445 -0.784 . . . . 0.0 111.069 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.535 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -147.47 160.01 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.641 -0.662 . . . . 0.0 109.61 179.331 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.75 159.97 28.03 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.932 ' CH2' HG21 ' A' ' 54' ' ' THR . 15.3 m-90 -118.22 166.91 12.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.666 -0.902 . . . . 0.0 109.53 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -72.49 119.88 17.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.501 -0.749 . . . . 0.0 109.271 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.8 140.35 98.04 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.495 -0.753 . . . . 0.0 110.296 -179.462 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.96 159.98 51.29 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.926 1.487 . . . . 0.0 110.268 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.82 142.11 31.4 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.905 1.476 . . . . 0.0 110.225 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.48 29.29 49.59 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.79 152.12 26.1 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.561 -0.964 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -88.3 167.57 13.43 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.689 -0.632 . . . . 0.0 110.038 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 47.5 t -144.04 164.37 30.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.623 -0.673 . . . . 0.0 110.16 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.4 mt -110.16 149.2 30.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.601 -0.687 . . . . 0.0 110.653 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.421 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 24.5 p -89.95 177.76 2.26 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.694 -0.629 . . . . 0.0 109.984 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -88.74 159.11 6.25 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 O-C-N 123.801 1.421 . . . . 0.0 110.566 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.788 ' HB2' HG22 ' A' ' 151' ' ' VAL . 48.9 t -68.76 130.39 42.67 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.716 -0.615 . . . . 0.0 110.113 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 38.7 p -134.49 54.04 1.96 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.738 -0.601 . . . . 0.0 109.754 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.71 -5.95 0.8 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.561 -0.712 . . . . 0.0 112.37 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.98 38.2 93.84 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -100.01 122.35 42.77 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.575 -0.956 . . . . 0.0 110.463 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.4 m -69.95 -29.43 66.55 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.643 -0.66 . . . . 0.0 110.176 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -64.31 132.58 50.6 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.542 -0.724 . . . . 0.0 110.21 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.581 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.1 mt -136.63 149.95 48.27 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.554 -0.716 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.439 ' HD1' HG22 ' A' ' 113' ' ' VAL . 62.9 m-85 -112.49 120.5 41.85 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.519 -0.738 . . . . 0.0 110.057 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.2 tp -93.7 131.45 39.02 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.432 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.21 119.98 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.516 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.1 m -97.56 169.78 9.48 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.52 -0.738 . . . . 0.0 110.62 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.685 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.8 mtp-105 -62.54 -27.62 69.3 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.682 -0.636 . . . . 0.0 110.129 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -94.6 28.38 2.65 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.24 41.9 31.76 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.195 -0.94 . . . . 0.0 111.036 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -100.04 122.12 42.43 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.516 -0.74 . . . . 0.0 109.961 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.574 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -97.86 70.61 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.665 . . . . 0.0 110.308 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.427 HG23 ' O ' ' A' ' 114' ' ' ILE . 5.3 tp -70.0 129.99 90.31 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.57 -0.706 . . . . 0.0 109.862 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 114' ' ' ILE . 48.6 Cg_endo -75.71 134.33 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.781 1.411 . . . . 0.0 110.599 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.86 130.06 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.636 -0.665 . . . . 0.0 109.558 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -92.37 133.55 35.76 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.49 -0.756 . . . . 0.0 110.095 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -80.42 125.85 30.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.652 -0.655 . . . . 0.0 110.357 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -122.48 24.23 9.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.587 -0.696 . . . . 0.0 110.288 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -178.49 -177.36 47.1 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.12 -40.0 78.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.539 -0.977 . . . . 0.0 110.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.2 p -133.09 24.46 4.21 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.513 -0.742 . . . . 0.0 110.691 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.44 151.79 50.54 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.3 171.56 25.05 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.4 p -115.24 154.55 28.86 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.912 . . . . 0.0 110.04 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -99.99 119.98 39.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.51 -0.744 . . . . 0.0 110.069 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.71 -39.98 88.24 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.583 -0.698 . . . . 0.0 110.101 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.3 m -110.22 114.36 55.74 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.622 -0.674 . . . . 0.0 110.169 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.67 114.26 2.66 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.782 1.412 . . . . 0.0 110.439 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -125.59 160.08 57.6 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.628 -0.67 . . . . 0.0 110.081 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.71 157.08 53.71 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.853 1.449 . . . . 0.0 110.362 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.573 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.06 -23.89 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.595 -0.691 . . . . 0.0 110.636 -179.801 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.1 m -59.98 -39.98 87.53 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.469 -0.769 . . . . 0.0 110.328 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -59.91 -50.13 74.96 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.483 -0.761 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.462 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.93 -26.1 63.98 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.684 -0.635 . . . . 0.0 110.097 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.8 tptm -58.74 129.95 44.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.437 -0.79 . . . . 0.0 110.311 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.95 -10.06 72.39 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.407 -0.902 . . . . 0.0 110.866 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 59.5 p -94.57 -3.22 50.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.0 -1.294 . . . . 0.0 111.251 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.079 -1.013 . . . . 0.0 109.667 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.482 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.24 -22.18 38.76 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.57 155.62 44.02 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.514 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.0 Cg_endo -95.77 150.07 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.845 1.445 . . . . 0.0 111.219 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -106.61 108.99 20.78 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.8 130.28 45.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 111.579 -178.513 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.02 159.54 83.88 Favored Pre-proline 0 N--CA 1.495 1.815 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.9 -26.51 24.82 Favored 'Trans proline' 0 N--CA 1.501 1.929 0 O-C-N 123.494 1.26 . . . . 0.0 112.28 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.1 m -62.68 -39.96 95.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.258 -0.901 . . . . 0.0 109.99 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.23 35.99 0.84 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 18.9 m-70 -131.8 149.47 52.45 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.409 -1.054 . . . . 0.0 110.314 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -68.21 139.96 56.06 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.66 -0.65 . . . . 0.0 110.272 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.788 HG22 ' HB2' ' A' ' 97' ' ' CYS . 64.7 t -114.46 -36.15 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.584 -0.697 . . . . 0.0 109.99 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 179.52 -166.61 36.03 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.482 HG23 ' C ' ' A' ' 140' ' ' GLY . 96.6 mt -130.97 140.07 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.563 -0.963 . . . . 0.0 110.263 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.408 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.3 t80 -64.25 138.57 58.51 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.7 -0.625 . . . . 0.0 109.58 179.507 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -118.49 -52.25 2.37 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.473 -0.767 . . . . 0.0 110.428 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.79 160.06 43.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.593 -0.692 . . . . 0.0 110.184 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.408 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.81 151.88 26.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.616 -0.677 . . . . 0.0 110.256 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -108.47 116.97 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.662 -0.649 . . . . 0.0 109.751 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.573 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.3 p -129.88 142.39 50.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.653 -0.654 . . . . 0.0 110.254 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.1 m -69.69 -49.61 51.78 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.566 -0.709 . . . . 0.0 110.103 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -162.91 54.15 0.19 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.71 -0.619 . . . . 0.0 109.823 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 114.78 -18.51 16.89 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -112.9 120.77 63.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.29 -1.124 . . . . 0.0 109.758 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -86.61 130.1 34.62 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.549 -0.72 . . . . 0.0 110.522 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -112.47 -26.15 8.84 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.583 -0.698 . . . . 0.0 110.33 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.32 157.99 44.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.663 -0.648 . . . . 0.0 109.974 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.25 179.5 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.431 -0.793 . . . . 0.0 110.608 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -135.36 134.58 39.94 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -138.18 153.13 49.2 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.35 -0.844 . . . . 0.0 110.809 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.952 HG11 HD11 ' A' ' 82' ' ' LEU . 60.5 t -95.09 119.12 66.26 Favored Pre-proline 0 N--CA 1.493 1.675 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 179.414 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -62.38 155.23 58.75 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.771 1.406 . . . . 0.0 110.589 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 151' ' ' VAL . 93.7 t -56.78 -23.18 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.611 -0.681 . . . . 0.0 110.669 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -60.04 -33.13 71.61 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.375 -0.828 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' SER . . . . . 0.454 ' HB3' HG12 ' A' ' 170' ' ' VAL . 18.4 t -60.07 -37.99 81.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.453 -0.78 . . . . 0.0 110.393 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.481 ' HE1' HD11 ' A' ' 153' ' ' ILE . 67.6 mtt -59.97 -39.97 87.46 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.521 -0.737 . . . . 0.0 110.502 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -62.31 -39.9 94.53 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.594 -0.691 . . . . 0.0 110.189 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.6 m -70.09 -39.97 75.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.596 -0.69 . . . . 0.0 109.965 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 84.8 m -59.98 -49.54 77.25 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.588 -0.695 . . . . 0.0 110.317 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.497 1.92 0 O-C-N 121.542 -0.723 . . . . 0.0 110.295 -179.935 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.537 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.046 0.45 . . . . 0.0 110.208 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.859 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp . . . . . 0 N--CA 1.496 1.865 0 O-C-N 121.647 -0.658 . . . . 0.0 109.985 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 . . . . . 0 N--CA 1.495 1.776 0 CA-C-O 121.085 0.469 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 123.27 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.688 -0.632 . . . . 0.0 109.817 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -123.72 157.89 32.9 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.589 -0.695 . . . . 0.0 110.312 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 67.9 t -87.34 131.71 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.605 -0.685 . . . . 0.0 109.812 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.483 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.1 m -127.13 152.89 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.587 -0.696 . . . . 0.0 110.367 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 64.0 m -135.96 -177.89 4.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.705 -0.622 . . . . 0.0 110.34 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.528 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.6 OUTLIER -144.75 -169.13 3.1 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.528 ' H ' HG22 ' A' ' 38' ' ' THR . . . -59.32 -38.67 80.87 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.395 -0.816 . . . . 0.0 110.098 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.1 t -138.58 -7.22 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.443 -0.786 . . . . 0.0 112.514 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -114.55 151.39 33.44 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.868 -1.145 . . . . 0.0 111.163 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -136.09 141.49 44.22 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.584 -0.697 . . . . 0.0 110.238 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.753 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 32.8 p90 -170.32 -177.53 2.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.426 -0.796 . . . . 0.0 110.023 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.749 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.1 mt -113.13 167.9 10.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.49 -0.756 . . . . 0.0 110.253 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -145.9 160.04 42.38 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.664 -0.647 . . . . 0.0 110.265 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.447 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.8 t -120.57 140.2 51.85 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.597 -0.69 . . . . 0.0 110.18 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 37.7 t -99.23 109.96 22.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.417 -0.802 . . . . 0.0 110.407 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.19 130.03 64.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.541 -0.724 . . . . 0.0 109.701 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 56.14 39.93 30.25 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.544 -0.723 . . . . 0.0 110.868 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.741 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 19.92 75.73 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.179 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.0 t -131.06 130.01 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.267 -1.137 . . . . 0.0 109.958 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 78.4 m -77.41 140.43 39.89 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.415 -0.803 . . . . 0.0 109.461 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -130.62 147.09 52.25 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.517 -0.739 . . . . 0.0 110.936 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.794 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -167.66 -179.19 4.21 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.783 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.6 p -88.68 156.63 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 110.356 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.433 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 53.0 t80 -70.04 -44.37 69.36 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.594 -0.691 . . . . 0.0 111.887 -178.676 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.783 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.9 p-80 -60.78 -24.26 65.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.195 -0.941 . . . . 0.0 110.787 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.563 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -77.1 -48.96 7.88 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.753 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -128.49 101.09 6.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.784 -0.833 . . . . 0.0 109.534 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.26 -164.93 2.34 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 35.0 p -72.21 65.92 0.62 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.655 -0.909 . . . . 0.0 109.844 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.39 169.87 16.77 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.604 -0.685 . . . . 0.0 110.595 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.7 p -69.89 159.92 32.78 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.579 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.858 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.0 tp -115.51 140.8 48.83 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.543 -0.723 . . . . 0.0 110.335 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.91 109.7 22.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.576 -0.702 . . . . 0.0 110.109 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.63 179.98 16.32 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.99 -32.34 65.21 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.854 1.45 . . . . 0.0 110.431 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 87.0 mttt -71.08 -31.49 67.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.663 -0.648 . . . . 0.0 110.037 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.11 -162.2 25.99 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.02 137.82 38.59 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.866 1.456 . . . . 0.0 110.155 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.7 mt -120.06 130.04 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.615 -0.678 . . . . 0.0 110.49 -179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 77.8 p -80.4 149.98 29.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.927 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -100.86 144.42 29.84 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.523 -0.736 . . . . 0.0 111.218 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.442 ' HE1' ' HG3' ' A' ' 86' ' ' GLN . 30.2 mtm -117.3 -21.76 8.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.631 . . . . 0.0 110.59 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -125.57 147.44 49.28 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.417 -0.802 . . . . 0.0 110.403 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.493 ' HA ' HG12 ' A' ' 83' ' ' VAL . 6.9 t -169.32 129.72 1.08 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.59 -0.694 . . . . 0.0 109.921 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.607 -0.683 . . . . 0.0 110.258 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 69.3 t -69.8 -49.61 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.582 -0.699 . . . . 0.0 109.811 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -60.28 -48.57 81.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.606 -0.684 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.783 ' HG2' HD12 ' A' ' 82' ' ' LEU . 50.7 tt0 -79.33 -10.11 59.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.634 -0.666 . . . . 0.0 110.612 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.0 t70 54.16 49.94 17.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.15 -0.969 . . . . 0.0 110.701 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.783 HD12 ' HG2' ' A' ' 80' ' ' GLN . 39.0 mt -143.25 130.98 21.38 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.385 -0.822 . . . . 0.0 111.43 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.4 m -130.03 159.98 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.609 -0.682 . . . . 0.0 109.592 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.14 159.06 27.82 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.858 ' CH2' HD22 ' A' ' 64' ' ' LEU . 9.3 m-90 -122.52 160.03 26.46 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.747 -0.855 . . . . 0.0 109.725 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLN . . . . . 0.442 ' HG3' ' HE1' ' A' ' 74' ' ' MET . 41.5 tt0 -77.79 107.77 10.53 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.543 -0.723 . . . . 0.0 109.51 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.741 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.45 137.84 86.29 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.594 -0.691 . . . . 0.0 110.291 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.04 158.79 55.45 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 O-C-N 123.93 1.49 . . . . 0.0 110.221 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.64 146.48 61.06 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.976 1.514 . . . . 0.0 110.388 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.94 -26.37 24.72 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -68.06 140.05 56.27 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.46 -1.023 . . . . 0.0 110.119 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -81.82 158.62 24.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.522 -0.736 . . . . 0.0 109.884 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -130.07 169.76 14.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.573 -0.704 . . . . 0.0 110.167 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.551 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 45.0 mt -106.03 131.91 52.75 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.625 -0.672 . . . . 0.0 110.731 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -73.66 160.03 83.11 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.577 -0.702 . . . . 0.0 109.793 179.443 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -77.35 161.12 32.04 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.787 1.414 . . . . 0.0 110.636 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.8 t -74.07 129.91 38.77 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.722 -0.611 . . . . 0.0 110.134 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -132.85 54.12 1.97 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.679 -0.638 . . . . 0.0 109.689 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.62 -8.12 0.75 Allowed 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.371 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.97 42.57 98.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.97 119.93 39.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.525 -0.985 . . . . 0.0 110.422 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.6 m -63.31 -39.99 96.11 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 110.48 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -60.71 129.98 44.25 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.561 -0.712 . . . . 0.0 110.481 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 1.097 HD22 HG11 ' A' ' 151' ' ' VAL . 93.2 mt -133.08 150.19 52.1 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.673 -0.642 . . . . 0.0 110.404 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -115.72 121.37 42.31 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.483 -0.76 . . . . 0.0 109.948 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.431 HD13 HD11 ' A' ' 143' ' ' LEU . 44.6 tp -101.05 143.82 30.71 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.528 -0.732 . . . . 0.0 110.369 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.7 t -108.87 129.12 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.57 -0.706 . . . . 0.0 109.87 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.476 HG21 HD11 ' A' ' 114' ' ' ILE . 75.2 p -106.26 178.85 4.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.543 -0.723 . . . . 0.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.749 ' HA ' HD11 ' A' ' 44' ' ' LEU . 68.3 mtm180 -59.98 -28.26 67.53 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.594 -0.691 . . . . 0.0 110.58 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -90.3 19.08 5.39 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.467 -0.77 . . . . 0.0 111.122 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.51 40.02 30.81 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.102 -0.999 . . . . 0.0 110.706 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -100.16 139.34 35.97 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.73 -0.606 . . . . 0.0 109.936 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 64.7 t -93.74 117.39 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.624 -0.672 . . . . 0.0 109.955 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 108' ' ' THR . 86.9 mt -107.53 110.05 62.73 Favored Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.694 -0.629 . . . . 0.0 109.599 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.85 116.4 4.55 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 123.886 1.466 . . . . 0.0 110.462 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.1 t -120.01 125.2 74.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.678 -0.639 . . . . 0.0 109.643 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -86.23 130.03 34.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.572 -0.705 . . . . 0.0 109.97 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.75 127.87 33.71 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.622 -0.674 . . . . 0.0 110.376 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 12.0 mmm180 -129.68 22.21 5.47 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.665 -0.647 . . . . 0.0 110.245 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.51 -179.75 43.07 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -67.51 -40.66 85.15 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.591 -0.946 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.7 p -131.67 22.51 4.66 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.493 -0.754 . . . . 0.0 110.743 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.38 151.93 51.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.384 -0.822 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.46 -173.98 18.17 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -125.49 154.91 41.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.641 -0.917 . . . . 0.0 110.162 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 25.1 tp -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.575 -0.703 . . . . 0.0 110.207 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.489 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -68.37 -36.61 79.44 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -111.04 113.05 55.06 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.685 -0.635 . . . . 0.0 110.039 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.28 116.57 3.82 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.726 1.382 . . . . 0.0 110.545 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -128.03 160.04 63.64 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.602 -0.686 . . . . 0.0 110.082 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.71 157.09 62.77 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.907 1.477 . . . . 0.0 110.398 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.502 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.4 m -66.12 -24.78 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.614 -0.679 . . . . 0.0 110.487 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.2 t -59.88 -38.44 82.22 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.456 -0.778 . . . . 0.0 110.332 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.585 -0.697 . . . . 0.0 110.342 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 135' ' ' LEU . 10.7 mp -83.11 -16.86 45.17 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.477 -0.765 . . . . 0.0 111.038 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.59 140.01 58.83 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.269 -0.894 . . . . 0.0 110.078 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.56 6.05 89.11 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 63.2 m -112.58 19.48 17.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.129 -1.218 . . . . 0.0 110.757 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -72.28 147.91 45.94 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.304 -0.873 . . . . 0.0 109.935 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.58 -15.31 60.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.02 139.98 48.17 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -87.79 148.93 7.2 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 O-C-N 123.77 1.405 . . . . 0.0 111.224 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.868 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -105.6 120.02 40.59 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.551 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -108.77 131.18 55.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.463 -0.773 . . . . 0.0 111.704 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.453 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.97 82.09 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.4 Cg_endo -51.72 -23.12 14.8 Favored 'Trans proline' 0 N--CA 1.502 2.004 0 O-C-N 123.51 1.268 . . . . 0.0 112.272 -178.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -66.32 -39.98 89.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.247 -0.908 . . . . 0.0 109.89 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.25 34.67 0.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 19.5 m-70 -131.77 144.72 51.15 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.422 -1.046 . . . . 0.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.551 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.91 138.67 52.63 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.515 -0.74 . . . . 0.0 110.125 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 1.097 HG11 HD22 ' A' ' 104' ' ' LEU . 8.3 p -118.05 -21.87 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.591 -0.693 . . . . 0.0 110.814 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 178.68 -173.75 46.02 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.423 HG12 HG21 ' A' ' 46' ' ' THR . 95.5 mt -131.55 139.99 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.605 -0.938 . . . . 0.0 110.096 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.2 t80 -61.0 139.64 58.0 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.579 -0.7 . . . . 0.0 110.148 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -120.21 -52.02 2.19 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.59 -0.694 . . . . 0.0 110.333 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.533 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -154.24 160.55 41.87 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.571 -0.706 . . . . 0.0 110.432 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.01 153.88 23.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.552 -0.717 . . . . 0.0 110.408 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.05 119.22 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.637 -0.664 . . . . 0.0 109.888 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.502 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -137.07 158.59 44.11 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.683 . . . . 0.0 110.307 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 6.2 p -99.0 -51.95 3.7 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.595 -0.691 . . . . 0.0 110.486 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -142.94 63.06 1.39 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.565 -0.709 . . . . 0.0 110.013 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.99 -8.81 79.14 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.66 126.55 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.193 -1.181 . . . . 0.0 109.967 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.58 131.69 46.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.6 -0.687 . . . . 0.0 110.372 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -113.66 -15.42 12.49 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.565 -0.709 . . . . 0.0 110.746 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 158.71 43.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.345 -0.847 . . . . 0.0 109.846 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.04 160.01 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.523 -0.736 . . . . 0.0 110.546 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -123.04 136.11 54.71 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.732 -0.605 . . . . 0.0 109.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -139.11 160.0 40.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.497 -0.752 . . . . 0.0 110.457 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.661 HG11 HD11 ' A' ' 82' ' ' LEU . 88.6 t -99.89 124.6 43.21 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.59 -0.693 . . . . 0.0 109.553 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -65.34 147.59 87.64 Favored 'Trans proline' 0 N--CA 1.489 1.259 0 O-C-N 123.82 1.432 . . . . 0.0 110.186 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.571 HG13 ' C ' ' A' ' 151' ' ' VAL . 35.7 m -60.6 -24.68 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.68 -0.638 . . . . 0.0 110.996 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -60.5 -39.97 89.67 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.485 -0.759 . . . . 0.0 110.693 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.2 p -61.67 -43.3 99.11 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.434 -0.791 . . . . 0.0 110.906 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.444 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.1 mtm -63.54 -39.98 95.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.825 . . . . 0.0 110.456 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -60.43 -40.01 89.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.424 -0.798 . . . . 0.0 110.029 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.0 m -70.23 -26.11 63.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.632 -0.668 . . . . 0.0 110.528 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.7 m -59.94 -40.83 90.29 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.517 -0.739 . . . . 0.0 110.282 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.2 mtt . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.471 -0.768 . . . . 0.0 110.208 179.883 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.533 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 60.2 tt0 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.03 0.443 . . . . 0.0 110.131 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.771 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp . . . . . 0 N--CA 1.495 1.788 0 O-C-N 121.608 -0.682 . . . . 0.0 110.222 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.568 ' HG3' HD11 ' A' ' 94' ' ' LEU . 2.9 pt-20 . . . . . 0 N--CA 1.496 1.848 0 CA-C-O 120.87 0.367 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.515 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.0 t -108.94 127.56 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.492 -0.755 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -121.16 155.5 34.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.666 -0.647 . . . . 0.0 110.345 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 63.7 t -91.52 120.59 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.668 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.603 ' CB ' HD21 ' A' ' 64' ' ' LEU . 33.4 m -116.56 158.32 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.659 -0.651 . . . . 0.0 110.156 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 33.0 m -145.68 172.77 12.79 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.126 -0.629 . . . . 0.0 110.577 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.93 -172.38 2.91 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.19 88.56 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.374 -0.829 . . . . 0.0 110.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 23.2 m -131.47 -7.12 3.72 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.526 -0.734 . . . . 0.0 111.975 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -113.96 159.71 19.62 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.967 -1.083 . . . . 0.0 110.906 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.2 t -146.1 136.96 24.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.0 p90 -166.72 -177.42 3.89 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.315 -0.866 . . . . 0.0 110.528 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.807 HD11 ' N ' ' A' ' 109' ' ' ARG . 73.3 mt -113.05 159.07 19.54 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.598 -0.689 . . . . 0.0 110.81 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -133.4 156.69 47.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.643 -0.661 . . . . 0.0 110.044 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 142' ' ' PRO . 47.3 m -121.82 134.57 54.9 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.444 -0.785 . . . . 0.0 110.44 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 31.7 t -92.76 110.44 21.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.56 -0.713 . . . . 0.0 110.594 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 94' ' ' LEU . 63.1 t -119.46 134.84 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.593 -0.692 . . . . 0.0 109.641 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 54.93 38.37 30.33 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.534 -0.729 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.509 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.09 26.04 74.81 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 178.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.4 t -139.9 131.73 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.364 -1.08 . . . . 0.0 109.906 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.8 m -75.29 148.57 39.27 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.377 -0.827 . . . . 0.0 109.181 179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.502 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 60.8 m95 -129.99 151.04 50.97 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.726 0.774 . . . . 0.0 111.313 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -169.37 -179.88 3.64 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.871 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.4 p -95.62 155.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.828 . . . . 0.0 110.37 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.437 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 62.1 t80 -70.01 -40.86 75.0 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.509 -0.745 . . . . 0.0 111.599 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.871 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.9 p-80 -70.04 -24.4 63.26 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.148 -0.97 . . . . 0.0 110.621 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.781 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.38 -56.28 2.71 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.576 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -101.97 -53.51 2.92 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.756 -0.849 . . . . 0.0 109.964 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.08 -168.99 46.87 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 97.9 p -86.48 64.45 8.54 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.644 -0.915 . . . . 0.0 109.911 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -140.27 170.02 16.6 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.533 -0.729 . . . . 0.0 110.38 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.9 m -65.3 139.59 58.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.549 -0.719 . . . . 0.0 110.043 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.91 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -113.56 136.22 53.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.64 -0.663 . . . . 0.0 110.014 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.28 119.08 33.17 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -123.05 176.42 16.6 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.69 -32.36 68.49 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.852 1.449 . . . . 0.0 110.414 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -71.89 -31.32 66.29 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.629 -0.67 . . . . 0.0 110.169 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.86 -156.57 26.72 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -70.04 154.33 66.76 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.872 1.459 . . . . 0.0 110.359 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.5 mt -130.35 142.65 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.579 -0.7 . . . . 0.0 110.311 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.4 p -99.47 139.98 34.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.496 -0.752 . . . . 0.0 110.591 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.418 ' NE2' HG22 ' A' ' 76' ' ' THR . 1.5 mm100 -71.04 144.55 50.35 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.613 -0.679 . . . . 0.0 111.216 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.41 ' HG3' ' N ' ' A' ' 86' ' ' GLN . 95.1 mmm -119.21 -45.41 2.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.65 -0.656 . . . . 0.0 110.211 179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -120.02 139.94 51.74 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.592 -0.693 . . . . 0.0 110.449 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.418 HG22 ' NE2' ' A' ' 73' ' ' GLN . 30.3 p -130.48 139.92 50.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.58 -0.7 . . . . 0.0 110.329 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.608 ' OD1' HG21 ' A' ' 178' ' ' THR . 34.6 m120 -148.33 82.59 1.48 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.616 -0.678 . . . . 0.0 110.083 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.435 HG22 ' CE1' ' A' ' 56' ' ' TYR . 94.2 t -62.34 -44.68 99.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.634 -0.666 . . . . 0.0 110.011 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.96 -44.54 94.36 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.508 -0.745 . . . . 0.0 110.216 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.606 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.8 tp60 -89.97 -0.0 57.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.514 -0.741 . . . . 0.0 111.002 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.437 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.2 t70 52.79 49.63 19.85 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.016 -1.052 . . . . 0.0 110.498 -179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.606 HD12 ' CG ' ' A' ' 80' ' ' GLN . 54.9 mt -140.02 144.51 36.97 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.601 -0.687 . . . . 0.0 111.101 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.629 HG23 HG23 ' A' ' 54' ' ' THR . 34.9 m -149.93 159.67 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.565 -0.709 . . . . 0.0 109.611 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.58 28.24 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.926 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.5 m-90 -120.9 159.98 24.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.824 -0.81 . . . . 0.0 109.742 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLN . . . . . 0.41 ' N ' ' HG3' ' A' ' 74' ' ' MET . 18.1 pt20 -68.45 122.47 18.5 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.425 -0.797 . . . . 0.0 109.373 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.509 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.42 130.54 79.52 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.538 -0.726 . . . . 0.0 110.187 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.06 159.97 51.29 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.887 1.467 . . . . 0.0 110.293 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.21 160.13 50.2 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 O-C-N 123.883 1.465 . . . . 0.0 110.275 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.58 29.43 69.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.06 156.64 21.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.615 -0.932 . . . . 0.0 110.113 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -99.12 139.72 34.35 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.0 p -118.84 157.74 27.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.616 -0.677 . . . . 0.0 110.181 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 76.7 mt -112.32 131.53 55.47 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.566 -0.709 . . . . 0.0 110.563 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.6 p -82.2 159.99 63.79 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.565 -0.709 . . . . 0.0 109.969 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.685 ' HB3' HG11 ' A' ' 172' ' ' VAL . 47.1 Cg_endo -70.61 165.81 30.72 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.823 1.433 . . . . 0.0 110.4 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.484 ' HB2' HG22 ' A' ' 151' ' ' VAL . 13.5 t -87.2 149.98 24.24 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.891 0.853 . . . . 0.0 110.367 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.6 m -133.91 62.21 1.66 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 m -141.57 -9.02 0.95 Allowed 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.831 -177.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.51 26.45 56.95 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 79.5 p -80.02 160.0 26.02 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.461 -1.023 . . . . 0.0 110.493 -179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.7 m -107.42 -27.07 10.67 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.707 -0.62 . . . . 0.0 110.329 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -73.83 129.37 37.77 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.75 . . . . 0.0 110.015 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.49 ' CD2' HG11 ' A' ' 151' ' ' VAL . 85.0 mt -135.3 150.05 49.92 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.576 -0.703 . . . . 0.0 110.662 -179.65 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -108.69 119.94 41.0 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.492 -0.755 . . . . 0.0 109.562 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.457 HD13 HD11 ' A' ' 143' ' ' LEU . 50.0 tp -100.97 141.51 33.75 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.48 -0.762 . . . . 0.0 110.78 -179.327 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.88 130.03 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.631 -0.668 . . . . 0.0 109.703 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' THR . . . . . 0.496 ' C ' HD11 ' A' ' 44' ' ' LEU . 73.9 p -111.89 169.97 8.47 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.442 -0.786 . . . . 0.0 110.705 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.807 ' N ' HD11 ' A' ' 44' ' ' LEU . 23.1 ptt-85 -64.68 -16.17 62.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.611 -0.68 . . . . 0.0 111.005 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -89.97 17.4 6.86 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.222 -0.923 . . . . 0.0 110.828 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.44 40.01 31.46 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.081 -1.012 . . . . 0.0 110.51 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -113.38 156.56 23.22 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.658 -0.651 . . . . 0.0 109.853 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -130.0 130.36 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.551 -0.718 . . . . 0.0 110.233 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.409 HG23 ' O ' ' A' ' 114' ' ' ILE . 16.1 tt -131.86 130.06 22.11 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.69 -0.631 . . . . 0.0 109.893 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.53 ' HG2' HD22 ' A' ' 127' ' ' LEU . 47.4 Cg_endo -71.71 126.79 12.37 Favored 'Trans proline' 0 N--CA 1.49 1.265 0 O-C-N 123.856 1.45 . . . . 0.0 110.355 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -120.04 125.58 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.692 -0.63 . . . . 0.0 109.72 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -86.23 149.99 24.7 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.484 -0.76 . . . . 0.0 110.059 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 70.0 ttp85 -93.71 120.65 34.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -110.01 20.0 18.41 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.649 -0.657 . . . . 0.0 110.349 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.55 -177.26 42.61 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.94 -40.03 91.72 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.526 -0.985 . . . . 0.0 110.281 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.6 p -132.33 26.43 4.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.521 -0.737 . . . . 0.0 110.394 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 16.6 tpt180 -124.35 139.97 53.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.451 -0.781 . . . . 0.0 110.495 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.54 167.22 25.35 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 78.3 p -118.95 152.33 36.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.937 . . . . 0.0 110.104 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 164' ' ' ALA . 19.2 tp -94.17 119.09 32.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.556 -0.715 . . . . 0.0 110.118 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.53 HD22 ' HG2' ' A' ' 115' ' ' PRO . 9.2 mp -65.79 -40.0 91.5 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.57 -0.706 . . . . 0.0 109.951 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 58.6 m -111.43 118.59 47.04 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.674 -0.641 . . . . 0.0 110.109 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.54 117.42 4.59 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 O-C-N 123.73 1.384 . . . . 0.0 110.352 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 21.3 mtt180 -129.87 159.95 67.4 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.54 -0.725 . . . . 0.0 110.267 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.27 160.22 43.34 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 O-C-N 123.931 1.49 . . . . 0.0 110.414 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.441 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.6 m -67.39 -25.02 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.665 -0.647 . . . . 0.0 110.816 -179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.4 p -59.96 -40.06 87.76 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.453 -0.779 . . . . 0.0 110.224 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -59.87 -49.82 76.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.534 -0.728 . . . . 0.0 110.023 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.452 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.03 -30.45 67.74 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.611 -0.681 . . . . 0.0 109.82 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 tptm -59.92 131.02 49.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.596 -0.69 . . . . 0.0 110.156 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.2 62.66 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.5 m -116.27 12.84 15.5 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.127 -1.219 . . . . 0.0 110.888 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.1 t -62.03 145.15 53.95 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.292 -0.88 . . . . 0.0 109.915 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.06 -12.08 68.8 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.94 140.39 47.9 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.59 ' HB3' HG21 ' A' ' 46' ' ' THR . 51.8 Cg_endo -92.05 150.31 3.2 Favored 'Trans proline' 0 C--N 1.316 -1.168 0 O-C-N 123.85 1.448 . . . . 0.0 111.393 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -100.39 103.05 14.42 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.224 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.507 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -85.74 149.54 25.21 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-O 122.083 0.944 . . . . 0.0 112.289 -177.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 1.6 t -87.78 145.2 36.32 Favored Pre-proline 0 N--CA 1.492 1.655 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -53.71 -24.8 31.45 Favored 'Trans proline' 0 N--CA 1.502 1.98 0 O-C-N 123.291 1.153 . . . . 0.0 110.375 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.3 m -71.87 -36.51 70.13 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.33 39.77 0.57 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 -130.02 138.69 50.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.438 -1.037 . . . . 0.0 110.594 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.603 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.95 141.55 58.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.444 -0.785 . . . . 0.0 109.899 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 172' ' ' VAL . 58.9 t -115.3 -44.0 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.508 -0.745 . . . . 0.0 110.582 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -170.64 -171.07 35.63 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.2 mt -132.92 140.03 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.937 . . . . 0.0 110.441 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.718 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.4 t80 -67.87 138.09 55.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.623 -0.673 . . . . 0.0 109.811 179.406 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.8 ttp180 -124.24 -52.58 1.74 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.538 -0.726 . . . . 0.0 110.499 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -139.78 159.5 42.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.514 -0.741 . . . . 0.0 110.286 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.718 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.41 136.45 54.96 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.604 -0.685 . . . . 0.0 110.612 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.1 t -93.7 119.82 42.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.441 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.6 p -137.37 159.91 40.58 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.235 -179.141 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 76.1 p -138.88 142.28 38.58 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 53.76 28.01 7.69 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.289 -0.882 . . . . 0.0 110.671 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 80.69 22.89 61.04 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.5 t -129.98 129.99 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.265 -1.138 . . . . 0.0 110.039 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ALA . . . . . 0.405 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -91.54 124.03 35.4 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.26 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 40.9 mttm -112.72 -26.38 8.63 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.587 -0.696 . . . . 0.0 110.352 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.2 161.57 38.54 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.532 -0.73 . . . . 0.0 109.838 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.03 178.49 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.517 -0.739 . . . . 0.0 111.476 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -134.03 135.52 43.42 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -139.99 145.59 38.03 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.326 -0.859 . . . . 0.0 110.719 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.563 HG11 HD11 ' A' ' 82' ' ' LEU . 72.9 t -86.7 124.72 68.88 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.627 -0.671 . . . . 0.0 109.353 179.337 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -66.54 162.52 36.46 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.845 1.444 . . . . 0.0 110.343 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.8 t -70.03 -24.67 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.681 -0.637 . . . . 0.0 110.487 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -57.93 -39.93 79.21 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.375 -0.828 . . . . 0.0 110.575 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.6 p -69.31 -38.43 78.24 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.502 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 93.0 mtp -60.19 -40.52 90.34 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.654 -0.654 . . . . 0.0 110.35 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -69.26 -39.97 78.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.623 -0.673 . . . . 0.0 110.336 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.12 -39.92 91.84 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.606 -0.684 . . . . 0.0 110.074 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' THR . . . . . 0.608 HG21 ' OD1' ' A' ' 77' ' ' ASN . 89.7 m -60.11 -47.52 85.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.545 -0.722 . . . . 0.0 110.375 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.631 -0.668 . . . . 0.0 110.41 -179.765 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.166 0.508 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.803 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.531 -0.731 . . . . 0.0 110.234 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.569 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.1 mt-10 . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 121.136 0.493 . . . . 0.0 110.214 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -102.64 126.52 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.701 . . . . 0.0 110.037 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -117.21 151.61 36.55 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.564 -0.71 . . . . 0.0 110.146 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.7 p -89.67 136.15 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.512 -0.743 . . . . 0.0 110.069 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.683 ' HB ' HD12 ' A' ' 64' ' ' LEU . 33.6 m -129.7 136.97 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.695 -0.628 . . . . 0.0 110.006 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.6 m -136.13 170.93 15.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -133.11 -170.67 2.51 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.636 -0.665 . . . . 0.0 109.449 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.3 -24.2 67.57 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.642 -0.661 . . . . 0.0 111.427 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.3 t -137.24 -15.45 1.47 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.133 -0.979 . . . . 0.0 113.175 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -125.29 149.66 47.85 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.872 -1.143 . . . . 0.0 111.249 -178.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 29.2 p -132.77 142.36 48.97 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.824 -0.548 . . . . 0.0 110.094 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.463 ' CE2' ' HB2' ' A' ' 59' ' ' ALA . 16.1 p90 -163.91 -177.33 5.03 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.469 -0.769 . . . . 0.0 109.88 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.79 HD11 ' CA ' ' A' ' 109' ' ' ARG . 29.1 mt -112.46 179.18 4.06 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.391 -0.818 . . . . 0.0 110.775 -177.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -155.36 160.34 40.63 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.784 -0.573 . . . . 0.0 109.725 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.1 t -125.65 138.41 53.91 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.481 -0.762 . . . . 0.0 110.231 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.9 t -96.66 107.01 19.38 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.474 -0.766 . . . . 0.0 110.653 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.435 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.2 t -110.35 130.0 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.717 -0.614 . . . . 0.0 109.348 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 56.84 36.37 27.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.502 -0.749 . . . . 0.0 110.725 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.543 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 74.28 17.7 79.71 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 179.037 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.2 t -131.21 130.03 63.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.942 0 O-C-N 121.118 -1.225 . . . . 0.0 110.102 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.3 t -73.06 150.05 42.66 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.511 -0.743 . . . . 0.0 109.592 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.435 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 87.4 m95 -135.72 150.0 49.4 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.528 -0.733 . . . . 0.0 110.93 -179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.843 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.0 t -168.51 -179.69 3.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.856 -0.528 . . . . 0.0 109.584 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.816 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.4 p -91.46 157.2 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.018 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.617 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.7 t80 -72.93 -43.65 62.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.543 -0.723 . . . . 0.0 112.14 -178.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.816 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.8 p-80 -60.84 -24.63 66.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.12 -0.988 . . . . 0.0 110.714 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.536 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -90.85 -35.51 7.18 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.362 -1.895 . . . . 0.0 108.362 178.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.463 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -135.59 97.0 3.56 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.792 -0.828 . . . . 0.0 109.879 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -80.03 -166.24 33.24 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 79.1 p -72.26 65.84 0.62 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.626 -0.926 . . . . 0.0 109.631 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.22 169.82 16.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.0 110.382 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 71' ' ' ILE . 69.0 m -74.94 139.25 42.88 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.661 -0.649 . . . . 0.0 110.141 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.683 HD12 ' HB ' ' A' ' 36' ' ' VAL . 0.2 OUTLIER -108.51 133.47 52.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.626 -0.671 . . . . 0.0 109.705 179.671 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.71 112.72 20.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.636 -0.665 . . . . 0.0 110.209 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -112.2 -176.74 19.95 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.79 -32.65 67.17 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.854 1.45 . . . . 0.0 110.499 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -74.93 -31.12 61.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.667 -0.646 . . . . 0.0 109.934 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.65 -144.17 13.27 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' PRO . . . . . 0.429 ' O ' HD13 ' A' ' 71' ' ' ILE . 47.5 Cg_endo -73.61 155.13 49.94 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.817 1.43 . . . . 0.0 110.238 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 63' ' ' THR . 49.1 mm -129.49 139.93 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.558 -0.714 . . . . 0.0 110.455 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 80.5 m -101.04 120.92 40.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.567 -0.708 . . . . 0.0 110.076 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.586 ' OE1' HG22 ' A' ' 76' ' ' THR . 32.2 tt0 -77.0 139.53 40.1 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.546 -0.721 . . . . 0.0 110.681 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 42.2 mtp -109.95 -30.01 8.0 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.663 -0.648 . . . . 0.0 110.441 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -112.85 138.42 49.72 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.523 -0.736 . . . . 0.0 110.612 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.586 HG22 ' OE1' ' A' ' 73' ' ' GLN . 7.0 p -139.41 126.91 21.62 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.706 -0.621 . . . . 0.0 110.023 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 -142.02 90.97 2.3 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.489 -0.757 . . . . 0.0 110.26 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.617 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 91.1 t -66.26 -40.35 86.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.6 -0.687 . . . . 0.0 109.882 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.58 -45.01 95.53 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.647 -0.658 . . . . 0.0 110.601 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.535 ' HG3' HD12 ' A' ' 82' ' ' LEU . 38.6 tp60 -87.79 -0.01 56.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.504 -0.747 . . . . 0.0 110.816 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.6 t70 53.54 42.71 31.88 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.055 -1.028 . . . . 0.0 110.538 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.682 HD11 HG11 ' A' ' 170' ' ' VAL . 67.0 mt -140.92 147.69 39.25 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.45 -0.781 . . . . 0.0 111.036 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.444 HG13 ' C ' ' A' ' 82' ' ' LEU . 34.6 m -148.32 177.1 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.695 -0.628 . . . . 0.0 109.404 179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -156.29 158.25 28.51 Favored Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.838 -1.172 . . . . 0.0 110.518 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.843 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.0 m-90 -120.38 160.77 22.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.816 -0.814 . . . . 0.0 109.848 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.2 tt0 -75.2 109.96 9.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.57 -0.706 . . . . 0.0 109.297 179.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.89 153.96 87.21 Favored Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.545 -0.722 . . . . 0.0 110.01 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.09 159.69 52.28 Favored 'Trans proline' 0 N--CA 1.488 1.196 0 O-C-N 123.83 1.437 . . . . 0.0 110.281 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.06 141.71 71.26 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.95 1.5 . . . . 0.0 110.357 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.18 27.47 72.84 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.19 149.87 26.57 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.467 -1.019 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 13.3 tpt180 -87.74 139.23 30.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.616 -0.678 . . . . 0.0 109.308 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.2 p -128.99 168.38 16.11 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.426 -0.796 . . . . 0.0 110.554 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.614 HD13 HD21 ' A' ' 144' ' ' LEU . 34.7 mt -111.65 131.97 54.91 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.735 -0.603 . . . . 0.0 110.714 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 73.8 p -74.76 159.95 81.98 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 109.799 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.29 161.01 46.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 O-C-N 123.865 1.456 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.792 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.8 t -70.25 134.73 48.31 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.721 -0.612 . . . . 0.0 110.063 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 22.4 p -136.15 52.35 1.98 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.667 -0.646 . . . . 0.0 109.827 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.1 p -143.81 -8.09 0.73 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.516 -0.74 . . . . 0.0 112.387 -179.143 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.01 42.26 98.3 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 54.0 m -100.0 120.04 39.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -1.04 . . . . 0.0 110.305 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.3 m -62.83 -40.05 96.22 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.579 -0.701 . . . . 0.0 110.429 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 137.54 58.06 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.538 -0.726 . . . . 0.0 110.497 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.563 ' CD2' HG21 ' A' ' 151' ' ' VAL . 89.3 mt -138.47 142.84 39.43 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.637 -0.664 . . . . 0.0 110.643 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -106.85 120.37 41.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.587 -0.696 . . . . 0.0 109.581 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.1 tp -102.57 146.16 28.56 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.406 -0.809 . . . . 0.0 110.829 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.4 t -105.34 130.01 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.676 -0.64 . . . . 0.0 109.647 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 76.3 p -98.25 173.57 6.93 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.573 -0.704 . . . . 0.0 111.004 -179.29 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.79 ' CA ' HD11 ' A' ' 44' ' ' LEU . 61.9 ttt-85 -70.0 -24.26 63.27 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.745 -0.597 . . . . 0.0 110.514 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -94.03 29.25 2.18 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.44 -0.787 . . . . 0.0 110.737 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.42 40.03 31.26 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.308 -0.87 . . . . 0.0 110.724 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -116.1 145.94 42.63 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.528 -0.733 . . . . 0.0 109.542 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.9 p -130.0 133.59 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.538 -0.726 . . . . 0.0 110.575 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 81.3 mt -124.91 150.06 64.95 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.651 -0.655 . . . . 0.0 109.485 179.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -81.46 123.05 4.22 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.945 1.498 . . . . 0.0 110.593 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 61.2 t -119.91 124.32 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 109.648 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -81.96 130.61 35.13 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.527 -0.733 . . . . 0.0 110.049 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -77.45 128.23 33.87 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.68 -0.638 . . . . 0.0 110.344 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -119.46 23.02 11.45 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.662 -0.649 . . . . 0.0 110.429 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.75 176.9 38.2 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -60.12 -40.82 91.07 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.54 -0.976 . . . . 0.0 110.127 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 20.8 p -130.0 27.4 5.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.622 -0.674 . . . . 0.0 110.331 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 3.1 tpt85 -128.93 137.06 51.19 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.461 -0.774 . . . . 0.0 110.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.2 166.57 26.0 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -124.87 146.22 49.41 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.558 -0.966 . . . . 0.0 110.058 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mp -97.73 125.25 42.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.554 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.73 -40.04 88.22 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.544 -0.723 . . . . 0.0 109.81 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.6 m -107.55 114.32 60.73 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.661 -0.649 . . . . 0.0 109.94 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.28 124.49 13.02 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.839 1.441 . . . . 0.0 110.487 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.9 mmt180 -120.48 160.09 45.38 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.641 -0.662 . . . . 0.0 109.972 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.33 156.67 62.01 Favored 'Trans proline' 0 N--CA 1.489 1.257 0 O-C-N 123.942 1.496 . . . . 0.0 110.385 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.458 HG11 ' OE1' ' B' ' 188' ' ' GLU . 65.7 t -66.83 -29.93 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.596 -0.69 . . . . 0.0 110.003 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.9 m -59.95 -40.05 87.67 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.482 -0.762 . . . . 0.0 110.352 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -61.76 -40.0 93.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.75 . . . . 0.0 109.994 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.47 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.22 -30.43 68.58 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.595 -0.691 . . . . 0.0 110.479 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 mmmm -60.01 140.4 56.81 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.388 -0.82 . . . . 0.0 110.246 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.01 14.67 80.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.0 m -114.78 10.06 16.46 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.283 -1.127 . . . . 0.0 110.936 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.7 m -62.06 140.2 58.39 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.223 -0.923 . . . . 0.0 110.048 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.75 -18.15 57.29 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.43 113.76 5.21 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.56 150.21 24.54 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.833 1.438 . . . . 0.0 110.82 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -101.49 109.1 20.85 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.614 HD21 HD13 ' A' ' 94' ' ' LEU . 9.9 mp -100.0 129.96 46.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.555 -0.716 . . . . 0.0 111.064 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.411 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.9 158.64 86.74 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.725 -0.61 . . . . 0.0 109.417 179.32 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.4 Cg_endo -53.77 -20.87 18.35 Favored 'Trans proline' 0 N--CA 1.501 1.925 0 O-C-N 123.634 1.333 . . . . 0.0 112.56 -178.327 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.8 p -67.22 -36.47 81.75 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.077 -1.015 . . . . 0.0 109.917 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 119.4 34.65 0.99 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -131.83 146.79 52.33 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.431 -1.04 . . . . 0.0 110.175 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.53 146.46 50.18 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.581 -0.699 . . . . 0.0 110.293 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.792 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.4 t -117.69 -40.1 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.579 -0.701 . . . . 0.0 109.991 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.22 -168.85 34.22 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.471 ' CD1' ' HE1' ' A' ' 175' ' ' MET . 93.8 mt -133.19 140.01 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.487 -1.008 . . . . 0.0 110.464 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -59.98 139.03 57.69 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.547 -0.72 . . . . 0.0 110.036 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 29.9 ttp85 -123.19 -52.01 1.86 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.573 -0.704 . . . . 0.0 110.186 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -146.9 160.41 42.36 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.677 . . . . 0.0 110.295 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.21 144.49 44.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.559 -0.713 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.7 t -110.03 120.05 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 120.18 -0.608 . . . . 0.0 109.807 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.409 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -130.4 145.87 51.88 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.689 -0.632 . . . . 0.0 110.345 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.5 m -70.05 -49.2 53.58 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.61 -0.681 . . . . 0.0 110.265 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -163.92 53.83 0.15 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.574 -0.703 . . . . 0.0 109.889 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 116.11 -17.58 14.76 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.11 126.3 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.217 -1.167 . . . . 0.0 109.777 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.54 126.95 40.15 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.567 -0.708 . . . . 0.0 110.398 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -112.29 -18.1 12.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.604 -0.685 . . . . 0.0 110.717 179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -149.1 159.14 44.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.218 -0.926 . . . . 0.0 110.157 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.8 m -140.01 166.86 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.531 -0.731 . . . . 0.0 110.853 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -119.97 136.78 54.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.655 -0.653 . . . . 0.0 109.773 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -138.04 155.68 48.56 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.493 -0.754 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.682 HG11 HD11 ' A' ' 82' ' ' LEU . 60.4 t -92.91 123.89 60.02 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.621 -0.674 . . . . 0.0 109.578 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.22 154.0 75.57 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.842 1.443 . . . . 0.0 110.581 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 151' ' ' VAL . 91.1 t -59.91 -23.47 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.594 -0.691 . . . . 0.0 110.575 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -58.16 -38.36 76.47 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.444 -0.785 . . . . 0.0 110.555 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' SER . . . . . 0.411 ' OG ' HG12 ' A' ' 170' ' ' VAL . 82.6 p -60.03 -37.11 78.79 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.311 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.471 ' HE1' ' CD1' ' A' ' 153' ' ' ILE . 68.4 mtt -60.13 -40.02 88.29 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.466 -0.771 . . . . 0.0 110.441 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -60.16 -41.27 92.44 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.565 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 73.5 p -72.92 -40.04 65.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.44 -0.787 . . . . 0.0 110.311 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.9 m -70.06 -44.4 69.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.622 -0.674 . . . . 0.0 110.121 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.337 -179.721 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.458 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.4 tt0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.061 0.457 . . . . 0.0 110.088 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.804 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.634 -0.666 . . . . 0.0 110.231 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.402 ' CG ' ' CG ' ' A' ' 92' ' ' ARG . 47.7 mt-10 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 121.115 0.483 . . . . 0.0 110.041 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.6 t -107.13 125.42 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 0.0 109.952 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -115.75 143.26 45.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.515 -0.741 . . . . 0.0 110.413 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.42 132.65 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.588 -0.695 . . . . 0.0 109.987 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CB ' HD21 ' A' ' 64' ' ' LEU . 26.7 m -128.77 159.86 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.634 -0.666 . . . . 0.0 109.972 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 m -139.43 160.52 39.65 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.62 -0.675 . . . . 0.0 110.478 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.37 -176.93 3.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.758 -0.589 . . . . 0.0 109.841 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.68 -12.53 59.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.622 -0.674 . . . . 0.0 110.803 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 41.7 p -120.04 -30.02 4.78 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.242 -0.911 . . . . 0.0 111.191 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -156.39 169.58 24.26 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.281 -0.887 . . . . 0.0 110.633 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.0 p -126.84 158.28 37.08 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.591 -0.693 . . . . 0.0 110.438 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.8 p90 -168.98 -176.38 2.62 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.507 -0.746 . . . . 0.0 109.89 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.586 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.8 mt -111.83 176.36 5.05 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.491 -0.755 . . . . 0.0 110.454 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.406 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -147.91 159.98 43.29 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.786 -0.571 . . . . 0.0 110.069 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.605 HG23 ' O ' ' A' ' 140' ' ' GLY . 39.8 p -120.17 130.88 54.79 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.577 -0.702 . . . . 0.0 110.525 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 33.8 t -92.52 109.66 21.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.429 -0.794 . . . . 0.0 110.386 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.454 HG22 ' HB2' ' A' ' 94' ' ' LEU . 58.6 t -119.2 131.74 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.603 -0.685 . . . . 0.0 109.641 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.57 39.35 27.77 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.539 -0.726 . . . . 0.0 110.845 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.561 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.04 75.98 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.69 130.01 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.143 -1.21 . . . . 0.0 110.022 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 94.1 m -72.63 149.93 43.48 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.44 -0.788 . . . . 0.0 109.457 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.568 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 83.4 m95 -131.79 151.07 51.93 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.524 -0.735 . . . . 0.0 111.175 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.1 t -167.65 -179.94 4.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.774 HG21 ' CE1' ' A' ' 57' ' ' HIS . 7.5 p -97.05 147.75 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.155 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.489 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 58.3 t80 -60.05 -46.94 87.88 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.611 -0.68 . . . . 0.0 112.095 -178.594 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.793 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.5 p-80 -64.7 -24.08 67.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.159 -0.963 . . . . 0.0 110.91 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.698 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.61 -52.96 3.53 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.679 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -109.42 -57.41 2.17 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.688 -0.89 . . . . 0.0 110.101 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.5 -163.8 52.98 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.1 p -88.98 66.2 7.78 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.662 -0.905 . . . . 0.0 110.037 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -139.63 168.39 19.93 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.508 -0.745 . . . . 0.0 110.282 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 60.2 m -65.0 139.63 58.78 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.056 -0.657 . . . . 0.0 109.961 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.815 HD22 ' CH2' ' A' ' 85' ' ' TRP . 13.8 tp -117.42 138.96 51.48 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.689 -0.632 . . . . 0.0 109.903 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.83 110.04 22.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.549 -0.719 . . . . 0.0 110.193 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.76 -179.65 19.06 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.04 -31.89 76.06 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.821 1.432 . . . . 0.0 110.469 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 6.7 mtpm? -73.06 -31.17 64.23 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.701 -0.624 . . . . 0.0 109.964 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.46 -150.41 21.6 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.71 147.11 44.45 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.886 1.466 . . . . 0.0 110.148 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -129.99 140.03 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.549 -0.719 . . . . 0.0 110.57 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.7 t -99.94 144.22 29.25 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.548 -0.72 . . . . 0.0 109.774 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -90.13 150.0 22.22 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.407 -0.808 . . . . 0.0 111.232 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 50.2 mtp -116.04 -25.98 7.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.762 -0.586 . . . . 0.0 110.427 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -122.86 139.96 53.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.561 ' HA ' HG12 ' A' ' 83' ' ' VAL . 60.9 m -141.38 133.72 28.13 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.621 -0.674 . . . . 0.0 110.312 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -145.54 95.66 2.69 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.509 -0.744 . . . . 0.0 110.019 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.489 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 80.2 t -66.27 -43.09 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.513 -0.742 . . . . 0.0 110.066 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -49.88 75.9 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.55 -0.719 . . . . 0.0 110.474 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.634 ' CG ' HD12 ' A' ' 82' ' ' LEU . 37.0 tp60 -81.72 -8.65 59.72 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.588 -0.695 . . . . 0.0 110.509 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.442 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.0 t70 57.5 45.9 18.81 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.115 -0.991 . . . . 0.0 110.304 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.779 HD11 HG11 ' A' ' 170' ' ' VAL . 82.6 mt -138.16 139.09 39.21 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.549 -0.719 . . . . 0.0 110.953 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.561 HG12 ' HA ' ' A' ' 76' ' ' THR . 34.7 m -144.39 158.04 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.627 -0.671 . . . . 0.0 109.439 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -140.62 157.94 25.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.3 m-90 -116.67 161.07 19.77 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.782 -0.834 . . . . 0.0 109.639 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -70.99 114.23 8.83 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.515 -0.741 . . . . 0.0 109.312 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.03 136.52 87.2 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 110.212 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 159.97 51.3 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.864 1.455 . . . . 0.0 110.228 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -66.15 153.63 77.32 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 123.882 1.464 . . . . 0.0 110.322 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.16 27.36 66.37 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.87 139.88 40.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.506 -0.996 . . . . 0.0 110.138 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.402 ' CG ' ' CG ' ' A' ' 32' ' ' GLU . 27.4 tpt180 -80.11 159.92 25.92 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.658 -0.651 . . . . 0.0 109.531 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.7 p -129.63 167.92 17.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.554 -0.716 . . . . 0.0 110.173 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.454 ' HB2' HG22 ' A' ' 48' ' ' VAL . 59.9 mt -109.8 131.54 54.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.526 -0.733 . . . . 0.0 110.651 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.466 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 9.8 t -75.37 159.97 80.86 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.582 -0.699 . . . . 0.0 109.986 179.505 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -84.76 164.17 12.07 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.753 1.396 . . . . 0.0 110.815 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.499 ' HB2' HG22 ' A' ' 151' ' ' VAL . 43.8 t -82.59 138.94 34.07 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.658 -0.651 . . . . 0.0 110.194 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -136.09 51.64 2.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.812 -0.555 . . . . 0.0 109.681 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' CYS . . . . . 0.402 ' SG ' ' SG ' ' A' ' 97' ' ' CYS . 29.2 p -143.43 -8.61 0.76 Allowed 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.843 -0.743 . . . . 0.0 112.411 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 33.44 74.75 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 86.0 p -76.73 149.92 36.31 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.431 -1.041 . . . . 0.0 110.415 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -92.66 -29.22 16.21 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.625 -0.672 . . . . 0.0 110.286 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -77.43 135.27 38.27 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.554 -0.716 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.4 mt -135.04 155.12 51.3 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.508 -0.745 . . . . 0.0 110.599 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -119.99 114.6 22.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.556 -0.715 . . . . 0.0 109.788 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.428 HD13 HD11 ' A' ' 143' ' ' LEU . 40.3 tp -100.41 140.01 35.27 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.617 -0.677 . . . . 0.0 110.445 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 113' ' ' VAL . 62.2 t -109.96 129.94 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.626 -0.671 . . . . 0.0 110.052 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 59.5 p -102.2 -179.58 4.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.592 -0.692 . . . . 0.0 110.42 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.586 ' HA ' HD11 ' A' ' 44' ' ' LEU . 31.9 mtp-105 -59.88 -22.52 62.47 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.535 -0.728 . . . . 0.0 110.808 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -90.11 19.57 4.9 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.276 -0.89 . . . . 0.0 111.15 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.0 40.07 31.21 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.123 -0.986 . . . . 0.0 110.686 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -106.76 134.84 49.3 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.611 -0.68 . . . . 0.0 109.957 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 107' ' ' VAL . 62.7 t -110.08 123.48 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 109.982 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.5 pt -119.97 150.0 50.01 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.564 -0.71 . . . . 0.0 110.06 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.616 ' HG2' HD22 ' A' ' 127' ' ' LEU . 50.6 Cg_endo -87.99 128.03 2.27 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.933 1.491 . . . . 0.0 110.44 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.9 t -124.75 129.41 73.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.662 -0.649 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.582 ' HG2' HD11 ' A' ' 127' ' ' LEU . 51.6 mmm-85 -80.35 156.0 26.93 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.572 -0.705 . . . . 0.0 110.309 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -101.14 118.63 37.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.634 -0.666 . . . . 0.0 110.064 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.8 mmm180 -113.13 20.02 16.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.59 -0.694 . . . . 0.0 110.437 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.02 -171.43 42.39 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.02 -39.93 90.66 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.566 -0.961 . . . . 0.0 110.442 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.0 p -132.69 24.14 4.34 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.524 -0.735 . . . . 0.0 110.816 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -126.26 139.88 52.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.325 -0.859 . . . . 0.0 110.506 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.84 169.35 27.97 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 52.1 p -112.06 156.82 21.58 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.41 -1.053 . . . . 0.0 110.537 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.457 HD23 ' O ' ' A' ' 164' ' ' ALA . 24.2 tp -98.59 120.4 38.94 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.559 -0.713 . . . . 0.0 110.074 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.616 HD22 ' HG2' ' A' ' 115' ' ' PRO . 8.0 mp -60.93 -40.21 92.39 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.569 -0.707 . . . . 0.0 110.352 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.2 p -117.8 127.25 26.76 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.504 -0.747 . . . . 0.0 110.075 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.31 117.93 5.36 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.87 1.458 . . . . 0.0 110.381 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 48.6 mtp85 -120.08 160.01 44.86 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.708 . . . . 0.0 110.227 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.77 148.84 83.35 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.875 1.461 . . . . 0.0 110.31 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.562 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.3 m -62.07 -26.59 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.613 -0.68 . . . . 0.0 110.426 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.4 t -59.95 -39.92 87.22 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.693 ' HD2' HD12 ' A' ' 135' ' ' LEU . 65.0 t80 -60.06 -49.16 78.73 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.607 -0.683 . . . . 0.0 110.227 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.693 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.4 mp -69.97 -28.93 65.95 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.466 -0.771 . . . . 0.0 110.537 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmtp -60.01 140.02 57.06 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.476 -0.765 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.99 9.99 86.09 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 28.9 m -112.05 16.79 20.09 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.141 -1.211 . . . . 0.0 110.785 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -60.17 140.03 57.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.287 -0.883 . . . . 0.0 110.023 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.34 -18.07 57.59 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -51.4 124.94 24.17 Favored Glycine 0 N--CA 1.5 2.906 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.557 ' HB3' HG21 ' A' ' 46' ' ' THR . 52.4 Cg_endo -80.77 146.32 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.868 1.457 . . . . 0.0 111.304 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.628 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -106.71 106.77 17.46 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.557 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -95.74 131.21 42.26 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.527 -0.733 . . . . 0.0 111.242 -178.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.444 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.75 159.39 84.14 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.185 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -51.92 -21.83 12.88 Favored 'Trans proline' 0 N--CA 1.501 1.954 0 O-C-N 123.506 1.266 . . . . 0.0 112.671 -178.224 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -69.77 -38.39 76.73 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.18 -0.95 . . . . 0.0 109.872 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.58 37.23 0.74 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -133.37 149.6 51.85 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.495 -1.003 . . . . 0.0 110.221 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -63.72 139.99 58.82 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.52 -0.737 . . . . 0.0 110.216 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.643 ' O ' HG23 ' A' ' 172' ' ' VAL . 49.6 t -115.96 -35.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.582 -0.698 . . . . 0.0 110.009 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.7 -169.98 38.69 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 90.0 mt -130.04 139.89 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.564 -0.962 . . . . 0.0 110.229 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -59.99 139.14 57.63 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.507 -0.746 . . . . 0.0 110.12 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -119.95 -52.34 2.21 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.615 -0.678 . . . . 0.0 110.29 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.681 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.58 166.88 30.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.522 -0.736 . . . . 0.0 110.5 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.25 148.55 43.01 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.627 -0.671 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.94 120.03 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.624 -0.672 . . . . 0.0 109.796 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.562 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.5 p -133.63 149.87 51.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.719 -0.613 . . . . 0.0 110.376 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.8 p -80.09 -47.48 14.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.568 -0.707 . . . . 0.0 110.41 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -161.65 57.41 0.27 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.671 -0.643 . . . . 0.0 110.033 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.03 -11.65 40.83 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.9 t -118.24 126.52 75.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.137 -1.213 . . . . 0.0 109.686 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ALA . . . . . 0.457 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -96.7 123.53 40.42 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.512 -0.743 . . . . 0.0 110.627 -179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -105.8 -18.46 14.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.723 -0.611 . . . . 0.0 110.392 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.6 158.77 44.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 109.821 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -130.07 -173.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.481 -0.762 . . . . 0.0 110.518 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -146.44 127.17 14.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.705 -0.622 . . . . 0.0 109.444 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -127.42 156.22 42.42 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.453 -0.779 . . . . 0.0 110.946 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.779 HG11 HD11 ' A' ' 82' ' ' LEU . 63.2 t -92.82 121.41 66.01 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -64.17 154.92 68.06 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.79 1.416 . . . . 0.0 110.496 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 151' ' ' VAL . 97.1 t -58.97 -24.06 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.612 -0.68 . . . . 0.0 110.531 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -59.85 -40.08 87.33 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.365 -0.835 . . . . 0.0 110.346 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 22.4 t -63.42 -38.42 91.06 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.476 -0.765 . . . . 0.0 110.144 179.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.568 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 93.3 mtp -60.0 -41.58 92.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.631 -0.668 . . . . 0.0 110.317 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.13 -40.08 78.5 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.567 -0.708 . . . . 0.0 110.162 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.1 m -61.06 -39.98 91.92 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.627 -0.671 . . . . 0.0 110.156 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.6 m -60.14 -40.36 89.55 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.542 -0.724 . . . . 0.0 110.114 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.495 1.795 0 O-C-N 121.594 -0.691 . . . . 0.0 110.169 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.681 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 41.2 tt0 . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.001 0.429 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.793 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.683 . . . . 0.0 110.245 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.815 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 121.09 0.472 . . . . 0.0 110.313 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.815 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.6 t -120.34 129.61 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.546 -0.721 . . . . 0.0 109.77 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -129.99 158.35 39.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.517 -0.739 . . . . 0.0 110.451 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.78 125.28 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.696 -0.628 . . . . 0.0 109.413 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.557 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.6 m -124.79 158.16 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.577 -0.702 . . . . 0.0 110.159 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.5 m -133.36 173.04 11.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.684 -0.635 . . . . 0.0 110.556 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.449 HG22 ' N ' ' A' ' 39' ' ' ALA . 35.0 m -139.69 171.54 14.08 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.449 ' N ' HG22 ' A' ' 38' ' ' THR . . . -56.09 -28.18 56.69 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.438 -0.789 . . . . 0.0 111.204 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.0 m -135.37 -7.26 2.26 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.263 -0.898 . . . . 0.0 112.597 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.7 mm-40 -129.98 159.17 37.48 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.89 -1.131 . . . . 0.0 111.69 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 68.1 m -132.12 133.98 44.92 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.419 ' HE1' ' HG1' ' A' ' 38' ' ' THR . 6.9 p90 -164.67 -177.4 4.76 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.242 -0.911 . . . . 0.0 111.068 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.86 HD11 ' HA ' ' A' ' 109' ' ' ARG . 51.6 mt -112.63 146.61 38.32 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.666 -0.647 . . . . 0.0 110.279 -178.422 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -111.24 161.01 16.44 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.58 -0.7 . . . . 0.0 110.165 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 63.6 p -125.16 143.38 50.96 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.593 -0.692 . . . . 0.0 110.314 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 93.3 m -102.85 113.18 26.4 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.574 -0.704 . . . . 0.0 110.501 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.3 130.0 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.658 -0.652 . . . . 0.0 109.428 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 55.49 36.68 27.64 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.421 -0.799 . . . . 0.0 110.76 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.803 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.69 19.16 74.67 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -132.36 130.05 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.202 -1.175 . . . . 0.0 109.998 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.5 m -78.21 144.97 35.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.483 -0.761 . . . . 0.0 109.514 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -128.36 151.41 49.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.525 -0.734 . . . . 0.0 110.863 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -167.77 -179.8 4.43 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.843 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.9 p -95.29 154.2 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.816 . . . . 0.0 110.562 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.7 t80 -69.95 -40.12 75.63 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.683 -0.636 . . . . 0.0 111.873 -178.87 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.843 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.4 p-80 -68.26 -24.35 64.88 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.135 -0.978 . . . . 0.0 110.499 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.697 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -82.64 -59.12 2.27 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.49 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -102.37 -47.95 4.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.069 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 66.0 -165.68 37.85 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.2 m -83.72 64.42 7.99 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.582 -0.952 . . . . 0.0 109.951 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -140.02 164.84 28.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.514 -0.741 . . . . 0.0 110.324 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.3 t -65.37 140.05 58.62 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.578 -0.701 . . . . 0.0 110.05 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.923 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.5 tp -109.9 130.54 55.51 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.658 -0.651 . . . . 0.0 110.178 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.46 118.45 30.57 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.578 -0.701 . . . . 0.0 110.106 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -122.89 177.74 16.48 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.63 -31.98 69.57 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.795 1.419 . . . . 0.0 110.338 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 61.0 tptt -70.55 -31.55 68.64 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.606 -0.684 . . . . 0.0 109.633 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.01 -150.41 22.01 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.79 155.75 53.51 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.891 1.469 . . . . 0.0 110.228 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.441 ' CD1' HD23 ' A' ' 64' ' ' LEU . 85.1 mt -125.91 139.94 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.555 -0.715 . . . . 0.0 110.272 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 73.1 m -94.39 137.9 32.99 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.413 -0.804 . . . . 0.0 110.265 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -70.16 139.96 52.49 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.575 -0.703 . . . . 0.0 110.599 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.82 -51.3 2.66 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.564 -0.71 . . . . 0.0 109.952 179.463 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -120.03 140.06 51.56 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.514 -0.742 . . . . 0.0 110.213 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.6 p -131.64 137.61 48.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.497 -0.752 . . . . 0.0 110.367 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -150.04 90.72 1.7 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.578 -0.702 . . . . 0.0 110.215 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CE1' ' A' ' 56' ' ' TYR . 85.9 t -68.04 -42.33 85.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.543 -0.723 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.91 -42.8 94.66 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.717 . . . . 0.0 110.27 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 82' ' ' LEU . 39.0 tp60 -89.98 0.12 57.27 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.537 -0.727 . . . . 0.0 110.93 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.443 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.65 44.63 29.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.059 -1.026 . . . . 0.0 110.687 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.615 HD11 HG11 ' A' ' 170' ' ' VAL . 70.9 mt -140.25 144.37 36.45 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.407 -0.808 . . . . 0.0 110.923 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.584 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.8 m -148.2 155.64 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.578 -0.701 . . . . 0.0 109.452 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -139.95 161.25 26.33 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 9.2 m-90 -117.75 160.06 21.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.751 -0.852 . . . . 0.0 109.565 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -74.54 104.42 5.24 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.463 -0.773 . . . . 0.0 109.677 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.37 130.04 88.16 Favored Pre-proline 0 N--CA 1.494 1.775 0 O-C-N 121.541 -0.724 . . . . 0.0 110.239 -179.713 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.08 159.98 51.24 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.827 1.435 . . . . 0.0 110.271 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.9 157.71 51.04 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.968 1.51 . . . . 0.0 110.319 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.9 -24.86 30.52 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.03 159.99 26.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.445 -1.032 . . . . 0.0 110.159 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 83.6 mtt180 -100.39 159.31 15.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.59 -0.694 . . . . 0.0 110.109 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.3 p -129.91 170.03 14.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.511 -0.743 . . . . 0.0 110.271 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.73 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 2.4 mm? -102.48 138.49 39.32 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.635 -0.666 . . . . 0.0 110.505 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.428 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 4.8 p -76.05 160.03 79.25 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.629 -0.669 . . . . 0.0 109.946 179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.55 153.32 30.41 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.779 1.41 . . . . 0.0 110.6 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.773 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.4 t -68.73 135.11 50.77 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.543 -0.723 . . . . 0.0 110.131 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.5 t -136.1 52.07 2.0 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.708 -0.62 . . . . 0.0 109.692 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.83 -8.51 0.72 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.542 -0.723 . . . . 0.0 112.405 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.96 33.84 80.66 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 p -88.15 139.64 30.29 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.533 -0.981 . . . . 0.0 110.411 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.5 m -82.1 -30.0 31.46 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.646 -0.659 . . . . 0.0 110.353 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -66.62 129.87 41.3 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.502 -0.749 . . . . 0.0 110.162 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.582 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.6 mt -137.14 139.81 41.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.7 . . . . 0.0 110.631 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.5 120.51 42.39 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.56 -0.713 . . . . 0.0 109.862 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.4 tp -103.1 140.06 37.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.5 -0.75 . . . . 0.0 110.488 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.506 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.6 t -90.44 138.66 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.585 -0.697 . . . . 0.0 109.758 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 13.5 m -110.2 159.48 17.34 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.519 -0.738 . . . . 0.0 110.489 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.86 ' HA ' HD11 ' A' ' 44' ' ' LEU . 2.7 ttp180 -60.1 -21.37 61.42 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.588 -0.695 . . . . 0.0 110.63 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.07 27.45 3.2 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.267 -0.896 . . . . 0.0 110.528 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.61 39.98 31.56 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.39 -0.819 . . . . 0.0 110.622 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -124.21 139.59 53.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.656 -0.653 . . . . 0.0 109.737 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' A' ' 107' ' ' VAL . 34.5 m -126.13 139.09 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.482 -0.761 . . . . 0.0 110.59 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.552 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.2 mp -124.52 150.05 63.6 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.733 -0.604 . . . . 0.0 109.559 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 114' ' ' ILE . 46.8 Cg_endo -79.15 133.41 10.94 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.888 1.468 . . . . 0.0 110.492 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 125' ' ' SER . 62.7 t -130.02 129.99 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.671 -0.643 . . . . 0.0 109.653 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.4 tpt180 -85.38 150.0 25.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.52 -0.738 . . . . 0.0 110.193 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -91.15 119.96 31.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.65 -0.656 . . . . 0.0 110.336 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -110.21 20.02 18.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.608 -0.683 . . . . 0.0 110.508 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.11 -174.26 43.59 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -65.8 -39.94 91.41 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.999 . . . . 0.0 110.245 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.6 p -130.74 24.52 5.04 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.553 -0.717 . . . . 0.0 110.535 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -124.93 139.96 53.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 110.36 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.37 165.79 25.67 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 116' ' ' VAL . 91.1 p -115.86 153.78 30.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.463 -1.022 . . . . 0.0 110.152 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.411 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.2 tp -99.72 119.96 38.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.584 -0.697 . . . . 0.0 110.193 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.527 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -68.96 -38.51 79.45 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.527 -0.733 . . . . 0.0 109.863 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.0 m -110.0 113.84 56.68 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.677 -0.639 . . . . 0.0 110.051 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -64.66 118.52 5.49 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.799 1.421 . . . . 0.0 110.523 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -122.44 160.02 50.05 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.626 -0.671 . . . . 0.0 110.211 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -66.15 154.88 72.37 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.913 1.481 . . . . 0.0 110.42 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 90.6 t -61.63 -39.97 85.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.607 -0.683 . . . . 0.0 110.126 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.3 p -56.14 -33.85 65.56 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.476 -0.765 . . . . 0.0 110.663 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -60.02 -39.95 87.64 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.556 -0.715 . . . . 0.0 110.107 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.5 mp -84.82 -20.95 30.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.542 -0.724 . . . . 0.0 110.931 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -59.9 139.85 57.08 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.251 -0.906 . . . . 0.0 110.117 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.66 10.05 86.19 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 18.2 m -116.14 10.3 14.93 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.19 -1.182 . . . . 0.0 110.884 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.2 t -65.0 150.49 47.98 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.164 -0.96 . . . . 0.0 109.597 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 95.56 -22.23 40.18 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.5 148.57 21.04 Favored Glycine 0 N--CA 1.498 2.83 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -98.8 147.57 0.58 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.889 1.468 . . . . 0.0 111.024 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.38 108.33 19.91 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.77 129.94 45.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.456 -0.777 . . . . 0.0 111.296 -178.691 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.03 158.31 87.67 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.0 Cg_endo -51.87 -25.36 21.22 Favored 'Trans proline' 0 N--CA 1.501 1.918 0 O-C-N 123.547 1.288 . . . . 0.0 112.343 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.2 m -62.74 -40.0 95.85 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.266 -0.896 . . . . 0.0 109.886 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.06 36.86 0.79 Allowed Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' HIS . . . . . 0.428 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 4.3 m-70 -132.95 143.69 49.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.445 -1.033 . . . . 0.0 110.188 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.73 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -65.42 142.33 58.23 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.523 -0.736 . . . . 0.0 110.233 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.773 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -115.34 -38.06 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.579 -0.701 . . . . 0.0 110.043 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.09 -168.38 36.23 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.693 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.8 mt -129.89 140.02 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.469 -1.018 . . . . 0.0 110.379 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.0 t80 -63.75 139.77 58.8 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.677 -0.639 . . . . 0.0 110.11 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.5 ttt180 -119.9 -52.42 2.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.57 -0.706 . . . . 0.0 110.331 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.28 158.77 44.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.514 -0.742 . . . . 0.0 110.335 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -113.94 152.02 31.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.619 -0.676 . . . . 0.0 110.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.86 119.77 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.736 -0.603 . . . . 0.0 109.692 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.26 144.22 51.14 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.721 -0.612 . . . . 0.0 110.373 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.5 m -69.86 -49.77 49.14 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.619 -0.676 . . . . 0.0 110.056 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -163.65 54.17 0.16 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.711 -0.618 . . . . 0.0 109.854 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.32 -16.51 17.33 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.15 125.15 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.228 -1.16 . . . . 0.0 109.661 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -95.3 123.05 38.61 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.591 -0.693 . . . . 0.0 110.578 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -105.2 -21.31 13.28 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.601 -0.687 . . . . 0.0 110.274 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.94 159.12 43.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.365 -0.834 . . . . 0.0 109.913 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 19.7 m -131.53 -175.73 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.551 -0.718 . . . . 0.0 110.519 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -142.93 132.18 23.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.77 -0.581 . . . . 0.0 109.595 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -133.23 155.79 48.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.523 -0.736 . . . . 0.0 110.894 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 82' ' ' LEU . 62.9 t -92.7 124.27 59.29 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.564 -0.71 . . . . 0.0 109.332 179.246 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.49 150.31 75.29 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.721 1.379 . . . . 0.0 110.675 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 151' ' ' VAL . 95.0 t -59.48 -24.04 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.666 -0.646 . . . . 0.0 110.408 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -59.12 -39.58 82.76 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.382 -0.824 . . . . 0.0 110.314 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.4 p -60.01 -39.34 85.5 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.555 -0.716 . . . . 0.0 110.212 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.693 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.7 mtt -59.92 -40.46 88.94 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 110.452 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.28 -40.02 88.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.675 -0.64 . . . . 0.0 110.281 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.4 m -60.76 -40.4 92.35 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.472 -0.767 . . . . 0.0 110.106 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -69.86 -41.03 75.4 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.58 -0.7 . . . . 0.0 110.079 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.835 0 O-C-N 121.594 -0.691 . . . . 0.0 110.348 -179.891 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.109 0.48 . . . . 0.0 110.074 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.833 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp . . . . . 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.0 110.343 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.81 ' HG3' HG23 ' A' ' 33' ' ' VAL . 17.5 pt-20 . . . . . 0 N--CA 1.497 1.893 0 CA-C-O 120.971 0.415 . . . . 0.0 110.553 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.81 HG23 ' HG3' ' A' ' 32' ' ' GLU . 82.7 t -116.86 128.54 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.401 -0.812 . . . . 0.0 109.663 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -129.27 154.44 46.83 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.533 -0.729 . . . . 0.0 110.6 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -91.74 128.36 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.602 ' HB ' HD21 ' A' ' 64' ' ' LEU . 27.0 m -126.17 159.69 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.614 -0.679 . . . . 0.0 110.36 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 58.6 m -137.85 162.48 33.87 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.517 0.675 . . . . 0.0 111.032 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.2 m -134.51 169.37 17.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.792 -0.567 . . . . 0.0 109.678 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -67.11 -12.67 60.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 111.323 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 48.6 p -118.39 -30.53 5.2 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.042 -1.036 . . . . 0.0 111.555 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -159.17 170.04 22.83 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.202 -0.936 . . . . 0.0 110.967 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 t -123.88 155.23 38.46 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.489 -0.757 . . . . 0.0 110.574 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.628 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 16.8 p90 -166.26 -177.71 4.22 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.546 -0.721 . . . . 0.0 110.091 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.554 HD11 ' HA ' ' A' ' 109' ' ' ARG . 63.7 mt -113.28 153.78 27.87 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.523 -0.736 . . . . 0.0 110.443 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -127.89 161.09 29.89 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.557 -0.714 . . . . 0.0 110.356 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.642 HG23 HD12 ' A' ' 94' ' ' LEU . 86.9 m -120.04 130.23 54.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.635 -0.666 . . . . 0.0 110.108 -179.819 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.4 t -89.94 104.0 16.61 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.628 -0.67 . . . . 0.0 110.42 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.436 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.3 t -111.06 132.81 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.479 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.77 38.71 29.67 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.559 -0.713 . . . . 0.0 110.678 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.676 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 20.07 75.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.4 t -132.31 129.89 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.234 -1.156 . . . . 0.0 110.079 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 5.2 t -71.81 146.49 47.97 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.539 -0.726 . . . . 0.0 109.433 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.627 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 59.5 m95 -129.4 151.05 50.46 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.474 -0.766 . . . . 0.0 111.273 -179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.877 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -169.78 -179.81 3.43 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.836 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.1 p -94.53 156.36 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.423 -0.798 . . . . 0.0 110.073 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.2 t80 -70.04 -42.35 73.02 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.548 -0.72 . . . . 0.0 111.79 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.836 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.5 p-80 -64.77 -20.76 66.54 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.144 -0.973 . . . . 0.0 110.643 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.603 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -86.84 -47.69 4.69 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.628 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -125.41 90.98 3.32 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.679 -0.895 . . . . 0.0 109.942 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.42 -169.99 2.0 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 20.4 p -72.22 66.93 0.66 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.438 -1.036 . . . . 0.0 109.555 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.62 166.8 23.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.62 -0.675 . . . . 0.0 110.729 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.2 m -65.58 139.62 58.46 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.778 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.904 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -108.32 132.72 53.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.636 -0.665 . . . . 0.0 110.11 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.7 118.37 30.6 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.549 -0.719 . . . . 0.0 110.36 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.09 -176.91 18.25 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.132 -1.587 . . . . 0.0 109.132 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.51 -32.51 70.36 Favored 'Trans proline' 0 N--CA 1.491 1.35 0 O-C-N 123.836 1.44 . . . . 0.0 110.579 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 76.0 tttt -75.46 -31.11 60.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.598 -0.689 . . . . 0.0 109.974 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.3 -140.26 9.22 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.06 156.93 47.14 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 O-C-N 123.806 1.424 . . . . 0.0 110.25 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.516 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.4 mt -127.41 139.99 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.065 -179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 p -88.46 150.76 22.97 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.755 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -96.75 140.03 31.94 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.612 -0.68 . . . . 0.0 110.441 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.6 mmm -119.29 -32.77 4.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.577 -0.702 . . . . 0.0 110.856 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -132.75 149.97 52.21 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.405 -0.809 . . . . 0.0 110.869 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.3 p -143.56 137.86 28.71 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.672 -0.643 . . . . 0.0 110.026 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.401 ' OD1' HG23 ' A' ' 178' ' ' THR . 1.6 m120 -150.02 93.92 2.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.467 -0.771 . . . . 0.0 110.169 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CE1' ' A' ' 56' ' ' TYR . 88.0 t -69.96 -43.06 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -59.87 -45.46 92.41 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.514 -0.741 . . . . 0.0 110.608 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.765 ' HG2' HD12 ' A' ' 82' ' ' LEU . 51.4 tt0 -85.71 -0.07 54.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.579 -0.7 . . . . 0.0 110.737 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.441 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.3 t70 53.73 45.29 28.26 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.036 -1.04 . . . . 0.0 110.704 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.765 HD12 ' HG2' ' A' ' 80' ' ' GLN . 57.6 mt -142.24 146.89 35.65 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.524 -0.735 . . . . 0.0 110.924 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.522 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -149.24 160.0 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.555 -0.715 . . . . 0.0 109.735 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.34 153.75 24.18 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.904 ' CH2' HD22 ' A' ' 64' ' ' LEU . 7.5 m-90 -114.58 168.09 10.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.668 -0.901 . . . . 0.0 109.535 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -77.57 110.05 12.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -0.788 . . . . 0.0 109.268 179.097 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.676 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.05 129.98 90.26 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.598 -0.689 . . . . 0.0 110.204 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.96 159.95 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 123.791 1.416 . . . . 0.0 110.28 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.35 160.14 50.54 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.961 1.506 . . . . 0.0 110.285 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 84.49 28.75 31.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.99 150.03 49.61 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.527 -0.984 . . . . 0.0 110.094 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -100.02 119.98 39.11 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.521 -0.737 . . . . 0.0 110.342 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.5 p -81.24 170.03 16.59 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.656 -0.653 . . . . 0.0 110.161 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.642 HD12 HG23 ' A' ' 46' ' ' THR . 79.3 mt -109.57 131.85 54.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.586 -0.696 . . . . 0.0 110.807 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.7 p -72.74 160.06 83.8 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.576 -0.703 . . . . 0.0 109.95 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.36 164.44 24.08 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.87 1.458 . . . . 0.0 110.594 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.538 ' HB2' HG22 ' A' ' 151' ' ' VAL . 54.1 t -80.16 129.99 34.9 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.537 -0.727 . . . . 0.0 110.241 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -133.24 55.79 1.88 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.646 -0.659 . . . . 0.0 109.522 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.95 -8.12 0.72 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.607 -0.683 . . . . 0.0 112.394 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.06 35.27 91.2 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -84.97 113.07 21.14 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.513 -0.992 . . . . 0.0 110.485 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -60.03 -40.01 87.88 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.64 -0.662 . . . . 0.0 110.342 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -64.89 138.66 58.51 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.55 -0.719 . . . . 0.0 110.414 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.47 ' CD2' HG11 ' A' ' 151' ' ' VAL . 91.5 mt -135.58 150.0 49.57 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.615 -0.678 . . . . 0.0 110.319 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -117.84 114.4 23.2 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.583 -0.698 . . . . 0.0 109.857 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 143' ' ' LEU . 40.2 tp -96.5 145.64 25.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.568 -0.707 . . . . 0.0 110.467 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.01 128.69 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.662 -0.649 . . . . 0.0 109.928 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 71.1 p -105.12 -178.59 3.7 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.597 -0.69 . . . . 0.0 110.441 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.554 ' HA ' HD11 ' A' ' 44' ' ' LEU . 55.0 mtp180 -69.76 -20.95 63.48 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.562 -0.711 . . . . 0.0 110.808 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.81 21.24 4.96 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.356 -0.84 . . . . 0.0 110.908 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.12 39.93 31.16 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.154 -0.966 . . . . 0.0 110.622 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -106.4 168.32 9.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.588 -0.695 . . . . 0.0 110.008 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.97 129.97 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.559 -0.713 . . . . 0.0 110.183 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.601 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -119.62 109.28 38.35 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.633 -0.667 . . . . 0.0 109.87 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -65.16 109.83 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.764 1.402 . . . . 0.0 110.263 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.2 t -110.83 124.12 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.608 -0.683 . . . . 0.0 109.937 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 35.1 mmm-85 -79.75 155.22 28.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.586 -0.696 . . . . 0.0 110.175 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -98.18 119.69 37.28 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -122.64 22.63 9.8 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.23 -176.95 47.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -70.07 -40.04 75.29 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.506 -0.997 . . . . 0.0 110.532 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -131.0 29.07 4.74 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.449 -0.782 . . . . 0.0 110.686 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -138.44 162.5 34.31 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.451 -0.78 . . . . 0.0 110.474 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -162.24 -179.39 36.83 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 79.4 p -120.92 149.01 43.28 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.542 -0.975 . . . . 0.0 110.232 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.446 HD11 ' CG2' ' A' ' 114' ' ' ILE . 19.4 tp -93.44 119.28 32.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.591 -0.693 . . . . 0.0 109.996 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.7 mp -65.02 -39.95 94.16 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.593 -0.692 . . . . 0.0 109.959 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.3 p -110.87 119.97 44.72 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.601 -0.687 . . . . 0.0 110.033 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.23 117.74 5.05 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.736 1.388 . . . . 0.0 110.281 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 13.1 mmt85 -120.59 160.0 45.97 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.56 -0.712 . . . . 0.0 110.197 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.58 159.21 54.41 Favored 'Trans proline' 0 N--CA 1.489 1.255 0 O-C-N 123.875 1.461 . . . . 0.0 110.475 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.495 HG11 ' OE1' ' B' ' 188' ' ' GLU . 92.5 t -64.66 -33.15 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.538 -0.726 . . . . 0.0 109.98 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 56.0 m -60.07 -38.09 81.82 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.588 -0.695 . . . . 0.0 110.223 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -60.05 -40.04 88.02 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.559 -0.713 . . . . 0.0 110.212 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.3 mp -83.6 -23.34 31.96 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.529 -0.732 . . . . 0.0 110.756 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.11 140.06 57.12 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.339 -0.851 . . . . 0.0 110.246 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.05 4.2 89.63 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.8 m -109.53 -0.89 18.59 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.075 -1.25 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 31.0 t -60.01 141.47 55.59 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.108 -0.995 . . . . 0.0 109.754 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 100.05 -19.79 51.64 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.75 147.05 44.0 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.547 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.1 Cg_endo -92.38 144.78 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.925 1.487 . . . . 0.0 111.181 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.35 111.11 23.25 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.65 131.72 45.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.526 -0.733 . . . . 0.0 111.453 -178.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.05 160.03 82.06 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -52.0 -22.88 15.47 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 O-C-N 123.532 1.28 . . . . 0.0 112.161 -178.684 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.66 -40.03 88.45 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.225 -0.922 . . . . 0.0 109.881 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.19 35.66 0.86 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -132.03 148.14 52.49 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.467 -1.019 . . . . 0.0 110.445 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.71 143.51 57.34 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.599 -0.688 . . . . 0.0 110.273 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 172' ' ' VAL . 54.4 t -118.29 -40.87 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.536 -0.727 . . . . 0.0 110.052 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.57 -175.59 41.41 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.0 mt -122.91 130.34 74.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.535 -0.979 . . . . 0.0 110.391 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.434 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 23.1 t80 -60.34 134.6 57.22 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.55 -0.719 . . . . 0.0 109.818 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.7 ttt180 -113.24 -52.13 2.78 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.458 -0.777 . . . . 0.0 110.443 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -155.09 160.01 40.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.44 -0.787 . . . . 0.0 110.558 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.434 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -111.73 153.71 26.08 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.614 -0.679 . . . . 0.0 110.193 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.05 118.99 58.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.625 -0.672 . . . . 0.0 109.751 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -132.99 149.29 52.24 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.654 -0.654 . . . . 0.0 110.307 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.7 p -82.26 -42.9 18.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.645 -0.659 . . . . 0.0 110.61 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -160.34 59.93 0.34 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.131 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 98.75 -10.01 62.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.33 122.25 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.134 -1.215 . . . . 0.0 109.843 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.57 126.12 41.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.68 -0.637 . . . . 0.0 110.78 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 47.5 mmtt -107.14 -25.45 11.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.733 -0.605 . . . . 0.0 110.118 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.73 154.54 46.37 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.728 . . . . 0.0 110.04 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 26.8 m -126.21 -171.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.557 -0.714 . . . . 0.0 110.786 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -146.93 134.57 21.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.69 -0.631 . . . . 0.0 109.444 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -137.48 159.19 42.64 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.446 -0.784 . . . . 0.0 110.8 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.618 HG11 HD11 ' A' ' 82' ' ' LEU . 65.5 t -98.42 121.2 57.49 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -62.37 159.94 33.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.711 1.374 . . . . 0.0 110.517 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.4 t -69.39 -27.09 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.615 -0.678 . . . . 0.0 110.829 -179.304 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -58.18 -39.67 79.5 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.366 -0.834 . . . . 0.0 110.7 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 89.3 p -67.08 -38.46 85.77 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.454 -0.779 . . . . 0.0 110.246 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.627 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 87.9 mtp -60.0 -40.04 87.85 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.489 -0.757 . . . . 0.0 110.319 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -64.27 -40.01 95.11 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.506 -0.746 . . . . 0.0 110.3 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.5 m -67.93 -28.78 67.77 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.713 -0.617 . . . . 0.0 110.372 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' THR . . . . . 0.401 HG23 ' OD1' ' A' ' 77' ' ' ASN . 94.1 m -59.97 -40.07 87.83 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.571 -0.706 . . . . 0.0 110.272 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.5 mtt . . . . . 0 N--CA 1.496 1.873 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 179.995 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.622 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.165 0.507 . . . . 0.0 110.071 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.829 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 110.45 -179.767 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.403 ' HG2' ' CB ' ' A' ' 92' ' ' ARG . 62.9 mt-10 . . . . . 0 N--CA 1.496 1.867 0 CA-C-O 121.123 0.487 . . . . 0.0 110.047 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.497 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.2 t -105.58 127.21 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.538 -0.726 . . . . 0.0 109.959 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -116.28 150.14 38.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.586 -0.696 . . . . 0.0 110.334 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 35' ' ' VAL . 12.5 p -79.72 129.02 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.63 -0.669 . . . . 0.0 110.04 179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.727 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.4 m -125.14 154.29 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 110.031 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.5 m -149.84 171.48 16.69 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.016 -0.673 . . . . 0.0 110.511 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.9 p -140.93 -173.35 3.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.766 -0.584 . . . . 0.0 109.434 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.34 -0.81 26.99 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.497 -0.752 . . . . 0.0 111.219 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.4 m -118.59 -46.75 2.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.109 -0.994 . . . . 0.0 111.359 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -147.76 171.18 16.09 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.268 -0.895 . . . . 0.0 111.407 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 32.1 t -119.15 146.65 44.98 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.664 -0.647 . . . . 0.0 109.926 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.609 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 15.1 p90 -158.17 -176.44 5.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.486 -0.758 . . . . 0.0 110.215 -179.548 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.765 HD11 ' HA ' ' A' ' 109' ' ' ARG . 42.0 mt -111.54 167.65 10.16 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.565 -0.709 . . . . 0.0 110.338 -178.309 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.497 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -142.91 155.69 44.77 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.698 -0.626 . . . . 0.0 110.039 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.529 HG21 ' HB3' ' A' ' 142' ' ' PRO . 73.4 p -120.28 129.45 54.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.453 -0.78 . . . . 0.0 110.177 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 35.0 t -91.13 107.42 19.19 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.514 -0.741 . . . . 0.0 110.517 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' HB2' ' A' ' 94' ' ' LEU . 57.6 t -115.29 135.87 53.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.624 -0.673 . . . . 0.0 109.552 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 54.78 37.42 28.41 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.536 -0.727 . . . . 0.0 111.021 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 23.14 77.35 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.6 t -138.25 129.91 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.248 -1.148 . . . . 0.0 110.089 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' CYS . . . . . 0.411 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 4.0 t -68.45 148.47 50.59 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.418 -0.801 . . . . 0.0 109.454 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 48.8 m95 -140.08 142.95 36.08 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.197 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.666 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.9 t -170.07 -178.6 2.9 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.818 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.7 p -83.23 159.01 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 110.401 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CD1' ' HA2' ' A' ' 60' ' ' GLY . 55.5 t80 -76.99 -40.03 48.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.67 -0.644 . . . . 0.0 112.069 -178.805 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.872 ' CG ' HD23 ' B' ' 189' ' ' LEU . 2.9 p-80 -61.0 -24.67 66.32 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.113 -0.992 . . . . 0.0 110.848 -178.626 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.446 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -74.75 -49.01 11.17 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.609 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -114.86 -55.56 2.47 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.561 -0.964 . . . . 0.0 110.458 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 85.09 -172.33 47.44 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 47.8 t -80.14 65.13 5.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.526 -0.985 . . . . 0.0 109.848 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -141.81 170.06 16.43 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.587 -0.696 . . . . 0.0 110.267 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.1 m -65.57 139.77 58.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.527 -0.733 . . . . 0.0 109.851 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.727 HD21 ' HB ' ' A' ' 36' ' ' VAL . 20.4 tp -108.81 141.02 41.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.692 -0.63 . . . . 0.0 110.099 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.15 111.56 23.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.57 -0.706 . . . . 0.0 110.166 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.12 -178.29 18.23 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -62.1 -31.96 83.37 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 O-C-N 123.765 1.403 . . . . 0.0 110.518 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.4 tttt -74.61 -31.27 61.97 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.669 -0.644 . . . . 0.0 109.769 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.33 -154.38 23.45 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.41 146.82 69.86 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 O-C-N 123.816 1.43 . . . . 0.0 109.953 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -130.3 139.98 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.514 -0.741 . . . . 0.0 110.599 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.3 m -89.83 139.9 30.13 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.563 -0.711 . . . . 0.0 110.211 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 pp0? -83.2 150.25 26.33 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.519 -0.738 . . . . 0.0 111.383 -179.348 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.2 mtp -110.37 -29.93 7.9 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.821 -0.549 . . . . 0.0 109.944 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -131.76 148.39 52.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.72 -0.613 . . . . 0.0 110.459 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.15 125.98 11.17 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.663 -0.648 . . . . 0.0 109.628 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -141.92 95.57 2.83 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.528 -0.733 . . . . 0.0 110.152 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 91.9 t -61.43 -44.67 98.95 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.673 -0.642 . . . . 0.0 109.921 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.15 -48.75 80.39 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.551 -0.718 . . . . 0.0 110.256 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.679 ' CG ' HD12 ' A' ' 82' ' ' LEU . 3.0 tp-100 -80.07 -9.15 59.68 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.66 -0.65 . . . . 0.0 110.478 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 5.7 t0 56.79 48.18 16.63 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.22 -0.925 . . . . 0.0 110.422 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.679 HD12 ' CG ' ' A' ' 80' ' ' GLN . 81.3 mt -137.96 149.83 46.49 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.48 -0.762 . . . . 0.0 110.892 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -150.05 149.97 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.611 -0.68 . . . . 0.0 109.493 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -133.86 149.55 19.75 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.335 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.713 ' CZ3' HD22 ' A' ' 64' ' ' LEU . 5.3 m-90 -120.16 168.19 11.47 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.68 -0.894 . . . . 0.0 110.204 179.516 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -72.86 120.42 18.46 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.455 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -68.98 132.24 90.5 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.448 -0.782 . . . . 0.0 109.958 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.99 157.07 61.15 Favored 'Trans proline' 0 N--CA 1.49 1.294 0 O-C-N 123.84 1.442 . . . . 0.0 110.478 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.56 160.23 48.94 Favored 'Trans proline' 0 N--CA 1.49 1.282 0 O-C-N 123.936 1.493 . . . . 0.0 110.185 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 29.97 70.44 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.04 160.87 22.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.6 -0.941 . . . . 0.0 110.106 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.403 ' CB ' ' HG2' ' A' ' 32' ' ' GLU . 75.1 mtp85 -105.19 153.75 21.13 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 110.275 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 54.5 m -111.3 160.9 16.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.605 -0.684 . . . . 0.0 110.294 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.486 ' HB2' HG22 ' A' ' 48' ' ' VAL . 84.5 mt -100.31 131.85 46.01 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.595 -0.691 . . . . 0.0 110.524 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.3 p -77.04 159.95 77.27 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.608 -0.682 . . . . 0.0 110.006 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -85.57 158.24 10.71 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 O-C-N 123.799 1.421 . . . . 0.0 110.54 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.4 t -79.81 129.75 34.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.587 -0.695 . . . . 0.0 110.087 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' THR . 6.8 t -132.88 56.45 1.85 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.677 -0.64 . . . . 0.0 109.678 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.87 -8.1 0.73 Allowed 'General case' 0 N--CA 1.497 1.913 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.252 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.92 46.09 94.73 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.98 119.77 38.77 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.518 -0.989 . . . . 0.0 110.45 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -62.95 -40.03 96.43 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.703 -0.623 . . . . 0.0 110.355 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -63.3 132.55 51.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.543 -0.723 . . . . 0.0 110.354 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 1.003 HD22 HG11 ' A' ' 151' ' ' VAL . 96.0 mt -137.29 145.24 43.22 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.568 -0.708 . . . . 0.0 110.488 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.47 122.15 46.05 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.541 -0.725 . . . . 0.0 109.858 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.432 HD13 ' HG ' ' A' ' 143' ' ' LEU . 40.6 tp -103.69 146.17 28.98 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.671 . . . . 0.0 110.605 -179.458 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.67 130.07 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.65 -0.656 . . . . 0.0 109.758 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -93.09 170.04 9.95 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.487 -0.758 . . . . 0.0 110.754 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.765 ' HA ' HD11 ' A' ' 44' ' ' LEU . 5.4 ttt-85 -64.6 -21.07 66.61 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.639 -0.663 . . . . 0.0 110.623 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 44.4 t-80 -94.42 29.41 2.25 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.416 -0.803 . . . . 0.0 110.488 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.7 40.02 30.86 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -107.44 157.32 18.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.648 -0.658 . . . . 0.0 109.926 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.99 130.32 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.589 -0.694 . . . . 0.0 110.193 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 76.5 mt -128.86 150.04 73.96 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.569 -0.707 . . . . 0.0 109.827 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -87.14 132.07 3.17 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.919 1.484 . . . . 0.0 110.409 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -129.84 130.01 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.641 -0.662 . . . . 0.0 109.526 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -92.18 136.21 33.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.455 -0.778 . . . . 0.0 110.192 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -79.17 128.82 33.78 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.571 -0.706 . . . . 0.0 110.318 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -121.68 23.02 10.38 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.616 -0.677 . . . . 0.0 110.169 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.0 179.73 41.23 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -61.37 -40.82 95.71 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.488 -1.007 . . . . 0.0 110.233 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 78.6 p -132.64 26.52 4.38 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.57 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -129.74 140.04 51.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.493 -0.754 . . . . 0.0 110.134 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.14 169.76 25.63 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -114.71 157.37 23.26 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.621 -0.929 . . . . 0.0 110.071 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.9 tp -100.41 119.15 38.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.566 -0.709 . . . . 0.0 110.165 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.497 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -69.68 -37.29 76.61 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.477 -0.765 . . . . 0.0 109.741 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.9 t -108.57 109.96 61.42 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.63 -0.669 . . . . 0.0 109.95 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.79 116.26 3.71 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.839 1.441 . . . . 0.0 110.469 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -119.95 160.03 44.47 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.544 -0.723 . . . . 0.0 110.185 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.74 157.74 60.62 Favored 'Trans proline' 0 N--CA 1.491 1.358 0 O-C-N 123.877 1.462 . . . . 0.0 110.442 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 94.3 t -61.53 -36.05 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.608 -0.682 . . . . 0.0 110.01 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -40.09 87.66 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.547 -0.721 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -59.89 -40.08 87.52 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.544 -0.723 . . . . 0.0 110.285 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.8 mp -82.65 -24.52 33.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.521 -0.737 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.39 140.23 57.29 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.295 -0.878 . . . . 0.0 109.972 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.02 10.23 85.8 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 20.6 m -116.17 18.83 15.23 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.173 -1.192 . . . . 0.0 110.606 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 1.8 m -69.95 149.95 47.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.356 -0.84 . . . . 0.0 109.857 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 46' ' ' THR . . . 90.05 -11.89 69.37 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.86 137.81 48.25 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.529 ' HB3' HG21 ' A' ' 46' ' ' THR . 50.0 Cg_endo -87.22 142.32 6.23 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.807 1.425 . . . . 0.0 111.327 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.87 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -103.6 109.56 21.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.444 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -102.74 132.33 48.96 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.457 -0.777 . . . . 0.0 111.62 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.447 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -68.56 159.62 80.62 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -51.9 -26.07 23.53 Favored 'Trans proline' 0 N--CA 1.5 1.874 0 O-C-N 123.446 1.235 . . . . 0.0 112.391 -178.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -62.69 -40.01 95.76 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.231 -0.918 . . . . 0.0 109.809 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 122.02 34.01 0.87 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -132.52 145.72 51.37 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.428 -1.042 . . . . 0.0 110.157 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.8 136.86 45.49 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.671 -0.643 . . . . 0.0 110.255 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 1.003 HG11 HD22 ' A' ' 104' ' ' LEU . 8.8 p -116.14 -21.28 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 110.78 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.29 -176.59 45.5 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.697 HD12 ' CE ' ' A' ' 175' ' ' MET . 92.7 mt -130.81 140.07 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.402 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.493 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.5 t80 -60.87 139.99 57.82 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.58 -0.7 . . . . 0.0 109.862 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 64.4 ttt180 -120.68 -52.5 2.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.56 -0.712 . . . . 0.0 110.393 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.793 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.32 157.62 43.49 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.486 -0.758 . . . . 0.0 110.325 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -110.23 145.52 37.19 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.548 -0.72 . . . . 0.0 110.265 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.1 t -110.0 119.96 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.631 -0.668 . . . . 0.0 109.794 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -130.59 152.17 50.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.639 -0.663 . . . . 0.0 110.39 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 p -77.8 -45.16 25.28 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.65 -0.656 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 45.6 ptt85 -164.0 54.78 0.16 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.621 -0.674 . . . . 0.0 109.975 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 111.93 -14.63 26.44 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.29 120.74 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.185 -1.185 . . . . 0.0 109.963 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -84.45 129.32 34.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.657 -0.652 . . . . 0.0 110.447 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 21.4 pttm -111.44 -24.31 10.25 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.621 -0.674 . . . . 0.0 110.604 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.13 159.23 42.68 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.619 -0.676 . . . . 0.0 109.909 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 m -134.91 167.32 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.611 -0.681 . . . . 0.0 110.668 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -126.78 139.65 52.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.669 -0.644 . . . . 0.0 109.771 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -138.04 154.7 49.28 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.402 -0.811 . . . . 0.0 110.833 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.512 HG11 HD11 ' A' ' 82' ' ' LEU . 62.6 t -93.29 121.15 65.89 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.68 -0.637 . . . . 0.0 109.472 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.64 154.11 75.57 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.734 1.386 . . . . 0.0 110.544 -179.602 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 63.7 t -62.99 -26.75 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.571 -0.706 . . . . 0.0 110.35 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -59.12 -39.9 83.75 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.478 -0.764 . . . . 0.0 110.351 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 86.2 p -60.0 -38.29 82.18 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.487 -0.758 . . . . 0.0 110.216 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.697 ' CE ' HD12 ' A' ' 153' ' ' ILE . 69.0 mtt -61.86 -40.03 93.93 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.507 -0.745 . . . . 0.0 110.257 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -41.81 92.85 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.539 -179.529 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 72.8 p -70.03 -27.46 64.68 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.3 m -60.06 -45.39 93.03 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.425 -0.797 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.6 mtt . . . . . 0 N--CA 1.497 1.9 0 O-C-N 121.578 -0.701 . . . . 0.0 110.083 179.939 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.793 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 61.5 tt0 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.045 0.45 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.872 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.617 -0.677 . . . . 0.0 110.25 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.902 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 . . . . . 0 N--CA 1.498 1.941 0 CA-C-O 120.823 0.344 . . . . 0.0 110.498 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.902 HG23 ' HG3' ' A' ' 32' ' ' GLU . 60.3 t -108.21 126.74 64.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.503 -0.748 . . . . 0.0 109.82 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -123.39 154.41 39.03 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.484 -0.76 . . . . 0.0 110.584 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.9 t -90.3 122.77 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.617 -0.677 . . . . 0.0 109.276 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.591 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.5 m -120.37 152.71 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.564 -0.71 . . . . 0.0 110.176 -179.555 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.2 m -141.75 169.56 17.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.662 -0.648 . . . . 0.0 110.513 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 39' ' ' ALA . 1.0 OUTLIER -132.37 -169.77 2.29 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.904 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.536 ' H ' HG22 ' A' ' 38' ' ' THR . . . -58.73 -41.73 87.11 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.42 -0.8 . . . . 0.0 110.575 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.8 m -134.24 -6.86 2.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.479 -0.763 . . . . 0.0 112.025 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.8 tp60 -111.76 160.43 17.32 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.899 -1.126 . . . . 0.0 110.864 -179.214 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -147.56 137.91 23.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.452 -0.78 . . . . 0.0 110.402 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 29.0 p90 -169.11 -177.67 2.99 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.312 -0.868 . . . . 0.0 110.434 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.857 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.6 mt -112.99 159.94 18.61 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.429 -0.795 . . . . 0.0 110.672 -178.551 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -136.26 159.84 40.53 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.689 -0.632 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.696 ' CG2' HD12 ' A' ' 94' ' ' LEU . 23.0 m -123.8 139.29 54.12 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.444 -0.785 . . . . 0.0 110.351 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.0 t -94.38 111.03 22.76 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 110.637 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.411 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.1 t -117.2 130.31 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.704 -0.623 . . . . 0.0 109.662 179.553 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.46 39.44 28.01 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.503 -0.748 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.721 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.85 19.89 75.56 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -133.53 129.77 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -1.163 . . . . 0.0 110.025 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 89.3 m -74.49 147.67 41.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.391 -0.818 . . . . 0.0 109.419 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.411 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 67.5 m95 -129.94 151.66 50.26 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.394 -0.816 . . . . 0.0 110.824 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.3 t -167.41 -179.62 4.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.756 -0.59 . . . . 0.0 109.771 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.4 p -90.03 158.19 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.454 -0.779 . . . . 0.0 110.319 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.444 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 71.4 t80 -74.27 -42.31 59.82 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.599 -0.688 . . . . 0.0 111.477 -179.042 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -70.03 -22.48 63.09 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.148 -0.97 . . . . 0.0 110.799 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.778 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -81.31 -59.98 2.31 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.555 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -91.01 -52.34 4.89 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.639 -0.918 . . . . 0.0 110.204 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 -174.33 47.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 36.4 p -81.93 61.7 5.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.561 -0.964 . . . . 0.0 109.806 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -141.53 170.13 16.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.582 -0.699 . . . . 0.0 110.533 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.5 p -66.32 156.71 33.63 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.678 -0.639 . . . . 0.0 109.725 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.86 HD22 ' CH2' ' A' ' 85' ' ' TRP . 27.3 tp -118.3 140.5 49.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.575 -0.703 . . . . 0.0 110.28 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.27 109.72 21.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.663 -0.648 . . . . 0.0 109.998 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.19 -174.31 15.79 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.4 -32.35 71.82 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 O-C-N 123.907 1.477 . . . . 0.0 110.542 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.4 mttt -77.15 -31.03 55.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.667 -0.646 . . . . 0.0 110.01 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.75 -150.57 21.8 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -75.03 138.69 23.28 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.89 1.469 . . . . 0.0 110.358 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -119.97 129.96 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.621 -0.674 . . . . 0.0 110.577 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.9 p -82.51 142.53 31.78 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.525 -0.735 . . . . 0.0 109.753 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.77 149.97 21.33 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.432 -0.793 . . . . 0.0 111.254 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.6 mmm -115.43 -26.3 7.61 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.752 -0.592 . . . . 0.0 110.451 179.748 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -119.95 139.95 51.66 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.396 -0.815 . . . . 0.0 110.724 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.554 ' HA ' HG12 ' A' ' 83' ' ' VAL . 91.7 m -140.35 130.0 24.3 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.654 -0.654 . . . . 0.0 109.944 179.551 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -137.37 103.27 5.03 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.389 -0.819 . . . . 0.0 110.441 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 70.9 t -71.15 -45.24 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.51 -0.744 . . . . 0.0 110.224 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -60.11 -49.89 75.85 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.437 -0.79 . . . . 0.0 110.223 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.72 ' HG3' HD12 ' A' ' 82' ' ' LEU . 3.7 tp-100 -80.04 -9.99 59.74 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.538 -0.726 . . . . 0.0 110.582 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.7 t70 56.01 44.95 24.66 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.147 -0.97 . . . . 0.0 109.985 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 1.118 HD11 HG21 ' A' ' 170' ' ' VAL . 64.9 mt -141.77 131.5 24.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.655 -0.653 . . . . 0.0 110.902 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.554 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -129.96 159.98 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.66 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -137.47 157.34 23.98 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.553 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.6 m-90 -115.39 157.05 24.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.874 -0.78 . . . . 0.0 109.467 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -69.48 108.16 3.66 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.521 -0.737 . . . . 0.0 109.377 179.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.16 143.34 91.09 Favored Pre-proline 0 N--CA 1.496 1.844 0 O-C-N 121.495 -0.753 . . . . 0.0 110.359 -179.549 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.1 158.42 56.57 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.089 1.573 . . . . 0.0 110.154 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.98 153.33 63.37 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.886 1.466 . . . . 0.0 110.27 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.12 29.68 62.17 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.28 154.33 20.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.514 -0.992 . . . . 0.0 110.09 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -80.18 159.25 26.06 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 110.005 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 97.2 p -139.98 159.73 41.53 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.292 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.696 HD12 ' CG2' ' A' ' 46' ' ' THR . 7.7 mt -106.09 132.19 52.46 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.591 -0.693 . . . . 0.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' HD2' ' A' ' 96' ' ' PRO . 86.7 m -80.0 141.29 54.5 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.693 -0.63 . . . . 0.0 109.916 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PRO . . . . . 0.596 ' HB3' HG11 ' A' ' 172' ' ' VAL . 44.6 Cg_endo -64.04 163.58 25.13 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.812 1.427 . . . . 0.0 110.377 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.677 ' HB2' HG22 ' A' ' 151' ' ' VAL . 51.5 t -87.74 123.54 32.66 Favored 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.65 0.738 . . . . 0.0 110.937 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.0 m -118.21 59.66 0.8 Allowed 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 177.802 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 3.5 m -141.76 -9.31 0.93 Allowed 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 119.99 -0.684 . . . . 0.0 111.899 -177.477 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.12 25.47 54.07 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.089 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -70.23 130.81 43.04 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.525 -0.985 . . . . 0.0 110.723 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 118' ' ' ARG . 56.4 m -74.37 -39.99 62.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.73 -0.606 . . . . 0.0 110.464 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.4 130.51 42.74 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.518 -0.739 . . . . 0.0 110.546 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.8 mt -131.23 140.2 49.82 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.649 -0.657 . . . . 0.0 110.637 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -106.85 124.37 49.52 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.494 -0.754 . . . . 0.0 109.817 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.531 HD13 ' HG ' ' A' ' 143' ' ' LEU . 37.7 tp -108.48 145.43 34.71 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.394 -0.816 . . . . 0.0 110.924 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.05 120.99 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.674 -0.641 . . . . 0.0 109.706 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.9 p -95.31 173.03 7.74 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.55 -0.719 . . . . 0.0 110.547 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.857 ' HA ' HD11 ' A' ' 44' ' ' LEU . 3.5 ptp180 -69.33 -11.95 61.25 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.544 -0.723 . . . . 0.0 111.103 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 58.2 m80 -93.01 21.69 5.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.209 -0.932 . . . . 0.0 110.399 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.33 40.05 31.42 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.222 -0.924 . . . . 0.0 110.575 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -124.02 147.65 47.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.658 -0.651 . . . . 0.0 109.64 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.0 p -129.98 130.69 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.565 -0.709 . . . . 0.0 110.405 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.621 HD12 HD11 ' A' ' 126' ' ' LEU . 43.8 pt -121.1 150.0 52.61 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.679 -0.638 . . . . 0.0 109.796 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -81.57 123.27 4.24 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.937 1.493 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -119.7 120.95 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.715 -0.616 . . . . 0.0 109.6 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -76.73 149.67 36.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.48 -0.762 . . . . 0.0 110.039 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB3' ' HA ' ' A' ' 102' ' ' SER . 64.6 ttt180 -90.89 120.06 31.6 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.359 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -109.94 20.09 18.36 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.659 -0.651 . . . . 0.0 110.399 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.85 -179.97 39.78 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.72 -39.92 90.41 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.972 . . . . 0.0 110.301 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.4 p -130.92 25.1 4.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.557 -0.714 . . . . 0.0 110.522 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -124.25 139.53 53.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.439 -0.788 . . . . 0.0 110.254 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.77 165.79 26.41 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 99.8 p -120.21 155.51 33.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.648 -0.913 . . . . 0.0 110.129 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.621 HD11 HD12 ' A' ' 114' ' ' ILE . 14.2 tp -99.97 119.5 38.35 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.516 -0.74 . . . . 0.0 110.158 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.04 -39.91 94.03 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.493 -0.754 . . . . 0.0 109.961 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 85.6 p -110.66 120.2 44.4 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.39 120.87 7.93 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 123.763 1.402 . . . . 0.0 110.4 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.2 mmt180 -129.93 159.98 67.34 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.539 -0.726 . . . . 0.0 110.251 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.39 156.72 61.82 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.982 1.517 . . . . 0.0 110.423 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.492 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.9 m -67.06 -25.44 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.658 -0.651 . . . . 0.0 110.618 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.7 m -59.94 -40.04 87.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.41 -0.806 . . . . 0.0 110.272 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.531 ' HD2' HD12 ' A' ' 135' ' ' LEU . 88.5 t80 -60.06 -40.08 88.23 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.497 -0.752 . . . . 0.0 109.935 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 134' ' ' TYR . 3.2 mp -83.85 -25.39 30.34 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.535 -0.728 . . . . 0.0 110.287 179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -59.96 132.02 52.66 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.408 -0.808 . . . . 0.0 110.105 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 91.96 0.93 70.84 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.306 -0.95 . . . . 0.0 110.732 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -109.96 19.99 18.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.136 -1.214 . . . . 0.0 110.66 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.4 t -68.65 147.68 51.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.327 -0.858 . . . . 0.0 109.724 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.78 -14.5 62.98 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.26 148.85 43.17 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -96.81 148.31 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.875 1.461 . . . . 0.0 111.123 -179.297 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.609 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -103.94 108.96 20.53 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.663 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.545 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.93 134.79 42.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.461 -0.774 . . . . 0.0 111.773 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 28.5 p -70.03 159.93 82.41 Favored Pre-proline 0 N--CA 1.494 1.75 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.812 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -52.62 -22.13 16.28 Favored 'Trans proline' 0 N--CA 1.5 1.904 0 O-C-N 123.512 1.269 . . . . 0.0 112.056 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 8.6 t -67.63 -42.92 81.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.228 -0.92 . . . . 0.0 110.055 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 125.51 35.93 0.59 Allowed Glycine 0 N--CA 1.496 2.671 0 C-N-CA 120.069 -1.062 . . . . 0.0 110.904 179.278 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 23.0 m-70 -133.02 144.63 50.2 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.237 -1.155 . . . . 0.0 110.283 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.477 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -62.67 145.21 55.19 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.588 -0.695 . . . . 0.0 110.357 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.677 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.2 t -119.15 -38.91 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.523 -0.735 . . . . 0.0 110.118 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.99 -177.73 42.47 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 85.4 mt -121.61 132.02 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -1.013 . . . . 0.0 110.521 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.697 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 35.6 t80 -60.32 137.16 58.18 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.586 -0.696 . . . . 0.0 109.799 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 68.5 ttt180 -121.17 -52.72 2.06 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.498 -0.752 . . . . 0.0 110.33 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -143.16 159.96 41.32 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.508 -0.745 . . . . 0.0 110.073 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.697 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.84 136.05 54.92 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.627 -0.671 . . . . 0.0 110.553 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.6 t -90.0 119.74 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.492 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -135.52 153.69 51.64 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.487 -0.758 . . . . 0.0 111.404 -179.14 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 160' ' ' THR . . . . . 0.562 HG22 ' HG2' ' A' ' 161' ' ' ARG . 37.1 m -130.53 137.38 49.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.756 -0.59 . . . . 0.0 109.522 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.562 ' HG2' HG22 ' A' ' 160' ' ' THR . 21.7 mmt180 54.21 37.14 26.63 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.272 -0.893 . . . . 0.0 110.755 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 74.19 23.28 76.31 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.4 t -129.98 129.87 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.295 -1.12 . . . . 0.0 110.065 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.78 125.57 35.75 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.539 -0.725 . . . . 0.0 110.131 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.51 -29.61 7.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.541 -0.725 . . . . 0.0 110.455 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.89 162.85 34.45 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.57 -0.706 . . . . 0.0 109.941 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -136.02 165.59 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.432 -0.792 . . . . 0.0 110.965 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -126.37 135.86 51.98 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.629 -0.67 . . . . 0.0 109.995 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -139.88 147.41 40.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.496 -0.752 . . . . 0.0 110.64 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 1.118 HG21 HD11 ' A' ' 82' ' ' LEU . 33.0 m -89.96 125.0 62.1 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.497 -0.752 . . . . 0.0 109.556 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.88 159.96 39.5 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.746 1.393 . . . . 0.0 110.711 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.9 t -60.22 -25.23 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.596 -0.69 . . . . 0.0 110.594 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -58.73 -39.01 79.62 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.456 -0.777 . . . . 0.0 110.354 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 67.5 m -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.468 -0.77 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.42 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.3 mtm -69.99 -37.37 75.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.35 -0.844 . . . . 0.0 110.331 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -59.97 -40.15 88.09 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.513 -0.742 . . . . 0.0 110.468 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 70.1 p -65.31 -37.12 86.16 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.471 -0.768 . . . . 0.0 110.253 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.0 m -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.593 -0.692 . . . . 0.0 110.139 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.534 -0.729 . . . . 0.0 110.058 179.888 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.1 0.476 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.743 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp . . . . . 0 N--CA 1.495 1.801 0 O-C-N 121.535 -0.728 . . . . 0.0 110.041 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.708 ' OE1' HD21 ' A' ' 94' ' ' LEU . 96.9 mt-10 . . . . . 0 N--CA 1.497 1.875 0 CA-C-O 121.101 0.477 . . . . 0.0 110.116 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.8 124.65 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.592 -0.692 . . . . 0.0 109.793 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -119.13 155.11 32.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.667 -0.645 . . . . 0.0 110.512 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.8 t -90.21 131.04 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.621 -0.674 . . . . 0.0 109.539 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.517 ' CB ' HD21 ' A' ' 64' ' ' LEU . 27.8 m -123.91 158.38 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.68 -0.637 . . . . 0.0 110.194 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.12 179.35 6.56 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.71 -0.619 . . . . 0.0 110.362 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.2 OUTLIER -141.46 -170.9 3.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.67 -0.643 . . . . 0.0 109.479 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.42 ' H ' HG22 ' A' ' 38' ' ' THR . . . -60.03 -38.88 84.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.523 -0.736 . . . . 0.0 110.258 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.6 t -136.92 -6.71 1.87 Allowed 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.546 -0.721 . . . . 0.0 112.555 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -118.8 156.71 28.93 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 120.839 -1.163 . . . . 0.0 111.129 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.1 m -136.34 139.75 42.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.566 -0.709 . . . . 0.0 110.341 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -165.61 -177.16 4.24 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.238 -0.914 . . . . 0.0 110.075 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.758 HD11 ' HA ' ' A' ' 109' ' ' ARG . 21.7 mt -112.33 175.16 5.55 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.529 -0.732 . . . . 0.0 110.273 -178.055 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.443 ' HB1' ' SG ' ' A' ' 52' ' ' CYS . . . -149.64 156.85 42.59 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.692 -0.63 . . . . 0.0 110.087 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.583 ' CG2' HD12 ' A' ' 94' ' ' LEU . 27.6 m -119.51 139.92 51.33 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.699 -0.626 . . . . 0.0 110.063 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.3 t -101.35 109.35 21.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.453 -0.78 . . . . 0.0 110.476 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.438 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.4 t -120.38 134.28 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.69 -0.631 . . . . 0.0 109.842 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASN . . . . . 0.438 ' OD1' HG12 ' A' ' 48' ' ' VAL . 28.7 m120 55.23 38.52 30.52 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.534 -0.729 . . . . 0.0 111.144 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.63 26.67 74.22 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 80.9 t -140.47 130.03 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.338 -1.095 . . . . 0.0 109.956 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' CYS . . . . . 0.443 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 23.7 t -86.71 108.58 18.73 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.468 -0.77 . . . . 0.0 109.37 179.677 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -91.42 151.21 20.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.595 -0.691 . . . . 0.0 111.05 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.5 t -159.88 -179.71 8.06 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.648 HG21 ' NE2' ' A' ' 57' ' ' HIS . 10.5 p -96.59 152.35 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.448 -0.783 . . . . 0.0 110.443 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.427 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.1 t80 -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.58 -0.7 . . . . 0.0 112.091 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.795 ' CG ' HD23 ' B' ' 189' ' ' LEU . 6.1 p80 -68.85 -19.52 64.26 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.139 -0.976 . . . . 0.0 111.068 -178.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.591 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -91.13 -52.28 2.42 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 179.037 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.637 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -103.2 -47.68 4.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.628 -0.925 . . . . 0.0 110.123 179.67 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.2 -168.89 40.78 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.496 ' OG ' HG21 ' A' ' 76' ' ' THR . 1.4 t -86.41 64.68 8.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.546 -0.973 . . . . 0.0 109.837 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -141.89 170.05 16.45 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.602 -0.686 . . . . 0.0 110.363 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.1 p -66.13 150.14 49.21 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.618 -0.676 . . . . 0.0 109.944 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.813 HD22 ' CH2' ' A' ' 85' ' ' TRP . 19.2 tp -117.08 142.62 46.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.611 -0.681 . . . . 0.0 110.082 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -97.62 110.26 22.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.621 -0.675 . . . . 0.0 110.093 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.33 177.11 16.31 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.7 -31.78 68.98 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.85 1.448 . . . . 0.0 110.412 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -71.7 -31.47 66.78 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.597 -0.689 . . . . 0.0 109.999 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.88 -160.56 26.21 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.94 137.23 40.73 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.886 1.466 . . . . 0.0 110.036 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.6 mt -119.94 129.98 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.506 -0.746 . . . . 0.0 110.564 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.3 p -84.86 150.23 25.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.574 -0.704 . . . . 0.0 109.707 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 10.5 pm0 -98.53 148.12 24.08 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.481 -0.762 . . . . 0.0 111.008 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.9 mtp -113.95 -25.55 8.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.766 -0.584 . . . . 0.0 110.504 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -120.01 135.88 54.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.428 -0.795 . . . . 0.0 110.572 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.643 ' HA ' HG12 ' A' ' 83' ' ' VAL . 29.9 m -140.91 126.11 18.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 109.88 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 30.1 t-20 -140.5 104.51 4.77 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.349 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 75.8 t -69.97 -45.3 77.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 0.0 109.871 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -59.87 -49.69 76.7 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.554 -0.716 . . . . 0.0 110.213 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.789 ' HG2' HD12 ' A' ' 82' ' ' LEU . 53.6 tt0 -79.95 -9.99 59.73 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.583 -0.698 . . . . 0.0 110.832 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.427 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 6.0 t70 55.2 46.22 24.25 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.031 -1.043 . . . . 0.0 110.446 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.789 HD12 ' HG2' ' A' ' 80' ' ' GLN . 41.3 mt -143.36 130.43 20.69 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.552 -0.717 . . . . 0.0 111.075 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.643 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -130.94 159.99 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.615 -0.678 . . . . 0.0 109.265 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.76 157.92 23.91 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.597 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 6.0 m-90 -119.93 160.28 23.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.792 -0.828 . . . . 0.0 109.778 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -71.88 124.57 25.15 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.088 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -72.7 130.01 86.08 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.489 -0.757 . . . . 0.0 110.212 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.02 159.64 52.47 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 O-C-N 123.876 1.461 . . . . 0.0 110.356 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.41 139.7 42.11 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.85 1.447 . . . . 0.0 110.306 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.58 -20.33 50.84 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.01 47.1 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.305 -1.115 . . . . 0.0 110.221 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.8 mtp85 -92.16 170.01 10.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.573 -0.705 . . . . 0.0 110.165 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -132.37 160.01 37.58 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.708 HD21 ' OE1' ' A' ' 32' ' ' GLU . 80.5 mt -110.74 132.23 54.37 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.9 p -76.34 160.05 78.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.693 -0.629 . . . . 0.0 109.95 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -77.21 164.04 29.67 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.833 1.438 . . . . 0.0 110.651 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.802 ' HB2' HG22 ' A' ' 151' ' ' VAL . 47.1 t -73.06 128.57 35.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.647 -0.658 . . . . 0.0 110.212 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.7 p -132.05 54.42 1.94 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.725 -0.609 . . . . 0.0 109.715 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.59 -7.52 0.77 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.519 -0.738 . . . . 0.0 112.376 -179.043 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.98 94.36 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -100.08 123.6 44.51 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.668 -0.901 . . . . 0.0 110.49 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 79.5 p -70.04 -26.06 63.86 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.617 -0.677 . . . . 0.0 110.352 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -63.73 129.99 42.38 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.58 -0.7 . . . . 0.0 109.969 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.616 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.2 mt -137.4 136.08 37.54 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.6 -0.688 . . . . 0.0 110.693 -179.745 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.88 119.99 40.83 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.55 -0.719 . . . . 0.0 109.718 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 57.2 tp -98.21 140.05 33.09 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.512 -0.742 . . . . 0.0 110.387 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.459 HG22 HG12 ' A' ' 113' ' ' VAL . 63.1 t -102.82 130.01 53.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.538 -0.726 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 22.9 p -98.2 179.17 4.84 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.583 -0.698 . . . . 0.0 110.761 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.758 ' HA ' HD11 ' A' ' 44' ' ' LEU . 15.8 ttt-85 -70.01 -18.58 63.32 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.692 -0.63 . . . . 0.0 110.969 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -93.21 25.46 3.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.293 -0.879 . . . . 0.0 110.868 -179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.14 38.97 30.2 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.347 -0.846 . . . . 0.0 110.765 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -120.25 139.58 52.47 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.662 -0.648 . . . . 0.0 109.599 179.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.459 HG12 HG22 ' A' ' 107' ' ' VAL . 34.0 m -116.66 140.07 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.515 -0.741 . . . . 0.0 110.701 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.563 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -124.32 149.99 62.7 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.681 -0.637 . . . . 0.0 109.572 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -83.6 126.53 4.1 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.842 1.443 . . . . 0.0 110.651 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 125' ' ' SER . 63.3 t -128.82 130.05 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.715 -0.616 . . . . 0.0 109.477 179.78 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.0 tpt180 -85.48 146.16 27.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.497 -0.752 . . . . 0.0 110.186 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -82.81 124.35 30.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.596 -0.69 . . . . 0.0 110.319 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -114.42 19.93 15.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.28 178.76 39.24 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -59.99 -41.11 91.35 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.509 -0.995 . . . . 0.0 110.293 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.1 p -130.43 25.52 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.464 -0.773 . . . . 0.0 110.654 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.2 tpp85 -126.84 140.49 52.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.507 -0.746 . . . . 0.0 110.356 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.27 166.81 25.95 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.516 ' O ' HG13 ' A' ' 116' ' ' VAL . 81.5 p -124.83 147.43 48.75 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.588 -0.948 . . . . 0.0 110.201 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 mp -95.43 121.7 37.38 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.583 -0.698 . . . . 0.0 110.312 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.516 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.8 -40.07 93.94 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.53 -0.731 . . . . 0.0 109.86 179.683 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.9 p -108.58 117.95 53.11 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.711 -0.618 . . . . 0.0 109.757 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.19 124.46 13.02 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.744 1.391 . . . . 0.0 110.63 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -121.46 160.17 47.18 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.591 -0.693 . . . . 0.0 110.013 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.09 158.88 56.14 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.93 1.489 . . . . 0.0 110.437 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.493 HG11 ' OE1' ' B' ' 188' ' ' GLU . 68.4 t -66.65 -29.99 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.62 -0.675 . . . . 0.0 110.033 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.6 t -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.552 -0.717 . . . . 0.0 110.295 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.692 ' HD2' HD12 ' A' ' 135' ' ' LEU . 64.7 t80 -60.01 -49.54 77.28 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.461 -0.774 . . . . 0.0 110.02 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.692 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.5 mp -69.91 -29.33 66.49 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.632 -0.667 . . . . 0.0 110.626 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 139.98 56.95 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.386 -0.821 . . . . 0.0 110.083 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.54 13.08 83.01 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 16.7 m -115.3 17.25 16.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.281 -1.129 . . . . 0.0 110.766 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.8 m -60.04 144.32 49.72 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.34 -19.34 54.68 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.52 109.8 1.36 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -77.09 151.18 30.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.875 1.46 . . . . 0.0 110.852 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.631 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -99.72 110.44 22.84 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.086 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.531 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -100.01 128.39 46.1 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.662 -0.649 . . . . 0.0 111.17 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.424 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.0 157.89 88.67 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.663 -0.648 . . . . 0.0 109.266 179.066 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.1 Cg_endo -52.16 -24.96 21.71 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 O-C-N 123.516 1.271 . . . . 0.0 112.314 -178.53 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 51.7 m -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.269 -0.895 . . . . 0.0 110.003 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.03 35.77 0.8 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -132.91 149.2 52.27 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -1.01 . . . . 0.0 110.289 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 145.52 51.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.628 -0.67 . . . . 0.0 110.223 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.802 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.6 t -118.23 -38.38 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.595 -0.691 . . . . 0.0 109.961 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -171.39 -170.02 34.98 Favored Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.423 HD12 ' CE ' ' A' ' 175' ' ' MET . 85.4 mt -130.99 140.02 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.466 -1.02 . . . . 0.0 110.286 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -62.41 138.55 58.47 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.536 -0.727 . . . . 0.0 109.873 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.6 ttp180 -122.54 -52.1 1.93 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.627 -0.671 . . . . 0.0 110.319 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.693 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.64 161.88 41.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.487 -0.758 . . . . 0.0 110.421 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.92 149.81 39.53 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.649 -0.657 . . . . 0.0 110.161 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -109.95 117.99 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.645 -0.659 . . . . 0.0 109.885 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.401 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.5 p -137.47 160.53 38.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.642 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 33.1 m -117.99 -56.63 2.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.573 -0.704 . . . . 0.0 110.765 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -109.33 29.96 7.06 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 110.42 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 100.18 0.3 55.94 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -116.39 126.04 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.098 -1.236 . . . . 0.0 109.649 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.78 123.62 37.24 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.653 . . . . 0.0 110.303 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -104.57 -24.04 13.04 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.651 -0.656 . . . . 0.0 110.503 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 159.65 41.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.429 -0.794 . . . . 0.0 110.184 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -141.37 162.4 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.507 -0.746 . . . . 0.0 110.635 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 -114.89 138.39 50.86 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.615 -0.678 . . . . 0.0 110.053 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -140.04 155.31 47.12 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.531 -0.73 . . . . 0.0 110.299 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.575 HG11 HD11 ' A' ' 82' ' ' LEU . 58.6 t -96.21 122.78 57.04 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.53 -0.731 . . . . 0.0 109.65 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -65.66 155.83 67.02 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.777 1.409 . . . . 0.0 110.615 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 61.3 t -63.78 -22.92 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.61 -0.681 . . . . 0.0 110.731 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.99 -39.11 84.61 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -0.829 . . . . 0.0 110.424 -179.452 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.0 p -59.81 -34.39 72.99 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.437 -0.789 . . . . 0.0 110.51 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.423 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.0 mtt -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.527 -0.733 . . . . 0.0 110.492 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -59.95 -40.06 87.7 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.1 m -60.59 -48.61 81.01 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.504 -0.748 . . . . 0.0 110.05 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 87.3 m -70.01 -46.17 65.68 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.575 -0.703 . . . . 0.0 110.0 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.639 -0.663 . . . . 0.0 110.181 -179.91 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.693 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.155 0.502 . . . . 0.0 110.117 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.795 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.7 mp . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.567 -0.708 . . . . 0.0 110.149 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.485 ' OE1' HD21 ' A' ' 94' ' ' LEU . 99.8 mt-10 . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 121.034 0.445 . . . . 0.0 109.993 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.55 128.51 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -124.84 159.78 30.27 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.567 -0.708 . . . . 0.0 110.075 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.17 113.81 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.519 -0.738 . . . . 0.0 109.83 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.43 ' HB ' HD11 ' A' ' 64' ' ' LEU . 34.5 m -110.17 143.21 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.677 -0.64 . . . . 0.0 109.763 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.48 ' O ' HD13 ' A' ' 64' ' ' LEU . 37.4 t -137.22 173.82 11.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.51 -0.744 . . . . 0.0 111.18 -179.125 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' N ' ' A' ' 39' ' ' ALA . 27.7 m -144.3 169.22 18.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.921 -0.487 . . . . 0.0 109.895 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.455 ' N ' HG22 ' A' ' 38' ' ' THR . . . -66.76 -16.72 64.45 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.669 -0.644 . . . . 0.0 110.617 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.8 m -111.05 -39.1 4.87 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.345 -0.847 . . . . 0.0 111.748 -179.062 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -146.86 170.7 16.49 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.157 -0.964 . . . . 0.0 111.573 -179.106 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.3 p -128.23 151.95 48.66 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.636 -0.665 . . . . 0.0 110.311 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.427 ' HE2' ' HG1' ' A' ' 54' ' ' THR . 30.7 p90 -165.87 -178.02 4.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.374 -0.829 . . . . 0.0 110.334 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.682 HD11 ' HA ' ' A' ' 109' ' ' ARG . 76.2 mt -113.61 150.45 33.09 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.506 -0.746 . . . . 0.0 110.717 -178.585 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.46 159.13 34.23 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.655 -0.653 . . . . 0.0 110.055 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.581 HG21 ' HB3' ' A' ' 142' ' ' PRO . 62.8 m -120.33 131.6 54.93 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.664 -179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.4 t -90.16 102.56 15.28 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.547 -0.721 . . . . 0.0 110.136 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.412 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.7 t -109.97 130.12 63.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.582 -0.699 . . . . 0.0 109.593 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.41 39.98 27.74 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.437 -0.789 . . . . 0.0 110.66 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.76 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.05 19.98 75.97 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 110.869 -0.893 . . . . 0.0 110.869 179.154 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.4 t -131.84 129.98 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.161 -1.2 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.0 m -74.79 147.81 40.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.53 -0.731 . . . . 0.0 109.42 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.465 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 74.5 m95 -129.97 152.31 49.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.426 -0.796 . . . . 0.0 111.072 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.943 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.0 t -169.5 -179.71 3.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.0 p -90.99 156.7 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.458 -0.776 . . . . 0.0 110.484 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.428 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 86.5 t80 -70.01 -42.69 72.69 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.57 -0.706 . . . . 0.0 111.194 -179.42 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.2 p-80 -71.51 -19.06 62.24 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.281 -0.887 . . . . 0.0 111.014 -179.194 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.815 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -73.84 -57.57 4.84 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -87.18 -41.59 13.63 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.583 -0.951 . . . . 0.0 110.139 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 75.72 28.91 60.25 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.28 57.45 4.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.361 -1.082 . . . . 0.0 110.54 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.53 178.99 6.82 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.081 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 77.7 p -65.06 139.49 58.74 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.209 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.48 HD13 ' O ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -115.04 130.04 56.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.576 -0.702 . . . . 0.0 110.842 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.23 109.38 20.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.551 -0.718 . . . . 0.0 109.663 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.29 -154.47 13.11 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -72.55 -31.04 11.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.928 1.489 . . . . 0.0 110.445 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -83.67 -22.43 32.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.586 -0.697 . . . . 0.0 110.74 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 135.31 -139.52 10.87 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.91 154.91 34.01 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.904 1.476 . . . . 0.0 110.083 179.719 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.402 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.7 mt -131.45 140.01 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.554 -0.716 . . . . 0.0 110.575 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 91.9 m -95.27 140.0 30.78 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.559 -0.713 . . . . 0.0 109.943 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.413 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 8.9 tt0 -93.05 140.05 29.9 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 0.0 110.58 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.2 mmm -112.18 -29.98 7.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.629 -0.669 . . . . 0.0 110.566 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -118.41 139.77 50.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.585 -0.697 . . . . 0.0 110.569 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.3 m -139.97 132.12 28.07 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.513 -0.742 . . . . 0.0 109.93 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.559 ' OD1' HG23 ' A' ' 178' ' ' THR . 0.1 OUTLIER -136.23 96.62 3.42 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.443 -0.786 . . . . 0.0 110.5 -179.79 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 82.6 t -70.02 -40.03 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.595 -0.691 . . . . 0.0 109.899 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.97 -47.34 86.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.562 -0.711 . . . . 0.0 110.297 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -90.05 0.15 57.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.531 -0.731 . . . . 0.0 110.97 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 3.8 t70 53.8 46.42 25.82 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.061 -1.025 . . . . 0.0 110.481 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.854 HD11 HG21 ' A' ' 170' ' ' VAL . 67.6 mt -141.45 135.92 30.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.476 -0.765 . . . . 0.0 110.747 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.518 ' CG2' HG23 ' A' ' 54' ' ' THR . 33.4 m -134.01 164.44 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.606 -0.684 . . . . 0.0 109.432 179.023 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.75 156.79 26.05 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.871 -1.157 . . . . 0.0 110.343 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.943 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.2 m-90 -116.48 152.71 33.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.85 -0.794 . . . . 0.0 109.52 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -66.61 106.37 1.78 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.41 -0.806 . . . . 0.0 109.606 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.51 143.57 87.81 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.576 -0.703 . . . . 0.0 110.097 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.95 150.4 66.97 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.965 1.508 . . . . 0.0 110.338 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.01 159.76 44.91 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.849 1.447 . . . . 0.0 110.094 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.79 29.6 69.2 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.76 149.81 28.5 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.48 -1.012 . . . . 0.0 109.949 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -85.21 146.03 27.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.626 -0.671 . . . . 0.0 109.283 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.4 p -136.91 174.14 10.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.577 -0.702 . . . . 0.0 110.601 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.485 HD21 ' OE1' ' A' ' 32' ' ' GLU . 44.0 mt -108.39 149.8 28.23 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.675 -0.641 . . . . 0.0 110.598 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 74.0 p -90.03 176.18 3.24 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.649 -0.657 . . . . 0.0 110.003 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -89.49 160.49 5.42 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 O-C-N 123.807 1.425 . . . . 0.0 110.609 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.752 ' HB2' HG12 ' A' ' 151' ' ' VAL . 51.3 t -68.7 133.13 47.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.671 -0.643 . . . . 0.0 110.158 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.453 HG22 ' CD2' ' A' ' 149' ' ' HIS . 6.4 t -135.95 53.41 1.95 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.678 -0.639 . . . . 0.0 109.751 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.88 -8.2 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.554 -0.716 . . . . 0.0 112.378 -179.056 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 38.17 93.9 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -99.95 124.16 44.99 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.565 -0.962 . . . . 0.0 110.502 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 19.6 p -69.91 -34.27 73.28 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.614 -0.679 . . . . 0.0 110.133 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -61.67 129.98 43.64 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.574 -0.704 . . . . 0.0 109.903 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 1.037 HD22 HG21 ' A' ' 151' ' ' VAL . 90.2 mt -135.64 149.99 49.49 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.55 -0.719 . . . . 0.0 110.771 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 143' ' ' LEU . 90.4 m-85 -112.54 140.01 47.65 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.617 -0.677 . . . . 0.0 109.556 179.511 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.447 ' CD1' HD11 ' A' ' 143' ' ' LEU . 52.3 tp -115.2 142.16 47.04 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.496 -0.752 . . . . 0.0 110.677 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 130.06 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.634 -0.666 . . . . 0.0 109.761 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 24.9 p -110.22 -179.9 3.91 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.519 -0.738 . . . . 0.0 110.643 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.682 ' HA ' HD11 ' A' ' 44' ' ' LEU . 32.8 mtp-105 -60.04 -26.38 66.08 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.586 -0.697 . . . . 0.0 110.652 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -89.96 17.91 6.32 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.393 -0.817 . . . . 0.0 111.181 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.09 38.38 27.26 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.057 -1.027 . . . . 0.0 110.748 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -100.76 139.8 35.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.699 -0.626 . . . . 0.0 109.893 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 63.4 t -110.02 119.99 60.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.597 -0.689 . . . . 0.0 109.928 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.55 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -118.91 122.16 29.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.646 -0.659 . . . . 0.0 109.435 179.868 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.513 ' N ' HD13 ' A' ' 114' ' ' ILE . 47.0 Cg_endo -65.33 132.9 32.98 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.744 1.392 . . . . 0.0 110.368 -179.654 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.481 HG13 ' O ' ' A' ' 125' ' ' SER . 63.2 t -129.93 130.04 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.678 -0.639 . . . . 0.0 109.731 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -86.36 132.72 33.89 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.497 -0.752 . . . . 0.0 109.972 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -70.76 130.03 40.65 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.581 -0.699 . . . . 0.0 110.438 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 24.5 mmm-85 -102.4 -20.9 14.38 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.653 -0.654 . . . . 0.0 110.377 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.24 -167.98 29.68 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -59.98 -39.98 87.56 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.606 -0.937 . . . . 0.0 110.401 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.4 p -129.89 25.37 5.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.508 -0.745 . . . . 0.0 110.581 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -125.88 140.04 52.98 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.483 -0.76 . . . . 0.0 110.278 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.87 167.18 24.69 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.481 ' O ' HG13 ' A' ' 116' ' ' VAL . 80.1 p -127.82 150.03 50.01 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.576 -0.956 . . . . 0.0 110.211 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.516 ' CD1' HG13 ' A' ' 167' ' ' VAL . 8.4 mp -103.02 131.39 50.04 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.442 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.514 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.79 -39.99 93.64 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.585 -0.697 . . . . 0.0 109.745 179.563 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.5 p -118.36 149.98 46.97 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.684 -0.635 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -84.42 82.65 1.8 Allowed 'Trans proline' 0 N--CA 1.489 1.237 0 O-C-N 123.843 1.444 . . . . 0.0 110.747 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -71.59 159.98 83.92 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 109.836 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.67 149.31 67.28 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.939 1.494 . . . . 0.0 110.292 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.4 -34.0 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.622 -0.674 . . . . 0.0 110.046 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.6 t -58.41 -36.67 73.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.549 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.652 ' HD1' HD12 ' A' ' 135' ' ' LEU . 64.9 t80 -60.06 -39.92 87.69 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.487 -0.758 . . . . 0.0 110.11 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.652 HD12 ' HD1' ' A' ' 134' ' ' TYR . 3.7 mp -81.37 -20.84 39.73 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.562 -0.711 . . . . 0.0 110.826 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -59.97 139.74 57.21 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.23 -0.919 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.6 1.07 86.12 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.5 m -101.51 3.07 39.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.107 -1.231 . . . . 0.0 110.975 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.9 t -59.97 139.93 57.08 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.145 -0.972 . . . . 0.0 109.863 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.96 -17.85 57.89 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.67 140.84 43.14 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 179.454 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.581 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.4 Cg_endo -87.96 144.91 6.34 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.831 1.438 . . . . 0.0 111.471 -178.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.892 ' O ' HG22 ' A' ' 151' ' ' VAL . 8.3 mp -103.32 129.95 50.47 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.495 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.722 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.46 130.9 56.21 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.366 -0.834 . . . . 0.0 111.598 -178.535 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.452 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -70.02 159.75 83.09 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.764 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.76 -26.91 25.05 Favored 'Trans proline' 0 N--CA 1.501 1.96 0 O-C-N 123.475 1.25 . . . . 0.0 112.368 -178.509 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.78 -40.02 96.02 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.222 -0.924 . . . . 0.0 109.963 179.647 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.2 36.46 0.81 Allowed Glycine 0 N--CA 1.496 2.641 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' HIS . . . . . 0.453 ' CD2' HG22 ' A' ' 98' ' ' THR . 21.2 m-70 -132.83 151.1 52.08 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.462 -1.023 . . . . 0.0 110.337 179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -67.08 139.96 57.59 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.623 -0.673 . . . . 0.0 110.435 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 1.037 HG21 HD22 ' A' ' 104' ' ' LEU . 33.9 m -117.19 -22.19 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.597 -0.689 . . . . 0.0 110.726 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 171.39 -171.53 44.05 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 86.0 mt -128.82 140.02 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.542 -0.975 . . . . 0.0 110.154 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.638 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 28.9 t80 -71.15 135.47 47.64 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.66 -0.65 . . . . 0.0 109.962 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.4 ttp85 -116.52 -53.01 2.54 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.617 -0.677 . . . . 0.0 110.178 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -148.18 159.96 43.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.757 . . . . 0.0 110.391 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.638 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.95 151.58 35.12 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.63 . . . . 0.0 110.262 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.51 120.03 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.704 -0.622 . . . . 0.0 109.525 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.09 158.13 41.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.707 -0.621 . . . . 0.0 110.632 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.0 m -101.77 -61.06 1.43 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.67 -0.644 . . . . 0.0 110.309 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -129.03 63.69 1.48 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.681 -0.637 . . . . 0.0 110.066 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.98 9.99 86.08 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 25.3 m -126.75 132.09 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.206 -1.173 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.7 124.28 38.64 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.513 -0.742 . . . . 0.0 110.215 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.86 -29.9 8.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.648 -0.657 . . . . 0.0 110.232 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.26 151.44 45.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.638 -0.663 . . . . 0.0 110.125 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.516 HG13 ' CD1' ' A' ' 126' ' ' LEU . 34.6 m -129.96 159.96 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.617 -0.677 . . . . 0.0 110.669 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -121.97 130.67 53.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.668 -0.645 . . . . 0.0 109.934 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -134.37 159.92 39.54 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.539 -0.726 . . . . 0.0 110.501 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.854 HG21 HD11 ' A' ' 82' ' ' LEU . 62.3 t -93.42 126.49 50.13 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.615 -0.678 . . . . 0.0 109.368 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.94 157.37 53.11 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.771 1.406 . . . . 0.0 110.599 -179.575 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 151' ' ' VAL . 76.3 t -59.85 -25.7 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.614 -0.679 . . . . 0.0 110.387 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -60.02 -39.97 87.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.422 -0.799 . . . . 0.0 110.364 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' SER . . . . . 0.464 ' HB3' HG12 ' A' ' 170' ' ' VAL . 21.7 t -65.42 -37.47 87.04 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.12 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.465 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 95.4 mtp -60.05 -41.82 93.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.56 -0.712 . . . . 0.0 110.293 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -69.12 -40.05 78.56 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.55 -0.719 . . . . 0.0 110.104 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.75 -40.08 93.87 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.673 -0.642 . . . . 0.0 109.92 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 77' ' ' ASN . 91.2 m -59.95 -41.06 91.03 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.558 -0.714 . . . . 0.0 110.189 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.642 -0.661 . . . . 0.0 110.176 -179.812 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.013 0.435 . . . . 0.0 110.136 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.814 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.4 mp . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.622 -0.674 . . . . 0.0 110.165 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.682 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.5 mt-10 . . . . . 0 N--CA 1.495 1.818 0 CA-C-O 121.103 0.477 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.67 126.91 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.537 -0.727 . . . . 0.0 109.947 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -119.12 142.91 47.5 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.555 -0.716 . . . . 0.0 110.359 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 35' ' ' VAL . 14.4 p -78.39 128.83 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.604 -0.685 . . . . 0.0 110.339 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.651 ' HB ' HD21 ' A' ' 64' ' ' LEU . 34.4 m -122.27 146.44 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.636 -0.665 . . . . 0.0 109.593 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.2 m -144.49 171.02 14.94 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.519 -0.738 . . . . 0.0 110.897 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.8 p -133.78 -170.92 2.6 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.93 -32.54 72.05 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.676 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 m -133.09 -11.1 2.94 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.356 -0.84 . . . . 0.0 112.639 -178.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -114.94 154.03 29.49 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.837 -1.165 . . . . 0.0 111.182 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.3 m -143.89 128.29 17.91 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.697 -0.627 . . . . 0.0 109.863 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -159.56 -178.72 7.31 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.307 -0.871 . . . . 0.0 110.469 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.495 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.8 mt -113.96 155.6 25.55 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.519 -0.738 . . . . 0.0 110.533 -178.751 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.52 160.52 33.88 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.625 -0.672 . . . . 0.0 110.304 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.498 HG21 ' HB3' ' A' ' 142' ' ' PRO . 87.1 m -119.97 130.78 54.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.553 -0.717 . . . . 0.0 110.142 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.2 t -89.34 104.03 16.62 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.541 -0.724 . . . . 0.0 110.67 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.18 130.1 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.621 -0.674 . . . . 0.0 109.492 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.21 39.55 28.67 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.428 -0.795 . . . . 0.0 110.707 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.604 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.98 19.97 75.85 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.1 t -133.73 129.98 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.224 -1.162 . . . . 0.0 110.031 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.9 m -71.57 147.52 47.56 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.437 -0.789 . . . . 0.0 109.667 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -139.71 145.47 38.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.47 -0.769 . . . . 0.0 110.867 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.67 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.6 t -170.02 -178.74 2.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.723 -0.61 . . . . 0.0 109.758 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.906 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -78.22 162.13 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.524 -0.735 . . . . 0.0 110.388 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -86.97 -35.1 19.04 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.6 -0.687 . . . . 0.0 111.773 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.906 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.2 p-80 -63.34 -22.14 66.7 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.02 -1.05 . . . . 0.0 110.583 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.434 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -79.68 -60.05 2.54 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.105 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.624 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -84.12 -61.99 1.68 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.583 -0.951 . . . . 0.0 109.943 179.421 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.11 36.84 20.33 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.3 p 53.72 40.05 31.0 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.48 -1.012 . . . . 0.0 110.71 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -111.57 179.5 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.672 -0.642 . . . . 0.0 109.755 179.551 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.7 m -64.74 139.36 58.75 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.489 -0.757 . . . . 0.0 109.102 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.651 HD21 ' HB ' ' A' ' 36' ' ' VAL . 12.5 tp -119.89 138.52 53.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.488 -0.757 . . . . 0.0 110.524 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -112.53 109.52 19.15 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.635 -0.666 . . . . 0.0 109.947 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.82 -172.59 25.55 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.44 -32.34 49.89 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.88 1.463 . . . . 0.0 110.362 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -75.96 -31.12 58.89 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.561 -0.712 . . . . 0.0 109.973 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.64 -144.92 14.25 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.72 155.61 58.33 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 O-C-N 123.85 1.447 . . . . 0.0 110.303 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.515 HG22 ' HB3' ' A' ' 85' ' ' TRP . 83.9 mt -130.05 140.01 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.553 -0.717 . . . . 0.0 110.102 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 23.2 m -87.31 150.49 23.83 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.486 -0.758 . . . . 0.0 110.789 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.412 ' HG2' ' NE1' ' A' ' 85' ' ' TRP . 72.8 mt-30 -93.08 139.95 30.01 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.544 -0.722 . . . . 0.0 110.484 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.8 mmm -118.45 -32.48 4.61 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.545 -0.722 . . . . 0.0 110.55 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -138.2 150.71 47.01 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.461 -0.774 . . . . 0.0 110.532 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 90.2 m -149.59 134.07 17.53 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.534 -0.729 . . . . 0.0 109.813 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.4 t-20 -141.71 100.32 3.73 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.495 -0.753 . . . . 0.0 110.424 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 74.6 t -70.0 -38.24 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.002 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -60.0 -45.36 92.99 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.544 -0.723 . . . . 0.0 110.495 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.98 2.79 54.72 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.464 -0.772 . . . . 0.0 111.121 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.7 t0 54.46 47.69 22.24 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.965 -1.084 . . . . 0.0 110.438 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.748 HD11 HG11 ' A' ' 170' ' ' VAL . 71.3 mt -140.0 143.07 36.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.547 -0.721 . . . . 0.0 110.864 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.624 HG11 ' HB3' ' A' ' 59' ' ' ALA . 7.7 p -139.5 144.68 28.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.619 -0.676 . . . . 0.0 109.248 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -128.28 153.5 19.53 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.292 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.67 ' CZ3' HG21 ' A' ' 54' ' ' THR . 8.4 m-90 -120.21 168.07 11.6 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.693 -0.887 . . . . 0.0 109.887 179.478 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -76.73 109.11 10.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.498 -0.751 . . . . 0.0 109.349 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.604 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.03 140.66 97.93 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.473 -0.767 . . . . 0.0 110.196 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.05 159.95 51.37 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.847 1.446 . . . . 0.0 110.262 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.05 157.52 59.54 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.931 1.49 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.98 30.01 70.36 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.04 140.67 47.65 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.554 -0.968 . . . . 0.0 110.221 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.89 152.8 23.3 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.53 -0.731 . . . . 0.0 109.786 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.7 p -130.0 170.04 14.48 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.536 -0.727 . . . . 0.0 110.433 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.682 HD21 ' OE1' ' A' ' 32' ' ' GLU . 66.6 mt -110.01 143.73 39.58 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.607 -0.683 . . . . 0.0 110.632 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 42.9 p -85.96 172.74 7.96 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.628 -0.67 . . . . 0.0 110.042 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -83.48 161.29 14.8 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.925 1.487 . . . . 0.0 110.534 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.2 t -77.79 129.98 36.14 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.655 -0.653 . . . . 0.0 110.25 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 35.3 m -135.54 56.81 1.82 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.675 -0.64 . . . . 0.0 109.511 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 p -143.94 -4.44 0.83 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.626 -0.671 . . . . 0.0 112.288 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 39.97 96.45 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.9 m -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.53 -0.982 . . . . 0.0 110.471 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.7 p -69.97 -27.3 64.61 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.676 -0.64 . . . . 0.0 110.376 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -66.39 129.43 39.8 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 110.124 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.523 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.4 mt -134.96 150.0 50.3 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.699 -0.626 . . . . 0.0 110.706 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -117.35 123.95 47.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.556 -0.715 . . . . 0.0 109.694 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.539 HD13 HD21 ' A' ' 143' ' ' LEU . 43.1 tp -99.99 139.99 34.86 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.461 -0.775 . . . . 0.0 110.757 -179.324 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.11 139.96 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.671 -0.643 . . . . 0.0 109.853 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.8 p -119.59 173.14 7.18 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.524 -0.735 . . . . 0.0 110.624 -179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.495 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.7 mtp180 -62.89 -25.67 68.41 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.532 -0.73 . . . . 0.0 110.627 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -92.64 24.41 3.56 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.418 -0.801 . . . . 0.0 110.922 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.1 23.09 4.97 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.237 -0.915 . . . . 0.0 110.849 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -94.85 155.44 16.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.811 . . . . 0.0 109.734 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 113' ' ' VAL . 9.1 p -130.02 129.94 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.517 -0.74 . . . . 0.0 110.505 -179.779 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.546 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -114.38 123.31 32.63 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.614 -0.679 . . . . 0.0 109.36 179.708 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.542 ' N ' HD13 ' A' ' 114' ' ' ILE . 46.5 Cg_endo -65.35 129.55 22.99 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.79 1.416 . . . . 0.0 110.484 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.3 t -129.14 130.02 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.696 -0.627 . . . . 0.0 109.663 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -86.01 149.46 25.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.505 -0.747 . . . . 0.0 109.967 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 46.2 ttp180 -90.62 120.01 31.34 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.559 -0.713 . . . . 0.0 110.412 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -112.49 20.04 17.01 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.64 -0.663 . . . . 0.0 110.519 179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.86 -179.94 40.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -62.64 -39.99 95.6 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.58 -0.953 . . . . 0.0 110.279 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 33.8 p -130.66 24.17 5.06 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.525 -0.734 . . . . 0.0 110.601 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -126.55 139.31 53.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.417 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.99 170.84 24.13 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 94.8 p -120.16 153.08 36.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.979 . . . . 0.0 110.085 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.425 ' HA ' HD12 ' A' ' 126' ' ' LEU . 17.6 tp -98.2 118.64 35.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.53 -0.732 . . . . 0.0 110.234 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.415 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.3 mp -65.62 -40.04 92.14 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -110.0 110.11 58.92 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.61 -0.681 . . . . 0.0 110.138 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -64.99 115.64 3.39 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.848 1.446 . . . . 0.0 110.391 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HD3' ' CD2' ' A' ' 134' ' ' TYR . 6.8 mtt180 -126.97 160.04 61.42 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.572 -0.705 . . . . 0.0 110.224 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.15 156.83 56.99 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 O-C-N 123.862 1.453 . . . . 0.0 110.255 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.46 HG11 ' OE1' ' B' ' 188' ' ' GLU . 33.8 m -59.96 -30.01 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.516 -0.74 . . . . 0.0 110.305 -179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -62.15 -32.37 72.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.595 -0.69 . . . . 0.0 109.924 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.549 ' CZ ' HD13 ' A' ' 135' ' ' LEU . 0.0 OUTLIER -59.98 -39.99 87.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.582 -0.699 . . . . 0.0 110.058 -179.812 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 8.2 tp -100.22 -1.92 35.22 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.489 -0.757 . . . . 0.0 111.527 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.04 139.99 52.76 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.113 -0.992 . . . . 0.0 109.851 179.52 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 83.3 -3.2 85.51 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.4 m -107.98 15.06 24.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.099 -1.236 . . . . 0.0 110.626 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -69.92 149.92 47.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 109.345 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.419 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 98.09 -19.95 52.5 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.132 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.45 151.0 29.17 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.498 ' HB3' HG21 ' A' ' 46' ' ' THR . 54.8 Cg_endo -95.38 149.14 1.51 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.826 1.435 . . . . 0.0 111.187 -179.102 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.539 HD21 HD13 ' A' ' 106' ' ' LEU . 84.4 mt -101.59 108.02 19.46 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.556 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.98 130.02 46.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 111.401 -178.665 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.441 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.64 83.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -52.32 -22.62 16.24 Favored 'Trans proline' 0 N--CA 1.501 1.957 0 O-C-N 123.569 1.299 . . . . 0.0 112.222 -178.755 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.28 -40.0 89.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.28 -0.888 . . . . 0.0 109.959 179.549 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.35 35.69 0.85 Allowed Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 18.5 m-70 -131.46 146.33 52.2 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.422 -1.046 . . . . 0.0 110.321 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.33 144.31 57.19 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.649 -0.657 . . . . 0.0 110.3 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.7 t -118.91 -39.74 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.619 -0.676 . . . . 0.0 109.931 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -167.33 33.9 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.588 HD11 ' HE1' ' A' ' 175' ' ' MET . 91.0 mt -130.0 137.04 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.51 -0.994 . . . . 0.0 110.332 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.661 ' CZ ' HD23 ' A' ' 135' ' ' LEU . 20.1 t80 -64.7 138.3 58.31 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.606 -0.684 . . . . 0.0 109.427 179.344 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -116.23 -52.43 2.59 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.537 -0.727 . . . . 0.0 110.534 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -157.45 161.62 38.92 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.563 -0.711 . . . . 0.0 110.563 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.04 151.74 26.81 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.657 -0.652 . . . . 0.0 110.017 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -108.26 118.03 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.605 -0.685 . . . . 0.0 109.734 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -132.96 166.85 21.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.694 -0.629 . . . . 0.0 110.337 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 29.4 m -126.81 -54.24 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.498 -0.752 . . . . 0.0 110.363 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.7 mmt180 -102.04 26.76 7.24 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.537 -0.727 . . . . 0.0 110.388 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.37 -2.31 57.58 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.99 128.7 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.108 -1.231 . . . . 0.0 109.659 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.82 127.42 35.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.628 -0.67 . . . . 0.0 110.722 -179.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -102.82 -19.66 14.6 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.632 -0.667 . . . . 0.0 110.313 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.93 160.71 39.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.093 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.77 173.95 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.554 -0.716 . . . . 0.0 110.409 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -133.76 132.83 41.0 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.664 -0.648 . . . . 0.0 109.886 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -136.69 156.06 49.04 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.422 -0.799 . . . . 0.0 110.59 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.748 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -98.54 123.46 50.01 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.661 -0.649 . . . . 0.0 109.373 179.31 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -63.42 153.04 77.09 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.726 1.382 . . . . 0.0 110.646 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 151' ' ' VAL . 67.2 t -57.06 -21.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.634 -0.667 . . . . 0.0 110.756 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -57.36 -37.11 72.1 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.319 -0.863 . . . . 0.0 110.615 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.5 t -60.08 -34.85 74.02 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.512 -0.742 . . . . 0.0 110.489 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.588 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.5 mtt -59.96 -40.02 87.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.483 -0.761 . . . . 0.0 110.495 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.35 -40.02 89.24 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.726 . . . . 0.0 110.334 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -66.37 -39.98 89.44 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.588 -0.695 . . . . 0.0 110.108 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.2 m -60.59 -46.8 88.88 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.484 -0.76 . . . . 0.0 110.171 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.497 1.909 0 O-C-N 121.521 -0.737 . . . . 0.0 110.205 -179.893 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.562 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.849 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.686 -0.634 . . . . 0.0 110.472 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.588 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.8 mt-10 . . . . . 0 N--CA 1.497 1.895 0 CA-C-O 121.046 0.451 . . . . 0.0 110.365 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.38 131.57 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.566 -0.709 . . . . 0.0 109.97 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -124.22 158.85 31.48 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.563 -0.711 . . . . 0.0 110.177 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.2 t -93.28 114.74 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.626 -0.671 . . . . 0.0 109.911 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.884 HG11 HD21 ' A' ' 64' ' ' LEU . 61.3 t -116.32 139.6 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 21.9 m -146.84 173.88 11.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.322 -0.861 . . . . 0.0 111.167 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.6 p -129.83 -179.17 5.04 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.836 -0.54 . . . . 0.0 109.576 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.26 -7.99 52.39 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.677 -0.639 . . . . 0.0 111.05 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -108.71 -37.61 5.85 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.118 -0.988 . . . . 0.0 111.772 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -152.83 169.25 23.25 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.172 -0.955 . . . . 0.0 111.299 -179.151 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 30.3 t -121.7 147.16 46.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.541 -0.725 . . . . 0.0 110.656 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 21.0 p90 -159.44 -177.72 6.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.78 HD11 ' HA ' ' A' ' 109' ' ' ARG . 82.7 mt -113.18 157.4 21.74 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.383 -0.823 . . . . 0.0 110.225 -178.812 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -134.89 146.5 49.26 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.492 -0.755 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.544 HG23 HD12 ' A' ' 94' ' ' LEU . 35.2 m -100.82 124.87 47.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.639 -0.663 . . . . 0.0 110.029 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.9 t -87.15 103.13 15.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.584 -0.697 . . . . 0.0 110.164 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.31 130.37 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.61 -0.681 . . . . 0.0 109.631 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 37.5 t30 57.15 39.41 28.96 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.423 -0.798 . . . . 0.0 110.606 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.729 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.97 20.61 76.36 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.01 130.03 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.257 -1.143 . . . . 0.0 109.976 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -74.5 140.34 44.48 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.455 -0.778 . . . . 0.0 109.275 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 62.6 m95 -132.07 137.38 47.75 Favored 'General case' 0 N--CA 1.494 1.746 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.792 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.682 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 11.8 t -160.06 -179.65 7.96 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.318 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.778 HG21 ' CE1' ' A' ' 57' ' ' HIS . 13.4 p -78.94 161.28 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 111.295 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 48.8 t80 -74.12 -41.92 60.86 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.686 -0.634 . . . . 0.0 111.613 -179.171 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.778 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -59.11 -24.62 63.12 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.155 -0.966 . . . . 0.0 110.707 -178.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.437 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -72.58 -50.45 15.07 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.996 -2.042 . . . . 0.0 107.996 178.222 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.407 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -148.58 78.23 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.752 -0.852 . . . . 0.0 109.45 179.015 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.481 ' HA2' HG11 ' A' ' 83' ' ' VAL . . . -84.63 102.82 2.59 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.294 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 21.4 p 48.97 56.03 8.38 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.68 -0.894 . . . . 0.0 111.468 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -139.82 174.76 10.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -64.91 139.2 58.74 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 120.044 -0.662 . . . . 0.0 109.6 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.897 HD22 ' CE2' ' A' ' 85' ' ' TRP . 12.0 tp -116.29 157.63 24.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.619 -0.676 . . . . 0.0 110.333 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -134.4 109.56 8.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.696 -0.628 . . . . 0.0 109.727 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.25 -164.01 15.69 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.78 -32.65 8.98 Favored 'Trans proline' 0 N--CA 1.49 1.31 0 O-C-N 123.95 1.5 . . . . 0.0 110.378 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 58.6 tptt -75.73 -31.19 59.5 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.681 -0.637 . . . . 0.0 109.823 -179.616 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.53 -149.21 20.91 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.14 141.09 20.44 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.89 1.468 . . . . 0.0 110.13 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.601 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.3 mt -130.02 140.07 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.483 -0.761 . . . . 0.0 110.259 -179.709 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.7 t -85.1 137.27 33.14 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.533 -0.729 . . . . 0.0 110.514 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 24.9 tt0 -77.12 141.14 40.32 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.509 -0.744 . . . . 0.0 110.662 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.1 mmm -110.71 -29.02 8.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.629 -0.669 . . . . 0.0 110.365 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.0 139.99 51.64 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.492 -0.755 . . . . 0.0 110.662 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 32.0 m -137.83 136.62 37.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.549 -0.719 . . . . 0.0 110.09 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ASN . . . . . 0.516 ' OD1' HG21 ' A' ' 178' ' ' THR . 26.4 m120 -149.75 92.15 1.88 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.528 -0.733 . . . . 0.0 110.461 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 92.1 t -70.0 -43.53 79.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.545 -0.722 . . . . 0.0 110.055 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -60.1 -43.77 95.33 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.482 -0.761 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.632 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.5 tp60 -90.11 0.08 57.34 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.553 -0.717 . . . . 0.0 110.881 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.456 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.1 t0 54.09 46.24 25.84 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.039 -1.038 . . . . 0.0 110.289 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.856 HD21 ' NH2' ' A' ' 155' ' ' ARG . 54.0 mt -134.03 147.58 50.97 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.514 -0.741 . . . . 0.0 110.959 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.508 HG23 ' CH2' ' A' ' 85' ' ' TRP . 16.1 m -150.25 168.89 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.646 -0.659 . . . . 0.0 109.786 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -163.36 157.84 30.09 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.897 ' CE2' HD22 ' A' ' 64' ' ' LEU . 9.9 m-90 -128.11 159.96 33.5 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.97 . . . . 0.0 109.813 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -67.13 113.06 4.78 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.521 -0.737 . . . . 0.0 109.597 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.729 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -78.35 135.16 61.65 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.522 -0.736 . . . . 0.0 110.265 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.95 159.97 51.32 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.83 1.437 . . . . 0.0 110.338 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.12 159.62 53.15 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 O-C-N 123.916 1.482 . . . . 0.0 110.286 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.17 -21.15 47.75 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.07 160.06 25.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.403 -1.057 . . . . 0.0 110.232 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 74.8 mtp85 -96.01 161.52 13.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.629 -0.669 . . . . 0.0 110.204 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 71.1 m -125.65 157.78 36.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.671 -0.643 . . . . 0.0 110.191 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.588 HD21 ' OE1' ' A' ' 32' ' ' GLU . 85.0 mt -110.01 132.17 54.4 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 110.559 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.1 p -78.04 159.95 74.73 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.601 -0.687 . . . . 0.0 110.05 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.6 163.91 28.85 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.8 1.421 . . . . 0.0 110.809 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.515 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -78.64 132.7 37.17 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.641 -0.662 . . . . 0.0 110.163 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.9 p -132.52 53.17 2.03 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.785 -0.572 . . . . 0.0 109.63 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.47 -8.48 0.76 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 119.907 -0.717 . . . . 0.0 112.412 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.03 34.21 82.56 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 80.3 p -83.62 138.13 33.49 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.51 -0.994 . . . . 0.0 110.448 -179.678 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.6 m -81.72 -30.98 32.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.559 -0.713 . . . . 0.0 110.385 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -69.99 130.06 41.17 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.53 -0.731 . . . . 0.0 110.187 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.1 mt -131.02 149.55 52.56 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.65 -0.656 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -119.97 113.91 21.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.52 -0.738 . . . . 0.0 109.701 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.419 HD13 HD11 ' A' ' 143' ' ' LEU . 39.7 tp -96.67 142.87 28.19 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.55 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.99 129.96 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.616 -0.677 . . . . 0.0 109.832 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 26.9 p -100.02 -172.31 2.2 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.488 -0.758 . . . . 0.0 110.567 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.78 ' HA ' HD11 ' A' ' 44' ' ' LEU . 86.9 mtm-85 -59.97 -28.98 68.12 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.586 -0.696 . . . . 0.0 110.57 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.26 20.04 5.45 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.603 -0.685 . . . . 0.0 111.018 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 26.33 6.7 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.115 -0.991 . . . . 0.0 110.745 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -80.07 159.99 25.95 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.605 -0.684 . . . . 0.0 109.911 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.4 t -109.97 119.95 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.569 -0.707 . . . . 0.0 109.97 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.59 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -114.32 110.0 48.29 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.68 . . . . 0.0 109.69 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.42 117.29 4.6 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.869 1.458 . . . . 0.0 110.354 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.0 t -120.05 129.13 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.701 -0.625 . . . . 0.0 109.737 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 mmm-85 -82.51 150.08 27.18 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.711 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -94.13 114.14 26.22 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -108.5 19.98 19.13 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.559 -0.713 . . . . 0.0 110.355 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.05 -178.54 40.07 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -61.32 -40.01 92.62 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.231 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.3 p -131.84 26.08 4.65 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.536 -0.728 . . . . 0.0 110.495 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.3 tpt180 -125.71 140.23 52.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.465 -0.772 . . . . 0.0 110.286 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.01 166.51 27.48 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 89.9 p -120.01 151.4 39.03 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.926 . . . . 0.0 110.265 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.421 HD23 ' O ' ' A' ' 128' ' ' SER . 6.3 tp -94.07 115.2 27.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.651 -0.656 . . . . 0.0 110.003 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.2 mp -62.15 -40.05 94.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.528 -0.732 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' SER . . . . . 0.421 ' O ' HD23 ' A' ' 126' ' ' LEU . 54.4 m -108.98 119.99 47.23 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -66.01 121.03 8.27 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 O-C-N 123.799 1.421 . . . . 0.0 110.537 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.449 ' CD ' ' CE2' ' A' ' 134' ' ' TYR . 89.4 mtt-85 -128.88 160.44 63.32 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.618 -0.676 . . . . 0.0 110.136 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.06 163.76 32.75 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.94 1.495 . . . . 0.0 110.517 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 67.2 t -67.02 -40.04 84.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.646 -0.659 . . . . 0.0 110.344 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.9 p -53.87 -30.87 47.64 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.409 -0.807 . . . . 0.0 110.991 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' TYR . . . . . 0.449 ' CE2' ' CD ' ' A' ' 130' ' ' ARG . 36.9 t80 -60.06 -40.01 87.99 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.454 -0.779 . . . . 0.0 110.091 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.488 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 9.0 mp -87.92 -23.73 23.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.57 -0.706 . . . . 0.0 110.625 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.2 tptm -59.99 129.32 41.22 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.347 -0.846 . . . . 0.0 110.0 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.04 -10.05 75.3 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.2 m -104.04 16.79 25.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.164 -1.197 . . . . 0.0 110.877 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -69.94 151.82 45.18 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.08 -17.93 57.81 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.56 149.46 28.49 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.494 ' HB3' HG21 ' A' ' 46' ' ' THR . 55.3 Cg_endo -98.39 146.71 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.852 1.448 . . . . 0.0 111.263 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.3 mp -102.69 105.52 16.0 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.529 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.558 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -93.35 130.89 38.95 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.728 . . . . 0.0 111.363 -178.485 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -69.98 159.31 84.71 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.99 -23.04 15.77 Favored 'Trans proline' 0 N--CA 1.502 1.993 0 O-C-N 123.418 1.22 . . . . 0.0 112.144 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -65.71 -39.99 91.77 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.335 -0.853 . . . . 0.0 109.823 179.554 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.71 35.3 0.85 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.8 m-70 -132.72 146.02 51.51 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.456 -1.026 . . . . 0.0 110.3 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.79 140.02 58.83 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.623 -0.673 . . . . 0.0 110.201 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.735 ' O ' HG23 ' A' ' 172' ' ' VAL . 47.0 t -111.1 -51.06 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.523 -0.736 . . . . 0.0 109.995 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -160.35 -172.21 27.29 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.6 mt -128.23 135.71 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.585 -0.95 . . . . 0.0 110.352 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.719 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.6 t80 -64.16 134.81 55.56 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 109.582 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ARG . . . . . 0.856 ' NH2' HD21 ' A' ' 82' ' ' LEU . 1.4 ttm105 -120.44 -52.45 2.15 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.489 -0.757 . . . . 0.0 110.733 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -142.25 157.29 45.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.751 . . . . 0.0 110.264 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.719 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -119.87 139.16 52.82 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 110.493 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -92.44 117.14 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.67 160.02 40.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.465 -0.772 . . . . 0.0 111.647 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 35.8 p -139.31 139.26 37.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.815 -0.553 . . . . 0.0 109.509 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.0 mtm180 55.62 30.87 16.18 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.466 -0.771 . . . . 0.0 110.539 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.02 22.89 64.84 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.1 t -129.53 129.73 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.341 -1.094 . . . . 0.0 109.89 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.06 129.98 46.17 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.542 -0.724 . . . . 0.0 110.5 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -118.83 -30.05 5.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.55 -0.719 . . . . 0.0 110.732 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -136.4 157.41 46.85 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.442 -0.786 . . . . 0.0 110.229 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.8 m -135.46 157.51 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.558 -0.714 . . . . 0.0 110.757 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -120.27 135.82 54.87 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.599 -0.688 . . . . 0.0 109.809 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -137.01 154.5 50.38 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.698 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.455 HG11 HD11 ' A' ' 82' ' ' LEU . 95.8 t -98.27 125.07 44.75 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.572 -0.705 . . . . 0.0 109.183 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -62.35 155.9 54.54 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 O-C-N 123.713 1.375 . . . . 0.0 110.797 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.3 t -56.19 -21.64 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.674 -0.641 . . . . 0.0 110.853 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -56.7 -37.25 70.64 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.362 -0.836 . . . . 0.0 110.768 -179.506 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 28.2 t -59.99 -44.54 94.45 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.392 -0.817 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 78.0 mtm -67.34 -39.92 85.85 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -60.3 -40.58 91.01 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -62.84 -40.04 96.2 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.616 -0.677 . . . . 0.0 110.055 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' THR . . . . . 0.516 HG21 ' OD1' ' A' ' 77' ' ' ASN . 94.5 m -60.95 -40.04 91.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.6 -0.687 . . . . 0.0 110.056 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.84 0 O-C-N 121.534 -0.729 . . . . 0.0 110.259 -179.851 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 44.4 tp10 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.048 0.452 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.776 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.598 -0.689 . . . . 0.0 110.07 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 33' ' ' VAL . 4.7 pt-20 . . . . . 0 N--CA 1.496 1.875 0 CA-C-O 120.928 0.394 . . . . 0.0 110.513 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.694 HG23 ' HG3' ' A' ' 32' ' ' GLU . 58.3 t -109.99 127.25 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.495 -0.753 . . . . 0.0 109.695 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -131.68 156.84 45.17 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.672 . . . . 0.0 110.376 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 35' ' ' VAL . 32.6 m -90.08 118.58 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.705 -0.622 . . . . 0.0 110.387 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.831 HG11 HD21 ' A' ' 64' ' ' LEU . 48.2 t -114.85 141.04 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.469 -0.769 . . . . 0.0 109.288 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 19.3 m -146.59 -178.92 6.42 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.748 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.3 p -141.49 -168.63 2.69 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.846 -0.534 . . . . 0.0 110.239 -179.618 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.47 -35.11 67.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.594 -0.691 . . . . 0.0 111.511 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.4 t -137.33 -8.01 1.74 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.266 -0.896 . . . . 0.0 113.033 -178.493 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 19.1 tp60 -115.38 143.71 44.88 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.881 -1.137 . . . . 0.0 110.88 -179.374 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.9 m -129.29 138.69 51.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.749 -0.595 . . . . 0.0 109.835 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.737 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.9 p90 -166.5 -177.52 4.03 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.46 -0.775 . . . . 0.0 110.466 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.2 mt -112.98 146.43 39.06 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.557 -0.714 . . . . 0.0 110.172 -178.761 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . . . -128.68 161.21 30.21 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.631 -0.668 . . . . 0.0 110.261 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.476 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.1 t -121.3 140.55 51.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.558 -0.714 . . . . 0.0 110.146 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.9 t -97.42 110.08 22.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.579 -0.701 . . . . 0.0 110.352 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.2 130.0 62.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 109.476 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 55.67 40.0 30.89 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.483 -0.761 . . . . 0.0 110.762 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.06 22.15 77.16 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.255 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -131.84 130.0 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.235 -1.156 . . . . 0.0 110.123 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -72.09 146.0 47.83 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.452 -0.78 . . . . 0.0 109.296 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -139.97 137.2 34.53 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.357 -0.839 . . . . 0.0 111.645 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.709 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 13.4 t -161.09 173.88 14.52 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.442 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.755 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.9 p -78.64 150.37 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.267 -0.896 . . . . 0.0 110.838 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.534 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.2 t80 -60.05 -49.2 78.59 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.58 -0.7 . . . . 0.0 111.894 -178.711 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.79 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.4 p-80 -57.94 -24.41 57.78 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.029 -1.044 . . . . 0.0 110.926 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.512 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.48 -46.31 15.51 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 178.584 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.737 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -136.38 94.53 3.03 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.723 -0.869 . . . . 0.0 109.433 179.349 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.73 -166.62 3.39 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.0 p -71.57 69.62 0.63 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.622 -0.928 . . . . 0.0 109.964 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.3 178.76 7.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.559 -0.713 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 31.0 p -65.54 147.38 53.51 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.713 . . . . 0.0 109.619 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.831 HD21 HG11 ' A' ' 36' ' ' VAL . 12.9 tp -113.1 133.4 55.03 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.611 -0.681 . . . . 0.0 109.99 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.03 109.63 21.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.617 -0.677 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.72 -171.74 17.76 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.24 -32.55 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.908 1.478 . . . . 0.0 110.456 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -76.14 -31.31 58.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.584 -0.698 . . . . 0.0 109.787 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.01 -146.15 17.24 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.7 144.43 31.4 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.895 1.471 . . . . 0.0 110.182 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.582 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.8 mt -130.03 140.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.485 -0.759 . . . . 0.0 110.316 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.3 m -86.05 136.3 33.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.529 -0.732 . . . . 0.0 110.288 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -83.38 149.49 26.68 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.589 -0.694 . . . . 0.0 110.959 -179.518 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 82.1 mtp -119.27 -18.92 8.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.666 -0.646 . . . . 0.0 110.986 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -128.12 147.98 50.56 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.245 -0.909 . . . . 0.0 110.588 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.8 p -144.49 126.0 14.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.743 -0.598 . . . . 0.0 109.975 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -142.48 90.75 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.62 -0.675 . . . . 0.0 110.053 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.534 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 86.7 t -69.82 -46.69 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.579 -0.7 . . . . 0.0 109.911 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -41.82 92.85 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.594 -0.691 . . . . 0.0 110.277 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.545 ' HG2' HD12 ' A' ' 82' ' ' LEU . 45.3 tt0 -90.31 -0.11 57.49 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.571 -0.706 . . . . 0.0 111.149 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 1.6 t70 53.25 44.49 30.1 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.99 -1.069 . . . . 0.0 110.85 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.776 HD11 HG11 ' A' ' 170' ' ' VAL . 45.5 mt -132.93 146.53 51.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.3 -0.875 . . . . 0.0 111.12 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.525 HG23 ' CH2' ' A' ' 85' ' ' TRP . 30.6 m -152.83 169.58 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.65 -0.656 . . . . 0.0 109.667 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -164.9 157.78 30.35 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.709 ' HZ3' HG22 ' A' ' 54' ' ' THR . 10.2 m-90 -128.67 168.1 16.27 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.66 -0.906 . . . . 0.0 109.835 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 54.8 tp60 -70.85 119.38 14.9 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.444 -0.785 . . . . 0.0 109.375 179.056 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.52 149.91 95.58 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.532 -0.73 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.96 154.34 67.04 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.884 1.465 . . . . 0.0 110.369 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.42 152.98 74.97 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.941 1.495 . . . . 0.0 110.178 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 30.0 70.42 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.79 147.74 30.44 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.481 -1.011 . . . . 0.0 110.12 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.4 mtp85 -88.82 150.05 23.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.575 -0.703 . . . . 0.0 109.958 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -126.95 169.91 12.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.605 -0.685 . . . . 0.0 110.111 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.635 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -109.15 137.4 47.11 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.581 -0.699 . . . . 0.0 110.738 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' THR . . . . . 0.411 ' OG1' ' CE1' ' A' ' 149' ' ' HIS . 3.3 p -79.29 165.68 46.86 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.652 -0.655 . . . . 0.0 109.904 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -80.11 153.29 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.827 1.435 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.778 ' HB2' HG22 ' A' ' 151' ' ' VAL . 50.3 t -65.04 131.63 47.09 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.663 -0.648 . . . . 0.0 110.117 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.2 t -135.97 54.26 1.91 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.714 -0.616 . . . . 0.0 109.727 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.89 -7.87 0.73 Allowed 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.599 -0.688 . . . . 0.0 112.322 -179.127 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.76 33.82 87.95 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.9 p -95.8 132.46 41.01 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.543 -0.975 . . . . 0.0 110.406 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.3 m -80.0 -26.65 39.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.641 . . . . 0.0 110.409 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -66.4 129.92 41.46 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.435 -0.791 . . . . 0.0 110.296 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.555 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.3 mt -131.29 157.13 44.12 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.54 -0.725 . . . . 0.0 110.558 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -119.94 115.73 24.36 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.528 -0.732 . . . . 0.0 109.876 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.61 HD13 HD11 ' A' ' 143' ' ' LEU . 65.0 tp -93.37 138.28 31.86 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.578 -0.701 . . . . 0.0 110.699 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.2 t -97.89 130.05 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.688 -0.633 . . . . 0.0 109.524 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -106.43 165.67 11.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.453 -0.779 . . . . 0.0 110.509 -179.461 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.656 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.3 mtp180 -59.99 -27.34 66.78 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.627 -0.671 . . . . 0.0 110.489 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 44.8 t-80 -94.49 29.22 2.32 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.528 -0.732 . . . . 0.0 110.62 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.28 39.95 31.3 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.236 -0.915 . . . . 0.0 110.777 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -104.62 127.62 52.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.612 -0.68 . . . . 0.0 109.972 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 120.13 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.498 -0.751 . . . . 0.0 109.993 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 40.2 pt -114.44 146.9 36.84 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.616 -0.678 . . . . 0.0 109.975 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -87.03 113.04 0.96 Allowed 'Trans proline' 0 N--CA 1.49 1.271 0 O-C-N 123.852 1.448 . . . . 0.0 110.531 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.0 119.94 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 109.517 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -79.34 136.95 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.493 -0.754 . . . . 0.0 110.259 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -80.01 129.6 34.62 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.661 -0.649 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -124.64 23.6 8.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.544 -0.722 . . . . 0.0 110.292 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.78 -177.92 47.41 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -68.75 -39.96 80.03 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.57 -0.959 . . . . 0.0 110.429 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.7 p -129.84 26.18 5.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.525 -0.735 . . . . 0.0 110.506 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.89 159.99 35.78 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.534 -0.729 . . . . 0.0 110.253 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -153.1 172.72 32.05 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.7 p -126.36 147.0 49.82 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.529 -0.983 . . . . 0.0 110.227 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.7 mp -99.79 121.14 40.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.547 -0.721 . . . . 0.0 110.256 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -60.88 -40.02 91.43 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.703 . . . . 0.0 109.955 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.7 m -109.95 112.91 57.65 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.588 -0.695 . . . . 0.0 109.967 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -64.19 127.47 19.32 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 123.845 1.445 . . . . 0.0 110.515 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 31.8 mtt-85 -127.04 160.04 61.61 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.568 -0.708 . . . . 0.0 110.041 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.09 146.43 81.95 Favored 'Trans proline' 0 N--CA 1.49 1.303 0 O-C-N 123.953 1.501 . . . . 0.0 110.303 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.636 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.1 m -60.03 -27.06 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.613 -0.679 . . . . 0.0 110.547 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -59.94 -40.06 87.64 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.468 -0.77 . . . . 0.0 110.389 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -65.36 -39.94 92.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.469 -0.77 . . . . 0.0 110.116 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.458 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -70.36 -27.16 64.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.595 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -58.21 140.04 53.84 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.388 -0.82 . . . . 0.0 110.448 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 87.28 6.98 77.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 56.0 p -111.43 -4.27 14.92 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.026 -1.279 . . . . 0.0 111.245 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.3 m -59.96 140.05 56.99 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.057 -1.027 . . . . 0.0 109.777 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.501 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 98.32 -23.7 35.06 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.65 150.08 42.65 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.692 ' C ' HD12 ' A' ' 143' ' ' LEU . 52.3 Cg_endo -91.8 156.74 3.43 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.785 1.413 . . . . 0.0 111.571 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.692 HD12 ' C ' ' A' ' 142' ' ' PRO . 9.8 mp -116.4 102.99 10.01 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.796 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.623 HD21 HD22 ' A' ' 94' ' ' LEU . 9.9 mp -94.79 133.19 38.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.561 -0.712 . . . . 0.0 111.661 -178.358 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.05 159.37 84.56 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.912 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.8 Cg_endo -52.61 -26.16 28.39 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 O-C-N 123.505 1.266 . . . . 0.0 112.276 -178.643 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.2 m -62.51 -40.06 95.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.32 39.52 0.58 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' HIS . . . . . 0.411 ' CE1' ' OG1' ' A' ' 95' ' ' THR . 3.6 m-70 -137.28 144.96 42.95 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.478 -1.013 . . . . 0.0 110.039 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.635 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -66.62 140.01 57.91 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.552 -0.717 . . . . 0.0 110.244 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 97' ' ' CYS . 63.0 t -112.63 -36.25 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.581 -0.7 . . . . 0.0 109.814 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.91 -168.51 38.75 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.751 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.7 mt -129.56 140.1 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.543 -0.975 . . . . 0.0 110.216 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -60.56 136.4 58.04 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.632 -0.667 . . . . 0.0 109.91 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.9 ttt180 -115.72 -52.22 2.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.532 -0.73 . . . . 0.0 110.369 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' ALA . . . . . 0.569 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -156.12 160.04 39.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.529 -0.732 . . . . 0.0 110.294 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.72 151.06 28.18 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.645 -0.659 . . . . 0.0 110.311 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.91 119.51 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.672 -0.643 . . . . 0.0 109.68 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.636 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -135.02 154.38 51.74 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.634 -0.666 . . . . 0.0 110.305 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.3 m -103.02 -48.68 3.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.549 -0.72 . . . . 0.0 110.653 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.5 mtm180 -131.04 50.2 2.25 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.53 -0.731 . . . . 0.0 110.373 -179.457 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.97 -4.36 83.16 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 59.6 t -113.29 129.4 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -1.21 . . . . 0.0 109.688 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -99.97 123.95 44.77 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.589 -0.694 . . . . 0.0 110.595 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.25 -18.35 13.62 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.59 -0.694 . . . . 0.0 110.698 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.48 153.7 43.89 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.328 -0.858 . . . . 0.0 110.224 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.75 163.58 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.517 -0.74 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -122.18 134.14 54.72 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.653 -0.654 . . . . 0.0 110.224 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -132.25 157.42 44.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.44 -0.787 . . . . 0.0 110.227 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.776 HG11 HD11 ' A' ' 82' ' ' LEU . 58.0 t -93.43 120.67 66.29 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.572 -0.705 . . . . 0.0 109.589 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.33 148.72 84.82 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.762 1.401 . . . . 0.0 110.492 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.5 -23.58 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.734 -0.604 . . . . 0.0 110.738 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -59.51 -34.58 72.78 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.626 -179.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.7 p -69.75 -37.37 76.43 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.493 -0.755 . . . . 0.0 110.435 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.751 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.1 mtt -59.96 -50.01 75.43 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.458 -0.776 . . . . 0.0 110.873 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -64.49 -29.3 70.34 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.494 -0.754 . . . . 0.0 110.359 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -60.51 -42.56 96.65 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.455 -0.778 . . . . 0.0 110.021 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -70.0 -40.8 75.07 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.497 1.893 0 O-C-N 121.528 -0.732 . . . . 0.0 110.331 -179.872 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' B' B ' 188' ' ' GLU . . . . . 0.569 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.4 tt0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.053 0.454 . . . . 0.0 110.15 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.79 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.6 mp . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.531 -0.731 . . . . 0.0 110.245 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 121.039 0.447 . . . . 0.0 110.298 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.34 130.04 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 109.757 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -128.03 158.56 37.59 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.54 -0.725 . . . . 0.0 110.53 -179.626 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.2 t -95.27 128.43 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 0.0 109.499 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.565 ' CB ' HD21 ' A' ' 64' ' ' LEU . 29.2 m -129.3 158.97 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.591 -0.693 . . . . 0.0 109.83 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -153.46 164.04 38.89 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.8 p -118.71 -169.68 1.76 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.635 -0.665 . . . . 0.0 109.598 179.376 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.99 -34.31 73.14 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.586 -0.696 . . . . 0.0 110.985 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 54.7 p -131.21 -10.69 3.71 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.184 -0.947 . . . . 0.0 112.64 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.2 tp60 -117.92 153.42 33.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.92 -1.113 . . . . 0.0 111.289 -179.086 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 35.2 t -138.44 138.31 38.04 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.623 -0.673 . . . . 0.0 109.736 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.78 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 22.4 p90 -167.24 -178.08 3.94 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.305 -0.872 . . . . 0.0 110.527 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.677 HD11 ' HA ' ' A' ' 109' ' ' ARG . 66.4 mt -113.61 157.61 21.89 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.619 -0.676 . . . . 0.0 110.649 -178.619 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -135.24 162.29 32.97 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.742 -0.599 . . . . 0.0 110.112 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -124.63 139.8 53.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.3 t -97.57 113.94 25.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.411 -0.806 . . . . 0.0 110.619 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' VAL . . . . . 0.427 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 61.4 t -121.03 133.88 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.609 -0.682 . . . . 0.0 109.945 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.54 39.95 27.39 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.509 -0.745 . . . . 0.0 111.256 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 67.9 26.89 73.78 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 178.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 65.5 t -140.02 138.59 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.468 -1.019 . . . . 0.0 109.696 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -81.07 147.37 30.16 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 109.298 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' TRP . . . . . 0.524 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 61.1 m95 -130.13 153.06 48.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.455 -0.778 . . . . 0.0 110.868 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.5 t -169.62 -179.5 3.39 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.842 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.1 p -95.25 144.87 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.476 -0.765 . . . . 0.0 110.473 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.431 ' CE1' HG22 ' A' ' 78' ' ' VAL . 64.9 t80 -60.47 -42.59 96.54 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.716 -0.615 . . . . 0.0 111.694 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.842 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.9 p-80 -70.02 -20.14 63.28 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.043 -1.036 . . . . 0.0 110.895 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.732 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -89.19 -43.32 5.34 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.78 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -132.6 85.05 2.19 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.668 -0.901 . . . . 0.0 109.804 179.462 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.2 -168.8 1.55 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.5 p -72.78 67.45 0.81 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.618 -0.93 . . . . 0.0 109.707 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -140.02 169.78 17.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.622 -0.674 . . . . 0.0 110.476 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.9 m -65.53 139.58 58.49 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.676 -0.64 . . . . 0.0 110.088 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.952 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.4 tp -115.3 133.47 56.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.625 -0.672 . . . . 0.0 109.801 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.78 119.37 30.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.555 -0.716 . . . . 0.0 110.334 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -125.42 176.37 17.25 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.03 -32.18 75.92 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.788 1.415 . . . . 0.0 110.455 -179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.2 mmtt -70.21 -31.39 68.81 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.555 -0.716 . . . . 0.0 109.782 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.31 -151.12 22.38 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.87 154.65 63.26 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.886 1.466 . . . . 0.0 110.131 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.431 HG22 ' CD1' ' A' ' 85' ' ' TRP . 86.0 mt -129.98 139.91 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.56 -0.713 . . . . 0.0 110.675 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.5 m -100.57 138.8 37.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.589 -0.694 . . . . 0.0 110.274 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 143.81 51.91 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.562 -0.711 . . . . 0.0 110.817 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' MET . . . . . 0.436 ' HB3' ' CD2' ' A' ' 75' ' ' TYR . 5.5 mtp -119.16 -50.03 2.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.532 -0.73 . . . . 0.0 110.452 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' TYR . . . . . 0.436 ' CD2' ' HB3' ' A' ' 74' ' ' MET . 98.8 m-85 -120.0 140.01 51.61 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.754 . . . . 0.0 110.462 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' THR . . . . . 0.599 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.5 m -136.03 133.02 37.0 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.556 -0.715 . . . . 0.0 110.411 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.7 t30 -145.83 100.56 3.43 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.495 -0.753 . . . . 0.0 109.98 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.431 HG22 ' CE1' ' A' ' 56' ' ' TYR . 59.8 t -69.98 -36.66 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.543 -0.723 . . . . 0.0 110.312 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -59.95 -50.0 75.48 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.469 -0.77 . . . . 0.0 110.981 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.5 mm-40 -90.47 0.15 57.43 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.466 -0.771 . . . . 0.0 111.309 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.6 t70 55.33 40.09 31.41 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.921 -1.112 . . . . 0.0 109.747 -179.41 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.465 ' CD2' HG21 ' A' ' 170' ' ' VAL . 0.6 OUTLIER -125.24 132.34 52.98 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.671 -0.643 . . . . 0.0 110.742 -179.07 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 54' ' ' THR . 27.1 m -145.08 157.16 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.645 -0.659 . . . . 0.0 109.462 179.05 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -144.84 175.03 24.72 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.594 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.952 ' CH2' HD22 ' A' ' 64' ' ' LEU . 8.5 m-90 -130.04 159.97 35.11 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.916 -0.755 . . . . 0.0 109.631 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -66.53 123.33 19.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.365 -0.834 . . . . 0.0 109.152 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -79.37 139.74 55.89 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.504 -0.747 . . . . 0.0 110.193 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HG2' ' HB2' ' A' ' 91' ' ' ALA . 48.3 Cg_endo -69.98 159.17 54.2 Favored 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.824 1.434 . . . . 0.0 110.4 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.52 136.1 27.76 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.961 1.506 . . . . 0.0 110.286 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.13 -24.16 33.39 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ALA . . . . . 0.465 ' HB2' ' HG2' ' A' ' 88' ' ' PRO . . . -60.1 140.01 57.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.374 -1.074 . . . . 0.0 110.3 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -80.91 158.9 25.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.635 -0.666 . . . . 0.0 109.659 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.8 p -130.49 168.93 16.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.521 -0.737 . . . . 0.0 110.325 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.421 ' O ' HG13 ' A' ' 48' ' ' VAL . 84.5 mt -112.94 140.01 48.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.561 -0.712 . . . . 0.0 110.702 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 44.6 p -82.1 165.54 42.4 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.647 -0.658 . . . . 0.0 110.142 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -81.63 162.04 19.14 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.797 1.42 . . . . 0.0 110.662 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -73.66 130.16 39.45 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.64 -0.662 . . . . 0.0 110.137 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.97 54.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.741 -0.599 . . . . 0.0 109.816 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.73 -8.49 0.73 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.713 . . . . 0.0 112.383 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 42.85 97.29 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -100.0 119.97 39.1 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.522 -0.987 . . . . 0.0 110.531 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.9 m -62.78 -40.08 96.19 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.649 -0.657 . . . . 0.0 110.296 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -63.41 130.47 44.57 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.583 -0.698 . . . . 0.0 110.261 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 151' ' ' VAL . 95.8 mt -137.97 155.37 48.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.617 -0.677 . . . . 0.0 110.577 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -106.69 135.58 47.98 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.465 -0.772 . . . . 0.0 109.545 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.506 HD11 ' HB2' ' A' ' 154' ' ' PHE . 39.8 tp -105.09 127.21 52.79 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.449 -0.782 . . . . 0.0 110.747 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 140.03 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.536 -0.727 . . . . 0.0 109.777 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.2 m -130.07 170.06 14.49 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.524 -0.735 . . . . 0.0 110.516 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.677 ' HA ' HD11 ' A' ' 44' ' ' LEU . 44.2 mtm180 -60.04 -23.2 63.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.51 -0.744 . . . . 0.0 110.781 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.11 19.37 5.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.395 -0.816 . . . . 0.0 111.194 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.49 39.9 30.63 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.077 -1.015 . . . . 0.0 110.693 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -113.27 157.65 21.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.533 -0.729 . . . . 0.0 109.955 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.4 m -129.43 133.68 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.52 -0.738 . . . . 0.0 110.371 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 49.0 mm -122.48 147.82 51.16 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.602 -0.687 . . . . 0.0 109.701 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' PRO . . . . . 0.437 ' HG2' HD22 ' A' ' 127' ' ' LEU . 48.6 Cg_endo -82.65 129.75 5.74 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.906 1.477 . . . . 0.0 110.378 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 125' ' ' SER . 63.0 t -130.0 130.02 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.697 -0.627 . . . . 0.0 109.602 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' ARG . . . . . 0.589 ' HG2' HD11 ' A' ' 127' ' ' LEU . 54.2 mmm-85 -79.53 153.1 29.78 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.517 -0.74 . . . . 0.0 110.276 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 51.4 ttt-85 -99.34 119.07 37.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.64 -0.662 . . . . 0.0 109.921 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.1 mmm-85 -114.6 24.34 11.93 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.671 -0.643 . . . . 0.0 110.219 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 162.07 -175.41 38.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -64.57 -39.97 94.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.53 -0.982 . . . . 0.0 110.378 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 52.8 p -130.87 28.87 4.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.543 -0.723 . . . . 0.0 110.753 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.6 tpp85 -132.44 146.63 52.09 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.422 -0.799 . . . . 0.0 110.656 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -160.69 169.83 36.48 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.423 ' O ' HG13 ' A' ' 116' ' ' VAL . 53.3 p -109.24 158.38 17.91 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.468 -1.019 . . . . 0.0 110.234 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.7 tp -102.02 119.94 39.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.541 -0.725 . . . . 0.0 110.152 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.589 HD11 ' HG2' ' A' ' 117' ' ' ARG . 7.6 mp -65.44 -40.04 92.79 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.988 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.8 109.94 59.35 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -66.14 118.68 5.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.82 1.432 . . . . 0.0 110.415 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -120.04 160.01 44.75 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.598 -0.689 . . . . 0.0 110.127 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.2 157.93 54.93 Favored 'Trans proline' 0 N--CA 1.491 1.352 0 O-C-N 123.919 1.484 . . . . 0.0 110.242 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.421 HG21 ' SG ' ' A' ' 159' ' ' CYS . 63.4 t -67.13 -30.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.601 -0.687 . . . . 0.0 110.191 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.6 p -60.04 -39.74 86.97 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.515 -0.74 . . . . 0.0 110.414 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -64.35 -40.02 95.03 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.566 -0.709 . . . . 0.0 110.222 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.448 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.02 -30.75 68.14 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.453 -0.779 . . . . 0.0 110.555 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -60.04 142.75 53.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.469 -0.769 . . . . 0.0 110.218 -179.742 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.96 8.72 87.41 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 17.5 m -113.37 -7.73 13.47 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.182 -1.187 . . . . 0.0 110.966 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 30.6 t -59.92 140.33 56.76 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.091 -1.005 . . . . 0.0 109.99 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.401 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.3 -21.23 42.05 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -61.45 145.05 48.85 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.42 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.1 Cg_endo -86.88 142.16 6.52 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.836 1.44 . . . . 0.0 111.262 -179.457 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.736 ' O ' HG12 ' A' ' 151' ' ' VAL . 9.7 mp -101.25 122.09 43.04 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 143' ' ' LEU . 10.0 mp -112.13 133.77 54.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.474 -0.766 . . . . 0.0 111.537 -178.693 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.439 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.08 160.03 82.1 Favored Pre-proline 0 N--CA 1.497 1.912 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.072 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 146' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -52.13 -23.02 16.32 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 O-C-N 123.464 1.244 . . . . 0.0 112.235 -178.821 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -65.84 -40.01 91.34 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.325 -0.859 . . . . 0.0 109.854 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.99 34.33 0.91 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 19.1 m-70 -131.68 145.52 51.69 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.464 -1.021 . . . . 0.0 110.326 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.29 137.19 46.55 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.545 -0.722 . . . . 0.0 110.265 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.736 HG12 ' O ' ' A' ' 143' ' ' LEU . 9.2 p -115.54 -22.49 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.536 -0.728 . . . . 0.0 110.696 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.65 -170.93 43.51 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ILE . . . . . 0.401 HG23 ' C ' ' A' ' 140' ' ' GLY . 63.5 mt -129.93 140.03 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.595 -0.944 . . . . 0.0 110.055 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.506 ' HB2' HD11 ' A' ' 106' ' ' LEU . 20.7 t80 -61.64 138.24 58.29 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.652 -0.655 . . . . 0.0 109.911 179.692 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -118.49 -52.3 2.37 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.545 -0.722 . . . . 0.0 110.563 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.11 160.39 42.9 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.57 -0.706 . . . . 0.0 110.403 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.94 147.58 39.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.599 -0.688 . . . . 0.0 110.384 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.01 120.03 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.677 -0.64 . . . . 0.0 109.642 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.421 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -125.93 143.99 50.86 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.645 -0.659 . . . . 0.0 110.631 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' THR . . . . . 0.511 HG22 ' HG2' ' A' ' 161' ' ' ARG . 58.6 m -82.01 -56.42 3.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.663 . . . . 0.0 110.44 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.511 ' HG2' HG22 ' A' ' 160' ' ' THR . 20.8 mmt180 -134.7 58.0 1.79 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.529 -0.732 . . . . 0.0 110.08 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.4 -10.0 75.76 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.86 121.35 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.128 -1.219 . . . . 0.0 109.688 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -78.83 128.3 33.18 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.631 -0.668 . . . . 0.0 110.552 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -111.5 -25.97 9.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.639 -0.663 . . . . 0.0 110.398 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.36 159.17 42.78 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.585 -0.697 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.8 160.01 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.539 -0.726 . . . . 0.0 111.006 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -121.76 133.88 54.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.682 -0.636 . . . . 0.0 110.055 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -138.18 151.44 47.71 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.421 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.465 HG21 ' CD2' ' A' ' 82' ' ' LEU . 57.3 t -88.09 123.42 68.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.497 -0.752 . . . . 0.0 109.505 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.34 155.13 71.76 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.764 1.402 . . . . 0.0 110.56 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 151' ' ' VAL . 88.9 t -58.24 -21.74 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.681 -0.637 . . . . 0.0 110.654 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -57.64 -40.01 78.27 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.268 -0.895 . . . . 0.0 110.656 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 3.4 m -73.65 -35.32 65.24 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.448 -0.783 . . . . 0.0 109.683 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 175' ' ' MET . . . . . 0.524 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 95.0 mtp -63.14 -40.48 97.71 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.66 -0.65 . . . . 0.0 110.133 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -69.54 -39.92 77.17 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.611 -0.681 . . . . 0.0 110.381 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.9 m -65.48 -39.97 92.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.662 -0.649 . . . . 0.0 110.075 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 90.5 m -61.72 -48.62 79.91 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.533 -0.729 . . . . 0.0 110.069 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 179' ' ' MET . . . . . 0.4 ' HG3' ' CZ ' ' A' ' 75' ' ' TYR . 26.6 ttt . . . . . 0 N--CA 1.496 1.852 0 O-C-N 121.56 -0.712 . . . . 0.0 110.308 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.108 0.48 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.789 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.2 mp . . . . . 0 N--CA 1.496 1.829 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.432 ' HB3' ' CD2' ' A' ' 94' ' ' LEU . 45.3 mt-10 . . . . . 0 N--CA 1.5 2.044 0 CA-C-O 120.816 0.341 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.427 HG23 ' C ' ' A' ' 32' ' ' GLU . 65.9 t -147.76 131.86 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.386 -0.821 . . . . 0.0 109.647 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -124.72 155.17 39.7 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.522 -0.736 . . . . 0.0 110.583 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.9 t -102.92 122.04 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.682 -0.636 . . . . 0.0 109.605 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.562 ' HB ' HD12 ' A' ' 64' ' ' LEU . 34.1 m -117.1 145.2 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.658 -0.651 . . . . 0.0 109.772 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' SER . . . . . 0.463 ' O ' HD13 ' A' ' 64' ' ' LEU . 6.2 t -131.85 168.5 17.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.548 -0.72 . . . . 0.0 110.6 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.436 HG22 ' H ' ' A' ' 39' ' ' ALA . 5.0 m -141.91 173.23 11.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.584 -0.698 . . . . 0.0 110.376 -179.671 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.436 ' H ' HG22 ' A' ' 38' ' ' THR . . . -68.88 -12.71 61.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.592 -0.692 . . . . 0.0 111.044 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 43.2 p -111.16 -41.5 4.17 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.202 -0.936 . . . . 0.0 111.088 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -157.48 168.14 28.17 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.402 -0.811 . . . . 0.0 110.831 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 80.6 p -119.85 152.64 37.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 3.7 p90 -154.26 -178.22 6.98 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.525 -0.735 . . . . 0.0 110.136 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.796 HD11 ' CA ' ' A' ' 109' ' ' ARG . 35.0 mt -113.49 153.76 28.16 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.487 -0.758 . . . . 0.0 110.817 -178.236 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -131.12 162.19 30.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.686 -0.634 . . . . 0.0 109.972 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 7.6 t -124.44 143.61 50.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.474 -0.766 . . . . 0.0 110.59 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 97.1 m -96.53 108.93 21.59 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.568 -0.707 . . . . 0.0 110.154 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.5 t -123.35 133.84 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.543 -0.723 . . . . 0.0 109.612 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 54.71 36.53 26.44 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.521 -0.737 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.02 75.96 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.268 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.38 129.97 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.226 -1.161 . . . . 0.0 110.043 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 90.7 m -74.23 149.2 40.94 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.473 -0.767 . . . . 0.0 109.527 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 77.1 m95 -136.11 151.85 50.23 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.512 -0.742 . . . . 0.0 111.069 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.937 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.4 t -168.4 -178.49 3.58 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.847 -0.533 . . . . 0.0 109.778 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.921 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.7 p -82.08 161.27 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.568 -0.707 . . . . 0.0 110.01 179.265 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 65.9 t80 -85.37 -34.6 21.74 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.399 -0.813 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.921 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.6 p-80 -70.01 -20.1 63.29 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.996 -1.065 . . . . 0.0 110.941 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.501 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -78.22 -51.15 5.85 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 179.544 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.416 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -95.16 -50.43 5.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.509 -0.995 . . . . 0.0 110.374 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.3 30.81 36.03 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.427 ' HA ' HG21 ' A' ' 83' ' ' VAL . 2.0 t 56.87 40.02 29.16 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.302 -1.116 . . . . 0.0 110.283 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.06 178.67 4.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.69 -0.631 . . . . 0.0 109.737 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -65.46 138.79 58.34 Favored 'General case' 0 N--CA 1.494 1.726 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.181 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.732 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -118.24 142.74 47.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.5 -0.75 . . . . 0.0 110.214 -179.406 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.99 115.94 30.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.645 -0.659 . . . . 0.0 109.911 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.58 174.29 15.25 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -62.78 -31.83 78.16 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.762 1.401 . . . . 0.0 110.422 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -71.93 -31.29 66.21 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.767 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.03 -147.58 19.03 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.63 151.32 64.04 Favored 'Trans proline' 0 N--CA 1.49 1.296 0 O-C-N 123.878 1.462 . . . . 0.0 110.241 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.732 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.8 mt -120.02 129.67 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.626 -0.671 . . . . 0.0 110.271 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.8 p -91.56 144.46 25.52 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.464 -0.772 . . . . 0.0 110.149 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 0.4 OUTLIER -88.0 134.17 33.79 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.558 -0.714 . . . . 0.0 110.872 -179.566 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.1 mmm -116.57 -33.22 4.95 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.625 -0.672 . . . . 0.0 110.239 179.41 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -131.27 137.67 48.96 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.577 -0.702 . . . . 0.0 110.326 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 84.6 m -139.97 130.62 25.75 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.528 -0.733 . . . . 0.0 109.978 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -136.86 100.67 4.37 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.545 -0.722 . . . . 0.0 110.353 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.432 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.8 t -70.01 -35.55 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.594 -0.691 . . . . 0.0 110.025 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -60.0 -47.88 84.0 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.606 -0.684 . . . . 0.0 110.512 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.96 3.03 54.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.479 -0.763 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.414 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 9.1 t70 54.08 49.4 18.89 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.113 -0.992 . . . . 0.0 110.425 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.73 HD11 HG11 ' A' ' 170' ' ' VAL . 68.4 mt -140.94 141.24 34.5 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.589 -0.694 . . . . 0.0 111.047 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.663 ' O ' HG22 ' A' ' 54' ' ' THR . 7.8 p -139.15 140.5 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.844 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -125.71 158.09 19.92 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.937 ' CH2' HG21 ' A' ' 54' ' ' THR . 11.2 m-90 -119.89 167.16 12.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.681 -0.893 . . . . 0.0 109.88 179.569 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -71.19 115.86 10.83 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.605 -0.685 . . . . 0.0 109.429 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.07 146.34 94.83 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.554 -0.716 . . . . 0.0 110.187 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.91 159.8 51.97 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.981 1.516 . . . . 0.0 110.314 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.02 151.2 61.64 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 124.019 1.536 . . . . 0.0 110.369 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.06 29.46 70.6 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.13 139.41 38.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.56 -0.965 . . . . 0.0 110.266 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -88.86 143.41 26.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.599 -0.688 . . . . 0.0 109.842 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.4 p -128.99 159.62 35.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 110.571 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.753 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 3.2 mm? -79.94 160.0 26.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.608 -0.682 . . . . 0.0 110.504 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.6 p -103.08 150.31 37.73 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.681 -0.637 . . . . 0.0 109.884 179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -60.53 141.32 95.03 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 O-C-N 123.783 1.412 . . . . 0.0 110.738 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.504 ' HG ' ' HG ' ' A' ' 145' ' ' CYS . 32.1 t -60.06 133.95 56.58 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.506 -0.746 . . . . 0.0 110.129 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 98' ' ' THR . 6.7 t -136.48 57.24 1.78 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.5 -8.8 0.75 Allowed 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.463 -178.895 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.08 44.1 96.54 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.2 m -108.36 132.59 53.59 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.537 -0.978 . . . . 0.0 110.671 -179.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -76.78 -27.26 55.21 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.661 -0.649 . . . . 0.0 110.427 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.76 129.97 41.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.463 -0.773 . . . . 0.0 110.214 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.601 HD22 HG21 ' A' ' 151' ' ' VAL . 92.6 mt -135.18 145.65 47.95 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.572 -0.705 . . . . 0.0 110.65 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -106.93 130.79 54.54 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.524 -0.735 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.42 HD13 HD11 ' A' ' 143' ' ' LEU . 50.7 tp -108.5 143.09 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.529 -0.732 . . . . 0.0 110.682 -179.221 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.02 129.97 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.666 -0.646 . . . . 0.0 109.533 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 77.3 p -102.58 176.76 5.06 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.509 -0.745 . . . . 0.0 110.791 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.796 ' CA ' HD11 ' A' ' 44' ' ' LEU . 11.9 ttp180 -68.44 -19.45 64.57 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.719 -0.613 . . . . 0.0 110.742 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -92.37 24.04 3.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.382 -0.824 . . . . 0.0 110.981 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.58 39.35 31.11 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.231 -0.918 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -114.46 159.47 20.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.592 -0.692 . . . . 0.0 109.724 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.92 136.45 58.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.539 -0.725 . . . . 0.0 110.437 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.553 HD12 HH21 ' A' ' 130' ' ' ARG . 16.6 tt -129.9 131.18 23.34 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.561 -0.712 . . . . 0.0 109.809 179.643 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.61 126.05 12.95 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.77 1.405 . . . . 0.0 110.552 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -124.11 129.91 73.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.785 -0.572 . . . . 0.0 109.691 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -86.77 136.57 32.95 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.446 -0.784 . . . . 0.0 109.945 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -84.38 121.43 27.53 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 110.435 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -110.03 20.06 18.33 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.642 -0.661 . . . . 0.0 110.449 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 164.85 -179.95 39.21 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -69.68 -40.08 76.58 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.482 -1.011 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 88.8 p -120.26 21.88 11.56 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.928 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -133.79 140.22 46.79 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.394 -0.816 . . . . 0.0 110.328 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.73 163.23 26.21 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -126.69 144.99 50.75 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.587 -0.949 . . . . 0.0 110.295 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.541 HD13 HG13 ' A' ' 167' ' ' VAL . 10.7 mp -100.03 129.94 46.14 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.628 -0.67 . . . . 0.0 110.44 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.6 mp -68.73 -40.03 80.1 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.642 -0.661 . . . . 0.0 109.723 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -109.15 112.69 59.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.661 -0.65 . . . . 0.0 109.878 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.95 136.77 50.04 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.756 1.398 . . . . 0.0 110.567 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' ARG . . . . . 0.553 HH21 HD12 ' A' ' 114' ' ' ILE . 20.1 mmt85 -129.84 160.0 67.11 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.712 . . . . 0.0 110.093 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.06 152.23 83.05 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.875 1.46 . . . . 0.0 110.375 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 162' ' ' GLY . 34.3 m -64.99 -25.56 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.605 -0.684 . . . . 0.0 110.487 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.7 m -59.99 -40.03 87.77 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.0 110.286 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -66.64 -39.96 88.48 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.593 -0.692 . . . . 0.0 109.987 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.458 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -65.19 -34.46 78.43 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.636 -0.665 . . . . 0.0 110.264 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -60.02 142.98 53.0 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.461 -0.774 . . . . 0.0 110.324 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.97 9.73 86.37 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.146 -1.182 . . . . 0.0 110.146 -179.472 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 15.9 m -116.9 -6.94 11.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.266 -1.137 . . . . 0.0 110.945 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.2 t -60.06 139.95 57.14 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.208 -0.932 . . . . 0.0 110.074 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.97 -17.66 56.9 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.378 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.04 151.48 44.85 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -95.66 144.97 1.25 Allowed 'Trans proline' 0 N--CA 1.489 1.211 0 O-C-N 123.797 1.419 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.561 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.4 mp -96.26 103.18 15.06 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.336 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.494 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -82.64 159.63 22.63 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.902 0.858 . . . . 0.0 111.905 -178.006 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.504 ' HG ' ' HG ' ' A' ' 97' ' ' CYS . 0.0 OUTLIER -96.15 164.27 18.9 Favored Pre-proline 0 N--CA 1.494 1.727 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.669 179.832 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -65.71 -30.57 50.39 Favored 'Trans proline' 0 N--CA 1.49 1.272 0 O-C-N 123.922 1.485 . . . . 0.0 108.378 177.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -70.0 -36.72 75.36 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.615 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.01 41.98 0.53 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -130.01 145.74 51.66 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.468 -1.019 . . . . 0.0 110.651 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' ALA . . . . . 0.753 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.99 140.32 52.92 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.421 -0.799 . . . . 0.0 109.867 179.408 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.3 t -112.91 -44.39 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 110.262 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.43 -179.52 44.15 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 45.9 mt -120.02 130.72 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.611 -0.935 . . . . 0.0 110.157 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' PHE . . . . . 0.547 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 26.4 t80 -60.09 136.49 58.04 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.648 -0.657 . . . . 0.0 109.961 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -115.49 -52.73 2.64 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.526 -0.734 . . . . 0.0 110.414 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.89 158.64 44.4 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.558 -0.714 . . . . 0.0 110.23 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' ALA . . . . . 0.547 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.95 148.39 31.7 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.401 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.0 t -110.03 119.99 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.732 -0.605 . . . . 0.0 109.65 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.43 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -131.34 148.63 52.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.608 -0.683 . . . . 0.0 110.547 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 94.0 m -69.99 -47.02 63.87 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.625 -0.672 . . . . 0.0 110.018 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -164.63 53.41 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.716 -0.615 . . . . 0.0 109.84 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.45 ' O ' HG13 ' A' ' 132' ' ' VAL . . . 115.66 -18.06 15.36 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.64 120.04 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.276 -1.132 . . . . 0.0 109.775 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -92.22 124.94 36.67 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.602 -0.686 . . . . 0.0 110.445 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.67 -29.16 7.22 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.693 -0.629 . . . . 0.0 110.199 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -129.89 150.15 51.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.612 -0.68 . . . . 0.0 110.053 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.541 HG13 HD13 ' A' ' 126' ' ' LEU . 35.3 m -130.06 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.539 -0.726 . . . . 0.0 110.653 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -122.9 132.86 54.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.698 -0.626 . . . . 0.0 109.838 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -139.94 160.01 40.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.492 -0.755 . . . . 0.0 110.616 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.73 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -94.19 123.58 58.5 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.584 -0.697 . . . . 0.0 109.248 179.25 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -62.76 153.15 74.38 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.743 1.391 . . . . 0.0 110.65 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 151' ' ' VAL . 69.3 t -58.09 -24.36 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.605 -0.684 . . . . 0.0 110.565 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.07 -39.98 87.94 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.397 -0.815 . . . . 0.0 110.388 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 53.3 m -60.15 -40.49 90.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.462 -0.774 . . . . 0.0 110.358 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.4 mtm -70.07 -40.0 75.28 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.61 -0.681 . . . . 0.0 110.214 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.0 -40.3 88.74 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.516 -0.74 . . . . 0.0 110.25 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -63.64 -40.38 96.73 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.572 -0.705 . . . . 0.0 109.85 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -69.95 -40.16 75.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.538 -0.726 . . . . 0.0 110.076 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.7 ttm . . . . . 0 N--CA 1.496 1.839 0 O-C-N 121.746 -0.596 . . . . 0.0 110.32 -179.742 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.127 0.489 . . . . 0.0 110.048 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.845 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 110.251 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLU . . . . . 0.766 ' OE1' HD21 ' A' ' 94' ' ' LEU . 98.1 mt-10 . . . . . 0 N--CA 1.496 1.836 0 CA-C-O 121.124 0.488 . . . . 0.0 110.005 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.91 127.53 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.607 -0.683 . . . . 0.0 109.838 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -123.95 156.56 36.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.563 -0.711 . . . . 0.0 110.288 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.3 t -89.16 119.02 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.735 -0.603 . . . . 0.0 109.834 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.849 HG11 HD21 ' A' ' 64' ' ' LEU . 58.9 t -109.23 144.43 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.2 m -144.71 164.68 30.27 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.209 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.0 p -141.53 -179.57 6.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.759 -0.588 . . . . 0.0 109.797 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.78 -6.55 49.56 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.51 -0.744 . . . . 0.0 111.119 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.1 m -105.18 -57.31 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.17 -0.956 . . . . 0.0 111.17 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -143.22 169.04 18.36 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.422 -0.799 . . . . 0.0 110.789 -179.282 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 70.5 m -116.92 148.46 41.33 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.512 -0.743 . . . . 0.0 110.591 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.516 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.9 p90 -163.1 -178.05 5.79 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.445 -0.784 . . . . 0.0 110.071 -179.725 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' LEU . . . . . 0.715 HD11 ' HA ' ' A' ' 109' ' ' ARG . 62.6 mt -113.15 148.8 34.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.492 -0.755 . . . . 0.0 110.327 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.3 159.74 32.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.662 -0.648 . . . . 0.0 109.937 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' THR . . . . . 0.582 HG21 ' HB3' ' A' ' 142' ' ' PRO . 58.8 m -119.93 138.78 53.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.571 -0.706 . . . . 0.0 110.546 -179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 45.1 m -93.14 110.97 22.47 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.644 -0.66 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.9 t -120.0 130.01 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.552 -0.718 . . . . 0.0 109.297 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.12 35.64 26.02 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.348 -0.845 . . . . 0.0 110.387 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLY . . . . . 0.669 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.0 19.97 75.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -130.06 130.0 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.189 -1.183 . . . . 0.0 110.278 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 34.1 t -76.0 129.94 37.65 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.416 -0.802 . . . . 0.0 109.408 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 42.3 m95 -126.4 137.1 53.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.462 -0.774 . . . . 0.0 111.68 -179.119 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.665 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 15.1 t -161.26 -179.6 7.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.832 HG21 ' CE1' ' A' ' 57' ' ' HIS . 14.5 p -81.19 155.29 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.314 -0.866 . . . . 0.0 110.67 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' TYR . . . . . 0.546 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 59.8 t80 -71.03 -39.93 72.03 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.752 -0.593 . . . . 0.0 111.935 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' HIS . . . . . 0.832 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.8 p-80 -63.56 -24.65 67.9 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.979 -1.076 . . . . 0.0 110.833 -178.708 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . 0.493 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.18 -51.45 6.82 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.516 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -108.14 -59.69 1.82 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.958 . . . . 0.0 110.07 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . 0.431 ' HA2' ' CD2' ' A' ' 56' ' ' TYR . . . 80.6 -176.51 54.64 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.9 t -79.84 68.13 5.83 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.554 -0.968 . . . . 0.0 109.806 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -142.47 177.73 8.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.623 -0.673 . . . . 0.0 110.243 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 58.9 m -65.14 139.93 58.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 109.899 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LEU . . . . . 0.849 HD21 HG11 ' A' ' 36' ' ' VAL . 12.7 tp -111.74 136.58 50.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.619 -0.676 . . . . 0.0 110.262 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -102.35 109.94 21.74 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.576 -0.703 . . . . 0.0 110.068 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.51 179.96 20.4 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -64.87 -32.35 55.51 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.878 1.462 . . . . 0.0 110.336 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -75.81 -31.19 59.31 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.638 -0.664 . . . . 0.0 110.046 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.88 -150.37 22.53 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.24 144.02 45.28 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 O-C-N 123.844 1.444 . . . . 0.0 110.269 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.652 HG22 ' HB3' ' A' ' 85' ' ' TRP . 51.1 mm -126.57 130.02 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.633 -0.667 . . . . 0.0 110.389 -179.518 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.9 p -77.62 149.76 34.73 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.523 -0.736 . . . . 0.0 109.915 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -100.42 140.5 34.59 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.523 -0.735 . . . . 0.0 110.834 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.4 mmm -113.38 -25.0 9.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.702 -0.623 . . . . 0.0 110.356 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -119.96 140.01 51.58 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 110.551 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 80.6 m -149.25 130.0 14.15 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.525 -0.735 . . . . 0.0 109.954 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 -149.91 98.07 2.67 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 110.319 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' VAL . . . . . 0.546 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 81.1 t -70.01 -40.45 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.541 -0.724 . . . . 0.0 110.082 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -44.8 94.25 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.57 -0.707 . . . . 0.0 110.319 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' GLN . . . . . 0.57 ' HG2' HD12 ' A' ' 82' ' ' LEU . 12.3 tt0 -89.99 0.05 57.32 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.563 -0.71 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ASP . . . . . 0.41 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.8 t0 53.58 45.14 28.75 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.059 -1.026 . . . . 0.0 110.781 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' LEU . . . . . 0.674 HD11 HG11 ' A' ' 170' ' ' VAL . 50.8 mt -134.46 143.53 47.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.481 -0.762 . . . . 0.0 110.682 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.691 HG13 ' CH2' ' A' ' 85' ' ' TRP . 7.1 p -150.06 157.58 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLY . . . . . 0.416 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -152.76 160.07 28.81 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.594 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' TRP . . . . . 0.691 ' CH2' HG13 ' A' ' 83' ' ' VAL . 11.3 m-90 -127.74 154.61 45.16 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.628 -0.925 . . . . 0.0 109.735 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -63.45 116.75 5.86 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.51 -0.744 . . . . 0.0 109.574 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.669 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -77.52 135.59 64.8 Favored Pre-proline 0 N--CA 1.495 1.786 0 O-C-N 121.553 -0.717 . . . . 0.0 110.225 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 160.0 51.23 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 123.868 1.457 . . . . 0.0 110.217 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.41 156.53 50.22 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 O-C-N 123.87 1.458 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.77 -22.04 42.94 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.97 159.99 26.09 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -1.124 . . . . 0.0 110.216 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -96.47 165.4 12.19 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.521 -0.737 . . . . 0.0 110.282 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -132.42 169.11 17.0 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.6 -0.687 . . . . 0.0 110.227 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' LEU . . . . . 0.766 HD21 ' OE1' ' A' ' 32' ' ' GLU . 84.2 mt -119.25 138.28 53.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.547 -0.721 . . . . 0.0 110.617 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -82.91 166.61 34.71 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.582 -0.698 . . . . 0.0 110.144 179.602 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -79.18 166.12 23.05 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.868 1.457 . . . . 0.0 110.533 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' CYS . . . . . 0.804 ' HB2' HG22 ' A' ' 151' ' ' VAL . 31.1 t -69.43 136.65 51.87 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.3 p -136.59 55.55 1.84 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.729 -0.607 . . . . 0.0 109.585 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 31.7 p -143.46 -8.46 0.76 Allowed 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.792 -0.763 . . . . 0.0 112.51 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.46 97.31 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.0 m -108.71 160.3 16.07 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.543 -0.975 . . . . 0.0 110.496 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -108.9 21.69 16.89 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.715 . . . . 0.0 110.798 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -99.94 120.05 39.2 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.371 -0.831 . . . . 0.0 110.051 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' LEU . . . . . 0.841 HD21 HG11 ' A' ' 151' ' ' VAL . 56.5 mt -130.57 133.13 45.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.557 -0.714 . . . . 0.0 110.537 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.0 120.0 40.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.507 -0.745 . . . . 0.0 109.693 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.8 tp -81.79 128.35 33.92 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.481 -0.762 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -97.85 118.6 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.626 -0.672 . . . . 0.0 109.37 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.4 p -104.32 177.93 4.7 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.553 -0.717 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ARG . . . . . 0.715 ' HA ' HD11 ' A' ' 44' ' ' LEU . 47.0 mtp180 -60.0 -22.77 63.0 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.602 -0.686 . . . . 0.0 110.461 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.46 19.07 5.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.344 -0.848 . . . . 0.0 111.126 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.84 40.0 31.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.1 -1.0 . . . . 0.0 110.924 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -100.31 122.81 43.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.572 -0.705 . . . . 0.0 109.961 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 114' ' ' ILE . 33.1 m -59.97 -39.36 79.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.577 -0.702 . . . . 0.0 110.501 -179.564 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ILE . . . . . 0.455 ' N ' HG23 ' A' ' 113' ' ' VAL . 50.8 mm 51.29 92.44 0.06 OUTLIER Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.38 -0.825 . . . . 0.0 110.648 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.93 121.41 8.44 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.94 1.495 . . . . 0.0 110.656 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.538 HG13 ' O ' ' A' ' 125' ' ' SER . 62.5 t -127.2 129.99 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.665 -0.647 . . . . 0.0 109.52 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.5 tpt180 -86.88 132.07 33.92 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.507 -0.746 . . . . 0.0 110.125 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.09 130.64 41.39 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.512 -0.743 . . . . 0.0 110.004 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -128.49 20.43 6.17 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.542 -0.724 . . . . 0.0 110.605 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -179.43 172.41 44.31 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -59.97 -40.64 89.78 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.47 -1.018 . . . . 0.0 110.278 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -133.43 28.98 3.98 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.561 -0.712 . . . . 0.0 110.616 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 22.0 ttp180 -139.89 138.37 35.61 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.422 -0.798 . . . . 0.0 110.592 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -126.4 -176.49 14.51 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' SER . . . . . 0.538 ' O ' HG13 ' A' ' 116' ' ' VAL . 86.8 p -133.24 150.87 51.93 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.557 -0.967 . . . . 0.0 110.211 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.419 HD13 HG13 ' A' ' 167' ' ' VAL . 2.3 mp -97.26 130.04 44.51 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.517 -0.739 . . . . 0.0 110.316 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.528 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.7 mp -67.64 -40.03 84.6 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.582 -0.699 . . . . 0.0 110.02 179.659 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -115.36 127.83 26.47 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -67.67 120.74 7.76 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.755 1.398 . . . . 0.0 110.468 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -120.46 160.06 45.44 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.588 -0.695 . . . . 0.0 110.009 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.68 154.19 73.66 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.956 1.503 . . . . 0.0 110.415 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' VAL . . . . . 0.49 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.18 -23.28 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.661 -0.649 . . . . 0.0 110.619 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 66.5 m -59.95 -40.06 87.71 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.403 -0.81 . . . . 0.0 110.211 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -60.0 -46.72 88.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.437 -0.789 . . . . 0.0 109.644 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.99 -29.42 66.51 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.672 -0.642 . . . . 0.0 109.545 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.3 tptm -60.03 129.46 41.9 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.6 -0.688 . . . . 0.0 110.006 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.82 -8.29 80.01 Favored Glycine 0 N--CA 1.495 2.592 0 C-N-CA 120.269 -0.967 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.0 p -96.86 6.01 49.47 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.071 -1.252 . . . . 0.0 111.135 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.03 142.94 53.11 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.038 -1.039 . . . . 0.0 109.929 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.92 -14.93 63.02 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.25 145.77 44.02 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' PRO . . . . . 0.582 ' HB3' HG21 ' A' ' 46' ' ' THR . 49.6 Cg_endo -92.03 141.54 2.46 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.859 1.452 . . . . 0.0 111.673 -179.066 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' LEU . . . . . 0.563 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -93.51 104.38 16.52 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.469 ' N ' HD12 ' A' ' 144' ' ' LEU . 11.0 mp -81.99 157.24 24.3 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 122.082 0.944 . . . . 0.0 111.867 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.57 162.2 24.13 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.496 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -63.98 -29.82 66.71 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.789 1.415 . . . . 0.0 108.577 177.646 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 79.6 p -70.91 -36.12 72.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 178.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.05 41.27 0.56 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -129.97 154.32 47.49 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.984 . . . . 0.0 110.592 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.32 119.55 25.81 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.504 -0.747 . . . . 0.0 109.857 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' VAL . . . . . 0.841 HG11 HD21 ' A' ' 104' ' ' LEU . 63.1 t -90.71 -42.01 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.566 -0.709 . . . . 0.0 110.483 -179.49 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -166.51 -168.87 29.35 Favored Glycine 0 N--CA 1.497 2.741 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.301 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.37 140.01 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.591 -0.947 . . . . 0.0 110.352 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -63.44 139.69 58.8 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.679 -0.638 . . . . 0.0 109.725 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.9 ttp85 -123.14 -52.76 1.85 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.48 -0.763 . . . . 0.0 110.529 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -147.99 165.18 31.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.491 -0.755 . . . . 0.0 110.436 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.95 143.87 49.21 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.621 -0.674 . . . . 0.0 110.371 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.06 119.9 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.76 -0.587 . . . . 0.0 109.456 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' CYS . . . . . 0.49 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -125.97 146.03 50.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.545 -0.722 . . . . 0.0 110.693 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 160' ' ' THR . . . . . 0.541 HG22 ' HG2' ' A' ' 161' ' ' ARG . 39.9 m -82.89 -64.2 1.22 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.447 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.541 ' HG2' HG22 ' A' ' 160' ' ' THR . 10.3 mmm180 -129.21 62.96 1.5 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.499 -0.751 . . . . 0.0 110.406 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.91 -8.76 79.22 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.621 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.2 m -115.8 131.14 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.154 -1.203 . . . . 0.0 110.299 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.34 124.93 34.4 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.638 -0.664 . . . . 0.0 110.3 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -108.79 -29.61 8.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.687 -0.633 . . . . 0.0 110.005 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -138.27 150.8 47.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.419 HG13 HD13 ' A' ' 126' ' ' LEU . 27.6 m -130.45 175.46 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.644 -0.66 . . . . 0.0 110.597 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -131.15 131.35 44.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.682 -0.637 . . . . 0.0 109.574 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -129.48 153.07 48.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.347 -0.845 . . . . 0.0 110.528 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 82' ' ' LEU . 90.5 t -93.55 119.53 67.14 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.607 -0.683 . . . . 0.0 109.429 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.63 153.51 74.67 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.808 1.425 . . . . 0.0 110.578 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.3 t -62.74 -27.42 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.629 -0.67 . . . . 0.0 110.428 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -59.94 -39.31 85.1 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.591 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 85.9 p -59.96 -45.14 93.62 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.504 -0.748 . . . . 0.0 110.669 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 76.7 mtm -69.97 -40.04 75.61 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.396 -0.815 . . . . 0.0 110.38 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.01 -40.04 87.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.479 -0.763 . . . . 0.0 110.259 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.5 m -63.98 -39.99 95.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.574 -0.703 . . . . 0.0 109.881 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 88.6 m -70.05 -40.15 75.27 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.596 -0.69 . . . . 0.0 110.063 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.6 ttm . . . . . 0 N--CA 1.495 1.789 0 O-C-N 121.648 -0.658 . . . . 0.0 110.396 -179.718 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.088 0.47 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 189' ' ' LEU . . . . . 0.775 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.496 1.836 0 O-C-N 121.622 -0.673 . . . . 0.0 110.188 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.066 0.46 . . . . 0.0 110.333 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.9 100.23 0.75 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.7 ttp180 -131.94 133.64 44.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.916 . . . . 0.0 110.141 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -40.01 87.97 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.603 -0.686 . . . . 0.0 110.301 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt 38.59 42.06 0.54 Allowed 'General case' 0 N--CA 1.509 2.519 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 m120 -75.09 130.93 40.11 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.528 -0.732 . . . . 0.0 110.12 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -149.77 159.69 44.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.54 -0.725 . . . . 0.0 110.177 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.2 t -88.33 138.96 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.594 -0.692 . . . . 0.0 109.816 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.95 130.79 48.49 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.502 -0.748 . . . . 0.0 110.252 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -169.9 100.23 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.58 -33.93 76.69 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.552 -0.97 . . . . 0.0 110.25 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -103.77 129.91 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.564 -0.71 . . . . 0.0 109.868 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -116.3 158.54 23.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.561 -0.712 . . . . 0.0 110.489 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.04 121.29 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.663 -0.648 . . . . 0.0 109.597 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.407 ' HB ' HD11 ' A' ' 64' ' ' LEU . 29.7 m -118.48 142.67 32.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.699 -0.626 . . . . 0.0 109.899 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.3 t -142.05 159.67 41.76 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.516 -0.74 . . . . 0.0 111.246 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.7 p -124.56 -170.12 2.09 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -84.02 5.89 24.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.528 -0.732 . . . . 0.0 110.91 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -128.65 -38.94 1.67 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.073 -1.017 . . . . 0.0 111.191 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -149.91 170.1 19.61 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.311 -0.868 . . . . 0.0 111.159 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 47.8 m -119.75 147.35 44.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.68 -0.638 . . . . 0.0 109.792 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 10.3 p90 -156.43 -178.63 7.48 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.391 -0.818 . . . . 0.0 110.275 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.553 HD11 ' CA ' ' A' ' 109' ' ' ARG . 74.0 mt -113.89 153.35 29.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.0 110.804 -178.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.43 161.34 31.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.711 -0.618 . . . . 0.0 109.972 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -126.23 140.12 52.79 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.573 -0.705 . . . . 0.0 110.4 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 38.5 t -98.33 105.48 17.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.59 -0.693 . . . . 0.0 110.489 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.0 t -109.98 129.99 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.423 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 56.8 t30 57.98 38.36 26.82 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.439 -0.788 . . . . 0.0 110.479 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.52 19.93 76.7 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.0 t -131.99 129.97 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.137 -1.214 . . . . 0.0 110.167 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 87.5 m -75.66 148.89 38.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.516 -0.74 . . . . 0.0 109.464 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -138.2 149.95 46.29 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.448 -0.783 . . . . 0.0 111.212 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.9 t -168.65 -179.09 3.67 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.85 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.6 p -89.17 158.33 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.448 -0.783 . . . . 0.0 110.027 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.471 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.1 t80 -76.39 -39.97 52.25 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.493 -0.754 . . . . 0.0 112.066 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.85 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.3 p-80 -64.95 -24.28 67.47 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.116 -0.99 . . . . 0.0 110.567 -178.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.565 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -84.28 -56.98 2.44 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 179.093 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.562 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -96.89 -61.28 1.43 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.68 -0.894 . . . . 0.0 109.987 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.427 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 79.96 -179.39 53.26 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 78.9 p -79.33 64.59 4.26 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.596 -0.943 . . . . 0.0 109.768 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.23 167.54 21.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.62 -0.675 . . . . 0.0 110.414 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.2 t -65.39 139.32 58.54 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 109.826 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.74 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -112.83 131.13 55.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.589 -0.694 . . . . 0.0 110.291 -179.576 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.53 109.29 21.9 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.564 -0.71 . . . . 0.0 109.815 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -105.53 -165.96 23.59 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.09 -32.36 34.53 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 124.025 1.539 . . . . 0.0 110.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.62 -31.09 59.76 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.83 -140.83 10.1 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -75.02 161.36 38.83 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.819 1.431 . . . . 0.0 110.292 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.74 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.5 mt -131.53 139.37 50.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.448 -0.782 . . . . 0.0 110.439 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.0 p -81.87 150.74 27.64 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.549 -0.719 . . . . 0.0 109.946 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 78.2 mm-40 -87.42 132.3 34.03 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.484 -0.76 . . . . 0.0 110.095 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -110.01 -44.86 3.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.552 -0.718 . . . . 0.0 110.116 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' TYR . . . . . 0.432 ' CE1' ' HG3' ' A' ' 179' ' ' MET . 83.9 m-85 -130.01 150.04 51.46 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.584 -0.697 . . . . 0.0 110.507 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.6 p -148.17 136.32 21.2 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.007 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -149.98 89.32 1.59 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.471 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 63.0 t -61.3 -40.09 84.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.623 -0.673 . . . . 0.0 109.988 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -61.58 -43.91 97.99 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.508 -0.745 . . . . 0.0 110.654 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.778 ' HG2' HD12 ' A' ' 82' ' ' LEU . 12.1 tt0 -87.6 -0.01 56.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.583 -0.698 . . . . 0.0 110.749 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.48 46.5 26.05 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.06 -1.025 . . . . 0.0 110.506 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' HG2' ' A' ' 80' ' ' GLN . 40.3 mt -144.25 138.39 27.96 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.543 -0.723 . . . . 0.0 110.875 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 54' ' ' THR . 8.3 p -134.12 157.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.605 -0.684 . . . . 0.0 109.26 179.076 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -138.43 153.66 22.59 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.196 -1.161 . . . . 0.0 110.196 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 5.8 m-90 -120.99 151.67 39.46 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.776 -0.838 . . . . 0.0 110.022 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -68.51 115.85 8.39 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.538 -0.726 . . . . 0.0 109.338 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.06 130.08 90.13 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.525 -0.735 . . . . 0.0 110.262 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.04 159.99 51.21 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.831 1.437 . . . . 0.0 110.285 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.67 156.32 58.01 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.897 1.472 . . . . 0.0 110.4 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.33 26.56 59.31 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.66 152.29 30.63 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.467 -1.019 . . . . 0.0 110.143 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -92.79 168.94 10.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.566 -0.709 . . . . 0.0 110.256 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.9 p -137.84 158.71 43.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.74 -0.6 . . . . 0.0 110.228 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.473 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 51.4 mt -108.02 131.63 54.38 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.526 -0.734 . . . . 0.0 110.485 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.7 p -76.91 160.06 77.3 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.555 -0.716 . . . . 0.0 109.784 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -75.58 163.68 33.64 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.832 1.438 . . . . 0.0 110.655 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.793 ' HB2' HG12 ' A' ' 151' ' ' VAL . 49.1 t -72.69 129.53 38.44 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.694 -0.629 . . . . 0.0 110.27 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -134.68 55.6 1.89 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.716 -0.615 . . . . 0.0 109.661 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.8 p -143.88 -7.82 0.73 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 120.027 -0.669 . . . . 0.0 112.26 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.97 39.54 97.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.8 m -99.94 119.99 39.1 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.544 -0.974 . . . . 0.0 110.404 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -66.71 -39.71 88.14 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.731 -0.606 . . . . 0.0 110.442 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 139.61 57.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.531 -0.731 . . . . 0.0 110.491 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.927 HD22 HG21 ' A' ' 151' ' ' VAL . 92.8 mt -139.29 153.1 47.72 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 0.0 110.409 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -115.73 123.72 49.01 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.53 -0.731 . . . . 0.0 109.887 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.639 HD13 HD11 ' A' ' 143' ' ' LEU . 66.3 tp -99.91 133.29 44.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.592 -0.693 . . . . 0.0 110.595 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.9 t -91.57 120.05 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.677 -0.639 . . . . 0.0 109.447 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.4 m -97.99 152.35 19.36 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.462 -0.774 . . . . 0.0 110.419 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.553 ' CA ' HD11 ' A' ' 44' ' ' LEU . 28.0 ptt85 -59.08 -20.03 49.68 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.639 -0.663 . . . . 0.0 110.751 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -94.59 26.76 3.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.452 -0.78 . . . . 0.0 110.214 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.49 40.07 31.16 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.348 -0.845 . . . . 0.0 110.663 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.49 135.03 54.62 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.572 -0.705 . . . . 0.0 109.976 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.97 120.03 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.579 -0.701 . . . . 0.0 110.022 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.523 ' O ' HG23 ' A' ' 116' ' ' VAL . 49.0 mm -106.19 117.36 57.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.622 -0.674 . . . . 0.0 109.79 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -64.42 120.74 8.13 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.801 1.422 . . . . 0.0 110.374 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.6 t -119.98 126.32 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.586 -0.696 . . . . 0.0 109.796 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -86.9 130.53 34.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.553 -0.717 . . . . 0.0 109.805 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 37.5 ttp180 -73.46 126.14 29.52 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.624 -0.672 . . . . 0.0 110.338 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -120.16 23.78 10.79 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.587 -0.696 . . . . 0.0 110.209 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.38 -179.06 42.18 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -63.19 -39.96 96.13 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.571 -0.958 . . . . 0.0 110.406 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 76.9 p -132.83 22.2 4.21 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.555 -0.715 . . . . 0.0 110.786 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -124.86 138.6 54.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.346 -0.847 . . . . 0.0 110.322 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.18 169.81 23.51 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.4 p -121.25 153.51 37.55 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.62 -0.929 . . . . 0.0 110.059 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.51 HD11 HG21 ' A' ' 114' ' ' ILE . 16.8 tp -99.27 119.87 38.63 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.505 -0.747 . . . . 0.0 110.221 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -68.61 -39.01 81.04 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.544 -0.722 . . . . 0.0 110.039 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.28 116.13 55.47 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.601 -0.687 . . . . 0.0 110.064 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -65.81 116.34 3.91 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.724 1.381 . . . . 0.0 110.43 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 5.7 mtt180 -122.69 160.04 50.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.581 -0.699 . . . . 0.0 110.139 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -67.43 152.04 79.36 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 124.017 1.536 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.32 -32.15 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.568 -0.708 . . . . 0.0 110.395 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.8 t -59.96 -38.66 83.1 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.511 -0.743 . . . . 0.0 110.162 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.539 -0.726 . . . . 0.0 110.34 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -81.46 -18.35 45.59 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 0.0 111.109 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -60.4 140.02 57.4 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.183 -0.948 . . . . 0.0 110.115 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 86.37 13.64 67.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.5 p -116.13 -8.29 11.79 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.127 -1.219 . . . . 0.0 110.908 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.7 t -59.97 139.08 57.66 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.123 -0.986 . . . . 0.0 109.698 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 97.33 -23.44 35.82 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.99 151.71 47.39 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 179.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.47 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.9 Cg_endo -93.87 148.78 2.15 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.841 1.443 . . . . 0.0 111.427 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.903 ' O ' HG22 ' A' ' 151' ' ' VAL . 9.3 mp -104.66 130.3 52.71 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.47 131.51 56.25 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.351 -0.843 . . . . 0.0 111.549 -178.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.5 p -70.01 159.16 85.32 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 178.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.85 -26.64 24.87 Favored 'Trans proline' 0 N--CA 1.502 1.992 0 O-C-N 123.504 1.265 . . . . 0.0 112.359 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.9 m -62.63 -39.99 95.57 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.261 -0.9 . . . . 0.0 109.96 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.67 36.37 0.79 Allowed Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.6 m-70 -132.48 149.61 52.3 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.419 -1.048 . . . . 0.0 110.128 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -70.0 142.48 52.78 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.576 -0.702 . . . . 0.0 110.45 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.927 HG21 HD22 ' A' ' 104' ' ' LEU . 34.4 m -117.17 -22.81 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.626 -0.671 . . . . 0.0 110.613 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 167.63 -169.92 41.45 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' HE1' ' A' ' 175' ' ' MET . 96.9 mt -127.84 139.94 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.517 -0.99 . . . . 0.0 110.224 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.495 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.7 t80 -65.82 136.79 56.65 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.649 -0.657 . . . . 0.0 109.981 179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -114.97 -52.39 2.69 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 0.0 110.427 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -153.72 160.02 42.17 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.463 -0.773 . . . . 0.0 110.393 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.495 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.96 151.13 27.5 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.66 -0.65 . . . . 0.0 110.203 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -108.27 119.6 58.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.666 -0.647 . . . . 0.0 109.693 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -134.1 158.96 42.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.693 -0.63 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 4.6 p -99.97 -50.68 3.92 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.71 . . . . 0.0 110.391 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -142.89 61.62 1.41 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.928 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.05 -7.47 81.57 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.8 t -116.82 125.92 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 109.905 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.81 127.86 43.2 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.592 -0.693 . . . . 0.0 110.422 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -107.14 -17.16 14.24 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.519 -0.738 . . . . 0.0 110.743 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -146.81 159.78 43.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.325 -0.859 . . . . 0.0 110.036 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -133.84 160.04 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.462 -0.774 . . . . 0.0 110.938 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.51 138.4 53.19 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.658 . . . . 0.0 110.015 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -140.3 155.65 46.75 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.404 -0.81 . . . . 0.0 110.794 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.554 HG11 HD11 ' A' ' 82' ' ' LEU . 59.3 t -94.47 126.04 49.5 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.56 -0.712 . . . . 0.0 109.459 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.46 158.58 57.03 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.795 1.419 . . . . 0.0 110.696 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 57.7 t -65.59 -24.66 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.665 -0.647 . . . . 0.0 110.478 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -58.6 -37.96 76.94 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.383 -0.823 . . . . 0.0 110.579 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 81.1 p -60.13 -34.45 73.54 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.524 -0.735 . . . . 0.0 110.417 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.431 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.3 mtt -61.14 -40.02 92.26 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.478 -0.764 . . . . 0.0 110.411 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.55 -42.14 95.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.496 -0.752 . . . . 0.0 110.495 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 75.2 p -70.03 -39.51 75.72 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.395 -0.816 . . . . 0.0 110.417 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 86.5 m -60.04 -50.03 75.32 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.432 ' HG3' ' CE1' ' A' ' 75' ' ' TYR . 59.9 ttp -68.63 -39.99 80.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.609 -0.682 . . . . 0.0 110.239 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -63.7 -39.98 95.64 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.608 -0.682 . . . . 0.0 110.274 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.05 -43.78 95.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.575 -0.703 . . . . 0.0 110.483 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 79.7 p -159.8 153.59 22.91 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.551 -0.718 . . . . 0.0 110.465 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 61.4 mttp -109.99 20.26 18.14 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.671 -0.643 . . . . 0.0 110.677 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 49.4 tttm 54.11 39.98 31.19 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.222 -0.924 . . . . 0.0 110.654 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 58.4 tttp -99.98 125.76 46.05 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.709 . . . . 0.0 110.094 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.6 pttt . . . . . 0 N--CA 1.497 1.915 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.492 -179.883 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.427 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.9 tt0 -127.95 129.99 47.7 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.181 . . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.807 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -77.84 143.35 37.91 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.587 -0.696 . . . . 0.0 110.226 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.457 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.4 t . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.072 0.463 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.91 170.66 54.07 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.4 ttp180 -59.91 -40.78 90.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.582 -0.952 . . . . 0.0 110.197 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -160.16 39.74 0.18 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.545 -0.722 . . . . 0.0 110.117 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.1 mttm -69.62 -40.02 76.84 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.639 -0.663 . . . . 0.0 110.259 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -134.87 150.44 50.46 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.569 -0.707 . . . . 0.0 110.293 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -129.48 152.96 48.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.638 -0.663 . . . . 0.0 110.018 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.3 t -109.98 120.01 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.531 -0.731 . . . . 0.0 110.016 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.73 33.23 3.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.605 -0.684 . . . . 0.0 110.238 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.26 173.25 45.74 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.541 ' OE1' HD21 ' A' ' 94' ' ' LEU . 28.3 mt-10 -102.71 9.77 38.98 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.656 -0.908 . . . . 0.0 111.171 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.02 128.41 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.113 -0.992 . . . . 0.0 109.946 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -116.31 146.29 42.54 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.588 -0.695 . . . . 0.0 109.992 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.3 t -91.55 122.81 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.615 ' HB ' HD12 ' A' ' 64' ' ' LEU . 32.7 m -115.62 140.17 38.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.734 -0.604 . . . . 0.0 109.707 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.1 m -138.4 162.87 33.35 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.562 -0.711 . . . . 0.0 110.753 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.55 -170.5 2.24 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.72 -0.612 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.08 -42.83 95.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.534 -0.728 . . . . 0.0 110.736 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.9 t -128.28 -7.66 5.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.385 -0.822 . . . . 0.0 111.849 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.8 tp60 -115.16 156.87 24.49 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.067 -1.02 . . . . 0.0 110.67 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.7 p -149.96 138.1 20.38 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.718 -0.614 . . . . 0.0 109.759 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.623 ' HZ ' HD21 ' A' ' 64' ' ' LEU . 20.0 p90 -164.39 -178.89 5.69 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.533 -0.73 . . . . 0.0 110.456 -179.591 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.555 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.6 mt -114.3 159.2 20.46 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.476 -0.765 . . . . 0.0 110.862 -178.48 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.54 ' HB1' ' O ' ' A' ' 53' ' ' TRP . . . -139.1 162.64 34.46 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.697 -0.627 . . . . 0.0 109.989 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.5 t -122.29 140.68 52.35 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.423 -0.798 . . . . 0.0 110.673 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.3 t -98.87 104.06 16.07 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.569 -0.707 . . . . 0.0 110.109 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.61 132.77 56.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.604 -0.685 . . . . 0.0 109.899 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 54.35 39.94 31.34 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.596 -0.69 . . . . 0.0 111.016 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 20.83 76.67 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.9 t -130.0 130.0 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.249 -1.148 . . . . 0.0 109.852 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.1 t -78.93 147.31 33.08 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.483 -0.761 . . . . 0.0 109.403 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.54 ' O ' ' HB1' ' A' ' 45' ' ' ALA . 57.5 m95 -128.66 150.38 50.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.538 -0.726 . . . . 0.0 110.932 -179.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.89 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.3 t -166.11 -179.73 5.29 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.866 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -100.46 154.25 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.73 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -70.05 -40.11 75.3 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.63 -0.669 . . . . 0.0 111.811 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.866 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.1 p-80 -70.62 -22.1 62.57 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.099 -1.001 . . . . 0.0 110.843 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.699 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -93.32 -46.41 3.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.907 -1.677 . . . . 0.0 108.907 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.422 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.43 -49.31 3.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.658 -0.907 . . . . 0.0 110.334 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.49 -162.3 41.17 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.2 t -93.12 63.37 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.577 -0.955 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.92 161.77 36.78 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.58 -0.7 . . . . 0.0 110.266 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 63.1 p -65.42 139.59 58.55 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.634 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.623 HD21 ' HZ ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -112.53 141.28 46.47 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.618 -0.677 . . . . 0.0 110.011 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.27 115.16 24.49 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.511 -0.743 . . . . 0.0 110.252 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.04 176.42 16.17 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.63 -31.97 69.59 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.793 1.417 . . . . 0.0 110.29 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.63 -31.41 66.84 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.657 -0.652 . . . . 0.0 109.829 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.7 -153.71 24.32 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.02 145.0 48.78 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.918 1.483 . . . . 0.0 110.092 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.585 HG22 ' CD1' ' A' ' 85' ' ' TRP . 85.6 mt -119.99 129.49 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.608 -0.682 . . . . 0.0 110.356 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 m -85.49 130.26 34.62 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.963 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.439 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 44.8 mm-40 -55.69 139.93 43.25 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.513 -0.742 . . . . 0.0 110.917 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.0 ttt -113.68 -49.1 2.9 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.73 -0.606 . . . . 0.0 110.179 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 70.3 m-85 -120.0 140.0 51.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.588 -0.695 . . . . 0.0 110.27 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.814 ' HA ' HG12 ' A' ' 83' ' ' VAL . 26.2 m -135.78 129.36 32.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.641 -0.662 . . . . 0.0 110.215 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -142.43 96.75 3.0 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.577 -0.702 . . . . 0.0 110.226 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 76.5 t -65.7 -39.99 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.593 -0.692 . . . . 0.0 110.049 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -60.01 -49.84 76.07 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.551 -0.718 . . . . 0.0 110.816 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -89.31 -0.05 57.17 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 110.934 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.4 t70 52.79 47.41 24.74 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.0 -1.062 . . . . 0.0 110.665 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.497 HD11 HG11 ' A' ' 170' ' ' VAL . 62.8 mt -141.63 137.14 31.63 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.443 -0.786 . . . . 0.0 111.141 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.814 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.6 m -138.37 161.35 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.555 -0.716 . . . . 0.0 109.301 178.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.32 164.56 26.55 Favored Glycine 0 N--CA 1.495 2.632 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.586 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.89 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.7 m-90 -123.13 159.38 28.67 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.829 -0.806 . . . . 0.0 109.253 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -79.9 109.34 14.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.45 -0.781 . . . . 0.0 109.528 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.68 141.08 87.17 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.59 -0.694 . . . . 0.0 110.298 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.03 160.02 51.12 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.917 1.482 . . . . 0.0 110.323 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.83 160.12 42.42 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.305 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.79 29.85 64.65 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.51 144.09 34.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.533 -0.981 . . . . 0.0 110.095 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 31.8 ttt180 -84.69 128.64 34.71 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.69 -0.631 . . . . 0.0 109.703 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.4 p -111.43 162.58 14.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.593 -0.692 . . . . 0.0 110.539 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.541 HD21 ' OE1' ' A' ' 32' ' ' GLU . 16.1 mt -106.37 131.99 52.93 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.614 -0.679 . . . . 0.0 110.73 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.4 p -75.46 160.01 80.56 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.597 -0.689 . . . . 0.0 109.691 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.51 162.63 40.85 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.825 1.434 . . . . 0.0 110.772 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.711 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.6 t -79.26 130.05 35.07 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.618 -0.676 . . . . 0.0 110.101 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.56 55.6 1.88 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.651 -0.656 . . . . 0.0 109.72 179.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.79 -8.02 0.74 Allowed 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 119.916 -0.714 . . . . 0.0 112.296 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.66 34.77 89.74 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 m -87.0 112.34 21.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.515 -0.991 . . . . 0.0 110.405 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -59.99 -39.97 87.56 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.6 -0.688 . . . . 0.0 110.35 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -63.15 132.88 53.27 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.613 -0.68 . . . . 0.0 110.184 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.51 ' CD2' HG21 ' A' ' 151' ' ' VAL . 91.4 mt -134.63 146.12 49.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.66 -0.65 . . . . 0.0 110.492 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.82 121.54 44.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.504 -0.748 . . . . 0.0 109.984 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.543 HD13 HD11 ' A' ' 143' ' ' LEU . 64.0 tp -95.51 137.94 33.88 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.547 -0.72 . . . . 0.0 110.408 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.24 119.96 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.598 -0.689 . . . . 0.0 109.75 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.2 p -97.74 170.07 9.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.487 -0.758 . . . . 0.0 110.573 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.555 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.9 mtp-105 -70.06 -20.19 63.25 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.646 -0.659 . . . . 0.0 110.813 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -94.32 26.59 3.28 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.323 -0.861 . . . . 0.0 110.679 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 39.03 30.46 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.273 -0.892 . . . . 0.0 110.751 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -120.14 137.08 54.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.688 -0.633 . . . . 0.0 109.723 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -120.04 143.4 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.446 -0.783 . . . . 0.0 110.67 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 46.0 pt -129.94 158.8 72.77 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.757 -0.59 . . . . 0.0 109.914 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -90.89 130.96 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.817 1.43 . . . . 0.0 110.588 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -130.1 130.01 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.699 -0.625 . . . . 0.0 109.548 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -82.81 149.28 27.29 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.507 -0.745 . . . . 0.0 110.175 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.0 ttt180 -95.56 119.94 34.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.581 -0.7 . . . . 0.0 110.123 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -110.04 19.94 18.46 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.615 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.7 179.41 42.69 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -61.47 -40.03 93.06 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.592 -0.946 . . . . 0.0 110.296 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 44.5 p -130.31 23.63 5.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.548 -0.72 . . . . 0.0 110.681 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -124.53 137.85 54.38 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.41 -0.806 . . . . 0.0 110.299 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -137.51 162.94 25.49 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 76.8 p -119.51 148.35 43.39 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.586 -0.949 . . . . 0.0 110.349 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.636 HD23 ' O ' ' A' ' 128' ' ' SER . 8.6 tp -95.27 126.84 40.86 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.595 -0.69 . . . . 0.0 110.158 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -61.26 -39.95 92.26 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.656 -0.653 . . . . 0.0 110.388 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' SER . . . . . 0.636 ' O ' HD23 ' A' ' 126' ' ' LEU . 79.4 p -120.39 149.6 50.13 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.536 -0.728 . . . . 0.0 110.339 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.411 ' HB2' ' CG2' ' A' ' 163' ' ' VAL . 48.0 Cg_endo -79.88 121.46 4.54 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.969 1.51 . . . . 0.0 110.491 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -122.16 160.56 47.07 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.565 -0.709 . . . . 0.0 110.116 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.53 150.76 80.24 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.955 1.502 . . . . 0.0 110.464 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 64.7 t -62.49 -30.18 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.628 -0.67 . . . . 0.0 109.783 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.2 m -60.03 -38.33 82.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.631 -0.668 . . . . 0.0 110.371 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -59.94 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.469 -0.77 . . . . 0.0 110.029 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.2 mp -86.94 -22.99 25.27 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.486 -0.759 . . . . 0.0 110.572 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.437 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 4.2 tptm -60.17 129.96 44.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.388 -0.82 . . . . 0.0 110.094 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.68 -9.84 73.19 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.1 p -89.94 -0.06 57.36 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.038 -1.272 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.1 m -59.92 139.95 57.03 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.108 -0.995 . . . . 0.0 109.765 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.17 -20.36 51.11 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.11 154.79 43.77 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.472 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.6 Cg_endo -98.01 147.49 0.73 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 O-C-N 123.803 1.423 . . . . 0.0 111.134 -179.597 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -104.41 109.19 20.95 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.4 132.15 44.09 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.503 -0.748 . . . . 0.0 111.507 -178.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.435 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.01 159.84 82.74 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.89 -26.58 25.0 Favored 'Trans proline' 0 N--CA 1.502 2.011 0 O-C-N 123.456 1.24 . . . . 0.0 112.266 -178.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.67 -40.1 96.01 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.181 -0.949 . . . . 0.0 109.848 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.68 36.13 0.8 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -131.81 146.37 52.1 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.459 -1.024 . . . . 0.0 110.29 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.525 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.59 143.65 57.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.554 -0.716 . . . . 0.0 110.324 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.748 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.1 t -118.25 -37.81 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.513 -0.742 . . . . 0.0 110.054 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.5 -170.39 39.04 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' CE ' ' A' ' 175' ' ' MET . 67.9 mt -127.93 133.33 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.523 -0.986 . . . . 0.0 110.24 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.619 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.2 t80 -61.78 137.04 58.21 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.607 -0.683 . . . . 0.0 109.908 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.8 ttt180 -116.88 -52.35 2.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.514 -0.742 . . . . 0.0 110.099 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.79 159.99 43.91 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.499 -0.751 . . . . 0.0 110.397 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.619 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.19 151.83 33.73 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.668 -0.645 . . . . 0.0 110.267 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -107.88 119.14 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.589 -0.694 . . . . 0.0 109.714 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.78 155.19 47.09 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.664 -0.647 . . . . 0.0 110.471 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 2.8 m -103.42 -60.31 1.58 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.57 -0.706 . . . . 0.0 110.272 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 71.8 mtt180 -127.92 66.72 1.35 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.704 -0.622 . . . . 0.0 109.933 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 71.84 22.58 78.7 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 163' ' ' VAL . 14.6 p -139.3 127.75 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.417 -1.049 . . . . 0.0 109.866 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.32 124.2 34.71 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.549 -0.719 . . . . 0.0 110.807 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -107.57 -19.93 13.4 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.694 -0.629 . . . . 0.0 110.073 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -150.04 157.36 43.06 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.454 -0.779 . . . . 0.0 109.849 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.9 m -133.03 164.3 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -0.764 . . . . 0.0 110.792 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -125.13 134.83 52.29 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.558 -0.714 . . . . 0.0 110.218 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -134.18 157.78 45.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.519 -0.738 . . . . 0.0 110.095 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.497 HG11 HD11 ' A' ' 82' ' ' LEU . 67.0 t -94.54 124.38 55.37 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.539 -0.726 . . . . 0.0 109.754 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.5 147.9 87.19 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.784 1.413 . . . . 0.0 110.41 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.5 t -59.89 -23.83 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.71 -0.619 . . . . 0.0 110.675 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -59.97 -40.75 90.12 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.372 -0.83 . . . . 0.0 110.633 -179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.8 p -70.0 -36.42 75.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.458 -0.776 . . . . 0.0 110.252 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.2 mtp -59.94 -40.09 87.76 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.604 -0.685 . . . . 0.0 110.378 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 75.3 mt-10 -64.34 -39.95 94.91 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.645 -0.659 . . . . 0.0 110.105 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -61.81 -40.0 93.71 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.67 -0.644 . . . . 0.0 110.049 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.4 m -60.12 -39.97 88.08 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.558 -0.714 . . . . 0.0 110.176 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -60.54 -39.98 89.86 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.479 -0.763 . . . . 0.0 110.238 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -66.71 -40.02 88.29 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.595 -0.691 . . . . 0.0 110.071 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.77 -40.05 88.07 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.54 -0.725 . . . . 0.0 110.153 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.5 t -69.97 150.01 47.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.621 -0.674 . . . . 0.0 110.153 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.4 135.97 40.03 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.552 -0.718 . . . . 0.0 110.215 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -60.22 -39.96 88.5 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.58 -0.7 . . . . 0.0 110.309 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 21.1 tptm -60.1 -39.95 87.95 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.524 -0.735 . . . . 0.0 110.171 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.9 tptt . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 118.084 -0.96 . . . . 0.0 110.153 -179.932 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.463 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 -123.72 131.03 53.51 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.762 -1.175 . . . . 0.0 110.066 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.866 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp -70.0 146.01 51.37 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 110.136 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.47 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.63 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.2 p . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.115 0.483 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -174.33 176.1 46.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.6 mmt-85 -119.98 140.67 50.59 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.606 -0.938 . . . . 0.0 110.186 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -108.82 129.43 55.39 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 110.164 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -62.89 140.06 58.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.566 -0.709 . . . . 0.0 110.17 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -75.34 73.21 2.41 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.582 -0.699 . . . . 0.0 110.459 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 95.6 mt-30 -99.79 112.26 24.53 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.14 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 96.9 t -69.97 -40.19 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.66 -0.65 . . . . 0.0 109.743 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -150.97 159.98 44.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.633 -0.667 . . . . 0.0 109.917 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 160.81 42.95 0.02 OUTLIER Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -61.84 -38.28 87.63 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.532 -0.981 . . . . 0.0 109.827 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.14 125.72 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.548 -0.72 . . . . 0.0 109.698 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -119.32 159.6 23.83 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.714 -0.617 . . . . 0.0 110.491 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.7 t -88.29 115.43 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.62 -0.675 . . . . 0.0 109.545 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.924 HG11 HD21 ' A' ' 64' ' ' LEU . 57.6 t -110.37 148.14 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.317 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -143.63 171.25 14.43 Favored 'General case' 0 N--CA 1.494 1.745 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.408 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 15.3 p -140.44 179.34 6.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.902 -0.499 . . . . 0.0 109.997 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -75.13 -8.56 56.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.5 -0.75 . . . . 0.0 111.036 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -109.82 -43.71 3.97 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.218 -0.926 . . . . 0.0 111.64 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.417 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 5.2 pt20 -148.88 177.35 9.62 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.251 -0.905 . . . . 0.0 111.296 -179.071 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.3 m -122.58 149.65 43.68 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.588 -0.695 . . . . 0.0 110.279 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.763 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.9 p90 -164.0 -177.65 5.17 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.245 -0.91 . . . . 0.0 110.461 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.594 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.2 mt -113.36 141.35 47.15 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.545 -0.722 . . . . 0.0 110.635 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.515 ' CB ' HG21 ' A' ' 36' ' ' VAL . . . -114.75 154.53 28.34 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.656 -0.652 . . . . 0.0 109.946 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.477 HG21 ' HB3' ' A' ' 142' ' ' PRO . 75.2 p -120.1 131.25 55.0 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.411 -0.806 . . . . 0.0 110.387 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.7 t -93.06 110.02 21.5 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.583 -0.698 . . . . 0.0 110.74 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.421 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.8 t -114.58 132.27 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.684 -0.635 . . . . 0.0 109.516 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.421 ' OD1' HG12 ' A' ' 48' ' ' VAL . 29.5 m120 55.56 39.0 30.96 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.516 -0.74 . . . . 0.0 110.933 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.593 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.96 19.07 75.06 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -130.67 130.01 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.267 -1.137 . . . . 0.0 109.851 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.6 m -76.79 139.53 40.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 109.443 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -133.03 136.45 45.98 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.508 -0.745 . . . . 0.0 110.898 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 45' ' ' ALA . 29.9 p -150.73 -179.85 7.61 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.746 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.6 p -88.25 150.19 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.284 -0.885 . . . . 0.0 110.238 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.423 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.3 t80 -60.06 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.571 -0.706 . . . . 0.0 111.891 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.822 ' CG ' HD23 ' B' ' 189' ' ' LEU . 5.7 p-80 -59.69 -24.29 63.83 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.09 -1.007 . . . . 0.0 110.739 -178.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.643 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.88 -42.49 20.3 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.763 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -151.24 95.45 2.17 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.771 -0.841 . . . . 0.0 109.786 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.63 -165.1 4.54 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.401 ' HB3' HG21 ' A' ' 76' ' ' THR . 88.0 p -71.15 69.79 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.621 -0.929 . . . . 0.0 109.87 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.99 179.22 6.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.562 -0.711 . . . . 0.0 110.293 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 33.0 p -64.93 139.9 58.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.646 -0.659 . . . . 0.0 109.801 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.924 HD21 HG11 ' A' ' 36' ' ' VAL . 14.8 tp -113.28 137.94 50.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.653 -0.654 . . . . 0.0 110.159 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.76 109.88 22.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.655 -0.653 . . . . 0.0 109.955 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.51 -175.07 15.84 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -64.78 -32.69 55.88 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 O-C-N 123.895 1.471 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -74.82 -31.5 61.7 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.575 -0.703 . . . . 0.0 110.06 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.41 -147.15 18.55 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.08 140.65 15.94 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.832 1.438 . . . . 0.0 110.377 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.49 140.02 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.606 -0.684 . . . . 0.0 110.351 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.6 t -93.23 133.48 36.39 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.537 -0.727 . . . . 0.0 110.439 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 34.1 tt0 -71.53 140.55 49.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.42 -0.8 . . . . 0.0 110.699 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.5 mmm -105.87 -29.1 10.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.663 -0.648 . . . . 0.0 110.323 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -118.39 139.61 51.12 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.565 -0.709 . . . . 0.0 110.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.401 HG21 ' HB3' ' A' ' 61' ' ' SER . 24.2 m -139.97 135.34 32.65 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.522 -0.736 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -150.05 98.95 2.77 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.602 -0.687 . . . . 0.0 109.897 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.42 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.3 t -69.67 -44.82 79.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.543 -0.723 . . . . 0.0 110.329 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.03 -50.02 75.38 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.553 -0.717 . . . . 0.0 110.46 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.648 ' HG2' HD12 ' A' ' 82' ' ' LEU . 1.8 tp-100 -80.41 -8.49 59.55 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.67 -0.644 . . . . 0.0 110.767 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.1 t70 56.56 45.24 22.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.173 -0.955 . . . . 0.0 110.248 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.648 HD12 ' HG2' ' A' ' 80' ' ' GLN . 75.8 mt -130.01 148.89 51.91 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.565 -0.709 . . . . 0.0 110.721 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.457 HG13 ' C ' ' A' ' 82' ' ' LEU . 32.6 m -149.97 169.92 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.66 -0.65 . . . . 0.0 109.626 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -165.05 160.31 33.58 Favored Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.845 -1.169 . . . . 0.0 110.416 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.729 ' CE2' HD22 ' A' ' 64' ' ' LEU . 16.1 m-90 -129.89 149.92 51.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.657 -0.908 . . . . 0.0 109.429 179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 15.6 pt20 -60.9 120.13 9.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.322 -0.861 . . . . 0.0 109.63 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.593 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.73 141.64 72.5 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.588 -0.695 . . . . 0.0 110.307 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.01 160.02 51.15 Favored 'Trans proline' 0 N--CA 1.49 1.275 0 O-C-N 123.902 1.475 . . . . 0.0 110.32 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.69 143.79 38.31 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 O-C-N 123.947 1.498 . . . . 0.0 110.274 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.48 -22.08 42.75 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.17 46.95 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.286 -1.126 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -92.81 165.42 12.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.611 -0.681 . . . . 0.0 110.109 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.2 p -130.48 169.95 14.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.473 -0.767 . . . . 0.0 110.307 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -103.38 132.0 50.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.573 -0.705 . . . . 0.0 110.379 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.414 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 50.9 p -72.06 159.99 83.92 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.594 -0.691 . . . . 0.0 109.941 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -83.26 150.27 13.51 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.766 1.403 . . . . 0.0 110.698 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -65.07 132.04 48.14 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.583 -0.698 . . . . 0.0 110.196 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.7 p -135.98 53.16 1.95 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.626 -0.671 . . . . 0.0 109.765 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.9 p -143.85 -3.49 0.88 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.332 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.94 32.31 74.84 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -91.44 129.95 37.35 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.58 -0.953 . . . . 0.0 110.331 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.9 m -77.48 -30.14 52.97 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.622 -0.674 . . . . 0.0 110.315 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.56 133.77 56.42 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.54 -0.725 . . . . 0.0 110.346 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.464 ' CD2' HG21 ' A' ' 151' ' ' VAL . 90.4 mt -134.95 151.66 51.05 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.631 -0.668 . . . . 0.0 110.359 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -119.85 123.17 42.97 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.512 -0.743 . . . . 0.0 109.969 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.453 HD13 HD21 ' A' ' 143' ' ' LEU . 67.0 tp -99.64 133.06 44.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.525 -0.734 . . . . 0.0 110.461 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.3 t -95.72 119.97 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.625 -0.672 . . . . 0.0 109.582 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -92.09 168.13 11.59 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.514 -0.741 . . . . 0.0 110.476 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.594 ' HA ' HD11 ' A' ' 44' ' ' LEU . 37.1 mtp-105 -60.14 -27.3 66.96 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.614 -0.679 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.413 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -93.69 29.07 2.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.494 -0.754 . . . . 0.0 110.744 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.77 40.0 30.97 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.197 -0.939 . . . . 0.0 111.057 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -99.44 168.7 9.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.562 -0.711 . . . . 0.0 109.928 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 113' ' ' VAL . 8.8 p -130.03 129.98 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.485 -0.759 . . . . 0.0 110.328 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.574 ' O ' HG23 ' A' ' 116' ' ' VAL . 82.8 mt -121.26 104.31 40.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.576 -0.702 . . . . 0.0 109.657 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.4 105.84 0.65 Allowed 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 123.79 1.416 . . . . 0.0 110.431 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.2 t -110.04 120.02 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.625 -0.672 . . . . 0.0 109.799 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.3 tpt180 -77.75 142.78 38.49 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.459 -0.776 . . . . 0.0 109.756 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -78.01 129.97 35.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.536 -0.727 . . . . 0.0 110.379 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -128.63 22.5 5.91 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.594 -0.692 . . . . 0.0 110.328 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 172.1 -179.86 43.46 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.376 -1.489 . . . . 0.0 109.376 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -66.79 -40.05 88.01 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.496 -1.002 . . . . 0.0 110.393 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.8 p -129.79 27.34 5.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.54 -0.725 . . . . 0.0 110.532 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.09 162.91 30.47 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.437 -0.789 . . . . 0.0 110.233 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -158.77 175.69 35.76 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 77.5 p -129.21 148.85 51.19 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.607 -0.937 . . . . 0.0 110.262 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 mp -100.76 123.12 44.5 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.607 -0.683 . . . . 0.0 110.438 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.525 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -64.04 -39.96 95.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.507 -0.746 . . . . 0.0 109.781 179.594 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -107.91 112.14 61.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.619 -0.675 . . . . 0.0 109.838 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.32 128.99 22.78 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.801 1.421 . . . . 0.0 110.631 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -125.09 160.03 56.51 Favored Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.592 -0.692 . . . . 0.0 109.906 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -65.48 153.95 75.88 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.863 1.454 . . . . 0.0 110.28 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.517 HG11 ' OE1' ' B' ' 188' ' ' GLU . 79.8 t -63.54 -34.75 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.658 -0.651 . . . . 0.0 110.102 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.4 p -59.74 -36.5 76.73 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.55 -0.719 . . . . 0.0 110.466 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -59.96 -40.01 87.55 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.11 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.5 mp -85.27 -16.18 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.563 -0.711 . . . . 0.0 111.119 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.23 132.83 55.14 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.173 -0.954 . . . . 0.0 110.069 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 89.98 -6.89 82.54 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 p -93.08 -0.04 57.17 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.254 -1.145 . . . . 0.0 111.168 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.403 ' HB2' ' H2A' ' B' ' 191' ' ' FE3 . 3.1 m -59.97 139.91 57.09 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.058 -1.026 . . . . 0.0 109.706 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.473 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.58 -19.65 53.54 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.093 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.49 167.87 3.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.477 ' HB3' HG21 ' A' ' 46' ' ' THR . 56.3 Cg_endo -106.07 149.04 0.11 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 O-C-N 123.801 1.422 . . . . 0.0 111.206 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.453 HD21 HD13 ' A' ' 106' ' ' LEU . 85.2 mt -110.01 102.51 11.24 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.513 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -98.12 133.69 42.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.517 -0.739 . . . . 0.0 111.713 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -70.0 159.41 84.38 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.88 -26.14 23.61 Favored 'Trans proline' 0 N--CA 1.501 1.946 0 O-C-N 123.423 1.223 . . . . 0.0 112.393 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.7 m -62.73 -39.99 95.81 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.262 -0.899 . . . . 0.0 110.029 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.29 36.36 0.75 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' HIS . . . . . 0.414 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 2.9 m-70 -132.26 143.25 49.78 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.423 -1.045 . . . . 0.0 110.193 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.92 142.69 58.35 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.593 -0.692 . . . . 0.0 110.332 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -114.91 -43.63 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.575 -0.703 . . . . 0.0 109.891 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.74 -170.0 33.67 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.448 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.9 mt -123.86 139.36 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.618 -0.931 . . . . 0.0 110.375 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.44 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.2 t80 -64.26 136.43 57.17 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.687 -0.633 . . . . 0.0 109.774 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.3 ttt180 -115.94 -52.27 2.62 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.32 159.95 41.47 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.618 -0.676 . . . . 0.0 110.25 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.04 150.36 34.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.602 -0.686 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.0 t -109.94 120.0 60.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.673 -0.642 . . . . 0.0 109.751 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.438 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -129.77 145.29 51.56 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.63 -0.669 . . . . 0.0 110.426 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.4 m -70.0 -48.86 56.44 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.684 -0.635 . . . . 0.0 110.119 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -162.64 54.73 0.21 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.658 -0.651 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 113.21 -17.89 21.49 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.0 t -111.68 120.52 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.226 -1.161 . . . . 0.0 109.781 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.82 123.73 37.36 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.542 -0.724 . . . . 0.0 110.527 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 52.3 mttp -108.57 -24.77 11.23 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.634 -0.666 . . . . 0.0 110.197 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.78 158.77 43.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.46 -0.775 . . . . 0.0 110.102 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 28.7 m -140.24 170.62 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.565 -0.71 . . . . 0.0 110.545 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -128.93 139.91 51.91 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.646 -0.659 . . . . 0.0 109.905 179.774 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -138.92 157.44 46.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.533 -0.729 . . . . 0.0 110.458 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 82' ' ' LEU . 59.6 t -96.16 121.52 60.38 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.606 -0.684 . . . . 0.0 109.49 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -65.01 150.06 88.56 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.845 1.445 . . . . 0.0 110.408 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 151' ' ' VAL . 87.8 t -60.84 -25.83 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.606 -0.684 . . . . 0.0 110.529 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 65.2 mm-40 -59.97 -36.98 78.3 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.46 -0.775 . . . . 0.0 110.497 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 80.8 p -60.09 -33.12 71.66 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.427 -0.796 . . . . 0.0 110.548 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.448 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.9 mtt -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.507 -0.745 . . . . 0.0 110.541 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -60.11 -40.0 88.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.595 -0.691 . . . . 0.0 110.406 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -60.93 -40.13 92.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 110.279 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -67.11 -50.04 62.87 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.481 -0.762 . . . . 0.0 110.206 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 78.7 mtm -68.81 -39.67 79.96 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.498 -0.751 . . . . 0.0 110.07 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -60.02 -39.99 87.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.609 -0.682 . . . . 0.0 110.172 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.96 -42.64 94.55 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.629 -0.669 . . . . 0.0 110.256 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.5 t -150.07 99.96 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.537 -0.727 . . . . 0.0 110.202 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -60.73 -40.03 90.84 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.58 -0.7 . . . . 0.0 110.169 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -80.14 156.27 27.07 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.527 -0.733 . . . . 0.0 110.331 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -79.97 159.74 26.18 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.57 -0.706 . . . . 0.0 110.402 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.112 179.997 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.517 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.2 tt0 -120.04 134.04 55.36 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.71 -1.196 . . . . 0.0 110.086 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.822 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -68.06 140.41 56.28 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.625 -0.672 . . . . 0.0 110.41 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.4 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.485 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.063 0.458 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.19 -40.01 96.7 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.6 mtm-85 -129.94 149.74 51.53 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.563 -0.963 . . . . 0.0 110.294 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -130.0 139.68 51.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.563 -0.711 . . . . 0.0 110.134 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.83 120.0 39.48 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.649 -0.657 . . . . 0.0 110.264 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -94.29 -39.66 10.39 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.53 -0.731 . . . . 0.0 110.221 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -139.82 150.89 45.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.568 -0.707 . . . . 0.0 110.206 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.0 t -60.65 -42.92 93.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.532 -0.73 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -122.54 139.8 53.49 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.632 -0.668 . . . . 0.0 110.193 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.32 27.71 0.88 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -65.94 -39.97 90.94 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.601 -0.941 . . . . 0.0 109.841 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -114.78 128.85 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.582 -0.699 . . . . 0.0 109.628 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -124.03 159.95 28.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.579 -0.701 . . . . 0.0 110.316 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -108.29 122.18 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.67 -0.644 . . . . 0.0 109.636 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.539 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.8 m -118.44 156.76 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.615 -0.678 . . . . 0.0 110.3 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 62.7 m -135.88 167.34 21.37 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.598 -0.688 . . . . 0.0 110.907 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.3 m -134.44 170.68 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.742 -0.599 . . . . 0.0 109.986 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -65.29 -16.63 63.77 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.501 -0.749 . . . . 0.0 111.109 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 m -117.39 -35.02 4.12 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.189 -0.944 . . . . 0.0 111.628 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.404 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 2.0 pm0 -150.81 170.68 18.68 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.225 -0.922 . . . . 0.0 111.096 -179.204 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 85.9 p -130.43 155.69 46.01 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.36 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.692 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.1 p90 -162.46 -178.33 6.2 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.383 -0.823 . . . . 0.0 110.256 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.685 HD11 ' HA ' ' A' ' 109' ' ' ARG . 73.5 mt -113.66 152.84 29.87 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.519 -0.738 . . . . 0.0 110.9 -178.399 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -132.41 161.09 34.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.662 -0.649 . . . . 0.0 110.013 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.2 t -122.95 139.0 54.52 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.572 -0.705 . . . . 0.0 110.518 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 46.4 t -93.96 104.65 16.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.36 -0.838 . . . . 0.0 110.422 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -112.44 133.35 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.692 -0.63 . . . . 0.0 109.714 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 56.97 38.25 29.26 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.502 -0.749 . . . . 0.0 110.893 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.2 27.11 74.06 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.079 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -141.79 131.85 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -1.07 . . . . 0.0 110.064 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.33 144.97 39.86 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.423 -0.798 . . . . 0.0 109.06 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -129.93 150.99 50.98 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 111.087 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.932 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -168.82 -179.78 3.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.823 -0.548 . . . . 0.0 109.574 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.811 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.5 p -90.04 160.02 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.478 -0.764 . . . . 0.0 110.218 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 60.2 t80 -73.27 -44.62 58.94 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.538 -0.726 . . . . 0.0 111.779 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.859 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.7 p-80 -60.6 -24.66 65.65 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.134 -0.979 . . . . 0.0 110.704 -178.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.584 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.7 -47.78 11.44 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 178.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.692 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -137.09 94.53 2.96 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.751 -0.852 . . . . 0.0 109.271 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.06 62.81 1.33 Allowed Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.8 t 53.38 39.97 30.65 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.255 -1.144 . . . . 0.0 110.809 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -110.02 179.29 4.15 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.571 -0.705 . . . . 0.0 110.021 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 87.0 m -64.9 139.13 58.73 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.866 -0.733 . . . . 0.0 109.225 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.854 HD22 ' CZ2' ' A' ' 85' ' ' TRP . 12.6 tp -125.78 133.12 52.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.549 -0.719 . . . . 0.0 110.177 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.76 113.54 25.1 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.586 -0.697 . . . . 0.0 109.922 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.43 -179.26 17.54 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -62.28 -31.13 82.02 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.871 1.459 . . . . 0.0 110.649 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -75.87 -20.19 58.28 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.563 -0.71 . . . . 0.0 110.626 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.54 -133.27 7.42 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -84.25 146.05 11.06 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.9 1.474 . . . . 0.0 110.136 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.9 mt -120.02 129.98 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.589 -0.694 . . . . 0.0 110.34 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.5 p -87.45 147.09 25.56 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.48 -0.762 . . . . 0.0 110.442 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -87.66 140.01 29.95 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.7 mmm -119.23 -41.8 2.71 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.573 -0.704 . . . . 0.0 110.422 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -120.06 140.0 51.68 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.519 -0.738 . . . . 0.0 110.684 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.489 ' HA ' HG12 ' A' ' 83' ' ' VAL . 33.4 m -139.97 130.01 24.93 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.605 -0.684 . . . . 0.0 110.09 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -142.19 98.33 3.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.499 -0.751 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 94.1 t -70.05 -40.15 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.59 -0.693 . . . . 0.0 109.96 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.1 -47.31 86.43 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.72 . . . . 0.0 110.644 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -87.14 -0.03 56.04 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.505 -0.747 . . . . 0.0 110.801 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.448 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.8 t70 52.96 45.14 29.42 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.113 -0.992 . . . . 0.0 110.543 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.952 HD11 HG11 ' A' ' 170' ' ' VAL . 64.5 mt -139.94 143.31 36.53 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.445 -0.784 . . . . 0.0 111.069 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.535 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -147.47 160.01 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.641 -0.662 . . . . 0.0 109.61 179.331 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.75 159.97 28.03 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.932 ' CH2' HG21 ' A' ' 54' ' ' THR . 15.3 m-90 -118.22 166.91 12.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.666 -0.902 . . . . 0.0 109.53 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -72.49 119.88 17.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.501 -0.749 . . . . 0.0 109.271 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.8 140.35 98.04 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.495 -0.753 . . . . 0.0 110.296 -179.462 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.96 159.98 51.29 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.926 1.487 . . . . 0.0 110.268 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.82 142.11 31.4 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.905 1.476 . . . . 0.0 110.225 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.48 29.29 49.59 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.79 152.12 26.1 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.561 -0.964 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -88.3 167.57 13.43 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.689 -0.632 . . . . 0.0 110.038 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 47.5 t -144.04 164.37 30.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.623 -0.673 . . . . 0.0 110.16 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.4 mt -110.16 149.2 30.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.601 -0.687 . . . . 0.0 110.653 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.421 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 24.5 p -89.95 177.76 2.26 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.694 -0.629 . . . . 0.0 109.984 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -88.74 159.11 6.25 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 O-C-N 123.801 1.421 . . . . 0.0 110.566 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.788 ' HB2' HG22 ' A' ' 151' ' ' VAL . 48.9 t -68.76 130.39 42.67 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.716 -0.615 . . . . 0.0 110.113 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 38.7 p -134.49 54.04 1.96 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.738 -0.601 . . . . 0.0 109.754 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.71 -5.95 0.8 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.561 -0.712 . . . . 0.0 112.37 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.98 38.2 93.84 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -100.01 122.35 42.77 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.575 -0.956 . . . . 0.0 110.463 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.4 m -69.95 -29.43 66.55 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.643 -0.66 . . . . 0.0 110.176 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -64.31 132.58 50.6 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.542 -0.724 . . . . 0.0 110.21 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.581 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.1 mt -136.63 149.95 48.27 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.554 -0.716 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.439 ' HD1' HG22 ' A' ' 113' ' ' VAL . 62.9 m-85 -112.49 120.5 41.85 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.519 -0.738 . . . . 0.0 110.057 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.2 tp -93.7 131.45 39.02 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.432 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.21 119.98 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.516 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.1 m -97.56 169.78 9.48 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.52 -0.738 . . . . 0.0 110.62 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.685 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.8 mtp-105 -62.54 -27.62 69.3 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.682 -0.636 . . . . 0.0 110.129 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -94.6 28.38 2.65 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.24 41.9 31.76 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.195 -0.94 . . . . 0.0 111.036 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -100.04 122.12 42.43 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.516 -0.74 . . . . 0.0 109.961 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.574 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -97.86 70.61 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.665 . . . . 0.0 110.308 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.427 HG23 ' O ' ' A' ' 114' ' ' ILE . 5.3 tp -70.0 129.99 90.31 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.57 -0.706 . . . . 0.0 109.862 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 114' ' ' ILE . 48.6 Cg_endo -75.71 134.33 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.781 1.411 . . . . 0.0 110.599 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.86 130.06 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.636 -0.665 . . . . 0.0 109.558 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -92.37 133.55 35.76 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.49 -0.756 . . . . 0.0 110.095 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -80.42 125.85 30.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.652 -0.655 . . . . 0.0 110.357 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -122.48 24.23 9.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.587 -0.696 . . . . 0.0 110.288 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -178.49 -177.36 47.1 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.12 -40.0 78.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.539 -0.977 . . . . 0.0 110.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.2 p -133.09 24.46 4.21 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.513 -0.742 . . . . 0.0 110.691 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.44 151.79 50.54 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.3 171.56 25.05 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.4 p -115.24 154.55 28.86 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.912 . . . . 0.0 110.04 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -99.99 119.98 39.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.51 -0.744 . . . . 0.0 110.069 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.71 -39.98 88.24 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.583 -0.698 . . . . 0.0 110.101 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.3 m -110.22 114.36 55.74 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.622 -0.674 . . . . 0.0 110.169 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.67 114.26 2.66 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.782 1.412 . . . . 0.0 110.439 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -125.59 160.08 57.6 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.628 -0.67 . . . . 0.0 110.081 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.71 157.08 53.71 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.853 1.449 . . . . 0.0 110.362 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.573 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.06 -23.89 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.595 -0.691 . . . . 0.0 110.636 -179.801 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.1 m -59.98 -39.98 87.53 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.469 -0.769 . . . . 0.0 110.328 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -59.91 -50.13 74.96 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.483 -0.761 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.462 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.93 -26.1 63.98 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.684 -0.635 . . . . 0.0 110.097 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.435 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 9.8 tptm -58.74 129.95 44.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.437 -0.79 . . . . 0.0 110.311 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.95 -10.06 72.39 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.407 -0.902 . . . . 0.0 110.866 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 59.5 p -94.57 -3.22 50.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.0 -1.294 . . . . 0.0 111.251 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.079 -1.013 . . . . 0.0 109.667 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.482 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.24 -22.18 38.76 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.57 155.62 44.02 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.514 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.0 Cg_endo -95.77 150.07 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.845 1.445 . . . . 0.0 111.219 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -106.61 108.99 20.78 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.8 130.28 45.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 111.579 -178.513 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.02 159.54 83.88 Favored Pre-proline 0 N--CA 1.495 1.815 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.9 -26.51 24.82 Favored 'Trans proline' 0 N--CA 1.501 1.929 0 O-C-N 123.494 1.26 . . . . 0.0 112.28 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.1 m -62.68 -39.96 95.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.258 -0.901 . . . . 0.0 109.99 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.23 35.99 0.84 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 18.9 m-70 -131.8 149.47 52.45 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.409 -1.054 . . . . 0.0 110.314 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -68.21 139.96 56.06 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.66 -0.65 . . . . 0.0 110.272 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.788 HG22 ' HB2' ' A' ' 97' ' ' CYS . 64.7 t -114.46 -36.15 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.584 -0.697 . . . . 0.0 109.99 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 179.52 -166.61 36.03 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.482 HG23 ' C ' ' A' ' 140' ' ' GLY . 96.6 mt -130.97 140.07 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.563 -0.963 . . . . 0.0 110.263 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.408 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.3 t80 -64.25 138.57 58.51 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.7 -0.625 . . . . 0.0 109.58 179.507 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -118.49 -52.25 2.37 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.473 -0.767 . . . . 0.0 110.428 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.79 160.06 43.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.593 -0.692 . . . . 0.0 110.184 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.408 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.81 151.88 26.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.616 -0.677 . . . . 0.0 110.256 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.565 HG13 ' CD2' ' B' ' 187' ' ' IBU . 62.9 t -108.47 116.97 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.662 -0.649 . . . . 0.0 109.751 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.573 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.3 p -129.88 142.39 50.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.653 -0.654 . . . . 0.0 110.254 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.1 m -69.69 -49.61 51.78 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.566 -0.709 . . . . 0.0 110.103 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -162.91 54.15 0.19 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.71 -0.619 . . . . 0.0 109.823 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 114.78 -18.51 16.89 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.509 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -112.9 120.77 63.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.29 -1.124 . . . . 0.0 109.758 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -86.61 130.1 34.62 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.549 -0.72 . . . . 0.0 110.522 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -112.47 -26.15 8.84 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.583 -0.698 . . . . 0.0 110.33 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.32 157.99 44.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.663 -0.648 . . . . 0.0 109.974 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.25 179.5 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.431 -0.793 . . . . 0.0 110.608 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -135.36 134.58 39.94 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -138.18 153.13 49.2 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.35 -0.844 . . . . 0.0 110.809 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.952 HG11 HD11 ' A' ' 82' ' ' LEU . 60.5 t -95.09 119.12 66.26 Favored Pre-proline 0 N--CA 1.493 1.675 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 179.414 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -62.38 155.23 58.75 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.771 1.406 . . . . 0.0 110.589 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 151' ' ' VAL . 93.7 t -56.78 -23.18 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.611 -0.681 . . . . 0.0 110.669 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -60.04 -33.13 71.61 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.375 -0.828 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' SER . . . . . 0.454 ' HB3' HG12 ' A' ' 170' ' ' VAL . 18.4 t -60.07 -37.99 81.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.453 -0.78 . . . . 0.0 110.393 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.481 ' HE1' HD11 ' A' ' 153' ' ' ILE . 67.6 mtt -59.97 -39.97 87.46 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.521 -0.737 . . . . 0.0 110.502 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -62.31 -39.9 94.53 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.594 -0.691 . . . . 0.0 110.189 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.6 m -70.09 -39.97 75.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.596 -0.69 . . . . 0.0 109.965 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 84.8 m -59.98 -49.54 77.25 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.588 -0.695 . . . . 0.0 110.317 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -68.22 -39.97 82.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.542 -0.723 . . . . 0.0 110.295 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 38.4 ttt180 -69.75 -39.97 76.42 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.608 -0.683 . . . . 0.0 110.206 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.96 -29.04 66.06 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.556 -0.715 . . . . 0.0 110.316 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 25.4 m -92.65 42.83 1.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.588 -0.695 . . . . 0.0 110.541 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -59.96 -49.98 75.56 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.401 -0.812 . . . . 0.0 110.262 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -151.0 120.02 6.69 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 81.8 mttt -143.27 159.99 41.31 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.551 -0.718 . . . . 0.0 110.192 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 29.9 tptp . . . . . 0 N--CA 1.501 2.114 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.686 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 187' ' ' IBU . . . . . 0.565 ' CD2' HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.537 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 -145.01 130.02 18.39 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.208 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.859 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp -73.51 145.54 45.53 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.647 -0.658 . . . . 0.0 109.985 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.457 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.653 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.017 0.437 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 178.77 -172.07 44.31 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -119.97 140.0 51.6 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.531 -0.982 . . . . 0.0 110.005 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -108.3 21.02 17.92 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.51 -0.744 . . . . 0.0 110.723 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.97 120.42 39.77 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.4 -0.812 . . . . 0.0 110.204 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -158.05 159.97 36.9 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.527 -0.733 . . . . 0.0 110.225 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -99.99 123.41 44.21 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.604 -0.685 . . . . 0.0 110.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.562 HG23 ' HG3' ' A' ' 30' ' ' GLU . 34.6 m -69.8 -26.3 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.587 -0.695 . . . . 0.0 110.556 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.562 ' HG3' HG23 ' A' ' 29' ' ' VAL . 98.6 mt-10 -123.57 149.1 45.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.449 -0.782 . . . . 0.0 110.25 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 140.41 59.02 0.04 OUTLIER Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -67.3 -37.44 83.38 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.48 -1.012 . . . . 0.0 109.903 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 123.27 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.688 -0.632 . . . . 0.0 109.817 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -123.72 157.89 32.9 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.589 -0.695 . . . . 0.0 110.312 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 67.9 t -87.34 131.71 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.605 -0.685 . . . . 0.0 109.812 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.483 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.1 m -127.13 152.89 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.587 -0.696 . . . . 0.0 110.367 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 64.0 m -135.96 -177.89 4.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.705 -0.622 . . . . 0.0 110.34 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.528 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.6 OUTLIER -144.75 -169.13 3.1 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.528 ' H ' HG22 ' A' ' 38' ' ' THR . . . -59.32 -38.67 80.87 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.395 -0.816 . . . . 0.0 110.098 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.1 t -138.58 -7.22 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.443 -0.786 . . . . 0.0 112.514 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -114.55 151.39 33.44 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.868 -1.145 . . . . 0.0 111.163 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -136.09 141.49 44.22 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.584 -0.697 . . . . 0.0 110.238 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.753 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 32.8 p90 -170.32 -177.53 2.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.426 -0.796 . . . . 0.0 110.023 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.749 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.1 mt -113.13 167.9 10.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.49 -0.756 . . . . 0.0 110.253 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -145.9 160.04 42.38 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.664 -0.647 . . . . 0.0 110.265 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.447 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.8 t -120.57 140.2 51.85 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.597 -0.69 . . . . 0.0 110.18 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 37.7 t -99.23 109.96 22.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.417 -0.802 . . . . 0.0 110.407 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.19 130.03 64.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.541 -0.724 . . . . 0.0 109.701 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 56.14 39.93 30.25 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.544 -0.723 . . . . 0.0 110.868 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.741 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 19.92 75.73 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.179 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.0 t -131.06 130.01 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.267 -1.137 . . . . 0.0 109.958 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 78.4 m -77.41 140.43 39.89 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.415 -0.803 . . . . 0.0 109.461 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -130.62 147.09 52.25 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.517 -0.739 . . . . 0.0 110.936 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.794 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -167.66 -179.19 4.21 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.783 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.6 p -88.68 156.63 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 110.356 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.433 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 53.0 t80 -70.04 -44.37 69.36 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.594 -0.691 . . . . 0.0 111.887 -178.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.783 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.9 p-80 -60.78 -24.26 65.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.195 -0.941 . . . . 0.0 110.787 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.563 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -77.1 -48.96 7.88 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.753 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -128.49 101.09 6.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.784 -0.833 . . . . 0.0 109.534 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.26 -164.93 2.34 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 35.0 p -72.21 65.92 0.62 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.655 -0.909 . . . . 0.0 109.844 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.39 169.87 16.77 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.604 -0.685 . . . . 0.0 110.595 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.7 p -69.89 159.92 32.78 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.579 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.858 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.0 tp -115.51 140.8 48.83 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.543 -0.723 . . . . 0.0 110.335 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.91 109.7 22.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.576 -0.702 . . . . 0.0 110.109 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.63 179.98 16.32 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.99 -32.34 65.21 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.854 1.45 . . . . 0.0 110.431 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 87.0 mttt -71.08 -31.49 67.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.663 -0.648 . . . . 0.0 110.037 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.11 -162.2 25.99 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.02 137.82 38.59 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.866 1.456 . . . . 0.0 110.155 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.7 mt -120.06 130.04 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.615 -0.678 . . . . 0.0 110.49 -179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 77.8 p -80.4 149.98 29.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.927 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -100.86 144.42 29.84 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.523 -0.736 . . . . 0.0 111.218 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.442 ' HE1' ' HG3' ' A' ' 86' ' ' GLN . 30.2 mtm -117.3 -21.76 8.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.631 . . . . 0.0 110.59 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -125.57 147.44 49.28 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.417 -0.802 . . . . 0.0 110.403 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.493 ' HA ' HG12 ' A' ' 83' ' ' VAL . 6.9 t -169.32 129.72 1.08 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.59 -0.694 . . . . 0.0 109.921 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.607 -0.683 . . . . 0.0 110.258 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 69.3 t -69.8 -49.61 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.582 -0.699 . . . . 0.0 109.811 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -60.28 -48.57 81.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.606 -0.684 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.783 ' HG2' HD12 ' A' ' 82' ' ' LEU . 50.7 tt0 -79.33 -10.11 59.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.634 -0.666 . . . . 0.0 110.612 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.0 t70 54.16 49.94 17.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.15 -0.969 . . . . 0.0 110.701 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.783 HD12 ' HG2' ' A' ' 80' ' ' GLN . 39.0 mt -143.25 130.98 21.38 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.385 -0.822 . . . . 0.0 111.43 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.4 m -130.03 159.98 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.609 -0.682 . . . . 0.0 109.592 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.14 159.06 27.82 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.858 ' CH2' HD22 ' A' ' 64' ' ' LEU . 9.3 m-90 -122.52 160.03 26.46 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.747 -0.855 . . . . 0.0 109.725 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLN . . . . . 0.442 ' HG3' ' HE1' ' A' ' 74' ' ' MET . 41.5 tt0 -77.79 107.77 10.53 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.543 -0.723 . . . . 0.0 109.51 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.741 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.45 137.84 86.29 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.594 -0.691 . . . . 0.0 110.291 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.04 158.79 55.45 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 O-C-N 123.93 1.49 . . . . 0.0 110.221 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.64 146.48 61.06 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.976 1.514 . . . . 0.0 110.388 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.94 -26.37 24.72 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -68.06 140.05 56.27 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.46 -1.023 . . . . 0.0 110.119 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -81.82 158.62 24.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.522 -0.736 . . . . 0.0 109.884 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -130.07 169.76 14.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.573 -0.704 . . . . 0.0 110.167 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.551 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 45.0 mt -106.03 131.91 52.75 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.625 -0.672 . . . . 0.0 110.731 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -73.66 160.03 83.11 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.577 -0.702 . . . . 0.0 109.793 179.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -77.35 161.12 32.04 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.787 1.414 . . . . 0.0 110.636 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.8 t -74.07 129.91 38.77 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.722 -0.611 . . . . 0.0 110.134 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -132.85 54.12 1.97 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.679 -0.638 . . . . 0.0 109.689 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.62 -8.12 0.75 Allowed 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.371 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.97 42.57 98.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.97 119.93 39.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.525 -0.985 . . . . 0.0 110.422 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.6 m -63.31 -39.99 96.11 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 110.48 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -60.71 129.98 44.25 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.561 -0.712 . . . . 0.0 110.481 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 1.097 HD22 HG11 ' A' ' 151' ' ' VAL . 93.2 mt -133.08 150.19 52.1 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.673 -0.642 . . . . 0.0 110.404 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -115.72 121.37 42.31 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.483 -0.76 . . . . 0.0 109.948 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.431 HD13 HD11 ' A' ' 143' ' ' LEU . 44.6 tp -101.05 143.82 30.71 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.528 -0.732 . . . . 0.0 110.369 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.7 t -108.87 129.12 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.57 -0.706 . . . . 0.0 109.87 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.476 HG21 HD11 ' A' ' 114' ' ' ILE . 75.2 p -106.26 178.85 4.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.543 -0.723 . . . . 0.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.749 ' HA ' HD11 ' A' ' 44' ' ' LEU . 68.3 mtm180 -59.98 -28.26 67.53 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.594 -0.691 . . . . 0.0 110.58 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -90.3 19.08 5.39 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.467 -0.77 . . . . 0.0 111.122 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.51 40.02 30.81 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.102 -0.999 . . . . 0.0 110.706 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -100.16 139.34 35.97 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.73 -0.606 . . . . 0.0 109.936 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 64.7 t -93.74 117.39 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.624 -0.672 . . . . 0.0 109.955 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 108' ' ' THR . 86.9 mt -107.53 110.05 62.73 Favored Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.694 -0.629 . . . . 0.0 109.599 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.85 116.4 4.55 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 123.886 1.466 . . . . 0.0 110.462 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.1 t -120.01 125.2 74.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.678 -0.639 . . . . 0.0 109.643 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -86.23 130.03 34.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.572 -0.705 . . . . 0.0 109.97 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.75 127.87 33.71 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.622 -0.674 . . . . 0.0 110.376 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 12.0 mmm180 -129.68 22.21 5.47 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.665 -0.647 . . . . 0.0 110.245 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.51 -179.75 43.07 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -67.51 -40.66 85.15 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.591 -0.946 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.7 p -131.67 22.51 4.66 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.493 -0.754 . . . . 0.0 110.743 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.38 151.93 51.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.384 -0.822 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.46 -173.98 18.17 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -125.49 154.91 41.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.641 -0.917 . . . . 0.0 110.162 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 25.1 tp -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.575 -0.703 . . . . 0.0 110.207 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.489 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -68.37 -36.61 79.44 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -111.04 113.05 55.06 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.685 -0.635 . . . . 0.0 110.039 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.28 116.57 3.82 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.726 1.382 . . . . 0.0 110.545 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -128.03 160.04 63.64 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.602 -0.686 . . . . 0.0 110.082 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.71 157.09 62.77 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.907 1.477 . . . . 0.0 110.398 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.502 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.4 m -66.12 -24.78 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.614 -0.679 . . . . 0.0 110.487 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.2 t -59.88 -38.44 82.22 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.456 -0.778 . . . . 0.0 110.332 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.585 -0.697 . . . . 0.0 110.342 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 135' ' ' LEU . 10.7 mp -83.11 -16.86 45.17 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.477 -0.765 . . . . 0.0 111.038 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.59 140.01 58.83 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.269 -0.894 . . . . 0.0 110.078 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.56 6.05 89.11 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 63.2 m -112.58 19.48 17.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.129 -1.218 . . . . 0.0 110.757 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.403 ' HB2' ' C ' ' B' ' 190' ' ' OBF . 0.4 OUTLIER -72.28 147.91 45.94 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.304 -0.873 . . . . 0.0 109.935 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.58 -15.31 60.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.02 139.98 48.17 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -87.79 148.93 7.2 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 O-C-N 123.77 1.405 . . . . 0.0 111.224 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.868 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -105.6 120.02 40.59 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.551 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -108.77 131.18 55.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.463 -0.773 . . . . 0.0 111.704 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.453 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.97 82.09 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.4 Cg_endo -51.72 -23.12 14.8 Favored 'Trans proline' 0 N--CA 1.502 2.004 0 O-C-N 123.51 1.268 . . . . 0.0 112.272 -178.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -66.32 -39.98 89.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.247 -0.908 . . . . 0.0 109.89 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.25 34.67 0.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 19.5 m-70 -131.77 144.72 51.15 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.422 -1.046 . . . . 0.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.551 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.91 138.67 52.63 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.515 -0.74 . . . . 0.0 110.125 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 1.097 HG11 HD22 ' A' ' 104' ' ' LEU . 8.3 p -118.05 -21.87 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.591 -0.693 . . . . 0.0 110.814 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 178.68 -173.75 46.02 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.423 HG12 HG21 ' A' ' 46' ' ' THR . 95.5 mt -131.55 139.99 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.605 -0.938 . . . . 0.0 110.096 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.2 t80 -61.0 139.64 58.0 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.579 -0.7 . . . . 0.0 110.148 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -120.21 -52.02 2.19 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.59 -0.694 . . . . 0.0 110.333 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.533 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -154.24 160.55 41.87 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.571 -0.706 . . . . 0.0 110.432 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.01 153.88 23.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.552 -0.717 . . . . 0.0 110.408 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.05 119.22 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.637 -0.664 . . . . 0.0 109.888 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.502 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -137.07 158.59 44.11 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.683 . . . . 0.0 110.307 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 6.2 p -99.0 -51.95 3.7 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.595 -0.691 . . . . 0.0 110.486 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -142.94 63.06 1.39 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.565 -0.709 . . . . 0.0 110.013 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.99 -8.81 79.14 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.66 126.55 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.193 -1.181 . . . . 0.0 109.967 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.58 131.69 46.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.6 -0.687 . . . . 0.0 110.372 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -113.66 -15.42 12.49 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.565 -0.709 . . . . 0.0 110.746 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 158.71 43.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.345 -0.847 . . . . 0.0 109.846 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.04 160.01 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.523 -0.736 . . . . 0.0 110.546 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -123.04 136.11 54.71 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.732 -0.605 . . . . 0.0 109.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -139.11 160.0 40.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.497 -0.752 . . . . 0.0 110.457 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.661 HG11 HD11 ' A' ' 82' ' ' LEU . 88.6 t -99.89 124.6 43.21 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.59 -0.693 . . . . 0.0 109.553 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -65.34 147.59 87.64 Favored 'Trans proline' 0 N--CA 1.489 1.259 0 O-C-N 123.82 1.432 . . . . 0.0 110.186 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.571 HG13 ' C ' ' A' ' 151' ' ' VAL . 35.7 m -60.6 -24.68 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.68 -0.638 . . . . 0.0 110.996 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -60.5 -39.97 89.67 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.485 -0.759 . . . . 0.0 110.693 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.2 p -61.67 -43.3 99.11 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.434 -0.791 . . . . 0.0 110.906 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.444 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.1 mtm -63.54 -39.98 95.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.825 . . . . 0.0 110.456 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -60.43 -40.01 89.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.424 -0.798 . . . . 0.0 110.029 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.0 m -70.23 -26.11 63.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.632 -0.668 . . . . 0.0 110.528 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.7 m -59.94 -40.83 90.29 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.517 -0.739 . . . . 0.0 110.282 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.2 mtt -69.15 -39.91 78.52 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.471 -0.768 . . . . 0.0 110.208 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 37.7 ttt180 -70.02 -39.99 75.46 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.555 -0.715 . . . . 0.0 110.231 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.11 -49.93 75.71 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.58 -0.7 . . . . 0.0 110.496 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.6 t -155.9 160.01 39.79 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.591 -0.693 . . . . 0.0 110.251 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 27.8 tttt -102.26 -158.02 0.64 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.566 -0.709 . . . . 0.0 109.955 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 55.9 tttp -60.04 -40.02 87.92 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.392 -0.817 . . . . 0.0 110.284 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -127.93 28.11 5.61 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.599 -0.688 . . . . 0.0 110.349 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 85.3 tttt . . . . . 0 N--CA 1.502 2.151 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.684 -179.963 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.533 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 60.2 tt0 -127.56 137.37 52.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.131 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.771 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp -88.8 137.43 32.33 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.608 -0.682 . . . . 0.0 110.222 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.411 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.501 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.048 0.451 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.17 166.62 50.1 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -129.98 150.11 51.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.604 -0.939 . . . . 0.0 110.174 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -59.92 -40.04 87.52 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.547 -0.721 . . . . 0.0 110.41 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -125.8 111.37 14.79 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.48 -0.763 . . . . 0.0 110.255 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 t30 -149.95 93.41 2.02 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.568 -0.708 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -121.41 129.93 53.3 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.57 -0.706 . . . . 0.0 110.181 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.05 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.497 -0.752 . . . . 0.0 110.342 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -138.5 135.57 35.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.636 -0.665 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 140.21 93.82 0.24 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.568 ' HG3' HD11 ' A' ' 94' ' ' LEU . 2.9 pt-20 -67.0 -22.55 65.9 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.599 -0.942 . . . . 0.0 110.693 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.515 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.0 t -108.94 127.56 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.492 -0.755 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -121.16 155.5 34.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.666 -0.647 . . . . 0.0 110.345 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 63.7 t -91.52 120.59 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.668 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.603 ' CB ' HD21 ' A' ' 64' ' ' LEU . 33.4 m -116.56 158.32 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.659 -0.651 . . . . 0.0 110.156 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 33.0 m -145.68 172.77 12.79 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.126 -0.629 . . . . 0.0 110.577 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.93 -172.38 2.91 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.19 88.56 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.374 -0.829 . . . . 0.0 110.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 23.2 m -131.47 -7.12 3.72 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.526 -0.734 . . . . 0.0 111.975 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -113.96 159.71 19.62 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.967 -1.083 . . . . 0.0 110.906 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.2 t -146.1 136.96 24.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.0 p90 -166.72 -177.42 3.89 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.315 -0.866 . . . . 0.0 110.528 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.807 HD11 ' N ' ' A' ' 109' ' ' ARG . 73.3 mt -113.05 159.07 19.54 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.598 -0.689 . . . . 0.0 110.81 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -133.4 156.69 47.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.643 -0.661 . . . . 0.0 110.044 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 142' ' ' PRO . 47.3 m -121.82 134.57 54.9 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.444 -0.785 . . . . 0.0 110.44 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 31.7 t -92.76 110.44 21.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.56 -0.713 . . . . 0.0 110.594 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 94' ' ' LEU . 63.1 t -119.46 134.84 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.593 -0.692 . . . . 0.0 109.641 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 54.93 38.37 30.33 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.534 -0.729 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.509 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.09 26.04 74.81 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 178.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.4 t -139.9 131.73 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.364 -1.08 . . . . 0.0 109.906 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.8 m -75.29 148.57 39.27 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.377 -0.827 . . . . 0.0 109.181 179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.502 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 60.8 m95 -129.99 151.04 50.97 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.726 0.774 . . . . 0.0 111.313 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -169.37 -179.88 3.64 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.871 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.4 p -95.62 155.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.828 . . . . 0.0 110.37 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.437 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 62.1 t80 -70.01 -40.86 75.0 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.509 -0.745 . . . . 0.0 111.599 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.871 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.9 p-80 -70.04 -24.4 63.26 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.148 -0.97 . . . . 0.0 110.621 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.781 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.38 -56.28 2.71 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.576 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -101.97 -53.51 2.92 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.756 -0.849 . . . . 0.0 109.964 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.08 -168.99 46.87 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 97.9 p -86.48 64.45 8.54 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.644 -0.915 . . . . 0.0 109.911 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -140.27 170.02 16.6 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.533 -0.729 . . . . 0.0 110.38 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.9 m -65.3 139.59 58.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.549 -0.719 . . . . 0.0 110.043 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.91 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -113.56 136.22 53.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.64 -0.663 . . . . 0.0 110.014 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.28 119.08 33.17 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -123.05 176.42 16.6 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.69 -32.36 68.49 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.852 1.449 . . . . 0.0 110.414 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -71.89 -31.32 66.29 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.629 -0.67 . . . . 0.0 110.169 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.86 -156.57 26.72 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -70.04 154.33 66.76 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.872 1.459 . . . . 0.0 110.359 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.5 mt -130.35 142.65 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.579 -0.7 . . . . 0.0 110.311 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.4 p -99.47 139.98 34.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.496 -0.752 . . . . 0.0 110.591 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.418 ' NE2' HG22 ' A' ' 76' ' ' THR . 1.5 mm100 -71.04 144.55 50.35 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.613 -0.679 . . . . 0.0 111.216 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.41 ' HG3' ' N ' ' A' ' 86' ' ' GLN . 95.1 mmm -119.21 -45.41 2.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.65 -0.656 . . . . 0.0 110.211 179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -120.02 139.94 51.74 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.592 -0.693 . . . . 0.0 110.449 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.418 HG22 ' NE2' ' A' ' 73' ' ' GLN . 30.3 p -130.48 139.92 50.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.58 -0.7 . . . . 0.0 110.329 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.608 ' OD1' HG21 ' A' ' 178' ' ' THR . 34.6 m120 -148.33 82.59 1.48 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.616 -0.678 . . . . 0.0 110.083 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.435 HG22 ' CE1' ' A' ' 56' ' ' TYR . 94.2 t -62.34 -44.68 99.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.634 -0.666 . . . . 0.0 110.011 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.96 -44.54 94.36 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.508 -0.745 . . . . 0.0 110.216 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.606 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.8 tp60 -89.97 -0.0 57.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.514 -0.741 . . . . 0.0 111.002 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.437 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.2 t70 52.79 49.63 19.85 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.016 -1.052 . . . . 0.0 110.498 -179.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.606 HD12 ' CG ' ' A' ' 80' ' ' GLN . 54.9 mt -140.02 144.51 36.97 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.601 -0.687 . . . . 0.0 111.101 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.629 HG23 HG23 ' A' ' 54' ' ' THR . 34.9 m -149.93 159.67 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.565 -0.709 . . . . 0.0 109.611 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.58 28.24 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.926 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.5 m-90 -120.9 159.98 24.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.824 -0.81 . . . . 0.0 109.742 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLN . . . . . 0.41 ' N ' ' HG3' ' A' ' 74' ' ' MET . 18.1 pt20 -68.45 122.47 18.5 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.425 -0.797 . . . . 0.0 109.373 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.509 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.42 130.54 79.52 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.538 -0.726 . . . . 0.0 110.187 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.06 159.97 51.29 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.887 1.467 . . . . 0.0 110.293 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.21 160.13 50.2 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 O-C-N 123.883 1.465 . . . . 0.0 110.275 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.58 29.43 69.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.06 156.64 21.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.615 -0.932 . . . . 0.0 110.113 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -99.12 139.72 34.35 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.0 p -118.84 157.74 27.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.616 -0.677 . . . . 0.0 110.181 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 76.7 mt -112.32 131.53 55.47 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.566 -0.709 . . . . 0.0 110.563 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.6 p -82.2 159.99 63.79 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.565 -0.709 . . . . 0.0 109.969 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.685 ' HB3' HG11 ' A' ' 172' ' ' VAL . 47.1 Cg_endo -70.61 165.81 30.72 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.823 1.433 . . . . 0.0 110.4 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.484 ' HB2' HG22 ' A' ' 151' ' ' VAL . 13.5 t -87.2 149.98 24.24 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.891 0.853 . . . . 0.0 110.367 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.6 m -133.91 62.21 1.66 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 m -141.57 -9.02 0.95 Allowed 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.831 -177.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.51 26.45 56.95 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 79.5 p -80.02 160.0 26.02 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.461 -1.023 . . . . 0.0 110.493 -179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.7 m -107.42 -27.07 10.67 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.707 -0.62 . . . . 0.0 110.329 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -73.83 129.37 37.77 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.75 . . . . 0.0 110.015 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.49 ' CD2' HG11 ' A' ' 151' ' ' VAL . 85.0 mt -135.3 150.05 49.92 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.576 -0.703 . . . . 0.0 110.662 -179.65 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -108.69 119.94 41.0 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.492 -0.755 . . . . 0.0 109.562 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.457 HD13 HD11 ' A' ' 143' ' ' LEU . 50.0 tp -100.97 141.51 33.75 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.48 -0.762 . . . . 0.0 110.78 -179.327 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.88 130.03 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.631 -0.668 . . . . 0.0 109.703 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' THR . . . . . 0.496 ' C ' HD11 ' A' ' 44' ' ' LEU . 73.9 p -111.89 169.97 8.47 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.442 -0.786 . . . . 0.0 110.705 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.807 ' N ' HD11 ' A' ' 44' ' ' LEU . 23.1 ptt-85 -64.68 -16.17 62.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.611 -0.68 . . . . 0.0 111.005 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -89.97 17.4 6.86 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.222 -0.923 . . . . 0.0 110.828 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.44 40.01 31.46 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.081 -1.012 . . . . 0.0 110.51 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -113.38 156.56 23.22 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.658 -0.651 . . . . 0.0 109.853 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -130.0 130.36 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.551 -0.718 . . . . 0.0 110.233 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.409 HG23 ' O ' ' A' ' 114' ' ' ILE . 16.1 tt -131.86 130.06 22.11 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.69 -0.631 . . . . 0.0 109.893 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.53 ' HG2' HD22 ' A' ' 127' ' ' LEU . 47.4 Cg_endo -71.71 126.79 12.37 Favored 'Trans proline' 0 N--CA 1.49 1.265 0 O-C-N 123.856 1.45 . . . . 0.0 110.355 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -120.04 125.58 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.692 -0.63 . . . . 0.0 109.72 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -86.23 149.99 24.7 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.484 -0.76 . . . . 0.0 110.059 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 70.0 ttp85 -93.71 120.65 34.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -110.01 20.0 18.41 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.649 -0.657 . . . . 0.0 110.349 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.55 -177.26 42.61 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.94 -40.03 91.72 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.526 -0.985 . . . . 0.0 110.281 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.6 p -132.33 26.43 4.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.521 -0.737 . . . . 0.0 110.394 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 16.6 tpt180 -124.35 139.97 53.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.451 -0.781 . . . . 0.0 110.495 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.54 167.22 25.35 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 78.3 p -118.95 152.33 36.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.937 . . . . 0.0 110.104 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 164' ' ' ALA . 19.2 tp -94.17 119.09 32.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.556 -0.715 . . . . 0.0 110.118 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.53 HD22 ' HG2' ' A' ' 115' ' ' PRO . 9.2 mp -65.79 -40.0 91.5 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.57 -0.706 . . . . 0.0 109.951 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 58.6 m -111.43 118.59 47.04 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.674 -0.641 . . . . 0.0 110.109 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.54 117.42 4.59 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 O-C-N 123.73 1.384 . . . . 0.0 110.352 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 21.3 mtt180 -129.87 159.95 67.4 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.54 -0.725 . . . . 0.0 110.267 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.27 160.22 43.34 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 O-C-N 123.931 1.49 . . . . 0.0 110.414 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.441 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.6 m -67.39 -25.02 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.665 -0.647 . . . . 0.0 110.816 -179.754 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.4 p -59.96 -40.06 87.76 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.453 -0.779 . . . . 0.0 110.224 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -59.87 -49.82 76.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.534 -0.728 . . . . 0.0 110.023 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.452 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.03 -30.45 67.74 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.611 -0.681 . . . . 0.0 109.82 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.412 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 2.0 tptm -59.92 131.02 49.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.596 -0.69 . . . . 0.0 110.156 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.2 62.66 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.5 m -116.27 12.84 15.5 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.127 -1.219 . . . . 0.0 110.888 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.1 t -62.03 145.15 53.95 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.292 -0.88 . . . . 0.0 109.915 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.06 -12.08 68.8 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.94 140.39 47.9 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.59 ' HB3' HG21 ' A' ' 46' ' ' THR . 51.8 Cg_endo -92.05 150.31 3.2 Favored 'Trans proline' 0 C--N 1.316 -1.168 0 O-C-N 123.85 1.448 . . . . 0.0 111.393 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -100.39 103.05 14.42 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.224 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.507 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -85.74 149.54 25.21 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-O 122.083 0.944 . . . . 0.0 112.289 -177.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 1.6 t -87.78 145.2 36.32 Favored Pre-proline 0 N--CA 1.492 1.655 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -53.71 -24.8 31.45 Favored 'Trans proline' 0 N--CA 1.502 1.98 0 O-C-N 123.291 1.153 . . . . 0.0 110.375 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.3 m -71.87 -36.51 70.13 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.33 39.77 0.57 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 -130.02 138.69 50.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.438 -1.037 . . . . 0.0 110.594 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.603 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.95 141.55 58.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.444 -0.785 . . . . 0.0 109.899 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 172' ' ' VAL . 58.9 t -115.3 -44.0 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.508 -0.745 . . . . 0.0 110.582 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -170.64 -171.07 35.63 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.2 mt -132.92 140.03 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.937 . . . . 0.0 110.441 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.718 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.4 t80 -67.87 138.09 55.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.623 -0.673 . . . . 0.0 109.811 179.406 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.8 ttp180 -124.24 -52.58 1.74 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.538 -0.726 . . . . 0.0 110.499 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -139.78 159.5 42.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.514 -0.741 . . . . 0.0 110.286 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.718 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.41 136.45 54.96 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.604 -0.685 . . . . 0.0 110.612 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.1 t -93.7 119.82 42.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.441 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.6 p -137.37 159.91 40.58 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.235 -179.141 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 76.1 p -138.88 142.28 38.58 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 53.76 28.01 7.69 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.289 -0.882 . . . . 0.0 110.671 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 80.69 22.89 61.04 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.5 t -129.98 129.99 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.265 -1.138 . . . . 0.0 110.039 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ALA . . . . . 0.405 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -91.54 124.03 35.4 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.26 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 40.9 mttm -112.72 -26.38 8.63 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.587 -0.696 . . . . 0.0 110.352 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.2 161.57 38.54 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.532 -0.73 . . . . 0.0 109.838 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.03 178.49 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.517 -0.739 . . . . 0.0 111.476 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -134.03 135.52 43.42 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -139.99 145.59 38.03 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.326 -0.859 . . . . 0.0 110.719 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.563 HG11 HD11 ' A' ' 82' ' ' LEU . 72.9 t -86.7 124.72 68.88 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.627 -0.671 . . . . 0.0 109.353 179.337 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -66.54 162.52 36.46 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.845 1.444 . . . . 0.0 110.343 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.8 t -70.03 -24.67 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.681 -0.637 . . . . 0.0 110.487 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -57.93 -39.93 79.21 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.375 -0.828 . . . . 0.0 110.575 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.6 p -69.31 -38.43 78.24 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.502 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 93.0 mtp -60.19 -40.52 90.34 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.654 -0.654 . . . . 0.0 110.35 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -69.26 -39.97 78.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.623 -0.673 . . . . 0.0 110.336 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.12 -39.92 91.84 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.606 -0.684 . . . . 0.0 110.074 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' THR . . . . . 0.608 HG21 ' OD1' ' A' ' 77' ' ' ASN . 89.7 m -60.11 -47.52 85.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.545 -0.722 . . . . 0.0 110.375 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.02 -49.98 75.52 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.631 -0.668 . . . . 0.0 110.41 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -69.68 -40.07 76.6 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.213 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.75 -27.07 64.64 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.602 -0.686 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 5.3 m -79.94 89.72 5.32 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.572 -0.705 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -160.08 29.13 0.17 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.554 -0.716 . . . . 0.0 110.054 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -66.54 -30.03 70.25 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.462 -0.774 . . . . 0.0 110.457 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -60.05 -39.99 87.87 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.538 -0.726 . . . . 0.0 110.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.185 -179.965 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -117.31 129.98 56.24 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.116 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.803 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -70.1 140.03 52.63 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.531 -0.731 . . . . 0.0 110.234 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.575 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.624 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.5 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.135 0.493 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.2 -179.97 48.38 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -108.16 139.76 42.36 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.604 -0.939 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -150.23 155.33 39.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.606 -0.684 . . . . 0.0 110.329 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -80.04 160.0 25.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.656 -0.653 . . . . 0.0 110.226 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -60.05 -39.93 87.68 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -62.65 139.99 58.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.538 -0.726 . . . . 0.0 109.87 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.41 129.28 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.58 -0.7 . . . . 0.0 110.027 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -62.43 -40.06 95.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.571 -0.706 . . . . 0.0 110.234 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.67 146.83 6.13 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.569 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.1 mt-10 -66.3 -37.23 84.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.622 -0.928 . . . . 0.0 110.214 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -102.64 126.52 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.701 . . . . 0.0 110.037 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -117.21 151.61 36.55 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.564 -0.71 . . . . 0.0 110.146 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.7 p -89.67 136.15 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.512 -0.743 . . . . 0.0 110.069 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.683 ' HB ' HD12 ' A' ' 64' ' ' LEU . 33.6 m -129.7 136.97 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.695 -0.628 . . . . 0.0 110.006 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.6 m -136.13 170.93 15.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -133.11 -170.67 2.51 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.636 -0.665 . . . . 0.0 109.449 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.3 -24.2 67.57 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.642 -0.661 . . . . 0.0 111.427 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.3 t -137.24 -15.45 1.47 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.133 -0.979 . . . . 0.0 113.175 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -125.29 149.66 47.85 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.872 -1.143 . . . . 0.0 111.249 -178.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 29.2 p -132.77 142.36 48.97 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.824 -0.548 . . . . 0.0 110.094 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.463 ' CE2' ' HB2' ' A' ' 59' ' ' ALA . 16.1 p90 -163.91 -177.33 5.03 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.469 -0.769 . . . . 0.0 109.88 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.79 HD11 ' CA ' ' A' ' 109' ' ' ARG . 29.1 mt -112.46 179.18 4.06 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.391 -0.818 . . . . 0.0 110.775 -177.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -155.36 160.34 40.63 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.784 -0.573 . . . . 0.0 109.725 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.1 t -125.65 138.41 53.91 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.481 -0.762 . . . . 0.0 110.231 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.9 t -96.66 107.01 19.38 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.474 -0.766 . . . . 0.0 110.653 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.435 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.2 t -110.35 130.0 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.717 -0.614 . . . . 0.0 109.348 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 56.84 36.37 27.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.502 -0.749 . . . . 0.0 110.725 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.543 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 74.28 17.7 79.71 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 179.037 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.2 t -131.21 130.03 63.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.942 0 O-C-N 121.118 -1.225 . . . . 0.0 110.102 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.3 t -73.06 150.05 42.66 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.511 -0.743 . . . . 0.0 109.592 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.435 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 87.4 m95 -135.72 150.0 49.4 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.528 -0.733 . . . . 0.0 110.93 -179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.843 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.0 t -168.51 -179.69 3.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.856 -0.528 . . . . 0.0 109.584 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.816 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.4 p -91.46 157.2 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.018 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.617 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.7 t80 -72.93 -43.65 62.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.543 -0.723 . . . . 0.0 112.14 -178.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.816 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.8 p-80 -60.84 -24.63 66.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.12 -0.988 . . . . 0.0 110.714 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.536 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -90.85 -35.51 7.18 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.362 -1.895 . . . . 0.0 108.362 178.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.463 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -135.59 97.0 3.56 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.792 -0.828 . . . . 0.0 109.879 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -80.03 -166.24 33.24 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 79.1 p -72.26 65.84 0.62 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.626 -0.926 . . . . 0.0 109.631 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.22 169.82 16.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.0 110.382 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 71' ' ' ILE . 69.0 m -74.94 139.25 42.88 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.661 -0.649 . . . . 0.0 110.141 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.683 HD12 ' HB ' ' A' ' 36' ' ' VAL . 0.2 OUTLIER -108.51 133.47 52.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.626 -0.671 . . . . 0.0 109.705 179.671 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.71 112.72 20.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.636 -0.665 . . . . 0.0 110.209 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -112.2 -176.74 19.95 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.79 -32.65 67.17 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.854 1.45 . . . . 0.0 110.499 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -74.93 -31.12 61.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.667 -0.646 . . . . 0.0 109.934 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.65 -144.17 13.27 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' PRO . . . . . 0.429 ' O ' HD13 ' A' ' 71' ' ' ILE . 47.5 Cg_endo -73.61 155.13 49.94 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.817 1.43 . . . . 0.0 110.238 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 63' ' ' THR . 49.1 mm -129.49 139.93 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.558 -0.714 . . . . 0.0 110.455 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 80.5 m -101.04 120.92 40.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.567 -0.708 . . . . 0.0 110.076 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.586 ' OE1' HG22 ' A' ' 76' ' ' THR . 32.2 tt0 -77.0 139.53 40.1 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.546 -0.721 . . . . 0.0 110.681 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 42.2 mtp -109.95 -30.01 8.0 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.663 -0.648 . . . . 0.0 110.441 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -112.85 138.42 49.72 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.523 -0.736 . . . . 0.0 110.612 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.586 HG22 ' OE1' ' A' ' 73' ' ' GLN . 7.0 p -139.41 126.91 21.62 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.706 -0.621 . . . . 0.0 110.023 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 -142.02 90.97 2.3 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.489 -0.757 . . . . 0.0 110.26 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.617 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 91.1 t -66.26 -40.35 86.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.6 -0.687 . . . . 0.0 109.882 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.58 -45.01 95.53 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.647 -0.658 . . . . 0.0 110.601 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.535 ' HG3' HD12 ' A' ' 82' ' ' LEU . 38.6 tp60 -87.79 -0.01 56.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.504 -0.747 . . . . 0.0 110.816 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.6 t70 53.54 42.71 31.88 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.055 -1.028 . . . . 0.0 110.538 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.682 HD11 HG11 ' A' ' 170' ' ' VAL . 67.0 mt -140.92 147.69 39.25 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.45 -0.781 . . . . 0.0 111.036 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.444 HG13 ' C ' ' A' ' 82' ' ' LEU . 34.6 m -148.32 177.1 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.695 -0.628 . . . . 0.0 109.404 179.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -156.29 158.25 28.51 Favored Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.838 -1.172 . . . . 0.0 110.518 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.843 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.0 m-90 -120.38 160.77 22.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.816 -0.814 . . . . 0.0 109.848 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.2 tt0 -75.2 109.96 9.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.57 -0.706 . . . . 0.0 109.297 179.16 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.89 153.96 87.21 Favored Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.545 -0.722 . . . . 0.0 110.01 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.09 159.69 52.28 Favored 'Trans proline' 0 N--CA 1.488 1.196 0 O-C-N 123.83 1.437 . . . . 0.0 110.281 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.06 141.71 71.26 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.95 1.5 . . . . 0.0 110.357 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.18 27.47 72.84 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.19 149.87 26.57 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.467 -1.019 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 13.3 tpt180 -87.74 139.23 30.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.616 -0.678 . . . . 0.0 109.308 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.2 p -128.99 168.38 16.11 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.426 -0.796 . . . . 0.0 110.554 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.614 HD13 HD21 ' A' ' 144' ' ' LEU . 34.7 mt -111.65 131.97 54.91 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.735 -0.603 . . . . 0.0 110.714 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 73.8 p -74.76 159.95 81.98 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 109.799 179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.29 161.01 46.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 O-C-N 123.865 1.456 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.792 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.8 t -70.25 134.73 48.31 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.721 -0.612 . . . . 0.0 110.063 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 22.4 p -136.15 52.35 1.98 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.667 -0.646 . . . . 0.0 109.827 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.1 p -143.81 -8.09 0.73 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.516 -0.74 . . . . 0.0 112.387 -179.143 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.01 42.26 98.3 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 54.0 m -100.0 120.04 39.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -1.04 . . . . 0.0 110.305 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.3 m -62.83 -40.05 96.22 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.579 -0.701 . . . . 0.0 110.429 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 137.54 58.06 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.538 -0.726 . . . . 0.0 110.497 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.563 ' CD2' HG21 ' A' ' 151' ' ' VAL . 89.3 mt -138.47 142.84 39.43 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.637 -0.664 . . . . 0.0 110.643 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -106.85 120.37 41.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.587 -0.696 . . . . 0.0 109.581 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.1 tp -102.57 146.16 28.56 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.406 -0.809 . . . . 0.0 110.829 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.4 t -105.34 130.01 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.676 -0.64 . . . . 0.0 109.647 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 76.3 p -98.25 173.57 6.93 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.573 -0.704 . . . . 0.0 111.004 -179.29 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.79 ' CA ' HD11 ' A' ' 44' ' ' LEU . 61.9 ttt-85 -70.0 -24.26 63.27 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.745 -0.597 . . . . 0.0 110.514 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -94.03 29.25 2.18 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.44 -0.787 . . . . 0.0 110.737 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.42 40.03 31.26 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.308 -0.87 . . . . 0.0 110.724 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -116.1 145.94 42.63 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.528 -0.733 . . . . 0.0 109.542 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.9 p -130.0 133.59 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.538 -0.726 . . . . 0.0 110.575 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 81.3 mt -124.91 150.06 64.95 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.651 -0.655 . . . . 0.0 109.485 179.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -81.46 123.05 4.22 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.945 1.498 . . . . 0.0 110.593 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 61.2 t -119.91 124.32 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 109.648 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -81.96 130.61 35.13 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.527 -0.733 . . . . 0.0 110.049 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -77.45 128.23 33.87 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.68 -0.638 . . . . 0.0 110.344 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -119.46 23.02 11.45 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.662 -0.649 . . . . 0.0 110.429 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.75 176.9 38.2 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -60.12 -40.82 91.07 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.54 -0.976 . . . . 0.0 110.127 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 20.8 p -130.0 27.4 5.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.622 -0.674 . . . . 0.0 110.331 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 3.1 tpt85 -128.93 137.06 51.19 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.461 -0.774 . . . . 0.0 110.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.2 166.57 26.0 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -124.87 146.22 49.41 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.558 -0.966 . . . . 0.0 110.058 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mp -97.73 125.25 42.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.554 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.73 -40.04 88.22 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.544 -0.723 . . . . 0.0 109.81 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.6 m -107.55 114.32 60.73 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.661 -0.649 . . . . 0.0 109.94 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.28 124.49 13.02 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.839 1.441 . . . . 0.0 110.487 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.9 mmt180 -120.48 160.09 45.38 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.641 -0.662 . . . . 0.0 109.972 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.33 156.67 62.01 Favored 'Trans proline' 0 N--CA 1.489 1.257 0 O-C-N 123.942 1.496 . . . . 0.0 110.385 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.458 HG11 ' OE1' ' B' ' 188' ' ' GLU . 65.7 t -66.83 -29.93 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.596 -0.69 . . . . 0.0 110.003 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.9 m -59.95 -40.05 87.67 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.482 -0.762 . . . . 0.0 110.352 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -61.76 -40.0 93.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.75 . . . . 0.0 109.994 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.47 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.22 -30.43 68.58 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.595 -0.691 . . . . 0.0 110.479 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 mmmm -60.01 140.4 56.81 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.388 -0.82 . . . . 0.0 110.246 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.01 14.67 80.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.0 m -114.78 10.06 16.46 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.283 -1.127 . . . . 0.0 110.936 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.7 m -62.06 140.2 58.39 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.223 -0.923 . . . . 0.0 110.048 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.75 -18.15 57.29 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.43 113.76 5.21 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.56 150.21 24.54 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.833 1.438 . . . . 0.0 110.82 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -101.49 109.1 20.85 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.614 HD21 HD13 ' A' ' 94' ' ' LEU . 9.9 mp -100.0 129.96 46.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.555 -0.716 . . . . 0.0 111.064 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.411 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.9 158.64 86.74 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.725 -0.61 . . . . 0.0 109.417 179.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.4 Cg_endo -53.77 -20.87 18.35 Favored 'Trans proline' 0 N--CA 1.501 1.925 0 O-C-N 123.634 1.333 . . . . 0.0 112.56 -178.327 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.8 p -67.22 -36.47 81.75 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.077 -1.015 . . . . 0.0 109.917 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 119.4 34.65 0.99 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 20.0 m-70 -131.83 146.79 52.33 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.431 -1.04 . . . . 0.0 110.175 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.53 146.46 50.18 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.581 -0.699 . . . . 0.0 110.293 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.792 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.4 t -117.69 -40.1 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.579 -0.701 . . . . 0.0 109.991 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.22 -168.85 34.22 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.471 ' CD1' ' HE1' ' A' ' 175' ' ' MET . 93.8 mt -133.19 140.01 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.487 -1.008 . . . . 0.0 110.464 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -59.98 139.03 57.69 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.547 -0.72 . . . . 0.0 110.036 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 29.9 ttp85 -123.19 -52.01 1.86 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.573 -0.704 . . . . 0.0 110.186 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -146.9 160.41 42.36 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.677 . . . . 0.0 110.295 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.21 144.49 44.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.559 -0.713 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.7 t -110.03 120.05 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 120.18 -0.608 . . . . 0.0 109.807 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.409 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -130.4 145.87 51.88 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.689 -0.632 . . . . 0.0 110.345 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.5 m -70.05 -49.2 53.58 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.61 -0.681 . . . . 0.0 110.265 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -163.92 53.83 0.15 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.574 -0.703 . . . . 0.0 109.889 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 116.11 -17.58 14.76 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.11 126.3 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.217 -1.167 . . . . 0.0 109.777 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.54 126.95 40.15 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.567 -0.708 . . . . 0.0 110.398 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -112.29 -18.1 12.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.604 -0.685 . . . . 0.0 110.717 179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -149.1 159.14 44.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.218 -0.926 . . . . 0.0 110.157 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.8 m -140.01 166.86 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.531 -0.731 . . . . 0.0 110.853 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -119.97 136.78 54.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.655 -0.653 . . . . 0.0 109.773 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -138.04 155.68 48.56 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.493 -0.754 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.682 HG11 HD11 ' A' ' 82' ' ' LEU . 60.4 t -92.91 123.89 60.02 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.621 -0.674 . . . . 0.0 109.578 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.22 154.0 75.57 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.842 1.443 . . . . 0.0 110.581 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 151' ' ' VAL . 91.1 t -59.91 -23.47 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.594 -0.691 . . . . 0.0 110.575 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -58.16 -38.36 76.47 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.444 -0.785 . . . . 0.0 110.555 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' SER . . . . . 0.411 ' OG ' HG12 ' A' ' 170' ' ' VAL . 82.6 p -60.03 -37.11 78.79 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.311 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.471 ' HE1' ' CD1' ' A' ' 153' ' ' ILE . 68.4 mtt -60.13 -40.02 88.29 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.466 -0.771 . . . . 0.0 110.441 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -60.16 -41.27 92.44 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.565 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 73.5 p -72.92 -40.04 65.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.44 -0.787 . . . . 0.0 110.311 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.9 m -70.06 -44.4 69.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.622 -0.674 . . . . 0.0 110.121 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.78 -40.17 91.6 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.337 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 62.8 ttt180 -60.18 -40.05 88.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.536 -0.728 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.83 -40.02 79.69 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.574 -0.704 . . . . 0.0 110.212 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 13.5 m 50.99 -160.0 0.08 Allowed 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.397 -0.815 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -149.44 120.31 7.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -107.64 -29.97 8.85 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.579 -0.701 . . . . 0.0 110.197 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -156.76 159.98 38.82 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.539 -0.726 . . . . 0.0 110.326 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 22.9 mmmt . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.16 179.928 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.458 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.4 tt0 -121.9 137.75 54.67 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 118.74 -1.184 . . . . 0.0 110.088 . . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.804 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp -84.13 135.55 34.35 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.634 -0.666 . . . . 0.0 110.231 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CG ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.402 ' CG ' ' C ' ' B' ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.079 0.466 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.14 -169.11 49.49 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 52.97 40.0 30.34 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.46 -1.023 . . . . 0.0 110.787 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.7 88.42 1.55 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.651 -0.656 . . . . 0.0 110.163 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -132.43 150.03 52.23 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 110.312 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -110.03 24.48 12.96 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.688 -0.633 . . . . 0.0 110.432 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -109.27 151.24 26.81 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.499 -0.751 . . . . 0.0 110.194 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 p -86.97 136.63 22.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.571 -0.705 . . . . 0.0 110.344 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -65.3 140.11 58.66 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.591 -0.693 . . . . 0.0 110.411 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.3 110.68 0.48 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.402 ' CG ' ' CG ' ' A' ' 92' ' ' ARG . 47.7 mt-10 -66.34 -37.85 86.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.539 -0.977 . . . . 0.0 110.041 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.6 t -107.13 125.42 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 0.0 109.952 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -115.75 143.26 45.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.515 -0.741 . . . . 0.0 110.413 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.42 132.65 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.588 -0.695 . . . . 0.0 109.987 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CB ' HD21 ' A' ' 64' ' ' LEU . 26.7 m -128.77 159.86 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.634 -0.666 . . . . 0.0 109.972 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 m -139.43 160.52 39.65 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.62 -0.675 . . . . 0.0 110.478 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.37 -176.93 3.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.758 -0.589 . . . . 0.0 109.841 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.68 -12.53 59.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.622 -0.674 . . . . 0.0 110.803 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 41.7 p -120.04 -30.02 4.78 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.242 -0.911 . . . . 0.0 111.191 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -156.39 169.58 24.26 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.281 -0.887 . . . . 0.0 110.633 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.0 p -126.84 158.28 37.08 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.591 -0.693 . . . . 0.0 110.438 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.8 p90 -168.98 -176.38 2.62 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.507 -0.746 . . . . 0.0 109.89 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.586 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.8 mt -111.83 176.36 5.05 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.491 -0.755 . . . . 0.0 110.454 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.406 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -147.91 159.98 43.29 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.786 -0.571 . . . . 0.0 110.069 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.605 HG23 ' O ' ' A' ' 140' ' ' GLY . 39.8 p -120.17 130.88 54.79 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.577 -0.702 . . . . 0.0 110.525 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 33.8 t -92.52 109.66 21.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.429 -0.794 . . . . 0.0 110.386 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.454 HG22 ' HB2' ' A' ' 94' ' ' LEU . 58.6 t -119.2 131.74 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.603 -0.685 . . . . 0.0 109.641 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.57 39.35 27.77 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.539 -0.726 . . . . 0.0 110.845 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.561 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.04 75.98 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.69 130.01 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.143 -1.21 . . . . 0.0 110.022 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 94.1 m -72.63 149.93 43.48 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.44 -0.788 . . . . 0.0 109.457 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.568 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 83.4 m95 -131.79 151.07 51.93 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.524 -0.735 . . . . 0.0 111.175 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.1 t -167.65 -179.94 4.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.774 HG21 ' CE1' ' A' ' 57' ' ' HIS . 7.5 p -97.05 147.75 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.155 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.489 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 58.3 t80 -60.05 -46.94 87.88 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.611 -0.68 . . . . 0.0 112.095 -178.594 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.793 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.5 p-80 -64.7 -24.08 67.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.159 -0.963 . . . . 0.0 110.91 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.698 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.61 -52.96 3.53 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.679 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -109.42 -57.41 2.17 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.688 -0.89 . . . . 0.0 110.101 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.5 -163.8 52.98 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.1 p -88.98 66.2 7.78 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.662 -0.905 . . . . 0.0 110.037 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -139.63 168.39 19.93 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.508 -0.745 . . . . 0.0 110.282 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 60.2 m -65.0 139.63 58.78 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.056 -0.657 . . . . 0.0 109.961 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.815 HD22 ' CH2' ' A' ' 85' ' ' TRP . 13.8 tp -117.42 138.96 51.48 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.689 -0.632 . . . . 0.0 109.903 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.83 110.04 22.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.549 -0.719 . . . . 0.0 110.193 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.76 -179.65 19.06 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.04 -31.89 76.06 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.821 1.432 . . . . 0.0 110.469 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 6.7 mtpm? -73.06 -31.17 64.23 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.701 -0.624 . . . . 0.0 109.964 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.46 -150.41 21.6 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.71 147.11 44.45 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.886 1.466 . . . . 0.0 110.148 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -129.99 140.03 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.549 -0.719 . . . . 0.0 110.57 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.7 t -99.94 144.22 29.25 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.548 -0.72 . . . . 0.0 109.774 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -90.13 150.0 22.22 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.407 -0.808 . . . . 0.0 111.232 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 50.2 mtp -116.04 -25.98 7.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.762 -0.586 . . . . 0.0 110.427 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -122.86 139.96 53.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.561 ' HA ' HG12 ' A' ' 83' ' ' VAL . 60.9 m -141.38 133.72 28.13 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.621 -0.674 . . . . 0.0 110.312 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -145.54 95.66 2.69 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.509 -0.744 . . . . 0.0 110.019 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.489 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 80.2 t -66.27 -43.09 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.513 -0.742 . . . . 0.0 110.066 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -49.88 75.9 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.55 -0.719 . . . . 0.0 110.474 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.634 ' CG ' HD12 ' A' ' 82' ' ' LEU . 37.0 tp60 -81.72 -8.65 59.72 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.588 -0.695 . . . . 0.0 110.509 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.442 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.0 t70 57.5 45.9 18.81 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.115 -0.991 . . . . 0.0 110.304 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.779 HD11 HG11 ' A' ' 170' ' ' VAL . 82.6 mt -138.16 139.09 39.21 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.549 -0.719 . . . . 0.0 110.953 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.561 HG12 ' HA ' ' A' ' 76' ' ' THR . 34.7 m -144.39 158.04 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.627 -0.671 . . . . 0.0 109.439 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -140.62 157.94 25.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.3 m-90 -116.67 161.07 19.77 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.782 -0.834 . . . . 0.0 109.639 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -70.99 114.23 8.83 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.515 -0.741 . . . . 0.0 109.312 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.03 136.52 87.2 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 110.212 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 159.97 51.3 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.864 1.455 . . . . 0.0 110.228 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -66.15 153.63 77.32 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 123.882 1.464 . . . . 0.0 110.322 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.16 27.36 66.37 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.87 139.88 40.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.506 -0.996 . . . . 0.0 110.138 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.402 ' CG ' ' CG ' ' A' ' 32' ' ' GLU . 27.4 tpt180 -80.11 159.92 25.92 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.658 -0.651 . . . . 0.0 109.531 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.7 p -129.63 167.92 17.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.554 -0.716 . . . . 0.0 110.173 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.454 ' HB2' HG22 ' A' ' 48' ' ' VAL . 59.9 mt -109.8 131.54 54.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.526 -0.733 . . . . 0.0 110.651 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.466 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 9.8 t -75.37 159.97 80.86 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.582 -0.699 . . . . 0.0 109.986 179.505 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -84.76 164.17 12.07 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.753 1.396 . . . . 0.0 110.815 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.499 ' HB2' HG22 ' A' ' 151' ' ' VAL . 43.8 t -82.59 138.94 34.07 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.658 -0.651 . . . . 0.0 110.194 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -136.09 51.64 2.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.812 -0.555 . . . . 0.0 109.681 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.2 p -143.43 -8.61 0.76 Allowed 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.843 -0.743 . . . . 0.0 112.411 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 33.44 74.75 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 86.0 p -76.73 149.92 36.31 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.431 -1.041 . . . . 0.0 110.415 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -92.66 -29.22 16.21 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.625 -0.672 . . . . 0.0 110.286 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -77.43 135.27 38.27 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.554 -0.716 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.4 mt -135.04 155.12 51.3 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.508 -0.745 . . . . 0.0 110.599 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -119.99 114.6 22.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.556 -0.715 . . . . 0.0 109.788 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.428 HD13 HD11 ' A' ' 143' ' ' LEU . 40.3 tp -100.41 140.01 35.27 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.617 -0.677 . . . . 0.0 110.445 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 113' ' ' VAL . 62.2 t -109.96 129.94 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.626 -0.671 . . . . 0.0 110.052 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 59.5 p -102.2 -179.58 4.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.592 -0.692 . . . . 0.0 110.42 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.586 ' HA ' HD11 ' A' ' 44' ' ' LEU . 31.9 mtp-105 -59.88 -22.52 62.47 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.535 -0.728 . . . . 0.0 110.808 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -90.11 19.57 4.9 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.276 -0.89 . . . . 0.0 111.15 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.0 40.07 31.21 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.123 -0.986 . . . . 0.0 110.686 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -106.76 134.84 49.3 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.611 -0.68 . . . . 0.0 109.957 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 107' ' ' VAL . 62.7 t -110.08 123.48 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 109.982 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.5 pt -119.97 150.0 50.01 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.564 -0.71 . . . . 0.0 110.06 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.616 ' HG2' HD22 ' A' ' 127' ' ' LEU . 50.6 Cg_endo -87.99 128.03 2.27 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.933 1.491 . . . . 0.0 110.44 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.9 t -124.75 129.41 73.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.662 -0.649 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.582 ' HG2' HD11 ' A' ' 127' ' ' LEU . 51.6 mmm-85 -80.35 156.0 26.93 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.572 -0.705 . . . . 0.0 110.309 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -101.14 118.63 37.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.634 -0.666 . . . . 0.0 110.064 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.8 mmm180 -113.13 20.02 16.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.59 -0.694 . . . . 0.0 110.437 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.02 -171.43 42.39 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.02 -39.93 90.66 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.566 -0.961 . . . . 0.0 110.442 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.0 p -132.69 24.14 4.34 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.524 -0.735 . . . . 0.0 110.816 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -126.26 139.88 52.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.325 -0.859 . . . . 0.0 110.506 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.84 169.35 27.97 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 52.1 p -112.06 156.82 21.58 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.41 -1.053 . . . . 0.0 110.537 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.457 HD23 ' O ' ' A' ' 164' ' ' ALA . 24.2 tp -98.59 120.4 38.94 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.559 -0.713 . . . . 0.0 110.074 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.616 HD22 ' HG2' ' A' ' 115' ' ' PRO . 8.0 mp -60.93 -40.21 92.39 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.569 -0.707 . . . . 0.0 110.352 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.2 p -117.8 127.25 26.76 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.504 -0.747 . . . . 0.0 110.075 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.31 117.93 5.36 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.87 1.458 . . . . 0.0 110.381 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 48.6 mtp85 -120.08 160.01 44.86 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.708 . . . . 0.0 110.227 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.77 148.84 83.35 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.875 1.461 . . . . 0.0 110.31 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.562 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.3 m -62.07 -26.59 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.613 -0.68 . . . . 0.0 110.426 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.4 t -59.95 -39.92 87.22 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.693 ' HD2' HD12 ' A' ' 135' ' ' LEU . 65.0 t80 -60.06 -49.16 78.73 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.607 -0.683 . . . . 0.0 110.227 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.693 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.4 mp -69.97 -28.93 65.95 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.466 -0.771 . . . . 0.0 110.537 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmtp -60.01 140.02 57.06 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.476 -0.765 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.99 9.99 86.09 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 28.9 m -112.05 16.79 20.09 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.141 -1.211 . . . . 0.0 110.785 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -60.17 140.03 57.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.287 -0.883 . . . . 0.0 110.023 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.34 -18.07 57.59 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -51.4 124.94 24.17 Favored Glycine 0 N--CA 1.5 2.906 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.557 ' HB3' HG21 ' A' ' 46' ' ' THR . 52.4 Cg_endo -80.77 146.32 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.868 1.457 . . . . 0.0 111.304 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.628 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -106.71 106.77 17.46 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.557 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -95.74 131.21 42.26 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.527 -0.733 . . . . 0.0 111.242 -178.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.444 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.75 159.39 84.14 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.185 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -51.92 -21.83 12.88 Favored 'Trans proline' 0 N--CA 1.501 1.954 0 O-C-N 123.506 1.266 . . . . 0.0 112.671 -178.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -69.77 -38.39 76.73 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.18 -0.95 . . . . 0.0 109.872 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.58 37.23 0.74 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 22.9 m-70 -133.37 149.6 51.85 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.495 -1.003 . . . . 0.0 110.221 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -63.72 139.99 58.82 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.52 -0.737 . . . . 0.0 110.216 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.643 ' O ' HG23 ' A' ' 172' ' ' VAL . 49.6 t -115.96 -35.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.582 -0.698 . . . . 0.0 110.009 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.7 -169.98 38.69 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 90.0 mt -130.04 139.89 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.564 -0.962 . . . . 0.0 110.229 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -59.99 139.14 57.63 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.507 -0.746 . . . . 0.0 110.12 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -119.95 -52.34 2.21 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.615 -0.678 . . . . 0.0 110.29 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.681 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.58 166.88 30.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.522 -0.736 . . . . 0.0 110.5 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.25 148.55 43.01 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.627 -0.671 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.94 120.03 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.624 -0.672 . . . . 0.0 109.796 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.562 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.5 p -133.63 149.87 51.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.719 -0.613 . . . . 0.0 110.376 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.8 p -80.09 -47.48 14.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.568 -0.707 . . . . 0.0 110.41 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -161.65 57.41 0.27 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.671 -0.643 . . . . 0.0 110.033 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.03 -11.65 40.83 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.9 t -118.24 126.52 75.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.137 -1.213 . . . . 0.0 109.686 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ALA . . . . . 0.457 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -96.7 123.53 40.42 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.512 -0.743 . . . . 0.0 110.627 -179.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -105.8 -18.46 14.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.723 -0.611 . . . . 0.0 110.392 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.6 158.77 44.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 109.821 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -130.07 -173.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.481 -0.762 . . . . 0.0 110.518 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -146.44 127.17 14.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.705 -0.622 . . . . 0.0 109.444 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -127.42 156.22 42.42 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.453 -0.779 . . . . 0.0 110.946 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.779 HG11 HD11 ' A' ' 82' ' ' LEU . 63.2 t -92.82 121.41 66.01 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -64.17 154.92 68.06 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.79 1.416 . . . . 0.0 110.496 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 151' ' ' VAL . 97.1 t -58.97 -24.06 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.612 -0.68 . . . . 0.0 110.531 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -59.85 -40.08 87.33 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.365 -0.835 . . . . 0.0 110.346 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 22.4 t -63.42 -38.42 91.06 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.476 -0.765 . . . . 0.0 110.144 179.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.568 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 93.3 mtp -60.0 -41.58 92.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.631 -0.668 . . . . 0.0 110.317 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.13 -40.08 78.5 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.567 -0.708 . . . . 0.0 110.162 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.1 m -61.06 -39.98 91.92 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.627 -0.671 . . . . 0.0 110.156 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.6 m -60.14 -40.36 89.55 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.542 -0.724 . . . . 0.0 110.114 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -68.25 -39.98 82.08 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.594 -0.691 . . . . 0.0 110.169 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 27.1 mmt180 -65.13 -40.07 93.93 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.569 -0.707 . . . . 0.0 110.137 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.459 ' HB1' ' HB2' ' A' ' 185' ' ' LYS . . . -60.22 -40.82 91.5 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.607 -0.683 . . . . 0.0 110.281 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.99 -164.72 0.06 Allowed 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.429 -0.794 . . . . 0.0 110.947 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -63.44 -27.7 69.47 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.624 -0.672 . . . . 0.0 110.531 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -59.97 -39.97 87.47 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.501 -0.75 . . . . 0.0 110.469 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' LYS . . . . . 0.459 ' HB2' ' HB1' ' A' ' 181' ' ' ALA . 58.3 mttm -119.95 140.04 51.52 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.57 -0.706 . . . . 0.0 110.21 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 22.0 pttm . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.283 -179.973 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.681 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 41.2 tt0 -119.96 137.94 53.77 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 118.744 -1.183 . . . . 0.0 110.058 . . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.793 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp -89.09 141.53 28.42 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.683 . . . . 0.0 110.245 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.467 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 m . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.107 0.479 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.01 177.44 54.3 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.3 mtt180 -100.19 125.86 46.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.526 -0.984 . . . . 0.0 110.193 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.67 -40.0 90.5 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.539 -0.726 . . . . 0.0 110.24 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 ttmm 56.75 167.94 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.148 0 O-C-N 121.507 -0.745 . . . . 0.0 110.586 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -80.42 166.97 20.74 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.47 -0.769 . . . . 0.0 110.338 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -70.07 140.74 52.83 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.555 -0.715 . . . . 0.0 110.155 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.6 p -139.0 140.39 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.623 -0.673 . . . . 0.0 110.21 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -94.38 139.84 30.59 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.567 -0.708 . . . . 0.0 110.197 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -131.03 31.23 3.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.815 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 -59.93 -37.29 79.08 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.518 -0.99 . . . . 0.0 110.313 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.815 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.6 t -120.34 129.61 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.546 -0.721 . . . . 0.0 109.77 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -129.99 158.35 39.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.517 -0.739 . . . . 0.0 110.451 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.78 125.28 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.696 -0.628 . . . . 0.0 109.413 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.557 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.6 m -124.79 158.16 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.577 -0.702 . . . . 0.0 110.159 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.5 m -133.36 173.04 11.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.684 -0.635 . . . . 0.0 110.556 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.449 HG22 ' N ' ' A' ' 39' ' ' ALA . 35.0 m -139.69 171.54 14.08 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.449 ' N ' HG22 ' A' ' 38' ' ' THR . . . -56.09 -28.18 56.69 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.438 -0.789 . . . . 0.0 111.204 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.0 m -135.37 -7.26 2.26 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.263 -0.898 . . . . 0.0 112.597 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.7 mm-40 -129.98 159.17 37.48 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.89 -1.131 . . . . 0.0 111.69 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 68.1 m -132.12 133.98 44.92 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.419 ' HE1' ' HG1' ' A' ' 38' ' ' THR . 6.9 p90 -164.67 -177.4 4.76 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.242 -0.911 . . . . 0.0 111.068 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.86 HD11 ' HA ' ' A' ' 109' ' ' ARG . 51.6 mt -112.63 146.61 38.32 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.666 -0.647 . . . . 0.0 110.279 -178.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -111.24 161.01 16.44 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.58 -0.7 . . . . 0.0 110.165 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 63.6 p -125.16 143.38 50.96 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.593 -0.692 . . . . 0.0 110.314 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 93.3 m -102.85 113.18 26.4 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.574 -0.704 . . . . 0.0 110.501 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.3 130.0 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.658 -0.652 . . . . 0.0 109.428 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 55.49 36.68 27.64 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.421 -0.799 . . . . 0.0 110.76 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.803 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.69 19.16 74.67 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -132.36 130.05 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.202 -1.175 . . . . 0.0 109.998 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.5 m -78.21 144.97 35.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.483 -0.761 . . . . 0.0 109.514 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -128.36 151.41 49.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.525 -0.734 . . . . 0.0 110.863 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -167.77 -179.8 4.43 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.843 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.9 p -95.29 154.2 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.816 . . . . 0.0 110.562 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.7 t80 -69.95 -40.12 75.63 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.683 -0.636 . . . . 0.0 111.873 -178.87 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.843 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.4 p-80 -68.26 -24.35 64.88 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.135 -0.978 . . . . 0.0 110.499 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.697 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -82.64 -59.12 2.27 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.49 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -102.37 -47.95 4.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.069 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 66.0 -165.68 37.85 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.2 m -83.72 64.42 7.99 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.582 -0.952 . . . . 0.0 109.951 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -140.02 164.84 28.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.514 -0.741 . . . . 0.0 110.324 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.3 t -65.37 140.05 58.62 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.578 -0.701 . . . . 0.0 110.05 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.923 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.5 tp -109.9 130.54 55.51 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.658 -0.651 . . . . 0.0 110.178 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.46 118.45 30.57 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.578 -0.701 . . . . 0.0 110.106 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -122.89 177.74 16.48 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.63 -31.98 69.57 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.795 1.419 . . . . 0.0 110.338 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 61.0 tptt -70.55 -31.55 68.64 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.606 -0.684 . . . . 0.0 109.633 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.01 -150.41 22.01 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.79 155.75 53.51 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.891 1.469 . . . . 0.0 110.228 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.441 ' CD1' HD23 ' A' ' 64' ' ' LEU . 85.1 mt -125.91 139.94 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.555 -0.715 . . . . 0.0 110.272 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 73.1 m -94.39 137.9 32.99 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.413 -0.804 . . . . 0.0 110.265 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -70.16 139.96 52.49 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.575 -0.703 . . . . 0.0 110.599 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.82 -51.3 2.66 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.564 -0.71 . . . . 0.0 109.952 179.463 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -120.03 140.06 51.56 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.514 -0.742 . . . . 0.0 110.213 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.6 p -131.64 137.61 48.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.497 -0.752 . . . . 0.0 110.367 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -150.04 90.72 1.7 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.578 -0.702 . . . . 0.0 110.215 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CE1' ' A' ' 56' ' ' TYR . 85.9 t -68.04 -42.33 85.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.543 -0.723 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.91 -42.8 94.66 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.717 . . . . 0.0 110.27 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 82' ' ' LEU . 39.0 tp60 -89.98 0.12 57.27 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.537 -0.727 . . . . 0.0 110.93 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.443 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.65 44.63 29.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.059 -1.026 . . . . 0.0 110.687 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.615 HD11 HG11 ' A' ' 170' ' ' VAL . 70.9 mt -140.25 144.37 36.45 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.407 -0.808 . . . . 0.0 110.923 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.584 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.8 m -148.2 155.64 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.578 -0.701 . . . . 0.0 109.452 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -139.95 161.25 26.33 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 9.2 m-90 -117.75 160.06 21.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.751 -0.852 . . . . 0.0 109.565 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -74.54 104.42 5.24 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.463 -0.773 . . . . 0.0 109.677 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.37 130.04 88.16 Favored Pre-proline 0 N--CA 1.494 1.775 0 O-C-N 121.541 -0.724 . . . . 0.0 110.239 -179.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.08 159.98 51.24 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.827 1.435 . . . . 0.0 110.271 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.9 157.71 51.04 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.968 1.51 . . . . 0.0 110.319 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.9 -24.86 30.52 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.03 159.99 26.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.445 -1.032 . . . . 0.0 110.159 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 83.6 mtt180 -100.39 159.31 15.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.59 -0.694 . . . . 0.0 110.109 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.3 p -129.91 170.03 14.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.511 -0.743 . . . . 0.0 110.271 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.73 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 2.4 mm? -102.48 138.49 39.32 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.635 -0.666 . . . . 0.0 110.505 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.428 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 4.8 p -76.05 160.03 79.25 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.629 -0.669 . . . . 0.0 109.946 179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.55 153.32 30.41 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.779 1.41 . . . . 0.0 110.6 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.773 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.4 t -68.73 135.11 50.77 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.543 -0.723 . . . . 0.0 110.131 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.5 t -136.1 52.07 2.0 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.708 -0.62 . . . . 0.0 109.692 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.83 -8.51 0.72 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.542 -0.723 . . . . 0.0 112.405 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.96 33.84 80.66 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 p -88.15 139.64 30.29 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.533 -0.981 . . . . 0.0 110.411 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.5 m -82.1 -30.0 31.46 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.646 -0.659 . . . . 0.0 110.353 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -66.62 129.87 41.3 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.502 -0.749 . . . . 0.0 110.162 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.582 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.6 mt -137.14 139.81 41.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.7 . . . . 0.0 110.631 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.5 120.51 42.39 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.56 -0.713 . . . . 0.0 109.862 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.4 tp -103.1 140.06 37.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.5 -0.75 . . . . 0.0 110.488 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.506 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.6 t -90.44 138.66 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.585 -0.697 . . . . 0.0 109.758 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 13.5 m -110.2 159.48 17.34 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.519 -0.738 . . . . 0.0 110.489 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.86 ' HA ' HD11 ' A' ' 44' ' ' LEU . 2.7 ttp180 -60.1 -21.37 61.42 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.588 -0.695 . . . . 0.0 110.63 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.07 27.45 3.2 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.267 -0.896 . . . . 0.0 110.528 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.61 39.98 31.56 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.39 -0.819 . . . . 0.0 110.622 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -124.21 139.59 53.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.656 -0.653 . . . . 0.0 109.737 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' A' ' 107' ' ' VAL . 34.5 m -126.13 139.09 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.482 -0.761 . . . . 0.0 110.59 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.552 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.2 mp -124.52 150.05 63.6 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.733 -0.604 . . . . 0.0 109.559 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 114' ' ' ILE . 46.8 Cg_endo -79.15 133.41 10.94 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.888 1.468 . . . . 0.0 110.492 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 125' ' ' SER . 62.7 t -130.02 129.99 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.671 -0.643 . . . . 0.0 109.653 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.4 tpt180 -85.38 150.0 25.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.52 -0.738 . . . . 0.0 110.193 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -91.15 119.96 31.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.65 -0.656 . . . . 0.0 110.336 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -110.21 20.02 18.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.608 -0.683 . . . . 0.0 110.508 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.11 -174.26 43.59 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -65.8 -39.94 91.41 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.999 . . . . 0.0 110.245 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.6 p -130.74 24.52 5.04 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.553 -0.717 . . . . 0.0 110.535 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -124.93 139.96 53.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 110.36 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.37 165.79 25.67 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 116' ' ' VAL . 91.1 p -115.86 153.78 30.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.463 -1.022 . . . . 0.0 110.152 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.411 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.2 tp -99.72 119.96 38.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.584 -0.697 . . . . 0.0 110.193 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.527 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -68.96 -38.51 79.45 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.527 -0.733 . . . . 0.0 109.863 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.0 m -110.0 113.84 56.68 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.677 -0.639 . . . . 0.0 110.051 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -64.66 118.52 5.49 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.799 1.421 . . . . 0.0 110.523 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -122.44 160.02 50.05 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.626 -0.671 . . . . 0.0 110.211 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -66.15 154.88 72.37 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.913 1.481 . . . . 0.0 110.42 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 90.6 t -61.63 -39.97 85.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.607 -0.683 . . . . 0.0 110.126 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.3 p -56.14 -33.85 65.56 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.476 -0.765 . . . . 0.0 110.663 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -60.02 -39.95 87.64 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.556 -0.715 . . . . 0.0 110.107 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.5 mp -84.82 -20.95 30.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.542 -0.724 . . . . 0.0 110.931 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -59.9 139.85 57.08 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.251 -0.906 . . . . 0.0 110.117 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.66 10.05 86.19 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 18.2 m -116.14 10.3 14.93 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.19 -1.182 . . . . 0.0 110.884 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.2 t -65.0 150.49 47.98 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.164 -0.96 . . . . 0.0 109.597 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 95.56 -22.23 40.18 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.5 148.57 21.04 Favored Glycine 0 N--CA 1.498 2.83 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -98.8 147.57 0.58 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.889 1.468 . . . . 0.0 111.024 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.38 108.33 19.91 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.77 129.94 45.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.456 -0.777 . . . . 0.0 111.296 -178.691 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.03 158.31 87.67 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.0 Cg_endo -51.87 -25.36 21.22 Favored 'Trans proline' 0 N--CA 1.501 1.918 0 O-C-N 123.547 1.288 . . . . 0.0 112.343 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.2 m -62.74 -40.0 95.85 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.266 -0.896 . . . . 0.0 109.886 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.06 36.86 0.79 Allowed Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' HIS . . . . . 0.428 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 4.3 m-70 -132.95 143.69 49.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.445 -1.033 . . . . 0.0 110.188 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.73 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -65.42 142.33 58.23 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.523 -0.736 . . . . 0.0 110.233 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.773 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -115.34 -38.06 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.579 -0.701 . . . . 0.0 110.043 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.09 -168.38 36.23 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.693 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.8 mt -129.89 140.02 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.469 -1.018 . . . . 0.0 110.379 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.0 t80 -63.75 139.77 58.8 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.677 -0.639 . . . . 0.0 110.11 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.5 ttt180 -119.9 -52.42 2.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.57 -0.706 . . . . 0.0 110.331 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.28 158.77 44.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.514 -0.742 . . . . 0.0 110.335 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -113.94 152.02 31.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.619 -0.676 . . . . 0.0 110.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.86 119.77 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.736 -0.603 . . . . 0.0 109.692 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.26 144.22 51.14 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.721 -0.612 . . . . 0.0 110.373 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.5 m -69.86 -49.77 49.14 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.619 -0.676 . . . . 0.0 110.056 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -163.65 54.17 0.16 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.711 -0.618 . . . . 0.0 109.854 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.32 -16.51 17.33 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.15 125.15 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.228 -1.16 . . . . 0.0 109.661 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -95.3 123.05 38.61 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.591 -0.693 . . . . 0.0 110.578 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -105.2 -21.31 13.28 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.601 -0.687 . . . . 0.0 110.274 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.94 159.12 43.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.365 -0.834 . . . . 0.0 109.913 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 19.7 m -131.53 -175.73 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.551 -0.718 . . . . 0.0 110.519 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -142.93 132.18 23.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.77 -0.581 . . . . 0.0 109.595 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -133.23 155.79 48.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.523 -0.736 . . . . 0.0 110.894 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 82' ' ' LEU . 62.9 t -92.7 124.27 59.29 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.564 -0.71 . . . . 0.0 109.332 179.246 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.49 150.31 75.29 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.721 1.379 . . . . 0.0 110.675 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 151' ' ' VAL . 95.0 t -59.48 -24.04 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.666 -0.646 . . . . 0.0 110.408 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -59.12 -39.58 82.76 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.382 -0.824 . . . . 0.0 110.314 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.4 p -60.01 -39.34 85.5 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.555 -0.716 . . . . 0.0 110.212 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.693 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.7 mtt -59.92 -40.46 88.94 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 110.452 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.28 -40.02 88.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.675 -0.64 . . . . 0.0 110.281 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.4 m -60.76 -40.4 92.35 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.472 -0.767 . . . . 0.0 110.106 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -69.86 -41.03 75.4 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.58 -0.7 . . . . 0.0 110.079 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -68.7 -39.99 80.23 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.594 -0.691 . . . . 0.0 110.348 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -61.39 -39.91 92.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.22 -50.97 71.54 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.599 -0.688 . . . . 0.0 110.301 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 2.9 m 50.14 40.01 20.81 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.465 -0.772 . . . . 0.0 111.073 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -131.24 147.17 52.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.532 -0.73 . . . . 0.0 110.169 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -100.11 29.19 4.39 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.378 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.536 -0.728 . . . . 0.0 110.249 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.289 -179.973 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -119.68 130.03 54.84 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.074 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.833 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp -71.08 139.98 50.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.0 110.343 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.568 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 59.5 m . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.076 0.465 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.0 -26.29 25.04 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -133.49 136.86 45.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.436 -1.038 . . . . 0.0 110.18 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.5 t0 52.43 45.43 28.54 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.383 -0.823 . . . . 0.0 110.812 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -60.82 -40.56 93.19 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.455 -0.778 . . . . 0.0 110.395 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -139.96 24.68 2.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.496 -0.753 . . . . 0.0 110.751 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -92.67 118.82 31.45 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.458 -0.776 . . . . 0.0 110.229 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 66.7 t -70.13 -50.01 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.612 -0.68 . . . . 0.0 110.13 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -160.03 160.24 33.0 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.497 -0.752 . . . . 0.0 110.471 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -141.52 29.58 2.25 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.81 ' HG3' HG23 ' A' ' 33' ' ' VAL . 17.5 pt-20 -60.23 -37.2 79.61 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -1.009 . . . . 0.0 110.553 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.81 HG23 ' HG3' ' A' ' 32' ' ' GLU . 82.7 t -116.86 128.54 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.401 -0.812 . . . . 0.0 109.663 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -129.27 154.44 46.83 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.533 -0.729 . . . . 0.0 110.6 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -91.74 128.36 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.602 ' HB ' HD21 ' A' ' 64' ' ' LEU . 27.0 m -126.17 159.69 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.614 -0.679 . . . . 0.0 110.36 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 58.6 m -137.85 162.48 33.87 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.517 0.675 . . . . 0.0 111.032 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.2 m -134.51 169.37 17.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.792 -0.567 . . . . 0.0 109.678 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -67.11 -12.67 60.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 111.323 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 48.6 p -118.39 -30.53 5.2 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.042 -1.036 . . . . 0.0 111.555 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -159.17 170.04 22.83 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.202 -0.936 . . . . 0.0 110.967 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 t -123.88 155.23 38.46 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.489 -0.757 . . . . 0.0 110.574 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.628 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 16.8 p90 -166.26 -177.71 4.22 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.546 -0.721 . . . . 0.0 110.091 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.554 HD11 ' HA ' ' A' ' 109' ' ' ARG . 63.7 mt -113.28 153.78 27.87 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.523 -0.736 . . . . 0.0 110.443 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -127.89 161.09 29.89 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.557 -0.714 . . . . 0.0 110.356 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.642 HG23 HD12 ' A' ' 94' ' ' LEU . 86.9 m -120.04 130.23 54.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.635 -0.666 . . . . 0.0 110.108 -179.819 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.4 t -89.94 104.0 16.61 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.628 -0.67 . . . . 0.0 110.42 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.436 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.3 t -111.06 132.81 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.479 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.77 38.71 29.67 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.559 -0.713 . . . . 0.0 110.678 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.676 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 20.07 75.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.4 t -132.31 129.89 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.234 -1.156 . . . . 0.0 110.079 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 5.2 t -71.81 146.49 47.97 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.539 -0.726 . . . . 0.0 109.433 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.627 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 59.5 m95 -129.4 151.05 50.46 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.474 -0.766 . . . . 0.0 111.273 -179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.877 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -169.78 -179.81 3.43 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.836 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.1 p -94.53 156.36 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.423 -0.798 . . . . 0.0 110.073 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.2 t80 -70.04 -42.35 73.02 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.548 -0.72 . . . . 0.0 111.79 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.836 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.5 p-80 -64.77 -20.76 66.54 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.144 -0.973 . . . . 0.0 110.643 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.603 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -86.84 -47.69 4.69 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.628 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -125.41 90.98 3.32 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.679 -0.895 . . . . 0.0 109.942 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.42 -169.99 2.0 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 20.4 p -72.22 66.93 0.66 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.438 -1.036 . . . . 0.0 109.555 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.62 166.8 23.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.62 -0.675 . . . . 0.0 110.729 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.2 m -65.58 139.62 58.46 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.778 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.904 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -108.32 132.72 53.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.636 -0.665 . . . . 0.0 110.11 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.7 118.37 30.6 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.549 -0.719 . . . . 0.0 110.36 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.09 -176.91 18.25 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.132 -1.587 . . . . 0.0 109.132 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.51 -32.51 70.36 Favored 'Trans proline' 0 N--CA 1.491 1.35 0 O-C-N 123.836 1.44 . . . . 0.0 110.579 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 76.0 tttt -75.46 -31.11 60.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.598 -0.689 . . . . 0.0 109.974 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.3 -140.26 9.22 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.06 156.93 47.14 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 O-C-N 123.806 1.424 . . . . 0.0 110.25 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.516 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.4 mt -127.41 139.99 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.065 -179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 p -88.46 150.76 22.97 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.755 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -96.75 140.03 31.94 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.612 -0.68 . . . . 0.0 110.441 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.6 mmm -119.29 -32.77 4.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.577 -0.702 . . . . 0.0 110.856 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -132.75 149.97 52.21 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.405 -0.809 . . . . 0.0 110.869 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.3 p -143.56 137.86 28.71 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.672 -0.643 . . . . 0.0 110.026 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.401 ' OD1' HG23 ' A' ' 178' ' ' THR . 1.6 m120 -150.02 93.92 2.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.467 -0.771 . . . . 0.0 110.169 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CE1' ' A' ' 56' ' ' TYR . 88.0 t -69.96 -43.06 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -59.87 -45.46 92.41 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.514 -0.741 . . . . 0.0 110.608 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.765 ' HG2' HD12 ' A' ' 82' ' ' LEU . 51.4 tt0 -85.71 -0.07 54.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.579 -0.7 . . . . 0.0 110.737 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.441 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.3 t70 53.73 45.29 28.26 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.036 -1.04 . . . . 0.0 110.704 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.765 HD12 ' HG2' ' A' ' 80' ' ' GLN . 57.6 mt -142.24 146.89 35.65 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.524 -0.735 . . . . 0.0 110.924 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.522 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -149.24 160.0 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.555 -0.715 . . . . 0.0 109.735 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.34 153.75 24.18 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.904 ' CH2' HD22 ' A' ' 64' ' ' LEU . 7.5 m-90 -114.58 168.09 10.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.668 -0.901 . . . . 0.0 109.535 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -77.57 110.05 12.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -0.788 . . . . 0.0 109.268 179.097 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.676 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.05 129.98 90.26 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.598 -0.689 . . . . 0.0 110.204 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.96 159.95 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 123.791 1.416 . . . . 0.0 110.28 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.35 160.14 50.54 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.961 1.506 . . . . 0.0 110.285 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 84.49 28.75 31.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.99 150.03 49.61 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.527 -0.984 . . . . 0.0 110.094 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -100.02 119.98 39.11 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.521 -0.737 . . . . 0.0 110.342 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.5 p -81.24 170.03 16.59 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.656 -0.653 . . . . 0.0 110.161 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.642 HD12 HG23 ' A' ' 46' ' ' THR . 79.3 mt -109.57 131.85 54.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.586 -0.696 . . . . 0.0 110.807 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.7 p -72.74 160.06 83.8 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.576 -0.703 . . . . 0.0 109.95 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.36 164.44 24.08 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.87 1.458 . . . . 0.0 110.594 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.538 ' HB2' HG22 ' A' ' 151' ' ' VAL . 54.1 t -80.16 129.99 34.9 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.537 -0.727 . . . . 0.0 110.241 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -133.24 55.79 1.88 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.646 -0.659 . . . . 0.0 109.522 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.95 -8.12 0.72 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.607 -0.683 . . . . 0.0 112.394 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.06 35.27 91.2 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -84.97 113.07 21.14 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.513 -0.992 . . . . 0.0 110.485 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -60.03 -40.01 87.88 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.64 -0.662 . . . . 0.0 110.342 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -64.89 138.66 58.51 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.55 -0.719 . . . . 0.0 110.414 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.47 ' CD2' HG11 ' A' ' 151' ' ' VAL . 91.5 mt -135.58 150.0 49.57 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.615 -0.678 . . . . 0.0 110.319 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -117.84 114.4 23.2 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.583 -0.698 . . . . 0.0 109.857 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 143' ' ' LEU . 40.2 tp -96.5 145.64 25.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.568 -0.707 . . . . 0.0 110.467 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.01 128.69 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.662 -0.649 . . . . 0.0 109.928 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 71.1 p -105.12 -178.59 3.7 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.597 -0.69 . . . . 0.0 110.441 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.554 ' HA ' HD11 ' A' ' 44' ' ' LEU . 55.0 mtp180 -69.76 -20.95 63.48 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.562 -0.711 . . . . 0.0 110.808 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.81 21.24 4.96 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.356 -0.84 . . . . 0.0 110.908 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.12 39.93 31.16 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.154 -0.966 . . . . 0.0 110.622 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -106.4 168.32 9.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.588 -0.695 . . . . 0.0 110.008 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.97 129.97 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.559 -0.713 . . . . 0.0 110.183 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.601 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -119.62 109.28 38.35 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.633 -0.667 . . . . 0.0 109.87 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -65.16 109.83 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.764 1.402 . . . . 0.0 110.263 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.2 t -110.83 124.12 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.608 -0.683 . . . . 0.0 109.937 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 35.1 mmm-85 -79.75 155.22 28.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.586 -0.696 . . . . 0.0 110.175 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -98.18 119.69 37.28 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -122.64 22.63 9.8 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.23 -176.95 47.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -70.07 -40.04 75.29 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.506 -0.997 . . . . 0.0 110.532 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -131.0 29.07 4.74 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.449 -0.782 . . . . 0.0 110.686 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -138.44 162.5 34.31 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.451 -0.78 . . . . 0.0 110.474 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -162.24 -179.39 36.83 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 79.4 p -120.92 149.01 43.28 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.542 -0.975 . . . . 0.0 110.232 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.446 HD11 ' CG2' ' A' ' 114' ' ' ILE . 19.4 tp -93.44 119.28 32.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.591 -0.693 . . . . 0.0 109.996 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.7 mp -65.02 -39.95 94.16 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.593 -0.692 . . . . 0.0 109.959 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.3 p -110.87 119.97 44.72 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.601 -0.687 . . . . 0.0 110.033 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.23 117.74 5.05 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.736 1.388 . . . . 0.0 110.281 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 13.1 mmt85 -120.59 160.0 45.97 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.56 -0.712 . . . . 0.0 110.197 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.58 159.21 54.41 Favored 'Trans proline' 0 N--CA 1.489 1.255 0 O-C-N 123.875 1.461 . . . . 0.0 110.475 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.495 HG11 ' OE1' ' B' ' 188' ' ' GLU . 92.5 t -64.66 -33.15 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.538 -0.726 . . . . 0.0 109.98 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 56.0 m -60.07 -38.09 81.82 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.588 -0.695 . . . . 0.0 110.223 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -60.05 -40.04 88.02 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.559 -0.713 . . . . 0.0 110.212 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.3 mp -83.6 -23.34 31.96 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.529 -0.732 . . . . 0.0 110.756 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.11 140.06 57.12 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.339 -0.851 . . . . 0.0 110.246 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.05 4.2 89.63 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.8 m -109.53 -0.89 18.59 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.075 -1.25 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 31.0 t -60.01 141.47 55.59 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.108 -0.995 . . . . 0.0 109.754 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 100.05 -19.79 51.64 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.75 147.05 44.0 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.547 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.1 Cg_endo -92.38 144.78 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.925 1.487 . . . . 0.0 111.181 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.35 111.11 23.25 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.65 131.72 45.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.526 -0.733 . . . . 0.0 111.453 -178.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.05 160.03 82.06 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -52.0 -22.88 15.47 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 O-C-N 123.532 1.28 . . . . 0.0 112.161 -178.684 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.66 -40.03 88.45 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.225 -0.922 . . . . 0.0 109.881 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.19 35.66 0.86 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 20.1 m-70 -132.03 148.14 52.49 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.467 -1.019 . . . . 0.0 110.445 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.71 143.51 57.34 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.599 -0.688 . . . . 0.0 110.273 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 172' ' ' VAL . 54.4 t -118.29 -40.87 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.536 -0.727 . . . . 0.0 110.052 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.57 -175.59 41.41 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.0 mt -122.91 130.34 74.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.535 -0.979 . . . . 0.0 110.391 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.434 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 23.1 t80 -60.34 134.6 57.22 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.55 -0.719 . . . . 0.0 109.818 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.7 ttt180 -113.24 -52.13 2.78 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.458 -0.777 . . . . 0.0 110.443 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -155.09 160.01 40.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.44 -0.787 . . . . 0.0 110.558 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.434 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -111.73 153.71 26.08 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.614 -0.679 . . . . 0.0 110.193 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.05 118.99 58.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.625 -0.672 . . . . 0.0 109.751 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -132.99 149.29 52.24 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.654 -0.654 . . . . 0.0 110.307 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.7 p -82.26 -42.9 18.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.645 -0.659 . . . . 0.0 110.61 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -160.34 59.93 0.34 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.131 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 98.75 -10.01 62.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.33 122.25 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.134 -1.215 . . . . 0.0 109.843 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.57 126.12 41.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.68 -0.637 . . . . 0.0 110.78 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 47.5 mmtt -107.14 -25.45 11.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.733 -0.605 . . . . 0.0 110.118 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.73 154.54 46.37 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.728 . . . . 0.0 110.04 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 26.8 m -126.21 -171.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.557 -0.714 . . . . 0.0 110.786 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -146.93 134.57 21.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.69 -0.631 . . . . 0.0 109.444 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -137.48 159.19 42.64 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.446 -0.784 . . . . 0.0 110.8 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.618 HG11 HD11 ' A' ' 82' ' ' LEU . 65.5 t -98.42 121.2 57.49 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -62.37 159.94 33.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.711 1.374 . . . . 0.0 110.517 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.4 t -69.39 -27.09 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.615 -0.678 . . . . 0.0 110.829 -179.304 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -58.18 -39.67 79.5 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.366 -0.834 . . . . 0.0 110.7 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 89.3 p -67.08 -38.46 85.77 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.454 -0.779 . . . . 0.0 110.246 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.627 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 87.9 mtp -60.0 -40.04 87.85 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.489 -0.757 . . . . 0.0 110.319 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -64.27 -40.01 95.11 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.506 -0.746 . . . . 0.0 110.3 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.5 m -67.93 -28.78 67.77 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.713 -0.617 . . . . 0.0 110.372 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' THR . . . . . 0.401 HG23 ' OD1' ' A' ' 77' ' ' ASN . 94.1 m -59.97 -40.07 87.83 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.571 -0.706 . . . . 0.0 110.272 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.5 mtt -61.55 -41.87 98.0 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -69.97 -39.95 75.67 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.556 -0.715 . . . . 0.0 110.234 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -81.72 -12.67 58.52 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.571 -0.706 . . . . 0.0 111.093 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.4 t -59.98 -50.03 75.35 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.242 -0.911 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 85.3 tttt 50.64 71.16 0.44 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.338 -0.851 . . . . 0.0 110.93 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -60.02 136.29 57.97 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.469 -0.769 . . . . 0.0 110.372 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -129.34 27.35 5.33 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.617 -0.677 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.6 tptm . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.053 -179.961 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.622 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 -119.98 140.01 51.61 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 118.731 -1.188 . . . . 0.0 110.071 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.829 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp -83.94 140.79 31.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 110.45 -179.767 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.46 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 22' ' ' THR . . . . . 0.412 HG23 ' O ' ' A' ' 22' ' ' THR . 7.5 t . . . . . 0 N--CA 1.493 1.683 0 CA-C-O 121.078 0.466 . . . . 0.0 110.281 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 160.05 44.58 0.02 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -99.89 120.44 39.78 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.616 -0.932 . . . . 0.0 110.208 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -128.07 26.82 5.74 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.568 -0.707 . . . . 0.0 110.431 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.1 tptt 57.0 -160.0 0.23 Allowed 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.346 -0.846 . . . . 0.0 110.317 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 m120 -69.43 -39.96 77.53 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.562 -0.712 . . . . 0.0 110.446 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -75.91 158.64 31.81 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.55 -0.719 . . . . 0.0 110.255 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -109.97 9.95 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.5 -0.75 . . . . 0.0 111.074 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -151.56 160.0 43.86 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.17 -0.956 . . . . 0.0 110.203 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.92 88.15 0.07 OUTLIER Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.403 ' HG2' ' CB ' ' A' ' 92' ' ' ARG . 62.9 mt-10 -62.14 -34.88 77.21 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.549 -0.971 . . . . 0.0 110.047 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.497 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.2 t -105.58 127.21 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.538 -0.726 . . . . 0.0 109.959 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -116.28 150.14 38.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.586 -0.696 . . . . 0.0 110.334 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 35' ' ' VAL . 12.5 p -79.72 129.02 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.63 -0.669 . . . . 0.0 110.04 179.739 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.727 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.4 m -125.14 154.29 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 110.031 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.5 m -149.84 171.48 16.69 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.016 -0.673 . . . . 0.0 110.511 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.9 p -140.93 -173.35 3.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.766 -0.584 . . . . 0.0 109.434 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.34 -0.81 26.99 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.497 -0.752 . . . . 0.0 111.219 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.4 m -118.59 -46.75 2.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.109 -0.994 . . . . 0.0 111.359 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -147.76 171.18 16.09 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.268 -0.895 . . . . 0.0 111.407 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 32.1 t -119.15 146.65 44.98 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.664 -0.647 . . . . 0.0 109.926 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.609 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 15.1 p90 -158.17 -176.44 5.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.486 -0.758 . . . . 0.0 110.215 -179.548 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.765 HD11 ' HA ' ' A' ' 109' ' ' ARG . 42.0 mt -111.54 167.65 10.16 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.565 -0.709 . . . . 0.0 110.338 -178.309 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.497 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -142.91 155.69 44.77 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.698 -0.626 . . . . 0.0 110.039 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.529 HG21 ' HB3' ' A' ' 142' ' ' PRO . 73.4 p -120.28 129.45 54.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.453 -0.78 . . . . 0.0 110.177 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 35.0 t -91.13 107.42 19.19 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.514 -0.741 . . . . 0.0 110.517 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' HB2' ' A' ' 94' ' ' LEU . 57.6 t -115.29 135.87 53.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.624 -0.673 . . . . 0.0 109.552 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 54.78 37.42 28.41 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.536 -0.727 . . . . 0.0 111.021 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 23.14 77.35 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.6 t -138.25 129.91 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.248 -1.148 . . . . 0.0 110.089 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' CYS . . . . . 0.411 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 4.0 t -68.45 148.47 50.59 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.418 -0.801 . . . . 0.0 109.454 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 48.8 m95 -140.08 142.95 36.08 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.197 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.666 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.9 t -170.07 -178.6 2.9 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.818 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.7 p -83.23 159.01 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 110.401 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CD1' ' HA2' ' A' ' 60' ' ' GLY . 55.5 t80 -76.99 -40.03 48.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.67 -0.644 . . . . 0.0 112.069 -178.805 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.872 ' CG ' HD23 ' B' ' 189' ' ' LEU . 2.9 p-80 -61.0 -24.67 66.32 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.113 -0.992 . . . . 0.0 110.848 -178.626 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.446 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -74.75 -49.01 11.17 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.609 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -114.86 -55.56 2.47 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.561 -0.964 . . . . 0.0 110.458 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 85.09 -172.33 47.44 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 47.8 t -80.14 65.13 5.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.526 -0.985 . . . . 0.0 109.848 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -141.81 170.06 16.43 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.587 -0.696 . . . . 0.0 110.267 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.1 m -65.57 139.77 58.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.527 -0.733 . . . . 0.0 109.851 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.727 HD21 ' HB ' ' A' ' 36' ' ' VAL . 20.4 tp -108.81 141.02 41.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.692 -0.63 . . . . 0.0 110.099 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.15 111.56 23.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.57 -0.706 . . . . 0.0 110.166 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.12 -178.29 18.23 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -62.1 -31.96 83.37 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 O-C-N 123.765 1.403 . . . . 0.0 110.518 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.4 tttt -74.61 -31.27 61.97 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.669 -0.644 . . . . 0.0 109.769 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.33 -154.38 23.45 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.41 146.82 69.86 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 O-C-N 123.816 1.43 . . . . 0.0 109.953 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -130.3 139.98 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.514 -0.741 . . . . 0.0 110.599 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.3 m -89.83 139.9 30.13 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.563 -0.711 . . . . 0.0 110.211 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 pp0? -83.2 150.25 26.33 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.519 -0.738 . . . . 0.0 111.383 -179.348 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.404 ' CE ' ' HA ' ' A' ' 186' ' ' LYS . 94.2 mtp -110.37 -29.93 7.9 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.821 -0.549 . . . . 0.0 109.944 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -131.76 148.39 52.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.72 -0.613 . . . . 0.0 110.459 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.15 125.98 11.17 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.663 -0.648 . . . . 0.0 109.628 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -141.92 95.57 2.83 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.528 -0.733 . . . . 0.0 110.152 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 91.9 t -61.43 -44.67 98.95 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.673 -0.642 . . . . 0.0 109.921 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.15 -48.75 80.39 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.551 -0.718 . . . . 0.0 110.256 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.679 ' CG ' HD12 ' A' ' 82' ' ' LEU . 3.0 tp-100 -80.07 -9.15 59.68 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.66 -0.65 . . . . 0.0 110.478 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 5.7 t0 56.79 48.18 16.63 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.22 -0.925 . . . . 0.0 110.422 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.679 HD12 ' CG ' ' A' ' 80' ' ' GLN . 81.3 mt -137.96 149.83 46.49 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.48 -0.762 . . . . 0.0 110.892 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -150.05 149.97 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.611 -0.68 . . . . 0.0 109.493 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -133.86 149.55 19.75 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.335 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.713 ' CZ3' HD22 ' A' ' 64' ' ' LEU . 5.3 m-90 -120.16 168.19 11.47 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.68 -0.894 . . . . 0.0 110.204 179.516 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -72.86 120.42 18.46 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.455 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -68.98 132.24 90.5 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.448 -0.782 . . . . 0.0 109.958 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.99 157.07 61.15 Favored 'Trans proline' 0 N--CA 1.49 1.294 0 O-C-N 123.84 1.442 . . . . 0.0 110.478 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.56 160.23 48.94 Favored 'Trans proline' 0 N--CA 1.49 1.282 0 O-C-N 123.936 1.493 . . . . 0.0 110.185 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 29.97 70.44 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.04 160.87 22.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.6 -0.941 . . . . 0.0 110.106 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.403 ' CB ' ' HG2' ' A' ' 32' ' ' GLU . 75.1 mtp85 -105.19 153.75 21.13 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 110.275 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 54.5 m -111.3 160.9 16.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.605 -0.684 . . . . 0.0 110.294 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.486 ' HB2' HG22 ' A' ' 48' ' ' VAL . 84.5 mt -100.31 131.85 46.01 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.595 -0.691 . . . . 0.0 110.524 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.3 p -77.04 159.95 77.27 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.608 -0.682 . . . . 0.0 110.006 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -85.57 158.24 10.71 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 O-C-N 123.799 1.421 . . . . 0.0 110.54 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.4 t -79.81 129.75 34.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.587 -0.695 . . . . 0.0 110.087 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' THR . 6.8 t -132.88 56.45 1.85 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.677 -0.64 . . . . 0.0 109.678 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.87 -8.1 0.73 Allowed 'General case' 0 N--CA 1.497 1.913 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.252 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.92 46.09 94.73 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.98 119.77 38.77 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.518 -0.989 . . . . 0.0 110.45 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -62.95 -40.03 96.43 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.703 -0.623 . . . . 0.0 110.355 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -63.3 132.55 51.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.543 -0.723 . . . . 0.0 110.354 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 1.003 HD22 HG11 ' A' ' 151' ' ' VAL . 96.0 mt -137.29 145.24 43.22 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.568 -0.708 . . . . 0.0 110.488 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.47 122.15 46.05 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.541 -0.725 . . . . 0.0 109.858 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.432 HD13 ' HG ' ' A' ' 143' ' ' LEU . 40.6 tp -103.69 146.17 28.98 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.671 . . . . 0.0 110.605 -179.458 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.67 130.07 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.65 -0.656 . . . . 0.0 109.758 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -93.09 170.04 9.95 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.487 -0.758 . . . . 0.0 110.754 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.765 ' HA ' HD11 ' A' ' 44' ' ' LEU . 5.4 ttt-85 -64.6 -21.07 66.61 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.639 -0.663 . . . . 0.0 110.623 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 44.4 t-80 -94.42 29.41 2.25 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.416 -0.803 . . . . 0.0 110.488 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.7 40.02 30.86 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -107.44 157.32 18.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.648 -0.658 . . . . 0.0 109.926 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.99 130.32 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.589 -0.694 . . . . 0.0 110.193 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 76.5 mt -128.86 150.04 73.96 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.569 -0.707 . . . . 0.0 109.827 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -87.14 132.07 3.17 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.919 1.484 . . . . 0.0 110.409 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -129.84 130.01 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.641 -0.662 . . . . 0.0 109.526 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -92.18 136.21 33.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.455 -0.778 . . . . 0.0 110.192 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -79.17 128.82 33.78 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.571 -0.706 . . . . 0.0 110.318 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -121.68 23.02 10.38 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.616 -0.677 . . . . 0.0 110.169 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.0 179.73 41.23 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -61.37 -40.82 95.71 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.488 -1.007 . . . . 0.0 110.233 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 78.6 p -132.64 26.52 4.38 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.57 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -129.74 140.04 51.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.493 -0.754 . . . . 0.0 110.134 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.14 169.76 25.63 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -114.71 157.37 23.26 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.621 -0.929 . . . . 0.0 110.071 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.9 tp -100.41 119.15 38.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.566 -0.709 . . . . 0.0 110.165 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.497 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -69.68 -37.29 76.61 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.477 -0.765 . . . . 0.0 109.741 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.9 t -108.57 109.96 61.42 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.63 -0.669 . . . . 0.0 109.95 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.79 116.26 3.71 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.839 1.441 . . . . 0.0 110.469 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -119.95 160.03 44.47 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.544 -0.723 . . . . 0.0 110.185 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.74 157.74 60.62 Favored 'Trans proline' 0 N--CA 1.491 1.358 0 O-C-N 123.877 1.462 . . . . 0.0 110.442 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 94.3 t -61.53 -36.05 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.608 -0.682 . . . . 0.0 110.01 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -40.09 87.66 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.547 -0.721 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -59.89 -40.08 87.52 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.544 -0.723 . . . . 0.0 110.285 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.8 mp -82.65 -24.52 33.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.521 -0.737 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.39 140.23 57.29 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.295 -0.878 . . . . 0.0 109.972 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.02 10.23 85.8 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 20.6 m -116.17 18.83 15.23 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.173 -1.192 . . . . 0.0 110.606 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 1.8 m -69.95 149.95 47.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.356 -0.84 . . . . 0.0 109.857 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 46' ' ' THR . . . 90.05 -11.89 69.37 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.86 137.81 48.25 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.529 ' HB3' HG21 ' A' ' 46' ' ' THR . 50.0 Cg_endo -87.22 142.32 6.23 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.807 1.425 . . . . 0.0 111.327 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.87 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -103.6 109.56 21.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.444 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -102.74 132.33 48.96 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.457 -0.777 . . . . 0.0 111.62 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.447 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -68.56 159.62 80.62 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -51.9 -26.07 23.53 Favored 'Trans proline' 0 N--CA 1.5 1.874 0 O-C-N 123.446 1.235 . . . . 0.0 112.391 -178.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -62.69 -40.01 95.76 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.231 -0.918 . . . . 0.0 109.809 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 122.02 34.01 0.87 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.0 m-70 -132.52 145.72 51.37 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.428 -1.042 . . . . 0.0 110.157 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.8 136.86 45.49 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.671 -0.643 . . . . 0.0 110.255 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 1.003 HG11 HD22 ' A' ' 104' ' ' LEU . 8.8 p -116.14 -21.28 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 110.78 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.29 -176.59 45.5 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.697 HD12 ' CE ' ' A' ' 175' ' ' MET . 92.7 mt -130.81 140.07 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.402 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.493 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.5 t80 -60.87 139.99 57.82 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.58 -0.7 . . . . 0.0 109.862 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 64.4 ttt180 -120.68 -52.5 2.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.56 -0.712 . . . . 0.0 110.393 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.793 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.32 157.62 43.49 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.486 -0.758 . . . . 0.0 110.325 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -110.23 145.52 37.19 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.548 -0.72 . . . . 0.0 110.265 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.56 HG13 ' CD2' ' B' ' 187' ' ' IBU . 63.1 t -110.0 119.96 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.631 -0.668 . . . . 0.0 109.794 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -130.59 152.17 50.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.639 -0.663 . . . . 0.0 110.39 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 p -77.8 -45.16 25.28 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.65 -0.656 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 45.6 ptt85 -164.0 54.78 0.16 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.621 -0.674 . . . . 0.0 109.975 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 111.93 -14.63 26.44 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.29 120.74 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.185 -1.185 . . . . 0.0 109.963 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -84.45 129.32 34.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.657 -0.652 . . . . 0.0 110.447 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 21.4 pttm -111.44 -24.31 10.25 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.621 -0.674 . . . . 0.0 110.604 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.13 159.23 42.68 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.619 -0.676 . . . . 0.0 109.909 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 m -134.91 167.32 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.611 -0.681 . . . . 0.0 110.668 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -126.78 139.65 52.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.669 -0.644 . . . . 0.0 109.771 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -138.04 154.7 49.28 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.402 -0.811 . . . . 0.0 110.833 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.512 HG11 HD11 ' A' ' 82' ' ' LEU . 62.6 t -93.29 121.15 65.89 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.68 -0.637 . . . . 0.0 109.472 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.64 154.11 75.57 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.734 1.386 . . . . 0.0 110.544 -179.602 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 63.7 t -62.99 -26.75 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.571 -0.706 . . . . 0.0 110.35 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -59.12 -39.9 83.75 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.478 -0.764 . . . . 0.0 110.351 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 86.2 p -60.0 -38.29 82.18 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.487 -0.758 . . . . 0.0 110.216 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.697 ' CE ' HD12 ' A' ' 153' ' ' ILE . 69.0 mtt -61.86 -40.03 93.93 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.507 -0.745 . . . . 0.0 110.257 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -41.81 92.85 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.539 -179.529 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 72.8 p -70.03 -27.46 64.68 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.3 m -60.06 -45.39 93.03 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.425 -0.797 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.6 mtt -67.26 -39.98 86.18 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.578 -0.701 . . . . 0.0 110.083 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 78.0 mtp180 -69.73 -25.59 63.91 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.479 -0.763 . . . . 0.0 110.396 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.81 94.93 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.526 -0.734 . . . . 0.0 110.803 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -139.97 -67.5 0.43 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.371 -0.831 . . . . 0.0 111.039 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -103.27 113.27 26.63 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.472 -0.768 . . . . 0.0 110.439 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.04 -39.99 75.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.658 -0.651 . . . . 0.0 110.112 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -137.38 159.99 40.35 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.545 -0.722 . . . . 0.0 110.242 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' LYS . . . . . 0.404 ' HA ' ' CE ' ' A' ' 74' ' ' MET . 38.4 ttpt . . . . . 0 N--CA 1.501 2.098 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.778 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 187' ' ' IBU . . . . . 0.56 ' CD2' HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.793 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 61.5 tt0 -158.85 159.95 35.62 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 118.711 -1.195 . . . . 0.0 110.139 . . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.872 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp -109.88 146.52 34.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.617 -0.677 . . . . 0.0 110.25 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.419 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 28.2 m . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.162 0.506 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.04 -40.1 96.59 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -108.41 130.05 55.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.619 -0.93 . . . . 0.0 110.141 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -120.47 142.41 49.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.574 -0.704 . . . . 0.0 110.171 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -100.05 128.08 46.18 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.587 -0.696 . . . . 0.0 110.304 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -118.73 32.12 6.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.587 -0.696 . . . . 0.0 110.113 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 57.23 -86.79 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.624 -0.673 . . . . 0.0 110.65 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.414 ' O ' HG13 ' A' ' 29' ' ' VAL . 9.0 p -134.75 129.65 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.035 -1.041 . . . . 0.0 110.265 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -114.02 -29.96 6.84 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.547 -0.721 . . . . 0.0 110.26 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.47 125.06 2.96 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.902 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 -64.17 -24.8 67.82 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.586 -0.949 . . . . 0.0 110.498 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.902 HG23 ' HG3' ' A' ' 32' ' ' GLU . 60.3 t -108.21 126.74 64.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.503 -0.748 . . . . 0.0 109.82 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -123.39 154.41 39.03 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.484 -0.76 . . . . 0.0 110.584 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.9 t -90.3 122.77 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.617 -0.677 . . . . 0.0 109.276 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.591 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.5 m -120.37 152.71 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.564 -0.71 . . . . 0.0 110.176 -179.555 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.2 m -141.75 169.56 17.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.662 -0.648 . . . . 0.0 110.513 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 39' ' ' ALA . 1.0 OUTLIER -132.37 -169.77 2.29 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.904 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.536 ' H ' HG22 ' A' ' 38' ' ' THR . . . -58.73 -41.73 87.11 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.42 -0.8 . . . . 0.0 110.575 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.8 m -134.24 -6.86 2.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.479 -0.763 . . . . 0.0 112.025 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.419 ' HG3' ' CD2' ' B' ' 191' ' ' FE3 . 3.0 tp-100 -111.76 160.43 17.32 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.899 -1.126 . . . . 0.0 110.864 -179.214 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -147.56 137.91 23.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.452 -0.78 . . . . 0.0 110.402 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 29.0 p90 -169.11 -177.67 2.99 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.312 -0.868 . . . . 0.0 110.434 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.857 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.6 mt -112.99 159.94 18.61 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.429 -0.795 . . . . 0.0 110.672 -178.551 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -136.26 159.84 40.53 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.689 -0.632 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.696 ' CG2' HD12 ' A' ' 94' ' ' LEU . 23.0 m -123.8 139.29 54.12 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.444 -0.785 . . . . 0.0 110.351 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.0 t -94.38 111.03 22.76 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 110.637 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.411 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.1 t -117.2 130.31 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.704 -0.623 . . . . 0.0 109.662 179.553 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.46 39.44 28.01 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.503 -0.748 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.721 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.85 19.89 75.56 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -133.53 129.77 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -1.163 . . . . 0.0 110.025 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 89.3 m -74.49 147.67 41.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.391 -0.818 . . . . 0.0 109.419 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.411 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 67.5 m95 -129.94 151.66 50.26 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.394 -0.816 . . . . 0.0 110.824 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.3 t -167.41 -179.62 4.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.756 -0.59 . . . . 0.0 109.771 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.4 p -90.03 158.19 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.454 -0.779 . . . . 0.0 110.319 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.444 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 71.4 t80 -74.27 -42.31 59.82 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.599 -0.688 . . . . 0.0 111.477 -179.042 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -70.03 -22.48 63.09 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.148 -0.97 . . . . 0.0 110.799 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.778 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -81.31 -59.98 2.31 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.555 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -91.01 -52.34 4.89 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.639 -0.918 . . . . 0.0 110.204 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 -174.33 47.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 36.4 p -81.93 61.7 5.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.561 -0.964 . . . . 0.0 109.806 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -141.53 170.13 16.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.582 -0.699 . . . . 0.0 110.533 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.5 p -66.32 156.71 33.63 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.678 -0.639 . . . . 0.0 109.725 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.86 HD22 ' CH2' ' A' ' 85' ' ' TRP . 27.3 tp -118.3 140.5 49.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.575 -0.703 . . . . 0.0 110.28 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.27 109.72 21.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.663 -0.648 . . . . 0.0 109.998 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.19 -174.31 15.79 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.4 -32.35 71.82 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 O-C-N 123.907 1.477 . . . . 0.0 110.542 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.4 mttt -77.15 -31.03 55.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.667 -0.646 . . . . 0.0 110.01 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.75 -150.57 21.8 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -75.03 138.69 23.28 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.89 1.469 . . . . 0.0 110.358 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -119.97 129.96 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.621 -0.674 . . . . 0.0 110.577 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.9 p -82.51 142.53 31.78 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.525 -0.735 . . . . 0.0 109.753 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.77 149.97 21.33 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.432 -0.793 . . . . 0.0 111.254 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.6 mmm -115.43 -26.3 7.61 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.752 -0.592 . . . . 0.0 110.451 179.748 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -119.95 139.95 51.66 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.396 -0.815 . . . . 0.0 110.724 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.554 ' HA ' HG12 ' A' ' 83' ' ' VAL . 91.7 m -140.35 130.0 24.3 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.654 -0.654 . . . . 0.0 109.944 179.551 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -137.37 103.27 5.03 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.389 -0.819 . . . . 0.0 110.441 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 70.9 t -71.15 -45.24 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.51 -0.744 . . . . 0.0 110.224 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -60.11 -49.89 75.85 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.437 -0.79 . . . . 0.0 110.223 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.72 ' HG3' HD12 ' A' ' 82' ' ' LEU . 3.7 tp-100 -80.04 -9.99 59.74 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.538 -0.726 . . . . 0.0 110.582 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.7 t70 56.01 44.95 24.66 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.147 -0.97 . . . . 0.0 109.985 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 1.118 HD11 HG21 ' A' ' 170' ' ' VAL . 64.9 mt -141.77 131.5 24.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.655 -0.653 . . . . 0.0 110.902 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.554 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -129.96 159.98 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.66 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -137.47 157.34 23.98 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.553 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.6 m-90 -115.39 157.05 24.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.874 -0.78 . . . . 0.0 109.467 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -69.48 108.16 3.66 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.521 -0.737 . . . . 0.0 109.377 179.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.16 143.34 91.09 Favored Pre-proline 0 N--CA 1.496 1.844 0 O-C-N 121.495 -0.753 . . . . 0.0 110.359 -179.549 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.1 158.42 56.57 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.089 1.573 . . . . 0.0 110.154 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.98 153.33 63.37 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.886 1.466 . . . . 0.0 110.27 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.12 29.68 62.17 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.28 154.33 20.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.514 -0.992 . . . . 0.0 110.09 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -80.18 159.25 26.06 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 110.005 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 97.2 p -139.98 159.73 41.53 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.292 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.696 HD12 ' CG2' ' A' ' 46' ' ' THR . 7.7 mt -106.09 132.19 52.46 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.591 -0.693 . . . . 0.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' HD2' ' A' ' 96' ' ' PRO . 86.7 m -80.0 141.29 54.5 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.693 -0.63 . . . . 0.0 109.916 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PRO . . . . . 0.596 ' HB3' HG11 ' A' ' 172' ' ' VAL . 44.6 Cg_endo -64.04 163.58 25.13 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.812 1.427 . . . . 0.0 110.377 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.677 ' HB2' HG22 ' A' ' 151' ' ' VAL . 51.5 t -87.74 123.54 32.66 Favored 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.65 0.738 . . . . 0.0 110.937 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.0 m -118.21 59.66 0.8 Allowed 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 177.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 3.5 m -141.76 -9.31 0.93 Allowed 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 119.99 -0.684 . . . . 0.0 111.899 -177.477 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.12 25.47 54.07 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.089 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -70.23 130.81 43.04 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.525 -0.985 . . . . 0.0 110.723 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 118' ' ' ARG . 56.4 m -74.37 -39.99 62.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.73 -0.606 . . . . 0.0 110.464 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.4 130.51 42.74 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.518 -0.739 . . . . 0.0 110.546 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.8 mt -131.23 140.2 49.82 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.649 -0.657 . . . . 0.0 110.637 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -106.85 124.37 49.52 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.494 -0.754 . . . . 0.0 109.817 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.531 HD13 ' HG ' ' A' ' 143' ' ' LEU . 37.7 tp -108.48 145.43 34.71 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.394 -0.816 . . . . 0.0 110.924 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.05 120.99 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.674 -0.641 . . . . 0.0 109.706 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.9 p -95.31 173.03 7.74 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.55 -0.719 . . . . 0.0 110.547 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.857 ' HA ' HD11 ' A' ' 44' ' ' LEU . 3.5 ptp180 -69.33 -11.95 61.25 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.544 -0.723 . . . . 0.0 111.103 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 58.2 m80 -93.01 21.69 5.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.209 -0.932 . . . . 0.0 110.399 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.33 40.05 31.42 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.222 -0.924 . . . . 0.0 110.575 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -124.02 147.65 47.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.658 -0.651 . . . . 0.0 109.64 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.0 p -129.98 130.69 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.565 -0.709 . . . . 0.0 110.405 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.621 HD12 HD11 ' A' ' 126' ' ' LEU . 43.8 pt -121.1 150.0 52.61 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.679 -0.638 . . . . 0.0 109.796 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -81.57 123.27 4.24 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.937 1.493 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -119.7 120.95 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.715 -0.616 . . . . 0.0 109.6 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -76.73 149.67 36.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.48 -0.762 . . . . 0.0 110.039 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB3' ' HA ' ' A' ' 102' ' ' SER . 64.6 ttt180 -90.89 120.06 31.6 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.359 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -109.94 20.09 18.36 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.659 -0.651 . . . . 0.0 110.399 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.85 -179.97 39.78 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.72 -39.92 90.41 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.972 . . . . 0.0 110.301 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.4 p -130.92 25.1 4.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.557 -0.714 . . . . 0.0 110.522 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -124.25 139.53 53.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.439 -0.788 . . . . 0.0 110.254 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.77 165.79 26.41 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 99.8 p -120.21 155.51 33.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.648 -0.913 . . . . 0.0 110.129 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.621 HD11 HD12 ' A' ' 114' ' ' ILE . 14.2 tp -99.97 119.5 38.35 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.516 -0.74 . . . . 0.0 110.158 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.04 -39.91 94.03 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.493 -0.754 . . . . 0.0 109.961 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 85.6 p -110.66 120.2 44.4 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.39 120.87 7.93 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 123.763 1.402 . . . . 0.0 110.4 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.2 mmt180 -129.93 159.98 67.34 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.539 -0.726 . . . . 0.0 110.251 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.39 156.72 61.82 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.982 1.517 . . . . 0.0 110.423 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.492 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.9 m -67.06 -25.44 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.658 -0.651 . . . . 0.0 110.618 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.7 m -59.94 -40.04 87.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.41 -0.806 . . . . 0.0 110.272 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.531 ' HD2' HD12 ' A' ' 135' ' ' LEU . 88.5 t80 -60.06 -40.08 88.23 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.497 -0.752 . . . . 0.0 109.935 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 134' ' ' TYR . 3.2 mp -83.85 -25.39 30.34 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.535 -0.728 . . . . 0.0 110.287 179.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.41 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 2.3 tptm -59.96 132.02 52.66 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.408 -0.808 . . . . 0.0 110.105 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.404 ' HA2' ' CE2' ' B' ' 191' ' ' FE3 . . . 91.96 0.93 70.84 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.306 -0.95 . . . . 0.0 110.732 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -109.96 19.99 18.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.136 -1.214 . . . . 0.0 110.66 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.4 t -68.65 147.68 51.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.327 -0.858 . . . . 0.0 109.724 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.78 -14.5 62.98 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.26 148.85 43.17 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -96.81 148.31 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.875 1.461 . . . . 0.0 111.123 -179.297 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.609 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -103.94 108.96 20.53 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.663 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.545 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.93 134.79 42.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.461 -0.774 . . . . 0.0 111.773 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 28.5 p -70.03 159.93 82.41 Favored Pre-proline 0 N--CA 1.494 1.75 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.812 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -52.62 -22.13 16.28 Favored 'Trans proline' 0 N--CA 1.5 1.904 0 O-C-N 123.512 1.269 . . . . 0.0 112.056 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 8.6 t -67.63 -42.92 81.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.228 -0.92 . . . . 0.0 110.055 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 125.51 35.93 0.59 Allowed Glycine 0 N--CA 1.496 2.671 0 C-N-CA 120.069 -1.062 . . . . 0.0 110.904 179.278 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 23.0 m-70 -133.02 144.63 50.2 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.237 -1.155 . . . . 0.0 110.283 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.477 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -62.67 145.21 55.19 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.588 -0.695 . . . . 0.0 110.357 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.677 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.2 t -119.15 -38.91 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.523 -0.735 . . . . 0.0 110.118 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.99 -177.73 42.47 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 85.4 mt -121.61 132.02 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -1.013 . . . . 0.0 110.521 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.697 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 35.6 t80 -60.32 137.16 58.18 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.586 -0.696 . . . . 0.0 109.799 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 68.5 ttt180 -121.17 -52.72 2.06 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.498 -0.752 . . . . 0.0 110.33 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -143.16 159.96 41.32 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.508 -0.745 . . . . 0.0 110.073 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.697 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.84 136.05 54.92 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.627 -0.671 . . . . 0.0 110.553 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.6 t -90.0 119.74 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.492 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -135.52 153.69 51.64 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.487 -0.758 . . . . 0.0 111.404 -179.14 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 160' ' ' THR . . . . . 0.562 HG22 ' HG2' ' A' ' 161' ' ' ARG . 37.1 m -130.53 137.38 49.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.756 -0.59 . . . . 0.0 109.522 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.562 ' HG2' HG22 ' A' ' 160' ' ' THR . 21.7 mmt180 54.21 37.14 26.63 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.272 -0.893 . . . . 0.0 110.755 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 74.19 23.28 76.31 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.4 t -129.98 129.87 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.295 -1.12 . . . . 0.0 110.065 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.78 125.57 35.75 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.539 -0.725 . . . . 0.0 110.131 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.51 -29.61 7.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.541 -0.725 . . . . 0.0 110.455 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.89 162.85 34.45 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.57 -0.706 . . . . 0.0 109.941 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -136.02 165.59 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.432 -0.792 . . . . 0.0 110.965 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -126.37 135.86 51.98 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.629 -0.67 . . . . 0.0 109.995 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -139.88 147.41 40.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.496 -0.752 . . . . 0.0 110.64 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 1.118 HG21 HD11 ' A' ' 82' ' ' LEU . 33.0 m -89.96 125.0 62.1 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.497 -0.752 . . . . 0.0 109.556 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.88 159.96 39.5 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.746 1.393 . . . . 0.0 110.711 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.9 t -60.22 -25.23 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.596 -0.69 . . . . 0.0 110.594 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -58.73 -39.01 79.62 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.456 -0.777 . . . . 0.0 110.354 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 67.5 m -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.468 -0.77 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.42 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.3 mtm -69.99 -37.37 75.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.35 -0.844 . . . . 0.0 110.331 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -59.97 -40.15 88.09 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.513 -0.742 . . . . 0.0 110.468 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 70.1 p -65.31 -37.12 86.16 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.471 -0.768 . . . . 0.0 110.253 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.0 m -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.593 -0.692 . . . . 0.0 110.139 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -67.61 -36.69 81.32 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.534 -0.729 . . . . 0.0 110.058 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 15.1 tpt180 -59.88 -40.08 87.46 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.558 -0.714 . . . . 0.0 110.11 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.02 -39.99 87.76 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.595 -0.69 . . . . 0.0 110.239 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 80.0 p -73.09 160.04 32.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.525 -0.734 . . . . 0.0 110.105 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 22.2 pttm -90.96 15.29 11.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.586 -0.696 . . . . 0.0 111.075 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 85.4 tttt 57.83 163.27 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.274 -0.891 . . . . 0.0 110.596 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -60.08 -40.01 88.08 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.4 -0.812 . . . . 0.0 110.231 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 60.1 tptt . . . . . 0 N--CA 1.501 2.113 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.632 -179.955 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -120.05 135.31 54.98 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 118.684 -1.206 . . . . 0.0 109.993 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.743 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp -69.95 139.52 52.87 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.535 -0.728 . . . . 0.0 110.041 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.606 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.678 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 16.9 m . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.094 0.473 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.94 -162.87 47.03 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 -100.09 124.97 46.09 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.552 -0.969 . . . . 0.0 110.12 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -129.94 170.0 14.51 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.601 -0.687 . . . . 0.0 110.321 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 52.94 40.01 30.26 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.399 -0.813 . . . . 0.0 110.89 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -149.27 91.62 1.86 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.532 -0.73 . . . . 0.0 110.317 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -159.81 -43.73 0.05 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.583 -0.698 . . . . 0.0 110.094 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.6 p -136.49 140.26 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.615 -0.678 . . . . 0.0 110.126 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -96.11 130.45 43.13 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.585 -0.697 . . . . 0.0 109.968 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 173.64 73.07 0.05 OUTLIER Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.708 ' OE1' HD21 ' A' ' 94' ' ' LEU . 96.9 mt-10 -62.98 -38.08 89.71 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.642 -0.917 . . . . 0.0 110.116 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.8 124.65 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.592 -0.692 . . . . 0.0 109.793 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -119.13 155.11 32.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.667 -0.645 . . . . 0.0 110.512 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.8 t -90.21 131.04 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.621 -0.674 . . . . 0.0 109.539 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.517 ' CB ' HD21 ' A' ' 64' ' ' LEU . 27.8 m -123.91 158.38 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.68 -0.637 . . . . 0.0 110.194 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.12 179.35 6.56 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.71 -0.619 . . . . 0.0 110.362 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.2 OUTLIER -141.46 -170.9 3.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.67 -0.643 . . . . 0.0 109.479 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.42 ' H ' HG22 ' A' ' 38' ' ' THR . . . -60.03 -38.88 84.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.523 -0.736 . . . . 0.0 110.258 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.6 t -136.92 -6.71 1.87 Allowed 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.546 -0.721 . . . . 0.0 112.555 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -118.8 156.71 28.93 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 120.839 -1.163 . . . . 0.0 111.129 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.1 m -136.34 139.75 42.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.566 -0.709 . . . . 0.0 110.341 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -165.61 -177.16 4.24 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.238 -0.914 . . . . 0.0 110.075 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.758 HD11 ' HA ' ' A' ' 109' ' ' ARG . 21.7 mt -112.33 175.16 5.55 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.529 -0.732 . . . . 0.0 110.273 -178.055 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.443 ' HB1' ' SG ' ' A' ' 52' ' ' CYS . . . -149.64 156.85 42.59 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.692 -0.63 . . . . 0.0 110.087 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.583 ' CG2' HD12 ' A' ' 94' ' ' LEU . 27.6 m -119.51 139.92 51.33 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.699 -0.626 . . . . 0.0 110.063 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.3 t -101.35 109.35 21.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.453 -0.78 . . . . 0.0 110.476 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.438 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.4 t -120.38 134.28 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.69 -0.631 . . . . 0.0 109.842 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASN . . . . . 0.438 ' OD1' HG12 ' A' ' 48' ' ' VAL . 28.7 m120 55.23 38.52 30.52 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.534 -0.729 . . . . 0.0 111.144 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.63 26.67 74.22 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 80.9 t -140.47 130.03 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.338 -1.095 . . . . 0.0 109.956 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' CYS . . . . . 0.443 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 23.7 t -86.71 108.58 18.73 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.468 -0.77 . . . . 0.0 109.37 179.677 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -91.42 151.21 20.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.595 -0.691 . . . . 0.0 111.05 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.5 t -159.88 -179.71 8.06 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.857 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.5 p -96.59 152.35 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.448 -0.783 . . . . 0.0 110.443 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.427 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.1 t80 -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.58 -0.7 . . . . 0.0 112.091 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.857 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.9 p-80 -68.85 -19.52 64.26 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.139 -0.976 . . . . 0.0 111.068 -178.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.591 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -91.13 -52.28 2.42 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 179.037 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.637 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -103.2 -47.68 4.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.628 -0.925 . . . . 0.0 110.123 179.67 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.2 -168.89 40.78 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.496 ' OG ' HG21 ' A' ' 76' ' ' THR . 1.4 t -86.41 64.68 8.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.546 -0.973 . . . . 0.0 109.837 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -141.89 170.05 16.45 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.602 -0.686 . . . . 0.0 110.363 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.1 p -66.13 150.14 49.21 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.618 -0.676 . . . . 0.0 109.944 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.813 HD22 ' CH2' ' A' ' 85' ' ' TRP . 19.2 tp -117.08 142.62 46.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.611 -0.681 . . . . 0.0 110.082 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -97.62 110.26 22.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.621 -0.675 . . . . 0.0 110.093 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.33 177.11 16.31 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.7 -31.78 68.98 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.85 1.448 . . . . 0.0 110.412 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -71.7 -31.47 66.78 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.597 -0.689 . . . . 0.0 109.999 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.88 -160.56 26.21 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.94 137.23 40.73 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.886 1.466 . . . . 0.0 110.036 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.6 mt -119.94 129.98 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.506 -0.746 . . . . 0.0 110.564 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.3 p -84.86 150.23 25.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.574 -0.704 . . . . 0.0 109.707 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 10.5 pm0 -98.53 148.12 24.08 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.481 -0.762 . . . . 0.0 111.008 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.9 mtp -113.95 -25.55 8.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.766 -0.584 . . . . 0.0 110.504 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -120.01 135.88 54.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.428 -0.795 . . . . 0.0 110.572 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.643 ' HA ' HG12 ' A' ' 83' ' ' VAL . 29.9 m -140.91 126.11 18.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 109.88 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 30.1 t-20 -140.5 104.51 4.77 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.349 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 75.8 t -69.97 -45.3 77.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 0.0 109.871 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -59.87 -49.69 76.7 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.554 -0.716 . . . . 0.0 110.213 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.789 ' HG2' HD12 ' A' ' 82' ' ' LEU . 53.6 tt0 -79.95 -9.99 59.73 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.583 -0.698 . . . . 0.0 110.832 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.427 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 6.0 t70 55.2 46.22 24.25 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.031 -1.043 . . . . 0.0 110.446 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.789 HD12 ' HG2' ' A' ' 80' ' ' GLN . 41.3 mt -143.36 130.43 20.69 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.552 -0.717 . . . . 0.0 111.075 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.643 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -130.94 159.99 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.615 -0.678 . . . . 0.0 109.265 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.76 157.92 23.91 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.597 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 6.0 m-90 -119.93 160.28 23.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.792 -0.828 . . . . 0.0 109.778 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -71.88 124.57 25.15 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.088 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -72.7 130.01 86.08 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.489 -0.757 . . . . 0.0 110.212 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.02 159.64 52.47 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 O-C-N 123.876 1.461 . . . . 0.0 110.356 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.41 139.7 42.11 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.85 1.447 . . . . 0.0 110.306 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.58 -20.33 50.84 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.01 47.1 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.305 -1.115 . . . . 0.0 110.221 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.8 mtp85 -92.16 170.01 10.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.573 -0.705 . . . . 0.0 110.165 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -132.37 160.01 37.58 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.708 HD21 ' OE1' ' A' ' 32' ' ' GLU . 80.5 mt -110.74 132.23 54.37 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.9 p -76.34 160.05 78.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.693 -0.629 . . . . 0.0 109.95 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -77.21 164.04 29.67 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.833 1.438 . . . . 0.0 110.651 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.802 ' HB2' HG22 ' A' ' 151' ' ' VAL . 47.1 t -73.06 128.57 35.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.647 -0.658 . . . . 0.0 110.212 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.7 p -132.05 54.42 1.94 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.725 -0.609 . . . . 0.0 109.715 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.59 -7.52 0.77 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.519 -0.738 . . . . 0.0 112.376 -179.043 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.98 94.36 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -100.08 123.6 44.51 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.668 -0.901 . . . . 0.0 110.49 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 79.5 p -70.04 -26.06 63.86 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.617 -0.677 . . . . 0.0 110.352 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -63.73 129.99 42.38 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.58 -0.7 . . . . 0.0 109.969 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.616 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.2 mt -137.4 136.08 37.54 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.6 -0.688 . . . . 0.0 110.693 -179.745 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.88 119.99 40.83 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.55 -0.719 . . . . 0.0 109.718 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 57.2 tp -98.21 140.05 33.09 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.512 -0.742 . . . . 0.0 110.387 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.459 HG22 HG12 ' A' ' 113' ' ' VAL . 63.1 t -102.82 130.01 53.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.538 -0.726 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 22.9 p -98.2 179.17 4.84 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.583 -0.698 . . . . 0.0 110.761 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.758 ' HA ' HD11 ' A' ' 44' ' ' LEU . 15.8 ttt-85 -70.01 -18.58 63.32 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.692 -0.63 . . . . 0.0 110.969 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -93.21 25.46 3.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.293 -0.879 . . . . 0.0 110.868 -179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.14 38.97 30.2 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.347 -0.846 . . . . 0.0 110.765 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -120.25 139.58 52.47 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.662 -0.648 . . . . 0.0 109.599 179.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.459 HG12 HG22 ' A' ' 107' ' ' VAL . 34.0 m -116.66 140.07 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.515 -0.741 . . . . 0.0 110.701 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.563 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -124.32 149.99 62.7 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.681 -0.637 . . . . 0.0 109.572 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -83.6 126.53 4.1 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.842 1.443 . . . . 0.0 110.651 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 125' ' ' SER . 63.3 t -128.82 130.05 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.715 -0.616 . . . . 0.0 109.477 179.78 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.0 tpt180 -85.48 146.16 27.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.497 -0.752 . . . . 0.0 110.186 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -82.81 124.35 30.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.596 -0.69 . . . . 0.0 110.319 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -114.42 19.93 15.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.28 178.76 39.24 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -59.99 -41.11 91.35 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.509 -0.995 . . . . 0.0 110.293 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.1 p -130.43 25.52 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.464 -0.773 . . . . 0.0 110.654 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.2 tpp85 -126.84 140.49 52.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.507 -0.746 . . . . 0.0 110.356 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.27 166.81 25.95 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.516 ' O ' HG13 ' A' ' 116' ' ' VAL . 81.5 p -124.83 147.43 48.75 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.588 -0.948 . . . . 0.0 110.201 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 mp -95.43 121.7 37.38 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.583 -0.698 . . . . 0.0 110.312 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.516 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.8 -40.07 93.94 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.53 -0.731 . . . . 0.0 109.86 179.683 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.9 p -108.58 117.95 53.11 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.711 -0.618 . . . . 0.0 109.757 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.19 124.46 13.02 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.744 1.391 . . . . 0.0 110.63 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -121.46 160.17 47.18 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.591 -0.693 . . . . 0.0 110.013 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.09 158.88 56.14 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.93 1.489 . . . . 0.0 110.437 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.493 HG11 ' OE1' ' B' ' 188' ' ' GLU . 68.4 t -66.65 -29.99 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.62 -0.675 . . . . 0.0 110.033 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.6 t -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.552 -0.717 . . . . 0.0 110.295 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.692 ' HD2' HD12 ' A' ' 135' ' ' LEU . 64.7 t80 -60.01 -49.54 77.28 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.461 -0.774 . . . . 0.0 110.02 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.692 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.5 mp -69.91 -29.33 66.49 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.632 -0.667 . . . . 0.0 110.626 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 139.98 56.95 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.386 -0.821 . . . . 0.0 110.083 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.54 13.08 83.01 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 16.7 m -115.3 17.25 16.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.281 -1.129 . . . . 0.0 110.766 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.8 m -60.04 144.32 49.72 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.34 -19.34 54.68 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.52 109.8 1.36 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -77.09 151.18 30.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.875 1.46 . . . . 0.0 110.852 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.631 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -99.72 110.44 22.84 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.086 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.531 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -100.01 128.39 46.1 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.662 -0.649 . . . . 0.0 111.17 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.424 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.0 157.89 88.67 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.663 -0.648 . . . . 0.0 109.266 179.066 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.1 Cg_endo -52.16 -24.96 21.71 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 O-C-N 123.516 1.271 . . . . 0.0 112.314 -178.53 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 51.7 m -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.269 -0.895 . . . . 0.0 110.003 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.03 35.77 0.8 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.3 m-70 -132.91 149.2 52.27 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -1.01 . . . . 0.0 110.289 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 145.52 51.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.628 -0.67 . . . . 0.0 110.223 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.802 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.6 t -118.23 -38.38 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.595 -0.691 . . . . 0.0 109.961 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -171.39 -170.02 34.98 Favored Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.423 HD12 ' CE ' ' A' ' 175' ' ' MET . 85.4 mt -130.99 140.02 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.466 -1.02 . . . . 0.0 110.286 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -62.41 138.55 58.47 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.536 -0.727 . . . . 0.0 109.873 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.6 ttp180 -122.54 -52.1 1.93 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.627 -0.671 . . . . 0.0 110.319 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.693 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.64 161.88 41.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.487 -0.758 . . . . 0.0 110.421 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.92 149.81 39.53 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.649 -0.657 . . . . 0.0 110.161 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.515 HG13 ' CD2' ' B' ' 187' ' ' IBU . 62.1 t -109.95 117.99 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.645 -0.659 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.401 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.5 p -137.47 160.53 38.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.642 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 33.1 m -117.99 -56.63 2.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.573 -0.704 . . . . 0.0 110.765 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -109.33 29.96 7.06 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 110.42 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 100.18 0.3 55.94 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -116.39 126.04 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.098 -1.236 . . . . 0.0 109.649 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.78 123.62 37.24 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.653 . . . . 0.0 110.303 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -104.57 -24.04 13.04 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.651 -0.656 . . . . 0.0 110.503 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 159.65 41.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.429 -0.794 . . . . 0.0 110.184 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -141.37 162.4 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.507 -0.746 . . . . 0.0 110.635 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 -114.89 138.39 50.86 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.615 -0.678 . . . . 0.0 110.053 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -140.04 155.31 47.12 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.531 -0.73 . . . . 0.0 110.299 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.575 HG11 HD11 ' A' ' 82' ' ' LEU . 58.6 t -96.21 122.78 57.04 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.53 -0.731 . . . . 0.0 109.65 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -65.66 155.83 67.02 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.777 1.409 . . . . 0.0 110.615 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 61.3 t -63.78 -22.92 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.61 -0.681 . . . . 0.0 110.731 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.99 -39.11 84.61 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -0.829 . . . . 0.0 110.424 -179.452 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.0 p -59.81 -34.39 72.99 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.437 -0.789 . . . . 0.0 110.51 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.423 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.0 mtt -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.527 -0.733 . . . . 0.0 110.492 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -59.95 -40.06 87.7 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.1 m -60.59 -48.61 81.01 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.504 -0.748 . . . . 0.0 110.05 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 87.3 m -70.01 -46.17 65.68 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.575 -0.703 . . . . 0.0 110.0 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -61.19 -39.97 92.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.639 -0.663 . . . . 0.0 110.181 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 33.6 ttt85 -59.99 -39.98 87.6 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.563 -0.711 . . . . 0.0 110.326 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' ALA . . . . . 0.406 ' O ' ' N ' ' A' ' 183' ' ' LYS . . . -60.04 -41.28 91.91 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.482 -0.761 . . . . 0.0 110.207 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 7.2 t 64.51 -69.06 0.09 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.717 -0.615 . . . . 0.0 111.046 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 181' ' ' ALA . 61.7 pttt -149.98 169.99 19.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.196 -0.94 . . . . 0.0 110.229 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -138.91 159.92 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.471 -0.768 . . . . 0.0 110.331 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -62.82 140.04 58.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 110.14 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.135 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' B' B ' 187' ' ' IBU . . . . . 0.515 ' CD2' HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.693 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 -149.8 149.95 31.28 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 118.696 -1.202 . . . . 0.0 110.117 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.795 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.7 mp -103.73 139.97 38.24 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.567 -0.708 . . . . 0.0 110.149 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.424 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.114 0.483 . . . . 0.0 110.279 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.96 -100.02 2.62 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -64.23 139.94 58.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.666 -0.902 . . . . 0.0 110.122 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -73.12 150.59 42.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.579 -0.7 . . . . 0.0 110.258 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -125.26 25.3 7.19 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.644 -0.66 . . . . 0.0 110.602 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -110.41 119.89 40.66 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.414 -0.804 . . . . 0.0 110.274 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -69.41 -40.31 77.4 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.533 -0.729 . . . . 0.0 110.321 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.93 160.01 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.605 -0.684 . . . . 0.0 110.433 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -126.53 -49.52 1.52 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.517 -0.74 . . . . 0.0 110.37 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.93 148.6 23.6 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.485 ' OE1' HD21 ' A' ' 94' ' ' LEU . 99.8 mt-10 -68.53 -36.84 79.4 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.579 -0.954 . . . . 0.0 109.993 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.55 128.51 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -124.84 159.78 30.27 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.567 -0.708 . . . . 0.0 110.075 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.17 113.81 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.519 -0.738 . . . . 0.0 109.83 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.43 ' HB ' HD11 ' A' ' 64' ' ' LEU . 34.5 m -110.17 143.21 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.677 -0.64 . . . . 0.0 109.763 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.48 ' O ' HD13 ' A' ' 64' ' ' LEU . 37.4 t -137.22 173.82 11.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.51 -0.744 . . . . 0.0 111.18 -179.125 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' N ' ' A' ' 39' ' ' ALA . 27.7 m -144.3 169.22 18.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.921 -0.487 . . . . 0.0 109.895 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.455 ' N ' HG22 ' A' ' 38' ' ' THR . . . -66.76 -16.72 64.45 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.669 -0.644 . . . . 0.0 110.617 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.8 m -111.05 -39.1 4.87 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.345 -0.847 . . . . 0.0 111.748 -179.062 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -146.86 170.7 16.49 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.157 -0.964 . . . . 0.0 111.573 -179.106 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.3 p -128.23 151.95 48.66 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.636 -0.665 . . . . 0.0 110.311 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.427 ' HE2' ' HG1' ' A' ' 54' ' ' THR . 30.7 p90 -165.87 -178.02 4.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.374 -0.829 . . . . 0.0 110.334 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.682 HD11 ' HA ' ' A' ' 109' ' ' ARG . 76.2 mt -113.61 150.45 33.09 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.506 -0.746 . . . . 0.0 110.717 -178.585 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.46 159.13 34.23 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.655 -0.653 . . . . 0.0 110.055 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.581 HG21 ' HB3' ' A' ' 142' ' ' PRO . 62.8 m -120.33 131.6 54.93 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.664 -179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.4 t -90.16 102.56 15.28 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.547 -0.721 . . . . 0.0 110.136 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.412 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.7 t -109.97 130.12 63.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.582 -0.699 . . . . 0.0 109.593 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.41 39.98 27.74 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.437 -0.789 . . . . 0.0 110.66 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.76 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.05 19.98 75.97 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 110.869 -0.893 . . . . 0.0 110.869 179.154 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.4 t -131.84 129.98 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.161 -1.2 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.0 m -74.79 147.81 40.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.53 -0.731 . . . . 0.0 109.42 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.465 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 74.5 m95 -129.97 152.31 49.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.426 -0.796 . . . . 0.0 111.072 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.943 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.0 t -169.5 -179.71 3.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.0 p -90.99 156.7 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.458 -0.776 . . . . 0.0 110.484 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.428 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 86.5 t80 -70.01 -42.69 72.69 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.57 -0.706 . . . . 0.0 111.194 -179.42 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.2 p-80 -71.51 -19.06 62.24 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.281 -0.887 . . . . 0.0 111.014 -179.194 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.815 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -73.84 -57.57 4.84 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -87.18 -41.59 13.63 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.583 -0.951 . . . . 0.0 110.139 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 75.72 28.91 60.25 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.28 57.45 4.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.361 -1.082 . . . . 0.0 110.54 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.53 178.99 6.82 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.081 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 77.7 p -65.06 139.49 58.74 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.209 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.48 HD13 ' O ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -115.04 130.04 56.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.576 -0.702 . . . . 0.0 110.842 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.23 109.38 20.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.551 -0.718 . . . . 0.0 109.663 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.29 -154.47 13.11 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -72.55 -31.04 11.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.928 1.489 . . . . 0.0 110.445 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -83.67 -22.43 32.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.586 -0.697 . . . . 0.0 110.74 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 135.31 -139.52 10.87 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.91 154.91 34.01 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.904 1.476 . . . . 0.0 110.083 179.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.402 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.7 mt -131.45 140.01 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.554 -0.716 . . . . 0.0 110.575 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 91.9 m -95.27 140.0 30.78 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.559 -0.713 . . . . 0.0 109.943 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.413 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 8.9 tt0 -93.05 140.05 29.9 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 0.0 110.58 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.2 mmm -112.18 -29.98 7.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.629 -0.669 . . . . 0.0 110.566 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -118.41 139.77 50.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.585 -0.697 . . . . 0.0 110.569 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.3 m -139.97 132.12 28.07 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.513 -0.742 . . . . 0.0 109.93 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.559 ' OD1' HG23 ' A' ' 178' ' ' THR . 0.1 OUTLIER -136.23 96.62 3.42 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.443 -0.786 . . . . 0.0 110.5 -179.79 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 82.6 t -70.02 -40.03 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.595 -0.691 . . . . 0.0 109.899 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.97 -47.34 86.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.562 -0.711 . . . . 0.0 110.297 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -90.05 0.15 57.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.531 -0.731 . . . . 0.0 110.97 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 3.8 t70 53.8 46.42 25.82 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.061 -1.025 . . . . 0.0 110.481 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.854 HD11 HG21 ' A' ' 170' ' ' VAL . 67.6 mt -141.45 135.92 30.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.476 -0.765 . . . . 0.0 110.747 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.518 ' CG2' HG23 ' A' ' 54' ' ' THR . 33.4 m -134.01 164.44 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.606 -0.684 . . . . 0.0 109.432 179.023 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.75 156.79 26.05 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.871 -1.157 . . . . 0.0 110.343 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.943 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.2 m-90 -116.48 152.71 33.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.85 -0.794 . . . . 0.0 109.52 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -66.61 106.37 1.78 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.41 -0.806 . . . . 0.0 109.606 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.51 143.57 87.81 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.576 -0.703 . . . . 0.0 110.097 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.95 150.4 66.97 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.965 1.508 . . . . 0.0 110.338 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.01 159.76 44.91 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.849 1.447 . . . . 0.0 110.094 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.79 29.6 69.2 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.76 149.81 28.5 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.48 -1.012 . . . . 0.0 109.949 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -85.21 146.03 27.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.626 -0.671 . . . . 0.0 109.283 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.4 p -136.91 174.14 10.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.577 -0.702 . . . . 0.0 110.601 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.485 HD21 ' OE1' ' A' ' 32' ' ' GLU . 44.0 mt -108.39 149.8 28.23 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.675 -0.641 . . . . 0.0 110.598 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 74.0 p -90.03 176.18 3.24 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.649 -0.657 . . . . 0.0 110.003 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -89.49 160.49 5.42 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 O-C-N 123.807 1.425 . . . . 0.0 110.609 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.752 ' HB2' HG12 ' A' ' 151' ' ' VAL . 51.3 t -68.7 133.13 47.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.671 -0.643 . . . . 0.0 110.158 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.453 HG22 ' CD2' ' A' ' 149' ' ' HIS . 6.4 t -135.95 53.41 1.95 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.678 -0.639 . . . . 0.0 109.751 179.74 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.88 -8.2 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.554 -0.716 . . . . 0.0 112.378 -179.056 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 38.17 93.9 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -99.95 124.16 44.99 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.565 -0.962 . . . . 0.0 110.502 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 19.6 p -69.91 -34.27 73.28 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.614 -0.679 . . . . 0.0 110.133 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -61.67 129.98 43.64 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.574 -0.704 . . . . 0.0 109.903 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 1.037 HD22 HG21 ' A' ' 151' ' ' VAL . 90.2 mt -135.64 149.99 49.49 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.55 -0.719 . . . . 0.0 110.771 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 143' ' ' LEU . 90.4 m-85 -112.54 140.01 47.65 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.617 -0.677 . . . . 0.0 109.556 179.511 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.447 ' CD1' HD11 ' A' ' 143' ' ' LEU . 52.3 tp -115.2 142.16 47.04 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.496 -0.752 . . . . 0.0 110.677 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 130.06 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.634 -0.666 . . . . 0.0 109.761 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 24.9 p -110.22 -179.9 3.91 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.519 -0.738 . . . . 0.0 110.643 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.682 ' HA ' HD11 ' A' ' 44' ' ' LEU . 32.8 mtp-105 -60.04 -26.38 66.08 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.586 -0.697 . . . . 0.0 110.652 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -89.96 17.91 6.32 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.393 -0.817 . . . . 0.0 111.181 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.09 38.38 27.26 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.057 -1.027 . . . . 0.0 110.748 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -100.76 139.8 35.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.699 -0.626 . . . . 0.0 109.893 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 63.4 t -110.02 119.99 60.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.597 -0.689 . . . . 0.0 109.928 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.55 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -118.91 122.16 29.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.646 -0.659 . . . . 0.0 109.435 179.868 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.513 ' N ' HD13 ' A' ' 114' ' ' ILE . 47.0 Cg_endo -65.33 132.9 32.98 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.744 1.392 . . . . 0.0 110.368 -179.654 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.481 HG13 ' O ' ' A' ' 125' ' ' SER . 63.2 t -129.93 130.04 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.678 -0.639 . . . . 0.0 109.731 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -86.36 132.72 33.89 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.497 -0.752 . . . . 0.0 109.972 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -70.76 130.03 40.65 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.581 -0.699 . . . . 0.0 110.438 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 24.5 mmm-85 -102.4 -20.9 14.38 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.653 -0.654 . . . . 0.0 110.377 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.24 -167.98 29.68 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -59.98 -39.98 87.56 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.606 -0.937 . . . . 0.0 110.401 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.4 p -129.89 25.37 5.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.508 -0.745 . . . . 0.0 110.581 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -125.88 140.04 52.98 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.483 -0.76 . . . . 0.0 110.278 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.87 167.18 24.69 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.481 ' O ' HG13 ' A' ' 116' ' ' VAL . 80.1 p -127.82 150.03 50.01 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.576 -0.956 . . . . 0.0 110.211 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.516 ' CD1' HG13 ' A' ' 167' ' ' VAL . 8.4 mp -103.02 131.39 50.04 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.442 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.514 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.79 -39.99 93.64 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.585 -0.697 . . . . 0.0 109.745 179.563 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.5 p -118.36 149.98 46.97 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.684 -0.635 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -84.42 82.65 1.8 Allowed 'Trans proline' 0 N--CA 1.489 1.237 0 O-C-N 123.843 1.444 . . . . 0.0 110.747 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -71.59 159.98 83.92 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 109.836 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.67 149.31 67.28 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.939 1.494 . . . . 0.0 110.292 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.4 -34.0 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.622 -0.674 . . . . 0.0 110.046 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.6 t -58.41 -36.67 73.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.549 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.652 ' HD1' HD12 ' A' ' 135' ' ' LEU . 64.9 t80 -60.06 -39.92 87.69 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.487 -0.758 . . . . 0.0 110.11 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.652 HD12 ' HD1' ' A' ' 134' ' ' TYR . 3.7 mp -81.37 -20.84 39.73 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.562 -0.711 . . . . 0.0 110.826 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -59.97 139.74 57.21 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.23 -0.919 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.6 1.07 86.12 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.5 m -101.51 3.07 39.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.107 -1.231 . . . . 0.0 110.975 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.407 ' HB2' ' C ' ' B' ' 190' ' ' OBF . 4.9 t -59.97 139.93 57.08 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.145 -0.972 . . . . 0.0 109.863 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.96 -17.85 57.89 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.67 140.84 43.14 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 179.454 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.581 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.4 Cg_endo -87.96 144.91 6.34 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.831 1.438 . . . . 0.0 111.471 -178.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.892 ' O ' HG22 ' A' ' 151' ' ' VAL . 8.3 mp -103.32 129.95 50.47 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.495 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.722 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.46 130.9 56.21 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.366 -0.834 . . . . 0.0 111.598 -178.535 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.452 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -70.02 159.75 83.09 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.764 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.76 -26.91 25.05 Favored 'Trans proline' 0 N--CA 1.501 1.96 0 O-C-N 123.475 1.25 . . . . 0.0 112.368 -178.509 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.78 -40.02 96.02 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.222 -0.924 . . . . 0.0 109.963 179.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.2 36.46 0.81 Allowed Glycine 0 N--CA 1.496 2.641 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' HIS . . . . . 0.453 ' CD2' HG22 ' A' ' 98' ' ' THR . 21.2 m-70 -132.83 151.1 52.08 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.462 -1.023 . . . . 0.0 110.337 179.772 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -67.08 139.96 57.59 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.623 -0.673 . . . . 0.0 110.435 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 1.037 HG21 HD22 ' A' ' 104' ' ' LEU . 33.9 m -117.19 -22.19 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.597 -0.689 . . . . 0.0 110.726 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 171.39 -171.53 44.05 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 86.0 mt -128.82 140.02 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.542 -0.975 . . . . 0.0 110.154 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.638 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 28.9 t80 -71.15 135.47 47.64 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.66 -0.65 . . . . 0.0 109.962 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.4 ttp85 -116.52 -53.01 2.54 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.617 -0.677 . . . . 0.0 110.178 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -148.18 159.96 43.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.757 . . . . 0.0 110.391 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.638 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.95 151.58 35.12 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.63 . . . . 0.0 110.262 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.411 HG13 H2D1 ' B' ' 187' ' ' IBU . 62.6 t -109.51 120.03 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.704 -0.622 . . . . 0.0 109.525 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.09 158.13 41.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.707 -0.621 . . . . 0.0 110.632 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.0 m -101.77 -61.06 1.43 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.67 -0.644 . . . . 0.0 110.309 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -129.03 63.69 1.48 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.681 -0.637 . . . . 0.0 110.066 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.98 9.99 86.08 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 25.3 m -126.75 132.09 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.206 -1.173 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.7 124.28 38.64 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.513 -0.742 . . . . 0.0 110.215 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.86 -29.9 8.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.648 -0.657 . . . . 0.0 110.232 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.26 151.44 45.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.638 -0.663 . . . . 0.0 110.125 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.516 HG13 ' CD1' ' A' ' 126' ' ' LEU . 34.6 m -129.96 159.96 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.617 -0.677 . . . . 0.0 110.669 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -121.97 130.67 53.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.668 -0.645 . . . . 0.0 109.934 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -134.37 159.92 39.54 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.539 -0.726 . . . . 0.0 110.501 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.854 HG21 HD11 ' A' ' 82' ' ' LEU . 62.3 t -93.42 126.49 50.13 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.615 -0.678 . . . . 0.0 109.368 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.94 157.37 53.11 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.771 1.406 . . . . 0.0 110.599 -179.575 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 151' ' ' VAL . 76.3 t -59.85 -25.7 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.614 -0.679 . . . . 0.0 110.387 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -60.02 -39.97 87.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.422 -0.799 . . . . 0.0 110.364 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' SER . . . . . 0.464 ' HB3' HG12 ' A' ' 170' ' ' VAL . 21.7 t -65.42 -37.47 87.04 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.12 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.465 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 95.4 mtp -60.05 -41.82 93.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.56 -0.712 . . . . 0.0 110.293 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -69.12 -40.05 78.56 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.55 -0.719 . . . . 0.0 110.104 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.75 -40.08 93.87 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.673 -0.642 . . . . 0.0 109.92 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 77' ' ' ASN . 91.2 m -59.95 -41.06 91.03 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.558 -0.714 . . . . 0.0 110.189 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.04 -46.45 89.47 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.642 -0.661 . . . . 0.0 110.176 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 61.3 ttt85 -69.98 -40.02 75.59 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.652 -0.655 . . . . 0.0 110.001 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.52 -24.27 66.36 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.579 -0.701 . . . . 0.0 110.6 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 58.3 m -60.05 -39.98 87.82 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.397 -0.815 . . . . 0.0 110.327 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -106.18 110.01 22.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.577 -0.702 . . . . 0.0 110.031 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 29.9 tptp -155.79 140.98 17.5 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.602 -0.686 . . . . 0.0 110.131 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 10.4 ptmm? -150.03 160.04 43.93 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.679 . . . . 0.0 110.258 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.255 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 187' ' ' IBU . . . . . 0.411 H2D1 HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -100.66 129.95 46.64 Favored 'General case' 0 N--CA 1.491 1.598 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.136 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.814 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.4 mp -62.59 140.01 58.64 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.622 -0.674 . . . . 0.0 110.165 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.436 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.56 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.091 0.472 . . . . 0.0 110.19 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.03 69.97 0.04 OUTLIER Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 52.68 39.98 29.44 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.44 -1.035 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -105.04 109.99 22.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.642 -0.661 . . . . 0.0 110.168 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -121.57 137.18 54.84 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.553 -0.717 . . . . 0.0 110.138 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t-20 -136.75 127.48 27.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.608 -0.683 . . . . 0.0 110.228 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 52.87 92.03 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.368 -0.832 . . . . 0.0 110.659 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG13 ' N ' ' A' ' 30' ' ' GLU . 12.0 p -60.02 -39.7 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.597 -0.689 . . . . 0.0 110.301 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.463 ' N ' HG13 ' A' ' 29' ' ' VAL . 86.1 tt0 -111.88 126.97 55.67 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.591 -0.693 . . . . 0.0 109.98 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 179.88 43.05 0.08 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.682 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.5 mt-10 -64.7 -34.33 78.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.618 -0.93 . . . . 0.0 110.201 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.67 126.91 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.537 -0.727 . . . . 0.0 109.947 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -119.12 142.91 47.5 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.555 -0.716 . . . . 0.0 110.359 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 35' ' ' VAL . 14.4 p -78.39 128.83 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.604 -0.685 . . . . 0.0 110.339 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.651 ' HB ' HD21 ' A' ' 64' ' ' LEU . 34.4 m -122.27 146.44 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.636 -0.665 . . . . 0.0 109.593 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.2 m -144.49 171.02 14.94 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.519 -0.738 . . . . 0.0 110.897 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.8 p -133.78 -170.92 2.6 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.93 -32.54 72.05 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.676 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 m -133.09 -11.1 2.94 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.356 -0.84 . . . . 0.0 112.639 -178.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -114.94 154.03 29.49 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.837 -1.165 . . . . 0.0 111.182 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.3 m -143.89 128.29 17.91 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.697 -0.627 . . . . 0.0 109.863 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -159.56 -178.72 7.31 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.307 -0.871 . . . . 0.0 110.469 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.495 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.8 mt -113.96 155.6 25.55 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.519 -0.738 . . . . 0.0 110.533 -178.751 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.52 160.52 33.88 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.625 -0.672 . . . . 0.0 110.304 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.498 HG21 ' HB3' ' A' ' 142' ' ' PRO . 87.1 m -119.97 130.78 54.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.553 -0.717 . . . . 0.0 110.142 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.2 t -89.34 104.03 16.62 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.541 -0.724 . . . . 0.0 110.67 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.18 130.1 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.621 -0.674 . . . . 0.0 109.492 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.21 39.55 28.67 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.428 -0.795 . . . . 0.0 110.707 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.604 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.98 19.97 75.85 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.1 t -133.73 129.98 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.224 -1.162 . . . . 0.0 110.031 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.9 m -71.57 147.52 47.56 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.437 -0.789 . . . . 0.0 109.667 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -139.71 145.47 38.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.47 -0.769 . . . . 0.0 110.867 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.67 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.6 t -170.02 -178.74 2.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.723 -0.61 . . . . 0.0 109.758 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.906 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -78.22 162.13 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.524 -0.735 . . . . 0.0 110.388 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -86.97 -35.1 19.04 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.6 -0.687 . . . . 0.0 111.773 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.906 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.2 p-80 -63.34 -22.14 66.7 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.02 -1.05 . . . . 0.0 110.583 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.434 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -79.68 -60.05 2.54 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.105 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.624 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -84.12 -61.99 1.68 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.583 -0.951 . . . . 0.0 109.943 179.421 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.11 36.84 20.33 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.3 p 53.72 40.05 31.0 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.48 -1.012 . . . . 0.0 110.71 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -111.57 179.5 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.672 -0.642 . . . . 0.0 109.755 179.551 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.7 m -64.74 139.36 58.75 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.489 -0.757 . . . . 0.0 109.102 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.651 HD21 ' HB ' ' A' ' 36' ' ' VAL . 12.5 tp -119.89 138.52 53.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.488 -0.757 . . . . 0.0 110.524 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -112.53 109.52 19.15 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.635 -0.666 . . . . 0.0 109.947 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.82 -172.59 25.55 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.44 -32.34 49.89 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.88 1.463 . . . . 0.0 110.362 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -75.96 -31.12 58.89 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.561 -0.712 . . . . 0.0 109.973 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.64 -144.92 14.25 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.72 155.61 58.33 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 O-C-N 123.85 1.447 . . . . 0.0 110.303 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.515 HG22 ' HB3' ' A' ' 85' ' ' TRP . 83.9 mt -130.05 140.01 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.553 -0.717 . . . . 0.0 110.102 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 23.2 m -87.31 150.49 23.83 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.486 -0.758 . . . . 0.0 110.789 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.412 ' HG2' ' NE1' ' A' ' 85' ' ' TRP . 72.8 mt-30 -93.08 139.95 30.01 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.544 -0.722 . . . . 0.0 110.484 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.8 mmm -118.45 -32.48 4.61 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.545 -0.722 . . . . 0.0 110.55 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -138.2 150.71 47.01 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.461 -0.774 . . . . 0.0 110.532 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 90.2 m -149.59 134.07 17.53 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.534 -0.729 . . . . 0.0 109.813 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.4 t-20 -141.71 100.32 3.73 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.495 -0.753 . . . . 0.0 110.424 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 74.6 t -70.0 -38.24 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.002 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -60.0 -45.36 92.99 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.544 -0.723 . . . . 0.0 110.495 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.98 2.79 54.72 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.464 -0.772 . . . . 0.0 111.121 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.7 t0 54.46 47.69 22.24 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.965 -1.084 . . . . 0.0 110.438 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.748 HD11 HG11 ' A' ' 170' ' ' VAL . 71.3 mt -140.0 143.07 36.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.547 -0.721 . . . . 0.0 110.864 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.624 HG11 ' HB3' ' A' ' 59' ' ' ALA . 7.7 p -139.5 144.68 28.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.619 -0.676 . . . . 0.0 109.248 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -128.28 153.5 19.53 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.292 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.67 ' CZ3' HG21 ' A' ' 54' ' ' THR . 8.4 m-90 -120.21 168.07 11.6 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.693 -0.887 . . . . 0.0 109.887 179.478 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -76.73 109.11 10.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.498 -0.751 . . . . 0.0 109.349 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.604 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.03 140.66 97.93 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.473 -0.767 . . . . 0.0 110.196 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.05 159.95 51.37 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.847 1.446 . . . . 0.0 110.262 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.05 157.52 59.54 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.931 1.49 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.98 30.01 70.36 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.04 140.67 47.65 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.554 -0.968 . . . . 0.0 110.221 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.89 152.8 23.3 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.53 -0.731 . . . . 0.0 109.786 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.7 p -130.0 170.04 14.48 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.536 -0.727 . . . . 0.0 110.433 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.682 HD21 ' OE1' ' A' ' 32' ' ' GLU . 66.6 mt -110.01 143.73 39.58 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.607 -0.683 . . . . 0.0 110.632 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 42.9 p -85.96 172.74 7.96 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.628 -0.67 . . . . 0.0 110.042 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -83.48 161.29 14.8 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.925 1.487 . . . . 0.0 110.534 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.2 t -77.79 129.98 36.14 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.655 -0.653 . . . . 0.0 110.25 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 35.3 m -135.54 56.81 1.82 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.675 -0.64 . . . . 0.0 109.511 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 p -143.94 -4.44 0.83 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.626 -0.671 . . . . 0.0 112.288 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 39.97 96.45 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.9 m -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.53 -0.982 . . . . 0.0 110.471 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.7 p -69.97 -27.3 64.61 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.676 -0.64 . . . . 0.0 110.376 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -66.39 129.43 39.8 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 110.124 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.523 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.4 mt -134.96 150.0 50.3 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.699 -0.626 . . . . 0.0 110.706 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -117.35 123.95 47.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.556 -0.715 . . . . 0.0 109.694 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.539 HD13 HD21 ' A' ' 143' ' ' LEU . 43.1 tp -99.99 139.99 34.86 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.461 -0.775 . . . . 0.0 110.757 -179.324 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.11 139.96 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.671 -0.643 . . . . 0.0 109.853 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.8 p -119.59 173.14 7.18 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.524 -0.735 . . . . 0.0 110.624 -179.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.495 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.7 mtp180 -62.89 -25.67 68.41 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.532 -0.73 . . . . 0.0 110.627 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -92.64 24.41 3.56 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.418 -0.801 . . . . 0.0 110.922 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.1 23.09 4.97 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.237 -0.915 . . . . 0.0 110.849 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -94.85 155.44 16.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.811 . . . . 0.0 109.734 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 113' ' ' VAL . 9.1 p -130.02 129.94 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.517 -0.74 . . . . 0.0 110.505 -179.779 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.546 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -114.38 123.31 32.63 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.614 -0.679 . . . . 0.0 109.36 179.708 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.542 ' N ' HD13 ' A' ' 114' ' ' ILE . 46.5 Cg_endo -65.35 129.55 22.99 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.79 1.416 . . . . 0.0 110.484 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.3 t -129.14 130.02 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.696 -0.627 . . . . 0.0 109.663 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -86.01 149.46 25.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.505 -0.747 . . . . 0.0 109.967 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 46.2 ttp180 -90.62 120.01 31.34 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.559 -0.713 . . . . 0.0 110.412 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -112.49 20.04 17.01 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.64 -0.663 . . . . 0.0 110.519 179.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.86 -179.94 40.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -62.64 -39.99 95.6 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.58 -0.953 . . . . 0.0 110.279 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 33.8 p -130.66 24.17 5.06 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.525 -0.734 . . . . 0.0 110.601 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -126.55 139.31 53.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.417 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.99 170.84 24.13 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 94.8 p -120.16 153.08 36.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.979 . . . . 0.0 110.085 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.425 ' HA ' HD12 ' A' ' 126' ' ' LEU . 17.6 tp -98.2 118.64 35.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.53 -0.732 . . . . 0.0 110.234 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.415 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.3 mp -65.62 -40.04 92.14 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -110.0 110.11 58.92 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.61 -0.681 . . . . 0.0 110.138 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -64.99 115.64 3.39 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.848 1.446 . . . . 0.0 110.391 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HD3' ' CD2' ' A' ' 134' ' ' TYR . 6.8 mtt180 -126.97 160.04 61.42 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.572 -0.705 . . . . 0.0 110.224 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.15 156.83 56.99 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 O-C-N 123.862 1.453 . . . . 0.0 110.255 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.46 HG11 ' OE1' ' B' ' 188' ' ' GLU . 33.8 m -59.96 -30.01 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.516 -0.74 . . . . 0.0 110.305 -179.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -62.15 -32.37 72.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.595 -0.69 . . . . 0.0 109.924 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.549 ' CZ ' HD13 ' A' ' 135' ' ' LEU . 0.0 OUTLIER -59.98 -39.99 87.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.582 -0.699 . . . . 0.0 110.058 -179.812 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 8.2 tp -100.22 -1.92 35.22 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.489 -0.757 . . . . 0.0 111.527 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.04 139.99 52.76 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.113 -0.992 . . . . 0.0 109.851 179.52 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 83.3 -3.2 85.51 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.4 m -107.98 15.06 24.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.099 -1.236 . . . . 0.0 110.626 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.406 ' HB2' ' C ' ' B' ' 190' ' ' OBF . 47.5 t -69.92 149.92 47.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 109.345 179.592 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.419 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 98.09 -19.95 52.5 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.132 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.45 151.0 29.17 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.498 ' HB3' HG21 ' A' ' 46' ' ' THR . 54.8 Cg_endo -95.38 149.14 1.51 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.826 1.435 . . . . 0.0 111.187 -179.102 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.539 HD21 HD13 ' A' ' 106' ' ' LEU . 84.4 mt -101.59 108.02 19.46 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.556 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.98 130.02 46.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 111.401 -178.665 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.441 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.64 83.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -52.32 -22.62 16.24 Favored 'Trans proline' 0 N--CA 1.501 1.957 0 O-C-N 123.569 1.299 . . . . 0.0 112.222 -178.755 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.28 -40.0 89.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.28 -0.888 . . . . 0.0 109.959 179.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.35 35.69 0.85 Allowed Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 18.5 m-70 -131.46 146.33 52.2 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.422 -1.046 . . . . 0.0 110.321 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.33 144.31 57.19 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.649 -0.657 . . . . 0.0 110.3 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.7 t -118.91 -39.74 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.619 -0.676 . . . . 0.0 109.931 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -167.33 33.9 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.588 HD11 ' HE1' ' A' ' 175' ' ' MET . 91.0 mt -130.0 137.04 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.51 -0.994 . . . . 0.0 110.332 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.661 ' CZ ' HD23 ' A' ' 135' ' ' LEU . 20.1 t80 -64.7 138.3 58.31 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.606 -0.684 . . . . 0.0 109.427 179.344 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -116.23 -52.43 2.59 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.537 -0.727 . . . . 0.0 110.534 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -157.45 161.62 38.92 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.563 -0.711 . . . . 0.0 110.563 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.04 151.74 26.81 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.657 -0.652 . . . . 0.0 110.017 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -108.26 118.03 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.605 -0.685 . . . . 0.0 109.734 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -132.96 166.85 21.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.694 -0.629 . . . . 0.0 110.337 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 29.4 m -126.81 -54.24 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.498 -0.752 . . . . 0.0 110.363 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.7 mmt180 -102.04 26.76 7.24 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.537 -0.727 . . . . 0.0 110.388 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.37 -2.31 57.58 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.99 128.7 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.108 -1.231 . . . . 0.0 109.659 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.82 127.42 35.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.628 -0.67 . . . . 0.0 110.722 -179.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -102.82 -19.66 14.6 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.632 -0.667 . . . . 0.0 110.313 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.93 160.71 39.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.093 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.77 173.95 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.554 -0.716 . . . . 0.0 110.409 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -133.76 132.83 41.0 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.664 -0.648 . . . . 0.0 109.886 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -136.69 156.06 49.04 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.422 -0.799 . . . . 0.0 110.59 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.748 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -98.54 123.46 50.01 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.661 -0.649 . . . . 0.0 109.373 179.31 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -63.42 153.04 77.09 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.726 1.382 . . . . 0.0 110.646 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 151' ' ' VAL . 67.2 t -57.06 -21.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.634 -0.667 . . . . 0.0 110.756 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -57.36 -37.11 72.1 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.319 -0.863 . . . . 0.0 110.615 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.5 t -60.08 -34.85 74.02 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.512 -0.742 . . . . 0.0 110.489 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.588 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.5 mtt -59.96 -40.02 87.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.483 -0.761 . . . . 0.0 110.495 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.35 -40.02 89.24 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.726 . . . . 0.0 110.334 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -66.37 -39.98 89.44 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.588 -0.695 . . . . 0.0 110.108 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.2 m -60.59 -46.8 88.88 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.484 -0.76 . . . . 0.0 110.171 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -64.8 -40.05 94.6 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.521 -0.737 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 54.5 mtt180 -69.38 -39.93 77.71 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.586 -0.696 . . . . 0.0 110.305 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.1 87.94 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.569 -0.707 . . . . 0.0 110.358 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 31.4 t -118.16 87.32 2.7 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.514 -0.742 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -60.17 -40.03 88.5 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.598 -0.689 . . . . 0.0 110.162 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -121.3 130.04 53.44 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.602 -0.686 . . . . 0.0 110.137 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.2 tptt -122.92 129.98 52.27 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 110.122 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.113 179.999 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.562 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 -114.09 129.92 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 118.766 -1.174 . . . . 0.0 110.112 . . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.849 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp -77.48 140.56 39.82 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.686 -0.634 . . . . 0.0 110.472 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.419 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.53 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.2 p . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.061 0.458 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.47 -39.98 97.06 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -118.46 139.99 50.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.568 -0.96 . . . . 0.0 110.171 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -139.74 86.2 2.09 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.542 -0.724 . . . . 0.0 110.085 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -160.0 -43.16 0.05 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.63 -0.669 . . . . 0.0 110.137 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -119.52 140.32 50.69 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.654 -0.653 . . . . 0.0 110.056 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -129.79 160.03 34.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.646 -0.659 . . . . 0.0 110.281 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.639 HG13 ' HD2' ' A' ' 92' ' ' ARG . 57.7 t 51.86 69.94 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.431 -0.793 . . . . 0.0 110.743 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -69.77 -40.05 76.32 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.58 -0.7 . . . . 0.0 110.03 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.73 147.36 4.76 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.588 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.8 mt-10 -68.73 -37.99 79.84 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.555 -0.968 . . . . 0.0 110.365 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.38 131.57 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.566 -0.709 . . . . 0.0 109.97 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -124.22 158.85 31.48 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.563 -0.711 . . . . 0.0 110.177 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.2 t -93.28 114.74 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.626 -0.671 . . . . 0.0 109.911 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.884 HG11 HD21 ' A' ' 64' ' ' LEU . 61.3 t -116.32 139.6 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 21.9 m -146.84 173.88 11.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.322 -0.861 . . . . 0.0 111.167 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.6 p -129.83 -179.17 5.04 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.836 -0.54 . . . . 0.0 109.576 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.26 -7.99 52.39 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.677 -0.639 . . . . 0.0 111.05 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -108.71 -37.61 5.85 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.118 -0.988 . . . . 0.0 111.772 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.423 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 0.4 OUTLIER -152.83 169.25 23.25 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.172 -0.955 . . . . 0.0 111.299 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 30.3 t -121.7 147.16 46.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.541 -0.725 . . . . 0.0 110.656 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 21.0 p90 -159.44 -177.72 6.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.78 HD11 ' HA ' ' A' ' 109' ' ' ARG . 82.7 mt -113.18 157.4 21.74 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.383 -0.823 . . . . 0.0 110.225 -178.812 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -134.89 146.5 49.26 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.492 -0.755 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.544 HG23 HD12 ' A' ' 94' ' ' LEU . 35.2 m -100.82 124.87 47.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.639 -0.663 . . . . 0.0 110.029 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.9 t -87.15 103.13 15.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.584 -0.697 . . . . 0.0 110.164 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.31 130.37 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.61 -0.681 . . . . 0.0 109.631 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 37.5 t30 57.15 39.41 28.96 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.423 -0.798 . . . . 0.0 110.606 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.729 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.97 20.61 76.36 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.01 130.03 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.257 -1.143 . . . . 0.0 109.976 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -74.5 140.34 44.48 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.455 -0.778 . . . . 0.0 109.275 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 62.6 m95 -132.07 137.38 47.75 Favored 'General case' 0 N--CA 1.494 1.746 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.792 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.682 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 11.8 t -160.06 -179.65 7.96 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.318 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.778 HG21 ' CE1' ' A' ' 57' ' ' HIS . 13.4 p -78.94 161.28 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 111.295 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 48.8 t80 -74.12 -41.92 60.86 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.686 -0.634 . . . . 0.0 111.613 -179.171 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.778 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -59.11 -24.62 63.12 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.155 -0.966 . . . . 0.0 110.707 -178.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.437 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -72.58 -50.45 15.07 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.996 -2.042 . . . . 0.0 107.996 178.222 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.407 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -148.58 78.23 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.752 -0.852 . . . . 0.0 109.45 179.015 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.481 ' HA2' HG11 ' A' ' 83' ' ' VAL . . . -84.63 102.82 2.59 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.294 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 21.4 p 48.97 56.03 8.38 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.68 -0.894 . . . . 0.0 111.468 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -139.82 174.76 10.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -64.91 139.2 58.74 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 120.044 -0.662 . . . . 0.0 109.6 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.897 HD22 ' CE2' ' A' ' 85' ' ' TRP . 12.0 tp -116.29 157.63 24.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.619 -0.676 . . . . 0.0 110.333 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -134.4 109.56 8.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.696 -0.628 . . . . 0.0 109.727 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.25 -164.01 15.69 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.78 -32.65 8.98 Favored 'Trans proline' 0 N--CA 1.49 1.31 0 O-C-N 123.95 1.5 . . . . 0.0 110.378 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 58.6 tptt -75.73 -31.19 59.5 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.681 -0.637 . . . . 0.0 109.823 -179.616 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.53 -149.21 20.91 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.14 141.09 20.44 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.89 1.468 . . . . 0.0 110.13 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.601 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.3 mt -130.02 140.07 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.483 -0.761 . . . . 0.0 110.259 -179.709 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.7 t -85.1 137.27 33.14 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.533 -0.729 . . . . 0.0 110.514 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 24.9 tt0 -77.12 141.14 40.32 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.509 -0.744 . . . . 0.0 110.662 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.1 mmm -110.71 -29.02 8.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.629 -0.669 . . . . 0.0 110.365 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.0 139.99 51.64 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.492 -0.755 . . . . 0.0 110.662 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 32.0 m -137.83 136.62 37.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.549 -0.719 . . . . 0.0 110.09 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.516 ' OD1' HG21 ' A' ' 178' ' ' THR . 26.4 m120 -149.75 92.15 1.88 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.528 -0.733 . . . . 0.0 110.461 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 92.1 t -70.0 -43.53 79.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.545 -0.722 . . . . 0.0 110.055 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -60.1 -43.77 95.33 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.482 -0.761 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.632 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.5 tp60 -90.11 0.08 57.34 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.553 -0.717 . . . . 0.0 110.881 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.456 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.1 t0 54.09 46.24 25.84 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.039 -1.038 . . . . 0.0 110.289 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.856 HD21 ' NH2' ' A' ' 155' ' ' ARG . 54.0 mt -134.03 147.58 50.97 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.514 -0.741 . . . . 0.0 110.959 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.508 HG23 ' CH2' ' A' ' 85' ' ' TRP . 16.1 m -150.25 168.89 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.646 -0.659 . . . . 0.0 109.786 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -163.36 157.84 30.09 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.897 ' CE2' HD22 ' A' ' 64' ' ' LEU . 9.9 m-90 -128.11 159.96 33.5 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.97 . . . . 0.0 109.813 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -67.13 113.06 4.78 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.521 -0.737 . . . . 0.0 109.597 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.729 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -78.35 135.16 61.65 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.522 -0.736 . . . . 0.0 110.265 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.95 159.97 51.32 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.83 1.437 . . . . 0.0 110.338 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.12 159.62 53.15 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 O-C-N 123.916 1.482 . . . . 0.0 110.286 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.17 -21.15 47.75 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.07 160.06 25.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.403 -1.057 . . . . 0.0 110.232 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.639 ' HD2' HG13 ' A' ' 29' ' ' VAL . 74.8 mtp85 -96.01 161.52 13.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.629 -0.669 . . . . 0.0 110.204 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 71.1 m -125.65 157.78 36.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.671 -0.643 . . . . 0.0 110.191 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.588 HD21 ' OE1' ' A' ' 32' ' ' GLU . 85.0 mt -110.01 132.17 54.4 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 110.559 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.1 p -78.04 159.95 74.73 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.601 -0.687 . . . . 0.0 110.05 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.6 163.91 28.85 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.8 1.421 . . . . 0.0 110.809 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.515 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -78.64 132.7 37.17 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.641 -0.662 . . . . 0.0 110.163 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.9 p -132.52 53.17 2.03 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.785 -0.572 . . . . 0.0 109.63 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.47 -8.48 0.76 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 119.907 -0.717 . . . . 0.0 112.412 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.03 34.21 82.56 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 80.3 p -83.62 138.13 33.49 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.51 -0.994 . . . . 0.0 110.448 -179.678 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.6 m -81.72 -30.98 32.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.559 -0.713 . . . . 0.0 110.385 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -69.99 130.06 41.17 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.53 -0.731 . . . . 0.0 110.187 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.1 mt -131.02 149.55 52.56 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.65 -0.656 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -119.97 113.91 21.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.52 -0.738 . . . . 0.0 109.701 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.419 HD13 HD11 ' A' ' 143' ' ' LEU . 39.7 tp -96.67 142.87 28.19 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.55 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.99 129.96 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.616 -0.677 . . . . 0.0 109.832 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 26.9 p -100.02 -172.31 2.2 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.488 -0.758 . . . . 0.0 110.567 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.78 ' HA ' HD11 ' A' ' 44' ' ' LEU . 86.9 mtm-85 -59.97 -28.98 68.12 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.586 -0.696 . . . . 0.0 110.57 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.26 20.04 5.45 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.603 -0.685 . . . . 0.0 111.018 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 26.33 6.7 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.115 -0.991 . . . . 0.0 110.745 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -80.07 159.99 25.95 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.605 -0.684 . . . . 0.0 109.911 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.4 t -109.97 119.95 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.569 -0.707 . . . . 0.0 109.97 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.59 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -114.32 110.0 48.29 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.68 . . . . 0.0 109.69 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.42 117.29 4.6 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.869 1.458 . . . . 0.0 110.354 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.0 t -120.05 129.13 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.701 -0.625 . . . . 0.0 109.737 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 mmm-85 -82.51 150.08 27.18 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.711 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -94.13 114.14 26.22 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -108.5 19.98 19.13 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.559 -0.713 . . . . 0.0 110.355 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.05 -178.54 40.07 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -61.32 -40.01 92.62 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.231 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.3 p -131.84 26.08 4.65 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.536 -0.728 . . . . 0.0 110.495 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.3 tpt180 -125.71 140.23 52.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.465 -0.772 . . . . 0.0 110.286 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.01 166.51 27.48 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 89.9 p -120.01 151.4 39.03 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.926 . . . . 0.0 110.265 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.421 HD23 ' O ' ' A' ' 128' ' ' SER . 6.3 tp -94.07 115.2 27.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.651 -0.656 . . . . 0.0 110.003 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.2 mp -62.15 -40.05 94.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.528 -0.732 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' SER . . . . . 0.421 ' O ' HD23 ' A' ' 126' ' ' LEU . 54.4 m -108.98 119.99 47.23 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -66.01 121.03 8.27 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 O-C-N 123.799 1.421 . . . . 0.0 110.537 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.449 ' CD ' ' CE2' ' A' ' 134' ' ' TYR . 89.4 mtt-85 -128.88 160.44 63.32 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.618 -0.676 . . . . 0.0 110.136 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.06 163.76 32.75 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.94 1.495 . . . . 0.0 110.517 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 67.2 t -67.02 -40.04 84.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.646 -0.659 . . . . 0.0 110.344 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.9 p -53.87 -30.87 47.64 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.409 -0.807 . . . . 0.0 110.991 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' TYR . . . . . 0.449 ' CE2' ' CD ' ' A' ' 130' ' ' ARG . 36.9 t80 -60.06 -40.01 87.99 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.454 -0.779 . . . . 0.0 110.091 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.488 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 9.0 mp -87.92 -23.73 23.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.57 -0.706 . . . . 0.0 110.625 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.413 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 5.2 tptm -59.99 129.32 41.22 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.347 -0.846 . . . . 0.0 110.0 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLY . . . . . 0.404 ' HA2' ' CE2' ' B' ' 191' ' ' FE3 . . . 90.04 -10.05 75.3 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.2 m -104.04 16.79 25.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.164 -1.197 . . . . 0.0 110.877 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -69.94 151.82 45.18 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.08 -17.93 57.81 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.56 149.46 28.49 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.494 ' HB3' HG21 ' A' ' 46' ' ' THR . 55.3 Cg_endo -98.39 146.71 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.852 1.448 . . . . 0.0 111.263 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.3 mp -102.69 105.52 16.0 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.529 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.558 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -93.35 130.89 38.95 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.728 . . . . 0.0 111.363 -178.485 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -69.98 159.31 84.71 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.99 -23.04 15.77 Favored 'Trans proline' 0 N--CA 1.502 1.993 0 O-C-N 123.418 1.22 . . . . 0.0 112.144 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -65.71 -39.99 91.77 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.335 -0.853 . . . . 0.0 109.823 179.554 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.71 35.3 0.85 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 21.8 m-70 -132.72 146.02 51.51 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.456 -1.026 . . . . 0.0 110.3 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.79 140.02 58.83 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.623 -0.673 . . . . 0.0 110.201 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.735 ' O ' HG23 ' A' ' 172' ' ' VAL . 47.0 t -111.1 -51.06 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.523 -0.736 . . . . 0.0 109.995 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -160.35 -172.21 27.29 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.6 mt -128.23 135.71 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.585 -0.95 . . . . 0.0 110.352 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.719 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.6 t80 -64.16 134.81 55.56 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 109.582 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ARG . . . . . 0.856 ' NH2' HD21 ' A' ' 82' ' ' LEU . 1.4 ttm105 -120.44 -52.45 2.15 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.489 -0.757 . . . . 0.0 110.733 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -142.25 157.29 45.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.751 . . . . 0.0 110.264 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.719 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -119.87 139.16 52.82 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 110.493 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -92.44 117.14 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.67 160.02 40.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.465 -0.772 . . . . 0.0 111.647 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 35.8 p -139.31 139.26 37.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.815 -0.553 . . . . 0.0 109.509 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.0 mtm180 55.62 30.87 16.18 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.466 -0.771 . . . . 0.0 110.539 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.02 22.89 64.84 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.1 t -129.53 129.73 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.341 -1.094 . . . . 0.0 109.89 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.06 129.98 46.17 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.542 -0.724 . . . . 0.0 110.5 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -118.83 -30.05 5.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.55 -0.719 . . . . 0.0 110.732 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -136.4 157.41 46.85 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.442 -0.786 . . . . 0.0 110.229 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.8 m -135.46 157.51 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.558 -0.714 . . . . 0.0 110.757 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -120.27 135.82 54.87 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.599 -0.688 . . . . 0.0 109.809 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -137.01 154.5 50.38 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.698 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.455 HG11 HD11 ' A' ' 82' ' ' LEU . 95.8 t -98.27 125.07 44.75 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.572 -0.705 . . . . 0.0 109.183 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -62.35 155.9 54.54 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 O-C-N 123.713 1.375 . . . . 0.0 110.797 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.3 t -56.19 -21.64 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.674 -0.641 . . . . 0.0 110.853 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -56.7 -37.25 70.64 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.362 -0.836 . . . . 0.0 110.768 -179.506 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 28.2 t -59.99 -44.54 94.45 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.392 -0.817 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 78.0 mtm -67.34 -39.92 85.85 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -60.3 -40.58 91.01 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -62.84 -40.04 96.2 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.616 -0.677 . . . . 0.0 110.055 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' THR . . . . . 0.516 HG21 ' OD1' ' A' ' 77' ' ' ASN . 94.5 m -60.95 -40.04 91.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.6 -0.687 . . . . 0.0 110.056 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.63 -40.0 93.31 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.534 -0.729 . . . . 0.0 110.259 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 58.1 ttt180 -61.49 -40.14 93.5 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.569 -0.707 . . . . 0.0 110.13 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.91 -53.51 17.63 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 9.3 p 50.6 -166.8 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.528 -0.732 . . . . 0.0 110.97 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 54.84 -87.76 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.705 -0.622 . . . . 0.0 110.874 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 55.7 tttp 51.65 65.67 1.42 Allowed 'General case' 0 N--CA 1.501 2.107 0 O-C-N 120.997 -1.064 . . . . 0.0 110.82 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.485 -0.759 . . . . 0.0 110.265 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 54.9 tttm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.181 -179.908 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 44.4 tp10 -118.69 131.67 56.15 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 118.741 -1.184 . . . . 0.0 110.122 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.776 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -67.31 140.01 57.28 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.598 -0.689 . . . . 0.0 110.07 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.573 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.716 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.8 m . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.106 0.479 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 160.06 44.01 0.02 OUTLIER Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 84.7 mtt180 -60.07 -39.99 87.97 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.578 -0.954 . . . . 0.0 110.217 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -108.29 25.01 12.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.519 -0.738 . . . . 0.0 110.553 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -96.29 25.1 5.18 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.437 -0.79 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 18.7 p-10 -106.86 20.94 18.3 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.327 -0.858 . . . . 0.0 110.628 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -80.04 161.38 25.42 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.467 -0.771 . . . . 0.0 110.13 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.1 t -102.02 127.28 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.597 -0.689 . . . . 0.0 110.023 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.43 141.7 52.07 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.697 -0.627 . . . . 0.0 110.461 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -176.37 120.06 0.73 Allowed Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 33' ' ' VAL . 4.7 pt-20 -68.74 -26.76 65.41 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.594 -0.945 . . . . 0.0 110.513 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.694 HG23 ' HG3' ' A' ' 32' ' ' GLU . 58.3 t -109.99 127.25 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.495 -0.753 . . . . 0.0 109.695 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -131.68 156.84 45.17 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.672 . . . . 0.0 110.376 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 35' ' ' VAL . 32.6 m -90.08 118.58 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.705 -0.622 . . . . 0.0 110.387 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.831 HG11 HD21 ' A' ' 64' ' ' LEU . 48.2 t -114.85 141.04 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.469 -0.769 . . . . 0.0 109.288 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 19.3 m -146.59 -178.92 6.42 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.748 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.3 p -141.49 -168.63 2.69 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.846 -0.534 . . . . 0.0 110.239 -179.618 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.47 -35.11 67.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.594 -0.691 . . . . 0.0 111.511 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.4 t -137.33 -8.01 1.74 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.266 -0.896 . . . . 0.0 113.033 -178.493 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.5 tp-100 -115.38 143.71 44.88 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.881 -1.137 . . . . 0.0 110.88 -179.374 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.9 m -129.29 138.69 51.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.749 -0.595 . . . . 0.0 109.835 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.737 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.9 p90 -166.5 -177.52 4.03 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.46 -0.775 . . . . 0.0 110.466 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.2 mt -112.98 146.43 39.06 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.557 -0.714 . . . . 0.0 110.172 -178.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . . . -128.68 161.21 30.21 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.631 -0.668 . . . . 0.0 110.261 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.476 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.1 t -121.3 140.55 51.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.558 -0.714 . . . . 0.0 110.146 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.9 t -97.42 110.08 22.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.579 -0.701 . . . . 0.0 110.352 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.2 130.0 62.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 109.476 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 55.67 40.0 30.89 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.483 -0.761 . . . . 0.0 110.762 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.06 22.15 77.16 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.255 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -131.84 130.0 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.235 -1.156 . . . . 0.0 110.123 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -72.09 146.0 47.83 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.452 -0.78 . . . . 0.0 109.296 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -139.97 137.2 34.53 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.357 -0.839 . . . . 0.0 111.645 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.709 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 13.4 t -161.09 173.88 14.52 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.442 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.755 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.9 p -78.64 150.37 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.267 -0.896 . . . . 0.0 110.838 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.534 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.2 t80 -60.05 -49.2 78.59 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.58 -0.7 . . . . 0.0 111.894 -178.711 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.79 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.4 p-80 -57.94 -24.41 57.78 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.029 -1.044 . . . . 0.0 110.926 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.512 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.48 -46.31 15.51 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 178.584 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.737 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -136.38 94.53 3.03 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.723 -0.869 . . . . 0.0 109.433 179.349 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.73 -166.62 3.39 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.0 p -71.57 69.62 0.63 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.622 -0.928 . . . . 0.0 109.964 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.3 178.76 7.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.559 -0.713 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 31.0 p -65.54 147.38 53.51 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.713 . . . . 0.0 109.619 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.831 HD21 HG11 ' A' ' 36' ' ' VAL . 12.9 tp -113.1 133.4 55.03 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.611 -0.681 . . . . 0.0 109.99 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.03 109.63 21.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.617 -0.677 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.72 -171.74 17.76 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.24 -32.55 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.908 1.478 . . . . 0.0 110.456 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -76.14 -31.31 58.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.584 -0.698 . . . . 0.0 109.787 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.01 -146.15 17.24 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.7 144.43 31.4 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.895 1.471 . . . . 0.0 110.182 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.582 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.8 mt -130.03 140.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.485 -0.759 . . . . 0.0 110.316 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.3 m -86.05 136.3 33.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.529 -0.732 . . . . 0.0 110.288 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -83.38 149.49 26.68 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.589 -0.694 . . . . 0.0 110.959 -179.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 82.1 mtp -119.27 -18.92 8.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.666 -0.646 . . . . 0.0 110.986 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -128.12 147.98 50.56 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.245 -0.909 . . . . 0.0 110.588 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.8 p -144.49 126.0 14.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.743 -0.598 . . . . 0.0 109.975 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -142.48 90.75 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.62 -0.675 . . . . 0.0 110.053 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.534 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 86.7 t -69.82 -46.69 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.579 -0.7 . . . . 0.0 109.911 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -41.82 92.85 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.594 -0.691 . . . . 0.0 110.277 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.545 ' HG2' HD12 ' A' ' 82' ' ' LEU . 45.3 tt0 -90.31 -0.11 57.49 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.571 -0.706 . . . . 0.0 111.149 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 1.6 t70 53.25 44.49 30.1 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.99 -1.069 . . . . 0.0 110.85 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.776 HD11 HG11 ' A' ' 170' ' ' VAL . 45.5 mt -132.93 146.53 51.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.3 -0.875 . . . . 0.0 111.12 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.525 HG23 ' CH2' ' A' ' 85' ' ' TRP . 30.6 m -152.83 169.58 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.65 -0.656 . . . . 0.0 109.667 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -164.9 157.78 30.35 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.709 ' HZ3' HG22 ' A' ' 54' ' ' THR . 10.2 m-90 -128.67 168.1 16.27 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.66 -0.906 . . . . 0.0 109.835 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 54.8 tp60 -70.85 119.38 14.9 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.444 -0.785 . . . . 0.0 109.375 179.056 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.52 149.91 95.58 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.532 -0.73 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.96 154.34 67.04 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.884 1.465 . . . . 0.0 110.369 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.42 152.98 74.97 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.941 1.495 . . . . 0.0 110.178 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 30.0 70.42 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.79 147.74 30.44 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.481 -1.011 . . . . 0.0 110.12 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.4 mtp85 -88.82 150.05 23.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.575 -0.703 . . . . 0.0 109.958 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -126.95 169.91 12.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.605 -0.685 . . . . 0.0 110.111 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.635 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -109.15 137.4 47.11 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.581 -0.699 . . . . 0.0 110.738 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' THR . . . . . 0.411 ' OG1' ' CE1' ' A' ' 149' ' ' HIS . 3.3 p -79.29 165.68 46.86 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.652 -0.655 . . . . 0.0 109.904 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -80.11 153.29 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.827 1.435 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.778 ' HB2' HG22 ' A' ' 151' ' ' VAL . 50.3 t -65.04 131.63 47.09 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.663 -0.648 . . . . 0.0 110.117 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.2 t -135.97 54.26 1.91 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.714 -0.616 . . . . 0.0 109.727 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.89 -7.87 0.73 Allowed 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.599 -0.688 . . . . 0.0 112.322 -179.127 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.76 33.82 87.95 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.9 p -95.8 132.46 41.01 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.543 -0.975 . . . . 0.0 110.406 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.3 m -80.0 -26.65 39.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.641 . . . . 0.0 110.409 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -66.4 129.92 41.46 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.435 -0.791 . . . . 0.0 110.296 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.555 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.3 mt -131.29 157.13 44.12 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.54 -0.725 . . . . 0.0 110.558 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -119.94 115.73 24.36 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.528 -0.732 . . . . 0.0 109.876 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.61 HD13 HD11 ' A' ' 143' ' ' LEU . 65.0 tp -93.37 138.28 31.86 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.578 -0.701 . . . . 0.0 110.699 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.2 t -97.89 130.05 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.688 -0.633 . . . . 0.0 109.524 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -106.43 165.67 11.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.453 -0.779 . . . . 0.0 110.509 -179.461 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.656 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.3 mtp180 -59.99 -27.34 66.78 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.627 -0.671 . . . . 0.0 110.489 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 44.8 t-80 -94.49 29.22 2.32 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.528 -0.732 . . . . 0.0 110.62 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.28 39.95 31.3 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.236 -0.915 . . . . 0.0 110.777 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -104.62 127.62 52.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.612 -0.68 . . . . 0.0 109.972 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 120.13 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.498 -0.751 . . . . 0.0 109.993 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 40.2 pt -114.44 146.9 36.84 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.616 -0.678 . . . . 0.0 109.975 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -87.03 113.04 0.96 Allowed 'Trans proline' 0 N--CA 1.49 1.271 0 O-C-N 123.852 1.448 . . . . 0.0 110.531 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.0 119.94 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 109.517 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -79.34 136.95 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.493 -0.754 . . . . 0.0 110.259 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -80.01 129.6 34.62 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.661 -0.649 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -124.64 23.6 8.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.544 -0.722 . . . . 0.0 110.292 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.78 -177.92 47.41 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -68.75 -39.96 80.03 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.57 -0.959 . . . . 0.0 110.429 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.7 p -129.84 26.18 5.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.525 -0.735 . . . . 0.0 110.506 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.89 159.99 35.78 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.534 -0.729 . . . . 0.0 110.253 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -153.1 172.72 32.05 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.7 p -126.36 147.0 49.82 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.529 -0.983 . . . . 0.0 110.227 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.7 mp -99.79 121.14 40.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.547 -0.721 . . . . 0.0 110.256 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -60.88 -40.02 91.43 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.703 . . . . 0.0 109.955 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.7 m -109.95 112.91 57.65 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.588 -0.695 . . . . 0.0 109.967 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -64.19 127.47 19.32 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 123.845 1.445 . . . . 0.0 110.515 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 31.8 mtt-85 -127.04 160.04 61.61 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.568 -0.708 . . . . 0.0 110.041 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.09 146.43 81.95 Favored 'Trans proline' 0 N--CA 1.49 1.303 0 O-C-N 123.953 1.501 . . . . 0.0 110.303 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.636 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.1 m -60.03 -27.06 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.613 -0.679 . . . . 0.0 110.547 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -59.94 -40.06 87.64 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.468 -0.77 . . . . 0.0 110.389 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -65.36 -39.94 92.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.469 -0.77 . . . . 0.0 110.116 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.458 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -70.36 -27.16 64.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.595 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -58.21 140.04 53.84 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.388 -0.82 . . . . 0.0 110.448 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 87.28 6.98 77.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 56.0 p -111.43 -4.27 14.92 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.026 -1.279 . . . . 0.0 111.245 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.411 ' HB2' ' H2A' ' B' ' 191' ' ' FE3 . 3.3 m -59.96 140.05 56.99 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.057 -1.027 . . . . 0.0 109.777 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.501 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 98.32 -23.7 35.06 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.65 150.08 42.65 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.692 ' C ' HD12 ' A' ' 143' ' ' LEU . 52.3 Cg_endo -91.8 156.74 3.43 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.785 1.413 . . . . 0.0 111.571 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.692 HD12 ' C ' ' A' ' 142' ' ' PRO . 9.8 mp -116.4 102.99 10.01 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.796 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.623 HD21 HD22 ' A' ' 94' ' ' LEU . 9.9 mp -94.79 133.19 38.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.561 -0.712 . . . . 0.0 111.661 -178.358 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.05 159.37 84.56 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.912 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.8 Cg_endo -52.61 -26.16 28.39 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 O-C-N 123.505 1.266 . . . . 0.0 112.276 -178.643 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.2 m -62.51 -40.06 95.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.32 39.52 0.58 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' HIS . . . . . 0.411 ' CE1' ' OG1' ' A' ' 95' ' ' THR . 3.6 m-70 -137.28 144.96 42.95 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.478 -1.013 . . . . 0.0 110.039 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.635 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -66.62 140.01 57.91 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.552 -0.717 . . . . 0.0 110.244 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 97' ' ' CYS . 63.0 t -112.63 -36.25 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.581 -0.7 . . . . 0.0 109.814 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.91 -168.51 38.75 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.751 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.7 mt -129.56 140.1 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.543 -0.975 . . . . 0.0 110.216 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -60.56 136.4 58.04 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.632 -0.667 . . . . 0.0 109.91 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.9 ttt180 -115.72 -52.22 2.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.532 -0.73 . . . . 0.0 110.369 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ALA . . . . . 0.569 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -156.12 160.04 39.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.529 -0.732 . . . . 0.0 110.294 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.72 151.06 28.18 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.645 -0.659 . . . . 0.0 110.311 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.91 119.51 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.672 -0.643 . . . . 0.0 109.68 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.636 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -135.02 154.38 51.74 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.634 -0.666 . . . . 0.0 110.305 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.3 m -103.02 -48.68 3.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.549 -0.72 . . . . 0.0 110.653 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.5 mtm180 -131.04 50.2 2.25 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.53 -0.731 . . . . 0.0 110.373 -179.457 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.97 -4.36 83.16 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 59.6 t -113.29 129.4 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -1.21 . . . . 0.0 109.688 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -99.97 123.95 44.77 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.589 -0.694 . . . . 0.0 110.595 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.25 -18.35 13.62 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.59 -0.694 . . . . 0.0 110.698 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.48 153.7 43.89 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.328 -0.858 . . . . 0.0 110.224 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.75 163.58 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.517 -0.74 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -122.18 134.14 54.72 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.653 -0.654 . . . . 0.0 110.224 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -132.25 157.42 44.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.44 -0.787 . . . . 0.0 110.227 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.776 HG11 HD11 ' A' ' 82' ' ' LEU . 58.0 t -93.43 120.67 66.29 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.572 -0.705 . . . . 0.0 109.589 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.33 148.72 84.82 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.762 1.401 . . . . 0.0 110.492 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.5 -23.58 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.734 -0.604 . . . . 0.0 110.738 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -59.51 -34.58 72.78 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.626 -179.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.7 p -69.75 -37.37 76.43 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.493 -0.755 . . . . 0.0 110.435 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.751 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.1 mtt -59.96 -50.01 75.43 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.458 -0.776 . . . . 0.0 110.873 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -64.49 -29.3 70.34 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.494 -0.754 . . . . 0.0 110.359 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -60.51 -42.56 96.65 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.455 -0.778 . . . . 0.0 110.021 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -70.0 -40.8 75.07 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -63.04 -40.06 96.58 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.528 -0.732 . . . . 0.0 110.331 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -68.58 -40.0 80.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.617 -0.677 . . . . 0.0 110.314 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.96 -40.01 95.44 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.527 -0.733 . . . . 0.0 110.245 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 46.7 t -60.01 -50.02 75.39 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.496 -0.753 . . . . 0.0 110.49 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.0 pttt -69.94 -29.59 66.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.422 -0.799 . . . . 0.0 110.417 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 85.3 tttt 52.8 85.13 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.375 -0.828 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt 54.22 176.85 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.365 -0.834 . . . . 0.0 110.692 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.7 tttp . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.221 -179.947 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' B' B ' 188' ' ' GLU . . . . . 0.569 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.4 tt0 -119.95 138.32 53.53 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.15 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.79 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.6 mp -89.34 138.57 31.32 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.531 -0.731 . . . . 0.0 110.245 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.411 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.443 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.4 m . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.01 0.433 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.01 140.52 11.43 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -60.06 -39.94 87.75 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.473 -1.016 . . . . 0.0 110.283 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 42.8 t0 55.24 85.24 0.07 Allowed 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.367 -0.833 . . . . 0.0 110.619 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -80.01 -11.07 59.81 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.571 -0.706 . . . . 0.0 111.212 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -91.3 117.8 29.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.135 -0.978 . . . . 0.0 110.419 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.476 ' HG3' HG13 ' A' ' 29' ' ' VAL . 56.7 tp60 -59.97 -49.49 77.47 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.552 -0.718 . . . . 0.0 110.308 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 29' ' ' VAL . 35.7 m -142.97 106.83 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.66 -0.65 . . . . 0.0 110.395 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -69.99 -39.99 75.59 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.435 -0.79 . . . . 0.0 110.214 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.71 89.13 0.11 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -63.15 -37.23 86.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.614 -0.933 . . . . 0.0 110.298 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.34 130.04 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 109.757 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -128.03 158.56 37.59 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.54 -0.725 . . . . 0.0 110.53 -179.626 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.2 t -95.27 128.43 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 0.0 109.499 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.565 ' CB ' HD21 ' A' ' 64' ' ' LEU . 29.2 m -129.3 158.97 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.591 -0.693 . . . . 0.0 109.83 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -153.46 164.04 38.89 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.8 p -118.71 -169.68 1.76 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.635 -0.665 . . . . 0.0 109.598 179.376 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.99 -34.31 73.14 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.586 -0.696 . . . . 0.0 110.985 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 54.7 p -131.21 -10.69 3.71 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.184 -0.947 . . . . 0.0 112.64 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -117.92 153.42 33.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.92 -1.113 . . . . 0.0 111.289 -179.086 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 35.2 t -138.44 138.31 38.04 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.623 -0.673 . . . . 0.0 109.736 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.78 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 22.4 p90 -167.24 -178.08 3.94 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.305 -0.872 . . . . 0.0 110.527 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.677 HD11 ' HA ' ' A' ' 109' ' ' ARG . 66.4 mt -113.61 157.61 21.89 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.619 -0.676 . . . . 0.0 110.649 -178.619 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -135.24 162.29 32.97 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.742 -0.599 . . . . 0.0 110.112 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -124.63 139.8 53.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.3 t -97.57 113.94 25.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.411 -0.806 . . . . 0.0 110.619 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' VAL . . . . . 0.427 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 61.4 t -121.03 133.88 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.609 -0.682 . . . . 0.0 109.945 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.54 39.95 27.39 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.509 -0.745 . . . . 0.0 111.256 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 67.9 26.89 73.78 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 178.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 65.5 t -140.02 138.59 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.468 -1.019 . . . . 0.0 109.696 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -81.07 147.37 30.16 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 109.298 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' TRP . . . . . 0.524 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 61.1 m95 -130.13 153.06 48.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.455 -0.778 . . . . 0.0 110.868 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.5 t -169.62 -179.5 3.39 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.842 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.1 p -95.25 144.87 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.476 -0.765 . . . . 0.0 110.473 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.431 ' CE1' HG22 ' A' ' 78' ' ' VAL . 64.9 t80 -60.47 -42.59 96.54 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.716 -0.615 . . . . 0.0 111.694 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.842 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.9 p-80 -70.02 -20.14 63.28 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.043 -1.036 . . . . 0.0 110.895 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.732 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -89.19 -43.32 5.34 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.78 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -132.6 85.05 2.19 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.668 -0.901 . . . . 0.0 109.804 179.462 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.2 -168.8 1.55 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.5 p -72.78 67.45 0.81 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.618 -0.93 . . . . 0.0 109.707 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -140.02 169.78 17.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.622 -0.674 . . . . 0.0 110.476 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.9 m -65.53 139.58 58.49 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.676 -0.64 . . . . 0.0 110.088 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.952 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.4 tp -115.3 133.47 56.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.625 -0.672 . . . . 0.0 109.801 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.78 119.37 30.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.555 -0.716 . . . . 0.0 110.334 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -125.42 176.37 17.25 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.03 -32.18 75.92 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.788 1.415 . . . . 0.0 110.455 -179.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.2 mmtt -70.21 -31.39 68.81 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.555 -0.716 . . . . 0.0 109.782 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.31 -151.12 22.38 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.87 154.65 63.26 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.886 1.466 . . . . 0.0 110.131 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.431 HG22 ' CD1' ' A' ' 85' ' ' TRP . 86.0 mt -129.98 139.91 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.56 -0.713 . . . . 0.0 110.675 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.5 m -100.57 138.8 37.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.589 -0.694 . . . . 0.0 110.274 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 143.81 51.91 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.562 -0.711 . . . . 0.0 110.817 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' MET . . . . . 0.436 ' HB3' ' CD2' ' A' ' 75' ' ' TYR . 5.5 mtp -119.16 -50.03 2.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.532 -0.73 . . . . 0.0 110.452 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' TYR . . . . . 0.436 ' CD2' ' HB3' ' A' ' 74' ' ' MET . 98.8 m-85 -120.0 140.01 51.61 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.754 . . . . 0.0 110.462 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.599 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.5 m -136.03 133.02 37.0 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.556 -0.715 . . . . 0.0 110.411 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.7 t30 -145.83 100.56 3.43 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.495 -0.753 . . . . 0.0 109.98 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.431 HG22 ' CE1' ' A' ' 56' ' ' TYR . 59.8 t -69.98 -36.66 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.543 -0.723 . . . . 0.0 110.312 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -59.95 -50.0 75.48 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.469 -0.77 . . . . 0.0 110.981 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.5 mm-40 -90.47 0.15 57.43 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.466 -0.771 . . . . 0.0 111.309 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.6 t70 55.33 40.09 31.41 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.921 -1.112 . . . . 0.0 109.747 -179.41 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.465 ' CD2' HG21 ' A' ' 170' ' ' VAL . 0.6 OUTLIER -125.24 132.34 52.98 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.671 -0.643 . . . . 0.0 110.742 -179.07 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 54' ' ' THR . 27.1 m -145.08 157.16 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.645 -0.659 . . . . 0.0 109.462 179.05 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -144.84 175.03 24.72 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.594 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.952 ' CH2' HD22 ' A' ' 64' ' ' LEU . 8.5 m-90 -130.04 159.97 35.11 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.916 -0.755 . . . . 0.0 109.631 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -66.53 123.33 19.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.365 -0.834 . . . . 0.0 109.152 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -79.37 139.74 55.89 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.504 -0.747 . . . . 0.0 110.193 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HG2' ' HB2' ' A' ' 91' ' ' ALA . 48.3 Cg_endo -69.98 159.17 54.2 Favored 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.824 1.434 . . . . 0.0 110.4 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.52 136.1 27.76 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.961 1.506 . . . . 0.0 110.286 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.13 -24.16 33.39 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ALA . . . . . 0.465 ' HB2' ' HG2' ' A' ' 88' ' ' PRO . . . -60.1 140.01 57.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.374 -1.074 . . . . 0.0 110.3 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -80.91 158.9 25.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.635 -0.666 . . . . 0.0 109.659 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.8 p -130.49 168.93 16.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.521 -0.737 . . . . 0.0 110.325 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.421 ' O ' HG13 ' A' ' 48' ' ' VAL . 84.5 mt -112.94 140.01 48.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.561 -0.712 . . . . 0.0 110.702 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 44.6 p -82.1 165.54 42.4 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.647 -0.658 . . . . 0.0 110.142 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -81.63 162.04 19.14 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.797 1.42 . . . . 0.0 110.662 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -73.66 130.16 39.45 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.64 -0.662 . . . . 0.0 110.137 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.97 54.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.741 -0.599 . . . . 0.0 109.816 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.73 -8.49 0.73 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.713 . . . . 0.0 112.383 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 42.85 97.29 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -100.0 119.97 39.1 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.522 -0.987 . . . . 0.0 110.531 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.9 m -62.78 -40.08 96.19 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.649 -0.657 . . . . 0.0 110.296 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -63.41 130.47 44.57 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.583 -0.698 . . . . 0.0 110.261 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 151' ' ' VAL . 95.8 mt -137.97 155.37 48.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.617 -0.677 . . . . 0.0 110.577 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -106.69 135.58 47.98 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.465 -0.772 . . . . 0.0 109.545 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.506 HD11 ' HB2' ' A' ' 154' ' ' PHE . 39.8 tp -105.09 127.21 52.79 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.449 -0.782 . . . . 0.0 110.747 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 140.03 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.536 -0.727 . . . . 0.0 109.777 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.2 m -130.07 170.06 14.49 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.524 -0.735 . . . . 0.0 110.516 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.677 ' HA ' HD11 ' A' ' 44' ' ' LEU . 44.2 mtm180 -60.04 -23.2 63.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.51 -0.744 . . . . 0.0 110.781 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.11 19.37 5.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.395 -0.816 . . . . 0.0 111.194 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.49 39.9 30.63 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.077 -1.015 . . . . 0.0 110.693 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -113.27 157.65 21.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.533 -0.729 . . . . 0.0 109.955 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.4 m -129.43 133.68 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.52 -0.738 . . . . 0.0 110.371 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 49.0 mm -122.48 147.82 51.16 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.602 -0.687 . . . . 0.0 109.701 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' PRO . . . . . 0.437 ' HG2' HD22 ' A' ' 127' ' ' LEU . 48.6 Cg_endo -82.65 129.75 5.74 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.906 1.477 . . . . 0.0 110.378 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 125' ' ' SER . 63.0 t -130.0 130.02 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.697 -0.627 . . . . 0.0 109.602 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ARG . . . . . 0.589 ' HG2' HD11 ' A' ' 127' ' ' LEU . 54.2 mmm-85 -79.53 153.1 29.78 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.517 -0.74 . . . . 0.0 110.276 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 51.4 ttt-85 -99.34 119.07 37.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.64 -0.662 . . . . 0.0 109.921 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.1 mmm-85 -114.6 24.34 11.93 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.671 -0.643 . . . . 0.0 110.219 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 162.07 -175.41 38.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -64.57 -39.97 94.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.53 -0.982 . . . . 0.0 110.378 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 52.8 p -130.87 28.87 4.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.543 -0.723 . . . . 0.0 110.753 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.6 tpp85 -132.44 146.63 52.09 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.422 -0.799 . . . . 0.0 110.656 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -160.69 169.83 36.48 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.423 ' O ' HG13 ' A' ' 116' ' ' VAL . 53.3 p -109.24 158.38 17.91 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.468 -1.019 . . . . 0.0 110.234 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.7 tp -102.02 119.94 39.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.541 -0.725 . . . . 0.0 110.152 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.589 HD11 ' HG2' ' A' ' 117' ' ' ARG . 7.6 mp -65.44 -40.04 92.79 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.988 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.8 109.94 59.35 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -66.14 118.68 5.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.82 1.432 . . . . 0.0 110.415 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -120.04 160.01 44.75 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.598 -0.689 . . . . 0.0 110.127 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.2 157.93 54.93 Favored 'Trans proline' 0 N--CA 1.491 1.352 0 O-C-N 123.919 1.484 . . . . 0.0 110.242 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.421 HG21 ' SG ' ' A' ' 159' ' ' CYS . 63.4 t -67.13 -30.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.601 -0.687 . . . . 0.0 110.191 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.6 p -60.04 -39.74 86.97 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.515 -0.74 . . . . 0.0 110.414 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -64.35 -40.02 95.03 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.566 -0.709 . . . . 0.0 110.222 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.448 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.02 -30.75 68.14 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.453 -0.779 . . . . 0.0 110.555 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -60.04 142.75 53.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.469 -0.769 . . . . 0.0 110.218 -179.742 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.96 8.72 87.41 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 17.5 m -113.37 -7.73 13.47 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.182 -1.187 . . . . 0.0 110.966 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 30.6 t -59.92 140.33 56.76 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.091 -1.005 . . . . 0.0 109.99 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.401 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.3 -21.23 42.05 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -61.45 145.05 48.85 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.42 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.1 Cg_endo -86.88 142.16 6.52 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.836 1.44 . . . . 0.0 111.262 -179.457 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.736 ' O ' HG12 ' A' ' 151' ' ' VAL . 9.7 mp -101.25 122.09 43.04 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 143' ' ' LEU . 10.0 mp -112.13 133.77 54.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.474 -0.766 . . . . 0.0 111.537 -178.693 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.439 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.08 160.03 82.1 Favored Pre-proline 0 N--CA 1.497 1.912 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.072 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 146' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -52.13 -23.02 16.32 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 O-C-N 123.464 1.244 . . . . 0.0 112.235 -178.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -65.84 -40.01 91.34 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.325 -0.859 . . . . 0.0 109.854 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.99 34.33 0.91 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 19.1 m-70 -131.68 145.52 51.69 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.464 -1.021 . . . . 0.0 110.326 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.29 137.19 46.55 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.545 -0.722 . . . . 0.0 110.265 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.736 HG12 ' O ' ' A' ' 143' ' ' LEU . 9.2 p -115.54 -22.49 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.536 -0.728 . . . . 0.0 110.696 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.65 -170.93 43.51 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ILE . . . . . 0.401 HG23 ' C ' ' A' ' 140' ' ' GLY . 63.5 mt -129.93 140.03 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.595 -0.944 . . . . 0.0 110.055 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.506 ' HB2' HD11 ' A' ' 106' ' ' LEU . 20.7 t80 -61.64 138.24 58.29 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.652 -0.655 . . . . 0.0 109.911 179.692 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -118.49 -52.3 2.37 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.545 -0.722 . . . . 0.0 110.563 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.11 160.39 42.9 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.57 -0.706 . . . . 0.0 110.403 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.94 147.58 39.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.599 -0.688 . . . . 0.0 110.384 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.01 120.03 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.677 -0.64 . . . . 0.0 109.642 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.421 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -125.93 143.99 50.86 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.645 -0.659 . . . . 0.0 110.631 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' THR . . . . . 0.511 HG22 ' HG2' ' A' ' 161' ' ' ARG . 58.6 m -82.01 -56.42 3.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.663 . . . . 0.0 110.44 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.511 ' HG2' HG22 ' A' ' 160' ' ' THR . 20.8 mmt180 -134.7 58.0 1.79 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.529 -0.732 . . . . 0.0 110.08 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.4 -10.0 75.76 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.86 121.35 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.128 -1.219 . . . . 0.0 109.688 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -78.83 128.3 33.18 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.631 -0.668 . . . . 0.0 110.552 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -111.5 -25.97 9.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.639 -0.663 . . . . 0.0 110.398 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.36 159.17 42.78 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.585 -0.697 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.8 160.01 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.539 -0.726 . . . . 0.0 111.006 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -121.76 133.88 54.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.682 -0.636 . . . . 0.0 110.055 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -138.18 151.44 47.71 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.421 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.465 HG21 ' CD2' ' A' ' 82' ' ' LEU . 57.3 t -88.09 123.42 68.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.497 -0.752 . . . . 0.0 109.505 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.34 155.13 71.76 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.764 1.402 . . . . 0.0 110.56 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 151' ' ' VAL . 88.9 t -58.24 -21.74 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.681 -0.637 . . . . 0.0 110.654 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -57.64 -40.01 78.27 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.268 -0.895 . . . . 0.0 110.656 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 3.4 m -73.65 -35.32 65.24 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.448 -0.783 . . . . 0.0 109.683 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' MET . . . . . 0.524 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 95.0 mtp -63.14 -40.48 97.71 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.66 -0.65 . . . . 0.0 110.133 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -69.54 -39.92 77.17 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.611 -0.681 . . . . 0.0 110.381 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.9 m -65.48 -39.97 92.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.662 -0.649 . . . . 0.0 110.075 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 90.5 m -61.72 -48.62 79.91 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.533 -0.729 . . . . 0.0 110.069 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' MET . . . . . 0.4 ' HG3' ' CZ ' ' A' ' 75' ' ' TYR . 26.6 ttt -60.07 -48.47 81.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.56 -0.712 . . . . 0.0 110.308 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 58.6 ttp180 -60.11 -39.9 87.8 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.578 -0.701 . . . . 0.0 110.208 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.83 -39.96 87.84 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.587 -0.695 . . . . 0.0 110.146 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 2.3 m 52.31 40.03 28.41 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.42 -0.8 . . . . 0.0 110.821 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -102.56 140.04 37.36 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.693 . . . . 0.0 110.275 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -102.87 140.03 37.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.526 -0.734 . . . . 0.0 110.196 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt 55.37 -87.24 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.676 -0.64 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.8 tptt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.121 -0.987 . . . . 0.0 110.078 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -119.79 133.15 55.71 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 118.738 -1.185 . . . . 0.0 110.071 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.789 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.2 mp -69.99 140.05 52.87 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.407 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.4 t . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 62.75 -133.78 44.05 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 52.88 40.03 30.12 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.414 -1.051 . . . . 0.0 110.737 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -67.58 -39.69 84.85 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.542 -0.724 . . . . 0.0 110.284 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 53.1 179.31 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.431 -0.793 . . . . 0.0 110.767 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 -108.79 119.96 41.07 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.522 -0.736 . . . . 0.0 110.256 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -60.61 -40.02 90.29 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.6 -0.688 . . . . 0.0 110.476 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.3 t -117.47 120.74 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.621 -0.674 . . . . 0.0 110.092 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -112.12 -27.24 8.45 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.597 -0.689 . . . . 0.0 110.432 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.4 11.58 11.71 Favored Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.804 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.432 ' HB3' ' CD2' ' A' ' 94' ' ' LEU . 45.3 mt-10 56.08 20.64 4.51 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.214 -1.168 . . . . 0.0 111.086 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.427 HG23 ' C ' ' A' ' 32' ' ' GLU . 65.9 t -147.76 131.86 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.386 -0.821 . . . . 0.0 109.647 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -124.72 155.17 39.7 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.522 -0.736 . . . . 0.0 110.583 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.9 t -102.92 122.04 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.682 -0.636 . . . . 0.0 109.605 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.562 ' HB ' HD12 ' A' ' 64' ' ' LEU . 34.1 m -117.1 145.2 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.658 -0.651 . . . . 0.0 109.772 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' SER . . . . . 0.463 ' O ' HD13 ' A' ' 64' ' ' LEU . 6.2 t -131.85 168.5 17.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.548 -0.72 . . . . 0.0 110.6 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.436 HG22 ' H ' ' A' ' 39' ' ' ALA . 5.0 m -141.91 173.23 11.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.584 -0.698 . . . . 0.0 110.376 -179.671 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.436 ' H ' HG22 ' A' ' 38' ' ' THR . . . -68.88 -12.71 61.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.592 -0.692 . . . . 0.0 111.044 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 43.2 p -111.16 -41.5 4.17 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.202 -0.936 . . . . 0.0 111.088 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -157.48 168.14 28.17 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.402 -0.811 . . . . 0.0 110.831 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 80.6 p -119.85 152.64 37.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 3.7 p90 -154.26 -178.22 6.98 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.525 -0.735 . . . . 0.0 110.136 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.796 HD11 ' CA ' ' A' ' 109' ' ' ARG . 35.0 mt -113.49 153.76 28.16 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.487 -0.758 . . . . 0.0 110.817 -178.236 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -131.12 162.19 30.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.686 -0.634 . . . . 0.0 109.972 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 7.6 t -124.44 143.61 50.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.474 -0.766 . . . . 0.0 110.59 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 97.1 m -96.53 108.93 21.59 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.568 -0.707 . . . . 0.0 110.154 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.5 t -123.35 133.84 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.543 -0.723 . . . . 0.0 109.612 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 54.71 36.53 26.44 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.521 -0.737 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.02 75.96 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.268 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.38 129.97 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.226 -1.161 . . . . 0.0 110.043 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 90.7 m -74.23 149.2 40.94 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.473 -0.767 . . . . 0.0 109.527 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 77.1 m95 -136.11 151.85 50.23 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.512 -0.742 . . . . 0.0 111.069 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.937 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.4 t -168.4 -178.49 3.58 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.847 -0.533 . . . . 0.0 109.778 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.921 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.7 p -82.08 161.27 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.568 -0.707 . . . . 0.0 110.01 179.265 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 65.9 t80 -85.37 -34.6 21.74 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.399 -0.813 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.921 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.6 p-80 -70.01 -20.1 63.29 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.996 -1.065 . . . . 0.0 110.941 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.501 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -78.22 -51.15 5.85 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 179.544 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.416 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -95.16 -50.43 5.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.509 -0.995 . . . . 0.0 110.374 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.3 30.81 36.03 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.427 ' HA ' HG21 ' A' ' 83' ' ' VAL . 2.0 t 56.87 40.02 29.16 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.302 -1.116 . . . . 0.0 110.283 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.06 178.67 4.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.69 -0.631 . . . . 0.0 109.737 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -65.46 138.79 58.34 Favored 'General case' 0 N--CA 1.494 1.726 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.181 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.732 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -118.24 142.74 47.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.5 -0.75 . . . . 0.0 110.214 -179.406 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.99 115.94 30.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.645 -0.659 . . . . 0.0 109.911 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.58 174.29 15.25 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -62.78 -31.83 78.16 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.762 1.401 . . . . 0.0 110.422 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -71.93 -31.29 66.21 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.767 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.03 -147.58 19.03 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.63 151.32 64.04 Favored 'Trans proline' 0 N--CA 1.49 1.296 0 O-C-N 123.878 1.462 . . . . 0.0 110.241 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.732 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.8 mt -120.02 129.67 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.626 -0.671 . . . . 0.0 110.271 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.8 p -91.56 144.46 25.52 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.464 -0.772 . . . . 0.0 110.149 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 0.4 OUTLIER -88.0 134.17 33.79 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.558 -0.714 . . . . 0.0 110.872 -179.566 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.1 mmm -116.57 -33.22 4.95 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.625 -0.672 . . . . 0.0 110.239 179.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -131.27 137.67 48.96 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.577 -0.702 . . . . 0.0 110.326 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 84.6 m -139.97 130.62 25.75 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.528 -0.733 . . . . 0.0 109.978 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -136.86 100.67 4.37 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.545 -0.722 . . . . 0.0 110.353 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.432 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.8 t -70.01 -35.55 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.594 -0.691 . . . . 0.0 110.025 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -60.0 -47.88 84.0 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.606 -0.684 . . . . 0.0 110.512 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.96 3.03 54.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.479 -0.763 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.414 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 9.1 t70 54.08 49.4 18.89 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.113 -0.992 . . . . 0.0 110.425 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.73 HD11 HG11 ' A' ' 170' ' ' VAL . 68.4 mt -140.94 141.24 34.5 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.589 -0.694 . . . . 0.0 111.047 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.663 ' O ' HG22 ' A' ' 54' ' ' THR . 7.8 p -139.15 140.5 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -125.71 158.09 19.92 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.937 ' CH2' HG21 ' A' ' 54' ' ' THR . 11.2 m-90 -119.89 167.16 12.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.681 -0.893 . . . . 0.0 109.88 179.569 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -71.19 115.86 10.83 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.605 -0.685 . . . . 0.0 109.429 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.07 146.34 94.83 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.554 -0.716 . . . . 0.0 110.187 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.91 159.8 51.97 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.981 1.516 . . . . 0.0 110.314 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.02 151.2 61.64 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 124.019 1.536 . . . . 0.0 110.369 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.06 29.46 70.6 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.13 139.41 38.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.56 -0.965 . . . . 0.0 110.266 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -88.86 143.41 26.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.599 -0.688 . . . . 0.0 109.842 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.4 p -128.99 159.62 35.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 110.571 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.753 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 3.2 mm? -79.94 160.0 26.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.608 -0.682 . . . . 0.0 110.504 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.6 p -103.08 150.31 37.73 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.681 -0.637 . . . . 0.0 109.884 179.633 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -60.53 141.32 95.03 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 O-C-N 123.783 1.412 . . . . 0.0 110.738 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 32.1 t -60.06 133.95 56.58 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.506 -0.746 . . . . 0.0 110.129 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 98' ' ' THR . 6.7 t -136.48 57.24 1.78 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.5 -8.8 0.75 Allowed 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.463 -178.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.08 44.1 96.54 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.2 m -108.36 132.59 53.59 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.537 -0.978 . . . . 0.0 110.671 -179.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -76.78 -27.26 55.21 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.661 -0.649 . . . . 0.0 110.427 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.76 129.97 41.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.463 -0.773 . . . . 0.0 110.214 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.601 HD22 HG21 ' A' ' 151' ' ' VAL . 92.6 mt -135.18 145.65 47.95 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.572 -0.705 . . . . 0.0 110.65 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -106.93 130.79 54.54 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.524 -0.735 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.42 HD13 HD11 ' A' ' 143' ' ' LEU . 50.7 tp -108.5 143.09 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.529 -0.732 . . . . 0.0 110.682 -179.221 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.02 129.97 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.666 -0.646 . . . . 0.0 109.533 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 77.3 p -102.58 176.76 5.06 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.509 -0.745 . . . . 0.0 110.791 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.796 ' CA ' HD11 ' A' ' 44' ' ' LEU . 11.9 ttp180 -68.44 -19.45 64.57 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.719 -0.613 . . . . 0.0 110.742 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -92.37 24.04 3.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.382 -0.824 . . . . 0.0 110.981 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.58 39.35 31.11 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.231 -0.918 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -114.46 159.47 20.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.592 -0.692 . . . . 0.0 109.724 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.92 136.45 58.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.539 -0.725 . . . . 0.0 110.437 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.553 HD12 HH21 ' A' ' 130' ' ' ARG . 16.6 tt -129.9 131.18 23.34 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.561 -0.712 . . . . 0.0 109.809 179.643 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.61 126.05 12.95 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.77 1.405 . . . . 0.0 110.552 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -124.11 129.91 73.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.785 -0.572 . . . . 0.0 109.691 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -86.77 136.57 32.95 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.446 -0.784 . . . . 0.0 109.945 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -84.38 121.43 27.53 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 110.435 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -110.03 20.06 18.33 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.642 -0.661 . . . . 0.0 110.449 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 164.85 -179.95 39.21 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -69.68 -40.08 76.58 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.482 -1.011 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 88.8 p -120.26 21.88 11.56 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.928 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -133.79 140.22 46.79 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.394 -0.816 . . . . 0.0 110.328 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.73 163.23 26.21 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -126.69 144.99 50.75 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.587 -0.949 . . . . 0.0 110.295 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.541 HD13 HG13 ' A' ' 167' ' ' VAL . 10.7 mp -100.03 129.94 46.14 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.628 -0.67 . . . . 0.0 110.44 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.6 mp -68.73 -40.03 80.1 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.642 -0.661 . . . . 0.0 109.723 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -109.15 112.69 59.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.661 -0.65 . . . . 0.0 109.878 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.95 136.77 50.04 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.756 1.398 . . . . 0.0 110.567 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' ARG . . . . . 0.553 HH21 HD12 ' A' ' 114' ' ' ILE . 20.1 mmt85 -129.84 160.0 67.11 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.712 . . . . 0.0 110.093 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.06 152.23 83.05 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.875 1.46 . . . . 0.0 110.375 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 162' ' ' GLY . 34.3 m -64.99 -25.56 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.605 -0.684 . . . . 0.0 110.487 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.7 m -59.99 -40.03 87.77 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.0 110.286 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -66.64 -39.96 88.48 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.593 -0.692 . . . . 0.0 109.987 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.458 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -65.19 -34.46 78.43 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.636 -0.665 . . . . 0.0 110.264 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -60.02 142.98 53.0 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.461 -0.774 . . . . 0.0 110.324 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.97 9.73 86.37 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.146 -1.182 . . . . 0.0 110.146 -179.472 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 15.9 m -116.9 -6.94 11.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.266 -1.137 . . . . 0.0 110.945 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.2 t -60.06 139.95 57.14 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.208 -0.932 . . . . 0.0 110.074 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.97 -17.66 56.9 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.378 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.04 151.48 44.85 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -95.66 144.97 1.25 Allowed 'Trans proline' 0 N--CA 1.489 1.211 0 O-C-N 123.797 1.419 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.561 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.4 mp -96.26 103.18 15.06 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.336 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.494 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -82.64 159.63 22.63 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.902 0.858 . . . . 0.0 111.905 -178.006 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.15 164.27 18.9 Favored Pre-proline 0 N--CA 1.494 1.727 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.669 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -65.71 -30.57 50.39 Favored 'Trans proline' 0 N--CA 1.49 1.272 0 O-C-N 123.922 1.485 . . . . 0.0 108.378 177.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -70.0 -36.72 75.36 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.615 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.01 41.98 0.53 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -130.01 145.74 51.66 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.468 -1.019 . . . . 0.0 110.651 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' ALA . . . . . 0.753 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.99 140.32 52.92 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.421 -0.799 . . . . 0.0 109.867 179.408 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.3 t -112.91 -44.39 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 110.262 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.43 -179.52 44.15 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 45.9 mt -120.02 130.72 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.611 -0.935 . . . . 0.0 110.157 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' PHE . . . . . 0.547 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 26.4 t80 -60.09 136.49 58.04 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.648 -0.657 . . . . 0.0 109.961 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -115.49 -52.73 2.64 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.526 -0.734 . . . . 0.0 110.414 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.89 158.64 44.4 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.558 -0.714 . . . . 0.0 110.23 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' ALA . . . . . 0.547 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.95 148.39 31.7 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.401 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.0 t -110.03 119.99 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.732 -0.605 . . . . 0.0 109.65 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.43 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -131.34 148.63 52.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.608 -0.683 . . . . 0.0 110.547 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 94.0 m -69.99 -47.02 63.87 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.625 -0.672 . . . . 0.0 110.018 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -164.63 53.41 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.716 -0.615 . . . . 0.0 109.84 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.45 ' O ' HG13 ' A' ' 132' ' ' VAL . . . 115.66 -18.06 15.36 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.64 120.04 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.276 -1.132 . . . . 0.0 109.775 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -92.22 124.94 36.67 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.602 -0.686 . . . . 0.0 110.445 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.67 -29.16 7.22 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.693 -0.629 . . . . 0.0 110.199 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -129.89 150.15 51.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.612 -0.68 . . . . 0.0 110.053 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.541 HG13 HD13 ' A' ' 126' ' ' LEU . 35.3 m -130.06 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.539 -0.726 . . . . 0.0 110.653 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -122.9 132.86 54.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.698 -0.626 . . . . 0.0 109.838 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -139.94 160.01 40.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.492 -0.755 . . . . 0.0 110.616 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.73 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -94.19 123.58 58.5 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.584 -0.697 . . . . 0.0 109.248 179.25 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -62.76 153.15 74.38 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.743 1.391 . . . . 0.0 110.65 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 151' ' ' VAL . 69.3 t -58.09 -24.36 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.605 -0.684 . . . . 0.0 110.565 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.07 -39.98 87.94 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.397 -0.815 . . . . 0.0 110.388 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 53.3 m -60.15 -40.49 90.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.462 -0.774 . . . . 0.0 110.358 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.4 mtm -70.07 -40.0 75.28 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.61 -0.681 . . . . 0.0 110.214 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.0 -40.3 88.74 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.516 -0.74 . . . . 0.0 110.25 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -63.64 -40.38 96.73 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.572 -0.705 . . . . 0.0 109.85 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -69.95 -40.16 75.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.538 -0.726 . . . . 0.0 110.076 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.7 ttm -60.45 -40.2 90.28 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.746 -0.596 . . . . 0.0 110.32 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -60.07 -40.06 88.22 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.595 -0.691 . . . . 0.0 110.166 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.25 -40.08 78.08 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.519 -0.738 . . . . 0.0 110.05 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 18.2 p 49.53 39.95 18.12 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.587 -0.696 . . . . 0.0 111.152 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.7 tttp -100.07 120.06 39.27 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.619 -0.675 . . . . 0.0 110.14 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -128.26 29.35 5.36 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.583 -0.698 . . . . 0.0 110.262 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 59.3 tptt -59.97 -39.98 87.52 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.617 -0.677 . . . . 0.0 110.223 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.9 tptt . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.123 -179.945 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -116.8 130.04 56.47 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 118.7 -1.2 . . . . 0.0 110.048 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.845 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -73.58 143.41 46.44 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 110.251 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.3 p . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.023 0.439 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 159.97 -80.02 0.16 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.0 ttt180 55.99 -87.22 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.634 -0.921 . . . . 0.0 110.665 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -111.57 24.96 12.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.01 -1.056 . . . . 0.0 110.464 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -91.85 119.98 32.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 110.325 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -149.58 88.78 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.652 -0.655 . . . . 0.0 109.96 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.61 -40.01 80.58 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.635 -0.666 . . . . 0.0 110.521 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -147.85 148.34 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.54 -0.725 . . . . 0.0 110.429 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -154.6 159.97 41.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.518 -0.738 . . . . 0.0 110.157 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 146.86 129.96 2.04 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLU . . . . . 0.766 ' OE1' HD21 ' A' ' 94' ' ' LEU . 98.1 mt-10 -62.55 -37.75 87.36 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.633 -0.922 . . . . 0.0 110.005 179.825 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.91 127.53 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.607 -0.683 . . . . 0.0 109.838 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -123.95 156.56 36.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.563 -0.711 . . . . 0.0 110.288 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.3 t -89.16 119.02 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.735 -0.603 . . . . 0.0 109.834 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.849 HG11 HD21 ' A' ' 64' ' ' LEU . 58.9 t -109.23 144.43 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.2 m -144.71 164.68 30.27 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.209 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.0 p -141.53 -179.57 6.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.759 -0.588 . . . . 0.0 109.797 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.78 -6.55 49.56 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.51 -0.744 . . . . 0.0 111.119 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.1 m -105.18 -57.31 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.17 -0.956 . . . . 0.0 111.17 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' GLN . . . . . 0.423 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 2.8 pt20 -143.22 169.04 18.36 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.422 -0.799 . . . . 0.0 110.789 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 70.5 m -116.92 148.46 41.33 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.512 -0.743 . . . . 0.0 110.591 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.516 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.9 p90 -163.1 -178.05 5.79 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.445 -0.784 . . . . 0.0 110.071 -179.725 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' LEU . . . . . 0.715 HD11 ' HA ' ' A' ' 109' ' ' ARG . 62.6 mt -113.15 148.8 34.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.492 -0.755 . . . . 0.0 110.327 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.3 159.74 32.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.662 -0.648 . . . . 0.0 109.937 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' THR . . . . . 0.582 HG21 ' HB3' ' A' ' 142' ' ' PRO . 58.8 m -119.93 138.78 53.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.571 -0.706 . . . . 0.0 110.546 -179.745 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 45.1 m -93.14 110.97 22.47 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.644 -0.66 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.9 t -120.0 130.01 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.552 -0.718 . . . . 0.0 109.297 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.12 35.64 26.02 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.348 -0.845 . . . . 0.0 110.387 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLY . . . . . 0.669 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.0 19.97 75.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -130.06 130.0 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.189 -1.183 . . . . 0.0 110.278 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 34.1 t -76.0 129.94 37.65 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.416 -0.802 . . . . 0.0 109.408 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 42.3 m95 -126.4 137.1 53.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.462 -0.774 . . . . 0.0 111.68 -179.119 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.665 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 15.1 t -161.26 -179.6 7.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.832 HG21 ' CE1' ' A' ' 57' ' ' HIS . 14.5 p -81.19 155.29 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.314 -0.866 . . . . 0.0 110.67 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' TYR . . . . . 0.546 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 59.8 t80 -71.03 -39.93 72.03 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.752 -0.593 . . . . 0.0 111.935 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' HIS . . . . . 0.832 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.8 p-80 -63.56 -24.65 67.9 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.979 -1.076 . . . . 0.0 110.833 -178.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . 0.493 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.18 -51.45 6.82 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.516 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -108.14 -59.69 1.82 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.958 . . . . 0.0 110.07 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . 0.431 ' HA2' ' CD2' ' A' ' 56' ' ' TYR . . . 80.6 -176.51 54.64 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.9 t -79.84 68.13 5.83 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.554 -0.968 . . . . 0.0 109.806 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -142.47 177.73 8.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.623 -0.673 . . . . 0.0 110.243 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 58.9 m -65.14 139.93 58.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 109.899 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LEU . . . . . 0.849 HD21 HG11 ' A' ' 36' ' ' VAL . 12.7 tp -111.74 136.58 50.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.619 -0.676 . . . . 0.0 110.262 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -102.35 109.94 21.74 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.576 -0.703 . . . . 0.0 110.068 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.51 179.96 20.4 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -64.87 -32.35 55.51 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.878 1.462 . . . . 0.0 110.336 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -75.81 -31.19 59.31 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.638 -0.664 . . . . 0.0 110.046 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.88 -150.37 22.53 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.24 144.02 45.28 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 O-C-N 123.844 1.444 . . . . 0.0 110.269 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.652 HG22 ' HB3' ' A' ' 85' ' ' TRP . 51.1 mm -126.57 130.02 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.633 -0.667 . . . . 0.0 110.389 -179.518 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.9 p -77.62 149.76 34.73 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.523 -0.736 . . . . 0.0 109.915 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -100.42 140.5 34.59 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.523 -0.735 . . . . 0.0 110.834 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.4 mmm -113.38 -25.0 9.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.702 -0.623 . . . . 0.0 110.356 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -119.96 140.01 51.58 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 110.551 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 80.6 m -149.25 130.0 14.15 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.525 -0.735 . . . . 0.0 109.954 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 -149.91 98.07 2.67 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 110.319 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' VAL . . . . . 0.546 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 81.1 t -70.01 -40.45 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.541 -0.724 . . . . 0.0 110.082 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -44.8 94.25 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.57 -0.707 . . . . 0.0 110.319 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' GLN . . . . . 0.57 ' HG2' HD12 ' A' ' 82' ' ' LEU . 12.3 tt0 -89.99 0.05 57.32 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.563 -0.71 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ASP . . . . . 0.41 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.8 t0 53.58 45.14 28.75 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.059 -1.026 . . . . 0.0 110.781 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' LEU . . . . . 0.674 HD11 HG11 ' A' ' 170' ' ' VAL . 50.8 mt -134.46 143.53 47.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.481 -0.762 . . . . 0.0 110.682 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.691 HG13 ' CH2' ' A' ' 85' ' ' TRP . 7.1 p -150.06 157.58 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . 0.416 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -152.76 160.07 28.81 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.594 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' TRP . . . . . 0.691 ' CH2' HG13 ' A' ' 83' ' ' VAL . 11.3 m-90 -127.74 154.61 45.16 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.628 -0.925 . . . . 0.0 109.735 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -63.45 116.75 5.86 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.51 -0.744 . . . . 0.0 109.574 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.669 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -77.52 135.59 64.8 Favored Pre-proline 0 N--CA 1.495 1.786 0 O-C-N 121.553 -0.717 . . . . 0.0 110.225 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 160.0 51.23 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 123.868 1.457 . . . . 0.0 110.217 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.41 156.53 50.22 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 O-C-N 123.87 1.458 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.77 -22.04 42.94 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.97 159.99 26.09 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -1.124 . . . . 0.0 110.216 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -96.47 165.4 12.19 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.521 -0.737 . . . . 0.0 110.282 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -132.42 169.11 17.0 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.6 -0.687 . . . . 0.0 110.227 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' LEU . . . . . 0.766 HD21 ' OE1' ' A' ' 32' ' ' GLU . 84.2 mt -119.25 138.28 53.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.547 -0.721 . . . . 0.0 110.617 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -82.91 166.61 34.71 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.582 -0.698 . . . . 0.0 110.144 179.602 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -79.18 166.12 23.05 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.868 1.457 . . . . 0.0 110.533 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' CYS . . . . . 0.804 ' HB2' HG22 ' A' ' 151' ' ' VAL . 31.1 t -69.43 136.65 51.87 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.3 p -136.59 55.55 1.84 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.729 -0.607 . . . . 0.0 109.585 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 31.7 p -143.46 -8.46 0.76 Allowed 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.792 -0.763 . . . . 0.0 112.51 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.46 97.31 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.0 m -108.71 160.3 16.07 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.543 -0.975 . . . . 0.0 110.496 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -108.9 21.69 16.89 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.715 . . . . 0.0 110.798 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -99.94 120.05 39.2 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.371 -0.831 . . . . 0.0 110.051 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' LEU . . . . . 0.841 HD21 HG11 ' A' ' 151' ' ' VAL . 56.5 mt -130.57 133.13 45.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.557 -0.714 . . . . 0.0 110.537 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.0 120.0 40.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.507 -0.745 . . . . 0.0 109.693 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.8 tp -81.79 128.35 33.92 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.481 -0.762 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -97.85 118.6 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.626 -0.672 . . . . 0.0 109.37 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.4 p -104.32 177.93 4.7 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.553 -0.717 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.715 ' HA ' HD11 ' A' ' 44' ' ' LEU . 47.0 mtp180 -60.0 -22.77 63.0 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.602 -0.686 . . . . 0.0 110.461 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.46 19.07 5.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.344 -0.848 . . . . 0.0 111.126 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.84 40.0 31.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.1 -1.0 . . . . 0.0 110.924 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -100.31 122.81 43.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.572 -0.705 . . . . 0.0 109.961 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 114' ' ' ILE . 33.1 m -59.97 -39.36 79.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.577 -0.702 . . . . 0.0 110.501 -179.564 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ILE . . . . . 0.455 ' N ' HG23 ' A' ' 113' ' ' VAL . 50.8 mm 51.29 92.44 0.06 OUTLIER Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.38 -0.825 . . . . 0.0 110.648 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.93 121.41 8.44 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.94 1.495 . . . . 0.0 110.656 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.538 HG13 ' O ' ' A' ' 125' ' ' SER . 62.5 t -127.2 129.99 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.665 -0.647 . . . . 0.0 109.52 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.5 tpt180 -86.88 132.07 33.92 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.507 -0.746 . . . . 0.0 110.125 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.09 130.64 41.39 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.512 -0.743 . . . . 0.0 110.004 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -128.49 20.43 6.17 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.542 -0.724 . . . . 0.0 110.605 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -179.43 172.41 44.31 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -59.97 -40.64 89.78 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.47 -1.018 . . . . 0.0 110.278 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -133.43 28.98 3.98 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.561 -0.712 . . . . 0.0 110.616 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 22.0 ttp180 -139.89 138.37 35.61 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.422 -0.798 . . . . 0.0 110.592 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -126.4 -176.49 14.51 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' SER . . . . . 0.538 ' O ' HG13 ' A' ' 116' ' ' VAL . 86.8 p -133.24 150.87 51.93 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.557 -0.967 . . . . 0.0 110.211 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.419 HD13 HG13 ' A' ' 167' ' ' VAL . 2.3 mp -97.26 130.04 44.51 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.517 -0.739 . . . . 0.0 110.316 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.528 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.7 mp -67.64 -40.03 84.6 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.582 -0.699 . . . . 0.0 110.02 179.659 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -115.36 127.83 26.47 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -67.67 120.74 7.76 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.755 1.398 . . . . 0.0 110.468 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -120.46 160.06 45.44 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.588 -0.695 . . . . 0.0 110.009 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.68 154.19 73.66 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.956 1.503 . . . . 0.0 110.415 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' VAL . . . . . 0.49 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.18 -23.28 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.661 -0.649 . . . . 0.0 110.619 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 66.5 m -59.95 -40.06 87.71 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.403 -0.81 . . . . 0.0 110.211 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -60.0 -46.72 88.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.437 -0.789 . . . . 0.0 109.644 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.99 -29.42 66.51 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.672 -0.642 . . . . 0.0 109.545 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.415 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 10.3 tptm -60.03 129.46 41.9 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.6 -0.688 . . . . 0.0 110.006 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.82 -8.29 80.01 Favored Glycine 0 N--CA 1.495 2.592 0 C-N-CA 120.269 -0.967 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.0 p -96.86 6.01 49.47 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.071 -1.252 . . . . 0.0 111.135 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' SER . . . . . 0.409 ' HB2' ' CA ' ' B' ' 191' ' ' FE3 . 0.3 OUTLIER -60.03 142.94 53.11 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.038 -1.039 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.92 -14.93 63.02 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.25 145.77 44.02 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' PRO . . . . . 0.582 ' HB3' HG21 ' A' ' 46' ' ' THR . 49.6 Cg_endo -92.03 141.54 2.46 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.859 1.452 . . . . 0.0 111.673 -179.066 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' LEU . . . . . 0.563 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -93.51 104.38 16.52 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.469 ' N ' HD12 ' A' ' 144' ' ' LEU . 11.0 mp -81.99 157.24 24.3 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 122.082 0.944 . . . . 0.0 111.867 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.57 162.2 24.13 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.496 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -63.98 -29.82 66.71 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.789 1.415 . . . . 0.0 108.577 177.646 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 79.6 p -70.91 -36.12 72.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 178.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.05 41.27 0.56 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -129.97 154.32 47.49 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.984 . . . . 0.0 110.592 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.32 119.55 25.81 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.504 -0.747 . . . . 0.0 109.857 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' VAL . . . . . 0.841 HG11 HD21 ' A' ' 104' ' ' LEU . 63.1 t -90.71 -42.01 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.566 -0.709 . . . . 0.0 110.483 -179.49 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -166.51 -168.87 29.35 Favored Glycine 0 N--CA 1.497 2.741 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.301 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.37 140.01 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.591 -0.947 . . . . 0.0 110.352 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -63.44 139.69 58.8 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.679 -0.638 . . . . 0.0 109.725 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.9 ttp85 -123.14 -52.76 1.85 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.48 -0.763 . . . . 0.0 110.529 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -147.99 165.18 31.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.491 -0.755 . . . . 0.0 110.436 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.95 143.87 49.21 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.621 -0.674 . . . . 0.0 110.371 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.06 119.9 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.76 -0.587 . . . . 0.0 109.456 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' CYS . . . . . 0.49 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -125.97 146.03 50.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.545 -0.722 . . . . 0.0 110.693 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 160' ' ' THR . . . . . 0.541 HG22 ' HG2' ' A' ' 161' ' ' ARG . 39.9 m -82.89 -64.2 1.22 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.447 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.541 ' HG2' HG22 ' A' ' 160' ' ' THR . 10.3 mmm180 -129.21 62.96 1.5 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.499 -0.751 . . . . 0.0 110.406 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.91 -8.76 79.22 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.621 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.2 m -115.8 131.14 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.154 -1.203 . . . . 0.0 110.299 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.34 124.93 34.4 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.638 -0.664 . . . . 0.0 110.3 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -108.79 -29.61 8.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.687 -0.633 . . . . 0.0 110.005 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -138.27 150.8 47.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.419 HG13 HD13 ' A' ' 126' ' ' LEU . 27.6 m -130.45 175.46 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.644 -0.66 . . . . 0.0 110.597 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -131.15 131.35 44.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.682 -0.637 . . . . 0.0 109.574 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -129.48 153.07 48.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.347 -0.845 . . . . 0.0 110.528 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 82' ' ' LEU . 90.5 t -93.55 119.53 67.14 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.607 -0.683 . . . . 0.0 109.429 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.63 153.51 74.67 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.808 1.425 . . . . 0.0 110.578 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.3 t -62.74 -27.42 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.629 -0.67 . . . . 0.0 110.428 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -59.94 -39.31 85.1 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.591 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 85.9 p -59.96 -45.14 93.62 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.504 -0.748 . . . . 0.0 110.669 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 76.7 mtm -69.97 -40.04 75.61 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.396 -0.815 . . . . 0.0 110.38 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.01 -40.04 87.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.479 -0.763 . . . . 0.0 110.259 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.5 m -63.98 -39.99 95.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.574 -0.703 . . . . 0.0 109.881 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 88.6 m -70.05 -40.15 75.27 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.596 -0.69 . . . . 0.0 110.063 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.6 ttm -60.51 -40.06 90.05 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.648 -0.658 . . . . 0.0 110.396 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 24.7 mmt85 -67.35 -39.95 85.8 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.544 -0.722 . . . . 0.0 110.252 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -70.0 -56.2 7.6 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.51 -0.744 . . . . 0.0 110.209 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 53.01 179.24 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.437 -0.789 . . . . 0.0 110.802 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -68.07 -40.0 82.81 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.581 -0.699 . . . . 0.0 110.155 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 28.2 ttpp -120.05 140.03 51.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.566 -0.709 . . . . 0.0 110.066 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.91 139.95 34.84 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.186 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 54.8 tttm . . . . . 0 N--CA 1.493 1.723 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.127 -179.87 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -128.52 130.58 47.67 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 189' ' ' LEU . . . . . 0.775 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -70.0 141.2 52.98 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.622 -0.673 . . . . 0.0 110.188 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 190' ' ' OBF . . . . . 0.619 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 191' ' ' FE3 . . . . . 0.685 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 . . . . . 0 N--CA 1.496 1.826 0 CA-C-O 121.104 0.478 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -103.77 129.91 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.564 -0.71 . . . . 0.0 109.868 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -116.3 158.54 23.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.561 -0.712 . . . . 0.0 110.489 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.04 121.29 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.663 -0.648 . . . . 0.0 109.597 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.407 ' HB ' HD11 ' A' ' 64' ' ' LEU . 29.7 m -118.48 142.67 32.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.699 -0.626 . . . . 0.0 109.899 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.3 t -142.05 159.67 41.76 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.516 -0.74 . . . . 0.0 111.246 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.7 p -124.56 -170.12 2.09 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -84.02 5.89 24.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.528 -0.732 . . . . 0.0 110.91 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -128.65 -38.94 1.67 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.073 -1.017 . . . . 0.0 111.191 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -149.91 170.1 19.61 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.311 -0.868 . . . . 0.0 111.159 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 47.8 m -119.75 147.35 44.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.68 -0.638 . . . . 0.0 109.792 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 10.3 p90 -156.43 -178.63 7.48 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.391 -0.818 . . . . 0.0 110.275 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.553 HD11 ' CA ' ' A' ' 109' ' ' ARG . 74.0 mt -113.89 153.35 29.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.0 110.804 -178.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.43 161.34 31.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.711 -0.618 . . . . 0.0 109.972 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -126.23 140.12 52.79 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.573 -0.705 . . . . 0.0 110.4 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 38.5 t -98.33 105.48 17.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.59 -0.693 . . . . 0.0 110.489 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.0 t -109.98 129.99 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.423 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 56.8 t30 57.98 38.36 26.82 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.439 -0.788 . . . . 0.0 110.479 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.52 19.93 76.7 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.0 t -131.99 129.97 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.137 -1.214 . . . . 0.0 110.167 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 87.5 m -75.66 148.89 38.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.516 -0.74 . . . . 0.0 109.464 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -138.2 149.95 46.29 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.448 -0.783 . . . . 0.0 111.212 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.9 t -168.65 -179.09 3.67 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.85 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.6 p -89.17 158.33 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.448 -0.783 . . . . 0.0 110.027 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.471 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.1 t80 -76.39 -39.97 52.25 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.493 -0.754 . . . . 0.0 112.066 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.85 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.3 p-80 -64.95 -24.28 67.47 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.116 -0.99 . . . . 0.0 110.567 -178.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.565 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -84.28 -56.98 2.44 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 179.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.562 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -96.89 -61.28 1.43 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.68 -0.894 . . . . 0.0 109.987 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.427 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 79.96 -179.39 53.26 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 78.9 p -79.33 64.59 4.26 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.596 -0.943 . . . . 0.0 109.768 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.23 167.54 21.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.62 -0.675 . . . . 0.0 110.414 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.2 t -65.39 139.32 58.54 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 109.826 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.74 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -112.83 131.13 55.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.589 -0.694 . . . . 0.0 110.291 -179.576 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.53 109.29 21.9 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.564 -0.71 . . . . 0.0 109.815 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -105.53 -165.96 23.59 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.09 -32.36 34.53 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 124.025 1.539 . . . . 0.0 110.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.62 -31.09 59.76 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.83 -140.83 10.1 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -75.02 161.36 38.83 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.819 1.431 . . . . 0.0 110.292 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.74 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.5 mt -131.53 139.37 50.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.448 -0.782 . . . . 0.0 110.439 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.0 p -81.87 150.74 27.64 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.549 -0.719 . . . . 0.0 109.946 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 78.2 mm-40 -87.42 132.3 34.03 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.484 -0.76 . . . . 0.0 110.095 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -110.01 -44.86 3.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.552 -0.718 . . . . 0.0 110.116 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . 0.432 ' CE1' ' HG3' ' A' ' 179' ' ' MET . 83.9 m-85 -130.01 150.04 51.46 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.584 -0.697 . . . . 0.0 110.507 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.6 p -148.17 136.32 21.2 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.007 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -149.98 89.32 1.59 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.471 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 63.0 t -61.3 -40.09 84.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.623 -0.673 . . . . 0.0 109.988 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -61.58 -43.91 97.99 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.508 -0.745 . . . . 0.0 110.654 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.778 ' HG2' HD12 ' A' ' 82' ' ' LEU . 50.7 tt0 -87.6 -0.01 56.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.583 -0.698 . . . . 0.0 110.749 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.48 46.5 26.05 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.06 -1.025 . . . . 0.0 110.506 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' HG2' ' A' ' 80' ' ' GLN . 40.3 mt -144.25 138.39 27.96 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.543 -0.723 . . . . 0.0 110.875 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 54' ' ' THR . 8.3 p -134.12 157.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.605 -0.684 . . . . 0.0 109.26 179.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -138.43 153.66 22.59 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.196 -1.161 . . . . 0.0 110.196 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 5.8 m-90 -120.99 151.67 39.46 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.776 -0.838 . . . . 0.0 110.022 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -68.51 115.85 8.39 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.538 -0.726 . . . . 0.0 109.338 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.06 130.08 90.13 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.525 -0.735 . . . . 0.0 110.262 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.04 159.99 51.21 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.831 1.437 . . . . 0.0 110.285 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.67 156.32 58.01 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.897 1.472 . . . . 0.0 110.4 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.33 26.56 59.31 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.66 152.29 30.63 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.467 -1.019 . . . . 0.0 110.143 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -92.79 168.94 10.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.566 -0.709 . . . . 0.0 110.256 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.9 p -137.84 158.71 43.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.74 -0.6 . . . . 0.0 110.228 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.473 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 51.4 mt -108.02 131.63 54.38 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.526 -0.734 . . . . 0.0 110.485 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.7 p -76.91 160.06 77.3 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.555 -0.716 . . . . 0.0 109.784 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -75.58 163.68 33.64 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.832 1.438 . . . . 0.0 110.655 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.793 ' HB2' HG12 ' A' ' 151' ' ' VAL . 49.1 t -72.69 129.53 38.44 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.694 -0.629 . . . . 0.0 110.27 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -134.68 55.6 1.89 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.716 -0.615 . . . . 0.0 109.661 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.8 p -143.88 -7.82 0.73 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 120.027 -0.669 . . . . 0.0 112.26 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.97 39.54 97.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.8 m -99.94 119.99 39.1 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.544 -0.974 . . . . 0.0 110.404 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -66.71 -39.71 88.14 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.731 -0.606 . . . . 0.0 110.442 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 139.61 57.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.531 -0.731 . . . . 0.0 110.491 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.927 HD22 HG21 ' A' ' 151' ' ' VAL . 92.8 mt -139.29 153.1 47.72 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 0.0 110.409 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -115.73 123.72 49.01 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.53 -0.731 . . . . 0.0 109.887 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.639 HD13 HD11 ' A' ' 143' ' ' LEU . 66.3 tp -99.91 133.29 44.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.592 -0.693 . . . . 0.0 110.595 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.9 t -91.57 120.05 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.677 -0.639 . . . . 0.0 109.447 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.4 m -97.99 152.35 19.36 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.462 -0.774 . . . . 0.0 110.419 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.553 ' CA ' HD11 ' A' ' 44' ' ' LEU . 28.0 ptt85 -59.08 -20.03 49.68 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.639 -0.663 . . . . 0.0 110.751 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -94.59 26.76 3.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.452 -0.78 . . . . 0.0 110.214 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.49 40.07 31.16 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.348 -0.845 . . . . 0.0 110.663 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.49 135.03 54.62 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.572 -0.705 . . . . 0.0 109.976 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.97 120.03 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.579 -0.701 . . . . 0.0 110.022 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.523 ' O ' HG23 ' A' ' 116' ' ' VAL . 49.0 mm -106.19 117.36 57.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.622 -0.674 . . . . 0.0 109.79 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -64.42 120.74 8.13 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.801 1.422 . . . . 0.0 110.374 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.6 t -119.98 126.32 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.586 -0.696 . . . . 0.0 109.796 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -86.9 130.53 34.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.553 -0.717 . . . . 0.0 109.805 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 37.5 ttp180 -73.46 126.14 29.52 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.624 -0.672 . . . . 0.0 110.338 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -120.16 23.78 10.79 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.587 -0.696 . . . . 0.0 110.209 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.38 -179.06 42.18 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -63.19 -39.96 96.13 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.571 -0.958 . . . . 0.0 110.406 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 76.9 p -132.83 22.2 4.21 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.555 -0.715 . . . . 0.0 110.786 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -124.86 138.6 54.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.346 -0.847 . . . . 0.0 110.322 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.18 169.81 23.51 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.4 p -121.25 153.51 37.55 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.62 -0.929 . . . . 0.0 110.059 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.51 HD11 HG21 ' A' ' 114' ' ' ILE . 16.8 tp -99.27 119.87 38.63 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.505 -0.747 . . . . 0.0 110.221 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -68.61 -39.01 81.04 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.544 -0.722 . . . . 0.0 110.039 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.28 116.13 55.47 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.601 -0.687 . . . . 0.0 110.064 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -65.81 116.34 3.91 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.724 1.381 . . . . 0.0 110.43 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 5.7 mtt180 -122.69 160.04 50.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.581 -0.699 . . . . 0.0 110.139 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -67.43 152.04 79.36 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 124.017 1.536 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.32 -32.15 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.568 -0.708 . . . . 0.0 110.395 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.8 t -59.96 -38.66 83.1 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.511 -0.743 . . . . 0.0 110.162 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.539 -0.726 . . . . 0.0 110.34 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -81.46 -18.35 45.59 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 0.0 111.109 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -60.4 140.02 57.4 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.183 -0.948 . . . . 0.0 110.115 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 86.37 13.64 67.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.5 p -116.13 -8.29 11.79 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.127 -1.219 . . . . 0.0 110.908 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.7 t -59.97 139.08 57.66 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.123 -0.986 . . . . 0.0 109.698 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 97.33 -23.44 35.82 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.99 151.71 47.39 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 179.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.47 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.9 Cg_endo -93.87 148.78 2.15 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.841 1.443 . . . . 0.0 111.427 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.903 ' O ' HG22 ' A' ' 151' ' ' VAL . 9.3 mp -104.66 130.3 52.71 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.47 131.51 56.25 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.351 -0.843 . . . . 0.0 111.549 -178.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.5 p -70.01 159.16 85.32 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 178.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.85 -26.64 24.87 Favored 'Trans proline' 0 N--CA 1.502 1.992 0 O-C-N 123.504 1.265 . . . . 0.0 112.359 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.9 m -62.63 -39.99 95.57 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.261 -0.9 . . . . 0.0 109.96 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.67 36.37 0.79 Allowed Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.4 m170 -132.48 149.61 52.3 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.419 -1.048 . . . . 0.0 110.128 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -70.0 142.48 52.78 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.576 -0.702 . . . . 0.0 110.45 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.927 HG21 HD22 ' A' ' 104' ' ' LEU . 34.4 m -117.17 -22.81 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.626 -0.671 . . . . 0.0 110.613 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 167.63 -169.92 41.45 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' HE1' ' A' ' 175' ' ' MET . 96.9 mt -127.84 139.94 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.517 -0.99 . . . . 0.0 110.224 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.495 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.7 t80 -65.82 136.79 56.65 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.649 -0.657 . . . . 0.0 109.981 179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -114.97 -52.39 2.69 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 0.0 110.427 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -153.72 160.02 42.17 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.463 -0.773 . . . . 0.0 110.393 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.495 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.96 151.13 27.5 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.66 -0.65 . . . . 0.0 110.203 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -108.27 119.6 58.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.666 -0.647 . . . . 0.0 109.693 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -134.1 158.96 42.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.693 -0.63 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 4.6 p -99.97 -50.68 3.92 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.71 . . . . 0.0 110.391 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -142.89 61.62 1.41 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.928 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.05 -7.47 81.57 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.8 t -116.82 125.92 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 109.905 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.81 127.86 43.2 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.592 -0.693 . . . . 0.0 110.422 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -107.14 -17.16 14.24 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.519 -0.738 . . . . 0.0 110.743 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -146.81 159.78 43.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.325 -0.859 . . . . 0.0 110.036 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -133.84 160.04 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.462 -0.774 . . . . 0.0 110.938 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.51 138.4 53.19 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.658 . . . . 0.0 110.015 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -140.3 155.65 46.75 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.404 -0.81 . . . . 0.0 110.794 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.554 HG11 HD11 ' A' ' 82' ' ' LEU . 59.3 t -94.47 126.04 49.5 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.56 -0.712 . . . . 0.0 109.459 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.46 158.58 57.03 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.795 1.419 . . . . 0.0 110.696 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 57.7 t -65.59 -24.66 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.665 -0.647 . . . . 0.0 110.478 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -58.6 -37.96 76.94 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.383 -0.823 . . . . 0.0 110.579 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 81.1 p -60.13 -34.45 73.54 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.524 -0.735 . . . . 0.0 110.417 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.431 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.3 mtt -61.14 -40.02 92.26 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.478 -0.764 . . . . 0.0 110.411 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.55 -42.14 95.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.496 -0.752 . . . . 0.0 110.495 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 75.2 p -70.03 -39.51 75.72 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.395 -0.816 . . . . 0.0 110.417 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 86.5 m -60.04 -50.03 75.32 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.432 ' HG3' ' CE1' ' A' ' 75' ' ' TYR . 59.9 ttp . . . . . 0 N--CA 1.495 1.782 0 O-C-N 121.609 -0.682 . . . . 0.0 110.239 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.427 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.9 tt0 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 121.1 0.476 . . . . 0.0 110.181 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.807 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.587 -0.696 . . . . 0.0 110.226 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.541 ' OE1' HD21 ' A' ' 94' ' ' LEU . 28.3 mt-10 . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 120.64 0.257 . . . . 0.0 111.171 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.02 128.41 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.113 -0.992 . . . . 0.0 109.946 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -116.31 146.29 42.54 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.588 -0.695 . . . . 0.0 109.992 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.3 t -91.55 122.81 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.615 ' HB ' HD12 ' A' ' 64' ' ' LEU . 32.7 m -115.62 140.17 38.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.734 -0.604 . . . . 0.0 109.707 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.1 m -138.4 162.87 33.35 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.562 -0.711 . . . . 0.0 110.753 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.55 -170.5 2.24 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.72 -0.612 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.08 -42.83 95.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.534 -0.728 . . . . 0.0 110.736 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.9 t -128.28 -7.66 5.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.385 -0.822 . . . . 0.0 111.849 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.8 tp60 -115.16 156.87 24.49 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.067 -1.02 . . . . 0.0 110.67 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.7 p -149.96 138.1 20.38 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.718 -0.614 . . . . 0.0 109.759 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.623 ' HZ ' HD21 ' A' ' 64' ' ' LEU . 20.0 p90 -164.39 -178.89 5.69 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.533 -0.73 . . . . 0.0 110.456 -179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.555 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.6 mt -114.3 159.2 20.46 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.476 -0.765 . . . . 0.0 110.862 -178.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.54 ' HB1' ' O ' ' A' ' 53' ' ' TRP . . . -139.1 162.64 34.46 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.697 -0.627 . . . . 0.0 109.989 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.5 t -122.29 140.68 52.35 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.423 -0.798 . . . . 0.0 110.673 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.3 t -98.87 104.06 16.07 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.569 -0.707 . . . . 0.0 110.109 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.61 132.77 56.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.604 -0.685 . . . . 0.0 109.899 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 54.35 39.94 31.34 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.596 -0.69 . . . . 0.0 111.016 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 20.83 76.67 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.9 t -130.0 130.0 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.249 -1.148 . . . . 0.0 109.852 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.1 t -78.93 147.31 33.08 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.483 -0.761 . . . . 0.0 109.403 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.54 ' O ' ' HB1' ' A' ' 45' ' ' ALA . 57.5 m95 -128.66 150.38 50.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.538 -0.726 . . . . 0.0 110.932 -179.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.89 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.3 t -166.11 -179.73 5.29 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.866 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -100.46 154.25 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.73 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -70.05 -40.11 75.3 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.63 -0.669 . . . . 0.0 111.811 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.866 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.1 p-80 -70.62 -22.1 62.57 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.099 -1.001 . . . . 0.0 110.843 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.699 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -93.32 -46.41 3.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.907 -1.677 . . . . 0.0 108.907 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.422 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.43 -49.31 3.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.658 -0.907 . . . . 0.0 110.334 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.49 -162.3 41.17 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.2 t -93.12 63.37 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.577 -0.955 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.92 161.77 36.78 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.58 -0.7 . . . . 0.0 110.266 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 63.1 p -65.42 139.59 58.55 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.634 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.623 HD21 ' HZ ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -112.53 141.28 46.47 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.618 -0.677 . . . . 0.0 110.011 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.27 115.16 24.49 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.511 -0.743 . . . . 0.0 110.252 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.04 176.42 16.17 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.63 -31.97 69.59 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.793 1.417 . . . . 0.0 110.29 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.63 -31.41 66.84 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.657 -0.652 . . . . 0.0 109.829 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.7 -153.71 24.32 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.02 145.0 48.78 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.918 1.483 . . . . 0.0 110.092 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.585 HG22 ' CD1' ' A' ' 85' ' ' TRP . 85.6 mt -119.99 129.49 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.608 -0.682 . . . . 0.0 110.356 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 m -85.49 130.26 34.62 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.963 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.439 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 44.8 mm-40 -55.69 139.93 43.25 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.513 -0.742 . . . . 0.0 110.917 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.0 ttt -113.68 -49.1 2.9 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.73 -0.606 . . . . 0.0 110.179 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 70.3 m-85 -120.0 140.0 51.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.588 -0.695 . . . . 0.0 110.27 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.814 ' HA ' HG12 ' A' ' 83' ' ' VAL . 26.2 m -135.78 129.36 32.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.641 -0.662 . . . . 0.0 110.215 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -142.43 96.75 3.0 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.577 -0.702 . . . . 0.0 110.226 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 76.5 t -65.7 -39.99 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.593 -0.692 . . . . 0.0 110.049 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -60.01 -49.84 76.07 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.551 -0.718 . . . . 0.0 110.816 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -89.31 -0.05 57.17 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 110.934 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.4 t70 52.79 47.41 24.74 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.0 -1.062 . . . . 0.0 110.665 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.497 HD11 HG11 ' A' ' 170' ' ' VAL . 62.8 mt -141.63 137.14 31.63 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.443 -0.786 . . . . 0.0 111.141 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.814 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.6 m -138.37 161.35 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.555 -0.716 . . . . 0.0 109.301 178.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.32 164.56 26.55 Favored Glycine 0 N--CA 1.495 2.632 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.586 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.89 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.7 m-90 -123.13 159.38 28.67 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.829 -0.806 . . . . 0.0 109.253 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -79.9 109.34 14.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.45 -0.781 . . . . 0.0 109.528 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.68 141.08 87.17 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.59 -0.694 . . . . 0.0 110.298 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.03 160.02 51.12 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.917 1.482 . . . . 0.0 110.323 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.83 160.12 42.42 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.305 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.79 29.85 64.65 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.51 144.09 34.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.533 -0.981 . . . . 0.0 110.095 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 31.8 ttt180 -84.69 128.64 34.71 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.69 -0.631 . . . . 0.0 109.703 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.4 p -111.43 162.58 14.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.593 -0.692 . . . . 0.0 110.539 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.541 HD21 ' OE1' ' A' ' 32' ' ' GLU . 16.1 mt -106.37 131.99 52.93 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.614 -0.679 . . . . 0.0 110.73 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.4 p -75.46 160.01 80.56 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.597 -0.689 . . . . 0.0 109.691 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.51 162.63 40.85 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.825 1.434 . . . . 0.0 110.772 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.711 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.6 t -79.26 130.05 35.07 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.618 -0.676 . . . . 0.0 110.101 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.56 55.6 1.88 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.651 -0.656 . . . . 0.0 109.72 179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.79 -8.02 0.74 Allowed 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 119.916 -0.714 . . . . 0.0 112.296 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.66 34.77 89.74 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 m -87.0 112.34 21.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.515 -0.991 . . . . 0.0 110.405 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -59.99 -39.97 87.56 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.6 -0.688 . . . . 0.0 110.35 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -63.15 132.88 53.27 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.613 -0.68 . . . . 0.0 110.184 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.51 ' CD2' HG21 ' A' ' 151' ' ' VAL . 91.4 mt -134.63 146.12 49.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.66 -0.65 . . . . 0.0 110.492 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.82 121.54 44.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.504 -0.748 . . . . 0.0 109.984 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.543 HD13 HD11 ' A' ' 143' ' ' LEU . 64.0 tp -95.51 137.94 33.88 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.547 -0.72 . . . . 0.0 110.408 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.24 119.96 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.598 -0.689 . . . . 0.0 109.75 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.2 p -97.74 170.07 9.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.487 -0.758 . . . . 0.0 110.573 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.555 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.9 mtp-105 -70.06 -20.19 63.25 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.646 -0.659 . . . . 0.0 110.813 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -94.32 26.59 3.28 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.323 -0.861 . . . . 0.0 110.679 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 39.03 30.46 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.273 -0.892 . . . . 0.0 110.751 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -120.14 137.08 54.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.688 -0.633 . . . . 0.0 109.723 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -120.04 143.4 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.446 -0.783 . . . . 0.0 110.67 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 46.0 pt -129.94 158.8 72.77 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.757 -0.59 . . . . 0.0 109.914 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -90.89 130.96 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.817 1.43 . . . . 0.0 110.588 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -130.1 130.01 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.699 -0.625 . . . . 0.0 109.548 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -82.81 149.28 27.29 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.507 -0.745 . . . . 0.0 110.175 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.0 ttt180 -95.56 119.94 34.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.581 -0.7 . . . . 0.0 110.123 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -110.04 19.94 18.46 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.615 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.7 179.41 42.69 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -61.47 -40.03 93.06 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.592 -0.946 . . . . 0.0 110.296 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 44.5 p -130.31 23.63 5.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.548 -0.72 . . . . 0.0 110.681 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -124.53 137.85 54.38 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.41 -0.806 . . . . 0.0 110.299 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -137.51 162.94 25.49 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 76.8 p -119.51 148.35 43.39 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.586 -0.949 . . . . 0.0 110.349 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.636 HD23 ' O ' ' A' ' 128' ' ' SER . 8.6 tp -95.27 126.84 40.86 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.595 -0.69 . . . . 0.0 110.158 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -61.26 -39.95 92.26 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.656 -0.653 . . . . 0.0 110.388 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . 0.636 ' O ' HD23 ' A' ' 126' ' ' LEU . 79.4 p -120.39 149.6 50.13 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.536 -0.728 . . . . 0.0 110.339 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.411 ' HB2' ' CG2' ' A' ' 163' ' ' VAL . 48.0 Cg_endo -79.88 121.46 4.54 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.969 1.51 . . . . 0.0 110.491 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -122.16 160.56 47.07 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.565 -0.709 . . . . 0.0 110.116 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.53 150.76 80.24 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.955 1.502 . . . . 0.0 110.464 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 64.7 t -62.49 -30.18 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.628 -0.67 . . . . 0.0 109.783 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.2 m -60.03 -38.33 82.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.631 -0.668 . . . . 0.0 110.371 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -59.94 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.469 -0.77 . . . . 0.0 110.029 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.2 mp -86.94 -22.99 25.27 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.486 -0.759 . . . . 0.0 110.572 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 4.2 tptm -60.17 129.96 44.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.388 -0.82 . . . . 0.0 110.094 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.68 -9.84 73.19 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.1 p -89.94 -0.06 57.36 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.038 -1.272 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.1 m -59.92 139.95 57.03 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.108 -0.995 . . . . 0.0 109.765 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.17 -20.36 51.11 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.11 154.79 43.77 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.472 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.6 Cg_endo -98.01 147.49 0.73 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 O-C-N 123.803 1.423 . . . . 0.0 111.134 -179.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -104.41 109.19 20.95 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.4 132.15 44.09 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.503 -0.748 . . . . 0.0 111.507 -178.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.435 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.01 159.84 82.74 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.89 -26.58 25.0 Favored 'Trans proline' 0 N--CA 1.502 2.011 0 O-C-N 123.456 1.24 . . . . 0.0 112.266 -178.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.67 -40.1 96.01 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.181 -0.949 . . . . 0.0 109.848 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.68 36.13 0.8 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -131.81 146.37 52.1 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.459 -1.024 . . . . 0.0 110.29 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.525 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.59 143.65 57.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.554 -0.716 . . . . 0.0 110.324 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.748 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.1 t -118.25 -37.81 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.513 -0.742 . . . . 0.0 110.054 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.5 -170.39 39.04 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' CE ' ' A' ' 175' ' ' MET . 67.9 mt -127.93 133.33 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.523 -0.986 . . . . 0.0 110.24 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.619 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.2 t80 -61.78 137.04 58.21 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.607 -0.683 . . . . 0.0 109.908 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.8 ttt180 -116.88 -52.35 2.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.514 -0.742 . . . . 0.0 110.099 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.79 159.99 43.91 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.499 -0.751 . . . . 0.0 110.397 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.619 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.19 151.83 33.73 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.668 -0.645 . . . . 0.0 110.267 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -107.88 119.14 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.589 -0.694 . . . . 0.0 109.714 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.78 155.19 47.09 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.664 -0.647 . . . . 0.0 110.471 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 2.8 m -103.42 -60.31 1.58 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.57 -0.706 . . . . 0.0 110.272 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 71.8 mtt180 -127.92 66.72 1.35 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.704 -0.622 . . . . 0.0 109.933 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 71.84 22.58 78.7 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 163' ' ' VAL . 14.6 p -139.3 127.75 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.417 -1.049 . . . . 0.0 109.866 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.32 124.2 34.71 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.549 -0.719 . . . . 0.0 110.807 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -107.57 -19.93 13.4 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.694 -0.629 . . . . 0.0 110.073 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -150.04 157.36 43.06 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.454 -0.779 . . . . 0.0 109.849 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.9 m -133.03 164.3 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -0.764 . . . . 0.0 110.792 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -125.13 134.83 52.29 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.558 -0.714 . . . . 0.0 110.218 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -134.18 157.78 45.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.519 -0.738 . . . . 0.0 110.095 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.497 HG11 HD11 ' A' ' 82' ' ' LEU . 67.0 t -94.54 124.38 55.37 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.539 -0.726 . . . . 0.0 109.754 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.5 147.9 87.19 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.784 1.413 . . . . 0.0 110.41 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.5 t -59.89 -23.83 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.71 -0.619 . . . . 0.0 110.675 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -59.97 -40.75 90.12 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.372 -0.83 . . . . 0.0 110.633 -179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.8 p -70.0 -36.42 75.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.458 -0.776 . . . . 0.0 110.252 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.2 mtp -59.94 -40.09 87.76 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.604 -0.685 . . . . 0.0 110.378 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 75.3 mt-10 -64.34 -39.95 94.91 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.645 -0.659 . . . . 0.0 110.105 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -61.81 -40.0 93.71 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.67 -0.644 . . . . 0.0 110.049 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.4 m -60.12 -39.97 88.08 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.558 -0.714 . . . . 0.0 110.176 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.828 0 O-C-N 121.479 -0.763 . . . . 0.0 110.238 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.463 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 . . . . . 0 N--CA 1.49 1.561 0 CA-C-O 121.101 0.476 . . . . 0.0 110.066 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.866 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp . . . . . 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 110.136 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 . . . . . 0 N--CA 1.495 1.782 0 CA-C-O 121.159 0.504 . . . . 0.0 109.827 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.14 125.72 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.548 -0.72 . . . . 0.0 109.698 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -119.32 159.6 23.83 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.714 -0.617 . . . . 0.0 110.491 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.7 t -88.29 115.43 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.62 -0.675 . . . . 0.0 109.545 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.924 HG11 HD21 ' A' ' 64' ' ' LEU . 57.6 t -110.37 148.14 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.317 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -143.63 171.25 14.43 Favored 'General case' 0 N--CA 1.494 1.745 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.408 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 15.3 p -140.44 179.34 6.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.902 -0.499 . . . . 0.0 109.997 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -75.13 -8.56 56.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.5 -0.75 . . . . 0.0 111.036 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -109.82 -43.71 3.97 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.218 -0.926 . . . . 0.0 111.64 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -148.88 177.35 9.62 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.251 -0.905 . . . . 0.0 111.296 -179.071 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.3 m -122.58 149.65 43.68 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.588 -0.695 . . . . 0.0 110.279 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.763 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.9 p90 -164.0 -177.65 5.17 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.245 -0.91 . . . . 0.0 110.461 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.594 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.2 mt -113.36 141.35 47.15 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.545 -0.722 . . . . 0.0 110.635 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.515 ' CB ' HG21 ' A' ' 36' ' ' VAL . . . -114.75 154.53 28.34 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.656 -0.652 . . . . 0.0 109.946 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.477 HG21 ' HB3' ' A' ' 142' ' ' PRO . 75.2 p -120.1 131.25 55.0 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.411 -0.806 . . . . 0.0 110.387 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.7 t -93.06 110.02 21.5 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.583 -0.698 . . . . 0.0 110.74 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.421 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.8 t -114.58 132.27 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.684 -0.635 . . . . 0.0 109.516 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.421 ' OD1' HG12 ' A' ' 48' ' ' VAL . 29.5 m120 55.56 39.0 30.96 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.516 -0.74 . . . . 0.0 110.933 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.593 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.96 19.07 75.06 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -130.67 130.01 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.267 -1.137 . . . . 0.0 109.851 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.6 m -76.79 139.53 40.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 109.443 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -133.03 136.45 45.98 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.508 -0.745 . . . . 0.0 110.898 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 45' ' ' ALA . 29.9 p -150.73 -179.85 7.61 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.746 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.6 p -88.25 150.19 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.284 -0.885 . . . . 0.0 110.238 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.423 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.3 t80 -60.06 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.571 -0.706 . . . . 0.0 111.891 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.822 ' CG ' HD23 ' B' ' 189' ' ' LEU . 5.7 p-80 -59.69 -24.29 63.83 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.09 -1.007 . . . . 0.0 110.739 -178.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.643 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.88 -42.49 20.3 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.763 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -151.24 95.45 2.17 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.771 -0.841 . . . . 0.0 109.786 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.63 -165.1 4.54 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.401 ' HB3' HG21 ' A' ' 76' ' ' THR . 88.0 p -71.15 69.79 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.621 -0.929 . . . . 0.0 109.87 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.99 179.22 6.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.562 -0.711 . . . . 0.0 110.293 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 33.0 p -64.93 139.9 58.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.646 -0.659 . . . . 0.0 109.801 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.924 HD21 HG11 ' A' ' 36' ' ' VAL . 14.8 tp -113.28 137.94 50.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.653 -0.654 . . . . 0.0 110.159 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.76 109.88 22.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.655 -0.653 . . . . 0.0 109.955 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.51 -175.07 15.84 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -64.78 -32.69 55.88 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 O-C-N 123.895 1.471 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -74.82 -31.5 61.7 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.575 -0.703 . . . . 0.0 110.06 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.41 -147.15 18.55 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.08 140.65 15.94 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.832 1.438 . . . . 0.0 110.377 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.49 140.02 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.606 -0.684 . . . . 0.0 110.351 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.6 t -93.23 133.48 36.39 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.537 -0.727 . . . . 0.0 110.439 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 34.1 tt0 -71.53 140.55 49.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.42 -0.8 . . . . 0.0 110.699 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.5 mmm -105.87 -29.1 10.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.663 -0.648 . . . . 0.0 110.323 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -118.39 139.61 51.12 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.565 -0.709 . . . . 0.0 110.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.401 HG21 ' HB3' ' A' ' 61' ' ' SER . 24.2 m -139.97 135.34 32.65 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.522 -0.736 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -150.05 98.95 2.77 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.602 -0.687 . . . . 0.0 109.897 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.42 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.3 t -69.67 -44.82 79.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.543 -0.723 . . . . 0.0 110.329 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.03 -50.02 75.38 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.553 -0.717 . . . . 0.0 110.46 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.648 ' HG2' HD12 ' A' ' 82' ' ' LEU . 1.8 tp-100 -80.41 -8.49 59.55 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.67 -0.644 . . . . 0.0 110.767 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.1 t70 56.56 45.24 22.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.173 -0.955 . . . . 0.0 110.248 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.648 HD12 ' HG2' ' A' ' 80' ' ' GLN . 75.8 mt -130.01 148.89 51.91 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.565 -0.709 . . . . 0.0 110.721 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.457 HG13 ' C ' ' A' ' 82' ' ' LEU . 32.6 m -149.97 169.92 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.66 -0.65 . . . . 0.0 109.626 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -165.05 160.31 33.58 Favored Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.845 -1.169 . . . . 0.0 110.416 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.729 ' CE2' HD22 ' A' ' 64' ' ' LEU . 16.1 m-90 -129.89 149.92 51.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.657 -0.908 . . . . 0.0 109.429 179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -60.9 120.13 9.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.322 -0.861 . . . . 0.0 109.63 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.593 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.73 141.64 72.5 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.588 -0.695 . . . . 0.0 110.307 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.01 160.02 51.15 Favored 'Trans proline' 0 N--CA 1.49 1.275 0 O-C-N 123.902 1.475 . . . . 0.0 110.32 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.69 143.79 38.31 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 O-C-N 123.947 1.498 . . . . 0.0 110.274 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.48 -22.08 42.75 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.17 46.95 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.286 -1.126 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -92.81 165.42 12.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.611 -0.681 . . . . 0.0 110.109 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.2 p -130.48 169.95 14.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.473 -0.767 . . . . 0.0 110.307 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -103.38 132.0 50.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.573 -0.705 . . . . 0.0 110.379 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.414 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 50.9 p -72.06 159.99 83.92 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.594 -0.691 . . . . 0.0 109.941 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -83.26 150.27 13.51 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.766 1.403 . . . . 0.0 110.698 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -65.07 132.04 48.14 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.583 -0.698 . . . . 0.0 110.196 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.7 p -135.98 53.16 1.95 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.626 -0.671 . . . . 0.0 109.765 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.9 p -143.85 -3.49 0.88 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.332 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.94 32.31 74.84 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -91.44 129.95 37.35 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.58 -0.953 . . . . 0.0 110.331 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.9 m -77.48 -30.14 52.97 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.622 -0.674 . . . . 0.0 110.315 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.56 133.77 56.42 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.54 -0.725 . . . . 0.0 110.346 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.464 ' CD2' HG21 ' A' ' 151' ' ' VAL . 90.4 mt -134.95 151.66 51.05 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.631 -0.668 . . . . 0.0 110.359 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -119.85 123.17 42.97 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.512 -0.743 . . . . 0.0 109.969 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.453 HD13 HD21 ' A' ' 143' ' ' LEU . 67.0 tp -99.64 133.06 44.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.525 -0.734 . . . . 0.0 110.461 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.3 t -95.72 119.97 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.625 -0.672 . . . . 0.0 109.582 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -92.09 168.13 11.59 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.514 -0.741 . . . . 0.0 110.476 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.594 ' HA ' HD11 ' A' ' 44' ' ' LEU . 37.1 mtp-105 -60.14 -27.3 66.96 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.614 -0.679 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.413 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -93.69 29.07 2.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.494 -0.754 . . . . 0.0 110.744 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.77 40.0 30.97 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.197 -0.939 . . . . 0.0 111.057 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -99.44 168.7 9.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.562 -0.711 . . . . 0.0 109.928 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 113' ' ' VAL . 8.8 p -130.03 129.98 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.485 -0.759 . . . . 0.0 110.328 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.574 ' O ' HG23 ' A' ' 116' ' ' VAL . 82.8 mt -121.26 104.31 40.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.576 -0.702 . . . . 0.0 109.657 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.4 105.84 0.65 Allowed 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 123.79 1.416 . . . . 0.0 110.431 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.2 t -110.04 120.02 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.625 -0.672 . . . . 0.0 109.799 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.3 tpt180 -77.75 142.78 38.49 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.459 -0.776 . . . . 0.0 109.756 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -78.01 129.97 35.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.536 -0.727 . . . . 0.0 110.379 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -128.63 22.5 5.91 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.594 -0.692 . . . . 0.0 110.328 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 172.1 -179.86 43.46 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.376 -1.489 . . . . 0.0 109.376 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -66.79 -40.05 88.01 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.496 -1.002 . . . . 0.0 110.393 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.8 p -129.79 27.34 5.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.54 -0.725 . . . . 0.0 110.532 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.09 162.91 30.47 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.437 -0.789 . . . . 0.0 110.233 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -158.77 175.69 35.76 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 77.5 p -129.21 148.85 51.19 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.607 -0.937 . . . . 0.0 110.262 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 mp -100.76 123.12 44.5 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.607 -0.683 . . . . 0.0 110.438 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.525 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -64.04 -39.96 95.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.507 -0.746 . . . . 0.0 109.781 179.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -107.91 112.14 61.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.619 -0.675 . . . . 0.0 109.838 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.32 128.99 22.78 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.801 1.421 . . . . 0.0 110.631 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -125.09 160.03 56.51 Favored Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.592 -0.692 . . . . 0.0 109.906 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -65.48 153.95 75.88 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.863 1.454 . . . . 0.0 110.28 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.517 HG11 ' OE1' ' B' ' 188' ' ' GLU . 79.8 t -63.54 -34.75 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.658 -0.651 . . . . 0.0 110.102 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.4 p -59.74 -36.5 76.73 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.55 -0.719 . . . . 0.0 110.466 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -59.96 -40.01 87.55 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.11 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.5 mp -85.27 -16.18 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.563 -0.711 . . . . 0.0 111.119 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.23 132.83 55.14 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.173 -0.954 . . . . 0.0 110.069 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 89.98 -6.89 82.54 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 p -93.08 -0.04 57.17 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.254 -1.145 . . . . 0.0 111.168 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.1 m -59.97 139.91 57.09 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.058 -1.026 . . . . 0.0 109.706 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.473 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.58 -19.65 53.54 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.49 167.87 3.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.477 ' HB3' HG21 ' A' ' 46' ' ' THR . 56.3 Cg_endo -106.07 149.04 0.11 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 O-C-N 123.801 1.422 . . . . 0.0 111.206 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.453 HD21 HD13 ' A' ' 106' ' ' LEU . 85.2 mt -110.01 102.51 11.24 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.513 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -98.12 133.69 42.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.517 -0.739 . . . . 0.0 111.713 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -70.0 159.41 84.38 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.88 -26.14 23.61 Favored 'Trans proline' 0 N--CA 1.501 1.946 0 O-C-N 123.423 1.223 . . . . 0.0 112.393 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.7 m -62.73 -39.99 95.81 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.262 -0.899 . . . . 0.0 110.029 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.29 36.36 0.75 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . 0.414 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 2.9 m-70 -132.26 143.25 49.78 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.423 -1.045 . . . . 0.0 110.193 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.92 142.69 58.35 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.593 -0.692 . . . . 0.0 110.332 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -114.91 -43.63 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.575 -0.703 . . . . 0.0 109.891 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.74 -170.0 33.67 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.448 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.9 mt -123.86 139.36 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.618 -0.931 . . . . 0.0 110.375 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.44 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.2 t80 -64.26 136.43 57.17 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.687 -0.633 . . . . 0.0 109.774 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.3 ttt180 -115.94 -52.27 2.62 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.32 159.95 41.47 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.618 -0.676 . . . . 0.0 110.25 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.04 150.36 34.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.602 -0.686 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.0 t -109.94 120.0 60.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.673 -0.642 . . . . 0.0 109.751 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.438 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -129.77 145.29 51.56 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.63 -0.669 . . . . 0.0 110.426 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.4 m -70.0 -48.86 56.44 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.684 -0.635 . . . . 0.0 110.119 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -162.64 54.73 0.21 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.658 -0.651 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 113.21 -17.89 21.49 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.0 t -111.68 120.52 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.226 -1.161 . . . . 0.0 109.781 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.82 123.73 37.36 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.542 -0.724 . . . . 0.0 110.527 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 52.3 mttp -108.57 -24.77 11.23 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.634 -0.666 . . . . 0.0 110.197 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.78 158.77 43.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.46 -0.775 . . . . 0.0 110.102 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 28.7 m -140.24 170.62 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.565 -0.71 . . . . 0.0 110.545 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -128.93 139.91 51.91 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.646 -0.659 . . . . 0.0 109.905 179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -138.92 157.44 46.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.533 -0.729 . . . . 0.0 110.458 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 82' ' ' LEU . 59.6 t -96.16 121.52 60.38 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.606 -0.684 . . . . 0.0 109.49 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -65.01 150.06 88.56 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.845 1.445 . . . . 0.0 110.408 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 151' ' ' VAL . 87.8 t -60.84 -25.83 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.606 -0.684 . . . . 0.0 110.529 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 65.2 mm-40 -59.97 -36.98 78.3 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.46 -0.775 . . . . 0.0 110.497 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 80.8 p -60.09 -33.12 71.66 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.427 -0.796 . . . . 0.0 110.548 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.448 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.9 mtt -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.507 -0.745 . . . . 0.0 110.541 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -60.11 -40.0 88.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.595 -0.691 . . . . 0.0 110.406 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -60.93 -40.13 92.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 110.279 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -67.11 -50.04 62.87 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.481 -0.762 . . . . 0.0 110.206 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 78.7 mtm . . . . . 0 N--CA 1.496 1.855 0 O-C-N 121.498 -0.751 . . . . 0.0 110.07 179.847 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.517 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.2 tt0 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 121.1 0.476 . . . . 0.0 110.086 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.822 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.625 -0.672 . . . . 0.0 110.41 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 . . . . . 0 N--CA 1.497 1.91 0 CA-C-O 121.135 0.493 . . . . 0.0 109.841 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -114.78 128.85 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.582 -0.699 . . . . 0.0 109.628 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -124.03 159.95 28.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.579 -0.701 . . . . 0.0 110.316 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -108.29 122.18 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.67 -0.644 . . . . 0.0 109.636 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.539 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.8 m -118.44 156.76 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.615 -0.678 . . . . 0.0 110.3 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 62.7 m -135.88 167.34 21.37 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.598 -0.688 . . . . 0.0 110.907 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.3 m -134.44 170.68 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.742 -0.599 . . . . 0.0 109.986 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -65.29 -16.63 63.77 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.501 -0.749 . . . . 0.0 111.109 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 m -117.39 -35.02 4.12 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.189 -0.944 . . . . 0.0 111.628 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.0 pm0 -150.81 170.68 18.68 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.225 -0.922 . . . . 0.0 111.096 -179.204 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 85.9 p -130.43 155.69 46.01 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.36 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.692 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.1 p90 -162.46 -178.33 6.2 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.383 -0.823 . . . . 0.0 110.256 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.685 HD11 ' HA ' ' A' ' 109' ' ' ARG . 73.5 mt -113.66 152.84 29.87 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.519 -0.738 . . . . 0.0 110.9 -178.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -132.41 161.09 34.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.662 -0.649 . . . . 0.0 110.013 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.2 t -122.95 139.0 54.52 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.572 -0.705 . . . . 0.0 110.518 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 46.4 t -93.96 104.65 16.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.36 -0.838 . . . . 0.0 110.422 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -112.44 133.35 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.692 -0.63 . . . . 0.0 109.714 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 56.97 38.25 29.26 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.502 -0.749 . . . . 0.0 110.893 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.2 27.11 74.06 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -141.79 131.85 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -1.07 . . . . 0.0 110.064 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.33 144.97 39.86 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.423 -0.798 . . . . 0.0 109.06 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -129.93 150.99 50.98 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 111.087 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.932 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -168.82 -179.78 3.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.823 -0.548 . . . . 0.0 109.574 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.811 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.5 p -90.04 160.02 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.478 -0.764 . . . . 0.0 110.218 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 60.2 t80 -73.27 -44.62 58.94 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.538 -0.726 . . . . 0.0 111.779 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.859 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.7 p-80 -60.6 -24.66 65.65 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.134 -0.979 . . . . 0.0 110.704 -178.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.584 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.7 -47.78 11.44 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 178.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.692 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -137.09 94.53 2.96 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.751 -0.852 . . . . 0.0 109.271 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.06 62.81 1.33 Allowed Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.8 t 53.38 39.97 30.65 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.255 -1.144 . . . . 0.0 110.809 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -110.02 179.29 4.15 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.571 -0.705 . . . . 0.0 110.021 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 87.0 m -64.9 139.13 58.73 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.866 -0.733 . . . . 0.0 109.225 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.854 HD22 ' CZ2' ' A' ' 85' ' ' TRP . 12.6 tp -125.78 133.12 52.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.549 -0.719 . . . . 0.0 110.177 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.76 113.54 25.1 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.586 -0.697 . . . . 0.0 109.922 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.43 -179.26 17.54 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -62.28 -31.13 82.02 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.871 1.459 . . . . 0.0 110.649 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -75.87 -20.19 58.28 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.563 -0.71 . . . . 0.0 110.626 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.54 -133.27 7.42 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -84.25 146.05 11.06 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.9 1.474 . . . . 0.0 110.136 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.9 mt -120.02 129.98 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.589 -0.694 . . . . 0.0 110.34 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.5 p -87.45 147.09 25.56 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.48 -0.762 . . . . 0.0 110.442 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 15.3 mp0 -87.66 140.01 29.95 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.7 mmm -119.23 -41.8 2.71 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.573 -0.704 . . . . 0.0 110.422 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -120.06 140.0 51.68 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.519 -0.738 . . . . 0.0 110.684 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.489 ' HA ' HG12 ' A' ' 83' ' ' VAL . 33.4 m -139.97 130.01 24.93 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.605 -0.684 . . . . 0.0 110.09 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -142.19 98.33 3.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.499 -0.751 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 94.1 t -70.05 -40.15 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.59 -0.693 . . . . 0.0 109.96 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.1 -47.31 86.43 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.72 . . . . 0.0 110.644 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -87.14 -0.03 56.04 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.505 -0.747 . . . . 0.0 110.801 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.448 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.8 t70 52.96 45.14 29.42 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.113 -0.992 . . . . 0.0 110.543 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.952 HD11 HG11 ' A' ' 170' ' ' VAL . 64.5 mt -139.94 143.31 36.53 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.445 -0.784 . . . . 0.0 111.069 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.535 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -147.47 160.01 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.641 -0.662 . . . . 0.0 109.61 179.331 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.75 159.97 28.03 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.932 ' CH2' HG21 ' A' ' 54' ' ' THR . 15.3 m-90 -118.22 166.91 12.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.666 -0.902 . . . . 0.0 109.53 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -72.49 119.88 17.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.501 -0.749 . . . . 0.0 109.271 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.8 140.35 98.04 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.495 -0.753 . . . . 0.0 110.296 -179.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.96 159.98 51.29 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.926 1.487 . . . . 0.0 110.268 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.82 142.11 31.4 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.905 1.476 . . . . 0.0 110.225 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.48 29.29 49.59 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.79 152.12 26.1 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.561 -0.964 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -88.3 167.57 13.43 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.689 -0.632 . . . . 0.0 110.038 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 47.5 t -144.04 164.37 30.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.623 -0.673 . . . . 0.0 110.16 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.4 mt -110.16 149.2 30.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.601 -0.687 . . . . 0.0 110.653 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.421 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 24.5 p -89.95 177.76 2.26 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.694 -0.629 . . . . 0.0 109.984 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -88.74 159.11 6.25 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 O-C-N 123.801 1.421 . . . . 0.0 110.566 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.788 ' HB2' HG22 ' A' ' 151' ' ' VAL . 48.9 t -68.76 130.39 42.67 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.716 -0.615 . . . . 0.0 110.113 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 38.7 p -134.49 54.04 1.96 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.738 -0.601 . . . . 0.0 109.754 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.71 -5.95 0.8 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.561 -0.712 . . . . 0.0 112.37 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.98 38.2 93.84 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -100.01 122.35 42.77 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.575 -0.956 . . . . 0.0 110.463 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.4 m -69.95 -29.43 66.55 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.643 -0.66 . . . . 0.0 110.176 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -64.31 132.58 50.6 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.542 -0.724 . . . . 0.0 110.21 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.581 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.1 mt -136.63 149.95 48.27 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.554 -0.716 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.439 ' HD1' HG22 ' A' ' 113' ' ' VAL . 62.9 m-85 -112.49 120.5 41.85 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.519 -0.738 . . . . 0.0 110.057 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.2 tp -93.7 131.45 39.02 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.432 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.21 119.98 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.516 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.1 m -97.56 169.78 9.48 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.52 -0.738 . . . . 0.0 110.62 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.685 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.8 mtp-105 -62.54 -27.62 69.3 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.682 -0.636 . . . . 0.0 110.129 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -94.6 28.38 2.65 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.24 41.9 31.76 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.195 -0.94 . . . . 0.0 111.036 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -100.04 122.12 42.43 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.516 -0.74 . . . . 0.0 109.961 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.574 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -97.86 70.61 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.665 . . . . 0.0 110.308 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.427 HG23 ' O ' ' A' ' 114' ' ' ILE . 5.3 tp -70.0 129.99 90.31 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.57 -0.706 . . . . 0.0 109.862 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 114' ' ' ILE . 48.6 Cg_endo -75.71 134.33 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.781 1.411 . . . . 0.0 110.599 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.86 130.06 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.636 -0.665 . . . . 0.0 109.558 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -92.37 133.55 35.76 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.49 -0.756 . . . . 0.0 110.095 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -80.42 125.85 30.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.652 -0.655 . . . . 0.0 110.357 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -122.48 24.23 9.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.587 -0.696 . . . . 0.0 110.288 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -178.49 -177.36 47.1 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.12 -40.0 78.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.539 -0.977 . . . . 0.0 110.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.2 p -133.09 24.46 4.21 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.513 -0.742 . . . . 0.0 110.691 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.44 151.79 50.54 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.3 171.56 25.05 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.4 p -115.24 154.55 28.86 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.912 . . . . 0.0 110.04 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -99.99 119.98 39.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.51 -0.744 . . . . 0.0 110.069 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.71 -39.98 88.24 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.583 -0.698 . . . . 0.0 110.101 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.3 m -110.22 114.36 55.74 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.622 -0.674 . . . . 0.0 110.169 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.67 114.26 2.66 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.782 1.412 . . . . 0.0 110.439 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -125.59 160.08 57.6 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.628 -0.67 . . . . 0.0 110.081 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.71 157.08 53.71 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.853 1.449 . . . . 0.0 110.362 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.573 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.06 -23.89 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.595 -0.691 . . . . 0.0 110.636 -179.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.1 m -59.98 -39.98 87.53 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.469 -0.769 . . . . 0.0 110.328 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -59.91 -50.13 74.96 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.483 -0.761 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.462 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.93 -26.1 63.98 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.684 -0.635 . . . . 0.0 110.097 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 9.8 tptm -58.74 129.95 44.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.437 -0.79 . . . . 0.0 110.311 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.95 -10.06 72.39 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.407 -0.902 . . . . 0.0 110.866 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 59.5 p -94.57 -3.22 50.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.0 -1.294 . . . . 0.0 111.251 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.079 -1.013 . . . . 0.0 109.667 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.482 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.24 -22.18 38.76 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.57 155.62 44.02 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.514 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.0 Cg_endo -95.77 150.07 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.845 1.445 . . . . 0.0 111.219 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -106.61 108.99 20.78 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.8 130.28 45.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 111.579 -178.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.02 159.54 83.88 Favored Pre-proline 0 N--CA 1.495 1.815 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.9 -26.51 24.82 Favored 'Trans proline' 0 N--CA 1.501 1.929 0 O-C-N 123.494 1.26 . . . . 0.0 112.28 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.1 m -62.68 -39.96 95.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.258 -0.901 . . . . 0.0 109.99 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.23 35.99 0.84 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -131.8 149.47 52.45 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.409 -1.054 . . . . 0.0 110.314 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -68.21 139.96 56.06 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.66 -0.65 . . . . 0.0 110.272 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.788 HG22 ' HB2' ' A' ' 97' ' ' CYS . 64.7 t -114.46 -36.15 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.584 -0.697 . . . . 0.0 109.99 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 179.52 -166.61 36.03 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.482 HG23 ' C ' ' A' ' 140' ' ' GLY . 96.6 mt -130.97 140.07 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.563 -0.963 . . . . 0.0 110.263 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.408 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.3 t80 -64.25 138.57 58.51 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.7 -0.625 . . . . 0.0 109.58 179.507 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -118.49 -52.25 2.37 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.473 -0.767 . . . . 0.0 110.428 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.79 160.06 43.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.593 -0.692 . . . . 0.0 110.184 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.408 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.81 151.88 26.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.616 -0.677 . . . . 0.0 110.256 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -108.47 116.97 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.662 -0.649 . . . . 0.0 109.751 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.573 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.3 p -129.88 142.39 50.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.653 -0.654 . . . . 0.0 110.254 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.1 m -69.69 -49.61 51.78 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.566 -0.709 . . . . 0.0 110.103 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -162.91 54.15 0.19 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.71 -0.619 . . . . 0.0 109.823 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 114.78 -18.51 16.89 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -112.9 120.77 63.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.29 -1.124 . . . . 0.0 109.758 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -86.61 130.1 34.62 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.549 -0.72 . . . . 0.0 110.522 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -112.47 -26.15 8.84 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.583 -0.698 . . . . 0.0 110.33 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.32 157.99 44.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.663 -0.648 . . . . 0.0 109.974 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.25 179.5 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.431 -0.793 . . . . 0.0 110.608 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -135.36 134.58 39.94 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -138.18 153.13 49.2 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.35 -0.844 . . . . 0.0 110.809 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.952 HG11 HD11 ' A' ' 82' ' ' LEU . 60.5 t -95.09 119.12 66.26 Favored Pre-proline 0 N--CA 1.493 1.675 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 179.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -62.38 155.23 58.75 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.771 1.406 . . . . 0.0 110.589 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 151' ' ' VAL . 93.7 t -56.78 -23.18 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.611 -0.681 . . . . 0.0 110.669 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -60.04 -33.13 71.61 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.375 -0.828 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . 0.454 ' HB3' HG12 ' A' ' 170' ' ' VAL . 18.4 t -60.07 -37.99 81.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.453 -0.78 . . . . 0.0 110.393 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.481 ' HE1' HD11 ' A' ' 153' ' ' ILE . 67.6 mtt -59.97 -39.97 87.46 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.521 -0.737 . . . . 0.0 110.502 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -62.31 -39.9 94.53 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.594 -0.691 . . . . 0.0 110.189 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.6 m -70.09 -39.97 75.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.596 -0.69 . . . . 0.0 109.965 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 84.8 m -59.98 -49.54 77.25 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.588 -0.695 . . . . 0.0 110.317 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.497 1.92 0 O-C-N 121.542 -0.723 . . . . 0.0 110.295 -179.935 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.537 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.046 0.45 . . . . 0.0 110.208 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.859 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp . . . . . 0 N--CA 1.496 1.865 0 O-C-N 121.647 -0.658 . . . . 0.0 109.985 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 . . . . . 0 N--CA 1.495 1.776 0 CA-C-O 121.085 0.469 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 123.27 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.688 -0.632 . . . . 0.0 109.817 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -123.72 157.89 32.9 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.589 -0.695 . . . . 0.0 110.312 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 67.9 t -87.34 131.71 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.605 -0.685 . . . . 0.0 109.812 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.483 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.1 m -127.13 152.89 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.587 -0.696 . . . . 0.0 110.367 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 64.0 m -135.96 -177.89 4.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.705 -0.622 . . . . 0.0 110.34 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.528 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.6 OUTLIER -144.75 -169.13 3.1 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.528 ' H ' HG22 ' A' ' 38' ' ' THR . . . -59.32 -38.67 80.87 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.395 -0.816 . . . . 0.0 110.098 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.1 t -138.58 -7.22 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.443 -0.786 . . . . 0.0 112.514 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -114.55 151.39 33.44 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.868 -1.145 . . . . 0.0 111.163 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -136.09 141.49 44.22 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.584 -0.697 . . . . 0.0 110.238 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.753 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 32.8 p90 -170.32 -177.53 2.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.426 -0.796 . . . . 0.0 110.023 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.749 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.1 mt -113.13 167.9 10.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.49 -0.756 . . . . 0.0 110.253 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -145.9 160.04 42.38 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.664 -0.647 . . . . 0.0 110.265 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.447 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.8 t -120.57 140.2 51.85 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.597 -0.69 . . . . 0.0 110.18 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 37.7 t -99.23 109.96 22.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.417 -0.802 . . . . 0.0 110.407 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.19 130.03 64.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.541 -0.724 . . . . 0.0 109.701 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 56.14 39.93 30.25 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.544 -0.723 . . . . 0.0 110.868 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.741 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 19.92 75.73 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.0 t -131.06 130.01 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.267 -1.137 . . . . 0.0 109.958 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 78.4 m -77.41 140.43 39.89 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.415 -0.803 . . . . 0.0 109.461 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -130.62 147.09 52.25 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.517 -0.739 . . . . 0.0 110.936 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.794 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -167.66 -179.19 4.21 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.783 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.6 p -88.68 156.63 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 110.356 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.433 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 53.0 t80 -70.04 -44.37 69.36 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.594 -0.691 . . . . 0.0 111.887 -178.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.783 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.9 p-80 -60.78 -24.26 65.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.195 -0.941 . . . . 0.0 110.787 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.563 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -77.1 -48.96 7.88 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.753 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -128.49 101.09 6.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.784 -0.833 . . . . 0.0 109.534 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.26 -164.93 2.34 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 35.0 p -72.21 65.92 0.62 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.655 -0.909 . . . . 0.0 109.844 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.39 169.87 16.77 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.604 -0.685 . . . . 0.0 110.595 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.7 p -69.89 159.92 32.78 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.579 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.858 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.0 tp -115.51 140.8 48.83 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.543 -0.723 . . . . 0.0 110.335 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.91 109.7 22.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.576 -0.702 . . . . 0.0 110.109 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.63 179.98 16.32 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.99 -32.34 65.21 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.854 1.45 . . . . 0.0 110.431 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 87.0 mttt -71.08 -31.49 67.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.663 -0.648 . . . . 0.0 110.037 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.11 -162.2 25.99 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.02 137.82 38.59 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.866 1.456 . . . . 0.0 110.155 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.7 mt -120.06 130.04 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.615 -0.678 . . . . 0.0 110.49 -179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 77.8 p -80.4 149.98 29.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.927 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -100.86 144.42 29.84 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.523 -0.736 . . . . 0.0 111.218 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.442 ' HE1' ' HG3' ' A' ' 86' ' ' GLN . 30.2 mtm -117.3 -21.76 8.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.631 . . . . 0.0 110.59 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -125.57 147.44 49.28 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.417 -0.802 . . . . 0.0 110.403 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.493 ' HA ' HG12 ' A' ' 83' ' ' VAL . 6.9 t -169.32 129.72 1.08 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.59 -0.694 . . . . 0.0 109.921 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.607 -0.683 . . . . 0.0 110.258 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 69.3 t -69.8 -49.61 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.582 -0.699 . . . . 0.0 109.811 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -60.28 -48.57 81.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.606 -0.684 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.783 ' HG2' HD12 ' A' ' 82' ' ' LEU . 50.7 tt0 -79.33 -10.11 59.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.634 -0.666 . . . . 0.0 110.612 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.0 t70 54.16 49.94 17.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.15 -0.969 . . . . 0.0 110.701 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.783 HD12 ' HG2' ' A' ' 80' ' ' GLN . 39.0 mt -143.25 130.98 21.38 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.385 -0.822 . . . . 0.0 111.43 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.4 m -130.03 159.98 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.609 -0.682 . . . . 0.0 109.592 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.14 159.06 27.82 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.858 ' CH2' HD22 ' A' ' 64' ' ' LEU . 9.3 m-90 -122.52 160.03 26.46 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.747 -0.855 . . . . 0.0 109.725 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . 0.442 ' HG3' ' HE1' ' A' ' 74' ' ' MET . 41.5 tt0 -77.79 107.77 10.53 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.543 -0.723 . . . . 0.0 109.51 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.741 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.45 137.84 86.29 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.594 -0.691 . . . . 0.0 110.291 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.04 158.79 55.45 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 O-C-N 123.93 1.49 . . . . 0.0 110.221 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.64 146.48 61.06 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.976 1.514 . . . . 0.0 110.388 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.94 -26.37 24.72 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -68.06 140.05 56.27 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.46 -1.023 . . . . 0.0 110.119 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -81.82 158.62 24.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.522 -0.736 . . . . 0.0 109.884 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -130.07 169.76 14.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.573 -0.704 . . . . 0.0 110.167 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.551 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 45.0 mt -106.03 131.91 52.75 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.625 -0.672 . . . . 0.0 110.731 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -73.66 160.03 83.11 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.577 -0.702 . . . . 0.0 109.793 179.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -77.35 161.12 32.04 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.787 1.414 . . . . 0.0 110.636 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.8 t -74.07 129.91 38.77 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.722 -0.611 . . . . 0.0 110.134 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -132.85 54.12 1.97 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.679 -0.638 . . . . 0.0 109.689 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.62 -8.12 0.75 Allowed 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.371 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.97 42.57 98.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.97 119.93 39.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.525 -0.985 . . . . 0.0 110.422 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.6 m -63.31 -39.99 96.11 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 110.48 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -60.71 129.98 44.25 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.561 -0.712 . . . . 0.0 110.481 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 1.097 HD22 HG11 ' A' ' 151' ' ' VAL . 93.2 mt -133.08 150.19 52.1 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.673 -0.642 . . . . 0.0 110.404 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -115.72 121.37 42.31 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.483 -0.76 . . . . 0.0 109.948 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.431 HD13 HD11 ' A' ' 143' ' ' LEU . 44.6 tp -101.05 143.82 30.71 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.528 -0.732 . . . . 0.0 110.369 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.7 t -108.87 129.12 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.57 -0.706 . . . . 0.0 109.87 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.476 HG21 HD11 ' A' ' 114' ' ' ILE . 75.2 p -106.26 178.85 4.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.543 -0.723 . . . . 0.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.749 ' HA ' HD11 ' A' ' 44' ' ' LEU . 68.3 mtm180 -59.98 -28.26 67.53 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.594 -0.691 . . . . 0.0 110.58 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -90.3 19.08 5.39 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.467 -0.77 . . . . 0.0 111.122 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.51 40.02 30.81 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.102 -0.999 . . . . 0.0 110.706 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -100.16 139.34 35.97 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.73 -0.606 . . . . 0.0 109.936 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 64.7 t -93.74 117.39 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.624 -0.672 . . . . 0.0 109.955 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 108' ' ' THR . 86.9 mt -107.53 110.05 62.73 Favored Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.694 -0.629 . . . . 0.0 109.599 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.85 116.4 4.55 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 123.886 1.466 . . . . 0.0 110.462 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.1 t -120.01 125.2 74.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.678 -0.639 . . . . 0.0 109.643 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -86.23 130.03 34.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.572 -0.705 . . . . 0.0 109.97 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.75 127.87 33.71 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.622 -0.674 . . . . 0.0 110.376 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 12.0 mmm180 -129.68 22.21 5.47 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.665 -0.647 . . . . 0.0 110.245 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.51 -179.75 43.07 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -67.51 -40.66 85.15 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.591 -0.946 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.7 p -131.67 22.51 4.66 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.493 -0.754 . . . . 0.0 110.743 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.38 151.93 51.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.384 -0.822 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.46 -173.98 18.17 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -125.49 154.91 41.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.641 -0.917 . . . . 0.0 110.162 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 25.1 tp -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.575 -0.703 . . . . 0.0 110.207 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.489 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -68.37 -36.61 79.44 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -111.04 113.05 55.06 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.685 -0.635 . . . . 0.0 110.039 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.28 116.57 3.82 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.726 1.382 . . . . 0.0 110.545 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -128.03 160.04 63.64 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.602 -0.686 . . . . 0.0 110.082 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.71 157.09 62.77 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.907 1.477 . . . . 0.0 110.398 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.502 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.4 m -66.12 -24.78 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.614 -0.679 . . . . 0.0 110.487 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.2 t -59.88 -38.44 82.22 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.456 -0.778 . . . . 0.0 110.332 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.585 -0.697 . . . . 0.0 110.342 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 135' ' ' LEU . 10.7 mp -83.11 -16.86 45.17 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.477 -0.765 . . . . 0.0 111.038 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.59 140.01 58.83 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.269 -0.894 . . . . 0.0 110.078 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.56 6.05 89.11 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 63.2 m -112.58 19.48 17.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.129 -1.218 . . . . 0.0 110.757 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -72.28 147.91 45.94 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.304 -0.873 . . . . 0.0 109.935 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.58 -15.31 60.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.02 139.98 48.17 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -87.79 148.93 7.2 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 O-C-N 123.77 1.405 . . . . 0.0 111.224 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.868 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -105.6 120.02 40.59 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.551 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -108.77 131.18 55.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.463 -0.773 . . . . 0.0 111.704 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.453 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.97 82.09 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.4 Cg_endo -51.72 -23.12 14.8 Favored 'Trans proline' 0 N--CA 1.502 2.004 0 O-C-N 123.51 1.268 . . . . 0.0 112.272 -178.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -66.32 -39.98 89.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.247 -0.908 . . . . 0.0 109.89 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.25 34.67 0.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -131.77 144.72 51.15 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.422 -1.046 . . . . 0.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.551 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.91 138.67 52.63 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.515 -0.74 . . . . 0.0 110.125 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 1.097 HG11 HD22 ' A' ' 104' ' ' LEU . 8.3 p -118.05 -21.87 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.591 -0.693 . . . . 0.0 110.814 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 178.68 -173.75 46.02 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.423 HG12 HG21 ' A' ' 46' ' ' THR . 95.5 mt -131.55 139.99 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.605 -0.938 . . . . 0.0 110.096 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.2 t80 -61.0 139.64 58.0 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.579 -0.7 . . . . 0.0 110.148 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -120.21 -52.02 2.19 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.59 -0.694 . . . . 0.0 110.333 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.533 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -154.24 160.55 41.87 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.571 -0.706 . . . . 0.0 110.432 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.01 153.88 23.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.552 -0.717 . . . . 0.0 110.408 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.05 119.22 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.637 -0.664 . . . . 0.0 109.888 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.502 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -137.07 158.59 44.11 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.683 . . . . 0.0 110.307 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 6.2 p -99.0 -51.95 3.7 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.595 -0.691 . . . . 0.0 110.486 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -142.94 63.06 1.39 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.565 -0.709 . . . . 0.0 110.013 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.99 -8.81 79.14 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.66 126.55 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.193 -1.181 . . . . 0.0 109.967 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.58 131.69 46.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.6 -0.687 . . . . 0.0 110.372 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -113.66 -15.42 12.49 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.565 -0.709 . . . . 0.0 110.746 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 158.71 43.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.345 -0.847 . . . . 0.0 109.846 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.04 160.01 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.523 -0.736 . . . . 0.0 110.546 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -123.04 136.11 54.71 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.732 -0.605 . . . . 0.0 109.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -139.11 160.0 40.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.497 -0.752 . . . . 0.0 110.457 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.661 HG11 HD11 ' A' ' 82' ' ' LEU . 88.6 t -99.89 124.6 43.21 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.59 -0.693 . . . . 0.0 109.553 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -65.34 147.59 87.64 Favored 'Trans proline' 0 N--CA 1.489 1.259 0 O-C-N 123.82 1.432 . . . . 0.0 110.186 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.571 HG13 ' C ' ' A' ' 151' ' ' VAL . 35.7 m -60.6 -24.68 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.68 -0.638 . . . . 0.0 110.996 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -60.5 -39.97 89.67 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.485 -0.759 . . . . 0.0 110.693 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.2 p -61.67 -43.3 99.11 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.434 -0.791 . . . . 0.0 110.906 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.444 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.1 mtm -63.54 -39.98 95.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.825 . . . . 0.0 110.456 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -60.43 -40.01 89.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.424 -0.798 . . . . 0.0 110.029 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.0 m -70.23 -26.11 63.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.632 -0.668 . . . . 0.0 110.528 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.7 m -59.94 -40.83 90.29 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.517 -0.739 . . . . 0.0 110.282 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.2 mtt . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.471 -0.768 . . . . 0.0 110.208 179.883 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.533 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 60.2 tt0 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.03 0.443 . . . . 0.0 110.131 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.771 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp . . . . . 0 N--CA 1.495 1.788 0 O-C-N 121.608 -0.682 . . . . 0.0 110.222 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.568 ' HG3' HD11 ' A' ' 94' ' ' LEU . 2.9 pt-20 . . . . . 0 N--CA 1.496 1.848 0 CA-C-O 120.87 0.367 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.515 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.0 t -108.94 127.56 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.492 -0.755 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -121.16 155.5 34.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.666 -0.647 . . . . 0.0 110.345 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 63.7 t -91.52 120.59 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.668 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.603 ' CB ' HD21 ' A' ' 64' ' ' LEU . 33.4 m -116.56 158.32 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.659 -0.651 . . . . 0.0 110.156 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 33.0 m -145.68 172.77 12.79 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.126 -0.629 . . . . 0.0 110.577 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.93 -172.38 2.91 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.19 88.56 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.374 -0.829 . . . . 0.0 110.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 23.2 m -131.47 -7.12 3.72 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.526 -0.734 . . . . 0.0 111.975 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -113.96 159.71 19.62 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.967 -1.083 . . . . 0.0 110.906 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.2 t -146.1 136.96 24.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.0 p90 -166.72 -177.42 3.89 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.315 -0.866 . . . . 0.0 110.528 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.807 HD11 ' N ' ' A' ' 109' ' ' ARG . 73.3 mt -113.05 159.07 19.54 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.598 -0.689 . . . . 0.0 110.81 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -133.4 156.69 47.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.643 -0.661 . . . . 0.0 110.044 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 142' ' ' PRO . 47.3 m -121.82 134.57 54.9 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.444 -0.785 . . . . 0.0 110.44 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 31.7 t -92.76 110.44 21.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.56 -0.713 . . . . 0.0 110.594 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 94' ' ' LEU . 63.1 t -119.46 134.84 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.593 -0.692 . . . . 0.0 109.641 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 54.93 38.37 30.33 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.534 -0.729 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.509 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.09 26.04 74.81 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 178.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.4 t -139.9 131.73 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.364 -1.08 . . . . 0.0 109.906 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.8 m -75.29 148.57 39.27 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.377 -0.827 . . . . 0.0 109.181 179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.502 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 60.8 m95 -129.99 151.04 50.97 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.726 0.774 . . . . 0.0 111.313 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -169.37 -179.88 3.64 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.871 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.4 p -95.62 155.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.828 . . . . 0.0 110.37 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.437 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 62.1 t80 -70.01 -40.86 75.0 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.509 -0.745 . . . . 0.0 111.599 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.871 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.9 p-80 -70.04 -24.4 63.26 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.148 -0.97 . . . . 0.0 110.621 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.781 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.38 -56.28 2.71 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.576 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -101.97 -53.51 2.92 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.756 -0.849 . . . . 0.0 109.964 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.08 -168.99 46.87 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 97.9 p -86.48 64.45 8.54 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.644 -0.915 . . . . 0.0 109.911 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -140.27 170.02 16.6 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.533 -0.729 . . . . 0.0 110.38 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.9 m -65.3 139.59 58.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.549 -0.719 . . . . 0.0 110.043 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.91 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -113.56 136.22 53.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.64 -0.663 . . . . 0.0 110.014 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.28 119.08 33.17 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -123.05 176.42 16.6 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.69 -32.36 68.49 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.852 1.449 . . . . 0.0 110.414 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -71.89 -31.32 66.29 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.629 -0.67 . . . . 0.0 110.169 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.86 -156.57 26.72 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -70.04 154.33 66.76 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.872 1.459 . . . . 0.0 110.359 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.5 mt -130.35 142.65 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.579 -0.7 . . . . 0.0 110.311 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.4 p -99.47 139.98 34.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.496 -0.752 . . . . 0.0 110.591 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.418 ' NE2' HG22 ' A' ' 76' ' ' THR . 1.5 mm100 -71.04 144.55 50.35 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.613 -0.679 . . . . 0.0 111.216 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.41 ' HG3' ' N ' ' A' ' 86' ' ' GLN . 95.1 mmm -119.21 -45.41 2.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.65 -0.656 . . . . 0.0 110.211 179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -120.02 139.94 51.74 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.592 -0.693 . . . . 0.0 110.449 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.418 HG22 ' NE2' ' A' ' 73' ' ' GLN . 30.3 p -130.48 139.92 50.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.58 -0.7 . . . . 0.0 110.329 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.608 ' OD1' HG21 ' A' ' 178' ' ' THR . 34.6 m120 -148.33 82.59 1.48 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.616 -0.678 . . . . 0.0 110.083 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.435 HG22 ' CE1' ' A' ' 56' ' ' TYR . 94.2 t -62.34 -44.68 99.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.634 -0.666 . . . . 0.0 110.011 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.96 -44.54 94.36 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.508 -0.745 . . . . 0.0 110.216 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.606 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.8 tp60 -89.97 -0.0 57.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.514 -0.741 . . . . 0.0 111.002 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.437 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.2 t70 52.79 49.63 19.85 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.016 -1.052 . . . . 0.0 110.498 -179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.606 HD12 ' CG ' ' A' ' 80' ' ' GLN . 54.9 mt -140.02 144.51 36.97 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.601 -0.687 . . . . 0.0 111.101 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.629 HG23 HG23 ' A' ' 54' ' ' THR . 34.9 m -149.93 159.67 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.565 -0.709 . . . . 0.0 109.611 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.58 28.24 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.926 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.5 m-90 -120.9 159.98 24.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.824 -0.81 . . . . 0.0 109.742 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . 0.41 ' N ' ' HG3' ' A' ' 74' ' ' MET . 4.3 pt20 -68.45 122.47 18.5 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.425 -0.797 . . . . 0.0 109.373 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.509 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.42 130.54 79.52 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.538 -0.726 . . . . 0.0 110.187 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.06 159.97 51.29 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.887 1.467 . . . . 0.0 110.293 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.21 160.13 50.2 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 O-C-N 123.883 1.465 . . . . 0.0 110.275 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.58 29.43 69.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.06 156.64 21.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.615 -0.932 . . . . 0.0 110.113 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -99.12 139.72 34.35 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.0 p -118.84 157.74 27.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.616 -0.677 . . . . 0.0 110.181 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 76.7 mt -112.32 131.53 55.47 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.566 -0.709 . . . . 0.0 110.563 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.6 p -82.2 159.99 63.79 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.565 -0.709 . . . . 0.0 109.969 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.685 ' HB3' HG11 ' A' ' 172' ' ' VAL . 47.1 Cg_endo -70.61 165.81 30.72 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.823 1.433 . . . . 0.0 110.4 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.484 ' HB2' HG22 ' A' ' 151' ' ' VAL . 13.5 t -87.2 149.98 24.24 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.891 0.853 . . . . 0.0 110.367 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.6 m -133.91 62.21 1.66 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 m -141.57 -9.02 0.95 Allowed 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.831 -177.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.51 26.45 56.95 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 79.5 p -80.02 160.0 26.02 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.461 -1.023 . . . . 0.0 110.493 -179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.7 m -107.42 -27.07 10.67 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.707 -0.62 . . . . 0.0 110.329 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -73.83 129.37 37.77 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.75 . . . . 0.0 110.015 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.49 ' CD2' HG11 ' A' ' 151' ' ' VAL . 85.0 mt -135.3 150.05 49.92 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.576 -0.703 . . . . 0.0 110.662 -179.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -108.69 119.94 41.0 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.492 -0.755 . . . . 0.0 109.562 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.457 HD13 HD11 ' A' ' 143' ' ' LEU . 50.0 tp -100.97 141.51 33.75 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.48 -0.762 . . . . 0.0 110.78 -179.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.88 130.03 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.631 -0.668 . . . . 0.0 109.703 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . 0.496 ' C ' HD11 ' A' ' 44' ' ' LEU . 73.9 p -111.89 169.97 8.47 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.442 -0.786 . . . . 0.0 110.705 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.807 ' N ' HD11 ' A' ' 44' ' ' LEU . 23.1 ptt-85 -64.68 -16.17 62.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.611 -0.68 . . . . 0.0 111.005 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -89.97 17.4 6.86 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.222 -0.923 . . . . 0.0 110.828 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.44 40.01 31.46 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.081 -1.012 . . . . 0.0 110.51 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -113.38 156.56 23.22 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.658 -0.651 . . . . 0.0 109.853 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -130.0 130.36 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.551 -0.718 . . . . 0.0 110.233 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.409 HG23 ' O ' ' A' ' 114' ' ' ILE . 16.1 tt -131.86 130.06 22.11 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.69 -0.631 . . . . 0.0 109.893 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.53 ' HG2' HD22 ' A' ' 127' ' ' LEU . 47.4 Cg_endo -71.71 126.79 12.37 Favored 'Trans proline' 0 N--CA 1.49 1.265 0 O-C-N 123.856 1.45 . . . . 0.0 110.355 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -120.04 125.58 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.692 -0.63 . . . . 0.0 109.72 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -86.23 149.99 24.7 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.484 -0.76 . . . . 0.0 110.059 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 70.0 ttp85 -93.71 120.65 34.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -110.01 20.0 18.41 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.649 -0.657 . . . . 0.0 110.349 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.55 -177.26 42.61 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.94 -40.03 91.72 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.526 -0.985 . . . . 0.0 110.281 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.6 p -132.33 26.43 4.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.521 -0.737 . . . . 0.0 110.394 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 16.6 tpt180 -124.35 139.97 53.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.451 -0.781 . . . . 0.0 110.495 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.54 167.22 25.35 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 78.3 p -118.95 152.33 36.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.937 . . . . 0.0 110.104 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 164' ' ' ALA . 19.2 tp -94.17 119.09 32.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.556 -0.715 . . . . 0.0 110.118 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.53 HD22 ' HG2' ' A' ' 115' ' ' PRO . 9.2 mp -65.79 -40.0 91.5 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.57 -0.706 . . . . 0.0 109.951 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 58.6 m -111.43 118.59 47.04 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.674 -0.641 . . . . 0.0 110.109 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.54 117.42 4.59 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 O-C-N 123.73 1.384 . . . . 0.0 110.352 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 21.3 mtt180 -129.87 159.95 67.4 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.54 -0.725 . . . . 0.0 110.267 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.27 160.22 43.34 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 O-C-N 123.931 1.49 . . . . 0.0 110.414 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.441 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.6 m -67.39 -25.02 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.665 -0.647 . . . . 0.0 110.816 -179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.4 p -59.96 -40.06 87.76 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.453 -0.779 . . . . 0.0 110.224 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -59.87 -49.82 76.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.534 -0.728 . . . . 0.0 110.023 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.452 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.03 -30.45 67.74 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.611 -0.681 . . . . 0.0 109.82 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 tptm -59.92 131.02 49.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.596 -0.69 . . . . 0.0 110.156 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.2 62.66 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.5 m -116.27 12.84 15.5 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.127 -1.219 . . . . 0.0 110.888 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.1 t -62.03 145.15 53.95 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.292 -0.88 . . . . 0.0 109.915 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.06 -12.08 68.8 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.94 140.39 47.9 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.59 ' HB3' HG21 ' A' ' 46' ' ' THR . 51.8 Cg_endo -92.05 150.31 3.2 Favored 'Trans proline' 0 C--N 1.316 -1.168 0 O-C-N 123.85 1.448 . . . . 0.0 111.393 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -100.39 103.05 14.42 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.507 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -85.74 149.54 25.21 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-O 122.083 0.944 . . . . 0.0 112.289 -177.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 1.6 t -87.78 145.2 36.32 Favored Pre-proline 0 N--CA 1.492 1.655 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -53.71 -24.8 31.45 Favored 'Trans proline' 0 N--CA 1.502 1.98 0 O-C-N 123.291 1.153 . . . . 0.0 110.375 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.3 m -71.87 -36.51 70.13 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.33 39.77 0.57 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 38.5 m170 -130.02 138.69 50.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.438 -1.037 . . . . 0.0 110.594 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.603 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.95 141.55 58.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.444 -0.785 . . . . 0.0 109.899 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 172' ' ' VAL . 58.9 t -115.3 -44.0 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.508 -0.745 . . . . 0.0 110.582 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -170.64 -171.07 35.63 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.2 mt -132.92 140.03 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.937 . . . . 0.0 110.441 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.718 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.4 t80 -67.87 138.09 55.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.623 -0.673 . . . . 0.0 109.811 179.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.8 ttp180 -124.24 -52.58 1.74 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.538 -0.726 . . . . 0.0 110.499 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -139.78 159.5 42.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.514 -0.741 . . . . 0.0 110.286 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.718 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.41 136.45 54.96 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.604 -0.685 . . . . 0.0 110.612 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.1 t -93.7 119.82 42.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.441 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.6 p -137.37 159.91 40.58 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.235 -179.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 76.1 p -138.88 142.28 38.58 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 53.76 28.01 7.69 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.289 -0.882 . . . . 0.0 110.671 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 80.69 22.89 61.04 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.5 t -129.98 129.99 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.265 -1.138 . . . . 0.0 110.039 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . 0.405 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -91.54 124.03 35.4 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.26 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 40.9 mttm -112.72 -26.38 8.63 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.587 -0.696 . . . . 0.0 110.352 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.2 161.57 38.54 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.532 -0.73 . . . . 0.0 109.838 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.03 178.49 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.517 -0.739 . . . . 0.0 111.476 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -134.03 135.52 43.42 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -139.99 145.59 38.03 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.326 -0.859 . . . . 0.0 110.719 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.563 HG11 HD11 ' A' ' 82' ' ' LEU . 72.9 t -86.7 124.72 68.88 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.627 -0.671 . . . . 0.0 109.353 179.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -66.54 162.52 36.46 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.845 1.444 . . . . 0.0 110.343 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.8 t -70.03 -24.67 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.681 -0.637 . . . . 0.0 110.487 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -57.93 -39.93 79.21 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.375 -0.828 . . . . 0.0 110.575 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.6 p -69.31 -38.43 78.24 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.502 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 93.0 mtp -60.19 -40.52 90.34 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.654 -0.654 . . . . 0.0 110.35 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -69.26 -39.97 78.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.623 -0.673 . . . . 0.0 110.336 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.12 -39.92 91.84 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.606 -0.684 . . . . 0.0 110.074 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . 0.608 HG21 ' OD1' ' A' ' 77' ' ' ASN . 89.7 m -60.11 -47.52 85.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.545 -0.722 . . . . 0.0 110.375 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.631 -0.668 . . . . 0.0 110.41 -179.765 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 121.166 0.508 . . . . 0.0 110.116 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.803 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.496 1.853 0 O-C-N 121.531 -0.731 . . . . 0.0 110.234 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.569 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.1 mt-10 . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 121.136 0.493 . . . . 0.0 110.214 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -102.64 126.52 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.701 . . . . 0.0 110.037 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -117.21 151.61 36.55 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.564 -0.71 . . . . 0.0 110.146 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.7 p -89.67 136.15 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.512 -0.743 . . . . 0.0 110.069 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.683 ' HB ' HD12 ' A' ' 64' ' ' LEU . 33.6 m -129.7 136.97 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.695 -0.628 . . . . 0.0 110.006 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.6 m -136.13 170.93 15.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -133.11 -170.67 2.51 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.636 -0.665 . . . . 0.0 109.449 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.3 -24.2 67.57 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.642 -0.661 . . . . 0.0 111.427 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.3 t -137.24 -15.45 1.47 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.133 -0.979 . . . . 0.0 113.175 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -125.29 149.66 47.85 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.872 -1.143 . . . . 0.0 111.249 -178.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 29.2 p -132.77 142.36 48.97 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.824 -0.548 . . . . 0.0 110.094 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.463 ' CE2' ' HB2' ' A' ' 59' ' ' ALA . 16.1 p90 -163.91 -177.33 5.03 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.469 -0.769 . . . . 0.0 109.88 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.79 HD11 ' CA ' ' A' ' 109' ' ' ARG . 29.1 mt -112.46 179.18 4.06 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.391 -0.818 . . . . 0.0 110.775 -177.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -155.36 160.34 40.63 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.784 -0.573 . . . . 0.0 109.725 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.1 t -125.65 138.41 53.91 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.481 -0.762 . . . . 0.0 110.231 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.9 t -96.66 107.01 19.38 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.474 -0.766 . . . . 0.0 110.653 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.435 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.2 t -110.35 130.0 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.717 -0.614 . . . . 0.0 109.348 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 56.84 36.37 27.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.502 -0.749 . . . . 0.0 110.725 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.543 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 74.28 17.7 79.71 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 179.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.2 t -131.21 130.03 63.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.942 0 O-C-N 121.118 -1.225 . . . . 0.0 110.102 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.3 t -73.06 150.05 42.66 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.511 -0.743 . . . . 0.0 109.592 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.435 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 87.4 m95 -135.72 150.0 49.4 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.528 -0.733 . . . . 0.0 110.93 -179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.843 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.0 t -168.51 -179.69 3.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.856 -0.528 . . . . 0.0 109.584 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.816 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.4 p -91.46 157.2 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.018 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.617 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.7 t80 -72.93 -43.65 62.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.543 -0.723 . . . . 0.0 112.14 -178.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.816 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.8 p-80 -60.84 -24.63 66.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.12 -0.988 . . . . 0.0 110.714 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.536 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -90.85 -35.51 7.18 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.362 -1.895 . . . . 0.0 108.362 178.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.463 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -135.59 97.0 3.56 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.792 -0.828 . . . . 0.0 109.879 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -80.03 -166.24 33.24 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 79.1 p -72.26 65.84 0.62 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.626 -0.926 . . . . 0.0 109.631 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.22 169.82 16.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.0 110.382 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 71' ' ' ILE . 69.0 m -74.94 139.25 42.88 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.661 -0.649 . . . . 0.0 110.141 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.683 HD12 ' HB ' ' A' ' 36' ' ' VAL . 0.2 OUTLIER -108.51 133.47 52.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.626 -0.671 . . . . 0.0 109.705 179.671 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.71 112.72 20.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.636 -0.665 . . . . 0.0 110.209 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -112.2 -176.74 19.95 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.79 -32.65 67.17 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.854 1.45 . . . . 0.0 110.499 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -74.93 -31.12 61.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.667 -0.646 . . . . 0.0 109.934 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.65 -144.17 13.27 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . 0.429 ' O ' HD13 ' A' ' 71' ' ' ILE . 47.5 Cg_endo -73.61 155.13 49.94 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.817 1.43 . . . . 0.0 110.238 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 63' ' ' THR . 49.1 mm -129.49 139.93 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.558 -0.714 . . . . 0.0 110.455 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 80.5 m -101.04 120.92 40.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.567 -0.708 . . . . 0.0 110.076 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.586 ' OE1' HG22 ' A' ' 76' ' ' THR . 32.2 tt0 -77.0 139.53 40.1 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.546 -0.721 . . . . 0.0 110.681 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 42.2 mtp -109.95 -30.01 8.0 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.663 -0.648 . . . . 0.0 110.441 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -112.85 138.42 49.72 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.523 -0.736 . . . . 0.0 110.612 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.586 HG22 ' OE1' ' A' ' 73' ' ' GLN . 7.0 p -139.41 126.91 21.62 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.706 -0.621 . . . . 0.0 110.023 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 -142.02 90.97 2.3 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.489 -0.757 . . . . 0.0 110.26 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.617 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 91.1 t -66.26 -40.35 86.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.6 -0.687 . . . . 0.0 109.882 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.58 -45.01 95.53 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.647 -0.658 . . . . 0.0 110.601 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.535 ' HG3' HD12 ' A' ' 82' ' ' LEU . 38.6 tp60 -87.79 -0.01 56.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.504 -0.747 . . . . 0.0 110.816 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.6 t70 53.54 42.71 31.88 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.055 -1.028 . . . . 0.0 110.538 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.682 HD11 HG11 ' A' ' 170' ' ' VAL . 67.0 mt -140.92 147.69 39.25 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.45 -0.781 . . . . 0.0 111.036 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.444 HG13 ' C ' ' A' ' 82' ' ' LEU . 34.6 m -148.32 177.1 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.695 -0.628 . . . . 0.0 109.404 179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -156.29 158.25 28.51 Favored Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.838 -1.172 . . . . 0.0 110.518 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.843 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.0 m-90 -120.38 160.77 22.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.816 -0.814 . . . . 0.0 109.848 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.2 tt0 -75.2 109.96 9.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.57 -0.706 . . . . 0.0 109.297 179.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.89 153.96 87.21 Favored Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.545 -0.722 . . . . 0.0 110.01 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.09 159.69 52.28 Favored 'Trans proline' 0 N--CA 1.488 1.196 0 O-C-N 123.83 1.437 . . . . 0.0 110.281 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.06 141.71 71.26 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.95 1.5 . . . . 0.0 110.357 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.18 27.47 72.84 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.19 149.87 26.57 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.467 -1.019 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 13.3 tpt180 -87.74 139.23 30.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.616 -0.678 . . . . 0.0 109.308 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.2 p -128.99 168.38 16.11 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.426 -0.796 . . . . 0.0 110.554 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.614 HD13 HD21 ' A' ' 144' ' ' LEU . 34.7 mt -111.65 131.97 54.91 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.735 -0.603 . . . . 0.0 110.714 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.404 ' OG1' ' CD2' ' A' ' 149' ' ' HIS . 73.8 p -74.76 159.95 81.98 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 109.799 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.29 161.01 46.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 O-C-N 123.865 1.456 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.792 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.8 t -70.25 134.73 48.31 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.721 -0.612 . . . . 0.0 110.063 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 22.4 p -136.15 52.35 1.98 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.667 -0.646 . . . . 0.0 109.827 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.1 p -143.81 -8.09 0.73 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.516 -0.74 . . . . 0.0 112.387 -179.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.01 42.26 98.3 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 54.0 m -100.0 120.04 39.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -1.04 . . . . 0.0 110.305 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.3 m -62.83 -40.05 96.22 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.579 -0.701 . . . . 0.0 110.429 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 137.54 58.06 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.538 -0.726 . . . . 0.0 110.497 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.563 ' CD2' HG21 ' A' ' 151' ' ' VAL . 89.3 mt -138.47 142.84 39.43 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.637 -0.664 . . . . 0.0 110.643 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -106.85 120.37 41.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.587 -0.696 . . . . 0.0 109.581 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.1 tp -102.57 146.16 28.56 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.406 -0.809 . . . . 0.0 110.829 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.4 t -105.34 130.01 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.676 -0.64 . . . . 0.0 109.647 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 76.3 p -98.25 173.57 6.93 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.573 -0.704 . . . . 0.0 111.004 -179.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.79 ' CA ' HD11 ' A' ' 44' ' ' LEU . 61.9 ttt-85 -70.0 -24.26 63.27 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.745 -0.597 . . . . 0.0 110.514 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -94.03 29.25 2.18 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.44 -0.787 . . . . 0.0 110.737 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.42 40.03 31.26 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.308 -0.87 . . . . 0.0 110.724 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -116.1 145.94 42.63 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.528 -0.733 . . . . 0.0 109.542 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.9 p -130.0 133.59 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.538 -0.726 . . . . 0.0 110.575 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 81.3 mt -124.91 150.06 64.95 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.651 -0.655 . . . . 0.0 109.485 179.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -81.46 123.05 4.22 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.945 1.498 . . . . 0.0 110.593 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 61.2 t -119.91 124.32 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 109.648 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -81.96 130.61 35.13 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.527 -0.733 . . . . 0.0 110.049 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -77.45 128.23 33.87 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.68 -0.638 . . . . 0.0 110.344 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -119.46 23.02 11.45 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.662 -0.649 . . . . 0.0 110.429 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.75 176.9 38.2 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -60.12 -40.82 91.07 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.54 -0.976 . . . . 0.0 110.127 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 20.8 p -130.0 27.4 5.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.622 -0.674 . . . . 0.0 110.331 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 3.1 tpt85 -128.93 137.06 51.19 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.461 -0.774 . . . . 0.0 110.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.2 166.57 26.0 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -124.87 146.22 49.41 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.558 -0.966 . . . . 0.0 110.058 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mp -97.73 125.25 42.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.554 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.73 -40.04 88.22 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.544 -0.723 . . . . 0.0 109.81 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.6 m -107.55 114.32 60.73 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.661 -0.649 . . . . 0.0 109.94 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.28 124.49 13.02 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.839 1.441 . . . . 0.0 110.487 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.9 mmt180 -120.48 160.09 45.38 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.641 -0.662 . . . . 0.0 109.972 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.33 156.67 62.01 Favored 'Trans proline' 0 N--CA 1.489 1.257 0 O-C-N 123.942 1.496 . . . . 0.0 110.385 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.458 HG11 ' OE1' ' B' ' 188' ' ' GLU . 65.7 t -66.83 -29.93 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.596 -0.69 . . . . 0.0 110.003 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.9 m -59.95 -40.05 87.67 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.482 -0.762 . . . . 0.0 110.352 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -61.76 -40.0 93.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.75 . . . . 0.0 109.994 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.47 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.22 -30.43 68.58 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.595 -0.691 . . . . 0.0 110.479 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 mmmm -60.01 140.4 56.81 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.388 -0.82 . . . . 0.0 110.246 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.01 14.67 80.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.0 m -114.78 10.06 16.46 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.283 -1.127 . . . . 0.0 110.936 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.7 m -62.06 140.2 58.39 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.223 -0.923 . . . . 0.0 110.048 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.75 -18.15 57.29 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.43 113.76 5.21 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.56 150.21 24.54 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.833 1.438 . . . . 0.0 110.82 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -101.49 109.1 20.85 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.614 HD21 HD13 ' A' ' 94' ' ' LEU . 9.9 mp -100.0 129.96 46.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.555 -0.716 . . . . 0.0 111.064 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.411 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.9 158.64 86.74 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.725 -0.61 . . . . 0.0 109.417 179.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.4 Cg_endo -53.77 -20.87 18.35 Favored 'Trans proline' 0 N--CA 1.501 1.925 0 O-C-N 123.634 1.333 . . . . 0.0 112.56 -178.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.8 p -67.22 -36.47 81.75 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.077 -1.015 . . . . 0.0 109.917 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 119.4 34.65 0.99 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . 0.404 ' CD2' ' OG1' ' A' ' 95' ' ' THR . 33.1 m170 -131.83 146.79 52.33 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.431 -1.04 . . . . 0.0 110.175 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.53 146.46 50.18 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.581 -0.699 . . . . 0.0 110.293 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.792 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.4 t -117.69 -40.1 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.579 -0.701 . . . . 0.0 109.991 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.22 -168.85 34.22 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.471 ' CD1' ' HE1' ' A' ' 175' ' ' MET . 93.8 mt -133.19 140.01 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.487 -1.008 . . . . 0.0 110.464 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -59.98 139.03 57.69 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.547 -0.72 . . . . 0.0 110.036 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 29.9 ttp85 -123.19 -52.01 1.86 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.573 -0.704 . . . . 0.0 110.186 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -146.9 160.41 42.36 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.677 . . . . 0.0 110.295 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.21 144.49 44.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.559 -0.713 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.7 t -110.03 120.05 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 120.18 -0.608 . . . . 0.0 109.807 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.409 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -130.4 145.87 51.88 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.689 -0.632 . . . . 0.0 110.345 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.5 m -70.05 -49.2 53.58 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.61 -0.681 . . . . 0.0 110.265 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -163.92 53.83 0.15 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.574 -0.703 . . . . 0.0 109.889 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 116.11 -17.58 14.76 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.11 126.3 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.217 -1.167 . . . . 0.0 109.777 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.54 126.95 40.15 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.567 -0.708 . . . . 0.0 110.398 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -112.29 -18.1 12.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.604 -0.685 . . . . 0.0 110.717 179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -149.1 159.14 44.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.218 -0.926 . . . . 0.0 110.157 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.8 m -140.01 166.86 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.531 -0.731 . . . . 0.0 110.853 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -119.97 136.78 54.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.655 -0.653 . . . . 0.0 109.773 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -138.04 155.68 48.56 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.493 -0.754 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.682 HG11 HD11 ' A' ' 82' ' ' LEU . 60.4 t -92.91 123.89 60.02 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.621 -0.674 . . . . 0.0 109.578 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.22 154.0 75.57 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.842 1.443 . . . . 0.0 110.581 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 151' ' ' VAL . 91.1 t -59.91 -23.47 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.594 -0.691 . . . . 0.0 110.575 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -58.16 -38.36 76.47 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.444 -0.785 . . . . 0.0 110.555 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . 0.411 ' OG ' HG12 ' A' ' 170' ' ' VAL . 82.6 p -60.03 -37.11 78.79 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.311 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.471 ' HE1' ' CD1' ' A' ' 153' ' ' ILE . 68.4 mtt -60.13 -40.02 88.29 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.466 -0.771 . . . . 0.0 110.441 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -60.16 -41.27 92.44 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.565 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 73.5 p -72.92 -40.04 65.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.44 -0.787 . . . . 0.0 110.311 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.9 m -70.06 -44.4 69.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.622 -0.674 . . . . 0.0 110.121 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.337 -179.721 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.458 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.4 tt0 . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.061 0.457 . . . . 0.0 110.088 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.804 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp . . . . . 0 N--CA 1.495 1.787 0 O-C-N 121.634 -0.666 . . . . 0.0 110.231 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.402 ' CG ' ' CG ' ' A' ' 92' ' ' ARG . 47.7 mt-10 . . . . . 0 N--CA 1.497 1.923 0 CA-C-O 121.115 0.483 . . . . 0.0 110.041 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.6 t -107.13 125.42 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 0.0 109.952 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -115.75 143.26 45.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.515 -0.741 . . . . 0.0 110.413 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.42 132.65 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.588 -0.695 . . . . 0.0 109.987 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CB ' HD21 ' A' ' 64' ' ' LEU . 26.7 m -128.77 159.86 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.634 -0.666 . . . . 0.0 109.972 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 m -139.43 160.52 39.65 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.62 -0.675 . . . . 0.0 110.478 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.37 -176.93 3.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.758 -0.589 . . . . 0.0 109.841 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.68 -12.53 59.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.622 -0.674 . . . . 0.0 110.803 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 41.7 p -120.04 -30.02 4.78 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.242 -0.911 . . . . 0.0 111.191 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -156.39 169.58 24.26 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.281 -0.887 . . . . 0.0 110.633 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.0 p -126.84 158.28 37.08 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.591 -0.693 . . . . 0.0 110.438 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.8 p90 -168.98 -176.38 2.62 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.507 -0.746 . . . . 0.0 109.89 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.586 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.8 mt -111.83 176.36 5.05 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.491 -0.755 . . . . 0.0 110.454 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.406 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -147.91 159.98 43.29 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.786 -0.571 . . . . 0.0 110.069 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.605 HG23 ' O ' ' A' ' 140' ' ' GLY . 39.8 p -120.17 130.88 54.79 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.577 -0.702 . . . . 0.0 110.525 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 33.8 t -92.52 109.66 21.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.429 -0.794 . . . . 0.0 110.386 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.454 HG22 ' HB2' ' A' ' 94' ' ' LEU . 58.6 t -119.2 131.74 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.603 -0.685 . . . . 0.0 109.641 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.57 39.35 27.77 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.539 -0.726 . . . . 0.0 110.845 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.561 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.04 75.98 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.69 130.01 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.143 -1.21 . . . . 0.0 110.022 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 94.1 m -72.63 149.93 43.48 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.44 -0.788 . . . . 0.0 109.457 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.568 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 83.4 m95 -131.79 151.07 51.93 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.524 -0.735 . . . . 0.0 111.175 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.1 t -167.65 -179.94 4.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.774 HG21 ' CE1' ' A' ' 57' ' ' HIS . 7.5 p -97.05 147.75 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.155 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.489 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 58.3 t80 -60.05 -46.94 87.88 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.611 -0.68 . . . . 0.0 112.095 -178.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.793 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.5 p-80 -64.7 -24.08 67.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.159 -0.963 . . . . 0.0 110.91 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.698 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.61 -52.96 3.53 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.679 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -109.42 -57.41 2.17 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.688 -0.89 . . . . 0.0 110.101 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.5 -163.8 52.98 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.1 p -88.98 66.2 7.78 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.662 -0.905 . . . . 0.0 110.037 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -139.63 168.39 19.93 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.508 -0.745 . . . . 0.0 110.282 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 60.2 m -65.0 139.63 58.78 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.056 -0.657 . . . . 0.0 109.961 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.815 HD22 ' CH2' ' A' ' 85' ' ' TRP . 13.8 tp -117.42 138.96 51.48 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.689 -0.632 . . . . 0.0 109.903 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.83 110.04 22.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.549 -0.719 . . . . 0.0 110.193 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.76 -179.65 19.06 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.04 -31.89 76.06 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.821 1.432 . . . . 0.0 110.469 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 6.7 mtpm? -73.06 -31.17 64.23 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.701 -0.624 . . . . 0.0 109.964 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.46 -150.41 21.6 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.71 147.11 44.45 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.886 1.466 . . . . 0.0 110.148 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -129.99 140.03 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.549 -0.719 . . . . 0.0 110.57 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.7 t -99.94 144.22 29.25 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.548 -0.72 . . . . 0.0 109.774 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -90.13 150.0 22.22 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.407 -0.808 . . . . 0.0 111.232 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 50.2 mtp -116.04 -25.98 7.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.762 -0.586 . . . . 0.0 110.427 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -122.86 139.96 53.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.561 ' HA ' HG12 ' A' ' 83' ' ' VAL . 60.9 m -141.38 133.72 28.13 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.621 -0.674 . . . . 0.0 110.312 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -145.54 95.66 2.69 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.509 -0.744 . . . . 0.0 110.019 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.489 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 80.2 t -66.27 -43.09 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.513 -0.742 . . . . 0.0 110.066 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -49.88 75.9 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.55 -0.719 . . . . 0.0 110.474 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.634 ' CG ' HD12 ' A' ' 82' ' ' LEU . 37.0 tp60 -81.72 -8.65 59.72 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.588 -0.695 . . . . 0.0 110.509 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.442 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.0 t70 57.5 45.9 18.81 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.115 -0.991 . . . . 0.0 110.304 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.779 HD11 HG11 ' A' ' 170' ' ' VAL . 82.6 mt -138.16 139.09 39.21 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.549 -0.719 . . . . 0.0 110.953 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.561 HG12 ' HA ' ' A' ' 76' ' ' THR . 34.7 m -144.39 158.04 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.627 -0.671 . . . . 0.0 109.439 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -140.62 157.94 25.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.3 m-90 -116.67 161.07 19.77 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.782 -0.834 . . . . 0.0 109.639 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -70.99 114.23 8.83 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.515 -0.741 . . . . 0.0 109.312 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.03 136.52 87.2 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 110.212 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 159.97 51.3 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.864 1.455 . . . . 0.0 110.228 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -66.15 153.63 77.32 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 123.882 1.464 . . . . 0.0 110.322 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.16 27.36 66.37 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.87 139.88 40.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.506 -0.996 . . . . 0.0 110.138 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.402 ' CG ' ' CG ' ' A' ' 32' ' ' GLU . 27.4 tpt180 -80.11 159.92 25.92 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.658 -0.651 . . . . 0.0 109.531 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.7 p -129.63 167.92 17.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.554 -0.716 . . . . 0.0 110.173 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.454 ' HB2' HG22 ' A' ' 48' ' ' VAL . 59.9 mt -109.8 131.54 54.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.526 -0.733 . . . . 0.0 110.651 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.466 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 9.8 t -75.37 159.97 80.86 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.582 -0.699 . . . . 0.0 109.986 179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -84.76 164.17 12.07 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.753 1.396 . . . . 0.0 110.815 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.499 ' HB2' HG22 ' A' ' 151' ' ' VAL . 43.8 t -82.59 138.94 34.07 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.658 -0.651 . . . . 0.0 110.194 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -136.09 51.64 2.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.812 -0.555 . . . . 0.0 109.681 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . 0.402 ' SG ' ' SG ' ' A' ' 97' ' ' CYS . 29.2 p -143.43 -8.61 0.76 Allowed 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.843 -0.743 . . . . 0.0 112.411 -179.015 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 33.44 74.75 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 86.0 p -76.73 149.92 36.31 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.431 -1.041 . . . . 0.0 110.415 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -92.66 -29.22 16.21 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.625 -0.672 . . . . 0.0 110.286 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -77.43 135.27 38.27 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.554 -0.716 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.4 mt -135.04 155.12 51.3 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.508 -0.745 . . . . 0.0 110.599 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -119.99 114.6 22.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.556 -0.715 . . . . 0.0 109.788 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.428 HD13 HD11 ' A' ' 143' ' ' LEU . 40.3 tp -100.41 140.01 35.27 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.617 -0.677 . . . . 0.0 110.445 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 113' ' ' VAL . 62.2 t -109.96 129.94 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.626 -0.671 . . . . 0.0 110.052 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 59.5 p -102.2 -179.58 4.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.592 -0.692 . . . . 0.0 110.42 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.586 ' HA ' HD11 ' A' ' 44' ' ' LEU . 31.9 mtp-105 -59.88 -22.52 62.47 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.535 -0.728 . . . . 0.0 110.808 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -90.11 19.57 4.9 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.276 -0.89 . . . . 0.0 111.15 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.0 40.07 31.21 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.123 -0.986 . . . . 0.0 110.686 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -106.76 134.84 49.3 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.611 -0.68 . . . . 0.0 109.957 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 107' ' ' VAL . 62.7 t -110.08 123.48 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 109.982 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.5 pt -119.97 150.0 50.01 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.564 -0.71 . . . . 0.0 110.06 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.616 ' HG2' HD22 ' A' ' 127' ' ' LEU . 50.6 Cg_endo -87.99 128.03 2.27 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.933 1.491 . . . . 0.0 110.44 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.9 t -124.75 129.41 73.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.662 -0.649 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.582 ' HG2' HD11 ' A' ' 127' ' ' LEU . 51.6 mmm-85 -80.35 156.0 26.93 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.572 -0.705 . . . . 0.0 110.309 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -101.14 118.63 37.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.634 -0.666 . . . . 0.0 110.064 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.8 mmm180 -113.13 20.02 16.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.59 -0.694 . . . . 0.0 110.437 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.02 -171.43 42.39 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.02 -39.93 90.66 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.566 -0.961 . . . . 0.0 110.442 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.0 p -132.69 24.14 4.34 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.524 -0.735 . . . . 0.0 110.816 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -126.26 139.88 52.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.325 -0.859 . . . . 0.0 110.506 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.84 169.35 27.97 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 52.1 p -112.06 156.82 21.58 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.41 -1.053 . . . . 0.0 110.537 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.457 HD23 ' O ' ' A' ' 164' ' ' ALA . 24.2 tp -98.59 120.4 38.94 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.559 -0.713 . . . . 0.0 110.074 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.616 HD22 ' HG2' ' A' ' 115' ' ' PRO . 8.0 mp -60.93 -40.21 92.39 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.569 -0.707 . . . . 0.0 110.352 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.2 p -117.8 127.25 26.76 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.504 -0.747 . . . . 0.0 110.075 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.31 117.93 5.36 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.87 1.458 . . . . 0.0 110.381 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 48.6 mtp85 -120.08 160.01 44.86 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.708 . . . . 0.0 110.227 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.77 148.84 83.35 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.875 1.461 . . . . 0.0 110.31 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.562 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.3 m -62.07 -26.59 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.613 -0.68 . . . . 0.0 110.426 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.4 t -59.95 -39.92 87.22 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.693 ' HD2' HD12 ' A' ' 135' ' ' LEU . 65.0 t80 -60.06 -49.16 78.73 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.607 -0.683 . . . . 0.0 110.227 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.693 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.4 mp -69.97 -28.93 65.95 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.466 -0.771 . . . . 0.0 110.537 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmtp -60.01 140.02 57.06 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.476 -0.765 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.99 9.99 86.09 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 28.9 m -112.05 16.79 20.09 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.141 -1.211 . . . . 0.0 110.785 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -60.17 140.03 57.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.287 -0.883 . . . . 0.0 110.023 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.34 -18.07 57.59 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -51.4 124.94 24.17 Favored Glycine 0 N--CA 1.5 2.906 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.557 ' HB3' HG21 ' A' ' 46' ' ' THR . 52.4 Cg_endo -80.77 146.32 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.868 1.457 . . . . 0.0 111.304 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.628 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -106.71 106.77 17.46 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.557 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -95.74 131.21 42.26 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.527 -0.733 . . . . 0.0 111.242 -178.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.444 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.75 159.39 84.14 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -51.92 -21.83 12.88 Favored 'Trans proline' 0 N--CA 1.501 1.954 0 O-C-N 123.506 1.266 . . . . 0.0 112.671 -178.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -69.77 -38.39 76.73 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.18 -0.95 . . . . 0.0 109.872 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.58 37.23 0.74 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -133.37 149.6 51.85 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.495 -1.003 . . . . 0.0 110.221 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -63.72 139.99 58.82 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.52 -0.737 . . . . 0.0 110.216 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.643 ' O ' HG23 ' A' ' 172' ' ' VAL . 49.6 t -115.96 -35.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.582 -0.698 . . . . 0.0 110.009 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.7 -169.98 38.69 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 90.0 mt -130.04 139.89 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.564 -0.962 . . . . 0.0 110.229 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -59.99 139.14 57.63 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.507 -0.746 . . . . 0.0 110.12 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -119.95 -52.34 2.21 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.615 -0.678 . . . . 0.0 110.29 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.681 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.58 166.88 30.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.522 -0.736 . . . . 0.0 110.5 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.25 148.55 43.01 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.627 -0.671 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.94 120.03 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.624 -0.672 . . . . 0.0 109.796 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.562 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.5 p -133.63 149.87 51.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.719 -0.613 . . . . 0.0 110.376 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.8 p -80.09 -47.48 14.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.568 -0.707 . . . . 0.0 110.41 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -161.65 57.41 0.27 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.671 -0.643 . . . . 0.0 110.033 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.03 -11.65 40.83 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.9 t -118.24 126.52 75.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.137 -1.213 . . . . 0.0 109.686 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . 0.457 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -96.7 123.53 40.42 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.512 -0.743 . . . . 0.0 110.627 -179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -105.8 -18.46 14.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.723 -0.611 . . . . 0.0 110.392 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.6 158.77 44.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 109.821 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -130.07 -173.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.481 -0.762 . . . . 0.0 110.518 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -146.44 127.17 14.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.705 -0.622 . . . . 0.0 109.444 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -127.42 156.22 42.42 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.453 -0.779 . . . . 0.0 110.946 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.779 HG11 HD11 ' A' ' 82' ' ' LEU . 63.2 t -92.82 121.41 66.01 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -64.17 154.92 68.06 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.79 1.416 . . . . 0.0 110.496 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 151' ' ' VAL . 97.1 t -58.97 -24.06 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.612 -0.68 . . . . 0.0 110.531 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -59.85 -40.08 87.33 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.365 -0.835 . . . . 0.0 110.346 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 22.4 t -63.42 -38.42 91.06 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.476 -0.765 . . . . 0.0 110.144 179.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.568 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 93.3 mtp -60.0 -41.58 92.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.631 -0.668 . . . . 0.0 110.317 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.13 -40.08 78.5 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.567 -0.708 . . . . 0.0 110.162 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.1 m -61.06 -39.98 91.92 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.627 -0.671 . . . . 0.0 110.156 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.6 m -60.14 -40.36 89.55 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.542 -0.724 . . . . 0.0 110.114 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.495 1.795 0 O-C-N 121.594 -0.691 . . . . 0.0 110.169 179.868 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.681 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 41.2 tt0 . . . . . 0 N--CA 1.492 1.653 0 CA-C-O 121.001 0.429 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.793 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp . . . . . 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.683 . . . . 0.0 110.245 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.815 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 . . . . . 0 N--CA 1.497 1.899 0 CA-C-O 121.09 0.472 . . . . 0.0 110.313 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.815 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.6 t -120.34 129.61 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.546 -0.721 . . . . 0.0 109.77 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -129.99 158.35 39.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.517 -0.739 . . . . 0.0 110.451 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.78 125.28 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.696 -0.628 . . . . 0.0 109.413 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.557 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.6 m -124.79 158.16 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.577 -0.702 . . . . 0.0 110.159 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.5 m -133.36 173.04 11.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.684 -0.635 . . . . 0.0 110.556 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.449 HG22 ' N ' ' A' ' 39' ' ' ALA . 35.0 m -139.69 171.54 14.08 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.449 ' N ' HG22 ' A' ' 38' ' ' THR . . . -56.09 -28.18 56.69 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.438 -0.789 . . . . 0.0 111.204 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.0 m -135.37 -7.26 2.26 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.263 -0.898 . . . . 0.0 112.597 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.7 mm-40 -129.98 159.17 37.48 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.89 -1.131 . . . . 0.0 111.69 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 68.1 m -132.12 133.98 44.92 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.419 ' HE1' ' HG1' ' A' ' 38' ' ' THR . 6.9 p90 -164.67 -177.4 4.76 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.242 -0.911 . . . . 0.0 111.068 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.86 HD11 ' HA ' ' A' ' 109' ' ' ARG . 51.6 mt -112.63 146.61 38.32 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.666 -0.647 . . . . 0.0 110.279 -178.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -111.24 161.01 16.44 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.58 -0.7 . . . . 0.0 110.165 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 63.6 p -125.16 143.38 50.96 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.593 -0.692 . . . . 0.0 110.314 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 93.3 m -102.85 113.18 26.4 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.574 -0.704 . . . . 0.0 110.501 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.3 130.0 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.658 -0.652 . . . . 0.0 109.428 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 55.49 36.68 27.64 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.421 -0.799 . . . . 0.0 110.76 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.803 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.69 19.16 74.67 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -132.36 130.05 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.202 -1.175 . . . . 0.0 109.998 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.5 m -78.21 144.97 35.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.483 -0.761 . . . . 0.0 109.514 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -128.36 151.41 49.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.525 -0.734 . . . . 0.0 110.863 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -167.77 -179.8 4.43 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.843 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.9 p -95.29 154.2 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.816 . . . . 0.0 110.562 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.7 t80 -69.95 -40.12 75.63 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.683 -0.636 . . . . 0.0 111.873 -178.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.843 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.4 p-80 -68.26 -24.35 64.88 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.135 -0.978 . . . . 0.0 110.499 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.697 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -82.64 -59.12 2.27 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.49 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -102.37 -47.95 4.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.069 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 66.0 -165.68 37.85 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.2 m -83.72 64.42 7.99 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.582 -0.952 . . . . 0.0 109.951 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -140.02 164.84 28.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.514 -0.741 . . . . 0.0 110.324 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.3 t -65.37 140.05 58.62 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.578 -0.701 . . . . 0.0 110.05 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.923 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.5 tp -109.9 130.54 55.51 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.658 -0.651 . . . . 0.0 110.178 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.46 118.45 30.57 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.578 -0.701 . . . . 0.0 110.106 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -122.89 177.74 16.48 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.63 -31.98 69.57 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.795 1.419 . . . . 0.0 110.338 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 61.0 tptt -70.55 -31.55 68.64 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.606 -0.684 . . . . 0.0 109.633 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.01 -150.41 22.01 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.79 155.75 53.51 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.891 1.469 . . . . 0.0 110.228 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.441 ' CD1' HD23 ' A' ' 64' ' ' LEU . 85.1 mt -125.91 139.94 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.555 -0.715 . . . . 0.0 110.272 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 73.1 m -94.39 137.9 32.99 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.413 -0.804 . . . . 0.0 110.265 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -70.16 139.96 52.49 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.575 -0.703 . . . . 0.0 110.599 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.82 -51.3 2.66 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.564 -0.71 . . . . 0.0 109.952 179.463 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -120.03 140.06 51.56 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.514 -0.742 . . . . 0.0 110.213 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.6 p -131.64 137.61 48.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.497 -0.752 . . . . 0.0 110.367 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -150.04 90.72 1.7 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.578 -0.702 . . . . 0.0 110.215 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CE1' ' A' ' 56' ' ' TYR . 85.9 t -68.04 -42.33 85.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.543 -0.723 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.91 -42.8 94.66 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.717 . . . . 0.0 110.27 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 82' ' ' LEU . 39.0 tp60 -89.98 0.12 57.27 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.537 -0.727 . . . . 0.0 110.93 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.443 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.65 44.63 29.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.059 -1.026 . . . . 0.0 110.687 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.615 HD11 HG11 ' A' ' 170' ' ' VAL . 70.9 mt -140.25 144.37 36.45 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.407 -0.808 . . . . 0.0 110.923 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.584 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.8 m -148.2 155.64 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.578 -0.701 . . . . 0.0 109.452 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -139.95 161.25 26.33 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 9.2 m-90 -117.75 160.06 21.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.751 -0.852 . . . . 0.0 109.565 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -74.54 104.42 5.24 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.463 -0.773 . . . . 0.0 109.677 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.37 130.04 88.16 Favored Pre-proline 0 N--CA 1.494 1.775 0 O-C-N 121.541 -0.724 . . . . 0.0 110.239 -179.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.08 159.98 51.24 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.827 1.435 . . . . 0.0 110.271 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.9 157.71 51.04 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.968 1.51 . . . . 0.0 110.319 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.9 -24.86 30.52 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.03 159.99 26.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.445 -1.032 . . . . 0.0 110.159 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 83.6 mtt180 -100.39 159.31 15.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.59 -0.694 . . . . 0.0 110.109 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.3 p -129.91 170.03 14.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.511 -0.743 . . . . 0.0 110.271 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.73 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 2.4 mm? -102.48 138.49 39.32 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.635 -0.666 . . . . 0.0 110.505 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.428 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 4.8 p -76.05 160.03 79.25 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.629 -0.669 . . . . 0.0 109.946 179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.55 153.32 30.41 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.779 1.41 . . . . 0.0 110.6 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.773 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.4 t -68.73 135.11 50.77 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.543 -0.723 . . . . 0.0 110.131 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.5 t -136.1 52.07 2.0 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.708 -0.62 . . . . 0.0 109.692 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.83 -8.51 0.72 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.542 -0.723 . . . . 0.0 112.405 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.96 33.84 80.66 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 p -88.15 139.64 30.29 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.533 -0.981 . . . . 0.0 110.411 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.5 m -82.1 -30.0 31.46 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.646 -0.659 . . . . 0.0 110.353 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -66.62 129.87 41.3 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.502 -0.749 . . . . 0.0 110.162 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.582 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.6 mt -137.14 139.81 41.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.7 . . . . 0.0 110.631 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.5 120.51 42.39 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.56 -0.713 . . . . 0.0 109.862 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.4 tp -103.1 140.06 37.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.5 -0.75 . . . . 0.0 110.488 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.506 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.6 t -90.44 138.66 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.585 -0.697 . . . . 0.0 109.758 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 13.5 m -110.2 159.48 17.34 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.519 -0.738 . . . . 0.0 110.489 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.86 ' HA ' HD11 ' A' ' 44' ' ' LEU . 2.7 ttp180 -60.1 -21.37 61.42 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.588 -0.695 . . . . 0.0 110.63 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.07 27.45 3.2 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.267 -0.896 . . . . 0.0 110.528 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.61 39.98 31.56 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.39 -0.819 . . . . 0.0 110.622 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -124.21 139.59 53.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.656 -0.653 . . . . 0.0 109.737 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' A' ' 107' ' ' VAL . 34.5 m -126.13 139.09 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.482 -0.761 . . . . 0.0 110.59 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.552 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.2 mp -124.52 150.05 63.6 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.733 -0.604 . . . . 0.0 109.559 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 114' ' ' ILE . 46.8 Cg_endo -79.15 133.41 10.94 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.888 1.468 . . . . 0.0 110.492 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 125' ' ' SER . 62.7 t -130.02 129.99 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.671 -0.643 . . . . 0.0 109.653 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.4 tpt180 -85.38 150.0 25.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.52 -0.738 . . . . 0.0 110.193 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -91.15 119.96 31.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.65 -0.656 . . . . 0.0 110.336 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -110.21 20.02 18.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.608 -0.683 . . . . 0.0 110.508 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.11 -174.26 43.59 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -65.8 -39.94 91.41 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.999 . . . . 0.0 110.245 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.6 p -130.74 24.52 5.04 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.553 -0.717 . . . . 0.0 110.535 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -124.93 139.96 53.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 110.36 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.37 165.79 25.67 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 116' ' ' VAL . 91.1 p -115.86 153.78 30.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.463 -1.022 . . . . 0.0 110.152 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.411 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.2 tp -99.72 119.96 38.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.584 -0.697 . . . . 0.0 110.193 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.527 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -68.96 -38.51 79.45 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.527 -0.733 . . . . 0.0 109.863 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.0 m -110.0 113.84 56.68 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.677 -0.639 . . . . 0.0 110.051 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -64.66 118.52 5.49 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.799 1.421 . . . . 0.0 110.523 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -122.44 160.02 50.05 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.626 -0.671 . . . . 0.0 110.211 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -66.15 154.88 72.37 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.913 1.481 . . . . 0.0 110.42 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 90.6 t -61.63 -39.97 85.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.607 -0.683 . . . . 0.0 110.126 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.3 p -56.14 -33.85 65.56 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.476 -0.765 . . . . 0.0 110.663 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -60.02 -39.95 87.64 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.556 -0.715 . . . . 0.0 110.107 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.5 mp -84.82 -20.95 30.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.542 -0.724 . . . . 0.0 110.931 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -59.9 139.85 57.08 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.251 -0.906 . . . . 0.0 110.117 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.66 10.05 86.19 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 18.2 m -116.14 10.3 14.93 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.19 -1.182 . . . . 0.0 110.884 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.2 t -65.0 150.49 47.98 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.164 -0.96 . . . . 0.0 109.597 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 95.56 -22.23 40.18 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.5 148.57 21.04 Favored Glycine 0 N--CA 1.498 2.83 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -98.8 147.57 0.58 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.889 1.468 . . . . 0.0 111.024 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.38 108.33 19.91 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.77 129.94 45.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.456 -0.777 . . . . 0.0 111.296 -178.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.03 158.31 87.67 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.0 Cg_endo -51.87 -25.36 21.22 Favored 'Trans proline' 0 N--CA 1.501 1.918 0 O-C-N 123.547 1.288 . . . . 0.0 112.343 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.2 m -62.74 -40.0 95.85 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.266 -0.896 . . . . 0.0 109.886 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.06 36.86 0.79 Allowed Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . 0.428 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 4.3 m-70 -132.95 143.69 49.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.445 -1.033 . . . . 0.0 110.188 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.73 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -65.42 142.33 58.23 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.523 -0.736 . . . . 0.0 110.233 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.773 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -115.34 -38.06 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.579 -0.701 . . . . 0.0 110.043 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.09 -168.38 36.23 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.693 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.8 mt -129.89 140.02 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.469 -1.018 . . . . 0.0 110.379 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.0 t80 -63.75 139.77 58.8 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.677 -0.639 . . . . 0.0 110.11 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.5 ttt180 -119.9 -52.42 2.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.57 -0.706 . . . . 0.0 110.331 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.28 158.77 44.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.514 -0.742 . . . . 0.0 110.335 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -113.94 152.02 31.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.619 -0.676 . . . . 0.0 110.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.86 119.77 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.736 -0.603 . . . . 0.0 109.692 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.26 144.22 51.14 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.721 -0.612 . . . . 0.0 110.373 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.5 m -69.86 -49.77 49.14 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.619 -0.676 . . . . 0.0 110.056 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -163.65 54.17 0.16 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.711 -0.618 . . . . 0.0 109.854 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.32 -16.51 17.33 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.15 125.15 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.228 -1.16 . . . . 0.0 109.661 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -95.3 123.05 38.61 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.591 -0.693 . . . . 0.0 110.578 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -105.2 -21.31 13.28 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.601 -0.687 . . . . 0.0 110.274 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.94 159.12 43.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.365 -0.834 . . . . 0.0 109.913 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 19.7 m -131.53 -175.73 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.551 -0.718 . . . . 0.0 110.519 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -142.93 132.18 23.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.77 -0.581 . . . . 0.0 109.595 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -133.23 155.79 48.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.523 -0.736 . . . . 0.0 110.894 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 82' ' ' LEU . 62.9 t -92.7 124.27 59.29 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.564 -0.71 . . . . 0.0 109.332 179.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.49 150.31 75.29 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.721 1.379 . . . . 0.0 110.675 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 151' ' ' VAL . 95.0 t -59.48 -24.04 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.666 -0.646 . . . . 0.0 110.408 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -59.12 -39.58 82.76 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.382 -0.824 . . . . 0.0 110.314 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.4 p -60.01 -39.34 85.5 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.555 -0.716 . . . . 0.0 110.212 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.693 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.7 mtt -59.92 -40.46 88.94 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 110.452 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.28 -40.02 88.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.675 -0.64 . . . . 0.0 110.281 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.4 m -60.76 -40.4 92.35 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.472 -0.767 . . . . 0.0 110.106 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -69.86 -41.03 75.4 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.58 -0.7 . . . . 0.0 110.079 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.835 0 O-C-N 121.594 -0.691 . . . . 0.0 110.348 -179.891 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.109 0.48 . . . . 0.0 110.074 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.833 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp . . . . . 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.0 110.343 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.81 ' HG3' HG23 ' A' ' 33' ' ' VAL . 17.5 pt-20 . . . . . 0 N--CA 1.497 1.893 0 CA-C-O 120.971 0.415 . . . . 0.0 110.553 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.81 HG23 ' HG3' ' A' ' 32' ' ' GLU . 82.7 t -116.86 128.54 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.401 -0.812 . . . . 0.0 109.663 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -129.27 154.44 46.83 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.533 -0.729 . . . . 0.0 110.6 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -91.74 128.36 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.602 ' HB ' HD21 ' A' ' 64' ' ' LEU . 27.0 m -126.17 159.69 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.614 -0.679 . . . . 0.0 110.36 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 58.6 m -137.85 162.48 33.87 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.517 0.675 . . . . 0.0 111.032 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.2 m -134.51 169.37 17.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.792 -0.567 . . . . 0.0 109.678 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -67.11 -12.67 60.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 111.323 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 48.6 p -118.39 -30.53 5.2 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.042 -1.036 . . . . 0.0 111.555 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -159.17 170.04 22.83 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.202 -0.936 . . . . 0.0 110.967 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 t -123.88 155.23 38.46 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.489 -0.757 . . . . 0.0 110.574 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.628 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 16.8 p90 -166.26 -177.71 4.22 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.546 -0.721 . . . . 0.0 110.091 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.554 HD11 ' HA ' ' A' ' 109' ' ' ARG . 63.7 mt -113.28 153.78 27.87 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.523 -0.736 . . . . 0.0 110.443 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -127.89 161.09 29.89 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.557 -0.714 . . . . 0.0 110.356 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.642 HG23 HD12 ' A' ' 94' ' ' LEU . 86.9 m -120.04 130.23 54.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.635 -0.666 . . . . 0.0 110.108 -179.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.4 t -89.94 104.0 16.61 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.628 -0.67 . . . . 0.0 110.42 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.436 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.3 t -111.06 132.81 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.479 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.77 38.71 29.67 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.559 -0.713 . . . . 0.0 110.678 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.676 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 20.07 75.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.4 t -132.31 129.89 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.234 -1.156 . . . . 0.0 110.079 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 5.2 t -71.81 146.49 47.97 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.539 -0.726 . . . . 0.0 109.433 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.627 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 59.5 m95 -129.4 151.05 50.46 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.474 -0.766 . . . . 0.0 111.273 -179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.877 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -169.78 -179.81 3.43 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.836 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.1 p -94.53 156.36 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.423 -0.798 . . . . 0.0 110.073 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.2 t80 -70.04 -42.35 73.02 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.548 -0.72 . . . . 0.0 111.79 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.836 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.5 p-80 -64.77 -20.76 66.54 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.144 -0.973 . . . . 0.0 110.643 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.603 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -86.84 -47.69 4.69 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.628 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -125.41 90.98 3.32 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.679 -0.895 . . . . 0.0 109.942 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.42 -169.99 2.0 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 20.4 p -72.22 66.93 0.66 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.438 -1.036 . . . . 0.0 109.555 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.62 166.8 23.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.62 -0.675 . . . . 0.0 110.729 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.2 m -65.58 139.62 58.46 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.778 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.904 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -108.32 132.72 53.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.636 -0.665 . . . . 0.0 110.11 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.7 118.37 30.6 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.549 -0.719 . . . . 0.0 110.36 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.09 -176.91 18.25 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.132 -1.587 . . . . 0.0 109.132 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.51 -32.51 70.36 Favored 'Trans proline' 0 N--CA 1.491 1.35 0 O-C-N 123.836 1.44 . . . . 0.0 110.579 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 76.0 tttt -75.46 -31.11 60.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.598 -0.689 . . . . 0.0 109.974 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.3 -140.26 9.22 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.06 156.93 47.14 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 O-C-N 123.806 1.424 . . . . 0.0 110.25 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.516 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.4 mt -127.41 139.99 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.065 -179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 p -88.46 150.76 22.97 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.755 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -96.75 140.03 31.94 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.612 -0.68 . . . . 0.0 110.441 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.6 mmm -119.29 -32.77 4.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.577 -0.702 . . . . 0.0 110.856 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -132.75 149.97 52.21 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.405 -0.809 . . . . 0.0 110.869 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.3 p -143.56 137.86 28.71 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.672 -0.643 . . . . 0.0 110.026 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.401 ' OD1' HG23 ' A' ' 178' ' ' THR . 1.6 m120 -150.02 93.92 2.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.467 -0.771 . . . . 0.0 110.169 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CE1' ' A' ' 56' ' ' TYR . 88.0 t -69.96 -43.06 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -59.87 -45.46 92.41 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.514 -0.741 . . . . 0.0 110.608 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.765 ' HG2' HD12 ' A' ' 82' ' ' LEU . 51.4 tt0 -85.71 -0.07 54.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.579 -0.7 . . . . 0.0 110.737 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.441 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.3 t70 53.73 45.29 28.26 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.036 -1.04 . . . . 0.0 110.704 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.765 HD12 ' HG2' ' A' ' 80' ' ' GLN . 57.6 mt -142.24 146.89 35.65 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.524 -0.735 . . . . 0.0 110.924 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.522 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -149.24 160.0 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.555 -0.715 . . . . 0.0 109.735 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.34 153.75 24.18 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.904 ' CH2' HD22 ' A' ' 64' ' ' LEU . 7.5 m-90 -114.58 168.09 10.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.668 -0.901 . . . . 0.0 109.535 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -77.57 110.05 12.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -0.788 . . . . 0.0 109.268 179.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.676 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.05 129.98 90.26 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.598 -0.689 . . . . 0.0 110.204 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.96 159.95 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 123.791 1.416 . . . . 0.0 110.28 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.35 160.14 50.54 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.961 1.506 . . . . 0.0 110.285 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 84.49 28.75 31.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.99 150.03 49.61 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.527 -0.984 . . . . 0.0 110.094 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -100.02 119.98 39.11 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.521 -0.737 . . . . 0.0 110.342 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.5 p -81.24 170.03 16.59 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.656 -0.653 . . . . 0.0 110.161 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.642 HD12 HG23 ' A' ' 46' ' ' THR . 79.3 mt -109.57 131.85 54.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.586 -0.696 . . . . 0.0 110.807 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.7 p -72.74 160.06 83.8 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.576 -0.703 . . . . 0.0 109.95 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.36 164.44 24.08 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.87 1.458 . . . . 0.0 110.594 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.538 ' HB2' HG22 ' A' ' 151' ' ' VAL . 54.1 t -80.16 129.99 34.9 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.537 -0.727 . . . . 0.0 110.241 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -133.24 55.79 1.88 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.646 -0.659 . . . . 0.0 109.522 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.95 -8.12 0.72 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.607 -0.683 . . . . 0.0 112.394 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.06 35.27 91.2 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -84.97 113.07 21.14 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.513 -0.992 . . . . 0.0 110.485 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -60.03 -40.01 87.88 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.64 -0.662 . . . . 0.0 110.342 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -64.89 138.66 58.51 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.55 -0.719 . . . . 0.0 110.414 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.47 ' CD2' HG11 ' A' ' 151' ' ' VAL . 91.5 mt -135.58 150.0 49.57 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.615 -0.678 . . . . 0.0 110.319 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -117.84 114.4 23.2 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.583 -0.698 . . . . 0.0 109.857 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 143' ' ' LEU . 40.2 tp -96.5 145.64 25.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.568 -0.707 . . . . 0.0 110.467 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.01 128.69 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.662 -0.649 . . . . 0.0 109.928 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 71.1 p -105.12 -178.59 3.7 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.597 -0.69 . . . . 0.0 110.441 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.554 ' HA ' HD11 ' A' ' 44' ' ' LEU . 55.0 mtp180 -69.76 -20.95 63.48 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.562 -0.711 . . . . 0.0 110.808 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.81 21.24 4.96 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.356 -0.84 . . . . 0.0 110.908 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.12 39.93 31.16 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.154 -0.966 . . . . 0.0 110.622 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -106.4 168.32 9.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.588 -0.695 . . . . 0.0 110.008 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.97 129.97 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.559 -0.713 . . . . 0.0 110.183 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.601 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -119.62 109.28 38.35 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.633 -0.667 . . . . 0.0 109.87 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -65.16 109.83 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.764 1.402 . . . . 0.0 110.263 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.2 t -110.83 124.12 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.608 -0.683 . . . . 0.0 109.937 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 35.1 mmm-85 -79.75 155.22 28.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.586 -0.696 . . . . 0.0 110.175 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -98.18 119.69 37.28 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -122.64 22.63 9.8 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.23 -176.95 47.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -70.07 -40.04 75.29 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.506 -0.997 . . . . 0.0 110.532 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -131.0 29.07 4.74 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.449 -0.782 . . . . 0.0 110.686 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -138.44 162.5 34.31 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.451 -0.78 . . . . 0.0 110.474 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -162.24 -179.39 36.83 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 79.4 p -120.92 149.01 43.28 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.542 -0.975 . . . . 0.0 110.232 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.446 HD11 ' CG2' ' A' ' 114' ' ' ILE . 19.4 tp -93.44 119.28 32.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.591 -0.693 . . . . 0.0 109.996 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.7 mp -65.02 -39.95 94.16 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.593 -0.692 . . . . 0.0 109.959 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.3 p -110.87 119.97 44.72 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.601 -0.687 . . . . 0.0 110.033 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.23 117.74 5.05 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.736 1.388 . . . . 0.0 110.281 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 13.1 mmt85 -120.59 160.0 45.97 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.56 -0.712 . . . . 0.0 110.197 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.58 159.21 54.41 Favored 'Trans proline' 0 N--CA 1.489 1.255 0 O-C-N 123.875 1.461 . . . . 0.0 110.475 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.495 HG11 ' OE1' ' B' ' 188' ' ' GLU . 92.5 t -64.66 -33.15 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.538 -0.726 . . . . 0.0 109.98 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 56.0 m -60.07 -38.09 81.82 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.588 -0.695 . . . . 0.0 110.223 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -60.05 -40.04 88.02 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.559 -0.713 . . . . 0.0 110.212 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.3 mp -83.6 -23.34 31.96 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.529 -0.732 . . . . 0.0 110.756 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.11 140.06 57.12 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.339 -0.851 . . . . 0.0 110.246 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.05 4.2 89.63 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.8 m -109.53 -0.89 18.59 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.075 -1.25 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 31.0 t -60.01 141.47 55.59 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.108 -0.995 . . . . 0.0 109.754 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 100.05 -19.79 51.64 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.75 147.05 44.0 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.547 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.1 Cg_endo -92.38 144.78 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.925 1.487 . . . . 0.0 111.181 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.35 111.11 23.25 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.65 131.72 45.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.526 -0.733 . . . . 0.0 111.453 -178.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.05 160.03 82.06 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -52.0 -22.88 15.47 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 O-C-N 123.532 1.28 . . . . 0.0 112.161 -178.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.66 -40.03 88.45 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.225 -0.922 . . . . 0.0 109.881 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.19 35.66 0.86 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -132.03 148.14 52.49 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.467 -1.019 . . . . 0.0 110.445 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.71 143.51 57.34 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.599 -0.688 . . . . 0.0 110.273 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 172' ' ' VAL . 54.4 t -118.29 -40.87 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.536 -0.727 . . . . 0.0 110.052 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.57 -175.59 41.41 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.0 mt -122.91 130.34 74.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.535 -0.979 . . . . 0.0 110.391 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.434 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 23.1 t80 -60.34 134.6 57.22 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.55 -0.719 . . . . 0.0 109.818 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.7 ttt180 -113.24 -52.13 2.78 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.458 -0.777 . . . . 0.0 110.443 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -155.09 160.01 40.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.44 -0.787 . . . . 0.0 110.558 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.434 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -111.73 153.71 26.08 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.614 -0.679 . . . . 0.0 110.193 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.05 118.99 58.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.625 -0.672 . . . . 0.0 109.751 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -132.99 149.29 52.24 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.654 -0.654 . . . . 0.0 110.307 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.7 p -82.26 -42.9 18.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.645 -0.659 . . . . 0.0 110.61 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -160.34 59.93 0.34 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.131 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 98.75 -10.01 62.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.33 122.25 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.134 -1.215 . . . . 0.0 109.843 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.57 126.12 41.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.68 -0.637 . . . . 0.0 110.78 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 47.5 mmtt -107.14 -25.45 11.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.733 -0.605 . . . . 0.0 110.118 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.73 154.54 46.37 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.728 . . . . 0.0 110.04 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 26.8 m -126.21 -171.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.557 -0.714 . . . . 0.0 110.786 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -146.93 134.57 21.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.69 -0.631 . . . . 0.0 109.444 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -137.48 159.19 42.64 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.446 -0.784 . . . . 0.0 110.8 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.618 HG11 HD11 ' A' ' 82' ' ' LEU . 65.5 t -98.42 121.2 57.49 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -62.37 159.94 33.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.711 1.374 . . . . 0.0 110.517 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.4 t -69.39 -27.09 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.615 -0.678 . . . . 0.0 110.829 -179.304 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -58.18 -39.67 79.5 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.366 -0.834 . . . . 0.0 110.7 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 89.3 p -67.08 -38.46 85.77 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.454 -0.779 . . . . 0.0 110.246 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.627 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 87.9 mtp -60.0 -40.04 87.85 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.489 -0.757 . . . . 0.0 110.319 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -64.27 -40.01 95.11 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.506 -0.746 . . . . 0.0 110.3 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.5 m -67.93 -28.78 67.77 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.713 -0.617 . . . . 0.0 110.372 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . 0.401 HG23 ' OD1' ' A' ' 77' ' ' ASN . 94.1 m -59.97 -40.07 87.83 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.571 -0.706 . . . . 0.0 110.272 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.5 mtt . . . . . 0 N--CA 1.496 1.873 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 179.995 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.622 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.165 0.507 . . . . 0.0 110.071 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.829 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 110.45 -179.767 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.403 ' HG2' ' CB ' ' A' ' 92' ' ' ARG . 62.9 mt-10 . . . . . 0 N--CA 1.496 1.867 0 CA-C-O 121.123 0.487 . . . . 0.0 110.047 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.497 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.2 t -105.58 127.21 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.538 -0.726 . . . . 0.0 109.959 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -116.28 150.14 38.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.586 -0.696 . . . . 0.0 110.334 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 35' ' ' VAL . 12.5 p -79.72 129.02 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.63 -0.669 . . . . 0.0 110.04 179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.727 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.4 m -125.14 154.29 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 110.031 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.5 m -149.84 171.48 16.69 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.016 -0.673 . . . . 0.0 110.511 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.9 p -140.93 -173.35 3.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.766 -0.584 . . . . 0.0 109.434 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.34 -0.81 26.99 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.497 -0.752 . . . . 0.0 111.219 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.4 m -118.59 -46.75 2.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.109 -0.994 . . . . 0.0 111.359 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -147.76 171.18 16.09 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.268 -0.895 . . . . 0.0 111.407 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 32.1 t -119.15 146.65 44.98 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.664 -0.647 . . . . 0.0 109.926 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.609 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 15.1 p90 -158.17 -176.44 5.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.486 -0.758 . . . . 0.0 110.215 -179.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.765 HD11 ' HA ' ' A' ' 109' ' ' ARG . 42.0 mt -111.54 167.65 10.16 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.565 -0.709 . . . . 0.0 110.338 -178.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.497 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -142.91 155.69 44.77 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.698 -0.626 . . . . 0.0 110.039 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.529 HG21 ' HB3' ' A' ' 142' ' ' PRO . 73.4 p -120.28 129.45 54.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.453 -0.78 . . . . 0.0 110.177 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 35.0 t -91.13 107.42 19.19 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.514 -0.741 . . . . 0.0 110.517 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' HB2' ' A' ' 94' ' ' LEU . 57.6 t -115.29 135.87 53.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.624 -0.673 . . . . 0.0 109.552 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 54.78 37.42 28.41 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.536 -0.727 . . . . 0.0 111.021 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 23.14 77.35 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.6 t -138.25 129.91 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.248 -1.148 . . . . 0.0 110.089 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . 0.411 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 4.0 t -68.45 148.47 50.59 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.418 -0.801 . . . . 0.0 109.454 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 48.8 m95 -140.08 142.95 36.08 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.197 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.666 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.9 t -170.07 -178.6 2.9 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.818 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.7 p -83.23 159.01 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 110.401 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CD1' ' HA2' ' A' ' 60' ' ' GLY . 55.5 t80 -76.99 -40.03 48.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.67 -0.644 . . . . 0.0 112.069 -178.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.872 ' CG ' HD23 ' B' ' 189' ' ' LEU . 2.9 p-80 -61.0 -24.67 66.32 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.113 -0.992 . . . . 0.0 110.848 -178.626 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.446 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -74.75 -49.01 11.17 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.609 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -114.86 -55.56 2.47 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.561 -0.964 . . . . 0.0 110.458 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 85.09 -172.33 47.44 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 47.8 t -80.14 65.13 5.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.526 -0.985 . . . . 0.0 109.848 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -141.81 170.06 16.43 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.587 -0.696 . . . . 0.0 110.267 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.1 m -65.57 139.77 58.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.527 -0.733 . . . . 0.0 109.851 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.727 HD21 ' HB ' ' A' ' 36' ' ' VAL . 20.4 tp -108.81 141.02 41.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.692 -0.63 . . . . 0.0 110.099 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.15 111.56 23.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.57 -0.706 . . . . 0.0 110.166 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.12 -178.29 18.23 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -62.1 -31.96 83.37 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 O-C-N 123.765 1.403 . . . . 0.0 110.518 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.4 tttt -74.61 -31.27 61.97 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.669 -0.644 . . . . 0.0 109.769 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.33 -154.38 23.45 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.41 146.82 69.86 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 O-C-N 123.816 1.43 . . . . 0.0 109.953 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -130.3 139.98 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.514 -0.741 . . . . 0.0 110.599 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.3 m -89.83 139.9 30.13 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.563 -0.711 . . . . 0.0 110.211 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 pp0? -83.2 150.25 26.33 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.519 -0.738 . . . . 0.0 111.383 -179.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.2 mtp -110.37 -29.93 7.9 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.821 -0.549 . . . . 0.0 109.944 179.444 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -131.76 148.39 52.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.72 -0.613 . . . . 0.0 110.459 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.15 125.98 11.17 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.663 -0.648 . . . . 0.0 109.628 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -141.92 95.57 2.83 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.528 -0.733 . . . . 0.0 110.152 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 91.9 t -61.43 -44.67 98.95 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.673 -0.642 . . . . 0.0 109.921 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.15 -48.75 80.39 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.551 -0.718 . . . . 0.0 110.256 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.679 ' CG ' HD12 ' A' ' 82' ' ' LEU . 3.0 tp-100 -80.07 -9.15 59.68 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.66 -0.65 . . . . 0.0 110.478 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 5.7 t0 56.79 48.18 16.63 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.22 -0.925 . . . . 0.0 110.422 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.679 HD12 ' CG ' ' A' ' 80' ' ' GLN . 81.3 mt -137.96 149.83 46.49 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.48 -0.762 . . . . 0.0 110.892 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -150.05 149.97 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.611 -0.68 . . . . 0.0 109.493 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -133.86 149.55 19.75 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.335 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.713 ' CZ3' HD22 ' A' ' 64' ' ' LEU . 5.3 m-90 -120.16 168.19 11.47 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.68 -0.894 . . . . 0.0 110.204 179.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -72.86 120.42 18.46 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -68.98 132.24 90.5 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.448 -0.782 . . . . 0.0 109.958 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.99 157.07 61.15 Favored 'Trans proline' 0 N--CA 1.49 1.294 0 O-C-N 123.84 1.442 . . . . 0.0 110.478 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.56 160.23 48.94 Favored 'Trans proline' 0 N--CA 1.49 1.282 0 O-C-N 123.936 1.493 . . . . 0.0 110.185 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 29.97 70.44 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.04 160.87 22.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.6 -0.941 . . . . 0.0 110.106 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.403 ' CB ' ' HG2' ' A' ' 32' ' ' GLU . 75.1 mtp85 -105.19 153.75 21.13 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 110.275 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 54.5 m -111.3 160.9 16.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.605 -0.684 . . . . 0.0 110.294 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.486 ' HB2' HG22 ' A' ' 48' ' ' VAL . 84.5 mt -100.31 131.85 46.01 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.595 -0.691 . . . . 0.0 110.524 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.3 p -77.04 159.95 77.27 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.608 -0.682 . . . . 0.0 110.006 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -85.57 158.24 10.71 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 O-C-N 123.799 1.421 . . . . 0.0 110.54 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.4 t -79.81 129.75 34.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.587 -0.695 . . . . 0.0 110.087 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' THR . 6.8 t -132.88 56.45 1.85 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.677 -0.64 . . . . 0.0 109.678 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.87 -8.1 0.73 Allowed 'General case' 0 N--CA 1.497 1.913 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.252 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.92 46.09 94.73 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.98 119.77 38.77 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.518 -0.989 . . . . 0.0 110.45 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -62.95 -40.03 96.43 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.703 -0.623 . . . . 0.0 110.355 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -63.3 132.55 51.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.543 -0.723 . . . . 0.0 110.354 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 1.003 HD22 HG11 ' A' ' 151' ' ' VAL . 96.0 mt -137.29 145.24 43.22 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.568 -0.708 . . . . 0.0 110.488 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.47 122.15 46.05 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.541 -0.725 . . . . 0.0 109.858 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.432 HD13 ' HG ' ' A' ' 143' ' ' LEU . 40.6 tp -103.69 146.17 28.98 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.671 . . . . 0.0 110.605 -179.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.67 130.07 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.65 -0.656 . . . . 0.0 109.758 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -93.09 170.04 9.95 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.487 -0.758 . . . . 0.0 110.754 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.765 ' HA ' HD11 ' A' ' 44' ' ' LEU . 5.4 ttt-85 -64.6 -21.07 66.61 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.639 -0.663 . . . . 0.0 110.623 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.6 t60 -94.42 29.41 2.25 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.416 -0.803 . . . . 0.0 110.488 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.7 40.02 30.86 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -107.44 157.32 18.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.648 -0.658 . . . . 0.0 109.926 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.99 130.32 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.589 -0.694 . . . . 0.0 110.193 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 76.5 mt -128.86 150.04 73.96 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.569 -0.707 . . . . 0.0 109.827 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -87.14 132.07 3.17 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.919 1.484 . . . . 0.0 110.409 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -129.84 130.01 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.641 -0.662 . . . . 0.0 109.526 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -92.18 136.21 33.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.455 -0.778 . . . . 0.0 110.192 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -79.17 128.82 33.78 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.571 -0.706 . . . . 0.0 110.318 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -121.68 23.02 10.38 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.616 -0.677 . . . . 0.0 110.169 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.0 179.73 41.23 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -61.37 -40.82 95.71 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.488 -1.007 . . . . 0.0 110.233 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 78.6 p -132.64 26.52 4.38 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.57 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -129.74 140.04 51.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.493 -0.754 . . . . 0.0 110.134 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.14 169.76 25.63 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -114.71 157.37 23.26 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.621 -0.929 . . . . 0.0 110.071 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.9 tp -100.41 119.15 38.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.566 -0.709 . . . . 0.0 110.165 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.497 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -69.68 -37.29 76.61 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.477 -0.765 . . . . 0.0 109.741 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.9 t -108.57 109.96 61.42 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.63 -0.669 . . . . 0.0 109.95 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.79 116.26 3.71 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.839 1.441 . . . . 0.0 110.469 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -119.95 160.03 44.47 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.544 -0.723 . . . . 0.0 110.185 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.74 157.74 60.62 Favored 'Trans proline' 0 N--CA 1.491 1.358 0 O-C-N 123.877 1.462 . . . . 0.0 110.442 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 94.3 t -61.53 -36.05 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.608 -0.682 . . . . 0.0 110.01 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -40.09 87.66 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.547 -0.721 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -59.89 -40.08 87.52 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.544 -0.723 . . . . 0.0 110.285 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.8 mp -82.65 -24.52 33.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.521 -0.737 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.39 140.23 57.29 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.295 -0.878 . . . . 0.0 109.972 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.02 10.23 85.8 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 20.6 m -116.17 18.83 15.23 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.173 -1.192 . . . . 0.0 110.606 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 1.8 m -69.95 149.95 47.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.356 -0.84 . . . . 0.0 109.857 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 46' ' ' THR . . . 90.05 -11.89 69.37 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.86 137.81 48.25 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.529 ' HB3' HG21 ' A' ' 46' ' ' THR . 50.0 Cg_endo -87.22 142.32 6.23 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.807 1.425 . . . . 0.0 111.327 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.87 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -103.6 109.56 21.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -102.74 132.33 48.96 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.457 -0.777 . . . . 0.0 111.62 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.447 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -68.56 159.62 80.62 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -51.9 -26.07 23.53 Favored 'Trans proline' 0 N--CA 1.5 1.874 0 O-C-N 123.446 1.235 . . . . 0.0 112.391 -178.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -62.69 -40.01 95.76 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.231 -0.918 . . . . 0.0 109.809 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 122.02 34.01 0.87 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.52 145.72 51.37 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.428 -1.042 . . . . 0.0 110.157 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.8 136.86 45.49 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.671 -0.643 . . . . 0.0 110.255 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 1.003 HG11 HD22 ' A' ' 104' ' ' LEU . 8.8 p -116.14 -21.28 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 110.78 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.29 -176.59 45.5 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.697 HD12 ' CE ' ' A' ' 175' ' ' MET . 92.7 mt -130.81 140.07 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.402 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.493 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.5 t80 -60.87 139.99 57.82 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.58 -0.7 . . . . 0.0 109.862 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 64.4 ttt180 -120.68 -52.5 2.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.56 -0.712 . . . . 0.0 110.393 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.793 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.32 157.62 43.49 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.486 -0.758 . . . . 0.0 110.325 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -110.23 145.52 37.19 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.548 -0.72 . . . . 0.0 110.265 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.1 t -110.0 119.96 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.631 -0.668 . . . . 0.0 109.794 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -130.59 152.17 50.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.639 -0.663 . . . . 0.0 110.39 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 p -77.8 -45.16 25.28 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.65 -0.656 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 45.6 ptt85 -164.0 54.78 0.16 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.621 -0.674 . . . . 0.0 109.975 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 111.93 -14.63 26.44 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.29 120.74 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.185 -1.185 . . . . 0.0 109.963 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -84.45 129.32 34.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.657 -0.652 . . . . 0.0 110.447 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 21.4 pttm -111.44 -24.31 10.25 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.621 -0.674 . . . . 0.0 110.604 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.13 159.23 42.68 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.619 -0.676 . . . . 0.0 109.909 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 m -134.91 167.32 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.611 -0.681 . . . . 0.0 110.668 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -126.78 139.65 52.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.669 -0.644 . . . . 0.0 109.771 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -138.04 154.7 49.28 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.402 -0.811 . . . . 0.0 110.833 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.512 HG11 HD11 ' A' ' 82' ' ' LEU . 62.6 t -93.29 121.15 65.89 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.68 -0.637 . . . . 0.0 109.472 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.64 154.11 75.57 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.734 1.386 . . . . 0.0 110.544 -179.602 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 63.7 t -62.99 -26.75 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.571 -0.706 . . . . 0.0 110.35 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -59.12 -39.9 83.75 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.478 -0.764 . . . . 0.0 110.351 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 86.2 p -60.0 -38.29 82.18 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.487 -0.758 . . . . 0.0 110.216 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.697 ' CE ' HD12 ' A' ' 153' ' ' ILE . 69.0 mtt -61.86 -40.03 93.93 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.507 -0.745 . . . . 0.0 110.257 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -41.81 92.85 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.539 -179.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 72.8 p -70.03 -27.46 64.68 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.3 m -60.06 -45.39 93.03 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.425 -0.797 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.6 mtt . . . . . 0 N--CA 1.497 1.9 0 O-C-N 121.578 -0.701 . . . . 0.0 110.083 179.939 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.793 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 61.5 tt0 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.045 0.45 . . . . 0.0 110.139 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.872 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.617 -0.677 . . . . 0.0 110.25 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.902 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 . . . . . 0 N--CA 1.498 1.941 0 CA-C-O 120.823 0.344 . . . . 0.0 110.498 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.902 HG23 ' HG3' ' A' ' 32' ' ' GLU . 60.3 t -108.21 126.74 64.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.503 -0.748 . . . . 0.0 109.82 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -123.39 154.41 39.03 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.484 -0.76 . . . . 0.0 110.584 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.9 t -90.3 122.77 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.617 -0.677 . . . . 0.0 109.276 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.591 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.5 m -120.37 152.71 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.564 -0.71 . . . . 0.0 110.176 -179.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.2 m -141.75 169.56 17.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.662 -0.648 . . . . 0.0 110.513 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 39' ' ' ALA . 1.0 OUTLIER -132.37 -169.77 2.29 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.904 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.536 ' H ' HG22 ' A' ' 38' ' ' THR . . . -58.73 -41.73 87.11 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.42 -0.8 . . . . 0.0 110.575 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.8 m -134.24 -6.86 2.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.479 -0.763 . . . . 0.0 112.025 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 16.8 tp60 -111.76 160.43 17.32 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.899 -1.126 . . . . 0.0 110.864 -179.214 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -147.56 137.91 23.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.452 -0.78 . . . . 0.0 110.402 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 29.0 p90 -169.11 -177.67 2.99 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.312 -0.868 . . . . 0.0 110.434 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.857 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.6 mt -112.99 159.94 18.61 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.429 -0.795 . . . . 0.0 110.672 -178.551 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -136.26 159.84 40.53 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.689 -0.632 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.696 ' CG2' HD12 ' A' ' 94' ' ' LEU . 23.0 m -123.8 139.29 54.12 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.444 -0.785 . . . . 0.0 110.351 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.0 t -94.38 111.03 22.76 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 110.637 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.411 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.1 t -117.2 130.31 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.704 -0.623 . . . . 0.0 109.662 179.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.46 39.44 28.01 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.503 -0.748 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.721 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.85 19.89 75.56 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -133.53 129.77 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -1.163 . . . . 0.0 110.025 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 89.3 m -74.49 147.67 41.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.391 -0.818 . . . . 0.0 109.419 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.411 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 67.5 m95 -129.94 151.66 50.26 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.394 -0.816 . . . . 0.0 110.824 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.3 t -167.41 -179.62 4.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.756 -0.59 . . . . 0.0 109.771 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.4 p -90.03 158.19 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.454 -0.779 . . . . 0.0 110.319 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.444 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 71.4 t80 -74.27 -42.31 59.82 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.599 -0.688 . . . . 0.0 111.477 -179.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -70.03 -22.48 63.09 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.148 -0.97 . . . . 0.0 110.799 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.778 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -81.31 -59.98 2.31 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.555 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -91.01 -52.34 4.89 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.639 -0.918 . . . . 0.0 110.204 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 -174.33 47.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 36.4 p -81.93 61.7 5.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.561 -0.964 . . . . 0.0 109.806 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -141.53 170.13 16.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.582 -0.699 . . . . 0.0 110.533 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.5 p -66.32 156.71 33.63 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.678 -0.639 . . . . 0.0 109.725 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.86 HD22 ' CH2' ' A' ' 85' ' ' TRP . 27.3 tp -118.3 140.5 49.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.575 -0.703 . . . . 0.0 110.28 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.27 109.72 21.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.663 -0.648 . . . . 0.0 109.998 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.19 -174.31 15.79 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.4 -32.35 71.82 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 O-C-N 123.907 1.477 . . . . 0.0 110.542 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.4 mttt -77.15 -31.03 55.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.667 -0.646 . . . . 0.0 110.01 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.75 -150.57 21.8 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -75.03 138.69 23.28 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.89 1.469 . . . . 0.0 110.358 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -119.97 129.96 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.621 -0.674 . . . . 0.0 110.577 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.9 p -82.51 142.53 31.78 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.525 -0.735 . . . . 0.0 109.753 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.77 149.97 21.33 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.432 -0.793 . . . . 0.0 111.254 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.6 mmm -115.43 -26.3 7.61 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.752 -0.592 . . . . 0.0 110.451 179.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -119.95 139.95 51.66 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.396 -0.815 . . . . 0.0 110.724 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.554 ' HA ' HG12 ' A' ' 83' ' ' VAL . 91.7 m -140.35 130.0 24.3 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.654 -0.654 . . . . 0.0 109.944 179.551 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -137.37 103.27 5.03 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.389 -0.819 . . . . 0.0 110.441 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 70.9 t -71.15 -45.24 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.51 -0.744 . . . . 0.0 110.224 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -60.11 -49.89 75.85 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.437 -0.79 . . . . 0.0 110.223 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.72 ' HG3' HD12 ' A' ' 82' ' ' LEU . 3.7 tp-100 -80.04 -9.99 59.74 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.538 -0.726 . . . . 0.0 110.582 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.7 t70 56.01 44.95 24.66 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.147 -0.97 . . . . 0.0 109.985 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 1.118 HD11 HG21 ' A' ' 170' ' ' VAL . 64.9 mt -141.77 131.5 24.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.655 -0.653 . . . . 0.0 110.902 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.554 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -129.96 159.98 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -137.47 157.34 23.98 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.553 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.6 m-90 -115.39 157.05 24.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.874 -0.78 . . . . 0.0 109.467 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -69.48 108.16 3.66 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.521 -0.737 . . . . 0.0 109.377 179.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.16 143.34 91.09 Favored Pre-proline 0 N--CA 1.496 1.844 0 O-C-N 121.495 -0.753 . . . . 0.0 110.359 -179.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.1 158.42 56.57 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.089 1.573 . . . . 0.0 110.154 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.98 153.33 63.37 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.886 1.466 . . . . 0.0 110.27 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.12 29.68 62.17 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.28 154.33 20.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.514 -0.992 . . . . 0.0 110.09 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -80.18 159.25 26.06 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 110.005 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 97.2 p -139.98 159.73 41.53 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.292 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.696 HD12 ' CG2' ' A' ' 46' ' ' THR . 7.7 mt -106.09 132.19 52.46 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.591 -0.693 . . . . 0.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' HD2' ' A' ' 96' ' ' PRO . 86.7 m -80.0 141.29 54.5 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.693 -0.63 . . . . 0.0 109.916 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . 0.596 ' HB3' HG11 ' A' ' 172' ' ' VAL . 44.6 Cg_endo -64.04 163.58 25.13 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.812 1.427 . . . . 0.0 110.377 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.677 ' HB2' HG22 ' A' ' 151' ' ' VAL . 51.5 t -87.74 123.54 32.66 Favored 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.65 0.738 . . . . 0.0 110.937 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.0 m -118.21 59.66 0.8 Allowed 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 177.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 3.5 m -141.76 -9.31 0.93 Allowed 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 119.99 -0.684 . . . . 0.0 111.899 -177.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.12 25.47 54.07 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.089 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -70.23 130.81 43.04 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.525 -0.985 . . . . 0.0 110.723 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 118' ' ' ARG . 56.4 m -74.37 -39.99 62.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.73 -0.606 . . . . 0.0 110.464 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.4 130.51 42.74 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.518 -0.739 . . . . 0.0 110.546 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.8 mt -131.23 140.2 49.82 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.649 -0.657 . . . . 0.0 110.637 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -106.85 124.37 49.52 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.494 -0.754 . . . . 0.0 109.817 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.531 HD13 ' HG ' ' A' ' 143' ' ' LEU . 37.7 tp -108.48 145.43 34.71 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.394 -0.816 . . . . 0.0 110.924 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.05 120.99 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.674 -0.641 . . . . 0.0 109.706 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.9 p -95.31 173.03 7.74 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.55 -0.719 . . . . 0.0 110.547 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.857 ' HA ' HD11 ' A' ' 44' ' ' LEU . 3.5 ptp180 -69.33 -11.95 61.25 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.544 -0.723 . . . . 0.0 111.103 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.01 21.69 5.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.209 -0.932 . . . . 0.0 110.399 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.33 40.05 31.42 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.222 -0.924 . . . . 0.0 110.575 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -124.02 147.65 47.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.658 -0.651 . . . . 0.0 109.64 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.0 p -129.98 130.69 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.565 -0.709 . . . . 0.0 110.405 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.621 HD12 HD11 ' A' ' 126' ' ' LEU . 43.8 pt -121.1 150.0 52.61 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.679 -0.638 . . . . 0.0 109.796 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -81.57 123.27 4.24 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.937 1.493 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -119.7 120.95 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.715 -0.616 . . . . 0.0 109.6 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -76.73 149.67 36.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.48 -0.762 . . . . 0.0 110.039 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB3' ' HA ' ' A' ' 102' ' ' SER . 64.6 ttt180 -90.89 120.06 31.6 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.359 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -109.94 20.09 18.36 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.659 -0.651 . . . . 0.0 110.399 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.85 -179.97 39.78 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.72 -39.92 90.41 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.972 . . . . 0.0 110.301 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.4 p -130.92 25.1 4.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.557 -0.714 . . . . 0.0 110.522 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -124.25 139.53 53.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.439 -0.788 . . . . 0.0 110.254 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.77 165.79 26.41 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 99.8 p -120.21 155.51 33.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.648 -0.913 . . . . 0.0 110.129 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.621 HD11 HD12 ' A' ' 114' ' ' ILE . 14.2 tp -99.97 119.5 38.35 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.516 -0.74 . . . . 0.0 110.158 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.04 -39.91 94.03 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.493 -0.754 . . . . 0.0 109.961 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 85.6 p -110.66 120.2 44.4 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.39 120.87 7.93 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 123.763 1.402 . . . . 0.0 110.4 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.2 mmt180 -129.93 159.98 67.34 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.539 -0.726 . . . . 0.0 110.251 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.39 156.72 61.82 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.982 1.517 . . . . 0.0 110.423 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.492 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.9 m -67.06 -25.44 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.658 -0.651 . . . . 0.0 110.618 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.7 m -59.94 -40.04 87.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.41 -0.806 . . . . 0.0 110.272 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.531 ' HD2' HD12 ' A' ' 135' ' ' LEU . 88.5 t80 -60.06 -40.08 88.23 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.497 -0.752 . . . . 0.0 109.935 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 134' ' ' TYR . 3.2 mp -83.85 -25.39 30.34 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.535 -0.728 . . . . 0.0 110.287 179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 tptm -59.96 132.02 52.66 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.408 -0.808 . . . . 0.0 110.105 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 91.96 0.93 70.84 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.306 -0.95 . . . . 0.0 110.732 -179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -109.96 19.99 18.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.136 -1.214 . . . . 0.0 110.66 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.4 t -68.65 147.68 51.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.327 -0.858 . . . . 0.0 109.724 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.78 -14.5 62.98 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.26 148.85 43.17 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -96.81 148.31 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.875 1.461 . . . . 0.0 111.123 -179.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.609 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -103.94 108.96 20.53 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.545 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.93 134.79 42.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.461 -0.774 . . . . 0.0 111.773 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 28.5 p -70.03 159.93 82.41 Favored Pre-proline 0 N--CA 1.494 1.75 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -52.62 -22.13 16.28 Favored 'Trans proline' 0 N--CA 1.5 1.904 0 O-C-N 123.512 1.269 . . . . 0.0 112.056 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 8.6 t -67.63 -42.92 81.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.228 -0.92 . . . . 0.0 110.055 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 125.51 35.93 0.59 Allowed Glycine 0 N--CA 1.496 2.671 0 C-N-CA 120.069 -1.062 . . . . 0.0 110.904 179.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -133.02 144.63 50.2 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.237 -1.155 . . . . 0.0 110.283 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.477 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -62.67 145.21 55.19 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.588 -0.695 . . . . 0.0 110.357 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.677 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.2 t -119.15 -38.91 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.523 -0.735 . . . . 0.0 110.118 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.99 -177.73 42.47 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 85.4 mt -121.61 132.02 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -1.013 . . . . 0.0 110.521 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.697 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 35.6 t80 -60.32 137.16 58.18 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.586 -0.696 . . . . 0.0 109.799 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 68.5 ttt180 -121.17 -52.72 2.06 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.498 -0.752 . . . . 0.0 110.33 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -143.16 159.96 41.32 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.508 -0.745 . . . . 0.0 110.073 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.697 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.84 136.05 54.92 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.627 -0.671 . . . . 0.0 110.553 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.6 t -90.0 119.74 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.492 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -135.52 153.69 51.64 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.487 -0.758 . . . . 0.0 111.404 -179.14 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . 0.562 HG22 ' HG2' ' A' ' 161' ' ' ARG . 37.1 m -130.53 137.38 49.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.756 -0.59 . . . . 0.0 109.522 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.562 ' HG2' HG22 ' A' ' 160' ' ' THR . 21.7 mmt180 54.21 37.14 26.63 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.272 -0.893 . . . . 0.0 110.755 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 74.19 23.28 76.31 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.4 t -129.98 129.87 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.295 -1.12 . . . . 0.0 110.065 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.78 125.57 35.75 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.539 -0.725 . . . . 0.0 110.131 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.51 -29.61 7.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.541 -0.725 . . . . 0.0 110.455 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.89 162.85 34.45 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.57 -0.706 . . . . 0.0 109.941 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -136.02 165.59 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.432 -0.792 . . . . 0.0 110.965 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -126.37 135.86 51.98 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.629 -0.67 . . . . 0.0 109.995 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -139.88 147.41 40.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.496 -0.752 . . . . 0.0 110.64 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 1.118 HG21 HD11 ' A' ' 82' ' ' LEU . 33.0 m -89.96 125.0 62.1 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.497 -0.752 . . . . 0.0 109.556 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.88 159.96 39.5 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.746 1.393 . . . . 0.0 110.711 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.9 t -60.22 -25.23 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.596 -0.69 . . . . 0.0 110.594 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -58.73 -39.01 79.62 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.456 -0.777 . . . . 0.0 110.354 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 67.5 m -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.468 -0.77 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.42 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.3 mtm -69.99 -37.37 75.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.35 -0.844 . . . . 0.0 110.331 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -59.97 -40.15 88.09 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.513 -0.742 . . . . 0.0 110.468 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 70.1 p -65.31 -37.12 86.16 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.471 -0.768 . . . . 0.0 110.253 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.0 m -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.593 -0.692 . . . . 0.0 110.139 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.496 1.846 0 O-C-N 121.534 -0.729 . . . . 0.0 110.058 179.888 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.1 0.476 . . . . 0.0 109.993 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.743 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp . . . . . 0 N--CA 1.495 1.801 0 O-C-N 121.535 -0.728 . . . . 0.0 110.041 179.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.708 ' OE1' HD21 ' A' ' 94' ' ' LEU . 96.9 mt-10 . . . . . 0 N--CA 1.497 1.875 0 CA-C-O 121.101 0.477 . . . . 0.0 110.116 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.8 124.65 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.592 -0.692 . . . . 0.0 109.793 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -119.13 155.11 32.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.667 -0.645 . . . . 0.0 110.512 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.8 t -90.21 131.04 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.621 -0.674 . . . . 0.0 109.539 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.517 ' CB ' HD21 ' A' ' 64' ' ' LEU . 27.8 m -123.91 158.38 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.68 -0.637 . . . . 0.0 110.194 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.12 179.35 6.56 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.71 -0.619 . . . . 0.0 110.362 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.2 OUTLIER -141.46 -170.9 3.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.67 -0.643 . . . . 0.0 109.479 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.42 ' H ' HG22 ' A' ' 38' ' ' THR . . . -60.03 -38.88 84.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.523 -0.736 . . . . 0.0 110.258 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.6 t -136.92 -6.71 1.87 Allowed 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.546 -0.721 . . . . 0.0 112.555 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -118.8 156.71 28.93 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 120.839 -1.163 . . . . 0.0 111.129 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.1 m -136.34 139.75 42.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.566 -0.709 . . . . 0.0 110.341 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -165.61 -177.16 4.24 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.238 -0.914 . . . . 0.0 110.075 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.758 HD11 ' HA ' ' A' ' 109' ' ' ARG . 21.7 mt -112.33 175.16 5.55 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.529 -0.732 . . . . 0.0 110.273 -178.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.443 ' HB1' ' SG ' ' A' ' 52' ' ' CYS . . . -149.64 156.85 42.59 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.692 -0.63 . . . . 0.0 110.087 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.583 ' CG2' HD12 ' A' ' 94' ' ' LEU . 27.6 m -119.51 139.92 51.33 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.699 -0.626 . . . . 0.0 110.063 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.3 t -101.35 109.35 21.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.453 -0.78 . . . . 0.0 110.476 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.438 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.4 t -120.38 134.28 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.69 -0.631 . . . . 0.0 109.842 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . 0.438 ' OD1' HG12 ' A' ' 48' ' ' VAL . 28.7 m120 55.23 38.52 30.52 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.534 -0.729 . . . . 0.0 111.144 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.63 26.67 74.22 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 80.9 t -140.47 130.03 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.338 -1.095 . . . . 0.0 109.956 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . 0.443 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 23.7 t -86.71 108.58 18.73 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.468 -0.77 . . . . 0.0 109.37 179.677 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -91.42 151.21 20.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.595 -0.691 . . . . 0.0 111.05 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.5 t -159.88 -179.71 8.06 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.857 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.5 p -96.59 152.35 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.448 -0.783 . . . . 0.0 110.443 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.427 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.1 t80 -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.58 -0.7 . . . . 0.0 112.091 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.857 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.9 p-80 -68.85 -19.52 64.26 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.139 -0.976 . . . . 0.0 111.068 -178.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.591 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -91.13 -52.28 2.42 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 179.037 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.637 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -103.2 -47.68 4.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.628 -0.925 . . . . 0.0 110.123 179.67 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.2 -168.89 40.78 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.496 ' OG ' HG21 ' A' ' 76' ' ' THR . 1.4 t -86.41 64.68 8.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.546 -0.973 . . . . 0.0 109.837 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -141.89 170.05 16.45 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.602 -0.686 . . . . 0.0 110.363 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.1 p -66.13 150.14 49.21 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.618 -0.676 . . . . 0.0 109.944 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.813 HD22 ' CH2' ' A' ' 85' ' ' TRP . 19.2 tp -117.08 142.62 46.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.611 -0.681 . . . . 0.0 110.082 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -97.62 110.26 22.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.621 -0.675 . . . . 0.0 110.093 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.33 177.11 16.31 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.7 -31.78 68.98 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.85 1.448 . . . . 0.0 110.412 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -71.7 -31.47 66.78 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.597 -0.689 . . . . 0.0 109.999 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.88 -160.56 26.21 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.94 137.23 40.73 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.886 1.466 . . . . 0.0 110.036 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.6 mt -119.94 129.98 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.506 -0.746 . . . . 0.0 110.564 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.3 p -84.86 150.23 25.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.574 -0.704 . . . . 0.0 109.707 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 10.5 pm0 -98.53 148.12 24.08 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.481 -0.762 . . . . 0.0 111.008 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.9 mtp -113.95 -25.55 8.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.766 -0.584 . . . . 0.0 110.504 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -120.01 135.88 54.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.428 -0.795 . . . . 0.0 110.572 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.643 ' HA ' HG12 ' A' ' 83' ' ' VAL . 29.9 m -140.91 126.11 18.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 109.88 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 30.1 t-20 -140.5 104.51 4.77 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.349 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 75.8 t -69.97 -45.3 77.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 0.0 109.871 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -59.87 -49.69 76.7 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.554 -0.716 . . . . 0.0 110.213 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.789 ' HG2' HD12 ' A' ' 82' ' ' LEU . 53.6 tt0 -79.95 -9.99 59.73 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.583 -0.698 . . . . 0.0 110.832 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.427 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 6.0 t70 55.2 46.22 24.25 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.031 -1.043 . . . . 0.0 110.446 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.789 HD12 ' HG2' ' A' ' 80' ' ' GLN . 41.3 mt -143.36 130.43 20.69 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.552 -0.717 . . . . 0.0 111.075 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.643 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -130.94 159.99 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.615 -0.678 . . . . 0.0 109.265 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.76 157.92 23.91 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.597 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 6.0 m-90 -119.93 160.28 23.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.792 -0.828 . . . . 0.0 109.778 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -71.88 124.57 25.15 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.088 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -72.7 130.01 86.08 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.489 -0.757 . . . . 0.0 110.212 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.02 159.64 52.47 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 O-C-N 123.876 1.461 . . . . 0.0 110.356 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.41 139.7 42.11 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.85 1.447 . . . . 0.0 110.306 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.58 -20.33 50.84 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.01 47.1 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.305 -1.115 . . . . 0.0 110.221 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.8 mtp85 -92.16 170.01 10.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.573 -0.705 . . . . 0.0 110.165 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -132.37 160.01 37.58 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.708 HD21 ' OE1' ' A' ' 32' ' ' GLU . 80.5 mt -110.74 132.23 54.37 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.9 p -76.34 160.05 78.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.693 -0.629 . . . . 0.0 109.95 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -77.21 164.04 29.67 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.833 1.438 . . . . 0.0 110.651 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.802 ' HB2' HG22 ' A' ' 151' ' ' VAL . 47.1 t -73.06 128.57 35.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.647 -0.658 . . . . 0.0 110.212 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.7 p -132.05 54.42 1.94 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.725 -0.609 . . . . 0.0 109.715 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.59 -7.52 0.77 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.519 -0.738 . . . . 0.0 112.376 -179.043 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.98 94.36 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -100.08 123.6 44.51 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.668 -0.901 . . . . 0.0 110.49 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 79.5 p -70.04 -26.06 63.86 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.617 -0.677 . . . . 0.0 110.352 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -63.73 129.99 42.38 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.58 -0.7 . . . . 0.0 109.969 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.616 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.2 mt -137.4 136.08 37.54 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.6 -0.688 . . . . 0.0 110.693 -179.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.88 119.99 40.83 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.55 -0.719 . . . . 0.0 109.718 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 57.2 tp -98.21 140.05 33.09 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.512 -0.742 . . . . 0.0 110.387 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.459 HG22 HG12 ' A' ' 113' ' ' VAL . 63.1 t -102.82 130.01 53.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.538 -0.726 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 22.9 p -98.2 179.17 4.84 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.583 -0.698 . . . . 0.0 110.761 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.758 ' HA ' HD11 ' A' ' 44' ' ' LEU . 15.8 ttt-85 -70.01 -18.58 63.32 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.692 -0.63 . . . . 0.0 110.969 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -93.21 25.46 3.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.293 -0.879 . . . . 0.0 110.868 -179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.14 38.97 30.2 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.347 -0.846 . . . . 0.0 110.765 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -120.25 139.58 52.47 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.662 -0.648 . . . . 0.0 109.599 179.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.459 HG12 HG22 ' A' ' 107' ' ' VAL . 34.0 m -116.66 140.07 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.515 -0.741 . . . . 0.0 110.701 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.563 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -124.32 149.99 62.7 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.681 -0.637 . . . . 0.0 109.572 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -83.6 126.53 4.1 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.842 1.443 . . . . 0.0 110.651 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 125' ' ' SER . 63.3 t -128.82 130.05 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.715 -0.616 . . . . 0.0 109.477 179.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.0 tpt180 -85.48 146.16 27.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.497 -0.752 . . . . 0.0 110.186 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -82.81 124.35 30.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.596 -0.69 . . . . 0.0 110.319 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -114.42 19.93 15.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.28 178.76 39.24 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -59.99 -41.11 91.35 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.509 -0.995 . . . . 0.0 110.293 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.1 p -130.43 25.52 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.464 -0.773 . . . . 0.0 110.654 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.2 tpp85 -126.84 140.49 52.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.507 -0.746 . . . . 0.0 110.356 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.27 166.81 25.95 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.516 ' O ' HG13 ' A' ' 116' ' ' VAL . 81.5 p -124.83 147.43 48.75 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.588 -0.948 . . . . 0.0 110.201 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 mp -95.43 121.7 37.38 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.583 -0.698 . . . . 0.0 110.312 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.516 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.8 -40.07 93.94 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.53 -0.731 . . . . 0.0 109.86 179.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.9 p -108.58 117.95 53.11 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.711 -0.618 . . . . 0.0 109.757 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.19 124.46 13.02 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.744 1.391 . . . . 0.0 110.63 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -121.46 160.17 47.18 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.591 -0.693 . . . . 0.0 110.013 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.09 158.88 56.14 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.93 1.489 . . . . 0.0 110.437 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.493 HG11 ' OE1' ' B' ' 188' ' ' GLU . 68.4 t -66.65 -29.99 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.62 -0.675 . . . . 0.0 110.033 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.6 t -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.552 -0.717 . . . . 0.0 110.295 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.692 ' HD2' HD12 ' A' ' 135' ' ' LEU . 64.7 t80 -60.01 -49.54 77.28 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.461 -0.774 . . . . 0.0 110.02 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.692 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.5 mp -69.91 -29.33 66.49 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.632 -0.667 . . . . 0.0 110.626 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 139.98 56.95 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.386 -0.821 . . . . 0.0 110.083 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.54 13.08 83.01 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 16.7 m -115.3 17.25 16.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.281 -1.129 . . . . 0.0 110.766 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.8 m -60.04 144.32 49.72 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.34 -19.34 54.68 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.52 109.8 1.36 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -77.09 151.18 30.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.875 1.46 . . . . 0.0 110.852 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.631 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -99.72 110.44 22.84 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.086 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.531 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -100.01 128.39 46.1 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.662 -0.649 . . . . 0.0 111.17 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.424 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.0 157.89 88.67 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.663 -0.648 . . . . 0.0 109.266 179.066 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.1 Cg_endo -52.16 -24.96 21.71 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 O-C-N 123.516 1.271 . . . . 0.0 112.314 -178.53 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 51.7 m -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.269 -0.895 . . . . 0.0 110.003 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.03 35.77 0.8 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.4 m170 -132.91 149.2 52.27 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -1.01 . . . . 0.0 110.289 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 145.52 51.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.628 -0.67 . . . . 0.0 110.223 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.802 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.6 t -118.23 -38.38 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.595 -0.691 . . . . 0.0 109.961 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -171.39 -170.02 34.98 Favored Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.423 HD12 ' CE ' ' A' ' 175' ' ' MET . 85.4 mt -130.99 140.02 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.466 -1.02 . . . . 0.0 110.286 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -62.41 138.55 58.47 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.536 -0.727 . . . . 0.0 109.873 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.6 ttp180 -122.54 -52.1 1.93 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.627 -0.671 . . . . 0.0 110.319 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.693 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.64 161.88 41.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.487 -0.758 . . . . 0.0 110.421 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.92 149.81 39.53 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.649 -0.657 . . . . 0.0 110.161 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -109.95 117.99 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.645 -0.659 . . . . 0.0 109.885 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.401 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.5 p -137.47 160.53 38.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.642 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 33.1 m -117.99 -56.63 2.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.573 -0.704 . . . . 0.0 110.765 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -109.33 29.96 7.06 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 110.42 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 100.18 0.3 55.94 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -116.39 126.04 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.098 -1.236 . . . . 0.0 109.649 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.78 123.62 37.24 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.653 . . . . 0.0 110.303 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -104.57 -24.04 13.04 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.651 -0.656 . . . . 0.0 110.503 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 159.65 41.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.429 -0.794 . . . . 0.0 110.184 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -141.37 162.4 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.507 -0.746 . . . . 0.0 110.635 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 -114.89 138.39 50.86 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.615 -0.678 . . . . 0.0 110.053 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -140.04 155.31 47.12 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.531 -0.73 . . . . 0.0 110.299 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.575 HG11 HD11 ' A' ' 82' ' ' LEU . 58.6 t -96.21 122.78 57.04 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.53 -0.731 . . . . 0.0 109.65 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -65.66 155.83 67.02 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.777 1.409 . . . . 0.0 110.615 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 61.3 t -63.78 -22.92 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.61 -0.681 . . . . 0.0 110.731 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.99 -39.11 84.61 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -0.829 . . . . 0.0 110.424 -179.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.0 p -59.81 -34.39 72.99 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.437 -0.789 . . . . 0.0 110.51 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.423 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.0 mtt -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.527 -0.733 . . . . 0.0 110.492 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -59.95 -40.06 87.7 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.1 m -60.59 -48.61 81.01 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.504 -0.748 . . . . 0.0 110.05 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 87.3 m -70.01 -46.17 65.68 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.575 -0.703 . . . . 0.0 110.0 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.495 1.776 0 O-C-N 121.639 -0.663 . . . . 0.0 110.181 -179.91 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.693 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.155 0.502 . . . . 0.0 110.117 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.795 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.7 mp . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.567 -0.708 . . . . 0.0 110.149 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.485 ' OE1' HD21 ' A' ' 94' ' ' LEU . 99.8 mt-10 . . . . . 0 N--CA 1.495 1.791 0 CA-C-O 121.034 0.445 . . . . 0.0 109.993 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.55 128.51 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -124.84 159.78 30.27 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.567 -0.708 . . . . 0.0 110.075 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.17 113.81 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.519 -0.738 . . . . 0.0 109.83 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.43 ' HB ' HD11 ' A' ' 64' ' ' LEU . 34.5 m -110.17 143.21 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.677 -0.64 . . . . 0.0 109.763 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.48 ' O ' HD13 ' A' ' 64' ' ' LEU . 37.4 t -137.22 173.82 11.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.51 -0.744 . . . . 0.0 111.18 -179.125 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' N ' ' A' ' 39' ' ' ALA . 27.7 m -144.3 169.22 18.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.921 -0.487 . . . . 0.0 109.895 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.455 ' N ' HG22 ' A' ' 38' ' ' THR . . . -66.76 -16.72 64.45 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.669 -0.644 . . . . 0.0 110.617 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.8 m -111.05 -39.1 4.87 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.345 -0.847 . . . . 0.0 111.748 -179.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -146.86 170.7 16.49 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.157 -0.964 . . . . 0.0 111.573 -179.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.3 p -128.23 151.95 48.66 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.636 -0.665 . . . . 0.0 110.311 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.427 ' HE2' ' HG1' ' A' ' 54' ' ' THR . 30.7 p90 -165.87 -178.02 4.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.374 -0.829 . . . . 0.0 110.334 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.682 HD11 ' HA ' ' A' ' 109' ' ' ARG . 76.2 mt -113.61 150.45 33.09 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.506 -0.746 . . . . 0.0 110.717 -178.585 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.46 159.13 34.23 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.655 -0.653 . . . . 0.0 110.055 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.581 HG21 ' HB3' ' A' ' 142' ' ' PRO . 62.8 m -120.33 131.6 54.93 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.664 -179.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.4 t -90.16 102.56 15.28 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.547 -0.721 . . . . 0.0 110.136 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.412 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.7 t -109.97 130.12 63.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.582 -0.699 . . . . 0.0 109.593 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.41 39.98 27.74 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.437 -0.789 . . . . 0.0 110.66 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.76 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.05 19.98 75.97 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 110.869 -0.893 . . . . 0.0 110.869 179.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.4 t -131.84 129.98 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.161 -1.2 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.0 m -74.79 147.81 40.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.53 -0.731 . . . . 0.0 109.42 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.465 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 74.5 m95 -129.97 152.31 49.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.426 -0.796 . . . . 0.0 111.072 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.943 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.0 t -169.5 -179.71 3.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.0 p -90.99 156.7 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.458 -0.776 . . . . 0.0 110.484 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.428 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 86.5 t80 -70.01 -42.69 72.69 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.57 -0.706 . . . . 0.0 111.194 -179.42 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.2 p-80 -71.51 -19.06 62.24 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.281 -0.887 . . . . 0.0 111.014 -179.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.815 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -73.84 -57.57 4.84 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -87.18 -41.59 13.63 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.583 -0.951 . . . . 0.0 110.139 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 75.72 28.91 60.25 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.28 57.45 4.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.361 -1.082 . . . . 0.0 110.54 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.53 178.99 6.82 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.081 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 77.7 p -65.06 139.49 58.74 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.209 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.48 HD13 ' O ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -115.04 130.04 56.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.576 -0.702 . . . . 0.0 110.842 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.23 109.38 20.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.551 -0.718 . . . . 0.0 109.663 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.29 -154.47 13.11 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -72.55 -31.04 11.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.928 1.489 . . . . 0.0 110.445 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -83.67 -22.43 32.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.586 -0.697 . . . . 0.0 110.74 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 135.31 -139.52 10.87 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.91 154.91 34.01 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.904 1.476 . . . . 0.0 110.083 179.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.402 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.7 mt -131.45 140.01 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.554 -0.716 . . . . 0.0 110.575 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 91.9 m -95.27 140.0 30.78 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.559 -0.713 . . . . 0.0 109.943 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.413 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 8.9 tt0 -93.05 140.05 29.9 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 0.0 110.58 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.2 mmm -112.18 -29.98 7.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.629 -0.669 . . . . 0.0 110.566 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -118.41 139.77 50.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.585 -0.697 . . . . 0.0 110.569 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.3 m -139.97 132.12 28.07 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.513 -0.742 . . . . 0.0 109.93 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.559 ' OD1' HG23 ' A' ' 178' ' ' THR . 0.1 OUTLIER -136.23 96.62 3.42 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.443 -0.786 . . . . 0.0 110.5 -179.79 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 82.6 t -70.02 -40.03 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.595 -0.691 . . . . 0.0 109.899 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.97 -47.34 86.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.562 -0.711 . . . . 0.0 110.297 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -90.05 0.15 57.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.531 -0.731 . . . . 0.0 110.97 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 3.8 t70 53.8 46.42 25.82 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.061 -1.025 . . . . 0.0 110.481 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.854 HD11 HG21 ' A' ' 170' ' ' VAL . 67.6 mt -141.45 135.92 30.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.476 -0.765 . . . . 0.0 110.747 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.518 ' CG2' HG23 ' A' ' 54' ' ' THR . 33.4 m -134.01 164.44 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.606 -0.684 . . . . 0.0 109.432 179.023 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.75 156.79 26.05 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.871 -1.157 . . . . 0.0 110.343 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.943 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.2 m-90 -116.48 152.71 33.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.85 -0.794 . . . . 0.0 109.52 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -66.61 106.37 1.78 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.41 -0.806 . . . . 0.0 109.606 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.51 143.57 87.81 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.576 -0.703 . . . . 0.0 110.097 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.95 150.4 66.97 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.965 1.508 . . . . 0.0 110.338 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.01 159.76 44.91 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.849 1.447 . . . . 0.0 110.094 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.79 29.6 69.2 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.76 149.81 28.5 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.48 -1.012 . . . . 0.0 109.949 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -85.21 146.03 27.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.626 -0.671 . . . . 0.0 109.283 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.4 p -136.91 174.14 10.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.577 -0.702 . . . . 0.0 110.601 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.485 HD21 ' OE1' ' A' ' 32' ' ' GLU . 44.0 mt -108.39 149.8 28.23 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.675 -0.641 . . . . 0.0 110.598 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 74.0 p -90.03 176.18 3.24 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.649 -0.657 . . . . 0.0 110.003 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -89.49 160.49 5.42 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 O-C-N 123.807 1.425 . . . . 0.0 110.609 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.752 ' HB2' HG12 ' A' ' 151' ' ' VAL . 51.3 t -68.7 133.13 47.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.671 -0.643 . . . . 0.0 110.158 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.4 t -135.95 53.41 1.95 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.678 -0.639 . . . . 0.0 109.751 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.88 -8.2 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.554 -0.716 . . . . 0.0 112.378 -179.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 38.17 93.9 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -99.95 124.16 44.99 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.565 -0.962 . . . . 0.0 110.502 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 19.6 p -69.91 -34.27 73.28 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.614 -0.679 . . . . 0.0 110.133 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -61.67 129.98 43.64 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.574 -0.704 . . . . 0.0 109.903 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 1.037 HD22 HG21 ' A' ' 151' ' ' VAL . 90.2 mt -135.64 149.99 49.49 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.55 -0.719 . . . . 0.0 110.771 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 143' ' ' LEU . 90.4 m-85 -112.54 140.01 47.65 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.617 -0.677 . . . . 0.0 109.556 179.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.447 ' CD1' HD11 ' A' ' 143' ' ' LEU . 52.3 tp -115.2 142.16 47.04 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.496 -0.752 . . . . 0.0 110.677 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 130.06 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.634 -0.666 . . . . 0.0 109.761 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 24.9 p -110.22 -179.9 3.91 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.519 -0.738 . . . . 0.0 110.643 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.682 ' HA ' HD11 ' A' ' 44' ' ' LEU . 32.8 mtp-105 -60.04 -26.38 66.08 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.586 -0.697 . . . . 0.0 110.652 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -89.96 17.91 6.32 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.393 -0.817 . . . . 0.0 111.181 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.09 38.38 27.26 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.057 -1.027 . . . . 0.0 110.748 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -100.76 139.8 35.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.699 -0.626 . . . . 0.0 109.893 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 63.4 t -110.02 119.99 60.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.597 -0.689 . . . . 0.0 109.928 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.55 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -118.91 122.16 29.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.646 -0.659 . . . . 0.0 109.435 179.868 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.513 ' N ' HD13 ' A' ' 114' ' ' ILE . 47.0 Cg_endo -65.33 132.9 32.98 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.744 1.392 . . . . 0.0 110.368 -179.654 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.481 HG13 ' O ' ' A' ' 125' ' ' SER . 63.2 t -129.93 130.04 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.678 -0.639 . . . . 0.0 109.731 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -86.36 132.72 33.89 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.497 -0.752 . . . . 0.0 109.972 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -70.76 130.03 40.65 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.581 -0.699 . . . . 0.0 110.438 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 24.5 mmm-85 -102.4 -20.9 14.38 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.653 -0.654 . . . . 0.0 110.377 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.24 -167.98 29.68 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -59.98 -39.98 87.56 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.606 -0.937 . . . . 0.0 110.401 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.4 p -129.89 25.37 5.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.508 -0.745 . . . . 0.0 110.581 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -125.88 140.04 52.98 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.483 -0.76 . . . . 0.0 110.278 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.87 167.18 24.69 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.481 ' O ' HG13 ' A' ' 116' ' ' VAL . 80.1 p -127.82 150.03 50.01 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.576 -0.956 . . . . 0.0 110.211 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.516 ' CD1' HG13 ' A' ' 167' ' ' VAL . 8.4 mp -103.02 131.39 50.04 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.442 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.514 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.79 -39.99 93.64 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.585 -0.697 . . . . 0.0 109.745 179.563 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.5 p -118.36 149.98 46.97 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.684 -0.635 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -84.42 82.65 1.8 Allowed 'Trans proline' 0 N--CA 1.489 1.237 0 O-C-N 123.843 1.444 . . . . 0.0 110.747 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -71.59 159.98 83.92 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 109.836 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.67 149.31 67.28 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.939 1.494 . . . . 0.0 110.292 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.4 -34.0 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.622 -0.674 . . . . 0.0 110.046 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.6 t -58.41 -36.67 73.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.549 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.652 ' HD1' HD12 ' A' ' 135' ' ' LEU . 64.9 t80 -60.06 -39.92 87.69 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.487 -0.758 . . . . 0.0 110.11 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.652 HD12 ' HD1' ' A' ' 134' ' ' TYR . 3.7 mp -81.37 -20.84 39.73 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.562 -0.711 . . . . 0.0 110.826 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -59.97 139.74 57.21 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.23 -0.919 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.6 1.07 86.12 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.5 m -101.51 3.07 39.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.107 -1.231 . . . . 0.0 110.975 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.9 t -59.97 139.93 57.08 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.145 -0.972 . . . . 0.0 109.863 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.96 -17.85 57.89 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.67 140.84 43.14 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 179.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.581 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.4 Cg_endo -87.96 144.91 6.34 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.831 1.438 . . . . 0.0 111.471 -178.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.892 ' O ' HG22 ' A' ' 151' ' ' VAL . 8.3 mp -103.32 129.95 50.47 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.722 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.46 130.9 56.21 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.366 -0.834 . . . . 0.0 111.598 -178.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.452 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -70.02 159.75 83.09 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.76 -26.91 25.05 Favored 'Trans proline' 0 N--CA 1.501 1.96 0 O-C-N 123.475 1.25 . . . . 0.0 112.368 -178.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.78 -40.02 96.02 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.222 -0.924 . . . . 0.0 109.963 179.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.2 36.46 0.81 Allowed Glycine 0 N--CA 1.496 2.641 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -132.83 151.1 52.08 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.462 -1.023 . . . . 0.0 110.337 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -67.08 139.96 57.59 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.623 -0.673 . . . . 0.0 110.435 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 1.037 HG21 HD22 ' A' ' 104' ' ' LEU . 33.9 m -117.19 -22.19 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.597 -0.689 . . . . 0.0 110.726 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 171.39 -171.53 44.05 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 86.0 mt -128.82 140.02 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.542 -0.975 . . . . 0.0 110.154 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.638 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 28.9 t80 -71.15 135.47 47.64 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.66 -0.65 . . . . 0.0 109.962 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.4 ttp85 -116.52 -53.01 2.54 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.617 -0.677 . . . . 0.0 110.178 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -148.18 159.96 43.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.757 . . . . 0.0 110.391 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.638 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.95 151.58 35.12 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.63 . . . . 0.0 110.262 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.51 120.03 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.704 -0.622 . . . . 0.0 109.525 179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.09 158.13 41.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.707 -0.621 . . . . 0.0 110.632 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.0 m -101.77 -61.06 1.43 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.67 -0.644 . . . . 0.0 110.309 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -129.03 63.69 1.48 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.681 -0.637 . . . . 0.0 110.066 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.98 9.99 86.08 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 25.3 m -126.75 132.09 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.206 -1.173 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.7 124.28 38.64 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.513 -0.742 . . . . 0.0 110.215 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.86 -29.9 8.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.648 -0.657 . . . . 0.0 110.232 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.26 151.44 45.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.638 -0.663 . . . . 0.0 110.125 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.516 HG13 ' CD1' ' A' ' 126' ' ' LEU . 34.6 m -129.96 159.96 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.617 -0.677 . . . . 0.0 110.669 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -121.97 130.67 53.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.668 -0.645 . . . . 0.0 109.934 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -134.37 159.92 39.54 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.539 -0.726 . . . . 0.0 110.501 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.854 HG21 HD11 ' A' ' 82' ' ' LEU . 62.3 t -93.42 126.49 50.13 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.615 -0.678 . . . . 0.0 109.368 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.94 157.37 53.11 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.771 1.406 . . . . 0.0 110.599 -179.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 151' ' ' VAL . 76.3 t -59.85 -25.7 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.614 -0.679 . . . . 0.0 110.387 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -60.02 -39.97 87.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.422 -0.799 . . . . 0.0 110.364 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . 0.464 ' HB3' HG12 ' A' ' 170' ' ' VAL . 21.7 t -65.42 -37.47 87.04 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.12 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.465 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 95.4 mtp -60.05 -41.82 93.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.56 -0.712 . . . . 0.0 110.293 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -69.12 -40.05 78.56 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.55 -0.719 . . . . 0.0 110.104 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.75 -40.08 93.87 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.673 -0.642 . . . . 0.0 109.92 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 77' ' ' ASN . 91.2 m -59.95 -41.06 91.03 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.558 -0.714 . . . . 0.0 110.189 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.496 1.841 0 O-C-N 121.642 -0.661 . . . . 0.0 110.176 -179.812 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 121.013 0.435 . . . . 0.0 110.136 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.814 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.4 mp . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.622 -0.674 . . . . 0.0 110.165 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.682 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.5 mt-10 . . . . . 0 N--CA 1.495 1.818 0 CA-C-O 121.103 0.477 . . . . 0.0 110.201 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.67 126.91 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.537 -0.727 . . . . 0.0 109.947 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -119.12 142.91 47.5 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.555 -0.716 . . . . 0.0 110.359 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 35' ' ' VAL . 14.4 p -78.39 128.83 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.604 -0.685 . . . . 0.0 110.339 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.651 ' HB ' HD21 ' A' ' 64' ' ' LEU . 34.4 m -122.27 146.44 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.636 -0.665 . . . . 0.0 109.593 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.2 m -144.49 171.02 14.94 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.519 -0.738 . . . . 0.0 110.897 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.8 p -133.78 -170.92 2.6 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.93 -32.54 72.05 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.676 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 m -133.09 -11.1 2.94 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.356 -0.84 . . . . 0.0 112.639 -178.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -114.94 154.03 29.49 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.837 -1.165 . . . . 0.0 111.182 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.3 m -143.89 128.29 17.91 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.697 -0.627 . . . . 0.0 109.863 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -159.56 -178.72 7.31 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.307 -0.871 . . . . 0.0 110.469 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.495 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.8 mt -113.96 155.6 25.55 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.519 -0.738 . . . . 0.0 110.533 -178.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.52 160.52 33.88 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.625 -0.672 . . . . 0.0 110.304 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.498 HG21 ' HB3' ' A' ' 142' ' ' PRO . 87.1 m -119.97 130.78 54.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.553 -0.717 . . . . 0.0 110.142 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.2 t -89.34 104.03 16.62 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.541 -0.724 . . . . 0.0 110.67 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.18 130.1 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.621 -0.674 . . . . 0.0 109.492 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.21 39.55 28.67 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.428 -0.795 . . . . 0.0 110.707 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.604 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.98 19.97 75.85 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.1 t -133.73 129.98 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.224 -1.162 . . . . 0.0 110.031 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.9 m -71.57 147.52 47.56 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.437 -0.789 . . . . 0.0 109.667 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -139.71 145.47 38.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.47 -0.769 . . . . 0.0 110.867 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.67 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.6 t -170.02 -178.74 2.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.723 -0.61 . . . . 0.0 109.758 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.906 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -78.22 162.13 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.524 -0.735 . . . . 0.0 110.388 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -86.97 -35.1 19.04 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.6 -0.687 . . . . 0.0 111.773 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.906 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.2 p-80 -63.34 -22.14 66.7 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.02 -1.05 . . . . 0.0 110.583 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.434 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -79.68 -60.05 2.54 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.105 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.624 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -84.12 -61.99 1.68 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.583 -0.951 . . . . 0.0 109.943 179.421 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.11 36.84 20.33 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.3 p 53.72 40.05 31.0 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.48 -1.012 . . . . 0.0 110.71 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -111.57 179.5 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.672 -0.642 . . . . 0.0 109.755 179.551 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.7 m -64.74 139.36 58.75 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.489 -0.757 . . . . 0.0 109.102 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.651 HD21 ' HB ' ' A' ' 36' ' ' VAL . 12.5 tp -119.89 138.52 53.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.488 -0.757 . . . . 0.0 110.524 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -112.53 109.52 19.15 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.635 -0.666 . . . . 0.0 109.947 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.82 -172.59 25.55 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.44 -32.34 49.89 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.88 1.463 . . . . 0.0 110.362 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -75.96 -31.12 58.89 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.561 -0.712 . . . . 0.0 109.973 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.64 -144.92 14.25 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.72 155.61 58.33 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 O-C-N 123.85 1.447 . . . . 0.0 110.303 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.515 HG22 ' HB3' ' A' ' 85' ' ' TRP . 83.9 mt -130.05 140.01 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.553 -0.717 . . . . 0.0 110.102 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 23.2 m -87.31 150.49 23.83 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.486 -0.758 . . . . 0.0 110.789 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.412 ' HG2' ' NE1' ' A' ' 85' ' ' TRP . 72.8 mt-30 -93.08 139.95 30.01 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.544 -0.722 . . . . 0.0 110.484 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.8 mmm -118.45 -32.48 4.61 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.545 -0.722 . . . . 0.0 110.55 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -138.2 150.71 47.01 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.461 -0.774 . . . . 0.0 110.532 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 90.2 m -149.59 134.07 17.53 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.534 -0.729 . . . . 0.0 109.813 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.4 t-20 -141.71 100.32 3.73 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.495 -0.753 . . . . 0.0 110.424 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 74.6 t -70.0 -38.24 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.002 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -60.0 -45.36 92.99 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.544 -0.723 . . . . 0.0 110.495 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.98 2.79 54.72 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.464 -0.772 . . . . 0.0 111.121 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.7 t0 54.46 47.69 22.24 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.965 -1.084 . . . . 0.0 110.438 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.748 HD11 HG11 ' A' ' 170' ' ' VAL . 71.3 mt -140.0 143.07 36.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.547 -0.721 . . . . 0.0 110.864 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.624 HG11 ' HB3' ' A' ' 59' ' ' ALA . 7.7 p -139.5 144.68 28.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.619 -0.676 . . . . 0.0 109.248 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -128.28 153.5 19.53 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.292 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.67 ' CZ3' HG21 ' A' ' 54' ' ' THR . 8.4 m-90 -120.21 168.07 11.6 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.693 -0.887 . . . . 0.0 109.887 179.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -76.73 109.11 10.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.498 -0.751 . . . . 0.0 109.349 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.604 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.03 140.66 97.93 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.473 -0.767 . . . . 0.0 110.196 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.05 159.95 51.37 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.847 1.446 . . . . 0.0 110.262 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.05 157.52 59.54 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.931 1.49 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.98 30.01 70.36 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.04 140.67 47.65 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.554 -0.968 . . . . 0.0 110.221 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.89 152.8 23.3 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.53 -0.731 . . . . 0.0 109.786 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.7 p -130.0 170.04 14.48 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.536 -0.727 . . . . 0.0 110.433 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.682 HD21 ' OE1' ' A' ' 32' ' ' GLU . 66.6 mt -110.01 143.73 39.58 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.607 -0.683 . . . . 0.0 110.632 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 42.9 p -85.96 172.74 7.96 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.628 -0.67 . . . . 0.0 110.042 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -83.48 161.29 14.8 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.925 1.487 . . . . 0.0 110.534 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.2 t -77.79 129.98 36.14 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.655 -0.653 . . . . 0.0 110.25 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 35.3 m -135.54 56.81 1.82 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.675 -0.64 . . . . 0.0 109.511 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 p -143.94 -4.44 0.83 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.626 -0.671 . . . . 0.0 112.288 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 39.97 96.45 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.9 m -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.53 -0.982 . . . . 0.0 110.471 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.7 p -69.97 -27.3 64.61 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.676 -0.64 . . . . 0.0 110.376 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -66.39 129.43 39.8 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 110.124 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.523 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.4 mt -134.96 150.0 50.3 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.699 -0.626 . . . . 0.0 110.706 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -117.35 123.95 47.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.556 -0.715 . . . . 0.0 109.694 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.539 HD13 HD21 ' A' ' 143' ' ' LEU . 43.1 tp -99.99 139.99 34.86 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.461 -0.775 . . . . 0.0 110.757 -179.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.11 139.96 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.671 -0.643 . . . . 0.0 109.853 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.8 p -119.59 173.14 7.18 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.524 -0.735 . . . . 0.0 110.624 -179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.495 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.7 mtp180 -62.89 -25.67 68.41 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.532 -0.73 . . . . 0.0 110.627 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -92.64 24.41 3.56 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.418 -0.801 . . . . 0.0 110.922 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.1 23.09 4.97 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.237 -0.915 . . . . 0.0 110.849 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -94.85 155.44 16.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.811 . . . . 0.0 109.734 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 113' ' ' VAL . 9.1 p -130.02 129.94 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.517 -0.74 . . . . 0.0 110.505 -179.779 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.546 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -114.38 123.31 32.63 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.614 -0.679 . . . . 0.0 109.36 179.708 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.542 ' N ' HD13 ' A' ' 114' ' ' ILE . 46.5 Cg_endo -65.35 129.55 22.99 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.79 1.416 . . . . 0.0 110.484 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.3 t -129.14 130.02 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.696 -0.627 . . . . 0.0 109.663 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -86.01 149.46 25.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.505 -0.747 . . . . 0.0 109.967 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 46.2 ttp180 -90.62 120.01 31.34 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.559 -0.713 . . . . 0.0 110.412 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -112.49 20.04 17.01 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.64 -0.663 . . . . 0.0 110.519 179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.86 -179.94 40.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -62.64 -39.99 95.6 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.58 -0.953 . . . . 0.0 110.279 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 33.8 p -130.66 24.17 5.06 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.525 -0.734 . . . . 0.0 110.601 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -126.55 139.31 53.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.417 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.99 170.84 24.13 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 94.8 p -120.16 153.08 36.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.979 . . . . 0.0 110.085 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.425 ' HA ' HD12 ' A' ' 126' ' ' LEU . 17.6 tp -98.2 118.64 35.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.53 -0.732 . . . . 0.0 110.234 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.415 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.3 mp -65.62 -40.04 92.14 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -110.0 110.11 58.92 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.61 -0.681 . . . . 0.0 110.138 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -64.99 115.64 3.39 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.848 1.446 . . . . 0.0 110.391 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HD3' ' CD2' ' A' ' 134' ' ' TYR . 6.8 mtt180 -126.97 160.04 61.42 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.572 -0.705 . . . . 0.0 110.224 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.15 156.83 56.99 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 O-C-N 123.862 1.453 . . . . 0.0 110.255 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.46 HG11 ' OE1' ' B' ' 188' ' ' GLU . 33.8 m -59.96 -30.01 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.516 -0.74 . . . . 0.0 110.305 -179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -62.15 -32.37 72.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.595 -0.69 . . . . 0.0 109.924 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.549 ' CZ ' HD13 ' A' ' 135' ' ' LEU . 0.0 OUTLIER -59.98 -39.99 87.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.582 -0.699 . . . . 0.0 110.058 -179.812 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 8.2 tp -100.22 -1.92 35.22 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.489 -0.757 . . . . 0.0 111.527 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.04 139.99 52.76 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.113 -0.992 . . . . 0.0 109.851 179.52 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 83.3 -3.2 85.51 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.4 m -107.98 15.06 24.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.099 -1.236 . . . . 0.0 110.626 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -69.92 149.92 47.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 109.345 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.419 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 98.09 -19.95 52.5 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.45 151.0 29.17 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.498 ' HB3' HG21 ' A' ' 46' ' ' THR . 54.8 Cg_endo -95.38 149.14 1.51 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.826 1.435 . . . . 0.0 111.187 -179.102 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.539 HD21 HD13 ' A' ' 106' ' ' LEU . 84.4 mt -101.59 108.02 19.46 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.556 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.98 130.02 46.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 111.401 -178.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.441 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.64 83.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -52.32 -22.62 16.24 Favored 'Trans proline' 0 N--CA 1.501 1.957 0 O-C-N 123.569 1.299 . . . . 0.0 112.222 -178.755 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.28 -40.0 89.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.28 -0.888 . . . . 0.0 109.959 179.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.35 35.69 0.85 Allowed Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 35.1 m170 -131.46 146.33 52.2 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.422 -1.046 . . . . 0.0 110.321 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.33 144.31 57.19 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.649 -0.657 . . . . 0.0 110.3 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.7 t -118.91 -39.74 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.619 -0.676 . . . . 0.0 109.931 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -167.33 33.9 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.588 HD11 ' HE1' ' A' ' 175' ' ' MET . 91.0 mt -130.0 137.04 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.51 -0.994 . . . . 0.0 110.332 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.661 ' CZ ' HD23 ' A' ' 135' ' ' LEU . 20.1 t80 -64.7 138.3 58.31 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.606 -0.684 . . . . 0.0 109.427 179.344 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -116.23 -52.43 2.59 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.537 -0.727 . . . . 0.0 110.534 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -157.45 161.62 38.92 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.563 -0.711 . . . . 0.0 110.563 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.04 151.74 26.81 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.657 -0.652 . . . . 0.0 110.017 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -108.26 118.03 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.605 -0.685 . . . . 0.0 109.734 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -132.96 166.85 21.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.694 -0.629 . . . . 0.0 110.337 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 29.4 m -126.81 -54.24 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.498 -0.752 . . . . 0.0 110.363 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.7 mmt180 -102.04 26.76 7.24 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.537 -0.727 . . . . 0.0 110.388 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.37 -2.31 57.58 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.99 128.7 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.108 -1.231 . . . . 0.0 109.659 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.82 127.42 35.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.628 -0.67 . . . . 0.0 110.722 -179.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -102.82 -19.66 14.6 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.632 -0.667 . . . . 0.0 110.313 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.93 160.71 39.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.093 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.77 173.95 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.554 -0.716 . . . . 0.0 110.409 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -133.76 132.83 41.0 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.664 -0.648 . . . . 0.0 109.886 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -136.69 156.06 49.04 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.422 -0.799 . . . . 0.0 110.59 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.748 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -98.54 123.46 50.01 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.661 -0.649 . . . . 0.0 109.373 179.31 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -63.42 153.04 77.09 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.726 1.382 . . . . 0.0 110.646 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 151' ' ' VAL . 67.2 t -57.06 -21.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.634 -0.667 . . . . 0.0 110.756 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -57.36 -37.11 72.1 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.319 -0.863 . . . . 0.0 110.615 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.5 t -60.08 -34.85 74.02 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.512 -0.742 . . . . 0.0 110.489 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.588 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.5 mtt -59.96 -40.02 87.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.483 -0.761 . . . . 0.0 110.495 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.35 -40.02 89.24 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.726 . . . . 0.0 110.334 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -66.37 -39.98 89.44 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.588 -0.695 . . . . 0.0 110.108 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.2 m -60.59 -46.8 88.88 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.484 -0.76 . . . . 0.0 110.171 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp . . . . . 0 N--CA 1.497 1.909 0 O-C-N 121.521 -0.737 . . . . 0.0 110.205 -179.893 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.562 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.03 0.443 . . . . 0.0 110.112 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.849 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp . . . . . 0 N--CA 1.496 1.827 0 O-C-N 121.686 -0.634 . . . . 0.0 110.472 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.588 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.8 mt-10 . . . . . 0 N--CA 1.497 1.895 0 CA-C-O 121.046 0.451 . . . . 0.0 110.365 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.38 131.57 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.566 -0.709 . . . . 0.0 109.97 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -124.22 158.85 31.48 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.563 -0.711 . . . . 0.0 110.177 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.2 t -93.28 114.74 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.626 -0.671 . . . . 0.0 109.911 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.884 HG11 HD21 ' A' ' 64' ' ' LEU . 61.3 t -116.32 139.6 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 21.9 m -146.84 173.88 11.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.322 -0.861 . . . . 0.0 111.167 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.6 p -129.83 -179.17 5.04 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.836 -0.54 . . . . 0.0 109.576 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.26 -7.99 52.39 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.677 -0.639 . . . . 0.0 111.05 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -108.71 -37.61 5.85 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.118 -0.988 . . . . 0.0 111.772 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -152.83 169.25 23.25 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.172 -0.955 . . . . 0.0 111.299 -179.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 30.3 t -121.7 147.16 46.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.541 -0.725 . . . . 0.0 110.656 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 21.0 p90 -159.44 -177.72 6.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.78 HD11 ' HA ' ' A' ' 109' ' ' ARG . 82.7 mt -113.18 157.4 21.74 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.383 -0.823 . . . . 0.0 110.225 -178.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -134.89 146.5 49.26 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.492 -0.755 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.544 HG23 HD12 ' A' ' 94' ' ' LEU . 35.2 m -100.82 124.87 47.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.639 -0.663 . . . . 0.0 110.029 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.9 t -87.15 103.13 15.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.584 -0.697 . . . . 0.0 110.164 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.31 130.37 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.61 -0.681 . . . . 0.0 109.631 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 37.5 t30 57.15 39.41 28.96 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.423 -0.798 . . . . 0.0 110.606 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.729 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.97 20.61 76.36 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.01 130.03 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.257 -1.143 . . . . 0.0 109.976 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -74.5 140.34 44.48 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.455 -0.778 . . . . 0.0 109.275 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 62.6 m95 -132.07 137.38 47.75 Favored 'General case' 0 N--CA 1.494 1.746 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.792 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.682 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 11.8 t -160.06 -179.65 7.96 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.778 HG21 ' CE1' ' A' ' 57' ' ' HIS . 13.4 p -78.94 161.28 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 111.295 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 48.8 t80 -74.12 -41.92 60.86 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.686 -0.634 . . . . 0.0 111.613 -179.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.778 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -59.11 -24.62 63.12 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.155 -0.966 . . . . 0.0 110.707 -178.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.437 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -72.58 -50.45 15.07 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.996 -2.042 . . . . 0.0 107.996 178.222 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.407 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -148.58 78.23 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.752 -0.852 . . . . 0.0 109.45 179.015 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.481 ' HA2' HG11 ' A' ' 83' ' ' VAL . . . -84.63 102.82 2.59 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.294 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 21.4 p 48.97 56.03 8.38 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.68 -0.894 . . . . 0.0 111.468 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -139.82 174.76 10.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -64.91 139.2 58.74 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 120.044 -0.662 . . . . 0.0 109.6 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.897 HD22 ' CE2' ' A' ' 85' ' ' TRP . 12.0 tp -116.29 157.63 24.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.619 -0.676 . . . . 0.0 110.333 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -134.4 109.56 8.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.696 -0.628 . . . . 0.0 109.727 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.25 -164.01 15.69 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.78 -32.65 8.98 Favored 'Trans proline' 0 N--CA 1.49 1.31 0 O-C-N 123.95 1.5 . . . . 0.0 110.378 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 58.6 tptt -75.73 -31.19 59.5 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.681 -0.637 . . . . 0.0 109.823 -179.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.53 -149.21 20.91 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.14 141.09 20.44 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.89 1.468 . . . . 0.0 110.13 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.601 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.3 mt -130.02 140.07 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.483 -0.761 . . . . 0.0 110.259 -179.709 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.7 t -85.1 137.27 33.14 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.533 -0.729 . . . . 0.0 110.514 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 24.9 tt0 -77.12 141.14 40.32 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.509 -0.744 . . . . 0.0 110.662 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.1 mmm -110.71 -29.02 8.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.629 -0.669 . . . . 0.0 110.365 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.0 139.99 51.64 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.492 -0.755 . . . . 0.0 110.662 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 32.0 m -137.83 136.62 37.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.549 -0.719 . . . . 0.0 110.09 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . 0.516 ' OD1' HG21 ' A' ' 178' ' ' THR . 26.4 m120 -149.75 92.15 1.88 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.528 -0.733 . . . . 0.0 110.461 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 92.1 t -70.0 -43.53 79.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.545 -0.722 . . . . 0.0 110.055 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -60.1 -43.77 95.33 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.482 -0.761 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.632 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.5 tp60 -90.11 0.08 57.34 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.553 -0.717 . . . . 0.0 110.881 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.456 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.1 t0 54.09 46.24 25.84 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.039 -1.038 . . . . 0.0 110.289 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.856 HD21 ' NH2' ' A' ' 155' ' ' ARG . 54.0 mt -134.03 147.58 50.97 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.514 -0.741 . . . . 0.0 110.959 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.508 HG23 ' CH2' ' A' ' 85' ' ' TRP . 16.1 m -150.25 168.89 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.646 -0.659 . . . . 0.0 109.786 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -163.36 157.84 30.09 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.897 ' CE2' HD22 ' A' ' 64' ' ' LEU . 9.9 m-90 -128.11 159.96 33.5 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.97 . . . . 0.0 109.813 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -67.13 113.06 4.78 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.521 -0.737 . . . . 0.0 109.597 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.729 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -78.35 135.16 61.65 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.522 -0.736 . . . . 0.0 110.265 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.95 159.97 51.32 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.83 1.437 . . . . 0.0 110.338 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.12 159.62 53.15 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 O-C-N 123.916 1.482 . . . . 0.0 110.286 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.17 -21.15 47.75 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.07 160.06 25.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.403 -1.057 . . . . 0.0 110.232 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 74.8 mtp85 -96.01 161.52 13.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.629 -0.669 . . . . 0.0 110.204 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 71.1 m -125.65 157.78 36.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.671 -0.643 . . . . 0.0 110.191 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.588 HD21 ' OE1' ' A' ' 32' ' ' GLU . 85.0 mt -110.01 132.17 54.4 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 110.559 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.1 p -78.04 159.95 74.73 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.601 -0.687 . . . . 0.0 110.05 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.6 163.91 28.85 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.8 1.421 . . . . 0.0 110.809 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.515 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -78.64 132.7 37.17 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.641 -0.662 . . . . 0.0 110.163 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.9 p -132.52 53.17 2.03 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.785 -0.572 . . . . 0.0 109.63 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.47 -8.48 0.76 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 119.907 -0.717 . . . . 0.0 112.412 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.03 34.21 82.56 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 80.3 p -83.62 138.13 33.49 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.51 -0.994 . . . . 0.0 110.448 -179.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.6 m -81.72 -30.98 32.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.559 -0.713 . . . . 0.0 110.385 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -69.99 130.06 41.17 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.53 -0.731 . . . . 0.0 110.187 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.1 mt -131.02 149.55 52.56 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.65 -0.656 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -119.97 113.91 21.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.52 -0.738 . . . . 0.0 109.701 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.419 HD13 HD11 ' A' ' 143' ' ' LEU . 39.7 tp -96.67 142.87 28.19 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.55 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.99 129.96 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.616 -0.677 . . . . 0.0 109.832 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 26.9 p -100.02 -172.31 2.2 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.488 -0.758 . . . . 0.0 110.567 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.78 ' HA ' HD11 ' A' ' 44' ' ' LEU . 86.9 mtm-85 -59.97 -28.98 68.12 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.586 -0.696 . . . . 0.0 110.57 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.26 20.04 5.45 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.603 -0.685 . . . . 0.0 111.018 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 26.33 6.7 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.115 -0.991 . . . . 0.0 110.745 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -80.07 159.99 25.95 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.605 -0.684 . . . . 0.0 109.911 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.4 t -109.97 119.95 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.569 -0.707 . . . . 0.0 109.97 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.59 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -114.32 110.0 48.29 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.68 . . . . 0.0 109.69 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.42 117.29 4.6 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.869 1.458 . . . . 0.0 110.354 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.0 t -120.05 129.13 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.701 -0.625 . . . . 0.0 109.737 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 mmm-85 -82.51 150.08 27.18 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.711 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -94.13 114.14 26.22 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -108.5 19.98 19.13 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.559 -0.713 . . . . 0.0 110.355 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.05 -178.54 40.07 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -61.32 -40.01 92.62 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.231 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.3 p -131.84 26.08 4.65 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.536 -0.728 . . . . 0.0 110.495 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.3 tpt180 -125.71 140.23 52.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.465 -0.772 . . . . 0.0 110.286 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.01 166.51 27.48 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 89.9 p -120.01 151.4 39.03 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.926 . . . . 0.0 110.265 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.421 HD23 ' O ' ' A' ' 128' ' ' SER . 6.3 tp -94.07 115.2 27.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.651 -0.656 . . . . 0.0 110.003 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.2 mp -62.15 -40.05 94.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.528 -0.732 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . 0.421 ' O ' HD23 ' A' ' 126' ' ' LEU . 54.4 m -108.98 119.99 47.23 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -66.01 121.03 8.27 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 O-C-N 123.799 1.421 . . . . 0.0 110.537 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.449 ' CD ' ' CE2' ' A' ' 134' ' ' TYR . 89.4 mtt-85 -128.88 160.44 63.32 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.618 -0.676 . . . . 0.0 110.136 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.06 163.76 32.75 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.94 1.495 . . . . 0.0 110.517 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 67.2 t -67.02 -40.04 84.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.646 -0.659 . . . . 0.0 110.344 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.9 p -53.87 -30.87 47.64 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.409 -0.807 . . . . 0.0 110.991 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . 0.449 ' CE2' ' CD ' ' A' ' 130' ' ' ARG . 36.9 t80 -60.06 -40.01 87.99 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.454 -0.779 . . . . 0.0 110.091 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.488 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 9.0 mp -87.92 -23.73 23.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.57 -0.706 . . . . 0.0 110.625 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 5.2 tptm -59.99 129.32 41.22 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.347 -0.846 . . . . 0.0 110.0 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.04 -10.05 75.3 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.2 m -104.04 16.79 25.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.164 -1.197 . . . . 0.0 110.877 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -69.94 151.82 45.18 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.08 -17.93 57.81 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.56 149.46 28.49 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.494 ' HB3' HG21 ' A' ' 46' ' ' THR . 55.3 Cg_endo -98.39 146.71 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.852 1.448 . . . . 0.0 111.263 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.3 mp -102.69 105.52 16.0 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.558 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -93.35 130.89 38.95 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.728 . . . . 0.0 111.363 -178.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -69.98 159.31 84.71 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.99 -23.04 15.77 Favored 'Trans proline' 0 N--CA 1.502 1.993 0 O-C-N 123.418 1.22 . . . . 0.0 112.144 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -65.71 -39.99 91.77 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.335 -0.853 . . . . 0.0 109.823 179.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.71 35.3 0.85 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.0 m170 -132.72 146.02 51.51 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.456 -1.026 . . . . 0.0 110.3 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.79 140.02 58.83 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.623 -0.673 . . . . 0.0 110.201 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.735 ' O ' HG23 ' A' ' 172' ' ' VAL . 47.0 t -111.1 -51.06 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.523 -0.736 . . . . 0.0 109.995 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -160.35 -172.21 27.29 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.6 mt -128.23 135.71 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.585 -0.95 . . . . 0.0 110.352 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.719 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.6 t80 -64.16 134.81 55.56 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 109.582 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . 0.856 ' NH2' HD21 ' A' ' 82' ' ' LEU . 1.4 ttm105 -120.44 -52.45 2.15 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.489 -0.757 . . . . 0.0 110.733 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -142.25 157.29 45.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.751 . . . . 0.0 110.264 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.719 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -119.87 139.16 52.82 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 110.493 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -92.44 117.14 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.67 160.02 40.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.465 -0.772 . . . . 0.0 111.647 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 35.8 p -139.31 139.26 37.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.815 -0.553 . . . . 0.0 109.509 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.0 mtm180 55.62 30.87 16.18 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.466 -0.771 . . . . 0.0 110.539 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.02 22.89 64.84 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.1 t -129.53 129.73 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.341 -1.094 . . . . 0.0 109.89 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.06 129.98 46.17 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.542 -0.724 . . . . 0.0 110.5 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -118.83 -30.05 5.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.55 -0.719 . . . . 0.0 110.732 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -136.4 157.41 46.85 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.442 -0.786 . . . . 0.0 110.229 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.8 m -135.46 157.51 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.558 -0.714 . . . . 0.0 110.757 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -120.27 135.82 54.87 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.599 -0.688 . . . . 0.0 109.809 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -137.01 154.5 50.38 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.698 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.455 HG11 HD11 ' A' ' 82' ' ' LEU . 95.8 t -98.27 125.07 44.75 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.572 -0.705 . . . . 0.0 109.183 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -62.35 155.9 54.54 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 O-C-N 123.713 1.375 . . . . 0.0 110.797 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.3 t -56.19 -21.64 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.674 -0.641 . . . . 0.0 110.853 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -56.7 -37.25 70.64 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.362 -0.836 . . . . 0.0 110.768 -179.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 28.2 t -59.99 -44.54 94.45 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.392 -0.817 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 78.0 mtm -67.34 -39.92 85.85 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -60.3 -40.58 91.01 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -62.84 -40.04 96.2 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.616 -0.677 . . . . 0.0 110.055 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . 0.516 HG21 ' OD1' ' A' ' 77' ' ' ASN . 94.5 m -60.95 -40.04 91.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.6 -0.687 . . . . 0.0 110.056 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.496 1.84 0 O-C-N 121.534 -0.729 . . . . 0.0 110.259 -179.851 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 44.4 tp10 . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 121.048 0.452 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.776 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp . . . . . 0 N--CA 1.497 1.899 0 O-C-N 121.598 -0.689 . . . . 0.0 110.07 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 33' ' ' VAL . 4.7 pt-20 . . . . . 0 N--CA 1.496 1.875 0 CA-C-O 120.928 0.394 . . . . 0.0 110.513 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.694 HG23 ' HG3' ' A' ' 32' ' ' GLU . 58.3 t -109.99 127.25 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.495 -0.753 . . . . 0.0 109.695 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -131.68 156.84 45.17 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.672 . . . . 0.0 110.376 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 35' ' ' VAL . 32.6 m -90.08 118.58 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.705 -0.622 . . . . 0.0 110.387 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.831 HG11 HD21 ' A' ' 64' ' ' LEU . 48.2 t -114.85 141.04 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.469 -0.769 . . . . 0.0 109.288 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 19.3 m -146.59 -178.92 6.42 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.748 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.3 p -141.49 -168.63 2.69 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.846 -0.534 . . . . 0.0 110.239 -179.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.47 -35.11 67.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.594 -0.691 . . . . 0.0 111.511 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.4 t -137.33 -8.01 1.74 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.266 -0.896 . . . . 0.0 113.033 -178.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 19.1 tp60 -115.38 143.71 44.88 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.881 -1.137 . . . . 0.0 110.88 -179.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.9 m -129.29 138.69 51.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.749 -0.595 . . . . 0.0 109.835 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.737 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.9 p90 -166.5 -177.52 4.03 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.46 -0.775 . . . . 0.0 110.466 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.2 mt -112.98 146.43 39.06 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.557 -0.714 . . . . 0.0 110.172 -178.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . . . -128.68 161.21 30.21 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.631 -0.668 . . . . 0.0 110.261 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.476 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.1 t -121.3 140.55 51.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.558 -0.714 . . . . 0.0 110.146 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.9 t -97.42 110.08 22.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.579 -0.701 . . . . 0.0 110.352 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.2 130.0 62.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 109.476 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 55.67 40.0 30.89 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.483 -0.761 . . . . 0.0 110.762 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.06 22.15 77.16 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.255 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -131.84 130.0 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.235 -1.156 . . . . 0.0 110.123 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -72.09 146.0 47.83 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.452 -0.78 . . . . 0.0 109.296 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -139.97 137.2 34.53 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.357 -0.839 . . . . 0.0 111.645 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.709 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 13.4 t -161.09 173.88 14.52 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.755 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.9 p -78.64 150.37 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.267 -0.896 . . . . 0.0 110.838 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.534 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.2 t80 -60.05 -49.2 78.59 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.58 -0.7 . . . . 0.0 111.894 -178.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.79 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.4 p-80 -57.94 -24.41 57.78 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.029 -1.044 . . . . 0.0 110.926 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.512 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.48 -46.31 15.51 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 178.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.737 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -136.38 94.53 3.03 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.723 -0.869 . . . . 0.0 109.433 179.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.73 -166.62 3.39 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.0 p -71.57 69.62 0.63 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.622 -0.928 . . . . 0.0 109.964 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.3 178.76 7.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.559 -0.713 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 31.0 p -65.54 147.38 53.51 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.713 . . . . 0.0 109.619 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.831 HD21 HG11 ' A' ' 36' ' ' VAL . 12.9 tp -113.1 133.4 55.03 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.611 -0.681 . . . . 0.0 109.99 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.03 109.63 21.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.617 -0.677 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.72 -171.74 17.76 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.24 -32.55 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.908 1.478 . . . . 0.0 110.456 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -76.14 -31.31 58.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.584 -0.698 . . . . 0.0 109.787 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.01 -146.15 17.24 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.7 144.43 31.4 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.895 1.471 . . . . 0.0 110.182 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.582 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.8 mt -130.03 140.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.485 -0.759 . . . . 0.0 110.316 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.3 m -86.05 136.3 33.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.529 -0.732 . . . . 0.0 110.288 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -83.38 149.49 26.68 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.589 -0.694 . . . . 0.0 110.959 -179.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 82.1 mtp -119.27 -18.92 8.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.666 -0.646 . . . . 0.0 110.986 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -128.12 147.98 50.56 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.245 -0.909 . . . . 0.0 110.588 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.8 p -144.49 126.0 14.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.743 -0.598 . . . . 0.0 109.975 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -142.48 90.75 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.62 -0.675 . . . . 0.0 110.053 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.534 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 86.7 t -69.82 -46.69 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.579 -0.7 . . . . 0.0 109.911 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -41.82 92.85 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.594 -0.691 . . . . 0.0 110.277 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.545 ' HG2' HD12 ' A' ' 82' ' ' LEU . 45.3 tt0 -90.31 -0.11 57.49 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.571 -0.706 . . . . 0.0 111.149 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 1.6 t70 53.25 44.49 30.1 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.99 -1.069 . . . . 0.0 110.85 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.776 HD11 HG11 ' A' ' 170' ' ' VAL . 45.5 mt -132.93 146.53 51.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.3 -0.875 . . . . 0.0 111.12 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.525 HG23 ' CH2' ' A' ' 85' ' ' TRP . 30.6 m -152.83 169.58 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.65 -0.656 . . . . 0.0 109.667 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -164.9 157.78 30.35 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.709 ' HZ3' HG22 ' A' ' 54' ' ' THR . 10.2 m-90 -128.67 168.1 16.27 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.66 -0.906 . . . . 0.0 109.835 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 54.8 tp60 -70.85 119.38 14.9 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.444 -0.785 . . . . 0.0 109.375 179.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.52 149.91 95.58 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.532 -0.73 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.96 154.34 67.04 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.884 1.465 . . . . 0.0 110.369 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.42 152.98 74.97 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.941 1.495 . . . . 0.0 110.178 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 30.0 70.42 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.79 147.74 30.44 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.481 -1.011 . . . . 0.0 110.12 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.4 mtp85 -88.82 150.05 23.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.575 -0.703 . . . . 0.0 109.958 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -126.95 169.91 12.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.605 -0.685 . . . . 0.0 110.111 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.635 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -109.15 137.4 47.11 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.581 -0.699 . . . . 0.0 110.738 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . 0.411 ' OG1' ' CE1' ' A' ' 149' ' ' HIS . 3.3 p -79.29 165.68 46.86 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.652 -0.655 . . . . 0.0 109.904 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -80.11 153.29 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.827 1.435 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.778 ' HB2' HG22 ' A' ' 151' ' ' VAL . 50.3 t -65.04 131.63 47.09 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.663 -0.648 . . . . 0.0 110.117 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.2 t -135.97 54.26 1.91 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.714 -0.616 . . . . 0.0 109.727 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.89 -7.87 0.73 Allowed 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.599 -0.688 . . . . 0.0 112.322 -179.127 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.76 33.82 87.95 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.9 p -95.8 132.46 41.01 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.543 -0.975 . . . . 0.0 110.406 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.3 m -80.0 -26.65 39.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.641 . . . . 0.0 110.409 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -66.4 129.92 41.46 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.435 -0.791 . . . . 0.0 110.296 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.555 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.3 mt -131.29 157.13 44.12 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.54 -0.725 . . . . 0.0 110.558 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -119.94 115.73 24.36 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.528 -0.732 . . . . 0.0 109.876 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.61 HD13 HD11 ' A' ' 143' ' ' LEU . 65.0 tp -93.37 138.28 31.86 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.578 -0.701 . . . . 0.0 110.699 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.2 t -97.89 130.05 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.688 -0.633 . . . . 0.0 109.524 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -106.43 165.67 11.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.453 -0.779 . . . . 0.0 110.509 -179.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.656 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.3 mtp180 -59.99 -27.34 66.78 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.627 -0.671 . . . . 0.0 110.489 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.8 t60 -94.49 29.22 2.32 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.528 -0.732 . . . . 0.0 110.62 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.28 39.95 31.3 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.236 -0.915 . . . . 0.0 110.777 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -104.62 127.62 52.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.612 -0.68 . . . . 0.0 109.972 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 120.13 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.498 -0.751 . . . . 0.0 109.993 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 40.2 pt -114.44 146.9 36.84 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.616 -0.678 . . . . 0.0 109.975 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -87.03 113.04 0.96 Allowed 'Trans proline' 0 N--CA 1.49 1.271 0 O-C-N 123.852 1.448 . . . . 0.0 110.531 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.0 119.94 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 109.517 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -79.34 136.95 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.493 -0.754 . . . . 0.0 110.259 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -80.01 129.6 34.62 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.661 -0.649 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -124.64 23.6 8.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.544 -0.722 . . . . 0.0 110.292 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.78 -177.92 47.41 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -68.75 -39.96 80.03 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.57 -0.959 . . . . 0.0 110.429 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.7 p -129.84 26.18 5.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.525 -0.735 . . . . 0.0 110.506 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.89 159.99 35.78 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.534 -0.729 . . . . 0.0 110.253 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -153.1 172.72 32.05 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.7 p -126.36 147.0 49.82 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.529 -0.983 . . . . 0.0 110.227 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.7 mp -99.79 121.14 40.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.547 -0.721 . . . . 0.0 110.256 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -60.88 -40.02 91.43 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.703 . . . . 0.0 109.955 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.7 m -109.95 112.91 57.65 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.588 -0.695 . . . . 0.0 109.967 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -64.19 127.47 19.32 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 123.845 1.445 . . . . 0.0 110.515 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 31.8 mtt-85 -127.04 160.04 61.61 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.568 -0.708 . . . . 0.0 110.041 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.09 146.43 81.95 Favored 'Trans proline' 0 N--CA 1.49 1.303 0 O-C-N 123.953 1.501 . . . . 0.0 110.303 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.636 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.1 m -60.03 -27.06 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.613 -0.679 . . . . 0.0 110.547 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -59.94 -40.06 87.64 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.468 -0.77 . . . . 0.0 110.389 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -65.36 -39.94 92.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.469 -0.77 . . . . 0.0 110.116 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.458 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -70.36 -27.16 64.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.595 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -58.21 140.04 53.84 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.388 -0.82 . . . . 0.0 110.448 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 87.28 6.98 77.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 56.0 p -111.43 -4.27 14.92 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.026 -1.279 . . . . 0.0 111.245 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.3 m -59.96 140.05 56.99 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.057 -1.027 . . . . 0.0 109.777 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.501 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 98.32 -23.7 35.06 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.65 150.08 42.65 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.692 ' C ' HD12 ' A' ' 143' ' ' LEU . 52.3 Cg_endo -91.8 156.74 3.43 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.785 1.413 . . . . 0.0 111.571 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.692 HD12 ' C ' ' A' ' 142' ' ' PRO . 9.8 mp -116.4 102.99 10.01 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.623 HD21 HD22 ' A' ' 94' ' ' LEU . 9.9 mp -94.79 133.19 38.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.561 -0.712 . . . . 0.0 111.661 -178.358 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.05 159.37 84.56 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.8 Cg_endo -52.61 -26.16 28.39 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 O-C-N 123.505 1.266 . . . . 0.0 112.276 -178.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.2 m -62.51 -40.06 95.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.32 39.52 0.58 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . 0.411 ' CE1' ' OG1' ' A' ' 95' ' ' THR . 3.6 m-70 -137.28 144.96 42.95 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.478 -1.013 . . . . 0.0 110.039 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.635 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -66.62 140.01 57.91 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.552 -0.717 . . . . 0.0 110.244 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 97' ' ' CYS . 63.0 t -112.63 -36.25 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.581 -0.7 . . . . 0.0 109.814 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.91 -168.51 38.75 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.751 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.7 mt -129.56 140.1 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.543 -0.975 . . . . 0.0 110.216 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -60.56 136.4 58.04 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.632 -0.667 . . . . 0.0 109.91 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.9 ttt180 -115.72 -52.22 2.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.532 -0.73 . . . . 0.0 110.369 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . 0.569 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -156.12 160.04 39.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.529 -0.732 . . . . 0.0 110.294 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.72 151.06 28.18 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.645 -0.659 . . . . 0.0 110.311 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.91 119.51 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.672 -0.643 . . . . 0.0 109.68 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.636 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -135.02 154.38 51.74 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.634 -0.666 . . . . 0.0 110.305 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.3 m -103.02 -48.68 3.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.549 -0.72 . . . . 0.0 110.653 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.5 mtm180 -131.04 50.2 2.25 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.53 -0.731 . . . . 0.0 110.373 -179.457 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.97 -4.36 83.16 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 59.6 t -113.29 129.4 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -1.21 . . . . 0.0 109.688 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -99.97 123.95 44.77 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.589 -0.694 . . . . 0.0 110.595 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.25 -18.35 13.62 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.59 -0.694 . . . . 0.0 110.698 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.48 153.7 43.89 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.328 -0.858 . . . . 0.0 110.224 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.75 163.58 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.517 -0.74 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -122.18 134.14 54.72 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.653 -0.654 . . . . 0.0 110.224 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -132.25 157.42 44.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.44 -0.787 . . . . 0.0 110.227 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.776 HG11 HD11 ' A' ' 82' ' ' LEU . 58.0 t -93.43 120.67 66.29 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.572 -0.705 . . . . 0.0 109.589 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.33 148.72 84.82 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.762 1.401 . . . . 0.0 110.492 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.5 -23.58 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.734 -0.604 . . . . 0.0 110.738 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -59.51 -34.58 72.78 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.626 -179.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.7 p -69.75 -37.37 76.43 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.493 -0.755 . . . . 0.0 110.435 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.751 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.1 mtt -59.96 -50.01 75.43 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.458 -0.776 . . . . 0.0 110.873 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -64.49 -29.3 70.34 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.494 -0.754 . . . . 0.0 110.359 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -60.51 -42.56 96.65 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.455 -0.778 . . . . 0.0 110.021 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -70.0 -40.8 75.07 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp . . . . . 0 N--CA 1.497 1.893 0 O-C-N 121.528 -0.732 . . . . 0.0 110.331 -179.872 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . 0.569 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.4 tt0 . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.053 0.454 . . . . 0.0 110.15 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.79 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.6 mp . . . . . 0 N--CA 1.493 1.715 0 O-C-N 121.531 -0.731 . . . . 0.0 110.245 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 . . . . . 0 N--CA 1.497 1.883 0 CA-C-O 121.039 0.447 . . . . 0.0 110.298 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.34 130.04 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 109.757 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -128.03 158.56 37.59 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.54 -0.725 . . . . 0.0 110.53 -179.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.2 t -95.27 128.43 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 0.0 109.499 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.565 ' CB ' HD21 ' A' ' 64' ' ' LEU . 29.2 m -129.3 158.97 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.591 -0.693 . . . . 0.0 109.83 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -153.46 164.04 38.89 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.8 p -118.71 -169.68 1.76 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.635 -0.665 . . . . 0.0 109.598 179.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.99 -34.31 73.14 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.586 -0.696 . . . . 0.0 110.985 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 54.7 p -131.21 -10.69 3.71 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.184 -0.947 . . . . 0.0 112.64 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.2 tp60 -117.92 153.42 33.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.92 -1.113 . . . . 0.0 111.289 -179.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 35.2 t -138.44 138.31 38.04 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.623 -0.673 . . . . 0.0 109.736 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.78 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 22.4 p90 -167.24 -178.08 3.94 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.305 -0.872 . . . . 0.0 110.527 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.677 HD11 ' HA ' ' A' ' 109' ' ' ARG . 66.4 mt -113.61 157.61 21.89 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.619 -0.676 . . . . 0.0 110.649 -178.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -135.24 162.29 32.97 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.742 -0.599 . . . . 0.0 110.112 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -124.63 139.8 53.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.3 t -97.57 113.94 25.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.411 -0.806 . . . . 0.0 110.619 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . 0.427 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 61.4 t -121.03 133.88 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.609 -0.682 . . . . 0.0 109.945 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.54 39.95 27.39 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.509 -0.745 . . . . 0.0 111.256 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 67.9 26.89 73.78 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 178.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 65.5 t -140.02 138.59 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.468 -1.019 . . . . 0.0 109.696 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -81.07 147.37 30.16 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 109.298 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . 0.524 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 61.1 m95 -130.13 153.06 48.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.455 -0.778 . . . . 0.0 110.868 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.5 t -169.62 -179.5 3.39 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.842 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.1 p -95.25 144.87 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.476 -0.765 . . . . 0.0 110.473 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.431 ' CE1' HG22 ' A' ' 78' ' ' VAL . 64.9 t80 -60.47 -42.59 96.54 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.716 -0.615 . . . . 0.0 111.694 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.842 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.9 p-80 -70.02 -20.14 63.28 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.043 -1.036 . . . . 0.0 110.895 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.732 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -89.19 -43.32 5.34 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.78 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -132.6 85.05 2.19 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.668 -0.901 . . . . 0.0 109.804 179.462 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.2 -168.8 1.55 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.5 p -72.78 67.45 0.81 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.618 -0.93 . . . . 0.0 109.707 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -140.02 169.78 17.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.622 -0.674 . . . . 0.0 110.476 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.9 m -65.53 139.58 58.49 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.676 -0.64 . . . . 0.0 110.088 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.952 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.4 tp -115.3 133.47 56.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.625 -0.672 . . . . 0.0 109.801 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.78 119.37 30.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.555 -0.716 . . . . 0.0 110.334 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -125.42 176.37 17.25 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.03 -32.18 75.92 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.788 1.415 . . . . 0.0 110.455 -179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.2 mmtt -70.21 -31.39 68.81 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.555 -0.716 . . . . 0.0 109.782 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.31 -151.12 22.38 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.87 154.65 63.26 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.886 1.466 . . . . 0.0 110.131 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.431 HG22 ' CD1' ' A' ' 85' ' ' TRP . 86.0 mt -129.98 139.91 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.56 -0.713 . . . . 0.0 110.675 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.5 m -100.57 138.8 37.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.589 -0.694 . . . . 0.0 110.274 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 143.81 51.91 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.562 -0.711 . . . . 0.0 110.817 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . 0.436 ' HB3' ' CD2' ' A' ' 75' ' ' TYR . 5.5 mtp -119.16 -50.03 2.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.532 -0.73 . . . . 0.0 110.452 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . 0.436 ' CD2' ' HB3' ' A' ' 74' ' ' MET . 98.8 m-85 -120.0 140.01 51.61 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.754 . . . . 0.0 110.462 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . 0.599 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.5 m -136.03 133.02 37.0 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.556 -0.715 . . . . 0.0 110.411 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.7 t30 -145.83 100.56 3.43 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.495 -0.753 . . . . 0.0 109.98 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.431 HG22 ' CE1' ' A' ' 56' ' ' TYR . 59.8 t -69.98 -36.66 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.543 -0.723 . . . . 0.0 110.312 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -59.95 -50.0 75.48 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.469 -0.77 . . . . 0.0 110.981 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.5 mm-40 -90.47 0.15 57.43 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.466 -0.771 . . . . 0.0 111.309 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.6 t70 55.33 40.09 31.41 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.921 -1.112 . . . . 0.0 109.747 -179.41 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.465 ' CD2' HG21 ' A' ' 170' ' ' VAL . 0.6 OUTLIER -125.24 132.34 52.98 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.671 -0.643 . . . . 0.0 110.742 -179.07 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 54' ' ' THR . 27.1 m -145.08 157.16 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.645 -0.659 . . . . 0.0 109.462 179.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -144.84 175.03 24.72 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.594 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.952 ' CH2' HD22 ' A' ' 64' ' ' LEU . 8.5 m-90 -130.04 159.97 35.11 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.916 -0.755 . . . . 0.0 109.631 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -66.53 123.33 19.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.365 -0.834 . . . . 0.0 109.152 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -79.37 139.74 55.89 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.504 -0.747 . . . . 0.0 110.193 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HG2' ' HB2' ' A' ' 91' ' ' ALA . 48.3 Cg_endo -69.98 159.17 54.2 Favored 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.824 1.434 . . . . 0.0 110.4 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.52 136.1 27.76 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.961 1.506 . . . . 0.0 110.286 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.13 -24.16 33.39 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . 0.465 ' HB2' ' HG2' ' A' ' 88' ' ' PRO . . . -60.1 140.01 57.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.374 -1.074 . . . . 0.0 110.3 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -80.91 158.9 25.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.635 -0.666 . . . . 0.0 109.659 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.8 p -130.49 168.93 16.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.521 -0.737 . . . . 0.0 110.325 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.421 ' O ' HG13 ' A' ' 48' ' ' VAL . 84.5 mt -112.94 140.01 48.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.561 -0.712 . . . . 0.0 110.702 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 44.6 p -82.1 165.54 42.4 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.647 -0.658 . . . . 0.0 110.142 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -81.63 162.04 19.14 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.797 1.42 . . . . 0.0 110.662 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -73.66 130.16 39.45 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.64 -0.662 . . . . 0.0 110.137 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.97 54.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.741 -0.599 . . . . 0.0 109.816 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.73 -8.49 0.73 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.713 . . . . 0.0 112.383 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 42.85 97.29 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -100.0 119.97 39.1 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.522 -0.987 . . . . 0.0 110.531 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.9 m -62.78 -40.08 96.19 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.649 -0.657 . . . . 0.0 110.296 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -63.41 130.47 44.57 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.583 -0.698 . . . . 0.0 110.261 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 151' ' ' VAL . 95.8 mt -137.97 155.37 48.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.617 -0.677 . . . . 0.0 110.577 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -106.69 135.58 47.98 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.465 -0.772 . . . . 0.0 109.545 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.506 HD11 ' HB2' ' A' ' 154' ' ' PHE . 39.8 tp -105.09 127.21 52.79 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.449 -0.782 . . . . 0.0 110.747 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 140.03 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.536 -0.727 . . . . 0.0 109.777 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.2 m -130.07 170.06 14.49 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.524 -0.735 . . . . 0.0 110.516 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.677 ' HA ' HD11 ' A' ' 44' ' ' LEU . 44.2 mtm180 -60.04 -23.2 63.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.51 -0.744 . . . . 0.0 110.781 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.11 19.37 5.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.395 -0.816 . . . . 0.0 111.194 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.49 39.9 30.63 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.077 -1.015 . . . . 0.0 110.693 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -113.27 157.65 21.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.533 -0.729 . . . . 0.0 109.955 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.4 m -129.43 133.68 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.52 -0.738 . . . . 0.0 110.371 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 49.0 mm -122.48 147.82 51.16 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.602 -0.687 . . . . 0.0 109.701 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . 0.437 ' HG2' HD22 ' A' ' 127' ' ' LEU . 48.6 Cg_endo -82.65 129.75 5.74 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.906 1.477 . . . . 0.0 110.378 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 125' ' ' SER . 63.0 t -130.0 130.02 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.697 -0.627 . . . . 0.0 109.602 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . 0.589 ' HG2' HD11 ' A' ' 127' ' ' LEU . 54.2 mmm-85 -79.53 153.1 29.78 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.517 -0.74 . . . . 0.0 110.276 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 51.4 ttt-85 -99.34 119.07 37.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.64 -0.662 . . . . 0.0 109.921 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.1 mmm-85 -114.6 24.34 11.93 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.671 -0.643 . . . . 0.0 110.219 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 162.07 -175.41 38.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -64.57 -39.97 94.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.53 -0.982 . . . . 0.0 110.378 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 52.8 p -130.87 28.87 4.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.543 -0.723 . . . . 0.0 110.753 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.6 tpp85 -132.44 146.63 52.09 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.422 -0.799 . . . . 0.0 110.656 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -160.69 169.83 36.48 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.423 ' O ' HG13 ' A' ' 116' ' ' VAL . 53.3 p -109.24 158.38 17.91 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.468 -1.019 . . . . 0.0 110.234 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.7 tp -102.02 119.94 39.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.541 -0.725 . . . . 0.0 110.152 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.589 HD11 ' HG2' ' A' ' 117' ' ' ARG . 7.6 mp -65.44 -40.04 92.79 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.988 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.8 109.94 59.35 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -66.14 118.68 5.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.82 1.432 . . . . 0.0 110.415 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -120.04 160.01 44.75 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.598 -0.689 . . . . 0.0 110.127 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.2 157.93 54.93 Favored 'Trans proline' 0 N--CA 1.491 1.352 0 O-C-N 123.919 1.484 . . . . 0.0 110.242 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.421 HG21 ' SG ' ' A' ' 159' ' ' CYS . 63.4 t -67.13 -30.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.601 -0.687 . . . . 0.0 110.191 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.6 p -60.04 -39.74 86.97 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.515 -0.74 . . . . 0.0 110.414 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -64.35 -40.02 95.03 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.566 -0.709 . . . . 0.0 110.222 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.448 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.02 -30.75 68.14 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.453 -0.779 . . . . 0.0 110.555 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -60.04 142.75 53.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.469 -0.769 . . . . 0.0 110.218 -179.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.96 8.72 87.41 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 17.5 m -113.37 -7.73 13.47 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.182 -1.187 . . . . 0.0 110.966 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 30.6 t -59.92 140.33 56.76 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.091 -1.005 . . . . 0.0 109.99 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.401 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.3 -21.23 42.05 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -61.45 145.05 48.85 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.42 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.1 Cg_endo -86.88 142.16 6.52 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.836 1.44 . . . . 0.0 111.262 -179.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.736 ' O ' HG12 ' A' ' 151' ' ' VAL . 9.7 mp -101.25 122.09 43.04 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 143' ' ' LEU . 10.0 mp -112.13 133.77 54.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.474 -0.766 . . . . 0.0 111.537 -178.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.439 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.08 160.03 82.1 Favored Pre-proline 0 N--CA 1.497 1.912 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.072 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -52.13 -23.02 16.32 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 O-C-N 123.464 1.244 . . . . 0.0 112.235 -178.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -65.84 -40.01 91.34 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.325 -0.859 . . . . 0.0 109.854 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.99 34.33 0.91 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -131.68 145.52 51.69 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.464 -1.021 . . . . 0.0 110.326 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.29 137.19 46.55 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.545 -0.722 . . . . 0.0 110.265 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.736 HG12 ' O ' ' A' ' 143' ' ' LEU . 9.2 p -115.54 -22.49 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.536 -0.728 . . . . 0.0 110.696 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.65 -170.93 43.51 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . 0.401 HG23 ' C ' ' A' ' 140' ' ' GLY . 63.5 mt -129.93 140.03 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.595 -0.944 . . . . 0.0 110.055 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.506 ' HB2' HD11 ' A' ' 106' ' ' LEU . 20.7 t80 -61.64 138.24 58.29 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.652 -0.655 . . . . 0.0 109.911 179.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -118.49 -52.3 2.37 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.545 -0.722 . . . . 0.0 110.563 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.11 160.39 42.9 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.57 -0.706 . . . . 0.0 110.403 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.94 147.58 39.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.599 -0.688 . . . . 0.0 110.384 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.01 120.03 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.677 -0.64 . . . . 0.0 109.642 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.421 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -125.93 143.99 50.86 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.645 -0.659 . . . . 0.0 110.631 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . 0.511 HG22 ' HG2' ' A' ' 161' ' ' ARG . 58.6 m -82.01 -56.42 3.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.663 . . . . 0.0 110.44 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.511 ' HG2' HG22 ' A' ' 160' ' ' THR . 20.8 mmt180 -134.7 58.0 1.79 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.529 -0.732 . . . . 0.0 110.08 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.4 -10.0 75.76 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.86 121.35 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.128 -1.219 . . . . 0.0 109.688 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -78.83 128.3 33.18 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.631 -0.668 . . . . 0.0 110.552 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -111.5 -25.97 9.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.639 -0.663 . . . . 0.0 110.398 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.36 159.17 42.78 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.585 -0.697 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.8 160.01 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.539 -0.726 . . . . 0.0 111.006 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -121.76 133.88 54.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.682 -0.636 . . . . 0.0 110.055 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -138.18 151.44 47.71 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.421 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.465 HG21 ' CD2' ' A' ' 82' ' ' LEU . 57.3 t -88.09 123.42 68.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.497 -0.752 . . . . 0.0 109.505 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.34 155.13 71.76 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.764 1.402 . . . . 0.0 110.56 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 151' ' ' VAL . 88.9 t -58.24 -21.74 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.681 -0.637 . . . . 0.0 110.654 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -57.64 -40.01 78.27 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.268 -0.895 . . . . 0.0 110.656 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 3.4 m -73.65 -35.32 65.24 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.448 -0.783 . . . . 0.0 109.683 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . 0.524 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 95.0 mtp -63.14 -40.48 97.71 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.66 -0.65 . . . . 0.0 110.133 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -69.54 -39.92 77.17 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.611 -0.681 . . . . 0.0 110.381 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.9 m -65.48 -39.97 92.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.662 -0.649 . . . . 0.0 110.075 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 90.5 m -61.72 -48.62 79.91 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.533 -0.729 . . . . 0.0 110.069 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . 0.4 ' HG3' ' CZ ' ' A' ' 75' ' ' TYR . 26.6 ttt . . . . . 0 N--CA 1.496 1.852 0 O-C-N 121.56 -0.712 . . . . 0.0 110.308 -179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.108 0.48 . . . . 0.0 110.071 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.789 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.2 mp . . . . . 0 N--CA 1.496 1.829 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.432 ' HB3' ' CD2' ' A' ' 94' ' ' LEU . 45.3 mt-10 . . . . . 0 N--CA 1.5 2.044 0 CA-C-O 120.816 0.341 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.427 HG23 ' C ' ' A' ' 32' ' ' GLU . 65.9 t -147.76 131.86 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.386 -0.821 . . . . 0.0 109.647 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -124.72 155.17 39.7 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.522 -0.736 . . . . 0.0 110.583 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.9 t -102.92 122.04 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.682 -0.636 . . . . 0.0 109.605 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.562 ' HB ' HD12 ' A' ' 64' ' ' LEU . 34.1 m -117.1 145.2 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.658 -0.651 . . . . 0.0 109.772 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . 0.463 ' O ' HD13 ' A' ' 64' ' ' LEU . 6.2 t -131.85 168.5 17.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.548 -0.72 . . . . 0.0 110.6 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.436 HG22 ' H ' ' A' ' 39' ' ' ALA . 5.0 m -141.91 173.23 11.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.584 -0.698 . . . . 0.0 110.376 -179.671 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.436 ' H ' HG22 ' A' ' 38' ' ' THR . . . -68.88 -12.71 61.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.592 -0.692 . . . . 0.0 111.044 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 43.2 p -111.16 -41.5 4.17 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.202 -0.936 . . . . 0.0 111.088 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -157.48 168.14 28.17 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.402 -0.811 . . . . 0.0 110.831 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 80.6 p -119.85 152.64 37.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 3.7 p90 -154.26 -178.22 6.98 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.525 -0.735 . . . . 0.0 110.136 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.796 HD11 ' CA ' ' A' ' 109' ' ' ARG . 35.0 mt -113.49 153.76 28.16 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.487 -0.758 . . . . 0.0 110.817 -178.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -131.12 162.19 30.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.686 -0.634 . . . . 0.0 109.972 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 7.6 t -124.44 143.61 50.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.474 -0.766 . . . . 0.0 110.59 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 97.1 m -96.53 108.93 21.59 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.568 -0.707 . . . . 0.0 110.154 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.5 t -123.35 133.84 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.543 -0.723 . . . . 0.0 109.612 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 54.71 36.53 26.44 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.521 -0.737 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.02 75.96 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.38 129.97 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.226 -1.161 . . . . 0.0 110.043 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 90.7 m -74.23 149.2 40.94 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.473 -0.767 . . . . 0.0 109.527 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 77.1 m95 -136.11 151.85 50.23 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.512 -0.742 . . . . 0.0 111.069 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.937 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.4 t -168.4 -178.49 3.58 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.847 -0.533 . . . . 0.0 109.778 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.921 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.7 p -82.08 161.27 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.568 -0.707 . . . . 0.0 110.01 179.265 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 65.9 t80 -85.37 -34.6 21.74 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.399 -0.813 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.921 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.6 p-80 -70.01 -20.1 63.29 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.996 -1.065 . . . . 0.0 110.941 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.501 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -78.22 -51.15 5.85 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 179.544 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.416 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -95.16 -50.43 5.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.509 -0.995 . . . . 0.0 110.374 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.3 30.81 36.03 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.427 ' HA ' HG21 ' A' ' 83' ' ' VAL . 2.0 t 56.87 40.02 29.16 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.302 -1.116 . . . . 0.0 110.283 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.06 178.67 4.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.69 -0.631 . . . . 0.0 109.737 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -65.46 138.79 58.34 Favored 'General case' 0 N--CA 1.494 1.726 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.181 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.732 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -118.24 142.74 47.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.5 -0.75 . . . . 0.0 110.214 -179.406 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.99 115.94 30.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.645 -0.659 . . . . 0.0 109.911 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.58 174.29 15.25 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -62.78 -31.83 78.16 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.762 1.401 . . . . 0.0 110.422 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -71.93 -31.29 66.21 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.767 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.03 -147.58 19.03 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.63 151.32 64.04 Favored 'Trans proline' 0 N--CA 1.49 1.296 0 O-C-N 123.878 1.462 . . . . 0.0 110.241 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.732 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.8 mt -120.02 129.67 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.626 -0.671 . . . . 0.0 110.271 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.8 p -91.56 144.46 25.52 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.464 -0.772 . . . . 0.0 110.149 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 0.4 OUTLIER -88.0 134.17 33.79 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.558 -0.714 . . . . 0.0 110.872 -179.566 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.1 mmm -116.57 -33.22 4.95 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.625 -0.672 . . . . 0.0 110.239 179.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -131.27 137.67 48.96 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.577 -0.702 . . . . 0.0 110.326 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 84.6 m -139.97 130.62 25.75 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.528 -0.733 . . . . 0.0 109.978 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -136.86 100.67 4.37 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.545 -0.722 . . . . 0.0 110.353 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.432 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.8 t -70.01 -35.55 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.594 -0.691 . . . . 0.0 110.025 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -60.0 -47.88 84.0 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.606 -0.684 . . . . 0.0 110.512 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.96 3.03 54.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.479 -0.763 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.414 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 9.1 t70 54.08 49.4 18.89 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.113 -0.992 . . . . 0.0 110.425 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.73 HD11 HG11 ' A' ' 170' ' ' VAL . 68.4 mt -140.94 141.24 34.5 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.589 -0.694 . . . . 0.0 111.047 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.663 ' O ' HG22 ' A' ' 54' ' ' THR . 7.8 p -139.15 140.5 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -125.71 158.09 19.92 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.937 ' CH2' HG21 ' A' ' 54' ' ' THR . 11.2 m-90 -119.89 167.16 12.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.681 -0.893 . . . . 0.0 109.88 179.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -71.19 115.86 10.83 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.605 -0.685 . . . . 0.0 109.429 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.07 146.34 94.83 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.554 -0.716 . . . . 0.0 110.187 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.91 159.8 51.97 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.981 1.516 . . . . 0.0 110.314 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.02 151.2 61.64 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 124.019 1.536 . . . . 0.0 110.369 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.06 29.46 70.6 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.13 139.41 38.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.56 -0.965 . . . . 0.0 110.266 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -88.86 143.41 26.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.599 -0.688 . . . . 0.0 109.842 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.4 p -128.99 159.62 35.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 110.571 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.753 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 3.2 mm? -79.94 160.0 26.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.608 -0.682 . . . . 0.0 110.504 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.6 p -103.08 150.31 37.73 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.681 -0.637 . . . . 0.0 109.884 179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -60.53 141.32 95.03 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 O-C-N 123.783 1.412 . . . . 0.0 110.738 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.504 ' HG ' ' HG ' ' A' ' 145' ' ' CYS . 32.1 t -60.06 133.95 56.58 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.506 -0.746 . . . . 0.0 110.129 -179.952 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 98' ' ' THR . 6.7 t -136.48 57.24 1.78 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.5 -8.8 0.75 Allowed 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.463 -178.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.08 44.1 96.54 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.2 m -108.36 132.59 53.59 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.537 -0.978 . . . . 0.0 110.671 -179.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -76.78 -27.26 55.21 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.661 -0.649 . . . . 0.0 110.427 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.76 129.97 41.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.463 -0.773 . . . . 0.0 110.214 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.601 HD22 HG21 ' A' ' 151' ' ' VAL . 92.6 mt -135.18 145.65 47.95 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.572 -0.705 . . . . 0.0 110.65 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -106.93 130.79 54.54 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.524 -0.735 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.42 HD13 HD11 ' A' ' 143' ' ' LEU . 50.7 tp -108.5 143.09 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.529 -0.732 . . . . 0.0 110.682 -179.221 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.02 129.97 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.666 -0.646 . . . . 0.0 109.533 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 77.3 p -102.58 176.76 5.06 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.509 -0.745 . . . . 0.0 110.791 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.796 ' CA ' HD11 ' A' ' 44' ' ' LEU . 11.9 ttp180 -68.44 -19.45 64.57 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.719 -0.613 . . . . 0.0 110.742 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -92.37 24.04 3.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.382 -0.824 . . . . 0.0 110.981 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.58 39.35 31.11 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.231 -0.918 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -114.46 159.47 20.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.592 -0.692 . . . . 0.0 109.724 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.92 136.45 58.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.539 -0.725 . . . . 0.0 110.437 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.553 HD12 HH21 ' A' ' 130' ' ' ARG . 16.6 tt -129.9 131.18 23.34 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.561 -0.712 . . . . 0.0 109.809 179.643 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.61 126.05 12.95 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.77 1.405 . . . . 0.0 110.552 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -124.11 129.91 73.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.785 -0.572 . . . . 0.0 109.691 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -86.77 136.57 32.95 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.446 -0.784 . . . . 0.0 109.945 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -84.38 121.43 27.53 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 110.435 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -110.03 20.06 18.33 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.642 -0.661 . . . . 0.0 110.449 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 164.85 -179.95 39.21 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -69.68 -40.08 76.58 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.482 -1.011 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 88.8 p -120.26 21.88 11.56 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.928 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -133.79 140.22 46.79 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.394 -0.816 . . . . 0.0 110.328 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.73 163.23 26.21 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -126.69 144.99 50.75 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.587 -0.949 . . . . 0.0 110.295 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.541 HD13 HG13 ' A' ' 167' ' ' VAL . 10.7 mp -100.03 129.94 46.14 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.628 -0.67 . . . . 0.0 110.44 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.6 mp -68.73 -40.03 80.1 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.642 -0.661 . . . . 0.0 109.723 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -109.15 112.69 59.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.661 -0.65 . . . . 0.0 109.878 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.95 136.77 50.04 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.756 1.398 . . . . 0.0 110.567 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . 0.553 HH21 HD12 ' A' ' 114' ' ' ILE . 20.1 mmt85 -129.84 160.0 67.11 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.712 . . . . 0.0 110.093 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.06 152.23 83.05 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.875 1.46 . . . . 0.0 110.375 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 162' ' ' GLY . 34.3 m -64.99 -25.56 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.605 -0.684 . . . . 0.0 110.487 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.7 m -59.99 -40.03 87.77 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.0 110.286 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -66.64 -39.96 88.48 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.593 -0.692 . . . . 0.0 109.987 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.458 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -65.19 -34.46 78.43 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.636 -0.665 . . . . 0.0 110.264 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -60.02 142.98 53.0 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.461 -0.774 . . . . 0.0 110.324 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.97 9.73 86.37 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.146 -1.182 . . . . 0.0 110.146 -179.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 15.9 m -116.9 -6.94 11.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.266 -1.137 . . . . 0.0 110.945 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.2 t -60.06 139.95 57.14 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.208 -0.932 . . . . 0.0 110.074 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.97 -17.66 56.9 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.04 151.48 44.85 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -95.66 144.97 1.25 Allowed 'Trans proline' 0 N--CA 1.489 1.211 0 O-C-N 123.797 1.419 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.561 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.4 mp -96.26 103.18 15.06 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.494 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -82.64 159.63 22.63 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.902 0.858 . . . . 0.0 111.905 -178.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.504 ' HG ' ' HG ' ' A' ' 97' ' ' CYS . 0.0 OUTLIER -96.15 164.27 18.9 Favored Pre-proline 0 N--CA 1.494 1.727 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.669 179.832 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -65.71 -30.57 50.39 Favored 'Trans proline' 0 N--CA 1.49 1.272 0 O-C-N 123.922 1.485 . . . . 0.0 108.378 177.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -70.0 -36.72 75.36 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.01 41.98 0.53 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -130.01 145.74 51.66 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.468 -1.019 . . . . 0.0 110.651 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . 0.753 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.99 140.32 52.92 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.421 -0.799 . . . . 0.0 109.867 179.408 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.3 t -112.91 -44.39 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 110.262 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.43 -179.52 44.15 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 45.9 mt -120.02 130.72 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.611 -0.935 . . . . 0.0 110.157 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . 0.547 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 26.4 t80 -60.09 136.49 58.04 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.648 -0.657 . . . . 0.0 109.961 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -115.49 -52.73 2.64 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.526 -0.734 . . . . 0.0 110.414 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.89 158.64 44.4 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.558 -0.714 . . . . 0.0 110.23 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . 0.547 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.95 148.39 31.7 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.401 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.0 t -110.03 119.99 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.732 -0.605 . . . . 0.0 109.65 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.43 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -131.34 148.63 52.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.608 -0.683 . . . . 0.0 110.547 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 94.0 m -69.99 -47.02 63.87 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.625 -0.672 . . . . 0.0 110.018 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -164.63 53.41 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.716 -0.615 . . . . 0.0 109.84 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.45 ' O ' HG13 ' A' ' 132' ' ' VAL . . . 115.66 -18.06 15.36 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.64 120.04 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.276 -1.132 . . . . 0.0 109.775 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -92.22 124.94 36.67 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.602 -0.686 . . . . 0.0 110.445 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.67 -29.16 7.22 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.693 -0.629 . . . . 0.0 110.199 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -129.89 150.15 51.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.612 -0.68 . . . . 0.0 110.053 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.541 HG13 HD13 ' A' ' 126' ' ' LEU . 35.3 m -130.06 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.539 -0.726 . . . . 0.0 110.653 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -122.9 132.86 54.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.698 -0.626 . . . . 0.0 109.838 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -139.94 160.01 40.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.492 -0.755 . . . . 0.0 110.616 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.73 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -94.19 123.58 58.5 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.584 -0.697 . . . . 0.0 109.248 179.25 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -62.76 153.15 74.38 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.743 1.391 . . . . 0.0 110.65 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 151' ' ' VAL . 69.3 t -58.09 -24.36 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.605 -0.684 . . . . 0.0 110.565 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.07 -39.98 87.94 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.397 -0.815 . . . . 0.0 110.388 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 53.3 m -60.15 -40.49 90.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.462 -0.774 . . . . 0.0 110.358 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.4 mtm -70.07 -40.0 75.28 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.61 -0.681 . . . . 0.0 110.214 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.0 -40.3 88.74 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.516 -0.74 . . . . 0.0 110.25 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -63.64 -40.38 96.73 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.572 -0.705 . . . . 0.0 109.85 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -69.95 -40.16 75.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.538 -0.726 . . . . 0.0 110.076 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.7 ttm . . . . . 0 N--CA 1.496 1.839 0 O-C-N 121.746 -0.596 . . . . 0.0 110.32 -179.742 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.127 0.489 . . . . 0.0 110.048 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.845 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 110.251 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLU . . . . . 0.766 ' OE1' HD21 ' A' ' 94' ' ' LEU . 98.1 mt-10 . . . . . 0 N--CA 1.496 1.836 0 CA-C-O 121.124 0.488 . . . . 0.0 110.005 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.91 127.53 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.607 -0.683 . . . . 0.0 109.838 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -123.95 156.56 36.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.563 -0.711 . . . . 0.0 110.288 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.3 t -89.16 119.02 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.735 -0.603 . . . . 0.0 109.834 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.849 HG11 HD21 ' A' ' 64' ' ' LEU . 58.9 t -109.23 144.43 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.2 m -144.71 164.68 30.27 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.209 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.0 p -141.53 -179.57 6.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.759 -0.588 . . . . 0.0 109.797 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.78 -6.55 49.56 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.51 -0.744 . . . . 0.0 111.119 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.1 m -105.18 -57.31 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.17 -0.956 . . . . 0.0 111.17 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.8 pt20 -143.22 169.04 18.36 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.422 -0.799 . . . . 0.0 110.789 -179.282 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 70.5 m -116.92 148.46 41.33 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.512 -0.743 . . . . 0.0 110.591 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.516 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.9 p90 -163.1 -178.05 5.79 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.445 -0.784 . . . . 0.0 110.071 -179.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' LEU . . . . . 0.715 HD11 ' HA ' ' A' ' 109' ' ' ARG . 62.6 mt -113.15 148.8 34.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.492 -0.755 . . . . 0.0 110.327 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.3 159.74 32.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.662 -0.648 . . . . 0.0 109.937 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' THR . . . . . 0.582 HG21 ' HB3' ' A' ' 142' ' ' PRO . 58.8 m -119.93 138.78 53.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.571 -0.706 . . . . 0.0 110.546 -179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 45.1 m -93.14 110.97 22.47 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.644 -0.66 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.9 t -120.0 130.01 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.552 -0.718 . . . . 0.0 109.297 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.12 35.64 26.02 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.348 -0.845 . . . . 0.0 110.387 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . 0.669 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.0 19.97 75.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -130.06 130.0 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.189 -1.183 . . . . 0.0 110.278 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 34.1 t -76.0 129.94 37.65 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.416 -0.802 . . . . 0.0 109.408 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 42.3 m95 -126.4 137.1 53.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.462 -0.774 . . . . 0.0 111.68 -179.119 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.665 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 15.1 t -161.26 -179.6 7.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.832 HG21 ' CE1' ' A' ' 57' ' ' HIS . 14.5 p -81.19 155.29 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.314 -0.866 . . . . 0.0 110.67 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' TYR . . . . . 0.546 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 59.8 t80 -71.03 -39.93 72.03 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.752 -0.593 . . . . 0.0 111.935 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' HIS . . . . . 0.832 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.8 p-80 -63.56 -24.65 67.9 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.979 -1.076 . . . . 0.0 110.833 -178.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . 0.493 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.18 -51.45 6.82 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.516 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -108.14 -59.69 1.82 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.958 . . . . 0.0 110.07 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . 0.431 ' HA2' ' CD2' ' A' ' 56' ' ' TYR . . . 80.6 -176.51 54.64 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.9 t -79.84 68.13 5.83 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.554 -0.968 . . . . 0.0 109.806 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -142.47 177.73 8.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.623 -0.673 . . . . 0.0 110.243 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 58.9 m -65.14 139.93 58.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 109.899 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LEU . . . . . 0.849 HD21 HG11 ' A' ' 36' ' ' VAL . 12.7 tp -111.74 136.58 50.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.619 -0.676 . . . . 0.0 110.262 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -102.35 109.94 21.74 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.576 -0.703 . . . . 0.0 110.068 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.51 179.96 20.4 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -64.87 -32.35 55.51 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.878 1.462 . . . . 0.0 110.336 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -75.81 -31.19 59.31 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.638 -0.664 . . . . 0.0 110.046 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.88 -150.37 22.53 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.24 144.02 45.28 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 O-C-N 123.844 1.444 . . . . 0.0 110.269 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.652 HG22 ' HB3' ' A' ' 85' ' ' TRP . 51.1 mm -126.57 130.02 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.633 -0.667 . . . . 0.0 110.389 -179.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.9 p -77.62 149.76 34.73 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.523 -0.736 . . . . 0.0 109.915 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -100.42 140.5 34.59 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.523 -0.735 . . . . 0.0 110.834 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.4 mmm -113.38 -25.0 9.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.702 -0.623 . . . . 0.0 110.356 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -119.96 140.01 51.58 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 110.551 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 80.6 m -149.25 130.0 14.15 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.525 -0.735 . . . . 0.0 109.954 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 -149.91 98.07 2.67 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 110.319 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' VAL . . . . . 0.546 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 81.1 t -70.01 -40.45 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.541 -0.724 . . . . 0.0 110.082 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -44.8 94.25 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.57 -0.707 . . . . 0.0 110.319 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' GLN . . . . . 0.57 ' HG2' HD12 ' A' ' 82' ' ' LEU . 12.3 tt0 -89.99 0.05 57.32 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.563 -0.71 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ASP . . . . . 0.41 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.8 t0 53.58 45.14 28.75 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.059 -1.026 . . . . 0.0 110.781 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' LEU . . . . . 0.674 HD11 HG11 ' A' ' 170' ' ' VAL . 50.8 mt -134.46 143.53 47.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.481 -0.762 . . . . 0.0 110.682 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.691 HG13 ' CH2' ' A' ' 85' ' ' TRP . 7.1 p -150.06 157.58 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . 0.416 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -152.76 160.07 28.81 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.594 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' TRP . . . . . 0.691 ' CH2' HG13 ' A' ' 83' ' ' VAL . 11.3 m-90 -127.74 154.61 45.16 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.628 -0.925 . . . . 0.0 109.735 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -63.45 116.75 5.86 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.51 -0.744 . . . . 0.0 109.574 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.669 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -77.52 135.59 64.8 Favored Pre-proline 0 N--CA 1.495 1.786 0 O-C-N 121.553 -0.717 . . . . 0.0 110.225 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 160.0 51.23 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 123.868 1.457 . . . . 0.0 110.217 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.41 156.53 50.22 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 O-C-N 123.87 1.458 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.77 -22.04 42.94 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.97 159.99 26.09 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -1.124 . . . . 0.0 110.216 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -96.47 165.4 12.19 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.521 -0.737 . . . . 0.0 110.282 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -132.42 169.11 17.0 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.6 -0.687 . . . . 0.0 110.227 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' LEU . . . . . 0.766 HD21 ' OE1' ' A' ' 32' ' ' GLU . 84.2 mt -119.25 138.28 53.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.547 -0.721 . . . . 0.0 110.617 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -82.91 166.61 34.71 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.582 -0.698 . . . . 0.0 110.144 179.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -79.18 166.12 23.05 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.868 1.457 . . . . 0.0 110.533 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' CYS . . . . . 0.804 ' HB2' HG22 ' A' ' 151' ' ' VAL . 31.1 t -69.43 136.65 51.87 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.3 p -136.59 55.55 1.84 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.729 -0.607 . . . . 0.0 109.585 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 31.7 p -143.46 -8.46 0.76 Allowed 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.792 -0.763 . . . . 0.0 112.51 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.46 97.31 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.0 m -108.71 160.3 16.07 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.543 -0.975 . . . . 0.0 110.496 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -108.9 21.69 16.89 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.715 . . . . 0.0 110.798 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -99.94 120.05 39.2 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.371 -0.831 . . . . 0.0 110.051 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' LEU . . . . . 0.841 HD21 HG11 ' A' ' 151' ' ' VAL . 56.5 mt -130.57 133.13 45.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.557 -0.714 . . . . 0.0 110.537 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.0 120.0 40.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.507 -0.745 . . . . 0.0 109.693 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.8 tp -81.79 128.35 33.92 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.481 -0.762 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -97.85 118.6 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.626 -0.672 . . . . 0.0 109.37 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.4 p -104.32 177.93 4.7 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.553 -0.717 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ARG . . . . . 0.715 ' HA ' HD11 ' A' ' 44' ' ' LEU . 47.0 mtp180 -60.0 -22.77 63.0 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.602 -0.686 . . . . 0.0 110.461 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.46 19.07 5.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.344 -0.848 . . . . 0.0 111.126 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.84 40.0 31.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.1 -1.0 . . . . 0.0 110.924 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -100.31 122.81 43.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.572 -0.705 . . . . 0.0 109.961 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 114' ' ' ILE . 33.1 m -59.97 -39.36 79.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.577 -0.702 . . . . 0.0 110.501 -179.564 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ILE . . . . . 0.455 ' N ' HG23 ' A' ' 113' ' ' VAL . 50.8 mm 51.29 92.44 0.06 OUTLIER Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.38 -0.825 . . . . 0.0 110.648 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.93 121.41 8.44 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.94 1.495 . . . . 0.0 110.656 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.538 HG13 ' O ' ' A' ' 125' ' ' SER . 62.5 t -127.2 129.99 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.665 -0.647 . . . . 0.0 109.52 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.5 tpt180 -86.88 132.07 33.92 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.507 -0.746 . . . . 0.0 110.125 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.09 130.64 41.39 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.512 -0.743 . . . . 0.0 110.004 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -128.49 20.43 6.17 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.542 -0.724 . . . . 0.0 110.605 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -179.43 172.41 44.31 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -59.97 -40.64 89.78 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.47 -1.018 . . . . 0.0 110.278 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -133.43 28.98 3.98 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.561 -0.712 . . . . 0.0 110.616 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 22.0 ttp180 -139.89 138.37 35.61 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.422 -0.798 . . . . 0.0 110.592 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -126.4 -176.49 14.51 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' SER . . . . . 0.538 ' O ' HG13 ' A' ' 116' ' ' VAL . 86.8 p -133.24 150.87 51.93 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.557 -0.967 . . . . 0.0 110.211 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.419 HD13 HG13 ' A' ' 167' ' ' VAL . 2.3 mp -97.26 130.04 44.51 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.517 -0.739 . . . . 0.0 110.316 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.528 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.7 mp -67.64 -40.03 84.6 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.582 -0.699 . . . . 0.0 110.02 179.659 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -115.36 127.83 26.47 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -67.67 120.74 7.76 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.755 1.398 . . . . 0.0 110.468 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -120.46 160.06 45.44 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.588 -0.695 . . . . 0.0 110.009 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.68 154.19 73.66 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.956 1.503 . . . . 0.0 110.415 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . 0.49 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.18 -23.28 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.661 -0.649 . . . . 0.0 110.619 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 66.5 m -59.95 -40.06 87.71 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.403 -0.81 . . . . 0.0 110.211 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -60.0 -46.72 88.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.437 -0.789 . . . . 0.0 109.644 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.99 -29.42 66.51 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.672 -0.642 . . . . 0.0 109.545 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.3 tptm -60.03 129.46 41.9 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.6 -0.688 . . . . 0.0 110.006 179.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.82 -8.29 80.01 Favored Glycine 0 N--CA 1.495 2.592 0 C-N-CA 120.269 -0.967 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.0 p -96.86 6.01 49.47 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.071 -1.252 . . . . 0.0 111.135 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -60.03 142.94 53.11 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.038 -1.039 . . . . 0.0 109.929 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.92 -14.93 63.02 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.25 145.77 44.02 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' PRO . . . . . 0.582 ' HB3' HG21 ' A' ' 46' ' ' THR . 49.6 Cg_endo -92.03 141.54 2.46 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.859 1.452 . . . . 0.0 111.673 -179.066 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' LEU . . . . . 0.563 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -93.51 104.38 16.52 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.469 ' N ' HD12 ' A' ' 144' ' ' LEU . 11.0 mp -81.99 157.24 24.3 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 122.082 0.944 . . . . 0.0 111.867 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.57 162.2 24.13 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.496 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -63.98 -29.82 66.71 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.789 1.415 . . . . 0.0 108.577 177.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 79.6 p -70.91 -36.12 72.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 178.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.05 41.27 0.56 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -129.97 154.32 47.49 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.984 . . . . 0.0 110.592 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.32 119.55 25.81 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.504 -0.747 . . . . 0.0 109.857 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' VAL . . . . . 0.841 HG11 HD21 ' A' ' 104' ' ' LEU . 63.1 t -90.71 -42.01 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.566 -0.709 . . . . 0.0 110.483 -179.49 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -166.51 -168.87 29.35 Favored Glycine 0 N--CA 1.497 2.741 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.301 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.37 140.01 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.591 -0.947 . . . . 0.0 110.352 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -63.44 139.69 58.8 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.679 -0.638 . . . . 0.0 109.725 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.9 ttp85 -123.14 -52.76 1.85 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.48 -0.763 . . . . 0.0 110.529 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -147.99 165.18 31.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.491 -0.755 . . . . 0.0 110.436 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.95 143.87 49.21 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.621 -0.674 . . . . 0.0 110.371 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.06 119.9 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.76 -0.587 . . . . 0.0 109.456 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' CYS . . . . . 0.49 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -125.97 146.03 50.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.545 -0.722 . . . . 0.0 110.693 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' THR . . . . . 0.541 HG22 ' HG2' ' A' ' 161' ' ' ARG . 39.9 m -82.89 -64.2 1.22 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.447 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.541 ' HG2' HG22 ' A' ' 160' ' ' THR . 10.3 mmm180 -129.21 62.96 1.5 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.499 -0.751 . . . . 0.0 110.406 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.91 -8.76 79.22 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.621 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.2 m -115.8 131.14 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.154 -1.203 . . . . 0.0 110.299 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.34 124.93 34.4 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.638 -0.664 . . . . 0.0 110.3 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -108.79 -29.61 8.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.687 -0.633 . . . . 0.0 110.005 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -138.27 150.8 47.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.419 HG13 HD13 ' A' ' 126' ' ' LEU . 27.6 m -130.45 175.46 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.644 -0.66 . . . . 0.0 110.597 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -131.15 131.35 44.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.682 -0.637 . . . . 0.0 109.574 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -129.48 153.07 48.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.347 -0.845 . . . . 0.0 110.528 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 82' ' ' LEU . 90.5 t -93.55 119.53 67.14 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.607 -0.683 . . . . 0.0 109.429 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.63 153.51 74.67 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.808 1.425 . . . . 0.0 110.578 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.3 t -62.74 -27.42 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.629 -0.67 . . . . 0.0 110.428 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -59.94 -39.31 85.1 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.591 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 85.9 p -59.96 -45.14 93.62 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.504 -0.748 . . . . 0.0 110.669 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 76.7 mtm -69.97 -40.04 75.61 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.396 -0.815 . . . . 0.0 110.38 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.01 -40.04 87.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.479 -0.763 . . . . 0.0 110.259 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.5 m -63.98 -39.99 95.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.574 -0.703 . . . . 0.0 109.881 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 88.6 m -70.05 -40.15 75.27 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.596 -0.69 . . . . 0.0 110.063 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.6 ttm . . . . . 0 N--CA 1.495 1.789 0 O-C-N 121.648 -0.658 . . . . 0.0 110.396 -179.718 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.088 0.47 . . . . 0.0 110.135 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 189' ' ' LEU . . . . . 0.775 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp . . . . . 0 N--CA 1.496 1.836 0 O-C-N 121.622 -0.673 . . . . 0.0 110.188 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.066 0.46 . . . . 0.0 110.333 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -69.9 100.23 0.75 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 34.7 ttp180 -131.94 133.64 44.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.642 -0.916 . . . . 0.0 110.141 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -40.01 87.97 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.603 -0.686 . . . . 0.0 110.301 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 14.7 ptmt 38.59 42.06 0.54 Allowed 'General case' 0 N--CA 1.509 2.519 0 N-CA-C 112.435 0.531 . . . . 0.0 112.435 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.3 m120 -75.09 130.93 40.11 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.528 -0.732 . . . . 0.0 110.12 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -149.77 159.69 44.15 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.54 -0.725 . . . . 0.0 110.177 -179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.2 t -88.33 138.96 18.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.594 -0.692 . . . . 0.0 109.816 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.95 130.79 48.49 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.502 -0.748 . . . . 0.0 110.252 -179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -169.9 100.23 0.16 Allowed Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 52.4 mt-10 -63.58 -33.93 76.69 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.552 -0.97 . . . . 0.0 110.25 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -103.77 129.91 55.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.564 -0.71 . . . . 0.0 109.868 -179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -116.3 158.54 23.23 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.561 -0.712 . . . . 0.0 110.489 -179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -85.04 121.29 36.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.663 -0.648 . . . . 0.0 109.597 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.407 ' HB ' HD11 ' A' ' 64' ' ' LEU . 29.7 m -118.48 142.67 32.16 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.699 -0.626 . . . . 0.0 109.899 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.3 t -142.05 159.67 41.76 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.516 -0.74 . . . . 0.0 111.246 -179.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.7 p -124.56 -170.12 2.09 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -84.02 5.89 24.1 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.528 -0.732 . . . . 0.0 110.91 179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 69.3 p -128.65 -38.94 1.67 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.073 -1.017 . . . . 0.0 111.191 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 5.1 pt20 -149.91 170.1 19.61 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.311 -0.868 . . . . 0.0 111.159 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 47.8 m -119.75 147.35 44.71 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.68 -0.638 . . . . 0.0 109.792 179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.411 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 10.3 p90 -156.43 -178.63 7.48 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.391 -0.818 . . . . 0.0 110.275 -179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.553 HD11 ' CA ' ' A' ' 109' ' ' ARG . 74.0 mt -113.89 153.35 29.37 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.588 -0.695 . . . . 0.0 110.804 -178.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.43 161.34 31.6 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.711 -0.618 . . . . 0.0 109.972 179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -126.23 140.12 52.79 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.573 -0.705 . . . . 0.0 110.4 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 38.5 t -98.33 105.48 17.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.59 -0.693 . . . . 0.0 110.489 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.0 t -109.98 129.99 63.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.695 -0.628 . . . . 0.0 109.423 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 56.8 t30 57.98 38.36 26.82 Favored 'General case' 0 N--CA 1.501 2.101 0 O-C-N 121.439 -0.788 . . . . 0.0 110.479 -179.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.529 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.52 19.93 76.7 Favored Glycine 0 N--CA 1.495 2.592 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 179.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.0 t -131.99 129.97 60.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.137 -1.214 . . . . 0.0 110.167 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 87.5 m -75.66 148.89 38.35 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.516 -0.74 . . . . 0.0 109.464 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 96.7 m95 -138.2 149.95 46.29 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.448 -0.783 . . . . 0.0 111.212 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.9 t -168.65 -179.09 3.67 Favored 'General case' 0 N--CA 1.494 1.749 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.85 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.6 p -89.17 158.33 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.448 -0.783 . . . . 0.0 110.027 179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.471 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.1 t80 -76.39 -39.97 52.25 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.493 -0.754 . . . . 0.0 112.066 -178.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.85 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.3 p-80 -64.95 -24.28 67.47 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.116 -0.99 . . . . 0.0 110.567 -178.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.565 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -84.28 -56.98 2.44 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 179.093 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.562 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -96.89 -61.28 1.43 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.68 -0.894 . . . . 0.0 109.987 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.427 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 79.96 -179.39 53.26 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 78.9 p -79.33 64.59 4.26 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.596 -0.943 . . . . 0.0 109.768 179.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.23 167.54 21.84 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.62 -0.675 . . . . 0.0 110.414 -179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.2 t -65.39 139.32 58.54 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 109.826 179.892 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.74 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -112.83 131.13 55.84 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.589 -0.694 . . . . 0.0 110.291 -179.576 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.53 109.29 21.9 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.564 -0.71 . . . . 0.0 109.815 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -105.53 -165.96 23.59 Favored Glycine 0 N--CA 1.494 2.542 0 N-CA-C 109.282 -1.527 . . . . 0.0 109.282 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.09 -32.36 34.53 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 124.025 1.539 . . . . 0.0 110.403 179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -75.62 -31.09 59.76 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.596 -0.69 . . . . 0.0 110.005 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.83 -140.83 10.1 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 -179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -75.02 161.36 38.83 Favored 'Trans proline' 0 N--CA 1.489 1.26 0 O-C-N 123.819 1.431 . . . . 0.0 110.292 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.74 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.5 mt -131.53 139.37 50.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.72 0 O-C-N 121.448 -0.782 . . . . 0.0 110.439 -179.639 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.0 p -81.87 150.74 27.64 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.549 -0.719 . . . . 0.0 109.946 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 78.2 mm-40 -87.42 132.3 34.03 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.484 -0.76 . . . . 0.0 110.095 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -110.01 -44.86 3.71 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.552 -0.718 . . . . 0.0 110.116 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . 0.432 ' CE1' ' HG3' ' A' ' 179' ' ' MET . 83.9 m-85 -130.01 150.04 51.46 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.584 -0.697 . . . . 0.0 110.507 -179.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.6 p -148.17 136.32 21.2 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.007 179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 52.7 t-20 -149.98 89.32 1.59 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.471 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 63.0 t -61.3 -40.09 84.92 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.885 0 O-C-N 121.623 -0.673 . . . . 0.0 109.988 -179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.3 m-20 -61.58 -43.91 97.99 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.508 -0.745 . . . . 0.0 110.654 -179.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.778 ' HG2' HD12 ' A' ' 82' ' ' LEU . 50.7 tt0 -87.6 -0.01 56.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.583 -0.698 . . . . 0.0 110.749 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.48 46.5 26.05 Favored 'General case' 0 N--CA 1.502 2.139 0 O-C-N 121.06 -1.025 . . . . 0.0 110.506 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.778 HD12 ' HG2' ' A' ' 80' ' ' GLN . 40.3 mt -144.25 138.39 27.96 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.543 -0.723 . . . . 0.0 110.875 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.468 ' CG1' HG23 ' A' ' 54' ' ' THR . 8.3 p -134.12 157.33 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.605 -0.684 . . . . 0.0 109.26 179.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -138.43 153.66 22.59 Favored Glycine 0 N--CA 1.494 2.543 0 N-CA-C 110.196 -1.161 . . . . 0.0 110.196 -179.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 5.8 m-90 -120.99 151.67 39.46 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.776 -0.838 . . . . 0.0 110.022 179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 43.0 tt0 -68.51 115.85 8.39 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.538 -0.726 . . . . 0.0 109.338 179.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.529 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.06 130.08 90.13 Favored Pre-proline 0 N--CA 1.496 1.848 0 O-C-N 121.525 -0.735 . . . . 0.0 110.262 -179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.04 159.99 51.21 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.831 1.437 . . . . 0.0 110.285 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.67 156.32 58.01 Favored 'Trans proline' 0 N--CA 1.492 1.384 0 O-C-N 123.897 1.472 . . . . 0.0 110.4 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.33 26.56 59.31 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.66 152.29 30.63 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.467 -1.019 . . . . 0.0 110.143 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 11.6 mmm180 -92.79 168.94 10.85 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.566 -0.709 . . . . 0.0 110.256 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.9 p -137.84 158.71 43.77 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.74 -0.6 . . . . 0.0 110.228 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.473 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 51.4 mt -108.02 131.63 54.38 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.526 -0.734 . . . . 0.0 110.485 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.7 p -76.91 160.06 77.3 Favored Pre-proline 0 N--CA 1.494 1.774 0 O-C-N 121.555 -0.716 . . . . 0.0 109.784 179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -75.58 163.68 33.64 Favored 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.832 1.438 . . . . 0.0 110.655 -179.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.793 ' HB2' HG12 ' A' ' 151' ' ' VAL . 49.1 t -72.69 129.53 38.44 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.694 -0.629 . . . . 0.0 110.27 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.8 t -134.68 55.6 1.89 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.716 -0.615 . . . . 0.0 109.661 179.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.8 p -143.88 -7.82 0.73 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 120.027 -0.669 . . . . 0.0 112.26 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.97 39.54 97.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 72.8 m -99.94 119.99 39.1 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.544 -0.974 . . . . 0.0 110.404 -179.669 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 56.7 m -66.71 -39.71 88.14 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.731 -0.606 . . . . 0.0 110.442 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 139.61 57.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.531 -0.731 . . . . 0.0 110.491 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.927 HD22 HG21 ' A' ' 151' ' ' VAL . 92.8 mt -139.29 153.1 47.72 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.613 -0.68 . . . . 0.0 110.409 -179.988 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 70.8 m-85 -115.73 123.72 49.01 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.53 -0.731 . . . . 0.0 109.887 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.639 HD13 HD11 ' A' ' 143' ' ' LEU . 66.3 tp -99.91 133.29 44.49 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.592 -0.693 . . . . 0.0 110.595 -179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.9 t -91.57 120.05 39.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.677 -0.639 . . . . 0.0 109.447 179.373 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 5.4 m -97.99 152.35 19.36 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.462 -0.774 . . . . 0.0 110.419 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.553 ' CA ' HD11 ' A' ' 44' ' ' LEU . 28.0 ptt85 -59.08 -20.03 49.68 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.639 -0.663 . . . . 0.0 110.751 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 84.1 t60 -94.59 26.76 3.31 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.452 -0.78 . . . . 0.0 110.214 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.49 40.07 31.16 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.348 -0.845 . . . . 0.0 110.663 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -118.49 135.03 54.62 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.572 -0.705 . . . . 0.0 109.976 179.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.97 120.03 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.579 -0.701 . . . . 0.0 110.022 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.523 ' O ' HG23 ' A' ' 116' ' ' VAL . 49.0 mm -106.19 117.36 57.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.622 -0.674 . . . . 0.0 109.79 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -64.42 120.74 8.13 Favored 'Trans proline' 0 N--CA 1.491 1.381 0 O-C-N 123.801 1.422 . . . . 0.0 110.374 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.523 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.6 t -119.98 126.32 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.586 -0.696 . . . . 0.0 109.796 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.2 tpt180 -86.9 130.53 34.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.553 -0.717 . . . . 0.0 109.805 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 37.5 ttp180 -73.46 126.14 29.52 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.624 -0.672 . . . . 0.0 110.338 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.0 mmt180 -120.16 23.78 10.79 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.587 -0.696 . . . . 0.0 110.209 179.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.38 -179.06 42.18 Favored Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.446 -1.461 . . . . 0.0 109.446 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -63.19 -39.96 96.13 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.571 -0.958 . . . . 0.0 110.406 -179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 76.9 p -132.83 22.2 4.21 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.555 -0.715 . . . . 0.0 110.786 -179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 6.9 tpp180 -124.86 138.6 54.25 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.346 -0.847 . . . . 0.0 110.322 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.18 169.81 23.51 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 69.4 p -121.25 153.51 37.55 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.62 -0.929 . . . . 0.0 110.059 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.51 HD11 HG21 ' A' ' 114' ' ' ILE . 16.8 tp -99.27 119.87 38.63 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.505 -0.747 . . . . 0.0 110.221 -179.811 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -68.61 -39.01 81.04 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.544 -0.722 . . . . 0.0 110.039 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.28 116.13 55.47 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.601 -0.687 . . . . 0.0 110.064 179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -65.81 116.34 3.91 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.724 1.381 . . . . 0.0 110.43 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 5.7 mtt180 -122.69 160.04 50.57 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.581 -0.699 . . . . 0.0 110.139 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -67.43 152.04 79.36 Favored 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 124.017 1.536 . . . . 0.0 110.363 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.32 -32.15 50.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.947 0 O-C-N 121.568 -0.708 . . . . 0.0 110.395 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.8 t -59.96 -38.66 83.1 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.511 -0.743 . . . . 0.0 110.162 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.539 -0.726 . . . . 0.0 110.34 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 3.2 mp -81.46 -18.35 45.59 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 0.0 111.109 -179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 1.4 mmmm -60.4 140.02 57.4 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.183 -0.948 . . . . 0.0 110.115 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 86.37 13.64 67.74 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 -179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.5 p -116.13 -8.29 11.79 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.127 -1.219 . . . . 0.0 110.908 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.7 t -59.97 139.08 57.66 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.123 -0.986 . . . . 0.0 109.698 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 97.33 -23.44 35.82 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.99 151.71 47.39 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.792 -1.723 . . . . 0.0 108.792 179.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.47 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.9 Cg_endo -93.87 148.78 2.15 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 O-C-N 123.841 1.443 . . . . 0.0 111.427 -179.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.903 ' O ' HG22 ' A' ' 151' ' ' VAL . 9.3 mp -104.66 130.3 52.71 Favored 'General case' 0 N--CA 1.488 1.47 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.726 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.47 131.51 56.25 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.351 -0.843 . . . . 0.0 111.549 -178.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.5 p -70.01 159.16 85.32 Favored Pre-proline 0 N--CA 1.495 1.79 0 N-CA-C 109.09 -0.708 . . . . 0.0 109.09 178.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.85 -26.64 24.87 Favored 'Trans proline' 0 N--CA 1.502 1.992 0 O-C-N 123.504 1.265 . . . . 0.0 112.359 -178.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.9 m -62.63 -39.99 95.57 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.261 -0.9 . . . . 0.0 109.96 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.67 36.37 0.79 Allowed Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.4 m170 -132.48 149.61 52.3 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.419 -1.048 . . . . 0.0 110.128 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.473 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -70.0 142.48 52.78 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.576 -0.702 . . . . 0.0 110.45 -179.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.927 HG21 HD22 ' A' ' 104' ' ' LEU . 34.4 m -117.17 -22.81 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.626 -0.671 . . . . 0.0 110.613 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 167.63 -169.92 41.45 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' HE1' ' A' ' 175' ' ' MET . 96.9 mt -127.84 139.94 50.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.517 -0.99 . . . . 0.0 110.224 -179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.495 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.7 t80 -65.82 136.79 56.65 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.649 -0.657 . . . . 0.0 109.981 179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -114.97 -52.39 2.69 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.575 -0.703 . . . . 0.0 110.427 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.427 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -153.72 160.02 42.17 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.463 -0.773 . . . . 0.0 110.393 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.495 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.96 151.13 27.5 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.66 -0.65 . . . . 0.0 110.203 179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.1 t -108.27 119.6 58.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.666 -0.647 . . . . 0.0 109.693 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -134.1 158.96 42.28 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.693 -0.63 . . . . 0.0 110.293 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 4.6 p -99.97 -50.68 3.92 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.565 -0.71 . . . . 0.0 110.391 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 87.2 mtt180 -142.89 61.62 1.41 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.531 -0.731 . . . . 0.0 109.928 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.05 -7.47 81.57 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.8 t -116.82 125.92 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.083 -1.245 . . . . 0.0 109.905 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.81 127.86 43.2 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.592 -0.693 . . . . 0.0 110.422 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -107.14 -17.16 14.24 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.519 -0.738 . . . . 0.0 110.743 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -146.81 159.78 43.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.325 -0.859 . . . . 0.0 110.036 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.2 m -133.84 160.04 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.462 -0.774 . . . . 0.0 110.938 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.51 138.4 53.19 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.648 -0.658 . . . . 0.0 110.015 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -140.3 155.65 46.75 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.404 -0.81 . . . . 0.0 110.794 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.554 HG11 HD11 ' A' ' 82' ' ' LEU . 59.3 t -94.47 126.04 49.5 Favored Pre-proline 0 N--CA 1.496 1.829 0 O-C-N 121.56 -0.712 . . . . 0.0 109.459 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -68.46 158.58 57.03 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.795 1.419 . . . . 0.0 110.696 -179.614 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 57.7 t -65.59 -24.66 35.0 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 121.665 -0.647 . . . . 0.0 110.478 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -58.6 -37.96 76.94 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.383 -0.823 . . . . 0.0 110.579 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 81.1 p -60.13 -34.45 73.54 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.524 -0.735 . . . . 0.0 110.417 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.431 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.3 mtt -61.14 -40.02 92.26 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.478 -0.764 . . . . 0.0 110.411 -179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.55 -42.14 95.97 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.496 -0.752 . . . . 0.0 110.495 -179.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 75.2 p -70.03 -39.51 75.72 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.395 -0.816 . . . . 0.0 110.417 -179.646 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 86.5 m -60.04 -50.03 75.32 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 -179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.432 ' HG3' ' CE1' ' A' ' 75' ' ' TYR . 59.9 ttp -68.63 -39.99 80.53 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.609 -0.682 . . . . 0.0 110.239 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -63.7 -39.98 95.64 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.608 -0.682 . . . . 0.0 110.274 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.05 -43.78 95.14 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.575 -0.703 . . . . 0.0 110.483 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 79.7 p -159.8 153.59 22.91 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.551 -0.718 . . . . 0.0 110.465 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 61.4 mttp -109.99 20.26 18.14 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.671 -0.643 . . . . 0.0 110.677 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 49.4 tttm 54.11 39.98 31.19 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.222 -0.924 . . . . 0.0 110.654 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 58.4 tttp -99.98 125.76 46.05 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.566 -0.709 . . . . 0.0 110.094 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.6 pttt . . . . . 0 N--CA 1.497 1.915 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.492 -179.883 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.427 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.9 tt0 -127.95 129.99 47.7 Favored 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 118.767 -1.173 . . . . 0.0 110.181 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.807 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -77.84 143.35 37.91 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.587 -0.696 . . . . 0.0 110.226 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.457 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.4 t . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 121.072 0.463 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -79.91 170.66 54.07 Favored Glycine 0 N--CA 1.492 2.428 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 46.4 ttp180 -59.91 -40.78 90.0 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.582 -0.952 . . . . 0.0 110.197 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.1 t0 -160.16 39.74 0.18 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.545 -0.722 . . . . 0.0 110.117 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.1 mttm -69.62 -40.02 76.84 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.639 -0.663 . . . . 0.0 110.259 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -134.87 150.44 50.46 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.569 -0.707 . . . . 0.0 110.293 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -129.48 152.96 48.44 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.638 -0.663 . . . . 0.0 110.018 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.3 t -109.98 120.01 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.531 -0.731 . . . . 0.0 110.016 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -133.73 33.23 3.49 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.605 -0.684 . . . . 0.0 110.238 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -178.26 173.25 45.74 Favored Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 -179.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.541 ' OE1' HD21 ' A' ' 94' ' ' LEU . 28.3 mt-10 -102.71 9.77 38.98 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.656 -0.908 . . . . 0.0 111.171 -179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -123.02 128.41 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 O-C-N 121.113 -0.992 . . . . 0.0 109.946 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -116.31 146.29 42.54 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.588 -0.695 . . . . 0.0 109.992 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.3 t -91.55 122.81 43.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.454 -0.779 . . . . 0.0 109.705 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.615 ' HB ' HD12 ' A' ' 64' ' ' LEU . 32.7 m -115.62 140.17 38.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.734 -0.604 . . . . 0.0 109.707 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 74.1 m -138.4 162.87 33.35 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.562 -0.711 . . . . 0.0 110.753 -179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -127.55 -170.5 2.24 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.72 -0.612 . . . . 0.0 109.432 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.08 -42.83 95.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.534 -0.728 . . . . 0.0 110.736 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 7.9 t -128.28 -7.66 5.31 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.385 -0.822 . . . . 0.0 111.849 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 12.8 tp60 -115.16 156.87 24.49 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.067 -1.02 . . . . 0.0 110.67 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 13.7 p -149.96 138.1 20.38 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.718 -0.614 . . . . 0.0 109.759 179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.623 ' HZ ' HD21 ' A' ' 64' ' ' LEU . 20.0 p90 -164.39 -178.89 5.69 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.533 -0.73 . . . . 0.0 110.456 -179.591 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.555 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.6 mt -114.3 159.2 20.46 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.476 -0.765 . . . . 0.0 110.862 -178.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.54 ' HB1' ' O ' ' A' ' 53' ' ' TRP . . . -139.1 162.64 34.46 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.697 -0.627 . . . . 0.0 109.989 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.5 t -122.29 140.68 52.35 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.423 -0.798 . . . . 0.0 110.673 -179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 6.3 t -98.87 104.06 16.07 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.569 -0.707 . . . . 0.0 110.109 179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.61 132.77 56.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.604 -0.685 . . . . 0.0 109.899 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 54.35 39.94 31.34 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.596 -0.69 . . . . 0.0 111.016 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.05 20.83 76.67 Favored Glycine 0 N--CA 1.496 2.697 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 179.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.9 t -130.0 130.0 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.249 -1.148 . . . . 0.0 109.852 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.1 t -78.93 147.31 33.08 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.483 -0.761 . . . . 0.0 109.403 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.54 ' O ' ' HB1' ' A' ' 45' ' ' ALA . 57.5 m95 -128.66 150.38 50.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.538 -0.726 . . . . 0.0 110.932 -179.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.89 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.3 t -166.11 -179.73 5.29 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.262 -0.644 . . . . 0.0 109.262 179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.866 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -100.46 154.25 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.374 -0.829 . . . . 0.0 110.73 -179.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 53.8 t80 -70.05 -40.11 75.3 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.63 -0.669 . . . . 0.0 111.811 -178.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.866 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.1 p-80 -70.62 -22.1 62.57 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.099 -1.001 . . . . 0.0 110.843 -179.319 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.699 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -93.32 -46.41 3.28 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 108.907 -1.677 . . . . 0.0 108.907 179.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.422 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -106.43 -49.31 3.37 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.658 -0.907 . . . . 0.0 110.334 179.718 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 65.49 -162.3 41.17 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.2 t -93.12 63.37 3.67 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.577 -0.955 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -139.92 161.77 36.78 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.58 -0.7 . . . . 0.0 110.266 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 63.1 p -65.42 139.59 58.55 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.586 -0.696 . . . . 0.0 109.634 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.623 HD21 ' HZ ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -112.53 141.28 46.47 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.618 -0.677 . . . . 0.0 110.011 -179.884 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.27 115.16 24.49 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.511 -0.743 . . . . 0.0 110.252 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.04 176.42 16.17 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -63.63 -31.97 69.59 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.793 1.417 . . . . 0.0 110.29 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 66.3 mttm -71.63 -31.41 66.84 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.657 -0.652 . . . . 0.0 109.829 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.7 -153.71 24.32 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.152 -1.579 . . . . 0.0 109.152 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -71.02 145.0 48.78 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.918 1.483 . . . . 0.0 110.092 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.585 HG22 ' CD1' ' A' ' 85' ' ' TRP . 85.6 mt -119.99 129.49 75.38 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.796 0 O-C-N 121.608 -0.682 . . . . 0.0 110.356 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 m -85.49 130.26 34.62 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.604 -0.685 . . . . 0.0 109.963 179.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.439 ' HA ' ' CD1' ' A' ' 85' ' ' TRP . 44.8 mm-40 -55.69 139.93 43.25 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.513 -0.742 . . . . 0.0 110.917 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 28.0 ttt -113.68 -49.1 2.9 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.73 -0.606 . . . . 0.0 110.179 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 70.3 m-85 -120.0 140.0 51.63 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.588 -0.695 . . . . 0.0 110.27 179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.814 ' HA ' HG12 ' A' ' 83' ' ' VAL . 26.2 m -135.78 129.36 32.41 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.641 -0.662 . . . . 0.0 110.215 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 17.4 t-20 -142.43 96.75 3.0 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.577 -0.702 . . . . 0.0 110.226 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 76.5 t -65.7 -39.99 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.593 -0.692 . . . . 0.0 110.049 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -60.01 -49.84 76.07 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.551 -0.718 . . . . 0.0 110.816 -179.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.3 mm-40 -89.31 -0.05 57.17 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.426 -0.796 . . . . 0.0 110.934 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 6.4 t70 52.79 47.41 24.74 Favored 'General case' 0 N--CA 1.502 2.166 0 O-C-N 121.0 -1.062 . . . . 0.0 110.665 179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.497 HD11 HG11 ' A' ' 170' ' ' VAL . 62.8 mt -141.63 137.14 31.63 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.443 -0.786 . . . . 0.0 111.141 -179.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.814 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.6 m -138.37 161.35 31.29 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.555 -0.716 . . . . 0.0 109.301 178.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.32 164.56 26.55 Favored Glycine 0 N--CA 1.495 2.632 0 C-N-CA 120.003 -1.094 . . . . 0.0 110.586 -179.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.89 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.7 m-90 -123.13 159.38 28.67 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.829 -0.806 . . . . 0.0 109.253 179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -79.9 109.34 14.24 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.45 -0.781 . . . . 0.0 109.528 179.181 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -70.68 141.08 87.17 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.59 -0.694 . . . . 0.0 110.298 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -70.03 160.02 51.12 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.917 1.482 . . . . 0.0 110.323 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.83 160.12 42.42 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.883 1.465 . . . . 0.0 110.305 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.79 29.85 64.65 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.51 144.09 34.98 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.533 -0.981 . . . . 0.0 110.095 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 31.8 ttt180 -84.69 128.64 34.71 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.69 -0.631 . . . . 0.0 109.703 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.4 p -111.43 162.58 14.92 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.593 -0.692 . . . . 0.0 110.539 -179.496 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.541 HD21 ' OE1' ' A' ' 32' ' ' GLU . 16.1 mt -106.37 131.99 52.93 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.614 -0.679 . . . . 0.0 110.73 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.4 p -75.46 160.01 80.56 Favored Pre-proline 0 N--CA 1.496 1.828 0 O-C-N 121.597 -0.689 . . . . 0.0 109.691 179.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.51 162.63 40.85 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.825 1.434 . . . . 0.0 110.772 -179.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.711 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.6 t -79.26 130.05 35.07 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.618 -0.676 . . . . 0.0 110.101 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.56 55.6 1.88 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.651 -0.656 . . . . 0.0 109.72 179.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.79 -8.02 0.74 Allowed 'General case' 0 N--CA 1.497 1.905 0 C-N-CA 119.916 -0.714 . . . . 0.0 112.296 -179.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 61.66 34.77 89.74 Favored Glycine 0 N--CA 1.494 2.532 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 32.3 m -87.0 112.34 21.73 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.515 -0.991 . . . . 0.0 110.405 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -59.99 -39.97 87.56 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.6 -0.688 . . . . 0.0 110.35 179.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -63.15 132.88 53.27 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.613 -0.68 . . . . 0.0 110.184 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.51 ' CD2' HG21 ' A' ' 151' ' ' VAL . 91.4 mt -134.63 146.12 49.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.66 -0.65 . . . . 0.0 110.492 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.0 m-85 -106.82 121.54 44.61 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.504 -0.748 . . . . 0.0 109.984 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.543 HD13 HD11 ' A' ' 143' ' ' LEU . 64.0 tp -95.51 137.94 33.88 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.547 -0.72 . . . . 0.0 110.408 -179.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -94.24 119.96 42.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.598 -0.689 . . . . 0.0 109.75 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.2 p -97.74 170.07 9.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.487 -0.758 . . . . 0.0 110.573 -179.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.555 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.9 mtp-105 -70.06 -20.19 63.25 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.646 -0.659 . . . . 0.0 110.813 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -94.32 26.59 3.28 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.323 -0.861 . . . . 0.0 110.679 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 39.03 30.46 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.273 -0.892 . . . . 0.0 110.751 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -120.14 137.08 54.36 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.688 -0.633 . . . . 0.0 109.723 179.67 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.5 m -120.04 143.4 31.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.446 -0.783 . . . . 0.0 110.67 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 46.0 pt -129.94 158.8 72.77 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.757 -0.59 . . . . 0.0 109.914 179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -90.89 130.96 1.49 Allowed 'Trans proline' 0 C--N 1.314 -1.275 0 O-C-N 123.817 1.43 . . . . 0.0 110.588 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 63.3 t -130.1 130.01 65.73 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.699 -0.625 . . . . 0.0 109.548 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 6.7 tpt180 -82.81 149.28 27.29 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.507 -0.745 . . . . 0.0 110.175 -179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.0 ttt180 -95.56 119.94 34.94 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.581 -0.7 . . . . 0.0 110.123 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -110.04 19.94 18.46 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.555 -0.716 . . . . 0.0 110.615 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.7 179.41 42.69 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -61.47 -40.03 93.06 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.592 -0.946 . . . . 0.0 110.296 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 44.5 p -130.31 23.63 5.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.548 -0.72 . . . . 0.0 110.681 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -124.53 137.85 54.38 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.41 -0.806 . . . . 0.0 110.299 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -137.51 162.94 25.49 Favored Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 76.8 p -119.51 148.35 43.39 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.586 -0.949 . . . . 0.0 110.349 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.636 HD23 ' O ' ' A' ' 128' ' ' SER . 8.6 tp -95.27 126.84 40.86 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.595 -0.69 . . . . 0.0 110.158 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.468 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -61.26 -39.95 92.26 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.656 -0.653 . . . . 0.0 110.388 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . 0.636 ' O ' HD23 ' A' ' 126' ' ' LEU . 79.4 p -120.39 149.6 50.13 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.536 -0.728 . . . . 0.0 110.339 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.411 ' HB2' ' CG2' ' A' ' 163' ' ' VAL . 48.0 Cg_endo -79.88 121.46 4.54 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.969 1.51 . . . . 0.0 110.491 179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 38.4 mtt-85 -122.16 160.56 47.07 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.565 -0.709 . . . . 0.0 110.116 179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.53 150.76 80.24 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 O-C-N 123.955 1.502 . . . . 0.0 110.464 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 64.7 t -62.49 -30.18 48.54 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.628 -0.67 . . . . 0.0 109.783 179.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.2 m -60.03 -38.33 82.41 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.631 -0.668 . . . . 0.0 110.371 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -59.94 -40.05 87.61 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.469 -0.77 . . . . 0.0 110.029 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.2 mp -86.94 -22.99 25.27 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.486 -0.759 . . . . 0.0 110.572 179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.437 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 4.2 tptm -60.17 129.96 44.32 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.388 -0.82 . . . . 0.0 110.094 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.68 -9.84 73.19 Favored Glycine 0 N--CA 1.494 2.531 0 N-CA-C 110.616 -0.993 . . . . 0.0 110.616 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 60.1 p -89.94 -0.06 57.36 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.038 -1.272 . . . . 0.0 111.149 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 4.1 m -59.92 139.95 57.03 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.108 -0.995 . . . . 0.0 109.765 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 97.17 -20.36 51.11 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.423 -1.471 . . . . 0.0 109.423 -179.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.11 154.79 43.77 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.472 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.6 Cg_endo -98.01 147.49 0.73 Allowed 'Trans proline' 0 N--CA 1.487 1.143 0 O-C-N 123.803 1.423 . . . . 0.0 111.134 -179.597 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.565 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -104.41 109.19 20.95 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 178.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.4 132.15 44.09 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.503 -0.748 . . . . 0.0 111.507 -178.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.435 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.01 159.84 82.74 Favored Pre-proline 0 N--CA 1.497 1.898 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.89 -26.58 25.0 Favored 'Trans proline' 0 N--CA 1.502 2.011 0 O-C-N 123.456 1.24 . . . . 0.0 112.266 -178.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.67 -40.1 96.01 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.181 -0.949 . . . . 0.0 109.848 179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.68 36.13 0.8 Allowed Glycine 0 N--CA 1.494 2.556 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -131.81 146.37 52.1 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.459 -1.024 . . . . 0.0 110.29 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.525 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.59 143.65 57.77 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.554 -0.716 . . . . 0.0 110.324 -179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.748 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.1 t -118.25 -37.81 1.91 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.513 -0.742 . . . . 0.0 110.054 -179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.5 -170.39 39.04 Favored Glycine 0 N--CA 1.495 2.604 0 N-CA-C 109.744 -1.342 . . . . 0.0 109.744 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.431 HD11 ' CE ' ' A' ' 175' ' ' MET . 67.9 mt -127.93 133.33 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.523 -0.986 . . . . 0.0 110.24 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.619 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.2 t80 -61.78 137.04 58.21 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.607 -0.683 . . . . 0.0 109.908 179.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.8 ttt180 -116.88 -52.35 2.54 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.514 -0.742 . . . . 0.0 110.099 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.79 159.99 43.91 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.499 -0.751 . . . . 0.0 110.397 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.619 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.19 151.83 33.73 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.668 -0.645 . . . . 0.0 110.267 179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.6 t -107.88 119.14 56.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.589 -0.694 . . . . 0.0 109.714 179.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -130.78 155.19 47.09 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.664 -0.647 . . . . 0.0 110.471 -179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 2.8 m -103.42 -60.31 1.58 Allowed 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.57 -0.706 . . . . 0.0 110.272 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 71.8 mtt180 -127.92 66.72 1.35 Allowed 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.704 -0.622 . . . . 0.0 109.933 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 71.84 22.58 78.7 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 -179.734 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.458 ' O ' HG13 ' A' ' 163' ' ' VAL . 14.6 p -139.3 127.75 27.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.417 -1.049 . . . . 0.0 109.866 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.32 124.2 34.71 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.549 -0.719 . . . . 0.0 110.807 -179.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -107.57 -19.93 13.4 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.694 -0.629 . . . . 0.0 110.073 179.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -150.04 157.36 43.06 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.454 -0.779 . . . . 0.0 109.849 179.644 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 35.9 m -133.03 164.3 35.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -0.764 . . . . 0.0 110.792 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -125.13 134.83 52.29 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.558 -0.714 . . . . 0.0 110.218 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -134.18 157.78 45.36 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.519 -0.738 . . . . 0.0 110.095 179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.497 HG11 HD11 ' A' ' 82' ' ' LEU . 67.0 t -94.54 124.38 55.37 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.539 -0.726 . . . . 0.0 109.754 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.5 147.9 87.19 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.784 1.413 . . . . 0.0 110.41 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.748 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.5 t -59.89 -23.83 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.71 -0.619 . . . . 0.0 110.675 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.7 mt-10 -59.97 -40.75 90.12 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.372 -0.83 . . . . 0.0 110.633 -179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.8 p -70.0 -36.42 75.12 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.458 -0.776 . . . . 0.0 110.252 179.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.447 ' CE ' ' CG ' ' A' ' 53' ' ' TRP . 95.2 mtp -59.94 -40.09 87.76 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.604 -0.685 . . . . 0.0 110.378 -179.774 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 75.3 mt-10 -64.34 -39.95 94.91 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.645 -0.659 . . . . 0.0 110.105 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -61.81 -40.0 93.71 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.67 -0.644 . . . . 0.0 110.049 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.4 m -60.12 -39.97 88.08 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.558 -0.714 . . . . 0.0 110.176 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -60.54 -39.98 89.86 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.479 -0.763 . . . . 0.0 110.238 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -66.71 -40.02 88.29 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.595 -0.691 . . . . 0.0 110.071 179.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.77 -40.05 88.07 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.54 -0.725 . . . . 0.0 110.153 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.5 t -69.97 150.01 47.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.621 -0.674 . . . . 0.0 110.153 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.4 135.97 40.03 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.552 -0.718 . . . . 0.0 110.215 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 71.9 mmtt -60.22 -39.96 88.5 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.58 -0.7 . . . . 0.0 110.309 -179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 21.1 tptm -60.1 -39.95 87.95 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.524 -0.735 . . . . 0.0 110.171 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.9 tptt . . . . . 0 N--CA 1.493 1.715 0 CA-C-O 118.084 -0.96 . . . . 0.0 110.153 -179.932 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.463 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 -123.72 131.03 53.51 Favored 'General case' 0 N--CA 1.49 1.561 0 C-N-CA 118.762 -1.175 . . . . 0.0 110.066 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.866 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp -70.0 146.01 51.37 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.619 -0.675 . . . . 0.0 110.136 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.47 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.63 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 14.2 p . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.115 0.483 . . . . 0.0 110.233 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -174.33 176.1 46.69 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.6 mmt-85 -119.98 140.67 50.59 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.606 -0.938 . . . . 0.0 110.186 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -108.82 129.43 55.39 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.515 -0.741 . . . . 0.0 110.164 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 86.0 tttt -62.89 140.06 58.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.566 -0.709 . . . . 0.0 110.17 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 17.9 p-10 -75.34 73.21 2.41 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.582 -0.699 . . . . 0.0 110.459 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 95.6 mt-30 -99.79 112.26 24.53 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.14 179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 96.9 t -69.97 -40.19 78.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.66 -0.65 . . . . 0.0 109.743 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -150.97 159.98 44.22 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.633 -0.667 . . . . 0.0 109.917 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 160.81 42.95 0.02 OUTLIER Glycine 0 N--CA 1.494 2.539 0 N-CA-C 109.888 -1.285 . . . . 0.0 109.888 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -61.84 -38.28 87.63 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.532 -0.981 . . . . 0.0 109.827 179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.0 t -107.14 125.72 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.548 -0.72 . . . . 0.0 109.698 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -119.32 159.6 23.83 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.714 -0.617 . . . . 0.0 110.491 -179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.7 t -88.29 115.43 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.62 -0.675 . . . . 0.0 109.545 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.924 HG11 HD21 ' A' ' 64' ' ' LEU . 57.6 t -110.37 148.14 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.651 -0.656 . . . . 0.0 109.317 179.734 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -143.63 171.25 14.43 Favored 'General case' 0 N--CA 1.494 1.745 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.408 -179.382 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 15.3 p -140.44 179.34 6.72 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.902 -0.499 . . . . 0.0 109.997 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -75.13 -8.56 56.9 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.5 -0.75 . . . . 0.0 111.036 179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 21.2 m -109.82 -43.71 3.97 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.218 -0.926 . . . . 0.0 111.64 -179.207 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.417 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 5.2 pt20 -148.88 177.35 9.62 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.251 -0.905 . . . . 0.0 111.296 -179.071 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.3 m -122.58 149.65 43.68 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.588 -0.695 . . . . 0.0 110.279 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.763 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.9 p90 -164.0 -177.65 5.17 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.245 -0.91 . . . . 0.0 110.461 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.594 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.2 mt -113.36 141.35 47.15 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.545 -0.722 . . . . 0.0 110.635 -178.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.515 ' CB ' HG21 ' A' ' 36' ' ' VAL . . . -114.75 154.53 28.34 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.656 -0.652 . . . . 0.0 109.946 179.846 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.477 HG21 ' HB3' ' A' ' 142' ' ' PRO . 75.2 p -120.1 131.25 55.0 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.411 -0.806 . . . . 0.0 110.387 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.7 t -93.06 110.02 21.5 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.583 -0.698 . . . . 0.0 110.74 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.421 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.8 t -114.58 132.27 64.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.684 -0.635 . . . . 0.0 109.516 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.421 ' OD1' HG12 ' A' ' 48' ' ' VAL . 29.5 m120 55.56 39.0 30.96 Favored 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.516 -0.74 . . . . 0.0 110.933 -179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.593 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.96 19.07 75.06 Favored Glycine 0 N--CA 1.495 2.628 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.2 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -130.67 130.01 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.267 -1.137 . . . . 0.0 109.851 179.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.6 m -76.79 139.53 40.41 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.487 -0.758 . . . . 0.0 109.443 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 87.3 m95 -133.03 136.45 45.98 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.508 -0.745 . . . . 0.0 110.898 -179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.44 HG22 ' CB ' ' A' ' 45' ' ' ALA . 29.9 p -150.73 -179.85 7.61 Favored 'General case' 0 N--CA 1.496 1.854 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 178.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.746 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.6 p -88.25 150.19 3.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.284 -0.885 . . . . 0.0 110.238 179.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.423 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.3 t80 -60.06 -49.97 75.57 Favored 'General case' 0 N--CA 1.499 1.985 0 O-C-N 121.571 -0.706 . . . . 0.0 111.891 -178.702 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.822 ' CG ' HD23 ' B' ' 189' ' ' LEU . 5.7 p-80 -59.69 -24.29 63.83 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.09 -1.007 . . . . 0.0 110.739 -178.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.643 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.88 -42.49 20.3 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.763 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -151.24 95.45 2.17 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.771 -0.841 . . . . 0.0 109.786 179.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -69.63 -165.1 4.54 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.401 ' HB3' HG21 ' A' ' 76' ' ' THR . 88.0 p -71.15 69.79 0.53 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.621 -0.929 . . . . 0.0 109.87 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -139.99 179.22 6.73 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.562 -0.711 . . . . 0.0 110.293 -179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 33.0 p -64.93 139.9 58.81 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.646 -0.659 . . . . 0.0 109.801 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.924 HD21 HG11 ' A' ' 36' ' ' VAL . 14.8 tp -113.28 137.94 50.74 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.653 -0.654 . . . . 0.0 110.159 -179.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.76 109.88 22.57 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.655 -0.653 . . . . 0.0 109.955 179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.51 -175.07 15.84 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -64.78 -32.69 55.88 Favored 'Trans proline' 0 N--CA 1.491 1.359 0 O-C-N 123.895 1.471 . . . . 0.0 110.401 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -74.82 -31.5 61.7 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.575 -0.703 . . . . 0.0 110.06 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.41 -147.15 18.55 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.08 140.65 15.94 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.832 1.438 . . . . 0.0 110.377 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.8 mt -130.49 140.02 49.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.606 -0.684 . . . . 0.0 110.351 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.6 t -93.23 133.48 36.39 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.537 -0.727 . . . . 0.0 110.439 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 34.1 tt0 -71.53 140.55 49.95 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.42 -0.8 . . . . 0.0 110.699 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.5 mmm -105.87 -29.1 10.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.663 -0.648 . . . . 0.0 110.323 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -118.39 139.61 51.12 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.565 -0.709 . . . . 0.0 110.188 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.401 HG21 ' HB3' ' A' ' 61' ' ' SER . 24.2 m -139.97 135.34 32.65 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.522 -0.736 . . . . 0.0 110.414 179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.9 t-20 -150.05 98.95 2.77 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.602 -0.687 . . . . 0.0 109.897 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.42 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.3 t -69.67 -44.82 79.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.543 -0.723 . . . . 0.0 110.329 -179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.03 -50.02 75.38 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.553 -0.717 . . . . 0.0 110.46 -179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.648 ' HG2' HD12 ' A' ' 82' ' ' LEU . 1.8 tp-100 -80.41 -8.49 59.55 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.67 -0.644 . . . . 0.0 110.767 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.425 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.1 t70 56.56 45.24 22.65 Favored 'General case' 0 N--CA 1.501 2.116 0 O-C-N 121.173 -0.955 . . . . 0.0 110.248 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.648 HD12 ' HG2' ' A' ' 80' ' ' GLN . 75.8 mt -130.01 148.89 51.91 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.565 -0.709 . . . . 0.0 110.721 -179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.457 HG13 ' C ' ' A' ' 82' ' ' LEU . 32.6 m -149.97 169.92 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.66 -0.65 . . . . 0.0 109.626 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -165.05 160.31 33.58 Favored Glycine 0 N--CA 1.495 2.618 0 C-N-CA 119.845 -1.169 . . . . 0.0 110.416 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.729 ' CE2' HD22 ' A' ' 64' ' ' LEU . 16.1 m-90 -129.89 149.92 51.41 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.657 -0.908 . . . . 0.0 109.429 179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -60.9 120.13 9.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.322 -0.861 . . . . 0.0 109.63 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.593 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.73 141.64 72.5 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.588 -0.695 . . . . 0.0 110.307 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -70.01 160.02 51.15 Favored 'Trans proline' 0 N--CA 1.49 1.275 0 O-C-N 123.902 1.475 . . . . 0.0 110.32 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -72.69 143.79 38.31 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 O-C-N 123.947 1.498 . . . . 0.0 110.274 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.48 -22.08 42.75 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.17 46.95 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.286 -1.126 . . . . 0.0 110.128 -179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -92.81 165.42 12.93 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.611 -0.681 . . . . 0.0 110.109 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.2 p -130.48 169.95 14.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.473 -0.767 . . . . 0.0 110.307 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.758 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -103.38 132.0 50.0 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.573 -0.705 . . . . 0.0 110.379 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.414 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 50.9 p -72.06 159.99 83.92 Favored Pre-proline 0 N--CA 1.496 1.855 0 O-C-N 121.594 -0.691 . . . . 0.0 109.941 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -83.26 150.27 13.51 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.766 1.403 . . . . 0.0 110.698 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -65.07 132.04 48.14 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.583 -0.698 . . . . 0.0 110.196 179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 17.7 p -135.98 53.16 1.95 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.626 -0.671 . . . . 0.0 109.765 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.9 p -143.85 -3.49 0.88 Allowed 'General case' 0 N--CA 1.497 1.924 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.332 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.94 32.31 74.84 Favored Glycine 0 N--CA 1.496 2.659 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -91.44 129.95 37.35 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.58 -0.953 . . . . 0.0 110.331 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.9 m -77.48 -30.14 52.97 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.622 -0.674 . . . . 0.0 110.315 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.56 133.77 56.42 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.54 -0.725 . . . . 0.0 110.346 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.464 ' CD2' HG21 ' A' ' 151' ' ' VAL . 90.4 mt -134.95 151.66 51.05 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.631 -0.668 . . . . 0.0 110.359 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 -119.85 123.17 42.97 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.512 -0.743 . . . . 0.0 109.969 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.453 HD13 HD21 ' A' ' 143' ' ' LEU . 67.0 tp -99.64 133.06 44.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.525 -0.734 . . . . 0.0 110.461 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.3 t -95.72 119.97 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.625 -0.672 . . . . 0.0 109.582 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -92.09 168.13 11.59 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.514 -0.741 . . . . 0.0 110.476 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.594 ' HA ' HD11 ' A' ' 44' ' ' LEU . 37.1 mtp-105 -60.14 -27.3 66.96 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.614 -0.679 . . . . 0.0 110.318 179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.413 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -93.69 29.07 2.13 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.494 -0.754 . . . . 0.0 110.744 -179.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.77 40.0 30.97 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.197 -0.939 . . . . 0.0 111.057 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.6 m-20 -99.44 168.7 9.82 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.562 -0.711 . . . . 0.0 109.928 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 113' ' ' VAL . 8.8 p -130.03 129.98 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.485 -0.759 . . . . 0.0 110.328 179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.574 ' O ' HG23 ' A' ' 116' ' ' VAL . 82.8 mt -121.26 104.31 40.9 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.576 -0.702 . . . . 0.0 109.657 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.4 105.84 0.65 Allowed 'Trans proline' 0 N--CA 1.491 1.341 0 O-C-N 123.79 1.416 . . . . 0.0 110.431 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.574 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.2 t -110.04 120.02 60.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.625 -0.672 . . . . 0.0 109.799 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.3 tpt180 -77.75 142.78 38.49 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.459 -0.776 . . . . 0.0 109.756 179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 31.8 ttp85 -78.01 129.97 35.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.536 -0.727 . . . . 0.0 110.379 -179.768 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.0 mmt180 -128.63 22.5 5.91 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.594 -0.692 . . . . 0.0 110.328 179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 172.1 -179.86 43.46 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.376 -1.489 . . . . 0.0 109.376 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -66.79 -40.05 88.01 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.496 -1.002 . . . . 0.0 110.393 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.8 p -129.79 27.34 5.21 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.54 -0.725 . . . . 0.0 110.532 -179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -133.09 162.91 30.47 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.437 -0.789 . . . . 0.0 110.233 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -158.77 175.69 35.76 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 77.5 p -129.21 148.85 51.19 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.607 -0.937 . . . . 0.0 110.262 -179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 8.6 mp -100.76 123.12 44.5 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.607 -0.683 . . . . 0.0 110.438 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.525 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -64.04 -39.96 95.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.507 -0.746 . . . . 0.0 109.781 179.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -107.91 112.14 61.92 Favored Pre-proline 0 N--CA 1.492 1.65 0 O-C-N 121.619 -0.675 . . . . 0.0 109.838 179.711 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.32 128.99 22.78 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 O-C-N 123.801 1.421 . . . . 0.0 110.631 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 40.0 mtt180 -125.09 160.03 56.51 Favored Pre-proline 0 N--CA 1.493 1.696 0 O-C-N 121.592 -0.692 . . . . 0.0 109.906 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -65.48 153.95 75.88 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.863 1.454 . . . . 0.0 110.28 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.517 HG11 ' OE1' ' B' ' 188' ' ' GLU . 79.8 t -63.54 -34.75 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 O-C-N 121.658 -0.651 . . . . 0.0 110.102 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.4 p -59.74 -36.5 76.73 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.55 -0.719 . . . . 0.0 110.466 -179.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 38.2 t80 -59.96 -40.01 87.55 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.11 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.5 mp -85.27 -16.18 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.563 -0.711 . . . . 0.0 111.119 -179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.23 132.83 55.14 Favored 'General case' 0 N--CA 1.499 2.022 0 O-C-N 121.173 -0.954 . . . . 0.0 110.069 179.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 89.98 -6.89 82.54 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.6 p -93.08 -0.04 57.17 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.254 -1.145 . . . . 0.0 111.168 -179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.403 ' HB2' ' H2A' ' B' ' 191' ' ' FE3 . 3.1 m -59.97 139.91 57.09 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.058 -1.026 . . . . 0.0 109.706 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.473 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.58 -19.65 53.54 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.093 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.49 167.87 3.73 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.477 ' HB3' HG21 ' A' ' 46' ' ' THR . 56.3 Cg_endo -106.07 149.04 0.11 Allowed 'Trans proline' 0 C--N 1.316 -1.132 0 O-C-N 123.801 1.422 . . . . 0.0 111.206 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.453 HD21 HD13 ' A' ' 106' ' ' LEU . 85.2 mt -110.01 102.51 11.24 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.513 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -98.12 133.69 42.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.517 -0.739 . . . . 0.0 111.713 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -70.0 159.41 84.38 Favored Pre-proline 0 N--CA 1.496 1.864 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -51.88 -26.14 23.61 Favored 'Trans proline' 0 N--CA 1.501 1.946 0 O-C-N 123.423 1.223 . . . . 0.0 112.393 -178.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.7 m -62.73 -39.99 95.81 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.262 -0.899 . . . . 0.0 110.029 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.29 36.36 0.75 Allowed Glycine 0 N--CA 1.495 2.588 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . 0.414 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 2.9 m-70 -132.26 143.25 49.78 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.423 -1.045 . . . . 0.0 110.193 179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.92 142.69 58.35 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.593 -0.692 . . . . 0.0 110.332 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -114.91 -43.63 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 121.575 -0.703 . . . . 0.0 109.891 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -169.74 -170.0 33.67 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 -179.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.448 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.9 mt -123.86 139.36 50.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.618 -0.931 . . . . 0.0 110.375 -179.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.44 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.2 t80 -64.26 136.43 57.17 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.687 -0.633 . . . . 0.0 109.774 179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.3 ttt180 -115.94 -52.27 2.62 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.539 -0.726 . . . . 0.0 110.267 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -154.32 159.95 41.47 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.618 -0.676 . . . . 0.0 110.25 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.04 150.36 34.07 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.602 -0.686 . . . . 0.0 110.348 180.0 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.0 t -109.94 120.0 60.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.673 -0.642 . . . . 0.0 109.751 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.438 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -129.77 145.29 51.56 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.63 -0.669 . . . . 0.0 110.426 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.4 m -70.0 -48.86 56.44 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.684 -0.635 . . . . 0.0 110.119 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 20.8 ptt180 -162.64 54.73 0.21 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.658 -0.651 . . . . 0.0 109.75 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 113.21 -17.89 21.49 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.862 -1.295 . . . . 0.0 109.862 -179.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.0 t -111.68 120.52 62.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.226 -1.161 . . . . 0.0 109.781 179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.82 123.73 37.36 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.542 -0.724 . . . . 0.0 110.527 -179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 52.3 mttp -108.57 -24.77 11.23 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.634 -0.666 . . . . 0.0 110.197 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -135.78 158.77 43.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.46 -0.775 . . . . 0.0 110.102 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 28.7 m -140.24 170.62 14.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.565 -0.71 . . . . 0.0 110.545 -179.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -128.93 139.91 51.91 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.646 -0.659 . . . . 0.0 109.905 179.774 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -138.92 157.44 46.02 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.533 -0.729 . . . . 0.0 110.458 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.625 HG11 HD11 ' A' ' 82' ' ' LEU . 59.6 t -96.16 121.52 60.38 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.606 -0.684 . . . . 0.0 109.49 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -65.01 150.06 88.56 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 O-C-N 123.845 1.445 . . . . 0.0 110.408 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 151' ' ' VAL . 87.8 t -60.84 -25.83 36.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.883 0 O-C-N 121.606 -0.684 . . . . 0.0 110.529 -179.784 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 65.2 mm-40 -59.97 -36.98 78.3 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.46 -0.775 . . . . 0.0 110.497 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 80.8 p -60.09 -33.12 71.66 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.427 -0.796 . . . . 0.0 110.548 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.448 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.9 mtt -60.0 -40.03 87.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.507 -0.745 . . . . 0.0 110.541 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -60.11 -40.0 88.15 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.595 -0.691 . . . . 0.0 110.406 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -60.93 -40.13 92.06 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 110.279 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -67.11 -50.04 62.87 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.481 -0.762 . . . . 0.0 110.206 -179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 78.7 mtm -68.81 -39.67 79.96 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.498 -0.751 . . . . 0.0 110.07 179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -60.02 -39.99 87.76 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.609 -0.682 . . . . 0.0 110.172 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.96 -42.64 94.55 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.629 -0.669 . . . . 0.0 110.256 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.5 t -150.07 99.96 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.537 -0.727 . . . . 0.0 110.202 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -60.73 -40.03 90.84 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.58 -0.7 . . . . 0.0 110.169 -179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -80.14 156.27 27.07 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.527 -0.733 . . . . 0.0 110.331 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -79.97 159.74 26.18 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.57 -0.706 . . . . 0.0 110.402 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.742 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.112 179.997 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.517 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.2 tt0 -120.04 134.04 55.36 Favored 'General case' 0 N--CA 1.49 1.563 0 C-N-CA 118.71 -1.196 . . . . 0.0 110.086 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.822 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -68.06 140.41 56.28 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.625 -0.672 . . . . 0.0 110.41 -179.807 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.4 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.485 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.492 1.643 0 CA-C-O 121.063 0.458 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.19 -40.01 96.7 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.817 -1.313 . . . . 0.0 109.817 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.6 mtm-85 -129.94 149.74 51.53 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.563 -0.963 . . . . 0.0 110.294 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -130.0 139.68 51.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.563 -0.711 . . . . 0.0 110.134 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -100.83 120.0 39.48 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.649 -0.657 . . . . 0.0 110.264 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 -94.29 -39.66 10.39 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.53 -0.731 . . . . 0.0 110.221 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.1 mt-30 -139.82 150.89 45.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.568 -0.707 . . . . 0.0 110.206 -179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 80.0 t -60.65 -42.92 93.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.918 0 O-C-N 121.532 -0.73 . . . . 0.0 109.939 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 -122.54 139.8 53.49 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.632 -0.668 . . . . 0.0 110.193 179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -152.32 27.71 0.88 Allowed Glycine 0 N--CA 1.492 2.431 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -65.94 -39.97 90.94 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.601 -0.941 . . . . 0.0 109.841 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -114.78 128.85 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.582 -0.699 . . . . 0.0 109.628 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -124.03 159.95 28.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.579 -0.701 . . . . 0.0 110.316 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 62.0 t -108.29 122.18 62.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.67 -0.644 . . . . 0.0 109.636 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.539 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.8 m -118.44 156.76 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.615 -0.678 . . . . 0.0 110.3 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 62.7 m -135.88 167.34 21.37 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.598 -0.688 . . . . 0.0 110.907 -179.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.3 m -134.44 170.68 15.39 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.742 -0.599 . . . . 0.0 109.986 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -65.29 -16.63 63.77 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.501 -0.749 . . . . 0.0 111.109 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.2 m -117.39 -35.02 4.12 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.189 -0.944 . . . . 0.0 111.628 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.404 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 2.0 pm0 -150.81 170.68 18.68 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.225 -0.922 . . . . 0.0 111.096 -179.204 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 85.9 p -130.43 155.69 46.01 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.608 -0.683 . . . . 0.0 110.36 -179.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.692 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 18.1 p90 -162.46 -178.33 6.2 Favored 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.383 -0.823 . . . . 0.0 110.256 -179.846 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.685 HD11 ' HA ' ' A' ' 109' ' ' ARG . 73.5 mt -113.66 152.84 29.87 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.519 -0.738 . . . . 0.0 110.9 -178.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -132.41 161.09 34.51 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.662 -0.649 . . . . 0.0 110.013 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.2 t -122.95 139.0 54.52 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.572 -0.705 . . . . 0.0 110.518 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 46.4 t -93.96 104.65 16.69 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.36 -0.838 . . . . 0.0 110.422 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 58.7 t -112.44 133.35 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.692 -0.63 . . . . 0.0 109.714 179.664 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 46.6 t-20 56.97 38.25 29.26 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.502 -0.749 . . . . 0.0 110.893 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.2 27.11 74.06 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 110.533 -1.027 . . . . 0.0 110.533 179.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -141.79 131.85 24.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.382 -1.07 . . . . 0.0 110.064 179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 84.3 m -76.33 144.97 39.86 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.423 -0.798 . . . . 0.0 109.06 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 78.8 m95 -129.93 150.99 50.98 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.528 -0.732 . . . . 0.0 111.087 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.932 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -168.82 -179.78 3.86 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.823 -0.548 . . . . 0.0 109.574 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.811 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.5 p -90.04 160.02 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.478 -0.764 . . . . 0.0 110.218 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 60.2 t80 -73.27 -44.62 58.94 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.538 -0.726 . . . . 0.0 111.779 -178.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.859 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.7 p-80 -60.6 -24.66 65.65 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.134 -0.979 . . . . 0.0 110.704 -178.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.584 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.7 -47.78 11.44 Favored Glycine 0 N--CA 1.493 2.485 0 N-CA-C 108.3 -1.92 . . . . 0.0 108.3 178.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.692 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -137.09 94.53 2.96 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.751 -0.852 . . . . 0.0 109.271 179.243 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -72.06 62.81 1.33 Allowed Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -179.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.8 t 53.38 39.97 30.65 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.255 -1.144 . . . . 0.0 110.809 179.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 94.9 mttt -110.02 179.29 4.15 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.571 -0.705 . . . . 0.0 110.021 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 87.0 m -64.9 139.13 58.73 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.866 -0.733 . . . . 0.0 109.225 179.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.854 HD22 ' CZ2' ' A' ' 85' ' ' TRP . 12.6 tp -125.78 133.12 52.14 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.549 -0.719 . . . . 0.0 110.177 -179.347 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.76 113.54 25.1 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.586 -0.697 . . . . 0.0 109.922 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -117.43 -179.26 17.54 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -62.28 -31.13 82.02 Favored 'Trans proline' 0 N--CA 1.492 1.419 0 O-C-N 123.871 1.459 . . . . 0.0 110.649 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 7.2 ptpt -75.87 -20.19 58.28 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.563 -0.71 . . . . 0.0 110.626 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 129.54 -133.27 7.42 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 -179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -84.25 146.05 11.06 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.9 1.474 . . . . 0.0 110.136 179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.9 mt -120.02 129.98 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 121.589 -0.694 . . . . 0.0 110.34 -179.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.5 p -87.45 147.09 25.56 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.48 -0.762 . . . . 0.0 110.442 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 15.3 mp0 -87.66 140.01 29.95 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.822 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.7 mmm -119.23 -41.8 2.71 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.573 -0.704 . . . . 0.0 110.422 179.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -120.06 140.0 51.68 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.519 -0.738 . . . . 0.0 110.684 -179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.489 ' HA ' HG12 ' A' ' 83' ' ' VAL . 33.4 m -139.97 130.01 24.93 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.605 -0.684 . . . . 0.0 110.09 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 51.6 t-20 -142.19 98.33 3.3 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.499 -0.751 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 94.1 t -70.05 -40.15 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.837 0 O-C-N 121.59 -0.693 . . . . 0.0 109.96 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -60.1 -47.31 86.43 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.72 . . . . 0.0 110.644 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 2.4 tp-100 -87.14 -0.03 56.04 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.505 -0.747 . . . . 0.0 110.801 -179.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.448 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.8 t70 52.96 45.14 29.42 Favored 'General case' 0 N--CA 1.502 2.154 0 O-C-N 121.113 -0.992 . . . . 0.0 110.543 -179.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.952 HD11 HG11 ' A' ' 170' ' ' VAL . 64.5 mt -139.94 143.31 36.53 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.445 -0.784 . . . . 0.0 111.069 -179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.535 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -147.47 160.01 8.46 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.641 -0.662 . . . . 0.0 109.61 179.331 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.75 159.97 28.03 Favored Glycine 0 N--CA 1.496 2.671 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.932 ' CH2' HG21 ' A' ' 54' ' ' THR . 15.3 m-90 -118.22 166.91 12.03 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.666 -0.902 . . . . 0.0 109.53 179.333 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -72.49 119.88 17.33 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.501 -0.749 . . . . 0.0 109.271 178.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -64.8 140.35 98.04 Favored Pre-proline 0 N--CA 1.496 1.85 0 O-C-N 121.495 -0.753 . . . . 0.0 110.296 -179.462 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.96 159.98 51.29 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.926 1.487 . . . . 0.0 110.268 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.82 142.11 31.4 Favored 'Trans proline' 0 C--N 1.313 -1.294 0 O-C-N 123.905 1.476 . . . . 0.0 110.225 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.48 29.29 49.59 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -109.79 152.12 26.1 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.561 -0.964 . . . . 0.0 110.141 179.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -88.3 167.57 13.43 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.689 -0.632 . . . . 0.0 110.038 179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 47.5 t -144.04 164.37 30.84 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.623 -0.673 . . . . 0.0 110.16 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . . . . . . . . . 84.4 mt -110.16 149.2 30.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.601 -0.687 . . . . 0.0 110.653 -179.628 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.421 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 24.5 p -89.95 177.76 2.26 Favored Pre-proline 0 N--CA 1.494 1.732 0 O-C-N 121.694 -0.629 . . . . 0.0 109.984 179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -88.74 159.11 6.25 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 O-C-N 123.801 1.421 . . . . 0.0 110.566 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.788 ' HB2' HG22 ' A' ' 151' ' ' VAL . 48.9 t -68.76 130.39 42.67 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.716 -0.615 . . . . 0.0 110.113 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 38.7 p -134.49 54.04 1.96 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.738 -0.601 . . . . 0.0 109.754 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.71 -5.95 0.8 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.561 -0.712 . . . . 0.0 112.37 -179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.98 38.2 93.84 Favored Glycine 0 N--CA 1.496 2.647 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 -179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -100.01 122.35 42.77 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.575 -0.956 . . . . 0.0 110.463 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.4 m -69.95 -29.43 66.55 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.643 -0.66 . . . . 0.0 110.176 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -64.31 132.58 50.6 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.542 -0.724 . . . . 0.0 110.21 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.581 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.1 mt -136.63 149.95 48.27 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.554 -0.716 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.439 ' HD1' HG22 ' A' ' 113' ' ' VAL . 62.9 m-85 -112.49 120.5 41.85 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.519 -0.738 . . . . 0.0 110.057 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 66.2 tp -93.7 131.45 39.02 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.552 -0.718 . . . . 0.0 110.432 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -93.21 119.98 41.85 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.516 179.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.1 m -97.56 169.78 9.48 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.52 -0.738 . . . . 0.0 110.62 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.685 ' HA ' HD11 ' A' ' 44' ' ' LEU . 29.8 mtp-105 -62.54 -27.62 69.3 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.682 -0.636 . . . . 0.0 110.129 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 84.5 t60 -94.6 28.38 2.65 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.529 -0.732 . . . . 0.0 110.587 -179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.24 41.9 31.76 Favored 'General case' 0 N--CA 1.501 2.088 0 O-C-N 121.195 -0.94 . . . . 0.0 111.036 179.668 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -100.04 122.12 42.43 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.516 -0.74 . . . . 0.0 109.961 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.574 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -97.86 70.61 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.637 -0.665 . . . . 0.0 110.308 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.427 HG23 ' O ' ' A' ' 114' ' ' ILE . 5.3 tp -70.0 129.99 90.31 Favored Pre-proline 0 N--CA 1.497 1.875 0 O-C-N 121.57 -0.706 . . . . 0.0 109.862 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.41 ' HD2' HD12 ' A' ' 114' ' ' ILE . 48.6 Cg_endo -75.71 134.33 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.781 1.411 . . . . 0.0 110.599 -179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -129.86 130.06 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.636 -0.665 . . . . 0.0 109.558 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -92.37 133.55 35.76 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.49 -0.756 . . . . 0.0 110.095 -179.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.0 ttt180 -80.42 125.85 30.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.652 -0.655 . . . . 0.0 110.357 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.9 mmt180 -122.48 24.23 9.35 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.587 -0.696 . . . . 0.0 110.288 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -178.49 -177.36 47.1 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.12 -40.0 78.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.539 -0.977 . . . . 0.0 110.393 -179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.2 p -133.09 24.46 4.21 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.513 -0.742 . . . . 0.0 110.691 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.44 151.79 50.54 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.437 -0.789 . . . . 0.0 110.168 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.3 171.56 25.05 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 -179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 81.4 p -115.24 154.55 28.86 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.65 -0.912 . . . . 0.0 110.04 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 19.2 tp -99.99 119.98 39.1 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.51 -0.744 . . . . 0.0 110.069 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.551 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.71 -39.98 88.24 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.583 -0.698 . . . . 0.0 110.101 179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.3 m -110.22 114.36 55.74 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.622 -0.674 . . . . 0.0 110.169 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -64.67 114.26 2.66 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.782 1.412 . . . . 0.0 110.439 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 51.9 mtt180 -125.59 160.08 57.6 Favored Pre-proline 0 N--CA 1.493 1.702 0 O-C-N 121.628 -0.67 . . . . 0.0 110.081 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -63.71 157.08 53.71 Favored 'Trans proline' 0 N--CA 1.492 1.392 0 O-C-N 123.853 1.449 . . . . 0.0 110.362 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.573 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.06 -23.89 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.595 -0.691 . . . . 0.0 110.636 -179.801 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.1 m -59.98 -39.98 87.53 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.469 -0.769 . . . . 0.0 110.328 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 39.6 t80 -59.91 -50.13 74.96 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.483 -0.761 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.462 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.93 -26.1 63.98 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.684 -0.635 . . . . 0.0 110.097 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.435 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 9.8 tptm -58.74 129.95 44.55 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.437 -0.79 . . . . 0.0 110.311 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.95 -10.06 72.39 Favored Glycine 0 N--CA 1.494 2.555 0 C-N-CA 120.407 -0.902 . . . . 0.0 110.866 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 59.5 p -94.57 -3.22 50.11 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.0 -1.294 . . . . 0.0 111.251 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.5 t -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.079 -1.013 . . . . 0.0 109.667 179.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.482 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.24 -22.18 38.76 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -178.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.57 155.62 44.02 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 108.977 -1.649 . . . . 0.0 108.977 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.514 ' C ' HD12 ' A' ' 143' ' ' LEU . 53.0 Cg_endo -95.77 150.07 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.845 1.445 . . . . 0.0 111.219 -179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -106.61 108.99 20.78 Favored 'General case' 0 N--CA 1.491 1.576 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.509 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -98.8 130.28 45.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 111.579 -178.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.437 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.02 159.54 83.88 Favored Pre-proline 0 N--CA 1.495 1.815 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 178.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.9 -26.51 24.82 Favored 'Trans proline' 0 N--CA 1.501 1.929 0 O-C-N 123.494 1.26 . . . . 0.0 112.28 -178.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.1 m -62.68 -39.96 95.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.258 -0.901 . . . . 0.0 109.99 179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.23 35.99 0.84 Allowed Glycine 0 N--CA 1.495 2.576 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.9 m170 -131.8 149.47 52.45 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.409 -1.054 . . . . 0.0 110.314 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.421 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -68.21 139.96 56.06 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.66 -0.65 . . . . 0.0 110.272 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.788 HG22 ' HB2' ' A' ' 97' ' ' CYS . 64.7 t -114.46 -36.15 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.584 -0.697 . . . . 0.0 109.99 -179.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 179.52 -166.61 36.03 Favored Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.482 HG23 ' C ' ' A' ' 140' ' ' GLY . 96.6 mt -130.97 140.07 49.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.563 -0.963 . . . . 0.0 110.263 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.408 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 21.3 t80 -64.25 138.57 58.51 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.7 -0.625 . . . . 0.0 109.58 179.507 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.7 ttt180 -118.49 -52.25 2.37 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.473 -0.767 . . . . 0.0 110.428 -179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.537 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.79 160.06 43.1 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.593 -0.692 . . . . 0.0 110.184 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.408 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.81 151.88 26.44 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.616 -0.677 . . . . 0.0 110.256 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.565 HG13 ' CD2' ' B' ' 187' ' ' IBU . 62.9 t -108.47 116.97 52.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.662 -0.649 . . . . 0.0 109.751 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.573 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.3 p -129.88 142.39 50.67 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.653 -0.654 . . . . 0.0 110.254 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 91.1 m -69.69 -49.61 51.78 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.566 -0.709 . . . . 0.0 110.103 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -162.91 54.15 0.19 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.71 -0.619 . . . . 0.0 109.823 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 114.78 -18.51 16.89 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.509 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -112.9 120.77 63.76 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.29 -1.124 . . . . 0.0 109.758 179.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -86.61 130.1 34.62 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.549 -0.72 . . . . 0.0 110.522 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 58.2 pttt -112.47 -26.15 8.84 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.583 -0.698 . . . . 0.0 110.33 179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.32 157.99 44.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.663 -0.648 . . . . 0.0 109.974 179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.0 m -125.25 179.5 3.08 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 121.431 -0.793 . . . . 0.0 110.608 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -135.36 134.58 39.94 Favored 'General case' 0 N--CA 1.492 1.654 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -138.18 153.13 49.2 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.35 -0.844 . . . . 0.0 110.809 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.952 HG11 HD11 ' A' ' 82' ' ' LEU . 60.5 t -95.09 119.12 66.26 Favored Pre-proline 0 N--CA 1.493 1.675 0 N-CA-C 109.184 -0.672 . . . . 0.0 109.184 179.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -62.38 155.23 58.75 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.771 1.406 . . . . 0.0 110.589 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 151' ' ' VAL . 93.7 t -56.78 -23.18 17.11 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.611 -0.681 . . . . 0.0 110.669 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 3.5 mp0 -60.04 -33.13 71.61 Favored 'General case' 0 N--CA 1.499 1.994 0 O-C-N 121.375 -0.828 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . 0.454 ' HB3' HG12 ' A' ' 170' ' ' VAL . 18.4 t -60.07 -37.99 81.53 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.453 -0.78 . . . . 0.0 110.393 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.481 ' HE1' HD11 ' A' ' 153' ' ' ILE . 67.6 mtt -59.97 -39.97 87.46 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.521 -0.737 . . . . 0.0 110.502 -179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -62.31 -39.9 94.53 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.594 -0.691 . . . . 0.0 110.189 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.6 m -70.09 -39.97 75.23 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.596 -0.69 . . . . 0.0 109.965 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 84.8 m -59.98 -49.54 77.25 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.588 -0.695 . . . . 0.0 110.317 -179.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -68.22 -39.97 82.22 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.542 -0.723 . . . . 0.0 110.295 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 38.4 ttt180 -69.75 -39.97 76.42 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.608 -0.683 . . . . 0.0 110.206 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.96 -29.04 66.06 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.556 -0.715 . . . . 0.0 110.316 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 25.4 m -92.65 42.83 1.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.588 -0.695 . . . . 0.0 110.541 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -59.96 -49.98 75.56 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.401 -0.812 . . . . 0.0 110.262 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 36.7 ttmt -151.0 120.02 6.69 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.539 -0.726 . . . . 0.0 110.288 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 81.8 mttt -143.27 159.99 41.31 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.551 -0.718 . . . . 0.0 110.192 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 29.9 tptp . . . . . 0 N--CA 1.501 2.114 0 CA-C-O 117.954 -1.022 . . . . 0.0 110.686 -179.999 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . 0.565 ' CD2' HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.537 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.3 tt0 -145.01 130.02 18.39 Favored 'General case' 0 N--CA 1.491 1.622 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.208 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.859 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp -73.51 145.54 45.53 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.647 -0.658 . . . . 0.0 109.985 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.457 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.653 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.017 0.437 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 178.77 -172.07 44.31 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 7.2 tpp180 -119.97 140.0 51.6 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.531 -0.982 . . . . 0.0 110.005 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -108.3 21.02 17.92 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.51 -0.744 . . . . 0.0 110.723 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.97 120.42 39.77 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.4 -0.812 . . . . 0.0 110.204 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.2 t-20 -158.05 159.97 36.9 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.527 -0.733 . . . . 0.0 110.225 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -99.99 123.41 44.21 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.604 -0.685 . . . . 0.0 110.17 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.562 HG23 ' HG3' ' A' ' 30' ' ' GLU . 34.6 m -69.8 -26.3 30.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.587 -0.695 . . . . 0.0 110.556 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.562 ' HG3' HG23 ' A' ' 29' ' ' VAL . 98.6 mt-10 -123.57 149.1 45.7 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.449 -0.782 . . . . 0.0 110.25 179.809 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 140.41 59.02 0.04 OUTLIER Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -67.3 -37.44 83.38 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.48 -1.012 . . . . 0.0 109.903 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 123.27 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.688 -0.632 . . . . 0.0 109.817 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -123.72 157.89 32.9 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.589 -0.695 . . . . 0.0 110.312 -179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 67.9 t -87.34 131.71 34.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.605 -0.685 . . . . 0.0 109.812 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.483 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.1 m -127.13 152.89 35.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.775 0 O-C-N 121.587 -0.696 . . . . 0.0 110.367 179.827 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 64.0 m -135.96 -177.89 4.9 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.705 -0.622 . . . . 0.0 110.34 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.528 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.6 OUTLIER -144.75 -169.13 3.1 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.528 ' H ' HG22 ' A' ' 38' ' ' THR . . . -59.32 -38.67 80.87 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.395 -0.816 . . . . 0.0 110.098 179.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.1 t -138.58 -7.22 1.49 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.443 -0.786 . . . . 0.0 112.514 -179.49 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -114.55 151.39 33.44 Favored 'General case' 0 N--CA 1.499 1.986 0 O-C-N 120.868 -1.145 . . . . 0.0 111.163 -179.148 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -136.09 141.49 44.22 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.584 -0.697 . . . . 0.0 110.238 179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.753 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 32.8 p90 -170.32 -177.53 2.49 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.426 -0.796 . . . . 0.0 110.023 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.749 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.1 mt -113.13 167.9 10.15 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.49 -0.756 . . . . 0.0 110.253 -178.814 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -145.9 160.04 42.38 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.664 -0.647 . . . . 0.0 110.265 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.447 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.8 t -120.57 140.2 51.85 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.597 -0.69 . . . . 0.0 110.18 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 37.7 t -99.23 109.96 22.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.417 -0.802 . . . . 0.0 110.407 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.19 130.03 64.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.541 -0.724 . . . . 0.0 109.701 179.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 56.14 39.93 30.25 Favored 'General case' 0 N--CA 1.501 2.098 0 O-C-N 121.544 -0.723 . . . . 0.0 110.868 -179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.741 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 19.92 75.73 Favored Glycine 0 N--CA 1.496 2.676 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.179 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 66.0 t -131.06 130.01 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.875 0 O-C-N 121.267 -1.137 . . . . 0.0 109.958 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 78.4 m -77.41 140.43 39.89 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.415 -0.803 . . . . 0.0 109.461 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 67.1 m95 -130.62 147.09 52.25 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.517 -0.739 . . . . 0.0 110.936 -179.561 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.794 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -167.66 -179.19 4.21 Favored 'General case' 0 N--CA 1.493 1.691 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.88 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.783 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.6 p -88.68 156.63 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.363 -0.836 . . . . 0.0 110.356 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.433 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 53.0 t80 -70.04 -44.37 69.36 Favored 'General case' 0 N--CA 1.5 2.068 0 O-C-N 121.594 -0.691 . . . . 0.0 111.887 -178.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.783 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.9 p-80 -60.78 -24.26 65.65 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.195 -0.941 . . . . 0.0 110.787 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.563 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -77.1 -48.96 7.88 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.522 -1.831 . . . . 0.0 108.522 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.753 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -128.49 101.09 6.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.784 -0.833 . . . . 0.0 109.534 179.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.26 -164.93 2.34 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 35.0 p -72.21 65.92 0.62 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.655 -0.909 . . . . 0.0 109.844 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.39 169.87 16.77 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.604 -0.685 . . . . 0.0 110.595 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 62.7 p -69.89 159.92 32.78 Favored 'General case' 0 N--CA 1.494 1.763 0 C-N-CA 120.232 -0.587 . . . . 0.0 109.579 179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.858 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.0 tp -115.51 140.8 48.83 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.543 -0.723 . . . . 0.0 110.335 -179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -96.91 109.7 22.37 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.576 -0.702 . . . . 0.0 110.109 179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -120.63 179.98 16.32 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.25 -1.54 . . . . 0.0 109.25 179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.99 -32.34 65.21 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.854 1.45 . . . . 0.0 110.431 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 87.0 mttt -71.08 -31.49 67.89 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.663 -0.648 . . . . 0.0 110.037 -179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.11 -162.2 25.99 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 109.318 -1.513 . . . . 0.0 109.318 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -69.02 137.82 38.59 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.866 1.456 . . . . 0.0 110.155 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.7 mt -120.06 130.04 74.75 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.615 -0.678 . . . . 0.0 110.49 -179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 77.8 p -80.4 149.98 29.98 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.61 -0.681 . . . . 0.0 109.927 179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -100.86 144.42 29.84 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.523 -0.736 . . . . 0.0 111.218 -179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.442 ' HE1' ' HG3' ' A' ' 86' ' ' GLN . 30.2 mtm -117.3 -21.76 8.58 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.631 . . . . 0.0 110.59 179.611 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -125.57 147.44 49.28 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.417 -0.802 . . . . 0.0 110.403 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.493 ' HA ' HG12 ' A' ' 83' ' ' VAL . 6.9 t -169.32 129.72 1.08 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.59 -0.694 . . . . 0.0 109.921 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.1 t-20 -137.6 116.61 12.45 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.607 -0.683 . . . . 0.0 110.258 -179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 69.3 t -69.8 -49.61 56.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.582 -0.699 . . . . 0.0 109.811 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.0 m-20 -60.28 -48.57 81.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.606 -0.684 . . . . 0.0 110.374 -179.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.783 ' HG2' HD12 ' A' ' 82' ' ' LEU . 50.7 tt0 -79.33 -10.11 59.74 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.634 -0.666 . . . . 0.0 110.612 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.0 t70 54.16 49.94 17.6 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.15 -0.969 . . . . 0.0 110.701 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.783 HD12 ' HG2' ' A' ' 80' ' ' GLN . 39.0 mt -143.25 130.98 21.38 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.385 -0.822 . . . . 0.0 111.43 -179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.493 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.4 m -130.03 159.98 41.53 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.609 -0.682 . . . . 0.0 109.592 178.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.14 159.06 27.82 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 -179.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.858 ' CH2' HD22 ' A' ' 64' ' ' LEU . 9.3 m-90 -122.52 160.03 26.46 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.747 -0.855 . . . . 0.0 109.725 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . 0.442 ' HG3' ' HE1' ' A' ' 74' ' ' MET . 41.5 tt0 -77.79 107.77 10.53 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.543 -0.723 . . . . 0.0 109.51 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.741 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.45 137.84 86.29 Favored Pre-proline 0 N--CA 1.495 1.778 0 O-C-N 121.594 -0.691 . . . . 0.0 110.291 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.04 158.79 55.45 Favored 'Trans proline' 0 N--CA 1.491 1.354 0 O-C-N 123.93 1.49 . . . . 0.0 110.221 -179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.64 146.48 61.06 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.976 1.514 . . . . 0.0 110.388 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.94 -26.37 24.72 Favored Glycine 0 N--CA 1.492 2.402 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -68.06 140.05 56.27 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.46 -1.023 . . . . 0.0 110.119 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 20.3 ttt180 -81.82 158.62 24.0 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.522 -0.736 . . . . 0.0 109.884 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -130.07 169.76 14.88 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.573 -0.704 . . . . 0.0 110.167 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.551 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 45.0 mt -106.03 131.91 52.75 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.625 -0.672 . . . . 0.0 110.731 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -73.66 160.03 83.11 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.577 -0.702 . . . . 0.0 109.793 179.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -77.35 161.12 32.04 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.787 1.414 . . . . 0.0 110.636 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 50.8 t -74.07 129.91 38.77 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.722 -0.611 . . . . 0.0 110.134 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -132.85 54.12 1.97 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.679 -0.638 . . . . 0.0 109.689 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.62 -8.12 0.75 Allowed 'General case' 0 N--CA 1.497 1.893 0 C-N-CA 119.967 -0.693 . . . . 0.0 112.371 -179.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.97 42.57 98.37 Favored Glycine 0 N--CA 1.495 2.581 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.97 119.93 39.01 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.525 -0.985 . . . . 0.0 110.422 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.6 m -63.31 -39.99 96.11 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 110.48 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -60.71 129.98 44.25 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.561 -0.712 . . . . 0.0 110.481 -179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 1.097 HD22 HG11 ' A' ' 151' ' ' VAL . 93.2 mt -133.08 150.19 52.1 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.673 -0.642 . . . . 0.0 110.404 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -115.72 121.37 42.31 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.483 -0.76 . . . . 0.0 109.948 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.431 HD13 HD11 ' A' ' 143' ' ' LEU . 44.6 tp -101.05 143.82 30.71 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.528 -0.732 . . . . 0.0 110.369 -179.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.7 t -108.87 129.12 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.57 -0.706 . . . . 0.0 109.87 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.476 HG21 HD11 ' A' ' 114' ' ' ILE . 75.2 p -106.26 178.85 4.44 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.543 -0.723 . . . . 0.0 110.597 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.749 ' HA ' HD11 ' A' ' 44' ' ' LEU . 68.3 mtm180 -59.98 -28.26 67.53 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.594 -0.691 . . . . 0.0 110.58 -179.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -90.3 19.08 5.39 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.467 -0.77 . . . . 0.0 111.122 -179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.51 40.02 30.81 Favored 'General case' 0 N--CA 1.502 2.162 0 O-C-N 121.102 -0.999 . . . . 0.0 110.706 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -100.16 139.34 35.97 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.73 -0.606 . . . . 0.0 109.936 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 64.7 t -93.74 117.39 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.624 -0.672 . . . . 0.0 109.955 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 108' ' ' THR . 86.9 mt -107.53 110.05 62.73 Favored Pre-proline 0 N--CA 1.494 1.753 0 O-C-N 121.694 -0.629 . . . . 0.0 109.599 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -69.85 116.4 4.55 Favored 'Trans proline' 0 N--CA 1.49 1.29 0 O-C-N 123.886 1.466 . . . . 0.0 110.462 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.1 t -120.01 125.2 74.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.678 -0.639 . . . . 0.0 109.643 179.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -86.23 130.03 34.65 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.572 -0.705 . . . . 0.0 109.97 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.75 127.87 33.71 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.622 -0.674 . . . . 0.0 110.376 -179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 12.0 mmm180 -129.68 22.21 5.47 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.665 -0.647 . . . . 0.0 110.245 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 171.51 -179.75 43.07 Favored Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.28 -1.528 . . . . 0.0 109.28 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -67.51 -40.66 85.15 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.591 -0.946 . . . . 0.0 110.312 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.7 p -131.67 22.51 4.66 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.493 -0.754 . . . . 0.0 110.743 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.38 151.93 51.5 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.384 -0.822 . . . . 0.0 110.05 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.46 -173.98 18.17 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -125.49 154.91 41.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.641 -0.917 . . . . 0.0 110.162 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 25.1 tp -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.575 -0.703 . . . . 0.0 110.207 -179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.489 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -68.37 -36.61 79.44 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 0.0 109.964 179.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -111.04 113.05 55.06 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.685 -0.635 . . . . 0.0 110.039 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.28 116.57 3.82 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.726 1.382 . . . . 0.0 110.545 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.9 mtt180 -128.03 160.04 63.64 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.602 -0.686 . . . . 0.0 110.082 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.71 157.09 62.77 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.907 1.477 . . . . 0.0 110.398 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.502 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.4 m -66.12 -24.78 34.36 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.614 -0.679 . . . . 0.0 110.487 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.2 t -59.88 -38.44 82.22 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.456 -0.778 . . . . 0.0 110.332 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -60.03 -39.9 87.48 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.585 -0.697 . . . . 0.0 110.342 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.47 HD12 ' N ' ' A' ' 135' ' ' LEU . 10.7 mp -83.11 -16.86 45.17 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.477 -0.765 . . . . 0.0 111.038 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -63.59 140.01 58.83 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.269 -0.894 . . . . 0.0 110.078 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.56 6.05 89.11 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 63.2 m -112.58 19.48 17.47 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.129 -1.218 . . . . 0.0 110.757 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.403 ' HB2' ' C ' ' B' ' 190' ' ' OBF . 0.4 OUTLIER -72.28 147.91 45.94 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.304 -0.873 . . . . 0.0 109.935 179.831 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.58 -15.31 60.58 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -179.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.02 139.98 48.17 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 179.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -87.79 148.93 7.2 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 O-C-N 123.77 1.405 . . . . 0.0 111.224 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.868 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -105.6 120.02 40.59 Favored 'General case' 0 N--CA 1.49 1.559 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.551 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -108.77 131.18 55.2 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.463 -0.773 . . . . 0.0 111.704 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.453 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.97 82.09 Favored Pre-proline 0 N--CA 1.496 1.851 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 178.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.453 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.4 Cg_endo -51.72 -23.12 14.8 Favored 'Trans proline' 0 N--CA 1.502 2.004 0 O-C-N 123.51 1.268 . . . . 0.0 112.272 -178.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -66.32 -39.98 89.63 Favored 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.247 -0.908 . . . . 0.0 109.89 179.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.25 34.67 0.93 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.351 -1.1 . . . . 0.0 110.351 179.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -131.77 144.72 51.15 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.422 -1.046 . . . . 0.0 110.3 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.551 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.91 138.67 52.63 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.515 -0.74 . . . . 0.0 110.125 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 1.097 HG11 HD22 ' A' ' 104' ' ' LEU . 8.3 p -118.05 -21.87 4.5 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.591 -0.693 . . . . 0.0 110.814 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 178.68 -173.75 46.02 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.423 HG12 HG21 ' A' ' 46' ' ' THR . 95.5 mt -131.55 139.99 49.34 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.605 -0.938 . . . . 0.0 110.096 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.2 t80 -61.0 139.64 58.0 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.579 -0.7 . . . . 0.0 110.148 179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 66.2 ttt180 -120.21 -52.02 2.19 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.59 -0.694 . . . . 0.0 110.333 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.533 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -154.24 160.55 41.87 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.571 -0.706 . . . . 0.0 110.432 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.01 153.88 23.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.552 -0.717 . . . . 0.0 110.408 -179.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.05 119.22 58.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.637 -0.664 . . . . 0.0 109.888 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.502 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -137.07 158.59 44.11 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.683 . . . . 0.0 110.307 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 6.2 p -99.0 -51.95 3.7 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.595 -0.691 . . . . 0.0 110.486 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.8 mtp180 -142.94 63.06 1.39 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.565 -0.709 . . . . 0.0 110.013 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.99 -8.81 79.14 Favored Glycine 0 N--CA 1.492 2.425 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 60.8 t -115.66 126.55 73.23 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.193 -1.181 . . . . 0.0 109.967 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.58 131.69 46.36 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.6 -0.687 . . . . 0.0 110.372 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 55.5 mtmt -113.66 -15.42 12.49 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.565 -0.709 . . . . 0.0 110.746 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 158.71 43.54 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.345 -0.847 . . . . 0.0 109.846 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 33.4 m -130.04 160.01 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 121.523 -0.736 . . . . 0.0 110.546 -179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 14.1 t70 -123.04 136.11 54.71 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.732 -0.605 . . . . 0.0 109.883 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.8 p90 -139.11 160.0 40.83 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.497 -0.752 . . . . 0.0 110.457 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.661 HG11 HD11 ' A' ' 82' ' ' LEU . 88.6 t -99.89 124.6 43.21 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.59 -0.693 . . . . 0.0 109.553 179.619 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -65.34 147.59 87.64 Favored 'Trans proline' 0 N--CA 1.489 1.259 0 O-C-N 123.82 1.432 . . . . 0.0 110.186 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.571 HG13 ' C ' ' A' ' 151' ' ' VAL . 35.7 m -60.6 -24.68 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.931 0 O-C-N 121.68 -0.638 . . . . 0.0 110.996 -179.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 72.6 mt-10 -60.5 -39.97 89.67 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.485 -0.759 . . . . 0.0 110.693 -179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.2 p -61.67 -43.3 99.11 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.434 -0.791 . . . . 0.0 110.906 -179.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.444 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.1 mtm -63.54 -39.98 95.81 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.381 -0.825 . . . . 0.0 110.456 -179.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -60.43 -40.01 89.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.424 -0.798 . . . . 0.0 110.029 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.0 m -70.23 -26.11 63.7 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.632 -0.668 . . . . 0.0 110.528 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.7 m -59.94 -40.83 90.29 Favored 'General case' 0 N--CA 1.499 1.979 0 O-C-N 121.517 -0.739 . . . . 0.0 110.282 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.2 mtt -69.15 -39.91 78.52 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.471 -0.768 . . . . 0.0 110.208 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 37.7 ttt180 -70.02 -39.99 75.46 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.555 -0.715 . . . . 0.0 110.231 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.11 -49.93 75.71 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.58 -0.7 . . . . 0.0 110.496 -179.891 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.6 t -155.9 160.01 39.79 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.591 -0.693 . . . . 0.0 110.251 -179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 27.8 tttt -102.26 -158.02 0.64 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.566 -0.709 . . . . 0.0 109.955 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 55.9 tttp -60.04 -40.02 87.92 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.392 -0.817 . . . . 0.0 110.284 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 22.3 pttp -127.93 28.11 5.61 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.599 -0.688 . . . . 0.0 110.349 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 85.3 tttt . . . . . 0 N--CA 1.502 2.151 0 CA-C-O 118.217 -0.897 . . . . 0.0 110.684 -179.963 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.533 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 60.2 tt0 -127.56 137.37 52.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.131 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.771 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp -88.8 137.43 32.33 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.608 -0.682 . . . . 0.0 110.222 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.411 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.501 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.7 p . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.048 0.451 . . . . 0.0 110.211 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.17 166.62 50.1 Favored Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 87.8 mtt180 -129.98 150.11 51.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.604 -0.939 . . . . 0.0 110.174 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -59.92 -40.04 87.52 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.547 -0.721 . . . . 0.0 110.41 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -125.8 111.37 14.79 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.48 -0.763 . . . . 0.0 110.255 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 t30 -149.95 93.41 2.02 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.568 -0.708 . . . . 0.0 110.337 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -121.41 129.93 53.3 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.57 -0.706 . . . . 0.0 110.181 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.1 m -130.05 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.497 -0.752 . . . . 0.0 110.342 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -138.5 135.57 35.25 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.636 -0.665 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 140.21 93.82 0.24 Allowed Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.568 ' HG3' HD11 ' A' ' 94' ' ' LEU . 2.9 pt-20 -67.0 -22.55 65.9 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.599 -0.942 . . . . 0.0 110.693 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.515 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.0 t -108.94 127.56 65.48 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.492 -0.755 . . . . 0.0 109.799 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.4 mm-40 -121.16 155.5 34.39 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.666 -0.647 . . . . 0.0 110.345 -179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 63.7 t -91.52 120.59 40.83 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.668 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.603 ' CB ' HD21 ' A' ' 64' ' ' LEU . 33.4 m -116.56 158.32 17.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.659 -0.651 . . . . 0.0 110.156 -179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 33.0 m -145.68 172.77 12.79 Favored 'General case' 0 N--CA 1.489 1.487 0 C-N-CA 120.126 -0.629 . . . . 0.0 110.577 -179.688 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -132.93 -172.38 2.91 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.19 88.56 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.374 -0.829 . . . . 0.0 110.295 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 23.2 m -131.47 -7.12 3.72 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.526 -0.734 . . . . 0.0 111.975 -179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.8 tp60 -113.96 159.71 19.62 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.967 -1.083 . . . . 0.0 110.906 -179.198 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 33.2 t -146.1 136.96 24.39 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.554 -0.716 . . . . 0.0 110.072 179.774 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.545 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.0 p90 -166.72 -177.42 3.89 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.315 -0.866 . . . . 0.0 110.528 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.807 HD11 ' N ' ' A' ' 109' ' ' ARG . 73.3 mt -113.05 159.07 19.54 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.598 -0.689 . . . . 0.0 110.81 -178.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -133.4 156.69 47.21 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.643 -0.661 . . . . 0.0 110.044 179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 142' ' ' PRO . 47.3 m -121.82 134.57 54.9 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.444 -0.785 . . . . 0.0 110.44 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 31.7 t -92.76 110.44 21.88 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.56 -0.713 . . . . 0.0 110.594 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.502 HG13 ' O ' ' A' ' 94' ' ' LEU . 63.1 t -119.46 134.84 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.593 -0.692 . . . . 0.0 109.641 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 54.93 38.37 30.33 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.534 -0.729 . . . . 0.0 111.148 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.509 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.09 26.04 74.81 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 178.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 70.4 t -139.9 131.73 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.364 -1.08 . . . . 0.0 109.906 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.8 m -75.29 148.57 39.27 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.377 -0.827 . . . . 0.0 109.181 179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.502 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 60.8 m95 -129.99 151.04 50.97 Favored 'General case' 0 N--CA 1.492 1.669 0 CA-C-O 121.726 0.774 . . . . 0.0 111.313 -179.172 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -169.37 -179.88 3.64 Favored 'General case' 0 N--CA 1.492 1.668 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.871 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.4 p -95.62 155.96 3.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.376 -0.828 . . . . 0.0 110.37 179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.437 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 62.1 t80 -70.01 -40.86 75.0 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.509 -0.745 . . . . 0.0 111.599 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.871 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.9 p-80 -70.04 -24.4 63.26 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.148 -0.97 . . . . 0.0 110.621 -179.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.781 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.38 -56.28 2.71 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.576 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -101.97 -53.51 2.92 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.756 -0.849 . . . . 0.0 109.964 179.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.08 -168.99 46.87 Favored Glycine 0 N--CA 1.494 2.513 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 97.9 p -86.48 64.45 8.54 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.644 -0.915 . . . . 0.0 109.911 179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.6 mtmt -140.27 170.02 16.6 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.533 -0.729 . . . . 0.0 110.38 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 76.9 m -65.3 139.59 58.62 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.549 -0.719 . . . . 0.0 110.043 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.91 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -113.56 136.22 53.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.64 -0.663 . . . . 0.0 110.014 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -95.28 119.08 33.17 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.599 -0.688 . . . . 0.0 110.155 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -123.05 176.42 16.6 Favored Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.196 -1.562 . . . . 0.0 109.196 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -63.69 -32.36 68.49 Favored 'Trans proline' 0 N--CA 1.492 1.413 0 O-C-N 123.852 1.449 . . . . 0.0 110.414 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -71.89 -31.32 66.29 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.629 -0.67 . . . . 0.0 110.169 -179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.86 -156.57 26.72 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -70.04 154.33 66.76 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.872 1.459 . . . . 0.0 110.359 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.5 mt -130.35 142.65 43.19 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.579 -0.7 . . . . 0.0 110.311 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 24.4 p -99.47 139.98 34.33 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.496 -0.752 . . . . 0.0 110.591 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.418 ' NE2' HG22 ' A' ' 76' ' ' THR . 1.5 mm100 -71.04 144.55 50.35 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.613 -0.679 . . . . 0.0 111.216 -179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.41 ' HG3' ' N ' ' A' ' 86' ' ' GLN . 95.1 mmm -119.21 -45.41 2.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.65 -0.656 . . . . 0.0 110.211 179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -120.02 139.94 51.74 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.592 -0.693 . . . . 0.0 110.449 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.418 HG22 ' NE2' ' A' ' 73' ' ' GLN . 30.3 p -130.48 139.92 50.53 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.58 -0.7 . . . . 0.0 110.329 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.608 ' OD1' HG21 ' A' ' 178' ' ' THR . 34.6 m120 -148.33 82.59 1.48 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.616 -0.678 . . . . 0.0 110.083 179.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.435 HG22 ' CE1' ' A' ' 56' ' ' TYR . 94.2 t -62.34 -44.68 99.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.634 -0.666 . . . . 0.0 110.011 -179.934 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.96 -44.54 94.36 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.508 -0.745 . . . . 0.0 110.216 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.606 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.8 tp60 -89.97 -0.0 57.33 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.514 -0.741 . . . . 0.0 111.002 179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.437 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.2 t70 52.79 49.63 19.85 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.016 -1.052 . . . . 0.0 110.498 -179.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.606 HD12 ' CG ' ' A' ' 80' ' ' GLN . 54.9 mt -140.02 144.51 36.97 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.601 -0.687 . . . . 0.0 111.101 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.629 HG23 HG23 ' A' ' 54' ' ' THR . 34.9 m -149.93 159.67 5.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.565 -0.709 . . . . 0.0 109.611 179.214 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -145.72 161.58 28.24 Favored Glycine 0 N--CA 1.495 2.623 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 -179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.926 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.5 m-90 -120.9 159.98 24.42 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.824 -0.81 . . . . 0.0 109.742 179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . 0.41 ' N ' ' HG3' ' A' ' 74' ' ' MET . 4.3 pt20 -68.45 122.47 18.5 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.425 -0.797 . . . . 0.0 109.373 179.058 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.509 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -75.42 130.54 79.52 Favored Pre-proline 0 N--CA 1.494 1.745 0 O-C-N 121.538 -0.726 . . . . 0.0 110.187 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.06 159.97 51.29 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 O-C-N 123.887 1.467 . . . . 0.0 110.293 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -68.21 160.13 50.2 Favored 'Trans proline' 0 N--CA 1.49 1.322 0 O-C-N 123.883 1.465 . . . . 0.0 110.275 -179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.58 29.43 69.74 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -112.06 156.64 21.87 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.615 -0.932 . . . . 0.0 110.113 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 17.1 tpt180 -99.12 139.72 34.35 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.949 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.0 p -118.84 157.74 27.01 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.616 -0.677 . . . . 0.0 110.181 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.603 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 76.7 mt -112.32 131.53 55.47 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.566 -0.709 . . . . 0.0 110.563 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.6 p -82.2 159.99 63.79 Favored Pre-proline 0 N--CA 1.496 1.827 0 O-C-N 121.565 -0.709 . . . . 0.0 109.969 179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.685 ' HB3' HG11 ' A' ' 172' ' ' VAL . 47.1 Cg_endo -70.61 165.81 30.72 Favored 'Trans proline' 0 N--CA 1.491 1.36 0 O-C-N 123.823 1.433 . . . . 0.0 110.4 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.484 ' HB2' HG22 ' A' ' 151' ' ' VAL . 13.5 t -87.2 149.98 24.24 Favored 'General case' 0 N--CA 1.495 1.787 0 CA-C-O 121.891 0.853 . . . . 0.0 110.367 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 18.6 m -133.91 62.21 1.66 Allowed 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 177.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 m -141.57 -9.02 0.95 Allowed 'General case' 0 N--CA 1.5 2.041 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.831 -177.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.51 26.45 56.95 Favored Glycine 0 N--CA 1.497 2.705 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 79.5 p -80.02 160.0 26.02 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.461 -1.023 . . . . 0.0 110.493 -179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.7 m -107.42 -27.07 10.67 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.707 -0.62 . . . . 0.0 110.329 179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.2 m-20 -73.83 129.37 37.77 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.501 -0.75 . . . . 0.0 110.015 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.49 ' CD2' HG11 ' A' ' 151' ' ' VAL . 85.0 mt -135.3 150.05 49.92 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.576 -0.703 . . . . 0.0 110.662 -179.65 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -108.69 119.94 41.0 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.492 -0.755 . . . . 0.0 109.562 179.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.457 HD13 HD11 ' A' ' 143' ' ' LEU . 50.0 tp -100.97 141.51 33.75 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.48 -0.762 . . . . 0.0 110.78 -179.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.88 130.03 63.75 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.631 -0.668 . . . . 0.0 109.703 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . 0.496 ' C ' HD11 ' A' ' 44' ' ' LEU . 73.9 p -111.89 169.97 8.47 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.442 -0.786 . . . . 0.0 110.705 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.807 ' N ' HD11 ' A' ' 44' ' ' LEU . 23.1 ptt-85 -64.68 -16.17 62.45 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.611 -0.68 . . . . 0.0 111.005 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -89.97 17.4 6.86 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.222 -0.923 . . . . 0.0 110.828 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.44 40.01 31.46 Favored 'General case' 0 N--CA 1.502 2.15 0 O-C-N 121.081 -1.012 . . . . 0.0 110.51 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -113.38 156.56 23.22 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.658 -0.651 . . . . 0.0 109.853 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.6 p -130.0 130.36 66.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.551 -0.718 . . . . 0.0 110.233 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.409 HG23 ' O ' ' A' ' 114' ' ' ILE . 16.1 tt -131.86 130.06 22.11 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.69 -0.631 . . . . 0.0 109.893 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.53 ' HG2' HD22 ' A' ' 127' ' ' LEU . 47.4 Cg_endo -71.71 126.79 12.37 Favored 'Trans proline' 0 N--CA 1.49 1.265 0 O-C-N 123.856 1.45 . . . . 0.0 110.355 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.8 t -120.04 125.58 74.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.692 -0.63 . . . . 0.0 109.72 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 10.4 tpt180 -86.23 149.99 24.7 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.484 -0.76 . . . . 0.0 110.059 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 70.0 ttp85 -93.71 120.65 34.25 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.53 -0.731 . . . . 0.0 110.426 -179.689 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 27.8 mmt180 -110.01 20.0 18.41 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.649 -0.657 . . . . 0.0 110.349 179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.55 -177.26 42.61 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.94 -40.03 91.72 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.526 -0.985 . . . . 0.0 110.281 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.6 p -132.33 26.43 4.48 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.521 -0.737 . . . . 0.0 110.394 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 16.6 tpt180 -124.35 139.97 53.39 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.451 -0.781 . . . . 0.0 110.495 -179.736 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.54 167.22 25.35 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 78.3 p -118.95 152.33 36.54 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.607 -0.937 . . . . 0.0 110.104 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.405 HD23 ' O ' ' A' ' 164' ' ' ALA . 19.2 tp -94.17 119.09 32.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.556 -0.715 . . . . 0.0 110.118 -179.839 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.53 HD22 ' HG2' ' A' ' 115' ' ' PRO . 9.2 mp -65.79 -40.0 91.5 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.57 -0.706 . . . . 0.0 109.951 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 58.6 m -111.43 118.59 47.04 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.674 -0.641 . . . . 0.0 110.109 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -65.54 117.42 4.59 Favored 'Trans proline' 0 N--CA 1.49 1.298 0 O-C-N 123.73 1.384 . . . . 0.0 110.352 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 21.3 mtt180 -129.87 159.95 67.4 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.54 -0.725 . . . . 0.0 110.267 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.27 160.22 43.34 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 O-C-N 123.931 1.49 . . . . 0.0 110.414 -179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.441 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.6 m -67.39 -25.02 32.44 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.665 -0.647 . . . . 0.0 110.816 -179.754 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.4 p -59.96 -40.06 87.76 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.453 -0.779 . . . . 0.0 110.224 -179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.4 t80 -59.87 -49.82 76.22 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.534 -0.728 . . . . 0.0 110.023 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.452 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.03 -30.45 67.74 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.611 -0.681 . . . . 0.0 109.82 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.412 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 2.0 tptm -59.92 131.02 49.57 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.596 -0.69 . . . . 0.0 110.156 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 93.57 6.2 62.66 Favored Glycine 0 N--CA 1.494 2.551 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 49.5 m -116.27 12.84 15.5 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.127 -1.219 . . . . 0.0 110.888 179.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.1 t -62.03 145.15 53.95 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.292 -0.88 . . . . 0.0 109.915 179.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.06 -12.08 68.8 Favored Glycine 0 N--CA 1.491 2.32 0 N-CA-C 109.96 -1.256 . . . . 0.0 109.96 -179.407 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.94 140.39 47.9 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.115 -1.594 . . . . 0.0 109.115 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.59 ' HB3' HG21 ' A' ' 46' ' ' THR . 51.8 Cg_endo -92.05 150.31 3.2 Favored 'Trans proline' 0 C--N 1.316 -1.168 0 O-C-N 123.85 1.448 . . . . 0.0 111.393 -179.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.564 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -100.39 103.05 14.42 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 178.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.507 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -85.74 149.54 25.21 Favored 'General case' 0 N--CA 1.492 1.647 0 CA-C-O 122.083 0.944 . . . . 0.0 112.289 -177.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 1.6 t -87.78 145.2 36.32 Favored Pre-proline 0 N--CA 1.492 1.655 0 N-CA-C 108.312 -0.995 . . . . 0.0 108.312 178.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -53.71 -24.8 31.45 Favored 'Trans proline' 0 N--CA 1.502 1.98 0 O-C-N 123.291 1.153 . . . . 0.0 110.375 178.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.3 m -71.87 -36.51 70.13 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.33 39.77 0.57 Allowed Glycine 0 N--CA 1.494 2.562 0 N-CA-C 110.061 -1.216 . . . . 0.0 110.061 179.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 38.5 m170 -130.02 138.69 50.92 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.438 -1.037 . . . . 0.0 110.594 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.603 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -64.95 141.55 58.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.444 -0.785 . . . . 0.0 109.899 179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.808 ' O ' HG23 ' A' ' 172' ' ' VAL . 58.9 t -115.3 -44.0 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.508 -0.745 . . . . 0.0 110.582 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -170.64 -171.07 35.63 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.205 -1.158 . . . . 0.0 110.205 -179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.2 mt -132.92 140.03 48.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.607 -0.937 . . . . 0.0 110.441 -179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.718 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 32.4 t80 -67.87 138.09 55.78 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.623 -0.673 . . . . 0.0 109.811 179.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.8 ttp180 -124.24 -52.58 1.74 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.538 -0.726 . . . . 0.0 110.499 -179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -139.78 159.5 42.04 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.514 -0.741 . . . . 0.0 110.286 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.718 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.41 136.45 54.96 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.604 -0.685 . . . . 0.0 110.612 -179.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.1 t -93.7 119.82 42.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.441 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.6 p -137.37 159.91 40.58 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 119.92 -0.712 . . . . 0.0 111.235 -179.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 76.1 p -138.88 142.28 38.58 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 109.312 -0.625 . . . . 0.0 109.312 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 24.9 mmt180 53.76 28.01 7.69 Favored 'General case' 0 N--CA 1.502 2.152 0 O-C-N 121.289 -0.882 . . . . 0.0 110.671 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 80.69 22.89 61.04 Favored Glycine 0 N--CA 1.494 2.537 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.5 t -129.98 129.99 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.265 -1.138 . . . . 0.0 110.039 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . 0.405 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -91.54 124.03 35.4 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.26 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 40.9 mttm -112.72 -26.38 8.63 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.587 -0.696 . . . . 0.0 110.352 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.2 161.57 38.54 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.532 -0.73 . . . . 0.0 109.838 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.6 m -131.03 178.49 5.44 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.986 0 O-C-N 121.517 -0.739 . . . . 0.0 111.476 -179.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 70.4 m-20 -134.03 135.52 43.42 Favored 'General case' 0 N--CA 1.493 1.685 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 48.1 p90 -139.99 145.59 38.03 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.326 -0.859 . . . . 0.0 110.719 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.563 HG11 HD11 ' A' ' 82' ' ' LEU . 72.9 t -86.7 124.72 68.88 Favored Pre-proline 0 N--CA 1.494 1.734 0 O-C-N 121.627 -0.671 . . . . 0.0 109.353 179.337 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -66.54 162.52 36.46 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.845 1.444 . . . . 0.0 110.343 -179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.808 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.8 t -70.03 -24.67 26.6 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.681 -0.637 . . . . 0.0 110.487 -179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -57.93 -39.93 79.21 Favored 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.375 -0.828 . . . . 0.0 110.575 -179.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.6 p -69.31 -38.43 78.24 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.502 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 93.0 mtp -60.19 -40.52 90.34 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.654 -0.654 . . . . 0.0 110.35 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -69.26 -39.97 78.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.623 -0.673 . . . . 0.0 110.336 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.12 -39.92 91.84 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.606 -0.684 . . . . 0.0 110.074 -179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . 0.608 HG21 ' OD1' ' A' ' 77' ' ' ASN . 89.7 m -60.11 -47.52 85.57 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.545 -0.722 . . . . 0.0 110.375 -179.835 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.02 -49.98 75.52 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.631 -0.668 . . . . 0.0 110.41 -179.765 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 42.8 ttt180 -69.68 -40.07 76.6 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.566 -0.709 . . . . 0.0 110.213 179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.75 -27.07 64.64 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.602 -0.686 . . . . 0.0 110.426 -179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 5.3 m -79.94 89.72 5.32 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.572 -0.705 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 81.4 tttt -160.08 29.13 0.17 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.554 -0.716 . . . . 0.0 110.054 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 18.6 pttp -66.54 -30.03 70.25 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.462 -0.774 . . . . 0.0 110.457 -179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 58.4 mttm -60.05 -39.99 87.87 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.538 -0.726 . . . . 0.0 110.284 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.749 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.185 -179.965 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -117.31 129.98 56.24 Favored 'General case' 0 N--CA 1.491 1.617 0 C-N-CA 118.474 -1.29 . . . . 0.0 110.116 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.803 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -70.1 140.03 52.63 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.531 -0.731 . . . . 0.0 110.234 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.575 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.624 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 34.5 p . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.135 0.493 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -87.2 -179.97 48.38 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 86.1 mtt180 -108.16 139.76 42.36 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.604 -0.939 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -150.23 155.33 39.53 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.606 -0.684 . . . . 0.0 110.329 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -80.04 160.0 25.99 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.656 -0.653 . . . . 0.0 110.226 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 28.0 m120 -60.05 -39.93 87.68 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.529 -0.732 . . . . 0.0 110.242 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 58.7 tt0 -62.65 139.99 58.67 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.538 -0.726 . . . . 0.0 109.87 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.41 129.28 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.58 -0.7 . . . . 0.0 110.027 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -62.43 -40.06 95.34 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.571 -0.706 . . . . 0.0 110.234 179.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 129.67 146.83 6.13 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.569 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.1 mt-10 -66.3 -37.23 84.92 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.622 -0.928 . . . . 0.0 110.214 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.5 t -102.64 126.52 56.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.701 . . . . 0.0 110.037 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -117.21 151.61 36.55 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.564 -0.71 . . . . 0.0 110.146 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 13.7 p -89.67 136.15 24.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.512 -0.743 . . . . 0.0 110.069 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.683 ' HB ' HD12 ' A' ' 64' ' ' LEU . 33.6 m -129.7 136.97 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.832 0 O-C-N 121.695 -0.628 . . . . 0.0 110.006 -179.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.6 m -136.13 170.93 15.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.562 -0.711 . . . . 0.0 110.586 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -133.11 -170.67 2.51 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.636 -0.665 . . . . 0.0 109.449 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -64.3 -24.2 67.57 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.642 -0.661 . . . . 0.0 111.427 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 10.3 t -137.24 -15.45 1.47 Allowed 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.133 -0.979 . . . . 0.0 113.175 -178.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 3.6 tp-100 -125.29 149.66 47.85 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 120.872 -1.143 . . . . 0.0 111.249 -178.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 29.2 p -132.77 142.36 48.97 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.824 -0.548 . . . . 0.0 110.094 179.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.463 ' CE2' ' HB2' ' A' ' 59' ' ' ALA . 16.1 p90 -163.91 -177.33 5.03 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.469 -0.769 . . . . 0.0 109.88 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.79 HD11 ' CA ' ' A' ' 109' ' ' ARG . 29.1 mt -112.46 179.18 4.06 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.391 -0.818 . . . . 0.0 110.775 -177.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -155.36 160.34 40.63 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.784 -0.573 . . . . 0.0 109.725 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.1 t -125.65 138.41 53.91 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.481 -0.762 . . . . 0.0 110.231 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 48.9 t -96.66 107.01 19.38 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.474 -0.766 . . . . 0.0 110.653 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.435 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.2 t -110.35 130.0 64.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.717 -0.614 . . . . 0.0 109.348 179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.8 t-20 56.84 36.37 27.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.502 -0.749 . . . . 0.0 110.725 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.543 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 74.28 17.7 79.71 Favored Glycine 0 N--CA 1.496 2.673 0 N-CA-C 111.049 -0.821 . . . . 0.0 111.049 179.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 63.2 t -131.21 130.03 63.13 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.942 0 O-C-N 121.118 -1.225 . . . . 0.0 110.102 179.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 4.3 t -73.06 150.05 42.66 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.511 -0.743 . . . . 0.0 109.592 179.75 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.435 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 87.4 m95 -135.72 150.0 49.4 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.528 -0.733 . . . . 0.0 110.93 -179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.843 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.0 t -168.51 -179.69 3.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.856 -0.528 . . . . 0.0 109.584 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.816 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.4 p -91.46 157.2 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.018 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.617 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.7 t80 -72.93 -43.65 62.12 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.543 -0.723 . . . . 0.0 112.14 -178.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.816 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.8 p-80 -60.84 -24.63 66.03 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.12 -0.988 . . . . 0.0 110.714 -178.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.536 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -90.85 -35.51 7.18 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.362 -1.895 . . . . 0.0 108.362 178.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.463 ' HB2' ' CE2' ' A' ' 43' ' ' PHE . . . -135.59 97.0 3.56 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.792 -0.828 . . . . 0.0 109.879 179.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -80.03 -166.24 33.24 Favored Glycine 0 N--CA 1.493 2.438 0 N-CA-C 109.164 -1.574 . . . . 0.0 109.164 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 79.1 p -72.26 65.84 0.62 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.626 -0.926 . . . . 0.0 109.631 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.22 169.82 16.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.623 -0.673 . . . . 0.0 110.382 -179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . 0.448 HG23 ' O ' ' A' ' 71' ' ' ILE . 69.0 m -74.94 139.25 42.88 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.661 -0.649 . . . . 0.0 110.141 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.683 HD12 ' HB ' ' A' ' 36' ' ' VAL . 0.2 OUTLIER -108.51 133.47 52.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.626 -0.671 . . . . 0.0 109.705 179.671 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -83.71 112.72 20.32 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.636 -0.665 . . . . 0.0 110.209 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -112.2 -176.74 19.95 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.15 -1.58 . . . . 0.0 109.15 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.79 -32.65 67.17 Favored 'Trans proline' 0 N--CA 1.492 1.391 0 O-C-N 123.854 1.45 . . . . 0.0 110.499 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.6 tttt -74.93 -31.12 61.44 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.667 -0.646 . . . . 0.0 109.934 -179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.65 -144.17 13.27 Favored Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . 0.429 ' O ' HD13 ' A' ' 71' ' ' ILE . 47.5 Cg_endo -73.61 155.13 49.94 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.817 1.43 . . . . 0.0 110.238 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 63' ' ' THR . 49.1 mm -129.49 139.93 50.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.558 -0.714 . . . . 0.0 110.455 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 80.5 m -101.04 120.92 40.89 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.567 -0.708 . . . . 0.0 110.076 179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.586 ' OE1' HG22 ' A' ' 76' ' ' THR . 32.2 tt0 -77.0 139.53 40.1 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.546 -0.721 . . . . 0.0 110.681 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 42.2 mtp -109.95 -30.01 8.0 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.663 -0.648 . . . . 0.0 110.441 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -112.85 138.42 49.72 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.523 -0.736 . . . . 0.0 110.612 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.586 HG22 ' OE1' ' A' ' 73' ' ' GLN . 7.0 p -139.41 126.91 21.62 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.706 -0.621 . . . . 0.0 110.023 179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.5 t-20 -142.02 90.97 2.3 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.489 -0.757 . . . . 0.0 110.26 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.617 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 91.1 t -66.26 -40.35 86.63 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.6 -0.687 . . . . 0.0 109.882 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.58 -45.01 95.53 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.647 -0.658 . . . . 0.0 110.601 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.535 ' HG3' HD12 ' A' ' 82' ' ' LEU . 38.6 tp60 -87.79 -0.01 56.37 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.504 -0.747 . . . . 0.0 110.816 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.433 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 5.6 t70 53.54 42.71 31.88 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.055 -1.028 . . . . 0.0 110.538 -179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.682 HD11 HG11 ' A' ' 170' ' ' VAL . 67.0 mt -140.92 147.69 39.25 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.45 -0.781 . . . . 0.0 111.036 -179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.444 HG13 ' C ' ' A' ' 82' ' ' LEU . 34.6 m -148.32 177.1 1.0 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.695 -0.628 . . . . 0.0 109.404 179.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -156.29 158.25 28.51 Favored Glycine 0 N--CA 1.495 2.621 0 C-N-CA 119.838 -1.172 . . . . 0.0 110.518 -179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.843 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.0 m-90 -120.38 160.77 22.4 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.816 -0.814 . . . . 0.0 109.848 179.523 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.2 tt0 -75.2 109.96 9.13 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.57 -0.706 . . . . 0.0 109.297 179.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.543 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.89 153.96 87.21 Favored Pre-proline 0 N--CA 1.496 1.861 0 O-C-N 121.545 -0.722 . . . . 0.0 110.01 -179.606 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.09 159.69 52.28 Favored 'Trans proline' 0 N--CA 1.488 1.196 0 O-C-N 123.83 1.437 . . . . 0.0 110.281 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.06 141.71 71.26 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.95 1.5 . . . . 0.0 110.357 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.18 27.47 72.84 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -83.19 149.87 26.57 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.467 -1.019 . . . . 0.0 110.087 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 13.3 tpt180 -87.74 139.23 30.74 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.616 -0.678 . . . . 0.0 109.308 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.2 p -128.99 168.38 16.11 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.426 -0.796 . . . . 0.0 110.554 -179.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.614 HD13 HD21 ' A' ' 144' ' ' LEU . 34.7 mt -111.65 131.97 54.91 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.735 -0.603 . . . . 0.0 110.714 -179.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.404 ' OG1' ' CD2' ' A' ' 149' ' ' HIS . 73.8 p -74.76 159.95 81.98 Favored Pre-proline 0 N--CA 1.496 1.84 0 O-C-N 121.636 -0.665 . . . . 0.0 109.799 179.469 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -68.29 161.01 46.52 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 O-C-N 123.865 1.456 . . . . 0.0 110.744 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.792 ' HB2' HG22 ' A' ' 151' ' ' VAL . 52.8 t -70.25 134.73 48.31 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.721 -0.612 . . . . 0.0 110.063 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 22.4 p -136.15 52.35 1.98 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.667 -0.646 . . . . 0.0 109.827 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.1 p -143.81 -8.09 0.73 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.516 -0.74 . . . . 0.0 112.387 -179.143 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.01 42.26 98.3 Favored Glycine 0 N--CA 1.496 2.689 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 54.0 m -100.0 120.04 39.21 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.433 -1.04 . . . . 0.0 110.305 -179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 73.3 m -62.83 -40.05 96.22 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.579 -0.701 . . . . 0.0 110.429 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -59.99 137.54 58.06 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.538 -0.726 . . . . 0.0 110.497 -179.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.563 ' CD2' HG21 ' A' ' 151' ' ' VAL . 89.3 mt -138.47 142.84 39.43 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.637 -0.664 . . . . 0.0 110.643 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 89.2 m-85 -106.85 120.37 41.84 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.587 -0.696 . . . . 0.0 109.581 179.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.1 tp -102.57 146.16 28.56 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.406 -0.809 . . . . 0.0 110.829 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.4 t -105.34 130.01 57.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.676 -0.64 . . . . 0.0 109.647 179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 76.3 p -98.25 173.57 6.93 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.573 -0.704 . . . . 0.0 111.004 -179.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.79 ' CA ' HD11 ' A' ' 44' ' ' LEU . 61.9 ttt-85 -70.0 -24.26 63.27 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.745 -0.597 . . . . 0.0 110.514 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -94.03 29.25 2.18 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.44 -0.787 . . . . 0.0 110.737 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.42 40.03 31.26 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.308 -0.87 . . . . 0.0 110.724 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -116.1 145.94 42.63 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.528 -0.733 . . . . 0.0 109.542 179.429 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.9 p -130.0 133.59 64.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.538 -0.726 . . . . 0.0 110.575 -179.667 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 81.3 mt -124.91 150.06 64.95 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.651 -0.655 . . . . 0.0 109.485 179.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -81.46 123.05 4.22 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.945 1.498 . . . . 0.0 110.593 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 61.2 t -119.91 124.32 72.54 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 109.648 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.8 tpt180 -81.96 130.61 35.13 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.527 -0.733 . . . . 0.0 110.049 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -77.45 128.23 33.87 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.68 -0.638 . . . . 0.0 110.344 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 14.1 mmt180 -119.46 23.02 11.45 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.662 -0.649 . . . . 0.0 110.429 179.774 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.75 176.9 38.2 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -60.12 -40.82 91.07 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.54 -0.976 . . . . 0.0 110.127 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 20.8 p -130.0 27.4 5.15 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.622 -0.674 . . . . 0.0 110.331 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 3.1 tpt85 -128.93 137.06 51.19 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.461 -0.774 . . . . 0.0 110.274 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.2 166.57 26.0 Favored Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.9 p -124.87 146.22 49.41 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.558 -0.966 . . . . 0.0 110.058 179.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 9.4 mp -97.73 125.25 42.43 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.628 -0.67 . . . . 0.0 110.467 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.554 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -66.73 -40.04 88.22 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.544 -0.723 . . . . 0.0 109.81 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.6 m -107.55 114.32 60.73 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.661 -0.649 . . . . 0.0 109.94 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.28 124.49 13.02 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.839 1.441 . . . . 0.0 110.487 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.9 mmt180 -120.48 160.09 45.38 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.641 -0.662 . . . . 0.0 109.972 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.33 156.67 62.01 Favored 'Trans proline' 0 N--CA 1.489 1.257 0 O-C-N 123.942 1.496 . . . . 0.0 110.385 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.458 HG11 ' OE1' ' B' ' 188' ' ' GLU . 65.7 t -66.83 -29.93 47.98 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.596 -0.69 . . . . 0.0 110.003 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.9 m -59.95 -40.05 87.67 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.482 -0.762 . . . . 0.0 110.352 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 53.0 t80 -61.76 -40.0 93.59 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.499 -0.75 . . . . 0.0 109.994 179.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.47 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -69.22 -30.43 68.58 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.595 -0.691 . . . . 0.0 110.479 -179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.3 mmmm -60.01 140.4 56.81 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.388 -0.82 . . . . 0.0 110.246 -179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.01 14.67 80.35 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 110.069 -1.212 . . . . 0.0 110.069 -179.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.0 m -114.78 10.06 16.46 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.283 -1.127 . . . . 0.0 110.936 179.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 3.7 m -62.06 140.2 58.39 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.223 -0.923 . . . . 0.0 110.048 179.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 98.75 -18.15 57.29 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.11 -1.196 . . . . 0.0 110.11 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -58.43 113.76 5.21 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -78.56 150.21 24.54 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 O-C-N 123.833 1.438 . . . . 0.0 110.82 -179.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.635 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -101.49 109.1 20.85 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.068 -0.715 . . . . 0.0 109.068 179.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.614 HD21 HD13 ' A' ' 94' ' ' LEU . 9.9 mp -100.0 129.96 46.11 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.555 -0.716 . . . . 0.0 111.064 -179.044 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.411 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.9 158.64 86.74 Favored Pre-proline 0 N--CA 1.495 1.822 0 O-C-N 121.725 -0.61 . . . . 0.0 109.417 179.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.4 Cg_endo -53.77 -20.87 18.35 Favored 'Trans proline' 0 N--CA 1.501 1.925 0 O-C-N 123.634 1.333 . . . . 0.0 112.56 -178.327 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.8 p -67.22 -36.47 81.75 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.077 -1.015 . . . . 0.0 109.917 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 119.4 34.65 0.99 Allowed Glycine 0 N--CA 1.494 2.538 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . 0.404 ' CD2' ' OG1' ' A' ' 95' ' ' THR . 33.1 m170 -131.83 146.79 52.33 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.431 -1.04 . . . . 0.0 110.175 179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.53 146.46 50.18 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.581 -0.699 . . . . 0.0 110.293 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.792 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.4 t -117.69 -40.1 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.579 -0.701 . . . . 0.0 109.991 -179.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.22 -168.85 34.22 Favored Glycine 0 N--CA 1.495 2.621 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.471 ' CD1' ' HE1' ' A' ' 175' ' ' MET . 93.8 mt -133.19 140.01 48.04 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 121.487 -1.008 . . . . 0.0 110.464 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 30.0 t80 -59.98 139.03 57.69 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.547 -0.72 . . . . 0.0 110.036 179.725 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 29.9 ttp85 -123.19 -52.01 1.86 Allowed 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.573 -0.704 . . . . 0.0 110.186 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -146.9 160.41 42.36 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.617 -0.677 . . . . 0.0 110.295 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -117.21 144.49 44.73 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.559 -0.713 . . . . 0.0 110.336 179.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.7 t -110.03 120.05 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 C-N-CA 120.18 -0.608 . . . . 0.0 109.807 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.409 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -130.4 145.87 51.88 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.689 -0.632 . . . . 0.0 110.345 179.862 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 89.5 m -70.05 -49.2 53.58 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.61 -0.681 . . . . 0.0 110.265 -179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 14.3 ptt180 -163.92 53.83 0.15 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.574 -0.703 . . . . 0.0 109.889 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 116.11 -17.58 14.76 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.474 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.4 t -114.11 126.3 71.59 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.217 -1.167 . . . . 0.0 109.777 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.54 126.95 40.15 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.567 -0.708 . . . . 0.0 110.398 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -112.29 -18.1 12.59 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.604 -0.685 . . . . 0.0 110.717 179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -149.1 159.14 44.5 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.218 -0.926 . . . . 0.0 110.157 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 30.8 m -140.01 166.86 19.72 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 121.531 -0.731 . . . . 0.0 110.853 -179.772 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -119.97 136.78 54.41 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.655 -0.653 . . . . 0.0 109.773 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.7 p90 -138.04 155.68 48.56 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.493 -0.754 . . . . 0.0 110.461 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.682 HG11 HD11 ' A' ' 82' ' ' LEU . 60.4 t -92.91 123.89 60.02 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.621 -0.674 . . . . 0.0 109.578 179.723 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.22 154.0 75.57 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.842 1.443 . . . . 0.0 110.581 -179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.599 HG23 ' O ' ' A' ' 151' ' ' VAL . 91.1 t -59.91 -23.47 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.909 0 O-C-N 121.594 -0.691 . . . . 0.0 110.575 -179.801 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -58.16 -38.36 76.47 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.444 -0.785 . . . . 0.0 110.555 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . 0.411 ' OG ' HG12 ' A' ' 170' ' ' VAL . 82.6 p -60.03 -37.11 78.79 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.413 -0.804 . . . . 0.0 110.311 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.471 ' HE1' ' CD1' ' A' ' 153' ' ' ILE . 68.4 mtt -60.13 -40.02 88.29 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.466 -0.771 . . . . 0.0 110.441 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -60.16 -41.27 92.44 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.573 -0.704 . . . . 0.0 110.565 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 73.5 p -72.92 -40.04 65.8 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.44 -0.787 . . . . 0.0 110.311 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 89.9 m -70.06 -44.4 69.23 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.622 -0.674 . . . . 0.0 110.121 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.78 -40.17 91.6 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.617 -0.677 . . . . 0.0 110.337 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 62.8 ttt180 -60.18 -40.05 88.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.536 -0.728 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -68.83 -40.02 79.69 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.574 -0.704 . . . . 0.0 110.212 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 13.5 m 50.99 -160.0 0.08 Allowed 'General case' 0 N--CA 1.501 2.123 0 O-C-N 121.397 -0.815 . . . . 0.0 110.92 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -149.44 120.31 7.62 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -107.64 -29.97 8.85 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.579 -0.701 . . . . 0.0 110.197 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -156.76 159.98 38.82 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.539 -0.726 . . . . 0.0 110.326 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 22.9 mmmt . . . . . 0 N--CA 1.496 1.862 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.16 179.928 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.458 ' OE1' HG11 ' A' ' 132' ' ' VAL . 86.4 tt0 -121.9 137.75 54.67 Favored 'General case' 0 N--CA 1.491 1.608 0 C-N-CA 118.74 -1.184 . . . . 0.0 110.088 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.804 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp -84.13 135.55 34.35 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.634 -0.666 . . . . 0.0 110.231 179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CG ' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.402 ' CG ' ' C ' ' B' ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 69.1 p . . . . . 0 N--CA 1.491 1.623 0 CA-C-O 121.079 0.466 . . . . 0.0 110.234 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 82.14 -169.11 49.49 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 85.6 mtt180 52.97 40.0 30.34 Favored 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.46 -1.023 . . . . 0.0 110.787 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.7 88.42 1.55 Allowed 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.651 -0.656 . . . . 0.0 110.163 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt -132.43 150.03 52.23 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.526 -0.734 . . . . 0.0 110.312 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -110.03 24.48 12.96 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.688 -0.633 . . . . 0.0 110.432 179.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -109.27 151.24 26.81 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.499 -0.751 . . . . 0.0 110.194 -179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.3 p -86.97 136.63 22.54 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.571 -0.705 . . . . 0.0 110.344 -179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 -65.3 140.11 58.66 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.591 -0.693 . . . . 0.0 110.411 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -150.3 110.68 0.48 Allowed Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.671 -1.372 . . . . 0.0 109.671 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.402 ' CG ' ' CG ' ' A' ' 92' ' ' ARG . 47.7 mt-10 -66.34 -37.85 86.3 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.539 -0.977 . . . . 0.0 110.041 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.406 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.6 t -107.13 125.42 63.28 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.525 -0.734 . . . . 0.0 109.952 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.5 mt-30 -115.75 143.26 45.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.515 -0.741 . . . . 0.0 110.413 -179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 14.4 p -81.42 132.65 31.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.588 -0.695 . . . . 0.0 109.987 179.591 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.512 ' CB ' HD21 ' A' ' 64' ' ' LEU . 26.7 m -128.77 159.86 40.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.634 -0.666 . . . . 0.0 109.972 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 24.1 m -139.43 160.52 39.65 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.62 -0.675 . . . . 0.0 110.478 -179.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -128.37 -176.93 3.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.758 -0.589 . . . . 0.0 109.841 -179.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.68 -12.53 59.81 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.622 -0.674 . . . . 0.0 110.803 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 41.7 p -120.04 -30.02 4.78 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.242 -0.911 . . . . 0.0 111.191 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.6 pt20 -156.39 169.58 24.26 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.281 -0.887 . . . . 0.0 110.633 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 66.0 p -126.84 158.28 37.08 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.591 -0.693 . . . . 0.0 110.438 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.8 p90 -168.98 -176.38 2.62 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.507 -0.746 . . . . 0.0 109.89 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.586 HD11 ' HA ' ' A' ' 109' ' ' ARG . 77.8 mt -111.83 176.36 5.05 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.491 -0.755 . . . . 0.0 110.454 -178.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.406 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -147.91 159.98 43.29 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.786 -0.571 . . . . 0.0 110.069 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.605 HG23 ' O ' ' A' ' 140' ' ' GLY . 39.8 p -120.17 130.88 54.79 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.577 -0.702 . . . . 0.0 110.525 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 33.8 t -92.52 109.66 21.06 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.429 -0.794 . . . . 0.0 110.386 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.454 HG22 ' HB2' ' A' ' 94' ' ' LEU . 58.6 t -119.2 131.74 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.603 -0.685 . . . . 0.0 109.641 179.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.57 39.35 27.77 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.539 -0.726 . . . . 0.0 110.845 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.561 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.04 75.98 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 178.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 68.2 t -133.69 130.01 55.82 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.143 -1.21 . . . . 0.0 110.022 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 94.1 m -72.63 149.93 43.48 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.44 -0.788 . . . . 0.0 109.457 179.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.568 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 83.4 m95 -131.79 151.07 51.93 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.524 -0.735 . . . . 0.0 111.175 -179.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.1 t -167.65 -179.94 4.56 Favored 'General case' 0 N--CA 1.492 1.626 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.774 HG21 ' CE1' ' A' ' 57' ' ' HIS . 7.5 p -97.05 147.75 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.155 179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.489 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 58.3 t80 -60.05 -46.94 87.88 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.611 -0.68 . . . . 0.0 112.095 -178.594 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.793 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.5 p-80 -64.7 -24.08 67.46 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.159 -0.963 . . . . 0.0 110.91 -178.671 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.698 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -83.61 -52.96 3.53 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.679 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -109.42 -57.41 2.17 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.688 -0.89 . . . . 0.0 110.101 179.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 70.5 -163.8 52.98 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 5.1 p -88.98 66.2 7.78 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.662 -0.905 . . . . 0.0 110.037 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.1 mtpt -139.63 168.39 19.93 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.508 -0.745 . . . . 0.0 110.282 -179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 60.2 m -65.0 139.63 58.78 Favored 'General case' 0 N--CA 1.495 1.788 0 C-N-CA 120.056 -0.657 . . . . 0.0 109.961 -179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.815 HD22 ' CH2' ' A' ' 85' ' ' TRP . 13.8 tp -117.42 138.96 51.48 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.689 -0.632 . . . . 0.0 109.903 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -98.83 110.04 22.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.549 -0.719 . . . . 0.0 110.193 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.76 -179.65 19.06 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.296 -1.522 . . . . 0.0 109.296 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -63.04 -31.89 76.06 Favored 'Trans proline' 0 N--CA 1.491 1.343 0 O-C-N 123.821 1.432 . . . . 0.0 110.469 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 6.7 mtpm? -73.06 -31.17 64.23 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.701 -0.624 . . . . 0.0 109.964 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.46 -150.41 21.6 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.216 -1.554 . . . . 0.0 109.216 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -72.71 147.11 44.45 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.886 1.466 . . . . 0.0 110.148 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.9 mt -129.99 140.03 49.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.825 0 O-C-N 121.549 -0.719 . . . . 0.0 110.57 -179.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 7.7 t -99.94 144.22 29.25 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.548 -0.72 . . . . 0.0 109.774 179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -90.13 150.0 22.22 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.407 -0.808 . . . . 0.0 111.232 -178.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 50.2 mtp -116.04 -25.98 7.46 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.762 -0.586 . . . . 0.0 110.427 179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -122.86 139.96 53.47 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.447 -0.783 . . . . 0.0 110.499 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.561 ' HA ' HG12 ' A' ' 83' ' ' VAL . 60.9 m -141.38 133.72 28.13 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.621 -0.674 . . . . 0.0 110.312 179.754 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 53.7 t-20 -145.54 95.66 2.69 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.509 -0.744 . . . . 0.0 110.019 179.792 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.489 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 80.2 t -66.27 -43.09 91.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.513 -0.742 . . . . 0.0 110.066 -179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.05 -49.88 75.9 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.55 -0.719 . . . . 0.0 110.474 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.634 ' CG ' HD12 ' A' ' 82' ' ' LEU . 37.0 tp60 -81.72 -8.65 59.72 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.588 -0.695 . . . . 0.0 110.509 179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.442 ' OD2' HG22 ' A' ' 55' ' ' VAL . 3.0 t70 57.5 45.9 18.81 Favored 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.115 -0.991 . . . . 0.0 110.304 -179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.779 HD11 HG11 ' A' ' 170' ' ' VAL . 82.6 mt -138.16 139.09 39.21 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.549 -0.719 . . . . 0.0 110.953 -179.79 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.561 HG12 ' HA ' ' A' ' 76' ' ' THR . 34.7 m -144.39 158.04 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.627 -0.671 . . . . 0.0 109.439 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -140.62 157.94 25.93 Favored Glycine 0 N--CA 1.495 2.619 0 N-CA-C 110.33 -1.108 . . . . 0.0 110.33 -179.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.3 m-90 -116.67 161.07 19.77 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.782 -0.834 . . . . 0.0 109.639 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.1 tt0 -70.99 114.23 8.83 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.515 -0.741 . . . . 0.0 109.312 179.167 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.561 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.03 136.52 87.2 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.533 -0.729 . . . . 0.0 110.212 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 159.97 51.3 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.864 1.455 . . . . 0.0 110.228 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -66.15 153.63 77.32 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 123.882 1.464 . . . . 0.0 110.322 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.16 27.36 66.37 Favored Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.87 139.88 40.57 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.506 -0.996 . . . . 0.0 110.138 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.402 ' CG ' ' CG ' ' A' ' 32' ' ' GLU . 27.4 tpt180 -80.11 159.92 25.92 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.658 -0.651 . . . . 0.0 109.531 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.7 p -129.63 167.92 17.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.554 -0.716 . . . . 0.0 110.173 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.454 ' HB2' HG22 ' A' ' 48' ' ' VAL . 59.9 mt -109.8 131.54 54.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.526 -0.733 . . . . 0.0 110.651 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.466 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 9.8 t -75.37 159.97 80.86 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.582 -0.699 . . . . 0.0 109.986 179.505 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -84.76 164.17 12.07 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.753 1.396 . . . . 0.0 110.815 -179.83 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.499 ' HB2' HG22 ' A' ' 151' ' ' VAL . 43.8 t -82.59 138.94 34.07 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.658 -0.651 . . . . 0.0 110.194 -179.814 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 21.7 p -136.09 51.64 2.02 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.812 -0.555 . . . . 0.0 109.681 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.2 p -143.43 -8.61 0.76 Allowed 'General case' 0 N--CA 1.498 1.965 0 C-N-CA 119.843 -0.743 . . . . 0.0 112.411 -179.015 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 33.44 74.75 Favored Glycine 0 N--CA 1.497 2.733 0 N-CA-C 110.116 -1.194 . . . . 0.0 110.116 179.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 86.0 p -76.73 149.92 36.31 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.431 -1.041 . . . . 0.0 110.415 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -92.66 -29.22 16.21 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.625 -0.672 . . . . 0.0 110.286 179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -77.43 135.27 38.27 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.554 -0.716 . . . . 0.0 110.202 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 92.4 mt -135.04 155.12 51.3 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.508 -0.745 . . . . 0.0 110.599 -179.79 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 74.1 m-85 -119.99 114.6 22.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.556 -0.715 . . . . 0.0 109.788 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.428 HD13 HD11 ' A' ' 143' ' ' LEU . 40.3 tp -100.41 140.01 35.27 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.617 -0.677 . . . . 0.0 110.445 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 113' ' ' VAL . 62.2 t -109.96 129.94 64.03 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 O-C-N 121.626 -0.671 . . . . 0.0 110.052 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 59.5 p -102.2 -179.58 4.03 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.592 -0.692 . . . . 0.0 110.42 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.586 ' HA ' HD11 ' A' ' 44' ' ' LEU . 31.9 mtp-105 -59.88 -22.52 62.47 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.535 -0.728 . . . . 0.0 110.808 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -90.11 19.57 4.9 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.276 -0.89 . . . . 0.0 111.15 -179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.0 40.07 31.21 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.123 -0.986 . . . . 0.0 110.686 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -106.76 134.84 49.3 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.611 -0.68 . . . . 0.0 109.957 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.448 HG22 HG22 ' A' ' 107' ' ' VAL . 62.7 t -110.08 123.48 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 109.982 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 43.5 pt -119.97 150.0 50.01 Favored Pre-proline 0 N--CA 1.493 1.717 0 O-C-N 121.564 -0.71 . . . . 0.0 110.06 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.616 ' HG2' HD22 ' A' ' 127' ' ' LEU . 50.6 Cg_endo -87.99 128.03 2.27 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.933 1.491 . . . . 0.0 110.44 179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.9 t -124.75 129.41 73.61 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.662 -0.649 . . . . 0.0 109.637 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.582 ' HG2' HD11 ' A' ' 127' ' ' LEU . 51.6 mmm-85 -80.35 156.0 26.93 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.572 -0.705 . . . . 0.0 110.309 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 23.9 ttm180 -101.14 118.63 37.37 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.634 -0.666 . . . . 0.0 110.064 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 6.8 mmm180 -113.13 20.02 16.65 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.59 -0.694 . . . . 0.0 110.437 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 168.02 -171.43 42.39 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.02 -39.93 90.66 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.566 -0.961 . . . . 0.0 110.442 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.0 p -132.69 24.14 4.34 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.524 -0.735 . . . . 0.0 110.816 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -126.26 139.88 52.97 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.325 -0.859 . . . . 0.0 110.506 -179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -146.84 169.35 27.97 Favored Glycine 0 N--CA 1.494 2.519 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 52.1 p -112.06 156.82 21.58 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.41 -1.053 . . . . 0.0 110.537 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.457 HD23 ' O ' ' A' ' 164' ' ' ALA . 24.2 tp -98.59 120.4 38.94 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.559 -0.713 . . . . 0.0 110.074 179.987 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.616 HD22 ' HG2' ' A' ' 115' ' ' PRO . 8.0 mp -60.93 -40.21 92.39 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.569 -0.707 . . . . 0.0 110.352 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.2 p -117.8 127.25 26.76 Favored Pre-proline 0 N--CA 1.494 1.733 0 O-C-N 121.504 -0.747 . . . . 0.0 110.075 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.31 117.93 5.36 Favored 'Trans proline' 0 N--CA 1.49 1.268 0 O-C-N 123.87 1.458 . . . . 0.0 110.381 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 48.6 mtp85 -120.08 160.01 44.86 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.568 -0.708 . . . . 0.0 110.227 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.77 148.84 83.35 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 O-C-N 123.875 1.461 . . . . 0.0 110.31 -179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.562 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.3 m -62.07 -26.59 40.49 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.613 -0.68 . . . . 0.0 110.426 -179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.4 t -59.95 -39.92 87.22 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.542 -0.724 . . . . 0.0 110.254 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.693 ' HD2' HD12 ' A' ' 135' ' ' LEU . 65.0 t80 -60.06 -49.16 78.73 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.607 -0.683 . . . . 0.0 110.227 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.693 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.4 mp -69.97 -28.93 65.95 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.466 -0.771 . . . . 0.0 110.537 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 3.6 mmtp -60.01 140.02 57.06 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.476 -0.765 . . . . 0.0 110.268 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.99 9.99 86.09 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.315 -1.114 . . . . 0.0 110.315 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 28.9 m -112.05 16.79 20.09 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.141 -1.211 . . . . 0.0 110.785 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -60.17 140.03 57.19 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.287 -0.883 . . . . 0.0 110.023 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 46' ' ' THR . . . 98.34 -18.07 57.59 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -51.4 124.94 24.17 Favored Glycine 0 N--CA 1.5 2.906 0 N-CA-C 109.875 -1.29 . . . . 0.0 109.875 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.557 ' HB3' HG21 ' A' ' 46' ' ' THR . 52.4 Cg_endo -80.77 146.32 16.54 Favored 'Trans proline' 0 N--CA 1.49 1.304 0 O-C-N 123.868 1.457 . . . . 0.0 111.304 -179.042 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.628 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -106.71 106.77 17.46 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 178.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.557 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.8 mp -95.74 131.21 42.26 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.527 -0.733 . . . . 0.0 111.242 -178.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.444 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -69.75 159.39 84.14 Favored Pre-proline 0 N--CA 1.495 1.817 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -51.92 -21.83 12.88 Favored 'Trans proline' 0 N--CA 1.501 1.954 0 O-C-N 123.506 1.266 . . . . 0.0 112.671 -178.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -69.77 -38.39 76.73 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.18 -0.95 . . . . 0.0 109.872 179.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.58 37.23 0.74 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 179.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 29.5 m170 -133.37 149.6 51.85 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.495 -1.003 . . . . 0.0 110.221 179.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.466 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -63.72 139.99 58.82 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.52 -0.737 . . . . 0.0 110.216 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.643 ' O ' HG23 ' A' ' 172' ' ' VAL . 49.6 t -115.96 -35.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 121.582 -0.698 . . . . 0.0 110.009 -179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.7 -169.98 38.69 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 90.0 mt -130.04 139.89 50.33 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.564 -0.962 . . . . 0.0 110.229 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 34.7 t80 -59.99 139.14 57.63 Favored 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.507 -0.746 . . . . 0.0 110.12 179.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.6 ttt180 -119.95 -52.34 2.21 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.615 -0.678 . . . . 0.0 110.29 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.681 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -152.58 166.88 30.69 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.522 -0.736 . . . . 0.0 110.5 -179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -119.25 148.55 43.01 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.627 -0.671 . . . . 0.0 110.17 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.2 t -109.94 120.03 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.624 -0.672 . . . . 0.0 109.796 179.985 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.562 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.5 p -133.63 149.87 51.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.719 -0.613 . . . . 0.0 110.376 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 70.8 p -80.09 -47.48 14.75 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.568 -0.707 . . . . 0.0 110.41 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 25.0 ptt180 -161.65 57.41 0.27 Allowed 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.671 -0.643 . . . . 0.0 110.033 -179.88 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.03 -11.65 40.83 Favored Glycine 0 N--CA 1.492 2.419 0 N-CA-C 110.175 -1.17 . . . . 0.0 110.175 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 61.9 t -118.24 126.52 75.07 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 O-C-N 121.137 -1.213 . . . . 0.0 109.686 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . 0.457 ' O ' HD23 ' A' ' 126' ' ' LEU . . . -96.7 123.53 40.42 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.512 -0.743 . . . . 0.0 110.627 -179.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 53.2 mttm -105.8 -18.46 14.05 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.723 -0.611 . . . . 0.0 110.392 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -148.6 158.77 44.36 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.373 -0.829 . . . . 0.0 109.821 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -130.07 -173.0 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.871 0 O-C-N 121.481 -0.762 . . . . 0.0 110.518 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 13.0 t70 -146.44 127.17 14.32 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.705 -0.622 . . . . 0.0 109.444 179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.4 p90 -127.42 156.22 42.42 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.453 -0.779 . . . . 0.0 110.946 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.779 HG11 HD11 ' A' ' 82' ' ' LEU . 63.2 t -92.82 121.41 66.01 Favored Pre-proline 0 N--CA 1.492 1.648 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.287 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -64.17 154.92 68.06 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.79 1.416 . . . . 0.0 110.496 -179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 151' ' ' VAL . 97.1 t -58.97 -24.06 25.78 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.919 0 O-C-N 121.612 -0.68 . . . . 0.0 110.531 -179.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -59.85 -40.08 87.33 Favored 'General case' 0 N--CA 1.499 1.992 0 O-C-N 121.365 -0.835 . . . . 0.0 110.346 -179.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 22.4 t -63.42 -38.42 91.06 Favored 'General case' 0 N--CA 1.498 1.969 0 O-C-N 121.476 -0.765 . . . . 0.0 110.144 179.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.568 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 93.3 mtp -60.0 -41.58 92.39 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.631 -0.668 . . . . 0.0 110.317 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -69.13 -40.08 78.5 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.567 -0.708 . . . . 0.0 110.162 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.1 m -61.06 -39.98 91.92 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.627 -0.671 . . . . 0.0 110.156 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.6 m -60.14 -40.36 89.55 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.542 -0.724 . . . . 0.0 110.114 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -68.25 -39.98 82.08 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.594 -0.691 . . . . 0.0 110.169 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 27.1 mmt180 -65.13 -40.07 93.93 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.569 -0.707 . . . . 0.0 110.137 -179.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.459 ' HB1' ' HB2' ' A' ' 185' ' ' LYS . . . -60.22 -40.82 91.5 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.607 -0.683 . . . . 0.0 110.281 -179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 51.99 -164.72 0.06 Allowed 'General case' 0 N--CA 1.501 2.094 0 O-C-N 121.429 -0.794 . . . . 0.0 110.947 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.7 pttt -63.44 -27.7 69.47 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.624 -0.672 . . . . 0.0 110.531 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 30.8 mmtp -59.97 -39.97 87.47 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.501 -0.75 . . . . 0.0 110.469 -179.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . 0.459 ' HB2' ' HB1' ' A' ' 181' ' ' ALA . 58.3 mttm -119.95 140.04 51.52 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.57 -0.706 . . . . 0.0 110.21 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 22.0 pttm . . . . . 0 N--CA 1.494 1.764 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.283 -179.973 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.681 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 41.2 tt0 -119.96 137.94 53.77 Favored 'General case' 0 N--CA 1.492 1.653 0 C-N-CA 118.744 -1.183 . . . . 0.0 110.058 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.793 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.8 mp -89.09 141.53 28.42 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.607 -0.683 . . . . 0.0 110.245 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.467 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 m . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.107 0.479 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -80.01 177.44 54.3 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.3 mtt180 -100.19 125.86 46.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.526 -0.984 . . . . 0.0 110.193 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -60.67 -40.0 90.5 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.539 -0.726 . . . . 0.0 110.24 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 17.8 ttmm 56.75 167.94 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.148 0 O-C-N 121.507 -0.745 . . . . 0.0 110.586 -179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 18.5 p30 -80.42 166.97 20.74 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.47 -0.769 . . . . 0.0 110.338 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -70.07 140.74 52.83 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.555 -0.715 . . . . 0.0 110.155 -179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.6 p -139.0 140.39 38.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.623 -0.673 . . . . 0.0 110.21 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -94.38 139.84 30.59 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.567 -0.708 . . . . 0.0 110.197 -179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -131.03 31.23 3.21 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.815 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 -59.93 -37.29 79.08 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.518 -0.99 . . . . 0.0 110.313 -179.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.815 HG23 ' HG3' ' A' ' 32' ' ' GLU . 63.6 t -120.34 129.61 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.773 0 O-C-N 121.546 -0.721 . . . . 0.0 109.77 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -129.99 158.35 39.81 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.517 -0.739 . . . . 0.0 110.451 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 57.4 t -91.78 125.28 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.696 -0.628 . . . . 0.0 109.413 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.557 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.6 m -124.79 158.16 32.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.577 -0.702 . . . . 0.0 110.159 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.5 m -133.36 173.04 11.89 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.684 -0.635 . . . . 0.0 110.556 -179.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.449 HG22 ' N ' ' A' ' 39' ' ' ALA . 35.0 m -139.69 171.54 14.08 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 179.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.449 ' N ' HG22 ' A' ' 38' ' ' THR . . . -56.09 -28.18 56.69 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.438 -0.789 . . . . 0.0 111.204 -179.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 13.0 m -135.37 -7.26 2.26 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.263 -0.898 . . . . 0.0 112.597 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 93.7 mm-40 -129.98 159.17 37.48 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 120.89 -1.131 . . . . 0.0 111.69 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 68.1 m -132.12 133.98 44.92 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.419 ' HE1' ' HG1' ' A' ' 38' ' ' THR . 6.9 p90 -164.67 -177.4 4.76 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.242 -0.911 . . . . 0.0 111.068 -179.054 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.86 HD11 ' HA ' ' A' ' 109' ' ' ARG . 51.6 mt -112.63 146.61 38.32 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.666 -0.647 . . . . 0.0 110.279 -178.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -111.24 161.01 16.44 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.58 -0.7 . . . . 0.0 110.165 179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 63.6 p -125.16 143.38 50.96 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.593 -0.692 . . . . 0.0 110.314 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 93.3 m -102.85 113.18 26.4 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.574 -0.704 . . . . 0.0 110.501 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 59.9 t -127.3 130.0 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.658 -0.652 . . . . 0.0 109.428 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 55.49 36.68 27.64 Favored 'General case' 0 N--CA 1.502 2.131 0 O-C-N 121.421 -0.799 . . . . 0.0 110.76 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.803 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.69 19.16 74.67 Favored Glycine 0 N--CA 1.496 2.691 0 N-CA-C 110.766 -0.933 . . . . 0.0 110.766 179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -132.36 130.05 59.88 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 121.202 -1.175 . . . . 0.0 109.998 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.5 m -78.21 144.97 35.82 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.483 -0.761 . . . . 0.0 109.514 179.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 79.2 m95 -128.36 151.41 49.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.525 -0.734 . . . . 0.0 110.863 -179.542 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.9 t -167.77 -179.8 4.43 Favored 'General case' 0 N--CA 1.493 1.686 0 N-CA-C 109.306 -0.628 . . . . 0.0 109.306 -179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.843 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.9 p -95.29 154.2 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.395 -0.816 . . . . 0.0 110.562 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.637 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.7 t80 -69.95 -40.12 75.63 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.683 -0.636 . . . . 0.0 111.873 -178.87 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.843 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.4 p-80 -68.26 -24.35 64.88 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.135 -0.978 . . . . 0.0 110.499 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.697 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -82.64 -59.12 2.27 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.49 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -102.37 -47.95 4.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.069 179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 66.0 -165.68 37.85 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.2 m -83.72 64.42 7.99 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.582 -0.952 . . . . 0.0 109.951 179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -140.02 164.84 28.95 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.514 -0.741 . . . . 0.0 110.324 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 7.3 t -65.37 140.05 58.62 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.578 -0.701 . . . . 0.0 110.05 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.923 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.5 tp -109.9 130.54 55.51 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.658 -0.651 . . . . 0.0 110.178 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.46 118.45 30.57 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.578 -0.701 . . . . 0.0 110.106 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -122.89 177.74 16.48 Favored Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.63 -31.98 69.57 Favored 'Trans proline' 0 N--CA 1.491 1.367 0 O-C-N 123.795 1.419 . . . . 0.0 110.338 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 61.0 tptt -70.55 -31.55 68.64 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.606 -0.684 . . . . 0.0 109.633 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 142.01 -150.41 22.01 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.374 -1.49 . . . . 0.0 109.374 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.79 155.75 53.51 Favored 'Trans proline' 0 C--N 1.313 -1.302 0 O-C-N 123.891 1.469 . . . . 0.0 110.228 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.441 ' CD1' HD23 ' A' ' 64' ' ' LEU . 85.1 mt -125.91 139.94 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.555 -0.715 . . . . 0.0 110.272 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 73.1 m -94.39 137.9 32.99 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.413 -0.804 . . . . 0.0 110.265 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 75.8 mt-30 -70.16 139.96 52.49 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.575 -0.703 . . . . 0.0 110.599 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -115.82 -51.3 2.66 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.564 -0.71 . . . . 0.0 109.952 179.463 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 86.9 m-85 -120.03 140.06 51.56 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.514 -0.742 . . . . 0.0 110.213 179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.6 p -131.64 137.61 48.42 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.497 -0.752 . . . . 0.0 110.367 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -150.04 90.72 1.7 Allowed 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.578 -0.702 . . . . 0.0 110.215 179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.637 HG22 ' CE1' ' A' ' 56' ' ' TYR . 85.9 t -68.04 -42.33 85.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.543 -0.723 . . . . 0.0 109.857 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.91 -42.8 94.66 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.552 -0.717 . . . . 0.0 110.27 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.522 ' HG3' HD12 ' A' ' 82' ' ' LEU . 39.0 tp60 -89.98 0.12 57.27 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.537 -0.727 . . . . 0.0 110.93 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.443 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.4 t70 53.65 44.63 29.46 Favored 'General case' 0 N--CA 1.5 2.056 0 O-C-N 121.059 -1.026 . . . . 0.0 110.687 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.615 HD11 HG11 ' A' ' 170' ' ' VAL . 70.9 mt -140.25 144.37 36.45 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.407 -0.808 . . . . 0.0 110.923 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.584 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.8 m -148.2 155.64 9.5 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.578 -0.701 . . . . 0.0 109.452 179.105 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -139.95 161.25 26.33 Favored Glycine 0 N--CA 1.495 2.591 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 9.2 m-90 -117.75 160.06 21.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.751 -0.852 . . . . 0.0 109.565 179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -74.54 104.42 5.24 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.463 -0.773 . . . . 0.0 109.677 179.487 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.803 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.37 130.04 88.16 Favored Pre-proline 0 N--CA 1.494 1.775 0 O-C-N 121.541 -0.724 . . . . 0.0 110.239 -179.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -70.08 159.98 51.24 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.827 1.435 . . . . 0.0 110.271 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.9 157.71 51.04 Favored 'Trans proline' 0 C--N 1.313 -1.331 0 O-C-N 123.968 1.51 . . . . 0.0 110.319 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.9 -24.86 30.52 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.03 159.99 26.01 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.445 -1.032 . . . . 0.0 110.159 179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 83.6 mtt180 -100.39 159.31 15.24 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.59 -0.694 . . . . 0.0 110.109 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 81.3 p -129.91 170.03 14.45 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.511 -0.743 . . . . 0.0 110.271 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.73 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 2.4 mm? -102.48 138.49 39.32 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.635 -0.666 . . . . 0.0 110.505 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.428 ' HB ' ' CE1' ' A' ' 149' ' ' HIS . 4.8 p -76.05 160.03 79.25 Favored Pre-proline 0 N--CA 1.496 1.858 0 O-C-N 121.629 -0.669 . . . . 0.0 109.946 179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.55 153.32 30.41 Favored 'Trans proline' 0 N--CA 1.491 1.332 0 O-C-N 123.779 1.41 . . . . 0.0 110.6 -179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.773 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.4 t -68.73 135.11 50.77 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.543 -0.723 . . . . 0.0 110.131 179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.5 t -136.1 52.07 2.0 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.708 -0.62 . . . . 0.0 109.692 179.621 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.83 -8.51 0.72 Allowed 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.542 -0.723 . . . . 0.0 112.405 -178.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.96 33.84 80.66 Favored Glycine 0 N--CA 1.496 2.641 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 p -88.15 139.64 30.29 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.533 -0.981 . . . . 0.0 110.411 -179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.5 m -82.1 -30.0 31.46 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.646 -0.659 . . . . 0.0 110.353 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -66.62 129.87 41.3 Favored 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.502 -0.749 . . . . 0.0 110.162 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.582 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.6 mt -137.14 139.81 41.44 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.579 -0.7 . . . . 0.0 110.631 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.5 120.51 42.39 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.56 -0.713 . . . . 0.0 109.862 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 40.4 tp -103.1 140.06 37.81 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.5 -0.75 . . . . 0.0 110.488 -179.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.506 ' HA ' HG12 ' A' ' 113' ' ' VAL . 62.6 t -90.44 138.66 19.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 O-C-N 121.585 -0.697 . . . . 0.0 109.758 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 13.5 m -110.2 159.48 17.34 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.519 -0.738 . . . . 0.0 110.489 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.86 ' HA ' HD11 ' A' ' 44' ' ' LEU . 2.7 ttp180 -60.1 -21.37 61.42 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.588 -0.695 . . . . 0.0 110.63 -179.775 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.07 27.45 3.2 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.267 -0.896 . . . . 0.0 110.528 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.61 39.98 31.56 Favored 'General case' 0 N--CA 1.501 2.124 0 O-C-N 121.39 -0.819 . . . . 0.0 110.622 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -124.21 139.59 53.77 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.656 -0.653 . . . . 0.0 109.737 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.506 HG12 ' HA ' ' A' ' 107' ' ' VAL . 34.5 m -126.13 139.09 52.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.482 -0.761 . . . . 0.0 110.59 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.552 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.2 mp -124.52 150.05 63.6 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.733 -0.604 . . . . 0.0 109.559 179.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.438 ' HD2' HG23 ' A' ' 114' ' ' ILE . 46.8 Cg_endo -79.15 133.41 10.94 Favored 'Trans proline' 0 N--CA 1.489 1.241 0 O-C-N 123.888 1.468 . . . . 0.0 110.492 -179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.495 HG13 ' O ' ' A' ' 125' ' ' SER . 62.7 t -130.02 129.99 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.671 -0.643 . . . . 0.0 109.653 179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.4 tpt180 -85.38 150.0 25.04 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.52 -0.738 . . . . 0.0 110.193 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -91.15 119.96 31.69 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.65 -0.656 . . . . 0.0 110.336 -179.638 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 37.3 mmt180 -110.21 20.02 18.29 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.608 -0.683 . . . . 0.0 110.508 179.632 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.11 -174.26 43.59 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.384 -1.486 . . . . 0.0 109.384 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.8 m-20 -65.8 -39.94 91.41 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.501 -0.999 . . . . 0.0 110.245 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.6 p -130.74 24.52 5.04 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.553 -0.717 . . . . 0.0 110.535 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 10.0 tpp180 -124.93 139.96 53.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.369 -0.832 . . . . 0.0 110.36 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.37 165.79 25.67 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.495 ' O ' HG13 ' A' ' 116' ' ' VAL . 91.1 p -115.86 153.78 30.9 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.463 -1.022 . . . . 0.0 110.152 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.411 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.2 tp -99.72 119.96 38.95 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.584 -0.697 . . . . 0.0 110.193 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.527 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.0 mp -68.96 -38.51 79.45 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.527 -0.733 . . . . 0.0 109.863 179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 53.0 m -110.0 113.84 56.68 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.677 -0.639 . . . . 0.0 110.051 179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -64.66 118.52 5.49 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.799 1.421 . . . . 0.0 110.523 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 16.2 mmt180 -122.44 160.02 50.05 Favored Pre-proline 0 N--CA 1.494 1.725 0 O-C-N 121.626 -0.671 . . . . 0.0 110.211 179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -66.15 154.88 72.37 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.913 1.481 . . . . 0.0 110.42 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 90.6 t -61.63 -39.97 85.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.607 -0.683 . . . . 0.0 110.126 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.3 p -56.14 -33.85 65.56 Favored 'General case' 0 N--CA 1.5 2.036 0 O-C-N 121.476 -0.765 . . . . 0.0 110.663 -179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -60.02 -39.95 87.64 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.556 -0.715 . . . . 0.0 110.107 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.5 mp -84.82 -20.95 30.12 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.542 -0.724 . . . . 0.0 110.931 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.2 mmmm -59.9 139.85 57.08 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.251 -0.906 . . . . 0.0 110.117 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.66 10.05 86.19 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 110.128 -1.189 . . . . 0.0 110.128 -179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 18.2 m -116.14 10.3 14.93 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.19 -1.182 . . . . 0.0 110.884 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 7.2 t -65.0 150.49 47.98 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.164 -0.96 . . . . 0.0 109.597 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.532 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 95.56 -22.23 40.18 Favored Glycine 0 N--CA 1.492 2.398 0 N-CA-C 109.745 -1.342 . . . . 0.0 109.745 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.5 148.57 21.04 Favored Glycine 0 N--CA 1.498 2.83 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -98.8 147.57 0.58 Allowed 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.889 1.468 . . . . 0.0 111.024 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.38 108.33 19.91 Favored 'General case' 0 N--CA 1.49 1.572 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.543 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.77 129.94 45.93 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.456 -0.777 . . . . 0.0 111.296 -178.691 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.03 158.31 87.67 Favored Pre-proline 0 N--CA 1.494 1.757 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 179.056 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.0 Cg_endo -51.87 -25.36 21.22 Favored 'Trans proline' 0 N--CA 1.501 1.918 0 O-C-N 123.547 1.288 . . . . 0.0 112.343 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.2 m -62.74 -40.0 95.85 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.266 -0.896 . . . . 0.0 109.886 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.06 36.86 0.79 Allowed Glycine 0 N--CA 1.495 2.611 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . 0.428 ' CE1' ' HB ' ' A' ' 95' ' ' THR . 4.3 m-70 -132.95 143.69 49.63 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.445 -1.033 . . . . 0.0 110.188 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.73 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -65.42 142.33 58.23 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.523 -0.736 . . . . 0.0 110.233 179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.773 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.6 t -115.34 -38.06 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.579 -0.701 . . . . 0.0 110.043 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -176.09 -168.38 36.23 Favored Glycine 0 N--CA 1.494 2.549 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 -179.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.693 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.8 mt -129.89 140.02 50.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.469 -1.018 . . . . 0.0 110.379 -179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.553 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.0 t80 -63.75 139.77 58.8 Favored 'General case' 0 N--CA 1.499 1.998 0 O-C-N 121.677 -0.639 . . . . 0.0 110.11 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.5 ttt180 -119.9 -52.42 2.21 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.57 -0.706 . . . . 0.0 110.331 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.28 158.77 44.51 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.514 -0.742 . . . . 0.0 110.335 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.553 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -113.94 152.02 31.45 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.619 -0.676 . . . . 0.0 110.488 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -109.86 119.77 59.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.736 -0.603 . . . . 0.0 109.692 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.26 144.22 51.14 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.721 -0.612 . . . . 0.0 110.373 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 88.5 m -69.86 -49.77 49.14 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.619 -0.676 . . . . 0.0 110.056 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ptt85 -163.65 54.17 0.16 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.711 -0.618 . . . . 0.0 109.854 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 115.32 -16.51 17.33 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.992 -1.243 . . . . 0.0 109.992 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.9 t -115.15 125.15 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.228 -1.16 . . . . 0.0 109.661 179.88 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -95.3 123.05 38.61 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.591 -0.693 . . . . 0.0 110.578 -179.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 49.6 mttm -105.2 -21.31 13.28 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.601 -0.687 . . . . 0.0 110.274 179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -144.94 159.12 43.43 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.365 -0.834 . . . . 0.0 109.913 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 19.7 m -131.53 -175.73 1.52 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.892 0 O-C-N 121.551 -0.718 . . . . 0.0 110.519 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -142.93 132.18 23.3 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.77 -0.581 . . . . 0.0 109.595 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -133.23 155.79 48.71 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.523 -0.736 . . . . 0.0 110.894 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.615 HG11 HD11 ' A' ' 82' ' ' LEU . 62.9 t -92.7 124.27 59.29 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.564 -0.71 . . . . 0.0 109.332 179.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -68.49 150.31 75.29 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.721 1.379 . . . . 0.0 110.675 -179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 151' ' ' VAL . 95.0 t -59.48 -24.04 27.24 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.946 0 O-C-N 121.666 -0.646 . . . . 0.0 110.408 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 57.2 tt0 -59.12 -39.58 82.76 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.382 -0.824 . . . . 0.0 110.314 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 88.4 p -60.01 -39.34 85.5 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.555 -0.716 . . . . 0.0 110.212 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.693 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.7 mtt -59.92 -40.46 88.94 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.586 -0.696 . . . . 0.0 110.452 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.28 -40.02 88.93 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.675 -0.64 . . . . 0.0 110.281 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.4 m -60.76 -40.4 92.35 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.472 -0.767 . . . . 0.0 110.106 -179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -69.86 -41.03 75.4 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.58 -0.7 . . . . 0.0 110.079 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -68.7 -39.99 80.23 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.594 -0.691 . . . . 0.0 110.348 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 26.4 mmt180 -61.39 -39.91 92.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.22 -50.97 71.54 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.599 -0.688 . . . . 0.0 110.301 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 2.9 m 50.14 40.01 20.81 Favored 'General case' 0 N--CA 1.501 2.085 0 O-C-N 121.465 -0.772 . . . . 0.0 111.073 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 84.5 tttt -131.24 147.17 52.56 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.532 -0.73 . . . . 0.0 110.169 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt -100.11 29.19 4.39 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.559 -0.713 . . . . 0.0 110.378 -179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -59.97 -40.04 87.72 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.536 -0.728 . . . . 0.0 110.249 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 N--CA 1.495 1.808 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.289 -179.973 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -119.68 130.03 54.84 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 118.722 -1.191 . . . . 0.0 110.074 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.833 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.1 mp -71.08 139.98 50.53 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.0 110.343 -179.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.568 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 59.5 m . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 121.076 0.465 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.0 -26.29 25.04 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 56.9 ttp180 -133.49 136.86 45.36 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.436 -1.038 . . . . 0.0 110.18 -179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 30.5 t0 52.43 45.43 28.54 Favored 'General case' 0 N--CA 1.501 2.115 0 O-C-N 121.383 -0.823 . . . . 0.0 110.812 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -60.82 -40.56 93.19 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.455 -0.778 . . . . 0.0 110.395 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 42.6 p-10 -139.96 24.68 2.36 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.496 -0.753 . . . . 0.0 110.751 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 97.2 mt-30 -92.67 118.82 31.45 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.458 -0.776 . . . . 0.0 110.229 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 66.7 t -70.13 -50.01 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.612 -0.68 . . . . 0.0 110.13 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -160.03 160.24 33.0 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.497 -0.752 . . . . 0.0 110.471 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -141.52 29.58 2.25 Favored Glycine 0 N--CA 1.492 2.389 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.81 ' HG3' HG23 ' A' ' 33' ' ' VAL . 17.5 pt-20 -60.23 -37.2 79.61 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.484 -1.009 . . . . 0.0 110.553 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.81 HG23 ' HG3' ' A' ' 32' ' ' GLU . 82.7 t -116.86 128.54 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.401 -0.812 . . . . 0.0 109.663 179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -129.27 154.44 46.83 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.533 -0.729 . . . . 0.0 110.6 -179.644 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.6 t -91.74 128.36 43.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 179.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.602 ' HB ' HD21 ' A' ' 64' ' ' LEU . 27.0 m -126.17 159.69 34.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.614 -0.679 . . . . 0.0 110.36 -179.538 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 58.6 m -137.85 162.48 33.87 Favored 'General case' 0 N--CA 1.495 1.784 0 CA-C-O 121.517 0.675 . . . . 0.0 111.032 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 5.2 m -134.51 169.37 17.37 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.792 -0.567 . . . . 0.0 109.678 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -67.11 -12.67 60.59 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.606 -0.684 . . . . 0.0 111.323 -179.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 48.6 p -118.39 -30.53 5.2 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.042 -1.036 . . . . 0.0 111.555 -179.278 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -159.17 170.04 22.83 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.202 -0.936 . . . . 0.0 110.967 -179.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 42.3 t -123.88 155.23 38.46 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.489 -0.757 . . . . 0.0 110.574 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.628 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 16.8 p90 -166.26 -177.71 4.22 Favored 'General case' 0 N--CA 1.499 1.984 0 O-C-N 121.546 -0.721 . . . . 0.0 110.091 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.554 HD11 ' HA ' ' A' ' 109' ' ' ARG . 63.7 mt -113.28 153.78 27.87 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.523 -0.736 . . . . 0.0 110.443 -178.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -127.89 161.09 29.89 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.557 -0.714 . . . . 0.0 110.356 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.642 HG23 HD12 ' A' ' 94' ' ' LEU . 86.9 m -120.04 130.23 54.61 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.635 -0.666 . . . . 0.0 110.108 -179.819 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 26.4 t -89.94 104.0 16.61 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.628 -0.67 . . . . 0.0 110.42 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.436 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 58.3 t -111.06 132.81 58.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.609 -0.682 . . . . 0.0 109.479 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.77 38.71 29.67 Favored 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.559 -0.713 . . . . 0.0 110.678 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.676 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.94 20.07 75.86 Favored Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.4 t -132.31 129.89 59.93 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.234 -1.156 . . . . 0.0 110.079 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 5.2 t -71.81 146.49 47.97 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.539 -0.726 . . . . 0.0 109.433 179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.627 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 59.5 m95 -129.4 151.05 50.46 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.474 -0.766 . . . . 0.0 111.273 -179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.877 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.4 t -169.78 -179.81 3.43 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.836 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.1 p -94.53 156.36 3.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.423 -0.798 . . . . 0.0 110.073 179.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CE1' HG22 ' A' ' 78' ' ' VAL . 58.2 t80 -70.04 -42.35 73.02 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.548 -0.72 . . . . 0.0 111.79 -178.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.836 ' CE1' HG21 ' A' ' 55' ' ' VAL . 3.5 p-80 -64.77 -20.76 66.54 Favored 'General case' 0 N--CA 1.498 1.947 0 O-C-N 121.144 -0.973 . . . . 0.0 110.643 -179.23 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.603 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -86.84 -47.69 4.69 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 108.675 -1.77 . . . . 0.0 108.675 179.011 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.628 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -125.41 90.98 3.32 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.679 -0.895 . . . . 0.0 109.942 179.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.42 -169.99 2.0 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 179.641 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 20.4 p -72.22 66.93 0.66 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.438 -1.036 . . . . 0.0 109.555 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.62 166.8 23.74 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.62 -0.675 . . . . 0.0 110.729 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 79.2 m -65.58 139.62 58.46 Favored 'General case' 0 N--CA 1.494 1.769 0 C-N-CA 120.231 -0.588 . . . . 0.0 109.778 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.904 HD22 ' CH2' ' A' ' 85' ' ' TRP . 14.7 tp -108.32 132.72 53.42 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.636 -0.665 . . . . 0.0 110.11 -179.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -91.7 118.37 30.6 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.549 -0.719 . . . . 0.0 110.36 -179.797 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.09 -176.91 18.25 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.132 -1.587 . . . . 0.0 109.132 179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -63.51 -32.51 70.36 Favored 'Trans proline' 0 N--CA 1.491 1.35 0 O-C-N 123.836 1.44 . . . . 0.0 110.579 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 76.0 tttt -75.46 -31.11 60.16 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.598 -0.689 . . . . 0.0 109.974 -179.699 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.3 -140.26 9.22 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 -179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -74.06 156.93 47.14 Favored 'Trans proline' 0 N--CA 1.49 1.301 0 O-C-N 123.806 1.424 . . . . 0.0 110.25 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.516 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.4 mt -127.41 139.99 50.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.527 -0.733 . . . . 0.0 110.065 -179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.6 p -88.46 150.76 22.97 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.587 -0.696 . . . . 0.0 110.755 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 35.2 mt-30 -96.75 140.03 31.94 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.612 -0.68 . . . . 0.0 110.441 -179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.6 mmm -119.29 -32.77 4.29 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.577 -0.702 . . . . 0.0 110.856 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -132.75 149.97 52.21 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.405 -0.809 . . . . 0.0 110.869 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.3 p -143.56 137.86 28.71 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.672 -0.643 . . . . 0.0 110.026 179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.401 ' OD1' HG23 ' A' ' 178' ' ' THR . 1.6 m120 -150.02 93.92 2.08 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.467 -0.771 . . . . 0.0 110.169 179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CE1' ' A' ' 56' ' ' TYR . 88.0 t -69.96 -43.06 79.7 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.586 -0.696 . . . . 0.0 110.011 -179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -59.87 -45.46 92.41 Favored 'General case' 0 N--CA 1.498 1.958 0 O-C-N 121.514 -0.741 . . . . 0.0 110.608 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.765 ' HG2' HD12 ' A' ' 82' ' ' LEU . 51.4 tt0 -85.71 -0.07 54.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.579 -0.7 . . . . 0.0 110.737 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.441 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 8.3 t70 53.73 45.29 28.26 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.036 -1.04 . . . . 0.0 110.704 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.765 HD12 ' HG2' ' A' ' 80' ' ' GLN . 57.6 mt -142.24 146.89 35.65 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.524 -0.735 . . . . 0.0 110.924 -179.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.522 HG23 ' CG2' ' A' ' 54' ' ' THR . 35.4 m -149.24 160.0 5.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.86 0 O-C-N 121.555 -0.715 . . . . 0.0 109.735 179.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.34 153.75 24.18 Favored Glycine 0 N--CA 1.495 2.618 0 N-CA-C 110.017 -1.233 . . . . 0.0 110.017 -179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.904 ' CH2' HD22 ' A' ' 64' ' ' LEU . 7.5 m-90 -114.58 168.09 10.17 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.668 -0.901 . . . . 0.0 109.535 179.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 39.0 tt0 -77.57 110.05 12.05 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.439 -0.788 . . . . 0.0 109.268 179.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.676 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.05 129.98 90.26 Favored Pre-proline 0 N--CA 1.496 1.826 0 O-C-N 121.598 -0.689 . . . . 0.0 110.204 -179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -69.96 159.95 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.321 0 O-C-N 123.791 1.416 . . . . 0.0 110.28 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -70.35 160.14 50.54 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.961 1.506 . . . . 0.0 110.285 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 84.49 28.75 31.91 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -126.99 150.03 49.61 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.527 -0.984 . . . . 0.0 110.094 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 95.2 mtt-85 -100.02 119.98 39.11 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.521 -0.737 . . . . 0.0 110.342 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.5 p -81.24 170.03 16.59 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.656 -0.653 . . . . 0.0 110.161 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.642 HD12 HG23 ' A' ' 46' ' ' THR . 79.3 mt -109.57 131.85 54.68 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.586 -0.696 . . . . 0.0 110.807 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 68.7 p -72.74 160.06 83.8 Favored Pre-proline 0 N--CA 1.497 1.893 0 O-C-N 121.576 -0.703 . . . . 0.0 109.95 179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -79.36 164.44 24.08 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.87 1.458 . . . . 0.0 110.594 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.538 ' HB2' HG22 ' A' ' 151' ' ' VAL . 54.1 t -80.16 129.99 34.9 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.537 -0.727 . . . . 0.0 110.241 -179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.7 t -133.24 55.79 1.88 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.646 -0.659 . . . . 0.0 109.522 179.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.95 -8.12 0.72 Allowed 'General case' 0 N--CA 1.497 1.917 0 O-C-N 121.607 -0.683 . . . . 0.0 112.394 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.06 35.27 91.2 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 17.4 m -84.97 113.07 21.14 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.513 -0.992 . . . . 0.0 110.485 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -60.03 -40.01 87.88 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.64 -0.662 . . . . 0.0 110.342 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -64.89 138.66 58.51 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.55 -0.719 . . . . 0.0 110.414 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.47 ' CD2' HG11 ' A' ' 151' ' ' VAL . 91.5 mt -135.58 150.0 49.57 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.615 -0.678 . . . . 0.0 110.319 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.6 m-85 -117.84 114.4 23.2 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.583 -0.698 . . . . 0.0 109.857 179.633 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.414 HD13 HD11 ' A' ' 143' ' ' LEU . 40.2 tp -96.5 145.64 25.5 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.568 -0.707 . . . . 0.0 110.467 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -110.01 128.69 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.662 -0.649 . . . . 0.0 109.928 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 71.1 p -105.12 -178.59 3.7 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.597 -0.69 . . . . 0.0 110.441 -179.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.554 ' HA ' HD11 ' A' ' 44' ' ' LEU . 55.0 mtp180 -69.76 -20.95 63.48 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.562 -0.711 . . . . 0.0 110.808 -179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.81 21.24 4.96 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.356 -0.84 . . . . 0.0 110.908 -179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.12 39.93 31.16 Favored 'General case' 0 N--CA 1.501 2.081 0 O-C-N 121.154 -0.966 . . . . 0.0 110.622 179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -106.4 168.32 9.24 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.588 -0.695 . . . . 0.0 110.008 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.97 129.97 66.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.559 -0.713 . . . . 0.0 110.183 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.601 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -119.62 109.28 38.35 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.633 -0.667 . . . . 0.0 109.87 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -65.16 109.83 1.41 Allowed 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.764 1.402 . . . . 0.0 110.263 -179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.546 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.2 t -110.83 124.12 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.608 -0.683 . . . . 0.0 109.937 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 35.1 mmm-85 -79.75 155.22 28.04 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.586 -0.696 . . . . 0.0 110.175 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 64.3 ttt180 -98.18 119.69 37.28 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.583 -0.698 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 7.3 mmm180 -122.64 22.63 9.8 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.642 -0.661 . . . . 0.0 110.224 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.23 -176.95 47.3 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.29 -1.524 . . . . 0.0 109.29 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 14.7 t70 -70.07 -40.04 75.29 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.506 -0.997 . . . . 0.0 110.532 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -131.0 29.07 4.74 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.449 -0.782 . . . . 0.0 110.686 -179.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -138.44 162.5 34.31 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.451 -0.78 . . . . 0.0 110.474 -179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -162.24 -179.39 36.83 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 79.4 p -120.92 149.01 43.28 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.542 -0.975 . . . . 0.0 110.232 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.446 HD11 ' CG2' ' A' ' 114' ' ' ILE . 19.4 tp -93.44 119.28 32.35 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.591 -0.693 . . . . 0.0 109.996 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.7 mp -65.02 -39.95 94.16 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.593 -0.692 . . . . 0.0 109.959 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.3 p -110.87 119.97 44.72 Favored Pre-proline 0 N--CA 1.492 1.667 0 O-C-N 121.601 -0.687 . . . . 0.0 110.033 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -67.23 117.74 5.05 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 O-C-N 123.736 1.388 . . . . 0.0 110.281 -179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 13.1 mmt85 -120.59 160.0 45.97 Favored Pre-proline 0 N--CA 1.494 1.739 0 O-C-N 121.56 -0.712 . . . . 0.0 110.197 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -69.58 159.21 54.41 Favored 'Trans proline' 0 N--CA 1.489 1.255 0 O-C-N 123.875 1.461 . . . . 0.0 110.475 -179.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.495 HG11 ' OE1' ' B' ' 188' ' ' GLU . 92.5 t -64.66 -33.15 61.3 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.81 0 O-C-N 121.538 -0.726 . . . . 0.0 109.98 179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 56.0 m -60.07 -38.09 81.82 Favored 'General case' 0 N--CA 1.498 1.936 0 O-C-N 121.588 -0.695 . . . . 0.0 110.223 -179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 41.8 t80 -60.05 -40.04 88.02 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.559 -0.713 . . . . 0.0 110.212 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 9.3 mp -83.6 -23.34 31.96 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.529 -0.732 . . . . 0.0 110.756 -179.888 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.11 140.06 57.12 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.339 -0.851 . . . . 0.0 110.246 179.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.05 4.2 89.63 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 110.316 -1.114 . . . . 0.0 110.316 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.8 m -109.53 -0.89 18.59 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.075 -1.25 . . . . 0.0 110.988 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 31.0 t -60.01 141.47 55.59 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.108 -0.995 . . . . 0.0 109.754 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 100.05 -19.79 51.64 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 -179.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.75 147.05 44.0 Favored Glycine 0 N--CA 1.494 2.522 0 N-CA-C 109.164 -1.575 . . . . 0.0 109.164 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.547 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.1 Cg_endo -92.38 144.78 2.69 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.925 1.487 . . . . 0.0 111.181 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.622 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.4 mp -101.35 111.11 23.25 Favored 'General case' 0 N--CA 1.49 1.558 0 N-CA-C 108.625 -0.88 . . . . 0.0 108.625 178.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.65 131.72 45.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.526 -0.733 . . . . 0.0 111.453 -178.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.05 160.03 82.06 Favored Pre-proline 0 N--CA 1.494 1.756 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 179.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.9 Cg_endo -52.0 -22.88 15.47 Favored 'Trans proline' 0 N--CA 1.502 2.02 0 O-C-N 123.532 1.28 . . . . 0.0 112.161 -178.684 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.66 -40.03 88.45 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.225 -0.922 . . . . 0.0 109.881 179.562 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.19 35.66 0.86 Allowed Glycine 0 N--CA 1.494 2.515 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.4 m170 -132.03 148.14 52.49 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.467 -1.019 . . . . 0.0 110.445 179.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -62.71 143.51 57.34 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.599 -0.688 . . . . 0.0 110.273 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.632 ' O ' HG23 ' A' ' 172' ' ' VAL . 54.4 t -118.29 -40.87 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.536 -0.727 . . . . 0.0 110.052 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.57 -175.59 41.41 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -179.777 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.0 mt -122.91 130.34 74.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.535 -0.979 . . . . 0.0 110.391 -179.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.434 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 23.1 t80 -60.34 134.6 57.22 Favored 'General case' 0 N--CA 1.499 1.987 0 O-C-N 121.55 -0.719 . . . . 0.0 109.818 179.544 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 65.7 ttt180 -113.24 -52.13 2.78 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.458 -0.777 . . . . 0.0 110.443 -179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.622 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -155.09 160.01 40.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.44 -0.787 . . . . 0.0 110.558 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.434 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -111.73 153.71 26.08 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.614 -0.679 . . . . 0.0 110.193 -179.907 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.05 118.99 58.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.625 -0.672 . . . . 0.0 109.751 179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -132.99 149.29 52.24 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.654 -0.654 . . . . 0.0 110.307 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 75.7 p -82.26 -42.9 18.25 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.645 -0.659 . . . . 0.0 110.61 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -160.34 59.93 0.34 Allowed 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.613 -0.679 . . . . 0.0 110.131 -179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 98.75 -10.01 62.33 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.33 122.25 69.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.134 -1.215 . . . . 0.0 109.843 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -96.57 126.12 41.53 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.68 -0.637 . . . . 0.0 110.78 -179.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 47.5 mmtt -107.14 -25.45 11.54 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.733 -0.605 . . . . 0.0 110.118 179.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.73 154.54 46.37 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.536 -0.728 . . . . 0.0 110.04 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 26.8 m -126.21 -171.35 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.497 1.907 0 O-C-N 121.557 -0.714 . . . . 0.0 110.786 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.0 t0 -146.93 134.57 21.03 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.69 -0.631 . . . . 0.0 109.444 179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -137.48 159.19 42.64 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.446 -0.784 . . . . 0.0 110.8 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.618 HG11 HD11 ' A' ' 82' ' ' LEU . 65.5 t -98.42 121.2 57.49 Favored Pre-proline 0 N--CA 1.492 1.662 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 179.169 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -62.37 159.94 33.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.711 1.374 . . . . 0.0 110.517 -179.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.4 t -69.39 -27.09 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.888 0 O-C-N 121.615 -0.678 . . . . 0.0 110.829 -179.304 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -58.18 -39.67 79.5 Favored 'General case' 0 N--CA 1.5 2.027 0 O-C-N 121.366 -0.834 . . . . 0.0 110.7 -179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 89.3 p -67.08 -38.46 85.77 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.454 -0.779 . . . . 0.0 110.246 179.961 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.627 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 87.9 mtp -60.0 -40.04 87.85 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.489 -0.757 . . . . 0.0 110.319 -179.668 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.2 mm-40 -64.27 -40.01 95.11 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.506 -0.746 . . . . 0.0 110.3 -179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 62.5 m -67.93 -28.78 67.77 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.713 -0.617 . . . . 0.0 110.372 -179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . 0.401 HG23 ' OD1' ' A' ' 77' ' ' ASN . 94.1 m -59.97 -40.07 87.83 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.571 -0.706 . . . . 0.0 110.272 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.5 mtt -61.55 -41.87 98.0 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.524 -0.735 . . . . 0.0 110.192 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 95.4 mtt180 -69.97 -39.95 75.67 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.556 -0.715 . . . . 0.0 110.234 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -81.72 -12.67 58.52 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.571 -0.706 . . . . 0.0 111.093 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 47.4 t -59.98 -50.03 75.35 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.242 -0.911 . . . . 0.0 110.276 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 85.3 tttt 50.64 71.16 0.44 Allowed 'General case' 0 N--CA 1.502 2.133 0 O-C-N 121.338 -0.851 . . . . 0.0 110.93 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -60.02 136.29 57.97 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.469 -0.769 . . . . 0.0 110.372 -179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -129.34 27.35 5.33 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.617 -0.677 . . . . 0.0 110.447 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 20.6 tptm . . . . . 0 N--CA 1.494 1.772 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.053 -179.961 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.622 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 -119.98 140.01 51.61 Favored 'General case' 0 N--CA 1.49 1.57 0 C-N-CA 118.731 -1.188 . . . . 0.0 110.071 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.829 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp -83.94 140.79 31.71 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.538 -0.726 . . . . 0.0 110.45 -179.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.46 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . 0.412 HG23 ' O ' ' A' ' 22' ' ' THR . 7.5 t . . . . . 0 N--CA 1.493 1.683 0 CA-C-O 121.078 0.466 . . . . 0.0 110.281 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 160.05 44.58 0.02 OUTLIER Glycine 0 N--CA 1.493 2.467 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 89.6 mtt180 -99.89 120.44 39.78 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.616 -0.932 . . . . 0.0 110.208 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -128.07 26.82 5.74 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.568 -0.707 . . . . 0.0 110.431 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 16.1 tptt 57.0 -160.0 0.23 Allowed 'General case' 0 N--CA 1.501 2.087 0 O-C-N 121.346 -0.846 . . . . 0.0 110.317 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.0 m120 -69.43 -39.96 77.53 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.562 -0.712 . . . . 0.0 110.446 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -75.91 158.64 31.81 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.55 -0.719 . . . . 0.0 110.255 -179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.6 m -109.97 9.95 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.5 -0.75 . . . . 0.0 111.074 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 17.6 pt-20 -151.56 160.0 43.86 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.17 -0.956 . . . . 0.0 110.203 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 166.92 88.15 0.07 OUTLIER Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 -179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.403 ' HG2' ' CB ' ' A' ' 92' ' ' ARG . 62.9 mt-10 -62.14 -34.88 77.21 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.549 -0.971 . . . . 0.0 110.047 179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.497 HG13 ' O ' ' A' ' 45' ' ' ALA . 61.2 t -105.58 127.21 60.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.538 -0.726 . . . . 0.0 109.959 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.7 mt-30 -116.28 150.14 38.08 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.586 -0.696 . . . . 0.0 110.334 -179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 35' ' ' VAL . 12.5 p -79.72 129.02 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.63 -0.669 . . . . 0.0 110.04 179.739 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.727 ' HB ' HD21 ' A' ' 64' ' ' LEU . 35.4 m -125.14 154.29 33.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.567 -0.708 . . . . 0.0 110.031 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 16.5 m -149.84 171.48 16.69 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 120.016 -0.673 . . . . 0.0 110.511 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.9 p -140.93 -173.35 3.69 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.766 -0.584 . . . . 0.0 109.434 179.893 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.34 -0.81 26.99 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.497 -0.752 . . . . 0.0 111.219 179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.4 m -118.59 -46.75 2.56 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.109 -0.994 . . . . 0.0 111.359 -179.527 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -147.76 171.18 16.09 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.268 -0.895 . . . . 0.0 111.407 -179.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 32.1 t -119.15 146.65 44.98 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.664 -0.647 . . . . 0.0 109.926 179.885 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.609 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 15.1 p90 -158.17 -176.44 5.91 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.486 -0.758 . . . . 0.0 110.215 -179.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.765 HD11 ' HA ' ' A' ' 109' ' ' ARG . 42.0 mt -111.54 167.65 10.16 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.565 -0.709 . . . . 0.0 110.338 -178.309 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.497 ' O ' HG13 ' A' ' 33' ' ' VAL . . . -142.91 155.69 44.77 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.698 -0.626 . . . . 0.0 110.039 -179.751 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.529 HG21 ' HB3' ' A' ' 142' ' ' PRO . 73.4 p -120.28 129.45 54.03 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.453 -0.78 . . . . 0.0 110.177 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 35.0 t -91.13 107.42 19.19 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.514 -0.741 . . . . 0.0 110.517 -179.781 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.486 HG22 ' HB2' ' A' ' 94' ' ' LEU . 57.6 t -115.29 135.87 53.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.624 -0.673 . . . . 0.0 109.552 179.525 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 54.78 37.42 28.41 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.536 -0.727 . . . . 0.0 111.021 -179.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.09 23.14 77.35 Favored Glycine 0 N--CA 1.496 2.658 0 N-CA-C 110.799 -0.92 . . . . 0.0 110.799 179.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 98.6 t -138.25 129.91 38.01 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.827 0 O-C-N 121.248 -1.148 . . . . 0.0 110.089 179.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . 0.411 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 4.0 t -68.45 148.47 50.59 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.418 -0.801 . . . . 0.0 109.454 179.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 48.8 m95 -140.08 142.95 36.08 Favored 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 119.875 -0.73 . . . . 0.0 111.197 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.666 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.9 t -170.07 -178.6 2.9 Favored 'General case' 0 N--CA 1.493 1.697 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.818 HG21 ' CE1' ' A' ' 57' ' ' HIS . 12.7 p -83.23 159.01 3.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.369 -0.832 . . . . 0.0 110.401 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CD1' ' HA2' ' A' ' 60' ' ' GLY . 55.5 t80 -76.99 -40.03 48.2 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.67 -0.644 . . . . 0.0 112.069 -178.805 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.872 ' CG ' HD23 ' B' ' 189' ' ' LEU . 2.9 p-80 -61.0 -24.67 66.32 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.113 -0.992 . . . . 0.0 110.848 -178.626 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.446 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -74.75 -49.01 11.17 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.56 -1.416 . . . . 0.0 109.56 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.609 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -114.86 -55.56 2.47 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.561 -0.964 . . . . 0.0 110.458 -179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.432 ' HA2' ' CD1' ' A' ' 56' ' ' TYR . . . 85.09 -172.33 47.44 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.285 -1.526 . . . . 0.0 109.285 -179.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 47.8 t -80.14 65.13 5.19 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.526 -0.985 . . . . 0.0 109.848 179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -141.81 170.06 16.43 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.587 -0.696 . . . . 0.0 110.267 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 67.1 m -65.57 139.77 58.48 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.527 -0.733 . . . . 0.0 109.851 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.727 HD21 ' HB ' ' A' ' 36' ' ' VAL . 20.4 tp -108.81 141.02 41.44 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.692 -0.63 . . . . 0.0 110.099 -179.83 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.15 111.56 23.92 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.57 -0.706 . . . . 0.0 110.166 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -116.12 -178.29 18.23 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -62.1 -31.96 83.37 Favored 'Trans proline' 0 N--CA 1.493 1.445 0 O-C-N 123.765 1.403 . . . . 0.0 110.518 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.4 tttt -74.61 -31.27 61.97 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.669 -0.644 . . . . 0.0 109.769 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.33 -154.38 23.45 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -68.41 146.82 69.86 Favored 'Trans proline' 0 N--CA 1.491 1.329 0 O-C-N 123.816 1.43 . . . . 0.0 109.953 179.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -130.3 139.98 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.514 -0.741 . . . . 0.0 110.599 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.3 m -89.83 139.9 30.13 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.563 -0.711 . . . . 0.0 110.211 179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 pp0? -83.2 150.25 26.33 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.519 -0.738 . . . . 0.0 111.383 -179.348 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.404 ' CE ' ' HA ' ' A' ' 186' ' ' LYS . 94.2 mtp -110.37 -29.93 7.9 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.821 -0.549 . . . . 0.0 109.944 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 89.8 m-85 -131.76 148.39 52.57 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.72 -0.613 . . . . 0.0 110.459 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -149.15 125.98 11.17 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.663 -0.648 . . . . 0.0 109.628 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.0 t-20 -141.92 95.57 2.83 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.528 -0.733 . . . . 0.0 110.152 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 91.9 t -61.43 -44.67 98.95 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 121.673 -0.642 . . . . 0.0 109.921 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.15 -48.75 80.39 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.551 -0.718 . . . . 0.0 110.256 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.679 ' CG ' HD12 ' A' ' 82' ' ' LEU . 3.0 tp-100 -80.07 -9.15 59.68 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.66 -0.65 . . . . 0.0 110.478 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.426 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 5.7 t0 56.79 48.18 16.63 Favored 'General case' 0 N--CA 1.5 2.055 0 O-C-N 121.22 -0.925 . . . . 0.0 110.422 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.679 HD12 ' CG ' ' A' ' 80' ' ' GLN . 81.3 mt -137.96 149.83 46.49 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.48 -0.762 . . . . 0.0 110.892 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.8 p -150.05 149.97 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.611 -0.68 . . . . 0.0 109.493 179.564 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -133.86 149.55 19.75 Favored Glycine 0 N--CA 1.496 2.662 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.335 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.713 ' CZ3' HD22 ' A' ' 64' ' ' LEU . 5.3 m-90 -120.16 168.19 11.47 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.68 -0.894 . . . . 0.0 110.204 179.516 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 -72.86 120.42 18.46 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 178.455 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -68.98 132.24 90.5 Favored Pre-proline 0 N--CA 1.495 1.781 0 O-C-N 121.448 -0.782 . . . . 0.0 109.958 -179.547 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -69.99 157.07 61.15 Favored 'Trans proline' 0 N--CA 1.49 1.294 0 O-C-N 123.84 1.442 . . . . 0.0 110.478 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.56 160.23 48.94 Favored 'Trans proline' 0 N--CA 1.49 1.282 0 O-C-N 123.936 1.493 . . . . 0.0 110.185 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 29.97 70.44 Favored Glycine 0 N--CA 1.492 2.427 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 -179.851 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -121.04 160.87 22.69 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.6 -0.941 . . . . 0.0 110.106 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.403 ' CB ' ' HG2' ' A' ' 32' ' ' GLU . 75.1 mtp85 -105.19 153.75 21.13 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.56 -0.713 . . . . 0.0 110.275 -179.784 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 54.5 m -111.3 160.9 16.59 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.605 -0.684 . . . . 0.0 110.294 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.486 ' HB2' HG22 ' A' ' 48' ' ' VAL . 84.5 mt -100.31 131.85 46.01 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.595 -0.691 . . . . 0.0 110.524 -179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.3 p -77.04 159.95 77.27 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.608 -0.682 . . . . 0.0 110.006 179.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -85.57 158.24 10.71 Favored 'Trans proline' 0 N--CA 1.489 1.25 0 O-C-N 123.799 1.421 . . . . 0.0 110.54 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 51.4 t -79.81 129.75 34.74 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.587 -0.695 . . . . 0.0 110.087 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' THR . 6.8 t -132.88 56.45 1.85 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.677 -0.64 . . . . 0.0 109.678 179.592 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.6 p -143.87 -8.1 0.73 Allowed 'General case' 0 N--CA 1.497 1.913 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.252 -179.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.92 46.09 94.73 Favored Glycine 0 N--CA 1.495 2.597 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.5 t -99.98 119.77 38.77 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.518 -0.989 . . . . 0.0 110.45 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.2 m -62.95 -40.03 96.43 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.703 -0.623 . . . . 0.0 110.355 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -63.3 132.55 51.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.543 -0.723 . . . . 0.0 110.354 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 1.003 HD22 HG11 ' A' ' 151' ' ' VAL . 96.0 mt -137.29 145.24 43.22 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.568 -0.708 . . . . 0.0 110.488 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.1 m-85 -107.47 122.15 46.05 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.541 -0.725 . . . . 0.0 109.858 179.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.432 HD13 ' HG ' ' A' ' 143' ' ' LEU . 40.6 tp -103.69 146.17 28.98 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.627 -0.671 . . . . 0.0 110.605 -179.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.0 t -109.67 130.07 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.872 0 O-C-N 121.65 -0.656 . . . . 0.0 109.758 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 2.5 m -93.09 170.04 9.95 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.487 -0.758 . . . . 0.0 110.754 -179.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.765 ' HA ' HD11 ' A' ' 44' ' ' LEU . 5.4 ttt-85 -64.6 -21.07 66.61 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.639 -0.663 . . . . 0.0 110.623 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.403 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.6 t60 -94.42 29.41 2.25 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.416 -0.803 . . . . 0.0 110.488 -179.767 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.7 40.02 30.86 Favored 'General case' 0 N--CA 1.501 2.108 0 O-C-N 121.265 -0.897 . . . . 0.0 110.643 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -107.44 157.32 18.08 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.648 -0.658 . . . . 0.0 109.926 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.402 ' O ' HG13 ' A' ' 113' ' ' VAL . 8.7 p -129.99 130.32 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.589 -0.694 . . . . 0.0 110.193 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 76.5 mt -128.86 150.04 73.96 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.569 -0.707 . . . . 0.0 109.827 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -87.14 132.07 3.17 Favored 'Trans proline' 0 C--N 1.314 -1.258 0 O-C-N 123.919 1.484 . . . . 0.0 110.409 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.6 t -129.84 130.01 66.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.641 -0.662 . . . . 0.0 109.526 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.9 tpt180 -92.18 136.21 33.37 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.455 -0.778 . . . . 0.0 110.192 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 63.9 ttt180 -79.17 128.82 33.78 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.571 -0.706 . . . . 0.0 110.318 -179.678 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 23.1 mmt180 -121.68 23.02 10.38 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.616 -0.677 . . . . 0.0 110.169 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 169.0 179.73 41.23 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 48.6 t0 -61.37 -40.82 95.71 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.488 -1.007 . . . . 0.0 110.233 -179.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 78.6 p -132.64 26.52 4.38 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.519 -0.738 . . . . 0.0 110.57 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -129.74 140.04 51.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.493 -0.754 . . . . 0.0 110.134 -179.799 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -143.14 169.76 25.63 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -114.71 157.37 23.26 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.621 -0.929 . . . . 0.0 110.071 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.41 HD12 ' HA ' ' A' ' 126' ' ' LEU . 17.9 tp -100.41 119.15 38.02 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.566 -0.709 . . . . 0.0 110.165 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.497 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -69.68 -37.29 76.61 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.477 -0.765 . . . . 0.0 109.741 179.604 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.9 t -108.57 109.96 61.42 Favored Pre-proline 0 N--CA 1.492 1.651 0 O-C-N 121.63 -0.669 . . . . 0.0 109.95 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.79 116.26 3.71 Favored 'Trans proline' 0 N--CA 1.489 1.262 0 O-C-N 123.839 1.441 . . . . 0.0 110.469 -179.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 24.8 mmt180 -119.95 160.03 44.47 Favored Pre-proline 0 N--CA 1.493 1.718 0 O-C-N 121.544 -0.723 . . . . 0.0 110.185 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -68.74 157.74 60.62 Favored 'Trans proline' 0 N--CA 1.491 1.358 0 O-C-N 123.877 1.462 . . . . 0.0 110.442 -179.83 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 94.3 t -61.53 -36.05 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.865 0 O-C-N 121.608 -0.682 . . . . 0.0 110.01 179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 55.2 m -59.92 -40.09 87.66 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.547 -0.721 . . . . 0.0 110.266 -179.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 45.9 t80 -59.89 -40.08 87.52 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.544 -0.723 . . . . 0.0 110.285 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 8.8 mp -82.65 -24.52 33.73 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.521 -0.737 . . . . 0.0 110.697 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.39 140.23 57.29 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.295 -0.878 . . . . 0.0 109.972 179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 80.02 10.23 85.8 Favored Glycine 0 N--CA 1.492 2.423 0 N-CA-C 110.269 -1.133 . . . . 0.0 110.269 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 20.6 m -116.17 18.83 15.23 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.173 -1.192 . . . . 0.0 110.606 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 1.8 m -69.95 149.95 47.23 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.356 -0.84 . . . . 0.0 109.857 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.49 ' O ' HG23 ' A' ' 46' ' ' THR . . . 90.05 -11.89 69.37 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 110.125 -1.19 . . . . 0.0 110.125 -179.699 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.86 137.81 48.25 Favored Glycine 0 N--CA 1.496 2.663 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.529 ' HB3' HG21 ' A' ' 46' ' ' THR . 50.0 Cg_endo -87.22 142.32 6.23 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.807 1.425 . . . . 0.0 111.327 -179.253 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.87 ' O ' HG12 ' A' ' 151' ' ' VAL . 6.8 mp -103.6 109.56 21.29 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 178.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.555 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -102.74 132.33 48.96 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.457 -0.777 . . . . 0.0 111.62 -178.391 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.447 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.3 p -68.56 159.62 80.62 Favored Pre-proline 0 N--CA 1.496 1.854 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 179.013 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -51.9 -26.07 23.53 Favored 'Trans proline' 0 N--CA 1.5 1.874 0 O-C-N 123.446 1.235 . . . . 0.0 112.391 -178.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -62.69 -40.01 95.76 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.231 -0.918 . . . . 0.0 109.809 179.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 122.02 34.01 0.87 Allowed Glycine 0 N--CA 1.495 2.61 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.9 m170 -132.52 145.72 51.37 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.428 -1.042 . . . . 0.0 110.157 179.701 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.8 136.86 45.49 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.671 -0.643 . . . . 0.0 110.255 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 1.003 HG11 HD22 ' A' ' 104' ' ' LEU . 8.8 p -116.14 -21.28 5.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.485 -0.76 . . . . 0.0 110.78 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -177.29 -176.59 45.5 Favored Glycine 0 N--CA 1.495 2.631 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.697 HD12 ' CE ' ' A' ' 175' ' ' MET . 92.7 mt -130.81 140.07 49.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 O-C-N 121.606 -0.938 . . . . 0.0 110.402 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.493 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 27.5 t80 -60.87 139.99 57.82 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 121.58 -0.7 . . . . 0.0 109.862 179.573 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 64.4 ttt180 -120.68 -52.5 2.12 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.56 -0.712 . . . . 0.0 110.393 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.793 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.32 157.62 43.49 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.486 -0.758 . . . . 0.0 110.325 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.493 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -110.23 145.52 37.19 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.548 -0.72 . . . . 0.0 110.265 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.56 HG13 ' CD2' ' B' ' 187' ' ' IBU . 63.1 t -110.0 119.96 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.631 -0.668 . . . . 0.0 109.794 179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.5 p -130.59 152.17 50.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.639 -0.663 . . . . 0.0 110.39 -179.925 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 41.1 p -77.8 -45.16 25.28 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.65 -0.656 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 45.6 ptt85 -164.0 54.78 0.16 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.621 -0.674 . . . . 0.0 109.975 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 111.93 -14.63 26.44 Favored Glycine 0 N--CA 1.491 2.347 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.3 t -116.29 120.74 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.185 -1.185 . . . . 0.0 109.963 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -84.45 129.32 34.87 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.657 -0.652 . . . . 0.0 110.447 -179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 21.4 pttm -111.44 -24.31 10.25 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.621 -0.674 . . . . 0.0 110.604 179.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -143.13 159.23 42.68 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.619 -0.676 . . . . 0.0 109.909 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 31.8 m -134.91 167.32 26.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.611 -0.681 . . . . 0.0 110.668 -179.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 8.0 t70 -126.78 139.65 52.96 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.669 -0.644 . . . . 0.0 109.771 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 51.2 p90 -138.04 154.7 49.28 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.402 -0.811 . . . . 0.0 110.833 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.512 HG11 HD11 ' A' ' 82' ' ' LEU . 62.6 t -93.29 121.15 65.89 Favored Pre-proline 0 N--CA 1.495 1.79 0 O-C-N 121.68 -0.637 . . . . 0.0 109.472 179.623 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -66.64 154.11 75.57 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.734 1.386 . . . . 0.0 110.544 -179.602 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 63.7 t -62.99 -26.75 41.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.571 -0.706 . . . . 0.0 110.35 -179.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -59.12 -39.9 83.75 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.478 -0.764 . . . . 0.0 110.351 -179.622 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 86.2 p -60.0 -38.29 82.18 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.487 -0.758 . . . . 0.0 110.216 179.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.697 ' CE ' HD12 ' A' ' 153' ' ' ILE . 69.0 mtt -61.86 -40.03 93.93 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.507 -0.745 . . . . 0.0 110.257 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -59.99 -41.81 92.85 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.539 -179.529 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 72.8 p -70.03 -27.46 64.68 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.562 -0.711 . . . . 0.0 110.32 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.3 m -60.06 -45.39 93.03 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.425 -0.797 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 67.6 mtt -67.26 -39.98 86.18 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.578 -0.701 . . . . 0.0 110.083 179.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 78.0 mtp180 -69.73 -25.59 63.91 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.479 -0.763 . . . . 0.0 110.396 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.97 -42.81 94.93 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.526 -0.734 . . . . 0.0 110.803 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -139.97 -67.5 0.43 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.371 -0.831 . . . . 0.0 111.039 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -103.27 113.27 26.63 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.472 -0.768 . . . . 0.0 110.439 -179.454 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -70.04 -39.99 75.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.658 -0.651 . . . . 0.0 110.112 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -137.38 159.99 40.35 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.545 -0.722 . . . . 0.0 110.242 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . 0.404 ' HA ' ' CE ' ' A' ' 74' ' ' MET . 38.4 ttpt . . . . . 0 N--CA 1.501 2.098 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.778 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . 0.56 ' CD2' HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.793 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 61.5 tt0 -158.85 159.95 35.62 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 118.711 -1.195 . . . . 0.0 110.139 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.872 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.8 mp -109.88 146.52 34.98 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.617 -0.677 . . . . 0.0 110.25 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.419 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 28.2 m . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.162 0.506 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.04 -40.1 96.59 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 41.8 ttm180 -108.41 130.05 55.24 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.619 -0.93 . . . . 0.0 110.141 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -120.47 142.41 49.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.574 -0.704 . . . . 0.0 110.171 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 61.3 mttp -100.05 128.08 46.18 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.587 -0.696 . . . . 0.0 110.304 -179.871 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -118.73 32.12 6.3 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.587 -0.696 . . . . 0.0 110.113 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 58.1 tt0 57.23 -86.79 0.02 OUTLIER 'General case' 0 N--CA 1.499 2.017 0 O-C-N 121.624 -0.673 . . . . 0.0 110.65 -179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.414 ' O ' HG13 ' A' ' 29' ' ' VAL . 9.0 p -134.75 129.65 51.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.035 -1.041 . . . . 0.0 110.265 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 -114.02 -29.96 6.84 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.547 -0.721 . . . . 0.0 110.26 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 90.47 125.06 2.96 Favored Glycine 0 N--CA 1.493 2.473 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.902 ' HG3' HG23 ' A' ' 33' ' ' VAL . 16.5 pt-20 -64.17 -24.8 67.82 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.586 -0.949 . . . . 0.0 110.498 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.902 HG23 ' HG3' ' A' ' 32' ' ' GLU . 60.3 t -108.21 126.74 64.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.503 -0.748 . . . . 0.0 109.82 179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -123.39 154.41 39.03 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.484 -0.76 . . . . 0.0 110.584 -179.9 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.9 t -90.3 122.77 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.617 -0.677 . . . . 0.0 109.276 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.591 ' CB ' HD21 ' A' ' 64' ' ' LEU . 35.5 m -120.37 152.71 23.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.564 -0.71 . . . . 0.0 110.176 -179.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 72.2 m -141.75 169.56 17.37 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.662 -0.648 . . . . 0.0 110.513 -179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 39' ' ' ALA . 1.0 OUTLIER -132.37 -169.77 2.29 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -179.904 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.536 ' H ' HG22 ' A' ' 38' ' ' THR . . . -58.73 -41.73 87.11 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.42 -0.8 . . . . 0.0 110.575 -179.637 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 16.8 m -134.24 -6.86 2.63 Favored 'General case' 0 N--CA 1.497 1.901 0 O-C-N 121.479 -0.763 . . . . 0.0 112.025 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.419 ' HG3' ' CD2' ' B' ' 191' ' ' FE3 . 16.8 tp60 -111.76 160.43 17.32 Favored 'General case' 0 N--CA 1.498 1.937 0 O-C-N 120.899 -1.126 . . . . 0.0 110.864 -179.214 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 69.4 m -147.56 137.91 23.14 Favored 'General case' 0 N--CA 1.499 1.999 0 O-C-N 121.452 -0.78 . . . . 0.0 110.402 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 29.0 p90 -169.11 -177.67 2.99 Favored 'General case' 0 N--CA 1.499 2.021 0 O-C-N 121.312 -0.868 . . . . 0.0 110.434 -179.869 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.857 HD11 ' HA ' ' A' ' 109' ' ' ARG . 54.6 mt -112.99 159.94 18.61 Favored 'General case' 0 N--CA 1.499 2.001 0 O-C-N 121.429 -0.795 . . . . 0.0 110.672 -178.551 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -136.26 159.84 40.53 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.689 -0.632 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.696 ' CG2' HD12 ' A' ' 94' ' ' LEU . 23.0 m -123.8 139.29 54.12 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.444 -0.785 . . . . 0.0 110.351 -179.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 49.0 t -94.38 111.03 22.76 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.571 -0.705 . . . . 0.0 110.637 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.411 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.1 t -117.2 130.31 72.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.704 -0.623 . . . . 0.0 109.662 179.553 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.46 39.44 28.01 Favored 'General case' 0 N--CA 1.501 2.102 0 O-C-N 121.503 -0.748 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.721 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.85 19.89 75.56 Favored Glycine 0 N--CA 1.496 2.674 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -133.53 129.77 56.12 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 O-C-N 121.222 -1.163 . . . . 0.0 110.025 179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 89.3 m -74.49 147.67 41.69 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.391 -0.818 . . . . 0.0 109.419 179.603 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.411 ' CD1' ' HB ' ' A' ' 48' ' ' VAL . 67.5 m95 -129.94 151.66 50.26 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.394 -0.816 . . . . 0.0 110.824 -179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.927 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.3 t -167.41 -179.62 4.53 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.756 -0.59 . . . . 0.0 109.771 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.4 p -90.03 158.19 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.454 -0.779 . . . . 0.0 110.319 179.835 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.444 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 71.4 t80 -74.27 -42.31 59.82 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.599 -0.688 . . . . 0.0 111.477 -179.042 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -70.03 -22.48 63.09 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.148 -0.97 . . . . 0.0 110.799 -179.325 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.778 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -81.31 -59.98 2.31 Favored Glycine 0 N--CA 1.492 2.414 0 N-CA-C 108.877 -1.689 . . . . 0.0 108.877 179.115 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.555 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -91.01 -52.34 4.89 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.639 -0.918 . . . . 0.0 110.204 179.772 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 73.17 -174.33 47.25 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.325 -1.51 . . . . 0.0 109.325 -179.751 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 36.4 p -81.93 61.7 5.37 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.561 -0.964 . . . . 0.0 109.806 179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -141.53 170.13 16.29 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.582 -0.699 . . . . 0.0 110.533 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.5 p -66.32 156.71 33.63 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.678 -0.639 . . . . 0.0 109.725 179.781 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.86 HD22 ' CH2' ' A' ' 85' ' ' TRP . 27.3 tp -118.3 140.5 49.74 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.575 -0.703 . . . . 0.0 110.28 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -94.27 109.72 21.51 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.663 -0.648 . . . . 0.0 109.998 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.19 -174.31 15.79 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.295 -1.522 . . . . 0.0 109.295 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -63.4 -32.35 71.82 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 O-C-N 123.907 1.477 . . . . 0.0 110.542 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 34.4 mttt -77.15 -31.03 55.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.667 -0.646 . . . . 0.0 110.01 -179.711 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 140.75 -150.57 21.8 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -75.03 138.69 23.28 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 O-C-N 123.89 1.469 . . . . 0.0 110.358 -179.973 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.2 mt -119.97 129.96 74.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.621 -0.674 . . . . 0.0 110.577 -179.739 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 76.9 p -82.51 142.53 31.78 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.525 -0.735 . . . . 0.0 109.753 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.0 pt20 -91.77 149.97 21.33 Favored 'General case' 0 N--CA 1.499 2.007 0 O-C-N 121.432 -0.793 . . . . 0.0 111.254 -179.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.6 mmm -115.43 -26.3 7.61 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.752 -0.592 . . . . 0.0 110.451 179.748 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -119.95 139.95 51.66 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.396 -0.815 . . . . 0.0 110.724 -179.503 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.554 ' HA ' HG12 ' A' ' 83' ' ' VAL . 91.7 m -140.35 130.0 24.3 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.654 -0.654 . . . . 0.0 109.944 179.551 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 48.5 t-20 -137.37 103.27 5.03 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.389 -0.819 . . . . 0.0 110.441 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 70.9 t -71.15 -45.24 72.43 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.51 -0.744 . . . . 0.0 110.224 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -60.11 -49.89 75.85 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.437 -0.79 . . . . 0.0 110.223 -179.671 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.72 ' HG3' HD12 ' A' ' 82' ' ' LEU . 3.7 tp-100 -80.04 -9.99 59.74 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.538 -0.726 . . . . 0.0 110.582 179.694 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.7 t70 56.01 44.95 24.66 Favored 'General case' 0 N--CA 1.5 2.066 0 O-C-N 121.147 -0.97 . . . . 0.0 109.985 -179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 1.118 HD11 HG21 ' A' ' 170' ' ' VAL . 64.9 mt -141.77 131.5 24.18 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.655 -0.653 . . . . 0.0 110.902 -179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.554 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -129.96 159.98 41.46 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 N-CA-C 109.184 -0.673 . . . . 0.0 109.184 178.66 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -137.47 157.34 23.98 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.937 -1.125 . . . . 0.0 110.553 -179.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.927 ' CH2' HG21 ' A' ' 54' ' ' THR . 8.6 m-90 -115.39 157.05 24.45 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.874 -0.78 . . . . 0.0 109.467 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 41.1 tt0 -69.48 108.16 3.66 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.521 -0.737 . . . . 0.0 109.377 179.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.721 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.16 143.34 91.09 Favored Pre-proline 0 N--CA 1.496 1.844 0 O-C-N 121.495 -0.753 . . . . 0.0 110.359 -179.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -70.1 158.42 56.57 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 124.089 1.573 . . . . 0.0 110.154 179.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.98 153.33 63.37 Favored 'Trans proline' 0 C--N 1.315 -1.235 0 O-C-N 123.886 1.466 . . . . 0.0 110.27 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 74.12 29.68 62.17 Favored Glycine 0 N--CA 1.493 2.447 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -106.28 154.33 20.9 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.514 -0.992 . . . . 0.0 110.09 179.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 19.8 mmt180 -80.18 159.25 26.06 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.571 -0.706 . . . . 0.0 110.005 179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 97.2 p -139.98 159.73 41.53 Favored 'General case' 0 N--CA 1.49 1.566 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.292 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.696 HD12 ' CG2' ' A' ' 46' ' ' THR . 7.7 mt -106.09 132.19 52.46 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.591 -0.693 . . . . 0.0 110.482 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.423 HG23 ' HD2' ' A' ' 96' ' ' PRO . 86.7 m -80.0 141.29 54.5 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.693 -0.63 . . . . 0.0 109.916 179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . 0.596 ' HB3' HG11 ' A' ' 172' ' ' VAL . 44.6 Cg_endo -64.04 163.58 25.13 Favored 'Trans proline' 0 N--CA 1.491 1.38 0 O-C-N 123.812 1.427 . . . . 0.0 110.377 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.677 ' HB2' HG22 ' A' ' 151' ' ' VAL . 51.5 t -87.74 123.54 32.66 Favored 'General case' 0 N--CA 1.493 1.703 0 CA-C-O 121.65 0.738 . . . . 0.0 110.937 -179.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.0 m -118.21 59.66 0.8 Allowed 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 107.586 -1.264 . . . . 0.0 107.586 177.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 3.5 m -141.76 -9.31 0.93 Allowed 'General case' 0 N--CA 1.501 2.119 0 C-N-CA 119.99 -0.684 . . . . 0.0 111.899 -177.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 57.12 25.47 54.07 Favored Glycine 0 N--CA 1.498 2.811 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 -179.089 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -70.23 130.81 43.04 Favored 'General case' 0 N--CA 1.498 1.939 0 O-C-N 121.525 -0.985 . . . . 0.0 110.723 -179.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.414 ' HA ' ' HB3' ' A' ' 118' ' ' ARG . 56.4 m -74.37 -39.99 62.38 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.73 -0.606 . . . . 0.0 110.464 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -69.4 130.51 42.74 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.518 -0.739 . . . . 0.0 110.546 -179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.8 mt -131.23 140.2 49.82 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.649 -0.657 . . . . 0.0 110.637 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 87.2 m-85 -106.85 124.37 49.52 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.494 -0.754 . . . . 0.0 109.817 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.531 HD13 ' HG ' ' A' ' 143' ' ' LEU . 37.7 tp -108.48 145.43 34.71 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.394 -0.816 . . . . 0.0 110.924 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.05 120.99 62.17 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.674 -0.641 . . . . 0.0 109.706 179.592 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 69.9 p -95.31 173.03 7.74 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.55 -0.719 . . . . 0.0 110.547 -179.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.857 ' HA ' HD11 ' A' ' 44' ' ' LEU . 3.5 ptp180 -69.33 -11.95 61.25 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.544 -0.723 . . . . 0.0 111.103 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.01 21.69 5.56 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.209 -0.932 . . . . 0.0 110.399 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.33 40.05 31.42 Favored 'General case' 0 N--CA 1.5 2.063 0 O-C-N 121.222 -0.924 . . . . 0.0 110.575 -179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -124.02 147.65 47.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.658 -0.651 . . . . 0.0 109.64 179.575 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 9.0 p -129.98 130.69 66.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.565 -0.709 . . . . 0.0 110.405 -179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.621 HD12 HD11 ' A' ' 126' ' ' LEU . 43.8 pt -121.1 150.0 52.61 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.679 -0.638 . . . . 0.0 109.796 179.778 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -81.57 123.27 4.24 Favored 'Trans proline' 0 C--N 1.314 -1.251 0 O-C-N 123.937 1.493 . . . . 0.0 110.48 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -119.7 120.95 64.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.715 -0.616 . . . . 0.0 109.6 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -76.73 149.67 36.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.48 -0.762 . . . . 0.0 110.039 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB3' ' HA ' ' A' ' 102' ' ' SER . 64.6 ttt180 -90.89 120.06 31.6 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.557 -0.714 . . . . 0.0 110.359 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 25.9 mmt180 -109.94 20.09 18.36 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.659 -0.651 . . . . 0.0 110.399 179.655 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.85 -179.97 39.78 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.09 -1.604 . . . . 0.0 109.09 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -60.72 -39.92 90.41 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.548 -0.972 . . . . 0.0 110.301 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 37.4 p -130.92 25.1 4.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.557 -0.714 . . . . 0.0 110.522 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.2 tpt180 -124.25 139.53 53.83 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.439 -0.788 . . . . 0.0 110.254 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.77 165.79 26.41 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 99.8 p -120.21 155.51 33.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.648 -0.913 . . . . 0.0 110.129 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.621 HD11 HD12 ' A' ' 114' ' ' ILE . 14.2 tp -99.97 119.5 38.35 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.516 -0.74 . . . . 0.0 110.158 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.6 mp -65.04 -39.91 94.03 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.493 -0.754 . . . . 0.0 109.961 179.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 85.6 p -110.66 120.2 44.4 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -67.39 120.87 7.93 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 O-C-N 123.763 1.402 . . . . 0.0 110.4 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 15.2 mmt180 -129.93 159.98 67.34 Favored Pre-proline 0 N--CA 1.494 1.768 0 O-C-N 121.539 -0.726 . . . . 0.0 110.251 179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.39 156.72 61.82 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.982 1.517 . . . . 0.0 110.423 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.492 HG11 ' SG ' ' A' ' 159' ' ' CYS . 33.9 m -67.06 -25.44 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.658 -0.651 . . . . 0.0 110.618 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 58.7 m -59.94 -40.04 87.61 Favored 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.41 -0.806 . . . . 0.0 110.272 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.531 ' HD2' HD12 ' A' ' 135' ' ' LEU . 88.5 t80 -60.06 -40.08 88.23 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.497 -0.752 . . . . 0.0 109.935 -179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.531 HD12 ' HD2' ' A' ' 134' ' ' TYR . 3.2 mp -83.85 -25.39 30.34 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.535 -0.728 . . . . 0.0 110.287 179.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.41 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 2.3 tptm -59.96 132.02 52.66 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.408 -0.808 . . . . 0.0 110.105 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.404 ' HA2' ' CE2' ' B' ' 191' ' ' FE3 . . . 91.96 0.93 70.84 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 120.306 -0.95 . . . . 0.0 110.732 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 51.7 m -109.96 19.99 18.45 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.136 -1.214 . . . . 0.0 110.66 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 8.4 t -68.65 147.68 51.54 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.327 -0.858 . . . . 0.0 109.724 179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 90.78 -14.5 62.98 Favored Glycine 0 N--CA 1.492 2.393 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 -179.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.26 148.85 43.17 Favored Glycine 0 N--CA 1.494 2.528 0 N-CA-C 109.122 -1.591 . . . . 0.0 109.122 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -96.81 148.31 1.0 Allowed 'Trans proline' 0 C--N 1.315 -1.232 0 O-C-N 123.875 1.461 . . . . 0.0 111.123 -179.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.609 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -103.94 108.96 20.53 Favored 'General case' 0 N--CA 1.491 1.595 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 178.663 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.545 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.0 mp -99.93 134.79 42.32 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.461 -0.774 . . . . 0.0 111.773 -178.482 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 28.5 p -70.03 159.93 82.41 Favored Pre-proline 0 N--CA 1.494 1.75 0 N-CA-C 108.912 -0.773 . . . . 0.0 108.912 178.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.434 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.7 Cg_endo -52.62 -22.13 16.28 Favored 'Trans proline' 0 N--CA 1.5 1.904 0 O-C-N 123.512 1.269 . . . . 0.0 112.056 -179.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 8.6 t -67.63 -42.92 81.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.228 -0.92 . . . . 0.0 110.055 179.631 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 125.51 35.93 0.59 Allowed Glycine 0 N--CA 1.496 2.671 0 C-N-CA 120.069 -1.062 . . . . 0.0 110.904 179.278 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 31.2 m170 -133.02 144.63 50.2 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.237 -1.155 . . . . 0.0 110.283 179.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.477 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -62.67 145.21 55.19 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.588 -0.695 . . . . 0.0 110.357 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.677 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.2 t -119.15 -38.91 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.866 0 O-C-N 121.523 -0.735 . . . . 0.0 110.118 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -172.99 -177.73 42.47 Favored Glycine 0 N--CA 1.495 2.61 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 85.4 mt -121.61 132.02 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.88 0 O-C-N 121.477 -1.013 . . . . 0.0 110.521 -179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.697 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 35.6 t80 -60.32 137.16 58.18 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.586 -0.696 . . . . 0.0 109.799 179.41 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 68.5 ttt180 -121.17 -52.72 2.06 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.498 -0.752 . . . . 0.0 110.33 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -143.16 159.96 41.32 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.508 -0.745 . . . . 0.0 110.073 -179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.697 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -121.84 136.05 54.92 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.627 -0.671 . . . . 0.0 110.553 -179.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 58.6 t -90.0 119.74 37.63 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.492 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -135.52 153.69 51.64 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.487 -0.758 . . . . 0.0 111.404 -179.14 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . 0.562 HG22 ' HG2' ' A' ' 161' ' ' ARG . 37.1 m -130.53 137.38 49.69 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.756 -0.59 . . . . 0.0 109.522 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.562 ' HG2' HG22 ' A' ' 160' ' ' THR . 21.7 mmt180 54.21 37.14 26.63 Favored 'General case' 0 N--CA 1.501 2.079 0 O-C-N 121.272 -0.893 . . . . 0.0 110.755 -179.859 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 74.19 23.28 76.31 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.4 t -129.98 129.87 65.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.295 -1.12 . . . . 0.0 110.065 179.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -90.78 125.57 35.75 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.539 -0.725 . . . . 0.0 110.131 179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.51 -29.61 7.12 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.541 -0.725 . . . . 0.0 110.455 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.89 162.85 34.45 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.57 -0.706 . . . . 0.0 109.941 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.3 m -136.02 165.59 29.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.432 -0.792 . . . . 0.0 110.965 -179.485 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 10.1 t70 -126.37 135.86 51.98 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.629 -0.67 . . . . 0.0 109.995 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -139.88 147.41 40.59 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.496 -0.752 . . . . 0.0 110.64 -179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 1.118 HG21 HD11 ' A' ' 82' ' ' LEU . 33.0 m -89.96 125.0 62.1 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.497 -0.752 . . . . 0.0 109.556 179.166 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -63.88 159.96 39.5 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.746 1.393 . . . . 0.0 110.711 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 151' ' ' VAL . 89.9 t -60.22 -25.23 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.596 -0.69 . . . . 0.0 110.594 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -58.73 -39.01 79.62 Favored 'General case' 0 N--CA 1.499 2.024 0 O-C-N 121.456 -0.777 . . . . 0.0 110.354 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 67.5 m -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.468 -0.77 . . . . 0.0 110.398 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.42 ' HE2' ' HA ' ' A' ' 172' ' ' VAL . 77.3 mtm -69.99 -37.37 75.69 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.35 -0.844 . . . . 0.0 110.331 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.4 tt0 -59.97 -40.15 88.09 Favored 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.513 -0.742 . . . . 0.0 110.468 -179.536 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 70.1 p -65.31 -37.12 86.16 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.471 -0.768 . . . . 0.0 110.253 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 94.0 m -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.593 -0.692 . . . . 0.0 110.139 -179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -67.61 -36.69 81.32 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.534 -0.729 . . . . 0.0 110.058 179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 15.1 tpt180 -59.88 -40.08 87.46 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.558 -0.714 . . . . 0.0 110.11 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -60.02 -39.99 87.76 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.595 -0.69 . . . . 0.0 110.239 -179.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 80.0 p -73.09 160.04 32.64 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.525 -0.734 . . . . 0.0 110.105 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 22.2 pttm -90.96 15.29 11.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.586 -0.696 . . . . 0.0 111.075 -179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 85.4 tttt 57.83 163.27 0.03 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.274 -0.891 . . . . 0.0 110.596 -179.938 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -60.08 -40.01 88.08 Favored 'General case' 0 N--CA 1.497 1.92 0 O-C-N 121.4 -0.812 . . . . 0.0 110.231 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 60.1 tptt . . . . . 0 N--CA 1.501 2.113 0 CA-C-O 118.057 -0.973 . . . . 0.0 110.632 -179.955 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -120.05 135.31 54.98 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 118.684 -1.206 . . . . 0.0 109.993 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.743 HD23 ' CG ' ' A' ' 57' ' ' HIS . 8.8 mp -69.95 139.52 52.87 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.535 -0.728 . . . . 0.0 110.041 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.606 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.678 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 16.9 m . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.094 0.473 . . . . 0.0 110.177 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 79.94 -162.87 47.03 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 55.5 ttt180 -100.09 124.97 46.09 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.552 -0.969 . . . . 0.0 110.12 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -129.94 170.0 14.51 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.601 -0.687 . . . . 0.0 110.321 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 52.94 40.01 30.26 Favored 'General case' 0 N--CA 1.501 2.089 0 O-C-N 121.399 -0.813 . . . . 0.0 110.89 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 19.3 t-20 -149.27 91.62 1.86 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.532 -0.73 . . . . 0.0 110.317 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 64.0 tt0 -159.81 -43.73 0.05 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.583 -0.698 . . . . 0.0 110.094 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.6 p -136.49 140.26 43.71 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.615 -0.678 . . . . 0.0 110.126 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -96.11 130.45 43.13 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.585 -0.697 . . . . 0.0 109.968 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 173.64 73.07 0.05 OUTLIER Glycine 0 N--CA 1.493 2.494 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.708 ' OE1' HD21 ' A' ' 94' ' ' LEU . 96.9 mt-10 -62.98 -38.08 89.71 Favored 'General case' 0 N--CA 1.497 1.875 0 O-C-N 121.642 -0.917 . . . . 0.0 110.116 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 64.5 t -109.8 124.65 66.7 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.592 -0.692 . . . . 0.0 109.793 179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -119.13 155.11 32.16 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.667 -0.645 . . . . 0.0 110.512 -179.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 86.8 t -90.21 131.04 38.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.621 -0.674 . . . . 0.0 109.539 179.517 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.517 ' CB ' HD21 ' A' ' 64' ' ' LEU . 27.8 m -123.91 158.38 30.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 121.68 -0.637 . . . . 0.0 110.194 -179.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -139.12 179.35 6.56 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.71 -0.619 . . . . 0.0 110.362 -179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.42 HG22 ' H ' ' A' ' 39' ' ' ALA . 0.2 OUTLIER -141.46 -170.9 3.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.67 -0.643 . . . . 0.0 109.479 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.42 ' H ' HG22 ' A' ' 38' ' ' THR . . . -60.03 -38.88 84.03 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.523 -0.736 . . . . 0.0 110.258 179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 5.6 t -136.92 -6.71 1.87 Allowed 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.546 -0.721 . . . . 0.0 112.555 -179.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -118.8 156.71 28.93 Favored 'General case' 0 N--CA 1.501 2.117 0 O-C-N 120.839 -1.163 . . . . 0.0 111.129 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 54.1 m -136.34 139.75 42.8 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.566 -0.709 . . . . 0.0 110.341 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -165.61 -177.16 4.24 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.238 -0.914 . . . . 0.0 110.075 179.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.758 HD11 ' HA ' ' A' ' 109' ' ' ARG . 21.7 mt -112.33 175.16 5.55 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.529 -0.732 . . . . 0.0 110.273 -178.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.443 ' HB1' ' SG ' ' A' ' 52' ' ' CYS . . . -149.64 156.85 42.59 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.692 -0.63 . . . . 0.0 110.087 -179.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.583 ' CG2' HD12 ' A' ' 94' ' ' LEU . 27.6 m -119.51 139.92 51.33 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.699 -0.626 . . . . 0.0 110.063 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.3 t -101.35 109.35 21.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.453 -0.78 . . . . 0.0 110.476 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.438 HG12 ' OD1' ' A' ' 49' ' ' ASN . 62.4 t -120.38 134.28 64.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.69 -0.631 . . . . 0.0 109.842 179.849 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . 0.438 ' OD1' HG12 ' A' ' 48' ' ' VAL . 28.7 m120 55.23 38.52 30.52 Favored 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.534 -0.729 . . . . 0.0 111.144 179.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 69.63 26.67 74.22 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 178.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 80.9 t -140.47 130.03 27.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.338 -1.095 . . . . 0.0 109.956 179.636 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . 0.443 ' SG ' ' HB1' ' A' ' 45' ' ' ALA . 23.7 t -86.71 108.58 18.73 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.468 -0.77 . . . . 0.0 109.37 179.677 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 97.6 m95 -91.42 151.21 20.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.595 -0.691 . . . . 0.0 111.05 -179.102 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.939 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.5 t -159.88 -179.71 8.06 Favored 'General case' 0 N--CA 1.492 1.658 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.857 HG21 ' CE1' ' A' ' 57' ' ' HIS . 10.5 p -96.59 152.35 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.448 -0.783 . . . . 0.0 110.443 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.427 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 60.1 t80 -70.04 -39.99 75.42 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.58 -0.7 . . . . 0.0 112.091 -178.671 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.857 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.9 p-80 -68.85 -19.52 64.26 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.139 -0.976 . . . . 0.0 111.068 -178.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.591 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -91.13 -52.28 2.42 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 108.945 -1.662 . . . . 0.0 108.945 179.037 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.637 ' HB1' ' HZ2' ' A' ' 85' ' ' TRP . . . -103.2 -47.68 4.25 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.628 -0.925 . . . . 0.0 110.123 179.67 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 68.2 -168.89 40.78 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.378 -1.489 . . . . 0.0 109.378 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.496 ' OG ' HG21 ' A' ' 76' ' ' THR . 1.4 t -86.41 64.68 8.67 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.546 -0.973 . . . . 0.0 109.837 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 58.0 mttm -141.89 170.05 16.45 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.602 -0.686 . . . . 0.0 110.363 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 75.1 p -66.13 150.14 49.21 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.618 -0.676 . . . . 0.0 109.944 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.813 HD22 ' CH2' ' A' ' 85' ' ' TRP . 19.2 tp -117.08 142.62 46.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.611 -0.681 . . . . 0.0 110.082 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -97.62 110.26 22.86 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.621 -0.675 . . . . 0.0 110.093 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -119.33 177.11 16.31 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -63.7 -31.78 68.98 Favored 'Trans proline' 0 N--CA 1.492 1.393 0 O-C-N 123.85 1.448 . . . . 0.0 110.412 -179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 10.2 mmmt -71.7 -31.47 66.78 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.597 -0.689 . . . . 0.0 109.999 -179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 139.88 -160.56 26.21 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.214 -1.554 . . . . 0.0 109.214 -179.836 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.94 137.23 40.73 Favored 'Trans proline' 0 N--CA 1.49 1.307 0 O-C-N 123.886 1.466 . . . . 0.0 110.036 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 85.6 mt -119.94 129.98 74.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.506 -0.746 . . . . 0.0 110.564 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.3 p -84.86 150.23 25.14 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.574 -0.704 . . . . 0.0 109.707 179.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 10.5 pm0 -98.53 148.12 24.08 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.481 -0.762 . . . . 0.0 111.008 -179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 46.9 mtp -113.95 -25.55 8.53 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.766 -0.584 . . . . 0.0 110.504 179.867 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -120.01 135.88 54.76 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.428 -0.795 . . . . 0.0 110.572 -179.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.643 ' HA ' HG12 ' A' ' 83' ' ' VAL . 29.9 m -140.91 126.11 18.51 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.561 -0.712 . . . . 0.0 109.88 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 30.1 t-20 -140.5 104.51 4.77 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.518 -0.739 . . . . 0.0 110.349 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 75.8 t -69.97 -45.3 77.06 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 0.0 109.871 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -59.87 -49.69 76.7 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.554 -0.716 . . . . 0.0 110.213 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.789 ' HG2' HD12 ' A' ' 82' ' ' LEU . 53.6 tt0 -79.95 -9.99 59.73 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.583 -0.698 . . . . 0.0 110.832 179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.427 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 6.0 t70 55.2 46.22 24.25 Favored 'General case' 0 N--CA 1.501 2.121 0 O-C-N 121.031 -1.043 . . . . 0.0 110.446 -179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.789 HD12 ' HG2' ' A' ' 80' ' ' GLN . 41.3 mt -143.36 130.43 20.69 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.552 -0.717 . . . . 0.0 111.075 -179.757 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.643 HG12 ' HA ' ' A' ' 76' ' ' THR . 33.1 m -130.94 159.99 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.615 -0.678 . . . . 0.0 109.265 178.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -136.76 157.92 23.91 Favored Glycine 0 N--CA 1.496 2.677 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.597 -179.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.939 ' CH2' HG21 ' A' ' 54' ' ' THR . 6.0 m-90 -119.93 160.28 23.02 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.792 -0.828 . . . . 0.0 109.778 179.425 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -71.88 124.57 25.15 Favored 'General case' 0 N--CA 1.492 1.628 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.088 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -72.7 130.01 86.08 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.489 -0.757 . . . . 0.0 110.212 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -70.02 159.64 52.47 Favored 'Trans proline' 0 N--CA 1.49 1.316 0 O-C-N 123.876 1.461 . . . . 0.0 110.356 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.41 139.7 42.11 Favored 'Trans proline' 0 C--N 1.314 -1.27 0 O-C-N 123.85 1.447 . . . . 0.0 110.306 179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 98.58 -20.33 50.84 Favored Glycine 0 N--CA 1.494 2.524 0 N-CA-C 110.084 -1.206 . . . . 0.0 110.084 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -70.0 150.01 47.1 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.305 -1.115 . . . . 0.0 110.221 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.8 mtp85 -92.16 170.01 10.17 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.573 -0.705 . . . . 0.0 110.165 179.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -132.37 160.01 37.58 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.58 -0.7 . . . . 0.0 110.152 -179.902 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.708 HD21 ' OE1' ' A' ' 32' ' ' GLU . 80.5 mt -110.74 132.23 54.37 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 -179.77 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 75.9 p -76.34 160.05 78.56 Favored Pre-proline 0 N--CA 1.494 1.76 0 O-C-N 121.693 -0.629 . . . . 0.0 109.95 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -77.21 164.04 29.67 Favored 'Trans proline' 0 N--CA 1.49 1.319 0 O-C-N 123.833 1.438 . . . . 0.0 110.651 -179.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.802 ' HB2' HG22 ' A' ' 151' ' ' VAL . 47.1 t -73.06 128.57 35.87 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.647 -0.658 . . . . 0.0 110.212 -179.955 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 25.7 p -132.05 54.42 1.94 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.725 -0.609 . . . . 0.0 109.715 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.59 -7.52 0.77 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.519 -0.738 . . . . 0.0 112.376 -179.043 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.67 37.98 94.36 Favored Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.64 -1.384 . . . . 0.0 109.64 -179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -100.08 123.6 44.51 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.668 -0.901 . . . . 0.0 110.49 -179.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 79.5 p -70.04 -26.06 63.86 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.617 -0.677 . . . . 0.0 110.352 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -63.73 129.99 42.38 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.58 -0.7 . . . . 0.0 109.969 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.616 ' CD2' HG21 ' A' ' 151' ' ' VAL . 96.2 mt -137.4 136.08 37.54 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.6 -0.688 . . . . 0.0 110.693 -179.745 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 86.8 m-85 -106.88 119.99 40.83 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.55 -0.719 . . . . 0.0 109.718 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 57.2 tp -98.21 140.05 33.09 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.512 -0.742 . . . . 0.0 110.387 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.459 HG22 HG12 ' A' ' 113' ' ' VAL . 63.1 t -102.82 130.01 53.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.858 0 O-C-N 121.538 -0.726 . . . . 0.0 109.937 179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 22.9 p -98.2 179.17 4.84 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.583 -0.698 . . . . 0.0 110.761 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.758 ' HA ' HD11 ' A' ' 44' ' ' LEU . 15.8 ttt-85 -70.01 -18.58 63.32 Favored 'General case' 0 N--CA 1.499 1.983 0 O-C-N 121.692 -0.63 . . . . 0.0 110.969 -179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -93.21 25.46 3.31 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.293 -0.879 . . . . 0.0 110.868 -179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.14 38.97 30.2 Favored 'General case' 0 N--CA 1.501 2.11 0 O-C-N 121.347 -0.846 . . . . 0.0 110.765 179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.7 m-20 -120.25 139.58 52.47 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.662 -0.648 . . . . 0.0 109.599 179.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.459 HG12 HG22 ' A' ' 107' ' ' VAL . 34.0 m -116.66 140.07 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.515 -0.741 . . . . 0.0 110.701 -179.687 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.563 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -124.32 149.99 62.7 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.681 -0.637 . . . . 0.0 109.572 179.797 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -83.6 126.53 4.1 Favored 'Trans proline' 0 C--N 1.314 -1.287 0 O-C-N 123.842 1.443 . . . . 0.0 110.651 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 125' ' ' SER . 63.3 t -128.82 130.05 68.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.715 -0.616 . . . . 0.0 109.477 179.78 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.0 tpt180 -85.48 146.16 27.07 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.497 -0.752 . . . . 0.0 110.186 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.5 ttp180 -82.81 124.35 30.21 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.596 -0.69 . . . . 0.0 110.319 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 18.5 mmm180 -114.42 19.93 15.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.631 -0.668 . . . . 0.0 110.639 179.701 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.28 178.76 39.24 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -59.99 -41.11 91.35 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.509 -0.995 . . . . 0.0 110.293 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 21.1 p -130.43 25.52 5.12 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.464 -0.773 . . . . 0.0 110.654 -179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 13.2 tpp85 -126.84 140.49 52.32 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.507 -0.746 . . . . 0.0 110.356 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -141.27 166.81 25.95 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.516 ' O ' HG13 ' A' ' 116' ' ' VAL . 81.5 p -124.83 147.43 48.75 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.588 -0.948 . . . . 0.0 110.201 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.3 mp -95.43 121.7 37.38 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.583 -0.698 . . . . 0.0 110.312 -179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.516 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.8 -40.07 93.94 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.53 -0.731 . . . . 0.0 109.86 179.683 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 84.9 p -108.58 117.95 53.11 Favored Pre-proline 0 N--CA 1.493 1.705 0 O-C-N 121.711 -0.618 . . . . 0.0 109.757 179.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.19 124.46 13.02 Favored 'Trans proline' 0 N--CA 1.49 1.276 0 O-C-N 123.744 1.391 . . . . 0.0 110.63 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 1.9 mtt180 -121.46 160.17 47.18 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.591 -0.693 . . . . 0.0 110.013 179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.09 158.88 56.14 Favored 'Trans proline' 0 C--N 1.314 -1.265 0 O-C-N 123.93 1.489 . . . . 0.0 110.437 -179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.493 HG11 ' OE1' ' B' ' 188' ' ' GLU . 68.4 t -66.65 -29.99 48.27 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 121.62 -0.675 . . . . 0.0 110.033 179.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 45.6 t -59.92 -40.08 87.64 Favored 'General case' 0 N--CA 1.497 1.904 0 O-C-N 121.552 -0.717 . . . . 0.0 110.295 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.692 ' HD2' HD12 ' A' ' 135' ' ' LEU . 64.7 t80 -60.01 -49.54 77.28 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.461 -0.774 . . . . 0.0 110.02 179.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.692 HD12 ' HD2' ' A' ' 134' ' ' TYR . 4.5 mp -69.91 -29.33 66.49 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.632 -0.667 . . . . 0.0 110.626 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 139.98 56.95 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.386 -0.821 . . . . 0.0 110.083 179.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.54 13.08 83.01 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.942 -1.263 . . . . 0.0 109.942 -179.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 16.7 m -115.3 17.25 16.64 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.281 -1.129 . . . . 0.0 110.766 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.8 m -60.04 144.32 49.72 Favored 'General case' 0 N--CA 1.497 1.902 0 O-C-N 121.295 -0.878 . . . . 0.0 110.012 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 95.34 -19.34 54.68 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -54.52 109.8 1.36 Allowed Glycine 0 N--CA 1.497 2.709 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.744 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_endo -77.09 151.18 30.26 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 O-C-N 123.875 1.46 . . . . 0.0 110.852 -179.015 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.631 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.5 mp -99.72 110.44 22.84 Favored 'General case' 0 N--CA 1.491 1.588 0 N-CA-C 108.952 -0.759 . . . . 0.0 108.952 179.086 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.531 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -100.01 128.39 46.1 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.662 -0.649 . . . . 0.0 111.17 -178.867 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.424 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.0 157.89 88.67 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.663 -0.648 . . . . 0.0 109.266 179.066 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.424 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 41.1 Cg_endo -52.16 -24.96 21.71 Favored 'Trans proline' 0 N--CA 1.502 1.985 0 O-C-N 123.516 1.271 . . . . 0.0 112.314 -178.53 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 51.7 m -62.54 -40.0 95.39 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.269 -0.895 . . . . 0.0 110.003 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.03 35.77 0.8 Allowed Glycine 0 N--CA 1.494 2.51 0 N-CA-C 110.265 -1.134 . . . . 0.0 110.265 179.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.4 m170 -132.91 149.2 52.27 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.483 -1.01 . . . . 0.0 110.289 179.776 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -70.0 145.52 51.74 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.628 -0.67 . . . . 0.0 110.223 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.802 HG22 ' HB2' ' A' ' 97' ' ' CYS . 57.6 t -118.23 -38.38 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 O-C-N 121.595 -0.691 . . . . 0.0 109.961 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -171.39 -170.02 34.98 Favored Glycine 0 N--CA 1.494 2.515 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.423 HD12 ' CE ' ' A' ' 175' ' ' MET . 85.4 mt -130.99 140.02 49.67 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.466 -1.02 . . . . 0.0 110.286 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 31.0 t80 -62.41 138.55 58.47 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.536 -0.727 . . . . 0.0 109.873 179.731 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.6 ttp180 -122.54 -52.1 1.93 Allowed 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.627 -0.671 . . . . 0.0 110.319 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.693 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -149.64 161.88 41.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.487 -0.758 . . . . 0.0 110.421 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -116.92 149.81 39.53 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.649 -0.657 . . . . 0.0 110.161 179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.515 HG13 ' CD2' ' B' ' 187' ' ' IBU . 62.1 t -109.95 117.99 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.645 -0.659 . . . . 0.0 109.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.401 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.5 p -137.47 160.53 38.85 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.642 . . . . 0.0 110.229 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 33.1 m -117.99 -56.63 2.16 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.573 -0.704 . . . . 0.0 110.765 -179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.0 mmt180 -109.33 29.96 7.06 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.568 -0.707 . . . . 0.0 110.42 -179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 100.18 0.3 55.94 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 110.431 -1.068 . . . . 0.0 110.431 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -116.39 126.04 73.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.098 -1.236 . . . . 0.0 109.649 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -93.78 123.62 37.24 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.655 -0.653 . . . . 0.0 110.303 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -104.57 -24.04 13.04 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.651 -0.656 . . . . 0.0 110.503 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.13 159.65 41.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.429 -0.794 . . . . 0.0 110.184 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 32.7 m -141.37 162.4 21.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.507 -0.746 . . . . 0.0 110.635 -179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 44.5 m-20 -114.89 138.39 50.86 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.615 -0.678 . . . . 0.0 110.053 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 50.1 p90 -140.04 155.31 47.12 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.531 -0.73 . . . . 0.0 110.299 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.575 HG11 HD11 ' A' ' 82' ' ' LEU . 58.6 t -96.21 122.78 57.04 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.53 -0.731 . . . . 0.0 109.65 179.692 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -65.66 155.83 67.02 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.777 1.409 . . . . 0.0 110.615 -179.73 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 61.3 t -63.78 -22.92 32.07 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.009 0 O-C-N 121.61 -0.681 . . . . 0.0 110.731 -179.703 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -59.99 -39.11 84.61 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.374 -0.829 . . . . 0.0 110.424 -179.452 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 82.0 p -59.81 -34.39 72.99 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.437 -0.789 . . . . 0.0 110.51 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.423 ' CE ' HD12 ' A' ' 153' ' ' ILE . 68.0 mtt -60.04 -39.95 87.69 Favored 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.527 -0.733 . . . . 0.0 110.492 -179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 59.7 tt0 -59.95 -40.06 87.7 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.471 -0.768 . . . . 0.0 110.293 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.1 m -60.59 -48.61 81.01 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.504 -0.748 . . . . 0.0 110.05 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 87.3 m -70.01 -46.17 65.68 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.575 -0.703 . . . . 0.0 110.0 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -61.19 -39.97 92.19 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.639 -0.663 . . . . 0.0 110.181 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 33.6 ttt85 -59.99 -39.98 87.6 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.563 -0.711 . . . . 0.0 110.326 -179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . 0.406 ' O ' ' N ' ' A' ' 183' ' ' LYS . . . -60.04 -41.28 91.91 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.482 -0.761 . . . . 0.0 110.207 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 7.2 t 64.51 -69.06 0.09 Allowed 'General case' 0 N--CA 1.506 2.364 0 O-C-N 121.717 -0.615 . . . . 0.0 111.046 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . 0.406 ' N ' ' O ' ' A' ' 181' ' ' ALA . 61.7 pttt -149.98 169.99 19.9 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.196 -0.94 . . . . 0.0 110.229 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 15.0 ptpt -138.91 159.92 40.99 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.471 -0.768 . . . . 0.0 110.331 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -62.82 140.04 58.75 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 110.14 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 88.4 tttt . . . . . 0 N--CA 1.494 1.734 0 CA-C-O 118.034 -0.984 . . . . 0.0 110.135 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . 0.515 ' CD2' HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.693 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 -149.8 149.95 31.28 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 118.696 -1.202 . . . . 0.0 110.117 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.795 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.7 mp -103.73 139.97 38.24 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.567 -0.708 . . . . 0.0 110.149 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.402 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.424 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.5 t . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.114 0.483 . . . . 0.0 110.279 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.96 -100.02 2.62 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 69.1 ttt180 -64.23 139.94 58.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.666 -0.902 . . . . 0.0 110.122 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 78.7 m-20 -73.12 150.59 42.11 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.579 -0.7 . . . . 0.0 110.258 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -125.26 25.3 7.19 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.644 -0.66 . . . . 0.0 110.602 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 8.8 p30 -110.41 119.89 40.66 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.414 -0.804 . . . . 0.0 110.274 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -69.41 -40.31 77.4 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.533 -0.729 . . . . 0.0 110.321 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 34.1 m -129.93 160.01 41.4 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.605 -0.684 . . . . 0.0 110.433 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 59.6 mm-40 -126.53 -49.52 1.52 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.517 -0.74 . . . . 0.0 110.37 179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 92.93 148.6 23.6 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.485 ' OE1' HD21 ' A' ' 94' ' ' LEU . 99.8 mt-10 -68.53 -36.84 79.4 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.579 -0.954 . . . . 0.0 109.993 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.0 t -114.55 128.51 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.82 0 O-C-N 121.541 -0.724 . . . . 0.0 110.206 -179.836 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 94.7 mt-30 -124.84 159.78 30.27 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.567 -0.708 . . . . 0.0 110.075 179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.17 113.81 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 O-C-N 121.519 -0.738 . . . . 0.0 109.83 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.43 ' HB ' HD11 ' A' ' 64' ' ' LEU . 34.5 m -110.17 143.21 20.63 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.677 -0.64 . . . . 0.0 109.763 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.48 ' O ' HD13 ' A' ' 64' ' ' LEU . 37.4 t -137.22 173.82 11.27 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.51 -0.744 . . . . 0.0 111.18 -179.125 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' N ' ' A' ' 39' ' ' ALA . 27.7 m -144.3 169.22 18.32 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.921 -0.487 . . . . 0.0 109.895 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.455 ' N ' HG22 ' A' ' 38' ' ' THR . . . -66.76 -16.72 64.45 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.669 -0.644 . . . . 0.0 110.617 179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 29.8 m -111.05 -39.1 4.87 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.345 -0.847 . . . . 0.0 111.748 -179.062 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 2.6 pm0 -146.86 170.7 16.49 Favored 'General case' 0 N--CA 1.5 2.049 0 O-C-N 121.157 -0.964 . . . . 0.0 111.573 -179.106 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 74.3 p -128.23 151.95 48.66 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.636 -0.665 . . . . 0.0 110.311 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.427 ' HE2' ' HG1' ' A' ' 54' ' ' THR . 30.7 p90 -165.87 -178.02 4.55 Favored 'General case' 0 N--CA 1.499 2.015 0 O-C-N 121.374 -0.829 . . . . 0.0 110.334 -179.821 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.682 HD11 ' HA ' ' A' ' 109' ' ' ARG . 76.2 mt -113.61 150.45 33.09 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.506 -0.746 . . . . 0.0 110.717 -178.585 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.46 159.13 34.23 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.655 -0.653 . . . . 0.0 110.055 179.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.581 HG21 ' HB3' ' A' ' 142' ' ' PRO . 62.8 m -120.33 131.6 54.93 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.492 -0.755 . . . . 0.0 110.664 -179.587 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 30.4 t -90.16 102.56 15.28 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.547 -0.721 . . . . 0.0 110.136 179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.412 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 62.7 t -109.97 130.12 63.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.582 -0.699 . . . . 0.0 109.593 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.41 39.98 27.74 Favored 'General case' 0 N--CA 1.502 2.128 0 O-C-N 121.437 -0.789 . . . . 0.0 110.66 -179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.76 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.05 19.98 75.97 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 110.869 -0.893 . . . . 0.0 110.869 179.154 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.4 t -131.84 129.98 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.161 -1.2 . . . . 0.0 110.107 179.572 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.0 m -74.79 147.81 40.92 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.53 -0.731 . . . . 0.0 109.42 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.465 ' CD2' ' HE3' ' A' ' 175' ' ' MET . 74.5 m95 -129.97 152.31 49.58 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.426 -0.796 . . . . 0.0 111.072 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.943 HG21 ' CH2' ' A' ' 85' ' ' TRP . 6.0 t -169.5 -179.71 3.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 109.639 -0.504 . . . . 0.0 109.639 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.881 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.0 p -90.99 156.7 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 121.458 -0.776 . . . . 0.0 110.484 179.913 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.428 ' CB ' ' HA ' ' A' ' 81' ' ' ASP . 86.5 t80 -70.01 -42.69 72.69 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.57 -0.706 . . . . 0.0 111.194 -179.42 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.881 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.2 p-80 -71.51 -19.06 62.24 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.281 -0.887 . . . . 0.0 111.014 -179.194 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.815 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -73.84 -57.57 4.84 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.211 -1.555 . . . . 0.0 109.211 179.355 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -87.18 -41.59 13.63 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.583 -0.951 . . . . 0.0 110.139 179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 75.72 28.91 60.25 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 56.28 57.45 4.96 Favored 'General case' 0 N--CA 1.502 2.149 0 O-C-N 121.361 -1.082 . . . . 0.0 110.54 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -139.53 178.99 6.82 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.485 -0.76 . . . . 0.0 110.081 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 77.7 p -65.06 139.49 58.74 Favored 'General case' 0 N--CA 1.494 1.732 0 C-N-CA 119.952 -0.699 . . . . 0.0 109.209 179.561 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.48 HD13 ' O ' ' A' ' 37' ' ' SER . 0.1 OUTLIER -115.04 130.04 56.84 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.576 -0.702 . . . . 0.0 110.842 -178.973 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -93.23 109.38 20.9 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.551 -0.718 . . . . 0.0 109.663 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -111.29 -154.47 13.11 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 -179.743 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -72.55 -31.04 11.47 Favored 'Trans proline' 0 N--CA 1.492 1.395 0 O-C-N 123.928 1.489 . . . . 0.0 110.445 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 15.1 ptpt -83.67 -22.43 32.1 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.586 -0.697 . . . . 0.0 110.74 -179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 135.31 -139.52 10.87 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 -179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -76.91 154.91 34.01 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.904 1.476 . . . . 0.0 110.083 179.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.402 ' CG2' ' HB3' ' A' ' 85' ' ' TRP . 85.7 mt -131.45 140.01 49.36 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.554 -0.716 . . . . 0.0 110.575 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 91.9 m -95.27 140.0 30.78 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.559 -0.713 . . . . 0.0 109.943 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.413 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 8.9 tt0 -93.05 140.05 29.9 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.503 -0.748 . . . . 0.0 110.58 -179.46 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.2 mmm -112.18 -29.98 7.38 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.629 -0.669 . . . . 0.0 110.566 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -118.41 139.77 50.88 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.585 -0.697 . . . . 0.0 110.569 -179.4 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.437 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.3 m -139.97 132.12 28.07 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.513 -0.742 . . . . 0.0 109.93 179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.559 ' OD1' HG23 ' A' ' 178' ' ' THR . 0.1 OUTLIER -136.23 96.62 3.42 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.443 -0.786 . . . . 0.0 110.5 -179.79 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 82.6 t -70.02 -40.03 78.04 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.595 -0.691 . . . . 0.0 109.899 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -59.97 -47.34 86.2 Favored 'General case' 0 N--CA 1.499 1.988 0 O-C-N 121.562 -0.711 . . . . 0.0 110.297 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.1 mm-40 -90.05 0.15 57.28 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.531 -0.731 . . . . 0.0 110.97 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 3.8 t70 53.8 46.42 25.82 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.061 -1.025 . . . . 0.0 110.481 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.854 HD11 HG21 ' A' ' 170' ' ' VAL . 67.6 mt -141.45 135.92 30.78 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.476 -0.765 . . . . 0.0 110.747 -179.759 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.518 ' CG2' HG23 ' A' ' 54' ' ' THR . 33.4 m -134.01 164.44 34.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.838 0 O-C-N 121.606 -0.684 . . . . 0.0 109.432 179.023 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -141.75 156.79 26.05 Favored Glycine 0 N--CA 1.494 2.559 0 C-N-CA 119.871 -1.157 . . . . 0.0 110.343 -179.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.943 ' CH2' HG21 ' A' ' 54' ' ' THR . 7.2 m-90 -116.48 152.71 33.49 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.85 -0.794 . . . . 0.0 109.52 179.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.3 tt0 -66.61 106.37 1.78 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.41 -0.806 . . . . 0.0 109.606 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.76 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -71.51 143.57 87.81 Favored Pre-proline 0 N--CA 1.495 1.805 0 O-C-N 121.576 -0.703 . . . . 0.0 110.097 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.95 150.4 66.97 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.965 1.508 . . . . 0.0 110.338 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -65.01 159.76 44.91 Favored 'Trans proline' 0 N--CA 1.49 1.292 0 O-C-N 123.849 1.447 . . . . 0.0 110.094 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.79 29.6 69.2 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.619 -1.392 . . . . 0.0 109.619 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -108.76 149.81 28.5 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.48 -1.012 . . . . 0.0 109.949 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 34.4 ttt180 -85.21 146.03 27.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.626 -0.671 . . . . 0.0 109.283 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.4 p -136.91 174.14 10.94 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.577 -0.702 . . . . 0.0 110.601 -179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.485 HD21 ' OE1' ' A' ' 32' ' ' GLU . 44.0 mt -108.39 149.8 28.23 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.675 -0.641 . . . . 0.0 110.598 -179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.426 ' O ' ' HB3' ' A' ' 150' ' ' ALA . 74.0 p -90.03 176.18 3.24 Favored Pre-proline 0 N--CA 1.494 1.731 0 O-C-N 121.649 -0.657 . . . . 0.0 110.003 179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -89.49 160.49 5.42 Favored 'Trans proline' 0 N--CA 1.49 1.293 0 O-C-N 123.807 1.425 . . . . 0.0 110.609 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.752 ' HB2' HG12 ' A' ' 151' ' ' VAL . 51.3 t -68.7 133.13 47.97 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.671 -0.643 . . . . 0.0 110.158 179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.4 t -135.95 53.41 1.95 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.678 -0.639 . . . . 0.0 109.751 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.88 -8.2 0.72 Allowed 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.554 -0.716 . . . . 0.0 112.378 -179.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 38.17 93.9 Favored Glycine 0 N--CA 1.496 2.695 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.6 t -99.95 124.16 44.99 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.565 -0.962 . . . . 0.0 110.502 -179.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 19.6 p -69.91 -34.27 73.28 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.614 -0.679 . . . . 0.0 110.133 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -61.67 129.98 43.64 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.574 -0.704 . . . . 0.0 109.903 179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 1.037 HD22 HG21 ' A' ' 151' ' ' VAL . 90.2 mt -135.64 149.99 49.49 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.55 -0.719 . . . . 0.0 110.771 -179.63 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . 0.4 ' O ' ' HA ' ' A' ' 143' ' ' LEU . 90.4 m-85 -112.54 140.01 47.65 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.617 -0.677 . . . . 0.0 109.556 179.511 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.447 ' CD1' HD11 ' A' ' 143' ' ' LEU . 52.3 tp -115.2 142.16 47.04 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.496 -0.752 . . . . 0.0 110.677 -179.284 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -110.06 130.06 63.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.634 -0.666 . . . . 0.0 109.761 179.656 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 24.9 p -110.22 -179.9 3.91 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.519 -0.738 . . . . 0.0 110.643 -179.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.682 ' HA ' HD11 ' A' ' 44' ' ' LEU . 32.8 mtp-105 -60.04 -26.38 66.08 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.586 -0.697 . . . . 0.0 110.652 -179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.8 m-70 -89.96 17.91 6.32 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.393 -0.817 . . . . 0.0 111.181 -179.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.09 38.38 27.26 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.057 -1.027 . . . . 0.0 110.748 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -100.76 139.8 35.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.699 -0.626 . . . . 0.0 109.893 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 63.4 t -110.02 119.99 60.18 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.597 -0.689 . . . . 0.0 109.928 -179.841 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.55 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -118.91 122.16 29.95 Favored Pre-proline 0 N--CA 1.49 1.566 0 O-C-N 121.646 -0.659 . . . . 0.0 109.435 179.868 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.513 ' N ' HD13 ' A' ' 114' ' ' ILE . 47.0 Cg_endo -65.33 132.9 32.98 Favored 'Trans proline' 0 N--CA 1.489 1.263 0 O-C-N 123.744 1.392 . . . . 0.0 110.368 -179.654 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.481 HG13 ' O ' ' A' ' 125' ' ' SER . 63.2 t -129.93 130.04 66.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.678 -0.639 . . . . 0.0 109.731 -179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 18.1 tpt85 -86.36 132.72 33.89 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.497 -0.752 . . . . 0.0 109.972 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 65.5 ttt180 -70.76 130.03 40.65 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.581 -0.699 . . . . 0.0 110.438 -179.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 24.5 mmm-85 -102.4 -20.9 14.38 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.653 -0.654 . . . . 0.0 110.377 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -168.24 -167.98 29.68 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.323 -1.511 . . . . 0.0 109.323 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -59.98 -39.98 87.56 Favored 'General case' 0 N--CA 1.498 1.971 0 O-C-N 121.606 -0.937 . . . . 0.0 110.401 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.4 p -129.89 25.37 5.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.508 -0.745 . . . . 0.0 110.581 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 12.4 tpp180 -125.88 140.04 52.98 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.483 -0.76 . . . . 0.0 110.278 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -136.87 167.18 24.69 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.481 ' O ' HG13 ' A' ' 116' ' ' VAL . 80.1 p -127.82 150.03 50.01 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.576 -0.956 . . . . 0.0 110.211 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.516 ' CD1' HG13 ' A' ' 167' ' ' VAL . 8.4 mp -103.02 131.39 50.04 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.617 -0.677 . . . . 0.0 110.442 -179.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.514 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.9 mp -61.79 -39.99 93.64 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.585 -0.697 . . . . 0.0 109.745 179.563 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 79.5 p -118.36 149.98 46.97 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.684 -0.635 . . . . 0.0 109.941 179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -84.42 82.65 1.8 Allowed 'Trans proline' 0 N--CA 1.489 1.237 0 O-C-N 123.843 1.444 . . . . 0.0 110.747 -179.821 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 2.5 mmp_? -71.59 159.98 83.92 Favored Pre-proline 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 109.836 179.629 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.67 149.31 67.28 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 O-C-N 123.939 1.494 . . . . 0.0 110.292 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 97.5 t -60.4 -34.0 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.937 0 O-C-N 121.622 -0.674 . . . . 0.0 110.046 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 43.6 t -58.41 -36.67 73.94 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.5 -0.75 . . . . 0.0 110.549 -179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.652 ' HD1' HD12 ' A' ' 135' ' ' LEU . 64.9 t80 -60.06 -39.92 87.69 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.487 -0.758 . . . . 0.0 110.11 179.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.652 HD12 ' HD1' ' A' ' 134' ' ' TYR . 3.7 mp -81.37 -20.84 39.73 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.562 -0.711 . . . . 0.0 110.826 -179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 2.0 mmmm -59.97 139.74 57.21 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.23 -0.919 . . . . 0.0 110.148 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.6 1.07 86.12 Favored Glycine 0 N--CA 1.494 2.502 0 N-CA-C 110.257 -1.137 . . . . 0.0 110.257 -179.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.5 m -101.51 3.07 39.82 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.107 -1.231 . . . . 0.0 110.975 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.407 ' HB2' ' C ' ' B' ' 190' ' ' OBF . 4.9 t -59.97 139.93 57.08 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.145 -0.972 . . . . 0.0 109.863 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 93.96 -17.85 57.89 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 -179.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.67 140.84 43.14 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 179.454 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.581 ' HB3' HG21 ' A' ' 46' ' ' THR . 53.4 Cg_endo -87.96 144.91 6.34 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.831 1.438 . . . . 0.0 111.471 -178.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.892 ' O ' HG22 ' A' ' 151' ' ' VAL . 8.3 mp -103.32 129.95 50.47 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.495 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.722 HD12 ' C ' ' A' ' 143' ' ' LEU . 9.9 mp -118.46 130.9 56.21 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.366 -0.834 . . . . 0.0 111.598 -178.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.452 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -70.02 159.75 83.09 Favored Pre-proline 0 N--CA 1.495 1.798 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.764 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.452 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -51.76 -26.91 25.05 Favored 'Trans proline' 0 N--CA 1.501 1.96 0 O-C-N 123.475 1.25 . . . . 0.0 112.368 -178.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.5 m -62.78 -40.02 96.02 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.222 -0.924 . . . . 0.0 109.963 179.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.2 36.46 0.81 Allowed Glycine 0 N--CA 1.496 2.641 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 33.6 m170 -132.83 151.1 52.08 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.462 -1.023 . . . . 0.0 110.337 179.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.426 ' HB3' ' O ' ' A' ' 95' ' ' THR . . . -67.08 139.96 57.59 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.623 -0.673 . . . . 0.0 110.435 -179.978 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 1.037 HG21 HD22 ' A' ' 104' ' ' LEU . 33.9 m -117.19 -22.19 4.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 O-C-N 121.597 -0.689 . . . . 0.0 110.726 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 171.39 -171.53 44.05 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 86.0 mt -128.82 140.02 50.35 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 O-C-N 121.542 -0.975 . . . . 0.0 110.154 -179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.638 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 28.9 t80 -71.15 135.47 47.64 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.66 -0.65 . . . . 0.0 109.962 179.664 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.4 ttp85 -116.52 -53.01 2.54 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.617 -0.677 . . . . 0.0 110.178 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -148.18 159.96 43.42 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.488 -0.757 . . . . 0.0 110.391 -179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.638 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -115.95 151.58 35.12 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.691 -0.63 . . . . 0.0 110.262 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.411 HG13 H2D1 ' B' ' 187' ' ' IBU . 62.6 t -109.51 120.03 59.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.704 -0.622 . . . . 0.0 109.525 179.812 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.4 p -131.09 158.13 41.21 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.707 -0.621 . . . . 0.0 110.632 -179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.0 m -101.77 -61.06 1.43 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.67 -0.644 . . . . 0.0 110.309 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 86.5 mtm-85 -129.03 63.69 1.48 Allowed 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.681 -0.637 . . . . 0.0 110.066 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.98 9.99 86.08 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 25.3 m -126.75 132.09 70.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.206 -1.173 . . . . 0.0 110.092 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -94.7 124.28 38.64 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.513 -0.742 . . . . 0.0 110.215 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.86 -29.9 8.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.648 -0.657 . . . . 0.0 110.232 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -140.26 151.44 45.13 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.638 -0.663 . . . . 0.0 110.125 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.516 HG13 ' CD1' ' A' ' 126' ' ' LEU . 34.6 m -129.96 159.96 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.835 0 O-C-N 121.617 -0.677 . . . . 0.0 110.669 179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -121.97 130.67 53.51 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.668 -0.645 . . . . 0.0 109.934 179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -134.37 159.92 39.54 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.539 -0.726 . . . . 0.0 110.501 -179.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.854 HG21 HD11 ' A' ' 82' ' ' LEU . 62.3 t -93.42 126.49 50.13 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.615 -0.678 . . . . 0.0 109.368 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -63.94 157.37 53.11 Favored 'Trans proline' 0 N--CA 1.49 1.281 0 O-C-N 123.771 1.406 . . . . 0.0 110.599 -179.575 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.601 HG23 ' O ' ' A' ' 151' ' ' VAL . 76.3 t -59.85 -25.7 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.881 0 O-C-N 121.614 -0.679 . . . . 0.0 110.387 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 74.1 mt-10 -60.02 -39.97 87.66 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.422 -0.799 . . . . 0.0 110.364 -179.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . 0.464 ' HB3' HG12 ' A' ' 170' ' ' VAL . 21.7 t -65.42 -37.47 87.04 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.582 -0.699 . . . . 0.0 110.12 179.729 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.465 ' HE3' ' CD2' ' A' ' 53' ' ' TRP . 95.4 mtp -60.05 -41.82 93.14 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.56 -0.712 . . . . 0.0 110.293 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 44.9 tp10 -69.12 -40.05 78.56 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.55 -0.719 . . . . 0.0 110.104 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -61.75 -40.08 93.87 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.673 -0.642 . . . . 0.0 109.92 179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . 0.559 HG23 ' OD1' ' A' ' 77' ' ' ASN . 91.2 m -59.95 -41.06 91.03 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.558 -0.714 . . . . 0.0 110.189 -179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 26.5 ttt -60.04 -46.45 89.47 Favored 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.642 -0.661 . . . . 0.0 110.176 -179.812 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 61.3 ttt85 -69.98 -40.02 75.59 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.652 -0.655 . . . . 0.0 110.001 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.52 -24.27 66.36 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.579 -0.701 . . . . 0.0 110.6 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 58.3 m -60.05 -39.98 87.82 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.397 -0.815 . . . . 0.0 110.327 -179.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -106.18 110.01 22.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.577 -0.702 . . . . 0.0 110.031 179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 29.9 tptp -155.79 140.98 17.5 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.602 -0.686 . . . . 0.0 110.131 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 10.4 ptmm? -150.03 160.04 43.93 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.679 . . . . 0.0 110.258 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 61.5 pttt . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.255 -179.967 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . 0.411 H2D1 HG13 ' A' ' 158' ' ' VAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -100.66 129.95 46.64 Favored 'General case' 0 N--CA 1.491 1.598 0 C-N-CA 118.808 -1.157 . . . . 0.0 110.136 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.814 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.4 mp -62.59 140.01 58.64 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.622 -0.674 . . . . 0.0 110.165 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.436 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.56 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 22.8 p . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.091 0.472 . . . . 0.0 110.19 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 170.03 69.97 0.04 OUTLIER Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 96.1 mtt180 52.68 39.98 29.44 Favored 'General case' 0 N--CA 1.5 2.067 0 O-C-N 121.44 -1.035 . . . . 0.0 110.867 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -105.04 109.99 22.21 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.642 -0.661 . . . . 0.0 110.168 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -121.57 137.18 54.84 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.553 -0.717 . . . . 0.0 110.138 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 t-20 -136.75 127.48 27.22 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.608 -0.683 . . . . 0.0 110.228 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 52.87 92.03 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.113 0 O-C-N 121.368 -0.832 . . . . 0.0 110.659 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.463 HG13 ' N ' ' A' ' 30' ' ' GLU . 12.0 p -60.02 -39.7 81.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.597 -0.689 . . . . 0.0 110.301 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.463 ' N ' HG13 ' A' ' 29' ' ' VAL . 86.1 tt0 -111.88 126.97 55.67 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.591 -0.693 . . . . 0.0 109.98 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 179.88 43.05 0.08 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.682 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.5 mt-10 -64.7 -34.33 78.05 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.618 -0.93 . . . . 0.0 110.201 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.8 t -105.67 126.91 60.93 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.841 0 O-C-N 121.537 -0.727 . . . . 0.0 109.947 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -119.12 142.91 47.5 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.555 -0.716 . . . . 0.0 110.359 -179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.437 HG13 ' O ' ' A' ' 35' ' ' VAL . 14.4 p -78.39 128.83 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.789 0 O-C-N 121.604 -0.685 . . . . 0.0 110.339 -179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.651 ' HB ' HD21 ' A' ' 64' ' ' LEU . 34.4 m -122.27 146.44 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.636 -0.665 . . . . 0.0 109.593 179.656 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 20.2 m -144.49 171.02 14.94 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.519 -0.738 . . . . 0.0 110.897 -179.413 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 37.8 p -133.78 -170.92 2.6 Favored 'General case' 0 N--CA 1.491 1.597 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -60.93 -32.54 72.05 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.676 -179.743 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 11.1 m -133.09 -11.1 2.94 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.356 -0.84 . . . . 0.0 112.639 -178.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 1.4 tp-100 -114.94 154.03 29.49 Favored 'General case' 0 N--CA 1.501 2.077 0 O-C-N 120.837 -1.165 . . . . 0.0 111.182 -179.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.3 m -143.89 128.29 17.91 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.697 -0.627 . . . . 0.0 109.863 179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.3 p90 -159.56 -178.72 7.31 Favored 'General case' 0 N--CA 1.5 2.05 0 O-C-N 121.307 -0.871 . . . . 0.0 110.469 -179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.495 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.8 mt -113.96 155.6 25.55 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.519 -0.738 . . . . 0.0 110.533 -178.751 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -130.52 160.52 33.88 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.625 -0.672 . . . . 0.0 110.304 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.498 HG21 ' HB3' ' A' ' 142' ' ' PRO . 87.1 m -119.97 130.78 54.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.553 -0.717 . . . . 0.0 110.142 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 34.2 t -89.34 104.03 16.62 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.541 -0.724 . . . . 0.0 110.67 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.18 130.1 64.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.621 -0.674 . . . . 0.0 109.492 179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 57.21 39.55 28.67 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.428 -0.795 . . . . 0.0 110.707 -179.706 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.604 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.98 19.97 75.85 Favored Glycine 0 N--CA 1.496 2.683 0 N-CA-C 110.847 -0.901 . . . . 0.0 110.847 179.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.1 t -133.73 129.98 55.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.914 0 O-C-N 121.224 -1.162 . . . . 0.0 110.031 179.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.9 m -71.57 147.52 47.56 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.437 -0.789 . . . . 0.0 109.667 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 73.8 m95 -139.71 145.47 38.39 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.47 -0.769 . . . . 0.0 110.867 -179.645 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.67 HG21 ' CZ3' ' A' ' 85' ' ' TRP . 7.6 t -170.02 -178.74 2.96 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.723 -0.61 . . . . 0.0 109.758 179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.906 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.5 p -78.22 162.13 4.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.524 -0.735 . . . . 0.0 110.388 -179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . . . . . . . . . 59.0 t80 -86.97 -35.1 19.04 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.6 -0.687 . . . . 0.0 111.773 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.906 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.2 p-80 -63.34 -22.14 66.7 Favored 'General case' 0 N--CA 1.498 1.948 0 O-C-N 121.02 -1.05 . . . . 0.0 110.583 -179.228 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.434 ' N ' ' CD2' ' A' ' 57' ' ' HIS . . . -79.68 -60.05 2.54 Favored Glycine 0 N--CA 1.493 2.443 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.105 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.624 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -84.12 -61.99 1.68 Allowed 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.583 -0.951 . . . . 0.0 109.943 179.421 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.11 36.84 20.33 Favored Glycine 0 N--CA 1.493 2.478 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 6.3 p 53.72 40.05 31.0 Favored 'General case' 0 N--CA 1.5 2.069 0 O-C-N 121.48 -1.012 . . . . 0.0 110.71 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 60.7 mttp -111.57 179.5 4.0 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.672 -0.642 . . . . 0.0 109.755 179.551 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 89.7 m -64.74 139.36 58.75 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.489 -0.757 . . . . 0.0 109.102 179.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.651 HD21 ' HB ' ' A' ' 36' ' ' VAL . 12.5 tp -119.89 138.52 53.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.488 -0.757 . . . . 0.0 110.524 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -112.53 109.52 19.15 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.635 -0.666 . . . . 0.0 109.947 179.769 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -103.82 -172.59 25.55 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.44 -32.34 49.89 Favored 'Trans proline' 0 N--CA 1.491 1.336 0 O-C-N 123.88 1.463 . . . . 0.0 110.362 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.0 tttt -75.96 -31.12 58.89 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.561 -0.712 . . . . 0.0 109.973 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.64 -144.92 14.25 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 109.454 -1.458 . . . . 0.0 109.454 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -71.72 155.61 58.33 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 O-C-N 123.85 1.447 . . . . 0.0 110.303 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.515 HG22 ' HB3' ' A' ' 85' ' ' TRP . 83.9 mt -130.05 140.01 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.821 0 O-C-N 121.553 -0.717 . . . . 0.0 110.102 -179.71 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 23.2 m -87.31 150.49 23.83 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.486 -0.758 . . . . 0.0 110.789 -179.566 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.412 ' HG2' ' NE1' ' A' ' 85' ' ' TRP . 72.8 mt-30 -93.08 139.95 30.01 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.544 -0.722 . . . . 0.0 110.484 179.924 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 94.8 mmm -118.45 -32.48 4.61 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.545 -0.722 . . . . 0.0 110.55 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -138.2 150.71 47.01 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.461 -0.774 . . . . 0.0 110.532 -179.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 90.2 m -149.59 134.07 17.53 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.534 -0.729 . . . . 0.0 109.813 179.685 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 54.4 t-20 -141.71 100.32 3.73 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.495 -0.753 . . . . 0.0 110.424 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . . . . . . . . . 74.6 t -70.0 -38.24 74.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.908 0 O-C-N 121.618 -0.676 . . . . 0.0 110.002 179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -60.0 -45.36 92.99 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.544 -0.723 . . . . 0.0 110.495 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.98 2.79 54.72 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.464 -0.772 . . . . 0.0 111.121 -179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . . . . . . . . . 10.7 t0 54.46 47.69 22.24 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 120.965 -1.084 . . . . 0.0 110.438 -179.779 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.748 HD11 HG11 ' A' ' 170' ' ' VAL . 71.3 mt -140.0 143.07 36.28 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.547 -0.721 . . . . 0.0 110.864 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.624 HG11 ' HB3' ' A' ' 59' ' ' ALA . 7.7 p -139.5 144.68 28.32 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 O-C-N 121.619 -0.676 . . . . 0.0 109.248 179.188 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -128.28 153.5 19.53 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 -179.292 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.67 ' CZ3' HG21 ' A' ' 54' ' ' THR . 8.4 m-90 -120.21 168.07 11.6 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.693 -0.887 . . . . 0.0 109.887 179.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 38.7 tt0 -76.73 109.11 10.23 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.498 -0.751 . . . . 0.0 109.349 179.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.604 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -64.03 140.66 97.93 Favored Pre-proline 0 N--CA 1.496 1.859 0 O-C-N 121.473 -0.767 . . . . 0.0 110.196 -179.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -70.05 159.95 51.37 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.847 1.446 . . . . 0.0 110.262 -179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -70.05 157.52 59.54 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.931 1.49 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.98 30.01 70.36 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 109.571 -1.411 . . . . 0.0 109.571 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -113.04 140.67 47.65 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.554 -0.968 . . . . 0.0 110.221 179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 9.1 tpt180 -84.89 152.8 23.3 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.53 -0.731 . . . . 0.0 109.786 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 79.7 p -130.0 170.04 14.48 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.536 -0.727 . . . . 0.0 110.433 -179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.682 HD21 ' OE1' ' A' ' 32' ' ' GLU . 66.6 mt -110.01 143.73 39.58 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.607 -0.683 . . . . 0.0 110.632 -179.79 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 42.9 p -85.96 172.74 7.96 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.628 -0.67 . . . . 0.0 110.042 179.641 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -83.48 161.29 14.8 Favored 'Trans proline' 0 N--CA 1.49 1.295 0 O-C-N 123.925 1.487 . . . . 0.0 110.534 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.769 ' HB2' HG22 ' A' ' 151' ' ' VAL . 53.2 t -77.79 129.98 36.14 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.655 -0.653 . . . . 0.0 110.25 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 35.3 m -135.54 56.81 1.82 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.675 -0.64 . . . . 0.0 109.511 179.564 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.0 p -143.94 -4.44 0.83 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.626 -0.671 . . . . 0.0 112.288 -179.002 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.06 39.97 96.45 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 66.9 m -99.98 119.97 39.08 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.53 -0.982 . . . . 0.0 110.471 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 88.7 p -69.97 -27.3 64.61 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.676 -0.64 . . . . 0.0 110.376 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -66.39 129.43 39.8 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.57 -0.706 . . . . 0.0 110.124 -179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.523 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.4 mt -134.96 150.0 50.3 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.699 -0.626 . . . . 0.0 110.706 -179.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 72.8 m-85 -117.35 123.95 47.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.556 -0.715 . . . . 0.0 109.694 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.539 HD13 HD21 ' A' ' 143' ' ' LEU . 43.1 tp -99.99 139.99 34.86 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.461 -0.775 . . . . 0.0 110.757 -179.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.0 t -97.11 139.96 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.671 -0.643 . . . . 0.0 109.853 179.762 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.8 p -119.59 173.14 7.18 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.524 -0.735 . . . . 0.0 110.624 -179.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.495 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.7 mtp180 -62.89 -25.67 68.41 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.532 -0.73 . . . . 0.0 110.627 -179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 92.7 m-70 -92.64 24.41 3.56 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.418 -0.801 . . . . 0.0 110.922 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 55.1 23.09 4.97 Favored 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.237 -0.915 . . . . 0.0 110.849 179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -94.85 155.44 16.79 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.403 -0.811 . . . . 0.0 109.734 179.556 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.406 ' O ' HG13 ' A' ' 113' ' ' VAL . 9.1 p -130.02 129.94 65.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.517 -0.74 . . . . 0.0 110.505 -179.779 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.546 ' C ' HD13 ' A' ' 114' ' ' ILE . 0.0 OUTLIER -114.38 123.31 32.63 Favored Pre-proline 0 N--CA 1.491 1.602 0 O-C-N 121.614 -0.679 . . . . 0.0 109.36 179.708 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.542 ' N ' HD13 ' A' ' 114' ' ' ILE . 46.5 Cg_endo -65.35 129.55 22.99 Favored 'Trans proline' 0 N--CA 1.49 1.28 0 O-C-N 123.79 1.416 . . . . 0.0 110.484 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.453 HG23 ' O ' ' A' ' 114' ' ' ILE . 62.3 t -129.14 130.02 67.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.696 -0.627 . . . . 0.0 109.663 179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 14.7 tpt180 -86.01 149.46 25.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.505 -0.747 . . . . 0.0 109.967 -179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 46.2 ttp180 -90.62 120.01 31.34 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.559 -0.713 . . . . 0.0 110.412 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.1 mmt85 -112.49 20.04 17.01 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.64 -0.663 . . . . 0.0 110.519 179.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 166.86 -179.94 40.35 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -179.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.6 m-20 -62.64 -39.99 95.6 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.58 -0.953 . . . . 0.0 110.279 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 33.8 p -130.66 24.17 5.06 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.525 -0.734 . . . . 0.0 110.601 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 4.0 tpp180 -126.55 139.31 53.3 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.411 -0.806 . . . . 0.0 110.417 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.99 170.84 24.13 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 94.8 p -120.16 153.08 36.73 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.536 -0.979 . . . . 0.0 110.085 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.425 ' HA ' HD12 ' A' ' 126' ' ' LEU . 17.6 tp -98.2 118.64 35.3 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.53 -0.732 . . . . 0.0 110.234 -179.785 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.415 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.3 mp -65.62 -40.04 92.14 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.529 -0.732 . . . . 0.0 109.971 179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -110.0 110.11 58.92 Favored Pre-proline 0 N--CA 1.493 1.689 0 O-C-N 121.61 -0.681 . . . . 0.0 110.138 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -64.99 115.64 3.39 Favored 'Trans proline' 0 N--CA 1.49 1.312 0 O-C-N 123.848 1.446 . . . . 0.0 110.391 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.452 ' HD3' ' CD2' ' A' ' 134' ' ' TYR . 6.8 mtt180 -126.97 160.04 61.42 Favored Pre-proline 0 N--CA 1.494 1.762 0 O-C-N 121.572 -0.705 . . . . 0.0 110.224 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -64.15 156.83 56.99 Favored 'Trans proline' 0 N--CA 1.491 1.361 0 O-C-N 123.862 1.453 . . . . 0.0 110.255 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.46 HG11 ' OE1' ' B' ' 188' ' ' GLU . 33.8 m -59.96 -30.01 44.55 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.917 0 O-C-N 121.516 -0.74 . . . . 0.0 110.305 -179.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -62.15 -32.37 72.96 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.595 -0.69 . . . . 0.0 109.924 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.549 ' CZ ' HD13 ' A' ' 135' ' ' LEU . 0.0 OUTLIER -59.98 -39.99 87.59 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.582 -0.699 . . . . 0.0 110.058 -179.812 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.661 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 8.2 tp -100.22 -1.92 35.22 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.489 -0.757 . . . . 0.0 111.527 -179.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -70.04 139.99 52.76 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.113 -0.992 . . . . 0.0 109.851 179.52 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 83.3 -3.2 85.51 Favored Glycine 0 N--CA 1.493 2.446 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.4 m -107.98 15.06 24.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.099 -1.236 . . . . 0.0 110.626 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.406 ' HB2' ' C ' ' B' ' 190' ' ' OBF . 47.5 t -69.92 149.92 47.29 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.378 -0.826 . . . . 0.0 109.345 179.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.419 ' O ' HG23 ' A' ' 153' ' ' ILE . . . 98.09 -19.95 52.5 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 -179.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.45 151.0 29.17 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 179.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.498 ' HB3' HG21 ' A' ' 46' ' ' THR . 54.8 Cg_endo -95.38 149.14 1.51 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.826 1.435 . . . . 0.0 111.187 -179.102 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.539 HD21 HD13 ' A' ' 106' ' ' LEU . 84.4 mt -101.59 108.02 19.46 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.531 -0.915 . . . . 0.0 108.531 178.697 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.556 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -99.98 130.02 46.1 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.54 -0.725 . . . . 0.0 111.401 -178.665 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.441 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.7 p -69.94 159.64 83.38 Favored Pre-proline 0 N--CA 1.495 1.803 0 N-CA-C 109.084 -0.71 . . . . 0.0 109.084 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.6 Cg_endo -52.32 -22.62 16.24 Favored 'Trans proline' 0 N--CA 1.501 1.957 0 O-C-N 123.569 1.299 . . . . 0.0 112.222 -178.755 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -66.28 -40.0 89.78 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.28 -0.888 . . . . 0.0 109.959 179.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.35 35.69 0.85 Allowed Glycine 0 N--CA 1.495 2.598 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 35.1 m170 -131.46 146.33 52.2 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.422 -1.046 . . . . 0.0 110.321 179.749 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -65.33 144.31 57.19 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.649 -0.657 . . . . 0.0 110.3 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.769 HG22 ' HB2' ' A' ' 97' ' ' CYS . 58.7 t -118.91 -39.74 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.619 -0.676 . . . . 0.0 109.931 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -174.68 -167.33 33.9 Favored Glycine 0 N--CA 1.495 2.568 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.588 HD11 ' HE1' ' A' ' 175' ' ' MET . 91.0 mt -130.0 137.04 57.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.808 0 O-C-N 121.51 -0.994 . . . . 0.0 110.332 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.661 ' CZ ' HD23 ' A' ' 135' ' ' LEU . 20.1 t80 -64.7 138.3 58.31 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.606 -0.684 . . . . 0.0 109.427 179.344 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -116.23 -52.43 2.59 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.537 -0.727 . . . . 0.0 110.534 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -157.45 161.62 38.92 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.563 -0.711 . . . . 0.0 110.563 -179.758 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.04 151.74 26.81 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.657 -0.652 . . . . 0.0 110.017 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -108.26 118.03 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.605 -0.685 . . . . 0.0 109.734 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -132.96 166.85 21.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.694 -0.629 . . . . 0.0 110.337 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 29.4 m -126.81 -54.24 1.42 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.498 -0.752 . . . . 0.0 110.363 -179.932 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 36.7 mmt180 -102.04 26.76 7.24 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.537 -0.727 . . . . 0.0 110.388 -179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.37 -2.31 57.58 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.6 t -119.99 128.7 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.108 -1.231 . . . . 0.0 109.659 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.82 127.42 35.62 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.628 -0.67 . . . . 0.0 110.722 -179.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -102.82 -19.66 14.6 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.632 -0.667 . . . . 0.0 110.313 179.271 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.93 160.71 39.83 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.416 -0.802 . . . . 0.0 110.093 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.77 173.95 13.91 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.839 0 O-C-N 121.554 -0.716 . . . . 0.0 110.409 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -133.76 132.83 41.0 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.664 -0.648 . . . . 0.0 109.886 179.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 49.6 p90 -136.69 156.06 49.04 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.422 -0.799 . . . . 0.0 110.59 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.748 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -98.54 123.46 50.01 Favored Pre-proline 0 N--CA 1.494 1.765 0 O-C-N 121.661 -0.649 . . . . 0.0 109.373 179.31 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -63.42 153.04 77.09 Favored 'Trans proline' 0 N--CA 1.492 1.39 0 O-C-N 123.726 1.382 . . . . 0.0 110.646 -179.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.432 HG23 ' O ' ' A' ' 151' ' ' VAL . 67.2 t -57.06 -21.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.634 -0.667 . . . . 0.0 110.756 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -57.36 -37.11 72.1 Favored 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.319 -0.863 . . . . 0.0 110.615 -179.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 21.5 t -60.08 -34.85 74.02 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.512 -0.742 . . . . 0.0 110.489 -179.861 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.588 ' HE1' HD11 ' A' ' 153' ' ' ILE . 68.5 mtt -59.96 -40.02 87.62 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.483 -0.761 . . . . 0.0 110.495 -179.769 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.35 -40.02 89.24 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.539 -0.726 . . . . 0.0 110.334 -179.874 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.2 m -66.37 -39.98 89.44 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.588 -0.695 . . . . 0.0 110.108 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.2 m -60.59 -46.8 88.88 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.484 -0.76 . . . . 0.0 110.171 -179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.1 mtp -64.8 -40.05 94.6 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.521 -0.737 . . . . 0.0 110.205 -179.893 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 54.5 mtt180 -69.38 -39.93 77.71 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.586 -0.696 . . . . 0.0 110.305 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -59.98 -40.1 87.94 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.569 -0.707 . . . . 0.0 110.358 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 31.4 t -118.16 87.32 2.7 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.514 -0.742 . . . . 0.0 110.308 -179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.9 tttp -60.17 -40.03 88.5 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.598 -0.689 . . . . 0.0 110.162 179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 36.6 ttmt -121.3 130.04 53.44 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.602 -0.686 . . . . 0.0 110.137 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 61.2 tptt -122.92 129.98 52.27 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.617 -0.677 . . . . 0.0 110.122 179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt . . . . . 0 N--CA 1.495 1.82 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.113 179.999 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.562 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 86.2 tt0 -114.09 129.92 56.6 Favored 'General case' 0 N--CA 1.49 1.565 0 C-N-CA 118.766 -1.174 . . . . 0.0 110.112 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.849 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.0 mp -77.48 140.56 39.82 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.686 -0.634 . . . . 0.0 110.472 -179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.419 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.53 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 41.2 p . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.061 0.458 . . . . 0.0 110.219 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . -60.47 -39.98 97.06 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 40.2 ttp-105 -118.46 139.99 50.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.568 -0.96 . . . . 0.0 110.171 -179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -139.74 86.2 2.09 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.542 -0.724 . . . . 0.0 110.085 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 19.5 ttmm -160.0 -43.16 0.05 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.63 -0.669 . . . . 0.0 110.137 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 33.3 m120 -119.52 140.32 50.69 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.654 -0.653 . . . . 0.0 110.056 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -129.79 160.03 34.7 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.646 -0.659 . . . . 0.0 110.281 -179.853 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.639 HG13 ' HD2' ' A' ' 92' ' ' ARG . 57.7 t 51.86 69.94 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.502 2.168 0 O-C-N 121.431 -0.793 . . . . 0.0 110.743 -179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -69.77 -40.05 76.32 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.58 -0.7 . . . . 0.0 110.03 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.73 147.36 4.76 Favored Glycine 0 N--CA 1.494 2.526 0 N-CA-C 109.459 -1.456 . . . . 0.0 109.459 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.588 ' OE1' HD21 ' A' ' 94' ' ' LEU . 97.8 mt-10 -68.73 -37.99 79.84 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.555 -0.968 . . . . 0.0 110.365 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.8 t -108.38 131.57 58.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 121.566 -0.709 . . . . 0.0 109.97 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -124.22 158.85 31.48 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.563 -0.711 . . . . 0.0 110.177 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.2 t -93.28 114.74 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.626 -0.671 . . . . 0.0 109.911 179.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.884 HG11 HD21 ' A' ' 64' ' ' LEU . 61.3 t -116.32 139.6 42.27 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 21.9 m -146.84 173.88 11.99 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.322 -0.861 . . . . 0.0 111.167 -179.22 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 36.6 p -129.83 -179.17 5.04 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.836 -0.54 . . . . 0.0 109.576 179.594 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -72.26 -7.99 52.39 Favored 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.677 -0.639 . . . . 0.0 111.05 179.959 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 27.3 p -108.71 -37.61 5.85 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.118 -0.988 . . . . 0.0 111.772 -179.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.423 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 0.4 OUTLIER -152.83 169.25 23.25 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.172 -0.955 . . . . 0.0 111.299 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 30.3 t -121.7 147.16 46.25 Favored 'General case' 0 N--CA 1.497 1.912 0 O-C-N 121.541 -0.725 . . . . 0.0 110.656 -179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 21.0 p90 -159.44 -177.72 6.62 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 -179.771 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.78 HD11 ' HA ' ' A' ' 109' ' ' ARG . 82.7 mt -113.18 157.4 21.74 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.383 -0.823 . . . . 0.0 110.225 -178.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -134.89 146.5 49.26 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.492 -0.755 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.544 HG23 HD12 ' A' ' 94' ' ' LEU . 35.2 m -100.82 124.87 47.12 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.639 -0.663 . . . . 0.0 110.029 179.782 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.9 t -87.15 103.13 15.11 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.584 -0.697 . . . . 0.0 110.164 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.3 t -110.31 130.37 63.69 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.61 -0.681 . . . . 0.0 109.631 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 37.5 t30 57.15 39.41 28.96 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.423 -0.798 . . . . 0.0 110.606 -179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.729 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 69.97 20.61 76.36 Favored Glycine 0 N--CA 1.494 2.552 0 N-CA-C 110.759 -0.937 . . . . 0.0 110.759 179.327 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.7 t -130.01 130.03 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.257 -1.143 . . . . 0.0 109.976 179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -74.5 140.34 44.48 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.455 -0.778 . . . . 0.0 109.275 179.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 62.6 m95 -132.07 137.38 47.75 Favored 'General case' 0 N--CA 1.494 1.746 0 C-N-CA 119.676 -0.81 . . . . 0.0 111.792 -179.236 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.682 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 11.8 t -160.06 -179.65 7.96 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 178.318 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.778 HG21 ' CE1' ' A' ' 57' ' ' HIS . 13.4 p -78.94 161.28 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 111.295 -179.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.653 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 48.8 t80 -74.12 -41.92 60.86 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.686 -0.634 . . . . 0.0 111.613 -179.171 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.778 ' CE1' HG21 ' A' ' 55' ' ' VAL . 4.3 p-80 -59.11 -24.62 63.12 Favored 'General case' 0 N--CA 1.498 1.955 0 O-C-N 121.155 -0.966 . . . . 0.0 110.707 -178.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.437 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -72.58 -50.45 15.07 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 107.996 -2.042 . . . . 0.0 107.996 178.222 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.407 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -148.58 78.23 1.41 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.752 -0.852 . . . . 0.0 109.45 179.015 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.481 ' HA2' HG11 ' A' ' 83' ' ' VAL . . . -84.63 102.82 2.59 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.185 -1.166 . . . . 0.0 110.185 -179.294 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 21.4 p 48.97 56.03 8.38 Favored 'General case' 0 N--CA 1.502 2.164 0 O-C-N 121.68 -0.894 . . . . 0.0 111.468 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 93.6 mttt -139.82 174.76 10.19 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.51 -0.744 . . . . 0.0 110.274 179.709 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -64.91 139.2 58.74 Favored 'General case' 0 N--CA 1.493 1.71 0 C-N-CA 120.044 -0.662 . . . . 0.0 109.6 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.897 HD22 ' CE2' ' A' ' 85' ' ' TRP . 12.0 tp -116.29 157.63 24.66 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.619 -0.676 . . . . 0.0 110.333 -179.61 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -134.4 109.56 8.85 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.696 -0.628 . . . . 0.0 109.727 179.609 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.25 -164.01 15.69 Favored Glycine 0 N--CA 1.493 2.455 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -72.78 -32.65 8.98 Favored 'Trans proline' 0 N--CA 1.49 1.31 0 O-C-N 123.95 1.5 . . . . 0.0 110.378 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 58.6 tptt -75.73 -31.19 59.5 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.681 -0.637 . . . . 0.0 109.823 -179.616 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.53 -149.21 20.91 Favored Glycine 0 N--CA 1.493 2.435 0 N-CA-C 109.314 -1.514 . . . . 0.0 109.314 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -77.14 141.09 20.44 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 O-C-N 123.89 1.468 . . . . 0.0 110.13 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.601 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.3 mt -130.02 140.07 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.894 0 O-C-N 121.483 -0.761 . . . . 0.0 110.259 -179.709 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 9.7 t -85.1 137.27 33.14 Favored 'General case' 0 N--CA 1.498 1.963 0 O-C-N 121.533 -0.729 . . . . 0.0 110.514 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 24.9 tt0 -77.12 141.14 40.32 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.509 -0.744 . . . . 0.0 110.662 -179.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 93.1 mmm -110.71 -29.02 8.18 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.629 -0.669 . . . . 0.0 110.365 179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -120.0 139.99 51.64 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.492 -0.755 . . . . 0.0 110.662 -179.619 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 32.0 m -137.83 136.62 37.35 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.549 -0.719 . . . . 0.0 110.09 179.731 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.516 ' OD1' HG21 ' A' ' 178' ' ' THR . 26.4 m120 -149.75 92.15 1.88 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.528 -0.733 . . . . 0.0 110.461 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.653 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 92.1 t -70.0 -43.53 79.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.898 0 O-C-N 121.545 -0.722 . . . . 0.0 110.055 179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -60.1 -43.77 95.33 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.482 -0.761 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.632 ' CG ' HD12 ' A' ' 82' ' ' LEU . 38.5 tp60 -90.11 0.08 57.34 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.553 -0.717 . . . . 0.0 110.881 -179.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.456 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.1 t0 54.09 46.24 25.84 Favored 'General case' 0 N--CA 1.501 2.122 0 O-C-N 121.039 -1.038 . . . . 0.0 110.289 -179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.856 HD21 ' NH2' ' A' ' 155' ' ' ARG . 54.0 mt -134.03 147.58 50.97 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.514 -0.741 . . . . 0.0 110.959 -179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.508 HG23 ' CH2' ' A' ' 85' ' ' TRP . 16.1 m -150.25 168.89 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.057 0 O-C-N 121.646 -0.659 . . . . 0.0 109.786 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.417 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -163.36 157.84 30.09 Favored Glycine 0 N--CA 1.496 2.679 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 -179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.897 ' CE2' HD22 ' A' ' 64' ' ' LEU . 9.9 m-90 -128.11 159.96 33.5 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.55 -0.97 . . . . 0.0 109.813 179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 49.2 tt0 -67.13 113.06 4.78 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.521 -0.737 . . . . 0.0 109.597 179.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.729 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -78.35 135.16 61.65 Favored Pre-proline 0 N--CA 1.494 1.763 0 O-C-N 121.522 -0.736 . . . . 0.0 110.265 -179.706 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.95 159.97 51.32 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 O-C-N 123.83 1.437 . . . . 0.0 110.338 179.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -69.12 159.62 53.15 Favored 'Trans proline' 0 N--CA 1.49 1.314 0 O-C-N 123.916 1.482 . . . . 0.0 110.286 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.17 -21.15 47.75 Favored Glycine 0 N--CA 1.493 2.436 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -80.07 160.06 25.93 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.403 -1.057 . . . . 0.0 110.232 -179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.639 ' HD2' HG13 ' A' ' 29' ' ' VAL . 74.8 mtp85 -96.01 161.52 13.95 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.629 -0.669 . . . . 0.0 110.204 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 71.1 m -125.65 157.78 36.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.671 -0.643 . . . . 0.0 110.191 -179.929 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.588 HD21 ' OE1' ' A' ' 32' ' ' GLU . 85.0 mt -110.01 132.17 54.4 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.644 -0.66 . . . . 0.0 110.559 -179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.1 p -78.04 159.95 74.73 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.601 -0.687 . . . . 0.0 110.05 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -77.6 163.91 28.85 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 O-C-N 123.8 1.421 . . . . 0.0 110.809 -179.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.515 ' HB2' HG22 ' A' ' 151' ' ' VAL . 49.1 t -78.64 132.7 37.17 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.641 -0.662 . . . . 0.0 110.163 -179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 43.9 p -132.52 53.17 2.03 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.785 -0.572 . . . . 0.0 109.63 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 29.1 p -143.47 -8.48 0.76 Allowed 'General case' 0 N--CA 1.498 1.964 0 C-N-CA 119.907 -0.717 . . . . 0.0 112.412 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.03 34.21 82.56 Favored Glycine 0 N--CA 1.496 2.692 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 80.3 p -83.62 138.13 33.49 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.51 -0.994 . . . . 0.0 110.448 -179.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 52.6 m -81.72 -30.98 32.3 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.559 -0.713 . . . . 0.0 110.385 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -69.99 130.06 41.17 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.53 -0.731 . . . . 0.0 110.187 -179.839 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . . . . . . . . . 91.1 mt -131.02 149.55 52.56 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.65 -0.656 . . . . 0.0 110.498 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -119.97 113.91 21.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.52 -0.738 . . . . 0.0 109.701 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.419 HD13 HD11 ' A' ' 143' ' ' LEU . 39.7 tp -96.67 142.87 28.19 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.533 -0.729 . . . . 0.0 110.55 -179.514 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -109.99 129.96 64.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.797 0 O-C-N 121.616 -0.677 . . . . 0.0 109.832 179.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 26.9 p -100.02 -172.31 2.2 Favored 'General case' 0 N--CA 1.495 1.803 0 O-C-N 121.488 -0.758 . . . . 0.0 110.567 -179.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.78 ' HA ' HD11 ' A' ' 44' ' ' LEU . 86.9 mtm-85 -59.97 -28.98 68.12 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.586 -0.696 . . . . 0.0 110.57 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.9 m-70 -91.26 20.04 5.45 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.603 -0.685 . . . . 0.0 111.018 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.26 26.33 6.7 Favored 'General case' 0 N--CA 1.501 2.075 0 O-C-N 121.115 -0.991 . . . . 0.0 110.745 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -80.07 159.99 25.95 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.605 -0.684 . . . . 0.0 109.911 179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.4 t -109.97 119.95 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.569 -0.707 . . . . 0.0 109.97 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.59 ' N ' HD12 ' A' ' 114' ' ' ILE . 5.3 mp -114.32 110.0 48.29 Favored Pre-proline 0 N--CA 1.494 1.752 0 O-C-N 121.613 -0.68 . . . . 0.0 109.69 179.861 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -66.42 117.29 4.6 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.869 1.458 . . . . 0.0 110.354 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 114' ' ' ILE . 63.0 t -120.05 129.13 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 121.701 -0.625 . . . . 0.0 109.737 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 26.1 mmm-85 -82.51 150.08 27.18 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.563 -0.711 . . . . 0.0 110.426 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.4 ttp180 -94.13 114.14 26.22 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 179.222 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 21.0 mmt180 -108.5 19.98 19.13 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.559 -0.713 . . . . 0.0 110.355 -179.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 165.05 -178.54 40.07 Favored Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.215 -1.554 . . . . 0.0 109.215 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -61.32 -40.01 92.62 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.485 -1.009 . . . . 0.0 110.231 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 12.3 p -131.84 26.08 4.65 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.536 -0.728 . . . . 0.0 110.495 -179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.3 tpt180 -125.71 140.23 52.87 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.465 -0.772 . . . . 0.0 110.286 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -145.01 166.51 27.48 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 89.9 p -120.01 151.4 39.03 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.625 -0.926 . . . . 0.0 110.265 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.421 HD23 ' O ' ' A' ' 128' ' ' SER . 6.3 tp -94.07 115.2 27.49 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.651 -0.656 . . . . 0.0 110.003 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.502 ' N ' HD12 ' A' ' 127' ' ' LEU . 10.2 mp -62.15 -40.05 94.67 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.528 -0.732 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . 0.421 ' O ' HD23 ' A' ' 126' ' ' LEU . 54.4 m -108.98 119.99 47.23 Favored Pre-proline 0 N--CA 1.494 1.747 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -66.01 121.03 8.27 Favored 'Trans proline' 0 N--CA 1.489 1.235 0 O-C-N 123.799 1.421 . . . . 0.0 110.537 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.449 ' CD ' ' CE2' ' A' ' 134' ' ' TYR . 89.4 mtt-85 -128.88 160.44 63.32 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.618 -0.676 . . . . 0.0 110.136 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -67.06 163.76 32.75 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.94 1.495 . . . . 0.0 110.517 -179.819 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 67.2 t -67.02 -40.04 84.66 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.646 -0.659 . . . . 0.0 110.344 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 82.9 p -53.87 -30.87 47.64 Favored 'General case' 0 N--CA 1.5 2.047 0 O-C-N 121.409 -0.807 . . . . 0.0 110.991 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . 0.449 ' CE2' ' CD ' ' A' ' 130' ' ' ARG . 36.9 t80 -60.06 -40.01 87.99 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.454 -0.779 . . . . 0.0 110.091 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.488 HD23 ' CZ ' ' A' ' 154' ' ' PHE . 9.0 mp -87.92 -23.73 23.82 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.57 -0.706 . . . . 0.0 110.625 -179.92 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.413 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 5.2 tptm -59.99 129.32 41.22 Favored 'General case' 0 N--CA 1.499 2.013 0 O-C-N 121.347 -0.846 . . . . 0.0 110.0 -179.858 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . 0.404 ' HA2' ' CE2' ' B' ' 191' ' ' FE3 . . . 90.04 -10.05 75.3 Favored Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 7.2 m -104.04 16.79 25.49 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.164 -1.197 . . . . 0.0 110.877 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 2.3 m -69.94 151.82 45.18 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.252 -0.905 . . . . 0.0 109.53 179.613 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 94.08 -17.93 57.81 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -56.56 149.46 28.49 Favored Glycine 0 N--CA 1.497 2.736 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.618 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.494 ' HB3' HG21 ' A' ' 46' ' ' THR . 55.3 Cg_endo -98.39 146.71 0.63 Allowed 'Trans proline' 0 C--N 1.314 -1.269 0 O-C-N 123.852 1.448 . . . . 0.0 111.263 -179.154 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.626 ' N ' HD12 ' A' ' 143' ' ' LEU . 6.3 mp -102.69 105.52 16.0 Favored 'General case' 0 N--CA 1.491 1.578 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.529 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.558 ' N ' HD12 ' A' ' 144' ' ' LEU . 9.9 mp -93.35 130.89 38.95 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.534 -0.728 . . . . 0.0 111.363 -178.485 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.448 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -69.98 159.31 84.71 Favored Pre-proline 0 N--CA 1.494 1.762 0 N-CA-C 109.049 -0.722 . . . . 0.0 109.049 178.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.448 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.1 Cg_endo -51.99 -23.04 15.77 Favored 'Trans proline' 0 N--CA 1.502 1.993 0 O-C-N 123.418 1.22 . . . . 0.0 112.144 -178.703 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.3 t -65.71 -39.99 91.77 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.335 -0.853 . . . . 0.0 109.823 179.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.71 35.3 0.85 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 32.0 m170 -132.72 146.02 51.51 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.456 -1.026 . . . . 0.0 110.3 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -63.79 140.02 58.83 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.623 -0.673 . . . . 0.0 110.201 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.735 ' O ' HG23 ' A' ' 172' ' ' VAL . 47.0 t -111.1 -51.06 6.21 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.523 -0.736 . . . . 0.0 109.995 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -160.35 -172.21 27.29 Favored Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 89.6 mt -128.23 135.71 61.98 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.585 -0.95 . . . . 0.0 110.352 -179.838 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.719 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 24.6 t80 -64.16 134.81 55.56 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.613 -0.679 . . . . 0.0 109.582 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . 0.856 ' NH2' HD21 ' A' ' 82' ' ' LEU . 1.4 ttm105 -120.44 -52.45 2.15 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.489 -0.757 . . . . 0.0 110.733 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -142.25 157.29 45.0 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.499 -0.751 . . . . 0.0 110.264 -179.861 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.719 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -119.87 139.16 52.82 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.47 -0.769 . . . . 0.0 110.493 -179.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.5 t -92.44 117.14 35.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 179.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . . . . . . . . . 26.6 p -137.67 160.02 40.35 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.465 -0.772 . . . . 0.0 111.647 -178.918 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 35.8 p -139.31 139.26 37.25 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.815 -0.553 . . . . 0.0 109.509 179.158 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.0 mtm180 55.62 30.87 16.18 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.466 -0.771 . . . . 0.0 110.539 179.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 79.02 22.89 64.84 Favored Glycine 0 N--CA 1.495 2.607 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 179.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.1 t -129.53 129.73 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.341 -1.094 . . . . 0.0 109.89 179.748 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -100.06 129.98 46.17 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.542 -0.724 . . . . 0.0 110.5 179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -118.83 -30.05 5.17 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.55 -0.719 . . . . 0.0 110.732 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -136.4 157.41 46.85 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.442 -0.786 . . . . 0.0 110.229 179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 34.8 m -135.46 157.51 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.558 -0.714 . . . . 0.0 110.757 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -120.27 135.82 54.87 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.599 -0.688 . . . . 0.0 109.809 179.835 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 45.5 p90 -137.01 154.5 50.38 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.449 -0.782 . . . . 0.0 110.698 -179.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.455 HG11 HD11 ' A' ' 82' ' ' LEU . 95.8 t -98.27 125.07 44.75 Favored Pre-proline 0 N--CA 1.491 1.6 0 O-C-N 121.572 -0.705 . . . . 0.0 109.183 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -62.35 155.9 54.54 Favored 'Trans proline' 0 N--CA 1.491 1.356 0 O-C-N 123.713 1.375 . . . . 0.0 110.797 -179.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.735 HG23 ' O ' ' A' ' 151' ' ' VAL . 96.3 t -56.19 -21.64 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.963 0 O-C-N 121.674 -0.641 . . . . 0.0 110.853 -179.829 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -56.7 -37.25 70.64 Favored 'General case' 0 N--CA 1.5 2.045 0 O-C-N 121.362 -0.836 . . . . 0.0 110.768 -179.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 28.2 t -59.99 -44.54 94.45 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.392 -0.817 . . . . 0.0 110.522 -179.733 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 78.0 mtm -67.34 -39.92 85.85 Favored 'General case' 0 N--CA 1.497 1.886 0 O-C-N 121.371 -0.831 . . . . 0.0 110.3 -179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 45.1 tp10 -60.3 -40.58 91.01 Favored 'General case' 0 N--CA 1.497 1.916 0 O-C-N 121.566 -0.709 . . . . 0.0 110.299 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -62.84 -40.04 96.2 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.616 -0.677 . . . . 0.0 110.055 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . 0.516 HG21 ' OD1' ' A' ' 77' ' ' ASN . 94.5 m -60.95 -40.04 91.77 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.6 -0.687 . . . . 0.0 110.056 -179.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -61.63 -40.0 93.31 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.534 -0.729 . . . . 0.0 110.259 -179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 58.1 ttt180 -61.49 -40.14 93.5 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.569 -0.707 . . . . 0.0 110.13 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.91 -53.51 17.63 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.566 -0.709 . . . . 0.0 110.221 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 9.3 p 50.6 -166.8 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.528 -0.732 . . . . 0.0 110.97 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 54.84 -87.76 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.705 -0.622 . . . . 0.0 110.874 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 55.7 tttp 51.65 65.67 1.42 Allowed 'General case' 0 N--CA 1.501 2.107 0 O-C-N 120.997 -1.064 . . . . 0.0 110.82 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -59.98 139.97 57.06 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.485 -0.759 . . . . 0.0 110.265 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 54.9 tttm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.181 -179.908 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 44.4 tp10 -118.69 131.67 56.15 Favored 'General case' 0 N--CA 1.491 1.605 0 C-N-CA 118.741 -1.184 . . . . 0.0 110.122 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.776 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.7 mp -67.31 140.01 57.28 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.598 -0.689 . . . . 0.0 110.07 179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.573 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.716 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 48.8 m . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.106 0.479 . . . . 0.0 110.208 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 160.06 44.01 0.02 OUTLIER Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 84.7 mtt180 -60.07 -39.99 87.97 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.578 -0.954 . . . . 0.0 110.217 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -108.29 25.01 12.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.519 -0.738 . . . . 0.0 110.553 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -96.29 25.1 5.18 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.437 -0.79 . . . . 0.0 110.291 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 18.7 p-10 -106.86 20.94 18.3 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.327 -0.858 . . . . 0.0 110.628 179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -80.04 161.38 25.42 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.467 -0.771 . . . . 0.0 110.13 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 61.1 t -102.02 127.28 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.597 -0.689 . . . . 0.0 110.023 -179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.43 141.7 52.07 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.697 -0.627 . . . . 0.0 110.461 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -176.37 120.06 0.73 Allowed Glycine 0 N--CA 1.494 2.56 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.694 ' HG3' HG23 ' A' ' 33' ' ' VAL . 4.7 pt-20 -68.74 -26.76 65.41 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.594 -0.945 . . . . 0.0 110.513 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.694 HG23 ' HG3' ' A' ' 32' ' ' GLU . 58.3 t -109.99 127.25 67.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.495 -0.753 . . . . 0.0 109.695 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 99.3 mt-30 -131.68 156.84 45.17 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.624 -0.672 . . . . 0.0 110.376 -179.739 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.534 ' O ' HG23 ' A' ' 35' ' ' VAL . 32.6 m -90.08 118.58 35.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.705 -0.622 . . . . 0.0 110.387 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.831 HG11 HD21 ' A' ' 64' ' ' LEU . 48.2 t -114.85 141.04 32.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.469 -0.769 . . . . 0.0 109.288 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 19.3 m -146.59 -178.92 6.42 Favored 'General case' 0 N--CA 1.491 1.602 0 C-N-CA 119.798 -0.761 . . . . 0.0 110.748 -179.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 12.3 p -141.49 -168.63 2.69 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.846 -0.534 . . . . 0.0 110.239 -179.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -56.47 -35.11 67.57 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.594 -0.691 . . . . 0.0 111.511 -179.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 9.4 t -137.33 -8.01 1.74 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.266 -0.896 . . . . 0.0 113.033 -178.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 19.1 tp60 -115.38 143.71 44.88 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 120.881 -1.137 . . . . 0.0 110.88 -179.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 67.9 m -129.29 138.69 51.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.749 -0.595 . . . . 0.0 109.835 179.732 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.737 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 25.9 p90 -166.5 -177.52 4.03 Favored 'General case' 0 N--CA 1.499 1.997 0 O-C-N 121.46 -0.775 . . . . 0.0 110.466 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.656 HD11 ' HA ' ' A' ' 109' ' ' ARG . 69.2 mt -112.98 146.43 39.06 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.557 -0.714 . . . . 0.0 110.172 -178.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.483 ' HB3' HG21 ' A' ' 36' ' ' VAL . . . -128.68 161.21 30.21 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.631 -0.668 . . . . 0.0 110.261 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.476 ' OG1' HD12 ' A' ' 94' ' ' LEU . 8.1 t -121.3 140.55 51.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.558 -0.714 . . . . 0.0 110.146 -179.973 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 47.9 t -97.42 110.08 22.71 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.579 -0.701 . . . . 0.0 110.352 -179.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 61.9 t -109.2 130.0 62.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.623 -0.673 . . . . 0.0 109.476 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.5 t-20 55.67 40.0 30.89 Favored 'General case' 0 N--CA 1.502 2.144 0 O-C-N 121.483 -0.761 . . . . 0.0 110.762 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.06 22.15 77.16 Favored Glycine 0 N--CA 1.495 2.605 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 179.255 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.6 t -131.84 130.0 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.879 0 O-C-N 121.235 -1.156 . . . . 0.0 110.123 179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 93.3 m -72.09 146.0 47.83 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.452 -0.78 . . . . 0.0 109.296 179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 58.8 m95 -139.97 137.2 34.53 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.357 -0.839 . . . . 0.0 111.645 -179.309 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.709 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 13.4 t -161.09 173.88 14.52 Favored 'General case' 0 N--CA 1.493 1.706 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 178.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.755 HG21 ' CE1' ' A' ' 57' ' ' HIS . 8.9 p -78.64 150.37 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.725 0 O-C-N 121.267 -0.896 . . . . 0.0 110.838 -179.441 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.534 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 57.2 t80 -60.05 -49.2 78.59 Favored 'General case' 0 N--CA 1.499 1.99 0 O-C-N 121.58 -0.7 . . . . 0.0 111.894 -178.711 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.79 ' CG ' HD23 ' B' ' 189' ' ' LEU . 4.4 p-80 -57.94 -24.41 57.78 Favored 'General case' 0 N--CA 1.5 2.062 0 O-C-N 121.029 -1.044 . . . . 0.0 110.926 -178.322 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.512 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -75.48 -46.31 15.51 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 108.407 -1.877 . . . . 0.0 108.407 178.584 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.737 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -136.38 94.53 3.03 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.723 -0.869 . . . . 0.0 109.433 179.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -67.73 -166.62 3.39 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.926 -1.269 . . . . 0.0 109.926 -179.41 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.0 p -71.57 69.62 0.63 Allowed 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.622 -0.928 . . . . 0.0 109.964 -179.939 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -142.3 178.76 7.35 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.559 -0.713 . . . . 0.0 110.266 -179.833 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 31.0 p -65.54 147.38 53.51 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.558 -0.713 . . . . 0.0 109.619 179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.831 HD21 HG11 ' A' ' 36' ' ' VAL . 12.9 tp -113.1 133.4 55.03 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.611 -0.681 . . . . 0.0 109.99 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -100.03 109.63 21.95 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.617 -0.677 . . . . 0.0 109.882 179.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -113.72 -171.74 17.76 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -65.24 -32.55 51.41 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.908 1.478 . . . . 0.0 110.456 -179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 60.3 tptt -76.14 -31.31 58.54 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.584 -0.698 . . . . 0.0 109.787 -179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.01 -146.15 17.24 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.343 -1.503 . . . . 0.0 109.343 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.7 144.43 31.4 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 O-C-N 123.895 1.471 . . . . 0.0 110.182 179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.582 HG22 ' HB3' ' A' ' 85' ' ' TRP . 85.8 mt -130.03 140.05 49.93 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.485 -0.759 . . . . 0.0 110.316 -179.699 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 70.3 m -86.05 136.3 33.29 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.529 -0.732 . . . . 0.0 110.288 -179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 16.4 pt20 -83.38 149.49 26.68 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.589 -0.694 . . . . 0.0 110.959 -179.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 82.1 mtp -119.27 -18.92 8.5 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.666 -0.646 . . . . 0.0 110.986 179.788 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -128.12 147.98 50.56 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.245 -0.909 . . . . 0.0 110.588 -179.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.8 p -144.49 126.0 14.97 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.743 -0.598 . . . . 0.0 109.975 179.662 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.1 m120 -142.48 90.75 2.26 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.62 -0.675 . . . . 0.0 110.053 179.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.534 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 86.7 t -69.82 -46.69 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.834 0 O-C-N 121.579 -0.7 . . . . 0.0 109.911 -179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -41.82 92.85 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.594 -0.691 . . . . 0.0 110.277 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.545 ' HG2' HD12 ' A' ' 82' ' ' LEU . 45.3 tt0 -90.31 -0.11 57.49 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.571 -0.706 . . . . 0.0 111.149 -179.903 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.444 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 1.6 t70 53.25 44.49 30.1 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 120.99 -1.069 . . . . 0.0 110.85 179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.776 HD11 HG11 ' A' ' 170' ' ' VAL . 45.5 mt -132.93 146.53 51.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.3 -0.875 . . . . 0.0 111.12 -179.869 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.525 HG23 ' CH2' ' A' ' 85' ' ' TRP . 30.6 m -152.83 169.58 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.65 -0.656 . . . . 0.0 109.667 179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -164.9 157.78 30.35 Favored Glycine 0 N--CA 1.495 2.58 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.709 ' HZ3' HG22 ' A' ' 54' ' ' THR . 10.2 m-90 -128.67 168.1 16.27 Favored 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.66 -0.906 . . . . 0.0 109.835 179.445 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 54.8 tp60 -70.85 119.38 14.9 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.444 -0.785 . . . . 0.0 109.375 179.056 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.474 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.52 149.91 95.58 Favored Pre-proline 0 N--CA 1.493 1.71 0 O-C-N 121.532 -0.73 . . . . 0.0 110.099 -179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.96 154.34 67.04 Favored 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.884 1.465 . . . . 0.0 110.369 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -68.42 152.98 74.97 Favored 'Trans proline' 0 N--CA 1.491 1.344 0 O-C-N 123.941 1.495 . . . . 0.0 110.178 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 69.95 30.0 70.42 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 -179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -107.79 147.74 30.44 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.481 -1.011 . . . . 0.0 110.12 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 48.4 mtp85 -88.82 150.05 23.1 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.575 -0.703 . . . . 0.0 109.958 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.1 p -126.95 169.91 12.82 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.605 -0.685 . . . . 0.0 110.111 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.635 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 84.3 mt -109.15 137.4 47.11 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.581 -0.699 . . . . 0.0 110.738 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . 0.411 ' OG1' ' CE1' ' A' ' 149' ' ' HIS . 3.3 p -79.29 165.68 46.86 Favored Pre-proline 0 N--CA 1.494 1.769 0 O-C-N 121.652 -0.655 . . . . 0.0 109.904 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -80.11 153.29 21.79 Favored 'Trans proline' 0 C--N 1.313 -1.3 0 O-C-N 123.827 1.435 . . . . 0.0 110.695 -179.825 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.778 ' HB2' HG22 ' A' ' 151' ' ' VAL . 50.3 t -65.04 131.63 47.09 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.663 -0.648 . . . . 0.0 110.117 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.2 t -135.97 54.26 1.91 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.714 -0.616 . . . . 0.0 109.727 179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.89 -7.87 0.73 Allowed 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.599 -0.688 . . . . 0.0 112.322 -179.127 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 62.76 33.82 87.95 Favored Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 56.9 p -95.8 132.46 41.01 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 121.543 -0.975 . . . . 0.0 110.406 -179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.3 m -80.0 -26.65 39.79 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.674 -0.641 . . . . 0.0 110.409 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -66.4 129.92 41.46 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.435 -0.791 . . . . 0.0 110.296 -179.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.555 ' CD2' HG21 ' A' ' 151' ' ' VAL . 95.3 mt -131.29 157.13 44.12 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.54 -0.725 . . . . 0.0 110.558 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 53.0 m-85 -119.94 115.73 24.36 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.528 -0.732 . . . . 0.0 109.876 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.61 HD13 HD11 ' A' ' 143' ' ' LEU . 65.0 tp -93.37 138.28 31.86 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.578 -0.701 . . . . 0.0 110.699 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 63.2 t -97.89 130.05 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.688 -0.633 . . . . 0.0 109.524 179.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 1.6 m -106.43 165.67 11.1 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.453 -0.779 . . . . 0.0 110.509 -179.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.656 ' HA ' HD11 ' A' ' 44' ' ' LEU . 72.3 mtp180 -59.99 -27.34 66.78 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.627 -0.671 . . . . 0.0 110.489 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.411 ' O ' ' CG ' ' A' ' 110' ' ' HIS . 83.8 t60 -94.49 29.22 2.32 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.528 -0.732 . . . . 0.0 110.62 -179.646 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.28 39.95 31.3 Favored 'General case' 0 N--CA 1.501 2.084 0 O-C-N 121.236 -0.915 . . . . 0.0 110.777 179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 83.4 m-20 -104.62 127.62 52.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.612 -0.68 . . . . 0.0 109.972 179.743 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 62.9 t -110.01 120.13 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.498 -0.751 . . . . 0.0 109.993 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 40.2 pt -114.44 146.9 36.84 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.616 -0.678 . . . . 0.0 109.975 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -87.03 113.04 0.96 Allowed 'Trans proline' 0 N--CA 1.49 1.271 0 O-C-N 123.852 1.448 . . . . 0.0 110.531 -179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.4 t -110.0 119.94 60.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.615 -0.678 . . . . 0.0 109.517 179.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.7 tpt180 -79.34 136.95 37.14 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.493 -0.754 . . . . 0.0 110.259 -179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 58.4 ttp180 -80.01 129.6 34.62 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.661 -0.649 . . . . 0.0 110.336 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -124.64 23.6 8.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.544 -0.722 . . . . 0.0 110.292 179.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 175.78 -177.92 47.41 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -68.75 -39.96 80.03 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.57 -0.959 . . . . 0.0 110.429 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.7 p -129.84 26.18 5.27 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.525 -0.735 . . . . 0.0 110.506 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -130.89 159.99 35.78 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.534 -0.729 . . . . 0.0 110.253 -179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -153.1 172.72 32.05 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.7 p -126.36 147.0 49.82 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.529 -0.983 . . . . 0.0 110.227 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 6.7 mp -99.79 121.14 40.83 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.547 -0.721 . . . . 0.0 110.256 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.503 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.8 mp -60.88 -40.02 91.43 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.703 . . . . 0.0 109.955 179.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.7 m -109.95 112.91 57.65 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.588 -0.695 . . . . 0.0 109.967 179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_endo -64.19 127.47 19.32 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 O-C-N 123.845 1.445 . . . . 0.0 110.515 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 31.8 mtt-85 -127.04 160.04 61.61 Favored Pre-proline 0 N--CA 1.494 1.735 0 O-C-N 121.568 -0.708 . . . . 0.0 110.041 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -66.09 146.43 81.95 Favored 'Trans proline' 0 N--CA 1.49 1.303 0 O-C-N 123.953 1.501 . . . . 0.0 110.303 -179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.636 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.1 m -60.03 -27.06 37.9 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.829 0 O-C-N 121.613 -0.679 . . . . 0.0 110.547 -179.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 47.0 t -59.94 -40.06 87.64 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.468 -0.77 . . . . 0.0 110.389 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 73.0 t80 -65.36 -39.94 92.97 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.469 -0.77 . . . . 0.0 110.116 -179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.458 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -70.36 -27.16 64.12 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.599 -0.688 . . . . 0.0 110.595 -179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -58.21 140.04 53.84 Favored 'General case' 0 N--CA 1.499 2.005 0 O-C-N 121.388 -0.82 . . . . 0.0 110.448 -179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 87.28 6.98 77.41 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 56.0 p -111.43 -4.27 14.92 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.026 -1.279 . . . . 0.0 111.245 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.411 ' HB2' ' H2A' ' B' ' 191' ' ' FE3 . 3.3 m -59.96 140.05 56.99 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.057 -1.027 . . . . 0.0 109.777 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.501 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 98.32 -23.7 35.06 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -60.65 150.08 42.65 Favored Glycine 0 N--CA 1.495 2.583 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 179.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.692 ' C ' HD12 ' A' ' 143' ' ' LEU . 52.3 Cg_endo -91.8 156.74 3.43 Favored 'Trans proline' 0 C--N 1.315 -1.234 0 O-C-N 123.785 1.413 . . . . 0.0 111.571 -179.209 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.692 HD12 ' C ' ' A' ' 142' ' ' PRO . 9.8 mp -116.4 102.99 10.01 Favored 'General case' 0 N--CA 1.491 1.591 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.796 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.623 HD21 HD22 ' A' ' 94' ' ' LEU . 9.9 mp -94.79 133.19 38.76 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.561 -0.712 . . . . 0.0 111.661 -178.358 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.429 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.4 p -70.05 159.37 84.56 Favored Pre-proline 0 N--CA 1.496 1.835 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 178.912 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 40.8 Cg_endo -52.61 -26.16 28.39 Favored 'Trans proline' 0 N--CA 1.501 1.916 0 O-C-N 123.505 1.266 . . . . 0.0 112.276 -178.643 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 52.2 m -62.51 -40.06 95.53 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.822 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 121.32 39.52 0.58 Allowed Glycine 0 N--CA 1.495 2.568 0 N-CA-C 110.149 -1.18 . . . . 0.0 110.149 179.572 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . 0.411 ' CE1' ' OG1' ' A' ' 95' ' ' THR . 3.6 m-70 -137.28 144.96 42.95 Favored 'General case' 0 N--CA 1.497 1.89 0 O-C-N 121.478 -1.013 . . . . 0.0 110.039 179.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.635 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -66.62 140.01 57.91 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.552 -0.717 . . . . 0.0 110.244 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 97' ' ' CYS . 63.0 t -112.63 -36.25 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.581 -0.7 . . . . 0.0 109.814 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -179.91 -168.51 38.75 Favored Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.808 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.751 HD12 ' CE ' ' A' ' 175' ' ' MET . 96.7 mt -129.56 140.1 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.543 -0.975 . . . . 0.0 110.216 -179.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -60.56 136.4 58.04 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.632 -0.667 . . . . 0.0 109.91 179.761 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.9 ttt180 -115.72 -52.22 2.64 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.532 -0.73 . . . . 0.0 110.369 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . 0.569 ' HB1' ' O ' ' B' ' 188' ' ' GLU . . . -156.12 160.04 39.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.529 -0.732 . . . . 0.0 110.294 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -110.72 151.06 28.18 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.645 -0.659 . . . . 0.0 110.311 -179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.4 t -109.91 119.51 59.17 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.672 -0.643 . . . . 0.0 109.68 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.636 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -135.02 154.38 51.74 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.634 -0.666 . . . . 0.0 110.305 -179.924 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 3.3 m -103.02 -48.68 3.98 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.549 -0.72 . . . . 0.0 110.653 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.5 mtm180 -131.04 50.2 2.25 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.53 -0.731 . . . . 0.0 110.373 -179.457 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.97 -4.36 83.16 Favored Glycine 0 N--CA 1.493 2.495 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 59.6 t -113.29 129.4 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.142 -1.21 . . . . 0.0 109.688 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -99.97 123.95 44.77 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.589 -0.694 . . . . 0.0 110.595 -179.422 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -109.25 -18.35 13.62 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.59 -0.694 . . . . 0.0 110.698 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -142.48 153.7 43.89 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.328 -0.858 . . . . 0.0 110.224 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.2 m -135.75 163.58 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.899 0 O-C-N 121.517 -0.74 . . . . 0.0 110.552 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -122.18 134.14 54.72 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.653 -0.654 . . . . 0.0 110.224 -179.751 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 55.6 p90 -132.25 157.42 44.42 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.44 -0.787 . . . . 0.0 110.227 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.776 HG11 HD11 ' A' ' 82' ' ' LEU . 58.0 t -93.43 120.67 66.29 Favored Pre-proline 0 N--CA 1.493 1.716 0 O-C-N 121.572 -0.705 . . . . 0.0 109.589 179.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.33 148.72 84.82 Favored 'Trans proline' 0 N--CA 1.49 1.279 0 O-C-N 123.762 1.401 . . . . 0.0 110.492 -179.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 76.3 t -59.5 -23.58 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.961 0 O-C-N 121.734 -0.604 . . . . 0.0 110.738 -179.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -59.51 -34.58 72.78 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.388 -0.82 . . . . 0.0 110.626 -179.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 79.7 p -69.75 -37.37 76.43 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.493 -0.755 . . . . 0.0 110.435 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.751 ' CE ' HD12 ' A' ' 153' ' ' ILE . 67.1 mtt -59.96 -50.01 75.43 Favored 'General case' 0 N--CA 1.497 1.915 0 O-C-N 121.458 -0.776 . . . . 0.0 110.873 -179.572 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -64.49 -29.3 70.34 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.494 -0.754 . . . . 0.0 110.359 -179.551 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.0 m -60.51 -42.56 96.65 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.455 -0.778 . . . . 0.0 110.021 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 93.9 m -70.0 -40.8 75.07 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.601 -0.687 . . . . 0.0 110.005 179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 98.2 mtp -63.04 -40.06 96.58 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.528 -0.732 . . . . 0.0 110.331 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 77.5 mtp85 -68.58 -40.0 80.73 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.617 -0.677 . . . . 0.0 110.314 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -63.96 -40.01 95.44 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.527 -0.733 . . . . 0.0 110.245 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 46.7 t -60.01 -50.02 75.39 Favored 'General case' 0 N--CA 1.498 1.933 0 O-C-N 121.496 -0.753 . . . . 0.0 110.49 -179.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 10.0 pttt -69.94 -29.59 66.76 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.422 -0.799 . . . . 0.0 110.417 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 85.3 tttt 52.8 85.13 0.05 OUTLIER 'General case' 0 N--CA 1.502 2.141 0 O-C-N 121.375 -0.828 . . . . 0.0 110.754 -179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 74.3 mmtt 54.22 176.85 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.097 0 O-C-N 121.365 -0.834 . . . . 0.0 110.692 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.7 tttp . . . . . 0 N--CA 1.494 1.76 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.221 -179.947 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . 0.569 ' O ' ' HB1' ' A' ' 156' ' ' ALA . 59.4 tt0 -119.95 138.32 53.53 Favored 'General case' 0 N--CA 1.492 1.643 0 C-N-CA 118.737 -1.185 . . . . 0.0 110.15 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.79 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.6 mp -89.34 138.57 31.32 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.531 -0.731 . . . . 0.0 110.245 179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.411 ' C ' ' CD1' ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.443 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 9.4 m . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.01 0.433 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 100.01 140.52 11.43 Favored Glycine 0 N--CA 1.493 2.449 0 N-CA-C 109.548 -1.421 . . . . 0.0 109.548 179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 73.3 ttt180 -60.06 -39.94 87.75 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.473 -1.016 . . . . 0.0 110.283 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 42.8 t0 55.24 85.24 0.07 Allowed 'General case' 0 N--CA 1.502 2.138 0 O-C-N 121.367 -0.833 . . . . 0.0 110.619 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -80.01 -11.07 59.81 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.571 -0.706 . . . . 0.0 111.212 -179.859 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 34.6 m120 -91.3 117.8 29.96 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.135 -0.978 . . . . 0.0 110.419 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.476 ' HG3' HG13 ' A' ' 29' ' ' VAL . 56.7 tp60 -59.97 -49.49 77.47 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.552 -0.718 . . . . 0.0 110.308 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 29' ' ' VAL . 35.7 m -142.97 106.83 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.66 -0.65 . . . . 0.0 110.395 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -69.99 -39.99 75.59 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.435 -0.79 . . . . 0.0 110.214 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 142.71 89.13 0.11 Allowed Glycine 0 N--CA 1.494 2.531 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -63.15 -37.23 86.41 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.614 -0.933 . . . . 0.0 110.298 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 62.7 t -106.34 130.04 58.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 121.572 -0.705 . . . . 0.0 109.757 -179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 97.8 mt-30 -128.03 158.56 37.59 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.54 -0.725 . . . . 0.0 110.53 -179.626 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 59.2 t -95.27 128.43 46.45 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.585 -0.697 . . . . 0.0 109.499 179.658 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.565 ' CB ' HD21 ' A' ' 64' ' ' LEU . 29.2 m -129.3 158.97 41.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.591 -0.693 . . . . 0.0 109.83 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 1.6 t -153.46 164.04 38.89 Favored 'General case' 0 N--CA 1.491 1.614 0 C-N-CA 119.879 -0.728 . . . . 0.0 110.618 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.8 p -118.71 -169.68 1.76 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.635 -0.665 . . . . 0.0 109.598 179.376 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -59.99 -34.31 73.14 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.586 -0.696 . . . . 0.0 110.985 -179.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 54.7 p -131.21 -10.69 3.71 Favored 'General case' 0 N--CA 1.498 1.972 0 O-C-N 121.184 -0.947 . . . . 0.0 112.64 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 21.2 tp60 -117.92 153.42 33.61 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 120.92 -1.113 . . . . 0.0 111.289 -179.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 35.2 t -138.44 138.31 38.04 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.623 -0.673 . . . . 0.0 109.736 179.631 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.78 ' CZ ' ' HB2' ' A' ' 59' ' ' ALA . 22.4 p90 -167.24 -178.08 3.94 Favored 'General case' 0 N--CA 1.5 2.073 0 O-C-N 121.305 -0.872 . . . . 0.0 110.527 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.677 HD11 ' HA ' ' A' ' 109' ' ' ARG . 66.4 mt -113.61 157.61 21.89 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.619 -0.676 . . . . 0.0 110.649 -178.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -135.24 162.29 32.97 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.742 -0.599 . . . . 0.0 110.112 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 9.0 t -124.63 139.8 53.53 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.557 -0.714 . . . . 0.0 110.29 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 29.3 t -97.57 113.94 25.76 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.411 -0.806 . . . . 0.0 110.619 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . 0.427 ' HB ' ' CD1' ' A' ' 53' ' ' TRP . 61.4 t -121.03 133.88 66.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 121.609 -0.682 . . . . 0.0 109.945 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 57.54 39.95 27.39 Favored 'General case' 0 N--CA 1.501 2.1 0 O-C-N 121.509 -0.745 . . . . 0.0 111.256 179.68 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 67.9 26.89 73.78 Favored Glycine 0 N--CA 1.496 2.65 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 178.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 65.5 t -140.02 138.59 37.8 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.468 -1.019 . . . . 0.0 109.696 179.607 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -81.07 147.37 30.16 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.44 -0.788 . . . . 0.0 109.298 179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . 0.524 ' CG ' ' HE3' ' A' ' 175' ' ' MET . 61.1 m95 -130.13 153.06 48.9 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.455 -0.778 . . . . 0.0 110.868 -179.482 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.926 HG21 ' CH2' ' A' ' 85' ' ' TRP . 5.5 t -169.62 -179.5 3.39 Favored 'General case' 0 N--CA 1.492 1.661 0 N-CA-C 109.327 -0.619 . . . . 0.0 109.327 -179.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.842 HG21 ' CE1' ' A' ' 57' ' ' HIS . 9.1 p -95.25 144.87 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.476 -0.765 . . . . 0.0 110.473 179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.431 ' CE1' HG22 ' A' ' 78' ' ' VAL . 64.9 t80 -60.47 -42.59 96.54 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.716 -0.615 . . . . 0.0 111.694 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.842 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.9 p-80 -70.02 -20.14 63.28 Favored 'General case' 0 N--CA 1.499 1.977 0 O-C-N 121.043 -1.036 . . . . 0.0 110.895 -179.094 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.732 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -89.19 -43.32 5.34 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 108.552 -1.819 . . . . 0.0 108.552 178.827 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.78 ' HB2' ' CZ ' ' A' ' 43' ' ' PHE . . . -132.6 85.05 2.19 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.668 -0.901 . . . . 0.0 109.804 179.462 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -64.2 -168.8 1.55 Allowed Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.269 -1.533 . . . . 0.0 109.269 -179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 69.5 p -72.78 67.45 0.81 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.618 -0.93 . . . . 0.0 109.707 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 54.2 mtmt -140.02 169.78 17.08 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.622 -0.674 . . . . 0.0 110.476 -179.713 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 50.9 m -65.53 139.58 58.49 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.676 -0.64 . . . . 0.0 110.088 -179.87 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.952 HD22 ' CH2' ' A' ' 85' ' ' TRP . 16.4 tp -115.3 133.47 56.01 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.625 -0.672 . . . . 0.0 109.801 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.78 119.37 30.95 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.555 -0.716 . . . . 0.0 110.334 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -125.42 176.37 17.25 Favored Glycine 0 N--CA 1.494 2.545 0 N-CA-C 109.279 -1.528 . . . . 0.0 109.279 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -63.03 -32.18 75.92 Favored 'Trans proline' 0 N--CA 1.492 1.412 0 O-C-N 123.788 1.415 . . . . 0.0 110.455 -179.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 74.2 mmtt -70.21 -31.39 68.81 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.555 -0.716 . . . . 0.0 109.782 -179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 141.31 -151.12 22.38 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.248 -1.541 . . . . 0.0 109.248 -179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -70.87 154.65 63.26 Favored 'Trans proline' 0 N--CA 1.49 1.267 0 O-C-N 123.886 1.466 . . . . 0.0 110.131 179.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.431 HG22 ' CD1' ' A' ' 85' ' ' TRP . 86.0 mt -129.98 139.91 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 121.56 -0.713 . . . . 0.0 110.675 -179.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.5 m -100.57 138.8 37.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.589 -0.694 . . . . 0.0 110.274 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.31 143.81 51.91 Favored 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.562 -0.711 . . . . 0.0 110.817 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . 0.436 ' HB3' ' CD2' ' A' ' 75' ' ' TYR . 5.5 mtp -119.16 -50.03 2.37 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.532 -0.73 . . . . 0.0 110.452 179.597 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . 0.436 ' CD2' ' HB3' ' A' ' 74' ' ' MET . 98.8 m-85 -120.0 140.01 51.61 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.493 -0.754 . . . . 0.0 110.462 -179.652 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.599 ' HA ' HG12 ' A' ' 83' ' ' VAL . 24.5 m -136.03 133.02 37.0 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.556 -0.715 . . . . 0.0 110.411 179.845 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 32.7 t30 -145.83 100.56 3.43 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.495 -0.753 . . . . 0.0 109.98 179.7 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.431 HG22 ' CE1' ' A' ' 56' ' ' TYR . 59.8 t -69.98 -36.66 69.82 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.929 0 O-C-N 121.543 -0.723 . . . . 0.0 110.312 -179.772 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -59.95 -50.0 75.48 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.469 -0.77 . . . . 0.0 110.981 -179.145 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.5 mm-40 -90.47 0.15 57.43 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.466 -0.771 . . . . 0.0 111.309 -179.794 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.428 ' HA ' ' CB ' ' A' ' 56' ' ' TYR . 2.6 t70 55.33 40.09 31.41 Favored 'General case' 0 N--CA 1.503 2.218 0 O-C-N 120.921 -1.112 . . . . 0.0 109.747 -179.41 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.465 ' CD2' HG21 ' A' ' 170' ' ' VAL . 0.6 OUTLIER -125.24 132.34 52.98 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.671 -0.643 . . . . 0.0 110.742 -179.07 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.776 HG23 HG23 ' A' ' 54' ' ' THR . 27.1 m -145.08 157.16 13.77 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.958 0 O-C-N 121.645 -0.659 . . . . 0.0 109.462 179.05 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -144.84 175.03 24.72 Favored Glycine 0 N--CA 1.495 2.584 0 C-N-CA 120.05 -1.071 . . . . 0.0 110.594 -179.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.952 ' CH2' HD22 ' A' ' 64' ' ' LEU . 8.5 m-90 -130.04 159.97 35.11 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.916 -0.755 . . . . 0.0 109.631 179.587 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -66.53 123.33 19.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.365 -0.834 . . . . 0.0 109.152 178.799 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -79.37 139.74 55.89 Favored Pre-proline 0 N--CA 1.494 1.729 0 O-C-N 121.504 -0.747 . . . . 0.0 110.193 -179.325 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . 0.465 ' HG2' ' HB2' ' A' ' 91' ' ' ALA . 48.3 Cg_endo -69.98 159.17 54.2 Favored 'Trans proline' 0 N--CA 1.489 1.256 0 O-C-N 123.824 1.434 . . . . 0.0 110.4 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -71.52 136.1 27.76 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 O-C-N 123.961 1.506 . . . . 0.0 110.286 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.13 -24.16 33.39 Favored Glycine 0 N--CA 1.494 2.514 0 N-CA-C 109.878 -1.289 . . . . 0.0 109.878 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . 0.465 ' HB2' ' HG2' ' A' ' 88' ' ' PRO . . . -60.1 140.01 57.14 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.374 -1.074 . . . . 0.0 110.3 179.991 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 14.4 tpt180 -80.91 158.9 25.13 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.635 -0.666 . . . . 0.0 109.659 179.839 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 82.8 p -130.49 168.93 16.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.521 -0.737 . . . . 0.0 110.325 -179.827 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.421 ' O ' HG13 ' A' ' 48' ' ' VAL . 84.5 mt -112.94 140.01 48.1 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.561 -0.712 . . . . 0.0 110.702 -179.837 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 44.6 p -82.1 165.54 42.4 Favored Pre-proline 0 N--CA 1.496 1.832 0 O-C-N 121.647 -0.658 . . . . 0.0 110.142 179.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -81.63 162.04 19.14 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 O-C-N 123.797 1.42 . . . . 0.0 110.662 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 52.6 t -73.66 130.16 39.45 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.64 -0.662 . . . . 0.0 110.137 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 6.3 t -132.97 54.29 1.96 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.741 -0.599 . . . . 0.0 109.816 179.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.7 p -143.73 -8.49 0.73 Allowed 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.56 -0.713 . . . . 0.0 112.383 -179.12 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.12 42.85 97.29 Favored Glycine 0 N--CA 1.496 2.694 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 47.8 t -100.0 119.97 39.1 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.522 -0.987 . . . . 0.0 110.531 -179.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 54.9 m -62.78 -40.08 96.19 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.649 -0.657 . . . . 0.0 110.296 179.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -63.41 130.47 44.57 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.583 -0.698 . . . . 0.0 110.261 -179.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.551 HD22 HG11 ' A' ' 151' ' ' VAL . 95.8 mt -137.97 155.37 48.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.617 -0.677 . . . . 0.0 110.577 180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 60.4 m-85 -106.69 135.58 47.98 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.465 -0.772 . . . . 0.0 109.545 179.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.506 HD11 ' HB2' ' A' ' 154' ' ' PHE . 39.8 tp -105.09 127.21 52.79 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.449 -0.782 . . . . 0.0 110.747 -179.268 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -86.45 140.03 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.536 -0.727 . . . . 0.0 109.777 179.606 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 3.2 m -130.07 170.06 14.49 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.524 -0.735 . . . . 0.0 110.516 -179.764 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.677 ' HA ' HD11 ' A' ' 44' ' ' LEU . 44.2 mtm180 -60.04 -23.2 63.53 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.51 -0.744 . . . . 0.0 110.781 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.11 19.37 5.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.395 -0.816 . . . . 0.0 111.194 -179.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 53.49 39.9 30.63 Favored 'General case' 0 N--CA 1.502 2.134 0 O-C-N 121.077 -1.015 . . . . 0.0 110.693 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.3 m-20 -113.27 157.65 21.51 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.533 -0.729 . . . . 0.0 109.955 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 34.4 m -129.43 133.68 64.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.52 -0.738 . . . . 0.0 110.371 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . . . . . . . . . 49.0 mm -122.48 147.82 51.16 Favored Pre-proline 0 N--CA 1.493 1.686 0 O-C-N 121.602 -0.687 . . . . 0.0 109.701 179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . 0.437 ' HG2' HD22 ' A' ' 127' ' ' LEU . 48.6 Cg_endo -82.65 129.75 5.74 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 O-C-N 123.906 1.477 . . . . 0.0 110.378 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.423 HG13 ' O ' ' A' ' 125' ' ' SER . 63.0 t -130.0 130.02 65.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.697 -0.627 . . . . 0.0 109.602 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . 0.589 ' HG2' HD11 ' A' ' 127' ' ' LEU . 54.2 mmm-85 -79.53 153.1 29.78 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.517 -0.74 . . . . 0.0 110.276 -179.958 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 51.4 ttt-85 -99.34 119.07 37.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.64 -0.662 . . . . 0.0 109.921 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 17.1 mmm-85 -114.6 24.34 11.93 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.671 -0.643 . . . . 0.0 110.219 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 162.07 -175.41 38.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 82.0 m-20 -64.57 -39.97 94.7 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.53 -0.982 . . . . 0.0 110.378 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 52.8 p -130.87 28.87 4.79 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.543 -0.723 . . . . 0.0 110.753 -179.74 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 14.6 tpp85 -132.44 146.63 52.09 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.422 -0.799 . . . . 0.0 110.656 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -160.69 169.83 36.48 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.339 -1.505 . . . . 0.0 109.339 179.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.423 ' O ' HG13 ' A' ' 116' ' ' VAL . 53.3 p -109.24 158.38 17.91 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.468 -1.019 . . . . 0.0 110.234 179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 17.7 tp -102.02 119.94 39.61 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.541 -0.725 . . . . 0.0 110.152 -179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.589 HD11 ' HG2' ' A' ' 117' ' ' ARG . 7.6 mp -65.44 -40.04 92.79 Favored 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.537 -0.727 . . . . 0.0 109.988 179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.9 m -109.8 109.94 59.35 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.599 -0.688 . . . . 0.0 110.084 179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -66.14 118.68 5.71 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 O-C-N 123.82 1.432 . . . . 0.0 110.415 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 17.7 mmt180 -120.04 160.01 44.75 Favored Pre-proline 0 N--CA 1.493 1.706 0 O-C-N 121.598 -0.689 . . . . 0.0 110.127 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -65.2 157.93 54.93 Favored 'Trans proline' 0 N--CA 1.491 1.352 0 O-C-N 123.919 1.484 . . . . 0.0 110.242 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.421 HG21 ' SG ' ' A' ' 159' ' ' CYS . 63.4 t -67.13 -30.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 121.601 -0.687 . . . . 0.0 110.191 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 79.6 p -60.04 -39.74 86.97 Favored 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.515 -0.74 . . . . 0.0 110.414 -179.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -64.35 -40.02 95.03 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.566 -0.709 . . . . 0.0 110.222 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.448 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -70.02 -30.75 68.14 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.453 -0.779 . . . . 0.0 110.555 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -60.04 142.75 53.49 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.469 -0.769 . . . . 0.0 110.218 -179.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.96 8.72 87.41 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.152 -1.179 . . . . 0.0 110.152 -179.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 17.5 m -113.37 -7.73 13.47 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.182 -1.187 . . . . 0.0 110.966 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 30.6 t -59.92 140.33 56.76 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.091 -1.005 . . . . 0.0 109.99 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.401 ' C ' HG23 ' A' ' 153' ' ' ILE . . . 102.3 -21.23 42.05 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.332 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -61.45 145.05 48.85 Favored Glycine 0 N--CA 1.493 2.497 0 N-CA-C 109.166 -1.574 . . . . 0.0 109.166 179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.42 ' C ' HD12 ' A' ' 143' ' ' LEU . 50.1 Cg_endo -86.88 142.16 6.52 Favored 'Trans proline' 0 C--N 1.314 -1.247 0 O-C-N 123.836 1.44 . . . . 0.0 111.262 -179.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.736 ' O ' HG12 ' A' ' 151' ' ' VAL . 9.7 mp -101.25 122.09 43.04 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 178.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.629 HD12 ' C ' ' A' ' 143' ' ' LEU . 10.0 mp -112.13 133.77 54.08 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.474 -0.766 . . . . 0.0 111.537 -178.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.439 ' HB2' ' HD2' ' A' ' 146' ' ' PRO . 27.6 p -70.08 160.03 82.1 Favored Pre-proline 0 N--CA 1.497 1.912 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.072 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . 0.439 ' HD2' ' HB2' ' A' ' 145' ' ' CYS . 39.7 Cg_endo -52.13 -23.02 16.32 Favored 'Trans proline' 0 N--CA 1.503 2.049 0 O-C-N 123.464 1.244 . . . . 0.0 112.235 -178.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.1 t -65.84 -40.01 91.34 Favored 'General case' 0 N--CA 1.498 1.931 0 O-C-N 121.325 -0.859 . . . . 0.0 109.854 179.543 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.99 34.33 0.91 Allowed Glycine 0 N--CA 1.495 2.579 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 34.8 m170 -131.68 145.52 51.69 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.464 -1.021 . . . . 0.0 110.326 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -72.29 137.19 46.55 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.545 -0.722 . . . . 0.0 110.265 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.736 HG12 ' O ' ' A' ' 143' ' ' LEU . 9.2 p -115.54 -22.49 4.61 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.536 -0.728 . . . . 0.0 110.696 -179.957 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . 177.65 -170.93 43.51 Favored Glycine 0 N--CA 1.495 2.584 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . 0.401 HG23 ' C ' ' A' ' 140' ' ' GLY . 63.5 mt -129.93 140.03 50.01 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 O-C-N 121.595 -0.944 . . . . 0.0 110.055 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.506 ' HB2' HD11 ' A' ' 106' ' ' LEU . 20.7 t80 -61.64 138.24 58.29 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.652 -0.655 . . . . 0.0 109.911 179.692 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -118.49 -52.3 2.37 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.545 -0.722 . . . . 0.0 110.563 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -153.11 160.39 42.9 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.57 -0.706 . . . . 0.0 110.403 -179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.43 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -114.94 147.58 39.82 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.599 -0.688 . . . . 0.0 110.384 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 61.8 t -110.01 120.03 60.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.713 0 O-C-N 121.677 -0.64 . . . . 0.0 109.642 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.421 ' SG ' HG21 ' A' ' 132' ' ' VAL . 26.4 p -125.93 143.99 50.86 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.645 -0.659 . . . . 0.0 110.631 -179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . 0.511 HG22 ' HG2' ' A' ' 161' ' ' ARG . 58.6 m -82.01 -56.42 3.96 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.639 -0.663 . . . . 0.0 110.44 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.511 ' HG2' HG22 ' A' ' 160' ' ' THR . 20.8 mmt180 -134.7 58.0 1.79 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.529 -0.732 . . . . 0.0 110.08 179.885 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 90.4 -10.0 75.76 Favored Glycine 0 N--CA 1.493 2.498 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -179.761 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.86 121.35 63.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.128 -1.219 . . . . 0.0 109.688 179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -78.83 128.3 33.18 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.631 -0.668 . . . . 0.0 110.552 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 59.0 pttt -111.5 -25.97 9.32 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.639 -0.663 . . . . 0.0 110.398 179.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -141.36 159.17 42.78 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.585 -0.697 . . . . 0.0 110.253 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 27.3 m -133.8 160.01 42.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.539 -0.726 . . . . 0.0 111.006 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -121.76 133.88 54.93 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.682 -0.636 . . . . 0.0 110.055 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.3 p90 -138.18 151.44 47.71 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.412 -0.805 . . . . 0.0 110.421 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.465 HG21 ' CD2' ' A' ' 82' ' ' LEU . 57.3 t -88.09 123.42 68.77 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.497 -0.752 . . . . 0.0 109.505 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -67.34 155.13 71.76 Favored 'Trans proline' 0 N--CA 1.491 1.331 0 O-C-N 123.764 1.402 . . . . 0.0 110.56 -179.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 151' ' ' VAL . 88.9 t -58.24 -21.74 18.22 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.681 -0.637 . . . . 0.0 110.654 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 41.1 tt0 -57.64 -40.01 78.27 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.268 -0.895 . . . . 0.0 110.656 -179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 3.4 m -73.65 -35.32 65.24 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.448 -0.783 . . . . 0.0 109.683 179.71 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . 0.524 ' HE3' ' CG ' ' A' ' 53' ' ' TRP . 95.0 mtp -63.14 -40.48 97.71 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.66 -0.65 . . . . 0.0 110.133 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 -69.54 -39.92 77.17 Favored 'General case' 0 N--CA 1.495 1.822 0 O-C-N 121.611 -0.681 . . . . 0.0 110.381 -179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 93.9 m -65.48 -39.97 92.58 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.662 -0.649 . . . . 0.0 110.075 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 90.5 m -61.72 -48.62 79.91 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.533 -0.729 . . . . 0.0 110.069 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . 0.4 ' HG3' ' CZ ' ' A' ' 75' ' ' TYR . 26.6 ttt -60.07 -48.47 81.6 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.56 -0.712 . . . . 0.0 110.308 -179.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 58.6 ttp180 -60.11 -39.9 87.8 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.578 -0.701 . . . . 0.0 110.208 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -66.83 -39.96 87.84 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.587 -0.695 . . . . 0.0 110.146 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 2.3 m 52.31 40.03 28.41 Favored 'General case' 0 N--CA 1.501 2.093 0 O-C-N 121.42 -0.8 . . . . 0.0 110.821 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -102.56 140.04 37.36 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.592 -0.693 . . . . 0.0 110.275 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -102.87 140.03 37.68 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.526 -0.734 . . . . 0.0 110.196 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 54.0 mtmt 55.37 -87.24 0.02 OUTLIER 'General case' 0 N--CA 1.5 2.043 0 O-C-N 121.676 -0.64 . . . . 0.0 110.892 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.8 tptt . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.121 -0.987 . . . . 0.0 110.078 179.994 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -119.79 133.15 55.71 Favored 'General case' 0 N--CA 1.491 1.584 0 C-N-CA 118.738 -1.185 . . . . 0.0 110.071 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.789 HD23 ' CG ' ' A' ' 57' ' ' HIS . 10.2 mp -69.99 140.05 52.87 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 121.55 -0.719 . . . . 0.0 110.417 -179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.407 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 7.4 t . . . . . 0 N--CA 1.492 1.654 0 CA-C-O 121.04 0.448 . . . . 0.0 110.23 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 62.75 -133.78 44.05 Favored Glycine 0 N--CA 1.493 2.499 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 -179.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 49.6 mtp180 52.88 40.03 30.12 Favored 'General case' 0 N--CA 1.502 2.142 0 O-C-N 121.414 -1.051 . . . . 0.0 110.737 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -67.58 -39.69 84.85 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.542 -0.724 . . . . 0.0 110.284 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 98.5 mttt 53.1 179.31 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.146 0 O-C-N 121.431 -0.793 . . . . 0.0 110.767 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 -108.79 119.96 41.07 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.522 -0.736 . . . . 0.0 110.256 -179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -60.61 -40.02 90.29 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.6 -0.688 . . . . 0.0 110.476 -179.836 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 62.3 t -117.47 120.74 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.9 0 O-C-N 121.621 -0.674 . . . . 0.0 110.092 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -112.12 -27.24 8.45 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.597 -0.689 . . . . 0.0 110.432 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 114.4 11.58 11.71 Favored Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.804 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.432 ' HB3' ' CD2' ' A' ' 94' ' ' LEU . 45.3 mt-10 56.08 20.64 4.51 Favored 'General case' 0 N--CA 1.5 2.044 0 O-C-N 121.214 -1.168 . . . . 0.0 111.086 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.427 HG23 ' C ' ' A' ' 32' ' ' GLU . 65.9 t -147.76 131.86 9.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.868 0 O-C-N 121.386 -0.821 . . . . 0.0 109.647 179.386 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -124.72 155.17 39.7 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.522 -0.736 . . . . 0.0 110.583 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 66.9 t -102.92 122.04 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.682 -0.636 . . . . 0.0 109.605 179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.562 ' HB ' HD12 ' A' ' 64' ' ' LEU . 34.1 m -117.1 145.2 23.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.658 -0.651 . . . . 0.0 109.772 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . 0.463 ' O ' HD13 ' A' ' 64' ' ' LEU . 6.2 t -131.85 168.5 17.73 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.548 -0.72 . . . . 0.0 110.6 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.436 HG22 ' H ' ' A' ' 39' ' ' ALA . 5.0 m -141.91 173.23 11.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.584 -0.698 . . . . 0.0 110.376 -179.671 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.436 ' H ' HG22 ' A' ' 38' ' ' THR . . . -68.88 -12.71 61.86 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.592 -0.692 . . . . 0.0 111.044 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 43.2 p -111.16 -41.5 4.17 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.202 -0.936 . . . . 0.0 111.088 -179.564 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . . . . . . . . . 6.8 pt20 -157.48 168.14 28.17 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.402 -0.811 . . . . 0.0 110.831 -179.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 80.6 p -119.85 152.64 37.0 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.572 -0.705 . . . . 0.0 110.2 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.406 ' CD1' ' N ' ' A' ' 43' ' ' PHE . 3.7 p90 -154.26 -178.22 6.98 Favored 'General case' 0 N--CA 1.498 1.973 0 O-C-N 121.525 -0.735 . . . . 0.0 110.136 -179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.796 HD11 ' CA ' ' A' ' 109' ' ' ARG . 35.0 mt -113.49 153.76 28.16 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.487 -0.758 . . . . 0.0 110.817 -178.236 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -131.12 162.19 30.43 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.686 -0.634 . . . . 0.0 109.972 179.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . . . . . . . . . 7.6 t -124.44 143.61 50.53 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.474 -0.766 . . . . 0.0 110.59 -179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 97.1 m -96.53 108.93 21.59 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.568 -0.707 . . . . 0.0 110.154 179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 57.5 t -123.35 133.84 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.543 -0.723 . . . . 0.0 109.612 179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 96.9 m-20 54.71 36.53 26.44 Favored 'General case' 0 N--CA 1.501 2.114 0 O-C-N 121.521 -0.737 . . . . 0.0 110.869 -179.705 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.527 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.03 20.02 75.96 Favored Glycine 0 N--CA 1.495 2.616 0 N-CA-C 110.744 -0.943 . . . . 0.0 110.744 179.268 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 64.2 t -136.38 129.97 46.83 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.226 -1.161 . . . . 0.0 110.043 179.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 90.7 m -74.23 149.2 40.94 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.473 -0.767 . . . . 0.0 109.527 179.519 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 77.1 m95 -136.11 151.85 50.23 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.512 -0.742 . . . . 0.0 111.069 -179.669 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.937 HG21 ' CH2' ' A' ' 85' ' ' TRP . 7.4 t -168.4 -178.49 3.58 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.847 -0.533 . . . . 0.0 109.778 -179.622 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.921 HG21 ' CE1' ' A' ' 57' ' ' HIS . 11.7 p -82.08 161.27 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.568 -0.707 . . . . 0.0 110.01 179.265 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.432 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 65.9 t80 -85.37 -34.6 21.74 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.399 -0.813 . . . . 0.0 111.796 -178.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.921 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.6 p-80 -70.01 -20.1 63.29 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 120.996 -1.065 . . . . 0.0 110.941 -179.282 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.501 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -78.22 -51.15 5.85 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.364 -1.495 . . . . 0.0 109.364 179.544 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.416 ' HB3' HG11 ' A' ' 83' ' ' VAL . . . -95.16 -50.43 5.07 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.509 -0.995 . . . . 0.0 110.374 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.3 30.81 36.03 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.427 ' HA ' HG21 ' A' ' 83' ' ' VAL . 2.0 t 56.87 40.02 29.16 Favored 'General case' 0 N--CA 1.502 2.136 0 O-C-N 121.302 -1.116 . . . . 0.0 110.283 -179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -116.06 178.67 4.23 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.69 -0.631 . . . . 0.0 109.737 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 61.0 m -65.46 138.79 58.34 Favored 'General case' 0 N--CA 1.494 1.726 0 C-N-CA 119.8 -0.76 . . . . 0.0 109.181 179.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.732 ' HB3' HD12 ' A' ' 71' ' ' ILE . 0.1 OUTLIER -118.24 142.74 47.16 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.5 -0.75 . . . . 0.0 110.214 -179.406 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -99.99 115.94 30.88 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.645 -0.659 . . . . 0.0 109.911 179.597 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -118.58 174.29 15.25 Favored Glycine 0 N--CA 1.494 2.547 0 N-CA-C 109.312 -1.515 . . . . 0.0 109.312 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -62.78 -31.83 78.16 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.762 1.401 . . . . 0.0 110.422 -179.841 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 73.8 mmtt -71.93 -31.29 66.21 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.576 -0.703 . . . . 0.0 109.767 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 143.03 -147.58 19.03 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -70.63 151.32 64.04 Favored 'Trans proline' 0 N--CA 1.49 1.296 0 O-C-N 123.878 1.462 . . . . 0.0 110.241 179.91 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.732 HD12 ' HB3' ' A' ' 64' ' ' LEU . 85.8 mt -120.02 129.67 75.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.764 0 O-C-N 121.626 -0.671 . . . . 0.0 110.271 -179.698 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 74.8 p -91.56 144.46 25.52 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.464 -0.772 . . . . 0.0 110.149 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . 0.431 ' HG3' ' CD1' ' A' ' 85' ' ' TRP . 0.4 OUTLIER -88.0 134.17 33.79 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 121.558 -0.714 . . . . 0.0 110.872 -179.566 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 97.1 mmm -116.57 -33.22 4.95 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.625 -0.672 . . . . 0.0 110.239 179.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -131.27 137.67 48.96 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.577 -0.702 . . . . 0.0 110.326 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 84.6 m -139.97 130.62 25.75 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.528 -0.733 . . . . 0.0 109.978 179.667 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 -136.86 100.67 4.37 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.545 -0.722 . . . . 0.0 110.353 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.432 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 67.8 t -70.01 -35.55 64.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.877 0 O-C-N 121.594 -0.691 . . . . 0.0 110.025 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -60.0 -47.88 84.0 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.606 -0.684 . . . . 0.0 110.512 -179.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . . . . . . . . . 97.2 mm-40 -89.96 3.03 54.35 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.479 -0.763 . . . . 0.0 111.116 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.414 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 9.1 t70 54.08 49.4 18.89 Favored 'General case' 0 N--CA 1.502 2.17 0 O-C-N 121.113 -0.992 . . . . 0.0 110.425 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.73 HD11 HG11 ' A' ' 170' ' ' VAL . 68.4 mt -140.94 141.24 34.5 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.589 -0.694 . . . . 0.0 111.047 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.663 ' O ' HG22 ' A' ' 54' ' ' THR . 7.8 p -139.15 140.5 37.99 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.875 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . -125.71 158.09 19.92 Favored Glycine 0 N--CA 1.495 2.57 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -179.219 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.937 ' CH2' HG21 ' A' ' 54' ' ' THR . 11.2 m-90 -119.89 167.16 12.41 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.681 -0.893 . . . . 0.0 109.88 179.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 37.7 tt0 -71.19 115.86 10.83 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.605 -0.685 . . . . 0.0 109.429 179.192 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.527 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -70.07 146.34 94.83 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.554 -0.716 . . . . 0.0 110.187 -179.66 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -69.91 159.8 51.97 Favored 'Trans proline' 0 N--CA 1.49 1.309 0 O-C-N 123.981 1.516 . . . . 0.0 110.314 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -71.02 151.2 61.64 Favored 'Trans proline' 0 N--CA 1.49 1.306 0 O-C-N 124.019 1.536 . . . . 0.0 110.369 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.06 29.46 70.6 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.601 -1.4 . . . . 0.0 109.601 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -103.13 139.41 38.68 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.56 -0.965 . . . . 0.0 110.266 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 66.4 ttt180 -88.86 143.41 26.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.599 -0.688 . . . . 0.0 109.842 179.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 80.4 p -128.99 159.62 35.31 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.561 -0.712 . . . . 0.0 110.571 -179.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.753 ' HB3' ' HB2' ' A' ' 150' ' ' ALA . 3.2 mm? -79.94 160.0 26.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.608 -0.682 . . . . 0.0 110.504 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 5.6 p -103.08 150.31 37.73 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.681 -0.637 . . . . 0.0 109.884 179.633 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -60.53 141.32 95.03 Favored 'Trans proline' 0 N--CA 1.495 1.576 0 O-C-N 123.783 1.412 . . . . 0.0 110.738 -179.627 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . . . . . . . . . 32.1 t -60.06 133.95 56.58 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.506 -0.746 . . . . 0.0 110.129 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . 0.419 HG23 ' O ' ' A' ' 98' ' ' THR . 6.7 t -136.48 57.24 1.78 Allowed 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 28.5 p -143.5 -8.8 0.75 Allowed 'General case' 0 N--CA 1.497 1.896 0 C-N-CA 119.858 -0.737 . . . . 0.0 112.463 -178.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 59.08 44.1 96.54 Favored Glycine 0 N--CA 1.497 2.719 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 62.2 m -108.36 132.59 53.59 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.537 -0.978 . . . . 0.0 110.671 -179.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.0 m -76.78 -27.26 55.21 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.661 -0.649 . . . . 0.0 110.427 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -66.76 129.97 41.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.463 -0.773 . . . . 0.0 110.214 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.601 HD22 HG21 ' A' ' 151' ' ' VAL . 92.6 mt -135.18 145.65 47.95 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.572 -0.705 . . . . 0.0 110.65 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 88.4 m-85 -106.93 130.79 54.54 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.524 -0.735 . . . . 0.0 109.422 179.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.42 HD13 HD11 ' A' ' 143' ' ' LEU . 50.7 tp -108.5 143.09 37.96 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.529 -0.732 . . . . 0.0 110.682 -179.221 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.5 t -110.02 129.97 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.851 0 O-C-N 121.666 -0.646 . . . . 0.0 109.533 179.612 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 77.3 p -102.58 176.76 5.06 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.509 -0.745 . . . . 0.0 110.791 -179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.796 ' CA ' HD11 ' A' ' 44' ' ' LEU . 11.9 ttp180 -68.44 -19.45 64.57 Favored 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.719 -0.613 . . . . 0.0 110.742 -179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 93.5 m-70 -92.37 24.04 3.62 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.382 -0.824 . . . . 0.0 110.981 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.58 39.35 31.11 Favored 'General case' 0 N--CA 1.502 2.14 0 O-C-N 121.231 -0.918 . . . . 0.0 110.827 179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.4 m-20 -114.46 159.47 20.28 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.592 -0.692 . . . . 0.0 109.724 179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.8 p -129.92 136.45 58.9 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 121.539 -0.725 . . . . 0.0 110.437 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.553 HD12 HH21 ' A' ' 130' ' ' ARG . 16.6 tt -129.9 131.18 23.34 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.561 -0.712 . . . . 0.0 109.809 179.643 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -69.61 126.05 12.95 Favored 'Trans proline' 0 N--CA 1.49 1.273 0 O-C-N 123.77 1.405 . . . . 0.0 110.552 -179.577 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 62.2 t -124.11 129.91 73.97 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.785 -0.572 . . . . 0.0 109.691 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.4 tpt180 -86.77 136.57 32.95 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.446 -0.784 . . . . 0.0 109.945 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 61.1 ttt180 -84.38 121.43 27.53 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.649 -0.657 . . . . 0.0 110.435 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 22.4 mmt180 -110.03 20.06 18.33 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.642 -0.661 . . . . 0.0 110.449 179.664 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . 164.85 -179.95 39.21 Favored Glycine 0 N--CA 1.492 2.385 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -69.68 -40.08 76.58 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.482 -1.011 . . . . 0.0 110.512 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 88.8 p -120.26 21.88 11.56 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 119.872 -0.731 . . . . 0.0 110.928 -179.446 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 17.4 tpt180 -133.79 140.22 46.79 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.394 -0.816 . . . . 0.0 110.328 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -139.73 163.23 26.21 Favored Glycine 0 N--CA 1.493 2.476 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . . . . . . . . . 80.1 p -126.69 144.99 50.75 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.587 -0.949 . . . . 0.0 110.295 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.541 HD13 HG13 ' A' ' 167' ' ' VAL . 10.7 mp -100.03 129.94 46.14 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.628 -0.67 . . . . 0.0 110.44 -179.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.569 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.6 mp -68.73 -40.03 80.1 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.642 -0.661 . . . . 0.0 109.723 179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 52.8 m -109.15 112.69 59.57 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.661 -0.65 . . . . 0.0 109.878 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -64.95 136.77 50.04 Favored 'Trans proline' 0 N--CA 1.49 1.313 0 O-C-N 123.756 1.398 . . . . 0.0 110.567 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . 0.553 HH21 HD12 ' A' ' 114' ' ' ILE . 20.1 mmt85 -129.84 160.0 67.11 Favored Pre-proline 0 N--CA 1.494 1.744 0 O-C-N 121.56 -0.712 . . . . 0.0 110.093 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -65.06 152.23 83.05 Favored 'Trans proline' 0 N--CA 1.491 1.325 0 O-C-N 123.875 1.46 . . . . 0.0 110.375 -179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 162' ' ' GLY . 34.3 m -64.99 -25.56 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 121.605 -0.684 . . . . 0.0 110.487 -179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 54.7 m -59.99 -40.03 87.77 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.444 -0.785 . . . . 0.0 110.286 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 59.6 t80 -66.64 -39.96 88.48 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.593 -0.692 . . . . 0.0 109.987 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.458 ' N ' HD22 ' A' ' 135' ' ' LEU . 4.5 mm? -65.19 -34.46 78.43 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.636 -0.665 . . . . 0.0 110.264 -179.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -60.02 142.98 53.0 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.461 -0.774 . . . . 0.0 110.324 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 79.97 9.73 86.37 Favored Glycine 0 N--CA 1.493 2.5 0 N-CA-C 110.146 -1.182 . . . . 0.0 110.146 -179.472 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 15.9 m -116.9 -6.94 11.46 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.266 -1.137 . . . . 0.0 110.945 179.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . . . . . . . . . 47.2 t -60.06 139.95 57.14 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.208 -0.932 . . . . 0.0 110.074 -179.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 99.97 -17.66 56.9 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.378 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -62.04 151.48 44.85 Favored Glycine 0 N--CA 1.494 2.535 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 179.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -95.66 144.97 1.25 Allowed 'Trans proline' 0 N--CA 1.489 1.211 0 O-C-N 123.797 1.419 . . . . 0.0 111.46 -179.43 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.561 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.4 mp -96.26 103.18 15.06 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.494 ' N ' HD12 ' A' ' 144' ' ' LEU . 10.9 mp -82.64 159.63 22.63 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.902 0.858 . . . . 0.0 111.905 -178.006 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.15 164.27 18.9 Favored Pre-proline 0 N--CA 1.494 1.727 0 CA-C-N 116.105 -0.498 . . . . 0.0 109.669 179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -65.71 -30.57 50.39 Favored 'Trans proline' 0 N--CA 1.49 1.272 0 O-C-N 123.922 1.485 . . . . 0.0 108.378 177.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 53.3 m -70.0 -36.72 75.36 Favored 'General case' 0 N--CA 1.491 1.596 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.01 41.98 0.53 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -130.01 145.74 51.66 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.468 -1.019 . . . . 0.0 110.651 -179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . 0.753 ' HB2' ' HB3' ' A' ' 94' ' ' LEU . . . -69.99 140.32 52.92 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.421 -0.799 . . . . 0.0 109.867 179.408 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.742 ' O ' HG23 ' A' ' 172' ' ' VAL . 59.3 t -112.91 -44.39 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.54 -0.725 . . . . 0.0 110.262 -179.77 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -173.43 -179.52 44.15 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 110.096 -1.201 . . . . 0.0 110.096 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 45.9 mt -120.02 130.72 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.806 0 O-C-N 121.611 -0.935 . . . . 0.0 110.157 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . 0.547 ' HZ ' ' HB2' ' A' ' 157' ' ' ALA . 26.4 t80 -60.09 136.49 58.04 Favored 'General case' 0 N--CA 1.499 2.006 0 O-C-N 121.648 -0.657 . . . . 0.0 109.961 179.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 67.1 ttt180 -115.49 -52.73 2.64 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.526 -0.734 . . . . 0.0 110.414 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -150.89 158.64 44.4 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.558 -0.714 . . . . 0.0 110.23 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . 0.547 ' HB2' ' HZ ' ' A' ' 154' ' ' PHE . . . -109.95 148.39 31.7 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.54 -0.725 . . . . 0.0 110.401 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 63.0 t -110.03 119.99 60.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.732 -0.605 . . . . 0.0 109.65 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.43 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.4 p -131.34 148.63 52.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.608 -0.683 . . . . 0.0 110.547 -179.822 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . . . . . . . . . 94.0 m -69.99 -47.02 63.87 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.625 -0.672 . . . . 0.0 110.018 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 27.7 ptt180 -164.63 53.41 0.13 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.716 -0.615 . . . . 0.0 109.84 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.45 ' O ' HG13 ' A' ' 132' ' ' VAL . . . 115.66 -18.06 15.36 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.951 -1.26 . . . . 0.0 109.951 -179.54 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 62.7 t -110.64 120.04 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.276 -1.132 . . . . 0.0 109.775 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -92.22 124.94 36.67 Favored 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.602 -0.686 . . . . 0.0 110.445 -179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -113.67 -29.16 7.22 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.693 -0.629 . . . . 0.0 110.199 179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -129.89 150.15 51.3 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.612 -0.68 . . . . 0.0 110.053 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.541 HG13 HD13 ' A' ' 126' ' ' LEU . 35.3 m -130.06 160.0 41.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.787 0 O-C-N 121.539 -0.726 . . . . 0.0 110.653 -179.722 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -122.9 132.86 54.36 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.698 -0.626 . . . . 0.0 109.838 179.747 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -139.94 160.01 40.88 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.492 -0.755 . . . . 0.0 110.616 -179.71 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.73 HG11 HD11 ' A' ' 82' ' ' LEU . 62.8 t -94.19 123.58 58.5 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 121.584 -0.697 . . . . 0.0 109.248 179.25 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -62.76 153.15 74.38 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 O-C-N 123.743 1.391 . . . . 0.0 110.65 -179.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.742 HG23 ' O ' ' A' ' 151' ' ' VAL . 69.3 t -58.09 -24.36 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.012 0 O-C-N 121.605 -0.684 . . . . 0.0 110.565 -179.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.07 -39.98 87.94 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.397 -0.815 . . . . 0.0 110.388 -179.386 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 53.3 m -60.15 -40.49 90.05 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 121.462 -0.774 . . . . 0.0 110.358 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 77.4 mtm -70.07 -40.0 75.28 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.61 -0.681 . . . . 0.0 110.214 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -60.0 -40.3 88.74 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.516 -0.74 . . . . 0.0 110.25 -179.85 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.3 m -63.64 -40.38 96.73 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.572 -0.705 . . . . 0.0 109.85 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 91.3 m -69.95 -40.16 75.61 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.538 -0.726 . . . . 0.0 110.076 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.7 ttm -60.45 -40.2 90.28 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.746 -0.596 . . . . 0.0 110.32 -179.742 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 66.9 ttt180 -60.07 -40.06 88.22 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.595 -0.691 . . . . 0.0 110.166 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -69.25 -40.08 78.08 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.519 -0.738 . . . . 0.0 110.05 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 18.2 p 49.53 39.95 18.12 Favored 'General case' 0 N--CA 1.501 2.086 0 O-C-N 121.587 -0.696 . . . . 0.0 111.152 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 58.7 tttp -100.07 120.06 39.27 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.619 -0.675 . . . . 0.0 110.14 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -128.26 29.35 5.36 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.583 -0.698 . . . . 0.0 110.262 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 59.3 tptt -59.97 -39.98 87.52 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.617 -0.677 . . . . 0.0 110.223 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 58.9 tptt . . . . . 0 N--CA 1.494 1.761 0 CA-C-O 118.032 -0.985 . . . . 0.0 110.123 -179.945 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 86.4 tt0 -116.8 130.04 56.47 Favored 'General case' 0 N--CA 1.491 1.613 0 C-N-CA 118.7 -1.2 . . . . 0.0 110.048 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.845 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -73.58 143.41 46.44 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.581 -0.699 . . . . 0.0 110.251 179.961 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' THR . . . . . . . . . . . . . 57.3 p . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.023 0.439 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 159.97 -80.02 0.16 Allowed Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . . . . . . . . . 63.0 ttt180 55.99 -87.22 0.02 OUTLIER 'General case' 0 N--CA 1.501 2.077 0 O-C-N 121.634 -0.921 . . . . 0.0 110.665 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -111.57 24.96 12.16 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.01 -1.056 . . . . 0.0 110.464 -179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -91.85 119.98 32.13 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 110.325 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.4 t-20 -149.58 88.78 1.58 Allowed 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.652 -0.655 . . . . 0.0 109.96 179.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 78.2 mt-30 -68.61 -40.01 80.58 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.635 -0.666 . . . . 0.0 110.521 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 8.7 p -147.85 148.34 16.39 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.54 -0.725 . . . . 0.0 110.429 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -154.6 159.97 41.18 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.518 -0.738 . . . . 0.0 110.157 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . 146.86 129.96 2.04 Favored Glycine 0 N--CA 1.493 2.469 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLU . . . . . 0.766 ' OE1' HD21 ' A' ' 94' ' ' LEU . 98.1 mt-10 -62.55 -37.75 87.36 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.633 -0.922 . . . . 0.0 110.005 179.825 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 63.1 t -102.91 127.53 56.61 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 121.607 -0.683 . . . . 0.0 109.838 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 78.1 mt-30 -123.95 156.56 36.15 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.563 -0.711 . . . . 0.0 110.288 -179.809 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 60.3 t -89.16 119.02 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.735 -0.603 . . . . 0.0 109.834 179.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.849 HG11 HD21 ' A' ' 64' ' ' LEU . 58.9 t -109.23 144.43 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 179.761 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' SER . . . . . . . . . . . . . 69.2 m -144.71 164.68 30.27 Favored 'General case' 0 N--CA 1.496 1.836 0 C-N-CA 119.737 -0.785 . . . . 0.0 111.209 -179.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 2.0 p -141.53 -179.57 6.23 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.759 -0.588 . . . . 0.0 109.797 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.78 -6.55 49.56 Favored 'General case' 0 N--CA 1.495 1.825 0 O-C-N 121.51 -0.744 . . . . 0.0 111.119 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . . . . . . . . . 17.1 m -105.18 -57.31 2.05 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.17 -0.956 . . . . 0.0 111.17 -179.407 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' GLN . . . . . 0.423 ' HB2' ' CD2' ' B' ' 191' ' ' FE3 . 2.8 pt20 -143.22 169.04 18.36 Favored 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.422 -0.799 . . . . 0.0 110.789 -179.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' SER . . . . . . . . . . . . . 70.5 m -116.92 148.46 41.33 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.512 -0.743 . . . . 0.0 110.591 -179.744 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.516 ' HZ ' ' HB2' ' A' ' 59' ' ' ALA . 24.9 p90 -163.1 -178.05 5.79 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.445 -0.784 . . . . 0.0 110.071 -179.725 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' LEU . . . . . 0.715 HD11 ' HA ' ' A' ' 109' ' ' ARG . 62.6 mt -113.15 148.8 34.63 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.492 -0.755 . . . . 0.0 110.327 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -126.3 159.74 32.28 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.662 -0.648 . . . . 0.0 109.937 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' THR . . . . . 0.582 HG21 ' HB3' ' A' ' 142' ' ' PRO . 58.8 m -119.93 138.78 53.24 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.571 -0.706 . . . . 0.0 110.546 -179.745 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' CYS . . . . . . . . . . . . . 45.1 m -93.14 110.97 22.47 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.644 -0.66 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' VAL . . . . . . . . . . . . . 62.9 t -120.0 130.01 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 121.552 -0.718 . . . . 0.0 109.297 179.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASN . . . . . . . . . . . . . 14.6 t-20 56.12 35.64 26.02 Favored 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.348 -0.845 . . . . 0.0 110.387 -179.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . 0.669 ' O ' ' HB3' ' A' ' 87' ' ' ALA . . . 70.0 19.97 75.88 Favored Glycine 0 N--CA 1.496 2.661 0 N-CA-C 110.586 -1.006 . . . . 0.0 110.586 179.578 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' VAL . . . . . . . . . . . . . 62.8 t -130.06 130.0 65.81 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.884 0 O-C-N 121.189 -1.183 . . . . 0.0 110.278 179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 34.1 t -76.0 129.94 37.65 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.416 -0.802 . . . . 0.0 109.408 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' TRP . . . . . . . . . . . . . 42.3 m95 -126.4 137.1 53.4 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.462 -0.774 . . . . 0.0 111.68 -179.119 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.665 HG22 ' HZ3' ' A' ' 85' ' ' TRP . 15.1 t -161.26 -179.6 7.56 Favored 'General case' 0 N--CA 1.492 1.662 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.832 HG21 ' CE1' ' A' ' 57' ' ' HIS . 14.5 p -81.19 155.29 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.752 0 O-C-N 121.314 -0.866 . . . . 0.0 110.67 -179.665 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' TYR . . . . . 0.546 ' CZ ' HG22 ' A' ' 78' ' ' VAL . 59.8 t80 -71.03 -39.93 72.03 Favored 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.752 -0.593 . . . . 0.0 111.935 -178.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' HIS . . . . . 0.832 ' CE1' HG21 ' A' ' 55' ' ' VAL . 2.8 p-80 -63.56 -24.65 67.9 Favored 'General case' 0 N--CA 1.498 1.951 0 O-C-N 120.979 -1.076 . . . . 0.0 110.833 -178.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . 0.493 ' H ' HG13 ' A' ' 55' ' ' VAL . . . -76.18 -51.45 6.82 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 109.068 -1.613 . . . . 0.0 109.068 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.516 ' HB2' ' HZ ' ' A' ' 43' ' ' PHE . . . -108.14 -59.69 1.82 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.571 -0.958 . . . . 0.0 110.07 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . 0.431 ' HA2' ' CD2' ' A' ' 56' ' ' TYR . . . 80.6 -176.51 54.64 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 23.9 t -79.84 68.13 5.83 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.554 -0.968 . . . . 0.0 109.806 179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' LYS . . . . . . . . . . . . . 25.6 mtpp -142.47 177.73 8.08 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.623 -0.673 . . . . 0.0 110.243 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' THR . . . . . . . . . . . . . 58.9 m -65.14 139.93 58.74 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.611 -0.681 . . . . 0.0 109.899 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LEU . . . . . 0.849 HD21 HG11 ' A' ' 36' ' ' VAL . 12.7 tp -111.74 136.58 50.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.619 -0.676 . . . . 0.0 110.262 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -102.35 109.94 21.74 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.576 -0.703 . . . . 0.0 110.068 179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLY . . . . . . . . . . . . . . . -110.51 179.96 20.4 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 47.9 Cg_endo -64.87 -32.35 55.51 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 O-C-N 123.878 1.462 . . . . 0.0 110.336 -179.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' LYS . . . . . . . . . . . . . 75.1 tttt -75.81 -31.19 59.31 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.638 -0.664 . . . . 0.0 110.046 -179.601 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLY . . . . . . . . . . . . . . . 144.88 -150.37 22.53 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -71.24 144.02 45.28 Favored 'Trans proline' 0 N--CA 1.491 1.353 0 O-C-N 123.844 1.444 . . . . 0.0 110.269 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.652 HG22 ' HB3' ' A' ' 85' ' ' TRP . 51.1 mm -126.57 130.02 71.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.633 -0.667 . . . . 0.0 110.389 -179.518 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' THR . . . . . . . . . . . . . 75.9 p -77.62 149.76 34.73 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.523 -0.736 . . . . 0.0 109.915 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 13.0 pt20 -100.42 140.5 34.59 Favored 'General case' 0 N--CA 1.498 1.974 0 O-C-N 121.523 -0.735 . . . . 0.0 110.834 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' MET . . . . . . . . . . . . . 92.4 mmm -113.38 -25.0 9.02 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.702 -0.623 . . . . 0.0 110.356 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -119.96 140.01 51.58 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.468 -0.77 . . . . 0.0 110.551 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 80.6 m -149.25 130.0 14.15 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.525 -0.735 . . . . 0.0 109.954 179.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 -149.91 98.07 2.67 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.553 -0.717 . . . . 0.0 110.319 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' VAL . . . . . 0.546 HG22 ' CZ ' ' A' ' 56' ' ' TYR . 81.1 t -70.01 -40.45 78.56 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 121.541 -0.724 . . . . 0.0 110.082 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -59.98 -44.8 94.25 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 121.57 -0.707 . . . . 0.0 110.319 -179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' GLN . . . . . 0.57 ' HG2' HD12 ' A' ' 82' ' ' LEU . 12.3 tt0 -89.99 0.05 57.32 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.563 -0.71 . . . . 0.0 111.118 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ASP . . . . . 0.41 ' HA ' ' HB3' ' A' ' 56' ' ' TYR . 4.8 t0 53.58 45.14 28.75 Favored 'General case' 0 N--CA 1.502 2.174 0 O-C-N 121.059 -1.026 . . . . 0.0 110.781 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . 0.674 HD11 HG11 ' A' ' 170' ' ' VAL . 50.8 mt -134.46 143.53 47.57 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.481 -0.762 . . . . 0.0 110.682 179.712 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.691 HG13 ' CH2' ' A' ' 85' ' ' TRP . 7.1 p -150.06 157.58 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.823 0 O-C-N 121.662 -0.649 . . . . 0.0 109.525 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . 0.416 ' HA2' ' CE3' ' A' ' 85' ' ' TRP . . . -152.76 160.07 28.81 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 -179.594 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' TRP . . . . . 0.691 ' CH2' HG13 ' A' ' 83' ' ' VAL . 11.3 m-90 -127.74 154.61 45.16 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.628 -0.925 . . . . 0.0 109.735 179.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLN . . . . . . . . . . . . . 45.5 tt0 -63.45 116.75 5.86 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.51 -0.744 . . . . 0.0 109.574 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.669 ' HB3' ' O ' ' A' ' 50' ' ' GLY . . . -77.52 135.59 64.8 Favored Pre-proline 0 N--CA 1.495 1.786 0 O-C-N 121.553 -0.717 . . . . 0.0 110.225 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.99 160.0 51.23 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 O-C-N 123.868 1.457 . . . . 0.0 110.217 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -73.41 156.53 50.22 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 O-C-N 123.87 1.458 . . . . 0.0 110.271 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 97.77 -22.04 42.94 Favored Glycine 0 N--CA 1.494 2.512 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ALA . . . . . . . . . . . . . . . -79.97 159.99 26.09 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.289 -1.124 . . . . 0.0 110.216 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 84.1 mtt180 -96.47 165.4 12.19 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.521 -0.737 . . . . 0.0 110.282 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 83.1 p -132.42 169.11 17.0 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.6 -0.687 . . . . 0.0 110.227 -179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' LEU . . . . . 0.766 HD21 ' OE1' ' A' ' 32' ' ' GLU . 84.2 mt -119.25 138.28 53.1 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.547 -0.721 . . . . 0.0 110.617 -179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' THR . . . . . . . . . . . . . 74.2 p -82.91 166.61 34.71 Favored Pre-proline 0 N--CA 1.494 1.756 0 O-C-N 121.582 -0.698 . . . . 0.0 110.144 179.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -79.18 166.12 23.05 Favored 'Trans proline' 0 N--CA 1.491 1.357 0 O-C-N 123.868 1.457 . . . . 0.0 110.533 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' CYS . . . . . 0.804 ' HB2' HG22 ' A' ' 151' ' ' VAL . 31.1 t -69.43 136.65 51.87 Favored 'General case' 0 N--CA 1.498 1.944 0 O-C-N 121.537 -0.727 . . . . 0.0 109.913 179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' THR . . . . . . . . . . . . . 11.3 p -136.59 55.55 1.84 Allowed 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.729 -0.607 . . . . 0.0 109.585 179.394 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' CYS . . . . . . . . . . . . . 31.7 p -143.46 -8.46 0.76 Allowed 'General case' 0 N--CA 1.497 1.886 0 C-N-CA 119.792 -0.763 . . . . 0.0 112.51 -178.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' GLY . . . . . . . . . . . . . . . 60.2 40.46 97.31 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 50.0 m -108.71 160.3 16.07 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.543 -0.975 . . . . 0.0 110.496 -179.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 4.9 p -108.9 21.69 16.89 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.556 -0.715 . . . . 0.0 110.798 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -99.94 120.05 39.2 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.371 -0.831 . . . . 0.0 110.051 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' LEU . . . . . 0.841 HD21 HG11 ' A' ' 151' ' ' VAL . 56.5 mt -130.57 133.13 45.95 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.557 -0.714 . . . . 0.0 110.537 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -107.0 120.0 40.88 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.507 -0.745 . . . . 0.0 109.693 179.387 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 67.8 tp -81.79 128.35 33.92 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.481 -0.762 . . . . 0.0 110.601 -179.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 62.6 t -97.85 118.6 44.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 121.626 -0.672 . . . . 0.0 109.37 179.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' THR . . . . . . . . . . . . . 74.4 p -104.32 177.93 4.7 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.553 -0.717 . . . . 0.0 110.664 -179.424 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.715 ' HA ' HD11 ' A' ' 44' ' ' LEU . 47.0 mtp180 -60.0 -22.77 63.0 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 121.602 -0.686 . . . . 0.0 110.461 179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 96.6 m-70 -90.46 19.07 5.52 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.344 -0.848 . . . . 0.0 111.126 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ALA . . . . . . . . . . . . . . . 54.84 40.0 31.74 Favored 'General case' 0 N--CA 1.502 2.135 0 O-C-N 121.1 -1.0 . . . . 0.0 110.924 179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 82.1 m-20 -100.31 122.81 43.68 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.572 -0.705 . . . . 0.0 109.961 179.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.455 HG23 ' N ' ' A' ' 114' ' ' ILE . 33.1 m -59.97 -39.36 79.97 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.923 0 O-C-N 121.577 -0.702 . . . . 0.0 110.501 -179.564 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ILE . . . . . 0.455 ' N ' HG23 ' A' ' 113' ' ' VAL . 50.8 mm 51.29 92.44 0.06 OUTLIER Pre-proline 0 N--CA 1.503 2.21 0 O-C-N 121.38 -0.825 . . . . 0.0 110.648 -179.936 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.93 121.41 8.44 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 O-C-N 123.94 1.495 . . . . 0.0 110.656 -179.676 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.538 HG13 ' O ' ' A' ' 125' ' ' SER . 62.5 t -127.2 129.99 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.665 -0.647 . . . . 0.0 109.52 179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 9.5 tpt180 -86.88 132.07 33.92 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.507 -0.746 . . . . 0.0 110.125 -179.751 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 67.3 ttt180 -72.09 130.64 41.39 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.512 -0.743 . . . . 0.0 110.004 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . . . . . . . . . 9.1 mmm180 -128.49 20.43 6.17 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.542 -0.724 . . . . 0.0 110.605 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -179.43 172.41 44.31 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.387 -1.485 . . . . 0.0 109.387 -179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -59.97 -40.64 89.78 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.47 -1.018 . . . . 0.0 110.278 -179.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 19.3 p -133.43 28.98 3.98 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.561 -0.712 . . . . 0.0 110.616 -179.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ARG . . . . . . . . . . . . . 22.0 ttp180 -139.89 138.37 35.61 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.422 -0.798 . . . . 0.0 110.592 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLY . . . . . . . . . . . . . . . -126.4 -176.49 14.51 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.469 -1.453 . . . . 0.0 109.469 179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' SER . . . . . 0.538 ' O ' HG13 ' A' ' 116' ' ' VAL . 86.8 p -133.24 150.87 51.93 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.557 -0.967 . . . . 0.0 110.211 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.419 HD13 HG13 ' A' ' 167' ' ' VAL . 2.3 mp -97.26 130.04 44.51 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.517 -0.739 . . . . 0.0 110.316 -179.811 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.528 ' N ' HD12 ' A' ' 127' ' ' LEU . 9.7 mp -67.64 -40.03 84.6 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.582 -0.699 . . . . 0.0 110.02 179.659 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.6 t -115.36 127.83 26.47 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.595 -0.691 . . . . 0.0 110.145 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -67.67 120.74 7.76 Favored 'Trans proline' 0 N--CA 1.49 1.297 0 O-C-N 123.755 1.398 . . . . 0.0 110.468 -179.804 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -120.46 160.06 45.44 Favored Pre-proline 0 N--CA 1.494 1.749 0 O-C-N 121.588 -0.695 . . . . 0.0 110.009 179.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -64.68 154.19 73.66 Favored 'Trans proline' 0 N--CA 1.491 1.333 0 O-C-N 123.956 1.503 . . . . 0.0 110.415 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . 0.49 HG11 ' SG ' ' A' ' 159' ' ' CYS . 34.7 m -67.18 -23.28 30.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.886 0 O-C-N 121.661 -0.649 . . . . 0.0 110.619 -179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' SER . . . . . . . . . . . . . 66.5 m -59.95 -40.06 87.71 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 121.403 -0.81 . . . . 0.0 110.211 -179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -60.0 -46.72 88.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.437 -0.789 . . . . 0.0 109.644 179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.478 HD13 ' HA ' ' A' ' 135' ' ' LEU . 4.5 mm? -69.99 -29.42 66.51 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.672 -0.642 . . . . 0.0 109.545 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.415 ' HD2' ' HA ' ' B' ' 190' ' ' OBF . 10.3 tptm -60.03 129.46 41.9 Favored 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.6 -0.688 . . . . 0.0 110.006 179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLY . . . . . . . . . . . . . . . 90.82 -8.29 80.01 Favored Glycine 0 N--CA 1.495 2.592 0 C-N-CA 120.269 -0.967 . . . . 0.0 110.894 -179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 53.0 p -96.86 6.01 49.47 Favored 'General case' 0 N--CA 1.497 1.903 0 O-C-N 121.071 -1.252 . . . . 0.0 111.135 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' SER . . . . . 0.409 ' HB2' ' CA ' ' B' ' 191' ' ' FE3 . 0.3 OUTLIER -60.03 142.94 53.11 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.038 -1.039 . . . . 0.0 109.929 179.921 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . 91.92 -14.93 63.02 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.193 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -59.25 145.77 44.02 Favored Glycine 0 N--CA 1.494 2.561 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 179.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' PRO . . . . . 0.582 ' HB3' HG21 ' A' ' 46' ' ' THR . 49.6 Cg_endo -92.03 141.54 2.46 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 O-C-N 123.859 1.452 . . . . 0.0 111.673 -179.066 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' LEU . . . . . 0.563 ' N ' HD12 ' A' ' 143' ' ' LEU . 9.7 mp -93.51 104.38 16.52 Favored 'General case' 0 N--CA 1.487 1.423 0 N-CA-C 107.432 -1.321 . . . . 0.0 107.432 177.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.469 ' N ' HD12 ' A' ' 144' ' ' LEU . 11.0 mp -81.99 157.24 24.3 Favored 'General case' 0 N--CA 1.493 1.713 0 CA-C-O 122.082 0.944 . . . . 0.0 111.867 -177.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.57 162.2 24.13 Favored Pre-proline 0 N--CA 1.49 1.551 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.496 -179.723 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -63.98 -29.82 66.71 Favored 'Trans proline' 0 N--CA 1.49 1.274 0 O-C-N 123.789 1.415 . . . . 0.0 108.577 177.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 79.6 p -70.91 -36.12 72.56 Favored 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 178.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 120.05 41.27 0.56 Allowed Glycine 0 N--CA 1.494 2.511 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' HIS . . . . . . . . . . . . . 37.9 m170 -129.97 154.32 47.49 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.528 -0.984 . . . . 0.0 110.592 -179.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' ALA . . . . . . . . . . . . . . . -85.32 119.55 25.81 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.504 -0.747 . . . . 0.0 109.857 179.586 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' VAL . . . . . 0.841 HG11 HD21 ' A' ' 104' ' ' LEU . 63.1 t -90.71 -42.01 13.73 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.566 -0.709 . . . . 0.0 110.483 -179.49 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' GLY . . . . . . . . . . . . . . . -166.51 -168.87 29.35 Favored Glycine 0 N--CA 1.497 2.741 0 C-N-CA 119.875 -1.155 . . . . 0.0 110.301 -179.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ILE . . . . . . . . . . . . . 94.2 mt -130.37 140.01 49.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 121.591 -0.947 . . . . 0.0 110.352 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' PHE . . . . . . . . . . . . . 27.9 t80 -63.44 139.69 58.8 Favored 'General case' 0 N--CA 1.499 2.002 0 O-C-N 121.679 -0.638 . . . . 0.0 109.725 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ARG . . . . . . . . . . . . . 31.9 ttp85 -123.14 -52.76 1.85 Allowed 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.48 -0.763 . . . . 0.0 110.529 -179.926 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ALA . . . . . . . . . . . . . . . -147.99 165.18 31.52 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.491 -0.755 . . . . 0.0 110.436 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' ALA . . . . . . . . . . . . . . . -121.95 143.87 49.21 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.621 -0.674 . . . . 0.0 110.371 -179.87 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.8 t -110.06 119.9 60.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.76 -0.587 . . . . 0.0 109.456 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' CYS . . . . . 0.49 ' SG ' HG11 ' A' ' 132' ' ' VAL . 26.7 p -125.97 146.03 50.04 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.545 -0.722 . . . . 0.0 110.693 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' THR . . . . . 0.541 HG22 ' HG2' ' A' ' 161' ' ' ARG . 39.9 m -82.89 -64.2 1.22 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.545 -0.722 . . . . 0.0 110.447 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.541 ' HG2' HG22 ' A' ' 160' ' ' THR . 10.3 mmm180 -129.21 62.96 1.5 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.499 -0.751 . . . . 0.0 110.406 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 89.91 -8.76 79.22 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.621 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 18.2 m -115.8 131.14 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.154 -1.203 . . . . 0.0 110.299 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ALA . . . . . . . . . . . . . . . -88.34 124.93 34.4 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.638 -0.664 . . . . 0.0 110.3 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -108.79 -29.61 8.57 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.687 -0.633 . . . . 0.0 110.005 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' ALA . . . . . . . . . . . . . . . -138.27 150.8 47.02 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.619 -0.676 . . . . 0.0 110.159 179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.419 HG13 HD13 ' A' ' 126' ' ' LEU . 27.6 m -130.45 175.46 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 121.644 -0.66 . . . . 0.0 110.597 -179.782 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -131.15 131.35 44.01 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.682 -0.637 . . . . 0.0 109.574 179.496 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' PHE . . . . . . . . . . . . . 52.9 p90 -129.48 153.07 48.34 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.347 -0.845 . . . . 0.0 110.528 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' VAL . . . . . 0.674 HG11 HD11 ' A' ' 82' ' ' LEU . 90.5 t -93.55 119.53 67.14 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.607 -0.683 . . . . 0.0 109.429 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -63.63 153.51 74.67 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 O-C-N 123.808 1.425 . . . . 0.0 110.578 -179.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 91.3 t -62.74 -27.42 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 121.629 -0.67 . . . . 0.0 110.428 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' GLU . . . . . . . . . . . . . 54.9 tt0 -59.94 -39.31 85.1 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.523 -0.736 . . . . 0.0 110.591 -179.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' SER . . . . . . . . . . . . . 85.9 p -59.96 -45.14 93.62 Favored 'General case' 0 N--CA 1.498 1.953 0 O-C-N 121.504 -0.748 . . . . 0.0 110.669 -179.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' MET . . . . . . . . . . . . . 76.7 mtm -69.97 -40.04 75.61 Favored 'General case' 0 N--CA 1.498 1.942 0 O-C-N 121.396 -0.815 . . . . 0.0 110.38 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' GLU . . . . . . . . . . . . . 86.2 tt0 -60.01 -40.04 87.86 Favored 'General case' 0 N--CA 1.498 1.956 0 O-C-N 121.479 -0.763 . . . . 0.0 110.259 -179.632 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' THR . . . . . . . . . . . . . 94.5 m -63.98 -39.99 95.38 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.574 -0.703 . . . . 0.0 109.881 -179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' THR . . . . . . . . . . . . . 88.6 m -70.05 -40.15 75.27 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.596 -0.69 . . . . 0.0 110.063 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' MET . . . . . . . . . . . . . 57.6 ttm -60.51 -40.06 90.05 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.648 -0.658 . . . . 0.0 110.396 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' ARG . . . . . . . . . . . . . 24.7 mmt85 -67.35 -39.95 85.8 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.544 -0.722 . . . . 0.0 110.252 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' ALA . . . . . . . . . . . . . . . -70.0 -56.2 7.6 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.51 -0.744 . . . . 0.0 110.209 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER 53.01 179.24 0.02 OUTLIER 'General case' 0 N--CA 1.502 2.13 0 O-C-N 121.437 -0.789 . . . . 0.0 110.802 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' LYS . . . . . . . . . . . . . 72.2 mmtt -68.07 -40.0 82.81 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.581 -0.699 . . . . 0.0 110.155 179.962 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' LYS . . . . . . . . . . . . . 28.2 ttpp -120.05 140.03 51.63 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.566 -0.709 . . . . 0.0 110.066 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -99.91 139.95 34.84 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.526 -0.734 . . . . 0.0 110.186 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' LYS . . . . . . . . . . . . . 54.8 tttm . . . . . 0 N--CA 1.493 1.723 0 CA-C-O 118.08 -0.962 . . . . 0.0 110.127 -179.87 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 187' ' ' IBU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 188' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -128.52 130.58 47.67 Favored 'General case' 0 N--CA 1.491 1.582 0 C-N-CA 118.744 -1.182 . . . . 0.0 110.135 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 189' ' ' LEU . . . . . 0.775 HD23 ' CG ' ' A' ' 57' ' ' HIS . 9.9 mp -70.0 141.2 52.98 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.622 -0.673 . . . . 0.0 110.188 179.956 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 190' ' ' OBF . . . . . 0.619 ' C ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 191' ' ' FE3 . . . . . 0.685 ' N ' CLD1 ' B' ' 191' ' ' FE3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_